{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ok\n"
     ]
    }
   ],
   "source": [
    "print(\"ok\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'d:\\\\work\\\\Githubdeskwork\\\\Medical-Chatbot\\\\research'"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%pwd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "os.chdir('../')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.document_loaders import PyPDFLoader,DirectoryLoader\n",
    "from langchain.text_splitter import  RecursiveCharacterTextSplitter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Extract Data From the PDF File\n",
    "def load_pdf_file(data):\n",
    "    loader = DirectoryLoader(data,\n",
    "                             glob=\"*.pdf\",\n",
    "                             loader_cls=PyPDFLoader)\n",
    "\n",
    "    documents = loader.load()\n",
    "\n",
    "    return documents\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "extracted_data = load_pdf_file(data=\"Data/\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 0, 'page_label': 'i'}, page_content=''),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 1, 'page_label': 'ii'}, page_content=''),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 2, 'page_label': 'iii'}, page_content=\"Table of Contents\\n1\\nFront  \\n  ................................................................................................................................................................................................................\\n1\\nCover  \\n  .......................................................................................................................................................................................................\\n2\\nFront Matter  \\n  ...........................................................................................................................................................................................\\n53\\n1 - Nutritional Disorders  \\n  ...............................................................................................................................................................\\n53\\nChapter 1. Nutrition: General Considerations  \\n  .....................................................................................................................\\n59\\nChapter 2. Undernutrition  \\n  .............................................................................................................................................................\\n69\\nChapter 3. Nutritional Support  \\n  ...................................................................................................................................................\\n76\\nChapter 4. Vitamin Deficiency, Dependency & Toxicity  \\n  ..................................................................................................\\n99\\nChapter 5. Mineral Deficiency & Toxicity  \\n  ..............................................................................................................................\\n108\\nChapter 6. Obesity & the Metabolic Syndrome  \\n  ...............................................................................................................\\n120\\n2 - Gastrointestinal Disorders  \\n  ..............................................................................................................................................\\n120\\nChapter 7. Approach to the Patient With Upper GI Complaints  \\n  ...............................................................................\\n132\\nChapter 8. Approach to the Patient With Lower GI Complaints  \\n  ...............................................................................\\n143\\nChapter 9. Diagnostic & Therapeutic GI Procedures  \\n  ....................................................................................................\\n150\\nChapter 10. GI Bleeding  \\n  ............................................................................................................................................................\\n158\\nChapter 11. Acute Abdomen & Surgical Gastroenterology  \\n  .........................................................................................\\n172\\nChapter 12. Esophageal & Swallowing Disorders  \\n  ..........................................................................................................\\n183\\nChapter 13. Gastritis & Peptic Ulcer Disease  \\n  ..................................................................................................................\\n196\\nChapter 14. Bezoars & Foreign Bodies  \\n  ..............................................................................................................................\\n199\\nChapter 15. Pancreatitis  \\n  ............................................................................................................................................................\\n206\\nChapter 16. Gastroenteritis  \\n  ......................................................................................................................................................\\n213\\nChapter 17. Malabsorption Syndromes  \\n  ..............................................................................................................................\\n225\\nChapter 18. Irritable Bowel Syndrome  \\n  ................................................................................................................................\\n229\\nChapter 19. Inflammatory Bowel Disease  \\n  .........................................................................................................................\\n241\\nChapter 20. Diverticular Disease  \\n  ...........................................................................................................................................\\n246\\nChapter 21. Anorectal Disorders  \\n  ............................................................................................................................................\\n254\\nChapter 22. Tumors of the GI Tract  \\n  ......................................................................................................................................\\n275\\n3 - Hepatic & Biliary Disorders  \\n  ............................................................................................................................................\\n275\\nChapter 23. Approach to the Patient With Liver Disease  \\n  ...........................................................................................\\n294\\nChapter 24. Testing for Hepatic & Biliary Disorders  \\n  ......................................................................................................\\n305\\nChapter 25. Drugs & the Liver  \\n  ................................................................................................................................................\\n308\\nChapter 26. Alcoholic Liver Disease  \\n  ....................................................................................................................................\\n314\\nChapter 27. Fibrosis & Cirrhosis  \\n  ............................................................................................................................................\\n322\\nChapter 28. Hepatitis  \\n  ..................................................................................................................................................................\\n333\\nChapter 29. Vascular Disorders of the Liver  \\n  .....................................................................................................................\\n341\\nChapter 30. Liver Masses & Granulomas  \\n  ..........................................................................................................................\\n348\\nChapter 31. Gallbladder & Bile Duct Disorders  \\n  ...............................................................................................................\\n362\\n4 - Musculoskeletal & Connective Tissue Disorders  \\n  .........................................................................................\\n362\\nChapter 32. Approach to the Patient With Joint Disease  \\n  ............................................................................................\\n373\\nChapter 33. Autoimmune Rheumatic Disorders  \\n  ..............................................................................................................\\n391\\nChapter 34. Vasculitis  \\n  .................................................................................................................................................................\\n416\\nChapter 35. Joint Disorders  \\n  .....................................................................................................................................................\\n435\\nChapter 36. Crystal-Induced Arthritides  \\n  ..............................................................................................................................\\n443\\nChapter 37. Osteoporosis  \\n  .........................................................................................................................................................\\n448\\nChapter 38. Paget's Disease of Bone  \\n  ..................................................................................................................................\\n451\\nChapter 39. Osteonecrosis  \\n  .......................................................................................................................................................\\n455\\nChapter 40. Infections of Joints & Bones  \\n  ...........................................................................................................................\\n463\\nChapter 41. Bursa, Muscle & Tendon Disorders  \\n  .............................................................................................................\\n470\\nChapter 42. Neck & Back Pain  \\n  ...............................................................................................................................................\\n481\\nChapter 43. Hand Disorders  \\n  ....................................................................................................................................................\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 3, 'page_label': 'iv'}, page_content='491 Chapter 44. Foot & Ankle Disorders    ..................................................................................................................................... 502 Chapter 45. Tumors of Bones & Joints    ...............................................................................................................................\\n5105 - Ear, Nose, Throat & Dental Disorders  \\n  ..................................................................................................................\\n510\\nChapter 46. Approach to the Patient With Ear Problems  \\n  ...........................................................................................\\n523\\nChapter 47. Hearing Loss  \\n  .........................................................................................................................................................\\n535\\nChapter 48. Inner Ear Disorders  \\n  ............................................................................................................................................\\n542\\nChapter 49. Middle Ear & Tympanic Membrane Disorders  \\n  ........................................................................................\\n550\\nChapter 50. External Ear Disorders  \\n  .....................................................................................................................................\\n554\\nChapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms  \\n  .......................................................\\n567\\nChapter 52. Oral & Pharyngeal Disorders  \\n  .........................................................................................................................\\n578\\nChapter 53. Nose & Paranasal Sinus Disorders  \\n  .............................................................................................................\\n584\\nChapter 54. Laryngeal Disorders  \\n  ...........................................................................................................................................\\n590\\nChapter 55. Tumors of the Head & Neck  \\n  ...........................................................................................................................\\n600\\nChapter 56. Approach to Dental & Oral Symptoms  \\n  .......................................................................................................\\n619\\nChapter 57. Common Dental Disorders  \\n  .............................................................................................................................\\n629\\nChapter 58. Dental Emergencies  \\n  ..........................................................................................................................................\\n635\\nChapter 59. Temporomandibular Disorders  \\n  ......................................................................................................................\\n641\\n6 - Eye Disorders  \\n  ............................................................................................................................................................................\\n641\\nChapter 60. Approach to the Ophthalmologic Patient  \\n  ..................................................................................................\\n669\\nChapter 61. Refractive Error  \\n  ...................................................................................................................................................\\n674\\nChapter 62. Eyelid & Lacrimal Disorders  \\n  ...........................................................................................................................\\n680\\nChapter 63. Conjunctival & Scleral Disorders  \\n  .................................................................................................................\\n690\\nChapter 64. Corneal Disorders  \\n  ...............................................................................................................................................\\n703\\nChapter 65. Glaucoma  \\n  ...............................................................................................................................................................\\n710\\nChapter 66. Cataract  \\n  ...................................................................................................................................................................\\n713\\nChapter 67. Uveitis  \\n  ......................................................................................................................................................................\\n719\\nChapter 68. Retinal Disorders  \\n  .................................................................................................................................................\\n731\\nChapter 69. Optic Nerve Disorders  \\n  ......................................................................................................................................\\n737\\nChapter 70. Orbital Diseases  \\n  ..................................................................................................................................................\\n742\\n7 - Dermatologic Disorders  \\n  ....................................................................................................................................................\\n742\\nChapter 71. Approach to the Dermatologic Patient  \\n  .......................................................................................................\\n755\\nChapter 72. Principles of Topical Dermatologic Therapy  \\n  ............................................................................................\\n760\\nChapter 73. Acne & Related Disorders  \\n  ...............................................................................................................................\\n766\\nChapter 74. Bullous Diseases  \\n  .................................................................................................................................................\\n771\\nChapter 75. Cornification Disorders  \\n  .....................................................................................................................................\\n775\\nChapter 76. Dermatitis  \\n  ...............................................................................................................................................................\\n786\\nChapter 77. Reactions to Sunlight  \\n  ........................................................................................................................................\\n791\\nChapter 78. Psoriasis & Scaling Diseases  \\n  ........................................................................................................................\\n799\\nChapter 79. Hypersensitivity & Inflammatory Disorders  \\n  .............................................................................................\\n808\\nChapter 80. Sweating Disorders  \\n  ............................................................................................................................................\\n811\\nChapter 81. Bacterial Skin Infections  \\n  ...................................................................................................................................\\n822\\nChapter 82. Fungal Skin Infections  \\n  ......................................................................................................................................\\n831\\nChapter 83. Parasitic Skin Infections  \\n  ...................................................................................................................................\\n836\\nChapter 84. Viral Skin Diseases  \\n  ............................................................................................................................................\\n841\\nChapter 85. Pigmentation Disorders  \\n  ....................................................................................................................................\\n846\\nChapter 86. Hair Disorders  \\n  .......................................................................................................................................................\\n855\\nChapter 87. Nail Disorders  \\n  .......................................................................................................................................................\\n861\\nChapter 88. Pressure Ulcers  \\n  ...................................................................................................................................................\\n867\\nChapter 89. Benign Tumors  \\n  .....................................................................................................................................................\\n874\\nChapter 90. Cancers of the Skin  \\n  ............................................................................................................................................\\n882\\n8 - Endocrine & Metabolic Disorders  \\n  .............................................................................................................................\\n882\\nChapter 91. Principles of Endocrinology  \\n  ............................................................................................................................\\n887\\nChapter 92. Pituitary Disorders  \\n  ..............................................................................................................................................\\n901\\nChapter 93. Thyroid Disorders  \\n  ................................................................................................................................................'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 4, 'page_label': 'v'}, page_content='921 Chapter 94. Adrenal Disorders    ................................................................................................................................................ 936 Chapter 95. Polyglandular Deficiency Syndromes    ........................................................................................................\\n939\\nChapter 96. Porphyrias  \\n  ..............................................................................................................................................................\\n949\\nChapter 97. Fluid & Electrolyte Metabolism  \\n  .....................................................................................................................\\n987\\nChapter 98. Acid-Base Regulation & Disorders  \\n  ..............................................................................................................\\n1001\\nChapter 99. Diabetes Mellitus & Disorders of Carbohydrate Metabolism  \\n  ........................................................\\n1024\\nChapter 100. Lipid Disorders  \\n  ................................................................................................................................................\\n1034\\nChapter 101. Amyloidosis  \\n  ......................................................................................................................................................\\n1037\\nChapter 102. Carcinoid Tumors  \\n  ..........................................................................................................................................\\n1040\\nChapter 103. Multiple Endocrine Neoplasia Syndromes  \\n  .........................................................................................\\n1046\\n9 - Hematology & Oncology  \\n  ...............................................................................................................................................\\n1046\\nChapter 104. Approach to the Patient With Anemia  \\n  ..................................................................................................\\n1050\\nChapter 105. Anemias Caused by Deficient Erythropoiesis  \\n  ...................................................................................\\n1061\\nChapter 106. Anemias Caused by Hemolysis  \\n  ...............................................................................................................\\n1078\\nChapter 107. Neutropenia & Lymphocytopenia  \\n  ...........................................................................................................\\n1086\\nChapter 108. Thrombocytopenia & Platelet Dysfunction  \\n  .........................................................................................\\n1097\\nChapter 109. Hemostasis  \\n  ......................................................................................................................................................\\n1104\\nChapter 110. Thrombotic Disorders  \\n  ...................................................................................................................................\\n1107\\nChapter 111. Coagulation Disorders  \\n  ..................................................................................................................................\\n1113\\nChapter 112. Bleeding Due to Abnormal Blood Vessels  \\n  ...........................................................................................\\n1116\\nChapter 113. Spleen Disorders  \\n  ............................................................................................................................................\\n1120\\nChapter 114. Eosinophilic Disorders  \\n  .................................................................................................................................\\n1126\\nChapter 115. Histiocytic Syndromes  \\n  .................................................................................................................................\\n1131\\nChapter 116. Myeloproliferative Disorders  \\n  .....................................................................................................................\\n1141\\nChapter 117. Leukemias  \\n  .........................................................................................................................................................\\n1154\\nChapter 118. Lymphomas  \\n  ......................................................................................................................................................\\n1164\\nChapter 119. Plasma Cell Disorders  \\n  .................................................................................................................................\\n1172\\nChapter 120. Iron Overload  \\n  ...................................................................................................................................................\\n1177\\nChapter 121. Transfusion Medicine  \\n  ...................................................................................................................................\\n1186\\nChapter 122. Overview of Cancer  \\n  ......................................................................................................................................\\n1198\\nChapter 123. Tumor Immunology  \\n  .......................................................................................................................................\\n1204\\nChapter 124. Principles of Cancer Therapy  \\n  ...................................................................................................................\\n1215\\n10 - Immunology; Allergic Disorders  \\n  ...........................................................................................................................\\n1215\\nChapter 125. Biology of the Immune System  \\n  ...............................................................................................................\\n1227\\nChapter 126. Immunodeficiency Disorders  \\n  ....................................................................................................................\\n1243\\nChapter 127. Allergic & Other Hypersensitivity Disorders  \\n  .......................................................................................\\n1263\\nChapter 128. Transplantation  \\n  ...............................................................................................................................................\\n1281\\n11 - Infectious Diseases  \\n  ........................................................................................................................................................\\n1281\\nChapter 129. Biology of Infectious Disease  \\n  ...................................................................................................................\\n1300\\nChapter 130. Laboratory Diagnosis of Infectious Disease  \\n  ......................................................................................\\n1306\\nChapter 131. Immunization  \\n  ...................................................................................................................................................\\n1313\\nChapter 132. Bacteria & Antibacterial Drugs  \\n  .................................................................................................................\\n1353\\nChapter 133. Gram-Positive Cocci  \\n  ....................................................................................................................................\\n1366\\nChapter 134. Gram-Positive Bacilli  \\n  ...................................................................................................................................\\n1376\\nChapter 135. Gram-Negative Bacilli  \\n  .................................................................................................................................\\n1405\\nChapter 136. Spirochetes  \\n  ......................................................................................................................................................\\n1413\\nChapter 137. Neisseriaceae  \\n  .................................................................................................................................................\\n1419\\nChapter 138. Chlamydia & Mycoplasmas  \\n  ......................................................................................................................\\n1421\\nChapter 139. Rickettsiae & Related Organisms  \\n  ..........................................................................................................\\n1431\\nChapter 140. Anaerobic Bacteria  \\n  ........................................................................................................................................\\n1450\\nChapter 141. Mycobacteria  \\n  ...................................................................................................................................................\\n1470\\nChapter 142. Fungi  \\n  ...................................................................................................................................................................\\n1493\\nChapter 143. Approach to Parasitic Infections  \\n  .............................................................................................................\\n1496\\nChapter 144. Nematodes (Roundworms)  \\n  .......................................................................................................................'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 5, 'page_label': 'vi'}, page_content='1513 Chapter 145. Trematodes (Flukes)    .................................................................................................................................... 1520 Chapter 146. Cestodes (Tapeworms)    ...............................................................................................................................\\n1527\\nChapter 147. Intestinal Protozoa  \\n  ........................................................................................................................................\\n1536\\nChapter 148. Extraintestinal Protozoa  \\n  .............................................................................................................................\\n1555\\nChapter 149. Viruses  \\n  ...............................................................................................................................................................\\n1559\\nChapter 150. Respiratory Viruses  \\n  ......................................................................................................................................\\n1571\\nChapter 151. Herpesviruses  \\n  .................................................................................................................................................\\n1584\\nChapter 152. Enteroviruses  \\n  ..................................................................................................................................................\\n1590\\nChapter 153. Arboviridae, Arenaviridae & Filoviridae  \\n  ...............................................................................................\\n1601\\nChapter 154. Human Immunodeficiency Virus  \\n  .............................................................................................................\\n1615\\nChapter 155. Other Viruses  \\n  ..................................................................................................................................................\\n1627\\nChapter 156. Sexually Transmitted Diseases  \\n  ...............................................................................................................\\n1647\\n12 - Psychiatric Disorders  \\n  ....................................................................................................................................................\\n1647\\nChapter 157. Approach to the Patient With Mental Symptoms  \\n  ............................................................................\\n1656\\nChapter 158. Anxiety Disorders  \\n  ..........................................................................................................................................\\n1665\\nChapter 159. Dissociative Disorders  \\n  .................................................................................................................................\\n1672\\nChapter 160. Drug Use & Dependence  \\n  ...........................................................................................................................\\n1706\\nChapter 161. Eating Disorders  \\n  ............................................................................................................................................\\n1712\\nChapter 162. Mood Disorders  \\n  ..............................................................................................................................................\\n1726\\nChapter 163. Personality Disorders  \\n  ...................................................................................................................................\\n1730\\nChapter 164. Schizophrenia & Related Disorders  \\n  ......................................................................................................\\n1740\\nChapter 165. Sexuality & Sexual Disorders  \\n  ..................................................................................................................\\n1748\\nChapter 166. Somatoform & Factitious Disorders  \\n  ......................................................................................................\\n1755\\nChapter 167. Suicidal Behavior  \\n  ..........................................................................................................................................\\n1759\\n13 - Neurologic Disorders  \\n  ....................................................................................................................................................\\n1759\\nChapter 168. Approach to the Neurologic Patient  \\n  .......................................................................................................\\n1779\\nChapter 169. Neurotransmission  \\n  ........................................................................................................................................\\n1783\\nChapter 170. Autonomic Nervous System  \\n  .....................................................................................................................\\n1790\\nChapter 171. Pain  \\n  .....................................................................................................................................................................\\n1803\\nChapter 172. Function & Dysfunction of the Cerebral Lobes  \\n  .................................................................................\\n1812\\nChapter 173. Stroke  \\n  .................................................................................................................................................................\\n1825\\nChapter 174. Coma & Impaired Consciousness  \\n  ..........................................................................................................\\n1836\\nChapter 175. Delirium & Dementia  \\n  ...................................................................................................................................\\n1857\\nChapter 176. Seizure Disorders  \\n  ..........................................................................................................................................\\n1867\\nChapter 177. Sleep & Wakefulness Disorders  \\n  .............................................................................................................\\n1880\\nChapter 178. Headache  \\n  ..........................................................................................................................................................\\n1891\\nChapter 179. Brain Infections  \\n  ..............................................................................................................................................\\n1902\\nChapter 180. Meningitis  \\n  ..........................................................................................................................................................\\n1913\\nChapter 181. Neuro-Ophthalmologic & Cranial Nerve Disorders  \\n  ........................................................................\\n1923\\nChapter 182. Craniocervical Junction Abnormalities  \\n  .................................................................................................\\n1926\\nChapter 183. Movement & Cerebellar Disorders  \\n  ........................................................................................................\\n1943\\nChapter 184. Demyelinating Disorders  \\n  ............................................................................................................................\\n1949\\nChapter 185. Peripheral Nervous System & Motor Unit Disorders  \\n  .....................................................................\\n1973\\nChapter 186. Spinal Cord Disorders  \\n  .................................................................................................................................\\n1983\\nChapter 187. Intracranial & Spinal Tumors  \\n  ....................................................................................................................\\n1994\\n14 - Pulmonary Disorders  \\n  ....................................................................................................................................................\\n1994\\nChapter 188. Approach to the Patient With Pulmonary Symptoms  \\n  ....................................................................\\n2016\\nChapter 189. Tests of Pulmonary Function  \\n  ....................................................................................................................\\n2024\\nChapter 190. Diagnostic & Therapeutic Pulmonary Procedures  \\n  ..........................................................................\\n2035\\nChapter 191. Asthma  \\n  ...............................................................................................................................................................\\n2048\\nChapter 192. Chronic Obstructive Pulmonary Disease  \\n  ............................................................................................\\n2063\\nChapter 193. Sleep Apnea  \\n  ....................................................................................................................................................\\n2070\\nChapter 194. Pulmonary Embolism  \\n  ..................................................................................................................................\\n2079\\nChapter 195. Acute Bronchitis  \\n  .............................................................................................................................................'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 6, 'page_label': 'vii'}, page_content='2081 Chapter 196. Pneumonia    ....................................................................................................................................................... 2094 Chapter 197. Lung Abscess    ..................................................................................................................................................\\n2097\\nChapter 198. Bronchiectasis  \\n  ................................................................................................................................................\\n2101\\nChapter 199. Interstitial Lung Diseases  \\n  ...........................................................................................................................\\n2122\\nChapter 200. Sarcoidosis  \\n  .......................................................................................................................................................\\n2127\\nChapter 201. Environmental Pulmonary Diseases  \\n  .....................................................................................................\\n2145\\nChapter 202. Pulmonary Hypertension  \\n  ............................................................................................................................\\n2150\\nChapter 203. Diffuse Alveolar Hemorrhage & Pulmonary-Renal Syndromes  \\n  ................................................\\n2156\\nChapter 204. Mediastinal & Pleural Disorders  \\n  ..............................................................................................................\\n2166\\nChapter 205. Tumors of the Lungs  \\n  ....................................................................................................................................\\n2176\\n15 - Cardiovascular Disorders  \\n  .........................................................................................................................................\\n2176\\nChapter 206. Approach to the Cardiac Patient  \\n  .............................................................................................................\\n2204\\nChapter 207. Cardiovascular Tests & Procedures  \\n  ......................................................................................................\\n2221\\nChapter 208. Arterial Hypertension  \\n  ...................................................................................................................................\\n2234\\nChapter 209. Arteriosclerosis  \\n  ...............................................................................................................................................\\n2242\\nChapter 210. Coronary Artery Disease  \\n  ............................................................................................................................\\n2268\\nChapter 211. Heart Failure  \\n  ....................................................................................................................................................\\n2285\\nChapter 212. Cardiomyopathies  \\n  .........................................................................................................................................\\n2293\\nChapter 213. Arrhythmias & Conduction Disorders  \\n  ....................................................................................................\\n2318\\nChapter 214. Valvular Disorders  \\n  .........................................................................................................................................\\n2336\\nChapter 215. Endocarditis  \\n  .....................................................................................................................................................\\n2343\\nChapter 216. Pericarditis  \\n  .......................................................................................................................................................\\n2349\\nChapter 217. Diseases of the Aorta & Its Branches  \\n  ...................................................................................................\\n2360\\nChapter 218. Peripheral Arterial Disorders  \\n  ....................................................................................................................\\n2370\\nChapter 219. Peripheral Venous & Lymphatic Disorders  \\n  .........................................................................................\\n2383\\nChapter 220. Sports & the Heart  \\n  ........................................................................................................................................\\n2387\\nChapter 221. Cardiac Tumors  \\n  ..............................................................................................................................................\\n2391\\n16 - Critical Care Medicine  \\n  .................................................................................................................................................\\n2391\\nChapter 222. Approach to the Critically Ill Patient  \\n  ......................................................................................................\\n2401\\nChapter 223. Cardiac Arrest  \\n  .................................................................................................................................................\\n2411\\nChapter 224. Respiratory Arrest  \\n  ..........................................................................................................................................\\n2422\\nChapter 225. Respiratory Failure & Mechanical Ventilation  \\n  ...................................................................................\\n2436\\nChapter 226. Shock & Fluid Resuscitation  \\n  .....................................................................................................................\\n2444\\nChapter 227. Sepsis & Septic Shock  \\n  ................................................................................................................................\\n2448\\n17 - Genitourinary Disorders  \\n  .............................................................................................................................................\\n2448\\nChapter 228. Approach to the Genitourinary Patient  \\n  .................................................................................................\\n2484\\nChapter 229. Male Reproductive Endocrinology  \\n  .........................................................................................................\\n2495\\nChapter 230. Voiding Disorders  \\n  ..........................................................................................................................................\\n2506\\nChapter 231. Obstructive Uropathy  \\n  ...................................................................................................................................\\n2510\\nChapter 232. Urinary Calculi  \\n  ................................................................................................................................................\\n2514\\nChapter 233. Urinary Tract Infections  \\n  ...............................................................................................................................\\n2525\\nChapter 234. Cystic Kidney Disease  \\n  ................................................................................................................................\\n2531\\nChapter 235. Glomerular Disorders  \\n  ..................................................................................................................................\\n2558\\nChapter 236. Tubulointerstitial Diseases  \\n  .........................................................................................................................\\n2571\\nChapter 237. Renal Transport Abnormalities  \\n  ................................................................................................................\\n2580\\nChapter 238. Renovascular Disorders  \\n  .............................................................................................................................\\n2589\\nChapter 239. Renal Failure  \\n  ...................................................................................................................................................\\n2600\\nChapter 240. Renal Replacement Therapy  \\n  ...................................................................................................................\\n2606\\nChapter 241. Penile & Scrotal Disorders  \\n  ........................................................................................................................\\n2612\\nChapter 242. Benign Prostate Disease  \\n  ............................................................................................................................\\n2618\\nChapter 243. Genitourinary Cancer  \\n  ..................................................................................................................................\\n2632\\n18 - Gynecology & Obstetrics  \\n  ...........................................................................................................................................\\n2632\\nChapter 244. Approach to the Gynecologic Patient  \\n  ...................................................................................................\\n2646\\nChapter 245. Female Reproductive Endocrinology  \\n  ...................................................................................................'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 7, 'page_label': 'viii'}, page_content='2649 Chapter 246. Menstrual Abnormalities    ............................................................................................................................. 2665 Chapter 247. Menopause    .......................................................................................................................................................\\n2668\\nChapter 248. Sexual Dysfunction in Women  \\n  ................................................................................................................\\n2678\\nChapter 249. Pelvic Relaxation Syndromes  \\n  ..................................................................................................................\\n2681\\nChapter 250. Benign Gynecologic Lesions  \\n  ....................................................................................................................\\n2688\\nChapter 251. Uterine Fibroids  \\n  ..............................................................................................................................................\\n2691\\nChapter 252. Endometriosis  \\n  .................................................................................................................................................\\n2694\\nChapter 253. Vaginitis & Pelvic Inflammatory Disease  \\n  ............................................................................................\\n2702\\nChapter 254. Medical Examination of the Rape Victim  \\n  ............................................................................................\\n2706\\nChapter 255. Breast Disorders  \\n  ............................................................................................................................................\\n2721\\nChapter 256. Gynecologic Tumors  \\n  ....................................................................................................................................\\n2738\\nChapter 257. Family Planning  \\n  .............................................................................................................................................\\n2747\\nChapter 258. Infertility  \\n  .............................................................................................................................................................\\n2755\\nChapter 259. Prenatal Genetic Counseling & Evaluation  \\n  ........................................................................................\\n2763\\nChapter 260. Conception & Prenatal Development  \\n  ...................................................................................................\\n2764\\nChapter 261. Approach to the Pregnant Woman & Prenatal Care  \\n  ......................................................................\\n2781\\nChapter 262. Normal Pregnancy, Labor & Delivery  \\n  ...................................................................................................\\n2793\\nChapter 263. Pregnancy Complicated by Disease  \\n  .....................................................................................................\\n2812\\nChapter 264. High-Risk Pregnancy  \\n  ...................................................................................................................................\\n2817\\nChapter 265. Abnormalities of Pregnancy  \\n  ......................................................................................................................\\n2842\\nChapter 266. Abnormalities & Complications of Labor & Delivery  \\n  ......................................................................\\n2854\\nChapter 267. Postpartum Care  \\n  ...........................................................................................................................................\\n2862\\n19 - Pediatrics  \\n  ................................................................................................................................................................................\\n2862\\nChapter 268. Approach to the Care of Normal Infants & Children  \\n  .......................................................................\\n2898\\nChapter 269. Approach to the Care of Adolescents  \\n  ...................................................................................................\\n2901\\nChapter 270. Caring for Sick Children & Their Families  \\n  ..........................................................................................\\n2904\\nChapter 271. Physical Growth & Development  \\n  ............................................................................................................\\n2908\\nChapter 272. Principles of Drug Treatment in Children  \\n  ............................................................................................\\n2912\\nChapter 273. Perinatal Physiology  \\n  ....................................................................................................................................\\n2916\\nChapter 274. Perinatal Problems  \\n  .......................................................................................................................................\\n2929\\nChapter 275. Perinatal Hematologic Disorders  \\n  ............................................................................................................\\n2936\\nChapter 276. Metabolic, Electrolyte & Toxic Disorders in Neonates  \\n  ...................................................................\\n2950\\nChapter 277. Gastrointestinal Disorders in Neonates & Infants  \\n  ...........................................................................\\n2958\\nChapter 278. Dehydration & Fluid Therapy  \\n  ...................................................................................................................\\n2962\\nChapter 279. Infections in Neonates  \\n  .................................................................................................................................\\n2990\\nChapter 280. Miscellaneous Infections in Infants & Children  \\n  ................................................................................\\n2996\\nChapter 281. Human Immunodeficiency Virus Infection in Infants & Children  \\n  ..............................................\\n3005\\nChapter 282. Rheumatic Fever  \\n  ...........................................................................................................................................\\n3010\\nChapter 283. Respiratory Disorders in Neonates, Infants & Young Children  \\n  ..................................................\\n3031\\nChapter 284. Cystic Fibrosis  \\n  ................................................................................................................................................\\n3038\\nChapter 285. Endocrine Disorders in Children  \\n  .............................................................................................................\\n3051\\nChapter 286. Neurologic Disorders in Children  \\n  ............................................................................................................\\n3060\\nChapter 287. Neurocutaneous Syndromes  \\n  ....................................................................................................................\\n3065\\nChapter 288. Bone & Connective Tissue Disorders in Children  \\n  ...........................................................................\\n3078\\nChapter 289. Eye Defects & Conditions in Children  \\n  ..................................................................................................\\n3083\\nChapter 290. Incontinence in Children  \\n  .............................................................................................................................\\n3089\\nChapter 291. Miscellaneous Disorders in Infants & Children  \\n  .................................................................................\\n3101\\nChapter 292. Pediatric Cancers  \\n  ..........................................................................................................................................\\n3110\\nChapter 293. Congenital Cardiovascular Anomalies  \\n  ..................................................................................................\\n3135\\nChapter 294. Congenital Craniofacial & Musculoskeletal Abnormalities  \\n  ..........................................................\\n3143\\nChapter 295. Congenital Gastrointestinal Anomalies  \\n  ................................................................................................\\n3151\\nChapter 296. Congenital Renal & Genitourinary Anomalies  \\n  ..................................................................................\\n3160\\nChapter 297. Congenital Renal Transport Abnormalities  \\n  .........................................................................................\\n3165\\nChapter 298. Congenital Neurologic Anomalies  \\n  ..........................................................................................................'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 8, 'page_label': 'ix'}, page_content='3172 Chapter 299. Chromosomal Anomalies    ........................................................................................................................... 3182 Chapter 300. Inherited Muscular Disorders    ...................................................................................................................\\n3187\\nChapter 301. Inherited Disorders of Metabolism  \\n  .........................................................................................................\\n3209\\nChapter 302. Hereditary Periodic Fever Syndromes  \\n  .................................................................................................\\n3214\\nChapter 303. Behavioral Concerns & Problems in Children  \\n  ..................................................................................\\n3222\\nChapter 304. Learning & Developmental Disorders  \\n  ..................................................................................................\\n3237\\nChapter 305. Mental Disorders in Children & Adolescents  \\n  .....................................................................................\\n3255\\nChapter 306. Child Maltreatment  \\n  .......................................................................................................................................\\n3262\\n20 - Geriatrics  \\n  ................................................................................................................................................................................\\n3262\\nChapter 307. Approach to the Geriatric Patient  \\n  ...........................................................................................................\\n3280\\nChapter 308. Drug Therapy in the Elderly  \\n  ......................................................................................................................\\n3290\\nChapter 309. Prevention of Disease & Disability in the Elderly  \\n  ............................................................................\\n3295\\nChapter 310. Quality of Life & Therapeutic Objectives  \\n  ............................................................................................\\n3297\\nChapter 311. Provision of Care  \\n  ...........................................................................................................................................\\n3312\\nChapter 312. Gait Disorders in the Elderly  \\n  ....................................................................................................................\\n3318\\nChapter 313. Falls in the Elderly  \\n  ........................................................................................................................................\\n3322\\nChapter 314. Social Issues in the Elderly  \\n  .......................................................................................................................\\n3333\\nChapter 315. The Older Driver  \\n  ............................................................................................................................................\\n3339\\nChapter 316. Funding Health Care for the Elderly  \\n  .....................................................................................................\\n3348\\n21 - Clinical Pharmacology  \\n  .................................................................................................................................................\\n3348\\nChapter 317. Concepts in Pharmacotherapy  \\n  ................................................................................................................\\n3354\\nChapter 318. Pharmacokinetics  \\n  ..........................................................................................................................................\\n3362\\nChapter 319. Pharmacodynamics  \\n  ......................................................................................................................................\\n3365\\nChapter 320. Adverse Drug Reactions  \\n  .............................................................................................................................\\n3367\\n22 - Injuries; Poisoning  \\n  ...........................................................................................................................................................\\n3367\\nChapter 321. Approach to the Trauma Patient  \\n  .............................................................................................................\\n3371\\nChapter 322. Lacerations  \\n  .......................................................................................................................................................\\n3379\\nChapter 323. Fractures, Dislocations & Sprains  \\n  ..........................................................................................................\\n3395\\nChapter 324. Traumatic Brain Injury  \\n  .................................................................................................................................\\n3404\\nChapter 325. Spinal Trauma  \\n  ................................................................................................................................................\\n3409\\nChapter 326. Facial Trauma  \\n  .................................................................................................................................................\\n3413\\nChapter 327. Eye Injuries  \\n  ......................................................................................................................................................\\n3418\\nChapter 328. Genitourinary Tract Trauma  \\n  ......................................................................................................................\\n3423\\nChapter 329. Burns  \\n  ...................................................................................................................................................................\\n3430\\nChapter 330. Electrical & Lightning Injuries  \\n  ..................................................................................................................\\n3435\\nChapter 331. Radiation Exposure & Contamination  \\n  ..................................................................................................\\n3445\\nChapter 332. Heat Illness  \\n  ......................................................................................................................................................\\n3455\\nChapter 333. Cold Injury  \\n  ........................................................................................................................................................\\n3460\\nChapter 334. Altitude Sickness  \\n  ...........................................................................................................................................\\n3464\\nChapter 335. Motion Sickness  \\n  .............................................................................................................................................\\n3467\\nChapter 336. Drowning  \\n  ...........................................................................................................................................................\\n3471\\nChapter 337. Injury During Diving or Work in Compressed Air  \\n  .............................................................................\\n3483\\nChapter 338. Exercise & Sports Injury  \\n  .............................................................................................................................\\n3504\\nChapter 339. Bites & Stings  \\n  ..................................................................................................................................................\\n3524\\nChapter 340. Poisoning  \\n  ..........................................................................................................................................................\\n3547\\n23 - Special Subjects  \\n  ...............................................................................................................................................................\\n3547\\nChapter 341. General Principles of Medical Genetics  \\n  ..............................................................................................\\n3557\\nChapter 342. Clinical Decision Making  \\n  ............................................................................................................................\\n3573\\nChapter 343. Principles of Radiologic Imaging  \\n  ............................................................................................................\\n3584\\nChapter 344. Complementary & Alternative Medicine  \\n  ..............................................................................................\\n3594\\nChapter 345. Dietary Supplements  \\n  ...................................................................................................................................\\n3605\\nChapter 346. Smoking Cessation  \\n  .......................................................................................................................................\\n3610\\nChapter 347. Medical Aspects of Travel  \\n  ..........................................................................................................................\\n3615\\nChapter 348. Syndromes of Uncertain Origin  \\n  ...............................................................................................................'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 9, 'page_label': 'x'}, page_content='3619 Chapter 349. Care of the Surgical Patient    ..................................................................................................................... 3625 Chapter 350. Rehabilitation    ..................................................................................................................................................\\n3640\\nChapter 351. Medicolegal Issues  \\n  .......................................................................................................................................\\n3647\\nChapter 352. Financial Issues in Health Care  \\n  ..............................................................................................................\\n3655\\nChapter 353. The Dying Patient  \\n  ..........................................................................................................................................\\n3664\\nAppendixes  \\n  .......................................................................................................................................................................................\\n3664\\nI: Ready Reference Guides  \\n  ...................................................................................................................................................\\n3667\\nII: Normal Laboratory Values  \\n  ................................................................................................................................................\\n3668\\nIII: Trade Names of Some Commonly Used Drugs  \\n  ....................................................................................................\\n3695\\nIndex  \\n  ......................................................................................................................................................................................................\\n3695\\nNote  \\n  .................................................................................................................................................................................................\\n3696\\nA  \\n  ........................................................................................................................................................................................................\\n3738\\nB  \\n  ........................................................................................................................................................................................................\\n3758\\nC  \\n  .......................................................................................................................................................................................................\\n3798\\nD  \\n  .......................................................................................................................................................................................................\\n3819\\nE  \\n  ........................................................................................................................................................................................................\\n3838\\nF  \\n  ........................................................................................................................................................................................................\\n3852\\nG  \\n  .......................................................................................................................................................................................................\\n3866\\nH  \\n  .......................................................................................................................................................................................................\\n3894\\nI  \\n  .........................................................................................................................................................................................................\\n3909\\nJ  \\n  ........................................................................................................................................................................................................\\n3911\\nK  \\n  ........................................................................................................................................................................................................\\n3916\\nL  \\n  ........................................................................................................................................................................................................\\n3932\\nM  \\n  .......................................................................................................................................................................................................\\n3954\\nN  \\n  .......................................................................................................................................................................................................\\n3968\\nO  \\n  .......................................................................................................................................................................................................\\n3977\\nP  \\n  ........................................................................................................................................................................................................\\n4017\\nQ  \\n  .......................................................................................................................................................................................................\\n4018\\nR  \\n  .......................................................................................................................................................................................................\\n4032\\nS  \\n  ........................................................................................................................................................................................................\\n4061\\nT  \\n  ........................................................................................................................................................................................................\\n4081\\nU  \\n  .......................................................................................................................................................................................................\\n4087\\nV  \\n  ........................................................................................................................................................................................................\\n4098\\nW  \\n  ......................................................................................................................................................................................................\\n4102\\nX  \\n  ........................................................................................................................................................................................................\\n4103\\nY  \\n  ........................................................................................................................................................................................................\\n4104\\nZ  \\n  ........................................................................................................................................................................................................'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 10, 'page_label': '1'}, page_content='The Merck Manual of Diagnosis & Therapy, 19th Edition Cover\\n1'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 11, 'page_label': '2'}, page_content='THE MERCK MANUAL OF DIAGNOSIS AND THERAPY - 19th Ed. (2011)\\nFront Matter\\nTitle Page\\nThe Merck Manual Of Diagnosis and Therapy, Nineteenth Edition\\nRobert S. Porter MD\\n, \\nEditor-in-Chief\\nJustin L. Kaplan MD\\n, \\nSenior Assistant Editor\\nEditorial Board\\nRichard K. Albert MD\\nMarjorie A. Bowman MD, MPA\\nGlenn D. Braunstein MD\\nSidney Cohen MD\\nLinda Emanuel PhD\\nJan Fawcett MD\\nEugene P. Frenkel MD\\nSusan L. Hendrix DO\\nMichael Jacewicz MD\\nMatthew E. Levison MD\\nJames Jeffrey Malatack MD\\nBrian F. Mandell MD, PhD\\nGerald L. Mandell MD\\nJudith S. Palfrey MD\\nAlbert A. Rundio Jr., PhD\\nDavid A. Spain MD\\nPaul H. Tanser MD\\nMichael R. Wasserman MD\\nMerck Sharp & Dohme Corp., A Subsidiary of Merck & Co., Inc.\\nWhitehouse Station, NJ\\n2011\\nCopyright Page\\nEditorial and Production Staff\\nExecutive Editor\\n: Keryn A.G. Lane\\nSenior Staff Writers\\n: Susan T. Schindler\\n                                  Susan C. Short\\nStaff Editor\\n: Michelle A. Steigerwald\\nSenior Operations Manager\\n: Diane C. Zenker\\nSenior Project Manager\\n: Diane Cosner Gartenmayer\\nManager, Electronic Publications\\n: Michael A. DeFerrari\\nExecutive Assistant\\n: Jean Perry\\nDesigner\\n: Alisha Webber\\nIllustrators\\n: Christopher C. Butts\\n                    Michael Reingold\\nIndexers\\n: Keryn A.G. Lane\\n                Susan Thomas, PhD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n2'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 12, 'page_label': '3'}, page_content=\"Publisher\\n: Gary Zelko\\nAdvertising and Promotions Supervisor\\n: Pamela J. Barnes-Paul\\nSubsidiary Rights Coordinator\\n: Jeanne Nilsen\\nSystems Administrator\\n: Leta S. Bracy\\nManufacturing books in the USA ensures compliance with strict environmental laws and eliminates the\\nneed for international freight shipping, a major contributor to global air pollution. Printing on recycled\\npaper helps minimize consumption of trees, water, and fossil fuels. The 19\\nth\\n Edition of \\nThe Merck\\nManual\\n uses paper with 10% post-consumer waste. According to Environmental Defense's Paper\\nCalculator, the following environmental benefits were achieved:\\nTrees Saved: 609  Air Emissions Eliminated: 57,930 pounds  Water Saved: 279,000 gallons  Solid\\nWaste Eliminated: 16,939 pounds\\n \\n \\n \\n \\n \\n \\nPlanet Friendly Publishing\\n Made in the United States\\n Printed on Recycled Paper Text: 10%\\nLearn more: www.greenedition.org\\n \\nLibrary of Congress Catalog Card Number   1-31760\\nISBN (13 digit) 978-0-911910-19-3\\nISBN (10 digit) 0-911910-19-0\\nISSN 0076-6526\\nCopyright  2011 by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co, Inc.\\nAll rights reserved. No part of this book may be reproduced or used in any form or by any means,\\nelectronic or mechanical, including photocopying, or by any information storage and retrieval system,\\nwithout permission in writing from the Publisher. Inquiries should be addressed to The Merck Manuals\\nDepartment, P.O. Box 4, Merck & Co., Inc., West Point, PA 19486.\\nPrinted in the USA.\\nForeign Language Editions of \\nThe Merck Manual\\nArabic\\nLarike Publications Services, Cyprus\\nChinese\\nPeople's Medical Publishing House, Beijing\\nCroatian\\nPlacebo, Split\\nCzech\\nEgem, Prague\\nFrench\\nEditions d'Apres, Paris\\nGerman\\nElsevier, Ltd., Munich\\nGreek\\nMedical & Scientific Publishing, Athens\\nHungarian\\nMelania, Budapest\\nItalian\\nSpringer-Verlag Italia Srl (Medicom), Milan\\nJapanese\\nNikkei Business Publications, Tokyo\\nKorean\\nHanwoori Publishing Co., Seoul\\nPolish\\nElsevier, Ltd, Wroclaw\\nPortuguese\\nEditora Roca Ltda, Sao Paolo\\nRomanian\\nAll Publishers, Bucharest\\nRussian\\nGeotar-Media Publishing Group, Moscow\\nSpanish\\nElsevier Espana, S.A., Madrid\\nTurkish\\nYuce, Istanbul\\nOther Merck Books\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n3\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 13, 'page_label': '4'}, page_content=\"The MERCK Manual\\n1st Edition - 1899\\n2nd Edition - 1901\\n3rd Edition - 1905\\n4th Edition - 1911\\n5th Edition - 1923\\n6th Edition - 1934\\n7th Edition - 1940\\n8th Edition - 1950\\n9th Edition - 1956\\n10th Edition - 1961\\n11th Edition - 1966\\n12th Edition - 1972\\n13th Edition - 1977\\n14th Edition - 1982\\n15th Edition - 1987\\n16th Edition - 1992\\n17th Edition - 1999\\n18th Edition - 2006\\n19th Edition - 2011\\nTHE MERCK INDEX\\nFirst Edition, 1889\\nTHE MERCK VETERINARY MANUAL\\nFirst Edition, 1955\\nTHE MERCK MANUAL OF GERIATRICS\\nFirst Edition, 1990\\nTHE MERCK MANUAL OF MEDICAL INFORMATIONHOME EDITION\\nFirst Edition, 1997\\nTHE MERCK MANUAL OF HEALTH & AGING\\nFirst Edition, 2004\\nTHE MERCK/MERIAL MANUAL FOR PET HEALTH\\nFirst Edition, 2007\\nTHE MERCK MANUAL OF PATIENT SYMPTOMS\\nFirst Edition, 2008\\nMerck books are published on a nonprofit basis as a service to the scientific community and the public.\\nPreface\\nAt the beginning of the 2nd decade of the 21st century, the amount of information available to health care\\npractitioners is immense. Medical websites and journals send daily messages announcing results of the\\nlatest studies. Within minutes, subspecialty data heretofore found only in university libraries can be\\nunearthed, along with a vast array of information from academics, commercial organizations, advocacy\\ngroups, the government, and seemingly anyone with a computer and an internet connection.\\nWhat is the role of a general reference work such as \\nThe Merck Manual\\n when seemingly the entire body\\nof medical knowledge is at one's fingertips electronically? With such a vast body of knowledge available,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n4\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 14, 'page_label': '5'}, page_content='finding a good starting place can be difficult. \\nThe Manual\\n has always been intended as the first stop on\\nthe road to understanding for readers encountering a topic for the first time or for the first time in a long\\ntime. After digesting a \\nMerck Manual\\n topic, readers will be well prepared to understand and evaluate the\\nwealth of more detailed information available elsewhere.\\nAs it has for over 110 years, \\nThe Merck Manual\\n focuses on discussions of specific disorders, organized\\nby organ system or medical specialty. In its structured introductions to medical disorders, \\nThe Manual\\nprovides health care practitioners and students with straightforward, practical explanations of \"what to do\"\\nto diagnose and treat those conditions. We discuss when to suspect a disease, the proper sequence of\\nevaluation, and the first-line options for treatment along with selected alternatives. In addition, we provide\\nenough background information on etiology and pathophysiology to ensure comprehension of the\\nmanagement recommendations.\\nThe Manual\\n continues to enhance its accessibility. In addition to having introductory \"nut-shells\" at the\\nbeginning of each disease discussion, we have included bulleted lists in the text whenever possible,\\nincluding at the beginning of diagnosis and treatment discussions.\\nIn the interest of brevity, \\nThe Merck Manual\\n has never cited references to the medical literature.\\nNonetheless, readers can be assured that our hundreds of contributors and dozens of peer reviewers are\\npresenting the best current recommendations, soundly based on available evidence.\\nAlthough the printed \\nMerck Manual\\n has long since grown too big to be carried in a lab coat, it has\\nreturned to the pocket as content on many different handheld electronic devices. In addition, \\nThe Merck\\nManual\\n continues to be available to all readers free of charge at www.merckmanuals.com\\n. Although our\\nelectronic versions have a currency that a printed product cannot, the book still provides a better in-depth\\nreading experience along with a tactile satisfaction and ease of perusal not possessed by electronic\\ndevices. Undoubtedly this will change as technology advances, but whatever the platform, we will\\ncontinue to strive to keep \\nThe Merck Manual\\n as useful as ever.\\nWe thank the numerous contributors who have worked diligently with us to craft this edition, and we hope\\nyou will find it worthy of continued and frequent use. As always, suggestions for improvements will be\\nwarmly welcomed and carefully considered.\\nRobert S. Porter, MD\\nEditor-in-Chief\\nCommitted to Providing Medical Information: Merck and The Merck Manuals\\nIn 1899, the American drug manufacturer Merck & Co. first published a small book titled \\nMerck\\'s Manual\\nof the Materia Medica\\n. It was meant as an aid to physicians and pharmacists, reminding doctors that\\n\"Memory is treacherous.\" Compact in size, easy to use, and comprehensive, \\nThe Merck Manual\\n (as it\\nwas later known) became a favorite of those involved in medical care and others in need of a medical\\nreference. Even Albert Schweitzer carried a copy to Africa in 1913, and Admiral Byrd carried a copy to the\\nSouth Pole in 1929.\\nBy the 1980s, the book had become the world\\'s largest selling medical text and was translated into more\\nthan a dozen languages. While the name of the parent company has changed somewhat over the years,\\nthe book\\'s name has remained constant, known officially as \\nThe Merck Manual of Diagnosis and\\nTherapy\\n but usually referred to as \\nThe Merck Manual\\n and sometimes \"The Merck.\"\\nIn 1990, the editors of \\nThe Merck Manual\\n introduced \\nThe Merck Manual of Geriatrics\\n. This new book\\nquickly became the best-selling textbook of geriatric medicine, providing specific and comprehensive\\ninformation on the care of older people. The 3rd edition was published in five languages.\\nIn 1997, \\nThe Merck Manual of Medical Information-Home Edition\\n was published. In this revolutionary\\nbook, the editors translated the complex medical information in \\nThe Merck Manual\\n into plain language,\\nproducing a book meant for all those people interested in medical care who did not have a medical\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n5'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 15, 'page_label': '6'}, page_content=\"degree. The book received critical acclaim and sold over 2 million copies. \\nThe Second Home Edition\\n was\\nreleased in 2003. Merck's commitment to providing comprehensive, understandable medical information\\nto all people continued with \\nThe Merck Manual Home Health Handbook\\n, published in 2009.\\nThe Merck Manual of Health & Aging\\n, published in 2004, continued Merck's commitment to education\\nand geriatric care, providing information on aging and the care of older people in words understandable\\nby the lay public.\\nIn 2008, \\nThe Merck Manual of Patient Symptoms\\n was introduced to complement \\nThe Merck Manual\\nand was intended to help newcomers to clinical diagnosis approach patients who present with certain\\ncommon symptoms.\\nAs part of its commitment to ensuring that all who need and want medical information can get it, Merck\\nprovides the content of these Merck Manuals on the web for free (www.merckmanuals.com\\n). Registration\\nis not required, and use is unlimited. The web publications are continuously updated to ensure that the\\ninformation is as up-to-date as possible.\\nMerck also supports the community of chemists and others with the need to know about chemical\\ncompounds with \\nThe Merck Index\\n. First published in 1889, this publication actually predates \\nThe Merck\\nManual\\n and is the most widely used text of its kind. \\nThe Merck Veterinary Manual\\n was first published in\\n1955. It provides information on the health care of animals and is the preeminent text in its field.\\nMerck & Co., Inc., is one of the world's largest pharmaceutical companies. Merck is committed to\\nproviding excellent medical information and, as part of that effort, continues to proudly provide all of The\\nMerck Manuals as a service to the community.\\nContents\\nGuide for Readers\\nviii\\nAbbreviations\\nix\\nEditors and Editorial Board\\nxi\\nConsultants\\nxiii\\nContributors\\nxv\\n1 Nutritional Disorders 1\\n2 Gastrointestinal Disorders 67\\n3 Hepatic and Biliary Disorders 203\\n4 Musculoskeletal and Connective Tissue Disorders 281\\n5 Ear, Nose, Throat, and Dental Disorders 411\\n6 Eye Disorders 535\\n7 Dermatologic Disorders 629\\n8 Endocrine and Metabolic Disorders 755\\n9 Hematology and Oncology 915\\n10 Immunology; Allergic Disorders 1077\\n11 Infectious Diseases 1143\\n12 Psychiatric Disorders 1483\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n6\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 16, 'page_label': '7'}, page_content='13 Neurologic Disorders 1583\\n14 Pulmonary Disorders 1823\\n15 Cardiovascular Disorders 2015\\n16 Critical Care Medicine 2243\\n17 Genitourinary Disorders 2303\\n18 Gynecology and Obstetrics 2479\\n19 Pediatrics 2691\\n20 Geriatrics 3069\\n21 Clinical Pharmacology 3165\\n22 Injuries; Poisoning 3187\\n23 Special Subjects 3371\\nAppendixes 3489\\nReady Reference Guides3489\\nNormal Laboratory Values3491\\nTrade Names of Some Commonly Used Drugs3505\\nIndex3521\\nGuide For Readers\\nThe \\nContents\\n (p. vii) shows the pages on which readers can find the Editors and Editorial Board\\nmembers, consultants, additional reviewers, and contributors, as well as titles of sections, appendixes,\\nand the index. Thumb tabs with appropriate abbreviations and section numbers mark each section and\\nthe index.\\nEach \\nSection\\n begins with its own table of contents, listing chapters and topics in that section. Chapters\\nare numbered serially from the beginning to the end of the book.\\nThe \\nIndex\\n is highly detailed and contains many cross-entries. In addition, readers will find many \\ncross-\\nreferences\\n throughout the text to specific pages where additional or related information can be found.\\nRunning heads\\n carry the section number and title on left-hand pages and the chapter number and title\\non right-hand pages.\\nAbbreviations and symbols,\\n used throughout the text as essential space savers, are listed on pages \\nix\\nand \\nx\\n. Other abbreviations in the text are expanded at first mention in the chapter or topic.\\nTables and figures\\n are referenced in the index but are not listed in a separate table of contents. An\\ninsert of color plates contains photographs of many eye, ear, endocrine, skin, and gynecologic disorders\\nas well as infectious diseases.\\nLaboratory values\\n in the book are given in conventional units. In most cases, SI units follow in\\nparentheses. \\nAppendix II\\n contains several tables listing normal laboratory values for many tests\\nconducted on blood, plasma, serum, urine, CSF, and stool.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n7'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 17, 'page_label': '8'}, page_content='Drugs\\n are designated in the text by generic (nonproprietary) names. In \\nAppendix III\\n, many of the drugs\\nmentioned in the book are listed alphabetically, with each generic name followed by one or more trade\\nnames.\\nSection 23\\n, \\nSpecial Subjects\\n,\\n has discussions on clinical decision making, radiologic imaging,\\ncomplementary and alternative medicine, dietary supplements, genetics, smoking cessation,\\nrehabilitation, care of the surgical patient, financial issues in health care, and care of the dying patient,\\namong others.\\nImportant:\\n The authors, reviewers, and editors of this book have made extensive efforts to ensure that\\ntreatments, drugs, and dosage regimens are accurate and conform to the standards accepted at the time\\nof publication. However, constant changes in information resulting from continuing research and clinical\\nexperience, reasonable differences in opinions among authorities, unique aspects of individual clinical\\nsituations, and the possibility of human error in preparing such an extensive text require that the reader\\nexercise individual judgment when making a clinical decision and, if necessary, consult and compare\\ninformation from other sources. In particular, the reader is advised to check the product information\\nprovided by the manufacturer of a drug product before prescribing or administering it, especially if the\\ndrug is unfamiliar or is used infrequently.\\nNote:\\n Readers can find up-to-date information, additional tables and figures, as well as multimedia\\nenhancements at www.merckmanuals.com\\n. Visit the web site frequently for new enhancements and the\\nlatest information on clinical developments.\\nAbbreviations\\nThe following abbreviations are used throughout the text; other abbreviations are expanded at first\\nmention in the chapter or subchapter.\\nABG\\narterial blood gas\\nACE\\nangiotensin converting enzyme\\nACTH\\nadrenocorticotropic hormone\\nADH\\nantidiuretic hormone\\nAIDS\\nacquired immunodeficiency syndrome\\nALT\\nalanine transaminase (formerly SGPT)\\nAST\\naspartate transaminase (formerly SGOT)\\nATP\\nadenosine triphosphate\\nBCG\\nbacille Calmette-Guerin\\nbid\\n2 times a day (only in dosages)\\nBMR\\nbasal metabolic rate\\nBP\\nblood pressure\\nBSA\\nbody surface area\\nBUN\\nblood urea nitrogen\\nC\\nCelsius; centigrade\\nCa\\ncalcium\\ncAMP\\ncyclic adenosine monophosphate\\nCBC\\ncomplete blood count\\ncGy\\ncentigray\\nCi\\ncurie\\nCK\\ncreatine kinase\\nCK-MB\\ncreatine kinase of muscle band\\nCl\\nchloride; chlorine\\ncm\\ncentimeter\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n8'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 18, 'page_label': '9'}, page_content='CNS\\ncentral nervous system\\nCO\\n2\\ncarbon dioxide\\nCOPD\\nchronic obstructive pulmonary disease\\nCPR\\ncardiopulmonary resuscitation\\nCSF\\ncerebrospinal fluid\\nCT\\ncomputed tomography\\ncu\\ncubic\\nD & C\\ndilation and curettage\\ndL\\ndeciliter (= 100 mL)\\nDNA\\ndeoxyribonucleic acid\\nDTP\\ndiphtheria-tetanus-pertussis (toxoids/vaccine)\\nD/W or D\\ndextrose\\nECF\\nextracellular fluid\\nECG\\nelectrocardiogram, electrocardiography\\nEEG\\nelectroencephalogram, electroencephalography\\nENT\\near, nose, and throat\\nERCP\\nendoscopic retrograde cholangiopancreatography\\nESR\\nerythrocyte sedimentation rate\\nF\\nFahrenheit\\nFDA\\nUS Food and Drug Administration\\nft\\nfoot; feet (measure)\\nFUO\\nfever of unknown origin\\ng\\ngram\\nGFR\\nglomerular filtration rate\\nGI\\ngastrointestinal\\nG6PD\\nglucose-6-phosphate dehydrogenase\\nGU\\ngenitourinary\\nGy\\ngray\\nh\\nhour\\nHb\\nhemoglobin\\nHCl\\nhydrochloric acid; hydrochloride\\nHCO\\n3\\nbicarbonate\\nHct\\nhematocrit\\nHg\\nmercury\\nHIV\\nhuman immunodeficiency virus\\nHLA\\nhuman leukocyte antigen\\nHMG-CoA\\nhydroxymethyl glutaryl coenzyme A\\nHz\\nhertz (cycles/second)\\nICF\\nintracellular fluid\\nICU\\nintensive care unit\\nIgA, etc\\nimmunoglobulin A, etc\\nIL-1, etc\\ninterleukin-1, etc\\nIM\\nintramuscular(ly)\\nINR\\ninternational normalized ratio\\nIU\\ninternational unit\\nIV\\nintravenous(ly)\\nIVU\\nintravenous urography\\nK\\npotassium\\nkcal\\nkilocalorie (food calorie)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n9'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 19, 'page_label': '10'}, page_content='kg\\nkilogram\\nL\\nliter\\nlb\\npound\\nLDH\\nlactic dehydrogenase\\nM\\nmolar\\nm\\nmeter\\nMAOI\\nmonoamine oxidase inhibitor\\nMCH\\nmean corpuscular hemoglobin\\nMCHC\\nmean corpuscular hemoglobin concentration\\nmCi\\nmillicurie\\nMCV\\nmean corpuscular volume\\nmEq\\nmilliequivalent\\nMg\\nmagnesium\\nmg\\nmilligram\\nMI\\nmyocardial infarction\\nMIC\\nminimum inhibitory concentration\\nmin\\nminute\\nmIU\\nmilli-international unit\\nmL\\nmilliliter\\nmm\\nmillimeter\\nmmol\\nmillimole\\nmo\\nmonth\\nmOsm\\nmilliosmole\\nMRI\\nmagnetic resonance imaging\\nN\\nnitrogen; normal (strength of solution)\\nNa\\nsodium\\nNaCl\\nsodium chloride\\nng\\nnanogram (= millimicrogram)\\nNGT\\nnasogastric tube\\nnm\\nnanometer (= millimicron)\\nnmol\\nnanomole\\nnpo\\nnothing by mouth\\nNSAID\\nnonsteroidal anti-inflammatory drug\\nO\\n2\\noxygen\\nOTC\\nover-the-counter (pharmaceuticals)\\noz\\nounce\\nP\\nphosphorus\\nPACO\\n2\\nalveolar carbon dioxide partial pressure\\nPaCO\\n2\\narterial carbon dioxide partial pressure\\nPAO\\n2\\nalveolar oxygen partial pressure\\nPaO\\n2\\narterial oxygen partial pressure\\nPCO\\n2\\ncarbon dioxide partial pressure (or tension)\\nPCR\\npolymerase chain reaction\\nPET\\npositron emission tomography\\npg\\npicogram (= micromicrogram)\\npH\\nhydrogen ion concentration\\nPMN\\npolymorphonuclear leukocyte\\npo\\norally\\nPO\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n10'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 20, 'page_label': '11'}, page_content='PO\\n2\\noxygen partial pressure (or tension)\\nPPD\\npurified protein derivative (tubercullin)\\nppm\\nparts per million\\nprn\\nas needed\\nPT\\nprothrombin time\\nPTT\\npartial thromboplastin time\\nq\\nevery (only in dosages)\\nqid\\n4 times a day (only in dosages)\\nRA\\nrheumatoid arthritis\\nRBC\\nred blood cell\\nRNA\\nribonucleic acid\\nSaO\\n2\\narterial oxygen saturation\\nsc\\nsubcutaneous\\nsec\\nsecond\\nSI\\nInternational System of Units\\nSIDS\\nsudden infant death syndrome\\nSLE\\nsystemic lupus erythematosus\\nsp\\nspecies (when referring to the singular) [eg, \\nClostridium\\n sp]\\nspp\\nspecies (when referring to the plural) [eg, \\nNocardia\\n and \\nMyocardia\\n spp]\\nsp gr\\nspecific gravity\\nsq\\nsquare\\nSSRI\\nselective serotonin reuptake inhibitor\\nTB\\ntuberculosis\\ntid\\n3 times a day (only in dosages)\\nTNF\\ntumor necrosis factor\\nTPN\\ntotal parenteral nutrition\\nTSH\\nthyroid-stimulating hormone\\nURI\\nupper respiratory infection\\nUTI\\nurinary tract infection\\nvs\\nversus\\nWBC\\nwhite blood cell\\nWHO\\nWorld Health Organization\\nwk\\nweek\\nwt\\nweight\\nyr\\nyear\\n\\nmicro-; micron\\n\\nCi\\nmicrocurie\\n\\ng\\nmicrogram\\n\\nL\\nmicroliter\\n\\nm\\nmicrometer (= micron)\\n\\nmol\\nmicromole\\n\\nOsm\\nmicro-osmole\\nm\\n\\nmillimicron\\nEditors\\nEditor-in-Chief\\nROBERT S. PORTER, MD\\nMerck & Co., Inc, and Clinical Assistant Professor, Department of Emergency Medicine, Jefferson\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n11'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 21, 'page_label': '12'}, page_content=\"Medical College\\nSenior Assistant Editor\\nJUSTIN L. KAPLAN, MD\\nMerck & Co., Inc, and Clinical Associate Professor, Department of Emergency Medicine, Jefferson\\nMedical College\\nEditorial Board\\nRICHARD K. ALBERT, MD\\nProfessor, Department of Medicine, University\\nof Colorado Health Sciences Center; Chief of\\nMedicine, Denver Health Medical Center\\nMARJORIE A. BOWMAN, MD, MPA\\nProfessor and Founding Chair of Family\\nPractice and Community Health, University of\\nPennsylvania School of Medicine\\nGLENN D. BRAUNSTEIN, MD\\nProfessor of Medicine, David Geffen School\\nof Medicine at University of California, Los\\nAngeles; Chairman, Department of Medicine,\\nCedars-Sinai Medical Center\\nSIDNEY COHEN, MD\\nProfessor of Medicine and Director, Research\\nPrograms, Thomas Jefferson University School\\nof Medicine\\nLINDA EMANUEL, PhD\\nProfessor of Medicine, Northwestern University,\\nFeinberg School of Medicine, Buehler Center\\non Aging\\nJAN FAWCETT, MD\\nProfessor of Psychiatry, University of New\\nMexico School of Medicine\\nEUGENE P. FRENKEL, MD\\nProfessor of Internal Medicine and Radiology,\\nPatsy R. and Raymond D. Nasher Distinguished\\nChair in Cancer Research, Elaine Dewey\\nSammons Distinguished Chair in Cancer\\nResearch in honor of Eugene P. Frenkel, MD,\\nA. Kenneth Pye Professorship in Cancer\\nResearch, Harold C. Simmons Comprehensive\\nCancer Center, The University of Texas\\nSouthwestern Medical Center at Dallas\\nSUSAN L. HENDRIX, DO\\nClinical Professor, Department of Obstetrics\\nand Gynecology, Michigan State University\\nSchool of Osteopathic Medicine, and a partner\\nin Hutzel Women's Hospital at the Detroit\\nMedical Center\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n12\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 22, 'page_label': '13'}, page_content='MICHAEL JACEWICZ, MD\\nProfessor of Neurology, University of\\nTennessee Health Science Center; Assistant\\nChief of Neurology, VA Medical Center,\\nMemphis\\nMATTHEW E. LEVISON, MD\\nAdjunct Professor of Medicine, Drexel\\nUniversity College of Medicine; Professor,\\nSchool of Public Health, Drexel University\\nJAMES JEFFREY MALATACK, MD\\nProfessor of Pediatrics, Thomas Jefferson\\nUniversity School of Medicine; Division Chief\\nof Diagnostic Referral Service and Medical\\nLiver Transplantation, Alfred I. duPont\\nHospital for Children\\nBRIAN F. MANDELL, MD, PhD\\nProfessor and Vice Chairman of Medicine,\\nDepartment of Rheumatic and Immunologic\\nDiseases, Center for Vasculitis Care and\\nResearch, Cleveland Clinic Lerner College of\\nMedicine at Case Western Reserve University\\nGERALD L. MANDELL, MD\\nProfessor of Medicine (Emeritus), Owen R.\\nCheatham Professor of the Sciences\\n(Emeritus), Chief of Infectious Diseases\\n(Emeritus), University of Virginia Health\\nSystem\\nJUDITH S. PALFREY, MD\\nT. Berry Brazelton Professor of Pediatrics,\\nHarvard Medical School\\nALBERT A. RUNDIO, Jr., PhD\\nAssociate Professor of Nursing, The Richard\\nStockton College of New Jersey; Nurse\\nPractitioner, Lighthouse at Mays Landing\\nDAVID A. SPAIN, MD\\nProfessor of Surgery and Chief of Trauma/\\nSurgical Critical Care, Stanford University\\nPAUL H. TANSER, MD\\nProfessor of Medicine (Emeritus), McMaster\\nUniversity; Medical Cardiologist, North Shore\\nand Waitakere Hospitals, Auckland\\nMICHAEL R. WASSERMAN, MD\\nCo-founder, Senior Care of Colorado, PC\\nConsultants\\nNOEL A. ARMENAKAS, MD\\nClinical Associate Professor, Department\\nof Urology, Weill Cornell Medical School;\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n13'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 23, 'page_label': '14'}, page_content='Attending Physician, Lenox Hill Hospital\\nand New York Presbyterian Hospital\\nGenitourinary (Urologic) Disorders\\nINA CALLIGARO, PharmD\\nAssistant Dean for Education and Associate\\nProfessor of Pharmacy Practice, Temple\\nUniversity School of Pharmacy\\nPediatric Pharmaceutical Preparations and\\nDosages\\nMICHAEL F. CELLUCCI, MD\\nAttending Physician, Department of Pediatrics,\\nDiagnostic Referral Division, Alfred I. duPont\\nHospital for Children; Clinical Instructor,\\nJefferson Medical College\\nPediatrics\\nROBERT B. COHEN, DMD\\nClinical Associate Professor of Dentistry\\nand Practice Coordinator, Tufts University\\nSchool of Dental Medicine\\nDental Disorders\\nDEBORAH M. CONSOLINI, MD\\nAssistant Professor of Pediatrics, Jefferson\\nMedical College; Staff Physician, Diagnostic\\nReferral Division, Alfred I. duPont Hospital\\nfor Children\\nPediatrics\\nJ. CARLTON GARTNER, Jr., MD\\nProfessor of Pediatrics, Jefferson Medical\\nCollege; Pediatrician-in-Chief, Alfred I. duPont\\nHospital for Children\\nPediatrics\\nSIDNEY N. KLAUS, MD\\nProfessor of Medicine, Section of Dermatology,\\nDartmouth Medical School; Chief of\\nDermatology, White River Junction, Vermont\\nVA Medical Center\\nDermatologic Disorders\\nCHRISTOPHER P. RAAB, MD\\nClinical Instructor, Thomas Jefferson University;\\nStaff Physician, Pediatrics Department,\\nDiagnostic Referral Division, Alfred I. duPont\\nHospital for Children\\nPediatrics\\nMELVIN I. ROAT, MD\\nClinical Associate Professor, Wills Eye Institute,\\nDepartment of Ophthalmology, Jefferson\\nMedical College, Thomas Jefferson University\\nEye Disorders\\nJAMES R. ROBERTS, MD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n14'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 24, 'page_label': '15'}, page_content='JAMES R. ROBERTS, MD\\nProfessor and Vice Chairman, Department\\nof Emergency Medicine, Drexel University\\nCollege of Medicine; Chair, Department of\\nEmergency Medicine and Director, Division\\nof Toxicology, Mercy Catholic Medical Center\\nInjuries and Poisoning\\nROBERT J. RUBEN, MD\\nDistinguished University Professor, Department\\nof Otorhinolaryngology-Head & Neck Surgery,\\nAlbert Einstein College of Medicine and\\nMontefiore Medical Center\\nEar, Nose, and Throat Disorders\\nSTEWART SHANKEL, MD\\nClinical Professor of Medicine and Director of\\nClinical Instruction, University of California,\\nRiverside\\nGenitourinary (Nephrotic) Disorders\\nEVA M. VIVIAN, PharmD\\nClinical Associate Professor, University of\\nWisconsin School of Pharmacy\\nAdult Pharmaceutical Preparations and\\nDosages\\nReviewers for Selected Chapters\\nWilliam E. Brant, MD\\nArthur Coverdale, MD\\nAlbert T. Derivan, MD\\nRobert A. Dobie, MD\\nNorton J. Greenberger, MD\\nJohn E. Greenlee, MD\\nMary L. Hardy, MD\\nRandall Hughes, MD\\nDiane Kraft, MS, RD, LDN\\nDouglas Lanska, MD, MS, MSPH\\nEdwin M. Leidholdt, Jr., PhD\\nMichael C. Levin, MD\\nS. Gene McNeeley, MD\\nColonel David F. Murchison, DDS, MMS\\nDavid S. Rootman, MD\\nMichael B. Steinberg, MD, MPH\\nJames Wayne Warnica, MD\\nAcknowledgments\\nWe thank Barbara P. Homeier, MD, Noelle Rotondo, DO, and Oren Traub, MD, PhD, for their editorial\\nassistance. We also thank Paul Fennessy and the team at Nesbitt Graphics for their assistance in\\nproducing this book.\\nWe thank the following people and institutions for allowing us to publish their photographs in the color\\nplates: Piet van Hasselt, MD (\\nPlate 1\\n); Bechara Ghorayeb, MD (\\nPlate 2\\n); Robert Machemer via the\\nOnline Journal of Ophthalmology (ONJOPH)\\n (\\nPlates 3\\n, \\n5\\n, \\n10\\n, \\n11\\n [bottom], \\n23\\n, and \\n25\\n [bottom]\\n);\\nOphthalmic Clinic of the Health Center of the University of Erlangen-Nurnberg via \\nONJOPH\\n (\\nPlates 4\\nand \\n17\\n [bottom]\\n); A. Viestenz via \\nONJOPH\\n (\\nPlate 6\\n); Jonathan J. Dutton via \\nONJOPH\\n (\\nPlate 7\\n);\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n15'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 25, 'page_label': '16'}, page_content=\"Professor J. Wollensak via \\nONJOPH\\n (\\nPlates 8\\n, \\n9\\n, \\n15\\n, \\n16\\n, \\n17\\n [top], and \\n18\\n); Dr. Brooks McCuen via\\nONJOPH\\n (\\nPlate 11\\n [top]\\n); Jonathan J. Dutton via \\nONJOPH\\n (\\nPlate 12\\n); University of California at San\\nDiego via \\nONJOPH\\n (\\nPlate 13\\n); Professor H.J. Meyer via \\nONJOPH\\n (\\nPlate 14\\n); Dr. James Garrity (\\nPlate\\n19\\n); World Health Organization via \\nONJOPH\\n (\\nPlate 20\\n); C. Newman (\\nPlate 21\\n) and B. Biller (\\nPlate 22\\n)\\nfrom \\nAtlas of Clinical Endocrinology: Neuroendocrinology and Pituitary Disease\\n; Thomas Habif, MD\\n(\\nPlates 24\\n, \\n26\\n-\\n30\\n, \\n32\\n-\\n37\\n, \\n38\\n [top], \\n39\\n-\\n47\\n, \\n49\\n, \\n51\\n-\\n55\\n, and \\n60\\n); Prof. Dr. K.W. Ruprecht and Dr. Med. B.\\nKaesmann-Kellner via \\nONJOPH\\n (\\nPlate 25\\n [top]\\n); Allen W. Mathies, MD, via the Public Health Image\\nLibrary of the Centers for Disease Control and Prevention (CDC) (\\nPlate 31\\n); Dennis D. Juranek, MD, via\\nthe Public Health Image Library of the CDC (\\nPlate 38\\n [bottom]\\n) and via www.doctorfungus.com\\n (\\nPlates\\n48\\n and \\n50\\n); S. Deitcher from \\nAtlas of Clinical Hematology\\n (\\nPlate 56\\n); E. Joe and N. Soter from \\nCurrent\\nDermatologic Diagnosis and Treatment\\n (\\nPlate 57\\n); Public Health Image Library of the CDC (\\nPlates 58\\n,\\n64\\n-\\n67\\n, and \\n70\\n); Drs. S.E. Thompson and J. Pledger via the Public Health Image Library of the CDC\\n(\\nPlate 59\\n); Noel Armenakas, MD (\\nPlate 61\\n); Dr. Susan Lindsley via the Public Health Image Library of the\\nCDC (\\nPlate 62\\n); Joe Miller and Dr. Cornelio Arevalo via the Public Health Image Library of the CDC\\n(\\nPlate 63\\n); M.S. Klempner from \\nAtlas of Infectious Diseases: External Manifestations of Systemic\\nInfections\\n (\\nPlate 68\\n); R. Kaufman and D. Brown from \\nAtlas of Clinical Gynecology: Gynecologic\\nPathology\\n (\\nPlate 69\\n); J.D. Sobel from \\nAtlas of Infectious Diseases: Fungal Infections\\n (\\nPlate 71\\n); A.\\nOster and R. Rosa from \\nAtlas of Ophthalmology\\n (\\nPlate 72\\n); I. Scott, R. Warman, and T. Murray from\\nAtlas of Ophthalmology\\n (\\nPlate 73\\n); J. Burns and M. Glode from \\nAtlas of Infectious Diseases: Pediatric\\nInfectious Diseases\\n (\\nPlate 74\\n); Steven E. Wolf, MD (\\nPlates 75\\n and \\n76\\n).\\nContributors\\nBOLA ADAMOLEKUN, MD\\nDirector of Epilepsy, Department of Neurology,\\nUniversity of Tennessee Health Science Center\\nSeizure Disorders\\nNEIL B. ALEXANDER, MD\\nProfessor, Department of Internal Medicine,\\nDivision of Geriatric Medicine, University of\\nMichigan; Associate Professor for Research;\\nDirector, VA Ann Arbor Health Care System,\\nGeriatrics Research, Education and Clinical\\nCenter\\nFalls in the Elderly\\nROY D. ALTMAN, MD\\nProfessor of Medicine, Division of\\nRheumatology and Immunology, University\\nof California, Los Angeles\\nJoint Disorders; Paget's Disease of Bone\\nBRADLEY D. ANAWALT, MD\\nAssociate Professor of Medicine, University\\nof Washington; Associate Chief of Medicine,\\nVA Puget Sound\\nMale Reproductive Endocrinology\\nMARY ANN ANDERSON, PhD, RN\\nAssociate Professor, University of Illinois at\\nChicago, College of Nursing, Quad Cities\\nRegional Program\\nProvision of Care\\nGERALD L. ANDRIOLE, MD\\nProfessor and Chief of Urologic Surgery,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n16\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 26, 'page_label': '17'}, page_content='Barnes-Jewish Hospital, Washington\\nUniversity School of Medicine\\nBenign Prostate Disease\\nPARSWA ANSARI, MD\\nAssistant Program Director, Department of\\nSurgery, Lenox Hill Hospital, New York\\nGI Bleeding; Acute Abdomen and Surgical\\nGastroenterology; Anorectal Disorders\\nBRIAN R. APATOFF, MD, PhD\\nAssociate Professor of Neurology and\\nNeuroscience, Weill Cornell Medical College;\\nClinical Attending of Neurology, New York\\nPresbyterian Hospital\\nDemyelinating Disorders\\nNOEL A. ARMENAKAS, MD\\nClinical Associate Professor, Department of\\nUrology, Weill Cornell Medical College;\\nAttending Physician, Lenox Hill Hospital and\\nNew York Presbyterian Hospital\\nGenitourinary Tract Trauma\\nJ. MALCOLM O. ARNOLD, MD\\nProfessor of Medicine, Physiology and\\nPharmacology, University of Western Ontario;\\nCardiologist, University Hospital, London\\nHealth Sciences Center\\nHeart Failure; Cardiomyopathies\\nALEXANDER AUCHUS, MD\\nProfessor and McCarty Chair of Neurology,\\nUniversity of Mississippi Medical Center\\nDelirium and Dementia; Function and\\nDysfunction of the Cerebral Lobes\\nGEORGE L. BAKRIS, MD\\nProfessor of Medicine and Director,\\nHypertensive Diseases Unit, University\\nof Chicago-Pritzker School of Medicine\\nArterial Hypertension\\nDAVID H. BARAD, MD, MS\\nAssociate Clinical Professor, Albert Einstein\\nCollege of Medicine\\nApproach to the Gynecologic Patient\\nPEGGY P. BARCO, MS, OTR/L\\nProgram in Occupational Therapy,\\nWashington University Medical School;\\nDriving Connections, The Rehabilitation\\nInstitute of Saint Louis\\nThe Older Driver\\nROBERT A. BARISH, MD, MBA\\nProfessor of Emergency Medicine, Chancellor,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n17'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 27, 'page_label': '18'}, page_content=\"Louisiana State University Health Sciences\\nCenter at Shreveport\\nBites and Stings\\nJOHN G. BARTLETT, MD\\nProfessor of Medicine, Johns Hopkins\\nUniversity School of Medicine\\nAcute Bronchitis; Pneumonia; Lung Abscess\\nROSEMARY BASSON, MD\\nClinical Professor, Department of Psychiatry,\\nUniversity of British Columbia and Vancouver\\nHospital\\nSexual Dysfunction in Women\\nBYRON E. BATTEIGER, MD\\nProfessor of Medicine and Microbiology and\\nImmunology, Division of Infectious Diseases,\\nIndiana University School of Medicine\\nChlamydia and Mycoplasmas\\nLEE B. BEERMAN, MD\\nProfessor of Pediatrics, Division of Pediatric\\nCardiology, Children's Hospital of Pittsburgh\\nof UPMC, University of Pittsburgh School of\\nMedicine\\nCongenital Cardiovascular Anomalies\\nJ. BRAD BELLOTTE, MD\\nDirector of Complex Spine Surgery and\\nDirector of Neurotrauma, Department of\\nNeurosurgery, Allegheny General Hospital,\\nPittsburgh\\nSpinal Trauma\\nJOSHUA O. BENDITT, MD\\nProfessor of Medicine, Division of Pulmonary\\nand Critical Care, University of Washington\\nSchool of Medicine; Director of Respiratory\\nCare Medicine, University of Washington\\nMedical Center\\nBronchiectasis\\nJAMES R. BERENSON, MD\\nMedical and Scientific Director, Institute for\\nMyeloma and Bone Cancer Research, West\\nHollywood\\nPlasma Cell Disorders\\nBARBARA J. BERKMAN, DSW, PhD\\nHelen Rehr/Ruth Fitzdale Professor, Columbia\\nUniversity School of Social Work; Principal\\nInvestigator and National Director, Hartford\\nGeriatric Social Work Faculty Scholars Program\\nSocial Issues in the Elderly\\nCHESTON M. BERLIN, Jr., MD\\nUniversity Professor of Pediatrics and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n18\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 28, 'page_label': '19'}, page_content=\"Professor of Pharmacology, Penn State\\nUniversity College of Medicine\\nPrinciples of Drug Treatment in Children\\nJESSICA R. BERMAN, MD\\nAssistant Professor of Medicine, Weill Cornell\\nMedical College; Assistant Attending Physician,\\nHospital for Special Surgery\\nApproach to the Patient With Joint Disease\\nRICHARD W. BESDINE, MD\\nProfessor of Medicine, Greer Professor of\\nGeriatric Medicine, and Director, Division of\\nGeriatrics (Medicine) and of the Center for\\nGerontology and Healthcare Research, The\\nWarren Alpert Medical School of Brown\\nUniversity\\nApproach to the Geriatric Patient; Quality of\\nLife and Therapeutic Objectives\\nADIL E. BHARUCHA, MBBS, MD\\nProfessor of Medicine, Division of\\nGastroenterology and Hepatology, Mayo\\nClinic College of Medicine\\nApproach to the Patient With Lower GI\\nComplaints; Irritable Bowel Syndrome\\nALBERT W. BIGLAN, MD\\nAdjunct Associate Professor of Ophthalmology,\\nUniversity of Pittsburgh School of Medicine;\\nStaff Physician, Children's Hospital of Pittsburgh\\nEye Defects and Conditions in Children\\nJOSEPH J. BIUNDO, MD\\nClinical Professor of Medicine, Tulane Medical\\nCenter\\nBursa, Muscle, and Tendon Disorders\\nSEAN C. BLACKWELL, MD\\nAssistant Professor, Department of Obstetrics,\\nGynecology, and Reproductive Sciences, The\\nUniversity of Texas Health Sciences Center at\\nHouston\\nPregnancy Complicated by Disease\\nRUSSELL BLAIR, MD\\nFellow, Section of Pulmonary, Critical Care,\\nAllergy and Immunologic Diseases, Wake\\nForest University Baptist Medical Center\\nAsthma\\nCHARLES D. BORTLE, EdD\\nDirector of Logistics and Field Operations,\\nDepartment of Emergency Medicine, Albert\\nEinstein Medical Center\\nRespiratory Arrest\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n19\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 29, 'page_label': '20'}, page_content='ANN S. BOTASH, MD\\nProfessor of Pediatrics, State University of\\nNew York, Upstate Medical University\\nChild Maltreatment\\nALFRED A. BOVE, MD, PhD\\nChief of Cardiology, Cardiology Section,\\nTemple University School of Medicine\\nInjury During Diving or Work in Compressed\\nAir\\nTHOMAS G. BOYCE, MD, MPH\\nAssociate Professor of Pediatrics and Consultant\\nin Pediatric Infectious Diseases and Immunology,\\nMayo Clinic College of Medicine\\nGastroenteritis\\nPETER C. BRAZY, MD\\nProfessor of Medicine, University of Wisconsin-\\nMadison\\nRenal Transport Abnormalities; Congenital\\nRenal Transport Abnormalities\\nJEREMY S. BREIT, MD\\nFellow, Section of Pulmonary, Critical Care,\\nAllergy and Immunologic Diseases, Wake Forest\\nUniversity Baptist Medical Center\\nAsthma\\nCHRISTIAN M. BRIERY, MD\\nDirector of Maternal-Fetal Medicine, Willis-\\nKnighton Medical Center, Shreveport\\nHigh-Risk Pregnancy\\nGEORGE R. BROWN, MD\\nProfessor and Associate Chairman, Department\\nof Psychiatry, East Tennessee State University;\\nChief of Psychiatry, James H. Quillen VA\\nMedical Center\\nSexuality and Sexual Disorders\\nHAYWOOD L. BROWN, MD\\nRoy T. Parker Professor and Chair, Department\\nof Obstetrics and Gynecology, Duke\\nUniversity Medical Center\\nNormal Pregnancy, Labor, and Delivery\\nROBERT G. BRZYSKI, MD, PhD\\nAssociate Professor of Obstetrics and\\nGynecology, The University of Texas\\nHealth Science Center at San Antonio\\nFemale Reproductive Endocrinology\\nREBECCA H. BUCKLEY, MD\\nJ. Buren Sidbury Professor of Pediatrics and\\nProfessor of Immunology, Duke University\\nSchool of Medicine\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n20'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 30, 'page_label': '21'}, page_content=\"Immunodeficiency Disorders\\nLARRY M. BUSH, MD\\nAssociate Clinical Professor of Medicine,\\nUniversity of Miami-Miller School of Medicine/\\nFlorida Atlantic University; Chief, Division of\\nInfectious Diseases, JFK Medical Center\\nGram-Positive Bacilli; Gram-Positive Cocci\\nJERROLD T. BUSHBERG, PhD,\\nDABMP\\nClinical Professor of Radiology and Radiation\\nOncology, School of Medicine, University of\\nCalifornia, Davis\\nRadiation Exposure and Contamination\\nJUAN R. BUSTILLO, MD\\nAssociate Professor of Psychiatry and\\nNeurosciences, University of New Mexico\\nSchizophrenia and Related Disorders\\nDAVID B. CARR, MD\\nAssociate Professor of Internal Medicine and\\nNeurology, Washington University School of\\nMedicine-Older Adult Health Center\\nThe Older Driver\\nMARY T. CASERTA, MD\\nAssociate Professor of Pediatrics, Division of\\nInfectious Diseases, University of Rochester\\nSchool of Medicine; Attending Physician,\\nGolisano Children's Hospital at Strong,\\nUniversity of Rochester Medical Center\\nEnteroviruses; Other Viruses; Infections in\\nNeonates\\nBRUCE A. CHABNER, MD\\nProfessor of Medicine, Harvard Medical School;\\nClinical Director, Massachusetts General\\nHospital Cancer Center\\nOverview of Cancer; Principles of Cancer\\nTherapy\\nFREDY CHAPARRO-ROJAS, MD\\nInternal Medicine Resident, University of\\nMiami-Miller School of Medicine/Florida\\nAtlantic University at JFK Medical Center\\nGram-Positive Cocci\\nIAN M. CHAPMAN, MBBS, PhD\\nAssociate Professor of Endocrinology,\\nUniversity of Adelaide, Department of\\nMedicine, Royal Adelaide Hospital\\nPituitary Disorders\\nRACHEL L. CHAPMAN, MD\\nAssociate Professor of Pediatrics, Division of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n21\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 31, 'page_label': '22'}, page_content=\"Neonatal-Perinatal Medicine, University of\\nMichigan, C.S. Mott Children's Hospital\\nApproach to the Care of Normal Infants and\\nChildren; Perinatal Physiology; Caring for\\nSick Children and Their Families\\nWILLIAM J. COCHRAN, MD\\nVice Chairman, Department of Pediatrics,\\nGeisinger Clinic, Danville, PA\\nGastrointestinal Disorders in Neonates and\\nInfants; Congenital Gastrointestinal Anomalies\\nALAN S. COHEN, MD\\nDistinguished Professor of Medicine (Emeritus),\\nConrad Wessolhoeft Professor of Medicine,\\nBoston University School of Medicine; Editor-\\nin-Chief, \\nAmyloid: The Journal of Protein\\nFolding Disorders\\nAmyloidosis\\nROBERT B. COHEN, DMD\\nClinical Associate Professor of Dentistry and\\nPractice Coordinator, Tufts University School\\nof Dental Medicine\\nApproach to Dental and Oral Symptoms\\nSIDNEY COHEN, MD\\nProfessor of Medicine and Director, Research\\nPrograms, Thomas Jefferson University\\nSchool of Medicine\\nGastritis and Peptic Ulcer Disease; Bezoars\\nand Foreign Bodies; Hepatitis\\nKATHRYN COLBY, MD, PhD\\nAssistant Professor of Ophthalmology, Harvard\\nMedical School; Director, Clinical Research\\nCenter, Massachusetts Eye and Ear Infirmary\\nApproach to the Ophthalmologic Patient;\\nCataract; Eye Injuries\\nDANIEL W. COLLISON, MD\\nAssociate Professor of Medicine and Surgery,\\nSection of Dermatology, Dartmouth Medical\\nSchool\\nSweating Disorders; Benign Tumors; Pressure\\nUlcers\\nEVE R. COLSON, MD\\nAssociate Professor of Pediatrics, Yale\\nUniversity School of Medicine; Director, Well\\nNewborn Nursery, Yale-New Haven Children's\\nHospital\\nApproach to the Care of Normal Infants and\\nChildren; Perinatal Physiology; Caring for\\nSick Children and Their Families\\nMARY ANN COOPER, MD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n22\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 32, 'page_label': '23'}, page_content='Professor, Department of Emergency\\nMedicine, University of Illinois at Chicago\\nElectrical and Lightning Injuries\\nWILLIAM CORYELL, MD\\nGeorge Winokur Professor of Psychiatry,\\nUniversity of Iowa\\nMood Disorders\\nBRYAN D. COWAN, MD\\nProfessor and Chairman, Department of\\nObstetrics and Gynecology, University of\\nMississippi Medical Center\\nUterine Fibroids\\nJILL P. CRANDALL, MD\\nAssociate Professor of Clinical Medicine,\\nAlbert Einstein College of Medicine\\nDiabetes Mellitus and Disorders of\\nCarbohydrate Metabolism\\nRICARDO CRUCIANI, MD, PhD\\nClinical Assistant and Professor, Department\\nof Neurology and Anesthesiology, Albert\\nEinstein College of Medicine; Director,\\nResearch Division, Department of Pain\\nMedicine and Palliative Care, Beth Israel\\nMedical Center\\nNeurotransmission\\nBURKE A. CUNHA, MD\\nProfessor of Medicine, State University of\\nNew York School of Medicine, Stony Brook;\\nChief, Infectious Disease Division, Winthrop-\\nUniversity Hospital, Mineola\\nGram-Negative Bacilli; Spirochetes\\nEMMETT T. CUNNINGHAM, Jr., MD,\\nPhD, MPH\\nProfessor of Ophthalmology, Stanford\\nUniversity; Director, The Uveitis Service,\\nCalifornia Pacific Medical Center and Clinic\\nUveitis\\nDREW C. CUTLER, MD\\nAssociate Professor of Pediatrics, Loma Linda\\nUniversity School of Medicine\\nCystic Kidney Disease\\nRALPH E. CUTLER, MD\\n (Deceased)\\nProfessor of Medicine (Emeritus), Loma Linda\\nUniversity School of Medicine; Consultant in\\nNephrology, Loma Linda VA Medical Center\\nObstructive Uropathy; Urinary Tract Infections\\nPATRICIA A. DALY, MD\\nVisiting Assistant Professor of Medicine,\\nUniversity of Virginia; Clinical Endocrinologist,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n23'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 33, 'page_label': '24'}, page_content='University of Virginia; Clinical Endocrinologist,\\nFront Royal Internal Medicine, VA\\nMultiple Endocrine Neoplasia Syndromes\\nDANIEL F. DANZL, MD\\nProfessor and Chair of Emergency Medicine,\\nUniversity of Louisville School of Medicine\\nCold Injury\\nNORMAN L. DEAN, MD\\nFellow (Emeritus), American College of Chest\\nPhysicians; Lifetime Fellow, American College\\nof Physicians\\nDrowning\\nALAN H. DeCHERNEY, MD\\nBranch Chief, Reproductive Biology and\\nMedicine, National Institute of Child Health\\nand Human Development, National Institutes\\nof Health\\nEndometriosis\\nPETER J. DELVES, PhD\\nReader in Immunology, Department of\\nImmunology and Molecular Pathology,\\nDivision of Infection and Immunity, University\\nCollege London\\nBiology of the Immune System; Allergic and\\nOther Hypersensitivity Disorders\\nARA DerMARDEROSIAN, PhD\\nProfessor of Pharmacognosy and Medicinal\\nChemistry, Roth Chair of Natural Products,\\nScientific Director, Complementary and\\nAlternative Medicine Institute, University of\\nthe Sciences in Philadelphia\\nDietary Supplements\\nDEEPINDER K. DHALIWAL, MD\\nAssociate Professor, Department of\\nOphthalmology, University of Pittsburgh\\nSchool of Medicine; Director of Cornea/\\nExternal Disease and Director of Refractive\\nSurgery, University of Pittsburgh Medical\\nCenter Eye Center; Medical Director,\\nUniversity of Pittsburgh Medical Center Laser\\nCenter; Director and Founder, Center for\\nIntegrative Eye Care, University of Pittsburgh\\nRefractive Error\\nA. DAMIAN DHAR, MD, JD\\nPrivate Practice, North Atlanta Dermatology\\nBacterial Skin Infections; Fungal Skin Infections\\nMICHAEL C. DiMARINO, MD\\nClinical Assistant Professor of Medicine,\\nDivision of Gastroenterology and Hepatology,\\nDepartment of Medicine, Thomas Jefferson\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n24'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 34, 'page_label': '25'}, page_content=\"University\\nEsophageal and Swallowing Disorders;\\nDiverticular Disease\\nJAMES G.H. DINULOS, MD\\nAssistant Professor of Medicine and Pediatrics\\n(Medicine), Dartmouth Medical School\\nParasitic Skin Infections; Viral Skin Diseases;\\nCornification Disorders\\nCAROLINE CARNEY DOEBBELING,\\nMD, MSc\\nChief Executive Officer, Cetan Health\\nConsultants LLC; Associate Professor of\\nInternal Medicine and Psychiatry, Indiana\\nUniversity School of Medicine; Research\\nScientist, Regenstrief Institute\\nApproach to the Patient With Mental Symptoms\\nKARL DOGHRAMJI, MD\\nProfessor of Psychiatry and Human Behavior\\nand Medical Director, Jefferson Sleep\\nDisorders Center, Thomas Jefferson University\\nSleep and Wakefulness Disorders\\nDANIEL A. DOYLE, MD\\nAssociate Professor of Pediatrics, Thomas\\nJefferson University; Division of Endocrinology,\\nA.I. duPont Children's Hospital\\nPhysical Growth and Development\\nANTONETTE T. DULAY, MD\\nAssistant Professor, Division of Maternal-\\nFetal Medicine, Department of Obstetrics,\\nGynecology, and Reproductive Sciences,\\nYale University School of Medicine\\nAbnormalities of Pregnancy\\nJEFFREY S. DUNGAN, MD\\nAssociate Professor, Department of Obstetrics\\nand Gynecology, Northwestern University,\\nFeinberg School of Medicine\\nPrenatal Genetic Counseling and Evaluation\\nSOUMITRA R. EACHEMPATI, MD\\nAssociate Professor of Surgery and Public\\nHealth, Weill Cornell Medical College\\nApproach to the Critically Ill Patient\\nMEGAN A. ECONOMIDIS, MD\\nAssociate Director, Fellowship in Family\\nPlanning, Department of Obstetrics and\\nGynecology, Keck School of Medicine,\\nUniversity of Southern California\\nFamily Planning\\nDAVID EIDELBERG, MD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n25\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 35, 'page_label': '26'}, page_content=\"Susan and Leonard Feinstein Professor of\\nNeurology and Neurosurgery, New York\\nUniversity School of Medicine; Director,\\nCenter for Neurosciences, The Feinstein\\nInstitute for Medical Research, North Shore-\\nLong Island Jewish Health System\\nMovement and Cerebellar Disorders\\nSHERMAN ELIAS, MD\\nJohn J. Sciarra Professor and Chair,\\nDepartment of Obstetrics and Gynecology,\\nNorthwestern University, Feinberg School\\nof Medicine; Chairman, Obstetrics and\\nGynecology, Prentice Women's Hospital of\\nNorthwestern Memorial Hospital\\nPrenatal Genetic Counseling and Evaluation\\nNORAH C. FEENY, PhD\\nAssociate Professor, Department of Psychology,\\nCase Western Reserve University\\nMedical Examination of the Rape Victim\\nMICHAEL C. FIORE, MD\\nProfessor of Medicine, University of\\nWisconsin School of Medicine and Public\\nHealth; Director, University of Wisconsin\\nCenter for Tobacco Research and Intervention\\nSmoking Cessation\\nCHIN-TO FONG, MD\\nAssociate Professor of Pediatrics and Medicine,\\nBiochemistry & Biophysics, Medical Humanities\\nand Dentistry; Chief, Division of Genetics,\\nDepartment of Pediatrics and Medicine;\\nUniversity of Rochester School of Medicine\\nand Dentistry\\nInherited Disorders of Metabolism\\nSTEVEN D. FREEDMAN, MD, PhD\\nAssociate Professor of Medicine, Harvard\\nMedical School; Director, The Pancreas\\nCenter, Beth Israel Deaconess Medical Center\\nPancreatitis\\nEMIL J FREIREICH, MD\\nProfessor, Department of Leukemia, and\\nDirector, Adult Leukemia Research Programs,\\nThe University of Texas MD Anderson Cancer\\nCenter\\nLeukemias\\nEUGENE P. FRENKEL, MD\\nProfessor of Internal Medicine and Radiology,\\nPatsy R. and Raymond D. Nasher Distinguished\\nChair in Cancer Research; Elaine Dewey\\nSammons Distinguished Chair in Cancer\\nResearch in honor of Eugene P. Frenkel, MD;\\nand A. Kenneth Pye Professorship in Cancer\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n26\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 36, 'page_label': '27'}, page_content='Research, Harold C. Simmons Comprehensive\\nCancer Center, The University of Texas\\nSouthwestern Medical Center at Dallas\\nIron Overload\\nMARVIN P. FRIED, MD\\nProfessor and Chairman, Department of\\nOtorhinolaryngology-Head & Neck Surgery,\\nAlbert Einstein College of Medicine and\\nMontefiore Medical Center\\nApproach to the Patient With Nasal and\\nPharyngeal Symptoms; Nose and Paranasal\\nSinus Disorders\\nMITCHELL H. FRIEDLAENDER, MD\\nAdjunct Professor, The Scripps Research\\nInstitute; Head, Division of Ophthalmology,\\nScripps Clinic\\nConjunctival and Scleral Disorders\\nDMITRY GABRILOVICH, MD, PhD\\nRobert Rothman Endowed Chair in Cancer\\nResearch, Head, Section of Dendritic Cell\\nBiology, H. Lee Moffitt Cancer Center and\\nResearch Institute; Professor of Oncologic\\nSciences and Molecular Medicine, University\\nof South Florida\\nTumor Immunology\\nSUNIR J. GARG, MD\\nAssistant Professor of Ophthalmology, Thomas\\nJefferson University; Assistant Surgeon, The\\nRetina Service of Wills Eye Institute\\nRetinal Disorders\\nJAMES GARRITY, MD\\nWhitney and Betty MacMillan Professor of\\nOphthalmology, Mayo Clinic\\nEyelid and Lacrimal Disorders; Optic Nerve\\nDisorders; Orbital Diseases\\nBRIAN K. GEHLBACH, MD\\nAssistant Professor of Medicine, Section of\\nPulmonary and Critical Medicine, University\\nof Chicago\\nRespiratory Failure and Mechanical Ventilation\\nJAMES N. GEORGE, MD\\nGeorge Lynn Cross Research Professor,\\nDepartment of Medicine, College of Medicine\\nand Department of Biostatistics and\\nEpidemiology, College of Public Health,\\nThe University of Oklahoma Health Sciences\\nCenter\\nThrombocytopenia and Platelet Dysfunction;\\nBleeding Due to Abnormal Blood Vessels\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n27'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 37, 'page_label': '28'}, page_content=\"DAVID M. GERSHENSON, MD\\nProfessor and Chairman, Department of\\nGynecologic Oncology and J. Taylor Wharton,\\nMD, Distinguished Chair in Gynecologic\\nOncology, The University of Texas MD\\nAnderson Cancer Center\\nGynecologic Tumors\\nELIAS A. GIRALDO, MD\\nAssistant Professor and Senior Associate\\nConsultant, Department of Neurology, Mayo\\nClinic\\nStroke\\nANNE CAROL GOLDBERG, MD\\nAssociate Professor of Medicine, Washington\\nUniversity School of Medicine\\nLipid Disorders\\nSTEPHEN E. GOLDFINGER, MD\\nProfessor of Medicine, Harvard Medical\\nSchool; Physician, Massachusetts General\\nHospital\\nHereditary Periodic Fever Syndromes\\nM. JAY GOODKIND, MD\\nAssociate Professor (Emeritus) of Clinical\\nMedicine, University of Pennsylvania School\\nof Medicine; Chief of Cardiology (Retired),\\nMercer Medical Center\\nCardiac Tumors\\nCARMEN E. GOTA, MD\\nStaff Physician, Department of Rheumatology,\\nCleveland Clinic Foundation\\nVasculitis\\nNORTON J. GREENBERGER, MD\\nClinical Professor of Medicine, Harvard\\nMedical School; Senior Physician, Brigham\\nand Women's Hospital\\nApproach to the Patient With Upper GI\\nComplaints; Diagnostic and Therapeutic GI\\nProcedures\\nJOHN H. GREIST, MD\\nClinical Professor of Psychiatry, University\\nof Wisconsin; Distinguished Senior Scientist,\\nMadison Institute of Medicine\\nAnxiety Disorders\\nASHLEY B. GROSSMAN, MD\\nProfessor of Neuroendocrinology, St.\\nBartholomew's Hospital and The London\\nSchool of Medicine\\nAdrenal Disorders\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n28\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 38, 'page_label': '29'}, page_content=\"JOHN G. GUNDERSON, MD\\nProfessor of Psychiatry, Harvard Medical\\nSchool; Director, Psychosocial and Personality\\nResearch, Borderline Personality Disorder\\nCenter, McLean Hospital\\nPersonality Disorders\\nRULA A. HAJJ-ALI, MD\\nStaff Physician, Center of Vasculitis Care\\nand Research, Department of Rheumatic and\\nImmunologic Disease, Cleveland Clinic\\nFoundation\\nAutoimmune Rheumatic Disorders\\nJESSE B. HALL, MD\\nProfessor of Medicine, Department of\\nAnesthesia and Critical Care and Section\\nChief, Pulmonary and Critical Care Medicine,\\nUniversity of Chicago\\nRespiratory Failure and Mechanical Ventilation\\nJUDITH G. HALL, MD\\nProfessor Emeritus of Pediatrics and Medical\\nGenetics, University of British Columbia\\nGeneral Principles of Medical Genetics\\nJOHN W. HALLETT, Jr., MD\\nClinical Professor of Surgery, Medical\\nUniversity of South Carolina; Medical Director\\nand Vascular Surgeon, Roper St. Francis Heart\\nand Vascular Center\\nDiseases of the Aorta and Its Branches;\\nPeripheral Arterial Disorders\\nKEVIN C. HAZEN, PhD\\nProfessor of Pathology and Microbiology\\nand Director of Clinical Microbiology and\\nMolecular Diagnostics-Infectious Disease,\\nUniversity of Virginia Health System\\nLaboratory Diagnosis of Infectious Disease\\nR. PHILLIPS HEINE, MD\\nAssociate Professor, Division of Maternal-\\nFetal Medicine, Department of Obstetrics and\\nGynecology, Duke University Medical Center\\nApproach to the Pregnant Woman and Prenatal\\nCare\\nMELISSA R. HELD, MD\\nAssistant Professor of Pediatrics, University of\\nConnecticut School of Medicine; Director,\\nInpatient Pediatrics Clerkship, Connecticut\\nChildren's Medical Center\\nApproach to the Care of Normal Infants and\\nChildren\\nSUSAN L. HENDRIX, DO\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n29\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 39, 'page_label': '30'}, page_content=\"Clinical Professor, Department of Obstetrics and\\nGynecology, Michigan State University School\\nof Osteopathic Medicine, and a partner in Hutzel\\nWomen's Hospital at the Detroit Medical Center\\nMenopause\\nSTEVEN K. HERRINE, MD\\nProfessor of Medicine, Division of\\nGastroenterology and Hepatology, Thomas\\nJefferson University; Assistant Dean for\\nAcademic Affairs, Jefferson Medical College\\nApproach to the Patient With Liver Disease;\\nDrugs and the Liver; Liver Masses and\\nGranulomas\\nJEROME M. HERSHMAN, MD\\nDistinguished Professor of Medicine, David\\nGeffen School of Medicine, University of\\nCalifornia, Los Angeles; Associate Chief,\\nEndocrinology and Diabetes Division, West\\nLos Angeles VA Medical Center\\nThyroid Disorders\\nMARTIN HERTL, MD, PhD\\nAssistant Professor of Surgery, Harvard\\nMedical School; Surgical Director, Liver\\nTransplantation Program, Massachusetts\\nGeneral Hospital\\nTransplantation\\nROBERT M. A. HIRSCHFELD, MD\\nHarry K. Davis Professor, Titus H. Harris\\nChair, Department of Psychiatry and\\nBehavioral Sciences, The University of Texas\\nMedical Branch at Galveston\\nSuicidal Behavior\\nBRIAN D. HOIT, MD\\nProfessor of Medicine and Physiology and\\nBiophysics, Case Western Reserve University;\\nDirector of Echocardiography, University\\nHospitals of Cleveland\\nPericarditis\\nWAUN KI HONG, MD\\nAmerican Cancer Society Professor and\\nSamsung Distinguished University Chair in\\nCancer Medicine; Professor of Medicine,\\nDepartment of Thoracic/Head and Neck\\nMedical Oncology, and Head, Division of\\nCancer Medicine, The University of Texas\\nMD Anderson Cancer Center\\nTumors of the Lungs\\nDANIEL A. HUSSAR, PhD\\nRemington Professor of Pharmacy, Philadelphia\\nCollege of Pharmacy, University of the Sciences\\nin Philadelphia\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n30\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 40, 'page_label': '31'}, page_content='Concepts in Pharmacotherapy\\nMICHAEL JACEWICZ, MD\\nProfessor of Neurology, University of\\nTennessee Health Science Center; Assistant\\nChief of Neurology, VA Medical Center,\\nMemphis\\nApproach to the Neurologic Patient;\\nNeuro-Ophthalmologic and Cranial Nerve\\nDisorders; Meningitis; Brain Infections\\nHARRY S. JACOB, MD\\nProfessor of Medicine, University of\\nMinnesota Medical School; Editor-in-Chief,\\nHematology/Oncology Today\\nSpleen Disorders\\nJON A. JACOBSON, MD\\nAssociate Professor of Radiology, University\\nof Michigan\\nPrinciples of Radiologic Imaging\\nNAVIN JAIPAUL, MD, MHS\\nAssistant Professor of Medicine, Loma Linda\\nUniversity School of Medicine; Staff\\nNephrologist, VA Loma Linda Healthcare\\nSystem\\nTubulointerstitial Diseases\\nJAMES W. JEFFERSON, MD\\nClinical Professor of Psychiatry, University of\\nWisconsin; Distinguished Senior Scientist,\\nMadison Institute of Medicine\\nAnxiety Disorders\\nJANI R. JENSEN, MD\\nFellow, Reproductive Endocrinology and\\nInfertility, The University of Texas Health\\nScience Center at San Antonio\\nFemale Reproductive Endocrinology\\nLARRY E. JOHNSON, MD, PhD\\nAssociate Professor of Geriatrics and\\nFamily and Preventive Medicine, University\\nof Arkansas for Medical Sciences; Attending\\nPhysician, Central Arkansas Veterans\\nHealthcare System\\nVitamin Deficiency, Dependency, and Toxicity;\\nMineral Deficiency and Toxicity\\nROBERT G. JOHNSON, MD\\nC. Rollins Hanlon Professor and Chair,\\nDepartment of Surgery, Saint Louis University\\nSchool of Medicine\\nCare of the Surgical Patient\\nBRIAN D. JOHNSTON\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n31'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 41, 'page_label': '32'}, page_content=\"Fitness Clinician and Educator with the\\nInternational Association of Resistance\\nTrainers, Ontario\\nExercise and Sports Injury\\nHUGH F. JOHNSTON, MD\\nClinical Associate Professor, Department of\\nPsychiatry and Office of Continuing Medical\\nEducation, University of Wisconsin Medical\\nSchool; Medical Director, Bureau of Mental\\nHealth and Substance Abuse\\nMental Disorders in Children and Adolescents\\nTHOMAS V. JONES, MD, MPH\\nDirector, Inflammatory Diseases, Specialty\\nCare Business Unit, Pfizer\\nMotion Sickness\\nNICHOLAS JOSPE, MD\\nProfessor of Pediatrics, University of\\nRochester School of Medicine and Dentistry\\nMetabolic, Electrolyte, and Toxic Disorders in\\nNeonates; Endocrine Disorders in Children\\nMICHAEL J. JOYCE, MD\\nAssociate Clinical Professor, Orthopaedic\\nSurgery, Case Western Reserve University;\\nOrthopaedic Surgeon, Cleveland Clinic\\nTumors of Bones and Joints\\nJAMES O. JUDGE, MD\\nAssociate Clinical Professor of Medicine,\\nUniversity of Connecticut School of Medicine;\\nMedical Director, Evercare Connecticut\\nGait Disorders in the Elderly\\nANAND D. KANTAK, MD\\nClinical Associate Professor of Pediatrics,\\nNortheastern Ohio Universities Colleges of\\nMedicine and Pharmacology, Rootstown;\\nDirector, Division of Neonatology, Akron\\nChildren's Hospital\\nRespiratory Disorders in Neonates, Infants,\\nand Young Children\\nDANIEL B. KAPLAN, MSW\\nDoctoral Student, Columbia University School\\nof Social Work; Program Evaluator, Hartford\\nFaculty Scholars Program\\nSocial Issues in the Elderly\\nKENNETH M. KAYE, MD\\nAssistant Professor, Division of Infectious\\nDiseases, Department of Medicine, Brigham and\\nWomen's Hospital, Harvard Medical School\\nViruses; Herpesviruses; Arboviridae,\\nArenaviridae, and Filoviridae\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n32\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 42, 'page_label': '33'}, page_content='JAMES W. KENDIG, MD\\n (Deceased)\\nProfessor of Pediatrics, Penn State University\\nCollege of Medicine\\nPerinatal Problems\\nTALMADGE E. KING, Jr., MD\\nChief, Department of Medicine; Julius R.\\nKrevans Distinguished Professorship in\\nInternal Medicine, University of California,\\nSan Francisco\\nInterstitial Lung Diseases\\nJAMES P. KNOCHEL, MD\\nClinical Professor of Internal Medicine, The\\nUniversity of Texas Southwestern Medical\\nCenter at Dallas; Past Chairman, Department\\nof Internal Medicine, Presbyterian Hospital of\\nDallas\\nHeat Illness\\nKAREN BIRCKELBAW KOPACEK, RPh\\nClinical Assistant Professor and Clinical\\nPharmacist, Division of Pharmacy Practice,\\nUniversity of Wisconsin School of Pharmacy\\nPharmacokinetics\\nDAVID N. KORONES, MD\\nAssociate Professor of Pediatrics, Oncology,\\nand Neurology, University of Rochester\\nMedical Center\\nPediatric Cancers\\nJULES Y.T. LAM, MD\\nAssociate Professor of Medicine, University\\nof Montreal; Cardiologist, Montreal Heart\\nInstitute\\nArteriosclerosis\\nLEWIS LANDSBERG, MD\\nIrving S. Cutter Professor of Medicine and\\nDean (Emeritus), Northwestern University\\nMultiple Endocrine Neoplasia Syndromes\\nNOAH LECHTZIN, MD, MHS\\nAssistant Professor, Department of Medicine,\\nDivision of Pulmonary and Critical Care\\nMedicine, Johns Hopkins University School of\\nMedicine\\nApproach to the Patient With Pulmonary\\nSymptoms; Diagnostic and Therapeutic\\nPulmonary Procedures\\nMATHEW H.M. LEE, MD\\nHoward A. Rusk Professor of Rehabilitation\\nMedicine and Chairman, Department of\\nRehabilitation Medicine, New York University\\nSchool of Medicine\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n33'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 43, 'page_label': '34'}, page_content=\"School of Medicine\\nRehabilitation\\nJOSEPH R. LENTINO, MD, PhD\\nProfessor of Medicine, Loyola University\\nStritch School of Medicine; Chief, Infectious\\nDiseases, Hines VA Hospital\\nAnaerobic Bacteria\\nWENDY S. LEVINBOOK, MD\\nAssistant Professor of Dermatology,\\nUniversity of Connecticut Health Center\\nHair Disorders\\nMATTHEW E. LEVISON, MD\\nAdjunct Professor of Medicine, Drexel\\nUniversity College of Medicine; Professor,\\nSchool of Public Health, Drexel University\\nBacteria and Antibacterial Drugs\\nRICHARD LEVITAN, MD\\nAssociate Professor of Emergency Medicine,\\nThomas Jefferson University Hospitals;\\nPresident, Airway Cam Tech, Inc.\\nRespiratory Arrest\\nSHARON LEVY, MD, MPH\\nAssistant Professor of Pediatrics, Harvard\\nMedical School; Center for Adolescent\\nSubstance Abuse Research, Children's\\nHospital, Boston\\nApproach to the Care of Adolescents\\nJAMES L. LEWIS, III, MD\\nNephrology Associates, P.C. of Birmingham\\nFluid and Electrolyte Metabolism; Acid-Base\\nRegulation and Disorders\\nALAN E. LICHTIN, MD\\nAssociate Professor, Department of Medicine,\\nCleveland Clinic Lerner College of Medicine\\nof Case Western Reserve; Staff Physician,\\nHematologic Oncology and Blood Disorders,\\nCleveland Clinic\\nApproach to the Patient With Anemia; Anemias\\nCaused by Deficient Erythropoiesis; Anemias\\nCaused by Hemolysis\\nPAUL LAWRENCE LIEBERT, MD\\nPrivate Practice, Tomah Memorial Hospital,\\nTomah, WI\\nExercise and Sports Injury\\nRICHARD W. LIGHT, MD\\nProfessor of Medicine, Division of Allergy,\\nPulmonary, and Critical Care Medicine,\\nVanderbilt University Medical Center\\nMediastinal and Pleural Disorders\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n34\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 44, 'page_label': '35'}, page_content=\"GREGORY S. LIPTAK, MD, MPH\\nProfessor of Pediatrics, and Director, Center\\nfor Development, Behavior, and Genetics,\\nUpstate Medical University\\nCongenital Craniofacial and Musculoskeletal\\nAbnormalities; Congenital Neurologic Anomalies;\\nChromosomal Anomalies\\nJEFFREY M. LIPTON, MD, PhD\\nChief, Hematology/Oncology, Schneider\\nChildren's Hospital; Professor of Pediatrics,\\nAlbert Einstein College of Medicine\\nHistiocytic Syndromes\\nELLIOT M. LIVSTONE, MD\\nAttending Physician, Sarasota Memorial\\nHospital, Sarasota, FL\\nTumors of the GI Tract\\nPHILIP LOW, MD\\nRobert D. and Patricia E. Kern Professor of\\nNeurology, Mayo Clinic College of Medicine\\nAutonomic Nervous System\\nPAUL D. LUI, MD\\nAssociate Professor of Urology, Loma Linda\\nUniversity School of Medicine\\nVoiding Disorders; Penile and Scrotal\\nDisorders\\nJOANNE LYNN, MD, MA, MS\\nClinical Improvement Expert, Colorado\\nFoundation for Medical Care\\nThe Dying Patient\\nROBERT J. MacNEAL, MD\\nAssistant Professor, Department of General\\nInternal Medicine and Section of Dermatology,\\nDartmouth Hitchcock Medical Center\\nApproach to the Dermatologic Patient;\\nReactions to Sunlight\\nMARCELLA A. MADERA, MD\\nInstructor, Department of Neurosurgery, Johns\\nHopkins University School of Medicine\\nTraumatic Brain Injury\\nKENNETH MAIESE, MD\\nProfessor and Chair, Department of Neurology\\nand Neurosciences, University of Dentistry and\\nMedicine of New Jersey\\nComa and Impaired Consciousness\\nJAMES F. MARKMANN, MD, PhD\\nProfessor of Surgery, Harvard Medical School;\\nClinical Director, Division of Transplantation,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n35\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 45, 'page_label': '36'}, page_content=\"Massachusetts General Hospital\\nTransplantation\\nJOHN T. McBRIDE, MD\\nProfessor of Pediatrics, Northeastern Ohio\\nUniversities Colleges of Medicine and\\nPharmacology, Rootstown; Vice-Chair,\\nDepartment of Pediatrics, Akron Children's\\nHospital\\nRespiratory Disorders in Neonates, Infants,\\nand Young Children\\nMARGARET C. McBRIDE, MD\\nProfessor of Pediatrics (Neurology),\\nNortheastern Ohio Universities Colleges of\\nMedicine and Pharmacology, Rootstown;\\nDirector, Neurodevelopmental Center,\\nAkron Children's Hospital\\nNeurologic Disorders in Children;\\nNeurocutaneous Syndromes\\nDANIEL J. McCARTY, MD\\nWill and Cava Ross Professor of Medicine\\n(Emeritus), Medical College of Wisconsin\\nCrystal-Induced Arthritides\\nJ. ALLEN McCUTCHAN, MD, MSc\\nProfessor of Medicine, Division of Infectious\\nDiseases, School of Medicine, University of\\nCalifornia at San Diego\\nHuman Immunodeficiency Virus; Sexually\\nTransmitted Diseases\\nDOUGLAS L. McGEE, DO\\nDirector, Emergency Medicine Residency\\nProgram, Albert Einstein Medical Center;\\nChief Academic Officer, Albert Einstein\\nHealthcare Network\\nClinical Decision Making\\nDANIEL E. McGINLEY-SMITH, MD\\nPrivate Practice, New England Dermatology,\\nLebanon, NH; Staff Dermatologist, New London\\nHospital\\nPigmentation Disorders\\nROBERT S. McKELVIE, MD, PhD, MSc\\nProfessor of Medicine, McMaster University;\\nMedical Director, Cardiac Health and\\nRehabilitation Center\\nSports and the Heart\\nKAREN McKOY, MD, MPH\\nAssistant Professor in Clinical Dermatology,\\nHarvard Medical School; Senior Staff, Group\\nPractice, Department of Dermatology, Lahey\\nClinic Medical Center\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n36\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 46, 'page_label': '37'}, page_content=\"Acne and Related Disorders; Dermatitis;\\nPrinciples of Topical Dermatologic Therapy\\nJAMES I. McMILLAN, MD\\nAssociate Professor of Medicine, Loma Linda\\nUniversity; Chief of Nephrology, VA Loma\\nLinda Healthcare System\\nRenal Failure; Renal Replacement Therapy;\\nGlomerular Disorders\\nS. GENE McNEELEY, MD\\nChief of Gynecology, Hutzel Women's\\nHospital; Clinical Professor, Michigan State\\nUniversity, College of Osteopathic Medicine,\\nHutzel Women's Health Specialists\\nBenign Gynecologic Lesions; Pelvic Relaxation\\nSyndromes\\nNOSHIR R. MEHTA, DMD, MDS, MS\\nProfessor and Chairman of General Dentistry;\\nAssistant Dean, International Relations; and\\nDirector, Craniofacial Pain Center, Tufts\\nUniversity School of Dental Medicine\\nTemporomandibular Disorders\\nDANIEL R. MISHELL, Jr., MD\\nThe Lyle G. McNeile Professor, Department\\nof Obstetrics and Gynecology, Keck School of\\nMedicine, University of Southern California;\\nChief Physician, Women's and Children's\\nHospital, Los Angeles County and University\\nof Southern California Medical Center\\nFamily Planning\\nL. BRENT MITCHELL, MD\\nProfessor and Head, Department of Cardiac\\nSciences, University of Calgary; Director,\\nLibin Cardiovascular Institute of Alberta,\\nCalgary Health Region and University of\\nCalgary\\nArrhythmias and Conduction Disorders\\nRICHARD T. MIYAMOTO, MD\\nArilla Spence DeVault Professor and\\nChairman, Department of Otolaryngology-\\nHead & Neck Surgery, Indiana University\\nSchool of Medicine\\nMiddle Ear and Tympanic Membrane Disorders\\nJOEL L. MOAKE, MD\\nSenior Research Scientist, Rice University;\\nProfessor of Medicine (Emeritus), Baylor\\nCollege of Medicine\\nHemostasis; Coagulation Disorders;\\nThrombotic Disorders\\nJULIE S. MOLDENHAUER, MD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n37\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 47, 'page_label': '38'}, page_content=\"Attending Physician, The Center for Fetal\\nDiagnosis and Treatment, The Children's\\nHospital of Philadelphia\\nAbnormalities and Complications of Labor and\\nDelivery; Postpartum Care\\nJOHN E. MORLEY, MB, BCh\\nDammert Professor of Gerontology and\\nDirector, Division of Geriatric Medicine, Saint\\nLouis University Medical Center; Director,\\nGeriatric Research, Education and Clinical\\nCenter, St. Louis VA Medical Center\\nUndernutrition; Principles of Endocrinology\\nANGELA CAFIERO MORONEY,\\nPharmD\\nSenior Clinical Science Manager and Global\\nPharmaceutical Research and Development,\\nAbbott Laboratories\\nPharmacodynamics\\nALEX MOROZ, MD\\nAssistant Professor, Department of\\nRehabilitation Medicine, New York\\nUniversity School of Medicine; Director of\\nMusculoskeletal Rehabilitation Unit and\\nDirector of Residency Training and Medical\\nEducation, Rusk Institute of Rehabilitation\\nMedicine\\nRehabilitation\\nJOHN MORRISON, MD\\nProfessor of Obstetrics/Gynecology and\\nPediatrics, University of Mississippi Medical\\nCenter\\nHigh-Risk Pregnancy\\nSAM P. MOST, MD\\nChief, Division of Facial Plastic and\\nReconstructive Surgery, Stanford University\\nFacial Trauma\\nDAVID F. MURCHISON, DDS, MMS\\nColonel, United States Air Force; Director, Air\\nForce Dental Operations, United States Air Force\\nDental Service, Lackland-Kelly Air Force Base\\nDental Emergencies\\nCARLENE A. MUTO, MD, MS\\nAssistant Professor, Epidemiology and\\nMedicine, Division of Infectious Diseases,\\nUniversity of Pittsburgh School of Medicine;\\nMedical Director of Infection Control, Donald\\nD. Wolff, Jr. Center for Quality Improvement\\nand Innovation, University of Pittsburgh\\nMedical Center Health System\\nNeisseriaceae\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n38\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 48, 'page_label': '39'}, page_content=\"RAJ K. NARAYAN, MD\\nFrank H. Mayfield Professor and Chairman,\\nThe Neuroscience Institute, Department of\\nNeurosurgery, University of Cincinnati\\nCollege of Medicine and Mayfield Clinic\\nTraumatic Brain Injury\\nEDWARD A. NARDELL, MD\\nAssociate Professor, Harvard Medical School,\\nHarvard School of Public Health, Brigham and\\nWomen's Hospital\\nMycobacteria\\nVICTOR J. NAVARRO, MD\\nProfessor of Medicine, Pharmacology and\\nExperimental Therapeutics and Medical\\nDirector, Hepatology and Liver Transplantation\\nProgram, Jefferson Medical College, Thomas\\nJefferson University\\nDrugs and the Liver\\nJOHN H. NEWMAN, MD\\nElsa S. Hanigan Professor of Pulmonary\\nMedicine, Vanderbilt University School of\\nMedicine\\nPulmonary Embolism; Pulmonary Hypertension\\nLEE S. NEWMAN, MD, MA\\nProfessor, Department of Environmental and\\nOccupational Health, Colorado School of\\nPublic Health and Department of Medicine,\\nUniversity of Colorado at Denver\\nEnvironmental Pulmonary Diseases;\\nSarcoidosis\\nJENNIFER R. NIEBYL, MD\\nProfessor, Department of Obstetrics and\\nGynecology, University of Iowa Carver\\nCollege of Medicine\\nConception and Prenatal Development\\nMARY LYNN R. NIERODZIK, MD\\nAssistant Professor, New York University\\nSchool of Medicine; Chief, Hematology/\\nOncology, Bellevue Hospital Center\\nEosinophilic Disorders\\nJAMES M. O'BRIEN, Jr., MD, MSc\\nAssociate Professor, Center for Critical Care,\\nDivision of Pulmonary, Allergy, Critical Care\\nand Sleep Medicine, The Ohio State University\\nMedical Center\\nTests of Pulmonary Function\\nPATRICK G. O'CONNOR, MD, MPH\\nProfessor of Medicine; Chief, Section of\\nGeneral Internal Medicine, Yale University\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n39\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 49, 'page_label': '40'}, page_content=\"School of Medicine\\nDrug Use and Dependence\\nGERALD F. O'MALLEY, DO\\nClinical Research Director, Thomas Jefferson\\nUniversity\\nPoisoning\\nJOHN S. OGHALAI, MD\\nAssistant Professor of Otology, Neurotology,\\nand Skull Base Surgery, Baylor College of\\nMedicine; Director, The Hearing Center at\\nTexas Children's Hospital\\nInner Ear Disorders\\nJAMES T. PACALA, MD, MS\\nAssociate Professor and Distinguished\\nUniversity Teaching Professor, Family\\nPractice and Community Health, University\\nof Minnesota Medical School\\nPrevention of Disease and Disability in the\\nElderly\\nSTEVEN A. PAGET, MD\\nProfessor of Medicine and Physician in Chief,\\nDivision of Rheumatology, Hospital for\\nSpecial Surgery and Weill Cornell Medical\\nCollege\\nApproach to the Patient With Joint Disease\\nELIZABETH J. PALUMBO, MD\\nPrivate Practice, The Pediatric Group, Fairfax,\\nVA\\nMiscellaneous Disorders in Infants and\\nChildren\\nDAVID A. PAUL, MD\\nProfessor of Pediatrics, Jefferson Medical\\nCollege, Thomas Jefferson University;\\nAttending Neonatologist, Christiana Care\\nHealth System\\nPerinatal Hematologic Disorders\\nRICHARD D. PEARSON, MD\\nProfessor of Medicine and Pathology,\\nAssociate Dean for Student Affairs, University\\nof Virginia School of Medicine\\nApproach to Parasitic Infections; Nematodes;\\nTrematodes; Cestodes; Intestinal Protozoa;\\nExtraintestinal Protozoa\\nLAWRENCE L. PELLETIER, Jr., MD\\nProfessor, Internal Medicine, University of\\nKansas School of Medicine; Staff Physician,\\nRobert J. Dole VA Medical and Regional\\nOffice Center, Wichita\\nEndocarditis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n40\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 50, 'page_label': '41'}, page_content='MARIA T. PEREZ, MD\\nAssociate Pathologist, Department of\\nPathology and Laboratory Medicine,\\nWellington Regional Medical Center,\\nWest Palm Beach\\nGram-Positive Bacilli; Gram-Positive Cocci\\nFRANK PESSLER, MD, PhD\\nPediatric Rheumatologist, Klinik und\\nPoliklinic fur Kinder und Jugendmedizin,\\nMedizinische Fakultat Carl-Gustav-Carus,\\nTechnische Universitat Dresden, Germany\\nRheumatic Fever; Bone and Connective\\nTissue Disorders in Children\\nSTEPHEN P. PETERS, MD, PhD\\nProfessor of Medicine and Pediatrics and\\nAssociate Director, Center for Human\\nGenomics, Wake Forest University Health\\nSciences\\nAsthma\\nWILLIAM A. PETRI, Jr., MD, PhD\\nWade Hampton Frost Professor of\\nEpidemiology and Chief, Division of\\nInfectious Diseases and International Health,\\nUniversity of Virginia School of Medicine\\nRickettsiae and Related Organisms\\nKATHARINE A. PHILLIPS, MD\\nProfessor of Psychiatry and Human Behavior,\\nButler Hospital and The Warren Alpert\\nMedical School of Brown University\\nSomatoform and Factitious Disorders\\nJoANN V. PINKERTON, MD\\nProfessor of Obstetrics and Gynecology\\nand Director, Midlife Health, University of\\nVirginia Health System\\nMenstrual Abnormalities\\nRUSSELL K. PORTENOY, MD\\nProfessor of Neurology and Anesthesiology,\\nAlbert Einstein College of Medicine;\\nChairman, Department of Pain Medicine and\\nPalliative Care, Beth Israel Medical Center\\nPain\\nCAROL S. PORTLOCK, MD\\nProfessor of Clinical Medicine, Weill Cornell\\nMedical College; Attending Physician,\\nLymphoma Service, Memorial Sloan-Kettering\\nCancer Center\\nLymphomas\\nMICHAEL POURFAR, MD\\nAssistant Professor, Department of Medicine,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n41'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 51, 'page_label': '42'}, page_content=\"New York University School of Medicine\\nMovement and Cerebellar Disorders\\nJOSEF T. PRCHAL, MD\\nProfessor of Medicine, Division of Hematology,\\nUniversity of Utah; George E. Wahlen VA\\nMedical Center\\nMyeloproliferative Disorders\\nGLENN M. PREMINGER, MD\\nProfessor of Urologic Surgery and Director,\\nComprehensive Kidney Stone Center, Duke\\nUniversity Medical Center\\nUrinary Calculi\\nSALLY PULLMAN-MOOAR, MD\\nClinical Associate Professor, Department\\nof Medicine, Division of Rheumatology,\\nUniversity of Pennsylvania; Chief, Department\\nof Rheumatology, Philadelphia VA Medical\\nCenter\\nNeck and Back Pain\\nRONALD RABINOWITZ, MD\\nProfessor of Urology and Pediatrics,\\nUniversity of Rochester School of Medicine and\\nDentistry; Chief of Pediatric Urology, Strong\\nMemorial and Rochester General Hospitals\\nCongenital Renal and Genitourinary Anomalies\\nLAWRENCE G. RAISZ, MD\\n (Deceased)\\nBoard of Trustees Distinguished Professor\\nof Medicine and Director, UConn Center for\\nOsteoporosis, University of Connecticut\\nHealth Center\\nOsteoporosis\\nPEDRO T. RAMIREZ, MD\\nAssistant Professor, Gynecologic Oncology\\nDepartment, The University of Texas MD\\nAnderson Cancer Center\\nGynecologic Tumors\\nLEONARD RAPPAPORT, MD, MS\\nMary Demig Scott Professor of Pediatrics,\\nHarvard Medical School; Chief, Division of\\nDevelopmental Medicine, Children's Hospital\\nIncontinence in Children\\nROBERT W. REBAR, MD\\nExecutive Director, American Society for\\nReproductive Medicine; Volunteer Clinical\\nProfessor, Department of Obstetrics and\\nGynecology, University of Alabama\\nInfertility\\nWINGFIELD E. REHMUS, MD, MPH\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n42\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 52, 'page_label': '43'}, page_content='Clinical Assistant Professor, University of\\nBritish Columbia\\nHypersensitivity and Inflammatory Disorders;\\nNail Disorders\\nDOUGLAS J. RHEE, MD\\nAssistant Professor, Massachusetts Eye and\\nEar Infirmary, Harvard Medical School\\nGlaucoma\\nMELVIN I. ROAT, MD\\nClinical Associate Professor, Wills Eye Institute,\\nDepartment of Ophthalmology, Jefferson\\nMedical College, Thomas Jefferson University\\nCorneal Disorders\\nJAMES R. ROBERTS, MD\\nProfessor and Vice Chairman, Department\\nof Emergency Medicine, Drexel University\\nCollege of Medicine; Chair, Department of\\nEmergency Medicine and Director, Division\\nof Toxicology, Mercy Catholic Medical Center\\nFractures, Dislocations, and Sprains; Heat\\nIllness\\nKENNETH B. ROBERTS, MD\\nProfessor of Pediatrics, University of North\\nCarolina School of Medicine; Director,\\nPediatric Teaching Program, Moses Cone\\nHealth System, Greensboro\\nDehydration and Fluid Therapy\\nBERYL J. ROSENSTEIN, MD\\nProfessor of Pediatrics, Johns Hopkins\\nUniversity School of Medicine\\nCystic Fibrosis\\nSTEVEN ROSENZWEIG, MD\\nClinical Associate Professor, Drexel\\nUniversity College of Medicine\\nComplementary and Alternative Medicine\\nNOELLE ROTONDO, DO\\nClinical Assistant Professor of Emergency\\nMedicine, Penn State Hershey Medical Center;\\nAdjunct Clinical Professor of Emergency\\nMedicine, Drexel University College of\\nMedicine\\nApproach to the Trauma Patient\\nROBERT J. RUBEN, MD\\nDistinguished University Professor,\\nDepartment of Otorhinolaryngology-Head &\\nNeck Surgery, Albert Einstein College of\\nMedicine and Montefiore Medical Center\\nHearing Loss\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n43'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 53, 'page_label': '44'}, page_content='FRED H. RUBIN, MD\\nProfessor of Medicine, University of\\nPittsburgh, School of Medicine; Chair,\\nDepartment of Medicine, University of\\nPittsburgh Medical Center Presbyterian\\nShadyside Hospital, Shadyside Campus\\nImmunization\\nMICHAEL RUBIN, MD\\nProfessor of Clinical Neurology,\\nWeill Cornell Medical College; Director,\\nNeuromuscular Service and EMG Laboratory,\\nNew York Presbyterian Hospital-Cornell\\nMedical Center\\nCraniocervical Junction Abnormalities;\\nInherited Muscular Disorders; Spinal Cord\\nDisorders; Peripheral Nervous System and\\nMotor Unit Disorders\\nATENODORO R. RUIZ, Jr., MD\\nSenior Attending Physician, Department of\\nMedicine-Gastroenterology, Kaiser Permanente,\\nSanta Clara\\nMalabsorption Syndromes\\nJ. MARK RUSCIN, PharmD\\nProfessor, Department of Pharmacy Practice,\\nSouthern Illinois University Edwardsville School\\nof Pharmacy\\nDrug Therapy in the Elderly\\nJULIE E. RUSSAK, MD\\nMelanoma Fellow, Rigel Dermatology\\n(Private Practice Associated With New York\\nUniversity Medical Center)\\nBullous Diseases\\nPAUL S. RUSSELL, MD\\nJohn Homans Distinguished Professor of\\nSurgery, Harvard Medical School; Senior\\nSurgeon, Massachusetts General Hospital\\nTransplantation\\nCHARLES SABATINO, JD\\nAdjunct Professor, Georgetown University\\nLaw Center; Director, Commission on Law\\nand Aging, American Bar Association\\nMedicolegal Issues\\nDAVID B. SACHAR, MD\\nClinical Professor of Medicine, Mount Sinai\\nSchool of Medicine; Director (Emeritus),\\nDr. Henry D. Janowitz Division of\\nGastroenterology, The Mount Sinai Hospital\\nInflammatory Bowel Disease\\nSEYED-ALI SADJADI, MD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n44'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 54, 'page_label': '45'}, page_content='Associate Professor of Medicine, Loma Linda\\nUniversity School of Medicine\\nApproach to the Genitourinary Patient;\\nRenovascular Disorders\\nSCOTT SAMUELSON, MD\\nInstructor of Medicine, Hematology Division,\\nUniversity of Utah; Attending Physician, Utah\\nCancer Specialists\\nMyeloproliferative Disorders\\nCHRISTOPHER SANFORD, MD, MPH,\\nDTM&H\\nClinical Assistant Professor, Department of\\nFamily Medicine; Co-Director, Travel Clinic,\\nHall Health Center, University of Washington\\nMedical Aspects of Travel\\nRAVINDRA SARODE, MD\\nProfessor of Pathology and Director,\\nTransfusion Medicine and Hemostasis\\nLaboratory, The University of Texas\\nSouthwestern Medical Center at Dallas\\nTransfusion Medicine\\nCLARENCE T. SASAKI, MD\\nThe Charles W. Oshe Professor of Surgery\\nand Chief of Otolaryngology, Yale School\\nof Medicine; Director, Head and Neck\\nTumor Board, Yale Comprehensive Cancer\\nCenter\\nLaryngeal Disorders, Oral and Pharyngeal\\nDisorders\\nPETER C. SCHALOCK, MD\\nInstructor in Dermatology, Harvard Medical\\nSchool; Assistant in Dermatology,\\nMassachusetts General Hospital\\nPsoriasis and Scaling Diseases\\nSTEVEN SCHMITT, MD\\nHead, Section of Bone and Joint Infections,\\nDepartment of Infectious Disease, Cleveland\\nClinic\\nInfections of Joints and Bones\\nMARVIN I. SCHWARZ, MD\\nThe James C. Campbell Professor of\\nPulmonary Medicine, Division of Pulmonary\\nSciences and Critical Care Medicine,\\nUniversity of Colorado Denver\\nDiffuser Alveolar Hemorrhage and Pulmonary-\\nRenal Syndromes\\nELDON A. SHAFFER, MD\\nProfessor of Medicine, Faculty of Medicine,\\nUniversity of Calgary\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n45'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 55, 'page_label': '46'}, page_content=\"Testing for Hepatic and Biliary Disorders;\\nAlcoholic Liver Disease; Fibrosis and Cirrhosis;\\nVascular Disorders of the Liver; Gallbladder\\nand Bile Duct Disorders\\nSTEWART SHANKEL, MD\\nClinical Professor of Medicine and Director\\nof Clinical Instruction, University of California,\\nRiverside\\nUrinary Tract Infections\\nWILLIAM R. SHAPIRO, MD\\nProfessor of Clinical Neurology, University\\nof Arizona College of Medicine, Tucson;\\nChief, Neuro-oncology, Barrow Neurological\\nInstitute\\nIntracranial and Spinal Tumors\\nMICHAEL J. SHEA, MD\\nProfessor of Internal Medicine, Section Head,\\nCardiovascular Medicine Outpatient Services\\nand Clinical Evaluation, University of\\nMichigan Health Systems\\nCardiovascular Tests and Procedures\\nDAVID D. SHERRY, MD\\nProfessor of Pediatrics, University of\\nPennsylvania; Director, Clinical\\nRheumatology, The Children's Hospital of\\nPhiladelphia\\nRheumatic Fever; Bone and Connective Tissue\\nDisorders in Children\\nSTEPHEN D. SILBERSTEIN, MD\\nProfessor of Neurology, Headache Center,\\nThomas Jefferson University\\nHeadache\\nDAPHNE SIMEON, MD\\nAssociate Professor, Department of\\nPsychiatry, Mount Sinai School of Medicine\\nDissociative Disorders\\nADAM J. SINGER, MD\\nProfessor and Vice Chairman for Research,\\nDepartment of Emergency Medicine, Stony\\nBrook University and Medical Center\\nLacerations\\nASHISH C. SINHA, MD, PhD\\nAssistant Professor, Anesthesiology and\\nCritical Care, University of Pennsylvania\\nSchool of Medicine\\nObesity and the Metabolic Syndrome\\n(Bariatric Surgery portion)\\nRICHARD V. SMITH, MD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n46\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 56, 'page_label': '47'}, page_content=\"Vice Chair, Department of Otolaryngology-\\nHead & Neck Surgery, Albert Einstein College\\nof Medicine; Director, Head & Neck Service,\\nMontefiore Medical Center\\nTumors of the Head and Neck\\nNORMAN SOHN, MD\\nClinical Assistant Professor of Surgery, New\\nYork University School of Medicine;\\nAttending Surgeon, Lenox Hill Hospital\\nAnorectal Disorders\\nDAVID E. SOPER, MD\\nProfessor and Vice Chairman for Clinical\\nAffairs, Department of Obstetrics and\\nGynecology, Medical University of South\\nCarolina\\nVaginitis and Pelvic Inflammatory Disease\\nDAVID R. STEINBERG, MD\\nAssociate Professor, Department of\\nOrthopaedic Surgery and Director, Hand &\\nUpper Extremity Fellowship, Department\\nof Orthopaedic Surgery, University of\\nPennsylvania\\nHand Disorders\\nMARVIN E. STEINBERG, MD\\nProfessor (Emeritus) of Orthopaedic Surgery,\\nUniversity of Pennsylvania School of\\nMedicine\\nOsteonecrosis\\nKINGMAN P. STROHL, MD\\nProfessor of Medicine and Oncology,\\nDepartment of Medicine, Division of\\nPulmonary, Critical Care and Sleep Medicine,\\nCase Medical Center; Director, Center for\\nSleep Disorders Research, Case Western\\nReserve University\\nSleep Apnea\\nALBERT J. STUNKARD, MD\\nProfessor of Psychiatry, University of\\nPennsylvania School of Medicine\\nEating Disorders\\nALAN M. SUGAR, MD\\nProfessor of Medicine (Emeritus), Boston\\nUniversity School of Medicine; Medical\\nDirector, Infectious Disease Clinical Services\\nand HIV/AIDS Program, Cape Cod Healthcare\\nFungi\\nSTEPHEN BRIAN SULKES, MD\\nProfessor of Pediatrics, Division of\\nNeurodevelopmental and Behavioral\\nPediatrics, Golisano Children's Hospital at\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n47\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 57, 'page_label': '48'}, page_content='Strong, University of Rochester School of\\nMedicine and Dentistry\\nLearning and Developmental Disorders;\\nBehavioral Concerns and Problems in Children\\nGEETA K. SWAMY, MD\\nAssociate Professor, Division of Maternal-\\nFetal Medicine, Department of Obstetrics and\\nGynecology, Duke University Medical Center\\nApproach to the Pregnant Woman and Prenatal\\nCare\\nDAVID A. SWANSON, MD\\nClinical Professor, Department of Urology,\\nThe University of Texas MD Anderson Cancer\\nCenter\\nGenitourinary Cancer\\nPAUL H. TANSER, MD\\nProfessor of Medicine (Emeritus), McMaster\\nUniversity; Medical Cardiologist, North Shore\\nand Waitakere Hospitals, Auckland\\nApproach to the Cardiac Patient; Valvular\\nDisorders\\nSYED H. TARIQ, MD\\nFellow, Division of Gastroenterology and\\nHepatology, Saint Louis University School\\nof Medicine\\nPolyglandular Deficiency Syndromes\\nJOAN B. TARLOFF, PhD\\nProfessor, Department of Pharmaceutical\\nSciences, University of the Sciences in\\nPhiladelphia\\nAdverse Drug Reactions\\nMARY TERRITO, MD\\nProfessor of Medicine, Director of\\nHematopoietic Stem Cell Transplantation,\\nUniversity of California, Los Angeles\\nNeutropenia and Lymphocytopenia\\nDAVID R. THOMAS, MD\\nProfessor of Medicine, Division of Geriatric\\nMedicine, Saint Louis University Health\\nSciences Center\\nNutritional Support\\nELIZABETH CHABNER THOMPSON,\\nMD, MPH\\nPrivate Practice, New York Group for Plastic\\nSurgery\\nOverview of Cancer; Principles of Cancer\\nTherapy\\nSTIG THUNELL, MD, PhD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n48'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 58, 'page_label': '49'}, page_content='Professor, Karolinska Institute; Senior\\nConsultant, Porphyria Center Sweden,\\nKarolinska University Hospital Huddinge,\\nStockholm\\nPorphyrias\\nSHELLY D. TIMMONS, MD, PhD\\nAssistant Professor and Chief of Neurotrauma\\nDivision, Department of Neurosurgery,\\nUniversity of Tennessee; Private Practice,\\nSemmes-Murphey Neurologic & Spine Institute\\nTraumatic Brain Injury\\nCOURTNEY M. TOWNSEND, Jr., MD\\nProfessor and John Woods Harris Distinguished\\nChairman, Department of Surgery, The\\nUniversity of Texas Medical Branch at\\nGalveston\\nCarcinoid Tumors\\nAMAL TRIVEDI, MD, MPH\\nAssistant Professor of Community Health,\\nThe Warren Alpert Medical School of\\nBrown University; Investigator, REAP On\\nOutcomes and Quality in Chronic Disease\\nand Rehabilitation, Providence VA Medical\\nCenter\\nFunding Health Care for the Elderly; Financial\\nIssues in Health Care\\nANNE S. TSAO, MD\\nAssistant Professor, Department of Thoracic/\\nHead & Neck Oncology, Division of Cancer\\nMedicine, The University of Texas MD\\nAnderson Cancer Center\\nTumors of the Lungs\\nDEBARA L. TUCCI, MD\\nAssociate Professor of Surgery, Division of\\nOtolaryngology-Head and Neck Surgery, Duke\\nUniversity Medical Center\\nApproach to the Patient With Ear Problems\\nALLAN R. TUNKEL, MD, PhD\\nChair, Department of Medicine, Monmouth\\nMedical Center; Professor of Medicine,\\nDrexel University College of Medicine\\nBiology of Infectious Disease\\nRONALD B. TURNER, MD\\nProfessor of Pediatrics, University of Virginia\\nSchool of Medicine\\nRespiratory Viruses\\nALEXANDER G.G. TURPIE, MD\\nProfessor of Medicine, McMaster University\\nand Hamilton Health Sciences General Hospital\\nPeripheral Venous and Lymphatic Disorders\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n49'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 59, 'page_label': '50'}, page_content=\"Peripheral Venous and Lymphatic Disorders\\nJAMES T. UBERTALLI, DMD\\nAssistant Clinical Professor, Tufts University\\nSchool of Dental Medicine; Private Practice,\\nHingham, MA\\nCommon Dental Disorders\\nVICTOR G. VOGEL, MD, MHS\\nNational Vice President for Research, American\\nCancer Society\\nBreast Disorders\\nAARON E. WALFISH, MD\\nClinical Assistant Attending, Division of\\nDigestive Diseases, Beth Israel Medical\\nCenter; Clinical Instructor, Mount Sinai\\nMedical Center\\nInflammatory Bowel Disease\\nJAMES WAYNE WARNICA, MD\\nProfessor of Medicine, Department of Cardiac\\nScience, University of Calgary; Director,\\nCardiac Intensive Care Unit, Foothills Medical\\nCenter\\nCoronary Artery Disease\\nMAX HARRY WEIL, MD, PhD, ScD\\n(Hon)\\nDistinguished Professor and Founding\\nPresident, Weil Institute of Critical Care\\nMedicine; Research Professor of Surgery,\\nKeck School of Medicine, The University of\\nSouthern California, Los Angeles\\nCardiac Arrest; Shock and Fluid Resuscitation;\\nSepsis and Septic Shock\\nGEOFFREY A. WEINBERG, MD\\nProfessor of Pediatrics, University of\\nRochester School of Medicine and Dentistry;\\nDirector, Pediatric HIV Program, Golisano\\nChildren's Hospital at Strong, University of\\nRochester Medical Center\\nMiscellaneous Infections in Infants and\\nChildren; Human Immunodeficiency Virus\\nInfection in Infants and Children\\nLAURA WEISSMAN, MD\\nAssistant Professor in Medicine and Instructor\\nin Pediatrics, Harvard Medical School\\nIncontinence in Children\\nGREGORY L. WELLS, MD\\nResident in Dermatology, Dartmouth Medical\\nSchool and Dartmouth-Hitchcock Medical\\nCenter\\nCancers of the Skin\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n50\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 60, 'page_label': '51'}, page_content='JOHN B. WEST, MD, PhD, DSc\\nProfessor of Medicine and Physiology,\\nUniversity of California, San Diego\\nAltitude Sickness\\nKENDRICK ALAN WHITNEY, DPM\\nAssistant Professor, Department of Medicine\\nand Orthopedics, Temple University School of\\nPodiatric Medicine\\nFoot and Ankle Disorders\\nFRANK H. WIANS, Jr., PhD\\nProfessor of Pathology (Retired), Department\\nof Pathology, The University of Texas\\nSouthwestern Medical Center at Dallas\\nNormal Laboratory Values\\nJAMES E. WILBERGER, MD\\nProfessor and Chairman, Department of\\nNeurosurgery, Allegheny General Hospital,\\nPittsburgh; Vice Dean, Drexel University\\nCollege of Medicine\\nSpinal Trauma\\nMARGARET-MARY G. WILSON, MD\\nMedical Director, Health Services, United\\nHealthcare, Maryland Heights\\nNutrition: General Considerations; Syndromes\\nof Uncertain Origin\\nG. TERENCE WILSON, PhD\\nOscar K. Buros Professor of Psychology,\\nGraduate School of Applied and Professional\\nPsychology, Rutgers University\\nEating Disorders\\nROBERT A. WISE, MD\\nProfessor of Medicine, Pulmonary and\\nCritical Care, Johns Hopkins University\\nSchool of Medicine\\nChronic Obstructive Pulmonary Disease\\nGARY WITTERT, MB, Bch, MD\\nProfessor and Head, Department of Medicine,\\nRoyal Adelaide Hospital\\nObesity and the Metabolic Syndrome\\nSTEVEN E. WOLF, MD\\nBetty and Bob Kelso Distinguished Chair in\\nBurns and Trauma, Vice Chair for Research,\\nand Professor, Department of Surgery, The\\nUniversity of Texas Health Science Center at\\nSan Antonio; Chief, Clinical Research, United\\nStates Army Institute of Surgical Research\\nBurns\\nEIJI YANAGISAWA, MD\\nClinical Professor of Otolaryngology, Yale\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n51'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 61, 'page_label': '52'}, page_content='Clinical Professor of Otolaryngology, Yale\\nUniversity School of Medicine\\nExternal Ear Disorders\\nHEIDI YEH, MD\\nInstructor in Surgery, Harvard Medical\\nSchool; Assistant in Surgery, Massachusetts\\nGeneral Hospital\\nTransplantation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Front Matter\\n52'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 62, 'page_label': '53'}, page_content='1 - Nutritional Disorders\\nChapter 1. Nutrition: General Considerations\\nIntroduction\\nNutrition is the science of food and its relationship to health. Nutrients are chemicals in foods that are\\nused by the body for growth, maintenance, and energy. Nutrients that cannot be synthesized by the body\\nand thus must be derived from the diet are considered essential. They include vitamins, minerals, some\\namino acids, and some fatty acids. Nutrients that the body can synthesize from other compounds,\\nalthough they may also be derived from the diet, are considered nonessential. Macronutrients are\\nrequired by the body in relatively large amounts; micronutrients are needed in minute amounts.\\nLack of nutrients can result in deficiency syndromes (eg, kwashiorkor, pellagra) or other disorders (see p.\\n9\\n). Excess intake of macronutrients can lead to obesity (see p. \\n56\\n) and related disorders; excess intake of\\nmicro-nutrients can be toxic. Also, the balance of various types of nutrients, such as how much\\nusaturated vs saturated fat is consumed, can influence the development of disorders.\\nMacronutrients\\nMacronutrients constitute the bulk of the diet and supply energy and many essential nutrients.\\nCarbohydrates, proteins (including essential amino acids), fats (including essential fatty acids),\\nmacrominerals, and water are macronutrients. Carbohydrates, fats, and proteins are interchangeable as\\nsources of energy; fats yield 9 kcal/g (37.8 kJ/g); proteins and carbohydrates yield 4 kcal/g (16.8 kJ/g).\\nCarbohydrates:\\n Dietary carbohydrates are broken down into glucose and other monosaccharides.\\nCarbohydrates increase blood glucose levels, supplying energy. Simple carbohydrates are composed of\\nsmall molecules, generally monosaccharides or disaccharides, which increase blood glucose levels\\nrapidly. Complex carbohydrates are composed of larger molecules, which are broken down into\\nmonosaccharides. Complex carbohydrates increase blood glucose levels more slowly but for a longer\\ntime. Glucose and sucrose are simple carbohydrates; starches and fiber are complex carbohydrates.\\nThe glycemic index measures how rapidly consumption of a carbohydrate increases plasma glucose\\nlevels. Values range from 1 (the slowest increase) to 100 (the fastest increase, equivalent to pure glucose\\nsee\\nTable 1-1\\n). However, the actual rate of increase also depends on what foods are consumed with the\\ncarbohydrate.\\nCarbohydrates with a high glycemic index may increase plasma glucose to high levels rapidly. It is\\nhypothesized that, as a result, insulin levels increase, inducing hypoglycemia and hunger, which tends to\\nlead to consumption of excess calories and weight gain. Carbohydrates with a low glycemic index\\nincrease plasma glucose levels slowly, resulting in lower postprandial insulin levels and less hunger,\\nwhich probably makes consumption of excess calories less likely. These effects are predicted to result in\\na more favorable lipid profile and a decreased risk of obesity, diabetes mellitus, and complications of\\ndiabetes if present.\\nProteins:\\n Dietary proteins are broken down into peptides and amino acids. Proteins are required for\\ntissue maintenance, replacement, function, and growth. However, if the body is not getting enough\\ncalories from dietary sources or tissue stores (particularly of fat), protein may be used for energy.\\nAs the body uses dietary protein for tissue production, there is a net gain of protein (positive nitrogen\\nbalance). During catabolic\\n[\\nTable 1-1.\\n Glycemic Index of Some Foods]\\nstates (eg, starvation, infections, burns), more protein may be used (because body tissues are broken\\ndown) than is absorbed, resulting in a net loss of protein (negative nitrogen balance). Nitrogen balance is\\nbest determined by subtracting the amount of nitrogen excreted in urine and feces from the amount of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\\n53'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 63, 'page_label': '54'}, page_content=\"nitrogen consumed.\\nOf the 20 amino acids, 9 are essential amino acids (EAAs); they cannot be synthesized and must be\\nobtained from the diet. All people require 8 EAAs; infants also require histidine.\\nThe weight-adjusted requirement for dietary protein correlates with growth rate, which decreases from\\ninfancy until adulthood. The daily dietary protein requirement decreases from 2.2 g/kg in 3-mo-old infants\\nto 1.2 g/kg in 5-yr-old children and to 0.8 g/kg in adults. Protein requirements correspond to EAA\\nrequirements (see\\nTable 1-2\\n). Adults trying to increase muscle mass need very little extra protein beyond the requirements in\\nthe table.\\nThe amino acid composition of protein varies widely. Biological value (BV) reflects the similarity in amino\\nacid composition of protein to that of animal tissues; thus, BV indicates what percentage of a dietary\\nprotein provides EAAs for the body. A perfect match is egg protein, with a value of 100. Animal proteins in\\nmilk and meat have a high BV (~90); proteins in cereal and vegetables have a lower BV (~40), and some\\nderived proteins (eg, gelatin) have a BV of 0. The extent to which dietary proteins supply each other's\\nmissing amino acids (complementarity) determines the overall BV of the diet. The recommended daily\\nallowances (RDA) for protein assumes that the average mixed diet has a BV of 70.\\nFats:\\n Fats are broken down into fatty acids and glycerol. Fats are required for tissue growth and hormone\\nproduction. Saturated fatty acids, common in animal fats, tend to be solid at room temperature. Except for\\npalm and coconut oils, fats derived from plants tend to be liquid at room temperature; these fats contain\\nhigh levels of monounsaturated fatty acids or polyunsaturated fatty acids (PUFAs).\\nPartial hydrogenation of unsaturated fatty acids (as occurs during food manufacturing) produces trans\\nfatty acids, which are solid or semisolid at room temperature. In the US, the main dietary source of trans\\nfatty acids is partially hydrogenated vegetable oils, used in manufacturing certain foods (eg, cookies,\\ncrackers, chips) to prolong shelf-life. Trans fatty acids may elevate LDL cholesterol and lower HDL; they\\nmay also independently increase the risk of coronary artery disease.\\nEssential fatty acids (EFAs) are linoleic acid, an \\n\\n-6 (n-6) fatty acid, and linolenic acid, an \\n\\n-3 (n-3) fatty\\nacid. Other \\n\\n-6 acids (eg, arachidonic acid) and other \\n\\n-3 fatty acids (eg, eicosapentaenoic acid,\\ndocosahexaenoic acid) are required by the body but can be synthesized from EFAs.\\nEFAs (see also p. \\n19\\n) are needed for the formation of various eicosanoids (biologically active lipids),\\nincluding prostaglandins, thromboxanes, prostacyclins, and leukotrienes. Consumption of \\n\\n-3 fatty acids\\nmay decrease the risk of coronary artery disease.\\n[\\nTable 1-2.\\n Essential Amino Acid Requirements in mg/kg Body Weight]\\nRequirements for EFAs vary by age. Adults require amounts of linoleic acid equal to at least 2% of total\\ncaloric needs and linolenic acid equal to at least 0.5%. Vegetable oils provide linoleic acid and linolenic\\nacid. Oils made from safflower, sunflower, corn, soya, primrose, pumpkin, and wheat germ provide large\\namounts of linoleic acid. Marine fish oils and oils made from flax-seeds, pumpkin, soy, and canola provide\\nlarge amounts of linolenic acid. Marine fish oils also provide some other \\n\\n-3 fatty acids in large amounts.\\nMacrominerals:\\n Na, Cl, K, Ca, P, and Mg are required in relatively large amounts per day (see\\nTables 1-3\\n,\\n1-4\\n, and\\n5-2\\n).\\nWater:\\n Water is considered a macronutrient because it is required in amounts of 1 mL/kcal (0.24 mL/kJ)\\nof energy expended, or about 2500 mL/day. Needs vary with fever, physical activity, and changes in\\nclimate and humidity.\\n[\\nTable 1-3.\\n Macrominerals]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\\n54\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 64, 'page_label': '55'}, page_content=\"[\\nTable 1-4.\\n Recommended Dietary Reference Intakes* for Some Macronutrients, Food and Nutrition\\nBoard, Institute of Medicine of the National Academies]\\nMicronutrients\\nVitamins and minerals required in minute amounts (trace minerals) are micronutrients (see \\nChs. 4\\n and \\n5\\n).\\nWater-soluble vitamins\\n are vitamin C (ascorbic acid) and 8 members of the vitamin B complex: biotin,\\nfolate, niacin, pantothenic acid, riboflavin (vitamin B\\n2\\n), thiamin (vitamin B\\n1\\n), vitamin B\\n6\\n (pyridoxine), and\\nvitamin B\\n12\\n (cobalamin).\\nFat-soluble vitamins\\n are vitamins A (retinol), D (cholecalciferol and ergocalciferol), E (\\n\\n-tocopherol), and\\nK (phylloquinone and menaquinone).\\nOnly vitamins A, E, and B\\n12\\n are stored to any significant extent in the body; the other vitamins must be\\nconsumed regularly to maintain tissue health.\\nEssential trace minerals\\n include chromium, copper, iodine, iron, manganese, molybdenum, selenium,\\nand zinc. Except for chromium, each of these is incorporated into enzymes or hormones required in\\nmetabolism. Except for deficiencies of iron and zinc, micromineral deficiencies are uncommon in\\ndeveloped countries (see \\nCh. 5\\n).\\nOther minerals (eg, aluminum, arsenic, boron, cobalt, fluoride, nickel, silicon, vanadium) have not been\\nproved essential for people. Fluoride, although not essential, helps prevent tooth decay by forming a\\ncompound with Ca (CaF\\n2\\n), which stabilizes the mineral matrix in teeth.\\nAll trace minerals are toxic at high levels, and some (arsenic, nickel, and chromium) may cause cancer.\\nOther Dietary Substances\\nThe daily human diet typically contains as many as 100,000 chemicals (eg, coffee contains 1000). Of\\nthese, only 300 are nutrients, only some of which are essential. However, many nonnutrients in foods are\\nuseful. For example, food additives (eg, preservatives, emulsifiers, antioxidants, stabilizers) improve the\\nproduction and stability of foods. Trace components (eg, spices, flavors, odors, colors, phytochemicals,\\nmany other natural products) improve appearance and taste.\\nFiber:\\n Fiber occurs in various forms (eg, cellulose, hemicellulose, pectin, gums). It \\nincreases GI motility,\\nprevents constipation, and helps control diverticular disease. Fiber is thought to accelerate the elimination\\nof cancer-causing substances produced by bacteria in the large intestine. Epidemiologic evidence\\nsuggests an association between colon cancer and low fiber intake and a beneficial effect of fiber in\\npatients with functional bowel disorders, Crohn's disease, obesity, and hemorrhoids. Soluble fiber\\n(present in fruits, vegetables, oats, barley, and legumes) reduces the postprandial increase in blood\\nglucose and insulin and can reduce cholesterol levels.\\nThe typical Western diet is low in fiber (about 12 g/day) because of a high intake of highly refined wheat\\nflour and a low intake of fruits and vegetables. Increasing fiber intake to about 30 g/day by consuming\\nmore vegetables, fruits, and high-fiber cereals and grains is generally recommended. However, very high\\nfiber intake may reduce absorption of certain minerals.\\nNutritional Requirements\\nGood nutrition aims to achieve and maintain a desirable body composition and high potential for physical\\nand mental work. Balancing energy intake with energy expenditure is necessary for a desirable body\\nweight. Energy expenditure depends on age, sex, weight (see \\nTable 1-4\\n), and metabolic and physical\\nactivity. If energy intake exceeds expenditure, weight is gained. Taking in about 100 calories/day more\\nthan needed results in a weight gain of about 4 to 5 kg in a year. If energy intake is less than expenditure,\\nweight is lost.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\\n55\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 65, 'page_label': '56'}, page_content='Daily dietary requirements for essential nutrients also depend on age, sex, weight, and metabolic and\\nphysical activity. Every 5 yr, the Food and Nutrition Board of the National Academy of Sciences/National\\nResearch Council and the US Department of Agriculture (USDA) issues the dietary reference intakes\\n(DRIs) for protein, energy, and some vitamins and minerals (see \\nTables 1-4\\n,\\n4-1\\n, and \\n5-2\\n). For vitamins and minerals about which less is known, safe and adequate daily dietary\\nintakes are estimated.\\nPregnant women (see p. \\n2608\\n) and infants (see p. \\n2703\\n) have special nutritional needs.\\nThe USDA publishes the Food Guide Pyramid, which specifies the number of recommended daily\\nservings of various food groups. The recommendations are individualized based on age, sex, and\\nphysical activity (see\\nTable 1-5\\n). Generally, the recommended intake decreases with aging because physical activity tends to\\ndecrease, resulting in less energy expended. The new Food Guide Pyramid emphasizes the following:\\n Increasing consumption of whole grains\\n Increasing consumption of vegetables and fruits\\n Substituting fat-free or low-fat milk products (or equivalents) for whole-fat milk products\\n Reducing consumption of saturated fats and trans fatty acids\\n Exercising regularly\\nAdequate fluid intake is also important.\\nFats should constitute  30% of total calories, and saturated and trans fatty acids should constitute <\\n10%. Excess intake of saturated fats contributes to atherosclerosis. Substituting polyunsaturated fatty\\nacids for saturated fats can decrease the risk of atherosclerosis. Routine use of nutritional supplements is\\nnot necessary or beneficial; some supplements can be harmful. For example, excess vitamin A can lead to\\nhypervitaminosis A, with headaches, osteoporosis, and rash.\\nNutrition in Clinical Medicine\\nNutritional deficiencies can often worsen health outcomes (whether a disorder is present or not), and\\nsome disorders (eg, malabsorption) can cause nutritional deficiencies. Also, many patients (eg, elderly\\npatients during acute hospitalization) have unsuspected nutritional deficiencies that require treatment.\\nMany medical centers have multi-disciplinary nutrition support teams of physicians, nurses, dietitians, and\\npharmacists to help the clinician prevent, diagnose, and treat occult nutritional deficiencies.\\nOvernutrition may contribute to chronic disorders, such as cancer, hypertension, obesity, diabetes\\nmellitus, and coronary artery disease. Dietary restrictions are necessary in many hereditary metabolic\\ndisorders (eg, galactosemia, phenylketonuria).\\nEvaluation of Nutritional Status\\nIndications for nutritional evaluation include undesirable body weight or body composition, suspicion of\\nspecific deficiencies or toxicities\\n[\\nTable 1-5.\\n Recommended Dietary Intake for 40-yr-Olds with Moderate Physical Activity*]\\nof essential nutrients, and, in infants and children, insufficient growth or development. Nutritional status\\nshould be evaluated routinely as part of the clinical examination for infants and children, the elderly,\\npeople taking several drugs, people with psychiatric disorders, and people with systemic disorders that\\nlast longer than several days.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\\n56'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 66, 'page_label': '57'}, page_content=\"Evaluating general nutritional status includes history, physical examination, and sometimes tests. If\\nundernutrition is suspected, laboratory tests (eg, albumin levels) and skin tests for delayed\\nhypersensitivity may be done (see p.\\n13\\n). Body composition analysis (eg, skinfold measurements, bioelectrical impedance analysis) is used to\\nestimate percentage of body fat and to evaluate obesity (see p. \\n58\\n).\\nHistory includes questions about dietary intake, weight change, and risk factors for nutritional deficiencies\\nand a focused review of systems (see\\nTable 2-1\\n on p. \\n11\\n). A dietitian can obtain a more detailed dietary history. It usually includes a list of foods\\neaten within the previous 24 h and a food questionnaire. A food diary may be used to record all foods\\neaten. The weighed ad libitum diet, in which the patient weighs and writes down all foods consumed, is\\nthe most accurate record.\\nA complete physical examination, including measurement of height and weight and distribution of body\\nfat, should be done. Body mass index (BMI)weight(kg)/height(m)\\n2\\n, which adjusts weight for height (see\\nTable 6-2\\n on p. \\n59\\n), is more accurate than height and weight tables. There are standards for growth and\\nweight gain in infants, children, and adolescents (see p. \\n2756\\n).\\nDistribution of body fat is important. Disproportionate truncal obesity (ie, waist/hip ratio > 0.8) is\\nassociated with cardiovascular and cerebrovascular disorders, hypertension, and diabetes mellitus more\\noften than fat located elsewhere. Measuring waist circumference in patients with a BMI of < 35 helps\\ndetermine whether they have truncal obesity and helps predict risk of diabetes, hypertension,\\nhypercholesterolemia, and cardiovascular disorders. Risk is increased if waist circumference is > 102 cm\\n(> 40 in) in men or > 88 cm (> 35 in) in women.\\nNutrient-Drug Interactions\\nNutrition can affect the body's response to drugs; conversely, drugs can affect the body's nutrition.\\nFoods can enhance, delay, or decrease drug absorption. Foods impair absorption of many antibiotics.\\nThey can alter metabolism of drugs; eg, high-protein diets can accelerate metabolism of certain drugs by\\nstimulating \\ncytochrome P-450. Eating grapefruit can inhibit cytochrome P-450 34A, slowing metabolism of\\nsome drugs (eg, amiodarone, carbamazepine, cyclosporine, certain Ca channel blockers). Diets that alter\\nthe bacterial flora may markedly affect the overall metabolism of certain drugs. Some foods affect the\\nbody's response to drugs. For example, tyramine, a component of cheese and a potent vasoconstrictor,\\ncan cause hypertensive crisis in some patients who take monoamine oxidase inhibitors and eat cheese.\\nNutritional deficiencies can affect drug absorption and metabolism. Severe energy and protein\\ndeficiencies reduce enzyme tissue concentrations and may impair the response to drugs by reducing\\nabsorption or protein binding and causing liver dysfunction. Changes in the GI tract can impair absorption\\nand affect the response to a drug. Deficiency of Ca, Mg, or zinc may impair drug metabolism. Vitamin C\\ndeficiency decreases activity of drug-metabolizing enzymes, especially in the elderly.\\nMany drugs affect appetite, food absorption, and tissue metabolism (see\\nTable 1-6\\n). Some drugs (eg, metoclopramide) increase GI motility, decreasing food absorption. Other\\ndrugs (eg, opioids, anticholinergics) decrease GI motility. Some drugs are better tolerated if taken with\\nfood.\\nCertain drugs affect mineral metabolism. For example, diuretics, especially thiazides, and corticosteroids\\ncan deplete body K, increasing susceptibility to digoxin-induced cardiac arrhythmias. Repeated use of\\nlaxatives may deplete K. Cortisol, desoxycorticosterone, and aldosterone cause marked Na and water\\nretention, at least temporarily; retention is much less with prednisone, prednisolone, and some other\\ncorticosteroid analogs. Sulfonylureas and lithium can impair the uptake or release of iodine by the thyroid.\\nOral contraceptives can lower blood zinc levels and increase copper levels. Certain antibiotics (eg,\\ntetracyclines) reduce iron absorption, as can certain foods (eg, vegetables, tea, bran).\\nCertain drugs affect vitamin absorption or metabolism. Ethanol impairs thiamin utilization, and isoniazid\\ninterferes with niacin and pyridoxine metabolism. Ethanol and oral contraceptives inhibit folate (folic acid)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\\n57\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 67, 'page_label': '58'}, page_content='absorption. Most patients receiving phenytoin, phenobarbital, primidone, or phenothiazines develop folate\\ndeficiency, probably because hepatic microsomal drug-metabolizing enzymes are affected. Folate\\nsupplements may\\n[\\nTable 1-6.\\n Effects of Some Drugs on Nutrition]\\nmake phenytoin less effective. Anticonvulsants can cause vitamin D deficiency. Malabsorption of vitamin\\nB\\n12\\n can occur with use of aminosalicylic acid, slow-release K iodide, colchicine, trifluoperazine, ethanol,\\nand oral contraceptives. Oral contraceptives with a high progestin dose can cause depression, probably\\nbecause of metabolically induced tryptophan deficiency.\\nFood Additives and Contaminants\\nAdditives:\\n Chemicals are often combined with foods to facilitate their processing and preservation or to\\nenhance their desirability. Only amounts of additives shown to be safe by laboratory tests are permitted in\\ncommercially prepared foods.\\nWeighing the benefits of additives (eg, reduced waste, increased variety of available foods, protection\\nagainst food-borne illness) against the risks is often complex. For example, nitrite, which is used in cured\\nmeats, inhibits the growth of \\nClostridium botulinum\\n and improves flavor. However, nitrite converts to\\nnitrosamines, which are carcinogens in animals. On the other hand, the amount of nitrite added to cured\\nmeat is small compared with the amount from naturally occurring food nitrates converted to nitrite by the\\nsalivary glands. Dietary vitamin C can reduce nitrite formation in the GI tract. Rarely, some additives (eg,\\nsulfites) cause food hypersensitivity (allergy) reactions. Most of these reactions are caused by ordinary\\nfoods (see p. \\n1118\\n).\\nContaminants:\\n Sometimes limited amounts of contaminants are allowed in foods because the\\ncontaminants cannot be completely eliminated without damaging the foods. Common contaminants are\\npesticides, heavy metals (lead, cadmium, mercury), nitrates (in green leafy vegetables), aflatoxins (in nuts\\nand milk), growth-promoting hormones (in dairy products and meat), animal hairs and feces, and insect\\nparts.\\nFDA-estimated safe levels are levels that have not caused illness or adverse effects in people. However,\\ndemonstrating a causal relationship between extremely low level exposures and adverse effects is\\ndifficult; long-term adverse effects, although unlikely, are still possible. Safe levels are often determined\\nby consensus rather than by hard evidence.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 1. Nutrition: General Considerations\\n58'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 68, 'page_label': '59'}, page_content=\"Chapter 2. Undernutrition\\nIntroduction\\nUndernutrition is a form of malnutrition. (Malnutrition also includes overnutritionsee \\nCh. 6\\n).\\nUndernutrition can result from inadequate ingestion of nutrients, malabsorption, impaired\\nmetabolism, loss of nutrients due to diarrhea, or increased nutritional requirements (as occurs\\nin cancer or infection). Undernutrition progresses in stages; each stage usually takes\\nconsiderable time to develop. First, nutrient levels in blood and tissues change, followed by\\nintracellular changes in biochemical functions and structure. Ultimately, symptoms and signs\\nappear.\\nRisk Factors\\nUndernutrition is associated with many disorders and circumstances, including poverty and social\\ndeprivation. Risk is also greater at certain times (ie, during infancy, early childhood, adolescence,\\npregnancy, breastfeeding, and old age).\\nInfancy and childhood:\\n Infants and children are particularly susceptible to undernutrition because of\\ntheir high demand for energy and essential nutrients. Because vitamin K does not readily cross the\\nplacenta, neonates may be deficient, so all are given a single injection of vitamin K within 1 h of birth to\\nprevent hemorrhagic disease of the newborn, a life-threatening disorder (see pp. \\n46\\n and\\n2783\\n). Infants fed only breast milk, which is typically low in vitamin D, are given supplemental vitamin D;\\nthey can develop vitamin B\\n12\\n deficiency if the mother is a vegan. Inadequately fed infants and children\\nare at risk of protein-energy undernutrition (PEUpreviously called protein-energy malnutrition) and\\ndeficiencies of iron, folate (folic acid), vitamins A and C, copper, and zinc. During adolescence, nutritional\\nrequirements increase because the growth rate accelerates. Anorexia nervosa (see p. \\n1535\\n) may affect\\nadolescent girls in particular.\\nPregnancy and breastfeeding:\\n Requirements for nutrients increase during pregnancy and\\nbreastfeeding. Aberrations of diet, including pica (consumption of nonnutritive substances, such as clay\\nand charcoal), may occur during \\npregnancy. Anemia due to iron deficiency is common, as is anemia due\\nto folate deficiency, especially among women who have taken oral contraceptives. Vitamin D deficiency is\\ncommon during late pregnancy, predisposing the child to decreased bone mass.\\nOld age:\\n Agingeven when disease or dietary deficiency is absentleads to sarcopenia (progressive\\nloss of lean body mass), starting after age 40 and eventually amounting to a muscle loss of about 10 kg\\n(22 lb) in men and 5 kg (11 lb) in women. Undernutrition contributes to sarcopenia, and sarcopenia\\naccounts for many of the complications of undernutrition (eg, decreased nitrogen balance, increased\\nsusceptibility to infections). Causes of sarcopenia include the following:\\n Decreased physical activity\\n Decreased food intake\\n Increased levels of cytokines (particularly interleukin-6)\\n Decreased levels of growth hormone and mechano growth factor (insulin-like growth factor-3)\\n In men, decreasing androgen levels\\nAging decreases basal metabolic rate (due mainly to decreased fat-free mass), total body weight, height,\\nand skeletal mass; aging increases mean body fat (as a percentage of body weight) to about 30% (from\\n20%) in men and to 40% (from 27%) in women.\\nFrom age 20 to 80, food intake decreases, especially in men. Anorexia due to aging itself has many\\ncauses, including reduced adaptive relaxation of the stomach's fundus, increased release and activity of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n59\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 69, 'page_label': '60'}, page_content='cholecystokinin (which produces satiation), and increased leptin (an anorectic hormone produced by fat\\ncells). Diminished taste and smell can decrease eating pleasure but usually decrease food intake only\\nslightly. Anorexia may have other causes (eg, loneliness, inability to shop or prepare meals, dementia,\\nsome chronic disorders, use of certain drugs). Depression is a common cause. Occasionally, anorexia\\nnervosa (sometimes called anorexia tardive in the elderly), paranoia, or mania interferes with eating.\\nDental problems limit the ability to chew and subsequently to digest foods. Swallowing difficulties (eg, due\\nto strokes, other neurologic disorders, esophageal candidiasis, or xerostomia) are common. Poverty or\\nfunctional impairment limits access to nutrients.\\nThe institutionalized elderly are at particular risk of PEU. They are often confused and may be unable to\\nexpress hunger or preferences for foods. They may be physically unable to feed themselves. Chewing or\\nswallowing may be very slow, making it tedious for another person to feed them enough food.\\nIn the elderly, particularly the institutionalized elderly, inadequate intake and often decreased absorption\\nor synthesis of vitamin D, increased demand for vitamin D, and inadequate exposure to sunshine\\ncontribute to osteomalacia (see p. \\n41\\n).\\nDisorders and medical procedures:\\n Diabetes, some chronic disorders that affect the GI tract, intestinal\\nresection, and certain other GI surgical procedures tend to impair absorption of fat-soluble vitamins,\\nvitamin B\\n12\\n, Ca, and iron. Gluten enteropathy, pancreatic insufficiency, or other disorders can result in\\nmalabsorption. Decreased absorption possibly contributes to iron deficiency and osteoporosis. Liver\\ndisorders impair storage of vitamins A and B\\n12\\n and interfere with metabolism of protein and energy\\nsources. Renal insufficiency predisposes to protein, iron, and vitamin D deficiencies. Anorexia causes\\nsome patients with cancer or depression and many with AIDS to consume inadequate amounts of food.\\nInfections, trauma, hyperthyroidism, extensive burns, and prolonged fever increase metabolic demands.\\nAny condition that increases cytokines may be accompanied by muscle loss, lipolysis, low albumin levels,\\nand anorexia.\\nVegetarian diets:\\n Iron deficiency can occur in ovo-lacto vegetarians (although such a diet can be\\ncompatible with good health). Vegans may develop vitamin B\\n12\\n deficiency unless they consume yeast\\nextracts or Asian-style fermented foods. Their intake of Ca, iron, and zinc also tends to be low. A fruit-only\\ndiet is not recommended because it is deficient in protein, Na, and many micronutrients.\\nFad diets:\\n Some fad diets result in vitamin, mineral, and protein deficiencies; cardiac, renal, and\\nmetabolic disorders; and sometimes death. Very low calorie diets (< 400 kcal/day) cannot sustain health\\nfor long.\\nDrugs and nutritional supplements:\\n Many drugs (eg, appetite suppressants, digoxin) decrease\\nappetite; others impair nutrient absorption or metabolism. Some drugs (eg, stimulants) have catabolic\\neffects. Certain drugs can impair absorption of many nutrients; eg, anticonvulsants can impair absorption\\nof vitamins.\\nAlcohol or drug dependency:\\n Patients with alcohol or drug dependency may neglect their nutritional\\nneeds. Absorption and metabolism of nutrients may also be impaired. IV drug addicts typically become\\nundernourished, as do\\n[\\nTable 2-1.\\n Symptoms and Signs of Nutritional Deficiency]\\nalcoholics who consume  1 quart of hard liquor/day. Alcoholism can cause deficiencies of Mg, zinc, and\\ncertain vitamins, including thiamin.\\nSymptoms and Signs\\nSymptoms vary depending on the cause and type of undernutrition (see p. \\n15\\n and \\nChs. 4\\n and \\n5\\n).\\nEvaluation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n60'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 70, 'page_label': '61'}, page_content=\"Diagnosis is based on results of medical and diet histories, physical examination, body composition\\nanalysis (see p. \\n58\\n), and selected laboratory tests.\\nHistory:\\n History should include questions about dietary intake (see\\nFig. 2-1\\n), recent changes in weight, and risk factors for undernutrition, including drug and alcohol use.\\nUnintentional loss of  10% of usual body weight during a 3-mo period indicates a high probability of\\nundernutrition. Social history should include questions about whether money is available for food and\\nwhether the patient can shop and cook.\\nReview of systems should focus on symptoms of nutritional deficiencies (see \\nTable 2-1\\n). For example,\\nimpaired night vision may indicate vitamin A deficiency.\\nPhysical examination:\\n Physical examination should include measurement of height and weight,\\ninspection of body fat distribution, and anthropometric measurements of lean body mass. Body mass\\nindex (BMI = weight(kg)/height(m)\\n2\\n) adjusts weight for height (see\\nTable 6-2\\n on p. \\n59\\n). If weight is < 80% of what is predicted for the patient's height or if BMI is  18,\\nundernutrition should be suspected. Although these findings are useful in diagnosing undernutrition and\\nare acceptably sensitive, they lack specificity.\\n[\\nFig. 2-1.\\n Mini nutritional assessment.]\\nThe mid upper arm muscle area estimates lean body mass. This area is derived from the triceps skinfold\\nthickness (TSF) and mid upper arm circumference. Both are measured at the same site, with the patient's\\nright arm in a relaxed position. The average mid upper arm circumference is about 32  5 cm for men and\\n28  6 cm for women. The formula for calculating the mid upper arm muscle area in cm\\n2\\n is as follows:\\nThis formula corrects the upper arm area for fat and bone. Average values for the mid upper arm muscle\\narea are 54  11 cm\\n2\\n for men and 30  7 cm\\n2\\n for women. A value < 75% of this standard (depending on\\nage) indicates depletion of lean body mass (see\\nTable 2-2\\n). This measurement may be affected by physical activity, genetic factors, and age-related\\nmuscle loss.\\nPhysical examination should focus on signs of specific nutritional deficiencies. Signs of PEU (eg, edema,\\nmuscle wasting, skin changes) should be sought. Examination should also focus on signs of conditions\\nthat could predispose to nutritional deficiencies, such as dental problems. Mental status should be\\nassessed, because depression and cognitive impairment can lead to weight loss.\\nThe widely used Subjective Global Assessment (SGA) uses information from the patient history (eg,\\nweight loss, change in intake, GI symptoms), physical examination findings (eg, loss of muscle and\\nsubcutaneous fat, edema, ascites), and the clinician's judgment of the patient's nutritional status. The\\nMini Nutritional Assessment (MNA) has been validated and is widely used, especially for elderly patients\\n(see \\nFig. 2-1\\n). The Simplified Nutrition Assessment Questionnaire (SNAQ), a simple, validated method of\\npredicting future weight loss, may be used (see\\nFig. 2-2\\n).\\nTesting:\\n The extent of laboratory testing needed is unclear and may depend on the patient's\\ncircumstances. If the cause is obvious and correctable (eg, a wilderness survival situation), testing is\\nprobably of little benefit. Other patients may require more detailed evaluation.\\nSerum albumin measurement is the laboratory test most often used. Decreases in albumin and other\\nproteins (eg, prealbumin [transthyretin], transferrin, retinol-binding protein) may indicate protein deficiency\\nor PEU. As undernutrition progresses, albumin decreases slowly; prealbumin, transferrin, and retinol-\\nbinding protein decrease rapidly. Albumin measurement is inexpensive and predicts morbidity and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n61\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 71, 'page_label': '62'}, page_content='mortality better than measurement of the other proteins. However, the correlation of albumin with\\nmorbidity and mortality may be related to nonnutritional as well as nutritional factors. Inflammation\\nproduces cytokines that cause albumin and other nutritional protein markers to extravasate, decreasing\\nserum levels. Because prealbumin, transferrin, and retinol-binding protein decrease more rapidly during\\nstarvation than does albumin, their measurements are sometimes used to diagnose or assess the severity\\nof acute starvation. However, whether they are more sensitive or specific than albumin is unclear.\\nTotal lymphocyte count, which often decreases as undernutrition progresses, may be determined.\\nUndernutrition causes a marked decline in CD4+ T lymphocytes, so this count may not be useful in\\npatients who have AIDS.\\nSkin tests using antigens can detect impaired cell-mediated immunity in PEU and in some other disorders\\nof undernutrition (see p.\\n1098\\n).\\nOther laboratory tests, such as measuring vitamin and mineral levels, are used selectively to diagnose\\nspecific deficiencies.\\n[\\nTable 2-2.\\n Mid Upper Arm Muscle Area in Adults]\\n[\\nFigure 2-2.\\n Simplified Nutrition Assessment Questionnaire (SNAQ).]\\nProtein-Energy Undernutrition\\nProtein-energy undernutrition (PEU), previously called protein-energy malnutrition, is an energy\\ndeficit due to chronic deficiency of all macronutrients. It commonly includes deficiencies of\\nmany micronutrients. PEU can be sudden and total (starvation) or gradual. Severity ranges from\\nsubclinical deficiencies to obvious wasting (with edema, hair loss, and skin atrophy) to\\nstarvation. Multiple organ systems are often impaired. Diagnosis usually involves laboratory\\ntesting, including serum albumin. Treatment consists of correcting fluid and electrolyte deficits\\nwith IV solutions, then gradually replenishing nutrients, orally if possible.\\nIn developed countries, PEU is common among the institutionalized elderly (although often not suspected)\\nand among patients with disorders that decrease appetite or impair nutrient digestion, absorption, or\\nmetabolism. In developing countries, PEU affects children who do not consume enough calories or\\nprotein.\\nClassification and Etiology\\nPEU is graded as mild, moderate, or severe. Grade is determined by calculating weight as a percentage\\nof expected weight for length or height using international standards (normal, 90 to 110%; mild PEU, 85 to\\n90%; moderate, 75 to 85%; severe, <75%).\\nPEU may be primary or secondary. Primary PEU is caused by inadequate nutrient intake. \\nSecondary PEU\\nresults from disorders or drugs that interfere with nutrient use.\\nPrimary PEU:\\n Worldwide, primary PEU occurs mostly in children and the elderly who lack access to\\nnutrients, although a common cause in the elderly is depression. PEU can also result from fasting or\\nanorexia nervosa. Child or elder abuse may be a cause.\\nIn children, chronic primary PEU has 2 common forms: marasmus and kwashiorkor. The form depends on\\nthe balance of nonprotein and protein sources of energy. Starvation is an acute severe form of primary\\nPEU.\\nMarasmus (also called the dry form of PEU) causes weight loss and depletion of fat and muscle. In\\ndeveloping countries, marasmus is the most common form of PEU in children.\\nKwashiorkor (also called the wet, swollen, or edematous form) is associated with premature abandonment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n62'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 72, 'page_label': '63'}, page_content=\"of breastfeeding, which typically occurs when a younger sibling is born, displacing the older child from the\\nbreast. So children with kwashiorkor tend to be older than those with marasmus. Kwashiorkor may also\\nresult from an acute illness, often gastroenteritis or another infection (probably secondary to cytokine\\nrelease), in a child who already has PEU. A diet that is more deficient in protein than energy may be more\\nlikely to cause kwashiorkor than marasmus. Less common than marasmus, kwashiorkor tends to be\\nconfined to specific parts of the world, such as rural Africa, the Caribbean, and the Pacific islands. In\\nthese areas, staple foods (eg, yams, cassavas, sweet potatoes, green bananas) are low in protein and\\nhigh in carbohydrates. In kwashiorkor, cell membranes leak, causing extravasation of intravascular fluid\\nand protein, resulting in peripheral edema.\\nStarvation is a complete lack of nutrients. It occasionally occurs when food is available (as in fasting or\\nanorexia nervosa) but usually occurs because food is unavailable (eg, during famine or wilderness\\nexposure).\\nSecondary PEU:\\n This type most commonly results from the following:\\n Disorders that affect GI function: These disorders can interfere with digestion (eg, pancreatic\\ninsufficiency), absorption (eg, enteritis, enteropathy), or lymphatic transport of nutrients (eg,\\nretroperitoneal fibrosis, Milroy's disease).\\n Wasting disorders: In wasting disorders (eg, AIDS, cancer) and renal failure, catabolism causes cytokine\\nexcess, resulting in undernutrition via anorexia and cachexia (wasting of muscle and fat). End-stage\\nheart failure can cause cardiac cachexia, a severe form of undernutrition; mortality rate is particularly\\nhigh. Factors contributing to cardiac cachexia may include passive hepatic congestion (causing\\nanorexia), edema of the intestinal tract (impairing absorption), and, in advanced disease, increased O\\n2\\nrequirement due to anaerobic metabolism. Wasting disorders can decrease appetite or impair\\nmetabolism of nutrients.\\n Conditions that increase metabolic demands: These conditions include infections, hyperthyroidism,\\npheochromocytoma, other endocrine disorders, burns, trauma, surgery, and other critical illnesses.\\nPathophysiology\\nThe initial metabolic response is decreased metabolic rate. To supply energy, the body first breaks down\\nadipose tissue. However, later when these tissues are depleted, the body may use protein for energy,\\nresulting in a negative nitrogen balance. Visceral organs and muscle are broken down and decrease in\\nweight. Loss of organ weight is greatest in the liver and intestine, intermediate in the heart and kidneys,\\nand least in the nervous system.\\nSymptoms and Signs\\nSymptoms of moderate PEU can be constitutional or involve specific organ systems. Apathy and irritability\\nare common. The patient is weak, and work capacity decreases. Cognition and sometimes\\nconsciousness are impaired. Temporary lactose deficiency and achlorhydria develop. Diarrhea is common\\nand can be aggravated by deficiency of intestinal disaccharidases, especially lactase (see p. \\n157\\n).\\nGonadal tissues atrophy. PEU can cause amenorrhea in women and loss of libido in men and women.\\nWasting of fat and muscle is common in all forms of PEU. In adult volunteers who fasted for 30 to 40\\ndays, weight loss was marked (25% of initial weight). If starvation is more prolonged, weight loss may\\nreach 50% in adults and possibly more in children.\\nIn adults, cachexia is most obvious in areas where prominent fat depots normally exist. Muscles shrink\\nand bones protrude. The skin becomes thin, dry, inelastic, pale, and cold. The hair is dry and falls out\\neasily, becoming sparse. Wound healing is impaired. In elderly patients, risk of hip fractures and pressure\\n(decubitus) ulcers increases.\\nWith acute or chronic severe PEU, heart size and cardiac output decrease; pulse slows\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n63\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 73, 'page_label': '64'}, page_content='[\\nTable 2-3.\\n Values Commonly Used to Grade the Severity of Protein-Energy Undernutrition]\\nand BP falls. Respiratory rate and vital capacity decrease. Body temperature falls, sometimes contributing\\nto death. Edema, anemia, jaundice, and petechiae can develop. Liver, kidney, or heart failure may occur.\\nCell-mediated immunity is impaired, increasing susceptibility to infections. Bacterial infections (eg,\\npneumonia, gastroenteritis, otitis media, UTIs, sepsis) are common in both forms of PEU. Infections result\\nin release of cytokines, which cause anorexia, worsen muscle wasting, and cause a marked decrease in\\nserum albumin levels.\\nMarasmus in infants causes hunger, weight loss, growth retardation, and wasting of subcutaneous fat\\nand muscle. Ribs and facial bones appear prominent. Loose, thin skin hangs in folds.\\nKwashiorkor is characterized by peripheral and periorbital edema. The abdomen protrudes because\\nabdominal muscles are weakened, the intestine is distended, the liver enlarges, and ascites is present.\\nThe skin is dry, thin, and wrinkled; it can become hyperpigmented and fissured and later hypopigmented,\\nfriable, and atrophic. Skin in different areas of the body may be affected at different times. The hair can\\nbecome thin, reddish brown, or gray. Scalp hair falls out easily, eventually becoming sparse, but eyelash\\nhair may grow excessively. Alternating episodes of undernutrition and adequate nutrition may cause the\\nhair to have a dramatic \"striped flag\" appearance. Affected children may be apathetic but become irritable\\nwhen held.\\nTotal starvation is fatal in 8 to 12 wk. Thus, certain symptoms of PEU do not have time to develop.\\nDiagnosis\\n Diagnosis usually based on history\\n To determine severity: BMI, serum albumin, total lymphocyte count, CD4+ count, serum transferrin\\n To diagnose complications and consequences: CBC, electrolytes, BUN, glucose, Ca, Mg, phosphate\\nDiagnosis can be based on history when dietary intake is markedly inadequate. The cause of inadequate\\nintake, particularly in children, needs to be identified. In children and adolescents, child abuse and\\nanorexia nervosa should be considered.\\nPhysical examination findings can usually confirm the diagnosis. Laboratory tests are required if dietary\\nhistory does not clearly indicate inadequate caloric intake. Measurement of serum albumin, total\\nlymphocyte count, CD4+ T lymphocytes, transferrin, and response to skin antigens may help determine\\nthe severity of PEU (see \\nTable 2-3\\n) or confirm the diagnosis in borderline cases. Many other test results\\nmay be abnormal: eg, decreased levels of hormones, vitamins, lipids, cholesterol, prealbumin, insulin\\ngrowth factor-1, fibronectin, and retinol-binding protein. Urinary creatine and methylhistidine levels can be\\nused to gauge the degree of muscle wasting. Because protein catabolism slows, urinary urea level also\\ndecreases. These findings rarely affect treatment.\\nLaboratory tests are required to identify causes of suspected secondary PEU. C-reactive protein or\\nsoluble interleukin-2 receptor should be measured when the cause of undernutrition \\nis unclear; these\\nmeasurements can help determine whether there is cytokine excess. Thyroid function tests may also be\\ndone.\\nOther laboratory tests can detect associated abnormalities that may require treatment. Serum\\nelectrolytes, BUN, glucose, and possibly levels of Ca, Mg, and phosphate should be measured. Levels of\\nserum glucose, electrolytes (especially K, occasionally Na), phosphate, Ca, and Mg are usually low. BUN\\nis often low unless renal failure is present. Metabolic acidosis may be present. CBC is usually obtained;\\nnormocytic anemia (usually due to protein deficiency) or microcytic anemia (due to simultaneous iron\\ndeficiency) is usually present.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n64'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 74, 'page_label': '65'}, page_content=\"Stool cultures should be obtained and checked for ova and parasites if diarrhea is severe or does not\\nresolve with treatment. Sometimes urinalysis, urine culture, blood cultures, tuberculin testing, and a chest\\nx-ray are used to diagnose occult infections because people with PEU may have a muted response to\\ninfections.\\nPrognosis\\nChildren:\\n In children, mortality varies from 5 to 40%. Mortality rates are lower in children with mild PEU\\nand those given intensive care. Death in the first days of treatment is usually due to electrolyte deficits,\\nsepsis, hypothermia, or heart failure. Impaired consciousness, jaundice, petechiae, hyponatremia, and\\npersistent diarrhea are ominous signs. Resolution of apathy, edema, and anorexia is a favorable sign.\\nRecovery is more rapid in kwashiorkor than in marasmus.\\nLong-term effects of PEU in children are not fully documented. Some children develop chronic\\nmalabsorption and pancreatic insufficiency. In very young children, mild intellectual disability may develop\\nand persist until at least school age. Permanent cognitive impairment may occur, depending on the\\nduration, severity, and age at onset of PEU.\\nAdults:\\n In adults, PEU can result in morbidity and mortality (eg, progressive weight loss increases\\nmortality rate for elderly patients in nursing homes). In elderly patients, PEU increases the risk of\\nmorbidity and mortality due to surgery, infections, or other disorders. Except when organ failure occurs,\\ntreatment is uniformly successful.\\nTreatment\\n Usually, oral feeding\\n Possibly avoidance of lactose (eg, if persistent diarrhea suggests lactose intolerance)\\n Supportive care (eg, environmental changes, assistance with feeding, orexigenic drugs)\\n For children, feeding delayed 24 to 48 h\\nWorldwide, the most important preventive strategy is to reduce poverty and improve nutritional education\\nand public health measures.\\nMild or moderate PEU, including brief starvation, can be treated by providing a balanced diet, preferably\\norally. Liquid oral food supplements (usually lactose-free) can be used when solid food cannot be\\nadequately ingested. Diarrhea often complicates oral feeding because starvation makes the GI tract more\\nlikely to move bacteria into Peyer's patches, facilitating infectious diarrhea. If diarrhea persists\\n(suggesting lactose intolerance), yogurt-based rather than milk-based formulas are given because people\\nwith lactose intolerance can tolerate yogurt. Patients should also be given a multivitamin supplement.\\nSevere PEU or prolonged starvation requires treatment in a hospital with a controlled diet. The first\\npriority is to correct fluid and electrolyte abnormalities (see \\nCh. 97\\n) and treat infections. Next is to supply\\nmacronutrients orally or, if necessary (eg, when swallowing is difficult), through a feeding tube, a\\nnasogastric tube (usually), or a gastrostomy tube. Parenteral nutrition is indicated if malabsorption is\\nsevere (see p. \\n23\\n).\\nOther treatments may be needed to correct specific deficiencies, which may become evident as weight\\nincreases. To avoid deficiencies, patients should take micronutrients at about twice the recommended\\ndaily allowance (RDA) until recovery is complete.\\nChildren:\\n Underlying disorders should be treated. For children with diarrhea, feeding may be delayed 24\\nto 48 h to avoid making the diarrhea worse; during this interval, children require oral or IV rehydration.\\nFeedings are given often (6 to 12 times/day) but, to avoid overwhelming the limited intestinal absorptive\\ncapacity, are limited to small amounts (< 100 mL). During the first week, milk-based formulas with\\nsupplements added are usually given in progressively increasing amounts; after a week, the full amounts\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n65\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 75, 'page_label': '66'}, page_content=\"of 175 kcal/kg and 4 g of protein/kg can be given. Twice the RDA of micronutrients should be given,\\nusing commercial multivitamin supplements. After 4 wk, the formula can be replaced with whole milk plus\\ncod liver oil and solid foods, including eggs, fruit, meats, and yeast.\\nEnergy distribution among macronutrients should be about 16% protein, 50% fat, and 34% carbohydrate.\\nAn example is a combination of powdered cow's skimmed milk (110 g), sucrose (100 g), vegetable oil (70\\ng), and water (900 mL). Many other formulas (eg, whole [full-fat] fresh milk plus corn oil and maltodextrin)\\ncan be used. Milk powders used in formulas are diluted with water.\\nUsually, supplements should be added to formulas:\\n Mg 0.4 mEq/kg/day IM is given for 7 days.\\n B-complex vitamins at twice the RDA are given parenterally for the first 3 days, usually with vitamin A,\\nphosphorus, zinc, manganese, copper, iodine, fluoride, molybdenum, and selenium.\\n Because absorption of oral iron is poor in children with PEU, oral or IM iron supplementation may be\\nnecessary.\\nParents are taught about nutritional requirements.\\nAdults:\\n Underlying disorders should be treated. For example, if AIDS or cancer results in excess cytokine\\nproduction, megestrol acetate or medroxyprogesterone may improve food intake. However, because\\nthese drugs dramatically decrease testosterone in men (possibly causing muscle loss), testosterone\\nshould be replaced. Because these drugs can cause adrenal insufficiency, they should be used only\\nshort-term (< 3 mo).\\nIn patients with functional limitations, home delivery of meals and feeding assistance are key.\\nAn orexigenic drug, such as the cannabis extract dronabinol, should be given to patients with anorexia\\nwhen no cause is obvious or to patients at the end of life when anorexia impairs quality of life. An\\nanabolic steroid (eg, enanthate, nandrolone, testosterone) or growth hormone can benefit patients with\\ncachexia due to renal failure and possibly elderly patients (eg, by increasing lean body mass or possibly\\nby improving function).\\nCorrection of PEU in adults generally resembles that in children; feedings are often limited to small\\namounts. However, for most adults, feeding does not need to be delayed. A commercial formula for oral\\nfeeding can be used. Daily nutrient supply should be given at a rate of 60 kcal/kg and 1.2 to 2 g of\\nprotein/kg. If liquid oral supplements are used with solid food, they should be given at least 1 h before\\nmeals so that the amount of food eaten at the meal is not reduced.\\nTreatment of institutionalized elderly patients with PEU requires multiple interventions:\\n Environmental measures (eg, making the dining area more attractive)\\n Feeding assistance\\n Changes in diet (eg, use of food enhancers and caloric supplements between meals)\\n Treatment of depression and other underlying disorders\\n Use of orexigenics, anabolic steroids, or both\\nThe long-term use of gastrostomy tube feeding is essential for patients with severe dysphagia; its use in\\npatients with dementia is controversial. Increasing evidence supports the avoidance of unpalatable\\ntherapeutic diets (eg, low salt, diabetic, low cholesterol) in institutionalized patients because these diets\\ndecrease food intake and may cause severe PEU.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n66\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 76, 'page_label': '67'}, page_content='Complications of treatment:\\n Treatment of PEU can cause complications (refeeding syndrome),\\nincluding fluid overload, electrolyte deficits, hyperglycemia, cardiac arrhythmias, and diarrhea. Diarrhea is\\nusually mild and resolves; however, diarrhea in patients with severe PEU occasionally causes severe\\ndehydration or death. Causes of diarrhea (eg, sorbitol used in elixir tube feedings, \\nClostridium difficile\\n if\\nthe patient has received an antibiotic) may be correctable. Osmotic diarrhea due to excess calories is rare\\nin adults and should be considered only when other causes have been excluded.\\nBecause PEU can impair cardiac and renal function, hydration can cause intravascular volume overload.\\nTreatment decreases extra-cellular K and Mg. Depletion of K or Mg may cause arrhythmias.\\nCarbohydrate metabolism that occurs during treatment stimulates insulin release, which drives phosphate\\ninto cells. Hypophosphatemia can cause muscle weakness, paresthesias, seizures, coma, and\\narrhythmias. Because phosphate levels can change rapidly during parenteral feeding, levels should be\\nmeasured regularly.\\nDuring treatment, endogenous insulin may become ineffective, leading to hyperglycemia. Dehydration\\nand hyperosmolarity can result. Fatal ventricular arrhythmias can develop, possibly caused by a\\nprolonged QT interval.\\nCarnitine Deficiency\\nCarnitine deficiency results from inadequate intake of or inability to metabolize the amino acid\\ncarnitine. It can cause a heterogeneous group of disorders. Muscle metabolism is impaired,\\ncausing myopathy, hypoglycemia, or cardiomyopathy. Infants typically present with\\nhypoglycemic, hypoketotic encephalopathy. Most often, treatment consists of dietary L-\\ncarnitine.\\nThe amino acid carnitine is required for the transport of long-chain fatty acyl coenzyme A (CoA) esters\\ninto myocyte mitochondria, where they are oxidized for energy. Carnitine is obtained from foods,\\nparticularly animal-based foods, and via endogenous synthesis.\\nCauses of carnitine deficiency include the following:\\n Inadequate intake (eg, due to fad diets, lack of access, or long-term TPN)\\n Inability to metabolize carnitine due to enzyme deficiencies (eg, carnitine palmitoyltransferase deficiency,\\nmethylmalonicaciduria, propionicacidemia, isovalericacidemia)\\n Decreased endogenous synthesis of carnitine due to a severe liver disorder\\n Excess loss of carnitine due to diarrhea, diuresis, or hemodialysis\\n A hereditary disorder in which carnitine leaks from renal tubules\\n Increased requirements for carnitine when ketosis is present or demand for fat oxidation is high (eg,\\nduring a critical illness such as sepsis or major burns; after major surgery of the GI tract)\\n Decreased muscle carnitine levels due to mitochondrial impairment (eg, due to use of zidovudine)\\n Use of valproate\\nThe deficiency may be generalized (systemic) or may affect mainly muscle (myopathic).\\nSymptoms and Signs\\nSymptoms and the age at which symptoms appear depend on the cause. Carnitine deficiency may cause\\nmuscle necrosis, myoglobinuria, lipid-storage myopathy, hypoglycemia, fatty liver, and hyperammonemia\\nwith muscle aches, fatigue, confusion, and cardiomyopathy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n67'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 77, 'page_label': '68'}, page_content=\"Diagnosis\\nIn neonates, carnitine palmitoyltransferase deficiency is diagnosed using mass spectrometry to screen\\nblood. Prenatal diagnosis may be possible using amniotic villous cells. In adults, the definitive diagnosis is\\nbased on acylcarnitine levels in serum, urine, and tissues (muscle and liver for systemic deficiency;\\nmuscle only for myopathic deficiency).\\nTreatment\\n Avoidance of fasting and strenuous exercise\\n Dietary interventions, based on cause\\nCarnitine deficiency due to inadequate dietary intake, increased requirements, excess losses, decreased\\nsynthesis, or (sometimes) enzyme deficiencies can be treated by giving L-carnitine 25 mg/kg po q 6 h.\\nAll patients must avoid fasting and strenuous exercise. Consuming uncooked cornstarch at bedtime\\nprevents early morning hypoglycemia. Some patients require supplementation with medium-chain\\ntriglycerides and essential fatty acids (eg, linoleic acid, linolenic acid). Patients with a fatty acid oxidation\\ndisorder require a high-carbohydrate, low-fat diet.\\nEssential Fatty Acid Deficiency\\nEssential fatty acid (EFA) deficiency is rare, occurring most often in infants fed diets deficient in\\nEFAs. Signs include scaly dermatitis, alopecia, thrombocytopenia, and, in children, growth\\nretardation. Diagnosis is clinical. Dietary replenishment of EFAs reverses the deficiency.\\nThe EFAs linoleic and linolenic acid are substrates for the endogenous synthesis of other fatty acids that\\nare needed for many physiologic processes, including maintaining the integrity of skin and cell\\nmembranes and synthesizing prostaglandins and leukotrienes. For example, eicosapentaenoic acid and\\ndocosahexaenoic acid, synthesized from EFAs, are important components of the brain and retina.\\nFor EFA deficiency to develop, dietary intake must be very low. Even small amounts of EFAs can prevent\\nEFA deficiency. Cow's milk has only about 25% of the linoleic acid in human milk, but when ingested in\\nnormal amounts, it has enough linoleic acid to prevent EFA deficiency. Total fat intake of people in many\\ndeveloping countries may be very low, but the fat is often vegetable based, with large amounts of linoleic\\nacid and enough linolenic acid to prevent EFA deficiency.\\nBabies fed a formula low in linoleic acid, such as a skim-milk formula, can develop EFA deficiency. EFA\\ndeficiency used to result from long-term TPN if fat was not included. But now, most TPN solutions include\\nfat emulsions to prevent EFA deficiency. In patients with fat malabsorption or increased metabolic needs\\n(eg, because of surgery, multiple trauma, or burns), laboratory evidence of EFA deficiency may be\\npresent without clinical signs.\\nDermatitis due to EFA deficiency is generalized and scaly; in infants, it can resemble congenital\\nichthyosis. The dermatitis increases water loss from the skin.\\nDiagnosis is usually clinical; however, laboratory assays are now available in large research centers.\\nTreatment consists of dietary EFAs, reversing the deficiency.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 2. Undernutrition\\n68\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 78, 'page_label': '69'}, page_content=\"Chapter 3. Nutritional Support\\nIntroduction\\nMany undernourished patients need nutritional support, which aims to increase lean body mass. Oral\\nfeeding can be difficult for some patients with anorexia or with eating or absorption problems. Behavioral\\nmeasures that sometimes enhance oral intake include the following:\\n Encouraging patients to eat\\n Heating or seasoning foods\\n Providing favorite or strongly flavored foods\\n Encouraging patients to eat small portions\\n Scheduling around meals\\n Assisting patients with feeding\\nIf behavioral measures are ineffective, nutritional supportoral, enteral tube, or parenteral nutritionis\\nindicated, except sometimes for dying or severely demented patients (see p. \\n25\\n).\\nPredicting Nutritional Requirements\\nNutritional requirements are predicted so that interventions can be planned. Requirements can be\\nestimated by formulas or measured by indirect calorimetry. Indirect calorimetry requires use of a metabolic\\ncart (a closed rebreathing system that determines energy expenditure based on total CO\\n2\\n production),\\nwhich requires special expertise and is not always available. Thus, total energy expenditure (TEE) and\\nprotein requirements usually are estimated.\\nEnergy expenditure:\\n TEE varies based on the patient's weight, activity level, and degree of metabolic\\nstress (metabolic demands); TEE ranges from 25 kcal/kg/day for people who are sedentary and not under\\nstress to about 40 kcal/kg/day for people who are critically ill. TEE equals the sum of\\n Resting metabolic rate (RMR, or resting energy expenditure rate), which is normally about 70% of TEE\\n Energy dissipated by metabolism of food (10% of TEE)\\n Energy expended during physical activity (20% of TEE)\\nUndernutrition can decrease RMR up to 20%. Conditions that increase metabolic stress (eg, critical\\nillness, infection, inflammation, trauma, surgery) can increase RMR but rarely by > 50%.\\nThe Mifflin-St. Jeor equation estimates RMR more precisely and with fewer errors than the commonly\\nused Harris-Benedict equation, usually providing results that are within 20% of those measured by\\nindirect calorimetry. The Mifflin-St. Jeor equation estimates RMR as follows:\\nMen\\n: kcal / day = 66 + (13.7  wt[kg]) + (5  height[cm]) - (6.8  age)\\nWomen\\n: kcal / day = 665 + (9.6  wt[kg]) + (1.8  height[cm]) - (4.7  age)\\nTEE can be estimated by adding about 10% (for sedentary people) to about 40% (for people who are\\ncritically ill) to RMR.\\nProtein requirements:\\n For healthy people, protein requirements are estimated at 0.8 g/kg/day.\\nHowever, for patients with metabolic stress or kidney failure and for elderly patients, requirements may be\\nhigher (see\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 3. Nutritional Support\\n69\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 79, 'page_label': '70'}, page_content='Table 3-1\\n).\\nAssessing Response to Nutritional Support\\nThere is no gold standard to assess response. Clinicians commonly use indicators of lean body mass\\nsuch as the following:\\n Body mass index (BMI)\\n Body composition analysis\\n Body fat distribution (see pp.\\n11\\n and \\n58\\n)\\nNitrogen balance, response to skin antigens, muscle strength measurement, and indirect calorimetry can\\nalso be used.\\n[\\nTable 3-1.\\n Estimated Adult Daily Protein Requirement]\\nNitrogen balance,\\n which reflects the balance between protein needs and supplies, is the difference\\nbetween amount of nitrogen ingested and amount lost. A positive balance (ie, more ingested than lost)\\nimplies adequate intake. Precise measurement is impractical, but estimates help assess response to\\nnutritional support. Nitrogen intake is estimated from protein intake: nitrogen (g) equals protein (g)/6.25.\\nEstimated nitrogen losses consist of urinary nitrogen losses (estimated by measuring urea nitrogen\\ncontent of an accurately obtained 24-h urine collection) plus stool losses (estimated at 1 g/day if stool is\\nproduced; negligible if stool is not produced) plus insensible and other unmeasured losses (estimated at\\n3 g).\\nResponse to skin antigens\\n, a measure of delayed hypersensitivity, often increases to normal as\\nundernourished patients respond to nutritional support. However, other factors can affect response to\\nskin antigens.\\nMuscle strength\\n indirectly reflects increases in lean body mass. It can be measured quantitatively, by\\nhand-grip dynamometry, or electrophysiologically (typically by stimulating the ulnar nerve with an\\nelectrode).\\nLevels of acute-phase reactant\\n serum proteins (particularly short-lived proteins such as prealbumin\\n[transthyretin], retinol-binding protein, and transferrin) sometimes correlate with improved nutritional\\nstatus, but these levels correlate better with inflammatory conditions.\\nEnteral Tube Nutrition\\nEnteral tube nutrition is indicated for patients who have a functioning GI tract but cannot ingest enough\\nnutrients orally because they are unable or unwilling to take oral feedings. Compared with parenteral\\nnutrition, enteral nutrition has the following advantages:\\n Better preservation of the structure and function of the GI tract\\n Lower cost\\n Probably fewer complications, particularly infections\\nSpecific indications\\n for enteral nutrition include the following:\\n Prolonged anorexia\\n Severe protein-energy undernutrition\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 3. Nutritional Support\\n70'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 80, 'page_label': '71'}, page_content=\" Coma or depressed sensorium\\n Liver failure\\n Inability to take oral feedings due to head or neck trauma or neurologic disorders\\n Critical illnesses (eg, burns) causing metabolic stress\\nOther indications may include bowel preparation for surgery in seriously ill or undernourished patients,\\nclosure of enterocutaneous fistulas, and small-bowel adaptation after massive intestinal resection or in\\ndisorders that may cause malabsorption (eg, Crohn's disease).\\nProcedure:\\n If tube feeding is needed for  4 to 6 wk, a small-caliber, soft nasogastric or nasoenteric (eg,\\nnasoduodenal) tube made of silicone or polyurethane is usually used. If a nasal injury or deformity makes\\nnasal placement difficult, an orogastric or other oroenteric tube can be placed.\\nTube feeding for > 4 to 6 wk usually requires a gastrostomy or jejunostomy tube, placed endoscopically,\\nsurgically, or radiologically. Choice depends on physician capabilities and patient preference.\\nJejunostomy tubes are useful for patients with contraindications to gastrostomy (eg, gastrectomy, bowel\\nobstruction proximal to the jejunum). However, these tubes do not pose less risk of tracheobronchial\\naspiration than gastrostomy tubes, as is often thought. Jejunostomy tubes are easily dislodged and are\\nusually used only for inpatients.\\nFeeding tubes are surgically placed if endoscopic and radiologic placement is unavailable, technically\\nimpossible, or unsafe (eg, because of overlying bowel). Open or laparoscopic techniques can be used.\\nFormulas:\\n Liquid formulas commonly used include feeding modules and polymeric or other specialized\\nformulas.\\nFeeding modules\\n are commercially available products that contain a single nutrient, such as proteins,\\nfats, or carbohydrates. Feeding modules may be used individually to treat a specific deficiency or\\ncombined with other formulas to completely satisfy nutritional requirements.\\nPolymeric formulas\\n (including blenderized food and milk-based or lactose-free commercial formulas)\\nare commercially available and generally provide a complete, balanced diet. For oral or tube feedings,\\nthey are usually preferred to feeding modules. In hospitalized patients, lactose-free formulas are the most\\ncommonly used polymeric formulas. However, milk-based formulas tend to taste better than lactose-free\\nformulas. Patients with lactose intolerance may be able to tolerate milk-based formulas given slowly by\\ncontinuous infusion.\\nSpecialized formulas\\n include hydrolyzed protein or sometimes amino acid formulas, which are used for\\npatients who have difficulty digesting complex proteins. However, these formulas are expensive and\\nusually unnecessary. Most patients with pancreatic insufficiency, if \\ngiven enzymes, and most patients with\\nmalabsorption can digest complex proteins. Other specialized formulas (eg, calorie- and protein-dense\\nformulas for patients whose fluids are restricted, fiber-enriched formulas for constipated patients) may be\\nhelpful.\\nAdministration:\\n Patients should be sitting upright at 30 to 45 during tube feeding and for 1 to 2 h\\nafterward to minimize incidence of nosocomial aspiration pneumonia and to allow gravity to help propel\\nthe food. Tube feedings are given in boluses several times a day or by continuous infusion. Bolus feeding\\nis more physiologic and may be preferred for patients with diabetes. Continuous infusion is necessary if\\nboluses cause nausea.\\n[\\nTable 3-2.\\n Complications of Enteral Tube Nutrition]\\nFor bolus feeding, total daily volume is divided into 4 to 6 separate feedings, which are injected through\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 3. Nutritional Support\\n71\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 81, 'page_label': '72'}, page_content=\"the tube with a syringe or infused by gravity from an elevated bag. After feedings, the tube is flushed with\\nwater to prevent clogging.\\nNasogastric or nasoduodenal tube feeding\\n often causes diarrhea initially; thus, feedings are usually\\nstarted with small amounts of dilute preparations and increased as tolerated. Most formulas contain 0.5,\\n1, or 2 kcal/mL. Formulas with higher caloric concentration (less water per calorie) may cause decreased\\ngastric emptying and thus higher gastric residuals than when more dilute formulas with the same number\\nof calories are used. Initially, a 1-kcal/mL commercially prepared solution may be given undiluted at 50\\nmL/h or, if patients have not been fed for a while, at 25 mL/h. Usually, these solutions do not supply\\nenough water, particularly if vomiting, diarrhea, sweating, or fever has increased water loss. Extra water\\nis supplied as boluses via the feeding tube or IV. After a few days, the rate or concentration can be\\nincreased as needed to meet caloric and water needs.\\nJejunostomy tube feeding\\n requires greater dilution and smaller volumes. Feeding usually begins at a\\nconcentration of  0.5 kcal/mL and a rate of 25 mL/h. After a few days, concentrations and volumes can\\nbe increased to eventually meet caloric and water needs. Usually, the maximum that can be tolerated is\\n0.8 kcal/mL at 125 mL/h, providing 2400 kcal/day.\\nComplications:\\n Complications are common and can be serious (see \\nTable 3-2\\n).\\nTotal Parenteral Nutrition\\nParenteral nutrition is by definition given IV.\\nPartial parenteral nutrition\\n supplies only part of daily nutritional requirements, supplementing oral\\nintake. Many hospitalized patients are given dextrose or amino acid solutions by this method.\\nTotal parenteral nutrition\\n (TPN) supplies all daily nutritional requirements. TPN can be used in the\\nhospital or at home. Because TPN solutions are concentrated and can cause thrombosis of peripheral\\nveins, a central venous catheter is usually required.\\nParenteral nutrition should not be used routinely in patients with an intact GI tract. Compared with enteral\\nnutrition, it causes more complications, does not preserve GI tract structure and function as well, and is\\nmore expensive.\\nIndications:\\n TPN may be the only feasible option for patients who do not have a functioning GI tract or\\nwho have disorders requiring complete bowel rest, such as the following:\\n Some stages of Crohn's disease or ulcerative colitis\\n Bowel obstruction\\n Certain pediatric GI disorders (eg, congenital GI anomalies, prolonged diarrhea regardless of its cause)\\n Short bowel syndrome due to surgery\\nNutritional content:\\n TPN requires water (30 to 40 mL/kg/day), energy (30 to 60 kcal/kg/day, depending\\non energy expenditure), amino acids (1 to 2.0 g/kg/day, depending on the degree of catabolism), essential\\nfatty acids, vitamins, and minerals (see\\nTable 3-3\\n). Children who need TPN may have different fluid requirements and need more energy (up to\\n120 kcal/kg/day) and amino acids (up to 2.5 or 3.5 g/kg/day).\\nBasic TPN solutions are prepared using sterile techniques, usually in liter batches according to standard\\nformulas. Normally, 2 L/day of the standard solution is needed. Solutions may be modified based on\\nlaboratory results, underlying disorders, hypermetabolism, or other factors.\\nMost calories are supplied as carbohydrate. Typically, about 4 to 5 mg/kg/day of dextrose is given.\\nStandard solutions contain up to about 25% dextrose, but the amount and concentration depend on other\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 3. Nutritional Support\\n72\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 82, 'page_label': '73'}, page_content=\"factors, such as metabolic needs and the proportion of caloric needs that are supplied by lipids.\\nCommercially available lipid emulsions are often added to supply essential fatty acids and triglycerides;\\n20 to 30% of total calories are usually supplied as lipids. However, withholding lipids and their calories\\nmay help obese patients mobilize endogenous fat stores, increasing insulin sensitivity.\\nSolutions:\\n Many solutions are commonly used. Electrolytes can be added to meet the patient's needs.\\nSolutions vary depending on other disorders present and patient age, as for the following:\\n For renal insufficiency not being treated with dialysis or for liver failure: Reduced protein content and a\\nhigh percentage of essential amino acids\\n For heart or kidney failure: Limited volume (liquid) intake\\n \\nFor respiratory failure: A lipid emulsion that provides most of nonprotein calories to minimize CO\\n2\\nproduction by carbohydrate metabolism\\n For neonates: Lower dextrose concentrations (17 to 18%)\\nBeginning TPN administration:\\n Because the central venous catheter needs to remain in place for a\\nlong time, strict sterile technique must be used during insertion and maintenance. The TPN line should\\nnot be used for any other purpose. External tubing should be changed every 24 h with the first bag of the\\nday. In-line filters have not been shown to decrease complications. Dressings should be kept sterile and\\nare usually changed every 48 h using strict sterile techniques. If TPN is given outside the hospital,\\npatients must be taught to recognize symptoms of infection, and qualified home nursing must be\\narranged.\\nThe solution is started slowly at 50% of the calculated requirements, using 5% dextrose to make up the\\nbalance of fluid requirements. Energy and nitrogen should be given simultaneously. The amount of\\nregular insulin given (added directly to the TPN solution) depends on the plasma glucose level; if the\\nlevel is normal and the final solution contains 25% dextrose, the usual starting dose is 5 to 10 units of\\nregular insulin/L of TPN fluid.\\nMonitoring:\\n Progress should be followed on a flowchart. An interdisciplinary nutrition team, if available,\\nshould monitor patients. Weight, CBC, electrolytes, and BUN should be monitored often (eg, daily for\\ninpatients). Plasma glucose should be monitored every 6 h until patients and glucose levels become\\nstable. Fluid intake and output should be monitored continuously. When patients become stable, blood\\ntests can be done much less often.\\nLiver function tests should be done. Plasma proteins (eg, serum albumin, possibly transthyretin or retinol-\\nbinding protein), PT, plasma and urine osmolality, and Ca, Mg, and phosphate should be measured\\ntwice/wk. Changes in transthyretin and retinol-binding protein reflect overall clinical status rather than\\nnutritional status alone. If possible, blood tests should not be done during glucose infusion. Full nutritional\\nassessment (including BMI calculation and anthropometric measurementssee pp. \\n11\\n and \\n58\\n) should be\\nrepeated at 2-wk intervals.\\nComplications:\\n About 5 to 10% of patients have complications related to central venous access.\\n[\\nTable 3-3.\\n Basic Adult Daily Requirements for Total Parenteral Nutrition]\\nCatheter-related sepsis occurs in about  50% of patients. Glucose abnormalities (hyperglycemia or\\nhypoglycemia) or liver dysfunction occurs in > 90% of patients.\\nGlucose abnormalities\\n are common. Hyperglycemia can be avoided by monitoring plasma glucose\\noften, adjusting the insulin dose in the TPN solution and giving subcutaneous insulin as needed.\\nHypoglycemia can be precipitated by suddenly stopping constant concentrated dextrose infusions.\\nTreatment depends on the degree of hypoglycemia. Short-term hypoglycemia may be reversed with 50%\\ndextrose IV; more prolonged hypoglycemia may require infusion of 5 or 10% dextrose for 24 h before\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 3. Nutritional Support\\n73\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 83, 'page_label': '74'}, page_content='resuming TPN via the central venous catheter.\\nHepatic complications\\n include liver dysfunction, painful hepatomegaly, and hyperammonemia. They can\\ndevelop at any age but are most common among infants, particularly premature ones (whose liver is\\nimmature).\\n Liver dysfunction may be transient, evidenced by increased transaminases, bilirubin, and alkaline\\nphosphatase; it commonly occurs when TPN is started. Delayed or persistent elevations may result\\nfrom excess amino acids. Pathogenesis is unknown, but cholestasis and inflammation may contribute.\\nProgressive fibrosis occasionally develops. Reducing protein delivery may help.\\n Painful hepatomegaly suggests fat accumulation; carbohydrate delivery should be reduced.\\n Hyperammonemia can develop in infants, causing lethargy, twitching, and generalized seizures. Arginine\\nsupplementation at 0.5 to 1.0 mmol/kg/day can correct it.\\nIf infants develop any hepatic complication, limiting amino acids to 1.0 g/kg/day may be necessary.\\nAbnormalities of serum electrolytes and minerals\\n should be corrected by modifying subsequent\\ninfusions or, if correction is urgently required, by beginning appropriate peripheral vein infusions. Vitamin\\nand mineral deficiencies are rare when solutions are given correctly. Elevated BUN may reflect\\ndehydration, which can be corrected by giving free water as 5% dextrose via a peripheral vein.\\nVolume overload\\n (suggested by > 1 kg/day weight gain) may occur when patients have high daily\\nenergy requirements and thus require large fluid volumes.\\nMetabolic bone disease\\n, or bone demineralization (osteoporosis or osteomalacia), develops in some\\npatients given TPN for > 3 mo. The mechanism is unknown. Advanced disease can cause severe\\nperiarticular, lower-extremity, and back pain. Temporarily or permanently stopping TPN is the only known\\ntreatment.\\nAdverse reactions to lipid emulsions\\n (eg, dyspnea, cutaneous allergic reactions, nausea, headache,\\nback pain, sweating, dizziness) are uncommon but may occur early, particularly if lipids are given at > 1.0\\nkcal/kg/h. Temporary hyperlipidemia may occur, particularly in patients with kidney or liver failure;\\ntreatment is usually not required. Delayed adverse reactions to lipid emulsions include hepatomegaly, mild\\nelevation of liver enzymes, splenomegaly, thrombocytopenia, leukopenia, and, especially in premature\\ninfants with respiratory distress syndrome, pulmonary function abnormalities. Temporarily or permanently\\nslowing or stopping lipid emulsion infusion may prevent or minimize these adverse reactions.\\nGallbladder complications\\n include cholelithiasis, gallbladder sludge, and cholecystitis. These\\ncomplications can be caused or worsened by prolonged gallbladder stasis. Stimulating contraction by\\nproviding about 20 to 30% of calories as fat and stopping glucose infusion several hours a day is helpful.\\nOral or enteral intake also helps. Treatment with metronidazole, ursodeoxycholic acid, phenobarbital, or\\ncholecystokinin helps some patients with cholestasis.\\nNutritional Support for Dying or Severely Demented Patients\\nAnorexia or loss of appetite is common among dying patients (see p. \\n3485\\n). Behavioral measures (eg,\\nusing flexible feeding schedules, feeding slowly, giving small portions or favorite or strongly flavored\\nfoods) can often increase oral intake. A small amount of a favorite alcoholic drink, given 30 min before\\nmeals, may also help. Certain antidepressants, megestrol acetate, and dronabinol may stimulate appetite.\\nMetoclopramide enhances gastric emptying, but it may take 1 to 2 wk to reach peak effectiveness.\\nAdvanced dementia eventually leads to inability to eat; sometimes affected patients are given tube\\nfeedings. However, there is no convincing evidence that tube feedings prolong life, provide comfort,\\nimprove function, or prevent complications (eg, aspiration, pressure ulcers).\\nTube feedings and parenteral nutrition cause discomfort and are usually not indicated for patients who\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 3. Nutritional Support\\n74'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 84, 'page_label': '75'}, page_content='are dying or too demented to eat. Forgoing nutritional support may be difficult for family members to\\naccept, but they should understand that patients are usually more comfortable eating and drinking as they\\nchoose. Sips of water and easy-to-swallow foods may be useful. Supportive care, including good oral\\nhygiene (eg, brushing the teeth, moistening the oral cavity with swabs and ice chips as needed, applying\\nlip salve), can physically and psychologically comfort the patients and the family members who provide\\nthe care.\\nCounseling may help family members who are dealing with anxieties about whether to use invasive\\nnutritional support.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 3. Nutritional Support\\n75'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 85, 'page_label': '76'}, page_content='Chapter 4. Vitamin Deficiency, Dependency, and Toxicity\\nIntroduction\\nVitamins may be fat soluble (vitamins A, D, E, and K) or water soluble (B vitamins and vitamin C). The B\\nvitamins include biotin, folate, niacin, pantothenic acid, riboflavin (B\\n2\\n), thiamin (B\\n1\\n), B\\n6\\n (eg, pyridoxine),\\nand B\\n12\\n (cobalamins). For dietary requirements, sources, functions, effects of deficiencies and toxicities,\\nblood levels, and usual therapeutic dosages for vitamins, see\\nTables 4-1\\n and\\n4-2\\n.\\nDietary requirements for vitamins (and other nutrients) are expressed as daily recommended intake (DRI).\\nThere are 3 types of DRI:\\n \\nRecommended daily allowance (RDA):\\n RDAs are set to meet the needs of 97 to 98% of healthy\\npeople.\\n \\nAdequate intake (AI):\\n When data to calculate an RDA are insufficient, AIs are based on observed or\\nexperimentally determined estimates of nutrient intake by healthy people.\\n \\nTolerable upper intake level (UL):\\n ULs are the largest amount of a nutrient that most adults can\\ningest daily without risk of adverse health effects.\\nIn developed countries, vitamin deficiencies result mainly from poverty, food faddism, drugs (see p. \\n7\\n and\\nTable 4-3\\n), alcoholism, or prolonged and inadequately supplemented parenteral feeding. Mild vitamin\\ndeficiency is common among frail and institutionalized elderly people who have protein-energy\\nundernutrition. In developing countries, deficiencies can result from lack of access to nutrients.\\nDeficiencies of water-soluble vitamins (except vitamin B\\n12\\n) may develop after weeks to months of\\nundernutrition. Deficiencies of fat-soluble vitamins and of vitamin B\\n12\\n take > 1 yr to develop because the\\nbody stores them in relatively large amounts. Intake of vitamins sufficient to prevent classic vitamin\\ndeficiencies (like scurvy or beriberi) may not be adequate for optimum health. This area remains one of\\ncontroversy and active research.\\nVitamin dependency results from a genetic defect involving metabolism of a vitamin. In some cases,\\nvitamin doses as high as 1000 times the DRI improve function of the altered metabolic pathway. Vitamin\\ntoxicity (hypervitaminosis) usually results from taking megadoses of vitamin A, D, C, B\\n6\\n, or niacin.\\nBecause many people eat irregularly, foods alone may provide suboptimal amounts of some vitamins. In\\nthese cases, the risk of certain cancers or other disorders may be increased. Because of this risk, routine\\ndaily multivitamin supplements are sometimes recommended.\\nBiotin and Pantothenic Acid\\nBiotin acts as a coenzyme for carboxylation reactions essential to fat and carbohydrate metabolism.\\nAdequate intake for adults is 30 \\n\\ng/day. Pantothenic acid is widely distributed in foods; it is an essential\\ncomponent of coenzyme A. Adults probably require about 5 mg/day. A beneficial role for pantothenic acid\\nsupplementation in lipid metabolism, RA, or athletic performance remains unproved. Isolated deficiency of\\nbiotin or pantothenic acid virtually never occurs.\\nFolate\\nFolate (folic acid) is now added to enriched grain foods in the US. Folate is also plentiful in various plant\\nfoods and meats, but its bioavailability is greater when it is in supplements\\n[\\nTable 4-1.\\n Recommended Daily Intakes for Vitamins]\\nor enriched foods than when it occurs naturally in food.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n76'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 86, 'page_label': '77'}, page_content='Folates are involved in RBC maturation and synthesis of purines and pyrimidines. They are required for\\ndevelopment of the fetal nervous system. Absorption occurs in the duodenum and upper jejunum.\\nEnterohepatic circulation of folate occurs. Folate supplements\\n[\\nTable 4-2.\\n Sources, Functions, and Effects of Vitamins]\\ndo not protect against coronary artery disease or stroke (by lowering homocysteine levels); their role in\\nreducing the risk of various cancers is unclear. The upper limit for folate intake is 1000 \\n\\ng; higher doses\\n(up to 5 mg) are recommended for women who have had a baby with a neural tube defect. Folate is\\nessentially nontoxic.\\nFolate Deficiency\\nFolate deficiency is common. It may result from inadequate intake, malabsorption, or use of various drugs.\\nDeficiency causes megaloblastic anemia (indistinguishable from that due to vitamin B\\n12\\n deficiency).\\nMaternal deficiency increases the risk of neural tube birth defects. Diagnosis requires laboratory testing\\nto confirm. Measurement of neutrophil hypersegmentation is sensitive and readily available. Treatment\\nwith oral folate is usually successful.\\nEtiology and Pathophysiology\\nThe most common causes are inadequate intake (usually in patients with undernutrition or alcoholism),\\nincreased demand (eg, due to pregnancy or breastfeeding), and impaired absorption (eg, in tropical\\nsprue, due to certain drugs). Deficiency can also result from inadequate bioavailability and increased\\nexcretion (see\\nTable 4-4\\n).\\nProlonged cooking destroys folate, predisposing to inadequate intake. Intake is sometimes barely\\nadequate (eg, in alcoholics). Liver stores provide only a several-month supply.\\nAlcohol interferes with folate absorption, metabolism, renal excretion, and enterohepatic reabsorption, as\\nwell as intake. 5-Fluorouracil, metformin, methotrexate, phenobarbital, phenytoin, sulfasalazine,\\ntriamterene, and trimethoprim impair folate metabolism.\\nIn the US, many dietary staples (eg, cereals, grain products) are routinely enriched with folate, tending to\\nreduce risk of deficiency.\\n[\\nTable 4-3.\\n Potential Vitamin-Drug Interactions]\\nSymptoms and Signs\\nFolate deficiency may cause glossitis, diarrhea, depression, and confusion. Anemia may develop\\ninsidiously and, because of compensatory mechanisms, be more severe than symptoms suggest.\\nFolate deficiency during pregnancy increases the risk of fetal neural tube defects and perhaps other brain\\ndefects (see p. \\n2992\\n).\\nDiagnosis\\n CBC and serum vitamin B\\n12\\n and folate levels\\nCBC may indicate megaloblastic anemia indistinguishable from that of vitamin B\\n12\\n deficiency. If serum\\nfolate is < 3 \\n\\ng/L or ng/mL (< 7 nmol/L), deficiency is likely. Serum folate reflects folate status unless\\nintake has recently increased or decreased. If intake has changed, erythrocyte (RBC) folate level better\\nreflects tissue stores. A level of < 140 \\n\\ng/L or ng/mL (< 305 nmol/L) indicates inadequate status. Also, an\\nincrease in the homocysteine level suggests tissue folate deficiency (but the level is also affected by\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n77'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 87, 'page_label': '78'}, page_content='vitamin B\\n12\\n and vitamin B\\n6\\n levels, renal insufficiency, and genetic factors). A normal methylmalonic acid\\n(MMA) level may differentiate folate deficiency from vitamin B\\n12\\n deficiency because MMA levels rise in\\nvitamin B\\n12\\n deficiency but not in folate deficiency.\\nTreatment\\n Supplemental oral folate\\nFolate 400 to 1000 \\n\\ng po once/day replenishes tissues and is usually successful even if deficiency has\\nresulted from malabsorption. The normal requirement is 400 \\n\\ng/day.\\n[\\nTable 4-4.\\n Causes of Folate Deficiency]\\n(CAUTION: \\nIn patients with megaloblastic anemia, vitamin B\\n12\\n deficiency must be ruled out before\\ntreating with folate. If vitamin B\\n12\\n deficiency is present, folate supplementation can alleviate the\\nanemia but does not reverse and may even worsen neurologic deficits\\n.) For pregnant women, the\\nrecommended daily allowance (RDA) is 600 \\n\\ng/day. For women who have had a fetus or infant with a\\nneural tube defect, the recommended dose is 1000 to 5000 \\n\\ng/day.\\nNiacin\\nNiacin (nicotinic acid, nicotinamide) derivatives include nicotinamide adenine dinucleotide (NAD) and\\nnicotinamide adenine dinucleotide phosphate (NADP), which are coenzymes in oxidation-reduction\\nreactions. They are vital in cell metabolism. Because dietary tryptophan can be metabolized to niacin,\\nfoods rich in tryptophan (eg, dairy products) can compensate for inadequate dietary niacin.\\nNiacin Deficiency\\nDietary niacin deficiency (causing pellagra) is uncommon in developed countries. Clinical\\nmanifestations include the \"three Ds\": localized pigmented rash (dermatitis); gastroenteritis\\n(diarrhea); and widespread neurologic deficits, including cognitive decline (dementia).\\nDiagnosis is usually clinical, and dietary supplementation (oral or, if needed, IM) is usually\\nsuccessful.\\nEtiology\\nPrimary deficiency results from extremely inadequate intake of both niacin and tryptophan, which usually\\noccurs in areas where maize (Indian corn) constitutes a substantial part of the diet. Bound niacin, found in\\nmaize, is not assimilated in the GI tract unless it has been previously treated with alkali, as when tortillas\\nare prepared. Corn protein is also deficient in tryptophan. The high incidence of pellagra in India among\\npeople who eat millet with a high leucine content has led to the hypothesis that amino acid imbalance may\\ncontribute to deficiency. Deficiencies of protein and many B vitamins commonly accompany primary niacin\\ndeficiency.\\nSecondary deficiency may be due to diarrhea, cirrhosis, or alcoholism. Pellagra also may occur in\\ncarcinoid syndrome (tryptophan is diverted to form 5-hydroxytryptophan and serotonin) and in Hartnup\\ndisease (absorption of tryptophan by the intestine and kidneys is defective).\\nSymptoms and Signs\\nPellagra is characterized by skin, mucous membrane, CNS, and GI symptoms. Advanced pellagra can\\ncause a symmetric photosensitive rash, stomatitis, glossitis, diarrhea, and mental aberrations. Symptoms\\nmay appear alone or in combination.\\nSkin symptoms\\n include several types of lesions, which are usually bilaterally symmetric. The distribution\\nof lesionsat pressure points or sun-exposed skinis more pathognomonic than the form of the lesions.\\nLesions can develop in a glovelike distribution on the hands (pellagrous glove) or in a boot-shaped\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n78'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 88, 'page_label': '79'}, page_content=\"distribution on the feet and legs (pellagrous boot). Sunlight causes Casal's necklace and butterfly-shaped\\nlesions on the face.\\nMucous membrane symptoms\\n affect primarily the mouth but may also affect the vagina and urethra.\\nGlossitis and stomatitis characterize acute deficiency. As the deficiency progresses, the tongue and oral\\nmucous membranes become reddened, followed by pain in the mouth, increased salivation, and edema of\\nthe tongue. Ulcerations may appear, especially under the tongue, on the mucosa of the lower lip, and\\nopposite the molar teeth.\\nGI symptoms\\n early in the deficiency include burning in the pharynx and esophagus and abdominal\\ndiscomfort and distention. Constipation is common. Later, nausea, vomiting, and diarrhea may occur.\\nDiarrhea is often bloody because of bowel hyperemia and ulceration.\\nCNS symptoms\\n include psychosis, encephalopathy (characterized by impaired consciousness), and\\ncognitive decline (dementia). Psychosis is characterized by memory impairment, disorientation, confusion,\\nand confabulation; the predominant symptom may be excitement, depression, mania, delirium, or\\nparanoia.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is clinical and may be straightforward when skin and mouth lesions, diarrhea, delirium, and\\ndementia occur simultaneously. More often, the presentation is not so specific. Differentiating the CNS\\nchanges from those in thiamin deficiency is difficult. A history of a diet lacking niacin and tryptophan may\\nhelp establish the diagnosis. A favorable response to treatment with niacin can usually \\nconfirm it. If\\navailable, laboratory testing can help confirm the diagnosis, particularly when the diagnosis is otherwise\\nunclear. Urinary excretion of N\\n1\\n-methylnicotinamide (NMN) is decreased; < 0.8 mg/day (< 5.8 \\n\\nmol/day)\\nsuggests a niacin deficiency.\\nTreatment\\n Nicotinamide and other nutrients\\nBecause multiple deficiencies are common, a balanced diet, including other B vitamins (particularly\\nriboflavin and pyridoxine), is needed. Nicotinamide is usually used to treat deficiency, because\\nnicotinamide, unlike nicotinic acid (the most common form of niacin), does not cause flushing, itching,\\nburning, or tingling sensations. Nicotinamide is given in doses ranging from 40 to 250 mg/day po in\\ndivided doses 3 to 4 times a day.\\nNiacin Toxicity\\nNiacin (nicotinic acid) in large amounts is sometimes used to lower low-density lipoprotein\\n(LDL) cholesterol and triglyceride levels and to increase high-density lipoprotein (HDL)\\ncholesterol levels. Symptoms may include flushing and, rarely, hepatotoxicity.\\nImmediate- and sustained-release preparations of niacin (but not nicotinamide) may improve lipid levels.\\nFlushing, which is prostaglandin-mediated, is more common with immediate-release preparations. It may\\nbe more intense after alcohol ingestion, aerobic activity, sun exposure, and consumption of spicy foods.\\nFlushing is minimized if niacin is taken after meals or if aspirin (325 mg) is taken 30 to 45 min before\\nniacin. The chance of severe flushing can be reduced by starting immediate-release niacin at a low dose\\n(eg, 50 mg tid) and increasing it very slowly. At intermediate doses (1000 mg/day), triglyceride levels\\ndecrease 15 to 20%, and HDL cholesterol levels increase 15 to 30%. Reductions in LDL cholesterol are\\nmodest (< 10%). Higher doses of niacin (3000 mg/day) reduce LDL cholesterol 15 to 20% but may cause\\njaundice, abdominal discomfort, blurred vision, worsening of hyperglycemia, and precipitation of\\npreexisting gout. People with a liver disorder probably should not take high-dose niacin.\\nHepatotoxicity may be more common with some sustained-release preparations. Some authorities\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n79\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 89, 'page_label': '80'}, page_content='recommend checking levels of uric acid, serum glucose, and plasma transaminases every 6 to 8 wk until\\nthe dose of niacin has been stabilized.\\nRiboflavin\\nRiboflavin (vitamin B\\n2\\n) is involved in carbohydrate metabolism as an essential coenzyme in many\\noxidation-reduction reactions. Riboflavin is essentially nontoxic.\\nRiboflavin Deficiency\\nRiboflavin deficiency usually occurs with other B-vitamin deficiencies. Symptoms and signs\\ninclude sore throat, lesions of the lips and mucosa of the mouth, glossitis, conjunctivitis,\\nseborrheic dermatitis, and normochromicnormocytic anemia. Diagnosis is usually clinical.\\nTreatment consists of oral or, if needed, IM riboflavin.\\nPrimary riboflavin deficiency results from inadequate intake of fortified cereals, milk, and other animal\\nproducts. The most common causes of secondary deficiency are chronic diarrhea, malabsorption\\nsyndromes, liver disorders, hemodialysis, peritoneal dialysis, long-term use of barbiturates, and chronic\\nalcoholism.\\nSymptoms and Signs\\nThe most common signs are pallor and maceration of the mucosa at the angles of the mouth (angular\\nstomatitis) and vermilion surfaces of the lips (cheilosis), eventually replaced by superficial linear fissures.\\nThe fissures can become infected with \\nCandida albicans\\n, causing grayish white lesions (perleche). The\\ntongue may appear magenta. Seborrheic dermatitis develops, usually affecting the nasolabial folds, ears,\\neyelids, and scrotum or labia majora. These areas become red, scaly, and greasy.\\nRarely, neovascularization and keratitis of the cornea occur, causing lacrimation and photophobia.\\nDiagnosis\\nThe lesions characteristic of riboflavin deficiency are nonspecific. Riboflavin deficiency should be\\nsuspected if characteristic signs develop in a patient with other B vitamin deficiencies. Diagnosis can be\\nconfirmed by a therapeutic trial or laboratory testing, usually by measuring urinary excretion of riboflavin.\\nTreatment\\nRiboflavin 5 to 10 mg/day po is given until recovery. Other water-soluble vitamins should also be given.\\nThiamin\\nThiamin (vitamin B\\n1\\n) is widely available in the diet. Thiamin is involved in carbohydrate, fat, amino acid,\\nglucose, and alcohol metabolism. Thiamin is essentially nontoxic.\\nThiamin Deficiency\\nThiamin deficiency (causing beriberi) is most common among people subsisting on white rice\\nor highly refined carbohydrates in developing countries and among alcoholics. Symptoms\\ninclude diffuse polyneuropathy, high-output heart failure, and Wernicke-Korsakoff syndrome.\\nThiamin is given to help diagnose and treat the deficiency.\\nEtiology\\nPrimary thiamin deficiency is caused by inadequate intake of thiamin. It is commonly due to a diet of\\nhighly refined carbohydrates (eg, polished rice, white flour, white sugar). It also develops when intake of\\nother nutrients is inadequate; it often occurs with other B vitamin deficiencies.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n80'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 90, 'page_label': '81'}, page_content=\"Secondary thiamin deficiency is caused by increased demand (eg, due to hyperthyroidism, pregnancy,\\nbreastfeeding, strenuous exercise, or fever), impaired absorption (eg, due to prolonged diarrhea), or\\nimpaired metabolism (eg, due to hepatic insufficiency). In alcoholics, many mechanisms contribute to\\nthiamin deficiency; they include decreased intake, impaired absorption and use, increased demand, and\\npossibly an apoenzyme defect.\\nPathophysiology\\nDeficiency causes degeneration of peripheral nerves, thalamus, mammillary bodies, and cerebellum.\\nCerebral blood flow is markedly reduced, and vascular resistance is increased.\\nThe heart may become dilated; muscle fibers become swollen, fragmented, and vacuolized, with\\ninterstitial spaces dilated by fluid. Vasodilation occurs and can result in edema in the feet and legs.\\nArteriovenous shunting of blood increases. Eventually, high-output heart failure may occur.\\nSymptoms and Signs\\nEarly symptoms are nonspecific: fatigue, irritability, poor memory, sleep disturbances, precordial pain,\\nanorexia, and abdominal discomfort.\\nDry beriberi\\n refers to peripheral neurologic deficits due to thiamin deficiency. These deficits are bilateral\\nand roughly symmetric, occurring in a stocking-glove distribution. They affect predominantly the lower\\nextremities, beginning with paresthesias in the toes, burning in the feet (particularly severe at night),\\nmuscle cramps in the calves, pains in the legs, and plantar dysesthesias. Calf muscle tenderness,\\ndifficulty rising from a squatting position, and decreased vibratory sensation in the toes are early signs.\\nMuscle wasting occurs. Continued deficiency worsens polyneuropathy, which can eventually affect the\\narms.\\nWernicke-Korsakoff syndrome,\\n which combines Wernicke's encephalopathy (see p. \\n1522\\n) and\\nKorsakoff's psychosis (see p. \\n1523\\n), occurs in some alcoholics who do not consume foods fortified with\\nthiamin. Wernicke's encephalopathy consists of psychomotor slowing or apathy, nystagmus, ataxia,\\nophthalmoplegia, impaired consciousness, and, if untreated, coma and death. It probably results from\\nsevere acute deficiency superimposed on chronic deficiency. Korsakoff's psychosis consists of mental\\nconfusion, dysphonia, and confabulation with impaired memory of recent events. It probably results from\\nchronic deficiency and may develop after repeated episodes of Wernicke's encephalopathy.\\nCardiovascular (wet) beriberi\\n is myocardial disease due to thiamin deficiency. The first effects are\\nvasodilation, tachycardia, a wide pulse pressure, sweating, warm skin, and lactic acidosis. Later, heart\\nfailure develops, causing orthopnea and pulmonary and peripheral edema. Vasodilation can continue,\\nsometimes resulting in shock.\\nInfantile beriberi\\n occurs in infants (usually by age 3 to 4 wk) who are breastfed by thiamin-deficient\\nmothers. Heart failure (which may occur suddenly), aphonia, and absent deep tendon reflexes are\\ncharacteristic.\\nBecause thiamin is necessary for glucose metabolism, glucose infusions may precipitate or worsen\\nsymptoms of deficiency in thiamin-deficient people.\\nDiagnosis\\n Favorable response to thiamin\\nDiagnosis is usually based on a favorable response to treatment with thiamin in a patient with symptoms\\nor signs of deficiency. Similar bilateral lower-extremity polyneuropathies due to other disorders (eg,\\ndiabetes, alcoholism, vitamin B\\n12\\n deficiency, heavy metal poisoning) do not respond to thiamin. Single-\\nnerve neuritides (mononeuropathieseg, sciatica) and multiple mononeuropathies (mononeuritis\\nmultiplex) are unlikely to result from thiamin deficiency.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n81\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 91, 'page_label': '82'}, page_content=\"Electrolytes, including Mg, should be measured to exclude other causes. For confirmation in equivocal\\ncases, erythrocyte transketolase activity and 24-h urinary thiamin excretion may be measured.\\nDiagnosis of cardiovascular beriberi can be difficult if other disorders that cause heart failure are present.\\nA therapeutic trial of thiamin can help.\\nTreatment\\n Supplemental thiamin, with dose based on clinical manifestations\\nEnsuring that dietary supplies of thiamin are adequate is important regardless of symptoms. Because IV\\nglucose can worsen thiamin deficiency, alcoholics and others at risk of thiamin deficiency should receive\\nIV thiamin 100 mg before receiving IV glucose solutions.\\nFor mild polyneuropathy, thiamin 10 to 20 mg po once/day is given for 2 wk. For moderate or advanced\\nneuropathy, the dose is 20 to 30 mg/day; it should be continued for several weeks after symptoms\\ndisappear. For edema and congestion due to cardiovascular beriberi, thiamin 100 mg IV once/day is given\\nfor several days. Heart failure is also treated.\\nFor Wernicke-Korsakoff syndrome, thiamin 50 to 100 mg IM or IV bid must usually be given for several\\ndays, followed by 10 to 20 mg once/day until a therapeutic response is obtained. Anaphylactic reactions\\nto IV thiamin are rare. Symptoms of ophthalmoplegia may resolve in a day; improvement in patients with\\nKorsakoff psychosis may take 1 to 3 mo. Recovery from neurologic deficits is often incomplete in\\nWernicke-Korsakoff syndrome and in other forms of thiamin deficiency.\\nBecause thiamin deficiency often occurs with other B vitamin deficiencies, multiple water-soluble vitamins\\nare usually given for several weeks. Patients should continue to consume a nutritious diet, supplying 1 to\\n2 times the daily recommended intake of vitamins; all alcohol intake should stop.\\nVitamin A\\nVitamin A (retinol) is required for the formation of rhodopsin, a photoreceptor pigment in the retina. Vitamin\\nA helps maintain epithelial tissues. Normally, the liver stores 80 to 90% of the body's vitamin A. To use\\nvitamin A, the body releases it into the circulation bound to prealbumin (transthyretin) and retinol-binding\\nprotein. \\n\\n-Carotene and other provitamin carotenoids, contained in green leafy and yellow vegetables\\nand deep- or bright-colored fruits, are converted to vitamin A. Carotenoids are absorbed better from\\nvegetables when they are cooked or homogenized and served with some fats or oils.\\nRetinol activity equivalents (RAE) were developed because provitamin A carotenoids have less vitamin A\\nactivity than preformed vitamin A; 1 \\n\\ng retinol = 3.33 IU.\\nSynthetic vitamin analogs (retinoids) are being used increasingly in dermatology. The possible protective\\nrole of \\n\\n-carotene, retinol, and retinoids against some epithelial cancers is under study. However, risk of\\ncertain cancers may be increased after \\n\\n-carotene supplementation.\\nVitamin A Deficiency\\nVitamin A deficiency can result from inadequate intake, fat malabsorption, or liver disorders.\\nDeficiency impairs immunity and hematopoiesis and causes rashes and typical ocular effects\\n(eg, xerophthalmia, night blindness). Diagnosis is based on typical ocular findings and low\\nvitamin A levels. Treatment consists of vitamin A given orally or, if symptoms are severe or\\nmalabsorption is the cause, parenterally.\\nEtiology\\nPrimary vitamin A deficiency is usually caused by prolonged dietary deprivation. It is endemic in areas\\nsuch as southern and eastern Asia, where rice, devoid of \\n\\n-carotene, is the staple food. Xerophthalmia\\ndue to primary deficiency is a common cause of blindness among young children in developing countries.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n82\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 92, 'page_label': '83'}, page_content=\"Secondary vitamin A deficiency may be due to decreased bioavailability of provitamin A carotenoids or to\\ninterference with absorption, storage, or transport of vitamin A. Interference with absorption or storage is\\nlikely in sprue, cystic fibrosis, pancreatic insufficiency, duodenal bypass, chronic diarrhea, bile duct\\nobstruction, giardiasis, and cirrhosis. Vitamin A deficiency is common in prolonged protein-energy\\nundernutrition not only because the diet is deficient but also because vitamin A storage and transport is\\ndefective. In children with complicated measles, vitamin A can shorten the duration of the disorder and\\nreduce the severity of symptoms and risk of death.\\nSymptoms and Signs\\nImpaired dark adaptation of the eyes, which can lead to night blindness, is an early symptom.\\nXerophthalmia (which is nearly pathognomonic) results from keratinization of the eyes. It involves drying\\n(xerosis) and thickening of the conjunctivae and corneas. Superficial foamy patches composed of\\nepithelial debris and secretions on the exposed bulbar conjunctiva (Bitot's spots) develop. In advanced\\ndeficiency, the cornea becomes hazy and can develop erosions, which can lead to its destruction\\n(keratomalacia).\\nKeratinization of the skin and of the mucous membranes in the respiratory, GI, and urinary tracts can\\noccur. Drying, scaling, and follicular thickening of the skin and respiratory infections can result. Immunity\\nis generally impaired.\\nThe younger the patient, the more severe are the effects of vitamin A deficiency. Growth retardation and\\ninfections are common among children. Mortality rate can exceed 50% in children with severe vitamin A\\ndeficiency.\\nDiagnosis\\n Serum retinol levels, clinical evaluation, and response to vitamin A\\nOcular findings suggest the diagnosis. Dark adaptation can be impaired in other disorders (eg, zinc\\ndeficiency, retinitis pigmentosa, severe refractive errors, cataracts, diabetic retinopathy). If dark\\nadaptation is impaired, rod scotometry and electroretinography are done to determine whether vitamin A\\ndeficiency is the cause.\\nSerum levels of retinol are measured. Normal range is 28 to 86 \\n\\ng/dL (1 to 3 \\n\\nmol/L). However, levels\\ndecrease only after the deficiency is advanced because the liver contains large stores of vitamin A. Also,\\ndecreased levels may result from acute infection, which causes retinol-binding protein and transthyretin\\n(also called prealbumin) levels to decrease transiently. A therapeutic trial of vitamin A may help confirm\\nthe diagnosis.\\nPrevention\\nThe diet should include dark green leafy vegetables, deep- or bright-colored fruits (eg, papayas,\\noranges), carrots, and yellow vegetables (eg, squash, pumpkin). Vitamin A-fortified milk and cereals, liver,\\negg yolks, and fish liver oils are helpful. Carotenoids are absorbed better when consumed with some\\ndietary fat. If milk allergy is suspected in infants, they should be given adequate vitamin A in formula\\nfeedings. In developing countries, prophylactic supplements of vitamin A palmitate in oil 60,000 RAE\\n(200,000 IU) po every 6 mo are advised for all children between 1 and 5 yr of age; infants < 6 mo can be\\ngiven a one-time dose of 15,000 RAE (50,000 IU), and those aged 6 to 12 mo can be given a one-time\\ndose of 30,000 RAE (100,000 IU).\\nTreatment\\n Vitamin A palmitate\\nDietary deficiency is traditionally treated with vitamin A palmitate in oil 60,000 IU po once/day for 2 days,\\nfollowed by 4500 IU po once/day. If vomiting or malabsorption is present or xerophthalmia is probable, a\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n83\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 93, 'page_label': '84'}, page_content='dose of 50,000 IU for infants < 6 mo, 100,000 IU for infants 6 to 12 mo, or 200,000 IU for children > 12 mo\\nand adults should be given for 2 days, with a third dose at least 2 wk later. The same doses are\\nrecommended for infants and children with complicated measles. Infants born of HIV-positive mothers\\nshould receive 50,000 IU (15,000 RAE) within 48 h of birth. Prolonged daily administration of large doses,\\nespecially to infants, must be avoided because toxicity may result.\\nFor pregnant or breastfeeding women, prophylactic or therapeutic doses should not exceed 10,000 IU\\n(3000 RAE)/day to avoid possible damage to the fetus or infant.\\nVitamin A Toxicity\\nVitamin A toxicity can be acute (usually due to accidental ingestion by children) or chronic. Both\\ntypes usually cause headache and increased intracranial pressure. Acute toxicity also causes\\nnausea and vomiting. Chronic toxicity also causes changes in skin, hair, and nails; abnormal\\nliver test results; and, in a fetus, birth defects. Diagnosis is usually clinical. Unless birth defects\\nare present, adjusting the dose almost always leads to complete recovery.\\nAcute vitamin A toxicity in children may result from taking large doses (> 100,000 RAE [> 300,000 IU]),\\nusually accidentally. In adults, acute toxicity has occurred when arctic explorers ingested polar bear or\\nseal livers, which contain several million units of vitamin A.\\nChronic toxicity in older children and adults usually develops after doses of > 30,000 RAE (> 100,000\\nIU)/day have been taken for months. Megavitamin therapy is a possible cause, as are massive daily\\ndoses (50,000 to 120,000 RAE [150,000 to 350,000 IU]) of vitamin A \\nor its metabolites, which are\\nsometimes given for nodular acne or other skin disorders. Adults who consume > 1500 RAE (> 4500\\nIU)/day of vitamin A may develop osteoporosis. Infants who are given excessive doses (6,000 to 20,000\\nRAE [18,000 to 60,000 IU]/day) of water-miscible vitamin A may develop toxicity within a few weeks. Birth\\ndefects occur in children of women receiving isotretinoin (which is related to vitamin A) for acne treatment\\nduring pregnancy.\\nAlthough carotene is converted to vitamin A in the body, excessive ingestion of carotene causes\\ncarotenemia, not vitamin A toxicity. Carotenemia is usually asymptomatic but may lead to carotenodermia,\\nin which the skin becomes yellow. When taken as a supplement, \\n\\n-carotene has been associated with\\nincreased cancer risk; risk does not seem to increase when carotenoids are consumed in fruits and\\nvegetables.\\nSymptoms and Signs\\nAlthough symptoms may vary, headache and rash usually develop during acute or chronic toxicity. Acute\\ntoxicity causes increased intracranial pressure. Drowsiness, irritability, abdominal pain, nausea, and\\nvomiting are common. Sometimes the skin subsequently peels.\\nEarly symptoms of chronic toxicity are sparsely distributed, coarse hair; alopecia of the eyebrows; dry,\\nrough skin; dry eyes; and cracked lips. Later, severe headache, pseudotumor cerebri, and generalized\\nweakness develop. Cortical hyperostosis of bone and arthralgia may occur, especially in children.\\nFractures may occur easily, especially in the elderly. In children, toxicity can cause pruritus, anorexia, and\\nfailure to thrive. Hepatomegaly and splenomegaly may occur.\\nIn carotenodermia, the skin (but not the sclera) becomes deep yellow, especially on the palms and soles.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is clinical. Blood vitamin levels correlate poorly with toxicity. However, if clinical diagnosis is\\nequivocal, laboratory testing may help. In vitamin A toxicity, fasting serum retinol levels may increase from\\nnormal (28 to 86 \\n\\ng/dL [1 to 3 \\n\\nmol/L]) to > 100 \\n\\ng/dL (> 3.49 \\n\\nmol/L), sometimes to > 2000 \\n\\ng/dL (> 69.8\\n\\nmol/L). Hypercalcemia is common.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n84'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 94, 'page_label': '85'}, page_content='Differentiating vitamin A toxicity from other disorders may be difficult. Carotenodermia may also occur in\\nsevere hypothyroidism and anorexia nervosa, possibly because carotene is converted to vitamin A more\\nslowly.\\nPrognosis\\nComplete recovery usually occurs if vitamin A ingestion stops. Symptoms and signs of chronic toxicity\\nusually disappear within 1 to 4 wk. However, birth defects in the fetus of a mother who has taken\\nmegadoses of vitamin A are not reversible.\\nTreatment\\nVitamin A is stopped.\\nVitamin B\\n6\\nVitamin B\\n6\\n includes a group of closely related compounds: pyridoxine, pyridoxal, and pyridoxamine. They\\nare metabolized in the body to pyridoxal phosphate, which acts as a coenzyme in many important\\nreactions in blood, CNS, and skin metabolism. Vitamin B\\n6\\n is important in heme and nucleic acid\\nbiosynthesis and in lipid, carbohydrate, and amino acid metabolism.\\nVitamin B\\n6\\n Deficiency and Dependency\\nBecause vitamin B\\n6\\n is present in most foods, dietary deficiency is rare. Secondary deficiency\\nmay result from various conditions. Symptoms can include peripheral neuropathy, a pellagra-\\nlike syndrome, anemia, and seizures, which, particularly in infants, may not resolve when\\ntreated with anticonvulsants. Impaired metabolism (dependency) is rare; it causes various\\nsymptoms, including seizures, intellectual disability, and anemia. Diagnosis is usually clinical;\\nno laboratory test readily assesses vitamin B\\n6\\n status. Treatment consists of giving oral vitamin\\nB\\n6\\n and, when possible, treating the cause.\\nDietary deficiency, though rare, can develop because extensive processing can deplete foods of vitamin\\nB\\n6\\n. Secondary deficiency most often results from protein-energy undernutrition, malabsorption,\\nalcoholism, use of pyridoxine-inactivating drugs (eg, anticonvulsants, isoniazid, cycloserine, hydralazine,\\ncorticosteroids, penicillamine), or excessive loss. Rarely, it results from increased metabolic demand (eg,\\nin hyperthyroidism).\\nRare inborn errors of metabolism can affect pyridoxine metabolism.\\nThe role of vitamin B\\n6\\n deficiency in increasing plasma homocysteine levels and in contributing to vascular\\ndisorders is under study.\\nSymptoms and Signs\\nDeficiency causes a pellagra-like syndrome, with seborrheic dermatitis, glossitis, and cheilosis, and, in\\nadults, can cause depression, confusion, EEG abnormalities, and seizures. Rarely, deficiency or\\ndependency causes seizures in infants. Seizures, particularly in infants, may be refractory to treatment\\nwith anticonvulsants. Normocytic, microcytic, or sideroblastic anemia can also develop.\\nDiagnosis\\n Clinical evaluation\\nVitamin B\\n6\\n deficiency should be considered in any infant who has seizures, any patient who has seizures\\nrefractory to treatment with anticonvulsants, and any patient with deficiencies of other B vitamins,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n85'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 95, 'page_label': '86'}, page_content=\"particularly in patients with alcoholism or protein-energy undernutrition. Diagnosis is usually clinical.\\nThere is no single accepted laboratory test of vitamin B\\n6\\n status; measurement of serum pyridoxal\\nphosphate is most common.\\nTreatment\\n Pyridoxine\\n Elimination of risk factors when possible\\nFor secondary deficiency, causes (eg, use of pyridoxine-inactivating drugs, malabsorption) should be\\ncorrected if possible. Usually, pyridoxine 50 to 100 mg po once/day corrects the deficiency in adults. Most\\npeople taking isoniazid should also be given pyridoxine 30 to 50 mg/day. For deficiency due to increased\\nmetabolic demand, amounts larger than the daily recommended intake may be required. For most cases\\nof inborn errors of metabolism, high doses of pyridoxine may be effective.\\nVitamin B\\n6\\n Toxicity\\nThe ingestion of megadoses (> 500 mg/day) of pyridoxine (eg, taken to treat carpal tunnel syndrome or\\npremenstrual syndrome although efficacy is unproved) may cause peripheral neuropathy with deficits in a\\nstocking-glove distribution, including progressive sensory ataxia and severe impairment of position and\\nvibration senses. Senses of touch, temperature, and pain are less affected. Motor and central nervous\\nsystems are usually intact.\\nDiagnosis is clinical. Treatment is to stop taking vitamin B\\n6\\n. Recovery is slow and, for some patients,\\nincomplete.\\nVitamin B\\n12\\nCobalamin is a general term for compounds with biologic vitamin B\\n12\\n activity. These compounds are\\ninvolved in nucleic acid metabolism, methyl transfer, and myelin synthesis and repair. They are necessary\\nfor the formation of normal RBCs.\\nFood-bound vitamin B\\n12\\n is released in the stomach's acid environment and is bound to R protein\\n(haptocorrin). Pancreatic enzymes cleave this B\\n12\\n complex (B\\n12\\n-R protein) in the small intestine. After\\ncleavage, intrinsic factor, secreted by parietal cells in the gastric mucosa, binds with vitamin B\\n12\\n. Intrinsic\\nfactor is required for absorption of vitamin B\\n12\\n, which takes place in the terminal ileum.\\nVitamin B\\n12\\n in plasma is bound to transcobalamins I and II. Transcobalamin II is responsible for delivering\\nvitamin B\\n12\\n to tissues. The liver stores large amounts of vitamin B\\n12\\n. Enterohepatic reabsorption helps\\nretain vitamin B\\n12\\n. Liver vitamin B\\n12\\n stores can normally sustain physiologic needs for 3 to 5 yr if B\\n12\\nintake stops (eg, in people who become vegans) and for months to 1 yr if enterohepatic reabsorption\\ncapacity is absent.\\nLarge amounts of vitamin B\\n12\\n seem to be nontoxic but are not recommended for regular use (ie, as a\\ngeneral tonic).\\nVitamin B\\n12\\n Deficiency\\nDietary vitamin B\\n12\\n deficiency usually results from inadequate absorption, but deficiency can\\ndevelop in vegans who do not take vitamin supplements. Deficiency causes megaloblastic\\nanemia, damage to the white matter of the spinal cord and brain, and peripheral neuropathy.\\nDiagnosis is usually made by measuring serum vitamin B\\n12\\n levels. The Schilling test helps\\ndetermine etiology. Treatment consists of oral or parenteral vitamin B\\n12\\n. Folate (folic acid)\\nshould not be used instead of vitamin B\\n12\\n because folate may alleviate the anemia but allow\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n86\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 96, 'page_label': '87'}, page_content=\"neurologic deficits to progress.\\nEtiology\\nInadequate vitamin B\\n12\\n intake is possible in vegans but is otherwise unlikely. Breastfed babies of vegan\\nmothers may develop vitamin B\\n12\\n deficiency by age 4 to 6 mo because their\\n[\\nTable 4-5.\\n Causes of Vitamin B\\n12\\n Deficiency]\\nliver stores (which are normally extensive) are limited and their rapid growth rate results in high demand.\\nVitamin B\\n12\\n deficiency usually results from inadequate absorption (see \\nTable 4-5\\n and p. \\n153\\n), which, in\\nthe elderly, most commonly results from decreased acid secretion. In such cases, crystalline vitamin B\\n12\\n(such as that available in vitamin supplements) can be absorbed, but food-bound vitamin B\\n12\\n is not\\nliberated and absorbed normally. Inadequate absorption may occur in blind loop syndrome (with\\novergrowth of bacteria) or fish tapeworm infestation; in these cases, bacteria or parasites use ingested\\nvitamin B\\n12\\n so that less is available for absorption. Vitamin B\\n12\\n absorption may be inadequate if ileal\\nabsorptive sites are destroyed by inflammatory bowel disease or are surgically removed. Less common\\ncauses of inadequate vitamin B\\n12\\n absorption include chronic pancreatitis, gastric surgery, malabsorption\\nsyndromes, AIDS, use of certain drugs (eg, antacids, metformin), repeated exposure to nitrous oxide, and\\na genetic disorder causing malabsorption in the ileum (Imerslund-Graesbeck syndrome).\\nPernicious anemia\\n is often used synonymously with vitamin B\\n12\\n deficiency. However, pernicious\\nanemia specifically refers to anemia resulting from vitamin B\\n12\\n deficiency caused by an autoimmune\\nmetaplastic atrophic gastritis with loss of intrinsic factor (see p. \\n133\\n). Patients with classic pernicious\\nanemia, most commonly younger adults, are at increased risk of stomach and other GI cancers.\\nSubacute combined degeneration\\n refers to degenerative changes in the nervous system due to\\nvitamin B\\n12\\n deficiency; they affect mostly brain and spinal cord white matter. Demyelinating or axonal\\nperipheral neuropathies can occur.\\nSymptoms and Signs\\nAnemia usually develops insidiously. It is often more severe than its symptoms indicate because its slow\\nevolution allows physiologic adaptation. Occasionally, splenomegaly and hepatomegaly occur. Various GI\\nsymptoms, including weight loss and poorly localized abdominal pain, may occur. Glossitis, usually\\ndescribed as burning of the tongue, is uncommon.\\nNeurologic symptoms develop independently from and often without hematologic abnormalities. In early\\nstages, decreased position and vibratory sensation in the extremities is accompanied by mild to moderate\\nweakness and hyporeflexia. In later stages, spasticity, extensor plantar responses, greater loss of position\\nand vibratory sensation in the lower extremities, and ataxia emerge. These deficits may develop in a\\nstocking-glove distribution. Tactile, pain, and temperature sensations are usually spared but may be\\ndifficult to assess in the elderly.\\nSome patients are also irritable and mildly depressed. Paranoia (megaloblastic madness), delirium,\\nconfusion, spastic ataxia, and, at times, postural hypotension may occur in advanced cases. The\\nconfusion may be difficult to differentiate from age-related dementias, such as Alzheimer's disease.\\nDiagnosis\\n CBC and vitamin B\\n12\\n and folate levels\\n Sometimes methylmalonic acid levels or Schilling test\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n87\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 97, 'page_label': '88'}, page_content='Diagnosis is based on CBC and vitamin B\\n12\\n and folate levels. It is important to remember that severe\\nneurologic disease may occur without anemia or macrocytosis.\\nCBC detects megaloblastic anemia. Tissue deficiency and macrocytic indexes may precede the\\ndevelopment of anemia. A vitamin B\\n12\\n level < 200 pg/mL (< 145 pmol/L) indicates vitamin B\\n12\\n deficiency.\\nThe folate level is measured because vitamin B\\n12\\n deficiency must be differentiated from folate deficiency\\nas a cause of megaloblastic anemia; folate supplementation can mask vitamin B\\n12\\n deficiency and may\\nalleviate megaloblastic anemia but allow the neurologic deficits to progress or even accelerate.\\nWhen clinical judgment suggests vitamin B\\n12\\n deficiency but the vitamin B\\n12\\n level is low-normal (200 to\\n350 pg/mL [145 to 260 pmol/L]) or hematologic indexes are normal, other tests can be done. Measuring\\nserum methylmalonic acid (MMA) levels may be useful. An elevated MMA level supports vitamin B\\n12\\ndeficiency but may be due to renal failure. MMA levels can also be used to monitor the response to\\ntreatment. MMA levels remain normal in folate deficiency; homocysteine levels may be elevated with\\neither vitamin B\\n12\\n or folate deficiency. Less commonly, holotranscobalamin II (transcobalamin II-B\\n12\\ncomplex) content is measured; when holotranscobalamin II is < 40 pg/mL (< 30 pmol/L), vitamin B\\n12\\n is\\ndeficient.\\nAfter deficiency is diagnosed, additional tests may be indicated for younger adults but usually not for the\\nelderly. Unless dietary vitamin B\\n12\\n is obviously inadequate, measurement of serum gastrin levels or\\nautoantibodies to intrinsic factor may be done; sensitivity and specificity of these tests may be poor.\\nSchilling test:\\n The Schilling test is useful only if diagnosing intrinsic factor deficiency is important, as in\\nclassic pernicious anemia. This test is not necessary for most elderly patients. The Schilling test\\nmeasures absorption of free radiolabeled vitamin B\\n12\\n. Radiolabeled vitamin B\\n12\\n is given orally, followed\\nin 1 to 6 h by 1000 \\n\\ng (1 mg) of parenteral vitamin B\\n12\\n, which reduces uptake of radiolabeled vitamin\\nB\\n12\\n by the liver. Absorbed radiolabeled vitamin B\\n12\\n is excreted in urine, which is collected for 24 h. The\\namount excreted is measured, and the percentage of total radiolabeled vitamin B\\n12\\n is determined. If\\nabsorption is normal,  9% of the dose given appears in the urine. Reduced urinary excretion (< 5% if\\nkidney function is normal) indicates inadequate vitamin B\\n12\\n absorption. Improved absorption with the\\nsubsequent addition of intrinsic factor to radiolabeled vitamin B\\n12\\n confirms the diagnosis of pernicious\\nanemia. The test is often difficult to do or interpret because of incomplete urine collection or renal\\ninsufficiency. In addition, because the Schilling test does not measure absorption of protein-bound vitamin\\nB\\n12\\n, the test does not detect defective liberation of vitamin B\\n12\\n from foods, which is common among the\\nelderly. The Schilling test repletes vitamin B\\n12\\n and can mask deficiency, so it should be done only after all\\nother diagnostic tests and therapeutic trials.\\nIf malabsorption is identified, the Schilling test can be repeated after a 2-wk trial of an oral antibiotic. If\\nantibiotic therapy corrects malabsorption, the likely cause is intestinal overgrowth of bacteria (eg, blind-\\nloop syndrome).\\nTreatment\\n Supplemental vitamin B\\n12\\nVitamin B\\n12\\n 1000 to 2000 \\n\\ng po can be given once/day to patients who do not have severe deficiency or\\nneurologic symptoms or signs. A nasal gel preparation of vitamin B\\n12\\n is available at a higher price. Large\\noral doses can be absorbed by mass action, even when intrinsic factor is absent. If the MMA level\\n(sometimes used to monitor treatment) does not decrease, patients may not be taking vitamin B\\n12\\n. For\\nmore severe deficiency, vitamin B\\n12\\n 1 mg IM is usually given 1 to 4 times/wk for several weeks until\\nhematologic abnormalities are corrected; then it is given once/mo.\\nAlthough hematologic abnormalities are usually corrected within 6 wk (reticulocyte count should improve\\nwithin 1 wk), resolution of neurologic symptoms may take much longer. Neurologic symptoms that persist\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n88'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 98, 'page_label': '89'}, page_content='for months or years become irreversible. In most elderly people with vitamin B\\n12\\n deficiency and dementia,\\ncognition does not improve after treatment. Vitamin B\\n12\\n treatment must be continued for life unless the\\npathophysiologic mechanism for the deficiency is corrected.\\nInfants of vegan mothers should receive supplemental vitamin B\\n12\\n from birth.\\nVitamin C\\nVitamin C (ascorbic acid) plays a role in collagen, carnitine, hormone, and amino acid formation. It is\\nessential for wound healing and facilitates recovery from burns. Vitamin C is also an antioxidant, supports\\nimmune function, and facilitates the absorption of iron.\\nVitamin C Deficiency\\nIn developed countries, vitamin C deficiency can occur as part of general undernutrition, but\\nsevere deficiency (causing scurvy) is uncommon. Symptoms include fatigue, depression, and\\nconnective tissue defects (eg, gingivitis, petechiae, rash, internal bleeding, impaired wound\\nhealing). In infants and children, bone growth may be impaired. Diagnosis is usually clinical.\\nTreatment consists of oral vitamin C.\\nSevere deficiency results in scurvy, a disorder characterized by hemorrhagic manifestations and abnormal\\nosteoid and dentin formation.\\nEtiology\\nIn adults, primary deficiency is usually due to inadequate diet. The need for dietary vitamin C is increased\\nby febrile illnesses, inflammatory disorders (particularly diarrheal disorders), achlorhydria, smoking,\\nthyrotoxicosis, iron deficiency, cold or heat stress, surgery, burns, and protein deficiency. Heat (eg,\\nsterilization of formulas, cooking) can destroy some of the vitamin C in food.\\nPathophysiology\\nFormation of intercellular cement substances in connective tissues, bones, and dentin is defective,\\nresulting in weakened capillaries with subsequent hemorrhage and defects in bone and related\\nstructures.\\nBone tissue formation becomes impaired, which, in children, causes bone lesions and poor bone growth.\\nFibrous tissue forms between the diaphysis and the epiphysis, and costochondral junctions enlarge.\\nDensely calcified fragments of cartilage are embedded in the fibrous tissue. Subperiosteal hemorrhages,\\nsometimes due to small fractures, may occur in children or adults.\\nSymptoms and Signs\\nIn adults, symptoms develop after weeks to months of vitamin C depletion. Lassitude, weakness,\\nirritability, weight loss, and vague myalgias and arthralgias may develop early.\\nLater, symptoms related to defects in connective tissues develop. Follicular hyperkeratosis, coiled hair,\\nand perifollicular hemorrhages may develop. Gums may become swollen, purple, spongy, and friable; they\\nbleed easily in severe deficiency. Eventually, teeth become loose and avulsed. Secondary infections may\\ndevelop. Wounds heal poorly and tear easily, and spontaneous hemorrhages may occur, especially as\\necchymoses in the skin of the lower limbs or as bulbar conjunctival hemorrhage.\\nOther symptoms and signs include femoral neuropathy due to hemorrhage into femoral sheaths (which\\nmay mimic deep venous thrombosis), lower-extremity edema, and painful bleeding or effusions within\\njoints.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n89'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 99, 'page_label': '90'}, page_content=\" Usually, skin or gingival findings and risk factors\\nDiagnosis is usually made clinically in a patient who has skin or gingival signs and is at risk of vitamin C\\ndeficiency. Laboratory confirmation may be available. Anemia is common. Bleeding, coagulation, and PT\\nare normal.\\nSkeletal x-rays can help diagnose childhood (but not adult) scurvy. Changes are most evident at the ends\\nof long bones, particularly at the knee. Early changes resemble atrophy. Loss of trabeculae results in a\\nground-glass appearance. The cortex thins. A line of calcified, irregular cartilage (white line of Fraenkel)\\nmay be visible at the metaphysis. A zone of rarefaction or a linear fracture proximal and parallel to the\\nwhite line may be visible as only a triangular defect at the bone's lateral margin but is specific. The\\nepiphysis may be compressed. Healing subperiosteal hemorrhages may elevate and calcify the\\nperiosteum.\\nLaboratory diagnosis, which requires measuring blood ascorbic acid, is sometimes done at academic\\ncenters. Levels of < 0.6 mg/dL (< 34 \\n\\nmol/L) are considered marginal; levels of < 0.2 mg/dL (< 11 \\n\\nmol/L)\\nindicate vitamin C deficiency. Measurement of ascorbic acid levels in the WBC-platelet layer of\\ncentrifuged blood is not widely available or standardized.\\nIn adults, scurvy must be differentiated from arthritis, hemorrhagic disorders, gingivitis, and protein-energy\\nundernutrition. Hyperkeratotic hair follicles with surrounding hyperemia or hemorrhage are almost\\npathognomonic. Bleeding gums, conjunctival hemorrhages, most petechiae, and ecchymoses are\\nnonspecific.\\nTreatment\\n Nutritious diet with supplemental ascorbic acid\\nFor scurvy in adults, ascorbic acid 100 to 500 mg po tid is given for 1 to 2 wk, until signs disappear, and\\nfollowed by a nutritious diet supplying 1 to 2 times the daily recommended intake. In scurvy, therapeutic\\ndoses \\nof ascorbic acid restore the functions of vitamin C in a few days. The symptoms and signs usually\\ndisappear over 1 to 2 wk. Chronic gingivitis with extensive subcutaneous hemorrhage persists longer.\\nPrevention\\nVitamin C 75 mg po once/day for women and 90 mg po once/day for men prevents deficiency. Smokers\\nshould consume an additional 35 mg/day. Five servings of most fruits and vegetables (recommended\\ndaily) provide > 200 mg of vitamin C.\\nVitamin C Toxicity\\nThe upper limit for vitamin C intake is 2000 mg/day. Up to 10 g/day of vitamin C are sometimes taken for\\nunproven health benefits, such as preventing or shortening the duration of viral infections or slowing or\\nreversing the progression of cancer or atherosclerosis. Such doses may acidify the urine, cause nausea\\nand diarrhea, interfere with the healthy antioxidant-prooxidant balance in the body, and, in patients with\\nthalassemia or hemochromatosis, promote iron overload. Intake below the upper limit does not have toxic\\neffects in healthy adults.\\nVitamin D\\nVitamin D has 2 main forms: D\\n2\\n (ergocalciferol) and D\\n3\\n (cholecalciferol); the latter is the naturally\\noccurring form and the form used for low-dose supplementation. Vitamin D\\n3\\n is synthesized in skin by\\nexposure to direct sunlight (ultraviolet B radiation) and obtained in the diet chiefly in fish liver oils and salt\\nwater fish. In some developed countries, milk and other foods are fortified with vitamin D. Human breast\\nmilk is low in vitamin D, containing an average of only 10% of the amount in fortified cow's milk.\\nRequirements for vitamin D increase with age because skin synthesis declines. Sunscreen use and dark\\nskin pigmentation also reduce skin synthesis of vitamin D.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n90\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 100, 'page_label': '91'}, page_content='Vitamin D is a prohormone with several active metabolites that act as hormones. Vitamin D is metabolized\\nby the liver to 25(OH)D, which is then converted by the kidneys to 1,25(OH)\\n2\\nD (1,25-\\ndihydroxycholecalciferol, calcitriol, or active vitamin D hormone). 25(OH)D, the major circulating form, has\\nsome metabolic activity, but 1,25(OH)\\n2\\nD is the most metabolically active. The conversion to 1,25(OH)\\n2\\nD\\nis regulated by its own concentration, parathyroid hormone (PTH), and serum concentrations of Ca and\\nphosphate.\\n[\\nTable 4-6.\\n Actions of Vitamin D and its Metabolites]\\nVitamin D affects many organ systems (see \\nTable 4-6\\n), but mainly it increases Ca and phosphate\\nabsorption from the intestine and promotes normal bone formation and mineralization. Vitamin D and\\nrelated analogs may be used to treat psoriasis, hypoparathyroidism, renal osteodystrophy, and possibly\\nleukemia and breast, prostate, and colon cancers; they may also be used for immunosuppression.\\nVitamin D Deficiency and Dependency\\nInadequate exposure to sunlight predisposes to vitamin D deficiency. Deficiency impairs bone\\nmineralization, causing rickets in children and osteomalacia in adults and possibly contributing\\nto osteoporosis. Treatment usually consists of oral vitamin D; Ca and phosphate are\\nsupplemented as needed. Prevention is often possible. Rarely, hereditary disorders cause\\nimpaired metabolism of vitamin D (dependency).\\nVitamin D deficiency is a common cause of rickets and osteomalacia, but these disorders may also result\\nfrom other conditions, such as various renal tubular disorders, familial hypophosphatemic (vitamin D-\\nresistant) rickets (see p. \\n2991\\n), chronic metabolic acidosis, hypoparathyroidism (which reduces vitamin D\\nabsorption), inadequate dietary Ca, and disorders or drugs that impair the mineralization of bone matrix.\\nVitamin D deficiency causes hypocalcemia, which stimulates production of PTH, causing\\nhyperparathyroidism. Hyperparathyroidism increases absorption, bone mobilization, and renal\\nconservation of Ca but increases excretion of phosphate. As a result, the serum level of Ca may be\\nnormal, but because of hypophosphatemia, bone mineralization is impaired.\\nEtiology\\nVitamin D deficiency may result from the following.\\nInadequate exposure or intake:\\n Inadequate direct sunlight exposure (or sunscreen use) and\\ninadequate intake usually occur simultaneously to result in clinical deficiency. Susceptible people include\\nthe elderly (who are often undernourished and are not exposed to enough sunlight), and certain\\ncommunities (eg, women and children who are confined to the home or who wear clothing that covers the\\nentire body and face). Inadequate vitamin D stores are common among the elderly, particularly those who\\nare house-bound, institutionalized, or hospitalized or who have had a hip fracture. Recommended direct\\nsunlight exposure is 5 to 15 min (suberythemal dose) to arms and legs, or face, arms and hands, at least\\n3 times a week.\\nReduced absorption:\\n Malabsorption can deprive the body of dietary vitamin D; only a small amount of\\n25(OH)D is recirculated enterohepatically.\\nAbnormal metabolism:\\n Vitamin D deficiency may result from defects in the production of 25(OH)D or\\n1,25(OH)\\n2\\nD. People with a chronic renal disorder commonly develop rickets or osteomalacia because\\nrenal production of 1,25 (OH)\\n2\\nD is decreased and phosphate levels are elevated. Hepatic dysfunction\\ncan also interfere with production of active vitamin D metabolites.\\nType I hereditary vitamin D-dependent rickets is an autosomal recessive disorder characterized by absent\\nor defective conversion of 25(OH)D to 1,25(OH)\\n2\\nD in the kidneys. X-linked familial hypophosphatemia\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n91'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 101, 'page_label': '92'}, page_content='reduces vitamin D synthesis in the kidneys. Many anticonvulsants and glucocorticoid use increase the\\nneed for vitamin D supplementation.\\nResistance to effects of vitamin D:\\n Type II hereditary vitamin D-dependent rickets has several forms\\nand is due to mutations in the 1,25(OH)\\n2\\nD receptor. This receptor affects the metabolism of gut, kidney,\\nbone, and other cells. In this disorder, 1,25(OH)\\n2\\nD is abundant but ineffective because the receptor is not\\nfunctional.\\nSymptoms and Signs\\nVitamin D deficiency can cause muscle aches, muscle weakness, and bone pain at any age.\\nVitamin D deficiency in a pregnant woman causes deficiency in the fetus. Occasionally, deficiency severe\\nenough to cause maternal osteomalacia results in rickets with metaphyseal lesions in neonates. In young\\ninfants, rickets causes softening of the entire skull (craniotabes). When palpated, the occiput and\\nposterior parietal bones feel like a ping pong ball. In older infants with rickets, sitting and crawling are\\ndelayed, as is fontanelle closure; there is bossing of the skull and costochondral thickening.\\nCostochondral thickening can look like beadlike prominences along the lateral chest wall (rachitic rosary).\\nIn children 1 to 4 yr, epiphyseal cartilage at the lower ends of the radius, ulna, tibia, and fibula enlarges;\\nkyphoscoliosis develops, and walking is delayed. In older children and adolescents, walking is painful; in\\nextreme cases, deformities such as bowlegs and knock-knees develop.\\nTetany is caused by hypocalcemia and may accompany infantile or adult vitamin D deficiency. Tetany may\\ncause paresthesias of the lips, tongue, and fingers; carpopedal and facial spasm; and, if very severe,\\nseizures. Maternal deficiency can cause tetany in neonates.\\nOsteomalacia predisposes to fractures. In the elderly, hip fractures may result from only minimal trauma.\\nDiagnosis\\n Levels of 25(OH)D (D\\n2\\n+D\\n3\\n)\\nDiagnosis may be suspected based on any of the following:\\n A history of inadequate sunlight exposure or dietary intake\\n Symptoms and signs of rickets, osteomalacia, or neonatal tetany\\n Characteristic bone changes seen on x-ray\\nX-rays of the radius and ulna plus serum levels of Ca, phosphate, alkaline phosphatase, PTH, and\\n25(OH)D are needed to differentiate vitamin D deficiency from other causes of bone demineralization.\\nAssessment of vitamin D status and serologic tests for syphilis can be considered for infants with\\ncraniotabes based on the history and physical, but most cases of craniotabes resolve spontaneously.\\nRickets can be distinguished from chondrodystrophy because the latter is characterized by a large head,\\nshort extremities, thick bones, and normal serum Ca, phosphate, and alkaline phosphatase levels.\\nTetany due to infantile rickets may be clinically indistinguishable from seizures due to other causes. Blood\\ntests and clinical history may help distinguish them.\\nBone changes, seen on x-rays, precede clinical signs. In rickets, changes are most evident at the lower\\nends of the radius and ulna. The diaphyseal ends lose their sharp, clear outline; they are cup-shaped and\\nshow a spotty or fringy rarefaction. Later, because the ends of the radius and ulna have become\\nnoncalcified and radiolucent, the distance between them and the metacarpal bones appears increased.\\nThe bone matrix elsewhere also becomes more radiolucent. Characteristic deformities result from the\\nbones bending at the cartilage-shaft junction because the shaft is weak. As healing begins, a thin white\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n92'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 102, 'page_label': '93'}, page_content=\"line of calcification appears at the epiphysis, becoming denser and thicker as calcification proceeds.\\nLater, the bone matrix becomes calcified and opacified at the subperiosteal level.\\nIn adults, bone demineralization, particularly in the spine, pelvis, and lower extremities, can be seen on x-\\nrays; the fibrous lamellae can also be seen, and incomplete ribbonlike areas of demineralization\\n(pseudofractures, Looser's lines, Milkman's syndrome) appear in the cortex.\\nBecause levels of serum 25(OH)D reflect body stores of vitamin D and correlate with symptoms and signs\\nof vitamin D deficiency better than levels of other vitamin D metabolites, 25(OH)D (D\\n2\\n+D\\n3\\n) measurement\\nis generally considered the best way to diagnose deficiency. Goal 25(OH)D levels are 30 to 40 ng/mL\\n(about 75 to 100 nmol/L); whether higher levels may be beneficial remains uncertain.\\nIf the diagnosis is unclear, serum levels of 1,25(OH)\\n2\\nD and urinary Ca concentration can be measured. In\\nsevere deficiency, serum 1,25(OH)\\n2\\nD is abnormally low, usually undetectable. Urinary Ca is low in all\\nforms of the deficiency except those associated with acidosis.\\nIn vitamin D deficiency, serum Ca may be low or, because of secondary hyperparathyroidism, may be\\nnormal. Serum phosphate usually decreases, and serum alkaline phosphatase usually increases. Serum\\nPTH is elevated.\\nType I hereditary vitamin D-dependent rickets results in normal serum 25(OH)D, low serum 1,25(OH)\\n2\\nD\\nand Ca, and normal or low serum phosphate.\\nTreatment\\n Correction of Ca and phosphate deficiencies\\n Supplemental vitamin D\\nCa deficiency (which is common) and phosphate deficiency should be corrected. As long as Ca and\\nphosphate intake is adequate, adults with osteomalacia and children with uncomplicated rickets can be\\ncured by giving vitamin D 40 \\n\\ng (1600 IU) po once/day. Serum 25(OH)D and 1,25(OH)\\n2\\nD begin to\\nincrease within 1 or 2 days. Serum Ca and phosphate increase and serum alkaline phosphatase\\ndecreases within about 10 days. During the 3rd wk, enough Ca and phosphate are deposited in bones to\\nbe visible on x-rays. After about 1 mo, the dose can usually be reduced gradually to the usual\\nmaintenance level of 10 to 15 \\n\\ng (400 to 600 IU) once/day. If tetany is present, vitamin D should be\\nsupplemented with IV Ca salts for up to 1 wk (see p. \\n841\\n). Elderly patients may need 25 to  50 \\n\\ng (1000\\nto  2000 IU) daily to maintain a 25(OH)D level > 30 ng/mL (> 75 nmol/L); this dose is higher than the\\nrecommended daily allowance (RDA) for people > 70 yr (600 IU) and may exceed the current upper limit\\nof 2000 IU/day.\\nBecause rickets and osteomalacia due to defective production of vitamin D metabolites are vitamin D-\\nresistant, they do not respond to the doses usually effective for rickets due to inadequate intake.\\nEndocrinologic evaluation is required because treatment depends on the specific defect. When 25(OH)D\\nproduction is defective, vitamin D 50 \\n\\ng (2000 IU) once/day increases serum levels and results in clinical\\nimprovement. Patients with kidney disorders often need 1,25(OH)\\n2\\nD supplementation.\\nType I hereditary vitamin D-dependent rickets responds to 1,25(OH)\\n2\\nD 1 to 2 \\n\\ng po once/day. Some\\npatients with type II hereditary vitamin D-dependent rickets respond to very high doses (eg, 10 to 24\\n\\ng/day) of 1,25(OH)\\n2\\nD; others require long-term infusions of Ca.\\nPrevention\\nDietary counseling is particularly important in communities whose members are at risk of vitamin D\\ndeficiency. Fortifying unleavened chapati flour with vitamin D (125 \\n\\ng/kg) has been effective among Indian\\nimmigrants in Britain. The benefits of sunlight exposure for vitamin D status must be weighed against the\\nincreased skin damage and skin cancer risks.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n93\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 103, 'page_label': '94'}, page_content='increased skin damage and skin cancer risks.\\nAll breastfed infants should be given supplemental vitamin D 5 \\n\\ng (200 IU) once/day from birth to 6 mo; at\\n6 mo, a more diversified diet is available. For adolescents at risk, a single IM dose of ergocalciferol 2.5\\nmg (100,000 IU) given in the fall can maintain adequate 25(OH)D levels throughout the winter. The\\nrecommended daily allowance (RDA) for vitamin D is 400 IU for people aged 51 to 70 and \\n600 IU for\\nthose >70; many consider this intake too low, and the 2005 Dietary Guidelines for Americans\\nrecommends that healthy older adults consume 1000 IU/day.\\nVitamin D Toxicity\\nUsually, vitamin D toxicity results from taking excessive amounts. Marked hypercalcemia\\ncommonly causes symptoms. Diagnosis is typically based on elevated blood levels of 25(OH)D.\\nTreatment consists of stopping vitamin D, restricting dietary Ca, restoring intravascular volume\\ndeficits, and, if toxicity is severe, giving corticosteroids or bisphosphonates.\\nBecause synthesis of 1,25(OH)\\n2\\nD (the most active metabolite of vitamin D) is tightly regulated, vitamin D\\ntoxicity usually occurs only if excessive doses (prescription or megavitamin) are taken. Vitamin D 1000 \\n\\ng\\n(40,000 IU)/day causes toxicity within 1 to 4 mo in infants. In adults, taking 1250 \\n\\ng (50,000 IU)/day for\\nseveral months can cause toxicity. Vitamin D toxicity can occur iatrogenically when hypoparathyroidism is\\ntreated too aggressively (see p.\\n844\\n).\\nSymptoms and Signs\\nThe main symptoms result from hypercalcemia. Anorexia, nausea, and vomiting can develop, often\\nfollowed by polyuria, polydipsia, weakness, nervousness, pruritus, and eventually renal failure.\\nProteinuria, urinary casts, azotemia, and metastatic calcifications (particularly in the kidneys) can develop.\\nDiagnosis\\n Hypercalcemia plus risk factors or elevated serum 25(OH)D levels\\nA history of excessive vitamin D intake may be the only clue differentiating vitamin D toxicity from other\\ncauses of hypercalcemia. Elevated serum Ca levels of 12 to 16 mg/dL (3 to 4 mmol/L) are a constant\\nfinding when toxic symptoms occur. Serum 25(OH)D levels are usually elevated > 150 ng/mL (> 375\\nnmol/L). Levels of 1,25(OH)\\n2\\nD, which need not be measured to confirm the diagnosis, may be normal.\\nSerum Ca should be measured often (weekly at first, then monthly) in all patients receiving large doses of\\nvitamin D, particularly the potent 1,25(OH)\\n2\\nD.\\nTreatment\\n IV hydration plus corticosteroids or bisphosphonates\\nAfter stopping vitamin D intake, hydration with IV normal saline and corticosteroids or bisphosphonates\\n(which inhibit bone resorption) are used to reduce blood Ca levels.\\nKidney damage or metastatic calcifications, if present, may be irreversible.\\nVitamin E\\nVitamin E is a group of compounds (including tocopherols and tocotrienols) that have similar biologic\\nactivities. The most biologically active is \\n\\n-tocopherol, but \\n\\n-, \\n\\n-, and \\n\\n-tocopherols, 4 tocotrienols, and\\nseveral stereoisomers may also have important biologic activity. These compounds act as antioxidants,\\nwhich prevent lipid peroxidation of polyunsaturated fatty acids in cellular membranes. Plasma tocopherol\\nlevels vary with total plasma lipid levels. Normally, the plasma \\n\\n-tocopherol level is 5 to 20 \\n\\ng/mL (11.6 to\\n46.4 \\n\\nmol/L). High-dose vitamin E supplements do not protect against cardiovascular disorders;whether\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n94'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 104, 'page_label': '95'}, page_content=\"supplements can protect against Alzheimer's disease, tardive dyskinesia, and prostate cancer among\\nsmokers is controversial.\\nAlthough the amount of vitamin E in many fortified foods and supplements is given in IU, current\\nrecommendations are to use mg.\\nVitamin E Deficiency\\nDietary vitamin E deficiency is common in developing countries; deficiency among adults in\\ndeveloped countries is uncommon and usually due to fat malabsorption. The main symptoms\\nare hemolytic anemia and neurologic deficits. Diagnosis is based on measuring the ratio of\\nplasma \\n\\n-tocopherol to total plasma lipids; a low ratio suggests vitamin E deficiency. Treatment\\nconsists of oral vitamin E, given in high doses if there are neurologic deficits or if deficiency\\nresults from malabsorption.\\nVitamin E deficiency causes fragility of RBCs and degeneration of neurons, particularly peripheral axons\\nand posterior column neurons.\\nEtiology\\nIn developing countries, the most common cause is inadequate intake of vitamin E. In developed\\ncountries, the most common causes are disorders that cause fat malabsorption, including\\nabetalipoproteinemia (Bassen-Kornzweig syndrome, due to genetic absence of apolipoprotein B), chronic\\ncholestatic \\nhepatobiliary disease, pancreatitis, short bowel syndrome, and cystic fibrosis. A rare genetic\\nform of vitamin E deficiency without fat malabsorption results from defective liver metabolism.\\nSymptoms and Signs\\nThe main symptoms are mild hemolytic anemia and nonspecific neurologic deficits. Abetalipoproteinemia\\nresults in progressive neuropathy and retinopathy in the first 2 decades of life (see p. \\n904\\n).\\nVitamin E deficiency may contribute to retinopathy of prematurity (also called retrolental fibroplasia) in\\npremature infants and to some cases of intraventricular and subependymal hemorrhage in neonates.\\nAffected premature neonates have muscle weakness.\\nIn children, chronic cholestatic hepatobiliary disease or cystic fibrosis causes neurologic deficits, including\\nspinocerebellar ataxia with loss of deep tendon reflexes, truncal and limb ataxia, loss of vibration and\\nposition senses, ophthalmoplegia, muscle weakness, ptosis, and dysarthria.\\nIn adults with malabsorption, vitamin E deficiency very rarely causes spinocerebellar ataxia because\\nadults have large vitamin E stores in adipose tissue.\\nDiagnosis\\n Low \\n\\n-tocopherol level or low ratio of serum \\n\\n-tocopherol to serum lipids\\nWithout a history of inadequate intake or a predisposing condition, vitamin E deficiency is unlikely.\\nConfirmation usually requires measuring the vitamin level. Measuring RBC hemolysis in response to\\nperoxide can suggest the diagnosis but is nonspecific. Hemolysis increases as vitamin E deficiency\\nimpairs RBC stability.\\nMeasuring the serum \\n\\n-tocopherol level is the most direct method of diagnosis. In adults, vitamin E\\ndeficiency is suggested if the \\n\\n-tocopherol level is < 5 \\n\\ng/mL (< 11.6 \\n\\nmol/L). Because abnormal lipid\\nlevels can affect vitamin E status, a low ratio of serum \\n\\n-tocopherol to lipids (< 0.8 mg/g total lipid) is the\\nmost accurate indicator in adults with hyperlipidemia.\\nIn children and adults with abetalipoproteinemia, serum \\n\\n-tocopherol levels are usually undetectable.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n95\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 105, 'page_label': '96'}, page_content='Treatment\\n Supplemental \\n\\n-tocopherol\\nIf malabsorption causes clinically evident deficiency, \\n\\n-tocopherol 15 to 25 mg/kg po once/day should be\\ngiven. However, larger doses given by injection are required to treat neuropathy during its early stages or\\nto overcome the defect of absorption and transport in abetalipoproteinemia.\\nPrevention\\nAlthough premature neonates may require supplementation, human milk and commercial formulas have\\nenough vitamin E for full-term neonates.\\nVitamin E Toxicity\\nMany adults take relatively large amounts of vitamin E (\\n\\n-tocopherol 400 to 800 mg/day) for months to\\nyears without any apparent harm. Occasionally, muscle weakness, fatigue, nausea, and diarrhea occur.\\nThe most significant risk is bleeding. However, bleeding is uncommon unless the dose is > 1000 mg/day\\nor the patient takes oral coumarin or warfarin. Thus, the upper limit for adults aged 19 yr is 1000 mg for\\nany form of \\n\\n-tocopherol. Recent analyses of previous studies report that high vitamin E intakes may\\nincrease the risk of hemorrhagic stroke and premature death.\\nVitamin K\\nVitamin K\\n1\\n (phylloquinone) is dietary vitamin K. Dietary fat enhances its absorption. Infant formulas\\ncontain supplemental vitamin K. Vitamin K\\n2\\n refers to a group of compounds (menaquinones) synthesized\\nby bacteria in the intestinal tract; the amount synthesized does not satisfy the vitamin K requirement.\\nVitamin K controls the formation of coagulation factors II (prothrombin), VII, IX, and X in the liver. Other\\ncoagulation factors dependent on vitamin K are protein C, protein S, and protein Z; proteins C and S are\\nanticoagulants. Metabolic pathways conserve vitamin K. Once vitamin K has participated in formation of\\ncoagulation factors, the reaction product, vitamin K epoxide, is enzymatically converted to the active form,\\nvitamin K hydroquinone.\\nThe actions of vitamin K-dependent proteins require Ca. The vitamin K-dependent proteins, osteocalcin\\nand matrix \\n\\n-carboxy-glutamyl (Gla) protein, may have important roles in bone and other tissues. Forms of\\nvitamin K are common therapy for osteoporosis in Japan and other countries.\\nVitamin K Deficiency\\nVitamin K deficiency results from extremely inadequate intake, fat malabsorption, or use of\\ncoumarin anticoagulants. Deficiency is particularly common among breastfed infants. It impairs\\nclotting. Diagnosis is suspected based on routine coagulation study findings and confirmed by\\nresponse to vitamin K. Treatment consists of vitamin K given orally or, when fat malabsorption\\nis the cause or risk of bleeding is high, parenterally.\\nVitamin K deficiency decreases levels of prothrombin and other vitamin K-dependent coagulation factors,\\ncausing defective coagulation and, potentially, bleeding.\\nEtiology\\nWorldwide, vitamin K deficiency causes infant morbidity and mortality. Vitamin K deficiency causes\\nhemorrhagic disease of the newborn, which usually occurs 1 to 7 days postpartum. In affected neonates,\\nbirth trauma can cause intracranial hemorrhage. Neonates are prone to vitamin K deficiency because of\\nthe following:\\n The placenta transmits lipids and vitamin K relatively poorly.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n96'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 106, 'page_label': '97'}, page_content=\" The neonatal liver is immature with respect to prothrombin synthesis.\\n Breast milk is low in vitamin K, containing about 2.5 \\n\\ng/L (cow's milk contains 5000 \\n\\ng/L).\\n The neonatal gut is sterile during the first few days of life.\\nLate hemorrhagic disease (occurring 3 to 8 wk postpartum) is usually associated with breastfeeding,\\nmalabsorption, or a liver disorder. If the mother has taken phenytoin anticonvulsants, coumarin\\nanticoagulants, or cephalosporin antibiotics, the risk of both types of hemorrhagic disease is increased.\\nIn healthy adults, dietary vitamin K deficiency is uncommon because vitamin K is widely distributed in\\ngreen vegetables and the bacteria of the normal gut synthesize menaquinones. However, biliary\\nobstruction, malabsorption, cystic fibrosis, and resection of the small intestine can contribute to vitamin K\\ndeficiency.\\nCoumarin anticoagulants interfere with the synthesis of vitamin K-dependent coagulation proteins (factors\\nII, VII, IX, and X) in the liver. Certain antibiotics (particularly some cephalosporins and other broad-\\nspectrum antibiotics), salicylates, megadoses of vitamin E, and hepatic insufficiency increase risk of\\nbleeding in patients with vitamin K deficiency.\\nSymptoms and Signs\\nBleeding is the usual manifestation. Easy bruisability and mucosal bleeding (especially epistaxis, GI\\nhemorrhage, menorrhagia, and hematuria) can occur. Blood may ooze from puncture sites or incisions.\\nHemorrhagic disease of the newborn and late hemorrhagic disease in infants may cause cutaneous, GI,\\nintrathoracic, or, in the worst cases, intracranial bleeding. If obstructive jaundice develops, bleedingif it\\noccursusually begins after the 4th or 5th day. It may begin as a slow ooze from a surgical incision, the\\ngums, the nose, or GI mucosa, or it may begin as massive bleeding into the GI tract.\\nDiagnosis\\n Usually, prolonged PT that decreases after phytonadione\\nVitamin K deficiency or antagonism (due to coumarin anticoagulants) is suspected when abnormal\\nbleeding occurs in a patient at risk. Blood coagulation studies can preliminarily confirm the diagnosis. PT,\\nusually reported as the INR, is prolonged, but PTT, thrombin time, platelet count, bleeding time, and\\nlevels of fibrinogen, fibrin-split products, and D-dimer are normal. If phytonadione (USP generic name for\\nvitamin K\\n1\\n) 1 mg IV significantly decreases PT within 2 to 6 h, a liver disorder is not the likely cause, and\\nthe diagnosis of vitamin K deficiency is confirmed. Some centers can detect vitamin K deficiency more\\ndirectly by measuring the serum vitamin level. The serum level of vitamin K\\n1\\n ranges from 0.2 to 1.0 ng/mL\\nin healthy people consuming adequate quantities of vitamin K\\n1\\n (50 to 150 \\n\\ng/day). Knowing vitamin K\\nintake can help interpret serum levels; recent intake affects levels in serum but not in tissues.\\nMore sensitive indicators of vitamin K status, such as PIVKA (\\nP\\nrotein \\nI\\nnduced in \\nV\\nitamin \\nK A\\nbsence or\\nA\\nntagonism) and under-carboxylated osteocalcin, are under study.\\nTreatment\\n Phytonadione\\nWhenever possible, phytonadione should be given po or sc. The usual adult dose is 5 to 20 mg. (Rarely,\\neven when phytonadione is correctly diluted and given slowly, IV replacement can result in anaphylaxis or\\nanaphylactoid reactions.) INR usually decreases within 6 to 12 h. The dose may be repeated in 6 to 8 h if\\nINR has not decreased satisfactorily. Phytonadione 2.5 to 10 mg po is indicated for \\nnonemergency\\ncorrection of a prolonged INR in patients taking anticoagulants. Correction usually occurs within 6 to 8 h.\\nWhen only partial correction of INR is desirable (eg, when INR should remain slightly elevated because of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n97\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 107, 'page_label': '98'}, page_content='a prosthetic heart valve), lower doses (eg, 1 to 2.5 mg) of phytonadione can be given.\\nIn infants, bleeding due to deficiency can be corrected by giving phytonadione 1 mg sc or IM once. The\\ndose is repeated if INR remains elevated. Higher doses may be necessary if the mother has been taking\\noral anticoagulants.\\nPrevention\\nPhytonadione 0.5 to 1 mg IM (or 0.3 mg/kg for preterm infants) is recommended for all neonates within 6 h\\nof birth to reduce the incidence of intracranial hemorrhage due to birth trauma and of classic hemorrhagic\\ndisease of the newborn (increased bleeding risks 1 to 7 days after birth). It is also used prophylactically\\nbefore surgery. Some clinicians recommend that pregnant women taking anticonvulsants receive\\nphytonadione 10 mg po once/day for the 1 mo or 20 mg po once/day for the 2 wk before delivery. The low\\nvitamin K\\n1\\n content in breast milk can be increased by increasing maternal dietary intake of phylloquinone\\nto 5 mg/day.\\nVitamin K Toxicity\\nVitamin K\\n1\\n (phylloquinone) is not toxic when consumed orally, even in large amounts. However,\\nmenadione (a synthetic, water-soluble vitamin K precursor) can cause toxicity and should not be used to\\ntreat vitamin K deficiency.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 4. Vitamin Deficiency, Dependency & Toxicity\\n98'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 108, 'page_label': '99'}, page_content=\"Chapter 5. Mineral Deficiency and Toxicity\\nIntroduction\\nSix macrominerals are required by people in gram amounts. Four (Na, K, Ca, and Mg) are cations; two (Cl\\nand P) are accompanying anions (see p. \\n820\\n). Daily requirements range from 0.3 to 2.0 g. Bone, muscle,\\nheart, and brain function depend on these minerals.\\nNine trace minerals (microminerals) are required by people in minute amounts: chromium, copper, iodine,\\niron, fluorine, manganese, molybdenum, selenium, and zinc. (For sources, functions, effects of deficiency\\nand toxicity, and dietary requirements, see\\nTables 5-1\\n and\\n5-2\\n.) All trace minerals are toxic at high levels; some minerals (arsenic, nickel, and chromium) may be\\ncarcinogens.\\nMineral deficiencies (except of iodine, iron, and zinc) do not often develop spontaneously in adults on\\nordinary diets; infants are more vulnerable because their growth is rapid and intake varies. Trace mineral\\nimbalances can result from hereditary disorders (eg, hemochromatosis, Wilson's disease), kidney dialysis,\\nparenteral nutrition, or restrictive diets prescribed for people with inborn errors of metabolism.\\nChromium\\nOnly 1 to 3% of biologically active trivalent chromium (Cr) is absorbed. Normal plasma levels are 0.05 to\\n0.50 \\n\\ng/L (1.0 to 9.6 nmol/L). Chromium potentiates insulin activity and increases the growth rate in\\nundernourished children. Supplements do not enhance muscle size or strength in men.\\nDeficiency:\\n Four patients receiving long-term TPN developed possible chromium deficiency, with\\nglucose intolerance, weight loss, ataxia, and peripheral neuropathy. Symptoms resolved in 3 who were\\ngiven trivalent chromium 150 to 250 mg.\\nToxicity:\\n High doses of trivalent chromium given parenterally cause skin irritation, but lower doses given\\norally are not toxic. Exposure to hexavalent chromium (CrO\\n3\\n) in the workplace may irritate the skin, lungs,\\nand GI tract and may cause perforation of the nasal septum and lung carcinoma.\\nCopper\\nCopper is a component of many body proteins; almost all of the body's copper is bound to copper\\nproteins. Unbound (free) copper ions are toxic. Genetic mechanisms control the incorporation of copper\\ninto apoproteins and the processes that prevent toxic accumulation of copper in the body. Copper\\nabsorbed in excess of metabolic requirements is excreted through bile.\\n[\\nTable 5-1.\\n Trace Minerals]\\nAcquired Copper Deficiency\\nIf the genetic mechanisms controlling copper metabolism are normal, dietary deficiency rarely causes\\nclinically significant copper deficiency. The only reported causes are kwashiorkor, persistent infantile\\ndiarrhea (usually associated with a diet limited to milk), severe malabsorption (as in sprue), and excessive\\nzinc intake.\\nDeficiency may cause neutropenia, impaired bone calcification, and hypochromic anemia not responsive\\nto iron supplements.\\nDiagnosis is based on low serum levels of copper and ceruloplasmin, although these tests are not always\\nreliable. Treatment is directed at the cause, and copper 1.5 to 3 mg/day po (usually as copper sulfate) is\\ngiven.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n99\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 109, 'page_label': '100'}, page_content='Inherited Copper Deficiency\\n(Menkes Syndrome)\\nInherited copper deficiency occurs in male infants who inherit a mutant X-linked gene. Incidence is about\\n1 in 50,000 live births. Copper is deficient in the liver, serum, and essential copper proteins, including\\ncytochrome-c oxidase, ceruloplasmin, and lysyl oxidase.\\nSymptoms are severe intellectual disability, vomiting, diarrhea, protein-losing enteropathy,\\nhypopigmentation, bone changes, and arterial rupture; the hair is sparse, steely, or kinky.\\nDiagnosis\\n Serum copper and ceruloplasmin levels\\n Serum levels of dopamine, norepinephrine, dihydroxyphenylacetic acid, and dihydroxyphenylglycol in\\ninfants at risk\\nDiagnosis is based on low copper and ceruloplasmin levels in serum, although these tests are not always\\nreliable. Because early diagnosis and treatment seem to result in a better prognosis, the disorder is\\nideally detected before age 2 wk. However, diagnostic accuracy of these tests is limited. Thus, infants at\\nrisk (eg, those with a family history) can be screened by measuring dopamine, norepinephrine,\\ndihydroxyphenylacetic acid, and dihydroxyphenylglycol in serum. A dihydroxyphenylacetic\\nacid:dihydroxyphenylglycol ratio of > 4 seems to indicate deficiency, and a dopamine:norepinephrine ratio\\nof > 0.2 seems to confirm it.\\nTreatment\\n Copper histidine\\nParenteral copper is usually given as copper histidine 250 \\n\\ng sc bid to age 1 yr, then 250 \\n\\ng sc once/day\\nuntil age 3 yr; monitoring kidney function is essential during treatment. Despite early treatment, many\\nchildren have abnormal neurodevelopment.\\nAcquired Copper Toxicity\\nAcquired copper toxicity can result from ingesting or absorbing excess copper (eg, from ingesting an\\nacidic food or beverage that has had prolonged contact with a copper container). Self-limited\\ngastroenteritis with nausea, vomiting, and diarrhea may occur.\\n[\\nTable 5-2.\\n Guidelines for Daily Intake of Minerals]\\nMore severe toxicity results from ingestion (usually with suicidal intent) of gram quantities of a copper salt\\n(eg, copper sulfate) or from absorption of large amounts through the skin (eg, if compresses saturated\\nwith a solution of a copper salt are applied to large areas of burned skin). Hemolytic anemia and anuria\\ncan result and may be fatal.\\nIndian childhood cirrhosis, non-Indian childhood cirrhosis, and idiopathic copper toxicity are probably\\nidentical disorders in which excess copper causes cirrhosis. All seem to be caused by ingesting milk that\\nhas been boiled or stored in corroded copper or brass vessels. Recent studies suggest that idiopathic\\ncopper toxicity may develop only in infants with an unknown genetic defect.\\nDiagnosis usually requires liver biopsy, which shows Mallory hyalin bodies.\\nTreatment\\n Chelation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n100'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 110, 'page_label': '101'}, page_content=\" Supportive measures\\nFor copper toxicity due to ingesting grams of copper, prompt gastric lavage is done. Copper toxicity that\\ncauses complications such as hemolytic anemia, anuria, or hepatotoxicity is also treated with either oral\\npenicillamine 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2 to 4 doses) or dimercaprol 3 to 5\\nmg/kg IM q 4 h for 2 days, then q 4 to 6 h (see also\\nTable 340-4\\n and copper salts in\\nTable 340-8\\n). If used early, hemodialysis may be effective. Occasionally, copper toxicity is fatal despite\\ntreatment.\\nInherited Copper Toxicity\\n(Wilson's Disease)\\nInherited copper toxicity results in accumulation of copper in the liver and other organs. Hepatic\\nor neurologic symptoms develop. Diagnosis is based on a low serum ceruloplasmin level, high\\nurinary excretion of copper, and sometimes liver biopsy results. Treatment consists of a low-\\ncopper diet and chelation, usually with penicillamine or dimercaprol.\\nWilson's disease is a progressive disorder of copper metabolism that affects 1 person in 30,000. Affected\\npeople are homozygous for the mutant recessive gene, located on chromosome 13. Heterozygous\\ncarriers, who constitute about 1.1% of the population, are asymptomatic.\\nPathophysiology\\nThe genetic defect impairs copper transport. The impaired transport decreases copper secretion into the\\nbile, thus causing the copper overload and resultant accumulation in the liver, which begins at birth. The\\nimpaired transport also interferes with incorporation of copper into the copper protein ceruloplasmin, thus\\ndecreasing serum levels of ceruloplasmin.\\nHepatic fibrosis develops, ultimately causing cirrhosis. Copper diffuses out of the liver into the blood, then\\ninto other tissues. It is most destructive to the brain but also damages the kidneys and reproductive\\norgans and causes hemolytic anemia. Some copper is deposited in Descemet's membrane of the cornea,\\ncausing Kayser-Fleischer rings.\\nSymptoms and Signs\\nSymptoms usually develop between ages 5 and 40. In almost half of patients, particularly adolescents,\\nthe first symptom is hepatitisacute, chronic active, or fulminant. But hepatitis may develop at any time.\\nIn about 40% of patients, particularly young adults, the first symptoms reflect CNS involvement. Motor\\ndeficits are common, including any combination of tremors, dystonia, dysarthria, dysphagia, chorea,\\ndrooling, and incoordination. Sometimes the first symptoms are cognitive or psychiatric abnormalities. In 5\\nto 10% of patients, the first symptom is incidentally noted gold or greenish gold Kayser-Fleischer rings or\\ncrescents (due to copper deposits in the cornea), amenorrhea or repeated miscarriages, or hematuria.\\nDiagnosis\\n Slit-lamp examination for Kayser-Fleischer rings\\n Serum ceruloplasmin and 24-h urinary copper excretion\\n Sometimes confirmation by penicillamine provocation test or liver biopsy\\nWilson's disease should be suspected in people < 40 with any of the following:\\n An unexplained hepatic, neurologic, or psychiatric disorder\\n An unexplained persistent elevation in hepatic transaminases\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n101\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 111, 'page_label': '102'}, page_content=\" A sibling, parent, or cousin with Wilson's disease\\n Fulminant hepatitis\\nIf Wilson's disease is suspected, slit-lamp examination for Kayser-Fleischer rings is required, and serum\\nceruloplasmin and copper levels and 24-h urinary copper excretion are measured. Transaminase levels\\nare also often measured; high levels are consistent with the diagnosis.\\nKayser-Fleischer rings:\\n These rings plus typical motor neurologic abnormalities or a decrease in\\nceruloplasmin are nearly pathognomonic for Wilson's disease. Rarely, these rings occur in other liver\\ndisorders (eg, biliary atresia, primary biliary cirrhosis), but ceruloplasmin levels should be unaffected.\\nCeruloplasmin:\\n Serum ceruloplasmin (normally 20 to 35 mg/dL) is usually low in Wilson's disease but\\ncan be normal. It can also be low in heterozygous carriers and those with other liver disorders (eg, viral\\nhepatitis, drug- or alcohol-induced liver disease). A low ceruloplasmin level in a patient with a \\nKayser-\\nFleischer ring is diagnostic. Also, a level of < 5 mg/dL is highly suggestive regardless of clinical findings.\\nSerum copper:\\n Despite the copper accumulation in the body, serum copper levels are decreased\\nbecause of the decreased ceruloplasmin levels.\\nUrinary copper excretion:\\n In Wilson's disease, 24-h urinary copper excretion (normally,  30 \\n\\ng/day) is\\nusually > 100 \\n\\ng/day. If serum ceruloplasmin is low and urinary copper excretion is high, diagnosis is\\nclear. If levels are equivocal, measuring urinary copper excretion after penicillamine is given\\n(penicillamine provocation test) may confirm the diagnosis; this test is not usually done in adults because\\ncutoff values are not well-established.\\nLiver biopsy:\\n In unclear cases (eg, elevated transaminases, no Kayser-Fleischer rings, indeterminate\\nvalues for ceruloplasmin and urinary copper), the diagnosis is made by doing a liver biopsy to measure\\nhepatic copper concentration. However, false-negative results may occur because of a sampling error\\n(due to large variations in copper concentrations in the liver) or fulminant hepatitis (causing necrosis that\\nreleases large amounts of copper).\\nScreening:\\n Because early treatment is most effective, screening is indicated for anyone who has a\\nsibling, cousin, or parent with Wilson's disease. Screening consists of a slit-lamp examination and\\nmeasurement of transaminase levels, serum copper and ceruloplasmin, and 24-h urine copper excretion.\\nIf any results are abnormal, liver biopsy is done to measure hepatic copper concentration. Infants should\\nnot be tested until after age 1 yr because ceruloplasmin levels are low during the first few months of life.\\nChildren < 6 yr with normal test results should be retested 5 to 10 yr later.\\nGenetic testing is under investigation.\\nPrognosis\\nPrognosis is usually good, unless disease is advanced before treatment begins. Untreated Wilson's\\ndisease is fatal, usually by age 30.\\nTreatment\\n Penicillamine or another chelating drug if needed to remove accumulated copper\\n Low-copper diet\\n For maintenance, lifelong low-dose chelation therapy or oral zinc\\nContinual, lifelong treatment is mandatory regardless of whether symptoms are present. Accumulated\\ncopper should be removed with chelating drugs. A low-copper diet (eg, avoiding beef liver, cashews,\\nblack-eyed peas, vegetable juice, shellfish, mushrooms, and cocoa) and use of either low-dose chelation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n102\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 112, 'page_label': '103'}, page_content=\"therapy or oral zinc can prevent copper from accumulating.\\nPenicillamine is the most commonly used chelating drug but has considerable toxicity (eg, fever, rash,\\nneutropenia, thrombocytopenia, proteinuria). Cross-reactivity may occur in people with penicillin allergy.\\nPatients > 5 yr are given oral doses of 62.5 mg q 6 h to 250 mg q 12 h (250 to 500 mg/day in 2 to 4\\ndoses) and slowly increased to a maximum of 250 mg q 6 h to 750 mg q 12 h (1000 to 1500 mg/day in 2\\nto 4 doses). Younger children are given 10 mg/kg bid or 6.7 mg/kg tid (20 mg/kg/d) po. Pyridoxine 25 mg\\npo once/day is given with penicillamine. Occasionally, use of penicillamine is associated with worsening\\nneurologic symptoms.\\nTrientine hydrochloride is an alternative treatment to penicillamine. Doses are 375 to 750 mg po bid or\\n250 to 500 mg po tid (750 to 1500 mg/day).\\nZinc acetate 50 mg po tid can prevent reaccumulation of copper in patients who cannot tolerate\\npenicillamine or trientine or who have neurologic symptoms that do not respond to the other drugs.\\n(CAUTION: \\nPenicillamine or trientine must not be given with zinc because either drug can bind zinc,\\nforming a compound with no therapeutic effect\\n.)\\nPoor long-term adherence to drug therapy is common. After 1 to 5 yr of therapy, lower dose maintenance\\ndrug therapy can be considered. Regular follow-up care with an expert in liver disease is recommended.\\nLiver transplantation may be lifesaving for patients who have Wilson's disease and fulminant hepatic\\nfailure or severe hepatic insufficiency refractory to drugs.\\nFluorine\\nMost of the body's fluorine (F) is contained in bones and teeth. Fluoride (the ionic form of fluorine) is\\nwidely distributed in nature. The main source of fluoride is fluoridated drinking water.\\nDeficiency:\\n Fluorine deficiency can lead to dental caries and possibly osteoporosis. Fluoridation of\\nwater that contains < 1 ppm (the ideal) reduces the incidence of dental caries. If a child's drinking water is\\nnot fluoridated, oral fluoride supplements can be prescribed.\\nToxicity:\\n Excess fluorine can accumulate in teeth and bones, causing fluorosis. Drinking water\\ncontaining > 10 ppm is a common cause. Permanent teeth that develop during \\nhigh fluoride intake are\\nmost likely to be affected. Exposure must be much greater to affect deciduous teeth.\\nThe earliest signs are chalky white, irregularly distributed patches on the surface of the enamel; these\\npatches become stained yellow or brown, producing a characteristic mottled appearance. Severe toxicity\\nweakens the enamel, pitting its surface. Bony changes, including osteosclerosis, exostoses of the spine,\\nand genu valgum, can develop but only in adults after prolonged high intake of fluoride.\\nNo tests to diagnose toxicity are available.\\nTreatment involves reducing fluoride intake; eg, in areas with high fluoride water levels, patients should\\nnot drink fluoridated water or take fluoride supplements. Children should always be told not to swallow\\nfluoridated toothpastes.\\nIodine\\nIn the body, iodine (I) is involved primarily in the synthesis of 2 thyroid hormones, thyroxine (T\\n4\\n) and\\ntriiodothyronine (T\\n3\\n). Iodine occurs in the environment and in the diet primarily as iodide. In adults, about\\n80% of the iodide absorbed is trapped by the thyroid gland. Most environmental iodine occurs in\\nseawater as iodide; a small amount enters the atmosphere and, through rain, enters ground water and\\nsoil near the sea. Thus, people living far from the sea and at higher altitudes are at particular risk of\\ndeficiency. Fortifying table salt with iodide (typically 70 \\n\\ng/g) helps ensure adequate intake (150 \\n\\ng/day).\\nRequirements are higher for pregnant (220 \\n\\ng/day) and breastfeeding (290 \\n\\ng/day) women.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n103\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 113, 'page_label': '104'}, page_content='Iodine Deficiency\\nDeficiency is rare in areas where iodized salt is used but common worldwide. Iodine deficiency develops\\nwhen iodide intake is < 20 \\n\\ng/day. In mild or moderate deficiency, the thyroid gland, influenced by thyroid-\\nstimulating hormone (TSH), hypertrophies to concentrate iodide in itself, resulting in colloid goiter.\\nUsually, patients remain euthyroid; however, severe iodine deficiency in adults may cause hypothyroidism\\n(endemic myxedema). It can decrease fertility and increase risk of stillbirth, spontaneous abortion, and\\nprenatal and infant mortality. Severe maternal iodine deficiency retards fetal growth and brain\\ndevelopment, sometimes resulting in birth defects, and, in infants, causes cretinism, which may include\\nintellectual disability, deaf-mutism, difficulty walking, short stature, and sometimes hypothyroidism.\\nDiagnosis\\n Assessment of thyroid structure and function\\nDiagnosis in adults and children is usually based on thyroid function, examination for goiter, and imaging\\ntests identifying abnormalities in thyroid function and structure (see p.\\n776\\n). All neonates should be screened by measuring the TSH level.\\nTreatment\\n Iodide with or without levothyroxine\\nInfants with iodine deficiency are given L-thyroxine 3 \\n\\ng/kg po once/day for a week plus iodide 50 to 90\\n\\ng po once/day for several weeks to quickly restore a euthyroid state. Children are treated with iodide 90\\nto 120 \\n\\ng once/day. Adults are given iodide 150 \\n\\ng once/day. Iodine deficiency can also be treated by\\ngiving levothyroxine. Serum TSH levels are monitored in all patients until the levels are normal (ie, < 5\\n\\nIU/mL).\\nIodine Toxicity\\nChronic toxicity may develop when intake is > 1.1 mg/day. Most people who ingest excess amounts of\\niodine remain euthyroid. Some people who ingest excess amounts of iodine, particularly those who were\\npreviously deficient, develop hyperthyroidism (Jod-Basedow phenomenon). Paradoxically, excess uptake\\nof iodine by the thyroid may inhibit thyroid hormone synthesis (called Wolff-Chaikoff effect). Thus, iodine\\ntoxicity can eventually cause iodide goiter, hypothyroidism, or myxedema. Very large amounts of iodide\\nmay cause a brassy taste in the mouth, increased salivation, GI irritation, and acneiform skin lesions.\\nPatients exposed to frequent large amounts of radiographic contrast dyes or the drug amiodarone also\\nneed to have their thyroid function monitored.\\nDiagnosis is usually based on thyroid function and imaging test findings (see p. \\n776\\n), which are\\ncorrelated with clinical data. Iodine excretion may be more specific but is not usually measured. Treatment\\nconsists of correcting thyroid abnormalities and, if intake is excessive, dietary modification.\\nIron\\nIron (Fe) is a component of hemoglobin, myoglobin, and many enzymes in the body. \\nHeme iron, contained\\nmainly in animal products, is absorbed much better than nonheme iron (eg, in plants and grains), which\\naccounts for > 85% of iron in the average diet. However, absorption of nonheme iron is increased when it\\nis consumed with animal protein and vitamin C.\\nDeficiency:\\n Iron deficiency is one of the most common mineral deficiencies in the world. It may result\\nfrom the following:\\n Inadequate iron intake, common in infants, adolescent girls, and pregnant women\\n Malabsorption (eg, celiac sprue)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n104'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 114, 'page_label': '105'}, page_content=\" Chronic bleeding\\nChronic bleeding due to colon cancer is a serious cause in middle-aged people and the elderly.\\nWhen deficiency is advanced, microcytic anemia develops (see p. \\n924\\n).\\nIn addition to anemia, iron deficiency may cause pica (a craving for nonfoods) and spoon nails and is\\nassociated with restless leg syndrome. Rarely, iron deficiency causes dysphagia due to postcricoid\\nesophageal web.\\nDiagnosis involves CBC, serum ferritin, and possibly measurement of transferrin saturation (iron\\ncapacity).\\nAll people with moderate or severe iron deficiency and some people with mild deficiency require iron\\nsupplementation.\\nToxicity:\\n Iron may accumulate in the body because of\\n Iron therapy given in excessive amounts or for too long\\n Repeated blood transfusions\\n Chronic alcoholism\\n Overdose of iron\\nIron overload can also result from an inherited iron overload disease (hemochromatosissee p. \\n1032\\n), a\\npotentially fatal but easily treatable genetic disorder in which too much iron is absorbed.\\nHemochromatosis affects > 1 million Americans.\\nAn overdose of iron is toxic (see p. \\n3341\\n), causing vomiting, diarrhea, and damage to the intestine and\\nother organs.\\nDiagnosis is similar to that for iron deficiency.\\nTreatment often involves deferoxamine, which binds with iron and is excreted in urine.\\nManganese\\nManganese (Mn), necessary for healthy bone structure, is a component of several enzyme systems,\\nincluding manganese-specific glycosyltransferases and phosphoenolpyruvate carboxykinase. Median\\nintake is between 1.6 and 2.3 mg/day; absorption is 5 to 10%.\\nDeficiency has not been conclusively documented, although one experimental case in a volunteer\\nresulted in transient dermatitis, hypocholesterolemia, and increased alkaline phosphatase levels.\\nToxicity is usually limited to people who mine and refine ore; prolonged exposure causes neurologic\\nsymptoms resembling those of parkinsonism or Wilson's disease.\\nMolybdenum\\nMolybdenum (Mo) is a component of coenzymes necessary for the activity of xanthine oxidase, sulfite\\noxidase, and aldehyde oxidase.\\nGenetic and nutritional deficiencies of molybdenum have been reported but are rare. Genetic sulfite\\noxidase deficiency was described in 1967 in a child. It resulted from the inability to form the molybdenum\\ncoenzyme despite the presence of adequate molybdenum. The deficiency caused intellectual disability,\\nseizures, opisthotonus, and lens dislocation.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n105\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 115, 'page_label': '106'}, page_content='Molybdenum deficiency resulting in sulfite toxicity occurred in a patient receiving long-term TPN.\\nSymptoms were tachycardia, tachypnea, headache, nausea, vomiting, and coma. Laboratory tests\\nshowed high levels of sulfite and xanthine and low levels of sulfate and uric acid in the blood and urine.\\nAmmonium molybdate 300 \\n\\ng/day IV caused dramatic recovery.\\nA case of molybdenum toxicity may have occurred in 1961; it caused goutlike symptoms and\\nabnormalities of the GI tract, liver, and kidneys.\\nSelenium\\nSelenium (Se) is a part of the enzyme glutathione peroxidase, which metabolizes hydro-peroxides formed\\nfrom polyunsaturated fatty acids. Selenium is also a part of the enzymes that deiodinate thyroid\\nhormones. Generally, selenium acts as an antioxidant that works with vitamin E. Some epidemiologic\\nstudies associate low selenium levels with cancer. In children with Down syndrome, selenium\\nsupplements may help prevent bacterial infections. Plasma levels vary from 8 to 25 \\n\\ng/dL, depending on\\nselenium intake. Diagnosis is usually clinical; sometimes blood glutathione peroxidase is measured.\\nDeficiency:\\n Deficiency is rare, even in New Zealand and Finland, where selenium intake \\nis 30 to 50\\n\\ng/day, compared with 100 to 250 \\n\\ng/day in the US and Canada. In certain areas of China, where intake\\naverages 10 to 15 \\n\\ng/day, selenium deficiency predisposes patients to Keshan disease, an endemic viral\\ncardiomyopathy affecting primarily children and young women. This cardiomyopathy can be prevented\\nbut not cured by sodium selenite supplements of 50 \\n\\ng/day po. Patients receiving long-term TPN have\\ndeveloped selenium deficiency with muscle pain and tenderness that responded to a selenomethionine\\nsupplement. In Siberian Russia and China, growing children with selenium deficiency may develop\\nchronic osteoarthropathy (Kashin-Beck disease). Selenium deficiency may contribute synergistically with\\niodine deficiency to the development of goiter and hypothyroidism.\\nDiagnosis is made clinically or sometimes by measuring glutathione peroxidase activity or plasma\\nselenium, but neither of these tests is readily available. Treatment consists of sodium selenite 100 \\n\\ng/day\\npo.\\nToxicity:\\n At high doses (> 900 \\n\\ng/day), selenium causes toxicity. Manifestations include hair loss,\\nabnormal nails, dermatitis, peripheral neuropathy, nausea, diarrhea, fatigue, irritability, and a garlic odor of\\nthe breath. Toxic levels of plasma selenium are not well defined.\\nZinc\\nZinc (Zn) is contained mainly in bones, teeth, hair, skin, liver, muscle, leukocytes, and testes. Zinc is a\\ncomponent of several hundred enzymes, including many nicotinamide adenine dinucleotide (NADH)\\ndehydrogenases, RNA and DNA polymerases, and DNA transcription factors as well as alkaline\\nphosphatase, superoxide dismutase, and carbonic anhydrase. A diet high in fiber and phytate (eg, in\\nwhole-grain bread) reduces zinc absorption.\\nDeficiency:\\n Dietary deficiency is unlikely in healthy people. Secondary zinc deficiency can develop in the\\nfollowing:\\n Some patients with hepatic insufficiency (because the ability to retain zinc is lost)\\n Patients taking diuretics\\n Patients with diabetes mellitus, sickle cell disease, chronic renal failure, or malabsorption\\n Patients with stressful conditions (eg, sepsis, burns, head injury)\\n Elderly institutionalized and homebound patients (common)\\nMaternal zinc deficiency may cause fetal malformations and low birth weight.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n106'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 116, 'page_label': '107'}, page_content=\"Zinc deficiency in children causes impaired growth and impaired taste (hypogeusia). Other symptoms and\\nsigns in children include delayed sexual maturation and hypogonadism. In children or adults, symptoms\\ninclude hypogonadism, alopecia, impaired immunity, anorexia, dermatitis, night blindness, anemia,\\nlethargy, and impaired wound healing.\\nZinc deficiency should be suspected in undernourished patients with typical symptoms or signs. However,\\nbecause many of the symptoms and signs are nonspecific, clinical diagnosis of mild zinc deficiency is\\ndifficult. Laboratory diagnosis is also difficult. Low albumin levels, common in zinc deficiency, make serum\\nzinc levels difficult to interpret; diagnosis usually requires the combination of low levels of zinc in serum\\nand increased urinary zinc excretion. If available, isotope studies can measure zinc status more\\naccurately.\\nTreatment consists of elemental zinc 15 to 120 mg/day po until symptoms and signs resolve.\\nAcrodermatitis enteropathica\\n (a rare, once fatal autosomal recessive disorder) causes malabsorption\\nof zinc. Psoriasiform dermatitis develops around the eyes, nose, and mouth; on the buttocks; and in an\\nacral distribution. The disorder also causes hair loss, paronychia, impaired immunity, recurrent infection,\\nimpaired growth, and diarrhea. Symptoms and signs usually develop after infants are weaned from breast\\nmilk. In such cases, doctors suspect the diagnosis. If deficiency is diagnosed, zinc sulfate 30 to 150\\nmg/day po usually results in complete remission.\\nToxicity:\\n The recommended upper limit for zinc intake is 40 mg/day. Toxicity is rare. Ingesting doses of\\nelemental zinc ranging from 100 to 150 mg/day for prolonged periods interferes with copper metabolism\\nand causes low blood copper levels, RBC microcytosis, neutropenia, and impaired immunity; higher\\ndoses should be given only for short periods of time and the patient should be followed closely. Ingesting\\nlarger amounts (200 to 800 mg/day), usually by consuming acidic food or drink from a galvanized (zinc-\\ncoated) container, can cause anorexia, vomiting, and diarrhea. Metal fume fever, also called brass-\\nfounders' ague or zinc shakes, is caused by inhaling industrial zinc oxide fumes; it results in neurologic\\ndamage. Symptoms usually resolve after 12 to 24 h in a zinc-free environment.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 5. Mineral Deficiency & Toxicity\\n107\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 117, 'page_label': '108'}, page_content='Chapter 6. Obesity and the Metabolic Syndrome\\nObesity\\nObesity is excess body fat; consequences depend not only on the absolute amount but also on\\nthe distribution of the fat. Complications include cardiovascular disorders, diabetes mellitus,\\nmany cancers, cholelithiasis, fatty liver and cirrhosis, osteoarthritis, reproductive disorders in\\nmen and women, psychologic disorders, and premature death. Diagnosis is based on body\\nmass index (BMIcalculated from height and weight) and waist circumference. BP, fasting\\nplasma glucose, and lipid levels should be measured. Treatment includes physical activity,\\ndietary and behavioral modification, and sometimes drugs or surgery.\\nPrevalence of obesity in the US is high and is increasing, particularly among children and adolescents\\n(see\\nTable 6-1\\n).\\nPrevalence is more than twice as high at age 55 as at age 20. Obesity is twice as common among women\\nin a lower socioeconomic group as among those in a higher group. Prevalence among black and white\\nmen does not differ significantly, but it is higher among black women than white women. More than 50%\\nof black women  40 yr are obese; > 80% are overweight.\\nIn the US, obesity and its complications cause as many as 300,000 premature deaths each year, making\\nit second only to cigarette smoking as a preventable cause of death.\\n[\\nTable 6-1.\\n Changes in Prevalence of Obesity According to Nhanes]\\nEtiology\\nAlmost all cases of obesity result from a combination of genetic predisposition and a chronic imbalance\\nbetween energy intake, energy utilization for basic metabolic processes, and energy expenditure from\\nphysical activity.\\nGenetic factors:\\n Heritability of BMI is about 66%. Genetic factors may affect the many signaling\\nmolecules and receptors used by parts of the hypothalamus and GI tract to regulate food intake (see\\nSidebar 6-1\\n). Rarely, obesity results from abnormal levels of peptides that regulate food intake (eg, leptin)\\nor abnormalities in their receptors (eg, melanocortin-4 receptor).\\nGenetic factors also regulate energy expenditure, including BMR, diet-induced thermogenesis, and\\nnonvoluntary activity-associated thermogenesis. Genetic factors may have a greater effect on the\\ndistribution of body fat, particularly abdominal fat (see \\nMetabolic Syndrome\\n on p. \\n64\\n), than on the amount\\nof body fat.\\nEnvironmental factors:\\n Weight is gained when caloric intake exceeds energy needs. Important\\ndeterminants of energy intake include portion sizes and the energy density of the food. High-fat foods,\\nprocessed foods, and diets high in refined carbohydrates, soft drinks, fruit juices, and alcohol promote\\nweight gain. Diets high in fresh fruit and vegetables, fiber, and complex carbohydrates, with water as the\\nmain fluid consumed, minimize weight gain. A sedentary lifestyle promotes weight gain.\\nRegulatory factors:\\n Prenatal maternal obesity, prenatal maternal smoking, intrauterine growth\\nrestriction, and insufficient sleep can disturb weight regulation. About 15% of women permanently gain \\n20 lb with each pregnancy. Obesity that persists beyond early childhood makes weight loss in later life\\nmore difficult.\\nDrugs, including corticosteroids, lithium, traditional antidepressants (tricyclics, tetracyclics, and\\nmonoamine oxidase inhibitors [MAOIs]), benzodiazepines, and antipsychotic drugs, often cause weight\\ngain.\\nUncommonly, weight gain is caused by one of the following disorders:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n108'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 118, 'page_label': '109'}, page_content=\" Brain damage caused by a tumor (especially a craniopharyngioma) or an infection (particularly those\\naffecting the hypothalamus), which can stimulate consumption of excess calories\\n Hyperinsulinism due to pancreatic tumors\\n Hypercortisolism due to Cushing's syndrome, which causes predominantly abdominal obesity\\n Hypothyroidism (rarely a cause of substantial weight gain)\\nSidebar 6-1 Pathways Regulating Food Intake\\nPreabsorptive and postabsorptive signals from the GI tract and changes in plasma nutrient levels provide\\nshort-term feedback to regulate food intake:\\n GI hormones (eg, glucagon-like peptide 1 [GLP-1], cholecystokinin [CCK]) reduce food intake.\\n Ghrelin, secreted primarily by the stomach, increases food intake.\\n Leptin, secreted from adipose tissue, informs the brain as to how much fat is stored; high leptin levels\\ncorrelate with increased body fat.\\nThe hypothalamus integrates various signals involved in the regulation of energy balance and then\\nactivates pathways that increase or decrease food intake:\\n Neuropeptide Y (NPY), agouti-related peptide (ARP), \\n\\n-melanocyte-stimulating hormone (\\n\\n-MSH),\\ncocaine- and amphetamine-related transcript (CART), orexin, and melanin-concentrating hormone\\n(MCH) increase food intake.\\n Corticotropic hormone (CRH) and urocortin decrease it.\\nEating disorders:\\n At least 2 pathologic eating patterns may be associated with obesity:\\n \\nBinge eating disorder\\n is consumption of large amounts of food quickly with a subjective sense of loss\\nof control during the binge and distress after it (see p. \\n1537\\n). This disorder does not include\\ncompensatory behaviors, such as vomiting. Prevalence is 1 to 3% among both sexes and 10 to 20%\\namong people entering weight reduction programs. Obesity is usually severe, large amounts of weight\\nare frequently gained or lost, and pronounced psychologic disturbances are present.\\n \\nNight-eating syndrome\\n consists of morning anorexia, evening hyperphagia, and insomnia. At least 25\\nto 50% of daily intake occurs after the evening meal. About 10% of people seeking treatment for severe\\nobesity may have this disorder. Rarely, a similar disorder is induced by use of a hypnotic such as\\nzolpidem.\\nSimilar but less extreme patterns, classified as eating disorders not otherwise specified (EDNOS),\\nprobably contribute to excess weight gain in more people. For example, nocturnal eating contributes to\\nexcess weight gain in many people who do not have night-eating syndrome.\\nComplications\\nComplications of obesity include the following:\\n Metabolic syndrome\\n Diabetes mellitus\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n109\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 119, 'page_label': '110'}, page_content=' Cardiovascular disease\\n Nonalcoholic steatohepatitis (fatty liver)\\n Gallbladder disease\\n Gastroesophageal reflux\\n Obstructive sleep apnea\\n Reproductive system disorders\\n Many cancers\\n Osteoarthritis\\n Social and psychologic problems\\nInsulin resistance, dyslipidemias, and hypertension (the metabolic syndrome) develop, often leading to\\ndiabetes mellitus and coronary artery disease (see p. \\n64\\n). These complications are more likely in patients\\nwith fat that is concentrated abdominally, a high serum triglyceride level, a family history of type 2\\ndiabetes mellitus or premature cardiovascular disease, or a combination of these risk factors.\\nObesity is also a risk factor for nonalcoholic steatohepatitis (which may lead to cirrhosis) and for\\nreproductive system disorders, such as a low serum testosterone level in men and polycystic ovary\\nsyndrome in women.\\nObstructive sleep apnea can result if excess fat in the neck compresses the airway during sleep.\\nBreathing stops for moments, as often as hundreds of times a night (see p. \\n1903\\n). This disorder, often\\nundiagnosed, can cause loud snoring and excessive daytime sleepiness and increases the risk of\\nhypertension, cardiac arrhythmias, and metabolic syndrome.\\nObesity may cause the obesity-hypoventilation syndrome (Pickwickian syndrome). Impaired breathing\\nleads to hypercapnia, \\nreduced sensitivity to CO\\n2\\n in stimulating respiration, hypoxia, cor pulmonale, and\\nrisk of premature death. This syndrome may occur alone or secondary to obstructive sleep apnea.\\nOsteoarthritis and tendon and fascial disorders may result from obesity. Skin disorders are common;\\nincreased sweat and skin secretions, trapped in thick folds of skin, are conducive to fungal and bacterial\\ngrowth, making intertriginous infections especially common. Being overweight probably predisposes to\\ncholelithiasis, gout, deep venous thrombosis and pulmonary embolism, and many cancers (especially\\ncolon and breast cancers).\\nObesity leads to social, economic, and psychologic problems as a result of prejudice, discrimination, poor\\nbody image, and low self-esteem. For example, people may be underemployed or unemployed.\\nDiagnosis\\n BMI\\n Waist circumference\\n Sometimes body composition analysis\\nIn adults, BMI, defined as weight (kg) divided by the square of the height (m\\n2\\n), is used to screen for\\noverweight or obesity. BMI of 25 to 29.9 kg/m\\n2\\n indicates overweight; BMI  30 kg/m\\n2\\n indicates obesity\\n(see\\nTable 6-2\\n). However, BMI is a crude screening tool and has limitations in many subpopulations. BMI is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n110'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 120, 'page_label': '111'}, page_content='age- and race-specific; its use is limited in children and the elderly. In children and adolescents,\\noverweight is BMI at the  95th percentile based on age- and sex-specific Centers for Disease Control\\nand Prevention (CDC) growth charts at the CDC web site.\\nAsians, Japanese, and many aboriginal populations have a lower cut-off (23 kg/m\\n2\\n) for overweight. In\\naddition, BMI may be high in muscular athletes who lack excess body fat, and normal or low in formerly\\noverweight people who have lost muscle mass.\\nThe risk of metabolic and cardiovascular complications due to obesity is determined more accurately by\\nthe following:\\n Other risk factors, particularly a family history of type 2 diabetes or premature cardiovascular disease\\n Waist circumference\\n Serum triglycerides\\nThe waist circumference that increases risk of complications due to obesity varies by ethnic group and\\nsex:\\n White men: > 93 cm (> 36.6 in), particularly > 101 cm (> 39.8 in)\\n White women: > 79 cm (> 31.1 in), particularly > 87 cm (> 34.2 in)\\n Asian Indian men: > 78 cm (> 30.7 in), particularly > 90 cm (> 35.4 in)\\n Asian Indian women: > 72 cm (> 28.3 in), particularly > 80 cm (> 31.5 in)\\nBody composition analysis:\\n Body compositionthe percentage of body fat and muscleis also\\nconsidered when obesity is diagnosed. Although probably unnecessary in routine clinical practice, body\\ncomposition analysis can be helpful if clinicians question whether elevated BMI is due to muscle or\\nexcessive fat.\\nThe percentage of body fat can be estimated by measuring skinfold thickness (usually over the triceps) or\\ndetermining mid upper arm area (see p.\\n13\\n).\\nBioelectrical impedance analysis (BIA) can estimate percentage of body fat simply and noninvasively. BIA\\nestimates percentage of total body water directly; percentage of body fat is derived indirectly. BIA is most\\nreliable in healthy people and in people with only a few chronic disorders that do not change the\\npercentage of total body water (eg, moderate obesity, diabetes mellitus). Whether measuring BIA poses\\nrisks in people with implanted defibrillators is unclear.\\nUnderwater (hydrostatic) weighing is the most accurate method for measuring percentage of body fat.\\nCostly and time-consuming, it is used more often in research than in clinical care. To be weighed\\naccurately while submerged, people must fully exhale beforehand.\\nImaging procedures, including CT, MRI, and dual-energy x-ray absorptiometry (DEXA), can also estimate\\nthe percentage and distribution of body fat but are usually used only for research.\\nOther testing:\\n Obese patients should be screened for obstructive sleep apnea with an instrument such\\nas the Epworth Sleepiness Scale and often the apnea-hypopnea index (total number of apnea or\\nhypopnea episodes occurring per hour of sleepsee p. \\n1904\\n). This disorder is often underdiagnosed,\\nand obesity increases the risk.\\nFasting glucose and lipid levels should be measured routinely in patients with a large waist circumference\\nor a family history of type 2 diabetes mellitus or premature cardiovascular disease.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n111'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 121, 'page_label': '112'}, page_content='Prognosis\\nUntreated, obesity tends to progress. The probability and severity of complications are proportional to the\\nabsolute amount of fat, the distribution of the fat, and absolute muscle mass. After weight loss, most\\npeople return to their pretreatment weight within 5 yr, and\\n[\\nTable 6-2.\\n Body Mass Index (BMI)]\\naccordingly, obesity requires a lifelong management program similar to that for any other chronic disorder.\\nTreatment\\n Nutrition management\\n Physical activity\\n Behavioral therapy\\n Drugs (eg, sibutramine, orlistat)\\n Bariatric surgery\\nWeight loss of even 5 to 10% improves overall health and well-being and in particular helps reduce risk of\\ncardiovascular disorders and type 2 diabetes. Weight loss can lead to improvement in patients with\\nobstructive sleep apnea, but sometimes a lot of weight must be lost for the disorder to resolve.\\nSupport from health care practitioners, peers, and family members and various structured programs can\\nhelp with weight loss and weight maintenance.\\nNutrition:\\n A normal eating pattern is important. People who miss breakfast tend to passively consume too\\nmany calories later in the day. Patients should eat small meals and avoid or carefully choose snacks.\\nLow-fat (particularly very low saturated fat), high-fiber diets with modest calorie restriction (by 600\\nkcal/day) and substitution of some protein for carbohydrate seem to have the best long-term outcome.\\nFresh fruits and vegetables and salads should be substituted for refined carbohydrates and processed\\nfood, and water for soft drinks or juices. Alcohol consumption should be limited to moderate levels. Foods\\nwith a low glycemic index (see\\nTable 1-1\\n on p. \\n3\\n) and marine fish oils or monounsaturated fats derived from plants (eg, olive oil) reduce\\nthe risk of cardiovascular disorders and diabetes. Low-fat dairy products are also part of a healthy diet.\\nPatients need an adequate amount of vitamin D, preferably obtained by exercising outdoors in the\\nsunshine.\\nUse of meal replacements has proven efficacy; use can be ongoing or intermittent. Diets that require\\nunusual eating habits should be avoided. They are unlikely to be maintained, and weight increases when\\npatients resume previous poor eating habits. Diets of < 1200 kcal/day cannot be sustained, but such diets\\nare sometimes needed to achieve rapid short-term weight loss (eg, to prepare for surgery, to lessen\\nobstructive sleep apnea). Diets of < 800 kcal/day do not produce greater weight loss and are less well\\ntolerated.\\nPhysical activity:\\n Exercise increases energy expenditure, BMR, and diet-induced thermogenesis.\\nExercise also seems to regulate appetite to more closely match caloric needs. Other benefits include\\n Increased insulin sensitivity\\n Improved lipid profile\\n Lower BP\\n Better aerobic fitness\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n112'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 122, 'page_label': '113'}, page_content=' Improved psychologic well-being\\nStrengthening (resistance) exercises increase muscle mass. Because muscle tissue burns more calories\\nat rest than does fat tissue, increasing muscle mass produces lasting increases in \\nBMR. Exercise that is\\ninteresting and enjoyable is more likely to be sustained. A combination of aerobic and resistance exercise\\nis better than either alone.\\nBehavioral therapy:\\n Behavioral therapy aims to improve eating habits and physical activity level. Rigid\\ndieting is discouraged in favor of healthy eating. Common-sense measures include the following:\\n Avoiding high-calorie snacks\\n Choosing healthful foods when dining out\\n Eating slowly\\n Substituting a physically active hobby for a passive one\\nSocial support, cognitive therapy, and stress management may help, particularly during the lapses usually\\nexperienced during any long-term weight loss program. Self-monitoring is useful, and maintenance of a\\ndiet diary is particularly effective.\\nDrugs:\\n Drugs may be used if BMI is > 30 or if BMI is > 27 and patients have complications (eg,\\nhypertension, insulin resistance). Most weight loss due to drug treatment is modest (5 to 10%) at best and\\noccurs during the first 6 mo; not all patients benefit. Drugs are more useful for maintaining weight loss but\\nmust be continued indefinitely for weight loss to be maintained. Premenopausal women taking\\nsystemically acting drugs for weight control should use contraception.\\nSibutramine is a centrally acting appetite suppressant that produces dose-related weight loss. The usual\\nstarting dose is 10 mg po once/day; the dose can be decreased to 5 mg or increased to 15 mg. Common\\nadverse effects are headache, dry mouth, insomnia, and constipation; the most common serious one is\\nhypertension. Cardiovascular disorders, particularly poorly controlled hypertension, are contraindications.\\nOrlistat inhibits intestinal lipase, decreasing fat absorption and improving serum glucose and lipids.\\nBecause orlistat is not absorbed, systemic effects are rare. Flatus, oily stools, and diarrhea are common\\nbut tend to resolve during the 2nd yr of treatment. A dose of 120 mg po tid should be taken with meals\\nthat include fat. A vitamin supplement should be taken at least 2 h before or after taking orlistat.\\nMalabsorption and cholestasis are contraindications; irritable bowel syndrome and other GI disorders may\\nmake orlistat difficult to tolerate. Orlistat is available OTC.\\nOther OTC weight-loss drugs are not recommended. Some (eg, caffeine, ephedrine, guarana,\\nphenylpropanolamine) may be marginally effective, but their adverse effects outweigh their advantages.\\nOthers (eg, brindleberry, L-carnitine, chitosan, pectin, grapeseed extract, horse chestnut, chromium\\npicolinate, fucus vesiculosus, ginkgo biloba) have not been shown to be effective and may have adverse\\neffects.\\nSurgery:\\n Surgery is the most effective treatment for extremely obese patients (see p. \\n61\\n).\\nSpecial Populations\\nObesity is a particular concern in children and the elderly.\\nChildren:\\n Childhood obesity is even more worrisome than adult obesity. For obese children,\\ncomplications are more likely because children are obese longer. About 20 to 25% of children and\\nadolescents are overweight or obese. Risk factors for obesity in infants are low birth weight and maternal\\nobesity, diabetes, and smoking. After puberty, food intake increases; in boys, the extra calories are used\\nto increase protein deposition, but in girls, fat storage is increased.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n113'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 123, 'page_label': '114'}, page_content='For obese children, psychologic complications (eg, poor self-esteem, social difficulties, depression) and\\nmusculoskeletal complications can develop early. Some musculoskeletal complications, such as slipped\\ncapital femoral epiphyses, occur only in children. Other early complications may include obstructive sleep\\napnea, insulin resistance, hyperlipidemia, and nonalcoholic steatohepatitis. Risk of cardiovascular,\\nrespiratory, metabolic, hepatic, and other obesity-related complications increases when these children\\nbecome adults.\\nRisk of obesity persisting into adulthood depends partly on when obesity first develops:\\n During infancy: Low risk\\n Between 6 mo and 5 yr: 25%\\n After 6 yr: > 50%\\n During adolescence if a parent is obese: > 80%\\nIn children, preventing further weight gain, rather than losing weight, is a reasonable goal. Diet should be\\nmodified, and physical activity increased. Increasing general activities and play is more likely to be\\neffective than a structured exercise program. Participating in physical activities during childhood may\\npromote a lifelong physically active lifestyle. Drugs and surgery are avoided but, if complications of\\nobesity are life threatening, may be warranted.\\nMeasures that control weight and prevent obesity in children may benefit public health the most. Such\\nmeasures should be implemented in the family, schools, and primary care programs.\\nThe elderly:\\n In the US, the percentage of obese elderly people has been increasing.\\nWith aging, body fat increases and is redistributed to the abdomen, and muscle mass is lost, largely\\nbecause of physical inactivity, but decreased androgens and growth hormone (which are anabolic) and\\ninflammatory cytokines produced in obesity may also play a role.\\nRisk of complications depends on\\n Body fat distribution (increasing with a predominantly abdominal distribution)\\n Duration and severity of obesity\\n Associated sarcopenia\\nIncreased waist circumference, suggesting abdominal fat distribution, predicts morbidity (eg,\\nhypertension, diabetes mellitus, coronary artery disease) and mortality risk better in the elderly than does\\nBMI.\\nFor the elderly, increased physical activity is usually preferable to dietary restriction unless restricted\\nmobility prohibits activity; in such cases, caloric restriction may be needed to reduce weight enough to\\nrestore mobility. Physical activity also improves muscle strength, endurance, and overall well-being.\\nActivity should include strengthening and endurance exercises.\\nRegardless of whether caloric restriction is considered necessary, nutrition should be optimized.\\nWeight-loss drugs such as sibutramine or fluoxetine are not recommended for the elderly because the\\npossible benefits do not outweigh the adverse effects. However, orlistat may be useful for obese elderly\\npatients, particularly those with diabetes mellitus or hypertension. Surgery is usually best avoided,\\nalthough it has proven efficacy and benefits outweigh risks in carefully selected patients.\\nPrevention\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n114'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 124, 'page_label': '115'}, page_content='Regular physical activity and healthy eating improve general fitness, can control weight, and help prevent\\nobesity and diabetes mellitus. Even without weight loss, exercise decreases the risk of cardiovascular\\ndisorders. Dietary fiber decreases the risk of colon cancer and cardiovascular disorders. Sufficient and\\ngood-quality sleep, management of stress, and moderation of alcohol intake are also important.\\nBariatric Surgery\\nBariatric surgery is the surgical alteration of the stomach, intestine, or both to cause weight\\nloss.\\nIn the US, bariatric surgery is done over 200,000 times annually, accounting for almost two thirds of all\\nbariatric operations done worldwide. Development of safer laparoscopic approaches has made this\\nsurgery more popular.\\nIndications\\nTo qualify for bariatric surgery, patients should\\n Have acceptable operative risk\\n Be well-informed and motivated\\n Have unsuccessfully tried all reasonable nonsurgical methods to lose weight and manage obesity-\\nassociated complications\\n Have a BMI of > 40 kg/m\\n2\\n or a BMI > 35 kg/m\\n2\\n plus a serious complication (eg, diabetes, hypertension,\\nobstructive sleep apnea, high-risk lipid profile) that could be expected to be meaningfully reduced with a\\nweight loss of 5 to 10%\\nContraindications include uncontrolled major depression or psychosis, binge eating disorders, current\\ndrug or alcohol abuse, severe coagulopathy, and inability to comply with nutritional requirements,\\nincluding lifelong vitamin replacement (when indicated). Whether bariatric surgery is appropriate for\\npatients < 18 or > 65 yr is controversial.\\nProcedures\\n Restrictive procedures (adjustable gastric banding, vertical banded gastroplasty)\\n Malabsorptive procedures (Roux-en-Y gastric bypass)\\nMost procedures can be done laparoscopically, but the approach depends on the type of procedure as\\nwell as patient weight. Morbidity and mortality tend to be lower with laparoscopic than with open surgery.\\nHowever, if patients weigh  180 kg, open surgery is more likely to be successful. In about 8% of cases\\noverall (fewer with experienced surgeons), surgery begun laparoscopically must be finished as open\\nsurgery.\\nProcedures can be restrictive, malabsorptive, or both.\\nRestrictive procedures:\\n Restrictive procedures limit the volume of the stomach available for ingested\\nfood. This limited volume helps restrict food intake, probably because of earlier satiety. The effects can\\nbe partially defeated by patients who consume more high-calorie liquid foods (eg, milk shakes, alcohol),\\nwhich pass through the restricted portion quicker.\\nPurely restrictive procedures include adjustable gastric banding and vertical banded gastroplasty.\\n[\\nFig. 6-1.\\n Adjustable gastric banding.]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n115'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 125, 'page_label': '116'}, page_content='Adjustable gastric banding accounts for about 15% of bariatric procedures done in the US; it is much\\nmore common in Europe and is growing in popularity in the US. It is the 2nd most common bariatric\\nprocedure. A band is placed around the upper part of the stomach to divide the stomach into a small\\nupper pouch and a larger lower pouch. Saline can be injected into the band via a subcutaneous access\\nport. When saline is injected, the band expands, decreasing the size of the passageway through the\\nstomach. As a result, the upper pouch fills more quickly, sending a message to the brain that the stomach\\nis full; patients eat smaller meals and lose substantial amounts of weight over time. This procedure is\\nusually done laparoscopically. Saline can be removed to make the passageway larger. Even though\\nweight loss from gastric banding is slightly less than that from Roux-en-Y, morbidity and mortality are\\nmuch less and gastric banding can be reversed if necessary.\\nVertical banded gastroplasty\\n is no longer commonly done. A stapler is used to divide the stomach into\\na small upper pouch and a larger lower pouch. A nonexpandable plastic band is placed around the\\nopening where the upper pouch empties into the lower pouch.\\nMalabsorptive procedures:\\n Malabsorptive procedures, such as biliopancreatic diversion with a\\nduodenal switch and Roux-en-Y gastric bypass, result in ingested food bypassing parts of the stomach\\nand small intestine, creating malabsorption, which leads to weight loss. These procedures are also\\nrestrictive.\\nRoux-en-Y gastric bypass surgery\\n accounts for about 80% of bariatric procedures in the US. It can\\noften be done laparoscopically. A small part of the proximal stomach is detached from the rest, creating a\\nstomach pouch of < 30 mL. Because stomach volume is smaller, satiety occurs earlier. Also, food\\nbypasses part of the stomach and small intestine, where it is normally absorbed, reducing the amount of\\nfood and calories absorbed. The pouch is connected to the proximal jejunum with a narrow opening,\\nproducing even more restriction. The segment of bypassed proximal small intestine (and thus the\\nbypassed stomach) is attached to the distal small intestine, enabling bile acids and pancreatic enzymes to\\nmix with GI contents; this mixing limits malabsorption and nutritional deficiencies. Because a\\ngastrojejunostomy is created, symptoms similar to the dumping-syndrome may occur after high glycemic\\nloads; symptoms (light-headedness, diaphoresis, nausea, abdominal pain, diarrhea) may inhibit the\\nconsumption of such foods by adverse conditioning.\\nBiliopancreatic diversion with a duodenal switch\\n accounts for < 5% of bariatric procedures done in\\nthe US. Part of the stomach is removed, causing restriction. The remaining part empties into the\\nduodenum. The duodenum is cut\\n[\\nFig. 6-2.\\n Roux-en-Y gastric bypass surgery.]\\nand attached to the ileum, bypassing much of the small intestine, including the sphincter of Oddi (where\\nbile acids and pancreatic enzymes enter); malabsorption results. This procedure is technically demanding\\nbut can sometimes be done laparoscopically. Malabsorption and nutritional deficiencies often develop.\\nPreoperative Evaluation\\nEvaluation should determine whether patients have a psychologic commitment to the lifestyle changes\\nand whether operative risks are acceptable. Sleep apnea testing is done.\\nExtensive preoperative evaluation is probably unnecessary. However, for certain morbidly obese patients\\n(BMI > 50 kg/m\\n2\\n), examining the cardiac, pulmonary, GI, metabolic, and psychologic systems helps\\nidentify patients with acceptable operative risk and helps select the appropriate procedure. For these\\npatients, routine preoperative tests may include\\n \\nLiver function tests:\\n Increased liver enzymes, especially ALT, are common but do not contraindicate\\nsurgery.\\n \\nKidney function tests:\\n If renal blood flow and glomerular filtration rate are increased, proteinuria is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n116'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 126, 'page_label': '117'}, page_content='more likely and renal clearance of drugs may be increased. Thus, drug dosages may need to be\\nadjusted.\\n \\nECG and echocardiography:\\n These tests are needed because identifying heart failure and pulmonary\\nhypertension clinically in morbidly obese patients is difficult. Signs of heart failure (eg, increased jugular\\nvenous pressure, hepatomegaly, pulmonary crackles) are hard to identify when body fat is excessive.\\nPulmonary hypertension is also difficult to identify because many patients cannot exercise to the point\\nwhere exertional dyspnea, fatigue, or syncope would result. Pulmonary hypertension is diagnosed if\\nechocardiography shows tricuspid regurgitation and ECG shows tall R waves, right axis deviation, and\\nright ventricular strain.\\n \\nSleep study:\\n Polysomnography (see p.\\n1706\\n) can confirm obstructive sleep apnea, which is common, and determine its severity. An apnea-\\nhypopnea index of > 30 signals high \\nrisk of morbidity and premature death. Obstructive sleep apnea\\ndoes not contraindicate surgery but is done to help plan for use of continuous positive airway pressure\\n(CPAP) postoperatively.\\nRisks\\nThe most common perioperative complication is wound infection (in about 3%); the most common late\\ncomplication is anastomotic stomach stenosis (in about 5%).\\nOther early complications include wound infection, incisional hernia, small-bowel obstruction, GI bleeding,\\nventral hernia, deep venous thrombosis, and pneumonia. These complications can cause significant\\nmorbidity, prolong hospitalization, and increase costs.\\nThe most common cause of early (within about 6 wk) postoperative death (in up to 0.5%) is pulmonary\\nembolism, followed by anastomotic leak. Tachycardia may be the only early sign of anastomotic leak.\\nLess common causes of early postoperative death are MI, pneumonia, and bowel obstruction.\\nLater problems may include prolonged nausea and vomiting secondary to small-bowel obstruction, and\\nanastomotic stenosis. Nutritional deficiencies (eg, protein-energy undernutrition, vitamin B\\n12\\n deficiency)\\nmay result from inadequate intake, inadequate supplementation, or malabsorption. Malodorous flatulence,\\ndiarrhea, or both may develop, particularly after malabsorptive procedures. Ca and vitamin D absorption\\nmay be impaired, causing deficiencies and sometimes hypocalcemia and secondary hyperparathyroidism.\\nWith prolonged vomiting, thiamin deficiency may occur. After Roux-en-Y gastric bypass, iron deficiency\\nmay result. Patients may have symptoms of reflux, especially after biliopancreatic diversion with a\\nduodenal switch. After rapid weight loss, cholelithiasis may develop.\\nEating habits may be disordered. Adjusting to new eating habits can be difficult.\\nPrognosis\\nOverall, 30-day postoperative risk of death is 0.2 to 1%. Risk is higher in elderly patients and in patients\\nwho have had an open procedure, who are extremely morbidly obese (> 50 kg), or who have established\\norgan failure. Risk of death may be lowest with laparoscopic adjustable gastric banding. Risk of death is\\nalmost 3 times higher in hospitals that do < 50 of these procedures/yr than in those that do >150\\nprocedures/yr. The American Society of Bariatric Surgery may designate hospitals with better results as a\\nCenter of Excellence, based on resources and excellent short- and long-term outcomes.\\nIn most patients, comorbidities (eg, insulin insensitivity, dyslipidemias, hypertension, obstructive sleep\\napnea, polycystic ovary syndrome, nonalcoholic steatohepatitis) tend to resolve.\\nAverage loss of excess weight (real weight minus ideal weight) is about 60%, or about 40 to 60 kg in most\\npatients. Depending on the procedure, excess weight loss can vary between 50% and 70%; loss tends to\\nbe lower with gastric banding and somewhat higher with Roux-en-Y gastric bypass. In many patients,\\nweight loss, although initially rapid, plateaus after about 2 yr; then patients may slowly regain weight.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n117'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 127, 'page_label': '118'}, page_content='Mood and work and personal relationships usually improve.\\nLong-term follow-up data are not yet available because these procedures are relatively new.\\nFollow-up\\nPatients should be monitored every 4 to 6 wk while weight loss is rapid (usually about the first 6 mo after\\nsurgery), then every 6 to 12 mo. Weight and BP are checked, and eating habits are reviewed. Blood tests\\n(usually CBC, electrolytes, glucose, BUN, creatinine, albumin, and protein) and liver function tests are\\ndone at each visit. If alkaline phosphatase is increased, parathyroid hormone level is measured; if\\nparathyroid hormone level is abnormal, bone density is monitored. If weight loss exceeds about 9 kg (20\\nlb)/mo, visits should be scheduled at least monthly, and blood tests should include Mg, phosphorus,\\nvitamin B\\n12\\n, and iron levels. Nutritional supplementation is sometimes necessary.\\nMetabolic Syndrome\\nMetabolic syndrome (syndrome X, insulin resistance syndrome) is characterized by a clustering\\nof risk factors for cardiovascular disease and type 2 diabetes mellitus. They commonly include\\nexcess intra-abdominal fat, insulin resistance, and  1 of the following: elevated serum\\ntriglyceride levels, decreased high-density lipoprotein (HDL) cholesterol level, and\\nhypertension. Causes, complications, diagnosis, and treatment are similar to those of obesity.\\nIn developed countries, metabolic syndrome is a serious problem. It is very common; in the US, > 40% of\\npeople > 50 yr may have it. Children and adolescents can develop\\n[\\nTable 6-3.\\n Criteria Often Used for Diagnosis of Metabolic Syndrome*]\\nmetabolic syndrome, but in these age groups, no definition is established.\\nDevelopment of metabolic syndrome depends on distribution as well as amount of fat. Excess fat in the\\nabdomen (called apple shape), particularly when it results in a high waist-to-hip ratio (reflecting a\\nrelatively low muscle-to-fat mass ratio), increases risk. The syndrome is less common among people who\\nhave excess subcutaneous fat around the hips (called pear shape) and a low waist-to-hip ratio (reflecting\\na higher muscle-to-fat mass ratio).\\nExcess abdominal fat leads to excess free fatty acids in the portal vein, increasing fat accumulation in the\\nliver. Fat also accumulates in muscle cells. Insulin resistance develops, with hyperinsulinemia. Glucose\\nmetabolism is impaired, and dyslipidemias and hypertension develop. Serum uric acid levels are typically\\nelevated, and a prothrombotic state (with increased levels of fibrinogen and plasminogen activator\\ninhibitor I) and an inflammatory state develop. Patients have an increased risk of obstructive sleep apnea.\\nOther risks include nonalcoholic steatohepatitis, chronic kidney disease, polycystic ovary syndrome (for\\nwomen), and low serum testosterone, erectile dysfunction, or both (for men).\\nDiagnosis\\n Waist circumference and BP\\n Fasting plasma glucose and a lipid profile\\nScreening is important. A family history plus measurement of waist circumference and BP are part of\\nroutine care. If patients with a family history of type 2 diabetes mellitus, particularly those  40 yr, have a\\nwaist circumference greater than that recommended for race and sex, fasting plasma glucose and a lipid\\nprofile must be determined.\\nMetabolic syndrome has many different definitions, but it is most often diagnosed when  3 of the\\nfollowing are present: excess abdominal fat, a high fasting plasma glucose level, hypertension, a high\\ntriglyceride level, and a low HDL cholesterol level (see \\nTable 6-3\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n118'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 128, 'page_label': '119'}, page_content='Treatment\\n Healthy diet and exercise\\n Sometimes metformin\\n Management of cardiovascular risk factors\\nOptimally, the management approach results in weight loss based on a healthy diet and regular physical\\nactivity, which includes a combination of aerobic activity and resistance training, reinforced with\\nbehavioral therapy. Metformin, an insulin sensitizer, may be useful. Weight loss of  7% may be sufficient\\nto reverse the syndrome, but if not, each feature of the syndrome should be managed to achieve\\nrecommended targets; available drug treatment is very effective.\\nOther cardiovascular risk factors (eg, smoking cessation) also need to be managed. Increased physical\\nactivity has cardiovascular benefits even if weight is not lost.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 6. Obesity & the Metabolic Syndrome\\n119'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 129, 'page_label': '120'}, page_content='2 - Gastrointestinal Disorders\\nChapter 7. Approach to the Patient With Upper GI Complaints\\nIntroduction\\nUpper GI complaints include chest pain (see p. \\n2025\\n), chronic and recurrent abdominal pain, dyspepsia,\\nlump in the throat, halitosis (see p. \\n506\\n), hiccups, nausea and vomiting, and rumination. Some upper GI\\ncomplaints represent functional illness (ie, no physiologic cause found after extensive evaluation).\\nHistory:\\n Using open-ended, interview-style questions, the physician identifies the location and quality of\\nsymptoms and any aggravating and alleviating factors. Psychologic stress factors must be specifically\\nsought. Because a psychiatric disorder does not preclude physiologic disease, the significance of vague,\\ndramatic, or bizarre complaints should not be minimized.\\nPatients report symptoms differently depending on their personality, the impact of the illness on their life,\\nand sociocultural influences. For example, nausea and vomiting may be minimized or reported indirectly\\nby a severely depressed patient but presented with dramatic urgency by a histrionic one.\\nPhysical examination:\\n Inspection of the abdomen with the patient supine may show a convex\\nappearance when bowel obstruction, ascites, or, rarely, a large mass is present. Auscultation to assess\\nbowel sounds and determine presence of bruits should follow. Percussion elicits hyperresonance\\n(tympany) in the presence of bowel obstruction and dullness with ascites and can determine the span of\\nthe liver. Palpation proceeds systematically, beginning gently to identify areas of tenderness and, if\\ntolerated, palpating deeper to locate masses or organomegaly. Digital rectal examination with testing for\\noccult blood and (in women) pelvic examination complete the evaluation of the abdomen.\\nTesting:\\n Patients with acute, nonspecific symptoms (eg, dyspepsia, nausea) and an unremarkable\\nphysical examination rarely require testing. Findings suggesting significant disease (alarm symptoms)\\nshould prompt further evaluation:\\n Anorexia\\n Anemia\\n Blood in stool (gross or occult)\\n Dysphagia\\n Fever\\n Hepatomegaly\\n Pain that awakens patient\\n Persistent nausea and vomiting\\n Weight loss\\nChronic or recurrent symptoms, even with an unremarkable examination, also warrant evaluation. Specific\\nGI tests are discussed in \\nCh. 9\\n.\\nChronic and Recurrent Abdominal Pain\\nChronic abdominal pain (CAP) persists for more than 3 mo either continuously or intermittently.\\nIntermittent pain may be referred to as recurrent abdominal pain (RAP). \\nAcute abdominal pain\\n is\\ndiscussed on p. \\n105\\n. CAP occurs any time after 5 yr of age. Up to 10% of children require evaluation for\\nRAP. About 2% of adults, predominantly women, have CAP (a much higher percentage of adults have\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n120'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 130, 'page_label': '121'}, page_content='some type of chronic GI symptoms, including nonulcer dyspepsia and various bowel disturbances).\\nNearly all patients with CAP have had prior medical evaluation that did not yield a diagnosis after history,\\nphysical, and basic testing.\\nPathophysiology\\nFunctional abdominal pain syndrome (FAPS) is pain that persists > 6 mo without evidence of physiologic\\ndisease, shows no relationship to physiologic events (eg, meals, defecation, menses), and interferes with\\ndaily functioning. FAPS is poorly understood but seems to involve altered nociception. Sensory neurons\\nin the dorsal horn of the spinal cord may become abnormally excitable and hyperalgesic due to a\\ncombination of factors. Cognitive and psychologic factors (eg, depression, stress, culture, secondary\\ngain, coping and support mechanisms) may cause efferent stimulation that amplifies pain signals,\\nresulting in perception of pain with low level inputs and persistence of pain long after the stimulus has\\nceased. Additionally, the pain itself may function as a stressor, perpetuating a positive feedback loop.\\nIn addition, menopause increases GI symptoms in several disorders including irritable bowel syndrome,\\ninflammatory bowel disease, endometriosis, and nonulcer dyspepsia.\\nEtiology\\nPerhaps 10% of patients have an occult physiologic illness (see\\nTable 7-1\\n); the remainder have a functional process. However, determining whether a particular\\nabnormality (eg, adhesions, ovarian cyst, endometriosis) is the cause of CAP symptoms or an incidental\\nfinding can be difficult.\\nEvaluation\\nHistory: History of present illness\\n should elicit pain location, quality, duration, timing and frequency of\\nrecurrence, and factors that worsen or relieve pain (particularly eating or moving bowels). A specific\\ninquiry as to whether milk and milk products cause abdominal cramps, bloating, or distention is needed,\\nbecause lactose intolerance is common, especially among blacks.\\nReview of systems\\n seeks concomitant GI symptoms such as gastroesophageal reflux, anorexia,\\nbloating or \"gas,\" nausea, vomiting, jaundice, melena, hematuria, hematemesis, weight loss, and mucus\\nor blood in the stool. Bowel symptoms, such as diarrhea, constipation, and changes in stool consistency,\\ncolor, or elimination pattern, are particularly important.\\nIn adolescents, a diet history is important because ingestion of large amounts of cola beverages and fruit\\njuices (which may contain significant quantities of fructose and sorbitol) can account for otherwise\\npuzzling abdominal pain.\\nPast medical history\\n should include nature and timing of any abdominal surgery and the results of\\nprevious tests that have been done and treatments that have been tried. A drug history should include\\ndetails concerning prescription and illicit drug use as well as alcohol.\\nFamily history of RAP, fevers, or both should be ascertained, as well as known diagnoses of sickle cell\\ntrait or disease, familial Mediterranean fever, and porphyria.\\nPhysical examination:\\n Review of vital signs should particularly note presence of fever or tachycardia.\\nGeneral examination should seek presence of jaundice, skin rash, and peripheral edema. Abdominal\\nexamination should note areas of tenderness, presence of peritoneal findings (eg, guarding, rigidity,\\nrebound), and any masses or organomegaly. Rectal examination and (in women) pelvic examination to\\nlocate tenderness, masses, and blood are essential.\\nRed flags:\\n The following findings are of particular concern:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n121'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 131, 'page_label': '122'}, page_content=' Fever\\n Anorexia, weight loss\\n Pain that awakens patient\\n Blood in stool or urine\\n Jaundice\\n Edema\\n Abdominal mass or organomegaly\\nInterpretation of findings:\\n Clinical examination alone infrequently provides a firm diagnosis.\\nDetermining whether CAP is physiologic or functional can be difficult. Although the presence of red flag\\nfindings indicates a high likelihood of a physiologic cause, their absence does not rule it out. Other hints\\nare that physiologic causes usually cause pain that is well localized, especially to areas other than the\\nperiumbilical region. Pain that wakes the patient is usually physiologic. Some findings suggestive of\\nspecific disorders are listed in \\nTable 7-1\\n.\\nFunctional CAP may result in pain similar to that of physiologic origin. However, there are no associated\\nred flag findings, and psychosocial features are often prominent. A history of physical or sexual abuse or\\nan unresolved loss (eg, divorce, miscarriage, or death of a family member) may be a clue.\\nThe Rome criteria for diagnosis of irritable bowel syndrome are the presence of abdominal pain or\\ndiscomfort for at least 3 days/mo in the last 3 mo along with at least 2 of the following: (1) improvement\\nwith defecation; (2) onset (of each episode of discomfort) associated with a change in frequency of\\ndefecation; and (3) change in consistency of stool.\\nTesting:\\n In general, simple tests (including urinalysis, CBC, liver tests, ESR, amylase, and lipase) should\\nbe done. Abnormalities in these tests, the presence of red flag findings, or specific clinical findings\\nmandate further testing, even if previous assessments have been negative. Specific tests depend on the\\nfindings (see \\nTable 7-1\\n) but typically include CT of the abdomen and pelvis with contrast, upper GI\\nendoscopy or colonoscopy, and perhaps small-bowel x-rays or stool testing.\\nThe benefits of testing patients with no red flag findings are unclear. Those > 50 should probably have a\\ncolonoscopy; those  50 can be observed or have CT of the abdomen and pelvis with contrast if an\\nimaging study is desired. Magnetic resonance cholangiopancreatography (MRCP), ERCP, and\\nlaparoscopy are rarely helpful in the absence of specific indications.\\nBetween the initial evaluation and the follow-up visit, the patient (or family, if the patient is a child) should\\nrecord any pain, including\\n[\\nTable 7-1.\\n Physiologic Causes of Chronic Abdominal Pain]\\nits nature, intensity, duration, and precipitating factors. Diet, defecation pattern, and any remedies tried\\n(and the results obtained) should also be recorded. This record may reveal inappropriate behavior\\npatterns and exaggerated responses to pain or otherwise suggest a diagnosis.\\nTreatment\\nPhysiologic conditions are treated.\\nIf the diagnosis of functional CAP is made, frequent examinations and tests should be avoided because\\nthey may focus on or magnify the physical complaints or imply that the physician lacks confidence in the\\ndiagnosis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n122'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 132, 'page_label': '123'}, page_content=\"There are no modalities to cure functional CAP; however, many helpful measures are available. These\\nmeasures rest on a foundation of a trusting, empathic relationship among the physician, patient, and\\nfamily. Patients should be reassured that they are not in danger; specific concerns should be sought and\\naddressed. The physician should explain the laboratory findings and the nature of the problem and\\ndescribe how the pain is generated and how the patient perceives it (ie, that there is a constitutional\\ntendency to feel pain at times of stress). It is important to avoid perpetuating the negative psychosocial\\nconsequences of chronic pain (eg, prolonged absences from school or work, withdrawal from social\\nactivities) and to promote independence, social participation, and self-reliance. These strategies help the\\npatient control or tolerate the symptoms while participating fully in everyday activities.\\nDrugs such as aspirin, NSAIDs, H\\n2\\n receptor blockers, proton pump inhibitors, and tricyclic\\nantidepressants can be effective. Opioids should be avoided because they invariably lead to dependency.\\nCognitive methods (eg, relaxation training, biofeedback, hypnosis) may help by contributing to the\\npatient's sense of well-being and control. Regular follow-up visits should be scheduled weekly, monthly, or\\nbimonthly, depending on the patient's needs, and should continue until well after the problem has\\nresolved. Psychiatric referral may be required if symptoms persist, especially if the patient is depressed\\nor there are significant psychologic difficulties in the family.\\nSchool personnel should become involved for children who have CAP. Children can rest briefly in the\\nnurse's office during the school day, with the expectation that they return to class after 15 to 30 min. The\\nschool nurse can be authorized to dispense a mild analgesic (eg, acetaminophen). The nurse can\\nsometimes allow the child to call a parent, who should encourage the child to stay in school. However,\\nonce parents stop treating their child as special or ill, the symptoms may worsen before they abate.\\nKey Points\\n Most cases represent a functional process.\\n Red flag findings indicate a physiologic cause and need for further assessment.\\n Testing is guided by clinical features.\\n Repeated testing after physiologic causes are ruled out is usually counterproductive.\\nDyspepsia\\nDyspepsia is a sensation of pain or discomfort in the upper abdomen; it often is recurrent. It may be\\ndescribed as indigestion, gassiness, early satiety, postprandial fullness, gnawing, or burning.\\nEtiology\\nThere are several common causes of dyspepsia (see\\nTable 7-2\\n).\\nMany patients have findings on testing (eg, duodenitis, pyloric dysfunction, motility disturbance,\\nHelicobacter pylori\\n gastritis, lactose deficiency, cholelithiasis) that correlate poorly with symptoms (ie,\\ncorrection of the condition does not alleviate dyspepsia).\\nNonulcer (functional) dyspepsia\\n is defined as dyspeptic symptoms in a patient who has no\\nabnormalities on physical examination and upper GI endoscopy.\\nEvaluation\\nHistory: History of present illness\\n should elicit a clear description of the symptoms, including whether\\nthey are acute or chronic and recurrent. Other elements include timing and frequency of recurrence, any\\ndifficulty swallowing, and relationship of symptoms to eating or taking drugs. Factors that worsen\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n123\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 133, 'page_label': '124'}, page_content='symptoms (particularly exertion, certain foods or alcohol) or relieve them (particularly eating or taking\\nantacids) are noted.\\nReview of systems\\n seeks concomitant GI symptoms such as anorexia, nausea, vomiting, hematemesis,\\nweight loss, and bloody or black (melanotic) stools. Other symptoms include dyspnea and diaphoresis.\\nPast medical history\\n should include known GI and cardiac diagnoses, cardiac risk factors (eg,\\nhypertension, hypercholesterolemia), and the results of previous tests that have been done and\\ntreatments that have been tried. Drug history should include prescription and illicit drug use as well as\\nalcohol.\\nPhysical examination:\\n Review of vital signs should note presence of tachycardia or irregular pulse.\\nGeneral examination should note presence of pallor or diaphoresis, cachexia, or jaundice. Abdomen is\\npalpated for tenderness, masses, and organomegaly. Rectal examination is done to detect gross or occult\\nblood.\\nRed flags:\\n The following findings are of particular concern:\\n[\\nTable 7-2.\\n Some Causes of Dyspepsia]\\n Acute episode with dyspnea, diaphoresis, or tachycardia\\n Anorexia\\n Nausea or vomiting\\n Weight loss\\n Blood in the stool\\n Dysphagia or odynophagia\\n Failure to respond to therapy with H\\n2\\n blockers or proton pump inhibitors (PPIs)\\nInterpretation of findings:\\n Some findings are helpful (see \\nTable 7-2\\n).\\nA patient presenting with a single, acute episode of dyspepsia is of concern, particularly if symptoms are\\naccompanied by dyspnea, diaphoresis, or tachycardia; such patients may have acute coronary ischemia.\\nChronic symptoms that occur with exertion and are relieved by rest may represent angina.\\nGI causes are most likely to manifest as chronic complaints. Symptoms are sometimes classified as ulcer-\\nlike, dysmotility-like, or reflux-like; these classifications suggest but do not confirm an etiology. Ulcer-like\\nsymptoms consist of pain that is localized in the epigastrium, frequently occurs before meals, and is\\npartially relieved by food, antacids, or H\\n2\\n blockers. Dysmotility-like symptoms consist of discomfort rather\\nthan pain, along with early satiety, postprandial fullness, nausea, vomiting, bloating, and symptoms that\\nare worsened by food. Reflux-like symptoms consist of heartburn or acid regurgitation. However,\\nsymptoms often overlap.\\nAlternating constipation and diarrhea with dyspepsia suggests irritable bowel syndrome or excessive use\\nof OTC laxatives or antidiarrheals.\\n[\\nTable 7-3.\\n Some Oral Drugs for Dyspepsia]\\nTesting:\\n Patients in whom symptoms suggest acute coronary ischemia, particularly those with risk\\nfactors, should be sent to the emergency department for urgent evaluation, including ECG and serum\\ncardiac markers.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n124'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 134, 'page_label': '125'}, page_content='For patients with chronic, nonspecific symptoms, routine tests include CBC (to exclude anemia caused by\\nGI blood loss) and routine blood chemistries. If results are abnormal, additional tests (eg, imaging studies,\\nendoscopy) should be considered. Because of the risk of cancer, patients > 45 and those with new-onset\\nred flag findings should undergo upper GI endoscopy. For patients < 45 with no red flag findings, some\\nauthorities recommend empiric therapy for 2 to 4 wk with antisecretory agents followed by endoscopy in\\ntreatment failures. Others recommend screening for \\nH. pylori\\n infection with a C\\n14\\n-urea breath test or\\nstool assay (see p. \\n129\\n). However, caution is required in using \\nH. pylori\\n or any other nonspecific findings\\nto explain symptoms.\\nEsophageal manometry and pH studies are indicated if reflux symptoms persist after upper GI endoscopy\\nand a 2- to 4-wk trial with a PPI.\\nTreatment\\nSpecific conditions are treated. Patients without identifiable conditions are observed over time and\\nreassured. Symptoms are treated with PPIs, H\\n2\\n blockers, or a cytoprotective agent (see \\nTable 7-3\\n).\\nProkinetic drugs (eg, metoclopramide, erythromycin) given as a liquid suspension also may be tried in\\npatients with dysmotility-like dyspepsia. However, there is no clear evidence that matching the drug class\\nto the specific symptoms (eg, reflux vs dysmotility) makes a difference. Misoprostol and anticholinergics\\nare not effective in functional dyspepsia. Drugs that alter sensory perception (eg, tricyclic\\nantidepressants) may be helpful.\\nKey Points\\n Coronary ischemia is possible in a patient with acute \"gas.\"\\n Endoscopy is indicated for those > 45 or with red flag findings.\\n Empiric treatment with an acid blocker is reasonable for those < 45 without red flag findings. Those who\\ndo not respond in 2 to 4 wk require further evaluation.\\nHiccups\\nHiccups (hiccough, singultus) are repeated involuntary spasms of the diaphragm \\nfollowed by sudden\\nclosure of the glottis, which checks the inflow of air and causes the characteristic sound. Transient\\nepisodes are very common. Persistent (> 2 days) and intractable (> 1 mo) hiccups are uncommon but\\nquite distressing.\\nEtiology\\nHiccups follow irritation of afferent or efferent diaphragmatic nerves or of medullary centers that control\\nthe respiratory muscles, particularly the diaphragm. Hiccups are more common among men.\\nCause is generally unknown, but transient hiccups are often caused by the following:\\n Gastric distention\\n Alcohol consumption\\n Swallowing hot or irritating substances\\nPersistent and intractable hiccups have myriad causes (see\\nTable 7-4\\n).\\nEvaluation\\nHistory: History of present illness\\n should note duration of hiccups, remedies tried, and relationship of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n125'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 135, 'page_label': '126'}, page_content='onset to recent illness or surgery.\\nReview of systems\\n seeks concomitant GI symptoms such as gastroesophageal reflux and swallowing\\ndifficulties; thoracic symptoms such as cough, fever, or chest pain; and any neurologic symptoms.\\nPast medical history\\n should query known GI and neurologic disorders. A drug history should include\\ndetails concerning alcohol use.\\nPhysical examination:\\n Examination is usually unrewarding but should seek signs of chronic disease\\n(eg, cachexia). A full neurologic examination is important.\\nRed flags:\\n The following is of particular concern:\\n Neurologic symptoms or signs\\nInterpretation of findings:\\n Few findings are specific. Hiccups after alcohol consumption or surgery may\\nwell be related to those events. Other possible causes (see \\nTable 7-4\\n) are both numerous and rarely a\\ncause of hiccups.\\nTesting:\\n No specific evaluation is required for acute hiccups if routine history and physical examination\\nare unremarkable; abnormalities are pursued with appropriate testing.\\nPatients with hiccups of longer duration and no obvious cause should have testing, probably including\\nserum electrolytes, BUN and creatinine, chest x-ray, and ECG. Upper GI endoscopy and perhaps\\nesophageal pH monitoring should be considered. If these are unremarkable, brain MRI and chest CT may\\nbe done.\\n[\\nTable 7-4.\\n Some Causes of Intractable Hiccups]\\nTreatment\\nIdentified problems are treated (eg, proton pump inhibitors for gastroesophageal reflux disease, dilation\\nfor esophageal stricture).\\nFor symptom relief, many simple measures can be tried, although none are more than slightly effective:\\nPaCO\\n2\\n can be increased and diaphragmatic activity can be inhibited by a series of deep breath-holds or\\nby breathing deeply in to and out of a paper bag. (CAUTION: \\nPlastic bags can cling to the nostrils and\\nshould not be used\\n.) Vagal stimulation by pharyngeal irritation (eg, swallowing dry bread, granulated\\nsugar, or crushed ice; applying traction on the tongue; stimulating gagging) may work. Numerous other\\nfolk remedies exist.\\nPersistent hiccups are often recalcitrant to treatment. Many drugs have been used in anecdotal series.\\nBaclofen, a \\n\\n-aminobutyric acid agonist (5 mg po q 6 h increasing to 20 mg/dose), may be effective. Other\\ndrugs include chlorpromazine 10 to 50 mg po tid as needed, metoclopramide 10 mg po bid to qid, and\\nvarious anticonvulsants (eg, gabapentin). Additionally, an empiric trial of proton pump inhibitors may be\\ngiven. For severe symptoms, chlorpromazine 25 to 50 mg IM or IV can be given. In intractable cases, the\\nphrenic nerve may be blocked by small amounts of 0.5% procaine solution, with caution being taken to\\navoid respiratory depression and pneumothorax. Even bilateral phrenicotomy does not cure all cases.\\nKey Points\\n The cause is usually unknown.\\n Rarely, a serious disorder is present.\\n Evaluation is typically unrewarding but should be pursued for hiccups of long duration.\\n Numerous remedies exist, none with clear superiority (or perhaps even effectiveness).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n126'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 136, 'page_label': '127'}, page_content='Lump in Throat\\nLump in the throat (globus sensation, globus hystericus) is the sensation of a lump or mass in the throat,\\nunrelated to swallowing, when no mass is present. (If a mass is present, see p.\\n461\\n.)\\nEtiology\\nNo specific etiology or physiologic mechanism has been established. Some studies suggest that elevated\\ncricopharyngeal (upper esophageal sphincter) pressure or abnormal hypopharyngeal motility occur during\\nthe time of symptoms. The sensation may also result from gastroesophageal reflux disease (GERD) or\\nfrom frequent swallowing and drying of the throat associated with anxiety or another emotional state.\\nAlthough not associated with stress factors or a specific psychiatric disorder, globus sensation may be a\\nsymptom of certain mood states (eg, grief, pride); some patients may have a predisposition to this\\nresponse.\\nDisorders that can be confused with globus sensation include cricopharyngeal (upper esophageal) webs,\\nsymptomatic diffuse esophageal spasm, GERD, skeletal muscle disorders (eg, myasthenia gravis,\\nmyotonia dystrophica, polymyositis), and mass lesions in the neck or mediastinum that cause esophageal\\ncompression.\\nEvaluation\\nThe main goal is to distinguish globus sensation from true \\ndysphagia\\n (see p. \\n120\\n), which suggests a\\nstructural or motor disorder of the pharynx or esophagus.\\nHistory: History of present illness\\n should elicit a clear description of the symptom, particularly as to\\nwhether there is any pain with swallowing, difficulty swallowing (including sensation of food sticking).\\nTiming of symptoms is important, particularly whether it occurs with eating or drinking or is independent of\\nthose activities; association with emotional events should be queried specifically.\\nReview of systems\\n seeks weight loss (as evidence of a swallowing disorder) and symptoms of muscle\\nweakness.\\nPast medical history\\n should include known neurologic diagnoses, particularly those causing weakness.\\nPhysical examination:\\n The neck and floor of the mouth are palpated for masses. The oropharynx is\\ninspected (including by direct laryngoscopy). Swallowing (of water and a solid food such as crackers)\\nshould be observed. Neurologic examination with particular attention to motor function is important.\\nRed flags:\\n The following findings are of particular concern:\\n Neck or throat pain\\n Weight loss\\n Abrupt onset after age 50\\n Pain, choking, or difficulty with swallowing\\n Regurgitation of food\\n Muscle weakness\\n Palpable or visible mass\\n Progressive worsening of symptoms\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n127'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 137, 'page_label': '128'}, page_content=\"Interpretation of findings:\\n Symptoms unrelated to swallowing, with no pain or difficulty with swallowing,\\nor sensation of food sticking in the throat in a patient with a normal examination imply globus sensation.\\nAny red flag findings or abnormal findings on examination suggest a mechanical or motor disorder of\\nswallowing. Chronic symptoms that occur during unresolved or pathologic grief and that may be relieved\\nby crying suggest globus sensation.\\nTesting:\\n Those with findings typical of globus sensation need no testing. If the diagnosis is unclear or the\\nclinician cannot adequately visualize the pharynx, testing as for dysphagia is done. Typical tests include\\nplain or video esophagography, measurement of swallowing time, chest x-ray, and esophageal\\nmanometry.\\nTreatment\\nTreatment involves reassurance and sympathetic concern. No drug is of proven benefit. Underlying\\ndepression, anxiety, or other behavioral disturbances should be managed supportively, with psychiatric\\nreferral if necessary. At times, communicating to the patient the association between symptoms and mood\\nstate can be beneficial.\\nKey Points\\n Globus symptoms are unrelated to swallowing.\\n Tests are not needed unless symptoms are related to swallowing, examination is abnormal, or there are\\nred flag findings.\\nNausea and Vomiting\\n(For nausea and vomiting in infants and children, see p. \\n2746\\n.)\\nNausea, the unpleasant feeling of needing to vomit, represents awareness of afferent stimuli (including\\nincreased parasympathetic tone) to the medullary vomiting center. Vomiting is the forceful expulsion of\\ngastric contents caused by involuntary contraction of the abdominal musculature when the gastric fundus\\nand lower esophageal sphincter are relaxed.\\nVomiting should be distinguished from regurgitation, the spitting up of gastric contents without associated\\nnausea or forceful abdominal muscular contractions. Patients with achalasia or a Zenker's diverticulum\\nmay regurgitate undigested food without nausea.\\nComplications:\\n Severe vomiting can lead to symptomatic dehydration and electrolyte abnormalities\\n(typically a metabolic alkalosis with hypokalemia) or rarely to an esophageal tear, either partial (Mallory-\\nWeiss) or complete (Boerhaave's syndrome). Chronic vomiting can result in undernutrition, weight loss,\\nand metabolic abnormalities.\\nEtiology\\nNausea and vomiting occur in response to conditions that affect the vomiting center. Causes may\\noriginate in the GI tract or CNS or may result from a number of systemic conditions (see\\nTable 7-5\\n).\\nThe most common causes are the following:\\n Gastroenteritis\\n Drugs\\n Toxins\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n128\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 138, 'page_label': '129'}, page_content='Cyclic vomiting syndrome is an uncommon disorder characterized by severe, discrete attacks of vomiting\\nor sometimes only nausea that occur at varying intervals, with normal health between episodes. It is most\\ncommon in childhood (mean age of onset 5 yr) and tends to remit with adulthood. The condition may be\\nassociated with migraine headaches, possibly representing a migraine variant.\\nEvaluation\\nHistory: History of present illness\\n should elicit frequency and duration of vomiting; its relation to\\npossible precipitants such as drug or toxin ingestion, head injury, and motion (eg, car, plane, boat,\\namusement rides); and whether vomitus contained bile (bitter, yellow-green) or blood (red or \"coffee\\nground\" material). Important associated symptoms include presence of abdominal pain and diarrhea; the\\nlast passage of stool and flatus; and presence of headache, vertigo, or both.\\nReview of systems\\n seeks symptoms of causative disorders such as amenorrhea, breast swelling\\n(pregnancy); polyuria, polydipsia (diabetes); and hematuria, flank pain (kidney stones).\\nPast medical history\\n should ascertain known causes such as pregnancy, diabetes, migraine, hepatic or\\nrenal disease, cancer (including timing of any chemotherapy or radiation therapy), and previous\\nabdominal surgery (which may cause bowel obstruction due to adhesions). All drugs and substances\\ningested recently should be ascertained; certain substances may not manifest toxicity until several days\\nafter ingestion (eg, acetaminophen, some mushrooms).\\nFamily history of recurrent vomiting should be noted.\\nPhysical examination:\\n Vital signs should particularly note presence of fever and signs of hypovolemia\\n(eg, tachycardia, hypotension, or both).\\nGeneral examination should seek presence of jaundice and skin rash.\\nOn abdominal examination, the clinician should look for distention and surgical scars; listen for presence\\nand quality of bowel sounds (eg, normal, high-pitched); percuss for tympany; and palpate for tenderness,\\nperitoneal findings (eg, guarding, rigidity, rebound), and any masses, organomegaly, or hernias. Rectal\\nexamination and (in women) pelvic examination to locate tenderness, masses, and blood are essential.\\nNeurologic examination should particularly note mental status, nystagmus, meningismus (eg, stiff neck,\\nKernig\\'s or Brudzinski\\'s signs), and ocular signs of increased intracranial pressure (eg, papilledema,\\nabsence of venous pulsations, 3rd cranial nerve palsy) or subarachnoid hemorrhage (retinal\\nhemorrhage).\\nRed flags:\\n The following findings are of particular concern:\\n Signs of hypovolemia\\n Headache, stiff neck, or mental status change\\n Peritoneal signs\\n Distended, tympanitic abdomen\\nInterpretation of findings:\\n Many findings are suggestive of a cause or group of causes (see \\nTable 7-5\\n).\\nVomiting occurring shortly after drug or toxin ingestion or exposure to motion in a patient with an\\nunremarkable neurologic and abdominal examination can confidently be ascribed to those causes, as\\nmay vomiting in a woman with a known pregnancy and a benign examination. Acute vomiting\\naccompanied by diarrhea in an otherwise\\n[\\nTable 7-5.\\n Some Causes of Nausea and Vomiting]\\nhealthy patient with a benign examination is highly likely to be infectious gastroenteritis; further\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n129'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 139, 'page_label': '130'}, page_content='assessment may be deferred.\\nVomiting that occurs at the thought of food or that is not temporally related to eating suggests a\\npsychogenic cause, as does personal or family history of functional nausea and vomiting. Patients should\\nbe questioned about the relationship between vomiting and stressful events because they may not\\nrecognize the association or even admit to feeling distress at those times.\\nTesting:\\n All females of childbearing age should have a urine pregnancy test. Patients with severe\\nvomiting, vomiting lasting over 1 day, or signs of dehydration on examination should have other laboratory\\ntests (eg, electrolytes, BUN, creatinine, glucose, urinalysis, and sometimes liver tests). Patients with red\\nflag findings should have testing appropriate to the symptoms (see \\nTable 7-5\\n).\\nThe assessment of chronic vomiting usually includes the previously listed laboratory tests plus upper GI\\nendoscopy, small-bowel x-rays, and tests to assess gastric emptying and antral-duodenal motility.\\nTreatment\\nSpecific conditions, including dehydration, are treated. Even without significant dehydration, IV fluid\\ntherapy (0.9% saline 1 L, or 20 mL/kg in children) often leads to reduction of symptoms. In adults, various\\nantiemetics are effective (see\\nTable 7-6\\n). Choice of agent varies somewhat with the cause and severity of symptoms. Typical use is the\\nfollowing:\\n Motion sickness: Antihistamines, scopolamine patches, or both\\n Mild to moderate symptoms: Prochlorperazine or metoclopramide\\n Severe or refractory vomiting and vomiting caused by chemotherapy: 5-HT\\n3\\n antagonists\\nObviously, only parenteral agents should be used in actively vomiting patients.\\nFor psychogenic vomiting, reassurance indicates awareness of the patient\\'s discomfort and a desire to\\nwork toward relief of symptoms, regardless of cause. Comments such as \"nothing is wrong\" or \"the\\nproblem is emotional\" should be avoided. Brief symptomatic treatment with antiemetics can be tried. If\\nlong-term management is necessary, supportive, regular office visits may help resolve the underlying\\nproblem.\\nKey Points\\n Many episodes have an obvious cause and benign examination and require only symptomatic treatment.\\n Physicians should be alert for signs of an acute abdomen or significant intracranial disorder.\\n Pregnancy should always be considered in females of childbearing age.\\nRumination\\nRumination is the (usually involuntary) regurgitation of small amounts of food from the stomach (most\\noften 15 to 30 min after eating) that are rechewed and, in most cases, again swallowed. Patients do not\\ncomplain of nausea or abdominal pain.\\n[\\nTable 7-6.\\n Some Drugs for Vomiting]\\nRumination is commonly observed in infants. The incidence in adults is unknown, because it is rarely\\nreported by patients themselves.\\nEtiology\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n130'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 140, 'page_label': '131'}, page_content=\"Patients with achalasia or a Zenker's diverticulum may regurgitate undigested food without nausea. In the\\nmajority of patients who do not have these obstructive esophageal conditions, the pathophysiology is\\npoorly understood. The reverse peristalsis in ruminants has not been reported in humans. The disorder is\\nprobably a learned, maladaptive habit and may be part of an eating disorder. The person learns to open\\nthe lower esophageal sphincter and propel gastric contents into the esophagus and throat by increasing\\ngastric pressure via rhythmic contraction and relaxation of the diaphragm.\\nSymptoms\\nNausea, pain, and dysphagia do not occur. During periods of stress, the patient may be less careful\\nabout concealing rumination. Seeing the act for the first time, others may refer the patient to a physician.\\nRarely, patients regurgitate and expel enough food to lose weight.\\nDiagnosis\\n Clinical evaluation\\n Sometimes endoscopy, esophageal motility studies, or both\\nRumination is usually diagnosed through observation. A psychosocial history may disclose underlying\\nemotional stress. Endoscopy or an upper GI series is necessary to exclude disorders causing mechanical\\nobstruction or Zenker's diverticulum. Esophageal manometry and tests to assess gastric emptying and\\nantral-duodenal motility may be used to identify a motility disturbance.\\nTreatment\\n Behavioral techniques\\nTreatment is supportive. Drug therapy generally does not help. Motivated patients may respond to\\nbehavioral techniques (eg, relaxation, biofeedback, training in diaphragmatic breathing [using the\\ndiaphragm instead of chest muscles to breathe]). Psychiatric consultation may be helpful.\\nFunctional GI Illness\\nOften, no physiologic cause for GI complaints is found, even after extensive evaluation. Such patients are\\nsaid to have functional illness, which accounts for 30 to 50% of referrals to gastroenterologists.\\nFunctional illness may manifest with upper and/or lower GI symptoms.\\nThe reasons for functional symptoms are not clear. Some evidence suggests that such patients have\\nvisceral hypersensitivity, a disturbance of nociception in which they experience discomfort caused by\\nsensations (eg, luminal distention, peristalsis) that other people do not find distressing. In some patients,\\npsychologic conditions such as anxiety (with or without aerophagia), conversion disorder, somatization in\\ndepression, or hypochondriasis are associated with GI symptoms. Psychologic theories hold that\\nfunctional symptoms may satisfy certain psychologic needs. For example, some patients with chronic\\nillness derive secondary benefits from being sick. For such patients, successful treatment of symptoms\\nmay lead to development of other symptoms.\\nMany referring physicians and GI specialists find functional GI complaints difficult to understand and treat,\\nand uncertainty may lead to frustration and judgmental attitudes. Physicians should avoid ordering\\nrepeated studies or multiple drug trials for the insistent patient with inexplicable complaints. When\\nsymptoms are not suggestive of serious illness, the physician should wait rather than embark on another\\ndiagnostic or therapeutic plan. In time, new information may direct evaluation and management.\\nFunctional complaints are sometimes present in patients with physiologic disease (eg, peptic ulcer,\\nesophagitis); such symptoms may not remit even when a physiologic illness is addressed.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 7. Approach to the Patient With Upper GI Complaints\\n131\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 141, 'page_label': '132'}, page_content='Chapter 8. Approach to the Patient With Lower GI Complaints\\nIntroduction\\nLower GI complaints include constipation, diarrhea, gas and bloating, abdominal pain (see also p. \\n105\\n),\\nand rectal pain or bleeding (see \\nCh. 21\\n). As with upper GI complaints, lower GI complaints result from\\nphysiologic illness or represent a functional disorder (ie, no radiologic, biochemical, or pathologic\\nabnormalities found even after extensive evaluation). The reasons for functional symptoms are not clear.\\nEvidence suggests that patients with functional symptoms may have disturbances of motility, nociception,\\nor both; ie, they perceive as uncomfortable certain sensations (eg, luminal distention, peristalsis) that\\nother people do not find distressing.\\nNo bodily function is more variable and subject to external influences than defecation. Bowel habits vary\\nconsiderably from person to person and are affected by age, physiology, diet, and social and cultural\\ninfluences. Some people have unwarranted preoccupation with bowel habits. In Western society, normal\\nstool frequency ranges from 2 to 3/day to 2 to 3/wk. Changes in stool frequency, consistency, volume, or\\ncomposition (ie, presence of blood, mucus, pus, or excess fatty material) may indicate disease.\\nConstipation\\nConstipation is difficult or infrequent passage of stool, hardness of stool, or a feeling of incomplete\\nevacuation.\\nMany people incorrectly believe that daily defecation is necessary and complain of constipation if stools\\noccur less frequently. Others are concerned with the appearance (size, shape, color) or consistency of\\nstools. Sometimes the major complaint is dissatisfaction with the act of defecation or the sense of\\nincomplete evacuation after defecation. Constipation is blamed for many complaints (abdominal pain,\\nnausea, fatigue, anorexia) that are actually symptoms of an underlying problem (eg, irritable bowel\\nsyndrome [IBS], depression). Patients should not expect all symptoms to be relieved by a daily bowel\\nmovement, and measures to aid bowel habits should be used judiciously.\\nObsessive-compulsive patients often feel the need to rid the body daily of \"unclean\" wastes. Such\\npatients often spend excessive time on the toilet or become chronic users of cathartics.\\nEtiology\\nAcute constipation suggests an organic cause, whereas chronic constipation may be organic or functional\\n(see\\nTable 8-1\\n).\\nIn many patients, constipation is associated with sluggish movement of stool through the colon. This\\ndelay may be due to drugs, organic conditions, or a disorder of defecatory function (ie, pelvic floor\\ndysfunction). Patients with disordered defecation do not generate adequate rectal propulsive forces, do\\nnot relax the puborectalis and the external anal sphincter during defecation, or both. In IBS, patients have\\nsymptoms (eg, abdominal discomfort and altered bowel habits) but generally normal colonic transit and\\nanorectal functions. However, IBS-disordered defecation may coexist.\\nExcessive straining, perhaps secondary to pelvic floor dysfunctions, may contribute to anorectal\\npathology (eg, hemorrhoids, anal fissures, and rectal prolapse) and possibly even to syncope. Fecal\\nimpaction, which may cause or develop from constipation, is also common among elderly patients,\\nparticularly with prolonged bed rest or decreased physical activity. It is also common after barium has\\nbeen given by mouth or enema.\\nChanges with aging:\\n Constipation is common among elderly people because of low-fiber diets, lack of\\nexercise, coexisting medical conditions, and use of constipating drugs. Many elderly people have\\nmisconceptions about normal bowel habits and use laxatives regularly. Other changes that predispose the\\nelderly to constipation include increased rectal compliance and impaired rectal sensation (such that larger\\nrectal volumes are needed to elicit the desire to defecate).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n132'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 142, 'page_label': '133'}, page_content='Evaluation\\nHistory:\\n A lifetime history of the patient\\'s stool frequency, consistency, need to strain or use perineal\\nmaneuvers (eg, pushing on the perineum, gluteal region, or recto-vaginal wall) during defecation, and\\nsatisfaction after defecation should be obtained, including frequency and duration of laxative or enema\\nuse. Some patients deny previous constipation\\n[\\nTable 8-1.\\n Causes of Constipation]\\nbut, when questioned specifically, admit to spending 15 to 20 min per bowel movement. The presence,\\namount, and duration of blood in the stool should also be elicited.\\nSymptoms of metabolic (eg, hypothyroidism, diabetes mellitus) and neurologic (eg, spinal cord injury)\\ndisorders and systemic symptoms (eg, weight loss) should also be sought. Prescription and\\nnonprescription drug use should be assessed, with specific questioning about anticholinergic and opioid\\ndrugs.\\nPhysical examination:\\n A general examination is done to look for signs of systemic disease, including\\nfever and cachexia. Abdominal masses should be sought by palpation. A rectal examination should be\\ndone not only for fissures, strictures, blood, or masses (including fecal impaction) but also to evaluate\\nanal resting tone (the puborectalis \"lift\" when patients squeeze the anal sphincter), perineal descent\\nduring simulated evacuation, and rectal sensation. Patients with defecatory disorders may have increased\\nanal resting tone (or anismus), reduced (ie, < 2 cm) or increased (ie, > 4 cm) perineal descent, and/or\\nparadoxical contraction of the puborectalis during simulated evacuation.\\nRed flags:\\n Certain findings raise suspicion of a more serious etiology of chronic constipation:\\n Distended, tympanitic abdomen\\n Vomiting\\n Blood in stool\\n Weight loss\\n Severe constipation of recent onset/worsening in elderly patients\\nInterpretation of findings:\\n Certain symptoms (eg, a sense of anorectal blockage, prolonged or difficult\\ndefecation), particularly when associated with abnormal (ie, increased or reduced) perineal motion during\\nsimulated evacuation, suggest a defecatory disorder. A tense, distended, tympanitic abdomen, particularly\\nwhen there is nausea and vomiting, suggests mechanical obstruction.\\nPatients with IBS typically have abdominal pain with disordered bowel habits (see p. \\n162\\n). Chronic\\nconstipation with modest abdominal discomfort in a patient who has used laxatives for a long time\\nsuggests slow-transit constipation. Acute constipation coincident with the start of a constipating drug in\\npatients without red flag findings suggests the drug is the cause. New-onset constipation that persists for\\nweeks or occurs intermittently with increasing frequency or severity, in the absence of a known cause,\\nsuggests colonic tumor or other causes of partial obstruction. Excessive straining or prolonged or\\nunsatisfactory defecation, with or without anal digitation, suggests a defecatory disorder. Patients with\\nfecal impaction may have cramps and may pass watery mucus or fecal material around the impacted\\nmass, mimicking diarrhea (paradoxic diarrhea).\\nTesting:\\n Testing is guided by clinical presentation.\\nConstipation with a clear etiology (drugs, trauma, bed rest) may be treated symptomatically without further\\nstudy. Patients with symptoms of bowel obstruction require flat and upright abdominal x-rays, possibly a\\nwater-soluble contrast enema to evaluate for colonic obstruction, and possibly a CT scan or barium x-ray\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n133'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 143, 'page_label': '134'}, page_content='of the small intestine (see also p.\\n116\\n). Most patients without a clear etiology should have sigmoidoscopy or colonoscopy and a laboratory\\nevaluation (CBC, thyroid-stimulating hormone, fasting glucose, electrolytes, and Ca).\\nFurther tests are usually reserved for patients with abnormal findings on the previously mentioned tests or\\nwho do not respond to symptomatic treatment. If the primary complaint is infrequent defecation, colonic\\ntransit times should be measured with radiopaque markers or scintigraphy. If the primary complaint is\\ndifficulty with defecation, anorectal manometry and rectal balloon expulsion should be assessed.\\nTreatment\\n Possibly discontinuation of causative drugs (some may be necessary)\\n Increase in dietary fiber\\n Possibly trial with a brief course of osmotic laxatives\\nAny identified conditions should be treated.\\nAgents used to treat constipation are summarized in\\nTable 8-2\\n. Laxatives should be used judiciously. Some (eg, phosphate, bran, cellulose) bind drugs and\\ninterfere with absorption. Rapid fecal transit may rush some drugs and nutrients beyond their optimal\\nabsorptive locus. Contraindications to laxative and cathartic use include acute abdominal pain of\\nunknown origin, inflammatory bowel disorders, intestinal obstruction, GI bleeding, and fecal impaction.\\nDiet and behavior:\\n The diet should contain enough fiber (typically 15 to 20 g/day) to ensure adequate\\nstool bulk. Vegetable fiber, which is largely indigestible and unabsorbable, increases stool bulk. Certain\\ncomponents of fiber also absorb fluid, making stools softer and facilitating their passage. Fruits and\\nvegetables are recommended sources, as are cereals containing bran. Fiber supplementation is\\nparticularly effective in treating normal-transit constipation but is not very effective for slow-transit\\nconstipation or defecatory disorders.\\n[\\nTable 8-2.\\n Agents Used to Treat Constipation]\\nBehavioral changes may help. Patients should try to move their bowels at the same time daily, preferably\\n15 to 45 min after breakfast, because food ingestion stimulates colonic motility. Initial efforts at regular,\\nunhurried bowel movements may be aided by glycerin suppositories.\\nExplanation is important, but it is difficult to convince obsessive-compulsive patients that their attitude\\ntoward defecation is abnormal. Physicians must explain that daily bowel movements are not essential,\\nthat the bowel must be given a chance to function, and that frequent use of laxatives or enemas (> once/3\\ndays) denies the bowel that chance.\\nTypes of laxatives:\\n Bulking agents (eg, psyllium, Ca polycarbophil, methylcellulose) act slowly and\\ngently and are the safest agents for promoting elimination. Proper use involves gradually increasing the\\ndoseideally taken tid or qid with sufficient liquid (eg, 500 mL/day of extra fluid) to prevent impaction\\nuntil a softer, bulkier stool results. Bloating may be reduced by gradually titrating the dose of dietary\\nfiber to the recommended dose, or by switching to a synthetic fiber preparation such as methylcellulose.\\nOsmotic agents contain poorly absorbed polyvalent ions (eg, Mg, phosphate, sulfate), polymers (eg,\\npolyethylene glycol), or carbohydrates (eg, lactulose, sorbitol) that remain in the bowel, increasing\\nintraluminal osmotic pressure and thereby drawing water into the intestine. The increased volume\\nstimulates peristalsis. These agents usually work within 3 h.\\nIn general, osmotic laxatives are reasonably safe even when used regularly. However, Na phosphate\\nshould not be used for bowel cleansing because it may rarely cause acute renal failure even after a single\\nuse for bowel preparation. These events occurred primarily in elderly patients, those with preexisting\\nrenal disease, and those who were taking drugs that affect renal perfusion or function (eg, diuretics, ACE\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n134'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 144, 'page_label': '135'}, page_content='inhibitors, angiotensin II receptor blockers). Also, Mg and phosphate are partially absorbed and may be\\ndetrimental in some conditions (eg, renal insufficiency). Na (in some preparations) may exacerbate heart\\nfailure. In large or frequent doses, these drugs may upset fluid and electrolyte balance. Another approach\\nto cleansing the bowel for diagnostic tests or surgery or sometimes for chronic constipation uses large\\nvolumes of a balanced osmotic agent (eg, polyethylene glycol-electrolyte solution) given orally or via\\nNGT.\\nSecretory or stimulant cathartics (eg, phenolphthalein, bisacodyl, anthraquinones, castor oil,\\nanthraquinones) act by irritating the intestinal mucosa or by directly stimulating the submucosal and\\nmyenteric plexus. Although phenolphthalein was withdrawn from the US market after animal studies\\nsuggested the compound was carcinogenic, there is no epidemiologic evidence of this in humans.\\nBisacodyl is an effective rescue drug for chronic constipation. The anthraquinones senna, cascara\\nsagrada, aloe, and rhubarb are common constituents of herbal and OTC laxatives. They pass unchanged\\nto the colon where bacterial metabolism converts them to active forms. Adverse effects include allergic\\nreactions, electrolyte depletion, melanosis coli, and cathartic colon. Melanosis coli is a brownish black\\ncolorectal pigmentation of unknown composition. Cathartic colon refers to alterations in colonic anatomy\\nobserved on barium enema in patients with chronic stimulant laxative use. It is unclear whether cathartic\\ncolon, which has been attributed to destruction of myenteric plexus neurons by anthraquinones, is caused\\nby currently available agents or other neurotoxic agents (eg, podophyllin), which are no longer available.\\nThere does not seem to be an increased risk of colon cancer with long-term anthraquinone use.\\nEnemas can be used, including tap water and commercially prepared hypertonic solutions.\\nEmollient agents (eg, docusate, mineral oil) act slowly to soften stools, making them easier to pass.\\nHowever, they are not potent stimulators of defecation. Docusate is a surfactant, which allows water to\\nenter the fecal mass to soften and increase its bulk.\\nFecal impaction:\\n Fecal impaction is treated initially with enemas of tap water followed by small enemas\\n(100 mL) of commercially prepared hypertonic solutions (eg, Na phosphate). If these do not work, manual\\nfragmentation and disimpaction of the mass is necessary. This procedure is painful, so perirectal and\\nintrarectal application of local anesthetics (eg, lidocaine 5% ointment or dibucaine 1% ointment) is\\nrecommended. Some patients require sedation.\\nKey Points\\n Drug causes are common (eg, chronic laxative abuse, use of anticholinergic or opioid drugs).\\n Clinicians should be wary of bowel obstruction when constipation is acute and severe.\\n Symptomatic treatment is reasonable in the absence of red flag findings and after excluding pelvic floor\\ndysfunction.\\nDyschezia\\n(Disordered Evacuation; Dysfunction of Pelvic Floor or Anal Sphincters; Functional Defecatory Disorders;\\nDyssynergia)\\nDyschezia is difficulty defecating. Patients sense the presence of stool and the need to\\ndefecate but are unable. It results from a lack of coordination of pelvic floor muscles and anal\\nsphincters. Diagnosis requires anorectal testing. Treatment is difficult, but biofeedback may be\\nof benefit.\\nEtiology\\nNormally, when a person tries to defecate, rectal pressure rises in coordination with relaxation of the\\nexternal anal sphincter. This process may be affected by one or more dysfunctions (eg, impaired rectal\\ncontraction, excessive contraction of the abdominal wall, paradoxic anal contraction, failure of anal\\nrelaxation) of unclear etiology. Functional defecatory disorders may manifest at any age. In contrast,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n135'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 145, 'page_label': '136'}, page_content=\"Hirschsprung's disease, which is due to an absent recto-anal inhibitory reflex, is almost always diagnosed\\nin infancy or childhood.\\nSymptoms and Signs\\nThe patient may or may not sense that stool is present in the rectum. Despite prolonged straining,\\nevacuation is tedious or impossible, frequently even for soft stool or enemas. Patients may complain of\\nanal blockage and may digitally remove stool from their rectum or manually support their perineum or\\nsplint the vagina to evacuate. Actual stool frequency may or may not be decreased.\\nDiagnosis\\nRectal and pelvic examinations may reveal hypertonia of the pelvic floor muscles and anal sphincters.\\nWith bearing down, patients may not demonstrate the expected anal relaxation and perineal descent.\\nWith excessive straining, the anterior rectal wall prolapses into the vagina in patients with impaired anal\\nrelaxation; thus rectoceles are usually a secondary rather than a primary disturbance. Long-standing\\ndyschezia with chronic straining may cause a solitary rectal ulcer or varying degrees of rectal prolapse or\\nexcessive perineal descent or an enterocoele. Anorectal manometry and rectal balloon expulsion,\\noccasionally supplemented by defecatory or magnetic resonance proctography, are necessary to\\ndiagnose the condition.\\nTreatment\\nBecause treatment with laxatives is unsatisfactory, it is important to assess anorectal functions in patients\\nwith refractory constipation. Biofeedback therapy can improve coordination between abdominal\\ncontraction and pelvic floor relaxation during defecation, thereby alleviating symptoms. However, pelvic\\nfloor retraining for defecatory disorders is highly specialized and available at select centers only. A\\ncollaborative approach (physiotherapists, dietitians, behavior therapists, gastroenterologists) is\\nnecessary.\\nDiarrhea\\n(See also \\nChs. 17\\n and \\n19\\n. For diarrhea in children, see p. \\n2737\\n.)\\nStool is 60 to 90% water. In Western society, stool amount is 100 to 200 g/day in healthy adults and 10\\ng/kg/day in infants, depending on the amount of unabsorbable dietary material (mainly carbohydrates).\\nDiarrhea is defined as stool weight > 200 g/day. However, many people consider any increased stool\\nfluidity to be diarrhea. Alternatively, many people who ingest fiber have bulkier but formed stools but do\\nnot consider themselves to have diarrhea.\\nComplications:\\n Complications may result from diarrhea of any etiology. Fluid loss with consequent\\ndehydration, electrolyte loss (Na, K, Mg, Cl), and even vascular collapse sometimes occur. Collapse can\\ndevelop rapidly in patients who have severe diarrhea (eg, patients with cholera) or are very young, very\\nold, or debilitated. HCO\\n3\\n loss can cause metabolic acidosis. Hypokalemia can occur when patients have\\nsevere or chronic diarrhea or if the stool contains excess mucus. Hypomagnesemia after prolonged\\ndiarrhea can cause tetany.\\nEtiology\\nNormally, the small intestine and colon absorb 99% of fluid resulting from oral intake and GI tract\\nsecretionsa total fluid load of about 9 of 10 L daily. Thus, even small reductions (ie, 1%) in intestinal\\nwater absorption or increases in secretion can increase water content enough to cause diarrhea.\\nThere are a number of causes of diarrhea (see\\nTable 8-3\\n). Several basic mechanisms are responsible for most clinically significant diarrheas: increased\\nosmotic load, increased secretions, and decreased contact time/surface area. In many disorders, more\\nthan one mechanism is active. For example, diarrhea in inflammatory bowel disease results from mucosal\\ndestruction, exudation into the lumen, and from multiple secretagogues and bacterial toxins that affect\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n136\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 146, 'page_label': '137'}, page_content='enterocyte function.\\n[\\nTable 8-3.\\n Some Causes of Diarrhea*]\\nOsmotic load:\\n Diarrhea occurs when unabsorbable, water-soluble solutes remain in the bowel and\\nretain water. Such solutes include polyethylene glycol, Mg salts (hydroxide and sulfate), and Na\\nphosphate, which are used as laxatives. Osmotic diarrhea occurs with sugar intolerance (eg, lactose\\nintolerance caused by lactase deficiency). Ingesting large amounts of hexitols (eg, sorbitol, mannitol,\\nxylitol) or high fructose corn syrups, which are used as sugar substitutes in candy, gum, and fruit juices,\\ncauses osmotic diarrhea because hexitols are poorly absorbed. Lactulose, which is used as a laxative,\\ncauses diarrhea by a similar mechanism. Overingesting certain foodstuffs (see\\nTable 8-4\\n) can cause osmotic diarrhea.\\nIncreased secretions:\\n Diarrhea occurs when the bowels secrete more electrolytes and water than they\\nabsorb. Causes of increased secretions include infections, unabsorbed fats, certain drugs, and various\\nintrinsic and extrinsic secretagogues.\\nInfections (eg, gastroenteritis; discussed in \\nCh. 16\\n) are the most common causes of secretory diarrhea.\\nInfections combined with food poisoning are the most common causes of acute diarrhea (< 4 days in\\nduration). Most enterotoxins block Na\\n+\\n-H\\n+\\n exchange, which is an important driving force for fluid\\nabsorption in the small bowel and colon.\\nUnabsorbed dietary fat and bile acids (as in malabsorption syndromes and after ileal resection) can\\nstimulate colonic secretion and cause diarrhea.\\nDrugs may stimulate intestinal secretions directly (eg, quinidine, quinine, colchicine, anthraquinone\\ncathartics, castor oil, prostaglandins) or indirectly by impairing fat absorption (eg, orlistat).\\nVarious endocrine tumors produce secretagogues, including vipomas (vasoactive intestinal peptide),\\ngastrinomas (gastrin), mastocytosis (histamine), medullary carcinoma of the thyroid (calcitonin and\\nprostaglandins), and carcinoid tumors (histamine, serotonin, and polypeptides). Some of these mediators\\n(eg, prostaglandins, serotonin, related compounds) also accelerate intestinal transit, colonic transit, or\\nboth.\\nReduced contact time/surface area:\\n Rapid intestinal transit and diminished surface area impair fluid\\nabsorption and cause diarrhea. Common causes include small-bowel or large-bowel resection or bypass,\\ngastric resection,\\n[\\nTable 8-4.\\n Dietary Factors that May Worsen Diarrhea]\\nand inflammatory bowel disease. Other causes include microscopic colitis (collagenous or lymphocytic\\ncolitis) and celiac sprue.\\nStimulation of intestinal smooth muscle by drugs (eg, Mg-containing antacids, laxatives, cholinesterase\\ninhibitors, SSRIs) or humoral agents (eg, prostaglandins, serotonin) also can speed transit.\\nEvaluation\\nHistory:\\n Duration and severity of diarrhea, circumstances of onset (including recent travel, food\\ningested, source of water), drug use (including any antibiotics within the previous 3 mo), abdominal pain\\nor vomiting, frequency and timing of bowel movements, changes in stool characteristics (eg, presence of\\nblood, pus, or mucus; changes in color or consistency; evidence of steatorrhea), associated changes in\\nweight or appetite, and rectal urgency or tenesmus should be noted. Simultaneous occurrence of\\ndiarrhea in close contacts should be ascertained.\\nPhysical examination:\\n Fluid and hydration status should be evaluated. A full examination with attention\\nto the abdomen and a digital rectal examination for sphincter competence and occult blood testing are\\nimportant.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n137'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 147, 'page_label': '138'}, page_content=\"Red flags:\\n Certain findings raise suspicion of an organic or more serious etiology of diarrhea:\\n Blood or pus\\n Fever\\n Signs of dehydration\\n Chronic diarrhea\\n Weight loss\\nInterpretation of findings:\\n Acute, watery diarrhea in an otherwise healthy person is likely to be of\\ninfectious etiology, particularly when travel, possibly tainted food, or an outbreak with a point-source is\\ninvolved. Acute bloody diarrhea with or without hemodynamic instability in an otherwise healthy person\\nsuggests an enteroinvasive infection. Diverticular bleeding and ischemic colitis also manifest with acute\\nbloody diarrhea. Recurrent bouts of bloody diarrhea in a younger person suggest inflammatory bowel\\ndisease. In the absence of laxative use, large-volume diarrhea (eg, daily stool volume > 1 L/day) strongly\\nsuggests an endocrine cause in patients with normal GI anatomy. A history of oil droplets in stool,\\nparticularly if associated with weight loss, suggests malabsorption.\\nDiarrhea that consistently follows ingestion of certain foods (eg, fats) suggests food intolerance. Recent\\nantibiotic use should raise suspicion for antibiotic-associated diarrhea, including \\nClostridium difficile\\ncolitis.\\nThe symptoms can help identify the affected part of the bowel. Generally, in small-bowel diseases, stools\\nare voluminous and watery or fatty. In colonic diseases, stools are frequent, sometimes small in volume,\\nand possibly accompanied by blood, mucus, pus, and abdominal discomfort. In irritable bowel syndrome\\n(IBS), abdominal discomfort is relieved by defecation, associated with more loose or frequent stools, or\\nboth. However, these symptoms alone do not discriminate IBS from other diseases (eg, inflammatory\\nbowel disease). Patients with IBS or rectal mucosal involvement often have marked urgency, tenesmus,\\nand small, frequent stools (see p. \\n163\\n).\\nExtra-abdominal findings that suggest an etiology include skin lesions or flushing (mastocytosis), thyroid\\nnodules (medullary carcinoma of the thyroid), right-sided heart murmur (carcinoid), lymphadenopathy\\n(lymphoma, AIDS), and arthritis (inflammatory bowel disease, celiac disease).\\nTesting:\\n Acute diarrhea (< 4 days) typically does not require testing. Exceptions are patients with signs of\\ndehydration, bloody stool, fever, severe pain, hypotension, or \\ntoxic featuresparticularly those who are\\nvery young or very old. These patients should have a CBC and measurement of electrolytes, BUN, and\\ncreatinine. Stool samples should be collected for microscopy, culture, fecal leukocyte testing, and, if\\nantibiotics have been taken recently, \\nC. difficile\\n toxin assay.\\nChronic diarrhea (> 4 wk) requires evaluation, as does a shorter (1 to 3 wk) bout of diarrhea in\\nimmunocompromised patients or those who appear significantly ill. Initial stool testing should include\\nculture, fecal leukocytes (detected by smear or measurement of fecal lactoferrin), microscopic\\nexamination for ova and parasites, pH (bacterial fermentation of unabsorbed carbohydrate lowers stool\\npH < 6.0), fat (by Sudan stain), and electrolytes (Na and K). If no standard pathogens are found, specific\\ntests for \\nGiardia\\n antigen and \\nAeromonas\\n, \\nPlesiomonas\\n, coccidia, and microsporidia should be requested.\\nSigmoidoscopy or colonoscopy with biopsies should follow to look for inflammatory causes.\\nIf no diagnosis is apparent and Sudan stain is positive for fat, fecal fat excretion should be measured,\\nfollowed by small-bowel enteroclysis or CT enterography (structural disease) and endoscopic small-bowel\\nbiopsy (mucosal disease). If evaluation still yields negative findings, assessment of pancreatic structure\\nand function (see p. \\n142\\n) should be considered for patients who have unexplained steatorrhea.\\nInfrequently, capsule endoscopy may uncover lesions, predominantly Crohn's disease or NSAID\\nenteropathy, not identified by other modalities.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n138\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 148, 'page_label': '139'}, page_content='The stool osmotic gap, which is calculated 290 - 2  (stool Na + stool K), indicates whether diarrhea is\\nsecretory or osmotic. An osmotic gap < 50 mEq/L indicates secretory diarrhea; a larger gap suggests\\nosmotic diarrhea. Patients with osmotic diarrhea may have covert Mg laxative ingestion (detectable by\\nstool Mg levels) or carbohydrate malabsorption (diagnosed by hydrogen breath test, lactase assay, and\\ndietary review).\\nUndiagnosed secretory diarrhea requires testing (eg, plasma gastrin, calcitonin, vasoactive intestinal\\npeptide levels, histamine, urinary 5-hydroxyindole acetic acid [5-HIAA]) for endocrine-related causes. A\\nreview for symptoms and signs of thyroid disease and adrenal insufficiency should be done. Surreptitious\\nlaxative abuse must be considered; it can be ruled out by a fecal laxative assay.\\nTreatment\\n Fluid and electrolytes for dehydration\\n Possibly antidiarrheals for nonbloody diarrhea in patients without systemic toxicity\\nSevere diarrhea requires fluid and electrolyte replacement to correct dehydration, electrolyte imbalance,\\nand acidosis. Parenteral fluids containing NaCl, KCl, and glucose are generally required. Salts to\\ncounteract acidosis (Na lactate, acetate, HCO\\n3\\n) may be indicated if serum HCO\\n3\\n is < 15 mEq/L. An oral\\nglucose-electrolyte solution can be given if diarrhea is not severe and nausea and vomiting are minimal\\n(see p.\\n2809\\n). Oral and parenteral fluids are sometimes given simultaneously when water and electrolytes must\\nbe replaced in massive amounts (eg, in cholera).\\nDiarrhea is a symptom. When possible, the underlying disorder should be treated, but symptomatic\\ntreatment is often necessary. Diarrhea may be decreased by oral loperamide 2 to 4 mg tid or qid\\n(preferably given 30 min before meals), diphenoxylate 2.5 to 5 mg (tablets or liquid) tid or qid, codeine\\nphosphate 15 to 30 mg bid or tid, or paregoric (camphorated opium tincture) 5 to 10 mL once/day to qid.\\nBecause antidiarrheals may exacerbate \\nC. difficile\\n colitis or increase the likelihood of hemolytic-uremic\\nsyndrome in \\nShiga\\n toxin-producing \\nEscherichia coli\\n infection, they should not be used in bloody diarrhea\\nof unknown cause. Their use should be restricted to patients with watery diarrhea and no signs of\\nsystemic toxicity. However, there is little evidence to justify previous concerns about prolonging excretion\\nof possible bacterial pathogens with antidiarrheals.\\nPsyllium or methylcellulose compounds provide bulk. Although usually prescribed for constipation, bulking\\nagents given in small doses decrease the fluidity of liquid stools. Kaolin, pectin, and activated attapulgite\\nadsorb fluid. Osmotically active dietary substances (see \\nTable 8-4\\n) and stimulatory drugs should be\\navoided.\\nKey Points\\n In patients with acute diarrhea, stool examination (cultures, ova and parasites, \\nC. difficile\\n cytotoxin) is\\nonly necessary for those who have prolonged symptoms (ie, > 1 wk) or red flag findings.\\n Antidiarrheals should be used cautiously if there is a possibility of \\nC. difficile\\n, \\nSalmonella\\n, or shigellosis.\\nGas-Related Complaints\\nThe gut contains < 200 mL of gas, whereas daily gas expulsion averages 600 to 700 mL after consuming\\na standard diet plus 200 g of baked beans. About 75% of flatus is derived from \\ncolonic bacterial\\nfermentation of ingested nutrients and endogenous glycoproteins. Gases include hydrogen (H\\n2\\n),\\nmethane (CH\\n4\\n), and carbon dioxide (CO\\n2\\n). Flatus odor correlates with H\\n2\\n sulphide concentrations.\\nSwallowed air (aerophagia) and diffusion from the blood into the lumen also contribute to intestinal gas.\\nGas diffuses between the lumen and the blood in a direction that depends on the difference in partial\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n139'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 149, 'page_label': '140'}, page_content='pressures. Thus, most nitrogen (N\\n2\\n) in the lumen originates from the bloodstream, and most H\\n2\\n in the\\nbloodstream originates from the lumen.\\nEtiology\\nThere are 3 main gas-related complaints: excessive belching, distention (bloating), and excessive flatus,\\neach with a number of causes (see\\nTable 8-5\\n). Infants 2 to 4 mo of age with recurrent crying spells often appear to observers to be in pain,\\nwhich in the past has been attributed to abdominal cramping or gas and termed colic. However, studies\\nshow no increase in H\\n2\\n production or in mouth-to-cecum transit times in colicky infants. Hence, the cause\\nof infantile colic remains unclear (see p. \\n2725\\n).\\nExcessive belching:\\n Belching (eructation) results from swallowed air or from gas generated by\\ncarbonated beverages. Aerophagia occurs normally in small amounts during eating and drinking, but\\nsome people unconsciously swallow air repeatedly while eating or smoking and at other times, especially\\nwhen anxious or in an attempt to induce belching. Excessive salivation increases aerophagia and may be\\nassociated with various GI disorders (eg, gastroesophageal reflux disease), ill-fitting dentures, certain\\ndrugs, gum chewing, or nausea of any cause.\\nMost swallowed air is eructated. Only a small amount of swallowed air passes into the small bowel; the\\namount is apparently influenced by position. In an upright person, air is readily belched; in a supine\\nperson, air trapped above the stomach fluid tends to be propelled into the duodenum. Excessive\\neructation may also be voluntary; patients who belch after taking antacids may attribute the relief of\\nsymptoms to belching rather than to antacids and may intentionally belch to relieve distress.\\nDistention (bloating):\\n Abdominal bloating may occur in isolation or along with other GI symptoms in\\npatients with functional disorders (eg, aerophagia, nonulcer dyspepsia, gastroparesis, irritable bowel\\nsyndrome) or organic disorders (eg, ovarian cancer, colon cancer). However, excessive intestinal gas is\\nnot clearly linked to these complaints. In most healthy people, 1 L/h of gas can be infused into the gut\\nwith minimal symptoms. It is likely that many symptoms are incorrectly attributed to \"too much gas.\"\\nOn the other hand, some patients with recurrent GI symptoms often cannot tolerate small quantities of\\ngas: Retrograde colonic distention by balloon inflation or air instillation during colonoscopy often elicits\\nsevere discomfort in some patients (eg, those with irritable bowel syndrome) but minimal symptoms in\\nothers. Similarly, patients with eating disorders (eg, anorexia nervosa, bulimia) often misperceive and are\\nparticularly stressed by symptoms such as bloating. Thus, the basic abnormality in patients with gas-\\nrelated symptoms may be a hypersensitive intestine. Altered motility may contribute further to symptoms.\\nExcessive flatus:\\n There is great variability in the quantity and frequency of rectal gas passage. As with\\nstool frequency, people who complain of flatulence often have a misconception of what is normal. The\\naverage number of gas passages is about 13 to 21/day. Objectively recording flatus frequency (using a\\ndiary kept by the patient) is a first step in evaluation.\\nFlatus is a metabolic byproduct of intestinal bacteria; almost none originates from swallowed air or back-\\ndiffusion of gases (primarily N\\n2\\n) from the bloodstream. Bacterial metabolism yields significant volumes of\\nH\\n2\\n, CH\\n4\\n, and CO\\n2\\n.\\nH\\n2\\n is produced in large quantities in patients with malabsorption syndromes and after ingestion of certain\\nfruits and vegetables containing indigestible carbohydrates (eg, baked beans), sugars (eg, fructose), or\\nsugar alcohols (eg, sorbitol). In patients with disaccharidase deficiencies (most commonly lactase\\ndeficiency), large amounts of disaccharides pass into the colon and are fermented to H\\n2\\n. Celiac disease,\\ntropical sprue, pancreatic insufficiency, and other causes of carbohydrate malabsorption should also be\\nconsidered in cases of excess colonic gas.\\nCH\\n4\\n is also produced by colonic bacterial metabolism of the same foods (eg, dietary fiber). However,\\nabout 10% of people have bacteria that produce CH\\n4\\n but not H\\n2\\n.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n140'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 150, 'page_label': '141'}, page_content='CO\\n2\\n is also produced by bacterial metabolism and generated in the reaction of HCO\\n3\\n-\\n and H\\n+\\n. H\\n+\\n may\\ncome from gastric HCl or from fatty acids released during digestion of fatsthe latter sometimes\\nproduces several hundred mEq of H\\n+\\n. The acid products released by bacterial fermentation of\\nunabsorbed carbohydrates in the colon may also react with HCO\\n3\\n-\\n to produce CO\\n2\\n. Although bloating\\nmay occasionally occur, the rapid diffusion of CO\\n2\\n into the blood generally prevents distention.\\n[\\nTable 8-5.\\n Some Causes of Gas-Related Complaints]\\nDiet accounts for much of the variation in flatus production among individuals, but poorly understood\\nfactors (eg, differences in colonic flora and motility) may also play a role.\\nDespite the flammable nature of the H\\n2\\n and CH\\n4\\n in flatulence, working near open flames is not\\nhazardous. However, gas explosion, even with fatal outcome, has been reported during jejunal and\\ncolonic surgery and colonoscopy, when diathermy was used during procedures in patients with\\nincomplete bowel cleaning.\\nEvaluation\\nHistory:\\n Patients with belching should have the history directed at finding the cause of aerophagia,\\nespecially dietary causes.\\nIn patients complaining of gas, bloating, or flatus, the relationship between symptoms and meals (both\\ntiming and type and amount of food), bowel movements, and exertion should be explored. Certain\\npatients, particularly in the acute setting, may use the term \"gas\" to describe their symptoms of coronary\\nischemia. Changes in frequency and color and consistency of stool are sought. History of weight loss is\\nnoted.\\nPhysical examination:\\n The examination is generally normal, but in patients with bloating or flatus, signs\\nof an underlying organic disorder should be sought on abdominal, rectal, and (for women) pelvic\\nexamination.\\nRed flags:\\n The following findings are of concern:\\n Weight loss\\n Blood in stool (occult or gross)\\nInterpretation of findings:\\n Chronic, recurrent bloating or distention relieved by defecation and\\nassociated with change in frequency or consistency of stool but without red flag findings suggests irritable\\nbowel syndrome.\\nLong-standing symptoms in an otherwise well young person who has not lost weight are unlikely to be\\ncaused by serious physiologic disease, although an eating disorder should be considered, particularly in\\nyoung women. Bloating accompanied by diarrhea, weight loss, or both (or only after ingestion of certain\\nfoods) suggests a malabsorption syndrome.\\nTesting:\\n Testing is not indicated for belching unless other symptoms suggest a particular disorder.\\nTesting for carbohydrate intolerance (eg, lactose, fructose) with breath tests should be considered\\nparticularly when the history suggests significant consumption of these sugars. Testing for small-bowel\\nbacterial overgrowth should also be considered, particularly in patients who also have diarrhea, weight\\nloss, or both, preferably by aerobic and anaerobic culture of small-bowel aspirates obtained during upper\\nGI endoscopy. Testing for bacterial overgrowth with H\\n2\\n breath tests, generally glucose-H\\n2\\n breath tests, is\\nprone to false-positive (ie, with rapid transit) and false-negative (ie, when there are no H\\n2\\n-producing\\nbacteria) results. New, persistent bloating in middle-aged or older women (or those with an abnormal\\npelvic examination) should prompt pelvic ultrasonography to rule out ovarian cancer.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n141'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 151, 'page_label': '142'}, page_content='Treatment\\nBelching and bloating are difficult to relieve because they are usually caused by unconscious aerophagia\\nor increased sensitivity \\nto normal amounts of gas. Aerophagia may be reduced by eliminating gum and\\ncarbonated beverages, cognitive behavioral techniques to prevent air swallowing, and management of\\nassociated upper GI diseases (eg, peptic ulcer). Foods containing unabsorbable carbohydrates should be\\navoided. Even lactose-intolerant patients generally tolerate up to 1 glass of milk drunk in small amounts\\nthroughout the day. The mechanism of repeated belching should be explained and demonstrated. When\\naerophagia is troublesome, behavioral therapy to encourage open-mouth, diaphragmatic breathing and\\nminimize swallowing may be effective.\\nSidebar 8-1 Essay on Flatulence\\n(First printed in the 14\\nth\\n Edition of \\nThe Merck Manual\\n)\\nFlatulence, which can cause great psychosocial distress, is unofficially described according to its salient\\ncharacteristics: (1) the \"slider\" (crowded elevator type), which is released slowly and noiselessly,\\nsometimes with devastating effect; (2) the open sphincter, or \"pooh\" type, which is said to be of higher\\ntemperature and more aromatic; (3) the staccato or drumbeat type, pleasantly passed in privacy; and (4)\\nthe \"bark\" type (described in a personal communication) is characterized by a sharp exclamatory eruption\\nthat effectively interrupts (and often concludes) conversation. Aromaticity is not a prominent feature.\\nRarely, this usually distressing symptom has been turned to advantage, as with a Frenchman referred to\\nas \"Le Petomane,\" who became affluent as an effluent performer who played tunes with the gas from his\\nrectum on the Moulin Rouge stage.\\nDrugs provide little benefit. Results with simethicone, an agent that breaks up small gas bubbles, and\\nvarious anticholinergics are poor. Some patients with dyspepsia and postprandial upper abdominal\\nfullness benefit from antacids, a low dose of tricyclic antidepressants (eg, nortriptyline 10 to 50 mg po\\nonce/day), or both to reduce visceral hypersensitivity.\\nComplaints of excess flatus are treated with avoidance of triggering substances (see \\nTable 8-5\\n).\\nRoughage (eg, bran, psyllium seed) may be added to the diet to try to increase colonic transit; however,\\nin some patients, worsening of symptoms may result. Activated charcoal can sometimes help reduce gas\\nand unpleasant odor; however, it stains clothing and the oral mucosa. Charcoal-lined undergarments are\\navailable. Probiotics (eg, VSL#3) may also reduce bloating and flatulence by modulating intestinal\\nbacterial flora. Antibiotics are useful in patients with documented bacterial overgrowth.\\nFunctional bloating, distention, and flatus may run an intermittent, chronic course that is only partially\\nrelieved by therapy. When appropriate, reassurance that these problems are not detrimental to health is\\nimportant.\\nKey Points\\n Testing should be guided by the clinical features.\\n Clinicians should be wary of new-onset, persistent symptoms in older patients.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 8. Approach to the Patient With Lower GI Complaints\\n142'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 152, 'page_label': '143'}, page_content=\"Chapter 9. Diagnostic and Therapeutic GI Procedures\\nIntroduction\\nDiagnostic tests and therapeutic procedures available for patients with GI disorders include acid-related\\ntests, endoscopy, laparoscopy, manometry, nuclear scans, x-ray contrast studies, nasogastric or intestinal\\nintubation, anoscopy and sigmoidoscopy, abdominal paracentesis, electrogastrography, and electrical\\nimpedance testing. CT, MRI, and ultrasonography are also commonly done for GI disorders, and\\nsometimes angiography is used. The selection of procedures is discussed in subsequent chapters.\\nERCP, percutaneous transhepatic cholangiography, and liver biopsy are discussed in \\nCh. 24\\n.\\nAcid-Related Tests\\nAcid-related tests are used to ascertain the effectiveness of acid-blocking drugs. All require nasogastric or\\nnasoesophageal intubation. Complications are very rare. Patients must have nothing by mouth (npo) after\\nmidnight.\\nAmbulatory pH Monitoring\\nAmbulatory 24-h esophageal pH monitoring is currently the best available test for quantifying esophageal\\nacid exposure. The principal indications are\\n To document excessive acid exposure in patients without endoscopic evidence of esophagitis\\n To evaluate the effectiveness of medical or surgical treatments\\nA thin tube containing a pH probe is positioned 5 cm above the lower esophageal sphincter. The patient\\nrecords symptoms, meals, and sleep for 24 h. Esophageal acid exposure is defined by the percentage of\\nthe 24-h recording time that the pH is < 4.0. Values > 3.5% are considered abnormal. However, symptoms\\nmay not correlate with acid exposure or the presence of esophagitis. This may be because symptoms\\nmay result from nonacidic as well as acidic refluxate. Multichannel intraluminal impedance testing allows\\nfor recognition of major acid, minor acid, nonacid, and gas reflux, all of which can cause reflux symptoms.\\nGastric Analysis\\nSamples of stomach contents obtained via NGT are used to measure gastric acid output in a basal and\\nstimulated state. This information may be useful in a patient who develops a recurrent ulcer after surgical\\nvagotomy for peptic ulcer disease. In this case, a positive acid response to stimulation (sham feeding)\\nindicates an incomplete vagotomy. The test also is used to evaluate a patient with elevated serum gastrin\\nlevels. Hyperchlorhydria in the presence of elevated gastrin usually indicates Zollinger-Ellison syndrome.\\nHypochlorhydria in the presence of elevated gastrin indicates impairment of acid output, such as occurs\\nin pernicious anemia, atrophic gastritis, and Menetrier's disease and after inhibition of gastric acid\\nsecretion by potent antisecretory drugs.\\nTo do gastric analysis, an NGT is inserted and the gastric contents are aspirated and discarded. Gastric\\njuice is then collected for 1 h, divided into four 15-min samples. These samples represent basal acid\\noutput.\\nEndoscopy\\nFlexible endoscopes equipped with video cameras can be used to view the upper GI tract from pharynx to\\nupper duodenum and the lower GI tract from anus to cecum (and, sometimes, terminal ileum). Several\\nother diagnostic and therapeutic interventions also can be done endoscopically. The potential to combine\\ndiagnosis and therapy in one procedure gives endoscopy a significant advantage over procedures that\\nprovide only imaging (eg, x-ray contrast studies, CT, MRI) and often outweighs endoscopy's higher cost\\nand need for sedation.\\nDiagnostic procedures include the use of ultrasound-equipped endoscopes to evaluate blood flow or\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 9. Diagnostic & Therapeutic GI Procedures\\n143\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 153, 'page_label': '144'}, page_content='provide imaging of lesions. Endoscopic ultrasound can provide information (eg, the depth and extent of\\nlesions) that is not available via conventional endoscopy. Other diagnostic procedures include cell and\\ntissue sample collection by brush or biopsy forceps.\\nScreening colonoscopy is recommended for patients at high risk of colon cancer and for everyone  50.\\nColonoscopy should be done every 10 yr for patients with no risk factors and with a normal initial\\ncolonoscopy. CT colonography (see p. \\n98\\n) is an alternative to colonoscopy for screening for colonic\\ntumors.\\nTherapeutic endoscopic procedures include removal of foreign bodies; hemostasis by thermal\\ncoagulation, laser photocoagulation, variceal banding, or sclerotherapy; debulking of tumors by laser or\\nbipolar electrocoagulation; dilation of webs or strictures; stent placement; reduction of volvulus or\\nintussusception; and decompression of acute or subacute colonic dilatation.\\nAbsolute contraindications\\n to endoscopy include\\n Shock\\n Acute MI\\n Peritonitis\\n Acute perforation\\n Fulminant colitis\\nRelative contraindications include poor patient cooperation, coma (unless the patient is intubated), and\\ncardiac arrhythmias or recent myocardial ischemia.\\nPatients taking anticoagulants or chronic NSAID therapy can safely undergo diagnostic endoscopy.\\nHowever, if there is a possibility \\nthat biopsy or photocoagulation will be done, these drugs should be\\nstopped for an appropriate interval before the procedure. Oral iron-containing drugs should be stopped 4\\nto 5 days before colonoscopy, because certain green vegetables interact with iron to form a sticky residue\\nthat is difficult to remove with a bowel preparation and interferes with visualization. The American Heart\\nAssociation no longer recommends endocarditis prophylaxis for patients having GI endoscopy.\\nRoutine preparations for endoscopy include no solids for 6 to 8 h and no liquids for 4 h before the\\nprocedure. Additionally, colonoscopy requires cleansing of the colon. A variety of regimens may be used,\\nbut all typically include a full or clear liquid diet for 24 to 48 h and some type of laxative, with or without an\\nenema. A common laxative preparation involves having the patient drink a high-volume (4 L) balanced\\nelectrolyte solution over a period of 3 to 4 h before the procedure. Patients who cannot tolerate this\\nsolution may be given Mg citrate, Na phosphate, lactulose, or other laxatives. Enemas can be done with\\neither Na phosphate or tap water. Phosphate preparations should not be used in patients with renal\\ninsufficiency.\\nEndoscopy generally requires IV sedation and, for upper endoscopy, topical anesthesia of the throat.\\nExceptions are anoscopy and sigmoidoscopy (see p. \\n98\\n), which generally require nothing. The overall\\ncomplication rate of endoscopy is 0.1 to 0.2%; mortality is about 0.03%. Complications are usually drug\\nrelated (eg, respiratory depression); procedural complications (eg, aspiration, perforation, significant\\nbleeding) are less common.\\nVideo capsule endoscopy:\\n In video capsule endoscopy (wireless video endoscopy), patients swallow a\\ncapsule containing a camera that transmits images to an external recorder. This noninvasive technology\\nprovides diagnostic imaging of the small bowel that is otherwise difficult to obtain. This procedure is\\nparticularly useful in patients with occult GI bleeding. Capsule endoscopy is more difficult in the colon;\\nproducts and procedures are under development.\\nLaparoscopy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 9. Diagnostic & Therapeutic GI Procedures\\n144'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 154, 'page_label': '145'}, page_content='Diagnostic laparoscopy is a surgical procedure used to evaluate intra-abdominal or pelvic pathology (eg,\\ntumor, endometriosis) in patients with acute or chronic abdominal pain and operability in patients with\\ncancer. It also is used for lymphoma staging and liver biopsy.\\nAbsolute contraindications\\n include\\n A coagulation or bleeding disorder\\n Poor patient cooperation\\n Peritonitis\\n Intestinal obstruction\\n Infection of the abdominal wall\\nRelative contraindications include severe cardiac or pulmonary disease, large abdominal hernias, multiple\\nabdominal operations, and tense ascites.\\nCBC, coagulation studies, and type and Rh testing are done before laparoscopy. X-rays of the chest and\\nabdomen (kidneys, ureters, and bladder) are also taken. Laparoscopy is done with sterile technique in an\\noperating room or a well-equipped endoscopy suite. The patient is given local anesthesia plus IV sedation\\nand analgesia with an opioid and short-acting sedative (eg, midazolam, propofol).\\nThe procedure involves insertion of a pneumoperitoneum needle into the peritoneal cavity and infusion of\\nnitrous oxide to distend the abdomen. After the opening is enlarged, a peritoneoscope is inserted into the\\nabdomen and the abdominal contents are examined. Surgical instruments for biopsy and other\\nprocedures are inserted through separate openings. When the procedure is completed, the nitrous oxide\\nis expelled by the patient with a Valsalva maneuver and the cannula is removed. Complications can\\ninclude bleeding, bacterial peritonitis, and perforation of a viscus.\\nManometry\\nManometry is measurement of pressure within various parts of the GI tract. It is done by passing a\\ncatheter containing solid-state or liquid-filled pressure transducers through the mouth or anus into the\\nlumen of the organ to be studied. Manometry typically is done to evaluate motility disorders in patients in\\nwhom structural lesions have been ruled out by other studies. Manometry is used in the esophagus,\\nstomach and duodenum, sphincter of Oddi, and rectum. Aside from minor discomfort, complications are\\nvery rare. Patients must have nothing by mouth (npo) after midnight.\\nEsophageal manometry:\\n This test is used to evaluate patients with dysphagia, heartburn, or chest\\npain. It measures the pressure in the upper and lower esophageal sphincters, determines the\\neffectiveness and coordination of propulsive movements, and detects abnormal contractions. Manometry\\nis used to diagnose achalasia, diffuse spasm, systemic sclerosis, and lower esophageal sphincter\\nhypotension \\nand hypertension. It also is used to evaluate esophageal function before certain therapeutic\\nprocedures (eg, antireflux surgery, pneumatic dilation for achalasia).\\nGastroduodenal manometry:\\n In this test, transducers are placed in the gastric antrum, duodenum, and\\nproximal jejunum. Pressure is monitored for 5 to 24 h in both fasting and fed states. This test is used\\nmainly in patients who have symptoms suggestive of dysmotility but normal gastric emptying studies.\\nBarostat:\\n This is a pressure-sensing device that is placed in the stomach to measure gastric\\naccommodation. The device consists of a plastic balloon and an electronic controller that varies the\\namount of air in the balloon to maintain constant pressure. This device is used mainly in research studies\\nassessing sensory threshold and altered visceral perception, particularly in functional GI disorders.\\nAnorectal manometry:\\n This test evaluates the anorectal sphincter mechanism and rectal sensation in\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 9. Diagnostic & Therapeutic GI Procedures\\n145'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 155, 'page_label': '146'}, page_content=\"patients with incontinence (and sometimes constipation) by means of a pressure transducer in the anus. It\\ncan help diagnose Hirschsprung's disease and provide biofeedback training for fecal incontinence.\\nNuclear Scans\\nGastric emptying\\n can be measured by having the patient ingest a radiolabeled meal (solid or liquid) and\\nobserving its passage out of the stomach with a gamma camera. Because this test cannot differentiate\\nphysical obstruction from gastroparesis, further diagnostic studies typically are done if emptying is\\ndelayed. The test also is useful in monitoring response to promotility drugs (eg, metoclopramide,\\nerythromycin).\\nBleeding scans\\n use \\n99m\\nTc-labeled RBCs, or occasionally \\n99m\\nTc-labeled colloid, to determine the origin\\nof lower GI hemorrhage before surgery or angiography. Active bleeding sites are identified by focal areas\\nof tracer that conform to bowel anatomy, increase with time, and move with peristalsis. Bleeding scans\\nare useful mainly for colonic bleeding in patients with significant hemorrhage and an unprepared bowel, in\\nwhom endoscopic visualization is difficult.\\nA \\nMeckel scan\\n identifies ectopic gastric mucosa (as in a Meckel's diverticulum) by using an injection of\\n99m\\nTc pertechnetate, which is taken up by mucus-secreting cells of the gastric mucosa. Focal uptake\\noutside of the stomach and in the small bowel indicates a Meckel's diverticulum.\\nX-Ray and Other Imaging Contrast Studies\\nX-ray and other imaging contrast studies visualize the entire GI tract from pharynx to rectum and are most\\nuseful for detecting mass lesions and structural abnormalities (eg, tumors, strictures). Single-contrast\\nstudies fill the lumen with radiopaque material, outlining the structure. Better, more detailed images are\\nobtained from double-contrast studies, in which a small amount of high-density barium coats the mucosal\\nsurface and gas distends the organ and enhances contrast. The gas is injected by the operator in double-\\ncontrast barium enema, whereas in other studies, intrinsic GI tract gas is adequate. In all cases, patients\\nturn themselves to properly distribute the gas and barium. Fluoroscopy can monitor the progress of the\\ncontrast material. Either video or plain films can be taken for documentation, but video is particularly\\nuseful when assessing motor disorders (eg, cricopharyngeal spasm, achalasia).\\nThe main contraindication to x-ray contrast studies is suspected perforation, because free barium is\\nhighly irritating to the mediastinum and peritoneum; water-soluble contrast is less irritating and may be\\nused if perforation is possible. Older patients may have difficulty turning themselves to properly distribute\\nthe barium and intraluminal gas.\\nPatients having upper GI x-ray contrast studies must have nothing by mouth (npo) after midnight. Patients\\nhaving barium enema follow a clear liquid diet the day before, take an oral Na phosphate laxative in the\\nafternoon, and take a bisacodyl suppository in the evening. Other laxative regimens are effective.\\nComplications are rare. Perforation can occur if barium enema is done in a patient with toxic megacolon.\\nBarium impaction may be prevented by postprocedure oral fluids and sometimes laxatives.\\nAn \\nupper GI examination\\n is best done as a biphasic study beginning with a double-contrast examination\\nof the esophagus, stomach, and duodenum, followed by a single-contrast study using low-density barium.\\nGlucagon 0.5 mg IV can facilitate the examination by causing gastric hypotonia.\\nA \\nsmall-bowel meal\\n is done by using fluoroscopy and provides a more detailed evaluation of the small\\nbowel. Shortly before the examination, the patient is given metoclopramide 20 mg po to hasten transit of\\nthe contrast material.\\nEnteroclysis\\n (small-bowel enema) provides still better visualization of the small bowel but requires\\nintubation of the duodenum \\nwith a flexible, balloon-tipped catheter. A barium suspension is injected,\\nfollowed by a solution of methylcellulose, which functions as a double-contrast agent that enhances\\nvisualization of the small-bowel mucosa.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 9. Diagnostic & Therapeutic GI Procedures\\n146\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 156, 'page_label': '147'}, page_content=\"A \\nbarium enema\\n can be done as a single-or double-contrast study. Single-contrast barium enemas are\\nused for potential obstruction, diverticulitis, fistulas, and megacolon. Double-contrast studies are\\npreferred for detection of tumors.\\nCT scanning of the abdomen:\\n CT scanning using oral and IV contrast allows excellent visualization of\\nboth the small bowel and colon as well as of other intra-abdominal structures.\\nCT enterography\\n provides optimal visualization of the small-bowel mucosa; it is preferably done by\\nusing a multidetector CT (MDCT) scanner. Patients are given a large volume (1350 mL) of 0.1% barium\\nsulfate before imaging. For certain indications (eg, obscure GI bleeding, small-bowel tumors, chronic\\nischemia), a biphasic contrast-enhanced MDCT study is done.\\nCT colonography\\n (virtual colonoscopy) generates 3D and 2D images of the colon by using MDCT and a\\ncombination of oral contrast and gas distention of the colon. Viewing the high-resolution 3D images\\nsomewhat simulates the appearance of optical endoscopy, hence the name. Optimal CT colonography\\ntechnique requires careful cleansing and distention of the colon. Residual stool causes problems similar\\nto those encountered with barium enema because it simulates polyps or masses. Three-dimensional\\nendoluminal images are useful to confirm the presence of a lesion and to improve diagnostic confidence.\\nCT enterography and CT colonoscopy have largely supplanted standard small-bowel series and barium\\nenema examinations.\\nGI Procedures for the Generalist\\nNasogastric or Intestinal Intubation\\nNasogastric or intestinal intubation is used to decompress the stomach. It is used to treat gastric atony,\\nileus, or obstruction; remove ingested toxins, give antidotes (eg, activated charcoal), or both; obtain a\\nsample of gastric contents for analysis (volume, acid content, blood); and supply nutrients.\\nContraindications\\n include\\n Nasopharyngeal or esophageal obstruction\\n Severe maxillofacial trauma\\n Uncorrected coagulation abnormalities\\nEsophageal varices previously have been considered a contraindication, but evidence of adverse effects\\nis lacking.\\nSeveral types of tubes are available. A Levin or Salem sump tube is used for gastric decompression or\\nanalysis and rarely for short-term feeding. A variety of long, thin, intestinal tubes are used for long-term\\nenteral feeding (see p. \\n21\\n).\\nFor intubation, the patient sits upright or, if unable, lies in the left lateral decubitus position. A topical\\nanesthetic sprayed in the nose and pharynx helps reduce discomfort. With the patient's head partially\\nflexed, the lubricated tube is inserted through the nares and aimed back and then down to conform to the\\nnasopharynx. As the tip reaches the posterior pharyngeal wall, the patient should sip water through a\\nstraw. Violent coughing with flow of air through the tube during respiration indicates that the tube is\\nmisplaced in the trachea. Aspiration of gastric juice verifies entry into the stomach. The position of larger\\ntubes can be confirmed by instilling 20 to 30 mL of air and listening with the stethoscope under the left\\nsubcostal region for a rush of air.\\nSome smaller, more flexible intestinal feeding tubes require the use of stiffening wires or stylets. These\\ntubes usually require fluoroscopic or endoscopic assistance for passage through the pylorus.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 9. Diagnostic & Therapeutic GI Procedures\\n147\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 157, 'page_label': '148'}, page_content='Complications are rare and include nasopharyngeal trauma with or without hemorrhage, pulmonary\\naspiration, traumatic esophageal or gastric hemorrhage or perforation, and (very rarely) intracranial or\\nmediastinal penetration.\\nAnoscopy and Sigmoidoscopy\\nAnoscopy and sigmoidoscopy are used to evaluate symptoms referable to the rectum or anus (eg, bright\\nrectal bleeding, discharge, protrusions, pain). There are no absolute contraindications. Patients with\\ncardiac arrhythmias or recent myocardial ischemia should have the procedure postponed until the\\ncomorbid conditions improve; otherwise, patients will need cardiac monitoring. Per changes in American\\nHeart Association guidelines, these procedures no longer require endocarditis prophylaxis.\\nThe perianal area and distal rectum can be examined with a 7-cm anoscope, and the rectum and sigmoid\\nwith either a rigid 25-cm or a flexible 60-cm instrument. Flexible sigmoidoscopy is much more comfortable\\nfor the patient and readily permits photography and biopsy of tissue. Considerable skill is required to pass\\na \\nrigid sigmoidoscope beyond the rectosigmoid junction (15 cm) without causing discomfort.\\nSigmoidoscopy is done after giving an enema to empty the rectum. IV drugs are usually not needed. The\\npatient is placed in the left lateral position. After external inspection and digital rectal examination, the\\nlubricated instrument is gently inserted 3 to 4 cm past the anal sphincter. At this point, the obturator of the\\nrigid sigmoidoscope is removed, and the instrument is inserted further under direct vision.\\nAnoscopy may be done without preparation. The anoscope is inserted its full length as described above\\nfor rigid sigmoidoscopy, usually with the patient in the left lateral position. Complications are exceedingly\\nrare when the procedure is done properly.\\nAbdominal Paracentesis\\nAbdominal paracentesis is used to obtain ascitic fluid for testing. It also can be used to remove tense\\nascites causing respiratory difficulties or pain or as a treatment for chronic ascites.\\nAbsolute contraindications\\n include\\n Severe, uncorrectable disorders of blood coagulation\\n Intestinal obstruction\\n An infected abdominal wall\\nPoor patient cooperation, surgical scarring over the puncture area, and severe portal hypertension with\\nabdominal collateral circulation are relative contraindications.\\nCBC, platelet count, and coagulation studies are done before the procedure. After emptying the bladder,\\nthe patient sits in bed with the head elevated 45 to 90. In patients with obvious and marked ascites, a\\npoint is located at the midline between the umbilicus and the pubic bone and is cleaned with an antiseptic\\nsolution and alcohol. In patients with moderate ascites, precise location of ascitic fluid by abdominal\\nultrasound is indicated. Under sterile technique, the area is anesthetized to the peritoneum with lidocaine\\n1%. For diagnostic paracentesis, an 18-gauge needle attached to a 50-mL syringe is inserted through the\\nperitoneum (generally a popping sensation is noted). Fluid is gently aspirated and sent for cell count,\\nprotein or amylase content, cytology, or culture as needed. For therapeutic (large-volume) paracentesis, a\\n14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid.\\nPostprocedure hypotension caused by fluid redistribution is rare as long as interstitial (leg) edema is\\npresent.\\nHemorrhage is the most common complication. Occasionally, with tense ascites, prolonged leakage of\\nascitic fluid occurs through the needle site.\\nOther Testing Procedures\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 9. Diagnostic & Therapeutic GI Procedures\\n148'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 158, 'page_label': '149'}, page_content='Electrogastrography\\n measures gastric electrical activity with adhesive cutaneous electrodes. This\\nprocedure is useful in patients with gastroparesis.\\nIn \\nelectrical impedance testing\\n, an electrical sensor is placed in the distal esophagus to assess\\nnonacid reflux, which is common among patients receiving gastric antisecretory drugs and among infants\\nwith reflux disease.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 9. Diagnostic & Therapeutic GI Procedures\\n149'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 159, 'page_label': '150'}, page_content='Chapter 10. GI Bleeding\\nIntroduction\\nGI bleeding can originate anywhere from the mouth to the anus and can be overt or occult. The\\nmanifestations depend on the location and rate of bleeding.\\nHematemesis is vomiting of red blood and indicates upper GI bleeding, usually from an arterial source or\\nvarix. Coffee-ground emesis is vomiting of dark brown, granular material that resembles coffee grounds. It\\nresults from upper GI bleeding that has slowed or stopped, with conversion of red Hb to brown hematin\\nby gastric acid.\\nHematochezia is the passage of gross blood from the rectum and usually indicates lower GI bleeding but\\nmay result from vigorous upper GI bleeding with rapid transit of blood through the intestines.\\nMelena is black, tarry stool and typically indicates upper GI bleeding, but bleeding from a source in the\\nsmall bowel or right colon may also be the cause. About 100 to 200 mL of blood in the upper GI tract is\\nrequired to cause \\nmelena, which may persist for several days after bleeding has ceased. Black stool that\\ndoes not contain occult blood may result from ingestion of iron, bismuth, or various foods and should not\\nbe mistaken for melena.\\nChronic occult bleeding can occur from anywhere in the GI tract and is detectable by chemical testing of a\\nstool specimen. Acute, severe bleeding also can occur from anywhere in the GI tract. Patients may\\npresent with signs of shock. Those with underlying ischemic heart disease may develop angina or MI\\nbecause of hypoperfusion.\\nGI bleeding may precipitate portal-systemic encephalopathy (see p. \\n220\\n) or hepatorenal syndrome\\n(kidney failure secondary to liver failuresee p. \\n223\\n).\\nEtiology\\nThere are many possible causes (see\\nTable 10-1\\n), which are divided into upper GI (above the ligament of Treitz), lower GI, and small bowel.\\nBleeding of any cause is more likely, and potentially more severe, in patients with chronic liver disease\\n(eg, caused by alcohol abuse or chronic hepatitis), in those with hereditary coagulation disorders, or in\\nthose taking certain drugs. Drugs associated with GI bleeding include anticoagulants (eg, heparin,\\nwarfarin), those affecting platelet function (eg, aspirin and certain other NSAIDs, clopidogrel, SSRIs), and\\nthose affecting mucosal defenses (eg, NSAIDs).\\nEvaluation\\nStabilization with airway management, IV fluids, or transfusions is essential before and during diagnostic\\nevaluation.\\nHistory: History of present illness\\n should attempt to ascertain quantity and frequency of blood\\npassage. However, quantity can be difficult to assess because even small amounts (5 to 10 mL) of blood\\nturn water in a toilet bowl an opaque red, and modest amounts of vomited blood appear huge to an\\nanxious patient. However, most can distinguish among blood streaks, a few teaspoons, and clots.\\nPatients with hematemesis should be asked whether blood was passed with initial vomiting or only after\\nan initial (or several) nonbloody emesis.\\nPatients with rectal bleeding should be asked whether pure blood was passed; whether it was mixed with\\nstool, pus, or mucus; or whether blood simply coated the stool. Those with bloody diarrhea should be\\nasked about travel or other possible exposure to GI pathogens.\\n[\\nTable 10-1.\\n Common Causes of GI Bleeding]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 10. GI Bleeding\\n150'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 160, 'page_label': '151'}, page_content=\"Review of symptoms\\n should include presence of abdominal discomfort, weight loss, easy bleeding or\\nbruising, previous colonoscopy results, and symptoms of anemia (eg, weakness, easy fatigability,\\ndizziness).\\nPast medical history\\n should inquire about previous GI bleeding (diagnosed or undiagnosed); known\\ninflammatory bowel disease, bleeding diatheses, and liver disease; and use of any drugs that increase\\nthe likelihood of bleeding or chronic liver disease (eg, alcohol).\\nPhysical examination:\\n General examination focuses on vital signs and other indicators of shock or\\nhypovolemia (eg, tachycardia, tachypnea, pallor, diaphoresis, oliguria, confusion) and anemia (eg, pallor,\\ndiaphoresis). Patients with lesser degrees of bleeding may simply have mild tachycardia (heart rate >\\n100). Orthostatic changes in pulse (a change of > 10 beats/min) or BP (a drop of  10 mm Hg) often\\ndevelop after acute loss of  2 units of blood. However, orthostatic measurements are unwise in patients\\nwith severe bleeding (possibly causing syncope) and generally lack sensitivity and \\nspecificity as a\\nmeasure of intravascular volume, especially in elderly patients.\\nExternal stigmata of bleeding disorders (eg, petechiae, ecchymoses) are sought, as are signs of chronic\\nliver disease (eg, spider angiomas, ascites, palmar erythema) and portal hypertension (eg, splenomegaly,\\ndilated abdominal wall veins).\\nA digital rectal examination is necessary to search for stool color, masses, and fissures. Anoscopy is done\\nto diagnose hemorrhoids. Chemical testing of a stool specimen for occult blood completes the\\nexamination if gross blood is not present.\\nRed flags:\\n Several findings suggest hypovolemia or hemorrhagic shock:\\n Syncope\\n Hypotension\\n Pallor\\n Diaphoresis\\n Tachycardia\\nInterpretation of findings:\\n The history and physical examination suggest a diagnosis in about 50% of\\npatients, but findings are rarely diagnostic and confirmatory testing is required.\\nEpigastric abdominal discomfort relieved by food or antacids suggests peptic ulcer disease. However,\\nmany patients with bleeding ulcers have no history of pain. Weight loss and anorexia, with or without a\\nchange in stool, suggest a GI cancer. A history of cirrhosis or chronic hepatitis suggests esophageal\\nvarices. Dysphagia suggests esophageal cancer or stricture. Vomiting and retching before the onset of\\nbleeding suggests a Mallory-Weiss tear of the esophagus, although about 50% of patients with Mallory-\\nWeiss tears do not have this history.\\nA history of bleeding (eg, purpura, ecchymosis, hematuria) may indicate a bleeding diathesis (eg,\\nhemophilia, hepatic failure). Bloody diarrhea, fever, and abdominal pain suggest ischemic colitis,\\ninflammatory bowel disease (eg, ulcerative colitis, Crohn's disease), or an infectious colitis (eg, \\nShigella\\n,\\nSalmonella\\n, \\nCampylobacter\\n, amebiasis). Hematochezia suggests diverticulosis or angiodysplasia. Fresh\\nblood only on toilet paper or the surface of formed stools suggests internal hemorrhoids or fissures,\\nwhereas blood mixed with the stool indicates a more proximal source. Occult blood in the stool may be the\\nfirst sign of colon cancer or a polyp, particularly in patients > 45 yr.\\nBlood in the nose or trickling down the pharynx suggests the nasopharynx as the source. Spider\\nangiomas, hepatosplenomegaly, or ascites is consistent with chronic liver disease and hence possible\\nesophageal varices. Arteriovenous malformations, especially of the mucous membranes, suggest\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 10. GI Bleeding\\n151\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 161, 'page_label': '152'}, page_content='hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Cutaneous nail bed and GI\\ntelangiectasia may indicate systemic sclerosis or mixed connective tissue disease.\\nTesting:\\n Several tests are done to help confirm the suspected diagnosis.\\n CBC and often other laboratory studies\\n NGT for all but those with minimal rectal bleeding\\n Upper endoscopy for suspected upper GI bleeding\\n Colonoscopy for lower GI bleeding (unless clearly caused by hemorrhoids)\\nCBC should be obtained in patients with occult blood loss. Those with more significant bleeding also\\nrequire coagulation studies (eg, platelet count, PT, PTT) and liver function tests (eg, bilirubin, alkaline\\nphosphatase, albumin, AST, ALT). Type and crossmatch are done if bleeding is ongoing. Hb and Hct may\\nbe repeated up to every 6 h in patients with severe bleeding. Additionally, one or more diagnostic\\nprocedures are typically required.\\nNasogastric aspiration and lavage should be done in all patients with suspected upper GI bleeding (eg,\\nhematemesis, coffee-ground emesis, melena, massive rectal bleeding). Bloody nasogastric aspirate\\nindicates active upper GI bleeding, but about 10% of patients with upper GI bleeding have no blood in the\\nnasogastric aspirate. Coffee-ground material indicates bleeding that is slow or stopped. If there is no sign\\nof bleeding, and bile is returned, the NGT is removed; otherwise, it is left in place to monitor continuing or\\nrecurrent bleeding. Nonbloody, nonbilious return is considered a nondiagnostic aspirate.\\nUpper endoscopy (examination of the esophagus, stomach, and duodenum) should be done for upper GI\\nbleeding. Because endoscopy may be therapeutic as well as diagnostic, it should be done rapidly for\\nsignificant bleeding but may be deferred for 24 h if bleeding stops or is minimal. Upper GI barium x-rays\\nhave no role in acute bleeding, and the contrast used may obscure subsequent attempts at angiography.\\nAngiography is useful in the diagnosis of upper GI bleeding and permits certain therapeutic maneuvers\\n(eg, embolization, vasoconstrictor infusion).\\nFlexible sigmoidoscopy and anoscopy may be all that is required acutely for patients with symptoms\\ntypical of hemorrhoidal bleeding. All other patients with hematochezia should have colonoscopy, which\\ncan be \\ndone electively after routine preparation unless there is significant ongoing bleeding. In such\\npatients, a rapid prep (5 to 10 L of polyethylene glycol solution delivered via NGT or by mouth over 3 to 4\\nh) often allows adequate visualization. If colonoscopy cannot visualize the source and ongoing bleeding is\\nsufficiently rapid (> 0.5 to 1 mL/min), angiography may localize the source. Some angiographers first take\\na radionuclide scan to focus the examination, because angiography is less sensitive than the radionuclide\\nscan.\\nDiagnosis of occult bleeding can be difficult, because heme-positive stools may result from bleeding\\nanywhere in the GI tract. Endoscopy is the preferred method, with symptoms determining whether the\\nupper or lower GI tract is examined first. Double-contrast barium enema and sigmoidoscopy can be used\\nfor the lower tract when colonoscopy is unavailable or the patient refuses it. If the results of upper\\nendoscopy and colonoscopy are negative and occult blood persists in the stool, an upper GI series with\\nsmall-bowel follow-through, small-bowel endoscopy (enteroscopy), capsule endoscopy, technetium-\\nlabeled colloid or RBC scan, and angiography should be considered.\\nTreatment\\n Secure airway if needed\\n IV fluid resuscitation\\n Blood transfusion if needed\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 10. GI Bleeding\\n152'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 162, 'page_label': '153'}, page_content=' In some, angiographic or endoscopic hemostasis\\nHematemesis, hematochezia, or melena should be considered an emergency. Admission to an ICU, with\\nconsultation by both a gastroenterologist and a surgeon, is recommended for all patients with severe GI\\nbleeding. General treatment is directed at maintenance of the airway and restoration of circulating\\nvolume. Hemostasis and other treatment depend on the cause of the bleeding.\\nAirway:\\n A major cause of morbidity and mortality in patients with active upper GI bleeding is aspiration of\\nblood with subsequent respiratory compromise. To prevent these problems, endotracheal intubation\\nshould be considered in patients who have inadequate gag reflexes or are obtunded or unconscious\\nparticularly if they will be undergoing upper endoscopy.\\nFluid resuscitation:\\n IV fluids are initiated as for any patient with hypovolemia or hemorrhagic shock (see\\np. \\n2297\\n): healthy adults are given normal saline IV in 500- to 1000-mL aliquots until signs of hypovolemia\\nremitup to a maximum of 2 L (for children, 20 mL/kg, that may be repeated once). Patients requiring\\nfurther resuscitation should receive transfusion with packed RBCs. Transfusions continue until\\nintravascular volume is restored and then are given as needed to replace ongoing blood loss.\\nTransfusions in older patients or those with coronary artery disease may be stopped when Hct is stable at\\n30 unless the patient is symptomatic. Younger patients or those with chronic bleeding are usually not\\ntransfused unless Hct is < 23 or they have symptoms such as dyspnea or coronary ischemia.\\nPlatelet count should be monitored closely; platelet transfusion may be required with severe bleeding.\\nPatients who are taking antiplatelet drugs (eg, clopidogrel, aspirin) have platelet dysfunction, often\\nresulting in increased bleeding. Platelet transfusion should be considered when patients taking these\\ndrugs have severe ongoing bleeding, although a residual circulating drug (particularly clopidogrel) may\\ninactivate transfused platelets. Fresh frozen plasma should be transfused after every 4 units of packed\\nRBCs.\\nHemostasis:\\n GI bleeding stops spontaneously in about 80% of patients. The remaining patients require\\nsome type of intervention. Specific therapy depends on the bleeding site. Early intervention to control\\nbleeding is important to minimize mortality, particularly in elderly patients.\\nFor peptic ulcer, ongoing bleeding or rebleeding is treated with endoscopic coagulation (with bipolar\\nelectrocoagulation, injection sclerotherapy, heater probes, or laser). Non-bleeding vessels that are visible\\nwithin an ulcer crater are also treated. If endoscopy does not stop the bleeding, surgery is required to\\noversew the bleeding site. If medical management does not control gastric acid secretion, surgeons do\\nacid-reduction surgery (see p. \\n136\\n) at the same time.\\nActive variceal bleeding can be treated with endoscopic banding, injection sclerotherapy, or a transjugular\\nintrahepatic portosystemic shunting (TIPS) procedure.\\nSevere, ongoing lower GI bleeding caused by diverticula or angiomas can sometimes be controlled\\ncolonoscopically by electrocautery, coagulation with a heater probe, or injection with dilute epinephrine.\\nPolyps can be removed by snare or cautery. If these methods are ineffective or unfeasible, angiography\\nwith embolization or vasopressin infusion may be successful. However, because collateral blood flow to\\nthe bowel is limited, angiographic techniques have a significant risk of bowel ischemia or infarction unless\\nsuper-selective catheterization techniques are used. \\nIn most series, the rate of ischemic complications is\\n< 5%. Vasopressin infusion has about an 80% success rate for stopping bleeding, but bleeding recurs in\\nabout 50% of patients. Also, there is a risk of hypertension and coronary ischemia. Furthermore,\\nangiography can be used to localize the source of bleeding more accurately. Surgery may be used in\\npatients with continued bleeding (requiring > 4 units transfusion/24 h), but localization of the bleeding site\\nis very important. Blind hemicolectomy (with no preoperative identification of the bleeding site) carries a\\nmuch higher mortality risk than does directed segmental resection. However, assessment must be\\nexpeditious so that surgery is not unnecessarily delayed.\\nAcute or chronic bleeding of internal hemorrhoids stops spontaneously in most cases. Patients with\\nrefractory bleeding are treated via anoscopy with rubber band ligation, injection, coagulation, or surgery.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 10. GI Bleeding\\n153'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 163, 'page_label': '154'}, page_content='Geriatrics Essentials\\nIn the elderly, hemorrhoids and colorectal cancer are the most common causes of minor bleeding. Peptic\\nulcer, diverticular disease, and angiodysplasia are the most common causes of major bleeding. Variceal\\nbleeding is less common than in younger patients.\\nMassive GI bleeding is tolerated poorly by elderly patients. Diagnosis must be made quickly, and\\ntreatment must be started sooner than in younger patients, who can better tolerate repeated episodes of\\nbleeding.\\nKey Points\\n Rectal bleeding may result from upper or lower GI bleeding.\\n Orthostatic changes in vital signs are unreliable markers for serious bleeding.\\n About 80% of patients stop bleeding spontaneously; various endoscopic techniques are usually the first\\nchoice for the remainder.\\nVarices\\nVarices are dilated veins in the distal esophagus or proximal stomach caused by elevated\\npressure in the portal venous system, typically from cirrhosis. They may bleed massively but\\ncause no other symptoms. Diagnosis is by upper endoscopy. Treatment is primarily with\\nendoscopic banding and IV octreotide. Sometimes a transjugular intrahepatic portosystemic\\nshunting procedure is needed.\\nPortal hypertension (see p. \\n218\\n) results from a number of conditions, predominantly liver cirrhosis. If\\nportal pressure remains higher than inferior vena caval pressure for a significant period, venous\\ncollaterals develop. The most dangerous collaterals occur in the distal esophagus and gastric fundus,\\ncausing engorged, serpentine submucosal vessels known as varices. These varices partially decompress\\nportal hypertension but can rupture, causing massive GI bleeding. The trigger for variceal rupture is\\nunknown, but bleeding almost never occurs unless the portal/systemic pressure gradient is > 12 mm Hg.\\nCoagulopathies caused by liver disease may facilitate bleeding. NGT passage in a patient with varices\\nhas not been shown to trigger bleeding.\\nSymptoms and Signs\\nPatients typically present with sudden, painless, upper GI bleeding, often massive. Signs of shock may be\\npresent. Bleeding is usually from the distal esophagus, less often from the gastric fundus. Bleeding from\\ngastric varices also may be acute but is more often subacute or chronic.\\nBleeding into the GI tract may precipitate portal-systemic encephalopathy in patients with impaired\\nhepatic function.\\nDiagnosis\\n Endoscopy\\n Evaluation for coagulopathy\\nBoth esophageal and gastric varices are best diagnosed by endoscopy, which may also identify varices at\\nhigh risk of bleeding (eg, those with red markings). Endoscopy is also critical to exclude other causes of\\nacute bleeding (eg, peptic ulcer), even in patients known to have varices; perhaps as many as one third\\nof patients with known varices who have upper GI bleeding have a nonvariceal source.\\nBecause varices are typically associated with significant hepatic disease, evaluation for possible\\ncoagulopathy is important. Laboratory tests include CBC with platelets, PT, PTT, and liver function tests.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 10. GI Bleeding\\n154'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 164, 'page_label': '155'}, page_content='Bleeding patients should have type and crossmatch for 6 units of packed RBCs.\\nPrognosis\\nIn about 80% of patients, variceal bleeding stops spontaneously. Nevertheless, mortality is high, often >\\n50%. Mortality depends primarily on severity of the associated liver disease rather than on the bleeding\\nitself. Bleeding is often fatal in patients with severe hepatocellular impairment (eg, advanced cirrhosis),\\nwhereas patients with good hepatic reserve usually recover.\\nSurviving patients are at high risk of further variceal bleeding; typically, 50 to 75% have recurrence within\\n1 to 2 yr. Ongoing endoscopic or drug therapy significantly lowers this risk, but the overall effect on long-\\nterm mortality seems to be marginal, probably because of the underlying hepatic disease.\\nTreatment\\n Fluid resuscitation\\n Endoscopic banding (sclerotherapy second choice)\\n IV octreotide\\n Possibly a transjugular intrahepatic portosystemic shunting (TIPS) procedure\\nManagement of hypovolemia and hemorrhagic shock is as described above and in \\nCh. 226\\n. Patients with\\ncoagulation abnormalities (eg, elevated INR) should be given 1 to 2 units of fresh frozen plasma and 2.5\\nto 10 mg vitamin K IM (or IV if severe).\\nBecause varices are invariably diagnosed during endoscopy, primary treatment is endoscopic.\\nEndoscopic banding of varices is preferred over injection sclerotherapy. At the same time, IV octreotide (a\\nsynthetic analog of somatostatin, which may also be used) should be given. Octreotide increases\\nsplanchnic vascular resistance by inhibiting the release of splanchnic vasodilator hormones (eg,\\nglucagon, vasoactive intestinal peptide). The usual dose is a 50 \\n\\ng IV bolus, followed by infusion of 50\\n\\ng/h. Octreotide is preferred over previously used agents such as vasopressin and terlipressin, because\\nit has fewer adverse effects.\\nIf bleeding continues or recurs despite these measures, emergency techniques to shunt blood from the\\nportal system to the vena cava can lower portal pressure and diminish bleeding. A TIPS procedure is the\\nemergency intervention of choice. TIPS is an invasive radiologic procedure in which a guidewire is\\npassed from the vena cava through the liver parenchyma into the portal circulation. The resultant\\npassage is dilated by a balloon catheter, and a metallic stent is inserted, creating a bypass between the\\nportal and hepatic venous circulations. Stent size is crucial. If the stent is too large, portal-systemic\\nencephalopathy results because of diversion of too much portal blood flow from the liver. If the stent is\\ntoo small, it is more likely to occlude. Surgical portacaval shunts, such as the distal spleno-renal shunt,\\nwork by a similar mechanism but are more invasive and have a higher immediate mortality.\\nMechanical compression of bleeding varices with a Sengstaken-Blakemore tube or one of its variants\\ncauses considerable morbidity and should not be used as primary management. However, such a tube\\nmay provide life-saving tamponade pending decompression with a TIPS or surgical procedure. The tube\\nis a flexible NGT with one gastric balloon and one esophageal balloon. After insertion, the gastric balloon\\nis inflated with a fixed volume of air, and traction is applied to the tube to pull the balloon snugly against\\nthe gastroesophageal junction. This balloon is often sufficient to control bleeding, but if not, the\\nesophageal balloon is inflated to a pressure of 25 mm Hg. The procedure is quite uncomfortable and may\\nresult in esophageal perforation and aspiration; thus, endotracheal intubation and IV sedation are often\\nrecommended.\\nLiver transplantation can also decompress the portal system but is a practical option only for patients\\nalready on a transplant list.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 10. GI Bleeding\\n155'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 165, 'page_label': '156'}, page_content=\"Long-term medical therapy of portal hypertension (with \\n\\n-blockers and nitrates) is discussed elsewhere\\n(see p.\\n219\\n). Treatment of portal-systemic encephalopathy may be needed (see p. \\n220\\n).\\nVascular GI Lesions\\nSeveral distinct congenital or acquired syndromes involve abnormal mucosal or submucosal\\nblood vessels in the GI tract. These vessels may cause recurrent bleeding, which is rarely\\nmassive. Diagnosis is by endoscopy and sometimes angiography. Treatment is endoscopic\\nhemostasis; occasionally, angiographic embolization or surgical resection may be needed.\\nVascular ectasias\\n (angiodysplasias, arteriovenous malformations) are dilated, tortuous vessels that\\ntypically develop in the cecum and ascending colon. They occur mainly in people > 60 and are the most\\ncommon cause of lower GI bleeding in that age group. They are thought to be degenerative and do not\\noccur in association with other vascular abnormalities. Most patients have 2 or 3 lesions, which are\\ntypically 0.5 to 1.0 cm, bright red, flat or slightly raised, and covered by very thin epithelium. Vascular\\nectasias also occur in association with a number of systemic diseases (eg, renal failure, cirrhosis, CREST\\nsyndrome [calcinosis cutis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly,\\ntelangiectasias]see p. \\n310\\n) and after radiation to the bowel.\\nGastric antral vascular ectasia\\n (watermelon stomach) consists of large dilated veins running linearly\\nalong the stomach, creating a striped appearance suggestive of a watermelon. \\nThe condition occurs\\nmainly in older women and is of unknown etiology.\\nHereditary hemorrhagic telangiectasia\\n (Rendu-Osler-Weber syndromesee also p. \\n982\\n) is an\\nautosomal dominant disorder that causes multiple vascular lesions in various parts of the body, including\\nthe entire GI tract. GI bleeding rarely occurs before age 40.\\nDieulafoy's lesion\\n is an abnormally large artery that penetrates the gut wall, occasionally eroding\\nthrough the mucosa and causing massive bleeding. It occurs mainly in the proximal stomach.\\nArteriovenous malformations\\n and \\nhemangiomas\\n, both congenital disorders of blood vessels, can\\noccur in the GI tract but are rare.\\nSymptoms and Signs\\nVascular lesions are painless. Patients often present with heme-positive stools or modest amounts of\\nbright red blood from the rectum. Bleeding is often intermittent, sometimes with long periods between\\nepisodes. Patients with upper GI lesions may present with melena. Major bleeding is unusual.\\nDiagnosis\\n Endoscopy\\nVascular lesions are most commonly diagnosed endoscopically. If routine endoscopy is nondiagnostic,\\nsmall-bowel endoscopy, capsule endoscopy, intraoperative endoscopy, or visceral angiography may be\\nrequired. \\n99m\\nTc-labeled RBC scans are less specific but may help localize the lesion enough to facilitate\\nendoscopy or angiography.\\nTreatment\\n Endoscopic coagulation\\nEndoscopic coagulation (with heater probe, laser, argon plasma, or bipolar electrocoagulation) is effective\\nfor many vascular lesions. Vascular ectasias often recur, although there is some evidence that oral\\nestrogen-progesterone combinations may limit recurrence.\\nMild recurrent bleeding can be treated simply with chronic iron therapy. More significant bleeding that is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 10. GI Bleeding\\n156\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 166, 'page_label': '157'}, page_content='unresponsive to endoscopic measures may require angiographic embolization or surgical resection.\\nHowever, rebleeding occurs in about 15 to 25% of surgically treated patients.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 10. GI Bleeding\\n157'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 167, 'page_label': '158'}, page_content=\"Chapter 11. Acute Abdomen and Surgical Gastroenterology\\nIntroduction\\nAcute abdomen refers to abdominal symptoms and signs of such severity or concern that disorders\\nrequiring surgery should be considered. The primary symptom is acute abdominal pain. Chronic\\nabdominal pain is discussed in \\nCh. 7\\n.\\nAcute Abdominal Pain\\nAbdominal pain is common and often inconsequential. Acute and severe abdominal pain, however, is\\nalmost always a symptom of intra-abdominal disease. It may be the sole indicator of the need for surgery\\nand must be attended to swiftly: Gangrene and perforation of the gut can occur < 6 h from onset of\\nsymptoms in certain conditions (eg, interruption of the intestinal blood supply caused by a strangulating\\nobstruction or an arterial embolus). Abdominal pain is of particular concern in patients who are very young\\nor very old and those who have HIV infection or are taking immunosuppressants.\\nTextbook descriptions of abdominal pain have limitations because people react to pain differently. Some,\\nparticularly elderly people, are stoic, whereas others exaggerate their symptoms. Infants, young children,\\nand some elderly people may have difficulty localizing the pain.\\nPathophysiology\\nVisceral pain\\n comes from the abdominal viscera, which are innervated by autonomic nerve fibers and\\nrespond mainly to the sensations of distention and muscular contractionnot to cutting, tearing, or local\\nirritation. Visceral pain is typically vague, dull, and nauseating. It is poorly localized and tends to be\\nreferred to areas corresponding to the embryonic origin of the affected structure. Foregut structures\\n(stomach, duodenum, liver, and pancreas) cause upper abdominal pain. Midgut structures (small bowel,\\nproximal colon, and appendix) \\ncause periumbilical pain. Hindgut structures (distal colon and GU tract)\\ncause lower abdominal pain.\\nSomatic pain\\n comes from the parietal peritoneum, which is innervated by somatic nerves, which respond\\nto irritation from infectious, chemical, or other inflammatory processes. Somatic pain is sharp and well\\nlocalized.\\nReferred pain\\n is pain perceived distant from its source and results from convergence of nerve fibers at\\nthe spinal cord. Common examples of referred pain are scapular pain due to biliary colic, groin pain due\\nto renal colic, and shoulder pain due to blood or infection irritating the diaphragm.\\nPeritonitis:\\n Peritonitis is inflammation of the peritoneal cavity. The most serious cause is perforation of\\nthe GI tract (see p. \\n111\\n), which causes immediate chemical inflammation followed shortly by infection from\\nintestinal organisms. Peritonitis can also result from any abdominal condition that causes marked\\ninflammation (eg, appendicitis, diverticulitis, strangulating intestinal obstruction, pancreatitis, pelvic\\ninflammatory disease, mesenteric ischemia). Intraperitoneal blood from any source (eg, ruptured\\naneurysm, trauma, surgery, ectopic pregnancy) is irritating and results in peritonitis. Barium causes\\nsevere peritonitis and should never be given to a patient with suspected GI tract perforation. Peritoneo-\\nsystemic shunts, drains, and dialysis catheters in the peritoneal cavity predispose a patient to infectious\\nperitonitis, as does ascitic fluid. Rarely, spontaneous bacterial peritonitis occurs, in which the peritoneal\\ncavity is infected by blood-borne bacteria.\\nPeritonitis causes fluid shift into the peritoneal cavity and bowel, leading to severe dehydration and\\nelectrolyte disturbances. Adult respiratory distress syndrome can develop rapidly. Kidney failure, liver\\nfailure, and disseminated intravascular coagulation follow. The patient's face becomes drawn into the\\nmasklike appearance typical of hippocratic facies. Death occurs within days.\\nEtiology\\nMany intra-abdominal disorders cause abdominal pain (see\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n158\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 168, 'page_label': '159'}, page_content=\"Fig. 11-1\\n); some are trivial but some are immediately life threatening, requiring rapid diagnosis and\\nsurgery. These include ruptured abdominal aortic aneurysm (AAA), perforated viscus, mesenteric\\nischemia, and ruptured ectopic pregnancy. Others (eg, intestinal obstruction, appendicitis, severe acute\\npancreatitis) are also serious and nearly as urgent. Several extra-abdominal disorders also cause\\nabdominal pain (see\\nTable 11-1\\n).\\nAbdominal pain in neonates, infants, and young children has numerous causes not encountered in adults,\\nincluding meconium peritonitis, pyloric stenosis, esophageal webs, volvulus of a gut with a common\\nmesentery, imperforate anus, intussusception, and intestinal obstruction caused by atresia.\\nEvaluation\\nEvaluation of mild and severe pain follows the same process, although with severe abdominal pain,\\ntherapy sometimes proceeds simultaneously and involves early consultation with a surgeon. History and\\nphysical examination usually exclude all but a few possible causes, with final diagnosis confirmed by\\njudicious use of laboratory and imaging tests. Life-threatening causes should always be ruled out before\\nfocusing on less serious diagnoses. In seriously ill patients with severe abdominal pain, the most\\nimportant diagnostic measure may be expeditious surgical exploration. In mildly ill patients, watchful\\nwaiting may be best.\\nHistory:\\n A thorough history usually suggests the diagnosis (see\\nTable 11-2\\n). Of particular importance are pain location (see \\nFig. 11-1\\n) and characteristics, history of\\nsimilar symptoms, and associated symptoms. Concomitant symptoms such as gastroesophageal reflux,\\nnausea, vomiting, diarrhea, constipation, jaundice, melena, hematuria, hematemesis, weight loss, and\\nmucus or blood in the stool help direct subsequent evaluation. A drug history should include details\\nconcerning prescription and illicit drug use as well as alcohol. Many drugs cause GI upset. Prednisone or\\nimmunosuppressants may inhibit the inflammatory response to perforation or peritonitis and result in less\\npain and leukocytosis than might otherwise be expected. Anticoagulants can increase the chances of\\nbleeding and hematoma formation. Alcohol predisposes to pancreatitis.\\nKnown medical conditions and previous abdominal surgeries are important to ascertain. Women should\\nbe asked whether they are pregnant.\\nPhysical examination:\\n The general appearance is important. A happy, comfortable-appearing patient\\nrarely has a serious problem, unlike one who is anxious, pale, diaphoretic, or in obvious pain. BP, pulse,\\nstate of consciousness, and other signs of peripheral perfusion must be evaluated. However, the focus\\n[\\nFig. 11-1.\\n Location of abdominal pain and possible causes.]\\n[\\nTable 11-1.\\n Extra-Abdominal Causes of Abdominal Pain]\\nof the examination is the abdomen, beginning with inspection and auscultation, followed by palpation and\\npercussion. Rectal examination and pelvic examination (for women) to locate tenderness, masses, and\\nblood are essential.\\nPalpation begins gently, away from the area of greatest pain, detecting areas of particular tenderness, as\\nwell as the presence of guarding, rigidity, and rebound (all suggesting peritoneal irritation) and any\\nmasses. Guarding is an involuntary contraction of the abdominal muscles that is slightly slower and more\\nsustained than the rapid, voluntary flinch exhibited by sensitive or anxious patients. Rebound is a distinct\\nflinch upon brisk withdrawal of the examiner's hand. The inguinal area and all surgical scars should be\\npalpated for hernias.\\nRed flags:\\n Certain findings raise suspicion of a more serious etiology:\\n Severe pain\\n Signs of shock (eg, tachycardia, hypotension, diaphoresis, confusion)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n159\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 169, 'page_label': '160'}, page_content=\" Signs of peritonitis\\n Abdominal distention\\nInterpretation of findings:\\n Distention, especially when surgical scars, tympany to percussion, and high-\\npitched peristalsis or borborygmi in rushes are present, strongly suggests bowel obstruction. Severe pain\\nin a patient with a silent abdomen who is lying as still as possible suggests peritonitis; location of\\ntenderness suggests etiology (eg, right upper quadrant suggests cholecystitis, right lower quadrant\\nsuggests appendicitis) but may not be diagnostic. Back pain with shock suggests ruptured AAA,\\nparticularly if there is a tender, pulsatile mass. Shock and vaginal bleeding in a pregnant woman suggest\\nruptured ectopic pregnancy. Ecchymoses of the costovertebral angles (Grey Turner's sign) or around the\\numbilicus (Cullen's sign) suggest hemorrhagic pancreatitis but are not very sensitive for this disorder.\\nHistory is often suggestive (see \\nTable 11-2\\n). Mild to moderate pain in the presence of active peristalsis of\\nnormal pitch suggests a nonsurgical disease (eg, gastroenteritis) but may also be the early manifestations\\nof a more serious disorder. A patient who is writhing around trying to get comfortable is more likely to\\nhave an obstructive mechanism (eg, renal or biliary colic).\\nPrevious abdominal surgery makes obstruction from adhesions more likely. Generalized atherosclerosis\\nincreases the possibility of MI, AAA, and mesenteric ischemia. HIV infection makes infectious causes and\\ndrug adverse effects likely.\\nTesting:\\n Tests are selected based on clinical suspicion.\\n Urine pregnancy test for all women of childbearing age\\n Selected imaging tests based on suspected diagnosis\\nStandard tests (eg, CBC, chemistries, urinalysis) are often done but are of little value due to poor\\nspecificity; patients with significant disease may have normal results. Abnormal results do not provide a\\nspecific diagnosis (the urinalysis in particular may show pyuria or hematuria in a wide variety of\\nconditions), and they can also occur in the absence of significant disease. An exception is serum lipase,\\nwhich strongly suggests a diagnosis of acute pancreatitis. A bedside urine pregnancy test should be done\\nfor all women of childbearing age because a negative result effectively excludes ruptured ectopic\\npregnancy.\\nAn abdominal series, consisting of flat and upright abdominal x-rays and upright chest x-rays (left lateral\\nrecumbent abdomen and anteroposterior chest x-ray for patients unable to stand), should be done when\\nperforation or obstruction is suspected. However, these plain x-rays are seldom diagnostic for other\\nconditions and need not be automatically done. Ultrasound should be done for suspected biliary tract\\ndisease or ectopic pregnancy (transvaginal\\n[\\nTable 11-2.\\n History in Patients with Acute Abdominal Pain]\\nprobe). Ultrasound can also detect AAA but cannot reliably identify rupture. Noncontrast helical CT is the\\nmodality of choice for suspected renal stones. CT with oral contrast is diagnostic in about 95% of patients\\nwith significant abdominal pain and has markedly lowered the negative laparotomy rate. However,\\nadvanced imaging must not be allowed to delay surgery in patients with definitive symptoms and signs.\\nTreatment\\nSome clinicians feel that providing pain relief before a diagnosis is made interferes with their ability to\\nevaluate. However, moderate doses of IV analgesics (eg, fentanyl 50 to 100 \\n\\ng, morphine 4 to 6 mg) do\\nnot mask peritoneal signs and, by diminishing anxiety and discomfort, often make examination easier.\\nKey Points\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n160\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 170, 'page_label': '161'}, page_content=' Life-threatening causes should be looked for first.\\n Pregnancy should be ruled out in women of childbearing age.\\n Signs of peritonitis, shock, and obstruction should be sought.\\n Blood tests are of minimal value.\\nAcute Mesenteric Ischemia\\nAcute mesenteric ischemia is interruption of intestinal blood flow by embolism, thrombosis, or\\na low-flow state. It leads to mediator release, inflammation, and ultimately infarction. Abdominal\\npain is out of proportion to physical findings. Early diagnosis is difficult, but angiography and\\nexploratory laparotomy have the most sensitivity; other imaging modalities often become\\npositive only late in the disease. Treatment is by embolectomy, revascularization of viable\\nsegments, or resection; sometimes vasodilator therapy is successful. Mortality is high.\\nPathophysiology\\nThe intestinal mucosa has a high metabolic rate and, accordingly, a high blood flow requirement (normally\\nreceiving 20 to 25% of cardiac output), making it very sensitive to the effects of decreased perfusion.\\nIschemia disrupts the mucosal barrier, allowing release of bacteria, toxins, and vasoactive mediators,\\nwhich in turn leads to myocardial depression, systemic inflammatory response syndrome (see p. \\n2299\\n),\\nmultisystem organ failure, and death. Mediator release may occur even before complete infarction.\\nNecrosis can occur as soon as 10 to 12 h after the onset of symptoms.\\nThree major vessels serve the abdominal contents: the celiac trunk, the superior mesenteric artery\\n(SMA), and the inferior mesenteric artery (IMA). The celiac trunk supplies the esophagus, stomach,\\nproximal duodenum, liver, gallbladder, pancreas, and spleen. The SMA supplies the distal duodenum,\\njejunum, ileum, and colon to the splenic flexure. The IMA supplies the descending colon and sigmoid\\ncolon and the rectum. Collateral vessels are abundant in the stomach, duodenum, and rectum; these\\nareas rarely develop ischemia. The splenic flexure is a watershed between the SMA and IMA and is at\\nparticular risk of ischemia.\\nEtiology\\nMesenteric blood flow may be disrupted on either the venous or arterial sides. In general, patients > 50\\nare at greatest risk and have the types of occlusions and risk factors shown in\\nTable 11-3\\n. However, many patients have no identifiable risk factors.\\nSymptoms and Signs\\nThe early hallmark of mesenteric ischemia is severe pain but minimal physical findings. The abdomen\\nremains soft, with little or no tenderness. Mild tachycardia may be present. Later, as necrosis develops,\\nsigns of peritonitis appear, with marked abdominal tenderness, guarding, rigidity, and no bowel sounds.\\nThe stool may be heme-positive (increasingly likely as ischemia progresses). The usual signs of shock\\ndevelop and are frequently followed by death.\\nSudden onset of pain suggests but is not diagnostic of an arterial embolism, whereas a more gradual\\nonset is typical of venous thrombosis. Patients with a history of postprandial abdominal discomfort (which\\nsuggests intestinal angina) may have arterial thrombosis.\\n[\\nTable 11-3.\\n Causes of Acute Mesenteric Ischemia]\\nDiagnosis\\n Clinical diagnosis more important than diagnostic tests\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n161'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 171, 'page_label': '162'}, page_content=' Mesenteric angiography if diagnosis unclear\\nEarly diagnosis is particularly important because mortality increases significantly once intestinal infarction\\nhas occurred. Mesenteric ischemia must be considered in any patient > 50 with known risk factors or\\npredisposing conditions who develops sudden, severe abdominal pain.\\nPatients with clear peritoneal signs should proceed directly to the operating room for both diagnosis and\\ntreatment. For others, selective mesenteric angiography is the diagnostic procedure of choice. Other\\nimaging studies and serum markers can show abnormalities but lack sensitivity and specificity early in the\\ncourse of the disease when diagnosis is most critical. Plain abdominal x-rays are useful mainly in ruling\\nout other causes of pain (eg, perforated viscus), although portal venous gas or pneumatosis intestinalis\\nmay be seen late in the disease. These findings also appear on CT, which may also directly visualize\\nvascular occlusionmore accurately on the venous side. Doppler ultrasonography can sometimes\\nidentify arterial occlusion, but sensitivity is low. \\nMRI is very accurate in proximal vascular occlusion, less\\nso in distal vascular occlusion. Serum markers (eg, creatine kinase, lactate) rise with necrosis but are\\nnonspecific findings that are seen later. Intestinal fatty acid binding protein in the urine may prove\\nvaluable in the future as an early marker.\\nPrognosis\\nIf diagnosis and treatment take place before infarction occurs, mortality is low; after intestinal infarction,\\nmortality approaches 70 to 90%. For this reason, clinical diagnosis of mesenteric ischemia should\\nsupersede diagnostic tests, which may delay treatment.\\nTreatment\\n Surgical: Embolectomy, revascularization, or resection\\n Angiographic: Vasodilators or thrombolysis\\n Long-term anticoagulation or antiplatelet therapy\\nIf diagnosis is made during exploratory laparotomy, options are surgical embolectomy, revascularization,\\nand resection. A \"second look\" laparotomy may be needed to reassess the viability of questionable areas\\nof bowel. If diagnosis is made by angiography, infusion of the vasodilator papaverine through the\\nangiography catheter may improve survival in both occlusive and nonocclusive ischemia. A 60-mg bolus is\\ngiven over 2 min, followed by an infusion of 30 to 60 mg/h. Papaverine is useful even when surgical\\nintervention is planned and is sometimes given during and after surgical intervention as well. In addition,\\nfor arterial occlusion, thrombolysis or surgical embolectomy may be done. The development of peritoneal\\nsigns at any time during the evaluation suggests the need for immediate surgery. Mesenteric venous\\nthrombosis without signs of peritonitis can be treated with papaverine followed by anticoagulation with\\nheparin and then warfarin.\\nPatients with arterial embolism or venous thrombosis require long-term anticoagulation with warfarin.\\nPatients with nonocclusive ischemia may be treated with antiplatelet therapy.\\nAcute Perforation\\nAny part of the GI tract may become perforated, releasing gastric or intestinal contents into the\\nperitoneal space. Causes vary. Symptoms develop suddenly, with severe pain followed shortly\\nby signs of shock. Diagnosis is usually made by the presence of free air in the abdomen on\\nimaging studies. Treatment is with fluid resuscitation, antibiotics, and surgery. Mortality is high,\\nvarying with the underlying disorder and the patient\\'s general health.\\nEtiology\\nBoth blunt and penetrating trauma can result in perforation of any part of the GI tract (see\\nTable 11-4\\n). Swallowed foreign bodies, even sharp ones, rarely cause perforation unless they become\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n162'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 172, 'page_label': '163'}, page_content=\"impacted, causing ischemia and necrosis from local pressure. Foreign bodies inserted via the anus may\\nperforate the rectum.\\nSymptoms and Signs\\nEsophageal, gastric, and duodenal perforation tends to manifest suddenly and catastrophically, with\\nabrupt onset of acute abdomen with severe generalized abdominal pain, tenderness, and peritoneal\\nsigns. Pain may radiate to the shoulder.\\nPerforation at other GI sites often occurs in the setting of other painful, inflammatory conditions. Because\\nsuch perforations are often small initially and frequently walled off by the omentum, pain often develops\\ngradually and may be localized. Tenderness also is more focal. Such findings can make it difficult to\\ndistinguish perforation from worsening of the underlying disorder or lack of response to treatment.\\nIn all types of perforation, nausea, vomiting, and anorexia are common. Bowel sounds are quiet to absent.\\nDiagnosis\\n Abdominal series\\n If nondiagnostic, abdominal CT\\nAn abdominal series (supine and upright abdominal x-rays and chest x-rays) may be diagnostic, showing\\nfree air under the diaphragm in 50 to 75% of cases. As time passes, this sign becomes more common. A\\nlateral chest x-ray is more sensitive for free air than a posteroanterior x-ray. If the abdominal series is\\nnondiagnostic, abdominal CT usually with oral and IV and/or rectal contrast may be helpful. Barium\\nshould not be used if perforation is suspected.\\nTreatment\\n Surgery\\n IV fluids and antibiotics\\n[\\nTable 11-4.\\n Some Causes of GI Tract Perforation]\\nIf a perforation is noted, immediate surgery is necessary because mortality caused by peritonitis\\nincreases rapidly the longer treatment is delayed. If an abscess or an inflammatory mass has formed, the\\nprocedure may be limited to drainage of the abscess.\\nAn NGT is inserted before operation. Patients with signs of volume depletion should have urine output\\nmonitored with a catheter. Fluid status is maintained by adequate IV fluid and electrolyte replacement. IV\\nantibiotics effective against intestinal flora should be given (eg, cefotetan 1 to 2 g bid, or amikacin 5\\nmg/kg tid plus clindamycin 600 to 900 mg qid).\\nAppendicitis\\nAppendicitis is acute inflammation of the vermiform appendix, typically resulting in abdominal\\npain, anorexia, and abdominal tenderness. Diagnosis is clinical, often supplemented by CT or\\nultrasound. Treatment is surgical removal.\\nIn the US, acute appendicitis is the most common cause of acute abdominal pain requiring surgery. Over\\n5% of the population develops appendicitis at some point. It most commonly occurs in the teens and 20s\\nbut may occur at any age.\\nOther conditions affecting the appendix include carcinoids, cancer, villous adenomas, and diverticula. The\\nappendix may also be affected by Crohn's disease or ulcerative colitis with pancolitis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n163\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 173, 'page_label': '164'}, page_content=\"Etiology\\nAppendicitis is thought to result from obstruction of the appendiceal lumen, typically by lymphoid\\nhyperplasia, but occasionally by a fecalith, foreign body, or even worms. The obstruction leads to\\ndistention, bacterial overgrowth, ischemia, and inflammation. If untreated, necrosis, gangrene, and\\nperforation occur. If the perforation is contained by the omentum, an appendiceal abscess results.\\nSymptoms and Signs\\nThe classic symptoms of acute appendicitis are epigastric or periumbilical pain followed by brief nausea,\\nvomiting, and anorexia; after a few hours, the pain shifts to the right lower quadrant. Pain increases with\\ncough and motion. \\nClassic signs are right lower quadrant direct and rebound tenderness located at\\nMcBurney's point (junction of the middle and outer thirds of the line joining the umbilicus to the anterior\\nsuperior spine). Additional signs are pain felt in the right lower quadrant with palpation of the left lower\\nquadrant (Rovsing sign), an increase in pain from passive extension of the right hip joint that stretches\\nthe iliopsoas muscle (psoas sign), or pain caused by passive internal rotation of the flexed thigh\\n(obturator sign). Low-grade fever (rectal temperature 37.7 to 38.3 C [100 to 101 F]) is common.\\nUnfortunately, these classic findings appear in < 50% of patients. Many variations of symptoms and signs\\noccur. Pain may not be localized, particularly in infants and children. Tenderness may be diffuse or, in rare\\ninstances, absent. Bowel movements are usually less frequent or absent; if diarrhea is a sign, a\\nretrocecal appendix should be suspected. RBCs or WBCs may be present in the urine. Atypical symptoms\\nare common among elderly patients and pregnant women; in particular, pain is less severe and local\\ntenderness is less marked.\\nDiagnosis\\n Clinical evaluation\\n Abdominal CT if necessary\\n Ultrasound an option to CT\\nWhen classic symptoms and signs are present, the diagnosis is clinical. In such patients, delaying\\nlaparotomy to do imaging tests only increases the likelihood of perforation and subsequent complications.\\nIn patients with atypical or equivocal findings, imaging studies should be done without delay. Contrast-\\nenhanced CT has reasonable accuracy in diagnosing appendicitis and can also reveal other causes of\\nan acute abdomen. Graded compression ultrasound can usually be done quickly and uses no radiation\\n(of particular concern in children); however, it is occasionally limited by the presence of bowel gas and is\\nless useful for recognizing nonappendiceal causes of pain. Appendicitis remains primarily a clinical\\ndiagnosis. Selective and judicious use of radiographic studies may reduce the rate of negative\\nlaparotomy.\\nLaparoscopy can be used for diagnosis as well as definitive treatment; it may be especially helpful in\\nwomen with lower abdominal pain of unclear etiology. Laboratory studies typically show leukocytosis\\n(12,000 to 15,000/\\n\\nL), but this finding is highly variable; a normal WBC count should not be used to\\nexclude appendicitis.\\nPrognosis\\nWithout surgery or antibiotics, mortality is > 50%.\\nWith early surgery, the mortality rate is < 1%, and convalescence is normally rapid and complete. With\\ncomplications (rupture and development of an abscess or peritonitis), the prognosis is worse: Repeat\\noperations and a long convalescence may follow.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n164\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 174, 'page_label': '165'}, page_content=\" Surgical removal\\n IV fluids and antibiotics\\nTreatment of acute appendicitis is open or laparoscopic appendectomy; because treatment delay\\nincreases mortality, a negative appendectomy rate of 15% is considered acceptable. The surgeon can\\nusually remove the appendix even if perforated. Occasionally, the appendix is difficult to locate: In these\\ncases, it usually lies behind the cecum or the ileum and mesentery of the right colon. A contraindication to\\nappendectomy is inflammatory bowel disease involving the cecum. However, in cases of terminal ileitis\\nand a normal cecum, the appendix should be removed.\\nAppendectomy should be preceded by IV antibiotics. Third-generation cephalosporins are preferred. For\\nnonperforated appendicitis, no further antibiotics are required. If the appendix is perforated, antibiotics\\nshould be continued until the patient's temperature and WBC count have normalized or continued for a\\nfixed course, according to the surgeon's preference. If surgery is impossible, antibioticsalthough not\\ncurativemarkedly improve the survival rate. When a large inflammatory mass is found involving the\\nappendix, terminal ileum, and cecum, resection of the entire mass and ileocolostomy are preferable. In\\nlate cases in which a pericolic abscess has already formed, the abscess is drained either by an\\nultrasound-guided percutaneous catheter or by open operation (with appendectomy to follow at a later\\ndate). A Meckel's diverticulum in a patient under the age of 40 should be removed concomitantly with the\\nappendectomy unless extensive inflammation around the appendix prevents the procedure.\\nHernias of the Abdominal Wall\\nA hernia of the abdominal wall is a protrusion of the abdominal contents through an acquired or\\ncongenital area of weakness or defect in the wall. Many hernias are asymptomatic, but some\\nbecome incarcerated or strangulated, causing pain and requiring immediate surgery. Diagnosis\\nis clinical. Treatment is elective surgical repair.\\nAbdominal hernias are extremely common, particularly among males, necessitating about 700,000\\noperations each year in the US.\\nClassification\\nAbdominal hernias are classified as either abdominal wall or groin hernias. Strangulated hernias are\\nischemic from physical constriction of their blood supply. Gangrene, perforation, and peritonitis may\\ndevelop. Incarcerated and strangulated hernias cannot be reduced manually.\\nAbdominal wall hernias include umbilical hernias, epigastric hernias, Spigelian hernias, and incisional\\n(ventral) hernias. Umbilical hernias (protrusions through the umbilical ring) are mostly congenital, but\\nsome are acquired in adulthood secondary to obesity, ascites, pregnancy, or chronic peritoneal dialysis.\\nEpigastric hernias occur through the linea alba. Spigelian hernias occur through defects in the\\ntransversus abdominis muscle lateral to the rectus sheath, usually below the level of the umbilicus.\\nIncisional hernias occur through an incision from previous abdominal surgery.\\nGroin hernias include inguinal hernias and femoral hernias. Inguinal hernias occur above the inguinal\\nligament. Indirect inguinal hernias traverse the internal inguinal ring into the inguinal canal, and direct\\ninguinal hernias extend directly forward and do not pass through the inguinal canal. Femoral hernias\\noccur below the inguinal ligament and go into the femoral canal.\\nAbout 75% of all abdominal hernias are inguinal. Incisional hernias comprise another 10 to 15%. Femoral\\nand unusual hernias account for the remaining 10 to 15%.\\nSymptoms and Signs\\nMost patients complain only of a visible bulge, which may cause vague discomfort or be asymptomatic.\\nMost hernias, even large ones, can be manually reduced with persistent gentle pressure; placing the\\npatient in the Trendelenburg position may help. An incarcerated hernia cannot be reduced but has no\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n165\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 175, 'page_label': '166'}, page_content='additional symptoms. A strangulated hernia causes steady, gradually increasing pain, typically with\\nnausea and vomiting. The hernia itself is tender, and the overlying skin may be erythematous; peritonitis\\nmay develop depending on location, with diffuse tenderness, guarding, and rebound.\\nDiagnosis\\n Clinical evaluation\\nThe diagnosis is clinical. Because the hernia may be apparent only when abdominal pressure is\\nincreased, the patient should be examined in a standing position. If no hernia is palpable, the patient\\nshould cough or perform a Valsalva maneuver as the examiner palpates the abdominal wall. Examination\\nfocuses on the umbilicus, the inguinal area (with a finger in the inguinal canal in males), the femoral\\ntriangle, and any incisions that are present.\\nInguinal masses that resemble hernias may be the result of adenopathy (infectious or malignant), an\\nectopic testis, or lipoma. These masses are solid and are not reducible. A scrotal mass may be a\\nvaricocele, hydrocele, or testicular tumor. Ultrasound may be done if physical examination is equivocal.\\nPrognosis\\nCongenital umbilical hernias rarely strangulate and are not treated; most resolve spontaneously within\\nseveral years. Very large defects may be repaired electively after age 2 yr. Umbilical hernias in adults\\ncause cosmetic concerns and can be electively repaired; strangulation and incarceration are unusual but,\\nif happen, usually contain omentum rather than intestine.\\nTreatment\\n Surgical repair\\nGroin hernias should be repaired electively because of the risk of strangulation, which results in higher\\nmorbidity (and possible mortality in elderly patients). Repair may be through a standard incision or\\nlaparoscopically.\\nAn incarcerated or strangulated hernia of any kind requires urgent surgical repair.\\nIleus\\n(Paralytic Ileus; Adynamic Ileus; Paresis)\\nIleus is a temporary arrest of intestinal peristalsis. It occurs most commonly after abdominal\\nsurgery, particularly when the intestines have been manipulated. Symptoms are nausea,\\nvomiting, and vague abdominal discomfort. Diagnosis is based on x-ray findings and clinical\\nimpression. Treatment is supportive, with nasogastric suction and IV fluids.\\nEtiology\\nIn addition to postoperative causes, ileus also results from intraperitoneal or retroperitoneal inflammation\\n(eg, appendicitis, diverticulitis, perforated duodenal ulcer), retroperitoneal or intra-abdominal hematomas\\n(eg, ruptured abdominal aortic aneurysm, lumbar compression fracture), metabolic disturbances (eg,\\nhypokalemia), or drugs (eg, opioids, anticholinergics, sometimes Ca channel blockers). Ileus sometimes\\noccurs in association with renal or thoracic disease (eg, lower rib fractures, lower lobe pneumonias, MI).\\nGastric and colonic motility disturbances after abdominal surgery are common. The small bowel is\\ntypically least affected, with motility and absorption returning to normal within hours after surgery.\\nStomach emptying is usually impaired for about 24 h or more. The colon is often most affected and may\\nremain inactive for 48 to 72 h or more.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n166'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 176, 'page_label': '167'}, page_content=\"Symptoms and signs include abdominal distention, vomiting, and vague discomfort. Pain rarely has the\\nclassic colicky pattern present in mechanical obstruction. There may be obstipation or passage of slight\\namounts of watery stool. Auscultation reveals a silent abdomen or minimal peristalsis. The abdomen is\\nnot tender unless the underlying cause is inflammatory.\\nDiagnosis\\n Clinical evaluation\\n Sometimes x-rays\\nThe most essential task is to distinguish ileus from intestinal obstruction. In both conditions, x-rays show\\ngaseous distention of isolated segments of intestine. In postoperative ileus, however, gas may\\naccumulate more in the colon than in the small bowel. Postoperative accumulation of gas in the small\\nbowel often implies development of a complication (eg, obstruction, peritonitis). In other types of ileus, x-\\nray findings are similar to obstruction; differentiation can be difficult unless clinical features clearly favor\\none or the other. Water-soluble contrast studies may help differentiate.\\nTreatment\\n NGT\\n IV fluids\\nTreatment involves continuous nasogastric suction, npo status, IV fluids and electrolytes, a minimal\\namount of sedatives, and avoidance of opioids and anticholinergic drugs. Maintaining an adequate serum\\nK level (> 4 mEq/L [> 4 mmol/L]) is especially important. Ileus persisting > 1 wk probably has a\\nmechanical obstructive cause, and laparotomy should be considered. Sometimes colonic ileus can be\\nrelieved by colonoscopic decompression; rarely, cecostomy is required. Colonoscopic decompression is\\nhelpful in treating pseudo-obstruction (Ogilvie's syndrome), which consists of apparent obstruction at the\\nsplenic flexure, although no cause can be found by contrast enema or colonoscopy for the failure of gas\\nand feces to pass this point. Some clinicians use IV neostigmine (requires cardiac monitoring) to treat\\nOgilvie's syndrome.\\nIntestinal Obstruction\\nIntestinal obstruction is significant mechanical impairment or complete arrest of the passage of\\ncontents through the intestine. Symptoms include cramping pain, vomiting, obstipation, and\\nlack of flatus. Diagnosis is clinical, confirmed by abdominal x-rays. Treatment is fluid\\nresuscitation, nasogastric suction, and, in most cases of complete obstruction, surgery.\\nMechanical obstruction is divided into obstruction of the small bowel (including the duodenum) and\\nobstruction of the large bowel. Obstruction may be partial or complete. About 85% of partial small-bowel\\nobstructions resolve with nonoperative treatment, whereas about 85% of complete small-bowel\\nobstructions require operation.\\nEtiology\\nOverall, the most common causes of mechanical obstruction are adhesions, hernias, and tumors. Other\\ngeneral causes are diverticulitis, foreign bodies (including gallstones), volvulus (twisting of bowel on its\\nmesentery), intussusception (telescoping of one segment of bowel into anothersee p. \\n2801\\n), and fecal\\nimpaction. Specific segments of the intestine are affected differently (see\\nTable 11-5\\n).\\nPathophysiology\\nIn simple mechanical obstruction, blockage occurs without vascular compromise. Ingested fluid and food,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n167\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 177, 'page_label': '168'}, page_content='digestive secretions, and gas accumulate above the obstruction. The proximal bowel distends, and the\\ndistal segment collapses. The normal secretory and absorptive functions of the mucosa are depressed,\\nand the bowel wall becomes edematous and congested. Severe intestinal distention is self-perpetuating\\nand progressive, intensifying\\n[\\nTable 11-5.\\n Causes of Intestinal Obstruction]\\nthe peristaltic and secretory derangements and increasing the risks of dehydration and progression to\\nstrangulating obstruction.\\nStrangulating obstruction is obstruction with compromised blood flow; it occurs in nearly 25% of patients\\nwith small-bowel obstruction. It is usually associated with hernia, volvulus, and intussusception.\\nStrangulating obstruction can progress to infarction and gangrene in as little as 6 h. Venous obstruction\\noccurs first, followed by arterial occlusion, resulting in rapid ischemia of the bowel wall. The ischemic\\nbowel becomes edematous and infarcts, leading to gangrene and perforation. In large-bowel obstruction,\\nstrangulation is rare (except with volvulus).\\nPerforation may occur in an ischemic segment (typically small bowel) or when marked dilation occurs.\\nThe risk is high if the cecum is dilated to a diameter  13 cm. Perforation of a tumor or a diverticulum may\\nalso occur at the obstruction site.\\nSymptoms and Signs\\nObstruction of the small bowel\\n causes symptoms shortly after onset: abdominal cramps centered\\naround the umbilicus or in the epigastrium, vomiting, andin patients with complete obstruction\\nobstipation. Patients with partial obstruction may develop diarrhea. Severe, steady pain suggests that\\nstrangulation has occurred. In the absence of strangulation, the abdomen is not tender. Hyperactive,\\nhigh-pitched peristalsis with rushes coinciding with cramps is typical. Sometimes, dilated loops of bowel\\nare palpable. With infarction, the abdomen becomes tender and auscultation reveals a silent abdomen or\\nminimal peristalsis. Shock and oliguria are serious signs that indicate either late simple obstruction or\\nstrangulation.\\nObstruction of the large bowel\\n usually causes milder symptoms that develop more gradually than\\nthose caused by small-bowel obstruction. Increasing constipation leads to obstipation and abdominal\\ndistention. Vomiting may occur (usually several hours after onset of other symptoms) but is not common.\\nLower abdominal cramps unproductive of feces occur. Physical examination typically shows a distended\\nabdomen with loud borborygmi. There is no tenderness, and the rectum is usually empty. A mass\\ncorresponding to the site of an obstructing tumor may be palpable. Systemic symptoms are relatively mild,\\nand fluid and electrolyte deficits are uncommon.\\nVolvulus\\n often has an abrupt onset. Pain is continuous, sometimes with superimposed waves of colicky\\npain.\\nDiagnosis\\n Abdominal series\\nSupine and upright abdominal x-rays should be taken and are usually adequate to diagnose obstruction.\\nAlthough only laparotomy can definitively diagnose strangulation, careful serial clinical examination may\\nprovide early warning. Elevated WBCs and acidosis may indicate that strangulation has already occurred.\\nOn plain x-rays, a ladderlike series of distended small-bowel loops is typical of small-bowel obstruction\\nbut may also occur with obstruction of the right colon. Fluid levels in the bowel can be seen in upright\\nviews. Similar, although perhaps less dramatic, x-ray findings and symptoms occur in ileus (paralysis of\\nthe intestine without obstructionsee p. \\n114\\n); differentiation can be difficult. Distended loops and fluid\\nlevels may be absent with an obstruction of the upper jejunum or with closed-loop strangulating\\nobstructions (as may occur with volvulus). Infarcted bowel may produce a mass effect on x-ray. Gas in the\\nbowel wall (pneumatosis intestinalis) indicates gangrene.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n168'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 178, 'page_label': '169'}, page_content='In large-bowel obstruction, abdominal x-ray shows distention of the colon proximal to the obstruction. In\\ncecal volvulus, there may be a large gas bubble in the mid-abdomen or left upper quadrant. With both\\ncecal and sigmoidal volvulus, a contrast enema shows the site of obstruction by a typical \"bird-beak\"\\ndeformity at the site of the twist; the procedure may actually reduce a sigmoid volvulus. If contrast enema\\nis not done, colonoscopy can be used to decompress a sigmoid volvulus but rarely works with a cecal\\nvolvulus.\\nTreatment\\n Nasogastric suction\\n IV fluids\\n IV antibiotics if bowel ischemia suspected\\nPatients with possible intestinal obstruction should be hospitalized. Treatment of acute intestinal\\nobstruction must proceed simultaneously with diagnosis. A surgeon should always be involved.\\nSupportive care is similar for small- and large-bowel obstruction: nasogastric suction, IV fluids (0.9%\\nsaline or lactated Ringer\\'s solution for intravascular volume repletion), and a urinary catheter to monitor\\nfluid output. Electrolyte replacement should be guided by test results, although in cases of repeated\\nvomiting serum Na and K are likely to be depleted. If bowel ischemia or infarction is suspected, antibiotics\\nshould be given (eg, a 3rd-generation cephalosporin, such as cefotetan 2 g IV) before laparotomy.\\nSpecific measures:\\n Obstruction of the duodenum in adults is treated by resection or, if the lesion\\ncannot be removed, palliative gastrojejunostomy (for treatment in children, see p. \\n2978\\n).\\nComplete obstruction of the small bowel is preferentially treated with early laparotomy, although surgery\\ncan be delayed 2 or 3 h to improve fluid status and urine output in a very ill, dehydrated patient. The\\noffending lesion is removed whenever possible. If a gallstone is the cause of obstruction, it is removed\\nthrough an enterotomy, and cholecystectomy need not be done. Procedures to prevent recurrence should\\nbe done, including repair of hernias, removal of foreign bodies, and lysis of the offending adhesions. In\\nsome patients with early postoperative obstruction or repeated obstruction caused by adhesions, simple\\nintubation with a long intestinal tube (many consider a standard NGT to be equally effective), rather than\\nsurgery, may be attempted in the absence of peritoneal signs.\\nDisseminated intraperitoneal cancer obstructing the small bowel is a major cause of death in adult\\npatients with GI tract cancer. Bypassing the obstruction, either surgically or with endoscopically placed\\nstents, may palliate symptoms briefly.\\nObstructing colon cancers can often be treated by a single-stage resection and anastomosis. Other\\noptions include a diverting ileostomy and distal anastomosis. Occasionally, a diverting colostomy with\\ndelayed resection is required.\\nWhen diverticulitis causes obstruction, perforation is often present. Removal of the involved area may be\\nvery difficult but is indicated if perforation and general peritonitis are present. Resection and colostomy\\nare done, and anastomosis is postponed.\\nFecal impaction usually occurs in the rectum and can be removed digitally and with enemas. However, a\\nfecal concretion alone or in a mixture (ie, with barium or antacids) that causes complete obstruction\\n(usually in the sigmoid) requires laparotomy.\\nTreatment of cecal volvulus consists of resection and anastomosis of the involved segment or fixation of\\nthe cecum in its normal position by cecostomy in the frail patient. In sigmoidal volvulus, an endoscope or a\\nlong rectal tube can often decompress the loop, and resection and anastomosis may be deferred for a\\nfew days. Without a resection, recurrence is almost inevitable.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n169'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 179, 'page_label': '170'}, page_content=\"Intra-Abdominal Abscesses\\nAbscesses can occur anywhere in the abdomen and retroperitoneum. They mainly occur after\\nsurgery, trauma, or conditions involving abdominal infection and inflammation, particularly\\nwhen peritonitis or perforation occurs. Symptoms are malaise, fever, and abdominal pain.\\nDiagnosis is by CT. Treatment is with drainage, either surgical or percutaneous. Antibiotics are\\nancillary.\\nEtiology\\nIntra-abdominal abscesses are classified as intraperitoneal, retroperitoneal, or visceral (see\\nTable 11-6\\n). Many intra-abdominal abscesses develop after perforation of a hollow viscus or colonic\\ncancer. Others develop by extension of infection or inflammation resulting from conditions such as\\nappendicitis, diverticulitis, Crohn's disease, pancreatitis, pelvic inflammatory disease, or indeed any\\ncondition causing generalized peritonitis. Abdominal surgery, particularly that involving the digestive or\\nbiliary tract, is another significant risk factor: The peritoneum may be contaminated during or after surgery\\nfrom such events as anastomotic leaks. Traumatic\\n[\\nTable 11-6.\\n Intra-Abdominal Abscesses]\\nabdominal injuriesparticularly lacerations and hematomas of the liver, pancreas, spleen, and intestines\\nmay develop abscesses, whether treated operatively or not.\\nThe infecting organisms typically reflect normal bowel flora and are a complex mixture of anaerobic and\\naerobic bacteria. Most frequent isolates are aerobic gram-negative bacilli (eg, \\nEscherichia coli\\n and\\nKlebsiella\\n) and anaerobes (especially \\nBacteroides fragilis\\n).\\nUndrained abscesses may extend to contiguous structures, erode into adjacent vessels (causing\\nhemorrhage or thrombosis), rupture into the peritoneum or bowel, or form a cutaneous fistula.\\nSubdiaphragmatic abscesses may extend into the thoracic cavity, causing an empyema, lung abscess, or\\npneumonia. An abscess in the lower abdomen may track down into the thigh or perirectal fossa. Splenic\\nabscess is a rare cause of sustained bacteremia in endocarditis that persists despite appropriate\\nantimicrobial therapy.\\nSymptoms and Signs\\nAbscesses may form within 1 wk of perforation or significant peritonitis, whereas postoperative abscesses\\nmay not occur until 2 to 3 wk after operation and, rarely, not for several months. Although manifestations\\nvary, most abscesses cause fever and abdominal discomfort ranging from minimal to severe (usually near\\nthe abscess). Paralytic ileus, either generalized or localized, may develop. Nausea, anorexia, and weight\\nloss are common.\\nAbscesses in Douglas' cul-de-sac, adjacent to the colon, may cause diarrhea. Contiguity to the bladder\\nmay result in urinary urgency and frequency and, if caused by diverticulitis, may create a colovesical\\nfistula.\\nSubphrenic abscesses may cause chest symptoms such as nonproductive cough, chest pain, dyspnea,\\nand shoulder pain. Rales, rhonchi, or a friction rub may be audible. Dullness to percussion and decreased\\nbreath sounds are typical when basilar atelectasis, pneumonia, or pleural effusion occurs.\\nGenerally, there is tenderness over the location of the abscess. Large abscesses may be palpable as a\\nmass.\\nDiagnosis\\n Abdominal CT\\n Rarely, radionuclide scanning\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n170\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 180, 'page_label': '171'}, page_content=\"CT of the abdomen and pelvis with oral contrast is the preferred diagnostic modality for suspected\\nabscess. Other imaging studies, if done, may show abnormalities; plain abdominal x-rays may reveal\\nextraintestinal gas in the abscess, displacement of adjacent organs, a soft-tissue density representing the\\nabscess, or loss of the psoas muscle shadow. Abscesses near the diaphragm may result in chest x-ray\\nabnormalities such as ipsilateral pleural effusion, elevated or immobile hemidiaphragm, lower lobe\\ninfiltrates, and atelectasis.\\nCBC and blood cultures should be done. Leukocytosis occurs in most patients, and anemia is common.\\nOccasionally, radionuclide scanning with indium\\n111\\n-labeled leukocytes may be helpful in identifying intra-\\nabdominal abscesses.\\nPrognosis\\nIntra-abdominal abscesses have a mortality rate of 10 to 40%. Outcome depends mainly on the patient's\\nprimary illness or injury and general medical condition rather than on the specific nature and location of\\nthe abscess.\\nTreatment\\n IV antibiotics\\n Drainage: Percutaneous or surgical\\nAll intra-abdominal abscesses require drainage, either by percutaneous catheters or surgery. Drainage\\nthrough catheters (placed with CT or ultrasound guidance) may be appropriate given the following\\nconditions: Few abscess cavities are present; the drainage route does not traverse bowel or\\nuncontaminated organs, pleura, or peritoneum; the source of contamination is controlled; and the pus is\\nthin enough to pass through the catheter.\\nAntibiotics are not curative but may limit hematogenous spread and should be given before and after\\nintervention. Therapy requires drugs active against bowel flora, such as a combination of an\\naminoglycoside (eg, gentamicin 1.5 mg/kg q 8 h) and metronidazole 500 mg q 8 h. Single-agent therapy\\nwith cefotetan 2 g q 12 h is also reasonable. Patients previously given antibiotics or those who have\\nhospital-acquired infections should receive drugs active against resistant aerobic gram-negative bacilli\\n(eg, \\nPseudomonas\\n) and anaerobes.\\nNutritional support is important, with the enteral route preferred. Parenteral nutrition should begin early if\\nthe enteral route is not feasible.\\nIschemic Colitis\\nIschemic colitis is a transient reduction in blood flow to the colon.\\nNecrosis may occur but is usually limited to the mucosa and submucosa, only occasionally causing full-\\nthickness necrosis necessitating surgery. It occurs mainly in older people (> 60) and is thought to be\\ncaused by small-vessel atherosclerosis.\\nSymptoms are milder and of slower onset than those of acute mesenteric ischemia and consist of left\\nlower quadrant pain followed by rectal bleeding. Diagnosis is made by colonoscopy; angiography or\\nmagnetic resonance angiography is not indicated. Treatment is supportive with IV fluids, bowel rest, and\\nantibiotics. Surgery is rarely required. About 5% of patients have a recurrence. Occasionally, strictures\\ndevelop at the site of the ischemia several weeks later, necessitating surgical resection.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 11. Acute Abdomen & Surgical Gastroenterology\\n171\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 181, 'page_label': '172'}, page_content=\"Chapter 12. Esophageal and Swallowing Disorders\\nIntroduction\\n(See also \\nEsophageal Cancer\\n on p. \\n186\\n and \\nEsophageal Atresia\\n on p. \\n2975\\n.)\\nThe swallowing apparatus consists of the pharynx, upper esophageal (cricopharyngeal) sphincter, the\\nbody of the esophagus, and the lower esophageal sphincter (LES). The upper third of the esophagus\\nand the structures proximal to it are composed of skeletal muscle; the distal esophagus and LES are\\ncomposed of smooth muscle. These components work as an integrated system that transports material\\nfrom the mouth to the stomach and prevents its reflux into the esophagus. Physical obstruction or\\ndisorders that interfere with motor function (motility disorders) can affect the system.\\nThe patient's history suggests the diagnosis almost 80% of the time. The only physical findings in\\nesophageal disorders are cervical and supraclavicular lymphadenopathy caused by metastasis, swellings\\nin the neck caused by large pharyngeal diverticula or thyromegaly, and prolonged swallowing time (the\\ntime from the act of swallowing to the sound of the bolus of fluid and air entering the stomachnormally \\n12 secheard by auscultation with the stethoscope over the epigastrium). Watching the patient swallow\\nmay help diagnose aspiration or nasal regurgitation. Most esophageal disorders require specific tests for\\ndiagnosis.\\nDysphagia\\nDysphagia is difficulty swallowing. The condition results from impeded transport of liquids, solids, or both\\nfrom the pharynx to the stomach. Dysphagia should not be confused with globus sensation (see p. \\n78\\n), a\\nfeeling of having a lump in the throat, which is unrelated to swallowing and occurs without impaired\\ntransport.\\nComplications:\\n Dysphagia can lead to tracheal aspiration of ingested material, oral secretions, or both.\\nAspiration can cause acute pneumonia; recurrent aspiration may eventually lead to chronic lung disease.\\nProlonged dysphagia often leads to inadequate nutrition and weight loss.\\nEtiology\\nDysphagia is classified as oropharyngeal or esophageal, depending on where it occurs.\\nOropharyngeal dysphagia:\\n Oropharyngeal dysphagia is difficulty emptying material from the\\noropharynx into the esophagus; it results from abnormal function proximal to the esophagus. Patients\\ncomplain of difficulty initiating swallowing, nasal regurgitation, and tracheal aspiration followed by\\ncoughing.\\nMost often, oropharyngeal dysphagia occurs in patients with neurologic conditions or muscular disorders\\nthat affect skeletal muscles (see\\nTable 12-1\\n).\\nEsophageal dysphagia:\\n Esophageal dysphagia is difficulty passing food down the esophagus. It results\\nfrom either a motility disorder or a mechanical obstruction (see\\nTable 12-2\\n).\\nEvaluation\\nHistory: History of present illness\\n begins with duration of symptoms and acuity of onset. Patients\\nshould describe what substances cause difficulty and where they feel the disturbance is located. Specific\\nconcerns include whether patients have difficulty swallowing solids, liquids, or both; whether food comes\\nout their nose; whether they drool or have food spill from their mouth; and whether they cough or choke\\nwhile eating.\\n[\\nTable 12-1.\\n Some Causes of Oropharyngeal Dysphagia]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n172\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 182, 'page_label': '173'}, page_content=\"Review of symptoms\\n should focus on symptoms suggestive of neuromuscular, GI, and connective\\ntissue disorders and on the presence of complications. Important neuromuscular symptoms include\\nweakness and easy fatigability, gait or balance disturbance, tremor, and difficulty speaking. Important GI\\nsymptoms include heartburn or other chest discomfort suggestive of reflux. Symptoms of connective\\ntissue disorders include muscle and joint pain, Raynaud's phenomenon, and skin changes (eg, rash,\\nswelling, thickening).\\nPast medical history\\n should ascertain known diseases that may cause dysphagia (see \\nTables 12-1\\n and\\n12-2\\n).\\nPhysical examination:\\n Examination focuses on findings suggestive of neuromuscular, GI, and\\nconnective tissue disorders and on the presence of complications.\\nGeneral examination should evaluate nutritional status (including body weight). A complete neurologic\\nexamination is essential, with attention to any resting tremor, the cranial nerves (note the gag reflex may\\nnormally be absent; this absence is thus not a good marker of swallowing dysfunction), and muscle\\nstrength. Patients who describe easy fatigability should be observed performing a repetitive action (eg,\\nblinking, counting aloud) for a rapid decrement in performance.\\n[\\nTable 12-2.\\n Some Causes of Esophageal Dysphagia]\\nThe patient's gait should be observed, and balance should be tested. Skin is examined for rash and\\nthickening or texture changes, particularly on the fingertips. Muscles are inspected for wasting and\\nfasciculations and are palpated for tenderness. The neck is evaluated for thyromegaly or other mass.\\nRed flags:\\n Any dysphagia is of concern, but certain findings are more urgent:\\n Symptoms of complete obstruction (eg, drooling, inability to swallow anything)\\n Dysphagia resulting in weight loss\\n New focal neurologic deficit, particularly any objective weakness\\nInterpretation of findings:\\n Dysphagia that occurs in conjunction with an acute neurologic event is likely\\nthe result of that event; new dysphagia in a patient with a stable, long-standing neurologic disorder may\\nhave another etiology. Dysphagia for solids alone suggests mechanical obstruction; however, a problem\\nwith both solids and liquids is nonspecific. Drooling and spilling food from the mouth while eating or nasal\\nregurgitation suggests an oropharyngeal disorder. Regurgitation of a small amount of food on lateral\\ncompression of the neck is virtually diagnostic of pharyngeal diverticulum.\\nPatients who complain of difficulty getting food to leave the mouth or of food sticking in the lower\\nesophagus are usually correct about the condition's location; the sensation of dysphagia in the upper\\nesophagus is less specific.\\nMany findings suggest specific disorders (see\\nTable 12-3\\n) but are of varying sensitivity and specificity and thus do not rule in or out a given cause;\\nhowever, they can guide testing.\\nTesting:\\n A barium swallow (with a solid bolus, usually a marshmallow or tablet) should be done. If this\\ntest shows obstruction, endoscopy (and possibly biopsy) should be done to rule out malignancy. If the\\nbarium swallow is negative or suggestive of a motility disorder, esophageal motility studies should be\\ndone. Other tests for specific causes are done as suggested by findings.\\nTreatment\\nTreatment is directed at the specific cause. If complete obstruction occurs, emergent upper endoscopy is\\nessential. If a stricture, ring, or web is found, careful endoscopic dilation is performed. Pending resolution,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n173\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 183, 'page_label': '174'}, page_content=\"patients with oropharyngeal dysphagia may benefit\\n[\\nTable 12-3.\\n Some Helpful Findings in Dysphagia]\\nfrom evaluation by a rehabilitation specialist. Sometimes patients benefit from changing head position\\nwhile eating, retraining the swallowing muscles, doing exercises that improve the ability to accommodate\\na food bolus in the oral cavity, or doing strength and coordination exercises for the tongue. Patients with\\nsevere dysphagia and recurrent aspiration may require a gastrostomy tube.\\nGeriatrics Essentials\\nChewing, swallowing, tasting, and communicating require intact, coordinated neuromuscular function in\\nthe mouth, face, and neck. Oral motor function in particular declines measurably with aging, even in\\nhealthy people. Decline in function may have many manifestations:\\n Reduction in masticatory muscle strength and coordination is common, especially among patients with\\npartial or complete dentures, and may lead to a tendency to swallow larger food particles, which can\\nincrease the risk of choking or aspiration.\\n Drooping of the lower face and lips caused by decreased circumoral muscle tone and, in edentulous\\npeople, reduced bone support, is an aesthetic concern and can lead to drooling, spilling of food and\\nliquids, and difficulty closing the lips while eating, sleeping, or resting. Sialorrhea (saliva leakage) is\\noften the first symptom.\\n Swallowing difficulties increase. It takes longer to move food from mouth to oropharynx, which increases\\nthe likelihood of aspiration.\\nAfter age-related changes, the most common causes of oral motor disorders are neuromuscular disorders\\n(eg, cranial neuropathies caused by diabetes, stroke, Parkinson's disease, amyotrophic lateral sclerosis,\\nmultiple sclerosis). Iatrogenic causes also contribute. Drugs (eg, anticholinergics, diuretics), radiation\\ntherapy to the head and neck, and chemotherapy can greatly impair saliva production. Hyposalivation is a\\nmajor cause of delayed and impaired swallowing.\\nOral motor dysfunction is best managed with a multidisciplinary approach. Coordinated referrals to\\nspecialists in prosthetic dentistry, rehabilitative medicine, speech pathology, otolaryngology, and\\ngastroenterology may be needed.\\nKey Points\\n All patients complaining of esophageal dysphagia should undergo upper endoscopy to rule out cancer.\\n If the upper endoscopy is normal, biopsies should be obtained to rule out eosinophilic esophagitis.\\n Treatment is geared toward the cause.\\nCricopharyngeal Incoordination\\nIn cricopharyngeal incoordination, the cricopharyngeal muscle (the upper esophageal sphincter) is\\nuncoordinated. It can cause a Zenker's diverticulum (see p. \\n125\\n). Repeated aspiration of material from the\\ndiverticulum can lead to chronic lung disease. The condition can be treated by surgical section of the\\ncricopharyngeal muscle.\\nObstructive Disorders\\n(See also \\nBenign Esophageal Tumors\\n and \\nEsophageal Cancer\\n on p. \\n186\\n.)\\nLower Esophageal Ring\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n174\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 184, 'page_label': '175'}, page_content=\"(Schatzki's Ring, B Ring)\\nA lower esophageal ring is a 2- to 4-mm mucosal stricture, probably congenital, causing a\\nringlike narrowing of the distal esophagus at the squamocolumnar junction.\\nThese rings cause intermittent dysphagia for solids. This symptom can begin at any age but usually does\\nnot begin until after age 25. The swallowing difficulty comes and goes and is especially aggravated by\\nmeat and dry bread. Symptoms usually occur only when the esophageal lumen is < 12 mm in diameter\\nand never when it is > 20 mm. If the distal esophagus is adequately distended, barium x-rays usually\\nshow the ring. Instructing the patient to chew food thoroughly is usually the only treatment required in\\nwider rings, but narrow-lumen rings require dilation by endoscopy or bougienage. Surgical resection is\\nrarely required.\\nEsophageal Web\\n(Plummer-Vinson Syndrome; Paterson-Kelly Syndrome; Sideropenic Dysphagia)\\nAn esophageal web is a thin mucosal membrane that grows across the lumen.\\nRarely, webs develop in patients with untreated severe iron-deficiency anemia; they develop even more\\nrarely in patients without anemia. Webs usually occur in the upper esophagus, causing dysphagia for\\nsolids. They are best diagnosed by barium swallow. Webs resolve with treatment of the anemia but can\\nbe easily ruptured during esophagoscopy.\\nDysphagia Lusoria\\nDysphagia lusoria is caused by compression of the esophagus from any of several congenital\\nvascular abnormalities.\\nThe vascular abnormality is usually an aberrant right subclavian artery arising from the left side of the\\naortic arch, a double aortic arch, or a right aortic arch with left ligamentum arteriosum. The dysphagia\\nmay develop in childhood or later in life as a result of arteriosclerotic changes in the aberrant vessel.\\nBarium swallow shows the extrinsic compression, but arteriography is necessary for absolute diagnosis.\\nMost patients require no treatment, but surgical repair is sometimes done.\\nMotility Disorders\\nAchalasia\\n(Cardiospasm; Esophageal Aperistalsis; Megaesophagus)\\nAchalasia is a neurogenic esophageal motility disorder characterized by impaired esophageal\\nperistalsis, a lack of lower esophageal sphincter relaxation during swallowing, and an elevation\\nof lower esophageal sphincter resting pressure. Symptoms are slowly progressive dysphagia,\\nusually to both liquids and solids, and regurgitation of undigested food. Evaluation typically\\nincludes barium swallow, endoscopy, and sometimes manometry. Treatments include dilation,\\nchemical denervation, and surgical myotomy.\\nAchalasia is thought to be caused by a loss of ganglion cells in the myenteric plexus of the esophagus,\\nresulting in denervation of esophageal muscle. Etiology of the denervation is unknown, although a viral\\ncause is suspected, and certain tumors may cause achalasia either by direct obstruction or as a\\nparaneoplastic process. Chagas disease, which causes destruction of autonomic ganglia, may result in\\nachalasia.\\nIncreased pressure at the lower esophageal sphincter (LES) causes obstruction with secondary dilation\\nof the esophagus. Esophageal retention of undigested food is common.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n175\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 185, 'page_label': '176'}, page_content=\"Achalasia occurs at any age but usually begins between ages 20 and 60. Onset is insidious, and\\nprogression is gradual over months or years. Dysphagia for both solids and liquids is the major symptom.\\nNocturnal regurgitation of undigested food occurs in about 33% of patients and may cause cough and\\npulmonary aspiration. Chest pain is less common but may occur on swallowing or spontaneously. Mild to\\nmoderate weight loss occurs; when weight loss is pronounced, particularly in elderly patients whose\\nsymptoms of dysphagia developed rapidly, achalasia secondary to a tumor of the gastroesophageal\\njunction should be considered.\\nDiagnosis\\n Barium swallow\\n Esophageal manometry\\nThe preferred test is barium swallow, which shows absence of progressive peristaltic contractions during\\nswallowing. The esophagus is dilated, often enormously, but is narrowed and beaklike at the LES. If\\nesophagoscopy is done, there is dilation but no obstructing lesion. The esophagoscope usually passes\\nreadily into the stomach; resistance raises the possibility of an inapparent cancer or stricture. To exclude\\ncancer, a retroflexed view of the gastric cardia, biopsies, and brushings for cytology should be obtained.\\nEsophageal manometry is usually done and typically shows aperistalsis, increased LES pressure, and\\nincomplete sphincteric relaxation during swallowing.\\nAchalasia must be differentiated from a distal stenosing carcinoma and a peptic stricture, particularly in\\npatients with systemic sclerosis (see p. \\n309\\n), in whom esophageal manometry may also show\\naperistalsis. Systemic sclerosis is usually accompanied by a history of Raynaud's phenomenon and\\nsymptoms of gastroesophageal reflux disease (GERD), due to low or absent LES pressure.\\nAchalasia due to cancer at the gastroesophageal junction can be diagnosed by CT of the chest and\\nabdomen or by endoscopic ultrasound.\\nPrognosis\\nPulmonary aspiration and the presence of cancer are the determining prognostic factors. \\nNocturnal\\nregurgitation and coughing suggest aspiration. Pulmonary complications secondary to aspiration are\\ndifficult to manage. Incidence of esophageal cancer in patients with achalasia may be increased; this\\npoint is controversial.\\nTreatment\\n Balloon dilation of the LES\\n Alternatively, botulinum toxin injection or surgical myotomy\\nNo therapy restores peristalsis; treatment aims at reducing the pressure (and thus the obstruction) at the\\nLES. Pneumatic balloon dilation of the LES is indicated initially. Results are satisfactory in about 85% of\\npatients, but repeated dilations may be needed. Esophageal rupture and secondary mediastinitis\\nrequiring surgical repair occur in < 2% of patients. Nitrates (eg, isosorbide dinitrate 5 to 10 mg\\nsublingually before meals) or Ca channel blockers (eg, nifedipine 10 mg po tid) are of limited\\neffectiveness but may reduce LES pressure enough to prolong the time between dilations.\\nAchalasia can also be treated by chemical denervation of cholinergic nerves in the distal esophagus by\\ndirect injection of botulinum toxin type A into the LES. Clinical improvement occurs in 70 to 80% of\\npatients, but results may last only 6 mo to 1 yr.\\nA Heller myotomy, in which the muscular fibers in the LES are cut, is usually reserved for patients who do\\nnot respond to dilation; its success rate is about 85%. It can be done via laparoscopy or thoracoscopy\\nand may be a viable alternative to dilation as primary therapy. Symptomatic GERD occurs after surgery in\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n176\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 186, 'page_label': '177'}, page_content='about 15% of patients.\\nSymptomatic Diffuse Esophageal Spasm\\n(Spastic Pseudodiverticulosis; Rosary Bead or Corkscrew Esophagus)\\nSymptomatic diffuse esophageal spasm is part of a spectrum of motility disorders\\ncharacterized variously by nonpropulsive contractions, hyperdynamic contractions, or elevated\\nlower esophageal sphincter pressure. Symptoms are chest pain and sometimes dysphagia.\\nDiagnosis is by barium swallow or manometry. Treatment is difficult but includes nitrates, Ca\\nchannel blockers, botulinum toxin injection, and antireflux therapy.\\nAbnormalities in esophageal motility correlate poorly with patient symptoms; similar abnormalities may\\ncause different or no symptoms in different people. Furthermore, neither symptoms nor abnormal\\ncontractions are definitively associated with histopathologic abnormalities of the esophagus.\\nSymptoms and Signs\\nDiffuse esophageal spasm typically causes substernal chest pain with dysphagia for both liquids and\\nsolids. The pain may waken the patient from sleep. Very hot or cold liquids may aggravate the pain. Over\\nmany years, this disorder may evolve into achalasia.\\nEsophageal spasms can cause severe pain without dysphagia. This pain is often described as a\\nsubsternal squeezing pain and may occur in association with exercise. Such pain may be\\nindistinguishable from angina pectoris.\\nSome patients have symptoms that combine those of achalasia and diffuse spasm. One such combination\\nhas been called vigorous achalasia because it features both the food retention and aspiration of\\nachalasia and the severe pain and spasm of diffuse spasm.\\nDiagnosis\\n Barium swallow\\n Esophageal manometry\\n Possibly testing for coronary ischemia\\nAlternative diagnoses include coronary ischemia. Definitive confirmation of an esophageal origin for\\nsymptoms is difficult. Barium swallow may show poor progression of a bolus and disordered,\\nsimultaneous contractions or tertiary contractions. Severe spasms may mimic the radiographic\\nappearance of diverticula but vary in size and position. Esophageal manometry (see p. \\n96\\n) provides the\\nmost specific description of the spasms. Contractions are usually simultaneous, prolonged or multiphasic,\\nand possibly of very high amplitude (\"nutcracker esophagus\"). However, spasms may not occur during\\ntesting. Lower esophageal sphincter (LES) pressure elevation or impaired relaxation is present in 30% of\\npatients. Esophageal scintigraphy and provocative tests with drugs (eg, edrophonium chloride 10 mg IV)\\nhave not proved helpful.\\nTreatment\\n Ca channel blockers\\n Botulinum toxin injection\\nEsophageal spasms are often difficult to treat, and controlled studies of treatment methods are lacking.\\nAnticholinergics, nitroglycerin, and long-acting nitrates have had limited success. Ca channel blockers\\ngiven orally (eg, verapamil 80 mg tid, nifedipine \\n10 mg tid) may be useful, as may injection of botulinum\\ntoxin type A into the LES.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n177'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 187, 'page_label': '178'}, page_content=\"Medical management is usually sufficient, but pneumatic dilation and bougienage, or even surgical\\nmyotomy along the full length of the esophagus, may be tried in intractable cases.\\nEsophageal Diverticula\\nAn esophageal diverticulum is an outpouching of mucosa through the muscular layer of the\\nesophagus. It can be asymptomatic or cause dysphagia and regurgitation. Diagnosis is made by\\nbarium swallow; surgical repair is rarely required.\\nThere are several types of esophageal diverticula, each of different origin.\\n Zenker's (pharyngeal) diverticula are posterior outpouchings of mucosa and submucosa through the\\ncricopharyngeal muscle, probably resulting from an incoordination between pharyngeal propulsion and\\ncricopharyngeal relaxation.\\n Midesophageal (traction) diverticula are caused by traction from mediastinal inflammatory lesions or,\\nsecondarily, by motility disorders.\\n Epiphrenic diverticula occur just above the diaphragm and usually accompany a motility disorder\\n(achalasia, diffuse esophageal spasm).\\nSymptoms and Signs\\nA Zenker's diverticulum fills with food that might be regurgitated when the patient bends or lies down.\\nAspiration pneumonitis may result if regurgitation is nocturnal. Rarely, the pouch becomes large, causing\\ndysphagia and sometimes a palpable neck mass.\\nTraction and epiphrenic diverticula are rarely symptomatic, although their underlying cause may be.\\nDiagnosis\\nAll diverticula are diagnosed by videotaped barium swallow.\\nTreatment\\n Usually none\\n Sometimes surgical resection\\nSpecific treatment is usually not required, although resection is occasionally necessary for large or\\nsymptomatic diverticula. Diverticula associated with motility disorders require treatment of the primary\\ndisorder. For example, case reports suggest doing a cricopharyngeal myotomy when resecting a Zenker's\\ndiverticulum.\\nGastroesophageal Reflux Disease\\nIncompetence of the lower esophageal sphincter allows reflux of gastric contents into the\\nesophagus, causing burning pain. Prolonged reflux may lead to esophagitis, stricture, and rarely\\nmetaplasia or cancer. Diagnosis is clinical, sometimes with endoscopy, with or without acid\\ntesting. Treatment involves lifestyle modification, acid suppression using proton pump\\ninhibitors, and sometimes surgical repair.\\nGastroesophageal reflux disease (GERD) is common, occurring in 30 to 40% of adults. It also occurs\\nfrequently in infants, typically beginning at birth.\\nEtiology\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n178\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 188, 'page_label': '179'}, page_content=\"The presence of reflux implies lower esophageal sphincter (LES) incompetence, which may result from a\\ngeneralized loss of intrinsic sphincter tone or from recurrent inappropriate transient relaxations (ie,\\nunrelated to swallowing). Transient LES relaxations are triggered by gastric distention or subthreshold\\npharyngeal stimulation.\\nFactors that contribute to the competence of the gastroesophageal junction include the angle of the\\ncardioesophageal junction, the action of the diaphragm, and gravity (ie, an upright position). Factors\\ncontributing to reflux include weight gain, fatty foods, caffeinated or carbonated beverages, alcohol,\\ntobacco smoking, and drugs. Drugs that lower LES pressure include anticholinergics, antihistamines,\\ntricyclic antidepressants, Ca channel blockers, progesterone, and nitrates.\\nComplications:\\n GERD may lead to esophagitis, peptic esophageal ulcer, esophageal stricture, Barrett's\\nesophagus, and esophageal adenocarcinoma (see p. \\n186\\n). Factors that contribute to the development of\\nesophagitis include the caustic nature of the refluxate, the inability to clear the refluxate from the\\nesophagus, the volume of gastric contents, and local mucosal protective functions. Some patients,\\nparticularly infants, aspirate the reflux material.\\nSymptoms and Signs\\nThe most prominent symptom of GERD is heartburn, with or without regurgitation of \\ngastric contents into\\nthe mouth. Infants present with vomiting, irritability, anorexia, and sometimes symptoms of chronic\\naspiration. Both adults and infants with chronic aspiration may have cough, hoarseness, or wheezing.\\nEsophagitis may cause odynophagia and even esophageal hemorrhage, which is usually occult but can\\nbe massive. Peptic stricture causes a gradually progressive dysphagia for solid foods. Peptic esophageal\\nulcers cause the same type of pain as gastric or duodenal ulcers, but the pain is usually localized to the\\nxiphoid or high substernal region. Peptic esophageal ulcers heal slowly, tend to recur, and usually leave a\\nstricture on healing.\\nDiagnosis\\n Clinical diagnosis\\n Endoscopy for those not responding to empiric treatment\\n 24-h pH testing for those with typical symptoms but normal endoscopy\\nA detailed history points to the diagnosis. Patients with typical symptoms of GERD may be given a trial of\\ntherapy. Patients who do not improve, or have long-standing symptoms or symptoms of complications,\\nshould be studied. Endoscopy, with cytologic washings and biopsy of abnormal areas, is the test of\\nchoice. Endoscopic biopsy is the only test that consistently detects the columnar mucosal changes of\\nBarrett's esophagus. Patients with unremarkable endoscopy findings who have typical symptoms despite\\ntreatment with proton pump inhibitors should undergo 24-h pH testing (see p. \\n95\\n). Although barium\\nswallow readily shows esophageal ulcers and peptic strictures, it is less useful for mild to moderate reflux;\\nin addition, most patients with abnormalities require subsequent endoscopy. Esophageal manometry may\\nbe used to guide pH probe placement and to evaluate esophageal peristalsis before surgical treatment.\\nTreatment\\n Head of bed elevated\\n Coffee, alcohol, fats, and smoking avoided\\n Proton pump inhibitors\\nManagement of uncomplicated GERD consists of elevating the head of the bed about 15 cm (6 in) and\\navoiding the following: eating within 2 to 3 h of bedtime, strong stimulants of acid secretion (eg, coffee,\\nalcohol), certain drugs (eg, anticholinergics), specific foods (eg, fats, chocolate), and smoking.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n179\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 189, 'page_label': '180'}, page_content=\"Drug therapy is with a proton pump inhibitor. For example, adults can be given omeprazole 20 mg,\\nlansoprazole 30 mg, or esomeprazole 40 mg 30 min before breakfast. In some cases, proton pump\\ninhibitors may be given bid. Infants and children may be given these drugs at an appropriate lower single\\ndaily dose (ie, omeprazole 20 mg in children > 3 yr, 10 mg in children < 3 yr; lansoprazole 15 mg in\\nchildren  30 kg, 30 mg in children > 30 kg). These drugs may be continued long-term, but the dose\\nshould be adjusted to the minimum required to prevent symptoms. H\\n2\\n blockers (eg, ranitidine 150 mg at\\nbedtime) or promotility agents (eg, metoclopramide 10 mg po 30 min before meals and at bedtime) are\\nless effective.\\nAntireflux surgery (usually via laparoscopy) is done on patients with serious esophagitis, large hiatal\\nhernias, hemorrhage, stricture, or ulcers. Esophageal strictures are managed by repeated balloon\\ndilation.\\nBarrett's esophagus may or may not regress with medical or surgical therapy. Because Barrett's\\nesophagus is a precursor to adenocarcinoma, endoscopic surveillance for malignant transformation is\\nrecommended every 1 to 2 yr. Surveillance has uncertain cost-effectiveness in patients with low-grade\\ndysplasia but is important in high-grade dysplasia in patients who are unable to undergo surgical\\nresection. Alternatively, Barrett's esophagus may be treated with endoscopic mucosal resection,\\nphotodynamic therapy, cryotherapy, or laser ablation.\\nHiatus Hernia\\nHiatus hernia is a protrusion of the stomach through the diaphragmatic hiatus. Most hernias are\\nasymptomatic, but an increased incidence of acid reflux may lead to symptoms of\\ngastroesophageal reflux disease (GERD). Diagnosis is by barium swallow. Treatment is directed\\nat symptoms of GERD if present.\\nEtiology\\nEtiology is usually unknown, but a hiatus hernia is thought to be acquired through stretching of the fascial\\nattachments between the esophagus and diaphragm at the hiatus (the opening through which the\\nesophagus traverses the diaphragm).\\nPathophysiology\\nIn a sliding hiatus hernia (the most common type), the gastroesophageal junction and a portion of the\\nstomach are above the diaphragm. In a paraesophageal hiatus hernia, \\nthe gastroesophageal junction is in\\nthe normal location, but a portion of the stomach is adjacent to the esophagus in the diaphragmatic\\nhiatus. Hernias may also occur through other parts of the diaphragm (see p. \\n2977\\n).\\nA sliding hiatus hernia is common and is an incidental finding on x-ray in > 40% of the population;\\ntherefore, the relationship of hernia to symptoms is unclear. Although most patients with GERD have\\nsome degree of hiatus hernia, < 50% of patients with hiatus hernia have GERD.\\nSymptoms and Signs\\nMost patients with a sliding hiatus hernia are asymptomatic, but chest pain and other reflux symptoms can\\noccur. A paraesophageal hiatus hernia is generally asymptomatic but, unlike a sliding hiatus hernia, may\\nincarcerate and strangulate. Occult or massive GI hemorrhage may occur with either type.\\nDiagnosis\\n Barium swallow\\nA large hiatus hernia is often discovered incidentally on chest x-ray. Smaller hernias are diagnosed with a\\nbarium swallow.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n180\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 190, 'page_label': '181'}, page_content=\"Treatment\\n Sometimes a proton pump inhibitor\\nAn asymptomatic sliding hiatus hernia requires no specific therapy. Patients with accompanying GERD\\nshould be treated with a proton pump inhibitor. A paraesophageal hernia should be reduced surgically\\nbecause of the risk of strangulation.\\nInfectious Esophageal Disorders\\nEsophageal infection occurs mainly in patients with impaired host defenses. Primary agents\\ninclude \\nCandida albicans\\n, herpes simplex virus, and cytomegalovirus. Symptoms are\\nodynophagia and chest pain. Diagnosis is by endoscopic visualization and culture. Treatment is\\nwith antifungal or antiviral drugs.\\nEsophageal infection is rare in patients with normal host defenses. Primary esophageal defenses include\\nsaliva, esophageal motility, and cellular immunity. Thus, at-risk patients include those with AIDS, organ\\ntransplants, alcoholism, diabetes, undernutrition, cancer, and motility disorders. \\nCandida\\n infection may\\noccur in any of these patients. Herpes simplex virus (HSV) and cytomegalovirus (CMV) infections occur\\nmainly in AIDS and transplant patients.\\nCandida:\\n Patients with \\nCandida\\n esophagitis usually complain of odynophagia and, less commonly,\\ndysphagia. About two thirds of patients have signs of oral thrush (thus its absence does not exclude\\nesophageal involvement). Patients with odynophagia and typical thrush may be given empiric treatment,\\nbut if significant improvement does not occur in 5 to 7 days, endoscopic evaluation is required. Barium\\nswallow is less accurate.\\nTreatment is with fluconazole 200 mg po or IV for one dose, then 100 mg po or IV q 24 h for 14 to 21\\ndays. Alternatives include the azoles (eg, itraconazole, voriconazole, ketoconazole) or echinocandins (eg,\\ncaspofungin). Topical therapy has no role.\\nHSV and CMV:\\n These infections are equally likely in transplant patients, but HSV occurs early after\\ntransplantation (reactivation) and CMV occurs 2 to 6 mo after. Among AIDS patients, CMV is much more\\ncommon than HSV, and viral esophagitis occurs mainly when the CD4+ count is < 200/\\n\\nL. Severe\\nodynophagia results from either infection.\\nEndoscopy, with cytology or biopsy, is usually necessary for diagnosis. HSV is treated with IV acyclovir 5\\nmg/kg q 8 h for 7 days or valacyclovir 1 g po tid. CMV is treated with ganciclovir 5 mg/kg IV q 12 h for 14\\nto 21 days with maintenance at 5 mg/kg IV 5 days/wk in immunocompromised patients. Alternatives\\ninclude foscarnet and cidofovir.\\nMallory-Weiss Syndrome\\nMallory-Weiss syndrome is a nonpenetrating mucosal laceration of the distal esophagus and\\nproximal stomach caused by vomiting, retching, or hiccuping.\\nInitially described in alcoholics, Mallory-Weiss syndrome can occur in any patient who vomits forcefully. It\\nis the cause of about 5% of episodes of upper GI hemorrhage. Most episodes of bleeding stop\\nspontaneously; severe bleeding occurs in about 10% of patients who require significant intervention,\\nsuch as transfusion or endoscopic hemostasis (by injection of ethanol, polidocanol, or epinephrine or by\\nelectrocautery). Intra-arterial infusion of pitressin or therapeutic embolization into the left gastric artery\\nduring angiography may also be used to control bleeding. Surgical repair is rarely required.\\nEsophageal Rupture\\nEsophageal rupture may be iatrogenic during endoscopic procedures or other instrumentation\\nor may be spontaneous (Boerhaave's syndrome). Patients are seriously ill, with symptoms of\\nmediastinitis. Diagnosis is by esophagography with a water-soluble contrast agent. Immediate\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n181\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 191, 'page_label': '182'}, page_content=\"surgical repair and drainage are required.\\nEndoscopic procedures are the primary cause of esophageal rupture, but spontaneous rupture may\\noccur, typically related to vomiting, retching, or swallowing a large food bolus. The most common site of\\nrupture is the distal esophagus on the left side. Acid and other stomach contents cause a fulminant\\nmediastinitis and shock. Pneumomediastinum is common.\\nSymptoms and Signs\\nSymptoms include chest and abdominal pain, vomiting, hematemesis, and shock. Subcutaneous\\nemphysema is palpable in about 30% of patients. Mediastinal crunch (Hamman's sign), a crackling sound\\nsynchronous with the heartbeat, may be present.\\nDiagnosis\\n Chest and abdominal x-rays\\n Esophagography\\nChest and abdominal x-rays showing mediastinal air, pleural effusion, or mediastinal widening suggest the\\ndiagnosis. Diagnosis is confirmed by esophagography with a water-soluble contrast agent, which avoids\\npotential mediastinal irritation from barium. CT of the thorax detects mediastinal air and fluid but does not\\nlocalize the perforation well. Endoscopy may miss a small perforation.\\nTreatment\\n Surgical repair\\nPending surgical repair, patients should receive broad-spectrum antibiotics (eg, gentamicin plus\\nmetronidazole or piperacillin/tazobactam) and fluid resuscitation as needed for shock. Even with\\ntreatment, mortality is high.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 12. Esophageal & Swallowing Disorders\\n182\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 192, 'page_label': '183'}, page_content='Chapter 13. Gastritis and Peptic Ulcer Disease\\nIntroduction\\nAcid is secreted by parietal cells in the proximal two thirds (body) of the stomach. Gastric acid aids\\ndigestion by creating the optimal pH for pepsin and gastric lipase and by stimulating pancreatic\\nbicarbonate secretion. Acid secretion is initiated by food: the thought, smell, or taste of food effects vagal\\nstimulation of the gastrin-secreting G cells located in the distal one third (antrum) of the stomach. The\\narrival of protein to the stomach further stimulates gastrin output. Circulating gastrin triggers the release\\nof histamine from enterochromaffin-like cells in the body of the stomach. Histamine stimulates the parietal\\ncells via their H\\n2\\n receptors. The parietal cells secrete acid, and the resulting drop in pH causes the antral\\nD cells to release somatostatin, which inhibits gastrin release (negative feedback control).\\nAcid secretion is present at birth and reaches adult levels (on a weight basis) by age 2. There is a decline\\nin acid output in elderly patients who develop chronic gastritis, but acid output is otherwise maintained\\nthroughout life.\\nNormally, the GI mucosa is protected by several distinct mechanisms: (1) Mucosal production of mucus\\nand HCO\\n3\\n creates a pH gradient from the gastric lumen (low pH) to the mucosa (neutral pH). The mucus\\nserves as a barrier to the diffusion of acid and pepsin. (2) Epithelial cells remove excess hydrogen ions\\n(H\\n+\\n) via membrane transport systems and have tight junctions, which prevent back diffusion of H\\n+\\n ions.\\n(3) Mucosal blood flow removes excess acid that has diffused across the epithelial layer. Several growth\\nfactors (eg, epidermal growth factor, insulin-like growth factor I) and prostaglandins have been linked to\\nmucosal repair and maintenance of mucosal integrity.\\nFactors that interfere with these mucosal defenses (particularly NSAIDs and \\nHelicobacter pylori\\ninfection) predispose to gastritis and peptic ulcer disease.\\nNSAIDs promote mucosal inflammation and ulcer formation (sometimes with GI bleeding) both topically\\nand systemically. By inhibiting prostaglandin production via blockage \\nof the enzyme cyclooxygenase\\n(COX), NSAIDs reduce gastric blood flow, reduce mucus and HCO\\n3\\n secretion, and decrease cell repair\\nand replication. Also, because NSAIDs are weak acids and are nonionized at gastric pH, they diffuse\\nfreely across the mucus barrier into gastric epithelial cells, where H\\n+\\n ions are liberated, leading to cellular\\ndamage. Because gastric prostaglandin production involves the COX-1 isoform, NSAIDs that are selective\\nCOX-2 inhibitors have fewer adverse gastric effects than other NSAIDs.\\nHelicobacter pylori\\n Infection\\nH. pylori\\n is a common gastric pathogen that causes gastritis, peptic ulcer disease, gastric\\nadenocarcinoma, and low-grade gastric lymphoma. Infection may be asymptomatic or result in\\nvarying degrees of dyspepsia. Diagnosis is by urea breath test and testing of endoscopic\\nbiopsy samples. Treatment is with a proton pump inhibitor plus two antibiotics.\\nH. pylori\\n is a spiral-shaped, gram-negative organism that has adapted to thrive in acid. In developing\\ncountries, it commonly causes chronic infections and is usually acquired during childhood. In the US,\\ninfection is less common among children but increases with age: by age 60, about 50% of people are\\ninfected. Infection is most common among blacks, Hispanics, and Asians.\\nThe organism has been cultured from stool, saliva, and dental plaque, which suggests oral-oral or fecal-\\noral transmission. Infections tend to cluster in families and in residents of custodial institutions. Nurses\\nand gastroenterologists seem to be at high risk because bacteria can be transmitted by improperly\\ndisinfected endoscopes.\\nPathophysiology\\nEffects of \\nH. pylori\\n infection vary depending on the location within the stomach. Antral-predominant\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n183'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 193, 'page_label': '184'}, page_content='infection results in increased gastrin production, probably via local impairment of somatostatin release.\\nResultant hypersecretion of acid predisposes to prepyloric and duodenal ulcer. Body-predominant\\ninfection leads to gastric atrophy and decreased acid production, possibly via increased local production\\nof IL-1\\n\\n. Patients with body-predominant infection are predisposed to gastric ulcer and adenocarcinoma.\\nSome patients have mixed infection of both antrum and body with varying clinical effects. Many patients\\nwith \\nH. pylori\\n infection have no noticeable clinical effects.\\nAmmonia produced by \\nH. pylori\\n enables the organism to survive in the acidic environment of the stomach\\nand may erode the mucus barrier. Cytotoxins and mucolytic enzymes (eg, bacterial protease, lipase)\\nproduced by \\nH. pylori\\n may play a role in mucosal damage and subsequent ulcerogenesis.\\nInfected people are 3 to 6 times more likely to develop stomach cancer. \\nH. pylori\\n infection is associated\\nwith intestinal-type adenocarcinoma of the gastric body and antrum but not cancer of the gastric cardia.\\nOther associated cancers include gastric lymphoma and mucosa-associated lymphoid tissue (MALT)\\nlymphoma, a monoclonally restricted B-cell tumor.\\nDiagnosis\\n For initial diagnosis: Serologic tests\\n For confirmation of cure: Urea breath test or stool antigen assay\\nScreening of asymptomatic patients is not warranted. Tests are done during evaluation for peptic ulcer\\nand gastritis. Posttreatment testing is typically done to confirm eradication of the organism. Different tests\\nare preferred for initial diagnosis and posttreatment.\\nNoninvasive tests:\\n Laboratory and office-based serologic assays for antibodies to \\nH. pylori\\n have\\nsensitivity and specificity of > 85% and are considered the noninvasive tests of choice for initial\\ndocumentation of \\nH. pylori\\n infection. However, because qualitative assays remain positive for up to 3 yr\\nafter successful treatment and because quantitative antibody levels do not decline significantly for 6 to 12\\nmo after treatment, serologic assays are not usually used to assess cure.\\nUrea breath tests use an oral dose of \\n13\\nC- or \\n14\\nC-labeled urea. In an infected patient, the organism\\nmetabolizes the urea and liberates labeled CO\\n2\\n, which is exhaled and can be quantified in breath\\nsamples taken 20 to 30 min after ingestion of the urea. Sensitivity and specificity are > 90%. Urea breath\\ntests are well suited for confirming eradication of the organism after therapy. False-negative results are\\npossible with recent antibiotic use or concomitant proton pump inhibitor therapy; therefore, follow-up\\ntesting should be delayed  4 wk after antibiotic therapy and 1 wk after proton pump inhibitor therapy. H\\n2\\nblockers do not affect the test.\\nStool antigen assays seem to have a sensitivity and specificity near that of urea breath tests, particularly\\nfor initial diagnosis; an office-based test is under development.\\nInvasive tests:\\n Endoscopy is used to obtain mucosal biopsy samples for a rapid urease \\ntest (RUT) or\\nhistologic staining. Bacterial culture is of limited use because of the fastidious nature of the organism.\\nEndoscopy is not recommended solely for diagnosis of \\nH. pylori;\\n noninvasive tests are preferred unless\\nendoscopy is indicated for other reasons.\\nThe RUT, in which presence of bacterial urease in the biopsy sample causes a color change on a special\\nmedium, is the diagnostic method of choice on tissue samples. Histologic staining of biopsy samples\\nshould be done for patients with negative RUT results but suspicious clinical findings, recent antibiotic\\nuse, or treatment with proton pump inhibitors. RUT and histologic staining each have a sensitivity and\\nspecificity of > 90%.\\nTreatment\\n Antibiotics (various regimens) plus a proton pump inhibitor\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n184'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 194, 'page_label': '185'}, page_content='Patients with complications (eg, gastritis, ulcer, cancer) should have the organism eradicated. Eradication\\nof \\nH. pylori\\n can even cure some cases of MALT lymphoma (but not other infection-related cancers).\\nTreatment of asymptomatic infection has been controversial, but the recognition of the role of \\nH. pylori\\n in\\ncancer has led to a recommendation for treatment. Vaccines, both preventive and therapeutic (ie, as an\\nadjunct to treatment of infected patients), are under development.\\nH. pylori\\n eradication requires multidrug therapy, typically antibiotics plus acid suppressants. Proton pump\\ninhibitors suppress \\nH. pylori\\n, and the increased gastric pH accompanying their use can enhance tissue\\nconcentration and efficacy of antimicrobials, creating a hostile environment for \\nH. pylori\\n.\\nTriple therapy is recommended. Oral omeprazole 20 mg bid or lansoprazole 30 mg bid, plus clarithromycin\\n500 mg bid, plus amoxicillin 1 g bid (or, for penicillin-allergic patients, metronidazole 500 mg bid) for 14\\ndays, cures infection in > 95% of cases. This regimen has excellent tolerability. Ranitidine bismuth citrate\\n400 mg po bid may be substituted for the proton pump inhibitor.\\nQuadruple therapy with a proton pump inhibitor bid, tetracycline 500 mg and bismuth subsalicylate or\\nsubcitrate 525 mg qid, and metronidazole 500 mg tid is also effective but more cumbersome.\\nInfected patients with duodenal or gastric ulcer require continuation of the acid suppression for at least 4\\nwk.\\nTreatment is repeated if \\nH. pylori\\n is not eradicated. If two courses are unsuccessful, some authorities\\nrecommend endoscopy to obtain cultures for sensitivity testing.\\nGastritis\\nGastritis is inflammation of the gastric mucosa caused by any of several conditions, including\\ninfection (\\nHelicobacter pylori\\n), drugs (NSAIDs, alcohol), stress, and autoimmune phenomena\\n(atrophic gastritis). Many cases are asymptomatic, but dyspepsia and GI bleeding sometimes\\noccur. Diagnosis is by endoscopy. Treatment is directed at the cause but often includes acid\\nsuppression and, for \\nH. pylori\\n infection, antibiotics.\\nGastritis is classified as erosive or nonerosive based on the severity of mucosal injury. It is also classified\\naccording to the site of involvement (ie, cardia, body, antrum). Gastritis can be further classified\\nhistologically as acute or chronic based on the inflammatory cell type. No classification scheme matches\\nperfectly with the pathophysiology; a large degree of overlap exists. Some forms of gastritis involve acid-\\npeptic and \\nH. pylori\\n disease. Additionally, the term is often loosely applied to nonspecific (and often\\nundiagnosed) abdominal discomfort and gastroenteritis.\\nAcute gastritis is characterized by PMN infiltration of the mucosa of the antrum and body.\\nChronic gastritis implies some degree of atrophy (with loss of function of the mucosa) or metaplasia. It\\npredominantly involves the antrum (with subsequent loss of G cells and decreased gastrin secretion) or\\nthe corpus (with loss of oxyntic glands, leading to reduced acid, pepsin, and intrinsic factor).\\nErosive Gastritis\\nErosive gastritis is gastric mucosal erosion caused by damage to mucosal defenses. It is\\ntypically acute, manifesting with bleeding, but may be subacute or chronic with few or no\\nsymptoms. Diagnosis is by endoscopy. Treatment is supportive, with removal of the inciting\\ncause. Certain ICU patients (eg, ventilator-bound, head trauma, burn, multisystem trauma)\\nbenefit from prophylaxis with acid suppressants.\\nCauses of erosive gastritis include NSAIDs, alcohol, stress, and less commonly radiation, viral infection\\n(eg, cytomegalovirus), vascular injury, and direct trauma (eg, nasogastric tubes).\\nSuperficial erosions and punctate mucosal lesions occur. These may develop as soon as 12 h after the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n185'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 195, 'page_label': '186'}, page_content='initial insult. Deep erosions, ulcers, and sometimes perforation may occur in severe or untreated cases.\\nLesions typically occur in the body, but the antrum may also be involved.\\nAcute stress gastritis\\n, a form of erosive gastritis, occurs in about 5% of critically ill patients. The\\nincidence increases with duration of ICU stay and length of time the patient is not receiving enteral\\nfeeding. Pathogenesis likely involves hypoperfusion of the GI mucosa, resulting in impaired mucosal\\ndefenses. Patients with head injury or burns may also have increased secretion of acid.\\nSymptoms and Signs\\nPatients with mild erosive gastritis are often asymptomatic, although some complain of dyspepsia,\\nnausea, or vomiting. Often, the first sign is hematemesis, melena, or blood in the nasogastric aspirate,\\nusually within 2 to 5 days of the inciting event. Bleeding is usually mild to moderate, although it can be\\nmassive if deep ulceration is present, particularly in acute stress gastritis. Acute and chronic erosive\\ngastritis are diagnosed endoscopically.\\nDiagnosis\\nAcute and chronic erosive gastritis are diagnosed endoscopically.\\nTreatment\\n For bleeding: Endoscopic hemostasis\\n For acid suppression: A proton pump inhibitor or H\\n2\\n blocker\\nIn severe gastritis, bleeding is managed with IV fluids and blood transfusion as needed. Endoscopic\\nhemostasis should be attempted, with surgery (total gastrectomy) a fallback procedure. Angiography is\\nunlikely to stop severe gastric bleeding because of the many collateral vessels supplying the stomach.\\nAcid suppression should be started if the patient is not already receiving it.\\nFor milder gastritis, removing the offending agent and using drugs to reduce gastric acidity (see p. \\n136\\n)\\nmay be all that is required.\\nPrevention\\nProphylaxis with acid-suppressive drugs can reduce the incidence of acute stress gastritis. However, it\\nmainly benefits certain high-risk ICU patients, including those with severe burns, CNS trauma,\\ncoagulopathy, sepsis, shock, multiple trauma, mechanical ventilation for > 48 h, hepatic or renal failure,\\nmultiorgan dysfunction, and history of peptic ulcer or GI bleeding.\\nProphylaxis consists of IV H\\n2\\n blockers, proton pump inhibitors, or oral antacids to raise intragastric pH >\\n4.0. Repeated pH measurement and titration of therapy are not required. Early enteral feeding also can\\ndecrease the incidence of bleeding.\\nAcid suppression is not recommended for patients simply taking NSAIDs unless they have previously had\\nan ulcer.\\nNonerosive Gastritis\\nNonerosive gastritis refers to a variety of histologic abnormalities that are mainly the result of\\nH. pylori\\n infection. Most patients are asymptomatic. Diagnosis is by endoscopy. Treatment is\\neradication of \\nH. pylori\\n and sometimes acid suppression.\\nPathology\\nSuperficial gastritis:\\n Lymphocytes and plasma cells mixed with neutrophils are the predominant\\ninfiltrating inflammatory cells. Inflammation is superficial and may involve the antrum, body, or both. It is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n186'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 196, 'page_label': '187'}, page_content='usually not accompanied by atrophy or metaplasia. Prevalence increases with age.\\nDeep gastritis:\\n Deep gastritis is more likely to be symptomatic (eg, vague dyspepsia). Mononuclear cells\\nand neutrophils infiltrate the entire mucosa to the level of the muscularis, but exudate or crypt abscesses\\nseldom result, as might be expected by such infiltration. Distribution may be patchy. Superficial gastritis\\nmay be present, as may partial gland atrophy and metaplasia.\\nGastric atrophy:\\n Atrophy of gastric glands may follow in gastritis, most often longstanding antral\\n(sometimes referred to as type B) gastritis. Some patients with gastric atrophy have autoantibodies to\\nparietal cells, usually in association with corpus (type A) gastritis and pernicious anemia.\\nAtrophy may occur without specific symptoms. Endoscopically, the mucosa may appear normal until\\natrophy is advanced, when submucosal vascularity may be visible. As atrophy becomes complete,\\nsecretion of acid and pepsin diminishes and intrinsic factor may be lost, resulting in vitamin B\\n12\\nmalabsorption.\\nMetaplasia:\\n Two types of metaplasia are common in chronic nonerosive gastritis: mucous gland and\\nintestinal.\\nMucous gland metaplasia (pseudopyloric metaplasia) occurs in the setting of severe atrophy of the\\ngastric glands, which are progressively replaced by mucous glands (antral mucosa), especially along the\\nlesser curve. Gastric ulcers may be present (typically at the junction of antral and corpus mucosa), but\\nwhether they are the cause or consequence of these metaplastic changes is not clear.\\nIntestinal metaplasia typically begins in the antrum in response to chronic mucosal injury and may extend\\nto the body. Gastric mucosa \\ncells change to resemble intestinal mucosawith goblet cells, endocrine\\n(enterochromaffin or enterochromaffin-like) cells, and rudimentary villiand may even assume functional\\n(absorptive) characteristics. Intestinal metaplasia is classified histologically as complete (most common)\\nor incomplete. With complete metaplasia, gastric mucosa is completely transformed into small-bowel\\nmucosa, both histologically and functionally, with the ability to absorb nutrients and secrete peptides. In\\nincomplete metaplasia, the epithelium assumes a histologic appearance closer to that of the large\\nintestine and frequently exhibits dysplasia. Intestinal metaplasia may lead to stomach cancer.\\nSymptoms and Signs\\nMost patients with \\nH. pylori\\n-associated gastritis are asymptomatic, although some have mild dyspepsia or\\nother vague symptoms.\\nDiagnosis\\n Endoscopy\\nOften, the condition is discovered during endoscopy done for other purposes. Testing of asymptomatic\\npatients is not indicated. Once gastritis is identified, testing for \\nH. pylori\\n is appropriate.\\nTreatment\\n Eradication of \\nH. pylori\\n Sometimes acid-suppressive drugs\\nTreatment of chronic nonerosive gastritis is \\nH. pylori\\n eradication (see p. \\n130\\n). Treatment of asymptomatic\\npatients is somewhat controversial given the high prevalence of \\nH. pylori\\n-associated superficial gastritis\\nand the relatively low incidence of clinical sequelae (ie, peptic ulcer disease). However, \\nH. pylori\\n is a\\nclass J carcinogen; eradication removes the cancer risk. In \\nH. pylori\\n-negative patients, treatment is\\ndirected at symptoms using acid-suppressive drugs (eg, H\\n2\\n blockers, proton pump inhibitors) or antacids.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n187'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 197, 'page_label': '188'}, page_content=\"Postgastrectomy Gastritis\\nPostgastrectomy gastritis is gastric atrophy developing after partial or subtotal gastrectomy\\n(except in cases of gastrinoma).\\nMetaplasia of the remaining corpus mucosa is common. The degree of gastritis is usually greatest at the\\nlines of anastomosis.\\nSeveral mechanisms are responsible: bile reflux, which is common after such surgery, damages the\\ngastric mucosa; loss of antral gastrin decreases stimulation of parietal and peptic cells, causing atrophy;\\nand vagotomy may result in a loss of vagal trophic action.\\nThere are no specific symptoms of gastritis. Postgastrectomy gastritis often progresses to severe atrophy\\nand achlorhydria. Production of intrinsic factor may cease with resultant vitamin B\\n12\\n deficiency (which\\nmay be worsened by bacterial overgrowth in the afferent loop). The relative risk of gastric\\nadenocarcinoma seems to increase 15 to 20 yr after partial gastrectomy; however, given the low absolute\\nincidence of postgastrectomy cancer, routine endoscopic surveillance is probably not cost effective, but\\nupper GI symptoms or anemia in such patients should prompt endoscopy.\\nUncommon Gastritis Syndromes\\nMenetrier's disease:\\n This rare idiopathic disorder affects adults aged 30 to 60 and is more common\\namong men. It manifests as a significant thickening of the gastric folds of the gastric body but not the\\nantrum. Gland atrophy and marked foveolar pit hyperplasia occur, often accompanied by mucous gland\\nmetaplasia and increased mucosal thickness with little inflammation. Hypoalbuminemia (the most\\nconsistent laboratory abnormality) caused by GI protein loss may be present (protein-losing gastropathy).\\nAs the disease progresses, the secretion of acid and pepsin decreases, causing hypochlorhydria.\\nSymptoms are nonspecific and commonly include epigastric pain, nausea, weight loss, edema, and\\ndiarrhea. Differential diagnosis includes (1) lymphoma, in which multiple gastric ulcers may occur; (2)\\nmucosa-associated lymphoid tissue (MALT) lymphoma, with extensive infiltration of monoclonal B\\nlymphocytes; (3) Zollinger-Ellison syndrome with associated gastric fold hypertrophy; and (4) Cronkhite-\\nCanada syndrome, a mucosal polypoid protein-losing syndrome associated with diarrhea. Diagnosis is\\nmade by endoscopy with deep mucosal biopsy or full-thickness laparoscopic gastric biopsy.\\nVarious treatments have been used, including anticholinergics, antisecretory drugs, and corticosteroids,\\nbut none have proved fully effective. Partial or complete gastric resection may be necessary in cases of\\nsevere hypoalbuminemia.\\nEosinophilic gastritis:\\n Extensive infiltration of the mucosa, submucosa, and muscle \\nlayers with\\neosinophils often occurs in the antrum. It is usually idiopathic but may result from nematode infestation.\\nSymptoms include nausea, vomiting, and early satiety. Diagnosis is by endoscopic biopsy of involved\\nareas. Corticosteroids can be successful in idiopathic cases; however, if pyloric obstruction develops,\\nsurgery may be required.\\nMucosa-associated lymphoid tissue (MALT) lymphoma:\\n This rare condition is characterized by\\nmassive lymphoid infiltration of the gastric mucosa, which can resemble Menetrier's disease.\\nGastritis caused by systemic disorders:\\n Sarcoidosis, TB, amyloidosis, and other granulomatous\\ndiseases can cause gastritis, which is seldom of primary importance.\\nGastritis caused by physical agents:\\n Radiation and ingestion of corrosives (especially acidic\\ncompounds) can cause gastritis. Exposure to > 16 Gy of radiation causes marked deep gastritis, usually\\ninvolving the antrum more than the corpus. Pyloric stenosis and perforation are possible complications of\\nradiation-induced gastritis.\\nInfectious (septic) gastritis:\\n Except for \\nH. pylori\\n infection, bacterial invasion of the stomach is rare and\\nmainly occurs after ischemia, ingestion of corrosives, or exposure to radiation. On x-ray, gas outlines the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n188\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 198, 'page_label': '189'}, page_content=\"mucosa. The condition can manifest as an acute surgical abdomen and has a very high mortality rate.\\nSurgery is often necessary.\\nDebilitated or immunocompromised patients may develop viral or fungal gastritis with cytomegalovirus,\\nCandida\\n, histoplasmosis, or mucormycosis; these diagnoses should be considered in patients with\\nexudative gastritis, esophagitis, or duodenitis.\\nAutoimmune Metaplastic Atrophic Gastritis\\nAutoimmune metaplastic atrophic gastritis (AMAG) is an inherited autoimmune disease that\\nattacks parietal cells, resulting in hypochlorhydria and decreased production of intrinsic factor.\\nConsequences include atrophic gastritis, B\\n12\\n malabsorption, and, frequently, pernicious\\nanemia. Risk of gastric adenocarcinoma increases 3-fold. Diagnosis is by endoscopy. Treatment\\nis with parenteral vitamin B\\n12\\n.\\nPatients with AMAG have antibodies to parietal cells and their components (which include intrinsic factor\\nand the proton pump H\\n+\\n,K\\n+\\n-ATPase). AMAG is inherited as an autosomal dominant trait. Some patients\\nalso develop Hashimoto's thyroiditis and 50% have thyroid antibodies; conversely, parietal cell antibodies\\nare found in 30% of patients with thyroiditis.\\nThe lack of intrinsic factor leads to vitamin B\\n12\\n deficiency that can result in a megaloblastic anemia\\n(pernicious anemiasee p. \\n932\\n) or neurologic symptoms (subacute combined degenerationsee p.\\n38\\n).\\nHypochlorhydria leads to G-cell hyperplasia and elevated serum gastrin levels (often >1000 pg/mL).\\nElevated gastrin levels lead to enterochromaffin-like cell hyperplasia, which occasionally undergoes\\ntransformation to a carcinoid tumor.\\nIn some patients, AMAG may be associated with chronic \\nHelicobacter pylori\\n infection, although the\\nrelationship is not clear. Gastrectomy and chronic acid suppression with proton pump inhibitors cause\\nsimilar deficiencies of intrinsic factor secretion.\\nThe areas of atrophic gastritis in the body and fundus may manifest metaplasia. Patients with AMAG have\\na 3-fold increased relative risk of developing gastric adenocarcinoma.\\nDiagnosis is made by endoscopic biopsy. Serum B\\n12\\n levels should be obtained. Parietal cell antibodies\\ncan be detected but are not measured routinely. The issue of surveillance endoscopy for cancer\\nscreening is unsettled; follow-up examinations are unnecessary unless histologic abnormalities (eg,\\ndysplasia) are present on initial biopsy or symptoms develop. No treatment is needed other than\\nparenteral replacement of vitamin B\\n12\\n.\\nPeptic Ulcer Disease\\nA peptic ulcer is an erosion in a segment of the GI mucosa, typically in the stomach (gastric\\nulcer) or the first few centimeters of the duodenum (duodenal ulcer), that penetrates through\\nthe muscularis mucosae. Nearly all ulcers are caused by \\nHelicobacter pylori\\n infection or NSAID\\nuse. Symptoms typically include burning epigastric pain that is often relieved by food.\\nDiagnosis is by endoscopy and testing for \\nH. pylori\\n. Treatment involves acid suppression,\\neradication of \\nH. pylori\\n (if present), and avoidance of NSAIDs.\\nUlcers may range in size from several millimeters to several centimeters. Ulcers are delineated from\\nerosions by the depth of penetration; \\nerosions are more superficial and do not involve the muscularis\\nmucosae. Ulcers can occur at any age, including infancy and childhood, but are most common among\\nmiddle-aged adults.\\nEtiology\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n189\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 199, 'page_label': '190'}, page_content='H. pylori\\n and NSAIDs disrupt normal mucosal defense and repair, making the mucosa more susceptible to\\nacid. \\nH. pylori\\n infection is present in 50 to 70% of patients with duodenal ulcers and 30 to 50% of\\npatients with gastric ulcers. If \\nH. pylori\\n is eradicated, only 10% of patients have recurrence of peptic ulcer\\ndisease, compared with 70% recurrence in patients treated with acid suppression alone. NSAIDs now\\naccount for > 50% of peptic ulcers.\\nCigarette smoking is a risk factor for the development of ulcers and their complications. Also, smoking\\nimpairs ulcer healing and increases the incidence of recurrence. Risk correlates with the number of\\ncigarettes smoked per day. Although alcohol is a strong promoter of acid secretion, no definitive data link\\nmoderate amounts of alcohol to the development or delayed healing of ulcers. Very few patients have\\nhypersecretion of gastrin (\\nZollinger-Ellison syndrome\\nsee p. \\n200\\n).\\nA family history exists in 50 to 60% of children with duodenal ulcer.\\nSymptoms and Signs\\nSymptoms depend on ulcer location and patient age; many patients, particularly elderly patients, have\\nfew or no symptoms. Pain is most common, often localized to the epigastrium and relieved by food or\\nantacids. The pain is described as burning or gnawing, or sometimes as a sensation of hunger. The\\ncourse is usually chronic and recurrent. Only about half of patients present with the characteristic pattern\\nof symptoms.\\nGastric ulcer\\n symptoms often do not follow a consistent pattern (eg, eating sometimes exacerbates\\nrather than relieves pain). This is especially true for pyloric channel ulcers, which are often associated\\nwith symptoms of obstruction (eg, bloating, nausea, vomiting) caused by edema and scarring.\\nDuodenal ulcers\\n tend to cause more consistent pain. Pain is absent when the patient awakens but\\nappears in mid-morning, is relieved by food, but recurs 2 to 3 h after a meal. Pain that awakens a patient\\nat night is common and is highly suggestive of duodenal ulcer. In neonates, perforation and hemorrhage\\nmay be the first manifestation of duodenal ulcer. Hemorrhage may also be the first recognized sign in later\\ninfancy and early childhood, although repeated vomiting or evidence of abdominal pain may be a clue.\\nDiagnosis\\n Endoscopy\\n Sometimes serum gastrin levels\\nDiagnosis of peptic ulcer is suggested by patient history and confirmed by endoscopy. Empiric therapy is\\noften begun without definitive diagnosis. However, endoscopy allows for biopsy or cytologic brushing of\\ngastric and esophageal lesions to distinguish between simple ulceration and ulcerating stomach cancer.\\nStomach cancer may manifest with similar manifestations and must be excluded, especially in patients\\nwho are > 45, have lost weight, or report severe or refractory symptoms. The incidence of malignant\\nduodenal ulcer is extremely low, so biopsies of lesions in that area are generally not warranted.\\nEndoscopy can also be used to definitively diagnose \\nH. pylori\\n infection, which should be sought when an\\nulcer is detected.\\nGastrin-secreting cancer and Zollinger-Ellison syndrome should be considered when there are multiple\\nulcers, when ulcers develop in atypical locations (eg, postbulbar) or are refractory to treatment, or when\\nthe patient has prominent diarrhea or weight loss. Serum gastrin levels should be measured in these\\npatients.\\nComplications\\nHemorrhage:\\n Mild to severe hemorrhage is the most common complication of peptic ulcer disease.\\nSymptoms include hematemesis (vomiting of fresh blood or \"coffee ground\" material); passage of bloody\\nstools (hematochezia) or black tarry stools (melena); and weakness, orthostasis, syncope, thirst, and\\nsweating caused by blood loss.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n190'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 200, 'page_label': '191'}, page_content=\"Penetration (confined perforation):\\n A peptic ulcer may penetrate the wall of the stomach. If adhesions\\nprevent leakage into the peritoneal cavity, free penetration is avoided and confined perforation occurs.\\nStill, the ulcer may penetrate into the duodenum and enter the adjacent confined space (lesser sac) or\\nanother organ (eg, pancreas, liver). Pain may be intense, persistent, referred to sites other than the\\nabdomen (usually the back when caused by penetration of a posterior duodenal ulcer into the pancreas),\\nand modified by body position. CT or MRI is usually needed to confirm the diagnosis. When therapy does\\nnot result in healing, surgery is required.\\nFree perforation:\\n Ulcers that perforate into the peritoneal cavity unchecked by adhesions \\nare usually\\nlocated in the anterior wall of the duodenum or, less commonly, in the stomach. The patient presents with\\nan acute abdomen. There is sudden, intense, continuous epigastric pain that spreads rapidly throughout\\nthe abdomen, often becoming prominent in the right lower quadrant and at times referred to one or both\\nshoulders. The patient usually lies still because even deep breathing worsens the pain. Palpation of the\\nabdomen is painful, rebound tenderness is prominent, abdominal muscles are rigid (boardlike), and bowel\\nsounds are diminished or absent. Shock may ensue, heralded by increased pulse rate and decreased BP\\nand urine output. Symptoms may be less striking in elderly or moribund patients and those receiving\\ncorticosteroids or immunosuppressants.\\nDiagnosis is confirmed if an x-ray or CT shows free air under the diaphragm or in the peritoneal cavity.\\nUpright views of the chest and abdomen are preferred. The most sensitive view is the lateral x-ray of the\\nchest. Severely ill patients may be unable to sit upright and should have a lateral decubitus x-ray of the\\nabdomen. Failure to detect free air does not exclude the diagnosis.\\nImmediate surgery is required. The longer the delay, the poorer is the prognosis. When surgery is\\ncontraindicated, the alternatives are continuous nasogastric suction and broad-spectrum antibiotics.\\nGastric outlet obstruction:\\n Obstruction may be caused by scarring, spasm, or inflammation from an\\nulcer. Symptoms include recurrent, large-volume vomiting, occurring more frequently at the end of the day\\nand often as late as 6 h after the last meal. Loss of appetite with persistent bloating or fullness after\\neating also suggests gastric outlet obstruction. Prolonged vomiting may cause weight loss, dehydration,\\nand alkalosis.\\nIf the patient's history suggests obstruction, physical examination, gastric aspiration, or x-rays may\\nprovide evidence of retained gastric contents. A succussion splash heard > 6 h after a meal or aspiration\\nof fluid or food residue > 200 mL after an overnight fast suggests gastric retention. If gastric aspiration\\nshows marked retention, the stomach should be emptied and endoscopy done or x-rays taken to\\ndetermine site, cause, and degree of obstruction.\\nEdema or spasm caused by an active pyloric channel ulcer is treated with gastric decompression by\\nnasogastric suction and acid suppression (eg, IV H\\n2\\n blockers). Dehydration and electrolyte imbalances\\nresulting from protracted vomiting or continued nasogastric suctioning should be vigorously sought and\\ncorrected. Prokinetic agents are not indicated. Generally, obstruction resolves within 2 to 5 days of\\ntreatment. Prolonged obstruction may result from peptic scarring and may respond to endoscopic pyloric\\nballoon dilation. Surgery is necessary to relieve obstruction in selected cases.\\nRecurrence:\\n Factors that affect recurrence of ulcer include failure to eradicate \\nH. pylori\\n, continued\\nNSAID use, and smoking. Less commonly, a gastrinoma (Zollinger-Ellison syndrome) may be the cause.\\nThe 3-yr recurrence rate for gastric and duodenal ulcers is < 10% when \\nH. pylori\\n is successfully\\neradicated but > 50% when it is not. Thus, a patient with recurrent disease should be tested for \\nH. pylori\\nand treated again if the tests are positive.\\nAlthough long-term treatment with H\\n2\\n blockers, proton pump inhibitors, or misoprostol reduces the risk of\\nrecurrence, their routine use for this purpose is not recommended. However, patients who require NSAIDs\\nafter having had a peptic ulcer are candidates for long-term therapy, as are those with a marginal ulcer or\\nprior perforation or bleeding.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n191\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 201, 'page_label': '192'}, page_content='Stomach cancer:\\n Patients with \\nH. pylori\\n-associated ulcers have a 3- to 6-fold increased risk of gastric\\ncancer later in life. There is no increased risk of cancer with ulcers of other etiology.\\nTreatment\\n Eradication of \\nH. pylori\\n (when present)\\n Acid-suppressive drugs\\nTreatment of gastric and duodenal ulcers requires eradication of \\nH. pylori\\n when present (see p. \\n130\\n) and\\na reduction of gastric acidity. For duodenal ulcers, it is particularly important to suppress nocturnal acid\\nsecretion.\\nMethods of decreasing acidity include a number of drugs, all of which are effective but which vary in cost,\\nduration of therapy, and convenience of dosing. In addition, mucosal protective drugs (eg, sucralfate) and\\nacid-reducing surgical procedures may be used. Drug therapy is discussed on p. \\n136\\n.\\nAdjuncts:\\n Smoking should be stopped, and alcohol consumption stopped or limited to small amounts of\\ndilute alcohol. There is no evidence that changing the diet speeds ulcer healing or prevents recurrence.\\nThus, many physicians recommend eliminating only foods that cause distress.\\nSurgery:\\n With current drug therapy, the number of patients requiring surgery has declined dramatically.\\nIndications include perforation, obstruction, uncontrolled or recurrent bleeding, and, although rare,\\nsymptoms that do not respond to drug therapy.\\nSurgery consists of a procedure to reduce acid secretion, often combined with a procedure to ensure\\ngastric drainage. The recommended operation for duodenal ulcer is highly selective, or parietal cell,\\nvagotomy (which is limited to nerves at the gastric body and spares antral innervation, thereby obviating\\nthe need for a drainage procedure). This procedure has a very low mortality rate and avoids the morbidity\\nassociated with resection and traditional vagotomy. Other acid-reducing surgical procedures include\\nantrectomy, hemigastrectomy, partial gastrectomy, and subtotal gastrectomy (ie, resection of 30 to 90% of\\nthe distal stomach). These are typically combined with truncal vagotomy. Patients who undergo a\\nresective procedure or who have an obstruction require gastric drainage via a gastroduodenostomy\\n(Billroth I) or gastrojejunostomy (Billroth II).\\nThe incidence and type of postsurgical symptoms vary with the type of operation. After resective surgery,\\nup to 30% of patients have significant symptoms, including weight loss, maldigestion, anemia, dumping\\nsyndrome, reactive hypoglycemia, bilious vomiting, mechanical problems, and ulcer recurrence.\\nWeight loss\\n is common after subtotal gastrectomy; the patient may limit food intake because of early\\nsatiety (because the residual gastric pouch is small) or to prevent dumping syndrome and other\\npostprandial syndromes. With a small gastric pouch, distention or discomfort may occur after a meal of\\neven moderate size; patients should be encouraged to eat smaller and more frequent meals.\\nMaldigestion\\n and steatorrhea caused by pancreaticobiliary bypass, especially with Billroth II\\nanastomosis, may contribute to weight loss.\\nAnemia\\n is common (usually from iron deficiency, but occasionally from vitamin B\\n12\\n deficiency caused by\\nloss of intrinsic factor or bacterial overgrowth) in the afferent limb, and osteomalacia may occur. IM\\nvitamin B\\n12\\n supplementation is recommended for all patients with total gastrectomy but may also be given\\nto patients with subtotal gastrectomy if deficiency is suspected.\\nDumping syndrome\\n may follow gastric surgical procedures, particularly resections. Weakness,\\ndizziness, sweating, nausea, vomiting, and palpitation occur soon after eating, especially hyperosmolar\\nfoods. This phenomenon is referred to as early dumping, the cause of which remains unclear but likely\\ninvolves autonomic reflexes, intravascular volume contraction, and release of vasoactive peptides from\\nthe small intestine. Dietary modifications, with smaller, more frequent meals and decreased carbohydrate\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n192'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 202, 'page_label': '193'}, page_content='intake, usually help.\\nReactive hypoglycemia\\n or \\nlate dumping\\n (another form of the syndrome) results from rapid emptying of\\ncarbohydrates from the gastric pouch. Early high peaks in blood glucose stimulate excess release of\\ninsulin, which leads to symptomatic hypoglycemia several hours after the meal. A high-protein, low-\\ncarbohydrate diet and adequate caloric intake (in frequent small feedings) are recommended.\\nMechanical problems\\n (including gastroparesis and bezoar formationsee p. \\n138\\n) may occur secondary\\nto a decrease in phase III gastric motor contractions, which are altered after antrectomy and vagotomy.\\nDiarrhea is especially common after vagotomy, even without a resection (pyloroplasty).\\nUlcer recurrence\\n, according to older studies, occurs in 5 to 12% after highly selective vagotomy and in 2\\nto 5% after resective surgery. Recurrent ulcers are diagnosed by endoscopy and generally respond to\\neither proton pump inhibitors or H\\n2\\n blockers. For ulcers that continue to recur, the completeness of\\nvagotomy should be tested by gastric analysis, \\nH. pylori\\n eliminated if present, and Zollinger-Ellison\\nsyndrome ruled out by serum gastrin studies.\\nDrug Treatment of Gastric Acidity\\nDrugs for decreasing acidity are used for peptic ulcer, gastroesophageal reflux disease (GERDsee p.\\n125\\n), and many forms of gastritis. Some drugs are used in regimens for treating \\nH. pylori\\n infection. Drugs\\ninclude proton pump inhibitors, H\\n2\\n blockers, antacids, and prostaglandins.\\nProton pump inhibitors:\\n These drugs are potent inhibitors of H\\n+\\n,K\\n+\\n-ATPase. This enzyme, located in\\nthe apical secretory membrane of the parietal cell, plays a key role in the secretion of H\\n+\\n (protons).\\nThese drugs can completely inhibit acid secretion and have a long duration of action. They promote ulcer\\nhealing and are also key components of \\nH. pylori\\n eradication regimens. Proton pump inhibitors have\\nreplaced H\\n2\\n blockers in most clinical situations because of greater rapidity of action and efficacy.\\nProton pump inhibitors include esomeprazole, lansoprazole, and pantoprazole, all available orally and IV,\\nand omeprazole and rabeprazole, available only orally in the US (see\\nTable 13-1\\n). Omeprazole is available without a prescription in the US. For uncomplicated duodenal ulcers,\\nomeprazole 20 mg po once/day or lansoprazole 30 mg po once/day is given for 4 wk. Complicated\\nduodenal ulcers (ie, multiple\\n[\\nTable 13-1.\\n Proton Pump Inhibitors]\\nulcers, bleeding ulcers, those > 1.5 cm, or those occurring in patients with serious underlying illness)\\nrespond better to higher doses (omeprazole 40 mg once/day, lansoprazole 60 mg once/day or 30 mg bid).\\nGastric ulcers require treatment for 6 to 8 wk. Gastritis and GERD require 8 to 12 wk of therapy; GERD\\nadditionally requires long-term maintenance.\\nLong-term proton pump inhibitor therapy produces elevated gastrin levels, which lead to\\nenterochromaffin-like cell hyperplasia. However, there is no evidence of dysplasia or malignant\\ntransformation in patients receiving this treatment. Some may develop vitamin B\\n12\\n malabsorption.\\nH\\n2\\n blockers:\\n These drugs (cimetidine, ranitidine, famotidine, available IV and orally; and nizatidine\\navailable orally) are competitive inhibitors of histamine at the H\\n2\\n receptor, thus suppressing gastrin-\\nstimulated acid secretion and proportionately reducing gastric juice volume. Histamine-mediated pepsin\\nsecretion is also decreased.\\nH\\n2\\n blockers are well absorbed from the GI tract, with onset of action 30 to 60 min after ingestion and\\npeak effects at 1 to 2 h. IV administration produces a more rapid onset of action. Duration of action is\\nproportional to dose and ranges from 6 to 20 h. Doses should often be reduced in elderly patients.\\nFor duodenal ulcers, once daily oral administration of cimetidine 800 mg, ranitidine 300 mg, famotidine 40\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n193'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 203, 'page_label': '194'}, page_content='mg, or nizatidine 300 mg given at bedtime or after dinner for 6 to 8 wk is effective. Gastric ulcers may\\nrespond to the same regimen continued for 8 to 12 wk, but because nocturnal acid secretion is less\\nimportant, morning administration may be equally or more effective. Children  40 kg may receive adult\\ndoses. Below that weight, the oral dosage is ranitidine 2 mg/kg q 12 h and cimetidine 10 mg/kg q 12 h.\\nFor GERD, H\\n2\\n blockers are now mostly used for pain management. Gastritis heals with famotidine or\\nranitidine given bid for 8 to 12 wk.\\nCimetidine has minor antiandrogen effects expressed as reversible gynecomastia and, less commonly,\\nerectile dysfunction with prolonged use. Mental status changes, diarrhea, rash, drug fever, myalgias,\\nthrombocytopenia, and sinus bradycardia and hypotension after rapid IV administration have been\\nreported with all H\\n2\\n blockers, generally in < 1% of treated patients but more commonly in elderly patients.\\nCimetidine and, to a lesser extent, other H\\n2\\n blockers interact with the P-450 microsomal enzyme system\\nand may delay metabolism of other drugs eliminated through this system (eg, phenytoin, warfarin,\\ntheophylline, diazepam, lidocaine).\\nAntacids:\\n These agents neutralize gastric acid and reduce pepsin activity (which diminishes as gastric\\npH rises to > 4.0). In addition, some antacids adsorb pepsin. Antacids may interfere with the absorption of\\nother drugs (eg, tetracycline, digoxin, iron).\\nAntacids relieve symptoms, promote ulcer healing, and reduce recurrence. They are relatively\\ninexpensive but must be taken 5 to 7 times/day. The optimal antacid regimen for ulcer healing seems to\\nbe 15 to 30 mL of liquid or 2 to 4 tablets 1 h and 3 h after each meal and at bedtime. The total daily\\ndosage of antacids should provide 200 to 400 mEq neutralizing capacity. However, antacids have been\\nsuperseded by \\nacid-suppressive therapy in the treatment of peptic ulcer and are used only for short-term\\nsymptom relief.\\nIn general, there are 2 types of antacids: absorbable and nonabsorbable. Absorbable antacids (eg, Na\\nbicarbonate, Ca carbonate) provide rapid, complete neutralization but may cause alkalosis and should be\\nused only briefly (1 or 2 days). Nonabsorbable antacids (eg, aluminum or Mg hydroxide) have fewer\\nsystemic adverse effects and are preferred.\\nAluminum hydroxide is a relatively safe, commonly used antacid. With chronic use, phosphate depletion\\noccasionally develops as a result of binding of phosphate by aluminum in the GI tract. The risk of\\nphosphate depletion increases in alcoholics, undernourished patients, and patients with renal disease\\n(including those receiving hemodialysis). Aluminum hydroxide causes constipation.\\nMg hydroxide is a more effective antacid than aluminum but may cause diarrhea. To limit diarrhea, many\\nproprietary antacids combine Mg and aluminum antacids. Because small amounts of Mg are absorbed,\\nMg preparations should be used with caution in patients with renal disease.\\nProstaglandins:\\n Certain prostaglandins (especially misoprostol) inhibit acid secretion by decreasing the\\ngeneration of cyclic AMP that is triggered by histamine stimulation of the parietal cell, and enhance\\nmucosal defense. Synthetic prostaglandin derivatives are used predominantly to decrease the risk of\\nNSAID-induced mucosal injury. Patients at high risk of NSAID-induced ulcers (ie, elderly patients, those\\nwith a history of ulcer or ulcer complication, those also taking corticosteroids) are candidates to take\\nmisoprostol 200 \\n\\ng po qid with food along with their NSAID. Common adverse effects of misoprostol are\\nabdominal cramping and diarrhea, which occur in 30% of patients. Misoprostol is a powerful abortifacient\\nand is absolutely contraindicated in women of childbearing age who are not using contraception.\\nSucralfate:\\n This drug is a sucrose-aluminum complex that dissociates in stomach acid and forms a\\nphysical barrier over an inflamed area, protecting it from acid, pepsin, and bile salts. It also inhibits\\npepsin-substrate interaction, stimulates mucosal prostaglandin production, and binds bile salts. It has no\\neffect on acid output or gastrin secretion. Sucralfate seems to have trophic effects on the ulcerated\\nmucosa, possibly by binding growth factors and concentrating them at an ulcer site. Systemic absorption\\nof sucralfate is negligible. Constipation occurs in 3 to 5% of patients. Sucralfate may bind to other drugs\\nand interfere with their absorption.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n194'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 204, 'page_label': '195'}, page_content='The Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 13. Gastritis & Peptic Ulcer Disease\\n195'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 205, 'page_label': '196'}, page_content='Chapter 14. Bezoars and Foreign Bodies\\nIntroduction\\nFood and other ingested materials may collect and form solid masses within the GI tract.\\nBezoars\\nA bezoar is a tightly packed collection of partially digested or undigested material that is unable\\nto exit the stomach. It often occurs in patients with abnormal gastric emptying, especially those\\nthat have diabetic gastroparesis, as well as after gastric surgery. Many bezoars are\\nasymptomatic, but some cause symptoms of gastric outlet obstruction. Some can be dissolved\\nenzymatically, others removed endoscopically, and some require surgery.\\nPartially digested agglomerations of vegetable matter are called phytobezoars; agglomerations of hair are\\ncalled trichobezoars. Pharmacobezoars are concretions of medication (particularly common with\\nsucralfate and aluminum hydroxide gel). Many other substances have been found in bezoars.\\nEtiology\\nTrichobezoars, which can weigh several kg, most commonly occur in patients with psychiatric\\ndisturbances who chew and swallow their own hair. Phytobezoars often occur in patients who have\\nundergone a Billroth I or II partial gastrectomy, especially when accompanied by vagotomy.\\nHypochlorhydria, diminished antral motility, and incomplete mastication are the main predisposing factors;\\nthese factors are more common \\namong the elderly, who are thus at higher risk of bezoar formation.\\nOthers include diabetic gastroparesis and gastroplasty for morbid obesity. Consumption of persimmons (a\\nfruit containing the tannin shibuol, which polymerizes in the stomach) has been known to cause bezoars\\nthat require surgery in > 90% of cases. Persimmon bezoars often occur in epidemics in regions where the\\nfruit is grown.\\nSymptoms and Signs\\nMost bezoars cause no symptoms, although postprandial fullness, nausea and vomiting, pain, and GI\\nbleeding may occur.\\nDiagnosis\\n Endoscopy\\nBezoars are detectable as a mass lesion on most tests (eg, x-ray, ultrasound, CT) that may be done to\\nevaluate upper GI symptoms. They may be mistaken for tumors; upper endoscopy is usually done. On\\nendoscopy, bezoars have an unmistakable irregular surface and may range in color from yellow-green to\\ngray-black. An endoscopic biopsy that yields hair or plant material is diagnostic.\\nTreatment\\n Observation\\n Sometimes manual removal via endoscopy\\n Sometimes enzymatic therapy\\nIf initial diagnosis is made by endoscopy, removal can be attempted at that time. Fragmentation with\\nforceps, wire snare, jet spray, or even laser may break up bezoars, allowing them to pass or be extracted.\\nMetoclopramide 40 mg IV over 24 h or 10 mg IM q 4 h for several days may increase peristalsis and aid\\ngastric emptying of fragmented material.\\nIf endoscopy was not initially done, treatment is based on symptoms. Asymptomatic patients that have a\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 14. Bezoars & Foreign Bodies\\n196'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 206, 'page_label': '197'}, page_content=\"bezoar discovered incidentally during testing for other reasons do not necessarily require intervention. In\\nsome cases, a trial of enzymatic therapy can be attempted. Enzymes include papain (10,000 U with each\\nmeal), meat tenderizer (5 mL [1 tsp] in 8 oz of clear liquid before each meal), or cellulase (10 g dissolved\\nin 1 L water, consumed over 24 h for 2 to 3 days). If enzymatic therapy is unsuccessful, or if patients are\\nsymptomatic, endoscopic removal may be tried. Rocklike concretions and trichobezoars usually require\\nlaparotomy.\\nForeign Bodies\\nA variety of foreign bodies may enter the GI tract. Many pass spontaneously, but some become\\nimpacted, causing symptoms of obstruction. Perforation may occur. The esophagus is the most\\ncommon (75%) site of impaction. Nearly all impacted objects can be removed endoscopically,\\nbut surgery is occasionally necessary.\\nUndigestible objects may be intentionally swallowed by children and demented adults. Denture wearers,\\nthe elderly, and inebriated people are prone to accidentally swallowing inadequately masticated food\\n(particularly meat), which may become impacted in the esophagus. Smugglers who swallow drug-filled\\nballoons, vials, or packages to escape detection (body packers or body stuffers) may develop intestinal\\nobstruction. The packaging may rupture, leading to drug overdose.\\nEsophageal foreign bodies:\\n Foreign bodies usually lodge in an area of esophageal narrowing such as\\nat the cricopharyngeus or aortic arch or just above the gastroesophageal junction. If obstruction is\\ncomplete, patients retch or vomit. Some patients drool because they are unable to swallow secretions.\\nImmediate endoscopic removal is required for sharp objects, coins in the proximal esophagus, and any\\nobstruction causing significant symptoms. Also, button batteries lodged in the esophagus may cause\\ndirect corrosive damage, low-voltage burns, and pressure necrosis and thus require prompt removal.\\nOther esophageal foreign bodies may be observed for a maximum of 12 to 24 h. Glucagon 1 mg IV\\nsometimes relaxes the esophagus enough to allow spontaneous passage. Other methods, such as use of\\neffervescent agents, meat tenderizer, and bougienage, are not recommended. Endoscopic removal is the\\ntreatment of choice. Removal is best achieved using a forceps, basket, or snare with an overtube placed\\nin the esophagus to prevent aspiration.\\nSometimes, foreign bodies scratch the esophagus but do not become lodged. In such cases, patients may\\nreport a foreign body sensation even though no foreign body is present.\\nGastric and intestinal foreign bodies:\\n Foreign bodies that pass through the esophagus are\\nasymptomatic unless obstruction or perforation occurs. Of the foreign bodies that reach the stomach, 80\\nto 90% pass spontaneously, 10 to 20% require nonoperative intervention, and  1% require surgery.\\nThus, most intragastric foreign bodies can be ignored. However, objects larger than 5  2 cm \\nrarely pass\\nthe stomach. Sharp objects should be retrieved from the stomach because 15 to 35% will cause intestinal\\nperforation, but small round objects (eg, coins and button batteries) can simply be observed. The patient's\\nstools should be searched, and if the object does not appear, x-rays are taken at 48-h intervals. A coin\\nthat remains in the stomach for > 4 wk or a battery showing signs of corrosion on x-ray that remains in the\\nstomach for > 48 h should be removed. A hand-held metal detector can localize metallic foreign bodies\\nand provide information comparable to that yielded by plain x-rays.\\nPatients with symptoms of obstruction or perforation require laparotomy. Ingested drug packages are of\\ngreat concern because of the risk of leakage and consequent drug overdose. Patients with symptoms of\\ndrug toxicity should have immediate laparotomy with interim medical management of symptoms (eg,\\nbenzodiazepines for cocaine toxicity). Asymptomatic patients should be admitted to the hospital. Some\\nclinicians advocate oral polyethylene glycol solution as a cathartic to enhance passage of the material;\\nothers suggest surgical removal. The best practice is unclear.\\nMost foreign objects that have passed into the small intestine usually traverse the GI tract without\\nproblem, even if they take weeks or months to do so. They tend to be held up just before the ileocecal\\nvalve or at any site of narrowing, as is present in Crohn's disease. Sometimes objects such as toothpicks\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 14. Bezoars & Foreign Bodies\\n197\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 207, 'page_label': '198'}, page_content='remain within the GI tract for many years, only to turn up in a granuloma or abscess.\\nRectal foreign bodies:\\n Gallstones, fecaliths, and swallowed foreign bodies (including toothpicks and\\nchicken and fish bones) may lodge at the anorectal junction. Urinary calculi, vaginal pessaries, or surgical\\nsponges or instruments may erode into the rectum. Foreign bodies, sometimes bizarre and/or related to\\nsexual play, may be introduced intentionally but become lodged unintentionally. Some objects are caught\\nin the rectal wall, and others are trapped just above the anal sphincter.\\nSudden, excruciating pain during defecation should arouse suspicion of a penetrating foreign body,\\nusually lodged at or just above the anorectal junction. Other manifestations depend on the size and shape\\nof the foreign body, its duration in situ, and the presence of infection or perforation.\\nForeign bodies usually become lodged in the mid rectum, where they cannot negotiate the anterior\\nangulation of the rectum. They can be felt on digital examination. Abdominal examination and chest x-rays\\nmay be necessary to exclude possible intraperitoneal rectal perforation.\\nIf the object can be palpated, a local anesthetic is given by sc and submucosal injections of 0.5%\\nlidocaine or bupivacaine. The anus is dilated with a rectal retractor, and the foreign body is grasped and\\nremoved. If the object cannot be palpated, the patient should be hospitalized. Peristalsis usually moves\\nthe foreign body down to the mid rectum, and the above routine can be followed. Removal via a\\nsigmoidoscope or proctoscope is rarely successful, and sigmoidoscopy usually forces the foreign body\\nproximally, delaying its extraction. Regional or general anesthesia is infrequently necessary, and\\nlaparotomy with milking of the foreign body toward the anus or colotomy with extraction of the foreign\\nbody is rarely necessary. After extraction, sigmoidoscopy should be done to rule out significant rectal\\ntrauma or perforation. Removal of a rectal foreign body may be of high risk and should be done by a\\nsurgeon or gastroenterologist skilled in foreign body removal.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 14. Bezoars & Foreign Bodies\\n198'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 208, 'page_label': '199'}, page_content='Chapter 15. Pancreatitis\\nIntroduction\\nPancreatitis is classified as either acute or chronic. Acute pancreatitis is inflammation that resolves both\\nclinically and histologically. Chronic pancreatitis is characterized by histologic changes that are\\nirreversible and progressive and that result in considerable loss of exocrine and endocrine pancreatic\\nfunction. Patients with chronic pancreatitis may have a flare-up of acute disease.\\nPancreatitis can affect both the exocrine and endocrine functions of the pancreas. Pancreatic acinar cells\\nsecrete bicarbonate and digestive enzymes into ducts that connect the pancreas to the duodenum at the\\nampulla of Vater (exocrine function). Pancreatic \\n\\n-cells secrete insulin directly into the bloodstream\\n(endocrine function).\\nAcute Pancreatitis\\nAcute pancreatitis is inflammation of the pancreas (and, sometimes, adjacent tissues) caused\\nby the release of activated pancreatic enzymes. The most common triggers are biliary tract\\ndisease and chronic heavy alcohol intake. The condition ranges from mild (abdominal pain and\\nvomiting) to severe (pancreatic necrosis and a systemic inflammatory process with shock and\\nmultiorgan failure). Diagnosis is based on clinical presentation and serum amylase and lipase\\nlevels. Treatment is supportive, with IV fluids, analgesics, and fasting.\\nEtiology\\nBiliary tract disease and alcoholism account for  80% of acute pancreatitis cases. The remaining 20%\\nresult from myriad causes (see\\nTable 15-1\\n).\\nPathophysiology\\nThe precise mechanism by which obstruction of the sphincter of Oddi by a gallstone or microlithiasis\\n(sludge) causes pancreatitis is unclear, although it probably involves increased ductal pressure.\\nProlonged alcohol intake (> 100 g/day for > 3 to 5 yr) may cause the protein of pancreatic enzymes to\\nprecipitate within small pancreatic ductules. Ductal obstruction by these protein plugs may cause\\npremature activation of pancreatic enzymes. An alcohol binge in such patients can trigger pancreatitis, but\\nthe exact mechanism is not known.\\nA number of genetic mutations predisposing to pancreatitis have been identified. One, an autosomal\\ndominant mutation of the cationic trypsinogen gene, causes pancreatitis in 80% of carriers; an obvious\\nfamilial pattern is present. Other mutations have lesser penetrance and are not readily apparent clinically\\nexcept through genetic testing. The genetic abnormality responsible for cystic fibrosis increases the risk\\nof recurrent acute as well as chronic pancreatitis.\\nRegardless of the etiology, pancreatic enzymes (including trypsin, phospholipase A\\n2\\n, and elastase)\\nbecome activated within the gland itself. The enzymes can damage tissue and activate complement and\\nthe inflammatory cascade, producing cytokines. This process causes inflammation, edema, and\\nsometimes necrosis. In mild pancreatitis, inflammation is confined to the pancreas; the mortality rate is <\\n5%. In severe pancreatitis, there is significant inflammation, with necrosis and hemorrhage of the gland\\nand a systemic inflammatory response; the mortality rate is 10 to 50%. After 5 to 7 days, necrotic\\npancreatic tissue may become infected by enteric bacteria.\\n[\\nTable 15-1.\\n Some Causes of Acute Pancreatitis]\\nActivated enzymes and cytokines that enter the peritoneal cavity cause a chemical burn and third spacing\\nof fluid; those that enter the systemic circulation cause a systemic inflammatory response that can result\\nin acute respiratory distress syndrome and renal failure. The systemic effects are mainly the result of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 15. Pancreatitis\\n199'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 209, 'page_label': '200'}, page_content=\"increased capillary permeability and decreased vascular tone, which result from the released cytokines\\nand chemokines. Phospholipase A\\n2\\n is thought to injure alveolar membranes of the lungs.\\nIn about 40% of patients, collections of enzyme-rich pancreatic fluid and tissue debris form in and around\\nthe pancreas. In about \\nhalf, the collections resolve spontaneously. In others, the collections become\\ninfected or form pseudocysts. Pseudocysts have a fibrous capsule without an epithelial lining.\\nPseudocysts may hemorrhage, rupture, or become infected.\\nDeath during the first several days is usually caused by cardiovascular instability (with refractory shock\\nand renal failure) or respiratory failure (with hypoxemia and at times adult respiratory distress syndrome).\\nOccasionally, death results from heart failure secondary to an unidentified myocardial depressant factor.\\nDeath after the first week is usually caused by multiorgan system failure.\\nSymptoms and Signs\\nAn acute attack causes steady, boring upper abdominal pain, typically severe enough to require large\\ndoses of parenteral opioids. The pain radiates through to the back in about 50% of patients; rarely, pain\\nis first felt in the lower abdomen. Pain usually develops suddenly in gallstone pancreatitis; in alcoholic\\npancreatitis, pain develops over a few days. The pain usually persists for several days. Sitting up and\\nleaning forward may reduce pain, but coughing, vigorous movement, and deep breathing may accentuate\\nit. Nausea and vomiting are common.\\nThe patient appears acutely ill and sweaty. Pulse rate is usually 100 to 140 beats/min. Respiration is\\nshallow and rapid. BP may be transiently high or low, with significant postural hypotension. Temperature\\nmay be normal or even subnormal at first but may increase to 37.7 to 38.3 C (100 to 101 F) within a few\\nhours. Sensorium may be blunted to the point of semicoma. Scleral icterus is occasionally present. The\\nlungs may have limited diaphragmatic excursion and evidence of atelectasis.\\nAbout 20% of patients experience upper abdominal distention caused by gastric distention or\\ndisplacement of the stomach by a pancreatic inflammatory mass. Pancreatic duct disruption may cause\\nascites (pancreatic ascites). Marked abdominal tenderness occurs, most often in the upper abdomen.\\nThere may be mild tenderness in the lower abdomen, but the rectum is not tender and the stool is usually\\nnegative for occult blood. Mild-to-moderate muscular rigidity may be present in the upper abdomen but is\\nrare in the lower abdomen. Rarely, severe peritoneal irritation results in a rigid and boardlike abdomen.\\nBowel sounds may be hypoactive. Grey Turner's sign (ecchymoses of the flanks) and Cullen's sign\\n(ecchymoses of the umbilical region) indicate extravasation of hemorrhagic exudate.\\nInfection in the pancreas or in an adjacent fluid collection should be suspected if the patient has a\\ngenerally toxic appearance with elevated temperature and WBC count or if deterioration follows an initial\\nperiod of stabilization.\\nDiagnosis\\n Serum markers (amylase, lipase)\\n Once pancreatitis is diagnosed, CT usually done\\nPancreatitis is suspected whenever severe abdominal pain occurs, especially in a patient with significant\\nalcohol use or known gallstones. Conditions causing similar symptoms include perforated gastric or\\nduodenal ulcer, mesenteric infarction, strangulating intestinal obstruction, dissecting aneurysm, biliary\\ncolic, appendicitis, diverticulitis, inferior wall MI, and hematoma of the abdominal muscles or spleen.\\nDiagnosis is made by clinical suspicion, serum markers (amylase and lipase), and the absence of other\\ncauses for the patient's symptoms. Thus, a broad range of tests is done, typically including CBC,\\nelectrolytes, Ca, Mg, glucose, BUN, creatinine, amylase, and lipase. Other routine tests include ECG and\\nan abdominal series (chest, flat, and upright abdomen). A urine dipstick for trypsinogen-2 has sensitivity\\nand specificity of > 90% for acute pancreatitis. Ultrasound and CT are not generally done specifically to\\ndiagnose pancreatitis but are often used to evaluate acute abdominal pain (see p.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 15. Pancreatitis\\n200\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 210, 'page_label': '201'}, page_content='108\\n).\\nLaboratory tests:\\n Serum amylase and lipase concentrations increase on the first day of acute\\npancreatitis and return to normal in 3 to 7 days. Lipase is more specific for pancreatitis, but both enzymes\\nmay be increased in renal failure and various abdominal conditions (eg, perforated ulcer, mesenteric\\nvascular occlusion, intestinal obstruction). Other causes of increased serum amylase include salivary\\ngland dysfunction, macroamylasemia, and tumors that secrete amylase. Both amylase and lipase levels\\nmay remain normal if destruction of acinar tissue during previous episodes precludes release of sufficient\\namounts of enzymes. The serum of patients with hypertriglyceridemia may contain a circulating inhibitor\\nthat must be diluted before an elevation in serum amylase can be detected.\\nAmylase:creatinine clearance ratio does not have sufficient sensitivity or specificity to diagnose\\npancreatitis. It is generally used to diagnose macroamylasemia when no pancreatitis exists. In\\nmacroamylasemia, amylase bound to serum immunoglobulin falsely elevates the serum amylase level.\\nFractionation of total serum amylase into pancreatic type (p-type) isoamylase and salivary-type (s-type)\\nisoamylase increases the accuracy of serum amylase. However, the level of p-type also increases in\\nrenal failure and in other severe abdominal conditions in which amylase clearance is altered.\\nThe WBC count usually increases to 12,000 to 20,000/\\n\\nL. Third-space fluid losses may increase the Hct\\nto as high as 50 to 55%, indicating severe inflammation. Hyperglycemia may occur. Serum Ca\\nconcentration falls as early as the first day because of the formation of Ca \"soaps\" secondary to excess\\ngeneration of free fatty acids, especially by pancreatic lipase. Serum bilirubin increases in 15 to 25% of\\npatients because pancreatic edema compresses the common bile duct.\\nImaging:\\n Plain x-rays of the abdomen may disclose calcifications within pancreatic ducts (evidence of\\nprior inflammation and hence chronic pancreatitis), calcified gallstones, or localized ileus in the left upper\\nquadrant or the center of the abdomen (a \"sentinel loop\" of small bowel, dilation of the transverse colon,\\nor duodenal ileus). Chest x-ray may reveal atelectasis or a pleural effusion (usually left-sided or bilateral\\nbut rarely confined to the right pleural space).\\nUltrasound should be done if gallstone pancreatitis is suspected (and another etiology is not obvious) to\\ndetect gallstones or dilation of the common bile duct (which indicates biliary tract obstruction). Edema of\\nthe pancreas may be visualized, but overlying gas frequently obscures the pancreas.\\nCT with IV contrast is generally done to identify necrosis, fluid collections, or pseudocysts once\\npancreatitis has been diagnosed. It is particularly recommended for severe pancreatitis or if a\\ncomplication ensues (eg, hypotension or progressive leukocytosis and elevation of temperature). IV\\ncontrast facilitates the recognition of pancreatic necrosis; however, it may cause pancreatic necrosis in\\nareas of low perfusion (ie, ischemia). Thus, contrast-enhanced CT should be done only after the patient\\nhas been adequately hydrated.\\nIf pancreatic infection is suspected, fluid obtained by percutaneous CT-guided needle aspiration of cysts\\nor areas of fluid collection or necrosis may reveal organisms on Gram stain or culture. The diagnosis is\\nsupported by positive blood cultures and, particularly, by the presence of air bubbles in the\\nretroperitoneum on abdominal CT. The advent of magnetic resonance cholangiopancreatography\\n(MRCP) may make the selection of pancreatic imaging simpler.\\nPrognosis\\nIn edematous pancreatitis, mortality is < 5%. In pancreatitis with necrosis and hemorrhage, mortality is 10\\nto 50%. In pancreatic infection, mortality is usually 100% without extensive surgical debridement or\\ndrainage of the infected area.\\nCT findings correlate with prognosis. If CT is normal or shows only mild pancreatic edema (Balthazar\\nclass A or B), the prognosis is excellent. Patients with peripancreatic inflammation or one area of fluid\\ncollection (classes C and D) have a 10 to 15% incidence of abscess formation; the incidence is over 60%\\nin patients with two or more areas of fluid collection (class E).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 15. Pancreatitis\\n201'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 211, 'page_label': '202'}, page_content=\"Ranson's prognostic signs\\n help predict the prognosis of acute pancreatitis. Five of Ranson's signs can\\nbe documented at admission:\\n Age > 55 yr\\n Plasma glucose > 200 mg/dL (> 11.1 mmol/L)\\n Serum LDH > 350 IU/L\\n AST > 250 UL\\n WBC count > 16,000/\\n\\nL\\nThe rest of Ranson's signs are determined within 48 h of admission:\\n Hct decrease > 10%\\n BUN increase > 5 mg/dL (> 1.78 mmol/L)\\n Serum Ca < 8 mg/dL (< 2 mmol/L)\\n Pao\\n2\\n < 60 mm Hg (< 7.98 kPa)\\n Base deficit > 4 mEq/L (> 4 mmol/L)\\n Estimated fluid sequestration > 6 L\\nMortality increases with the number of positive signs: If < 3 signs are positive, the mortality rate is < 5%; if\\n 3 are positive, mortality is 15 to 20%.\\nThe APACHE II index (see\\nTable 222-4\\n on p. \\n2248\\n), calculated on the second hospital day, also correlates with prognosis.\\nTreatment\\n Fluid resuscitation\\n Fasting\\n Drugs, including adequate analgesia and acid blockers\\n Antibiotics for pancreatic necrosis\\n Drainage of infected pseudocysts or areas of necrosis\\nAdequate fluid resuscitation is essential; up to 6 to 8 L/day of fluid containing appropriate electrolytes may\\nbe required. Inadequate fluid therapy increases the risk of pancreatic necrosis.\\nFasting is indicated until acute inflammation subsides (ie, cessation of abdominal tenderness and pain,\\nnormalization of serum \\namylase, return of appetite, feeling better). Fasting can last from a few days in\\nmild pancreatitis to several weeks. TPN should be initiated in severe cases within the first few days to\\nprevent undernutrition.\\nPain relief requires parenteral opioids, which should be given in adequate doses. Although morphine may\\ncause the sphincter of Oddi to contract, this is of doubtful clinical significance. Antiemetic agents (eg,\\nprochlorperazine 5 to 10 mg IV q 6 h) should be given to alleviate vomiting. An NGT is required only if\\nsignificant vomiting persists or ileus is present.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 15. Pancreatitis\\n202\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 212, 'page_label': '203'}, page_content=\"Parenteral H\\n2\\n blockers or proton pump inhibitors are given. Efforts to reduce pancreatic secretion with\\ndrugs (eg, anticholinergics, glucagon, somatostatin, octreotide) have no proven benefit.\\nSevere acute pancreatitis should be treated in an ICU, particularly in patients with hypotension, oliguria,\\nRanson's score  3, APACHE II  8, or pancreatic necrosis on CT > 30%. In the ICU, vital signs and urine\\noutput are monitored hourly; metabolic parameters (Hct, glucose, and electrolytes) are reassessed every\\n8 h; ABG is determined as needed; central venous pressure line or Swan-Ganz catheter measurements\\nare determined every 6 h if the patient is hemodynamically unstable or if fluid requirements are unclear.\\nCBC, platelet count, coagulation parameters, total protein with albumin, BUN, creatinine, Ca, and Mg are\\nmeasured daily.\\nHypoxemia is treated with humidified O\\n2\\n via mask or nasal prongs. If hypoxemia persists or adult\\nrespiratory distress syndrome develops, assisted ventilation may be required. Glucose > 170 to 200\\nmg/dL (9.4 to 11.1 mmol/L) should be treated cautiously with sc or IV insulin and carefully monitored.\\nHypocalcemia generally is not treated unless neuromuscular irritability occurs; 10 to 20 mL of 10% Ca\\ngluconate in 1 L of IV fluid is given over 4 to 6 h. Chronic alcoholics and patients with documented\\nhypomagnesemia should receive Mg sulfate 1 g/L of replacement fluid for a total of 2 to 4 g, or until levels\\nnormalize. If renal failure occurs, serum Mg levels are monitored and IV Mg is given cautiously. With\\nrestoration of normal Mg levels, serum Ca levels usually return to normal.\\nHeart failure should be treated (see p. \\n2126\\n). Prerenal azotemia should be treated by increased fluid\\nreplacement. Renal failure may require dialysis (usually peritoneal).\\nAntibiotic prophylaxis with imipenem can prevent infection of sterile pancreatic necrosis, although the\\neffect on reducing mortality is unclear. Infected areas of pancreatic necrosis require surgical debridement,\\nbut infected fluid collections outside the pancreas may be drained percutaneously. A pseudocyst that is\\nexpanding rapidly, infected, bleeding, or likely to rupture requires drainage. Whether drainage is\\npercutaneous, surgical, or endoscopic depends on location of the pseudocyst and institutional expertise.\\nPeritoneal lavage to wash out activated pancreatic enzymes and inflammatory mediators has no proven\\nbenefit.\\nSurgical intervention during the first several days is justified for severe blunt or penetrating trauma or\\nuncontrolled biliary sepsis. Although > 80% of patients with gallstone pancreatitis pass the stone\\nspontaneously, ERCP with sphincterotomy and stone removal is indicated for patients who do not improve\\nafter 24 h of treatment. Patients who spontaneously improve generally undergo elective laparoscopic\\ncholecystectomy. Elective cholangiography remains controversial.\\nChronic Pancreatitis\\nChronic pancreatitis is persistent inflammation of the pancreas that results in permanent\\nstructural damage with fibrosis and ductal strictures, followed by a decline in exocrine and\\nendocrine function. It can occur as the result of chronic alcohol abuse but may be idiopathic.\\nInitial symptoms are recurrent attacks of pain. Later in the disease, some patients develop\\nmalabsorption and glucose intolerance. Diagnosis is usually made by imaging studies such as\\nERCP, endoscopic ultrasound, or secretin pancreatic function testing. Treatment is supportive,\\nwith dietary modification, analgesics, and enzyme supplements. In some cases, surgical\\ntreatment is helpful.\\nEtiology\\nIn the US, 70 to 80% of cases result from alcoholism, and 15 to 25% are idiopathic. However, recent data\\nsuggest that alcohol is becoming less of a cause. Less common causes include hereditary pancreatitis,\\nhyperparathyroidism, and obstruction of the main pancreatic duct caused by stenosis, stones, or cancer.\\nIn India, Indonesia, and Nigeria, idiopathic calcific pancreatitis occurs among children and young adults\\n(tropical pancreatitis).\\nPathophysiology\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 15. Pancreatitis\\n203\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 213, 'page_label': '204'}, page_content='Similar to acute pancreatitis, the mechanism of disease may be ductal obstruction by protein plugs. The\\nprotein plugs may result from excess secretion of glycoprotein-2 or a \\ndeficiency of lithostatin, a protein in\\npancreatic fluid that inhibits Ca precipitation. If obstruction is chronic, persistent inflammation leads to\\nfibrosis and alternating areas of ductal dilation and stricture, which may become calcified. Neuronal\\nsheath hypertrophy and perineural inflammation occur and may contribute to chronic pain.\\nAfter several years, progressive fibrosis leads to loss of exocrine and endocrine function. Diabetes\\ndevelops in 20 to 30% of patients within 10 to 15 yr of onset.\\nSymptoms and Signs\\nMost patients present with episodic abdominal pain. About 10 to 15% have no pain and present with\\nmalabsorption. Pain is epigastric, severe, and may last many hours or several days. Episodes typically\\nsubside spontaneously after 6 to 10 yr as the acinar cells that secrete pancreatic digestive enzymes are\\nprogressively destroyed. When lipase and protease secretions are reduced to < 10% of normal, the\\npatient develops steatorrhea, passing greasy stools or even oil droplets, and creatorrhea (the presence\\nof undigested muscle fibers in the feces). Symptoms of glucose intolerance may appear at this time.\\nDiagnosis\\n Clinical suspicion\\n Abdominal CT\\n Sometimes magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasonography, or\\nERCP\\nDiagnosis can be difficult because amylase and lipase levels are frequently normal because of significant\\nloss of pancreatic function. In a patient with a typical history of alcohol abuse and recurrent episodes of\\nacute pancreatitis, detection of pancreatic calcification on plain x-ray of the abdomen may be sufficient.\\nHowever, such calcifications typically occur late in the disease and then are visible in only about 30% of\\npatients. In patients without a typical history, pancreatic cancer must be excluded as the cause of pain:\\nabdominal CT is recommended. CT can show calcifications and other pancreatic abnormalities (eg,\\npseudocyst or dilated ducts) but still may be normal early in the disease.\\nThe primary options for patients with normal CT findings include ERCP, endoscopic ultrasonography, and\\nsecretin pancreatic function testing. These tests are quite sensitive, but ERCP precipitates acute\\npancreatitis in about 5% of patients. MRCP may prove an acceptable alternative.\\nLate in the disease, tests of pancreatic exocrine function become abnormal. A 72-h test for stool fat is\\ndiagnostic for steatorrhea but cannot establish a cause. The secretin test collects pancreatic secretions\\nvia a duodenal tube for analysis but is done in only a few centers. Levels of serum trypsinogen and fecal\\nchymotrypsin and elastase may be decreased. In the bentiromide test and the pancreolauryl test,\\nsubstances are given orally, and urine is analyzed for cleavage products generated by pancreatic\\nenzymes. All such exocrine tests are less sensitive than ERCP or endoscopic ultrasonography early in the\\ndisease.\\nTreatment\\n IV fluids\\n Fasting\\n Drugs, including adequate analgesia and acid blockers\\n Pancreatic enzyme supplements\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 15. Pancreatitis\\n204'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 214, 'page_label': '205'}, page_content=' Sometimes drainage of pseudocysts (surgical or endoscopic)\\nA relapse requires treatment similar to acute pancreatitis with fasting, IV fluids, and analgesics. When\\nfeeding resumes, the patient must eschew alcohol and consume a low-fat (< 25 g/day) diet (to reduce\\nsecretion of pancreatic enzymes). An H\\n2\\n blocker or proton pump inhibitor may reduce acid-stimulated\\nrelease of secretin, thereby decreasing the flow of pancreatic secretions. Too often, these measures do\\nnot relieve pain, requiring increased amounts of opioids, with the threat of addiction. Medical treatment of\\nchronic pancreatic pain is often unsatisfactory.\\nPancreatic enzyme supplementation may reduce chronic pain by inhibiting the release of cholecystokinin,\\nthereby reducing the secretion of pancreatic enzymes. Supplementation is more likely to be successful in\\nmild idiopathic pancreatitis than in alcoholic pancreatitis. Enzymes are also used to treat steatorrhea.\\nVarious preparations are available, and a dose providing at least 30,000 U of lipase should be used. Non-\\nenteric coated tablets should be used, and they should be taken with meals. An H\\n2\\n blocker or proton\\npump inhibitor should be given to prevent acid breakdown of the enzymes.\\nFavorable clinical responses include weight gain, fewer bowel movements, elimination of oil droplet\\nseepage, and improved well-being. Clinical response can be documented by showing a decrease in stool\\nfat after enzyme therapy. If steatorrhea is particularly severe and refractory to these measures, medium-\\nchain triglycerides can be provided as a source of fat (they are absorbed without pancreatic enzymes),\\nreducing \\nother dietary fats proportionally. Supplementation with fat-soluble vitamins (A, D, K) should be\\ngiven, including vitamin E, which may minimize inflammation.\\nSurgical treatment may be effective for pain relief. A pancreatic pseudocyst, which may cause chronic\\npain, can be decompressed into a nearby structure to which it firmly adheres (eg, the stomach) or into a\\ndefunctionalized loop of jejunum (via a Roux-en-Y cystojejunostomy). If the main pancreatic duct is dilated\\n> 5 to 8 mm, a lateral pancreaticojejunostomy (Puestow procedure) relieves pain in about 70 to 80% of\\npatients. If the duct is not dilated, a partial resection is similarly effective; either distal pancreatectomy (for\\nextensive disease at the tail of the pancreas) or Whipple procedure (for extensive disease at the head of\\nthe pancreas) is done. Operative approaches should be reserved for patients who have stopped using\\nalcohol and who can manage diabetes that may be intensified by pancreatic resection.\\nSome pseudocysts can be drained endoscopically. Endoscopic ultrasound-guided denervation of the\\nceliac plexus with alcohol and bupivacaine may provide pain relief. If there is significant stricture at the\\npapilla or distal pancreatic duct, ERCP with sphincterotomy, stent placement, or dilatation may be\\neffective.\\nOral hypoglycemic drugs rarely help treat diabetes caused by chronic pancreatitis. Insulin should be given\\ncautiously because the coexisting deficiency of glucagon secretion by \\n\\n-cells means that the\\nhypoglycemic effects of insulin are unopposed and prolonged hypoglycemia may occur.\\nPatients are at increased risk of pancreatic cancer. Worsening of symptoms, especially with development\\nof a pancreatic duct stricture, should prompt an evaluation for cancer. Evaluation may include brushing\\nstrictures for cytologic analysis or measuring serum markers (eg, CA 19-9, carcinoembryonic antigen).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 15. Pancreatitis\\n205'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 215, 'page_label': '206'}, page_content='Chapter 16. Gastroenteritis\\nIntroduction\\n(See also \\nFood Allergy\\n on p. \\n1118\\n and \\nMushroom Poisoning\\n on p. \\n3336\\n.)\\nGastroenteritis is inflammation of the lining of the stomach and small and large intestines. Most\\ncases are infectious, although gastroenteritis may occur after ingestion of drugs and chemical\\ntoxins (eg, metals, plant substances). Symptoms include anorexia, nausea, vomiting, diarrhea,\\nand abdominal discomfort. Diagnosis is clinical or by stool culture, although immunoassays are\\nincreasingly used. Treatment is symptomatic, although parasitic and some bacterial infections\\nrequire specific anti-infective therapy.\\nGastroenteritis is usually uncomfortable but self-limited. Electrolyte and fluid loss is usually little more than\\nan inconvenience to an otherwise healthy adult but can be grave for people who are very young (see p.\\n2806\\n), elderly, or debilitated or who have serious concomitant illnesses. Worldwide, an estimated 3 to 6\\nmillion children die each year from infectious gastroenteritis.\\nEtiology\\nInfectious gastroenteritis may be caused by viruses, bacteria, or parasites. Many specific organisms are\\ndiscussed further in the Infectious Diseases section.\\nViruses:\\n The viruses most commonly implicated are\\n Rotavirus\\n Norovirus\\nViruses are the most common cause of gastroenteritis in the US. They infect enterocytes in the villous\\nepithelium of the small bowel. The result is transudation of fluid and salts into the intestinal lumen;\\nsometimes, malabsorption of carbohydrates worsens symptoms by causing osmotic diarrhea. Diarrhea is\\nwatery. Inflammatory diarrhea (dysentery), with fecal WBCs and RBCs or gross blood, is uncommon. Four\\ncategories of viruses cause most gastroenteritis: rotavirus and calicivirus (predominantly the norovirus\\n[formerly Norwalk virus]) cause the majority of viral gastroenteritis, followed by astrovirus and enteric\\nadenovirus.\\nRotavirus is the most common cause of sporadic, severe, dehydrating diarrhea in young children (peak\\nincidence, 3 to 15 mo). Rotavirus is highly contagious; most infections occur by the fecal-oral route. Adults\\nmay be infected after close contact with an infected infant. The illness in adults is generally mild.\\nIncubation is 1 to 3 days. In temperate climates, most infections occur in the winter. Each year in the US,\\na wave of rotavirus illness begins in the Southwest in November and ends in the Northeast in March.\\nNorovirus most commonly infects older children and adults. Infections occur year-round. Norovirus is the\\nprincipal cause of sporadic viral gastroenteritis in adults and of epidemic viral gastroenteritis in all age\\ngroups; large waterborne and food-borne outbreaks occur. Person-to-person transmission also occurs\\nbecause the virus is highly contagious. Incubation is 24 to 48 h.\\nAstrovirus can infect people of all ages but usually infects infants and young children. Infection is most\\ncommon in winter. Transmission is by the fecal-oral route. Incubation is 3 to 4 days.\\nAdenoviruses are the 4th most common cause of childhood viral gastroenteritis. Infections occur year-\\nround, with a slight increase in summer. Children < 2 yr are primarily affected. Transmission is by the\\nfecal-oral route. Incubation is 3 to 10 days.\\nIn immunocompromised patients, additional viruses (eg, cytomegalovirus, enterovirus) can cause\\ngastroenteritis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 16. Gastroenteritis\\n206'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 216, 'page_label': '207'}, page_content=\"Bacteria:\\n The bacteria most commonly implicated are\\n \\nSalmonella\\n \\nCampylobacter\\n \\nShigella\\n \\nEscherichia coli\\n (especially serotype O157:H7)\\nBacterial gastroenteritis is less common than viral. Bacteria cause gastroenteritis by several mechanisms.\\nCertain species (eg, \\nVibrio cholerae\\n, enterotoxigenic strains of \\nE. coli\\n) adhere to intestinal mucosa\\nwithout invading and produce enterotoxins. These toxins impair intestinal absorption and cause secretion\\nof electrolytes and water by stimulating adenylate cyclase, resulting in watery diarrhea. \\nClostridium\\ndifficile\\n produces a similar toxin when overgrowth follows antibiotic use (see p. \\n1292\\n).\\nSome bacteria (eg, \\nStaphylococcus aureus\\n, \\nBacillus cereus\\n, \\nClostridium perfringens\\n) produce an\\nexotoxin that is ingested in contaminated food. The exotoxin can cause gastroenteritis without bacterial\\ninfection. These toxins generally cause acute nausea, vomiting, and diarrhea within 12 h of ingestion of\\ncontaminated food. Symptoms abate within 36 h.\\nOther bacteria (eg, \\nShigella\\n, \\nSalmonella\\n, \\nCampylobacter\\n, some \\nE. coli\\n subtypes) invade the mucosa of\\nthe small bowel or colon and cause microscopic ulceration, bleeding, exudation of protein-rich fluid, and\\nsecretion of electrolytes and water. The invasive process and its results can occur whether or not the\\norganism produces an enterotoxin. The resulting diarrhea contains WBCs and RBCs and sometimes\\ngross blood.\\nSalmonella\\n and \\nCampylobacter\\n are the most common bacterial causes of diarrheal illness in the US.\\nBoth infections are most frequently acquired through undercooked poultry; unpasteurized milk is also a\\npossible source. \\nCampylobacter\\n is occasionally transmitted from dogs or cats with diarrhea. \\nSalmonella\\ncan be transmitted by undercooked eggs and by contact with reptiles. Species of \\nShigella\\n are the 3rd\\nmost common bacterial cause of diarrhea in the US and are usually transmitted person to person,\\nalthough food-borne epidemics occur. \\nShigella dysenteriae\\n type 1 (not present in the US) produces\\nShiga toxin, which can cause hemolytic-uremic syndrome (see p. \\n961\\n).\\nSeveral different subtypes of \\nE. coli\\n cause diarrhea. The epidemiology and clinical manifestations vary\\ngreatly depending on the subtype: (1) Enterohemorrhagic \\nE. coli\\n is the most clinically significant subtype\\nin the US. It produces Shiga toxin, which causes bloody diarrhea (hemorrhagic colitis). \\nE. coli\\n O157:H7 is\\nthe most common strain of this subtype in the US. Undercooked ground beef, unpasteurized milk and\\njuice, and contaminated water are possible sources. Person-to-person transmission is common in the day\\ncare setting. Hemolytic-uremic syndrome is a serious complication that develops in 2 to 7% of cases,\\nmost commonly among the young and old. (2) Enterotoxigenic \\nE. coli\\n produces two toxins (one similar to\\ncholera toxin) that cause watery diarrhea. This subtype is the most common cause of traveler's diarrhea.\\n(3) Enteropathogenic \\nE. coli\\n causes watery diarrhea. Once a common cause of diarrhea outbreaks in\\nnurseries, this subtype is now rare. (4) Enteroinvasive \\nE. coli\\n causes bloody or nonbloody diarrhea,\\nprimarily in the developing world. It is rare in the US.\\nSeveral other bacteria cause gastroenteritis, but most are uncommon in the US. \\nYersinia enterocolitica\\ncan cause gastroenteritis or a syndrome that mimics appendicitis. It is transmitted by undercooked pork,\\nunpasteurized milk, or contaminated water. Several \\nVibrio\\n species (eg, \\nV. parahaemolyticus\\n) cause\\ndiarrhea after ingestion of undercooked seafood. \\nV. cholerae\\n sometimes causes severe dehydrating\\ndiarrhea in the developing world. \\nListeria\\n causes food-borne gastroenteritis. \\nAeromonas\\n is acquired from\\nswimming \\nin or drinking contaminated fresh or brackish water. \\nPlesiomonas shigelloides\\n can cause\\ndiarrhea in patients who have eaten raw shellfish or traveled to tropical regions of the developing world.\\nParasites:\\n The parasites most commonly implicated are\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 16. Gastroenteritis\\n207\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 217, 'page_label': '208'}, page_content=' \\nGiardia\\n \\nCryptosporidium\\nCertain intestinal parasites, notably \\nGiardia intestinalis\\n (\\nlamblia\\nsee p. \\n1371\\n), adhere to or invade the\\nintestinal mucosa, causing nausea, vomiting, diarrhea, and general malaise. Giardiasis occurs in every\\nregion of the US and throughout the world. The infection can become chronic and cause a malabsorption\\nsyndrome. It is usually acquired via person-to-person transmission (often in day care centers) or from\\ncontaminated water.\\nCryptosporidium parvum\\n causes watery diarrhea sometimes accompanied by abdominal cramps, nausea,\\nand vomiting. In healthy people, the illness is self-limited, lasting about 2 wk. In immunocompromised\\npatients, illness may be severe, causing substantial electrolyte and fluid loss. \\nCryptosporidium\\n is usually\\nacquired through contaminated water.\\nOther parasites that can cause symptoms similar to those of cryptosporidiosis include \\nCyclospora\\ncayetanensis\\n and, in immunocompromised patients, \\nCystoisospora\\n (\\nIsospora\\n) \\nbelli\\n, and a collection of\\norganisms referred to as microsporidia (eg, \\nEnterocytozoon bieneusi\\n, \\nEncephalitozoon intestinalis\\n).\\nEntamoeba histolytica\\n (amebiasis) is a common cause of subacute bloody diarrhea in the developing\\nworld and occasionally occurs in the US.\\nSymptoms and Signs\\nThe character and severity of symptoms vary. Generally, onset is sudden, with anorexia, nausea,\\nvomiting, borborygmi, abdominal cramps, and diarrhea (with or without blood and mucus). Malaise,\\nmyalgias, and prostration may occur. The abdomen may be distended and mildly tender; in severe cases,\\nmuscle guarding may be present. Gas-distended intestinal loops may be palpable. Borborygmi are\\npresent even without diarrhea (an important differential feature from paralytic ileus). Persistent vomiting\\nand diarrhea can result in intravascular fluid depletion with hypotension and tachycardia. In severe cases,\\nshock, with vascular collapse and oliguric renal failure, occurs.\\nIf vomiting is the main cause of fluid loss, metabolic alkalosis with hypochloremia can occur. If diarrhea is\\nmore prominent, acidosis is more likely. Both vomiting and diarrhea can cause hypokalemia.\\nHyponatremia may develop, particularly if hypotonic fluids are used in replacement therapy.\\nIn viral infections, watery diarrhea is the most common symptom; stools rarely contain mucus or blood.\\nRotavirus gastroenteritis in infants and young children may last 5 to 7 days. Vomiting occurs in 90% of\\npatients, and fever > 39 C (> 102.2 F) occurs in about 30%. Norovirus typically causes acute onset of\\nvomiting, abdominal cramps, and diarrhea, with symptoms lasting only 1 to 2 days. In children, vomiting is\\nmore prominent than diarrhea, whereas in adults, diarrhea usually predominates. Patients may also\\nexperience fever, headache, and myalgias. The hallmark of adenovirus gastroenteritis is diarrhea lasting\\n1 to 2 wk. Affected infants and children may have mild vomiting that typically starts 1 to 2 days after the\\nonset of diarrhea. Low-grade fever occurs in about 50% of patients. Astrovirus causes a syndrome similar\\nto mild rotavirus infection.\\nBacteria that cause invasive disease (eg, \\nShigella\\n, \\nSalmonella\\n) are more likely to result in fever,\\nprostration, and bloody diarrhea. Bacteria that produce an enterotoxin (eg, \\nS. aureus\\n, \\nB. cereus\\n, \\nC.\\nperfringens\\n) usually cause watery diarrhea.\\nParasitic infections typically cause subacute or chronic diarrhea. Most cause nonbloody diarrhea; an\\nexception is \\nE. histolytica\\n, which causes amebic dysentery. Fatigue and weight loss are common when\\ndiarrhea is persistent.\\nDiagnosis\\n Clinical evaluation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 16. Gastroenteritis\\n208'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 218, 'page_label': '209'}, page_content=' Stool testing in select cases\\nOther GI disorders that cause similar symptoms (eg, appendicitis, cholecystitis, ulcerative colitis) must be\\nexcluded. Findings suggestive of gastroenteritis include copious, watery diarrhea; ingestion of potentially\\ncontaminated food (particularly during a known outbreak), untreated surface water, or a known GI irritant;\\nrecent travel; or contact with similarly ill people. \\nE. coli\\n O157:H7-induced diarrhea is notorious for\\nappearing to be a hemorrhagic rather than an infectious process, manifesting as GI bleeding with little or\\nno stool. Hemolyticuremic syndrome may follow as evidenced by renal failure and hemolytic anemia (see\\np. \\n961\\n). Recent oral antibiotic use (within 3 mo) must raise suspicion for \\nC. difficile\\n infection (see p.\\n1292\\n).\\nStool testing:\\n If a rectal examination shows occult blood or if watery diarrhea persists > 48 h, stool\\nexamination (fecal WBCs, ova, parasites) and culture are indicated. However, for \\nthe diagnosis of\\ngiardiasis or cryptosporidiosis, stool antigen detection using an enzyme immunoassay has a higher\\nsensitivity. Rotavirus and enteric adenovirus infections can be diagnosed using commercially available\\nrapid assays that detect viral antigen in the stool, but these are usually done only to document an\\noutbreak.\\nAll patients with grossly bloody diarrhea should be tested for \\nE. coli\\n O157:H7, as should patients with\\nnonbloody diarrhea during a known outbreak. Specific cultures must be requested because this organism\\nis not detected on standard stool culture media. Alternatively, a rapid enzyme assay for the detection of\\nShiga toxin in stool can be done; a positive test indicates infection with \\nE. coli\\n O157:H7 or one of the\\nother serotypes of enterohemorrhagic \\nE. coli\\n. (NOTE: \\nShigella\\n species in the US do not produce Shiga\\ntoxin.)\\nAdults with grossly bloody diarrhea should usually have sigmoidoscopy with cultures and biopsy.\\nAppearance of the colonic mucosa may help diagnose amebic dysentery, shigellosis, and \\nE. coli\\nO157:H7 infection, although ulcerative colitis may cause similar lesions. Patients with recent antibiotic\\nuse should have a stool assay for \\nC. difficile\\n toxin.\\nGeneral tests:\\n Serum electrolytes, BUN, and creatinine should be obtained to evaluate hydration and\\nacid-base status in patients who appear seriously ill. CBC is nonspecific, although eosinophilia may\\nindicate parasitic infection.\\nTreatment\\n Oral or IV rehydration\\n Consideration of antidiarrheal agents if there is no suspicion of \\nC. difficile\\n or \\nE. coli\\n O157:H7 infection\\n Antibiotics only in select cases\\nSupportive treatment is all that is needed for most patients. Bed rest with convenient access to a toilet or\\nbedpan is desirable. Oral glucose-electrolyte solutions, broth, or bouillon may prevent dehydration or treat\\nmild dehydration. Even if vomiting, the patient should take frequent small sips of such fluids: vomiting may\\nabate with volume replacement. For patients with \\nE. coli\\n O157:H7 infection, rehydration with isotonic IV\\nfluids may attenuate the severity of any renal injury should hemolytic-uremic syndrome develop. Children\\nmay become dehydrated more quickly and should be given an appropriate rehydration solution (several\\nare available commerciallysee also p.\\n2809\\n). Carbonated beverages and sports drinks lack the correct ratio of glucose to Na and thus are not\\nappropriate for children < 5 yr. If the child is breastfed, breastfeeding should continue. If vomiting is\\nprotracted or if severe dehydration is prominent, IV replacement of volume and electrolytes is necessary\\n(see p. \\n2297\\n).\\nWhen the patient can tolerate fluids without vomiting and the appetite has begun to return, food may be\\ngradually restarted. There is no demonstrated benefit from restriction to bland food (eg, cereal, gelatin,\\nbananas, toast). Some patients have temporary lactose intolerance.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 16. Gastroenteritis\\n209'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 219, 'page_label': '210'}, page_content=\"Antidiarrheal agents are safe for patients > 5 yr with watery diarrhea (as shown by heme-negative stool).\\nHowever, antidiarrheals may cause deterioration of patients with \\nC. difficile\\n or \\nE. coli\\n O157:H7 infection\\nand thus should not be given to any patient with recent antibiotic use or heme-positive stool, pending\\nspecific diagnosis. Effective antidiarrheals include loperamide 4 mg po initially, followed by 2 mg po for\\neach subsequent episode of diarrhea (maximum of 6 doses/day or 16 mg/day), or diphenoxylate 2.5 to 5\\nmg tid or qid in tablet or liquid form.\\nIf vomiting is severe and a surgical condition has been excluded, an antiemetic may be beneficial. Agents\\nuseful in adults include prochlorperazine 5 to 10 mg IV tid or qid, or 25 mg per rectum bid; and\\npromethazine 12.5 to 25 mg IM tid or qid, or 25 to 50 mg per rectum qid. These drugs are usually avoided\\nin children because of lack of demonstrated efficacy and the high incidence of dystonic reactions.\\nAntimicrobials:\\n Empiric antibiotics are generally not recommended except for certain cases of traveler's\\ndiarrhea or when suspicion of \\nShigella\\n or \\nCampylobacter\\n infection is high (eg, contact with a known\\ncase). Otherwise, antibiotics should not be given until stool culture results are known, particularly in\\nchildren, who have a higher rate of infection with \\nE. coli\\n O157:H7 (antibiotics increase the risk of\\nhemolytic-uremic syndrome in patients infected with \\nE. coli\\n O157:H7).\\nIn proven bacterial gastroenteritis, antibiotics are not always required. They do not help with \\nSalmonella\\nand prolong the duration of shedding in the stool. Exceptions include immunocompromised patients,\\nneonates, and patients with \\nSalmonella\\n bacteremia. Antibiotics are also ineffective against toxic\\ngastroenteritis (eg, \\nS. aureus\\n, \\nB. cereus\\n, \\nC. perfringens\\n). Indiscriminate use of antibiotics fosters the\\nemergence of drug-resistant organisms. However, certain infections do require antibiotics (see\\nTable 16-1\\n).\\nThe use of probiotics, such as lactobacillus, is generally safe and may have some benefit in relieving\\nsymptoms. They can be given in the form of yogurt with active cultures.\\n[\\nTable 16-1.\\n Selected Oral Antibiotics for Infectious Gastroenteritis*]\\nFor cryptosporidiosis, nitazoxanide may be helpful in immunocompetent patients. The dose is 100 mg po\\nbid for children 1 to 3 yr, 200 mg po bid for children 4 to 11 yr, and 500 mg po bid for children  12 yr and\\nadults.\\nPrevention\\nA new oral pentavalent rotavirus vaccine is available that is safe and effective against the majority of\\nstrains responsible for disease. This vaccine is now part of the recommended infant vaccination schedule\\nand is given at 2, 4, and 6 mo of age (see p.\\n2718\\n).\\nPrevention of infection is complicated by the frequency of asymptomatic infection and the ease with which\\nmany agents, particularly viruses, are transmitted from person to person. In general, proper procedures\\nfor handling and preparing food must be followed. Travelers must avoid potentially contaminated food and\\ndrink.\\nBreastfeeding affords some protection to neonates and infants. Caregivers should wash their hands\\nthoroughly with soap and water after changing diapers, and diaper-changing areas should be disinfected\\nwith a freshly prepared solution of 1:64 household bleach (one fourth cup diluted in 1 gallon of water).\\nChildren with diarrhea should be excluded from child care facilities for the duration of symptoms. Children\\ninfected with enterohemorrhagic \\nE. coli\\n or \\nShigella\\n should also have two negative stool cultures before\\nreadmission to the facility.\\nTraveler's Diarrhea\\n(Turista)\\nTraveler's diarrhea is gastroenteritis that is usually caused by bacteria endemic to local water.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 16. Gastroenteritis\\n210\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 220, 'page_label': '211'}, page_content=\"Symptoms include vomiting and diarrhea. \\nDiagnosis is mainly clinical. Treatment is with\\nciprofloxacin or azithromycin, loperamide, and replacement fluids.\\nEtiology\\nTraveler's diarrhea may be caused by any of several bacteria, viruses, or, less commonly, parasites.\\nHowever, enterotoxigenic \\nEscherichia coli\\n is most common. \\nE. coli\\n is common in the water supplies of\\nareas that lack adequate purification. Infection is common among people traveling to developing\\ncountries. Norovirus infection has been a particular problem on some cruise ships.\\nBoth food and water can be the source of infection. Travelers who avoid drinking local water may still\\nbecome infected by brushing their teeth with an improperly rinsed toothbrush, drinking bottled drinks with\\nice made from local water, or eating food that is improperly handled or washed with local water. People\\ntaking drugs that decrease stomach acid (antacids, H\\n2\\n blockers, and proton pump inhibitors) are at risk of\\nmore severe illness.\\nSymptoms and Signs\\nNausea, vomiting, borborygmi, abdominal cramps, and diarrhea begin 12 to 72 h after ingesting\\ncontaminated food or water. Severity is variable. Some people develop fever and myalgias. Most cases\\nare mild and self-limited, although dehydration can occur, especially in warm climates.\\nDiagnosis\\n Clinical evaluation\\nSpecific diagnostic measures are usually not necessary. However, fever, severe abdominal pain, and\\nbloody diarrhea suggest more serious disease and should prompt immediate evaluation.\\nTreatment\\n Fluid replacement\\n Sometimes antimotility drugs\\n Rarely antibiotics (eg, ciprofloxacin, azithromycin)\\nThe mainstay of treatment is fluid replacement and an antimotility drug such as loperamide 4 mg po\\ninitially, followed by 2 mg po for each subsequent episode of diarrhea (maximum of 6 doses/day or 16\\nmg/day), or diphenoxylate 2.5 to 5 mg po tid or qid in tablet or liquid form. Antimotility drugs are\\ncontraindicated in patients with fever or bloody stools and in children < 2 yr. Iodochlorhydroxyquin, which\\nmay be available in some developing countries, should not be used because it may cause neurologic\\ndamage.\\nGenerally, antibiotics are not necessary for mild diarrhea. In patients with moderate to severe diarrhea (\\n3 loose stools over 8 h), antibiotics are given, especially if vomiting, abdominal cramps, fever, or bloody\\nstools are present. For adults, ciprofloxacin 500 mg po bid for 3 days or levofloxacin 500 mg po once/day\\nfor 3 days is recommended. Azithromycin 250 mg po once/day for 3 days or rifaximin 200 mg po tid for 3\\ndays may also be used. For children, azithromycin 5 to 10 mg/kg po once/day for 3 days is preferred.\\nPrevention\\nTravelers should dine at restaurants with a reputation for safety and avoid foods and beverages from\\nstreet vendors. They should consume only cooked foods that are still steaming hot, fruit that can be\\npeeled, and carbonated beverages without ice served in sealed bottles (bottles of noncarbonated\\nbeverages can contain tap water added by unscrupulous vendors); uncooked vegetables should be\\navoided. Buffets and fast food restaurants pose an increased risk.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 16. Gastroenteritis\\n211\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 221, 'page_label': '212'}, page_content='Prophylactic antibiotics are effective in preventing diarrhea, but because of concerns about adverse\\neffects and development of resistance, they should probably be reserved for immunocompromised\\npatients.\\nDrug- and Chemical-Related Gastroenteritis\\nMany drugs cause nausea, vomiting, and diarrhea as adverse effects. A detailed drug history must be\\nobtained. In mild cases, cessation followed by reuse of the drug may establish a causal relationship.\\nCommonly responsible drugs include antacids containing Mg, antibiotics, antihelminthics, cytotoxics (used\\nin cancer therapy), colchicine, digoxin, heavy metals, laxatives, and radiation therapy. Use of antibiotics\\nmay lead to \\nClostridium difficile\\n-induced diarrhea (see p. \\n1292\\n).\\nIatrogenic, accidental, or intentional heavy-metal poisoning frequently causes nausea, vomiting,\\nabdominal pain, and diarrhea.\\nLaxative abuse, sometimes denied by patients, may lead to weakness, vomiting, diarrhea, electrolyte\\ndepletion, and metabolic disturbances.\\nVarious plants and mushrooms cause a syndrome of gastroenteritis (see p. \\n3336\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 16. Gastroenteritis\\n212'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 222, 'page_label': '213'}, page_content='Chapter 17. Malabsorption Syndromes\\nIntroduction\\nMalabsorption is inadequate assimilation of dietary substances due to defects in digestion, absorption, or\\ntransport. Malabsorption can affect macronutrients (eg, proteins, carbohydrates, fats), micronutrients (eg,\\nvitamins, minerals), or both, causing excessive fecal excretion, nutritional deficiencies, and GI symptoms.\\nPathophysiology\\nDigestion and absorption occur in three phases: (1) intraluminal hydrolysis of fats, proteins, and\\ncarbohydrates by enzymesbile salts enhance the solubilization of fat in this phase; (2) digestion by\\nbrush border enzymes and uptake of end-products; and (3) lymphatic transport of nutrients.\\nMalabsorption occurs when any of these phases is impaired.\\nFats:\\n Pancreatic enzymes split long-chain triglycerides into fatty acids and monoglycerides, which\\ncombine with bile acids and phospholipids to form micelles that pass through jejunal enterocytes.\\nAbsorbed fatty acids are resynthesized and combined with protein, cholesterol, and phospholipid to form\\nchylomicrons, which are transported by the lymphatic system. Medium-chain triglycerides are absorbed\\ndirectly.\\nUnabsorbed fats trap fat-soluble vitamins (A, D, E, K) and possibly some minerals, causing deficiency.\\nBacterial overgrowth results in deconjugation and dehydroxylation of bile salts, limiting the absorption of\\nfats. Unabsorbed bile salts stimulate the colon, causing diarrhea.\\nCarbohydrates:\\n Enzymes on microvilli lyse carbohydrates and disaccharides into constituent\\nmonosaccharides. Colonic bacteria ferment unabsorbed carbohydrates into CO\\n2\\n, methane, H\\n2\\n, and\\nshort-chain fatty acids (butyrate, propionate, acetate, and lactate). These fatty acids cause diarrhea. The\\ngases cause abdominal distention and bloating.\\nProteins:\\n Enterokinase, a brush border enzyme, activates trypsinogen into trypsin, which converts many\\npancreatic proteases into their active forms. Active pancreatic enzymes hydrolyze proteins into\\noligopeptides, which are absorbed directly or hydrolyzed into amino acids.\\nEtiology\\nMalabsorption has many causes (see\\nTable 17-1\\n). Some malabsorptive disorders (eg, celiac sprue) impair the absorption of most nutrients,\\nvitamins, and trace minerals (global malabsorption); others (eg, pernicious anemia) are more selective.\\n[\\nTable 17-1.\\n Causes of Malabsorption]\\nPancreatic insufficiency causes malabsorption if > 90% of function is lost. Increased luminal acidity (eg,\\nZollinger-Ellison syndrome) inhibits lipase and fat digestion. Cirrhosis and cholestasis reduce hepatic bile\\nsynthesis or delivery of bile salts to the duodenum, causing malabsorption. Other causes are discussed\\nelsewhere in this chapter.\\nSymptoms and Signs\\nThe effects of unabsorbed substances include diarrhea, steatorrhea, abdominal bloating, and gas. Other\\nsymptoms result from nutritional deficiencies. Patients often lose weight despite adequate food intake.\\nChronic diarrhea is the most common symptom and is what usually prompts evaluation of the patient.\\nSteatorrheafatty stool, the hallmark of malabsorptionoccurs when > 7 g/day of fat are excreted.\\nSteatorrhea causes foul-smelling, pale, bulky, and greasy stools.\\nSevere vitamin and mineral deficiencies occur in advanced malabsorption; symptoms are related to the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n213'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 223, 'page_label': '214'}, page_content=\"specific nutrient deficiency (see\\nTable 17-2\\n). Vitamin B\\n12\\n deficiency may occur in blind loop syndrome or after extensive resection of the\\ndistal ileum or stomach.\\nAmenorrhea may result from undernutrition and is an important manifestation of celiac sprue in young\\nwomen.\\nDiagnosis\\n Diagnosis typically clinically apparent\\n Blood tests to screen for consequences of malabsorption\\n Stool fat testing to confirm malabsorption (if unclear)\\n Cause diagnosed with endoscopy, contrast x-rays, or other tests based on findings\\nMalabsorption is suspected in a patient with chronic diarrhea, weight loss, and anemia. The etiology is\\nsometimes obvious. For example, those with malabsorption due to chronic pancreatitis usually have had\\nprior bouts of acute pancreatitis. Patients with celiac sprue can present with classic lifelong diarrhea\\nexacerbated by gluten products and may have dermatitis herpetiformis. Those with cirrhosis and\\npancreatic cancer can present with jaundice. Abdominal distention, excessive flatus, and watery diarrhea\\noccurring 30 to 90 min after carbohydrate ingestion suggest deficiency of a disaccharidase enzyme,\\nusually lactase. Previous extensive abdominal operations suggest short bowel syndrome.\\nIf the history suggests a specific cause, testing should be directed to that condition (see\\nFig. 17-1\\n). If no cause is readily apparent, blood tests can be used as screening tools (eg, CBC, RBC\\nindices, ferritin, vitamin B\\n12\\n, folate, Ca, albumin, cholesterol, PT). These results may suggest a diagnosis\\nand direct further investigation.\\n[\\nTable 17-2.\\n Symptoms of Malabsorption]\\nMacrocytic anemia should prompt measurement of serum folate and B\\n12\\n levels. Folate deficiency is\\ncommon in mucosal disorders involving the proximal small bowel (eg, celiac sprue, tropical sprue,\\nWhipple's disease). Low B\\n12\\n levels can occur in pernicious anemia, chronic pancreatitis, bacterial\\novergrowth, and terminal ileal disease. A combination of low B\\n12\\n and high folate levels is suggestive of\\nbacterial overgrowth, because intestinal bacteria use vitamin B\\n12\\n and synthesize folate.\\nMicrocytic anemia suggests iron deficiency, which may occur with celiac sprue. Albumin is a general\\nindicator of nutritional state. Low albumin can result from poor intake, decreased synthesis in cirrhosis, or\\nprotein wasting. Low serum carotene (a precursor of vitamin A) suggests malabsorption if intake is\\nadequate.\\nConfirming malabsorption:\\n Tests to confirm malabsorption are appropriate when symptoms are vague\\nand the etiology is not apparent. Most tests for malabsorption assess fat malabsorption because it is\\nrelatively easy to measure. Confirmation of carbohydrate malabsorption is not helpful once steatorrhea is\\ndocumented. Tests for protein malabsorption are rarely used because fecal nitrogen is difficult to\\nmeasure.\\n[\\nFig. 17-1.\\n Suggested evaluation for malabsorption.]\\n[\\nTable 17-3.\\n Small-Bowel Mucosal Histology in Certain Malabsorptive Disorders]\\nDirect measurement of fecal fat from a 72-h stool collection is the gold standard for establishing\\nsteatorrhea but unnecessary with gross steatorrhea of obvious cause. However, this test is available\\nroutinely in only a few centers. Stool is collected for a 3-day period during which the patient consumes \\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n214\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 224, 'page_label': '215'}, page_content='100 g fat/day. Total fat in the stool is measured. Fecal fat > 7 g/day is abnormal. Although severe fat\\nmalabsorption (fecal fat  40 g/day) suggests pancreatic insufficiency or small-bowel mucosal disease,\\nthis test cannot determine the specific cause of malabsorption. Because the test is messy, unpleasant,\\nand time consuming, it is unacceptable to most patients and difficult to do.\\nSudan III staining of a stool smear is a simple and direct, but nonquantitative, screening test for fecal fat.\\nAcid steatocrit is a gravimetric assay done on a single stool sample; it has a reported high sensitivity and\\nspecificity (using 72-h collection as the standard). Near-infrared reflectance analysis (NIRA)\\nsimultaneously tests stool for fat, nitrogen, and carbohydrates and may become the preferred test in the\\nfuture.\\nMeasurement of elastase and chymotrypsin in the stool can also help differentiate pancreatic and\\nintestinal causes of malabsorption; both are decreased in pancreatic exocrine insufficiency.\\nThe D-xylose absorption test, if available, can be done if the etiology is not obvious. It is the best\\nnoninvasive test to assess intestinal mucosal integrity and differentiate mucosal from pancreatic disease.\\nThis test has a reported specificity of 98% and sensitivity of 91% for small-bowel malabsorption.\\nD-Xylose is absorbed by passive diffusion and does not require pancreatic enzymes for digestion. A\\nnormal D-xylose test in the presence of moderate to severe steatorrhea indicates pancreatic exocrine\\ninsufficiency rather than small-bowel mucosal disease. Bacterial overgrowth syndrome can cause\\nabnormal results because the enteric bacteria metabolize pentose, thus decreasing the D-xylose available\\nfor absorption.\\nAfter fasting, the patient is given 25 g of D-xylose in 200 to 300 mL of water po. Urine is collected over 5\\nh, and a venous sample is obtained after 1 h. Serum D-xylose < 20 mg/dL or < 4 g in the urine sample\\nindicates abnormal absorption. Falsely low levels can also occur in renal diseases, portal hypertension,\\nascites, or delayed gastric emptying time. This test is rarely used today. In addition, an abnormal D-xylose\\ntest will require an endoscopic examination with biopsies of the small-bowel mucosa. As a result, small-\\nbowel biopsy has replaced this test to establish intestinal mucosal disease.\\nDiagnosing the cause of malabsorption:\\n More specific diagnostic tests (eg, upper endoscopy,\\ncolonoscopy, barium x-rays) are indicated to diagnose several causes of malabsorption.\\nEndoscopy with small-bowel biopsy is done when mucosal disease of the small bowel is suspected or if\\nthe D-xylose test is abnormal in a patient with massive steatorrhea. Aspirate from the small bowel can be\\nsent for bacterial culture and colony count to document bacterial overgrowth. Histologic features on small-\\nbowel biopsy (see \\nTable 17-3\\n) can establish the specific mucosal disease.\\nSmall-bowel x-rays (eg, small-bowel follow-through, enteroclysis) can detect anatomic conditions that\\npredispose to bacterial overgrowth. These include jejunal diverticula, fistulas, surgically created blind\\nloops and anastomoses, ulcerations, and strictures. Abdominal flat plate x-ray may show pancreatic\\ncalcifications indicative of chronic pancreatitis. Barium contrast studies of the small bowel are neither\\nsensitive nor specific but may have findings suggestive of mucosal disease (eg, dilated small-bowel\\nloops, thinned or thickened mucosal folds, coarse fragmentation of the barium column).\\nTests for pancreatic insufficiency (eg, secretin stimulation test, bentiromide test, pancreolauryl test, serum\\ntrypsinogen, fecal elastase, fecal chymotrypsinsee p. \\n145\\n) are done if history is suggestive but are not\\nsensitive for mild pancreatic disease.\\nThe \\n14\\nC-xylose breath test helps diagnose bacterial overgrowth. \\n14\\nC-xylose is given orally, and the\\nexhaled \\n14\\nCO\\n2\\n concentration is measured. Catabolism of ingested xylose by the overgrowth flora causes\\n14\\nCO\\n2\\n to appear in exhaled breath.\\nThe H\\n2\\n breath test measures the exhaled H\\n2\\n produced by the bacterial degradation of carbohydrates. In\\npatients with disaccharidase deficiencies, enteric bacteria degrade nonabsorbed carbohydrates in the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n215'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 225, 'page_label': '216'}, page_content=\"colon, increasing exhaled H\\n2\\n. The lactose-H\\n2\\n breath test is useful only to confirm lactase deficiency (see\\np. \\n158\\n) and is not used as an initial diagnostic test in the work-up of malabsorption.\\nThe Schilling test assesses malabsorption of vitamin B\\n12\\n. Its 4 stages determine whether the deficiency\\nresults from pernicious anemia, pancreatic exocrine insufficiency, bacterial overgrowth, or ileal disease.\\n Stage 1: The patient is given 1 \\n\\ng of radiolabeled cyanocobalamin po concurrent with 1000 \\n\\ng of\\nnonlabeled cobalamin IM to saturate hepatic binding sites. A 24-h urine collection is analyzed for\\nradioactivity; urinary excretion of < 8% of the oral dose indicates malabsorption of cobalamin.\\n Stage 2: If stage 1 is abnormal, the test is repeated with the addition of intrinsic factor. Pernicious\\nanemia is present if this normalizes absorption.\\n Stage 3: Stage 3 is done after adding pancreatic enzymes; normalization in this stage indicates\\ncobalamin malabsorption secondary to pancreatic insufficiency.\\n Stage 4: Stage 4 is done after antimicrobial therapy with anaerobic coverage; normalization after\\nantibiotics suggests bacterial overgrowth.\\nCobalamin deficiency secondary to ileal disease or ileal resection results in abnormalities in all stages.\\nTests for less common causes of malabsorption include serum gastrin (Zollinger-Ellison syndrome),\\nintrinsic factor and parietal cell antibodies (pernicious anemia), sweat chloride (cystic fibrosis), lipoprotein\\nelectrophoresis (abetalipoproteinemia), and serum cortisol (Addison's disease).\\nBacterial Overgrowth Syndrome\\nSmall-bowel bacterial overgrowth can occur from alterations in intestinal anatomy or GI motility,\\nor lack of gastric acid secretion. This condition can lead to vitamin deficiencies, fat\\nmalabsorption, and undernutrition. Diagnosis is by breath test or quantitative culture of\\nintestinal fluid aspirate. Treatment is with oral antibiotics.\\nUnder normal conditions, the proximal small bowel contains < 10\\n5\\n bacteria/mL, mainly gram-positive\\naerobic bacteria. This low bacterial count is maintained by normal peristalsis, normal gastric acid\\nsecretion, mucus, secretory IgA, and an intact ileocecal valve.\\nEtiology\\nUsually, bacterial overgrowth occurs when anatomic alterations promote stasis of intestinal contents.\\nThese conditions include small-bowel diverticulosis, surgical blind loops, postgastrectomy states\\n(especially in the afferent loop of a Billroth II), strictures, or partial obstruction. Intestinal motility disorders\\nassociated with diabetic neuropathy, systemic sclerosis, amyloidosis, and idiopathic intestinal pseudo-\\nobstruction can also impair bacterial clearance. Achlorhydria and idiopathic changes in intestinal motility\\nmay cause bacterial overgrowth in elderly people.\\nPathophysiology\\nThe excess bacteria consume nutrients, including vitamin B\\n12\\n and carbohydrates, leading to caloric\\ndeprivation and vitamin B\\n12\\n deficiency. However, because the bacteria produce folate, this deficiency is\\nrare. The bacteria deconjugate bile salts, causing failure of micelle formation and subsequent fat\\nmalabsorption. Severe bacterial overgrowth also damages the intestinal mucosa. Fat malabsorption and\\nmucosal damage can cause diarrhea.\\nSymptoms and Signs\\nMany patients are asymptomatic and present with only weight loss or nutrient deficiencies. \\nSome have\\nsignificant diarrhea or steatorrhea.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n216\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 226, 'page_label': '217'}, page_content='Diagnosis\\n \\n14\\nC-xylose breath test or quantitative culture of intestinal aspirate\\n Upper GI series with small-bowel follow-through\\nSome clinicians advocate response to empiric antibiotic therapy as a diagnostic test. However, because\\nbacterial overgrowth can mimic other malabsorptive disorders (eg, Crohn\\'s disease) and adverse effects\\nof the antibiotics can worsen symptoms, establishing a definitive etiology is preferred.\\nThe standard for diagnosis is quantitative culture of intestinal fluid aspirate showing bacterial count >\\n10\\n5\\n/mL. This method, however, requires endoscopy. Breath tests, using substrates like glucose,\\nlactulose, and xylose, are noninvasive and easy to do. The \\n14\\nC-xylose breath test seems to perform\\nbetter than the other breath tests. In addition, an upper GI series with small-bowel follow-through should\\nbe done to identify predisposing anatomic lesions.\\nTreatment\\n Oral antibiotics (various)\\nTreatment is with 10 to 14 days of oral antibiotics. Empiric regimens include tetracycline 250 mg qid,\\namoxicillin/clavulanic acid 250 to 500 mg tid, cephalexin 250 mg qid, trimethoprim/sulfamethoxazole\\n160/800 mg bid, and metronidazole 250 to 500 mg tid or qid. Antibiotics should be changed based on\\nculture and sensitivity results. Underlying conditions and nutritional deficiencies (eg, vitamin B\\n12\\n) should\\nbe corrected.\\nCarbohydrate Intolerance\\nCarbohydrate intolerance is the inability to digest certain carbohydrates due to a lack of one or\\nmore intestinal enzymes. Symptoms include diarrhea, abdominal distention, and flatulence.\\nDiagnosis is clinical and by an H\\n2\\n breath test. Treatment is removal of the causative\\ndisaccharide from the diet.\\nPathophysiology\\nDisaccharides are normally split into monosaccharides by disaccharidases (eg, lactase, maltase,\\nisomaltase, sucrase [invertase]) located in the brush border of small-bowel enterocytes. Undigested\\ndisaccharides cause an osmotic load that attracts water and electrolytes into the bowel, causing watery\\ndiarrhea. Bacterial fermentation of carbohydrates in the colon produces gases (H\\n2\\n, CO\\n2\\n, and methane),\\nresulting in excessive flatus, bloating and distention, and abdominal pain.\\nEtiology\\nEnzyme deficiencies can be congenital, acquired (primary), or secondary. Congenital deficiencies are\\nrare.\\nAcquired lactase deficiency (primary adult hypolactasia) is the most common form of carbohydrate\\nintolerance. Lactase levels are high in neonates, permitting digestion of milk; in most ethnic groups (80%\\nof blacks and Hispanics, almost 100% of Asians), the levels decrease in the post-weaning period\\nrendering older children and adults unable to digest significant amounts of lactose. However, 80 to 85%\\nof whites of Northwest European descent produce lactase throughout life and are thus able to digest milk\\nand milk products. It is unclear why the normal state of > 75% of the world\\'s population should be labeled\\na \"deficiency.\"\\nSecondary lactase deficiency occurs in conditions that damage the small-bowel mucosa (eg, celiac sprue,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n217'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 227, 'page_label': '218'}, page_content='tropical sprue, acute intestinal infections). In infants, temporary secondary disaccharidase deficiency may\\ncomplicate enteric infections or abdominal surgery. Recovery from the underlying disease is followed by\\nan increase in activity of the enzyme.\\nSymptoms and Signs\\nSymptoms and signs are similar in all disaccharidase deficiencies. A child who cannot tolerate lactose\\ndevelops diarrhea after ingesting significant amounts of milk and may not gain weight. An affected adult\\nmay have watery diarrhea, bloating, excessive flatus, nausea, borborygmi, and abdominal cramps after\\ningesting lactose. The patient often recognizes this early in life and avoids eating dairy products.\\nSymptoms typically require ingestion of more than the equivalent of 8 to 12 oz of milk. Diarrhea may be\\nsevere enough to purge other nutrients before they can be absorbed. Symptoms may be similar to and\\ncan be confused with irritable bowel syndrome (see p. \\n162\\n).\\nDiagnosis\\n Clinical diagnosis\\n H\\n2\\n breath test for confirmation\\nLactose intolerance can usually be diagnosed with a careful history supported by \\ndietary challenge.\\nPatients usually have a history of intolerance to milk and dairy foods. The diagnosis is also suggested if\\nthe stool from chronic or intermittent diarrhea is acidic (pH < 6) and can be confirmed by an H\\n2\\n breath or\\na lactose tolerance test.\\nIn the H\\n2\\n breath test, 50 g of lactose is given orally and the H\\n2\\n produced by bacterial metabolism of\\nundigested lactose is measured with a breath meter at 2, 3, and 4 h postingestion. Most affected patients\\nhave an increase in expired H\\n2\\n of > 20 ppm over baseline. Sensitivity and specificity are > 95%.\\nThe lactose tolerance test is less specific. Oral lactose (1.0 to 1.5 g/kg body weight) is given. Serum\\nglucose is measured before ingestion and 60 and 120 min after. Lactose-intolerant patients develop\\ndiarrhea, abdominal bloating, and discomfort within 20 to 30 min, and their serum glucose levels do not\\nrise > 20 mg/dL (< 1.1 mmol/L) above baseline. Low lactase activity in a jejunal biopsy specimen is\\ndiagnostic, but endoscopy is needed to obtain a specimen and is not routine.\\nTreatment\\n Dietary restriction\\nCarbohydrate malabsorption is readily controlled by avoiding dietary sugars that cannot be absorbed (ie,\\nfollowing a lactose-free diet in cases of lactase deficiency). However, because the degree of lactose\\nmalabsorption varies greatly, many patients can ingest up to 12 oz (18 g of lactose) of milk daily without\\nsymptoms. Yogurt is usually tolerated because it contains an appreciable amount of lactase produced by\\nintrinsic \\nLactobacilli\\n.\\nFor symptomatic patients wishing to drink milk, lactose in milk can be predigested by the addition of a\\ncommercially prepared lactase, and pretreated milk is now available. Enzyme supplements should be an\\nadjunct to, not a substitute for, dietary restriction. Lactose-intolerant patients must take Ca supplements\\n(1200 to 1500 mg/day).\\nCeliac Sprue\\n(Nontropical Sprue; Gluten Enteropathy; Celiac Disease)\\nCeliac sprue is an immunologically mediated disease in genetically susceptible people caused\\nby intolerance to gluten, resulting in mucosal inflammation, which causes malabsorption.\\nSymptoms usually include diarrhea and abdominal discomfort. Diagnosis is by small-bowel\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n218'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 228, 'page_label': '219'}, page_content='biopsies showing characteristic though not specific pathologic changes of villous atrophy that\\nresolve with a strict gluten-free diet.\\nEtiology\\nCeliac sprue is a hereditary disorder caused by sensitivity to the gliadin fraction of gluten, a protein found\\nin wheat; similar proteins are present in rye and barley. In a genetically susceptible person, gluten-\\nsensitive T cells are activated when gluten-derived peptide epitopes are presented. The inflammatory\\nresponse causes characteristic mucosal villous atrophy in the small bowel.\\nEpidemiology:\\n Celiac sprue mainly affects whites of northern European descent. Prevalence estimates\\nbased on serologic screens (sometimes confirmed by biopsy) indicate the disorder is present in about\\n1/300 in Europe and perhaps 1/250 in the US overall (but there may be significant variation among\\nregions in the US).\\nThe disease affects about 10 to 20% of 1st-degree relatives. Female:male ratio is 2:1. Onset is generally\\nin childhood but may occur later.\\nSymptoms and Signs\\nThe clinical presentation varies; no typical presentation exists. Some patients are asymptomatic or have\\nonly signs of nutritional deficiency. Others have significant GI symptoms.\\nCeliac sprue can manifest in infancy and childhood after introduction of cereals into the diet. The child\\nhas failure to thrive, apathy, anorexia, pallor, generalized hypotonia, abdominal distention, and muscle\\nwasting. Stools are soft, bulky, clay-colored, and offensive. Older children may present with anemia or\\nfailure to grow normally.\\nIn adults, lassitude, weakness, and anorexia are most common. Mild and intermittent diarrhea is\\nsometimes the presenting symptom. Steatorrhea ranges from mild to severe (7 to 50 g fat/day). Some\\npatients have weight loss, rarely enough to become underweight. Anemia, glossitis, angular stomatitis,\\nand aphthous ulcers are usually seen in these patients. Manifestations of vitamin D and Ca deficiencies\\n(eg, osteomalacia, osteopenia, osteoporosis) are common. Both men and women may have reduced\\nfertility.\\nAbout 10% have dermatitis herpetiformis, an intensely pruritic papulovesicular rash that is symmetrically\\ndistributed over the extensor areas of the elbows, knees, buttocks, shoulders, and scalp. This rash can\\nbe induced by a high-gluten diet. Celiac sprue is also associated with diabetes mellitus, autoimmune\\nthyroid disease, and Down syndrome.\\nDiagnosis\\n Serologic markers\\n Small-bowel biopsy\\nThe diagnosis is suspected clinically and by laboratory abnormalities suggestive of malabsorption. Family\\nincidence is a valuable clue. Celiac sprue should be strongly considered in a patient with iron deficiency\\nwithout obvious GI bleeding.\\nConfirmation requires a small-bowel biopsy from the second portion of the duodenum. Findings include\\nlack or shortening of villi (villous atrophy), increased intraepithelial cells, and crypt hyperplasia. However,\\nsuch findings can also occur in tropical sprue, severe intestinal bacterial overgrowth, eosinophilic\\nenteritis, lactose intolerance, and lymphoma.\\nBecause biopsy lacks specificity, serologic markers can aid diagnosis. Anti-tissue transglutaminase\\nantibody (AGA) and anti-endomysial antibody (EMAan antibody against an intestinal connective tissue\\nprotein) each have sensitivity and specificity > 90%. These markers can also be used to screen\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n219'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 229, 'page_label': '220'}, page_content='populations with high prevalence of celiac sprue, including 1st-degree relatives of affected patients and\\npatients with diseases that occur at a greater frequency in association with celiac sprue. If either test is\\npositive, the patient should have a diagnostic small-bowel biopsy. If both are negative, celiac sprue is\\nextremely unlikely. These antibodies decrease in titer in patients on a gluten-free diet and thus are useful\\nin monitoring dietary compliance.\\nOther laboratory abnormalities often occur and should be sought. They include anemia (iron-deficiency\\nanemia in children and folate-deficiency anemia in adults); low albumin, Ca, K, and Na; and elevated\\nalkaline phosphatase and PT.\\nMalabsorption tests are not specific for celiac sprue. If done, common findings include steatorrhea of 10\\nto 40 g/day and abnormal results with D-xylose and (in severe ileal disease) Schilling tests.\\nPrognosis\\nMortality is 10 to 30% without a gluten-free diet. With proper diet, mortality is < 1%, mainly in adults who\\nhave severe disease at the outset. Complications include refractory sprue, collagenous sprue, and\\nintestinal lymphomas. Intestinal lymphomas affect 6 to 8% of patients with celiac sprue, usually\\nmanifesting after 20 to 40 yr of disease. The incidence of other GI cancers (eg, carcinoma of the\\nesophagus or oropharynx, small-bowel adenocarcinoma) also increases. Adherence to a gluten-free diet\\ncan significantly reduce the risk of cancer.\\nTreatment\\n Gluten-free diet\\n Supplements to replace any serious deficiencies\\nTreatment is a gluten-free diet (avoiding foods containing wheat, rye, or barley). Gluten is so widely used\\n(eg, in commercial soups, sauces, ice creams, hot dogs) that a patient needs a detailed list of foods to\\navoid. Patients are encouraged to consult a dietitian and join a celiac support group. The response to a\\ngluten-free diet is usually rapid, and symptoms resolve in 1 to 2 wk. Ingesting even small amounts of food\\ncontaining gluten may prevent remission or induce relapse.\\nSmall-bowel biopsy should be repeated after 3 to 4 mo of a gluten-free diet. If abnormalities persist, other\\ncauses of villous atrophy (eg, lymphoma) should be considered. Lessening of symptoms and\\nimprovement in small-bowel morphology are accompanied by a decrease in AGA and EMA titers.\\nSupplementary vitamins, minerals, and hematinics may be given, depending on the deficiencies. Mild\\ncases may not require supplementation, whereas severe cases may require comprehensive replacement.\\nFor adults, replacement includes ferrous sulfate 300 mg po once/day to tid, folate 5 to 10 mg po once/day,\\nCa supplements, and any standard multivitamin. Sometimes children (but rarely adults) who are seriously\\nill on initial diagnosis require bowel rest and TPN.\\nIf a patient responds poorly to gluten withdrawal, either the diagnosis is incorrect or the disease has\\nbecome refractory. Corticosteroids can control symptoms in the latter case.\\nInfection and Infestation\\nAcute bacterial, viral, and parasitic infections may cause transient malabsorption, probably as a result of\\ntemporary, superficial damage to the villi and microvilli. Chronic bacterial infections of the small bowel are\\nuncommon, apart from blind loops, systemic sclerosis, and diverticula. Intestinal bacteria may use up\\ndietary vitamin B\\n12\\n and other nutrients, perhaps interfere with enzyme systems, and cause mucosal\\ninjury.\\nIntestinal Lymphangiectasia\\n(Idiopathic Hypoproteinemia)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n220'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 230, 'page_label': '221'}, page_content=\"Intestinal lymphangiectasia is obstruction or malformation of the intramucosal lymphatics \\nof the\\nsmall bowel. It primarily affects children and young adults. Symptoms include those of\\nmalabsorption, with edema and growth retardation. Diagnosis is by small-bowel biopsy.\\nTreatment is usually supportive.\\nMalformation of the lymphatic system is congenital or acquired. Congenital cases usually manifest in\\nchildren and young adults (mean age of onset: 11 yr). Males and females are equally affected. In acquired\\ncases, the defect may be secondary to retroperitoneal fibrosis, constrictive pericarditis, pancreatitis,\\nneoplastic tumors, and infiltrative disorders that block the lymphatics.\\nImpaired lymphatic drainage leads to increased pressure and leakage of lymph into the intestinal lumen.\\nImpairment of chylomicron and lipoprotein absorption results in malabsorption of fats and protein.\\nBecause carbohydrates are not absorbed through the lymphatic system, their uptake is not impaired.\\nSymptoms and Signs\\nEarly manifestations include massive and often asymmetric peripheral edema, intermittent diarrhea,\\nnausea, vomiting, and abdominal pain. Some patients have mild to moderate steatorrhea. Chylous pleural\\neffusions (chylothorax) and chylous ascites may be present. Growth is retarded if onset is in the first\\ndecade of life.\\nDiagnosis\\n Endoscopic small-bowel biopsy\\n Sometimes contrast lymphangiography\\nDiagnosis usually requires endoscopic small-bowel biopsy, which shows marked dilation and ectasia of\\nthe mucosal and submucosal lymphatic vessels. Alternatively, contrast lymphangiography (injection of\\ncontrast material via the pedal vein) can show abnormal intestinal lymphatics.\\nLaboratory abnormalities include lymphocytopenia and low levels of serum albumin, cholesterol, IgA, IgM,\\nIgG, transferrin, and ceruloplasmin. Barium studies may show thickened, nodular mucosal folds that\\nresemble stacked coins. D-Xylose absorption is normal. Intestinal protein loss can be shown by using\\nchromium-51-labeled albumin.\\nTreatment\\n Supportive care\\n Sometimes surgical resection or repair\\nAbnormal lymphatics cannot be corrected. Supportive treatment includes a low-fat (< 30 g/day), high-\\nprotein diet containing medium-chain triglyceride supplements. Supplemental Ca and fat-soluble vitamins\\nare given. Intestinal resection or anastomosis of the abnormal lymphatics to the venous channels may be\\nbeneficial. Pleural effusions should be drained by thoracentesis.\\nShort Bowel Syndrome\\nShort bowel syndrome is malabsorption resulting from extensive resection of the small bowel.\\nSymptoms depend on the length and function of the remaining small bowel, but diarrhea can be\\nsevere, and nutritional deficiencies are common. Treatment is with small feedings,\\nantidiarrheals, and sometimes TPN or intestinal transplantation.\\nCommon reasons for extensive resection are Crohn's disease, mesenteric infarction, radiation enteritis,\\ncancer, volvulus, and congenital anomalies.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n221\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 231, 'page_label': '222'}, page_content=\"Because the jejunum is the primary digestive and absorptive site for most nutrients, jejunal resection\\nsignificantly reduces nutrient absorption. In response, the ileum adapts by increasing the length and\\nabsorptive function of its villi, resulting in gradual improvement of nutrient absorption.\\nThe ileum is the site of vitamin B\\n12\\n and bile acid absorption. Severe diarrhea and bile acid malabsorption\\nresult when > 100 cm of the ileum is resected. Notably, there is no compensatory adaptation of the\\nremaining jejunum. Consequently, malabsorption of fat, fat-soluble vitamins, and vitamin B\\n12\\n occurs. In\\naddition, unabsorbed bile acids in the colon result in secretory diarrhea. Preservation of the colon can\\nsignificantly reduce water and electrolyte losses. Resection of the terminal ileum and ileocecal valve can\\npredispose to bacterial overgrowth.\\nTreatment\\n TPN\\n Eventual oral feeding if > 100 cm of jejunum remain\\n Antidiarrheals, cholestyramine, proton pump inhibitors, vitamin supplements\\nIn the immediate postoperative period, diarrhea is typically severe, with significant electrolyte losses.\\nPatients typically require TPN and intensive monitoring of fluid and electrolytes (including Ca and Mg). An\\noral iso-osmotic solution of Na and glucose (similar to WHO oral rehydration formulasee p.\\n2809\\n) is slowly introduced in the postoperative phase once the patient stabilizes and stool output is < 2\\nL/day.\\nPatients with extensive resection (< 100 cm of remaining jejunum) and those with excessive fluid and\\nelectrolyte losses require TPN for life.\\nPatients with > 100 cm of jejunum left can achieve adequate nutrition through oral feeding. Fat and\\nprotein in the diet are usually well tolerated, unlike carbohydrates, which contribute a significant osmotic\\nload. Small feedings reduce the osmotic load. Ideally, 40% of calories should consist of fat.\\nPatients who have diarrhea after meals should take antidiarrheals (eg, loperamide) 1 h before eating.\\nCholestyramine 2 to 4 g taken with meals reduces diarrhea associated with bile acid malabsorption.\\nMonthly IM injections of vitamin B\\n12\\n should be given to patients with a documented deficiency. Most\\npatients should take supplemental vitamins, Ca, and Mg.\\nGastric acid hypersecretion can develop, which can deactivate pancreatic enzymes; thus, most patients\\nare given H\\n2\\n blockers or proton pump inhibitors.\\nSmall-bowel transplantation is advocated for patients who are not candidates for long-term TPN and in\\nwhom adaptation does not occur.\\nTropical Sprue\\nTropical sprue is an acquired disease, probably of infectious etiology, characterized by\\nmalabsorption and megaloblastic anemia. Diagnosis is clinical and by small-bowel biopsy.\\nTreatment is with tetracycline and folate for 6 mo.\\nEtiology\\nTropical sprue occurs chiefly in the Caribbean, southern India, and Southeast Asia, affecting both natives\\nand visitors. The illness is rare in visitors spending < 1 mo in areas where the disease is endemic.\\nAlthough etiology is unclear, it is thought to result from chronic infection of the small bowel by toxigenic\\nstrains of coliform bacteria. Malabsorption of folate and vitamin B\\n12\\n deficiency result in megaloblastic\\nanemia. The incidence of tropical sprue is decreasing, perhaps because of increasing use of antibiotics\\nfor acute traveler's diarrhea.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n222\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 232, 'page_label': '223'}, page_content=\"Symptoms and Signs\\nPatients commonly have acute diarrhea with fever and malaise. A chronic phase of milder diarrhea,\\nnausea, anorexia, abdominal cramps, and fatigue follows. Steatorrhea is common. Nutritional\\ndeficiencies, especially of folate and vitamin B\\n12\\n, eventually develop after several months to years. The\\npatient may also have weight loss, glossitis, stomatitis, and peripheral edema.\\nDiagnosis\\n Endoscopy with small-bowel biopsy\\n Blood tests to screen for consequences of malabsorption\\nTropical sprue is suspected in people who live in or have visited areas where the disease is endemic and\\nwho have megaloblastic anemia and symptoms of malabsorption. The definitive test is upper GI\\nendoscopy with small-bowel biopsy. Characteristic histologic changes (see \\nTable 17-3\\n) usually involve the\\nentire small bowel and include blunting of the villi with infiltration of chronic inflammatory cells in the\\nepithelium and lamina propria. Celiac disease and parasitic infection must be ruled out.\\nAdditional laboratory studies (eg, CBC; albumin; Ca; PT; iron, folate, and B\\n12\\n levels) help evaluate\\nnutritional status. Barium small-bowel follow-through may show segmentation of the barium, dilation of\\nthe lumen, and thickening of the mucosal folds. D-Xylose absorption is abnormal in > 90% of cases.\\nHowever, these tests are not specific or essential for diagnosis.\\nTreatment\\n Long-term tetracycline\\nTreatment is tetracycline 250 mg po qid for 1 or 2 mo, then bid for up to 6 mo, depending on disease\\nseverity and response to treatment. Folate 5 to 10 mg po once/day should be given for the first month\\nalong with vitamin B\\n12\\n 1 mg IM weekly for several weeks. Megaloblastic anemia promptly abates, and the\\nclinical response is dramatic. Other nutritional replacements are given as needed. Relapse may occur in\\n20%. Failure to respond after 4 wk of therapy suggests another condition.\\nWhipple's Disease\\n(Intestinal Lipodystrophy)\\nWhipple's disease is a rare systemic illness caused by the bacterium \\nTropheryma whippelii\\n.\\nMain symptoms are arthritis, weight loss, and diarrhea. Diagnosis is by small-bowel biopsy.\\nTreatment is with a minimum 1 yr of trimethoprim/sulfamethoxazole\\n.\\nWhipple's disease predominately affects white men aged 30 to 60. Although it affects many parts of the\\nbody (eg, heart, lung, brain, \\nserous cavities, joints, eye, GI tract), the mucosa of the small bowel is almost\\nalways involved. Affected patients may have subtle defects of cell-mediated immunity that predispose to\\ninfection with \\nT. whippelii\\n. About 30% of patients have HLA-B27.\\nSymptoms and Signs\\nClinical presentation varies depending on the organ systems affected. Usually, the first symptoms are\\narthritis and fever. Intestinal symptoms (eg, watery diarrhea, steatorrhea, abdominal pain, anorexia,\\nweight loss) usually manifest later, sometimes years after the initial complaint. Gross or occult intestinal\\nbleeding may occur. Severe malabsorption may be present in patients diagnosed late in the clinical\\ncourse. Other findings include increased skin pigmentation, anemia, lymphadenopathy, chronic cough,\\nserositis, peripheral edema, and CNS symptoms.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n223\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 233, 'page_label': '224'}, page_content=\"Diagnosis\\n Endoscopy with small-bowel biopsy\\nThe diagnosis may be missed in patients without prominent GI symptoms. Whipple's disease should be\\nsuspected in middle-aged white men who have arthritis and abdominal pain, diarrhea, weight loss, or\\nother symptoms of malabsorption. Such patients should have upper endoscopy with small-bowel biopsy;\\nthe intestinal lesions are specific and diagnostic. The most severe and consistent changes are in the\\nproximal small bowel. Light microscopy shows periodic acid-Schiff-positive macrophages that distort the\\nvillus architecture. Gram-positive, acid fast-negative bacilli (\\nT. whippelii\\n) are seen in the lamina propria\\nand in the macrophages. Confirmation by electron microscopy is recommended.\\nWhipple's disease should be differentiated from intestinal infection with \\nMycobacterium avium-\\nintracellulare\\n (MAI), which has similar histologic findings. However, MAI stains positive with acid fast.\\nPCR testing may be useful for confirmation.\\nTreatment\\n Antibiotics\\n Late relapse a possibility\\nUntreated disease is progressive and fatal. Many antibiotics are curative (eg, tetracycline,\\ntrimethoprim/sulfamethoxazole, chloramphenicol, ampicillin, penicillin, cephalosporins). Treatment is\\ninitiated with ceftriaxone (2 g IV daily) or with procaine (1.2 million units IM once/day) or penicillin G (1.5 to\\n6 million units IV q 6 h) plus streptomycin (1.0 g IM once/day for 10 to 14 days). This regimen is followed\\nby a long-term course of trimethoprim/sulfamethoxazole (160/800 mg po bid for 1 yr). Sulfa-allergic\\npatients may substitute oral penicillin VK or ampicillin. Prompt clinical improvement occurs, with fever and\\njoint pains resolving in a few days. Intestinal symptoms usually abate within 1 to 4 wk.\\nSome authorities do not recommend repeat small-bowel biopsies because macrophages may persist for\\nyears after treatment. However, others recommend repeat biopsy after 1 yr. In the latter approach,\\nelectron microscopy is needed to document bacilli (not just macrophages). Relapses are common and\\nmay occur years later. If relapse is suspected, small-bowel biopsies should be done (regardless of\\naffected organ systems) to determine presence of free bacilli.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 17. Malabsorption Syndromes\\n224\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 234, 'page_label': '225'}, page_content='Chapter 18. Irritable Bowel Syndrome\\n(Spastic Colon)\\nIrritable bowel syndrome (IBS) is characterized by abdominal discomfort or pain that is\\naccompanied by at least two of the following: relief by defecation, change in frequency of stool,\\nor change in consistency of stool. The cause is unknown, and the pathophysiology is\\nincompletely understood. Diagnosis is clinical. Treatment is symptomatic, consisting of dietary\\nmanagement and drugs, including anticholinergics and agents active at serotonin receptors.\\nEtiology\\nThe cause of IBS is unknown. No anatomic cause can be found on laboratory tests, x-rays, and biopsies.\\nEmotional factors, diet, drugs, or hormones may precipitate or aggravate GI symptoms. Historically, the\\ndisorder was often considered as purely psychosomatic. Although psychosocial factors are involved, IBS\\nis better understood as a combination of psychosocial and physiologic factors.\\nPsychosocial factors:\\n Psychologic distress is common among patients with IBS, especially among\\nthose who seek medical care. Some patients have anxiety disorders, depression, or a somatization\\ndisorder. Sleep disturbances also \\ncoexist. However, stress and emotional conflict do not always coincide\\nwith symptom onset and recurrence. Some patients with IBS seem to have a learned aberrant illness\\nbehavior (ie, they express emotional conflict as a GI complaint, usually abdominal pain). The physician\\nevaluating patients with IBS, particularly those with refractory symptoms, should investigate for\\nunresolved psychologic issues, including the possibility of sexual or physical abuse. Psychosocial factors\\nalso affect the outcome in IBS.\\nPhysiologic factors:\\n A variety of physiologic factors seem to be involved in IBS symptoms. Factors\\ninclude altered motility, visceral hyperalgesia, and various genetic and environmental factors.\\nVisceral hyperalgesia refers to hypersensitivity to normal amounts of intraluminal distention and\\nheightened perception of pain in the presence of normal quantities of intestinal gas; it may result from\\nremodeling of neural pathways in the brain-gut axis. Some patients (perhaps 1 in 7) have reported their\\nIBS symptoms began after an episode of acute gastroenteritis (termed postinfectious IBS). A subset of\\npatients with IBS has autonomic dysfunctions. However, many patients have no demonstrable physiologic\\nabnormalities, and even in those that do, the abnormalities may not correlate with symptoms.\\nConstipation may be explained by slower colonic transit, and diarrhea may be explained by faster colonic\\ntransit. Some patients with constipation have fewer colonic high amplitude-propagated contractions,\\nwhich propel colonic contents over several segments. Conversely, excess sigmoid motor activity may\\nretard transit in functional constipation.\\nPostprandial abdominal discomfort may be attributed to an exaggerated gastro-colonic reflex (the colonic\\ncontractile response to a meal), the presence of colonic high amplitude-propagated contractions,\\nincreased intestinal sensitivity (visceral hyperalgesia), or a combination of these. Fat ingestion may\\nexaggerate hypersensitivity.\\nHormonal fluctuations affect bowel functions in women. Rectal sensitivity is increased during menses but\\nnot during other phases of the menstrual cycle. The effects of sex steroids on GI transit are subtle. The\\nrole of small-bowel bacterial overgrowth in IBS is controversial.\\nSymptoms and Signs\\nIBS tends to begin in the teens and 20s, causing bouts of symptoms that recur at irregular periods. Onset\\nin late adult life is less common but not rare. Symptoms rarely rouse the sleeping patient. Symptoms are\\noften triggered by food, particularly fats, or by stress.\\nPatients have abdominal discomfort, which varies considerably but is often located in the lower quadrant,\\nsteady or cramping in nature, and relieved by defecation. In addition, abdominal discomfort is temporally\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 18. Irritable Bowel Syndrome\\n225'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 235, 'page_label': '226'}, page_content=\"associated with alterations in stool frequency (increased in diarrhea-predominant IBS and decreased in\\nconstipation-predominant IBS) and consistency (ie, loose or lumpy and hard). Pain or discomfort related\\nto defecation is likely to be of bowel origin; that associated with exercise, movement, urination, or\\nmenstruation usually has a different cause. Although bowel patterns are relatively consistent in most\\npatients, it is not unusual for patients to alternate between constipation and diarrhea. Patients may also\\nhave symptoms of abnormal stool passage (straining, urgency, or feeling of incomplete evacuation), pass\\nmucus, or complain of bloating or abdominal distention. Many patients also have symptoms of dyspepsia.\\nExtraintestinal symptoms (eg, fatigue, fibromyalgia, sleep disturbances, chronic headaches) are common.\\nDiagnosis\\n Clinical evaluation, based on Rome criteria\\n Screening for organic causes with basic laboratory tests and sigmoidoscopy or colonoscopy\\n Other tests for patients with red flag findings (rectal blood, weight loss, fever)\\nDiagnosis is based on characteristic bowel patterns, time and character of pain, and exclusion of other\\ndisease processes through physical examination and routine diagnostic tests. Diagnostic testing should\\nbe more intensive when the following red flag findings are present either at initial presentation or at any\\ntime after diagnosis: older age, fever, weight loss, rectal bleeding, vomiting. Because patients with IBS\\ncan develop organic conditions, testing for other conditions should also be considered in patients who\\ndevelop alarm symptoms or markedly different symptoms during the course of IBS. Common illnesses that\\nmay be confused with IBS include lactose intolerance, drug-induced diarrhea, post-cholecystectomy\\ndiarrhea, laxative abuse, parasitic diseases (eg, giardiasis), eosinophilic gastritis or enteritis, microscopic\\ncolitis, and early inflammatory bowel disease. However, uninflamed colonic diverticula do not cause\\nsymptoms, and their presence should not be considered explanatory.\\nThe bimodal age distribution of patients with inflammatory bowel disease makes it imperative to evaluate\\nboth younger and older \\npatients. In patients > 60 with acute symptoms, ischemic colitis should be\\nconsidered. Patients with constipation and no anatomic lesion should be evaluated for hypothyroidism\\nand hyperparathyroidism. If the patient's symptoms suggest malabsorption, tropical sprue, celiac disease,\\nand Whipple's disease must be considered. Defecatory disorders should be considered as a cause of\\nconstipation in patients who report symptoms of difficult defecation. Rare causes of diarrhea include\\nhyperthyroidism, medullary cancer of the thyroid, or carcinoid syndrome, gastrinoma, vipoma, and\\nZollinger-Ellison syndrome. However, secretory diarrhea caused by vasoactive intestinal peptide (VIP),\\ncalcitonin, or gastrin is typically accompanied by stool volumes > 1000 mL daily.\\nHistory:\\n Particular attention should be given to the character of the pain, bowel habits, familial\\ninterrelationships, and drug and dietary histories. Equally important are the patient's overall emotional\\nstate, interpretation of personal problems and quality of life. The quality of the patient-physician\\ninteraction is key to diagnostic and therapeutic efficacy.\\nThe \\nRome criteria\\n are standardized symptom-based criteria for diagnosing IBS. The Rome criteria\\nrequire the presence of abdominal pain or discomfort for at least 3 days/mo in the last 3 mo along with  2\\nof the following: (1) improvement with defecation, (2) onset (of each episode of discomfort) associated\\nwith a change in frequency of defecation, or (3) change in consistency of stool.\\nPhysical examination:\\n Patients generally appear to be healthy. Palpation of the abdomen may reveal\\ntenderness, particularly in the left lower quadrant, at times associated with a palpable, tender sigmoid. A\\ndigital rectal examination, including a test for occult blood, should be done on all patients. In women, a\\npelvic examination helps rule out ovarian tumors and cysts or endometriosis, which may mimic IBS.\\nTesting:\\n The diagnosis of IBS can reasonably be made using the Rome criteria as long as patients have\\nno red flag findings, such as rectal bleeding, weight loss, and fever, or other findings that might suggest\\nanother etiology. Many patients with IBS are overtested; however, CBC, biochemical profile (including\\nliver tests), ESR, stool examination for ova and parasites (in those with diarrhea predominance), thyroid-\\nstimulating hormone and Ca for those with constipation, and flexible sigmoidoscopy or colonoscopy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 18. Irritable Bowel Syndrome\\n226\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 236, 'page_label': '227'}, page_content=\"should be done. During flexible fiber-optic proctosigmoidoscopy, introduction of the instrument and air\\ninsufflation frequently trigger bowel spasm and pain. The mucosal and vascular patterns in IBS usually\\nappear normal. Colonoscopy is preferred for patients > 50 with a change in bowel habits, particularly\\nthose with no previous IBS symptoms, to exclude colonic polyps and tumors. In patients with chronic\\ndiarrhea, particularly older women, mucosal biopsy can rule out possible microscopic colitis.\\nAdditional studies (such as ultrasound, CT, barium enema x-ray, upper GI esophagogastroduodenoscopy,\\nand small-bowel x-rays) should be undertaken only when there are other objective abnormalities. Fecal\\nfat excretion should be measured when there is a concern about steatorrhea. Testing for celiac sprue and\\nsmall-bowel x-rays are recommended when malabsorption is suspected. Testing for carbohydrate\\nintolerance should be considered in appropriate circumstances.\\nIntercurrent disease:\\n Patients with IBS may subsequently develop additional GI disorders, and the\\nclinician must not summarily dismiss their complaints. Changes in symptoms (eg, in the location, type, or\\nintensity of pain; in bowel habits; in constipation and diarrhea) and new symptoms or complaints (eg,\\nnocturnal diarrhea) may signal another disease process. Other symptoms that require investigation\\ninclude fresh blood in the stool, weight loss, very severe abdominal pain or unusual abdominal distention,\\nsteatorrhea or noticeably foul-smelling stools, fever or chills, persistent vomiting, hematemesis, symptoms\\nthat wake the patient from sleep (eg, pain, the urge to defecate), and a steady progressive worsening of\\nsymptoms. Patients > 40 are more likely than younger patients to develop an intercurrent physiologic\\nillness.\\nTreatment\\n Support and understanding\\n Normal diet, avoiding gas-producing and diarrhea-producing foods\\n Increased fiber intake constipation\\n Loperamide for diarrhea\\n Possibly tricyclic antidepressants\\nTherapy is directed at specific symptoms. An effective therapeutic relationship is essential for effectively\\nmanaging IBS. Patients should be invited to express not only their symptoms but also their understanding\\nof their symptoms and the reasons prompting a visit to the health care practitioner (eg, fear of serious\\ndisease). Patients should be educated about the disorder (eg, normal bowel physiology and the bowel's\\nhypersensitivity to stress and food) and reassured, after appropriate tests, about the absence of a serious\\nor life-threatening \\ndisease. Appropriate therapeutic goals (eg, expectations regarding the normal course\\nor variability in symptoms, adverse effects of drugs, the appropriate and available working relationship\\nbetween the physician and the patient) should be established. Finally, patients can benefit by being\\nactively involved in the management of their condition. When successful, this can enhance the patient's\\nmotivation to adhere to treatment, foster a more positive physician-patient relationship, and mobilize the\\ncoping resources of even the most chronically passive patients. Psychologic stress, anxiety, or mood\\ndisorders should be identified, evaluated, and treated. Regular physical activity helps relieve stress and\\nassists in bowel function, particularly in patients with constipation.\\nDiet:\\n In general, a normal diet should be followed. Meals should not be overly large, and eating should be\\nslow and paced. Patients with abdominal distention and increased flatulence may benefit from reducing or\\neliminating beans, cabbage, and other foods containing fermentable carbohydrates. Reduced intake of\\nsweeteners (eg, sorbitol, mannitol, fructose), which are constituents of natural and processed foods (eg,\\napple and grape juice, bananas, nuts, and raisins), may alleviate flatulence, bloating, and diarrhea.\\nPatients with evidence of lactose intolerance should reduce their intake of milk and dairy products. A low-\\nfat diet may reduce postprandial abdominal symptoms.\\nDietary fiber supplements may soften stool and improve the ease of evacuation. A bland bulk-producing\\nagent may be used (eg, raw bran, starting with 15 mL [1 tbsp] with each meal, supplemented with\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 18. Irritable Bowel Syndrome\\n227\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 237, 'page_label': '228'}, page_content='increased fluid intake). Alternatively, psyllium hydrophilic mucilloid with two glasses of water may be used.\\nHowever, excessive use of fiber can lead to bloating and diarrhea, so fiber doses must be individualized.\\nOccasionally, flatulence may be reduced by switching to a synthetic fiber preparation (eg,\\nmethylcellulose).\\nDrug therapy:\\n Drug therapy is directed toward the dominant symptoms. Anticholinergic drugs (eg,\\nhyoscyamine 0.125 mg po 30 to 60 min before meals) may be used for their antispasmodic effects.\\nSerotonin receptor modulation may be of benefit. Tegaserod, a 5HT4 agonist, stimulates motility and\\nalleviates constipation. In 2007, tegaserod was withdrawn from the market because, in clinical trials, it\\nslightly increased the incidence of cardiovascular ischemic events (ie, MI, unstable angina pectoris,\\nstroke) compared with placebo. Tegaserod has since been reintroduced under a restricted program. The\\nchloride channel activator lubiprostone may help patients with constipation.\\nIn patients with diarrhea, oral diphenoxylate 2.5 to 5 mg or loperamide 2 to 4 mg may be given before\\nmeals. The dose of loperamide should be titrated upward to reduce diarrhea while avoiding constipation.\\nFor many patients, tricyclic antidepressants (TCAs) help relieve symptoms of diarrhea, abdominal pain,\\nand bloating. These drugs are thought to reduce pain by down-regulating the activity of spinal cord and\\ncortical afferent pathways arriving from the intestine. Secondary amine TCAs (eg, nortriptyline,\\ndesipramine) are often better tolerated than parent tertiary amines (eg, amitriptyline, imipramine, doxepin)\\nbecause of fewer anticholinergic, sedating antihistaminic, and \\n\\n-adrenergic adverse effects. Treatment\\nshould begin with a very low dose of a TCA (eg, desipramine 10 to 25 mg once/day at bedtime),\\nincreasing as necessary and tolerated up to about 100 to 150 mg once/day. SSRIs are also useful,\\nparticularly for patients with anxiety or an affective disorder, but may exacerbate diarrhea. 5HT3\\nantagonists (eg, alosetron) may benefit female patients with severe diarrhea refractory to other drugs.\\nBecause alosetron is associated with ischemic colitis, its use is restricted.\\nPreliminary data suggest that certain probiotics (eg, \\nBifidobacterium infantis\\n) alleviate IBS symptoms,\\nparticularly bloating. The beneficial effects of probiotics are not generic to the entire species but specific\\nto certain strains. Certain aromatic oils (carminatives) can relax smooth muscle and relieve pain caused\\nby cramps in some patients. Peppermint oil is the most commonly used agent in this class.\\nPsychologic therapies:\\n Cognitive-behavioral therapy, standard psychotherapy, and hypnotherapy may\\nhelp some IBS patients.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 18. Irritable Bowel Syndrome\\n228'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 238, 'page_label': '229'}, page_content=\"Chapter 19. Inflammatory Bowel Disease\\nIntroduction\\nInflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis (UC), is a\\nrelapsing and remitting condition characterized by chronic inflammation at various sites in the GI tract,\\nwhich results in diarrhea and abdominal pain.\\nInflammation results from a cell-mediated immune response in the GI mucosa. The precise etiology is\\nunknown, but evidence suggests that the normal intestinal flora trigger an immune reaction in patients\\nwith a multifactorial genetic predisposition (perhaps involving abnormal epithelial barriers and mucosal\\nimmune defenses). No specific environmental, dietary, or infectious causes have been identified. The\\nimmune reaction involves the release of inflammatory mediators, including cytokines, interleukins, and\\ntumor necrosis factor (TNF).\\nAlthough Crohn's disease and UC are similar, they can be distinguished in most cases (see\\nTable 19-1\\n). About 10% of colitis cases are considered indeterminate. The term colitis applies only to\\ninflammatory disease of the colon (eg, ulcerative, granulomatous, ischemic, radiation-induced, infectious).\\nSpastic (mucous) colitis is a misnomer sometimes applied to a functional disorder, irritable bowel\\nsyndrome (see p. \\n162\\n).\\nEpidemiology:\\n IBD affects people of all ages but usually begins before age 30, with peak incidence from\\n14 to 24. IBD may have a second smaller peak between ages 50 and 70; however, this later peak may\\ninclude some cases of ischemic colitis.\\nIBD is most common among people of Northern European and Anglo-Saxon origin and is 2 to 4 times\\nmore common among Ashkenazi Jews than in non-Jewish whites. The incidence is lower in central and\\nsouthern Europe and lower still in South America, Asia, and Africa. However, the incidence is increasing\\namong blacks and Latin Americans living in North America. Both sexes are equally affected. First-degree\\nrelatives of patients with IBD have a 4- to 20-fold increased risk; their absolute risk may be as high as\\n7%. Familial tendency is much higher in Crohn's disease than in UC.\\n[\\nTable 19-1.\\n Differentiating Crohn's Disease and Ulcerative Colitis]\\nSeveral gene mutations conferring a higher risk of Crohn's disease (and some possibly related to UC)\\nhave been identified.\\nCigarette smoking seems to contribute to development or exacerbation of Crohn's disease but decreases\\nrisk of UC. NSAIDs may exacerbate IBD.\\nExtraintestinal Manifestations\\nCrohn's disease and UC both affect organs other than the intestines. Most extraintestinal manifestations\\nare more common in UC and Crohn's colitis than in Crohn's disease limited to the small bowel.\\nExtraintestinal manifestations are categorized in 3 ways:\\n1. Disorders that usually parallel (ie, wax and wane with) IBD flare-ups. These disorders include\\nperipheral arthritis, episcleritis, aphthous stomatitis, erythema nodosum, and pyoderma gangrenosum.\\nArthritis tends to involve large joints and be migratory and transient. One or more of these parallel\\ndisorders develops in more than one third of patients hospitalized with IBD.\\n2. Disorders that are clearly associated with IBD but appear independently of IBD activity. These\\ndisorders include ankylosing spondylitis, sacroiliitis, uveitis, and primary sclerosing cholangitis.\\nAnkylosing spondylitis occurs more commonly in IBD patients with the HLA-B27 antigen. Most patients\\nwith spinal or sacroiliac involvement have evidence of uveitis and vice versa. Primary sclerosing\\ncholangitis, which is a risk factor for cancer of the biliary tract, is strongly associated with UC or Crohn's\\ncolitis. Cholangitis may appear before or concurrently with the bowel disease or even 20 yr after\\ncolectomy. Liver disease (eg, fatty liver, autoimmune hepatitis, pericholangitis, cirrhosis) occurs in 3 to\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n229\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 239, 'page_label': '230'}, page_content=\"5% of patients, although minor abnormalities in liver function tests are more common. Some of these\\nconditions (eg, primary sclerosing cholangitis) may precede IBD by many years and, when diagnosed,\\nshould prompt an evaluation for IBD.\\n3. Disorders that are consequences of disrupted bowel physiology. These disorders occur mainly in\\nsevere Crohn's disease of the small bowel. Malabsorption may result from extensive ileal resection and\\ncause deficiencies of fat-soluble vitamins, vitamin B\\n12\\n, or minerals, resulting in anemia, hypocalcemia,\\nhypomagnesemia, clotting disorders, and bone demineralization. In children, malabsorption retards\\ngrowth and development. Other disorders include kidney stones from excessive dietary oxalate\\nabsorption, hydroureter and hydronephrosis from ureteral compression by the intestinal inflammatory\\nprocess, gallstones from impaired ileal reabsorption of bile salts, and amyloidosis secondary to long-\\nstanding inflammatory and suppurative disease.\\nThromboembolic disease may occur as a result of multiple factors in all 3 categories.\\nTreatment\\n Supportive care\\n 5-Aminosalicylic acid\\n Corticosteroids\\n Immunomodulating drugs\\n Anticytokine drugs\\n Sometimes antibiotics (eg, metronidazole, ciprofloxacin) and probiotics\\nSeveral classes of drugs are helpful for IBD. Details of their selection and use are discussed under each\\ndisorder.\\n5-Aminosalicylic acid (5-ASA, mesalamine):\\n 5-ASA blocks production of prostaglandins and\\nleukotrienes and has other beneficial effects on the inflammatory cascade. Because 5-ASA is active only\\nintraluminally and is rapidly absorbed by the proximal small bowel, it must be formulated for delayed\\nabsorption when given orally. Sulfasalazine, the original agent in this class, delays absorption by\\ncomplexing 5-ASA with a sulfa moiety, sulfapyridine. The complex is cleaved by bacterial flora in the lower\\nileum and colon, releasing the 5-ASA. The sulfa moiety, however, causes numerous adverse effects (eg,\\nnausea, dyspepsia, headache), interferes with folate (folic acid) absorption, and occasionally causes\\nserious adverse reactions (eg, hemolytic anemia or agranulocytosis and, rarely, hepatitis or pneumonitis).\\nReversible decreases in sperm count and motility occur in up to 80% of men. If used, sulfasalazine should\\nbe given with food, initially in a low dosage (eg, 0.5 g po bid) and gradually increased over several days\\nto 1 to 2 g bid to tid. Patients should take daily folate supplements 1 mg po and have CBC and liver tests\\nevery 6 to 12 mo. Acute interstitial nephritis secondary to mesalamine occurs rarely; periodic monitoring of\\nrenal function is advisable because most cases are reversible if recognized early.\\nNewer drugs that complex 5-ASA with other vehicles seem almost equally effective but have fewer\\nadverse effects. Olsalazine (a 5-ASA dimer) and balsalazide (5-ASA conjugated to an inactive compound)\\nare cleaved by bacterial azoreductases (as is sulfasalazine). These drugs are activated mainly in the\\ncolon and are less effective for proximal small-bowel disease. Olsalazine dosage is 500 to 1500 mg po\\nbid, and balsalazide is 2.25 g po tid. Olsalazine sometimes causes diarrhea, especially in patients with\\npancolitis. \\nThis problem is minimized by gradual escalation of dose and administration with meals.\\nOther forms of 5-ASA use delayed-release coatings. Asacol (typical dose 800 to 1200 mg po tid) is 5-ASA\\ncoated with an acrylic polymer whose pH solubility delays release of the drug until entry into the distal\\nileum and colon. Pentasa (1 g po qid) is 5-ASA encapsulated in ethylcellulose microgranules that release\\n35% of the drug in the small bowel. Two once/day formulations of mesalamine (Lialda, Apriso) are\\navailable; this less frequent dosing may improve adherence.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n230\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 240, 'page_label': '231'}, page_content=\"5-ASA is also available as a suppository (500 or 1000 mg at bedtime or bid) or enema (4 g at bedtime or\\nbid) for proctitis and left-sided colon disease. These rectal preparations are effective for both acute\\ntreatment and long-term maintenance in proctitis and left-sided colon disease, and they have incremental\\nbenefit in combination with oral 5-ASA.\\nCorticosteroids:\\n Corticosteroids are useful for acute flare-ups of most forms of IBD when 5-ASA\\ncompounds are inadequate. However, corticosteroids are not appropriate for maintenance. IV\\nhydrocortisone 300 mg/day or methylprednisolone 60 to 80 mg/day by continuous drip or in divided doses\\nis used for severe disease; oral prednisone or prednisolone 40 to 60 mg once/day may be used for\\nmoderate disease. Treatment is continued until symptoms remit (usually 7 to 28 days) and then tapered\\nby 5 to 10 mg weekly to 20 mg once/day. Treatment is then further tapered by 2.5 to 5 mg weekly while\\ninstituting maintenance therapy with 5-ASA or immunomodulators. Adverse effects of short-term\\ncorticosteroids in high doses include hyperglycemia, hypertension, insomnia, hyperactivity, and acute\\npsychotic episodes.\\nHydrocortisone enemas or foam may be used for proctitis and left-sided colon disease; as an enema, 100\\nmg in 60 mL of isotonic solution is given once/day or bid. The enema should be retained in the bowel as\\nlong as possible; instillation at night, with the patient lying on the left side with hips elevated, may prolong\\nretention and extend distribution. Treatment, if effective, should be continued daily for about 2 to 4 wk,\\nthen every other day for 1 to 2 wk, and then gradually discontinued over 1 to 2 wk.\\nBudesonide is a corticosteroid with a high (> 90%) first-pass liver metabolism; thus, oral administration\\nmay have a significant effect on GI tract disease but minimal adrenal suppression. Oral budesonide has\\nfewer adverse effects than prednisolone but is not as rapidly effective and is typically used for less severe\\ndisease. Budesonide may be effective in maintaining remission for 3 to 6 mo but has not yet proved\\neffective for long-term maintenance. Dosage is 9 mg once/day. It is also available outside the US as an\\nenema.\\nImmunomodulating drugs:\\n Azathioprine and its metabolite 6-mercaptopurine inhibit T-cell function.\\nThey are effective long-term and may diminish corticosteroid requirements and maintain remission for\\nyears. These drugs often require 1 to 3 mo to produce clinical benefits, so corticosteroids cannot be\\nwithdrawn until at least the 2nd month. Dosage of azathioprine is usually 2.5 to 3.0 mg/kg po once/day\\nand 6-mercaptopurine 1.5 to 2.5 mg/kg po once/day but varies depending on individual metabolism. Signs\\nof bone marrow suppression must be monitored with regular WBC count (biweekly for 1 mo, then every 1\\nto 2 mo). Pancreatitis or high fever occurs in about 3 to 5% of patients; either is an absolute\\ncontraindication to rechallenge. Hepatotoxicity is rarer and can be screened by blood tests every 6 to 12\\nmo. Newly available blood tests that measure the activity of one of the enzymes that metabolize\\nazathioprine and 6-mercaptopurine and that directly measure metabolite levels may sometimes be helpful\\nin ensuring safe and effective drug dosages.\\nMethotrexate 15 to 25 mg po or sc weekly is of benefit to many patients with corticosteroid-refractory or\\ncorticosteroid-dependent Crohn's disease, even those who have not responded to azathioprine or 6-\\nmercaptopurine. Adverse effects include nausea, vomiting, and asymptomatic liver function test\\nabnormalities. Folate 1 mg po once/day may diminish some of the adverse effects. Alcohol use, obesity,\\ndiabetes, and possibly psoriasis are risk factors for hepatotoxicity. Patients with these conditions should\\nhave a liver biopsy after a total dose of 1.5 g, but otherwise, concerns over hepatotoxicity are too often\\nexaggerated. Pulmonary toxicity can also occur with methotrexate therapy.\\nCyclosporine, which blocks lymphocyte activation, may benefit patients with severe UC unresponsive to\\ncorticosteroids and who may otherwise require colectomy. Its only well-documented use in Crohn's\\ndisease is for patients with refractory fistulas or pyoderma. Initial dose is 4 mg/kg IV in continuous infusion\\nover 24 h; responders are converted to an oral dose of 6 to 8 mg/kg once/day with early introduction of\\nazathioprine or 6-mercaptopurine. Long-term use (> 6 mo) is contraindicated by multiple adverse effects\\n(eg, renal toxicity, seizures, opportunistic infections, hypertension, neuropathy). Generally, patients are\\nnot \\noffered cyclosporine unless there is a reason to avoid the safer curative option of colectomy. If the\\ndrug is used, trough blood levels should be kept between 200 to 400 ng/mL and \\nPneumocystis jirovecii\\nprophylaxis should be considered during the period of concomitant corticosteroid, cyclosporine, and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n231\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 241, 'page_label': '232'}, page_content=\"antimetabolite treatment. Tacrolimus, an immunosuppressant also used in transplant patients, seems as\\neffective as cyclosporine.\\nAnticytokine drugs:\\n Infliximab, certolizumab, and adalimumab are antibodies to TNF. These agents may\\nbe useful in Crohn's disease; additionally infliximab may be beneficial in UC for refractory or\\ncorticosteroid-dependent disease. Several anti-interleukin antibodies and interleukins may decrease the\\ninflammatory response and are being studied for Crohn's disease. An antibody to leukocyte adhesion\\nmolecules (natalizumab) is approved as monotherapy for the most refractory cases of Crohn's disease;\\nother analogs (eg, vedolizumab) are also being studied.\\nInfliximab is given as a single IV infusion of 5 mg/kg over 2 h. Monotherapy with infliximab is clearly\\neffective for both induction and maintenance of remission, but some studies suggest better short-term\\nresults when infliximab is initiated in combination with a thiopurine (eg, azathioprine). Ideally, infliximab\\nwould eventually be stopped and patients would be maintained on the antimetabolite, but this strategy\\nhas not been validated in controlled studies. Corticosteroid tapering may begin after 2 wk. The initial\\ninfliximab infusion is usually followed by repeat infusions at weeks 2 and 6. Subsequently, it is given every\\n8 wk or at intervals determined by the patient's clinical course. Adverse effects during infusion (infusion\\nreaction) include immediate hypersensitivity reactions (eg, rash, itching, sometimes anaphylactoid\\nreactions), fever, chills, headache, and nausea. Delayed hypersensitivity reactions have also occurred.\\nAnti-TNF drugs given subcutaneously (eg, adalimumab) do not cause infusion reactions, although they\\nmay cause local erythema, pain, and itching (injection site reaction). Patients who are intolerant or who\\nhave lost their initial response to infliximab may respond to adalimumab therapy.\\nSeveral patients have died of sepsis after infliximab use, so it is contraindicated when uncontrolled\\nbacterial infection is present. Furthermore, TB reactivation has been attributed to this drug; therefore,\\nscreening by PPD and chest x-ray is required before its use. Lymphoma, demyelinating disease, and liver\\nand hematologic toxicity are other potential concerns with anti-TNF antibody treatment. Other\\nanticytokine, anti-integrin, and growth factors are under investigation, as is leukopheresis therapy to\\ndeplete activated immunocytes.\\nAntibiotics and probiotics:\\n Antibiotics may be helpful in Crohn's disease but are of limited use in UC.\\nMetronidazole 500 to 750 mg po tid for 4 to 8 wk may control mild Crohn's disease and help heal fistulas.\\nHowever, adverse effects (particularly neurotoxicity) often preclude completion of treatment. Ciprofloxacin\\n500 to 750 mg po bid may prove less toxic. Many experts recommend metronidazole and ciprofloxacin in\\ncombination. Rifaximin, a nonabsorbable antibiotic, at a dose of 200 mg po tid is also being studied as\\ntreatment for active Crohn's disease.\\nVarious nonpathogenic microorganisms (eg, commensal \\nEscherichia coli\\n, \\nLactobacillus\\n species,\\nSaccharomyces\\n) given daily serve as probiotics and may be effective in preventing pouchitis (see p. \\n176\\n),\\nbut other therapeutic roles have yet to be clearly defined. Therapeutic infestation with the parasite\\nTrichuris suis\\n has been tried in an effort to stimulate T2-helper cell immunity and may decrease disease\\nactivity in UC.\\nSupportive care:\\n Most patients and their families are interested in diet and stress management.\\nAlthough there are anecdotal reports of clinical improvement on certain diets, including one with rigid\\ncarbohydrate restrictions, controlled trials have shown no benefit. Stress management may be helpful.\\nCrohn's Disease\\n(Regional Enteritis; Granulomatous Ileitis or Ileocolitis)\\nCrohn's disease is a chronic transmural inflammatory disease that usually affects the distal\\nileum and colon but may occur in any part of the GI tract. Symptoms include diarrhea and\\nabdominal pain. Abscesses, internal and external fistulas, and bowel obstruction may arise.\\nExtraintestinal symptoms, particularly arthritis, may occur. Diagnosis is by colonoscopy and\\nbarium contrast studies. Treatment is with 5-aminosalicylic acid, corticosteroids,\\nimmunomodulators, anticytokines, antibiotics, and often surgery.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n232\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 242, 'page_label': '233'}, page_content='Pathophysiology\\nCrohn\\'s disease begins with crypt inflammation and abscesses, which progress to tiny focal aphthoid\\nulcers. These mucosal lesions \\nmay develop into deep longitudinal and transverse ulcers with intervening\\nmucosal edema, creating a characteristic cobblestoned appearance to the bowel.\\nTransmural spread of inflammation leads to lymphedema and thickening of the bowel wall and mesentery.\\nMesenteric fat typically extends onto the serosal surface of the bowel. Mesenteric lymph nodes often\\nenlarge. Extensive inflammation may result in hypertrophy of the muscularis mucosae, fibrosis, and\\nstricture formation, which can lead to bowel obstruction. Abscesses are common, and fistulas often\\npenetrate into adjoining structures, including other loops of bowel, the bladder, or psoas muscle. Fistulas\\nmay even extend to the skin of the anterior abdomen or flanks. Independently of intra-abdominal disease\\nactivity, perianal fistulas and abscesses occur in 25 to 33% of cases; these complications are frequently\\nthe most troublesome aspects of Crohn\\'s disease.\\nNoncaseating granulomas can occur in lymph nodes, peritoneum, the liver, and all layers of the bowel\\nwall. Although pathognomonic when present, granulomas are not detected in about half of patients with\\nCrohn\\'s disease. The presence of granulomas does not seem to be related to the clinical course.\\nSegments of diseased bowel are sharply demarcated from adjacent normal bowel (\"skip areas\"); hence,\\nthe name regional enteritis. About 35% of Crohn\\'s disease cases involve the ileum alone (ileitis); about\\n45% involve the ileum and colon (ileocolitis), with a predilection for the right side of the colon; and about\\n20% involve the colon alone (granulomatous colitis), most of which, unlike ulcerative colitis (UC), spare\\nthe rectum. Occasionally, the entire small bowel is involved (jejunoileitis). The stomach, duodenum, or\\nesophagus is clinically involved only rarely, although microscopic evidence of disease is often detectable\\nin the gastric antrum, especially in younger patients. In the absence of surgical intervention, the disease\\nalmost never extends into areas of small bowel that are not involved at first diagnosis.\\nThere is an increased risk of cancer in affected small-bowel segments. Patients with colonic involvement\\nhave a long-term risk of colorectal cancer equal to that of UC, given the same extent and duration of\\ndisease.\\nSymptoms and Signs\\nThe most common initial manifestation is chronic diarrhea with abdominal pain, fever, anorexia, and\\nweight loss. The abdomen is tender, and a mass or fullness may be palpable. Gross rectal bleeding is\\nunusual except in isolated colonic disease, which may manifest similarly to UC. Some patients present\\nwith an acute abdomen that simulates acute appendicitis or intestinal obstruction. About 33% of patients\\nhave perianal disease (especially fissures and fistulas), which is sometimes the most prominent or even\\ninitial complaint. In children, extraintestinal manifestations frequently predominate over GI symptoms;\\narthritis, FUO, anemia, or growth retardation may be a presenting symptom, whereas abdominal pain or\\ndiarrhea may be absent.\\nWith recurrent disease, symptoms vary. Pain is most common and occurs with both simple recurrence and\\nabscess formation. Patients with severe flare-up or abscess are likely to have marked tenderness,\\nguarding, rebound, and a general toxic appearance. Stenotic segments may cause bowel obstruction,\\nwith colicky pain, distention, obstipation, and vomiting. Adhesions from previous surgery may also cause\\nbowel obstruction, which begins rapidly, without the prodrome of fever, pain, and malaise typical of\\nobstruction due to a Crohn\\'s disease flare-up. An enterovesical fistula may produce air bubbles in the\\nurine (pneumaturia). Draining cutaneous fistulas may occur. Free perforation into the peritoneal cavity is\\nunusual.\\nChronic disease causes a variety of systemic symptoms, including fever, weight loss, undernutrition, and\\nextraintestinal manifestations (see p. \\n166\\n).\\nThe Vienna Classification and its recent Montreal modification categorize Crohn\\'s disease into 3 principal\\npatterns: (1) primarily inflammatory, which after several years commonly evolves into either (2) primarily\\nstenotic or obstructing or (3) primarily penetrating or fistulizing. These different clinical patterns dictate\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n233'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 243, 'page_label': '234'}, page_content=\"different therapeutic approaches. Some genetic studies suggest a molecular basis for this classification.\\nDiagnosis\\n Barium x-rays of the stomach, small bowel, and colon\\n Abdominal CT (conventional or CT enterography)\\n Sometimes magnetic resonance (MR) enterography, upper endoscopy, and/or colonoscopy\\nCrohn's disease should be suspected in a patient with inflammatory or obstructive symptoms or in a\\npatient without prominent GI symptoms but with perianal fistulas or abscesses or with otherwise\\nunexplained arthritis, erythema nodosum, fever, anemia, or (in a child) stunted growth. A family history of\\nCrohn's disease also increases the index of suspicion. Similar symptoms and signs (eg, abdominal pain,\\ndiarrhea) may be caused by other GI disorders. Differentiation from UC (see \\nTable 19-1\\n) may be an issue\\nin the 20% of cases in which Crohn's disease is confined to the colon. However, because treatment is\\nsimilar, this distinction is critical only when surgery or experimental therapy is contemplated.\\nPatients presenting with an acute abdomen (either initially or on relapse) should have flat and upright\\nabdominal x-rays and an abdominal CT scan. These studies may show obstruction, abscesses or fistulas,\\nand other possible causes of an acute abdomen (eg, appendicitis). Ultrasound may better delineate\\ngynecologic pathology in women with lower abdominal and pelvic pain.\\nIf initial presentation is less acute, an upper GI series with small-bowel follow-through and spot films of\\nthe terminal ileum is preferred over conventional CT. However, newer techniques of CT or MR\\nenterography, which combine high-resolution CT or MR imaging with large volumes of ingested contrast,\\nare becoming the procedures of choice in some centers. These imaging studies are virtually diagnostic if\\nthey show characteristic strictures or fistulas with accompanying separation of bowel loops. If findings are\\nquestionable, CT enteroclysis or video capsule enteroscopy may show superficial aphthous and linear\\nulcers. Barium enema x-ray may be used if symptoms seem predominantly colonic (eg, diarrhea) and may\\nshow reflux of barium into the terminal ileum with irregularity, nodularity, stiffness, wall thickening, and a\\nnarrowed lumen. Differential diagnoses in patients with similar x-ray findings include cancer of the cecum,\\nileal carcinoid, lymphoma, systemic vasculitis, radiation enteritis, ileocecal TB, and ameboma.\\nIn atypical cases (eg, predominantly diarrhea, with minimal pain), evaluation is similar to suspected UC,\\nwith colonoscopy (including biopsy, sampling for enteric pathogens, and, when possible, visualization of\\nthe terminal ileum). Upper GI endoscopy may identify subtle gastroduodenal involvement even in the\\nabsence of upper GI symptoms.\\nLaboratory tests should be done to screen for anemia, hypoalbuminemia, and electrolyte abnormalities.\\nLiver function tests should be done; elevated alkaline phosphatase and \\n\\n-glutamyl transpeptidase levels\\nin patients with major colonic involvement suggest possible primary sclerosing cholangitis. Leukocytosis\\nor increased levels of acute-phase reactants (eg, ESR, C-reactive protein) are nonspecific but may be\\nused serially to monitor disease activity.\\nPerinuclear antineutrophil cytoplasmic antibodies are present in 60 to 70% of patients with UC and in only\\n5 to 20% of patients with Crohn's disease. Anti-\\nSaccharomyces cerevisiae\\n antibodies are relatively\\nspecific for Crohn's disease. However, these tests do not reliably separate the 2 diseases. They have\\nuncertain value in cases of indeterminate colitis and are not recommended for routine diagnosis.\\nPrognosis\\nEstablished Crohn's disease is rarely cured but is characterized by intermittent exacerbations and\\nremissions. Some patients have severe disease with frequent, debilitating periods of pain. However, with\\njudicious medical therapy and, where appropriate, surgical therapy, most patients function well and adapt\\nsuccessfully. Disease-related mortality is very low. GI cancer, including cancer of the colon and small\\nbowel, is the leading cause of excess Crohn's disease-related mortality.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n234\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 244, 'page_label': '235'}, page_content=\"Treatment\\n Loperamide or antispasmodics for symptom relief\\n 5-Aminosalicylic acid (5-ASA) or antibiotics\\n Other drugs depending on symptoms and severity\\n Sometimes surgery\\nDetails of specific drugs and dosages are discussed on p. \\n167\\n.\\nGeneral management:\\n Cramps and diarrhea may be relieved by oral administration of loperamide 2 to 4\\nmg or antispasmodic drugs up to 4 times/day (ideally before meals). Such symptomatic treatment is safe,\\nexcept in cases of severe, acute Crohn's colitis, which may progress to toxic megacolon as in UC.\\nHydrophilic mucilloids (eg, methylcellulose or psyllium preparations) sometimes help prevent anal irritation\\nby increasing stool firmness. Dietary roughage is to be avoided in stricturing disease or active colonic\\ninflammation.\\nMild to moderate disease:\\n This category includes ambulatory patients who tolerate oral intake and\\nhave no signs of toxicity, tenderness, mass, or obstruction. 5-ASA (mesalamine) is commonly used as\\nfirst-line treatment, although its benefits for small-bowel disease are modest at best. Pentasa is the most\\neffective formulation for disease proximal to the terminal ileum; Asacol is effective in distal ileal disease. All\\nformulations are roughly equivalent for Crohn's colitis, although none of the newer preparations rival\\nsulfasalazine for efficacy on a dose-for-dose basis.\\nAntibiotics are considered a first-line agent by some clinicians, or they may be reserved for patients not\\nresponding to 4 wk of 5-ASA; their use is strictly empiric. With any of these drugs, 8 to 16 wk of treatment\\nmay be required.\\nResponders should receive maintenance therapy.\\nModerate to severe disease:\\n Patients without fistulas or abscesses but with significant pain,\\ntenderness, fever, or vomiting, or those who have not responded to treatment for mild disease, require\\ncorticosteroids, either oral or parenteral, depending on severity of symptoms and frequency of vomiting.\\nOral prednisone or prednisolone may act more rapidly and reliably than oral budesonide, but budesonide\\nhas somewhat fewer adverse effects and is considered the corticosteroid of choice in many centers,\\nespecially in Europe. Patients not responding to corticosteroids, or those whose doses cannot be\\ntapered, should receive azathioprine, 6-mercaptopurine, or possibly methotrexate. Infliximab is preferred\\nby some as a second-line agent after corticosteroids, and even as a first-line agent in preference to\\ncorticosteroids, but it is contraindicated in active uncontrolled infection.\\nObstruction is managed initially with nasogastric suction and IV fluids. Obstruction due to uncomplicated\\nCrohn's disease should resolve within a few days and therefore does not require parenteral nutrition;\\nabsence of prompt response indicates a complication or another etiology and demands immediate\\nsurgery.\\nFulminant disease or abscess:\\n Patients with toxic appearance, high fever, persistent vomiting,\\nrebound, or a tender or palpable mass must be hospitalized for administration of IV fluids and antibiotics.\\nAbscesses must be drained, either percutaneously or surgically. IV corticosteroids should be given only\\nwhen infection has been ruled out or controlled. If there is no response to corticosteroids and antibiotics\\nwithin 5 to 7 days, surgery is usually indicated.\\nFistulas:\\n Fistulas are treated initially with metronidazole and ciprofloxacin. Patients who do not respond\\nin 3 to 4 wk may receive an immunomodulator (eg, azathioprine, 6-mercaptopurine), with or without an\\ninduction regimen of infliximab for more rapid response. Cyclosporine is an alternative, but fistulas often\\nrelapse after treatment. Severe refractory perianal fistulas may require temporary diverting colostomy but\\nalmost invariably recur after reconnection; hence, diversion is more appropriately considered a\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n235\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 245, 'page_label': '236'}, page_content='preparation for definitive surgery or at best an adjunct to infliximab rather than a primary treatment.\\nMaintenance therapy:\\n Patients who require only 5-ASA or an antibiotic to achieve remission can be\\nmaintained on this drug. Patients requiring acute treatment with corticosteroids or infliximab generally\\nrequire azathioprine, 6-mercaptopurine, methotrexate, or infliximab for maintenance. Systemically active\\ncorticosteroids are neither safe nor effective for long-term maintenance, although budesonide has been\\nshown to delay relapse with fewer adverse effects. Patients who respond to infliximab for acute disease\\nbut who are not well maintained on antimetabolites may stay in remission with repeat doses of infliximab 5\\nto 10 mg/kg at 8-wk intervals. Monitoring during remission can be done by following symptoms and blood\\ntests and does not require routine x-rays or colonoscopy (other than regular surveillance for dysplasia\\nafter 7 to 8 yr of disease).\\nSurgery:\\n Even though about 70% of patients ultimately require an operation, surgery is always done\\nreluctantly. It is best reserved for recurrent intestinal obstruction or intractable fistulas or abscesses.\\nResection of the involved bowel may ameliorate symptoms but does not cure the disease, which is likely\\nto recur even after resection of all clinically apparent lesions. The recurrence rate, defined by endoscopic\\nlesions at the anastomotic site, is > 70% at 1 yr and > 85% at 3 yr; defined by clinical symptoms, it is\\nabout 25 to 30% at 3 yr and 40 to 50% at 5 yr. Ultimately, further surgery is required in nearly 50% of\\ncases. However, recurrence rates seem to be reduced by early postoperative prophylaxis with 6-\\nmercaptopurine, metronidazole, or possibly infliximab or 5-ASA. Moreover, when surgery is done for\\nappropriate indications, almost all patients have improved quality of life.\\nUlcerative Colitis\\nUlcerative colitis (UC) is a chronic inflammatory and ulcerative disease arising in the colonic\\nmucosa, characterized most often by bloody diarrhea. Extraintestinal symptoms, particularly\\narthritis, may occur. Long-term risk of colon cancer is high. Diagnosis is by colonoscopy.\\nTreatment is with 5-aminosalicylic acid, corticosteroids, immunomodulators, anticytokines,\\nantibiotics, and occasionally surgery.\\nPathophysiology\\nUC usually begins in the rectum. It may remain localized to the rectum (ulcerative proctitis) or extend\\nproximally, sometimes involving the entire colon. Rarely, it involves most of the large bowel at once.\\nThe inflammation caused by UC affects the mucosa and submucosa, and there is a sharp border\\nbetween normal and affected tissue. Only in severe disease is the muscularis involved. In early cases, the\\nmucous membrane is erythematous, finely granular, and friable, with loss of the normal vascular pattern\\nand often with scattered hemorrhagic areas. Large mucosal ulcers with copious purulent exudate\\ncharacterize severe disease. Islands of relatively normal or hyperplastic inflammatory mucosa\\n(pseudopolyps) project above areas of ulcerated mucosa. Fistulas and abscesses do not occur.\\nToxic or fulminant colitis\\n occurs when transmural extension of ulceration results in localized ileus and\\nperitonitis. Within hours to days, the colon loses muscular tone and begins to dilate. The terms toxic\\nmegacolon or toxic dilation are discouraged because the toxic inflammatory state and its complications\\ncan occur without frank megacolon (defined as transverse colon > 6 cm diameter during an exacerbation).\\nToxic colitis is a medical emergency that usually occurs spontaneously in the course of very severe colitis\\nbut is sometimes precipitated by opioid or anticholinergic antidiarrheal drugs. Colonic perforation may\\noccur, which increases mortality significantly.\\nSymptoms and Signs\\nBloody diarrhea of varied intensity and duration is interspersed with asymptomatic intervals. Usually an\\nattack begins insidiously, with increased urgency to defecate, mild lower abdominal cramps, and blood\\nand mucus in the stools. Some cases develop after an infection (eg, amebiasis, bacillary dysentery).\\nWhen ulceration is confined to the rectosigmoid, the stool may be normal or hard and dry, but rectal\\ndischarges of mucus loaded with RBCs and WBCs accompany or occur between bowel movements.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n236'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 246, 'page_label': '237'}, page_content=\"Systemic symptoms are absent or mild. If ulceration extends proximally, stools become looser and the\\npatient may have > 10 bowel movements per day, often with severe cramps and distressing rectal\\ntenesmus, without respite at night. The stools may be watery or contain mucus and frequently consist\\nalmost entirely of blood and pus.\\nToxic or fulminant colitis manifests initially with sudden violent diarrhea, fever to 40 C (104 F),\\nabdominal pain, signs of peritonitis (eg, rebound tenderness), and profound toxemia.\\nSystemic symptoms and signs, more common with extensive UC, include malaise, fever, anemia,\\nanorexia, and weight loss. Extraintestinal manifestations (particularly joint and skin complicationssee p.\\n167\\n) are most common when systemic symptoms are present.\\nDiagnosis\\n Stool cultures and microscopy (to exclude infectious causes)\\n Sigmoidoscopy with biopsy\\nInitial presentation:\\n Diagnosis is suggested by typical symptoms and signs, particularly when\\naccompanied by extraintestinal manifestations or a history of previous similar attacks. UC should be\\ndistinguished from Crohn's disease (see \\nTable 19-1\\n) but more importantly from other causes of acute\\ncolitis (eg, infection; in elderly patients, ischemia).\\nIn all patients, stool cultures for enteric pathogens should be done, and \\nEntamoeba histolytica\\n should be\\nexcluded by examination of fresh stool specimens. When amebiasis is suspected because of\\nepidemiologic or travel history, serologic titers and biopsies should be done. History of prior antibiotic use\\nor recent hospitalization should prompt stool assay for \\nClostridium difficile\\n toxin. Patients at risk should\\nbe tested for HIV, gonorrhea, herpesvirus, chlamydia, and amebiasis. Opportunistic infections (eg,\\ncytomegalovirus, \\nMycobacterium avium-intracellulare\\n) or Kaposi's sarcoma must also be considered in\\nimmunosuppressed patients. In women using oral contraceptives, contraceptive-induced colitis is\\npossible; it usually resolves spontaneously after hormone therapy is stopped.\\nSigmoidoscopy should be done; it allows visual confirmation of colitis and permits direct sampling of stool\\nor mucus for culture and microscopic evaluation, as well as biopsy of affected areas. Although visual\\ninspection and biopsies may be nondiagnostic, because there is much overlap in appearance among\\ndifferent types of colitis, acute, self-limited, infectious colitis can usually be distinguished histologically\\nfrom chronic idiopathic UC or Crohn's colitis. Severe perianal disease, rectal sparing, absence of\\nbleeding, and asymmetric or segmental involvement of the colon indicate Crohn's disease rather than UC\\n(see \\nTable 19-1\\n). Colonoscopy is usually unnecessary initially but should be done electively if\\ninflammation has extended proximal to the reach of the sigmoidoscope.\\nLaboratory tests should be done to screen for anemia, hypoalbuminemia, and electrolyte abnormalities.\\nLiver function tests should \\nbe done; elevated alkaline phosphatase and \\n\\n-glutamyl transpeptidase levels\\nsuggest possible primary sclerosing cholangitis. Perinuclear antineutrophil cytoplasmic antibodies are\\nrelatively specific (60 to 70%) for UC. Anti-\\nSaccharomyces cerevisiae\\n antibodies are relatively specific for\\nCrohn's disease. However, these tests do not reliably separate the 2 diseases and are not recommended\\nfor routine diagnosis. Other possible laboratory abnormalities include leukocytosis, thrombocytosis, and\\nelevated acute-phase reactants (eg, ESR, C-reactive protein).\\nX-rays are not diagnostic but occasionally show abnormalities. Plain x-rays of the abdomen may show\\nmucosal edema, loss of haustration, and absence of formed stool in the diseased bowel. Barium enema\\nshows similar changes, albeit more clearly, and may also show ulcerations, but the enema should not be\\ndone during an acute presentation. A shortened, rigid colon with an atrophic or pseudopolypoid mucosa is\\noften seen after several years' illness. X-ray findings of thumbprinting and segmental distribution are more\\nsuggestive of intestinal ischemia or possibly Crohn's colitis rather than of UC.\\nRecurrent symptoms:\\n Patients with known disease and a recurrence of typical symptoms should be\\nexamined, but extensive testing is not always required. Depending on duration and severity of symptoms,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n237\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 247, 'page_label': '238'}, page_content='sigmoidoscopy or colonoscopy may be done and a CBC obtained. Cultures, ova and parasite\\nexamination, and \\nC. difficile\\n toxin assay should be done when there are atypical features to the relapse\\nor when there is an exacerbation after prolonged remission, during a contagious outbreak, after antibiotic\\nexposure, or whenever the clinician is suspicious.\\nFulminant symptoms:\\n Patients require further evaluation during severe flare-ups. Flat and upright\\nabdominal x-rays should be taken; they may show megacolon or intraluminal gas accumulated over a\\nlong, continuous, paralyzed segment of colona result of lost muscle tone. Colonoscopy and barium\\nenema should be avoided because of the risk of perforation. CBC, ESR, electrolytes, PT, PTT, and type\\nand crossmatch should be obtained.\\nThe patient must be watched closely for progressive peritonitis or perforation. Percussion over the liver is\\nimportant because loss of hepatic dullness may be the first clinical sign of free perforation, especially in a\\npatient whose peritoneal signs are suppressed by high-dose corticosteroids. Abdominal x-rays are taken\\nevery 1 or 2 days to follow the course of colonic distention and to detect free or intramural air.\\nPrognosis\\nUsually, UC is chronic with repeated exacerbations and remissions. In about 10% of patients, an initial\\nattack becomes fulminant with massive hemorrhage, perforation, or sepsis and toxemia. Complete\\nrecovery after a single attack occurs in another 10%.\\nPatients with localized ulcerative proctitis have the best prognosis. Severe systemic manifestations, toxic\\ncomplications, and malignant degeneration are unlikely, and late extension of the disease occurs in only\\nabout 20 to 30%. Surgery is rarely required, and life expectancy is normal. The symptoms, however, may\\nprove stubborn and refractory. Moreover, because extensive UC may begin in the rectum and spread\\nproximally, proctitis should not be considered localized until it has been observed for  6 mo. Localized\\ndisease that later extends is often more severe and more refractory to therapy.\\nColon cancer:\\n The risk of colon cancer is proportional to the duration of disease and amount of colon\\naffected, but not necessarily to the clinical severity of the attacks. Some recent studies suggest that\\nsustained microscopic inflammation is a risk factor, and that use of aminosalicylate to control inflammation\\nis protective. Cancer begins to appear by 7 yr from onset of illness in patients with extensive colitis. The\\ncumulative likelihood of cancer is about 3% at 15 yr, 5% at 20 yr, and 9% at 25 yr, representing an annual\\nrisk of about 0.5 to 1% after the 10th yr. There is probably no higher absolute cancer risk among patients\\nwith childhood-onset colitis independent of the longer duration of disease. However, patients who have\\ninflammatory bowel disease and primary sclerosing cholangitis are at a higher risk of cancer from the time\\nof colitis diagnosis.\\nRegular colonoscopic surveillance, preferably during remission, is advised for patients with disease\\nduration > 8 to 10 yr (except for those with isolated proctitis). Endoscopic biopsies should be taken every\\n10 cm throughout the colon. Newer techniques, especially chromoendoscopy, may better identify areas of\\nsuspicion in preference to totally random biopsies. Any grade of definite dysplasia within an area affected\\nby colitis is liable to progress to more advanced neoplasia and even cancer and is a strong indication for\\ntotal colectomy unless the dysplasia is strictly confined to a discrete, completely excisable polyp. It is\\nimportant to distinguish definite neoplastic dysplasia from reactive or regenerative atypia secondary to\\ninflammation. However, if the dysplasia is unequivocal, delaying colectomy in favor of \\nrepeated follow-up\\nsurveillance is a risky strategy. Pseudopolyps have no prognostic significance but may be difficult to\\ndistinguish from neoplastic polyps; thus, any suspect polyp should undergo excision biopsy.\\nThe optimal frequency of colonoscopic surveillance has not been established, but some authorities\\nrecommend every 2 yr during the 2nd decade of disease and annually thereafter.\\nLong-term survival after diagnosis of colitis-related cancer is about 50%, a figure comparable to that for\\ncolorectal cancer in the general population.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n238'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 248, 'page_label': '239'}, page_content=' Loperamide and dietary management for symptom relief\\n 5-Aminosalicylic acid (5-ASA)\\n Corticosteroids and other drugs depending on symptoms and severity\\n Anticytokine drugs\\n Sometimes surgery\\nDetails of specific drugs and regimens are discussed on p. \\n167\\n.\\nGeneral management:\\n Avoiding raw fruits and vegetables limits trauma to the inflamed colonic mucosa\\nand may lessen symptoms. A milk-free diet may help but need not be continued if no benefit is noted.\\nLoperamide 2 mg po bid to qid is indicated for relatively mild diarrhea; higher oral doses (4 mg in the\\nmorning and 2 mg after each bowel movement) may be required for more intense diarrhea. Antidiarrheal\\ndrugs must be used with extreme caution in severe cases because they may precipitate toxic dilation.\\nMild left-sided disease:\\n Patients with proctitis, or colitis that does not extend proximally beyond the\\nsplenic flexure, are treated with 5-ASA (mesalamine) enemas once/day or bid depending on severity.\\nSuppositories are effective for more distal disease and are usually preferred by patients. Corticosteroid\\nand budesonide enemas are slightly less effective but should be used if 5-ASA is unsuccessful or not\\ntolerated. Once remission is achieved, dosage is slowly tapered to maintenance levels. Oral 5-ASA drugs\\ntheoretically have some incremental benefit in lessening the probability of proximal spread of disease.\\nModerate or extensive disease:\\n Patients with inflammation proximal to the splenic flexure or left-sided\\ndisease unresponsive to topical agents should receive an oral 5-ASA formulation in addition to 5-ASA\\nenemas. High-dose corticosteroids are added for more severe symptoms; after 1 to 2 wk, the daily dose is\\nreduced by about 5 to 10 mg each wk. Immunomodulater therapy with azathioprine or 6-mercaptopurine\\ncan be used in patients who are refractory to maximal doses of 5-ASA and would otherwise need long-\\nterm corticosteroid therapy. Additionally, infliximab is beneficial in some patients and may be considered\\nfor those refractory to immunomodulator or corticosteroid therapy as well as those who are corticosteroid\\ndependent.\\nSevere disease:\\n Patients with > 10 bloody bowel movements per day, tachycardia, high fever, or severe\\nabdominal pain require hospitalization to receive high-dose IV corticosteroids. 5-ASA may be continued. IV\\nfluids and blood transfusion are given as needed for dehydration and anemia. The patient must be\\nobserved closely for the development of toxic megacolon. Parenteral hyperalimentation is sometimes\\nused for nutritional support but is of no value as primary therapy; patients who can tolerate food should\\neat.\\nPatients who do not respond within 3 to 7 days should be considered for IV cyclosporine or infliximab or\\nelse for surgery. Patients who do respond to a corticosteroid regimen are switched within a week or so to\\nprednisone 60 mg po once/day, which may be gradually reduced at home based on clinical response.\\nPatients who are started on IV cyclosporine and respond to therapy are switched to oral cyclosporine and\\nconcomitant azathioprine or 6-mercaptopurine. Oral cyclosporine is continued for about 3 to 4 mo, during\\nwhich time corticosteroids are tapered and cyclosporine levels are closely monitored. Some clinicians\\nrecommend prophylaxis against \\nPneumocystis jirovecii\\n pneumonia during the interval of overlapping\\ntreatment with corticosteroids, cyclosporine, and an antimetabolite.\\nFulminant colitis:\\n If fulminant colitis or toxic megacolon is suspected, the patient should (1) stop all\\nantidiarrheal drugs; (2) take nothing by mouth and have inserted a long intestinal tube attached to\\nintermittent suction; (3) receive aggressive IV fluid and electrolyte therapy with 0.9% NaCl, and potassium\\nchloride and blood as needed; (4) be treated with high-dose IV corticosteroid or cyclosporine; and (5)\\nreceive antibiotics (eg, metronidazole 500 mg IV q 8 h and ciprofloxacin 500 mg IV q 12 h).\\nHaving the patient roll over in bed from the supine to prone position every 2 to 3 h may help redistribute\\ncolonic gas and prevent progressive distention. Passage of a soft rectal tube may also be helpful but\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n239'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 249, 'page_label': '240'}, page_content=\"must be done with extreme caution to avoid bowel perforation.\\nIf intensive medical measures do not produce definite improvement within 24 to 48 h, immediate surgery\\nis required or the patient may die of sepsis caused by bacterial translocation or even perforation.\\nMaintenance therapy:\\n After effective treatment of a flare-up, corticosteroids are tapered based on\\nclinical response and then stopped because they are ineffective as maintenance. Patients should remain\\non 5-ASA drugs indefinitelyoral or rectal, depending on location of diseasebecause stopping\\nmaintenance therapy often allows disease relapse. Dosage intervals for rectal preparations may be\\ngradually lengthened to every 2nd or 3rd day.\\nPatients who cannot be withdrawn from corticosteroids should be given azathioprine or 6-mercaptopurine.\\nAlso, infliximab is becoming more widely accepted as maintenance therapy for UC as well as for Crohn's\\ndisease.\\nSurgery:\\n Nearly one third of patients with extensive UC ultimately require surgery. Total proctocolectomy\\nis curative: Life expectancy and quality of life are restored to normal, the disease does not recur (unlike\\nCrohn's disease), and the risk of colon cancer is eliminated.\\nEmergency colectomy is indicated for massive hemorrhage, fulminating toxic colitis, or perforation.\\nSubtotal colectomy with ileostomy and rectosigmoid closure or mucous fistula is usually the procedure of\\nchoice because most critically ill patients cannot tolerate more extensive surgery. The rectosigmoid stump\\nmay be electively removed later or may be used for ileoanal anastomosis with a pouch. The intact rectal\\nstump should not be allowed to remain indefinitely because of the risk of disease activation and malignant\\ntransformation.\\nElective surgery is indicated for cancer, symptomatic strictures, growth retardation in children, or, most\\ncommonly, intractable chronic disease resulting in invalidism or corticosteroid dependence. Colectomy is\\nalso done for high-grade and perhaps even low-grade mucosal dysplasia confirmed on pathologic\\nconsultation, unless the dysplasia is limited exclusively to a completely excisable polyp. Severe colitis-\\nrelated extraintestinal manifestations (eg, pyoderma gangrenosum), now better controlled by intensive\\nmedical therapies, are only rarely indications for surgery.\\nThe elective procedure of choice in patients with normal sphincter function is restorative proctocolectomy\\nwith ileoanal anastomosis. This procedure creates a pelvic reservoir or pouch from distal ileum, which is\\nconnected to the anus. The intact sphincter allows continence, typically with 8 to 10 bowel\\nmovements/day. Pouchitis is an inflammatory reaction occurring after this procedure in about 50% of\\npatients. It is thought to be related to bacterial overgrowth and is treated with antibiotics (eg, quinolones).\\nProbiotics may be protective. Most cases of pouchitis are readily controlled, but 5 to 10% prove refractory\\nto all medical therapy and require conversion to a conventional (Brooke) ileostomy. For a minority of\\npatients who are older, who have well-established families and lifestyles, who have poor sphincter tone or\\ncannot tolerate frequent bowel movements, or who are simply unable or unwilling to face the\\nconsequences of frequent or chronic pouchitis, the Brooke ileostomy remains the procedure of choice.\\nIn any event, the physical and emotional burdens imposed by any form of colon resection must be\\nrecognized, and care should be taken to see that the patient receives all the instructions and all the\\nmedical and psychologic support that is necessary before and after surgery.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 19. Inflammatory Bowel Disease\\n240\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 250, 'page_label': '241'}, page_content=\"Chapter 20. Diverticular Disease\\nIntroduction\\nDiverticula are saclike mucosal outpouchings that protrude from a tubular structure. True diverticula\\ncontain all layers of the parent structure. False or pseudodiverticula are mucosal projections through the\\nmuscular layer. Esophageal (see p. \\n125\\n) and Meckel's diverticula are true diverticula. Colonic diverticula\\nare pseudodiverticula; they cause symptoms by trapping feces and becoming inflamed or infected,\\nbleeding, or rupturing.\\nDiverticulosis\\nDiverticulosis is the presence of multiple diverticula in the colon, probably resulting from a\\nlifelong low-fiber diet. Most diverticula are asymptomatic, but some become inflamed or bleed.\\nDiagnosis is by colonoscopy or barium enema. Treatment varies depending on manifestation.\\nDiverticula occur anywhere in the large bowelusually in the sigmoid but rarely below the peritoneal\\nreflection of the rectum. They vary in diameter from 3 mm to > 3 cm. \\nPatients with diverticula usually have\\nseveral of them. Diverticulosis is uncommon in people < 40 but becomes common rapidly thereafter;\\nessentially every 90-yr-old person has many diverticula. Giant diverticula, which are rare, range in\\ndiameter from 3 to 15 cm and may be single.\\nPathophysiology\\nDiverticula are probably caused by increased intraluminal pressure leading to mucosal extrusion through\\nthe weakest points of the muscular layer of the bowelareas adjacent to intramural blood vessels.\\nDiverticula are more common among people who eat a low-fiber diet; however, the mechanism is not\\nclear. One theory is that increased intraluminal pressure is required to move low-bulk stool through the\\ncolon. Another theory is that low-stool bulk causes a smaller diameter colon, which by Laplace's law\\nwould have increased pressure.\\nThe etiology of giant diverticula is unclear. One theory is that a valvelike abnormality exists at the base of\\nthe diverticulum, so bowel gas can enter but escapes less freely.\\nSymptoms and Signs\\nMost (70%) diverticula are asymptomatic, 15 to 25% become painfully inflamed (diverticulitis), and 10 to\\n15% bleed painlessly. The bleeding is probably caused by erosion of the adjacent vessel by local trauma\\nfrom impacted feces in the diverticulum. Although most diverticula are distal, 75% of bleeding occurs from\\ndiverticula proximal to the splenic flexure. In 33% of patients (5% overall), bleeding is serious enough to\\nrequire transfusion.\\nDiagnosis\\n Usually colonoscopy\\nAsymptomatic diverticula are usually found incidentally during barium enema or colonoscopy.\\nDiverticulosis is suspected when painless rectal bleeding develops, particularly in an elderly patient.\\nEvaluation of rectal bleeding typically includes colonoscopy, which can be done electively after routine\\npreparation unless there is significant ongoing bleeding. In such patients, a rapid preparation (5 to 10 L of\\npolyethylene glycol solution delivered via NGT over 3 to 4 h) often allows adequate visualization. If\\ncolonoscopy cannot visualize the source and ongoing bleeding is sufficiently rapid (> 0.5 to 1 mL/min),\\nangiography may localize the source. Some angiographers first do a radionuclide scan to focus the\\nexamination.\\nTreatment\\n High-fiber diet\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 20. Diverticular Disease\\n241\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 251, 'page_label': '242'}, page_content=' Sometimes angiographic or endoscopic treatment of bleeding\\nTreatment of diverticulosis aims at reducing segmental spasm. A high-fiber diet helps and may be\\nsupplemented by psyllium seed preparations or bran. Low-fiber diets are contraindicated. The intuitive\\ninjunction to avoid seeds or other dietary material that might become impacted in a diverticulum has no\\nestablished medical basis. Antispasmodics (eg, belladonna) are not of benefit and may cause adverse\\neffects. Surgery is unwarranted for uncomplicated disease. Giant diverticula, however, require surgery.\\nDiverticular bleeding stops spontaneously in 75% of patients. Treatment is often given during diagnostic\\nprocedures. If angiography was done for diagnosis, ongoing bleeding can be controlled in 70 to 90% of\\npatients by intraarterial injection of vasopressin. In some cases, bleeding recurs within a few days and\\nrequires surgery. Angiographic embolization effectively stops bleeding but leads to bowel infarction in up\\nto 20% of patients and is not recommended. Colonoscopy allows heat or laser coagulation of vessels or\\ninjection of epinephrine. If these measures fail to stop bleeding, segmental resection or subtotal\\ncolectomy is indicated.\\nDiverticulitis\\nDiverticulitis is inflammation of a diverticulum, which can result in phlegmon of the bowel wall,\\nperitonitis, perforation, fistula, or abscess. The primary symptom is abdominal pain. Diagnosis\\nis by CT. Treatment is with antibiotics (ciprofloxacin, or a 3rd-generation cephalosporin plus\\nmetronidazole) and occasionally surgery.\\nDiverticulitis occurs when a micro or macro perforation develops in a diverticulum, releasing intestinal\\nbacteria. The resultant inflammation remains localized in about 75% of patients. The remaining 25% may\\ndevelop abscess, free intraperitoneal perforation, bowel obstruction, or fistulas. The most common\\nfistulas involve the bladder but may also involve the small bowel, uterus, vagina, abdominal wall, or even\\nthe thigh.\\nDiverticulitis is most serious in elderly patients, especially those taking prednisone or other drugs that\\nincrease the risk of infection. Nearly all serious diverticulitis occurs in the sigmoid.\\nSymptoms and Signs\\nDiverticulitis usually manifests with pain or tenderness in the left lower quadrant of the abdomen and\\nfever. Peritoneal signs (eg, rebound or guarding) may be present, particularly with abscess or free\\nperforation. Fistulas may manifest as pneumaturia, feculent vaginal discharge, or a cutaneous or\\nmyofascial infection of the abdominal wall, perineum, or upper leg. Patients with bowel obstruction have\\nnausea, vomiting, and abdominal distention. Bleeding is uncommon.\\nDiagnosis\\n Abdominal CT\\n Colonoscopy after resolution\\nClinical suspicion is high in patients with known diverticulosis. However, because other disorders (eg,\\nappendicitis, colon or ovarian cancer) may cause similar symptoms, testing is required. Abdominal CT\\nwith oral and IV contrast is preferred, although findings in about 10% of patients cannot be distinguished\\nfrom colon cancer. Colonoscopy, after resolution of the acute infection, is necessary for definitive\\ndiagnosis.\\nTreatment\\n Varies with severity\\n Liquid diet, oral antibiotics for mild disease\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 20. Diverticular Disease\\n242'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 252, 'page_label': '243'}, page_content=\" IV antibiotics, npo for more severe disease\\n CT-guided percutaneous drainage of abscess\\n Sometimes surgery\\nA patient who is not very ill is treated at home with rest, a liquid diet, and oral antibiotics (eg, ciprofloxacin\\n500 mg bid amoxicillin/clavulanate 500 mg tid plus metronidazole 500 mg qid). Symptoms usually subside\\nrapidly. The patient gradually advances to a soft low-fiber diet and a daily psyllium seed preparation. The\\ncolon should be evaluated after 2 to 4 wk with a colonoscopy or barium enema. After 1 mo, a high-fiber\\ndiet is resumed.\\nPatients with more severe symptoms (eg, pain, fever, marked leukocytosis) should be hospitalized, as\\nshould patients taking prednisone (who are at higher risk of perforation and general peritonitis).\\nTreatment is bed rest, npo, IV fluids, and IV antibiotics (eg, ceftazidime 1 g IV q 8 h plus metronidazole\\n500 mg IV q 6 to 8 h).\\nAbout 80% of patients can be treated successfully without surgery. An abscess may respond to\\npercutaneous drainage (CT guided). If response is satisfactory, the patient remains hospitalized until\\nsymptoms are relieved and a soft diet is resumed. A colonoscopy or barium enema is done  2 wk after\\nsymptoms have resolved.\\nSurgery:\\n Surgery is required immediately for patients with free perforation or general peritonitis and for\\npatients with severe symptoms that do not respond to nonsurgical treatment within 48 h. Increasing pain,\\ntenderness, and fever are other signs that surgery is needed. Surgery should also be considered in\\npatients with any of the following:  2 previous attacks of mild diverticulitis (or one attack in a patient <\\n50); a persistent tender mass; clinical, endoscopic, or x-ray signs suggestive of cancer; and dysuria\\nassociated with diverticulitis in men (or in women who have had a hysterectomy), because this symptom\\nmay presage perforation into the bladder.\\nThe involved section of the colon is resected. The ends can be reanastomosed immediately in healthy\\npatients without perforation, abscess, or significant inflammation. Other patients have a temporary\\ncolostomy with anastomosis carried out in a subsequent operation after inflammation resolves and the\\npatient's general condition improves.\\nMeckel's Diverticulum\\nMeckel's diverticulum is a congenital sacculation of the distal ileum occurring in 2 to 3% of\\npeople. It is usually located within 100 cm of the ileocecal valve and often contains heterotopic\\ngastric tissue, pancreatic tissue, or both. Symptoms are uncommon but include bleeding, bowel\\nobstruction, and inflammation (diverticulitis). Diagnosis is difficult and often involves\\nradionuclide scanning and barium studies. Treatment is surgical resection.\\nPathophysiology\\nIn early fetal life, the vitelline duct running from the terminal ileum to the umbilicus and yolk sac is normally\\nobliterated by the 7th wk. If the portion connecting to the ileum fails to atrophy, a Meckel's diverticulum\\nresults. This congenital diverticulum arises from the antimesenteric margin of the intestine and contains\\nall layers of the normal bowel. About 50% of diverticula also contain heterotopic tissue of the stomach\\n(and thus contain parietal cells that secrete HCl), pancreas, or both.\\nOnly about 2% of people with Meckel's diverticulum develop complications. Although diverticula are\\nequally common among males and females, males are 2 to 3 times more likely to have complications.\\nComplications include the following:\\n \\nBleeding\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 20. Diverticular Disease\\n243\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 253, 'page_label': '244'}, page_content=\" Obstruction\\n Diverticulitis\\n Tumors\\nBleeding is more common among young children (< 5 yr) and occurs when acid secreted from ectopic\\ngastric mucosa in the diverticulum ulcerates the adjacent ileum. Obstruction can occur at any age but is\\nmore common among older children and adults. In children, obstruction is most likely caused by\\nintussusception of the diverticulum. Obstruction may also result from adhesions, volvulus, retained foreign\\nbodies, tumors, or incarceration in a hernia (Littre's hernia). Acute Meckel's diverticulitis can occur at any\\nage, but its incidence peaks in older children. Tumors, including carcinoids, are rare and occur mainly in\\nadults.\\nSymptoms and Signs\\nIn all ages, intestinal obstruction is manifested by cramping abdominal pain, nausea, and vomiting. Acute\\nMeckel's diverticulitis is characterized by abdominal pain and tenderness typically localized below or to\\nthe left of the umbilicus; it is often accompanied by vomiting and is similar to appendicitis except for\\nlocation of pain.\\nChildren may present with repeated episodes of painless, bright red rectal bleeding, which is usually not\\nsevere enough to cause shock. Adults may also bleed, typically resulting in melena rather than frank\\nblood.\\nDiagnosis\\n Based on symptoms\\n Radionuclide scan for bleeding\\n CT for pain\\nDiagnosis is difficult, and tests are chosen based on presenting symptoms. If rectal bleeding is suspected\\nto originate from a Meckel's diverticulum, a \\n99m\\nTc pertechnetate scan may identify ectopic gastric\\nmucosa and hence the diverticulum. Patients presenting with abdominal pain and focal tenderness should\\nhave a CT scan with oral contrast. If vomiting and signs of obstruction are predominant, flat and upright x-\\nrays of the abdomen are done. Sometimes diagnosis is made only during surgical exploration for\\npresumed appendicitis; whenever a normal appendix is found, Meckel's diverticulum should be\\nsuspected.\\nTreatment\\n Surgery\\nPatients with intestinal obstruction caused by Meckel's diverticulum require early surgery. For detailed\\ntreatment of intestinal obstruction, see p. \\n117\\n.\\nA bleeding diverticulum with an indurated area in the adjacent ileum requires resection of this section of\\nthe bowel and the diverticulum. A bleeding diverticulum without ileal induration requires only resection of\\nthe diverticulum.\\nMeckel's diverticulitis also requires resection. Small, asymptomatic diverticula encountered incidentally at\\nlaparotomy need not be removed.\\nDiverticular Disease of the Stomach and Small Bowel\\nDiverticula rarely involve the stomach but occur in the duodenum in up to 25% of people. Most duodenal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 20. Diverticular Disease\\n244\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 254, 'page_label': '245'}, page_content=\"diverticula are solitary and occur in the second portion of the duodenum near the ampulla of Vater\\n(periampullary). Jejunal diverticula occur in about 0.26% of patients and are more common among\\npatients with disorders of intestinal motility. Meckel's diverticulum occurs in the distal ileum.\\nDuodenal and jejunal diverticula are asymptomatic in > 90% of cases and are usually detected\\nincidentally during radiologic or endoscopic investigation of the upper GI tract for an unrelated disease.\\nRarely, small-bowel diverticula bleed or become inflamed, causing pain and nausea. Some even\\nperforate. For poorly understood reasons, patients with periampullary diverticula are at increased risk of\\ngallstones and pancreatitis. Treatment is surgical resection; however, the clinician should be cautious of\\nrecommending surgery for patients with a diverticulum and vague GI symptoms (eg, dyspepsia).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 20. Diverticular Disease\\n245\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 255, 'page_label': '246'}, page_content=\"Chapter 21. Anorectal Disorders\\nIntroduction\\n(See also \\nForeign Bodies\\n on p. \\n139\\n and \\nAnorectal Cancer\\n on p. \\n195\\n.)\\nThe anal canal begins at the anal sphincter and ends at the anorectal junction (pectinate line,\\nmucocutaneous junction, dentate line), where there are 8 to 12 anal crypts and 5 to 8 papillae. The canal\\nis lined with anoderm, a continuation of the external skin. The anal canal and adjacent skin are\\ninnervated by somatic sensory nerves and are highly susceptible to painful stimuli. Venous drainage from\\nthe anal canal occurs through the caval system, but the anorectal junction can drain into both the portal\\nand caval systems. Lymphatics from the anal canal pass to the internal iliac nodes, the posterior vaginal\\nwall, and the inguinal nodes. The venous and lymphatic distributions determine how malignant disease\\nand infection spread.\\nThe rectum is a continuation of the sigmoid colon beginning at the level of the 3rd sacral vertebra and\\ncontinuing to the anorectal junction. The rectal lining consists of red, glistening glandular mucosa, which\\nhas an autonomic nerve supply and is relatively insensitive to pain. Venous drainage occurs through the\\nportal system. Lymphatic return from the rectum occurs along the superior hemorrhoidal vascular pedicle\\nto the inferior mesenteric and aortic nodes.\\nThe sphincteric ring encircling the anal canal is composed of the internal sphincter, the central portion of\\nthe levators, and components of the external sphincter. Anteriorly, it is more vulnerable to trauma, which\\ncan result in incontinence. The puborectalis forms a muscular sling around the rectum for support and\\nassistance in defecation.\\nHistory:\\n History should include the details of bleeding, pain, protrusion, discharge, swelling, abnormal\\nsensations, bowel movements, incontinence, stool characteristics, use of cathartics and enemas, and\\nabdominal and urinary symptoms. All patients should be asked about anal intercourse and other possible\\ncauses of trauma and infection.\\nPhysical examination:\\n Examination should be done gently and with good lighting. It consists of external\\ninspection, perianal and intrarectal digital palpation, abdominal examination, and rectovaginal bidigital\\npalpation. Anoscopy and rigid or flexible sigmoidoscopy to 15 to 60 cm above the anal verge are often\\nincluded (see p. \\n98\\n). Inspection, palpation, and anoscopy and sigmoidoscopy are best done with the\\npatient in the left lateral (Sims') position or inverted on a tilt table. In cases of painful anal lesions, topical\\n(lidocaine 5% ointment), regional, or even general anesthesia may be required. If it can be tolerated, a\\ncleansing phosphate enema may facilitate sigmoidoscopy. Biopsies, smears, and cultures may be taken,\\nand x-ray examination done if indicated.\\nAnal Fissure\\n(Fissure in Ano; Anal Ulcer)\\nAn anal fissure is an acute longitudinal tear or a chronic ovoid ulcer in the squamous epithelium\\nof the anal canal. It causes severe pain, sometimes with bleeding, particularly with defecation.\\nDiagnosis is by inspection. Treatment is local hygiene, stool softeners, and sometimes\\nbotulinum toxin injection.\\nAnal fissures are believed to result from laceration by a hard or large stool, with secondary infection.\\nTrauma (eg, anal intercourse) is a rare cause. The fissure may cause internal sphincter spasm,\\ndecreasing blood supply and perpetuating the fissure.\\nSymptoms and Signs\\nAnal fissures usually lie in the posterior midline but may occur in the anterior midline. Those off the\\nmidline may have specific etiologies, particularly Crohn's disease. An external skin tag (the sentinel pile)\\nmay be present at the lower end of the fissure, and an enlarged (hypertrophic) papilla may be present at\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 21. Anorectal Disorders\\n246\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 256, 'page_label': '247'}, page_content='the upper end.\\nInfants may develop acute fissures, but chronic fissures are rare. Chronic fissures must be differentiated\\nfrom cancer, primary lesions of syphilis, TB, and ulceration caused by Crohn\\'s disease.\\nFissures cause pain and bleeding. The pain typically occurs with or shortly after defecation, lasts for\\nseveral hours, and subsides until the next bowel movement. Examination must be gentle but with\\nadequate spreading of the buttocks to allow visualization.\\nDiagnosis\\nDiagnosis is made by inspection. Unless findings suggest a specific cause, further studies are not\\nrequired.\\nTreatment\\n Stool softeners\\n Protective ointments, sitz baths\\n Nitroglycerin ointment or botulinum toxin type A injection\\nFissures often respond to conservative measures that minimize trauma during defecation (eg, stool\\nsofteners, psyllium, fiber). Healing is aided by use of protective zinc oxide ointments or bland\\nsuppositories (eg, glycerin) that lubricate the lower rectum and soften stool. Topical anesthetics (eg,\\nbenzocaine, lidocaine) and warm (not hot) sitz baths for 10 or 15 min after each bowel movement and prn\\ngive temporary relief.\\nTopical nitroglycerin 0.2% ointment, nifedipine cream 0.2% or 0.3%, arginine gel, and injections of\\nbotulinum toxin type A into the internal sphincter relax the anal sphincter and decrease maximum anal\\nresting pressure, allowing healing. When conservative measures fail, surgery (internal anal\\nsphincterotomy or controlled anal dilation) is needed to interfere with the cycle of internal anal sphincter\\nspasm.\\nAnorectal Abscess\\nAn anorectal abscess is a localized collection of pus in the perirectal spaces. Abscesses usually\\noriginate in an anal crypt. Symptoms are pain and swelling. Diagnosis is primarily by\\nexamination and CT or pelvic MRI for deeper abscesses. Treatment is surgical drainage.\\nAn abscess may be located in various spaces surrounding the rectum and may be superficial or deep. A\\nperianal abscess is superficial and points to the skin. An ischiorectal abscess is deeper, extending across\\nthe sphincter into the ischiorectal space below the levator ani; it may penetrate to the contralateral side,\\nforming a \"horseshoe\" abscess. An abscess above the levator ani (ie, supralevator abscess) is quite deep\\nand may extend to the peritoneum or abdominal organs; this abscess often results from diverticulitis or\\npelvic inflammatory disease. Crohn\\'s disease (especially of the colon) sometimes causes anorectal\\nabscess. A mixed infection usually occurs, with \\nEscherichia coli\\n, \\nProteus vulgaris\\n, \\nBacteroides\\n,\\nstreptococci, and staphylococci predominating.\\nSymptoms and Signs\\nSuperficial abscesses can be very painful; perianal swelling, redness, and tenderness are characteristic.\\nDeeper abscesses may be less painful but cause toxic symptoms (eg, fever, chills, malaise). There may\\nbe no perianal findings, but digital rectal examination may reveal a tender, fluctuant swelling of the rectal\\nwall. High pelvirectal abscesses may cause lower abdominal pain and fever without rectal symptoms.\\nSometimes fever is the only symptom.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 21. Anorectal Disorders\\n247'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 257, 'page_label': '248'}, page_content=\" Clinical evaluation\\n Rarely examination under anesthesia or CT\\nPatients who have a pointing cutaneous abscess, a normal digital rectal examination, and no signs of\\nsystemic illness do not require imaging. Those with any findings suggestive of a deeper abscess or\\nCrohn's disease should have an examination under anesthesia at the time of drainage. Higher\\n(supralevator) abscesses require CT to determine the intra-abdominal source of sepsis.\\nTreatment\\n Incision and drainage\\n Antibiotics for high-risk patients\\nPrompt incision and adequate drainage are required and should not wait until the abscess points. Many\\nabscesses can be drained as an in-office procedure; deeper abscesses may require drainage in the\\noperating room. Febrile, neutropenic, or diabetic patients or those with marked cellulitis should also\\nreceive antibiotics (eg, ciprofloxacin 500 mg IV q 12 h and metronidazole 500 mg IV q 8 h,\\nampicillin/sulbactam 1.5 g IV q 8 h). Antibiotics are not indicated for healthy patients with superficial\\nabscesses. Anorectal fistulas may develop after drainage.\\nAnorectal Fistula\\n(Fistula in Ano)\\nAn anorectal fistula is a tubelike tract with one opening in the anal canal and the other usually in\\nthe perianal skin. Symptoms are discharge and sometimes pain. Diagnosis is by examination\\nand sigmoidoscopy. Treatment often requires surgery.\\nFistulas arise spontaneously or occur secondary to drainage of a perirectal abscess. Predisposing\\ncauses include Crohn's disease and TB. Most fistulas originate in the anorectal crypts; others may result\\nfrom diverticulitis, tumors, or trauma. Fistulas in infants are congenital and are more common among\\nboys. Rectovaginal fistulas may be secondary \\nto Crohn's disease, obstetric injuries, radiation therapy, or\\ncancer.\\nSymptoms and Signs\\nA history of recurrent abscess followed by intermittent or constant discharge is usual. Discharge material\\nis purulent, serosanguineous, or both. Pain may be present if there is infection. On inspection, one or\\nmore secondary openings can be seen. A cordlike tract can often be palpated. A probe inserted into the\\ntract can determine the depth and direction and often the primary opening.\\nDiagnosis\\n Clinical evaluation\\n Sigmoidoscopy\\nDiagnosis is by examination. Sigmoidoscopy should follow to rule out Crohn's disease. Hidradenitis\\nsuppurativa, pilonidal sinus, dermal suppurative sinuses, and urethro-perineal fistulas must be\\ndifferentiated from cryptogenic fistulas.\\nTreatment\\n Various surgical procedures\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 21. Anorectal Disorders\\n248\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 258, 'page_label': '249'}, page_content=' Medical treatment if caused by Crohn\\'s disease\\nIn the past, the only effective treatment was surgery, in which the primary opening and the entire tract are\\nunroofed and converted into a \"ditch.\" Partial division of the sphincters may be necessary. Some degree\\nof incontinence may occur if a considerable portion of the sphincteric ring is divided. Alternatives to\\nconventional surgery include advancement flaps, biologic plugs, and fibrin glue instillations into the\\nfistulous tract.\\nIf diarrhea or Crohn\\'s disease is present, fistulotomy is inadvisable because of delayed wound healing.\\nFor patients with Crohn\\'s disease, metronidazole, other appropriate antibiotics, and suppressive therapies\\ncan be given (see p. \\n171\\n). Infliximab is very effective in closing fistulas caused by Crohn\\'s disease.\\nFecal Incontinence\\nFecal incontinence is involuntary defecation.\\nFecal incontinence can result from injuries or diseases of the spinal cord, congenital abnormalities,\\naccidental injuries to the rectum and anus, procidentia, diabetes, severe dementia, fecal impaction,\\nextensive inflammatory processes, tumors, obstetric injuries, and operations involving division or dilation\\nof the anal sphincters.\\nPhysical examination should evaluate gross sphincter function and perianal sensation and rule out fecal\\nimpaction. Anal sphincter ultrasonography, pelvic and perineal MRIs, pelvic floor electromyography, and\\nanorectal manometry are also useful.\\nTreatment\\n Program of stool regulation\\n Perineal exercises, sometimes with biofeedback\\n Sometimes a surgical procedure\\nTreatment includes a bowel management program to develop a predictable pattern of defecation. The\\nprogram includes intake of adequate fluid and sufficient dietary bulk. Sitting on a toilet or using another\\ncustomary defecatory stimulant (eg, coffee) encourages defecation. A suppository (eg, glycerin,\\nbisacodyl) or a phosphate enema may also be used. If a regular defecatory pattern does not develop, a\\nlow-residue diet and oral loperamide may reduce the frequency of defecation.\\nSimple perineal exercises, in which the patient repeatedly contracts the sphincters, perineal muscles, and\\nbuttocks, may strengthen these structures and contribute to continence, particularly in mild cases.\\nBiofeedback (to train the patient to use the sphincters maximally and to better appreciate physiologic\\nstimuli) should be considered before recommending surgery in well-motivated patients who can\\nunderstand and follow instructions and who have an anal sphincter capable of recognizing the cue of\\nrectal distention. About 70% of such patients respond to biofeedback.\\nA defect in the sphincter can be sutured directly. When there is insufficient residual sphincter for repair,\\nparticularly in patients < 50 yr of age, a gracilis muscle can be transposed. Some centers attach a\\npacemaker to the gracilis muscle, as well as an artificial sphincter; these or other experimental\\nprocedures are available in only a few centers in the US, as research protocols. Alternatively, a Thiersch\\nwire or other material can be used to encircle the anus. When all else fails, a colostomy can be\\nconsidered.\\nHemorrhoids\\n(Piles)\\nHemorrhoids are dilated veins of the hemorrhoidal plexus in the lower rectum. Symptoms\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 21. Anorectal Disorders\\n249'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 259, 'page_label': '250'}, page_content='include irritation and bleeding. Thrombosed hemorrhoids are painful. Diagnosis is by \\ninspection\\nor anoscopy. Treatment is symptomatic or with endoscopic banding, injection sclerotherapy, or\\nsometimes surgery.\\nExternal hemorrhoids are located below the dentate line and are covered by squamous epithelium.\\nInternal hemorrhoids are located above the dentate line and are lined by rectal mucosa. Hemorrhoids\\ntypically occur in the right anterior, right posterior, and left lateral zones. They occur in adults and\\nchildren.\\nSymptoms and Signs\\nHemorrhoids are often asymptomatic, or they may simply protrude. Pruritus ani is not commonly caused\\nby hemorrhoids.\\nExternal hemorrhoids may become thrombosed, resulting in a painful, purplish swelling. Rarely, they\\nulcerate and cause minor bleeding. Cleansing the anal region may be difficult.\\nInternal hemorrhoids typically manifest with bleeding after defecation; blood is noted on toilet tissue and\\nsometimes in the toilet bowl. Internal hemorrhoids may be uncomfortable but are not as painful as\\nthrombosed external hemorrhoids. Internal hemorrhoids sometimes cause mucus discharge and a\\nsensation of incomplete evacuation.\\nStrangulated hemorrhoids occur when protrusion and constriction occlude the blood supply. They cause\\npain that is occasionally followed by necrosis and ulceration.\\nDiagnosis\\n Anoscopy\\n Sometimes sigmoidoscopy or colonoscopy\\nMost painful hemorrhoids, thrombosed, ulcerated or not, are seen on inspection of the anus and rectum.\\nAnoscopy is essential in evaluating painless or bleeding hemorrhoids. Rectal bleeding should be\\nattributed to hemorrhoids only after more serious conditions are excluded (eg, by sigmoidoscopy or\\ncolonoscopy).\\nTreatment\\n Stool softeners, sitz baths\\n Rarely excision for thrombosed external hemorrhoids\\n Injection sclerotherapy or rubber band ligation for internal hemorrhoids\\nSymptomatic treatment is usually all that is needed. It is accomplished with stool softeners (eg, docusate,\\npsyllium), warm sitz baths (ie, sitting in a tub of tolerably hot water for 10 min) after each bowel movement\\nand prn, anesthetic ointments containing lidocaine, or witch hazel (hamamelis) compresses (which soothe\\nby an unknown mechanism). Pain caused by a thrombosed hemorrhoid can be treated with NSAIDs.\\nInfrequently, simple excision of the hemorrhoid may relieve pain rapidly; after infiltration with 1% lidocaine,\\nthe thrombosed portion of the hemorrhoid is excised, and the defect is closed with an absorbable suture.\\nBleeding hemorrhoids can be treated by injection sclerotherapy with 5% phenol in vegetable oil. Bleeding\\nshould cease at least temporarily.\\nRubber band ligation is used for larger, prolapsing internal hemorrhoids or those that do not respond to\\nconservative management. With mixed internal and external hemorrhoids, only the internal component\\nshould be rubber band ligated. The internal hemorrhoid is grasped and withdrawn through a stretched\\n1/2-cm diameter band, which is released to ligate the hemorrhoid, resulting in its necrosis and sloughing.\\nOne hemorrhoid is ligated every 2 wk; 3 to 6 treatments may be required. Sometimes, multiple\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 21. Anorectal Disorders\\n250'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 260, 'page_label': '251'}, page_content='hemorrhoids can be ligated at a single visit.\\nInfrared photocoagulation is useful for ablating small internal hemorrhoids, hemorrhoids that cannot be\\nrubber band ligated because of pain sensitivity, or hemorrhoids that are not cured with rubber band\\nligation. Laser destruction, cryotherapy, and various types of electrodestruction are of unproven efficacy.\\nSurgical hemorrhoidectomy is required for patients who do not respond to other forms of therapy.\\nSignificant postoperative pain is common, as is urinary retention and constipation. Stapled\\nhemorrhoidopexy is an alternative procedure for circumferential hemorrhoids, although its advantages\\nand the indications have yet to be defined.\\nLevator Syndrome\\nEpisodic rectal pain caused by spasm of the levator ani muscle.\\nProctalgia fugax\\n (fleeting pain in the rectum) and \\ncoccydynia\\n (pain in the coccygeal region) are\\nvariants of levator syndrome. Rectal spasm causes pain, typically unrelated to defecation, usually lasting\\n< 20 min. The pain may be brief and intense or a vague ache high in the rectum. It may occur\\nspontaneously or with sitting and can waken the patient from sleep. The pain may feel as if it would be\\nrelieved by the passage of gas or a bowel movement. In severe cases, the pain can persist for many\\nhours and recur frequently. The patient may have undergone various rectal operations for these\\nsymptoms, with no benefit.\\nDiagnosis\\n Clinical evaluation\\nPhysical examination can exclude other painful rectal conditions (eg, thrombosed hemorrhoids, fissures,\\nabscesses). Physical examination is often normal, although tenderness or tightness of the levator muscle,\\nusually on the left, may be present. Occasional cases are caused by low back or prostate disorders.\\nTreatment\\n Analgesics, sitz baths\\n Sometimes electrogalvanic stimulation\\nTreatment consists of explanations to the patient of the benign nature of the condition. An acute episode\\nmay be relieved by the passage of gas or a bowel movement, by a sitz bath, or by a mild analgesic. When\\nthe symptoms are more intense, physical therapy with electrogalvanic stimulation applied to the lower\\nrectum is usually effective. Skeletal muscle relaxants or anal sphincter massage under local or regional\\nanesthesia can be tried, but the benefit is unclear.\\nPilonidal Disease\\nPilonidal disease refers to an acute abscess or chronic draining sinus in the sacrococcygeal\\narea.\\nPilonidal disease usually occurs in young, hirsute, white males but can also occur in women. One or\\nseveral midline or adjacent-to-the-midline pits or sinuses occur in the skin of the sacral region and may\\nform a cavity, often containing hair. The lesion is usually asymptomatic; infected lesions are painful.\\nTreatment of an acute abscess is by incision and drainage. Usually, one or more chronic draining sinuses\\npersist and must be extirpated by excision and primary closure or, preferably, by an open technique (eg,\\ncystotomy, marsupialization). Antibiotics are generally not needed.\\nProctitis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 21. Anorectal Disorders\\n251'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 261, 'page_label': '252'}, page_content='Proctitis is inflammation of the rectal mucosa, which may result from infection, inflammatory\\nbowel disease, or radiation. Symptoms are rectal discomfort and bleeding. Diagnosis is by\\nsigmoidoscopy, usually with cultures and biopsy. Treatment depends on etiology.\\nProctitis may be a manifestation of sexually transmitted disease, certain enteric infections (eg,\\nCampylobacter\\n, \\nShigella\\n, \\nSalmonella\\n), inflammatory bowel disease, or radiation treatments; it may be\\nassociated with prior antibiotic use. Sexually transmitted pathogens cause proctitis more commonly\\namong homosexual men. Immunocompromised patients are at particular risk of infections with herpes\\nsimplex and cytomegalovirus.\\nSymptoms and Signs\\nTypically, patients report rectal bleeding or passage of mucus. Proctitis resulting from gonorrhea, herpes\\nsimplex, or cytomegalovirus may cause intense anorectal pain.\\nDiagnosis\\n Proctoscopy or sigmoidoscopy\\n Tests for syphilis and \\nClostridium difficile\\nDiagnosis requires proctoscopy or sigmoidoscopy, which may reveal an inflamed rectal mucosa. Small\\ndiscrete ulcers and vesicles suggest herpes infection. Smears should be sent for culture of \\nNeisseria\\ngonorrhoeae, Chlamydia\\n sp, enteric pathogens, and viral pathogens. Serologic tests for syphilis and stool\\ntests for \\nC. difficile\\n toxin are done. Sometimes mucosal biopsy is needed. Colonoscopy may be valuable\\nin some patients.\\nTreatment\\n Various treatments depending on cause\\nInfective proctitis can be treated with antibiotics. Homosexual men with nonspecific proctitis may be\\ntreated empirically with ceftriaxone 125 mg IM once (or ciprofloxacin 500 mg po bid for 7 days), plus\\ndoxycycline 100 mg po bid for 7 days. Antibiotic-associated proctitis is treated with metronidazole (250 mg\\npo qid) or vancomycin (125 mg po qid) for 7 to 10 days.\\nRadiation proctitis is usually effectively treated with topical formalin carefully applied to the affected\\nmucosa. Alternative treatments include topical corticosteroids as foam (hydrocortisone 90 mg) or enemas\\n(hydrocortisone 100 mg or methylprednisolone 40 mg) bid for 3 wk, or mesalamine (4 g) enema at\\nbedtime for 3 to 6 wk. Mesalamine suppositories 500 mg once/day or bid, mesalamine 800 mg po tid, or\\nsulfasalazine 500 to 1000 mg po qid for  3 wk alone or in combination with topical therapy may also be\\neffective. Patients unresponsive to these forms of therapy may benefit from a course of systemic\\ncorticosteroids.\\nPruritus Ani\\nPruritus ani is anal and perianal itching.\\nThe perianal skin tends to itch, which can result from numerous causes (see\\nTable 21-1\\n).\\n[\\nTable 21-1.\\n Causes of Pruritus Ani]\\nOccasionally, the irritation is misinterpreted by the patient as pain, so other causes of perianal pain (eg,\\nabscess) should be ruled out.\\nDiagnosis is based on the appearance of the anal skin and relevant information from the history. The skin\\ntypically shows dullness and thickening, although the underlying pathology is often obscured by\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 21. Anorectal Disorders\\n252'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 262, 'page_label': '253'}, page_content=\"excoriation caused by scratching and secondary infection. A scraping of local skin is taken to rule out a\\nfungal infection, and a stool sample should be examined for ova and parasites. Visible lesions should be\\nbiopsied.\\nFoods suspected of causing pruritus ani should be eliminated from the diet. Clothing should be loose, and\\nbed clothing light. After bowel movements, the patient should cleanse the anal area with absorbent cotton\\nor plain soft tissue moistened with water. Liberal, frequent dusting with nonmedicated talcum powder or\\ncornstarch helps combat moisture. Hydrocortisone acetate 1% ointment, applied sparingly qid, may\\nrelieve symptoms. Systemic causes and parasitic or fungal infections must be treated specifically.\\nRectal Prolapse and Procidentia\\nRectal prolapse is painless protrusion of the rectum through the anus. Procidentia is complete\\nprolapse of the entire thickness of the rectum. Diagnosis is by inspection. Surgery is usually\\nrequired in adults.\\nTransient, minor prolapse of just the rectal mucosa often occurs in otherwise normal infants. Mucosal\\nprolapse in adults persists and may progressively worsen.\\nProcidentia is complete prolapse of the entire thickness of the rectum. The primary cause is unclear. Most\\npatients are women > 60.\\nSymptoms and Signs\\nThe most prominent symptom is protrusion. It may only occur while straining or while walking or standing.\\nRectal bleeding can occur, and incontinence is frequent. Pain is uncommon unless incarceration occurs.\\nDiagnosis\\n Clinical evaluation\\n Sigmoidoscopy, colonoscopy, or barium enema\\nTo determine the full extent of the prolapse, the clinician should examine the patient while the patient is\\nstanding or squatting and straining. Rectal procidentia can be distinguished from hemorrhoids by the\\npresence of circumferential mucosal folds. Anal sphincter tone is usually diminished. Sigmoidoscopy,\\ncolonoscopy, or barium enema x-rays of the colon must be done to search for other disease. Primary\\nneurologic disorders (eg, spinal cord tumors) must be ruled out.\\nTreatment\\n Elimination of causes of straining\\n For infants and children: Sometimes strapping buttocks together\\n For adults: Sometimes surgery\\nIn infants and children, conservative treatment is most satisfactory. Causes of straining should be\\neliminated. Firmly strapping the buttocks together with tape between bowel movements usually facilitates\\nspontaneous resolution of the prolapse. For simple mucosal prolapse in adults, the excess mucosa can\\nbe excised. For procidentia, an abdominal operation may be required. In patients who are very old or in\\npoor health, a wire or synthetic plastic loop can encircle the sphincteric ring (Thiersch's procedure). Other\\nperineal operations (eg, Delorme or Altemeier procedure) can be considered.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 21. Anorectal Disorders\\n253\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 263, 'page_label': '254'}, page_content=\"Chapter 22. Tumors of the GI Tract\\nIntroduction\\nVarious benign and malignant tumors can develop anywhere in the GI tract. Tumors of the mouth are\\ndiscussed in \\nCh. 55\\n.\\nBenign Esophageal Tumors\\nAlthough there are many types of benign esophageal tumors, most are of little consequence except for\\ncausing annoying swallowing symptoms (see p. \\n120\\n) and rarely ulceration or bleeding. Leiomyoma, the\\nmost common, may be multiple but usually has an excellent prognosis.\\nEsophageal Cancer\\nThe most common malignant tumor in the proximal two thirds of the esophagus is squamous\\ncell carcinoma; adenocarcinoma is the most common in the distal one third. Symptoms are\\nprogressive dysphagia and weight loss. Diagnosis is by endoscopy, followed by CT and\\nendoscopic ultrasound for staging. Treatment varies with stage and generally includes surgery\\nwith or without chemotherapy and radiation. Long-term survival is poor except for those with\\nlocal disease.\\nEsophageal cancer accounts for an estimated 15,500 cases and 13,900 deaths in the US annually.\\nSquamous cell carcinoma:\\n About 8000 cases occur annually in the US. It is more common in parts of\\nAsia and in South Africa. In the US, it is 4 to 5 times more common among blacks than whites, and 2 to 3\\ntimes more common among men than women.\\nThe primary risk factors are alcohol ingestion and tobacco use (in any form). Other factors include\\nachalasia, human papillomavirus, lye ingestion (resulting in stricture), sclerotherapy, Plummer-Vinson\\nsyndrome, irradiation of the esophagus, and esophageal webs. Genetic causes are unclear, but 50% of\\npatients with tylosis (hyperkeratosis palmaris et plantaris), an autosomal dominant disorder, have\\nesophageal cancer by age 45, and 95% have it by age 55.\\nAdenocarcinoma:\\n Adenocarcinoma occurs in the distal esophagus. Its incidence is increasing; it\\naccounts for 50% of esophageal carcinoma in whites. It is 4 times more common among whites than\\nblacks. Alcohol is not an important risk factor, but smoking is contributory. Adenocarcinoma of the distal\\nesophagus is difficult to distinguish from adenocarcinoma of the gastric cardia invading the distal\\nesophagus.\\nMost adenocarcinomas arise in Barrett's esophagus, which results from chronic gastroesophageal reflux\\ndisease and reflux esophagitis. In Barrett's esophagus, a metaplastic, columnar, glandular, intestine-like\\nmucosa with brush border and goblet cells replaces the normal stratified squamous epithelium of the\\ndistal esophagus during the healing phase of acute esophagitis when healing takes place in the\\ncontinued presence of stomach acid.\\nOther malignant tumors:\\n Less common malignant tumors include spindle cell carcinoma (a poorly\\ndifferentiated variant of squamous cell carcinoma), verrucous carcinoma (a well-differentiated variant of\\nsquamous cell carcinoma), pseudosarcoma, mucoepidermoid carcinoma, adenosquamous carcinoma,\\ncylindroma (adenoid cystic carcinoma), primary oat cell carcinoma, choriocarcinoma, carcinoid tumor,\\nsarcoma, and primary malignant melanoma.\\nMetastatic cancer constitutes 3% of esophageal cancer. Melanoma and breast cancer are most likely to\\nmetastasize to the esophagus; others include cancers of the head and neck, lung, stomach, liver, kidney,\\nprostate, testis, and bone. These tumors usually seed \\nthe loose connective tissue stroma around the\\nesophagus, whereas primary esophageal cancers begin in the mucosa or submucosa.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n254\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 264, 'page_label': '255'}, page_content=\"Early-stage esophageal cancer tends to be asymptomatic. When the lumen of the esophagus becomes\\nconstricted to < 14 mm, dysphagia commonly occurs. The patient first has difficulty swallowing solid food,\\nthen semisolid food, and finally liquid food and saliva; this steady progression suggests a growing\\nmalignant process rather than a spasm, benign ring, or peptic stricture. Chest pain may be present,\\nusually radiating to the back.\\nWeight loss, even when the patient maintains a good appetite, is almost universal. Compression of the\\nrecurrent laryngeal nerve may lead to vocal cord paralysis and hoarseness. Compression of sympathetic\\nnerves may lead to Horner's syndrome, and nerve compression elsewhere may cause spinal pain,\\nhiccups, or paralysis of the diaphragm. Malignant pleural effusions or pulmonary metastasis may cause\\ndyspnea. Intraluminal tumor involvement may cause odynophagia, vomiting, hematemesis, melena, iron\\ndeficiency anemia, aspiration, and cough. Fistulas between the esophagus and tracheobronchial tree\\nmay cause lung abscess and pneumonia. Other findings may include superior vena cava syndrome,\\nmalignant ascites, and bone pain.\\nLymphatic spread to internal jugular, cervical, supraclavicular, mediastinal, and celiac nodes is common.\\nThe tumor usually metastasizes to lung and liver and occasionally to distant sites (eg, bone, heart, brain,\\nadrenal glands, kidneys, peritoneum).\\nDiagnosis\\n Endoscopy with biopsy\\n Then CT and endoscopic ultrasound\\nThere are no screening tests. Patients suspected of having esophageal cancer should have endoscopy\\nwith cytology and biopsy. Although barium x-ray may show an obstructive lesion, endoscopy is required\\nfor biopsy and tissue diagnosis.\\nPatients in whom esophageal cancer is identified require CT of the chest and abdomen to determine\\nextent of tumor spread. If CT results are negative for metastasis, endoscopic ultrasound should be done\\nto determine the depth of the tumor in the esophageal wall and regional lymph node involvement.\\nFindings guide therapy and help determine prognosis.\\nBasic blood tests, including CBC, electrolytes, and liver function, should be done.\\nPrognosis\\nPrognosis depends greatly on stage, but overall is poor (5-yr survival: < 5%) because many patients\\npresent with advanced disease. Patients with cancer restricted to the mucosa have about an 80%\\nsurvival rate, which drops to < 50% with submucosal involvement, 20% with extension to the muscularis\\npropria, 7% with extension to adjacent structures, and < 3% with distant metastases.\\nTreatment\\n Surgical resection, often combined with chemotherapy and radiation\\nTreatment decisions depend on tumor staging, size, location, and the patient's wishes (many choose to\\nforgo aggressive treatment).\\nGeneral principles:\\n Patients with stage 0, I, or IIa disease (see\\nTable 22-1\\n) respond well to surgical resection; preoperative chemotherapy and radiation provide\\nadditional benefit. Those with stage IIb and III have poor survival with surgery alone; response and\\nsurvival are enhanced by preoperative (neoadjuvant) use of radiation and chemotherapy to reduce tumor\\nvolume before surgery. Patients unable or unwilling to undergo surgery may receive some benefit from\\ncombined radiation and chemotherapy. Radiation or chemotherapy alone is of little benefit. Patients with\\nstage IV disease require palliation and should not undergo surgery.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n255\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 265, 'page_label': '256'}, page_content=\"After treatment, patients are screened for recurrence by endoscopy and CT of the neck, chest, and\\nabdomen at 6-mo intervals for 3 yr and annually thereafter.\\nPatients with Barrett's esophagus require intense long-term treatment for gastroesophageal reflux disease\\n(see p. \\n125\\n) and endoscopic surveillance for malignant transformation at 3- to 12-mo intervals depending\\non the degree of metaplasia.\\nSurgery:\\n En bloc resection for cure requires removal of the entire tumor, proximal and distal margins of\\nnormal tissue, all potentially malignant lymph nodes, and a portion of the proximal stomach sufficient to\\ncontain the distal draining lymphatics. The procedure requires gastric pull-up with esophagogastric\\nanastomosis, small-bowel interposition, or colonic interposition. Pyloroplasty is required to ensure proper\\ngastric drainage because esophagectomy necessarily results in bilateral vagotomy. This extensive\\nsurgery may be poorly tolerated by patients > 75 yr, particularly those\\n[\\nTable 22-1.\\n Staging Esophageal Cancer*]\\nwith underlying cardiac or pulmonary disease (ejection fraction < 40%, or forced expiratory volume in 1\\nsec [FEV\\n1\\n] < 1.5 L/min). Overall, operative mortality is about 5%.\\nComplications of surgery include anastomotic leaks, fistulas, and strictures; bilious gastroesophageal\\nreflux; and dumping syndrome. The burning chest pain of bile reflux after distal esophagectomy can be\\nmore annoying than the original symptom of dysphagia and may require subsequent Roux-en-Y\\njejunostomy for bile diversion. An interposed segment of small bowel or colon in the chest has a tenuous\\nblood supply, and torsion, ischemia, or gangrene of the interposed bowel may result.\\nExternal beam radiation therapy:\\n Radiation is usually used in combination with chemotherapy for\\npatients who are poor candidates for curative surgery, including those with advanced disease. Radiation\\nis contraindicated in patients with tracheoesophageal fistula because tumor shrinkage enlarges the\\nfistula. Similarly, patients with vascular encasement by tumor may experience massive hemorrhage with\\ntumor shrinkage. During the early stages of radiation therapy, edema may worsen esophageal\\nobstruction, dysphagia, and odynophagia. This problem may require esophageal dilation or preradiation\\nplacement of a percutaneous gastrostomy feeding tube. Other adverse effects of radiation therapy\\ninclude nausea, vomiting, anorexia, fatigue, esophagitis, excess esophageal mucus production,\\nxerostomia, stricture, radiation pneumonitis, radiation pericarditis, myocarditis, and myelitis (spinal cord\\ninflammation).\\nChemotherapy:\\n Tumors are poorly responsive to chemotherapy alone. Response rates (defined as \\n50% reduction in all measurable areas of tumor) vary from 10 to 40%, but responses generally are\\nincomplete (minor shrinkage of tumor) and temporary. No drug is notably more effective than another.\\nMost commonly, cisplatin and 5-fluorouracil are used in combination. However, several other drugs,\\nincluding mitomycin, doxorubicin, vindesine, bleomycin, and methotrexate, also are active against\\nsquamous cell carcinoma.\\nPalliation:\\n Palliation is directed at reducing esophageal obstruction sufficiently to allow oral intake.\\nSuffering caused by esophageal obstruction can be significant, with salivation and recurrent aspiration.\\nOptions include manual dilation procedures (bougienage), orally inserted stents, radiation therapy, laser\\nphotocoagulation, and photodynamic therapy. In some cases, cervical esophagostomy with feeding\\njejunostomy is required.\\nRelief provided by esophageal dilation rarely lasts more than a few days. Flexible metal mesh stents are\\nmore effective at maintaining esophageal patency. Some plastic-coated models can also be used to\\nocclude tracheoesophageal fistulas, and some are available with a valve that prevents reflux when the\\nstent must be placed near the lower esophageal sphincter.\\nEndoscopic laser therapy can palliate dysphagia by burning a central channel through the tumor and can\\nbe repeated if needed. Photodynamic therapy uses an injection of porfimer sodium, a hematoporphyrin\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n256\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 266, 'page_label': '257'}, page_content='derivative that is taken up by tissues and acts as a photosensitizer. When activated by a laser beam\\ndirected on the tumor, this substance releases cytotoxic oxygen singlets that destroy tumor cells. Patients\\nreceiving this treatment must avoid sun exposure for 6 wk after treatment because the skin is also\\nsensitized to light.\\nSupportive care:\\n Nutritional support by enteral or parenteral supplementation enhances the tolerability\\nand feasibility of all treatments. \\nAn endoscopically or surgically placed feeding tube provides a more distal\\nroute for feeding when the esophagus is obstructed.\\nBecause nearly all cases of esophageal cancer are fatal, end-of-life care should always aim to control\\nsymptoms, especially pain and inability to swallow secretions (see also p. \\n3483\\n). At some point, many\\npatients need substantial doses of opioids. Patients should be advised to make end-of-life care decisions\\nearly in the course of disease and to record their wishes in an advance directive (see p. \\n3471\\n).\\nStomach Cancer\\nEtiology of stomach cancer is multifactorial, but \\nHelicobacter pylori\\n plays a significant role.\\nSymptoms include early satiety, obstruction, and bleeding but tend to occur late in the disease.\\nDiagnosis is by endoscopy, followed by CT and endoscopic ultrasound for staging. Treatment is\\nmainly surgery; chemotherapy may provide a temporary response. Long-term survival is poor\\nexcept for those with local disease.\\nStomach cancer accounts for an estimated 21,000 cases and over 11,000 deaths in the US annually.\\nGastric adenocarcinoma accounts for 95% of malignant tumors of the stomach; less common are\\nlocalized gastric lymphomas (see p. \\n1016\\n) and leiomyosarcomas. Stomach cancer is the 2nd most\\ncommon cancer worldwide, but the incidence varies widely; incidence is extremely high in Japan, China,\\nChile, and Iceland. In the US, incidence has declined in recent decades to the 7th most common cause of\\ndeath from cancer. In the US, it is most common among blacks, Hispanics, and American Indians. Its\\nincidence increases with age; > 75% of patients are > 50 yr.\\nEtiology\\nHelicobacter pylori\\n infection is the cause of most stomach cancer. Autoimmune atrophic gastritis (see p.\\n133\\n) and various genetic factors (see \\nGastrointestinal Stromal Tumors\\n on p. \\n190\\n) are also risk factors.\\nDietary factors are not proven causes.\\nGastric polyps can be precursors of cancer. Inflammatory polyps may develop in patients taking NSAIDs,\\nand fundic foveolar polyps are common among patients taking proton pump inhibitors. Adenomatous\\npolyps, particularly multiple ones, although rare, are the most likely to develop cancer. Cancer is\\nparticularly likely if an adenomatous polyp is > 2 cm in diameter or has a villous histology. Because\\nmalignant transformation cannot be detected by inspection, all polyps seen at endoscopy should be\\nremoved. The incidence of stomach cancer is generally decreased in patients with duodenal ulcer.\\nPathophysiology\\nGastric adenocarcinomas can be classified by gross appearance:\\n Protruding: The tumor is polypoid or fungating.\\n Penetrating: The tumor is ulcerated.\\n Superficial spreading: The tumor spreads along the mucosa or infiltrates superficially within the wall of\\nthe stomach.\\n Linitis plastica: The tumor infiltrates the stomach wall with an associated fibrous reaction that causes a\\nrigid \"leather bottle\" stomach.\\n Miscellaneous: The tumor shows characteristics of  2 of the other types; this classification is the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n257'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 267, 'page_label': '258'}, page_content='largest.\\nPrognosis is better with protruding tumors than with spreading tumors because protruding tumors become\\nsymptomatic earlier.\\nSymptoms and Signs\\nInitial symptoms are nonspecific, often consisting of dyspepsia suggestive of peptic ulcer. Patients and\\nphysicians alike tend to dismiss symptoms or treat the patient for acid disease. Later, early satiety\\n(fullness after ingesting a small amount of food) may occur if the cancer obstructs the pyloric region or if\\nthe stomach becomes nondistensible secondary to linitis plastica. Dysphagia may result if cancer in the\\ncardiac region of the stomach obstructs the esophageal outlet. Loss of weight or strength, usually\\nresulting from dietary restriction, is common. Massive hematemesis or melena is uncommon, but\\nsecondary anemia may follow occult blood loss. Occasionally, the first symptoms are caused by\\nmetastasis (eg, jaundice, ascites, fractures).\\nPhysical findings may be unremarkable or limited to heme-positive stools. Late in the course,\\nabnormalities include an epigastric mass; umbilical, left supraclavicular, or left axillary lymph nodes;\\nhepatomegaly; and an ovarian or rectal mass. Pulmonary, CNS, and bone lesions may occur.\\nDiagnosis\\n Endoscopy with biopsy\\n Then CT and endoscopic ultrasound\\nDifferential diagnosis commonly includes peptic ulcer and its complications.\\nPatients suspected of having stomach cancer should have endoscopy with multiple biopsies and brush\\ncytology. Occasionally, a biopsy limited to the mucosa misses tumor tissue in the submucosa. X-rays,\\nparticularly double-contrast barium studies, may show lesions but rarely obviate the need for subsequent\\nendoscopy.\\nPatients in whom cancer is identified require CT of the chest and abdomen to determine extent of tumor\\nspread. If CT is negative for metastasis, endoscopic ultrasound should be done to determine the depth of\\nthe tumor and regional lymph node involvement. Findings guide therapy and help determine prognosis.\\nBasic blood tests, including CBC, electrolytes, and liver function tests, should be done to assess anemia,\\nhydration, general condition, and possible liver metastases. Carcinoembryonic antigen (CEA) should be\\nmeasured before and after surgery.\\nScreening:\\n Screening with endoscopy is used in high-risk populations (eg, Japanese) but is not\\nrecommended in the US. Follow-up screening for recurrence in treated patients consists of endoscopy\\nand CT of the chest, abdomen, and pelvis. If an elevated CEA dropped after surgery, follow-up should\\ninclude CEA levels; a rise signifies recurrence.\\nPrognosis\\nPrognosis depends greatly on stage but overall is poor (5-yr survival: < 5 to 15%) because most patients\\npresent with advanced disease. If the tumor is limited to the mucosa or submucosa, 5-yr survival may be\\nas high as 80%. For tumors involving local lymph nodes, survival is 20 to 40%. More widespread disease\\nis almost always fatal within 1 yr. Gastric lymphomas have a better prognosis and are discussed in \\nCh.\\n118\\n.\\nTreatment\\n Surgical resection, sometimes combined with chemotherapy, radiation, or both\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n258'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 268, 'page_label': '259'}, page_content=\"Treatment decisions depend on tumor staging and the patient's wishes (some may choose to forgo\\naggressive treatmentsee p. \\n3471\\n).\\nCurative surgery involves removal of most or all of the stomach and adjacent lymph nodes and is\\nreasonable in patients with disease limited to the stomach and perhaps the regional lymph nodes (< 50%\\nof patients). Adjuvant chemotherapy or combined chemotherapy and radiation therapy after surgery may\\nbe beneficial if the tumor is resectable.\\nResection of locally advanced regional disease results in a 10-mo median survival (vs 3 to 4 mo without\\nresection).\\nMetastasis or extensive nodal involvement precludes curative surgery, and at most, palliative procedures\\nshould be undertaken. However, the true extent of tumor spread often is not recognized until curative\\nsurgery is attempted. Palliative surgery typically consists of a gastroenterostomy to bypass a pyloric\\nobstruction and should be done only if the patient's quality of life can be improved. In patients not\\nundergoing surgery, combination chemotherapy regimens (5-fluorouracil, doxorubicin, mitomycin,\\ncisplatin, or leucovorin in various combinations) may produce temporary response but little improvement\\nin 5-yr survival. Radiation therapy is of limited benefit.\\nGastrointestinal Stromal Tumors\\nGastrointestinal stromal tumors are tumors of the GI tract derived from mesenchymal precursor cells in\\nthe gut wall. They result from mutations of a growth factor receptor gene, \\nCKIT\\n. Some are caused by\\nprevious radiation therapy to the abdomen for other tumors.\\nTumors are slow growing, and malignant potential varies from minimal to significant. Most (60 to 70%)\\noccur in the stomach, 20 to 25% in the small bowel, and a small number in the esophagus, colon, and\\nrectum. Average age at presentation is 50 to 60.\\nSymptoms vary with location but include bleeding, dyspepsia, and obstruction. Diagnosis is usually by\\nendoscopy, with biopsy and endoscopic ultrasound for staging. Treatment is surgical removal. The role of\\nradiation and chemotherapy is unclear, but the tyrosine kinase inhibitor imatinib has been beneficial.\\nSmall-Bowel Tumors\\nSmall-bowel tumors account for 1 to 5% of GI tumors (over 5000 cases in the US annually).\\nBenign tumors\\n include leiomyomas, lipomas, neurofibromas, and fibromas. All may cause abdominal\\ndistention, pain, bleeding, diarrhea, and, if obstruction develops, vomiting. Polyps are not as common as\\nin the colon.\\nAdenocarcinoma\\n, a malignant tumor, is uncommon. Usually it arises in the duodenum or proximal\\njejunum and causes minimal symptoms. In patients with Crohn's disease, the tumors tend to occur distally\\nand in bypassed or \\ninflamed loops of bowel; adenocarcinoma occurs more often in Crohn's disease of the\\nsmall bowel than in Crohn's disease of the colon.\\nPrimary malignant \\nlymphoma\\n (see p. \\n1016\\n) arising in the ileum may cause a long, rigid segment. Small-\\nbowel lymphomas arise often in long-standing untreated celiac sprue.\\nCarcinoid tumors\\n (see p. \\n907\\n) occur most often in the small bowel, particularly the ileum, and the\\nappendix, and in these locations are often malignant. Multiple tumors occur in 50% of cases. Of those > 2\\ncm in diameter, 80% have metastasized locally or to the liver by the time of operation. About 30% of\\nsmall-bowel carcinoids cause obstruction, pain, bleeding, or carcinoid syndrome. Treatment is surgical\\nresection; repeat operations may be required.\\nKaposi's sarcoma\\n (see p. \\n753\\n), first described as a disease of elderly Jewish and Italian men, occurs in\\nan aggressive form in Africans, transplant recipients, and AIDS patients, who have GI tract involvement 40\\nto 60% of the time. Lesions may occur anywhere in the GI tract but usually in the stomach, small bowel,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n259\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 269, 'page_label': '260'}, page_content=\"or distal colon. GI lesions usually are asymptomatic, but bleeding, diarrhea, proteinlosing enteropathy,\\nand intussusception may occur. A second primary intestinal cancer occurs in  20% of patients; most\\noften it is lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, or adenocarcinoma of the\\nGI tract. Treatment depends on the cell type and location and extent of the lesions.\\nDiagnosis\\n Enteroclysis\\n Sometimes push endoscopy or capsule video endoscopy\\nEnteroclysis (sometimes CT enteroclysis) is probably the most common study for mass lesions of the\\nsmall bowel. Push endoscopy of the small bowel with an enteroscope may be used to visualize and\\nbiopsy tumors. Capsule video endoscopy can help identify small-bowel lesions, particularly bleeding sites;\\na swallowed capsule transmits 2 images/sec to an external recorder. The original capsule is not useful in\\nthe stomach or colon because it tumbles in these larger organs; a colon capsule camera with better optics\\nand illumination is under development for use in these larger-diameter organs.\\nTreatment\\n Surgical resection\\nTreatment is surgical resection. Electrocautery, thermal obliteration, or laser phototherapy at the time of\\nenteroscopy or surgery may be an alternative to resection.\\nPolyps of the Colon and Rectum\\nAn intestinal polyp is any mass of tissue that arises from the bowel wall and protrudes into the\\nlumen. Most are asymptomatic except for minor bleeding, which is usually occult. The main\\nconcern is malignant transformation; most colon cancers arise in a previously benign\\nadenomatous polyp. Diagnosis is by endoscopy. Treatment is endoscopic removal.\\nPolyps may be sessile or pedunculated and vary considerably in size. Incidence of polyps ranges from 7\\nto 50%; the higher figure includes very small polyps (usually hyperplastic polyps or adenomas) found at\\nautopsy. Polyps, often multiple, occur most commonly in the rectum and sigmoid and decrease in\\nfrequency toward the cecum. Multiple polyps may represent familial adenomatous polyposis (see p. \\n192\\n).\\nAbout 25% of patients with cancer of the large bowel also have satellite adenomatous polyps.\\nAdenomatous (neoplastic) polyps\\n are of greatest concern. Such lesions are classified histologically as\\ntubular adenomas, tubulo-villous adenomas (villoglandular polyps), or villous adenomas. The likelihood of\\ncancer in an adenomatous polyp at the time of discovery is related to size, histologic type, and degree of\\ndysplasia; a 1.5-cm tubular adenoma has a 2% risk of containing a cancer vs a 35% risk in 3-cm villous\\nadenomas. Serrated adenomas, a somewhat more aggressive type of adenoma, may develop from\\nhyperplastic polyps.\\nNonadenomatous (nonneoplastic) polyps\\n include hyperplastic polyps, hamartomas, juvenile polyps,\\npseudopolyps, lipomas, leiomyomas, and other rarer tumors. Juvenile polyps occur in children, typically\\noutgrow their blood supply, and autoamputate some time during or after puberty. Treatment is required\\nonly for uncontrollable bleeding or intussusception. Inflammatory polyps and pseudopolyps occur in\\nchronic ulcerative colitis and in Crohn's disease of the colon. Multiple juvenile polyps (but not sporadic\\nones) convey an increased cancer risk. The specific number of polyps resulting in increased risk is not\\nknown.\\nSymptoms and Signs\\nMost polyps are asymptomatic. Rectal bleeding, usually occult and rarely massive, is the most frequent\\ncomplaint. Cramps, abdominal pain, or obstruction may occur with a \\nlarge lesion. Rectal polyps may be\\npalpable by digital examination. Occasionally, a polyp on a long pedicle may prolapse through the anus.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n260\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 270, 'page_label': '261'}, page_content=\"Large villous adenomas may rarely cause watery diarrhea that may result in hypokalemia.\\nDiagnosis\\n Colonoscopy\\nDiagnosis is usually made by colonoscopy. Barium enema, particularly double-contrast examination, is\\neffective, but colonoscopy is preferred because polyps also may be removed during that procedure.\\nBecause rectal polyps are often multiple and may coexist with cancer, complete colonoscopy to the\\ncecum is mandatory even if a distal lesion is found by flexible sigmoidoscopy.\\nTreatment\\n Complete removal during colonoscopy\\n Sometimes follow with surgical resection\\n Follow-up surveillance colonoscopy\\nPolyps should be removed completely with a snare or electrosurgical biopsy forceps during total\\ncolonoscopy; complete excision is particularly important for large villous adenomas, which have a high\\npotential for cancer. If colonoscopic removal is unsuccessful, laparotomy should be done.\\nSubsequent treatment depends on the histology of the polyp. If dysplastic epithelium does not invade the\\nmuscularis mucosa, the line of resection in the polyp's stalk is clear, and the lesion is well differentiated,\\nendoscopic excision and close endoscopic follow-up should suffice. Patients with deeper invasion, an\\nunclear resection line, or a poorly differentiated lesion should have segmental resection of the colon.\\nBecause invasion through the muscularis mucosa provides access to lymphatics and increases the\\npotential for lymph node metastasis, such patients should have further evaluation (as in colon cancer\\nsee p. \\n193\\n).\\nThe scheduling of follow-up examinations after polypectomy is controversial. Most authorities recommend\\ntotal colonoscopy annually for 2 yr (or barium enema if total colonoscopy is impossible), with removal of\\nnewly discovered lesions. If 2 annual examinations are negative for new lesions, colonoscopy is\\nrecommended every 2 to 3 yr.\\nPrevention\\nAspirin and COX-2 inhibitors may help prevent formation of new polyps in patients with polyps or colon\\ncancer.\\nFamilial Adenomatous Polyposis\\nFamilial adenomatous polyposis (FAP) is a hereditary disorder causing numerous colonic\\npolyps and resulting in colon carcinoma by age 40. Patients are usually asymptomatic but may\\nhave heme-positive stool. Diagnosis is by colonoscopy and genetic testing. Treatment is\\ncolectomy.\\nFAP is an autosomal dominant disease in which  100 adenomatous polyps carpet the colon and rectum.\\nThe disorder occurs in 1 in 8,000 to 14,000 people. Polyps are present in 50% of patients by age 15, and\\n95% by 35. Cancer develops before age 40 in nearly all untreated patients.\\nPatients also can develop various extracolonic manifestations (previously termed Gardner's syndrome),\\nboth benign and malignant. Benign manifestations include desmoid tumors, osteomas of the skull or\\nmandible, sebaceous cysts, and adenomas in other parts of the GI tract. Patients are at increased risk of\\ncancer in the duodenum (5 to 11%), pancreas (2%), thyroid (2%), brain (medulloblastoma in < 1%), and\\nliver (hepatoblastoma in 0.7% of children < 5).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n261\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 271, 'page_label': '262'}, page_content='Symptoms and Signs\\nMany patients are asymptomatic, but rectal bleeding, typically occult, occurs.\\nDiagnosis\\n Colonoscopy\\n Genetic testing of patient and 1st-degree relatives\\n Offspring screened for hepatoblastoma\\nDiagnosis is made by finding > 100 polyps on colonoscopy. Diagnosed patients should have genetic\\ntesting to identify the specific mutation, which should then be sought in 1st-degree relatives. If genetic\\ntesting is unavailable, relatives should be screened with annual sigmoidoscopy beginning at age 12,\\nreducing frequency with each decade. If no polyps are evident by age 50, screening frequency is then the\\nsame as for average-risk patients.\\nChildren of parents with FAP should be screened for hepatoblastoma from birth to age 5 yr with annual\\nserum fetoprotein levels and possibly liver ultrasound.\\nTreatment\\n Colectomy\\n Endoscopic surveillance of remainder of GI tract\\n Perhaps aspirin or coxibs\\nColectomy should be done at the time of diagnosis. Total proctocolectomy, either with ileostomy or\\nmucosal proctectomy and ileoanal pouch, eliminates the risk of cancer. If subtotal colectomy (removal of\\nmost of the colon, leaving the rectum) with ileorectal anastomosis is done, the rectal remnant must be\\ninspected every 3 to 6 mo; new polyps must be excised or fulgurated. Aspirin or coxibs may inhibit new\\npolyp formation. If new ones appear too rapidly or prolifically to remove, excision of the rectum and\\npermanent ileostomy are needed.\\nAfter colectomy, patients should have upper endoscopy every 6 mo to 4 yr, depending on the number of\\npolyps (if any) in the stomach and duodenum. Annual physical examination of the thyroid, and possibly\\nultrasound, also is recommended.\\nPeutz-Jeghers Syndrome\\nPeutz-Jeghers syndrome is an autosomal dominant disease with multiple hamartomatous\\npolyps in the stomach, small bowel, and colon along with distinctive pigmented skin lesions.\\nPatients are at a significantly increased risk of GI and non-GI cancers; possibly the genetic defect\\ninvolves a tumor suppressor gene. GI cancers include those of the pancreas, small intestine, and colon.\\nNon-GI cancers include those of the breast, lung, uterus, and ovaries.\\nThe skin lesions are melanotic macules of the skin and mucous membranes, especially of the perioral\\nregion, lips and gums, hands, and feet. All but the buccal lesions tend to fade by puberty. Polyps may\\nbleed and often cause obstruction or intussusception.\\nDiagnosis is suggested by the clinical picture. Genetic testing is not routinely available but should be\\nconsidered. First-degree relatives should be evaluated and have routine surveillance for cancers, but\\nthere is no firm consensus on specific tests and intervals.\\nColonic polyps larger than 1 cm typically are removed.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n262'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 272, 'page_label': '263'}, page_content='Colorectal Cancer\\nColorectal cancer (CRC) is extremely common. Symptoms include blood in the stool or change\\nin bowel habits. Screening is with fecal occult blood testing. Diagnosis is by colonoscopy.\\nTreatment is surgical resection and chemotherapy for nodal involvement.\\nCRC accounts for an estimated 153,000 cases and 52,000 deaths in the US annually. In Western\\ncountries, the colon and rectum account for more new cases of cancer per year than any anatomic site\\nexcept the lung. Incidence begins to rise at age 40 and peaks at age 60 to 75. Overall, 70% of cases\\noccur in the rectum and sigmoid, and 95% are adenocarcinomas. Colon cancer is more common among\\nwomen; rectal cancer is more common among men. Synchronous cancers (more than one) occur in 5% of\\npatients.\\nEtiology\\nCRC most often occurs as transformation within adenomatous polyps. Serrated adenomas are particularly\\naggressive in their malignant transformation. About 80% of cases are sporadic, and 20% have an\\ninheritable component. Predisposing factors include chronic ulcerative colitis and granulomatous colitis;\\nthe risk of cancer increases with the duration of these disorders.\\nPopulations with a high incidence of CRC eat low-fiber diets that are high in animal protein, fat, and\\nrefined carbohydrates. Carcinogens may be ingested in the diet but are more likely produced by bacterial\\naction on dietary substances or biliary or intestinal secretions. The exact mechanism is unknown.\\nCRC spreads by direct extension through the bowel wall, hematogenous metastasis, regional lymph node\\nmetastasis, perineural spread, and intraluminal metastasis.\\nSymptoms and Signs\\nColorectal adenocarcinoma grows slowly, and a long interval elapses before it is large enough to cause\\nsymptoms. Symptoms depend on lesion location, type, extent, and complications.\\nThe right colon has a large caliber, a thin wall, and its contents are liquid; thus, obstruction is a late event.\\nBleeding is usually occult. Fatigue and weakness caused by severe anemia may be the only complaints.\\nTumors sometimes grow large enough to be palpable through the abdominal wall before other symptoms\\nappear.\\nThe left colon has a smaller lumen, the feces are semisolid, and cancer tends to encircle the bowel,\\ncausing alternating constipation and increased stool frequency or diarrhea. Partial obstruction with colicky\\nabdominal pain or complete obstruction may be the initial manifestation. The stool may be streaked or\\nmixed with blood. Some patients present with symptoms of perforation, usually walled off (focal pain and\\ntenderness), or rarely with diffuse peritonitis.\\nIn rectal cancer, the most common initial symptom is bleeding with defecation. Whenever\\n[\\nTable 22-2.\\n Staging Colorectal Cancer*]\\nrectal bleeding occurs, even with obvious hemorrhoids or known diverticular disease, coexisting cancer\\nmust be ruled out. Tenesmus or a sensation of incomplete evacuation may be present. Pain is common\\nwith perirectal involvement.\\nSome patients first present with symptoms and signs of metastatic disease (eg, hepatomegaly, ascites,\\nsupraclavicular lymph node enlargement).\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n263'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 273, 'page_label': '264'}, page_content=' Colonoscopy\\nScreening tests:\\n Early diagnosis depends on routine examination, particularly fecal occult blood (FOB)\\ntesting. Cancer detected by this method tends to be at an earlier stage and hence more curable. For\\naverage-risk patients, FOB testing should be done annually after age 50, with flexible sigmoidoscopy\\nevery 5 yr. Some authorities recommend colonoscopy every 10 yr instead of sigmoidoscopy. Colonoscopy\\nevery 3 yr may be even better. Screening of patients with high-risk conditions (eg, ulcerative colitis) is\\ndiscussed under the specific condition.\\nCT colonography (virtual colonoscopy) generates 3D and 2D images of the colon using multidetector row\\nCT and a combination of oral contrast and gas distention of the colon. Viewing the high-resolution 3D\\nimages somewhat simulates the appearance of optical endoscopy, hence the name. It has some promise\\nas a screening test for people who are unable or unwilling to undergo endoscopic colonoscopy but is less\\nsensitive and highly interpreter dependent. It avoids the need for sedation but still requires thorough\\nbowel preparation, and the gas distention may be uncomfortable. Additionally, unlike with optical\\ncolonoscopy, lesions cannot be biopsied during the diagnostic procedure.\\nVideo capsule endoscopy of the colon has many technical problems and is not currently acceptable as a\\nscreening test.\\nDiagnostic tests:\\n Patients with positive FOB tests require colonoscopy, as do those with lesions seen on\\nsigmoidoscopy or imaging study. All lesions should be completely removed for histologic examination. If a\\nlesion is sessile or not removable at colonoscopy, surgical excision should be strongly considered.\\nBarium enema x-ray, particularly a double-contrast study, can detect many lesions but is somewhat less\\naccurate than colonoscopy and is not preferred as follow up to a positive FOB test.\\nOnce cancer is diagnosed, patients should have abdominal CT, chest x-ray, and routine laboratory tests\\nto seek metastatic disease and anemia and to evaluate overall condition.\\nElevated serum carcinoembryonic antigen (CEA) levels are present in 70% of patients with CRC, but this\\ntest is not specific and therefore is not recommended for screening. However, if CEA is high\\npreoperatively and low after removal of a colon tumor, monitoring CEA may help to detect recurrence\\nearlier. CA 199 and CA 125 are other tumor markers that may be similarly used.\\nPrognosis\\nPrognosis depends greatly on stage (see \\nTable 22-2\\n). The 10-yr survival rate for cancer limited to the\\nmucosa approaches 90%; with extension through the bowel wall, 70 to 80%; with positive lymph nodes,\\n30 to 50%; and with metastatic disease, < 20%.\\nTreatment\\n Surgical resection, sometimes combined with chemotherapy, radiation, or both\\nSurgery:\\n Surgery for cure can be attempted in the 70% of patients presenting without metastatic\\ndisease. Attempt to cure consists of wide resection of the tumor and its regional lymphatic drainage with\\nreanastomosis of bowel segments. If there is  5 cm of normal bowel present between the lesion and the\\nanal verge, an abdominoperineal resection is done, with permanent colostomy.\\nResection of a limited number (1 to 3) of liver metastases is recommended in select nondebilitated\\npatients as a subsequent procedure. Criteria include those whose primary tumor has been resected,\\nwhose liver metastases are in one hepatic lobe, and who have no extrahepatic metastases. Only a small\\nnumber of patients with liver metastases meet these criteria, but 5-yr postoperative survival is 25%.\\nAdjuvant therapy:\\n Chemotherapy (typically 5-fluorouracil and leucovorin) improves survival by 10 to\\n30% in colon cancer patients with positive lymph nodes. Rectal cancer patients with 1 to 4 positive lymph\\nnodes benefit from combined radiation and chemotherapy; when > 4 positive lymph nodes are found,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n264'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 274, 'page_label': '265'}, page_content='combined modalities are less effective. Preoperative radiation therapy and chemotherapy to improve the\\nresectability rate of rectal cancer or decrease the incidence of lymph node metastasis are gaining favor.\\nFollow-up:\\n Postoperatively, colonoscopy should be done annually for 5 yr and every 3 yr thereafter if no\\npolyps or tumors are found. If preoperative colonoscopy was incomplete because of an obstructing\\ncancer, a \"completion\" colonoscopy should be done 3 mo after surgery.\\nAdditional screening for recurrence should include history, physical examination, and laboratory tests (eg,\\nCBC, liver function tests) every 3 mo for 3 yr and then every 6 mo for 2 yr. Imaging studies (CT or MRI)\\nare often recommended at 1-yr intervals but are of uncertain benefit for routine follow up in the absence\\nof abnormalities on examination or blood tests.\\nPalliation:\\n When curative surgery is not possible or the patient is an unacceptable surgical risk, limited\\npalliative surgery (eg, to relieve obstruction or resect a perforated area) may be indicated; median\\nsurvival is 7 mo. Some obstructing tumors can be debulked by endoscopic laser treatment or\\nelectrocoagulation or held open by stents. Chemotherapy may shrink tumors and prolong life for several\\nmonths.\\nNewer drugs used singly or in drug combinations include capecitabine (a 5-fluorouracil precursor),\\nirinotecan, and oxaliplatin. Monoclonal antibodies such as bevacizumab, cetuximab, and panitumumab\\nare also being used with some effectiveness. No regimen is clearly more effective for prolonging life in\\npatients with metastatic CRC, although some have been shown to delay disease progression.\\nChemotherapy for advanced colon cancer should be managed by an experienced chemotherapist who\\nhas access to investigational drugs.\\nWhen metastases are confined to the liver, ambulatory hepatic artery infusion with floxuridine or\\nradioactive microspheres via an implantable sc pump or an external pump worn on the belt may offer\\nmore benefit than systemic chemotherapy; however, these therapies are of uncertain benefit. When\\nmetastases are also extrahepatic, intrahepatic arterial chemotherapy offers no advantage over systemic\\nchemotherapy.\\nAnorectal Cancer\\nThe most common anorectal cancer is adenocarcinoma. Squamous cell (nonkeratinizing squamous cell or\\nbasaloid) carcinoma of the anorectum accounts for 3 to 5% of distal large-bowel cancers. Basal cell\\ncarcinoma, Bowen\\'s disease (intradermal carcinoma), extramammary Paget\\'s disease, cloacogenic\\ncarcinoma, and malignant melanoma are less common. Other tumors include lymphoma and various\\nsarcomas. Metastasis occurs along the lymphatics of the rectum and into the inguinal lymph nodes.\\nRisk factors include infection with human papillomavirus (HPV), chronic fistulas, irradiated anal skin,\\nleukoplakia, lymphogranuloma venereum, and condyloma acuminatum. Gay men practicing receptive anal\\nintercourse are at increased risk. Patients with HPV infection may manifest dysplasia in slightly abnormal\\nor normal-appearing anal epithelium (anal intraepithelial neoplasiahistologically graded I, II, or III).\\nThese changes are more common among HIV-infected patients, particularly gay men. Higher grades may\\nprogress to invasive carcinoma. It is unclear whether early recognition and eradication improve long-term\\noutcome; hence, screening recommendations are unclear.\\nWide local excision is often satisfactory treatment of perianal carcinomas. Combination chemotherapy\\nand radiation therapy result in a high rate of cure when used for anal squamous and cloacogenic tumors.\\nAbdominoperineal resection is indicated when radiation \\nand chemotherapy do not result in complete\\nregression of tumor and there are no metastases outside of the radiation field.\\nHereditary Nonpolyposis Colorectal Carcinoma\\nHereditary nonpolyposis colorectal carcinoma (HNPCC) is an autosomal dominant disorder\\nresponsible for 3 to 5% of cases of colorectal cancer (CRC). Symptoms, initial diagnosis, and\\ntreatment are similar to other forms of CRC. HNPCC is suspected by history and is confirmed by\\ngenetic testing. Patients also require surveillance for other cancer, particularly endometrial and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n265'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 275, 'page_label': '266'}, page_content='ovarian cancer.\\nPatients with one of several known mutations have a 70 to 80% lifetime risk of developing CRC.\\nCompared to sporadic forms of colon cancer, HNPCC occurs at a younger age (mid 40s), and the lesion\\nis more likely to be proximal to the splenic flexure. The precursor lesion is usually a single colonic\\nadenoma, unlike the multiple adenomas present in patients with familial adenomatous polyposis (FAP),\\nthe other main hereditary form of CRC.\\nHowever, similar to FAP, numerous extracolonic manifestations occur. Nonmalignant disorders include\\ncafe-au-lait spots, sebaceous gland tumors, and keratoacanthomas. Common associated cancers include\\nendometrial and ovarian tumors (39% risk of endometrial and 9% risk of ovarian by age 70). Patients also\\nhave an elevated risk of cancer of the ureter, renal pelvis, stomach, biliary tree, and small bowel.\\nSymptoms and Signs\\nSymptoms and signs are similar to other forms of CRC, and diagnosis and management of the tumor\\nitself are the same. The specific diagnosis of HNPCC is confirmed by genetic testing. However, deciding\\nwho to test is difficult because (unlike FAP) there is no typical clinical appearance. Thus, suspicion of\\nHNPCC requires a detailed family history, which should be obtained in all younger patients identified with\\nCRC.\\nDiagnosis\\n Clinical criteria followed by testing for microsatellite instability (MSI)\\n Genetic testing for confirmation\\nTo meet the Amsterdam II criteria for HNPCC, all three of the following historical elements must be\\npresent:\\n Three or more relatives with CRC or an HNPCC-associated cancer\\n CRC involving at least two generations\\n At least one case of CRC before age 50\\nPatients meeting these criteria should have their tumor tissue tested for MSI, a DNA abnormality. If MSI is\\npresent, genetic testing for specific HNPCC mutations is indicated. Other authorities use additional\\ncriteria (eg, Bethesda criteria) to initiate MSI testing. If MSI testing is not available locally, the patient\\nshould be referred to an appropriate center.\\nPatients with confirmed HNPCC require ongoing screening for other cancers. For endometrial cancer,\\nannual endometrial aspiration or transvaginal ultrasound is recommended. For ovarian cancer, options\\ninclude annual transvaginal ultrasound and serum CA 125 levels. Prophylactic hysterectomy and\\noophorectomy are also options. Urinalysis may be used to screen for renal tumors.\\nFirst-degree relatives of patients with HNPCC should have colonoscopy every 1 to 2 yr beginning in their\\n20s, and annually after age 40. Female 1st-degree relatives should be tested annually for endometrial\\nand ovarian cancer. More distant blood relatives should have genetic testing; if results are negative, they\\nshould have colonoscopy at the frequency for average-risk patients.\\nTreatment\\n Surgical resection\\nThe most common treatment is resection of the index lesion with frequent surveillance for another colon\\ncancer and any associated tumors in other organs. Because most HNPCC tumors occur proximal to the\\nsplenic flexure, subtotal colectomy, leaving the rectosigmoid intact, has been suggested as an alternative.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n266'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 276, 'page_label': '267'}, page_content='In either case, close follow up is needed.\\nPancreatic Cancer\\nPancreatic cancer, primarily ductal adenocarcinoma, accounts for an estimated 37,000 cases\\nand 33,000 deaths in the US annually. Symptoms include weight loss, abdominal pain, and\\njaundice. Diagnosis is by CT. Treatment is surgical resection and adjuvant chemotherapy and\\nradiation therapy. Prognosis is poor because disease is often advanced at the time of diagnosis.\\nMost pancreatic cancers are exocrine tumors that develop from ductal and acinar \\ncells. Pancreatic\\nendocrine tumors are discussed below.\\nAdenocarcinomas of the exocrine pancreas arise from duct cells 9 times more often than from acinar\\ncells; 80% occur in the head of the gland. Adenocarcinomas appear at the mean age of 55 yr and occur\\n1.5 to 2 times more often in men. Prominent risk factors include smoking, a history of chronic pancreatitis,\\nand possibly long-standing diabetes mellitus (primarily in women). Heredity plays some role. Alcohol and\\ncaffeine consumption do not seem to be risk factors.\\nSymptoms and Signs\\nSymptoms occur late. By diagnosis, 90% of patients have locally advanced tumors that have involved\\nretroperitoneal structures, spread to regional lymph nodes, or metastasized to the liver or lung.\\nMost patients have severe upper abdominal pain, which usually radiates to the back. The pain may be\\nrelieved by bending forward or assuming the fetal position. Weight loss is common. Adenocarcinomas of\\nthe head of the pancreas cause obstructive jaundice (often causing pruritus) in 80 to 90% of patients.\\nCancer in the body and tail may cause splenic vein obstruction, resulting in splenomegaly, gastric and\\nesophageal varices, and GI hemorrhage. The cancer causes diabetes in 25 to 50% of patients, leading to\\nsymptoms of glucose intolerance (eg, polyuria and polydipsia).\\nDiagnosis\\n CT or magnetic resonance cholangiopancreatography (MRCP)\\n CA 19-9 antigen to follow (not for screening)\\nThe preferred tests are an abdominal helical CT or MRCP. If CT or MRCP shows apparent unresectable\\nor metastatic disease, a percutaneous needle aspiration of an accessible lesion might be considered to\\nobtain a tissue diagnosis. If CT shows a potentially resectable tumor or no tumor, MRCP or endoscopic\\nultrasound may be used to stage disease or detect small tumors not visible with CT. Patients with\\nobstructive jaundice may have ERCP as the first diagnostic procedure.\\nRoutine laboratory tests should be done. Elevation of alkaline phosphatase and bilirubin indicate bile duct\\nobstruction or liver metastases. Pancreas-associated antigen CA 19-9 may be used to monitor patients\\ndiagnosed with pancreatic carcinoma and to screen those at high risk. However, this test is not sensitive\\nor specific enough to be used for population screening. Elevated levels should drop with successful\\ntreatment; subsequent increases indicate progression. Amylase and lipase levels are usually normal.\\nPrognosis\\nPrognosis varies with stage but overall is poor (5-yr survival: < 2%), because many patients have\\nadvanced disease at the time of diagnosis.\\nTreatment\\n Whipple procedure\\n Adjuvant chemotherapy and radiation therapy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n267'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 277, 'page_label': '268'}, page_content=' Symptom control\\nAbout 80 to 90% of cancers are considered surgically unresectable at time of diagnosis because of\\nmetastases or invasion of major blood vessels. Depending on location of the tumor, the procedure of\\nchoice is most commonly a Whipple procedure (pancreatoduodenectomy). Adjuvant therapy with 5-\\nfluorouracil (5-FU) and external beam radiation therapy is typically given, resulting in about 40% 2-yr and\\n25% 5-yr survival. This combination is also used for patients with localized but unresectable tumors and\\nresults in median survival of about 1 yr. Newer drugs (eg, gemcitabine, irinotecan, paclitaxel, oxaliplatin,\\ncarboplatin) may be more effective than 5-FU-based chemotherapy, but no drug, singly or in combination,\\nis clearly superior in prolonging survival. Patients with hepatic or distant metastases may be offered\\nchemotherapy as part of an investigational program, but the outlook is dismal with or without such\\ntreatment and some patients may choose to forego it.\\nIf an unresectable tumor is found at operation and gastroduodenal or bile duct obstruction is present or\\npending, a double gastric and biliary bypass operation is usually done to relieve obstruction. In patients\\nwith inoperable lesions and jaundice, endoscopic placement of a bile duct stent relieves jaundice.\\nHowever, surgical bypass should be considered in patients with unresectable lesions if life expectancy is\\n> 6 to 7 mo because of complications associated with stents.\\nSymptomatic treatment:\\n Ultimately, most patients experience pain and die. Thus, symptomatic\\ntreatment is as important as controlling disease. Appropriate end-of-life care should be discussed (see\\nalso p. \\n3480\\n).\\nPatients with moderate to severe pain should receive an oral opioid in doses adequate to provide relief.\\nConcern about addiction should not be a barrier to effective pain control. For chronic pain, long-acting\\npreparations (eg, transdermal fentanyl, oxycodone, oxymorphone) are usually best. Percutaneous or\\noperative splanchnic \\n(celiac) block effectively controls pain in most patients. In cases of intolerable pain,\\nopioids given sc or by IV, epidural, or intrathecal infusion provides additional relief.\\nIf palliative surgery or endoscopic placement of a biliary stent fails to relieve pruritus secondary to\\nobstructive jaundice, the patient can be managed with cholestyramine (4 g po once/day to qid).\\nPhenobarbital 30 to 60 mg po tid to qid may be helpful.\\nExocrine pancreatic insufficiency is treated with tablets of porcine pancreatic enzymes (pancrelipase).\\nThe patient should take enough to supply 16,000 to 20,000 lipase units before each meal or snack. If a\\nmeal is prolonged (as in a restaurant), some of the tablets should be taken during the meal. Optimal\\nintraluminal pH for the enzymes is 8; thus, some clinicians give a proton pump inhibitor or H\\n2\\n blocker 2\\ntimes/day. Diabetes mellitus should be closely monitored and controlled.\\nCystadenocarcinoma\\nCystadenocarcinoma is a rare adenomatous pancreatic cancer that arises as a malignant degeneration of\\na mucous cystadenoma and manifests as upper abdominal pain and a palpable abdominal mass.\\nDiagnosis is made by abdominal CT or MRI, which typically shows a cystic mass containing debris; the\\nmass may be misinterpreted as necrotic adenocarcinoma or pancreatic pseudocyst. Unlike ductal\\nadenocarcinoma, cystadenocarcinoma has a relatively good prognosis. Only 20% of patients have\\nmetastasis at the time of operation; complete excision of the tumor by distal or total pancreatectomy or by\\na Whipple procedure results in a 65% 5-yr survival.\\nIntraductal Papillary-Mucinous Tumor\\nIntraductal papillary-mucinous tumor (IPMT) is a rare cancer resulting in mucus hypersecretion and ductal\\nobstruction. Histology may be benign, borderline, or malignant. Most (80%) occur in women and in the tail\\nof the pancreas (66%).\\nSymptoms consist of pain and recurrent bouts of pancreatitis. Diagnosis is made by CT, sometimes along\\nwith endoscopic ultrasonography, magnetic resonance cholangiopancreatography, or ERCP. Benign and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n268'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 278, 'page_label': '269'}, page_content='malignant disease cannot be differentiated without surgical removal, which is the treatment of choice.\\nWith surgery, 5-yr survival is > 95% for benign or borderline cases, but 50 to 75% for malignant tumors.\\nPancreatic Endocrine Tumors\\nPancreatic endocrine tumors arise from islet and gastrin-producing cells and often produce many\\nhormones. They have 2 general manifestations. Nonfunctioning tumors may cause obstructive symptoms\\nof the biliary tract or duodenum, bleeding into the GI tract, or abdominal masses. Functioning tumors\\nhypersecrete a particular hormone, causing various syndromes (see\\nTable 22-3\\n). These clinical syndromes can also occur in multiple endocrine neoplasia, in which tumors or\\nhyperplasia affects two or more endocrine glands, usually the parathyroid, pituitary, thyroid, or adrenals\\n(see p. \\n909\\n).\\nTreatment for functioning and nonfunctioning tumors is surgical resection. If metastases preclude curative\\nsurgery, various antihormone treatments may be tried for functioning tumors. Because of tumor rarity,\\nchemotherapy trials have not identified definitive treatment. However, streptozotocin has selective activity\\nagainst pancreatic islet cells and is commonly used, either alone or in combination with 5-fluorouracil or\\ndoxorubicin. Some centers use chlorozotocin and interferon.\\nInsulinoma\\nAn insulinoma is a rare pancreatic \\n\\n-cell tumor that hypersecretes insulin. The main symptom is\\nfasting hypoglycemia. Diagnosis is by a 48- or 72-h fast with measurement of glucose and\\ninsulin levels, followed by endoscopic ultrasound. Treatment is surgery when possible. Drugs\\nthat block insulin secretion (eg, diazoxide, octreotide, Ca channel blockers, \\n\\n-blockers,\\nphenytoin) are used for patients not responding to surgery.\\nOf all insulinomas, 80% are single and may be curatively resected if identified. Only 10% of insulinomas\\nare malignant. Insulinoma occurs in 1/250,000 at a median age of 50 yr, except in multiple endocrine\\nneoplasia (MEN) type I (about 10% of insulinomas), when it occurs in the 20s. Insulinomas associated\\nwith MEN type I are more likely to be multiple.\\nSurreptitious administration of exogenous insulin can cause episodic hypoglycemia mimicking insulinoma.\\nSymptoms and Signs\\nHypoglycemia secondary to an insulinoma occurs during fasting. Symptoms are insidious and may mimic\\nvarious psychiatric and\\n[\\nTable 22-3.\\n Pancreatic Endocrine Tumors]\\nneurologic disorders. CNS disturbances include headache, confusion, visual disturbances, motor\\nweakness, palsy, ataxia, marked personality changes, and possible progression to loss of consciousness,\\nseizures, and coma. Symptoms of sympathetic stimulation (faintness, weakness, tremulousness,\\npalpitation, sweating, hunger, nervousness) are often present.\\nDiagnosis\\n Insulin level\\n Sometimes C-peptide or proinsulin levels\\n Endoscopic ultrasound\\nPlasma glucose should be measured during symptoms. If hypoglycemia is present (glucose < 40 mg/dL\\n[2.78 mmol/L]), an insulin level should be measured on a simultaneous sample. Hyperinsulinemia of > 6\\n\\nU/mL (42 pmol/L) suggests an insulin-mediated cause, as does a serum insulin to plasma glucose ratio\\n> 0.3 (\\n\\nU/mL)/(mg/dL).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n269'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 279, 'page_label': '270'}, page_content=\"Insulin is secreted as proinsulin, consisting of an \\n\\n chain and \\n\\n chain connected by a C peptide. Because\\npharmaceutical insulin consists only of the \\n\\n chain, surreptitious insulin administration can be detected by\\nmeasuring C-peptide and proinsulin levels. In patients with insulinoma, C peptide is  0.2 nmol/L and\\nproinsulin is  5 pmol/L. These levels are normal or low in patients with surreptitious insulin\\nadministration.\\nBecause many patients have no symptoms (and hence no hypoglycemia) at the time of evaluation,\\ndiagnosis requires admission to the hospital for a 48- or 72-h fast. Nearly all (98%) with insulinoma\\ndevelop symptoms within 48 h of fasting; 70 to 80% within 24 h. Hypoglycemia as the cause of the\\nsymptoms is established by Whipple's triad: (1) Symptoms occur during the fast; (2) symptoms occur in\\nthe presence of hypoglycemia; and (3) ingestion of carbohydrates relieves the symptoms. Hormone levels\\nare obtained as described above when the patient is having symptoms.\\nIf Whipple's triad is not observed after prolonged fasting and the plasma glucose after an overnight fast is\\n> 50 mg/dL (> 2.78 mmol/L), a C-peptide suppression test can be done. During insulin infusion (0.1\\nU/kg/h), patients with insulinoma fail to suppress C peptide to normal levels ( 1.2 ng/mL [ 0.40 nmol/L]).\\nEndoscopic ultrasonography has > 90% sensitivity and helps localize the tumor. PET also may be used.\\nCT has not proved useful, and arteriography or selective portal and splenic vein catheterization is\\ngenerally unnecessary.\\nTreatment\\n Surgical resection\\n Diazoxide or sometimes octreotide for hypoglycemia\\nOverall surgical cure rates approach 90%. A small, single insulinoma at or near the \\nsurface of the\\npancreas can usually be enucleated surgically. If a single large or deep adenoma is within the pancreatic\\nbody or tail, if there are multiple lesions of the body or tail (or both), or if no insulinoma is found (an\\nunusual circumstance), a distal, subtotal pancreatectomy is done. In < 1% of cases, the insulinoma is\\nectopically located in peripancreatic sites of the duodenal wall or periduodenal area and can be found\\nonly by diligent search during surgery. Pancreatoduodenectomy (Whipple procedure) is done for\\nresectable malignant insulinomas of the proximal pancreas. Total pancreatectomy is done if a previous\\nsubtotal pancreatectomy proves inadequate.\\nIf hypoglycemia continues, diazoxide starting at 1.5 mg/kg po bid with a natriuretic can be used. Doses\\ncan be increased up to 4 mg/kg. A somatostatin analog, octreotide (100 to 500 \\n\\ng sc bid to tid), is variably\\neffective and should be considered for patients with continuing hypoglycemia refractory to diazoxide.\\nPatients who respond may be converted to a long-acting octreotide formulation given as 20 to 30 mg IM\\nonce/mo. Patients using octreotide may also need to take supplemental pancreatic enzymes because\\noctreotide suppresses pancreatic enzyme secretion. Other drugs that have modest and variable effect on\\ninsulin secretion include verapamil, diltiazem, and phenytoin.\\nIf symptoms are not controlled, chemotherapy may be tried, but response is limited. Streptozotocin has a\\n30 to 40% response rate, and when combined with 5-fluorouracil, a 60% response rate lasting up to 2 yr.\\nOther agents include doxorubicin, chlorozotocin, and interferon.\\nZollinger-Ellison Syndrome\\n(Z-E Syndrome; Gastrinoma)\\nZollinger-Ellison syndrome is caused by a gastrin-producing tumor usually located in the\\npancreas or the duodenal wall. Gastric acid hypersecretion and peptic ulceration result.\\nDiagnosis is by measuring serum gastrin levels. Treatment is proton pump inhibitors and\\nsurgical removal.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n270\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 280, 'page_label': '271'}, page_content='Gastrinomas occur in the pancreas or duodenal wall 80 to 90% of the time. The remainder occur in the\\nsplenic hilum, mesentery, stomach, lymph node, or ovary. About 50% of patients have multiple tumors.\\nGastrinomas usually are small (< 1 cm in diameter) and grow slowly. About 50% are malignant. About 40\\nto 60% of patients with gastrinoma have multiple endocrine neoplasia (see p. \\n909\\n).\\nSymptoms and Signs\\nZollinger-Ellison syndrome typically manifests as aggressive peptic ulcer disease, with ulcers occurring in\\natypical locations (up to 25% are located distal to the duodenal bulb). However, as many as 25% do not\\nhave an ulcer at diagnosis. Typical ulcer symptoms and complications (eg, perforation, bleeding,\\nobstruction) can occur. Diarrhea is the initial symptom in 25 to 40% of patients.\\nDiagnosis\\n Serum gastrin level\\n CT, scintigraphy, or PET to localize\\nThe syndrome is suspected by history, particularly when symptoms are refractory to standard acid\\nsuppressant therapy.\\nThe most reliable test is serum gastrin. All patients have levels > 150 pg/mL; markedly elevated levels of\\n> 1000 pg/mL in a patient with compatible clinical features and gastric acid hypersecretion of > 15 mEq/h\\nestablish the diagnosis. However, moderate hypergastrinemia can occur with hypochlorhydric states (eg,\\npernicious anemia, chronic gastritis, use of proton pump inhibitors), in renal insufficiency with decreased\\nclearance of gastrins, in massive intestinal resection, and in pheochromocytoma.\\nA secretin provocative test may be useful in patients with gastrin levels < 1000 pg/mL. An IV bolus of\\nsecretin 2 \\n\\ng/kg is given with serial measurements of serum gastrin (10 and 1 min before, and 2, 5, 10,\\n15, 20, and 30 min after injection). The characteristic response in gastrinoma is an increase in gastrin\\nlevels, the opposite of what occurs in those with antral G-cell hyperplasia or typical peptic ulcer disease.\\nPatients also should be evaluated for \\nHelicobacter pylori\\n infection, which commonly results in peptic\\nulceration and moderate excess gastrin secretion.\\nOnce the diagnosis has been established, the tumor or tumors must be localized. The first test is\\nabdominal CT or somatostatin receptor scintigraphy, which may identify the primary tumor and metastatic\\ndisease. PET or selective arteriography with magnification and subtraction is also helpful. If no signs of\\nmetastases are present and the primary is uncertain, endoscopic ultrasonography should be done.\\nSelective arterial secretin injection is an alternative.\\nPrognosis\\nFive- and 10-yr survival is > 90% when an isolated tumor is removed surgically vs 43% at 5 yr and 25% at\\n10 yr with incomplete removal.\\nTreatment\\n Acid suppression\\n Surgical resection for localized disease\\n Chemotherapy for metastatic disease\\nAcid suppression:\\n Proton pump inhibitors are the drugs of choice: omeprazole or esomeprazole 40 mg\\npo bid. The dose may be decreased gradually once symptoms resolve and acid output declines. A\\nmaintenance dose is needed; patients need to take these drugs indefinitely unless they undergo surgery.\\nOctreotide injections, 100 to 500 \\n\\ng sc bid to tid, may also decrease gastric acid production and may be\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n271'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 281, 'page_label': '272'}, page_content='palliative in patients not responding well to proton pump inhibitors. A long-acting form of octreotide can be\\nused 20 to 30 mg IM once/mo.\\nSurgery:\\n Surgical removal should be attempted in patients without apparent metastases. At surgery,\\nduodenotomy and intraoperative endoscopic transillumination or ultrasound help localize tumors. Surgical\\ncure is possible in 20% of patients if the gastrinoma is not part of a multiple endocrine neoplasia\\nsyndrome.\\nChemotherapy:\\n In patients with metastatic disease, streptozocin in combination with 5-fluorouracil or\\ndoxorubicin is the preferred chemotherapy for islet cell tumors. It may reduce tumor mass (in 50 to 60%)\\nand serum gastrin levels and is a useful adjunct to omeprazole. Patients with metastatic disease are not\\ncured by chemotherapy.\\nVipoma\\nA vipoma is a non-\\n\\n pancreatic islet cell tumor secreting vasoactive intestinal peptide (VIP),\\nresulting in a syndrome of watery diarrhea, hypokalemia, and achlorhydria (WDHA syndrome).\\nDiagnosis is by serum VIP levels. Tumor is localized with CT and endoscopic ultrasound.\\nTreatment is surgical resection.\\nOf these tumors, 50 to 75% are malignant, and some may be quite large (7 cm) at diagnosis. In about 6%,\\nvipoma occurs as part of multiple endocrine neoplasia (see p. \\n909\\n).\\nSymptoms and Signs\\nThe major symptoms are prolonged massive watery diarrhea (fasting stool volume > 750 to 1000 mL/day\\nand nonfasting volumes of > 3000 mL/day) and symptoms of hypokalemia, acidosis, and dehydration. In\\nhalf, diarrhea is constant; in the rest, diarrhea severity varies over time. About 33% have diarrhea < 1 yr\\nbefore diagnosis, but 25% have diarrhea  5 yr before diagnosis. Lethargy, muscular weakness, nausea,\\nvomiting, and crampy abdominal pain occur frequently. Flushing similar to the carcinoid syndrome occurs\\nin 20% of patients during attacks of diarrhea.\\nDiagnosis\\n Confirmation of secretory diarrhea\\n Serum VIP levels\\n Endoscopic ultrasonography, PET, or scintigraphy can localize\\nDiagnosis requires demonstration of secretory diarrhea (stool osmolality is close to plasma osmolality,\\nand twice the sum of Na and K concentration in the stool accounts for all measured stool osmolality).\\nOther causes of secretory diarrhea and, in particular, laxative abuse must be excluded (see p. \\n88\\n). In\\nsuch patients, serum VIP levels should be measured (ideally during a bout of diarrhea). Markedly\\nelevated levels establish the diagnosis, but mild elevations may occur with short bowel syndrome and\\ninflammatory diseases. Patients with elevated VIP levels should have tumor localization studies, such as\\nendoscopic ultrasonography, PET, and octreotide scintigraphy or arteriography to localize metastases.\\nElectrolytes and CBC should be measured. Hyperglycemia and impaired glucose tolerance occur in \\n50% of patients. Hypercalcemia occurs in 50% of patients.\\nTreatment\\n Fluid and electrolyte replacement\\n Octreotide\\n Surgical resection for localized disease\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n272'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 282, 'page_label': '273'}, page_content='Initially, fluids and electrolytes must be replaced. Bicarbonate must be given to replace fecal loss and\\navoid acidosis. Because fecal losses of water and electrolytes increase as rehydration is achieved,\\ncontinual IV replacement may become difficult.\\nOctreotide usually controls diarrhea, but large doses may be needed. Responders may benefit from a\\nlong-acting octreotide formulation given 20 to 30 mg IM once/mo. Patients using octreotide may also need\\nto take supplemental pancreatic enzymes because octreotide suppresses pancreatic enzyme secretion.\\nTumor resection is curative in 50% of patients with a localized tumor. In those with metastatic tumor,\\nresection of all visible tumor may provide temporary relief of symptoms. The combination of streptozocin\\nand doxorubicin may reduce diarrhea and tumor mass if objective response occurs (in 50 to 60%).\\nChemotherapy is not curative.\\nGlucagonoma\\nA glucagonoma is a pancreatic \\n\\n-cell tumor that secretes glucagon, causing hyperglycemia and\\na characteristic skin rash. Diagnosis is by elevated glucagon levels and imaging studies. Tumor\\nis localized with CT and endoscopic ultrasound. Treatment is surgical resection.\\nGlucagonomas are very rare but similar to other islet cell tumors in that the primary and metastatic lesions\\nare slow-growing: 15-yr survival is common. Eighty percent of glucagonomas are malignant. The average\\nage at symptom onset is 50 yr; 80% of patients are women. A few patients have multiple endocrine\\nneoplasia type I.\\nSymptoms and Signs\\nBecause glucagonomas produce glucagon, the symptoms are the same as those of diabetes. Frequently,\\nweight loss, normochromic anemia, hypoaminoacidemia, and hypolipidemia are present, but the most\\ndistinctive clinical feature is a chronic eruption involving the extremities, often associated with a smooth,\\nshiny, vermilion tongue and cheilitis. The exfoliating, brownish red, erythematous lesion with superficial\\nnecrolysis is termed necrolytic migratory erythema.\\nDiagnosis\\n Serum glucagon level\\n CT and endoscopic ultrasonography to localize\\nMost patients with glucagonoma have glucagon levels > 1000 pg/mL (normal < 200). However, moderate\\nelevations occur in renal insufficiency, acute pancreatitis, severe stress, and fasting. Correlation with\\nsymptoms is required. Patients should have abdominal CT followed by endoscopic ultrasonography; MRI\\nor PET may be used if CT is unrevealing.\\nTreatment\\n Surgical resection for localized disease\\n Chemotherapy for metastatic disease\\n Octreotide to suppress glucagon production\\nResection of the tumor alleviates all symptoms. Unresectable, metastatic, or recurrent tumors are treated\\nwith combination streptozocin and doxorubicin, which may decrease levels of circulating immunoreactive\\nglucagon, lessen symptoms, and improve response rates (50%) but are unlikely to improve survival.\\nOctreotide injections partially suppress glucagon production and relieve the erythema, but glucose\\ntolerance may also decrease because octreotide decreases insulin secretion. Octreotide may quickly\\nreverse anorexia and weight loss caused by the catabolic effect of glucagon excess. Patients who\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n273'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 283, 'page_label': '274'}, page_content='respond may be converted to a long-acting octreotide formulation given 20 to 30 mg IM once/mo. Patients\\nusing octreotide may also need to take supplemental pancreatic enzymes because octreotide suppresses\\npancreatic enzyme secretion.\\nLocally applied, oral, or parenteral zinc may cause the erythema to disappear, but resolution may occur\\nafter simple hydration or IV administration of amino or fatty acids, suggesting that the erythema is not\\nsolely caused by zinc deficiency.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 22. Tumors of the GI Tract\\n274'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 284, 'page_label': '275'}, page_content=\"3 - Hepatic and Biliary Disorders\\nChapter 23. Approach to the Patient With Liver Disease\\nIntroduction\\nThe liver is the most metabolically complex organ. Hepatocytes (liver parenchymal cells) perform the\\nliver's metabolic functions:\\n Formation and excretion of bile during bilirubin metabolism (see \\nSidebar 23-1\\n)\\n Regulation of carbohydrate homeostasis\\n Lipid synthesis and secretion of plasma lipoproteins\\n Control of cholesterol metabolism\\n Formation of urea, serum albumin, clotting factors, enzymes, and numerous other proteins\\n Metabolism or detoxification of drugs and other foreign substances\\nAt the cellular level, portal triads consist of adjacent and parallel terminal branches of bile ducts, portal\\nveins, and hepatic arteries that border the hepatocytes (see\\nFig. 23-1\\n). Terminal branches of the hepatic veins are in the center of hepatic lobules. Because blood\\nflows from the portal triads past the hepatocytes and drains via vein branches in the center of the lobule,\\nthe center of the lobule is the area most susceptible to ischemia.\\nPathophysiology\\nLiver disorders can result from a wide variety of insults, including infections, drugs, toxins, ischemia, and\\nautoimmune disorders. Occasionally, liver disorders occur postoperatively (see p. \\n223\\n). Most liver\\ndisorders cause some degree of hepatocellular injury and necrosis, resulting in various abnormal\\nlaboratory test results and, sometimes, symptoms.\\n[\\nFig. 23-1.\\n Organization of the liver.]\\nSymptoms may be due to liver disease itself (eg, jaundice due to acute hepatitis) or to complications of\\nliver disease (eg, acute GI bleeding due to cirrhosis and portal hypertension).\\nSidebar 23-1 Overview of Bilirubin Metabolism\\nThe breakdown of heme produces bilirubin (an insoluble waste product) and other bile pigments. Bilirubin\\nmust be made water soluble to be excreted. This transformation occurs in 5 steps: formation, plasma\\ntransport, liver uptake, conjugation, and biliary excretion.\\nFormation:\\n About 250 to 350 mg of unconjugated bilirubin forms daily; 70 to 80% derives from the\\nbreakdown of degenerating RBCs, and 20 to 30% (early-labeled bilirubin) derives primarily from other\\nheme proteins in the bone marrow and liver. Hb is degraded to iron and biliverdin, which is converted to\\nbilirubin.\\nPlasma transport:\\n Unconjugated (indirect-reacting) bilirubin is not water soluble and so is transported in\\nthe plasma bound to albumin. It cannot pass through the glomerular membrane into the urine. Albumin\\nbinding weakens under certain conditions (eg, acidosis), and some substances (eg, salicylates, certain\\nantibiotics) compete for the binding sites.\\nLiver uptake:\\n The liver takes up bilirubin rapidly but does not take up the attached serum albumin.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n275\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 285, 'page_label': '276'}, page_content='Conjugation:\\n Unconjugated bilirubin in the liver is conjugated to form mainly bilirubin diglucuronide, or\\nconjugated (direct-reacting) bilirubin. This reaction, catalyzed by the microsomal enzyme glucuronyl\\ntransferase, renders the bilirubin water soluble.\\nBiliary excretion:\\n Tiny canaliculi formed by adjacent hepatocytes progressively coalesce into ductules,\\ninterlobular bile ducts, and larger hepatic ducts. Outside the porta hepatis, the main hepatic duct joins the\\ncystic duct from the gallbladder to form the common bile duct, which drains into the duodenum at the\\nampulla of Vater.\\nConjugated bilirubin is secreted into the bile canaliculus with other bile constituents. In the intestine,\\nbacteria metabolize bilirubin to form urobilinogen, much of which is further metabolized to stercobilins,\\nwhich render the stool brown. In complete biliary obstruction, stools lose their normal color and become\\nlight gray (clay-colored stool). Some urobilinogen is reabsorbed, extracted by hepatocytes, and re-\\nexcreted in bile (enterohepatic circulation). A small amount is excreted in urine.\\nBecause conjugated bilirubin is excreted in urine and unconjugated bilirubin is not, only conjugated\\nhyperbilirubinemia (eg, due to hepatocellular or cholestatic jaundice) causes bilirubinuria.\\nDespite necrosis, the liver can regenerate itself. Even extensive patchy necrosis can resolve completely\\n(eg, in acute viral hepatitis). Incomplete regeneration and fibrosis, however, may result from injury that\\nbridges entire lobules or from less pronounced but ongoing damage.\\nSpecific diseases preferentially affect certain hepatobiliary structures or functions (eg, acute viral hepatitis\\nis primarily manifested by damage to hepatocytes or hepatocellular injury; primary biliary cirrhosis, by\\nimpairment of biliary secretion; and cryptogenic cirrhosis, by liver fibrosis and resultant portal venous\\nhypertension). The part of the hepatobiliary system affected determines the symptoms, signs, and\\nlaboratory abnormalities (see also \\nCh. 24\\n). Some disorders (eg, severe alcoholic liver disease) affect\\nmultiple liver structures, resulting in a combination of patterns of symptoms, signs, and laboratory\\nabnormalities.\\nThe prognosis of serious complications is worse in older adults, who are less able to recover from severe\\nphysiologic stresses and to tolerate toxic accumulations.\\nEvaluation\\nHistory:\\n Various symptoms may develop, but few are specific for liver disorders:\\n Common nonspecific symptoms include fatigue, anorexia, nausea, and, occasionally, vomiting,\\nparticularly in severe disorders.\\n Loose, fatty stools (steatorrhea) can occur when cholestasis prevents sufficient bile from reaching the\\nintestines. Patients with steatorrhea are at risk of deficiencies of fat-soluble vitamins (A, D, E, K).\\nCommon clinical consequences may include osteoporosis and bleeding.\\n Fever can develop in viral or alcoholic hepatitis.\\n Jaundice (see p. \\n212\\n), occurring in both hepatocellular dysfunction and cholestatic disorders, is the\\nmost specific symptom. It is often accompanied by dark urine and light stools.\\n Right upper quadrant pain due to liver disorders usually results from distention (eg, by passive venous\\ncongestion or tumor) or inflammation of the liver capsule.\\n Erectile dysfunction and feminization develop; however, these symptoms may reflect the effects of\\nalcohol more than liver disorders.\\nFamily history, social history, and drug and substance use history should note risk factors for liver\\ndisorders (see\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n276'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 286, 'page_label': '277'}, page_content=\"Table 23-1\\n).\\nPhysical examination:\\n Abnormalities detectable on a physical examination usually do not develop until\\nlate in the course of the disease. Some common findings suggest a cause (see\\nTable 23-2\\n).\\nAscites\\nAscites is free fluid in the peritoneal cavity. The most common cause is portal hypertension.\\nSymptoms usually result from abdominal distention. Diagnosis is based on physical\\nexamination and often ultrasonography or CT. Treatments include bed rest, dietary Na\\nrestriction, diuretics, and therapeutic paracentesis. Ascitic fluid can become infected\\n(spontaneous bacterial peritonitis), often with pain and fever. Diagnosis of infection involves\\nanalysis and culture of ascitic fluid. Infection is treated with antibiotics.\\n[\\nTable 23-1.\\n Risk Factors for Liver Disorders]\\nEtiology\\nAscites can result from chronic, but not acute, liver diseases.\\nHepatic causes\\n include the following:\\n Portal hypertension (accounts for > 90% of hepatic cases), usually due to cirrhosis\\n Chronic hepatitis\\n Severe alcoholic hepatitis without cirrhosis\\n Hepatic vein obstruction (Budd-Chiari syndrome)\\nPortal vein thrombosis does not usually cause ascites unless hepatocellular damage is also present.\\nNonhepatic causes\\n include the following:\\n Generalized fluid retention associated with systemic diseases (eg, heart failure, nephrotic syndrome,\\nsevere hypoalbuminemia, constrictive pericarditis)\\n Peritoneal disorders (eg, carcinomatous or infectious peritonitis, biliary leak due to surgery or another\\nmedical procedure)\\n Less common causes, such as renal dialysis, pancreatitis, SLE, and endocrine disorders (eg,\\nmyxedema)\\nPathophysiology\\nMechanisms are complex and incompletely understood. Factors include altered Starling's forces in the\\nportal vessels (low oncotic pressure due to hypoalbuminemia plus increased portal venous pressure),\\navid renal Na retention (urinary Na concentration is typically < 5 mEq/L), and possibly increased hepatic\\nlymph formation.\\nMechanisms that seem to contribute to renal Na retention include activation of the renin-angiotensin-\\naldosterone system; increased sympathetic tone; intrarenal shunting of blood away from the cortex;\\nincreased formation of nitric oxide; and altered formation or metabolism of ADH, kinins, prostaglandins,\\nand atrial natriuretic factor. Vasodilation in the splanchnic arterial circulation may be a trigger, but the\\nspecific roles and interrelationships of these abnormalities remain uncertain.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n277\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 287, 'page_label': '278'}, page_content='Small amounts of ascitic fluid cause no symptoms. Moderate amounts cause increased abdominal girth\\nand weight gain. Massive amounts may cause nonspecific diffuse abdominal pressure, but actual pain is\\nuncommon and suggests another cause of acute abdominal pain (see p. \\n106\\n). If ascites results in\\nelevation of the diaphragm, dyspnea may occur. Symptoms of spontaneous bacterial peritonitis (SBP)\\nmay include new abdominal discomfort and fever.\\nSigns include shifting dullness on abdominal percussion and a fluid wave. Volumes < 1500 mL may not\\ncause physical findings. Massive ascites causes tautness of the abdominal wall and flattening of the\\numbilicus. In liver diseases or peritoneal disorders, ascites is usually isolated or disproportionate to\\nperipheral edema; in systemic diseases (eg, heart failure), the reverse is usually true.\\nDiagnosis\\n Ultrasonography or CT unless physical findings make diagnosis obvious\\n Often tests of ascitic fluid\\nDiagnosis may be based on physical examination if there is a large amount of fluid, but imaging tests are\\nmore sensitive. Ultrasonography and CT reveal much smaller volumes of fluid (100 to 200 mL) than does\\nphysical examination. SBP is suspected if a patient with ascites also has abdominal pain, fever, or\\nunexplained deterioration.\\nDiagnostic paracentesis (see p. \\n99\\n) should be done if any of the following occur:\\n Ascites is newly diagnosed.\\n Its cause is unknown.\\n SBP is suspected.\\n[\\nTable 23-2.\\n Interpretation of Some Physical Findings]\\nAbout 50 to 100 mL of fluid is removed and analyzed for gross appearance, protein content, cell count\\nand differential, cytology, culture, and, as clinically indicated, acid-fast stain, amylase, or both. In contrast\\nto ascites due to inflammation or infection, ascites due to portal hypertension produces fluid that is clear\\nand straw-colored, has a low protein concentration, a low PMN count (< 250 cells/\\n\\nL), and, most reliably,\\na high serum-to-ascites albumin concentration gradient, which is the serum albumin concentration minus\\nthe ascitic albumin concentration. Gradients > 1.1 g/dL are relatively specific for ascites due to portal\\nhypertension. In ascitic fluid, turbidity and a PMN count > 250 cells/\\n\\nL indicate SBP, whereas bloody fluid\\ncan suggest a tumor or TB. The rare milky (chylous) ascites is most common with lymphoma.\\nTreatment\\n Bed rest and dietary Na restriction\\n Sometimes spironolactone, possibly plus furosemide\\n Sometimes therapeutic paracentesis\\nBed rest and dietary Na restriction (2000 mg/day) are the first and least risky treatments for ascites due to\\nportal hypertension. Diuretics should be used if rigid Na restriction fails to initiate diuresis within a few\\ndays. Spironolactone is usually effective (in oral doses ranging from 50 mg once/day to 200 mg bid). A\\nloop diuretic (eg, furosemide 20 to 160 mg po usually once/day or 20 to 80 mg po bid) should be added if\\nspironolactone is insufficient. Because spironolactone can cause K retention and furosemide K depletion,\\nthe combination of these drugs often provides optimal diuresis with a lower risk of K abnormalities. Fluid\\nrestriction is indicated only for treatment of hyponatremia (serum Na < 120 mEq/L). Changes in body\\nweight and urinary Na determinations reflect response to treatment. Weight loss of about 0.5 kg/day is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n278'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 288, 'page_label': '279'}, page_content='optimal because the ascitic compartment cannot be mobilized much more rapidly. More aggressive\\ndiuresis depletes fluid from the intravascular compartment, especially when peripheral edema is absent;\\nthis depletion may cause renal failure or electrolyte imbalance (eg, hypokalemia) that may precipitate\\nportal-systemic encephalopathy. Inadequate dietary Na restriction is the usual cause of persistent ascites.\\nTherapeutic paracentesis is an alternative. Removal of 4 L/day is safe; many clinicians infuse IV salt-poor\\nalbumin (about 40 g/paracentesis) at about the same time to prevent intravascular volume depletion.\\nEven single total paracentesis may be safe. Therapeutic paracentesis shortens the hospital stay with\\nrelatively little risk of electrolyte imbalance or renal failure; nevertheless, patients require ongoing\\ndiuretics and tend to reaccumulate fluid more rapidly than those treated without paracentesis.\\nTechniques for the autologous infusion of ascitic fluid (eg, the LeVeen peritoneovenous shunt) often\\ncause complications and are generally no longer used. Transjugular intrahepatic portosystemic shunting\\n(TIPS) can lower portal pressure and successfully treat ascites resistant to other treatments, but TIPS is\\ninvasive and may cause complications, including portal-systemic encephalopathy and worsening\\nhepatocellular function.\\nSpontaneous Bacterial Peritonitis\\nSpontaneous bacterial peritonitis (SBP) is infection of ascitic fluid without an apparent source.\\nManifestations may include fever, malaise, and symptoms of ascites and worsening hepatic\\nfailure. Diagnosis is by examination of ascitic fluid. Treatment is with cefotaxime or another\\nantibiotic.\\nSBP is particularly common in cirrhotic ascites, especially among alcoholics. This infection can cause\\nserious sequelae or death. The most common bacteria causing SBP are gram-negative \\nEscherichia coli\\nand \\nKlebsiella pneumoniae\\n and gram-positive \\nStreptococcus pneumoniae\\n; usually only a single\\norganism is involved.\\nSymptoms and Signs\\nPatients have symptoms and signs of ascites. Discomfort is usually present; it typically is diffuse,\\nconstant, and mild to moderate in severity.\\nSigns of SBP may include fever, malaise, encephalopathy, worsening hepatic failure, and unexplained\\nclinical deterioration. Peritoneal signs (eg, abdominal tenderness and rebound) are present but may be\\nsomewhat diminished by the presence of ascitic fluid.\\nDiagnosis\\n Diagnostic paracentesis\\nClinical diagnosis of SBP can be difficult; diagnosis requires a high index of suspicion and liberal use of\\ndiagnostic paracentesis, including \\nculture. Transferring ascitic fluid to blood culture media before\\nincubation increases the sensitivity of culture to almost 70%. PMN count of > 250 cells/\\n\\nL is diagnostic of\\nSBP. Blood cultures are also indicated. Because SBP usually results from a single organism, finding\\nmixed flora on culture suggests a perforated abdominal viscus or contaminated specimen.\\nTreatment\\n Cefotaxime or another antibiotic\\nIf SBP is diagnosed, an antibiotic such as cefotaxime 2 g IV q 4 to 8 h (pending Gram stain and culture\\nresults) is given for at least 5 days and until ascitic fluid shows < 250 PMNs/\\n\\nL. Antibiotics increase the\\nchance of survival. Because SBP recurs within a year in up to 70% of patients, prophylactic antibiotics\\nare indicated; quinolones (eg, norfloxacin 400 mg po once/day) are most widely used.\\nAntibiotic prophylaxis in ascitic patients with variceal hemorrhage decreases the risk of SBP.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n279'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 289, 'page_label': '280'}, page_content=\"Fatty Liver\\n(Hepatic Steatosis)\\nFatty liver is excessive accumulation of lipid in hepatocytes, the most common liver response\\nto injury.\\nFatty liver develops for many reasons, involves many different biochemical mechanisms, and causes\\ndifferent types of liver damage. Clinically, it is most useful to distinguish fatty liver due to pregnancy or\\nalcoholic liver disease (see p. \\n235\\n) from that occurring in the absence of pregnancy and alcoholism\\n(nonalcoholic fatty liver disease [NAFLD]). NAFLD includes simple fatty infiltration (a benign condition)\\nand nonalcoholic steatohepatitis, a less common but more important variant.\\n(See also the American Gastroenterological Association's Medical Position Statement and Technical\\nReview on nonalcoholic fatty liver disease.)\\nNonalcoholic Steatohepatitis\\nNonalcoholic steatohepatitis (NASH) is a syndrome that develops in patients who are not\\nalcoholics; it causes liver damage that is histologically indistinguishable from alcoholic\\nhepatitis. It develops most often in patients with at least one of the following risk factors:\\nobesity, dyslipidemia, and glucose intolerance. Pathogenesis is poorly understood but seems to\\nbe linked to insulin resistance (eg, as in obesity or metabolic syndrome). Most patients are\\nasymptomatic. Laboratory findings include elevations in aminotransferase levels. Biopsy is\\nrequired to confirm the diagnosis. Treatment includes elimination of causes and risk factors.\\nNASH (sometimes called steatonecrosis) is diagnosed most often in patients between 40 yr and 60 yr but\\ncan occur in all age groups. Many affected patients have obesity, type 2 diabetes mellitus, or\\ndyslipidemia.\\nPathophysiology\\nPathophysiology involves fat accumulation (steatosis), inflammation, and, variably, fibrosis. Steatosis\\nresults from hepatic triglyceride accumulation. Possible mechanisms for steatosis include reduced\\nsynthesis of very low density lipoprotein (VLDL) and increased hepatic triglyceride synthesis (possibly\\ndue to decreased oxidation of fatty acids or increased free fatty acids being delivered to the liver).\\nInflammation may result from lipid peroxidative damage to cell membranes. These changes can stimulate\\nhepatic stellate cells, resulting in fibrosis. If advanced, NASH can cause cirrhosis and portal hypertension.\\nSymptoms and Signs\\nMost patients are asymptomatic. However, some have fatigue, malaise, or right upper quadrant abdominal\\ndiscomfort. Hepatomegaly develops in about 75% of patients. Splenomegaly may develop if advanced\\nhepatic fibrosis is present and is usually the first indication that portal hypertension has developed.\\nPatients with cirrhosis due to NASH can be asymptomatic and may lack the usual signs of chronic liver\\ndisease.\\nDiagnosis\\n Presence of risk factors\\n Absence of hepatitis B and C and excessive alcohol intake\\n Liver biopsy\\nThe diagnosis should be suspected in patients with risk factors such as obesity, type 2 diabetes mellitus,\\nor dyslipidemia and in patients with unexplained laboratory abnormalities suggesting liver disease. The\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n280\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 290, 'page_label': '281'}, page_content='most common laboratory abnormalities are elevations in aminotransferase levels. Unlike in alcoholic liver\\ndisease, the ratio of AST/ALT in NASH is usually < 1. Alkaline phosphatase \\nand \\n\\n-glutamyl transpeptidase\\n(GGT) occasionally increase. Hyperbilirubinemia, prolongation of PT, and hypoalbuminemia are\\nuncommon.\\nFor diagnosis, strong evidence (such as a history corroborated by friends and relatives) that alcohol\\nintake is not excessive (eg, is < 20 g/day) is needed. Serologic tests should show absence of hepatitis B\\nand C infection (ie, hepatitis B surface antigen and hepatitis C virus antibody should be negative). Liver\\nbiopsy should reveal damage similar to that seen in alcoholic hepatitis, usually including large fat droplets\\n(macrovesicular fatty infiltration). Indications for biopsy include unexplained signs of portal hypertension\\n(including splenomegaly or cytopenia) and unexplained elevations in aminotransferase levels that persist\\nfor > 6 mo in a patient with diabetes, obesity, or dyslipidemia.\\nImaging tests, including ultrasonography, CT, and particularly MRI, may identify hepatic steatosis.\\nHowever, these tests cannot identify the inflammation typical of NASH and cannot differentiate NASH\\nfrom other causes of hepatic steatosis.\\nPrognosis\\nPrognosis is controversial. Probably, most patients do not develop hepatic insufficiency or cirrhosis.\\nHowever, some drugs (eg, cytotoxic drugs) and metabolic disorders are associated with acceleration of\\nNASH. Prognosis is often good unless complications (eg, variceal hemorrhage) develop.\\nTreatment\\n Elimination of causes and control of risk factors\\nThe only widely accepted treatment goal is to eliminate potential causes and risk factors. Such a goal\\nmay include discontinuation of drugs or toxins, weight loss, and treatment for dyslipidemia or\\nhyperglycemia. Preliminary evidence suggests that thiazolidinediones can help correct biochemical and\\nhistologic abnormalities in NASH. Many other treatments (eg, ursodeoxycholic acid, vitamin E,\\nmetronidazole, metformin, betaine, glucagon, glutamine infusion) have not been proved effective.\\nJaundice\\nJaundice is a yellowish discoloration of the skin and mucous membranes caused by\\nhyperbilirubinemia. Jaundice becomes visible when the bilirubin level is about 2 to 3 mg/dL (34\\nto 51 \\n\\nmol/L).\\nPathophysiology\\nMost bilirubin is produced when Hb is broken down into unconjugated bilirubin (and other substances).\\nUnconjugated bilirubin binds to albumin in the blood for transport to the liver, where it is taken up by\\nhepatocytes and conjugated with glucuronic acid to make it water soluble. Conjugated bilirubin is\\nexcreted in bile into the duodenum. In the intestine, bacteria metabolize bilirubin to form urobilinogen.\\nSome urobilinogen is eliminated in the feces, and some is reabsorbed, extracted by hepatocytes,\\nreprocessed, and re-excreted in bile (enterohepatic circulationsee p. \\n205\\n).\\nMechanisms of hyperbilirubinemia:\\n Hyperbilirubinemia may involve predominantly unconjugated or\\nconjugated bilirubin.\\nUnconjugated hyperbilirubinemia\\n is most often caused by  1 of the following:\\n Increased production\\n Decreased hepatic uptake\\n Decreased conjugation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n281'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 291, 'page_label': '282'}, page_content='Conjugated hyperbilirubinemia\\n is most often caused by  1 of the following:\\n Dysfunction of hepatocytes (hepatocellular dysfunction)\\n Slowing of bile egress from the liver (intrahepatic cholestasis)\\n Obstruction of extrahepatic bile flow (extra-hepatic cholestasis)\\nConsequences:\\n Outcome is determined primarily by the cause of jaundice and the presence and\\nseverity of hepatic dysfunction. Hepatic dysfunction can result in coagulopathy, encephalopathy, and\\nportal hypertension (which can lead to GI bleeding).\\nEtiology\\nAlthough hyperbilirubinemia can be classified as predominantly unconjugated or conjugated, many\\nhepatobiliary disorders cause both forms.\\nMany conditions (see\\nTable 23-3\\n), including use of certain drugs (see\\nTable 23-4\\n), can cause jaundice, but the most common causes overall are\\n Inflammatory hepatitis (viral hepatitis, autoimmune hepatitis, toxic hepatic injury)\\n Alcoholic liver disease\\n Biliary obstruction\\nEvaluation\\nHistory: History of present illness\\n should include onset and duration of jaundice. Hyperbilirubinemia\\ncan cause urine to darken before\\n[\\nTable 23-3.\\n Mechanisms and Some Causes of Jaundice in Adults]\\njaundice is visible. Therefore, the onset of dark urine indicates onset of hyperbilirubinemia more\\naccurately than onset of jaundice. Important associated symptoms include fever, prodromal symptoms\\n(eg, fever, malaise, myalgias) before jaundice, urine and stool color, pruritus, steatorrhea, and abdominal\\npain (including location, severity, duration, and radiation). Important symptoms suggesting severe disease\\ninclude nausea and vomiting, weight loss, and possible symptoms of coagulopathy (eg, easy bruising or\\nbleeding, tarry or bloody stools).\\nReview of systems\\n should seek symptoms of possible causes, including weight loss and abdominal\\npain (cancer); joint pain and swelling\\n[\\nTable 23-4.\\n Some Drugs and Toxins that Can Cause Jaundice]\\n(autoimmune or viral hepatitis, hemochromatosis, primary sclerosing cholangitis, sarcoidosis); and missed\\nmenses (pregnancy).\\nPast medical history\\n should identify known causative disorders, such as hepatobiliary disease (eg,\\ngallstones, hepatitis, cirrhosis); disorders that can cause hemolysis (eg, hemoglobinopathy, G6PD\\ndeficiency); and disorders associated with liver or biliary disease, including inflammatory bowel disease,\\ninfiltrative disorders (eg, amyloidosis, lymphoma, sarcoidosis, TB), and HIV infection or AIDS.\\nDrug history should include questions about use of drugs or exposure to toxins known to affect the liver\\n(see \\nTable 23-4\\n) and about vaccination against hepatitis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n282'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 292, 'page_label': '283'}, page_content=\"Surgical history should include questions about previous surgery on the biliary tract (a potential cause of\\nstrictures).\\nSocial history should include questions about risk factors for hepatitis (see\\nTable 23-5\\n), amount and duration of alcohol use, injection drug use, and sexual history.\\nFamily history should include questions about recurrent, mild jaundice in family members and diagnosed\\nhereditary liver disorders. The patient's history of recreational drug and alcohol use should be\\ncorroborated by friends or family members when possible.\\nPhysical examination:\\n Vital signs are reviewed for fever and signs of systemic toxicity (eg, hypotension,\\ntachycardia).\\nGeneral appearance is noted, particularly for cachexia and lethargy.\\nHead and neck examination includes inspection of the sclerae and tongue for icterus and the eyes for\\nKayser-Fleischer rings. Mild jaundice is best seen by examining the sclerae in natural light; it is usually\\ndetectable when serum bilirubin reaches 2 to 2.5 mg/dL (34 to 43 \\n\\nmol/L). Breath odor should be noted\\n(eg, for fetor hepaticus).\\nThe abdomen is inspected for collateral vasculature, ascites, and surgical scars. The liver is palpated for\\nhepatomegaly, masses, nodularity, and tenderness. The spleen is palpated for splenomegaly. The\\nabdomen is examined for umbilical hernia, shifting dullness, fluid wave, masses, and tenderness. The\\nrectum is examined for gross or occult blood.\\nMen are checked for testicular atrophy and gynecomastia.\\nThe upper extremities are examined for Dupuytren's contractures.\\nNeurologic examination includes mental status assessment and evaluation for asterixis.\\nThe skin is examined for jaundice, palmar erythema, needle tracks, vascular spiders, excoriations,\\nxanthomas (consistent with primary biliary cirrhosis), paucity of axillary and pubic hair, hyperpigmentation,\\necchymoses, petechiae, and purpura.\\nRed flags:\\n The following findings are of particular concern:\\n Marked abdominal pain and tenderness\\n Altered mental status\\n GI bleeding (occult or gross)\\n Ecchymoses, petechiae, or purpura\\nInterpretation of findings: Severity of illness\\n is indicated mainly by the degree (if any) of hepatic\\ndysfunction. Ascending cholangitis is a concern because it requires emergency treatment.\\nSevere hepatic dysfunction is indicated by encephalopathy (eg, mental status change, asterixis) or\\ncoagulopathy (eg, easy bleeding, purpura, tarry or heme-positive stool), particularly in patients with signs\\nof portal hypertension\\n[\\nTable 23-5.\\n Some Risk Factors for Hepatitis]\\n(eg, abdominal collateral vasculature, ascites, splenomegaly). Massive upper GI bleeding suggests\\nvariceal bleeding due to portal hypertension (and possibly coagulopathy).\\nAscending cholangitis is suggested by fever and marked, continuous right upper quadrant abdominal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n283\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 293, 'page_label': '284'}, page_content=\"pain; acute pancreatitis with biliary obstruction (eg, due to a common duct stone or pancreatic\\npseudocyst) may manifest similarly.\\nCause of jaundice\\n may be suggested by the following:\\n Acute jaundice in the young and healthy suggests acute viral hepatitis, particularly when a viral\\nprodrome, risk factors, or both are present; however, acetaminophen overdose is also common.\\n Acute jaundice after acute drug or toxin exposure in healthy patients is likely due to that substance.\\n A long history of heavy alcohol use suggests alcoholic liver disease, particularly when typical stigmata\\nare present.\\n A personal or family history of recurrent, mild jaundice without findings of hepatobiliary dysfunction\\nsuggests a hereditary disorder, usually Gilbert syndrome.\\n Gradual onset of jaundice with pruritus, weight loss, and clay-colored stools suggests intrahepatic or\\nextrahepatic cholestasis.\\n Painless jaundice in elderly patients with weight loss and a mass but with minimal pruritus suggests\\nbiliary obstruction caused by cancer.\\nOther examination findings can also be helpful (see\\nTable 23-6\\n).\\nTesting:\\n The following are done:\\n Blood tests (bilirubin, aminotransferase, alkaline phosphatase)\\n Usually imaging\\n Sometimes biopsy or laparoscopy\\nBlood tests include measurement of total and direct bilirubin, aminotransferase, and alkaline phosphatase\\nlevels in all patients. Results help differentiate cholestasis from hepatocellular dysfunction (important\\nbecause patients with cholestasis usually require imaging tests):\\n Hepatocellular dysfunction: Marked aminotransferase elevation (> 500 U/L) and moderate alkaline\\nphosphatase elevation (< 3 times normal)\\n Cholestasis: Moderate aminotransferase elevation (< 200 U/L) and marked alkaline phosphatase\\nelevation (> 3 times normal)\\n Hyperbilirubinemia without hepatobiliary dysfunction: Mild hyperbilirubinemia (eg, < 3.5 mg/dL [< 59\\n\\nmol/L]) with normal aminotransferase and alkaline phosphatase levels\\nAlso, patients with hepatocellular dysfunction or cholestasis have dark urine due to bilirubinuria because\\nconjugated bilirubin is excreted in urine; unconjugated bilirubin is not. Bilirubin fractionation also\\ndifferentiates conjugated from unconjugated forms. When aminotransferase and alkaline phosphatase\\nlevels are normal, fractionation of bilirubin can help suggest causes, such as Gilbert syndrome or\\nhemolysis (unconjugated) vs Dubin-Johnson syndrome or Rotor's syndrome (conjugated).\\nOther blood tests are done based on clinical suspicion and initial test findings, as for the following:\\n Signs of hepatic insufficiency (eg, encephalopathy, ascites, ecchymoses) or GI bleeding: Coagulation\\nprofile (PT/PTT)\\n Hepatitis risk factors (see \\nTable 23-5\\n) or a hepatocellular mechanism suggested by blood test results:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n284\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 294, 'page_label': '285'}, page_content=\"Hepatitis viral and autoimmune serologic tests\\n Fever, abdominal pain, and tenderness: CBC and, if patients appear ill, blood cultures\\n[\\nTable 23-6.\\n Findings Suggesting a Cause of Jaundice]\\nSuspicion of hemolysis can be confirmed by a peripheral blood smear.\\nImaging is done if pain suggests extrahepatic obstruction or cholangitis or if blood test results suggest\\ncholestasis.\\nAbdominal ultrasonography usually is done first; usually, it is highly accurate in detecting extrahepatic\\nobstruction. CT and MRI are alternatives. Ultrasonography is usually more accurate for gallstones, and\\nCT is more accurate for pancreatic lesions. All these tests can detect abnormalities in the biliary tree and\\nfocal liver lesions but are less accurate in detecting diffuse hepatocellular disorders (eg, hepatitis,\\ncirrhosis).\\nIf ultrasonography shows extrahepatic cholestasis, other tests may be necessary to determine the cause;\\nusually, magnetic resonance cholangiopancreatography (MRCP) or ERCP is used. ERCP is more\\ninvasive but allows treatment of some obstructive lesions (eg, stone removal, stenting of strictures).\\nLiver biopsy is not commonly required but can help diagnose certain disorders (eg, disorders causing\\nintrahepatic cholestasis, some kinds of hepatitis, some infiltrative disorders, Dubin-Johnson syndrome,\\nhemochromatosis, Wilson's disease). Biopsy can also help when liver enzyme abnormalities are\\nunexplained by other tests.\\nLaparoscopy (peritoneoscopy) allows direct inspection of the liver and gallbladder without the trauma of a\\nfull laparotomy. Unexplained cholestatic jaundice warrants laparoscopy occasionally and diagnostic\\nlaparotomy rarely.\\nTreatment\\nThe cause and any complications are treated. Jaundice itself requires no treatment in adults (unlike in\\nneonatessee p. \\n2788\\n). Itching, if bothersome, may be relieved with cholestyramine 2 to 8 g po bid.\\nHowever, cholestyramine is ineffective in patients with complete biliary obstruction.\\nGeriatrics Essentials\\nSymptoms may be attenuated or missed in the elderly; eg, abdominal pain may be mild or absent in acute\\nviral hepatitis. A sleep disturbance or mild confusion resulting from portosystemic encephalopathy may be\\nmisattributed to dementia.\\nKey Points\\n Acute jaundice, particularly with a viral prodrome, in the young and healthy suggests acute viral\\nhepatitis.\\n Painless jaundice in elderly patients with weight loss, an abdominal mass, and minimal pruritus suggests\\nbiliary obstruction caused by cancer.\\n Aminotransferase levels of > 500 U/L and alkaline phosphatase elevation < 3 times normal suggest\\nhepatocellular dysfunction.\\n Aminotransferase levels of < 200 U/L and alkaline phosphatase elevation > 3 times normal suggest\\ncholestasis.\\n Significant hepatic dysfunction is indicated by altered mental status and coagulopathy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n285\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 295, 'page_label': '286'}, page_content=\"Inborn Metabolic Disorders Causing Hyperbilirubinemia\\nHereditary or inborn metabolic disorders may cause unconjugated or conjugated hyperbilirubinemia.\\n Unconjugated hyperbilirubinemia: Gilbert syndrome, Crigler-Najjar syndrome, and primary shunt\\nhyperbilirubinemia\\n Conjugated hyperbilirubinemia: Dubin-Johnson syndrome and Rotor's syndrome\\nGilbert Syndrome\\nGilbert syndrome is a presumably lifelong disorder in which the only significant abnormality is\\nasymptomatic, mild, unconjugated hyperbilirubinemia. It can be mistaken for chronic hepatitis or other liver\\ndisorders. Gilbert syndrome may affect as many as 5% of people. Although family members may be\\naffected, a clear genetic pattern is difficult to establish.\\nPathogenesis may involve complex defects in the liver's uptake of bilirubin. Glucuronyl transferase activity\\nis low, though not as low as in Crigler-Najjar syndrome type II. In many patients, RBC destruction is also\\nslightly accelerated, but this acceleration does not explain hyperbilirubinemia. Liver histology is normal.\\nGilbert syndrome is most often detected in young adults serendipitously by finding an elevated bilirubin\\nlevel, which usually fluctuates between 2 and 5 mg/dL (34 and 86 \\n\\nmol/L) and tends to increase with\\nfasting and other stresses.\\nGilbert syndrome is differentiated from hepatitis by fractionation that shows predominantly unconjugated\\nbilirubin, otherwise normal liver function test results, and absence of urinary bilirubin. It is differentiated\\nfrom hemolysis by the absence of anemia and reticulocytosis. Treatment is unnecessary. Patients \\nshould\\nbe reassured that they do not have liver disease.\\nCrigler-Najjar Syndrome\\nThis rare inherited disorder is caused by deficiency of the enzyme glucuronyl transferase. Patients with\\nautosomal recessive type I (complete) disease have severe hyperbilirubinemia. They usually die of\\nkernicterus by age 1 yr but may survive into adulthood. Treatment may include phototherapy and liver\\ntransplantation. Patients with autosomal dominant type II (partial) disease (which has variable\\npenetrance) often have less severe hyperbilirubinemia (< 20 mg/dL [< 342 \\n\\nmol/L]) and usually live into\\nadulthood without neurologic damage. Phenobarbital 1.5 to 2 mg/kg po tid, which induces the partially\\ndeficient glucuronyl transferase, may be effective.\\nPrimary Shunt Hyperbilirubinemia\\nThis rare, familial, benign condition is characterized by overproduction of early-labeled bilirubin.\\nDubin-Johnson Syndrome and Rotor's Syndrome\\nDubin-Johnson syndrome and Rotor's syndrome cause conjugated hyperbilirubinemia, but without\\ncholestasis, causing no symptoms or sequelae other than jaundice. In contrast to unconjugated\\nhyperbilirubinemia in Gilbert syndrome (which also causes no other symptoms), bilirubin may appear in\\nthe urine. Aminotransferase and alkaline phosphatase levels are usually normal. Treatment is\\nunnecessary.\\nDubin-Johnson syndrome:\\n This rare autosomal recessive disorder involves impaired excretion of\\nbilirubin glucuronides. It is usually diagnosed by liver biopsy; the liver is deeply pigmented as a result of\\nan intracellular melanin-like substance but is otherwise histologically normal.\\nRotor's syndrome:\\n This rare disorder is clinically similar to Dubin-Johnson syndrome, but the liver is not\\npigmented, and other subtle metabolic differences are present.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n286\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 296, 'page_label': '287'}, page_content=\"Portal Hypertension\\nPortal hypertension is caused most often by cirrhosis (in developed countries), schistosomiasis\\n(in endemic areas), or hepatic vascular abnormalities. Consequences include esophageal\\nvarices and portal-systemic encephalopathy. Diagnosis is based on clinical criteria, often in\\nconjunction with imaging tests and endoscopy. Treatment involves prevention of GI bleeding\\nwith endoscopy, drugs, or both and sometimes with portocaval shunting.\\nThe portal vein, formed by the superior mesenteric and splenic veins, drains blood from the abdominal GI\\ntract, spleen, and pancreas into the liver. Within reticuloendotheliumlined blood channels (sinusoids),\\nblood from the terminal portal venules merges with hepatic arterial blood. Blood flows out of the sinusoids\\nvia the hepatic veins into the inferior vena cava.\\nNormal portal pressure is 5 to 10 mm Hg (7 to 14 cm H\\n2\\nO), which exceeds inferior vena caval pressure\\nby 4 to 5 mm Hg (portal venous gradient). Higher values are defined as portal hypertension.\\nEtiology\\nPortal hypertension results mainly from increased resistance to flow, which commonly arises from disease\\nwithin the liver itself or uncommonly from blockage of the splenic or portal vein or impaired hepatic\\nvenous outflow (see\\nTable 23-7\\n). Increased flow volume is a rare cause, although it often contributes to portal hypertension in\\ncirrhosis and in hematologic disorders that cause massive splenomegaly.\\nPathophysiology\\nIn cirrhosis, tissue fibrosis and regeneration increase resistance in the sinusoids and terminal portal\\nvenules. However, other potentially reversible factors contribute; they include contractility of sinusoidal\\nlining cells, production of vasoactive substances (eg, endothelins, nitric oxide), various systemic\\nmediators of arteriolar resistance, and possibly swelling of hepatocytes.\\nOver time, portal hypertension creates portal-systemic venous collaterals. They may slightly decrease\\nportal vein pressure but can cause complications. Engorged serpentine submucosal vessels (varices) in\\nthe distal esophagus and sometimes in the gastric fundus can rupture, causing sudden, catastrophic GI\\nbleeding. Bleeding rarely occurs unless the portal pressure gradient is > 12 mm Hg. Gastric mucosal\\nvascular congestion (portal hypertensive gastropathy) can cause acute or chronic bleeding independent\\nof varices. Visible abdominal wall collaterals are common; veins radiating from the umbilicus (caput\\nmedusae) are much rarer and indicate extensive flow in the umbilical and periumbilical veins.\\n[\\nTable 23-7.\\n Most Common Causes of Portal Hypertension]\\nCollaterals around the rectum can cause rectal varices that can bleed.\\nPortal-systemic collaterals shunt blood away from the liver. Thus, less blood reaches the liver when portal\\nflow increases (diminished hepatic reserve). In addition, toxic substances from the intestine are shunted\\ndirectly to the systemic circulation, contributing to portal-systemic encephalopathy (see p. \\n220\\n). Venous\\ncongestion within visceral organs due to portal hypertension contributes to ascites via altered Starling's\\nforces. Splenomegaly and hypersplenism (see p. \\n984\\n) commonly occur as a result of increased splenic\\nvein pressure. Thrombocytopenia, leukopenia, and, less commonly, hemolytic anemia may result.\\nPortal hypertension is often associated with a hyperdynamic circulation. Mechanisms are complex and\\nseem to involve altered sympathetic tone, production of nitric oxide and other endogenous vasodilators,\\nand enhanced activity of humoral factors (eg, glucagon).\\nSymptoms and Signs\\nPortal hypertension is asymptomatic; symptoms and signs result from its complications. The most\\ndangerous is acute variceal bleeding (see p. \\n103\\n). Patients typically present with sudden painless upper\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n287\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 297, 'page_label': '288'}, page_content='GI bleeding, often massive. Bleeding from portal hypertensive gastropathy is often subacute or chronic.\\nAscites, splenomegaly, or portal-systemic encephalopathy may be present.\\nDiagnosis\\n Usually, clinical evaluation\\nPortal hypertension is inferred in a patient with chronic liver disease by the presence of collateral\\ncirculation, splenomegaly, ascites, or portal-systemic encephalopathy. Proof requires direct portal\\npressure measurement by a transjugular catheter, which is invasive and usually not done. Imaging may\\nhelp when cirrhosis is suspected. Ultrasonography or CT often reveals dilated intra-abdominal collaterals,\\nand Doppler ultrasonography can determine portal vein patency and flow.\\nEsophagogastric varices and portal hypertensive gastropathy are best diagnosed by endoscopy, which\\nmay also identify predictors of esophagogastric variceal bleeding (eg, red markings on a varix).\\nPrognosis\\nMortality during acute variceal hemorrhage may exceed 50%. Prognosis is predicted by the degree of\\nhepatic reserve and the degree of bleeding. For survivors, the bleeding risk within the next 1 to 2 yr is 50\\nto 75%. Ongoing endoscopic or drug therapy lowers the bleeding risk but decreases long-term mortality\\nonly marginally. For treatment of acute bleeding, see pp. \\n102\\n and \\n104\\n.\\nTreatment\\n Ongoing endoscopic therapy and surveillance\\n \\n\\n-Blockers with or without isosorbide mononitrate\\n Sometimes portal vein shunting\\nWhen possible, the underlying disorder is treated. Long-term treatment of esophagogastric varices that\\nhave bled is a series of endoscopic banding sessions to obliterate residual varices, then periodic\\nsurveillance endoscopy for recurrent varices.\\nLong-term drug therapy for varices that have bled involves \\n\\n-blockers; these drugs lower portal pressure\\nprimarily by diminishing portal flow, although the effects vary. Propranolol (40 to 80 mg po bid) or nadolol\\n(40 to 160 mg \\npo once/day) is preferred, with dosage titrated to decrease heart rate by about 25%.\\nAdding isosorbide mononitrate 10 to 20 mg po bid may further reduce portal pressure. Combined long-\\nterm endoscopic and drug therapy may be slightly more effective than either alone. Patients who do not\\nadequately respond to either treatment should be considered for transjugular intrahepatic portosystemic\\nshunting (TIPS) or, less frequently, a surgical portocaval shunt. TIPS creates a stent between the portal\\nand hepatic venous circulation within the liver. Although TIPS may result in fewer immediate deaths than\\nsurgical shunting, particularly during acute bleeding, maintenance of patency may require repeat\\nprocedures because the stent may become stenosed or occluded over time. Long-term benefits are\\nunknown. Liver transplantation may help some patients.\\nFor patients with varices that have not yet bled, \\n\\n-blockers lower the risk of bleeding.\\nFor bleeding due to portal hypertensive gastropathy, drugs can be used to decrease portal pressure. A\\nshunt should be considered if drugs are ineffective, but results may be less successful than for\\nesophageal variceal bleeding.\\nBecause it rarely causes clinical problems, hypersplenism requires no specific treatment, and\\nsplenectomy should be avoided.\\nPortal-Systemic Encephalopathy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n288'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 298, 'page_label': '289'}, page_content='Portal-systemic encephalopathy is a neuropsychiatric syndrome. It most often results from high\\ngut protein or acute metabolic stress (eg, GI bleeding, infection, electrolyte abnormality) in a\\npatient with portal-systemic shunting. Symptoms are mainly neuropsychiatric (eg, confusion,\\nflapping tremor, coma). Diagnosis is based on clinical findings. Treatment usually is correction\\nof the acute cause, restriction of dietary protein, and oral lactulose.\\nPortal-systemic encephalopathy better describes the pathophysiology than hepatic encephalopathy or\\nhepatic coma, but all 3 terms are used interchangeably.\\nEtiology\\nPortal-systemic encephalopathy may occur in fulminant hepatitis caused by viruses, drugs, or toxins, but it\\nmore commonly occurs in cirrhosis or other chronic disorders when extensive portal-systemic collaterals\\nhave developed as a result of portal hypertension. Encephalopathy also follows portal-systemic\\nanastomoses, such as surgically created anastomoses connecting the portal vein and vena cava\\n(portacaval shunts, transjugular intrahepatic portosystemic shunting [TIPS]).\\nPrecipitants:\\n In patients with chronic liver disease, acute episodes of encephalopathy are usually\\nprecipitated by reversible causes. The most common are the following:\\n Metabolic stress (eg, infection; electrolyte imbalance, especially hypokalemia; dehydration; use of\\ndiuretic drugs)\\n Disorders that increase gut protein (eg, GI bleeding, high-protein diet)\\n Nonspecific cerebral depressants (eg, alcohol, sedatives, analgesics)\\nPathophysiology\\nIn portal-systemic shunting, absorbed products that would otherwise be detoxified by the liver enter the\\nsystemic circulation, where they may be toxic to the brain, particularly the cerebral cortex. The\\nsubstances causing brain toxicity are not precisely known. Ammonia, a product of protein digestion, is an\\nimportant cause, but other factors (eg, alterations in cerebral benzodiazepine receptors and\\nneurotransmission by \\n\\n-aminobutyric acid [GABA]) may also contribute. Aromatic amino acid levels in\\nserum are usually high and branched-chain levels are low, but these levels probably do not cause\\nencephalopathy.\\nSymptoms and Signs\\nSymptoms and signs of encephalopathy tend to develop in progressive stages (see\\nTable 23-8\\n).\\nSymptoms usually do not become apparent until brain function is moderately impaired. Constructional\\napraxia, in which patients cannot reproduce simple designs (eg, a star), develops early. Agitation and\\nmania can develop but are uncommon. A characteristic flapping tremor (asterixis) is elicited when patients\\nhold their arms outstretched with wrists dorsiflexed. Neurologic deficits are symmetric. Neurologic signs in\\ncoma usually reflect bilateral diffuse hemispheric dysfunction. Signs of brain stem dysfunction develop\\nonly in advanced coma, often during the hours or days before death. A musty, sweet breath odor (fetor\\nhepaticus) can occur regardless of the stage of encephalopathy.\\nDiagnosis\\n Clinical evaluation\\n Often adjunctive testing with psychometric evaluation, ammonia level, EEG, or a combination\\n Exclusion of other treatable disorders\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n289'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 299, 'page_label': '290'}, page_content='[\\nTable 23-8.\\n Clinical Stages of Portal-Systemic Encephalopathy]\\nDiagnosis is ultimately based on clinical findings, but testing may help:\\n Psychometric testing may reveal subtle neuropsychiatric deficits, which can help confirm early\\nencephalopathy.\\n Ammonia levels are usually done.\\n An EEG usually shows diffuse slow-wave activity, even in mild cases, and may be sensitive but is not\\nspecific for early encephalopathy.\\nCSF examination is not routinely necessary; the only usual abnormality is mild protein elevation.\\nOther potentially reversible disorders that could cause similar manifestations (eg, infection, subdural\\nhematoma, hypoglycemia, intoxication) should be ruled out. If portal-systemic encephalopathy is\\nconfirmed, the precipitating cause should be sought.\\nPrognosis\\nIn chronic liver disease, correction of the precipitating cause usually causes encephalopathy to regress\\nwithout permanent neurologic sequelae. Some patients, especially those with portacaval shunts or TIPS,\\nrequire continuous therapy, and irreversible extrapyramidal signs or spastic paraparesis rarely develops.\\nComa (stage 4 encephalopathy) associated with fulminant hepatitis is fatal in up to 80% of patients\\ndespite intensive therapy; the combination of advanced chronic liver failure and portal-systemic\\nencephalopathy is often fatal.\\nTreatment\\n Treatment of the cause\\n Bowel cleansing using oral lactulose or enemas\\n Dietary protein restriction\\nTreating the cause usually reverses mild cases. Eliminating toxic enteric products is the other goal and is\\naccomplished using several methods. The bowels should be cleared using enemas or, more often, oral\\nlactulose syrup, which can be tube-fed to comatose patients. This synthetic disaccharide is an osmotic\\ncathartic. It also lowers colonic pH, decreasing fecal ammonia production. The initial dosage, 30 to 45 mL\\npo tid, should be adjusted to produce 2 or 3 soft stools daily. Dietary protein should be about 1.0\\nmg/kg/day, primarily from vegetable sources. Oral nonabsorbable antibiotics such as neomycin and\\nrifaximin are effective for hepatic encephalopathy. Rifaximin is usually preferred because neomycin is an\\naminoglycoside, which can precipitate ototoxicity or nephrotoxicity.\\nSedation deepens encephalopathy and should be avoided whenever possible. For coma caused by\\nfulminant hepatitis, meticulous supportive and nursing care coupled with prevention and treatment of\\ncomplications increase the chance of survival. High-dose corticosteroids, exchange transfusion, and\\nother complex procedures designed to remove circulating toxins generally do not \\nimprove outcome.\\nPatients deteriorating because of fulminant hepatic failure may be saved by liver transplantation.\\nOther potential therapies, including levodopa, bromocriptine, flumazenil, Na benzoate, infusions of\\nbranched-chain amino acids, keto-analogs of essential amino acids, and prostaglandins, have not proved\\neffective. Complex plasma-filtering systems (artificial liver) show some promise but require much more\\nstudy.\\nSystemic Abnormalities in Liver Disease\\nLiver disease often causes systemic symptoms and abnormalities (see \\nPortal-Systemic Encephalopathy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n290'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 300, 'page_label': '291'}, page_content='on p. \\n220\\n).\\nCirculatory Abnormalities\\nHypotension in advanced liver failure may contribute to renal dysfunction. The pathogenesis of the\\nhyperdynamic circulation (increased cardiac output and heart rate) and hypotension that develop in\\nadvanced liver failure or cirrhosis is poorly understood. However, peripheral arterial vasodilation probably\\ncontributes to both. Factors that may contribute in cirrhosis may include altered sympathetic tone,\\nproduction of nitric oxide and other endogenous vasodilators, and enhanced activity of humoral factors\\n(eg, glucagon).\\nFor specific disorders of hepatic circulation (eg, Budd-Chiari syndrome), see \\nCh. 29\\n.\\nEndocrine Abnormalities\\nGlucose intolerance, hyperinsulinism, insulin resistance, and hyperglucagonemia are often present in\\npatients with cirrhosis; the elevated insulin levels reflect decreased hepatic degradation rather than\\nincreased secretion, whereas the opposite is true for hyperglucagonemia. Abnormal thyroid function tests\\nmay reflect altered hepatic handling of thyroid hormones and changes in plasma binding proteins rather\\nthan thyroid abnormalities.\\nSexual effects\\n are common. Chronic liver disease commonly impairs menstruation and fertility. Males\\nwith cirrhosis, especially alcoholics, often have both hypogonadism (including testicular atrophy, erectile\\ndysfunction, decreased spermatogenesis) and feminization (gynecomastia, female habitus). The\\nbiochemical basis is not fully understood. Gonadotropin reserve of the hypothalamicpituitary axis is often\\nblunted. Circulating testosterone levels are low, resulting mainly from decreased synthesis but also from\\nincreased peripheral conversion to estrogens. Levels of estrogens other than estradiol are usually\\nincreased, but the relationship between estrogens and feminization is complex. These changes are more\\nprevalent in alcoholic liver disease than in cirrhosis of other etiologies, suggesting that alcohol, rather\\nthan liver disease, may be the cause. In fact, evidence indicates that alcohol itself is toxic to the testes.\\nHematologic Abnormalities\\nAnemia\\n is common among patients with liver disease. Contributing factors may include blood loss, folate\\n(folic acid) deficiency, hemolysis, marrow suppression by alcohol, and a direct effect of chronic liver\\ndisease.\\nLeukopenia\\n and \\nthrombocytopenia\\n often accompany splenomegaly in advanced portal hypertension.\\nClotting and coagulation abnormalities\\n are common and complex. Hepatocellular dysfunction and\\ninadequate absorption of vitamin K may impair liver synthesis of clotting factors. An abnormal PT,\\ndepending on the severity of hepatocellular dysfunction, may respond to parenteral phytonadione (vitamin\\nK\\n1\\n) 5 to 10 mg once/day for 2 to 3 days. Thrombocytopenia, disseminated intravascular coagulation, and\\nfibrinogen abnormalities also contribute to clotting disturbances in many patients.\\nRenal and Electrolyte Abnormalities\\nRenal and electrolyte abnormalities are common, especially among patients with ascites.\\nHypokalemia\\n may result from excess urinary K loss due to increased circulating aldosterone, renal\\nretention of ammonium ion in exchange for K, secondary renal tubular acidosis, or diuretic therapy.\\nManagement consists of giving oral KCl supplements and withholding K-wasting diuretics.\\nHyponatremia\\n is common even though the kidneys may avidly retain Na (see \\nAscites\\n on p. \\n206\\n); it\\nusually occurs with advanced hepatocellular disease and is difficult to correct. Relative water overload is\\nmore often responsible than total body Na depletion; K depletion may also contribute. Water restriction\\nand K supplements may help; use of diuretics that increase free water clearance is \\ncontroversial. Saline\\nsolution IV is indicated only if profound hyponatremia causes seizures or if total body Na depletion is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n291'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 301, 'page_label': '292'}, page_content=\"suspected; it should be avoided in patients with cirrhosis and fluid retention because it worsens ascites\\nand only temporarily increases serum Na levels.\\nAdvanced liver failure can alter acid-base balance, usually causing metabolic alkalosis. BUN levels are\\noften low because of impaired liver synthesis; GI bleeding causes elevations because of an increased\\nenteric load rather than renal impairment. When GI bleeding elevates BUN, normal creatinine values tend\\nto confirm normal kidney function.\\nRenal failure\\n in liver disease may reflect\\n Rare disorders that directly affect both the kidneys and the liver (eg, carbon tetrachloride toxicity)\\n Circulatory failure with decreased renal perfusion, with or without frank acute tubular necrosis\\n Functional renal failure, often called hepatorenal syndrome\\nHepatorenal syndrome:\\n This syndrome consists of progressive oliguria and azotemia in the absence of\\nstructural damage to the kidney; it usually occurs in patients with fulminant hepatitis or advanced cirrhosis\\nwith ascites. Its unknown pathogenesis probably involves extreme vasodilation of the splanchnic arterial\\ncirculation, leading to decreased central arterial volume. Neural or humoral reductions in renocortical\\nblood flow follow, resulting in a diminished glomerular filtration rate. Low urinary Na concentration and\\nbenign sediment usually distinguish it from tubular necrosis, but prerenal azotemia may be more difficult to\\ndistinguish; in equivocal cases, response to a volume load should be assessed.\\nOnce established, renal failure due to hepatorenal syndrome is usually rapidly progressive and fatal (type\\n1 hepatorenal syndrome), although some cases are less severe, with stable low-grade renal insufficiency\\n(type 2).\\nLiver transplantation is the only accepted treatment for type 1 hepatorenal syndrome; transjugular\\nintrahepatic portosystemic shunting (TIPS) and vasoconstrictors show some promise, but more study is\\nneeded.\\nThe Asymptomatic Patient With Abnormal Laboratory Test Results\\nBecause aminotransferases and alkaline phosphatase are included in commonly done laboratory test\\npanels, abnormalities are often detected in patients without symptoms or signs of liver disease. In such\\npatients, the physician should obtain a history of exposure to possible liver toxins, including alcohol,\\nprescription and nonprescription drugs, herbal teas and remedies, and occupational or other chemical\\nexposures.\\nAminotransferases:\\n Mild isolated elevations of ALT or AST (< 2 times normal) may require only repeat\\ntesting; they resolve in about one third of cases. If abnormalities are present in other laboratory tests, are\\nsevere, or persist on subsequent testing, further evaluation is indicated as follows:\\n Fatty liver should be considered; it can often be recognized clinically (see p. \\n211\\n).\\n Patients should be screened for hepatitis B and C (see p. \\n251\\n).\\n Patients > 40 should be screened for hemochromatosis (see p. \\n1032\\n).\\n Patients < 30 should be screened for Wilson's disease (see p. \\n51\\n).\\n Most patients, especially young or middle-aged women, should be screened for autoimmune disorders.\\n Patients at risk should be screened for malaria and schistosomiasis.\\nIf at this point the results are negative, screening for \\n\\n1\\n-antitrypsin deficiency (see p. \\n1901\\n) is indicated. If\\nthe entire evaluation reveals no cause, liver biopsy may be warranted.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n292\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 302, 'page_label': '293'}, page_content='Alkaline phosphatase:\\n Isolated elevation of alkaline phosphatase levels in an asymptomatic patient\\nrequires confirmation of hepatic origin by showing elevation of 5-nucleotidase or \\n\\n-glutamyl\\ntranspeptidase. If hepatic origin is confirmed, liver imaging, usually with ultrasonography or magnetic\\nresonance cholangiopancreatography, is indicated. If no structural abnormality is found on imaging,\\nintrahepatic cholestasis is possible and may be suggested by a history of exposure to drugs or toxins.\\nInfiltrative diseases and liver metastases (eg, due to colon cancer) should also be considered. In women,\\nantimitochondrial antibody should be obtained. Persistent unexplained elevations or suspicion of\\nintrahepatic cholestasis warrants consideration of liver biopsy.\\nPostoperative Liver Dysfunction\\nMild liver dysfunction sometimes occurs after major surgery even in the absence of preexisting liver\\ndisorders. This dysfunction \\nusually results from hepatic ischemia or poorly understood effects of\\nanesthesia. Patients with preexisting well-compensated liver disease (eg, cirrhosis with normal liver\\nfunction) usually tolerate surgery well. However, surgery can increase the severity of some preexisting\\nliver disorders; eg, laparotomy may precipitate acute liver failure in a patient with viral or alcoholic\\nhepatitis.\\nPostoperative jaundice:\\n Diagnosis of postoperative jaundice requires liver laboratory tests. Timing of\\nsymptoms also aids in diagnosis.\\nMultifactorial mixed hyperbilirubinemia is the most common reason for postoperative jaundice. It is caused\\nby increased formation of bilirubin and decreased hepatic clearance. This disorder most often occurs\\nafter major surgery or trauma requiring multiple transfusions. Hemolysis, sepsis, resorption of\\nhematomas, and blood transfusions can increase the bilirubin load; simultaneously, hypoxemia, hepatic\\nischemia, and other poorly understood factors impair hepatic function. This condition is usually maximal\\nwithin a few days of operation. Hepatic insufficiency is rare, and hyperbilirubinemia typically resolves\\nslowly but completely. Liver laboratory tests can often differentiate multifactorial mixed hyperbilirubinemia\\nfrom hepatitis. In multifactorial mixed hyperbilirubinemia, severe hyperbilirubinemia with mild\\naminotransferase and alkaline phosphatase elevations are common. In hepatitis, aminotransferase levels\\nare usually very high.\\nPostoperative hepatitis:\\n Ischemic postoperative \"hepatitis\" results from insufficient liver perfusion, not\\ninflammation. The cause is transient perioperative hypotension or hypoxia. Typically, aminotransferase\\nlevels increase rapidly (often > 1000 units/L), but bilirubin is only mildly elevated. Ischemic hepatitis is\\nusually maximal within a few days of operation and resolves within a few days.\\nHalothane-related hepatitis can result from use of anesthetics containing halothane or related agents. It\\nusually develops within 2 wk, is often preceded by fever, and is sometimes accompanied by a skin rash\\nand eosinophilia.\\nTrue postoperative hepatitis is now rare. It used to result mainly from transmission of hepatitis C virus\\nduring blood transfusion.\\nPostoperative cholestasis:\\n The most common cause of postoperative cholestasis is extrahepatic biliary\\nobstruction due to intra-abdominal complications or drugs given postoperatively. Intrahepatic cholestasis\\noccasionally develops after major surgery, especially after abdominal or cardiovascular procedures\\n(benign postoperative intrahepatic cholestasis). The pathogenesis is unknown, but the condition usually\\nresolves slowly and spontaneously. Occasionally, postoperative cholestasis results from acute acalculous\\ncholecystitis or pancreatitis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 23. Approach to the Patient With Liver Disease\\n293'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 303, 'page_label': '294'}, page_content=\"Chapter 24. Testing for Hepatic and Biliary Disorders\\nIntroduction\\nDiagnosis of liver and biliary system disorders may include laboratory tests, imaging tests, and liver\\nbiopsy. Individual tests, particularly those of liver biochemistry and excretion, often have limited sensitivity\\nand specificity. A combination of tests often best defines the cause and severity of disease. Useful\\nalgorithms (eg, Model of End-Stage Liver Disease [MELD], Child-Pugh score) have incorporated clinical\\nand laboratory features to predict survival in patients with decompensated cirrhosis.\\nLaboratory Tests\\nLaboratory tests are generally effective for the following:\\n Detecting hepatic dysfunction\\n Assessing the severity of liver injury\\n Monitoring the course of liver diseases and the response to treatment\\n Refining the diagnosis\\nMany tests of liver biochemistry and excretory performance are called liver function tests. However, rather\\nthan assessing liver function, several of these tests measure liver enzymes that are released into the\\nbloodstream (eg, release of aminotransferases from injured liver cells or of alkaline phosphatase due to\\ncholestasis). Only certain tests actually assess liver \\nfunction by evaluating hepatobiliary excretion (eg,\\nbilirubin) or the liver's synthetic capability (eg, PT, usually reported as the INR; albumin).\\nThe most useful laboratory tests to screen for liver disorders are serum aminotransferases (the most\\ncommonly used liver function tests), bilirubin, and alkaline phosphatase. Certain patterns of biochemical\\nabnormalities help distinguish hepatocellular injury from impaired bile excretion (cholestasissee\\nTable 24-1\\n). Tests that detect viral hepatitis, liver inflammation, or altered immunoregulation include\\nhepatitis serologic tests (see p. \\n251\\n) and measurement of immunoglobulins, antibodies, and\\nautoantibodies.\\nA few laboratory tests are diagnostic by themselves; they include the following:\\n IgM antibody to hepatitis A virus (anti-HAV) for acute hepatitis A\\n Hepatitis B surface antigen (HBsAg) for hepatitis B\\n Antibody to hepatitis C virus (anti-HCV) and HCV-RNA for hepatitis C\\n Antimitochondrial antibody for primary biliary cirrhosis\\n Serum ceruloplasmin (reduced) and urinary copper (elevated) for Wilson's disease\\n Serum \\n\\n1\\n-antitrypsin for \\n\\n1\\n-antitrypsin deficiency\\n \\n\\n-Fetoprotein for hepatocellular carcinoma\\nTests for Liver Injury\\nAminotransferases:\\n Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) leak from\\ndamaged cells; thus, these enzymes are sensitive indicators of liver injury. Markedly high values (> 500\\nIU/L; normal,  40 IU/L), which indicate acute hepatocellular necrosis or injury, usually result from the\\nfollowing:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n294\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 304, 'page_label': '295'}, page_content=' Acute viral hepatitis\\n Toxin- or drug-induced hepatitis\\n Ischemic hepatitis or hepatic infarction\\nHigh levels continue usually for days or, in viral hepatitis, for weeks. The degree of elevation may not\\nreflect the extent of liver injury. Serial measurements better reflect severity and prognosis than does a\\nsingle measurement. A fall to normal indicates recovery unless accompanied by an increase in bilirubin\\nand in PT or INR (which indicates fulminant liver failure). Fulminant liver failure results in fewer liver cells\\nthat can leak enzymes.\\nAminotransferase levels may also be markedly high in the following:\\n Acute exacerbation of autoimmune hepatitis\\n Reactivation of chronic hepatitis B\\n Acute Budd-Chiari syndrome\\n Acute fatty liver of pregnancy\\n Passage of a common duct stone\\nModest elevations (300 to 500 IU/L) persist in chronic liver disorders (eg, chronic hepatitis, alcoholic\\nhepatitis) and in biliary obstruction, except when passage of a common duct stone can transiently result\\nin markedly high levels, sometimes into the thousands.\\nMild increases (< 300 IU/L) are nonspecific and often present in disorders such as\\n[\\nTable 24-1.\\n Common Patterns of Laboratory Test Abnormalities]\\n \\nCirrhosis secondary to viral hepatitis\\n Nonalcoholic fatty liver disease (NAFLD)\\n Cholestatic liver disorders\\n Hepatocellular cancer\\nAminotransferases can be normal in certain liver disorders, such as\\n Hemochromatosis\\n Methotrexate- or amiodarone-induced liver injury\\n Chronic hepatitis C\\n NAFLD\\nElevated ALT is somewhat specific for liver injury. Because AST is present in the heart, skeletal muscle,\\nkidneys, and pancreas, elevated AST may reflect rhabdomyolysis or injury to one of these organs. In most\\nliver disorders, the ratio of AST to ALT is < 1. However, in alcohol-related liver disease, the ratio is\\ncharacteristically > 2 because pyridoxal-5-phosphate is deficient in alcoholic patients; it is required for\\nALT synthesis but is less essential for AST synthesis. This deficiency also explains why elevations of ALT\\nand AST are low (< 300 IU/L) in alcoholic patients.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n295'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 305, 'page_label': '296'}, page_content='Lactate dehydrogenase:\\n LDH, commonly included in routine analysis, is present in many other tissues\\nand is insensitive and nonspecific for hepatocellular injury. LDH is typically elevated in ischemic hepatitis\\nand cancers that extensively infiltrate the liver.\\nTests for Cholestasis\\nBilirubin:\\n Bilirubin, the pigment in bile, is produced from the breakdown of heme proteins, mostly from\\nthe heme moiety of hemoglobin in senescent RBCs. Unconjugated (free) bilirubin is insoluble in water\\nand thus cannot be excreted in urine; most unconjugated bilirubin is bound to albumin in plasma. Bilirubin\\nis conjugated in the liver with glucuronic acid to form the more water-soluble bilirubin diglucuronide.\\nConjugated bilirubin is then excreted through the biliary tract into the duodenum, where it is metabolized\\ninto urobilinogens (some of which are reabsorbed and resecreted into bile), then into orange-colored\\nurobilins (most of which are eliminated in feces). These bile pigments give stool its typical color.\\nHyperbilirubinemia results from one or more of the following:\\n Increased bilirubin production\\n Decreased liver uptake or conjugation\\n Decreased biliary excretion (see p. \\n212\\n)\\nNormally, total bilirubin is mostly unconjugated, with values of < 1.2 mg/dL (< 20 \\n\\nmol/L). Fractionation\\nmeasures the proportion of bilirubin that is conjugated (ie, direct, so-called because it is measured\\ndirectly, without the need for solvents). Fractionation is most helpful for evaluating neonatal jaundice and\\nfor evaluating elevated bilirubin when other liver test results are normal, suggesting that hepatobiliary\\ndysfunction is not the cause.\\nUnconjugated hyperbilirubinemia\\n (indirect bilirubin fraction > 85%) reflects increased bilirubin\\nproduction (eg, in hemolysis) or defective liver uptake or conjugation (eg, in Gilbert syndrome). Such\\nincreases in unconjugated bilirubin are usually < 5 times normal (to < 6 mg/dL [<100 \\n\\nmol/L]) unless there\\nis concurrent liver injury.\\nConjugated hyperbilirubinemia\\n (direct bilirubin fraction > 50%) results from decreased bile formation or\\nexcretion (cholestasis). When associated with other liver function test abnormalities, a high serum\\nbilirubin indicates hepatocellular dysfunction. Serum bilirubin is somewhat insensitive for liver dysfunction.\\nHowever, the development of severe hyperbilirubinemia in primary biliary cirrhosis, alcoholic hepatitis,\\nand acute liver failure suggests a poor prognosis.\\nBilirubinuria\\n reflects the presence of conjugated bilirubin in urine; bilirubin spills into urine because\\nblood levels are markedly elevated, indicating severe disease. Unconjugated bilirubin is water insoluble\\nand bound to albumin and so cannot be excreted in urine. Bilirubinuria can be detected at the bedside\\nwith commercial urine test strips in acute viral hepatitis or other hepatobiliary disorders, even before\\njaundice appears. However, the diagnostic accuracy of such urine tests is limited. Results can be falsely\\nnegative when the urine specimen has been stored a long time, vitamin C has been ingested, or urine\\ncontains nitrates (eg, due to UTIs). Similarly, increases in urobilinogen are neither specific nor sensitive.\\nAlkaline phosphatase:\\n Increased levels of this hepatocyte enzyme suggest cholestasis. Results may\\nnot be specific because alkaline phosphatase consists of several isoenzymes and has a widespread\\nextrahepatic distribution (eg, in the placenta, the small intestine, WBCs, kidneys, and particularly bone).\\nAlkaline phosphatase levels increase to  4 times normal 1 to 2 days after onset of biliary obstruction,\\nregardless of the site of obstruction. Levels may remain elevated for several days after the obstruction\\nresolves because \\nthe half-life of alkaline phosphatase is about 7 days. Increases of up to 3 times normal\\noccur in many liver disorders, including\\n Hepatitis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n296'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 306, 'page_label': '297'}, page_content=\" Cirrhosis\\n Space-occupying lesions (eg, carcinoma)\\n Infiltrative disorders (eg, amyloidosis, sarcoidosis, TB, metastases, abscesses)\\n Syphilitic hepatitis (alkaline phosphatase may be disproportionately elevated compared with the modest\\nchanges in other liver tests)\\nIsolated elevations (ie, when other liver test results are normal) may accompany\\n Focal liver lesions (eg, abscess, tumor)\\n Partial or intermittent bile duct obstruction (eg, stone, stricture, cholangiocarcinoma)\\n Syphilitic hepatitis\\n Occasionally, infiltrative disorders\\nIsolated elevations also occur in the absence of any apparent liver or biliary disorder, as in the following:\\n Some cancers without apparent liver involvement (eg, bronchogenic carcinoma, Hodgkin lymphoma,\\nrenal cell carcinoma)\\n After ingestion of fatty meals (because of an enzyme produced in the small intestine)\\n Pregnancy (because of an enzyme produced in the placenta)\\n Children and adolescents who are still growing (because of bone growth)\\n Chronic renal failure (because of an enzyme produced in the intestine and bone)\\nLevels of \\n\\n-glutamyl transpeptidase or 5-nucleotidase, which are more specific to the liver, can\\ndifferentiate hepatic from extrahepatic sources of alkaline phosphatase better than fractionation of\\nalkaline phosphatase, which is technically difficult. Also, in otherwise asymptomatic elderly people, an\\nincrease in alkaline phosphatase usually originates in bone (eg, in Paget's disease) and does not require\\nfurther investigation for liver injury.\\n5-Nucleotidase:\\n Increases in levels of this enzyme are as sensitive as alkaline phosphatase for\\ndetecting cholestasis and biliary obstruction but are more specific, almost always indicating hepatobiliary\\ndysfunction. Because levels of alkaline phosphatase and 5-nucleotidase do not always correlate, one\\ncan be normal while the other is increased.\\n\\n-Glutamyl transpeptidase (GGT):\\n Levels of this enzyme increase in hepatobiliary dysfunction,\\nespecially cholestasis, and correlate loosely with levels of alkaline phosphatase and 5-nucleotidase.\\nLevels do not increase because of bone lesions, during childhood, or during pregnancy. However, alcohol\\nand certain drugs (eg, some anticonvulsants, warfarin) can induce hepatic microsomal (cytochrome P-\\n450) enzymes, markedly increasing GGT and thus somewhat limiting its specificity.\\nTests of Hepatic Synthetic Capacity\\nPT and INR:\\n PT may be expressed in time (sec) or, preferably, as a ratio of the patient's measured PT to\\nthe laboratory's control value (INRsee p. \\n971\\n). The INR is more accurate than PT for monitoring\\nanticoagulation. PT or INR is a valuable measure of the liver's ability to synthesize fibrinogen and vitamin\\nK-dependent clotting factors: factors II (prothrombin), V, VII, and X. Changes can occur rapidly because\\nsome of the involved clotting factors have short biologic half-lives (eg, 6 h for factor VII). Abnormalities\\nindicate severe hepatocellular dysfunction, an ominous sign in acute liver disorders. In chronic liver\\ndisorders, an increasing PT or INR indicates progression to liver failure. The PT or INR does not increase\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n297\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 307, 'page_label': '298'}, page_content=\"in mild hepatocellular dysfunction and is often normal in cirrhosis.\\nA prolonged PT and an abnormal INR can result from coagulation disorders such as a consumptive\\ncoagulopathy or vitamin K deficiency. Fat malabsorption, including cholestasis, can cause vitamin K\\ndeficiency. In chronic cholestasis, marked hepatocellular dysfunction can be ruled out if vitamin K\\nreplacement (10 mg sc) corrects PT by  30% within 24 h.\\nSerum proteins:\\n Hepatocytes synthesize most serum proteins, including \\n\\n- and \\n\\n-globulins, albumin,\\nand most clotting factors (but not factor VIII, produced by the vascular endothelium, or \\n\\n-globulin,\\nproduced by B cells). Hepatocytes also make proteins that aid in the diagnosis of specific disorders:\\n \\n\\n1\\n-Antitrypsin (absent in \\n\\n1\\n-antitrypsin deficiency)\\n Ceruloplasmin (reduced in Wilson's disease)\\n Transferrin (saturated with iron in hemochromatosis)\\n Ferritin (greatly increased in hemochromatosis)\\nThese proteins usually increase in response to damage (eg, inflammation) to various tissues, so that\\nelevations may not specifically reflect liver disorders.\\nSerum albumin\\n commonly decreases in chronic liver disorders because of an increase in volume of\\ndistribution (eg, due to ascites), a decrease in hepatic synthesis, or both. Values \\n< 3 g/dL (< 30 g/L)\\nsuggest decreased synthesis, caused by one of the following:\\n Advanced cirrhosis (the most common cause)\\n Alcoholism\\n Chronic inflammation\\n Protein undernutrition\\nHypoalbuminemia can also result from excessive loss of albumin from the kidneys (ie, nephrotic\\nsyndrome), gut (eg, due to proteinlosing gastroenteropathies), or skin (eg, due to burns or exfoliative\\ndermatitis).\\nBecause albumin has a half-life of about 20 days, serum levels take weeks to increase or decrease.\\nOther Laboratory Tests\\nAmmonia:\\n Nitrogen compounds that enter the colon (eg, ingested protein, secreted urea) are degraded\\nby resident bacteria, liberating ammonia. The ammonia is then absorbed and transported via the portal\\nvein to the liver. The healthy liver readily clears the ammonia from the portal vein and converts it to\\nglutamine, which is metabolized by the kidneys into urea to be excreted. In patients with portal-systemic\\nshunting, the diseased liver does not clear ammonia, which then enters the systemic circulation, possibly\\ncontributing to portal-systemic (hepatic) encephalopathy. Elevated ammonia levels occur in hepatic\\nencephalopathy, but levels may be falsely low or high. In advanced liver disorders, the following may\\nincrease ammonia levels:\\n High-protein meals\\n GI bleeding\\n Hypokalemia\\n Metabolic alkalosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n298\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 308, 'page_label': '299'}, page_content=\" Certain drugs (eg, alcohol, barbiturates, diuretics, opioids, valproate)\\n High-dose chemotherapy\\n Parenteral nutrition\\n Renal insufficiency\\n Extreme muscle exertion and muscle wasting\\n Salicylate intoxication\\n Shock\\n Ureterosigmoidostomy\\nUTI with a urease-producing organism (eg, \\nProteus mirabilis\\n)\\nBecause the degree of elevation in the ammonia level correlates poorly with severity of hepatic\\nencephalopathy, this level has limited usefulness in monitoring therapy.\\nSerum immunoglobulins:\\n In chronic liver disorders, serum immunoglobulins often increase. However,\\nelevations are not specific and are usually not helpful clinically. Levels increase slightly in acute hepatitis,\\nmoderately in chronic active hepatitis, and markedly in autoimmune hepatitis. The pattern of\\nimmunoglobulin elevation adds little information, although different immunoglobulins are usually very high\\nin different disorders:\\n IgM in primary biliary cirrhosis\\n IgA in alcoholic liver disease\\n IgG in autoimmune hepatitis\\nAntimitochondrial antibodies:\\n These heterogeneous antibodies are positive, usually in high titers, in >\\n95% of patients with primary biliary cirrhosis. They are also occasionally present in the following:\\n Autoimmune hepatitis\\n Drug-induced hepatitis\\n Other autoimmune disorders, such as connective tissue disorders, myasthenia gravis, autoimmune\\nthyroiditis, Addison's disease, and autoimmune hemolytic anemia\\nAntimitochondrial antibodies can help determine the cause of cholestasis because they are usually\\nabsent in extrahepatic biliary obstruction and primary sclerosing cholangitis.\\nOther antibodies:\\n Other antibodies may help in diagnosis of the following:\\n Autoimmune hepatitis: Smooth muscle antibodies against actin, antinuclear antibodies (ANA) that\\nprovide a homogeneous (diffuse) fluorescence, and antibodies to liver-kidney microsome type 1 (anti-\\nLKM1) are often present.\\n Primary biliary cirrhosis: Antimitochondrial antibody is key to the diagnosis.\\n Primary sclerosing cholangitis: Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) can help\\nraise the index of suspicion.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n299\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 309, 'page_label': '300'}, page_content='Isolated abnormalities of any of these antibodies are never diagnostic and do not elucidate pathogenesis.\\n\\n-Fetoprotein (AFP):\\n AFP, a glycoprotein normally synthesized by the yolk sac in the embryo and then\\nby the fetal liver, is elevated in neonates and hence the pregnant mother. AFP decreases rapidly during\\nthe first year of life, reaching adult values (normally, < 10 to 20 ng/mL or < 10 to 20 mg/L depending on\\nthe laboratory) by the age of 1 yr. An increase in AFP, no matter how small, should prompt consideration\\nof primary hepatocellular carcinoma (HCC). Serum AFP generally correlates with tumor size,\\ndifferentiation and metastatic involvement. Because small tumors may produce low levels of AFP,\\nincreasing values suggest the presence of HCC, especially when tumors are > 3 cm diameter. AFP also\\nhelps predict prognosis.\\nMild AFP elevations also occur in acute and chronic hepatitis, probably reflecting liver regeneration; AFP\\ncan occasionally increase to 500 ng/mL in fulminant hepatitis. High AFP levels can occur in a few other\\ndisorders (eg, embryonic teratocarcinomas, hepatoblastomas in children, some hepatic metastases from\\nGI tract cancers, some cholangiocarcinomas), but these circumstances are not common and usually can\\nbe differentiated based on clinical and histopathologic grounds.\\nSensitivity, specificity, and peak levels of AFP in patients with HCC vary by population, reflecting\\ndifferences in factors such as hepatitis prevalence and ethnicity. In areas with a relatively low prevalence\\nof hepatitis (eg, North America and western Europe), AFP cutoff values of 20 ng/mL have a sensitivity of\\n39 to 64% and a specificity of 76 to 91%. However, not all HCCs produce AFP. Thus, AFP is not an ideal\\nscreening test but does have a role in detecting HCC. Levels exceeding normal (> 20 ng/mL), especially\\nwhen increasing, strongly suggest HCC. In cirrhotic patients with a mass and a high value (eg, > 200\\nng/mL), the predictive value is high. The combined use of AFP and ultrasonography currently provides\\nthe best surveillance.\\nImaging Tests\\nImaging is essential for accurately diagnosing biliary tract disorders and is important for detecting focal\\nliver lesions (eg, abscess, tumor). It is limited in detecting and diagnosing diffuse hepatocellular disease\\n(eg, hepatitis, cirrhosis).\\nUltrasonography:\\n Ultrasonography, traditionally done transabdominally and requiring a period of fasting,\\nprovides structural, but not functional, information. It is the least expensive, safest, and most sensitive\\ntechnique for imaging the biliary system, especially the gallbladder. Ultrasonography is the procedure of\\nchoice for\\n Screening for biliary tract abnormalities\\n Evaluating the hepatobiliary tract in patients with right upper quadrant abdominal pain\\n Differentiating intrahepatic from extrahepatic causes of jaundice\\n Detecting liver masses\\nThe kidneys, pancreas, and blood vessels are also often visible on hepatobiliary ultrasounds.\\nUltrasonography can measure spleen size and thus help diagnose splenomegaly, which suggests portal\\nhypertension.\\nUse of endoscopic ultrasonography may further refine the approaches to hepatobiliary abnormalities.\\nUltrasonography can be difficult in patients with intestinal gas or obesity and is operator-dependent.\\nEndoscopic ultrasonography incorporates an ultrasound transducer into the tip of an endoscope and thus\\nprovides greater image resolution even when intestinal gas is present.\\nGallstones\\n cast intense echoes with distal acoustic shadowing that move with gravity. Transabdominal\\nultrasonography is extremely accurate (sensitivity > 95%) for gallstones > 2 mm in diameter. Endoscopic\\nultrasonography can detect stones as small as 0.5 mm (microlithiasis) in the gallbladder or biliary system.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n300'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 310, 'page_label': '301'}, page_content=\"Transabdominal and endoscopic ultrasonography can also identify biliary sludge (a mixture of particulate\\nmaterial and bile) as low-level echoes that layer in the dependent portion of the gallbladder without\\nacoustic shadowing.\\nCholecystitis\\n typically causes\\n A thickened gallbladder wall (> 3 mm)\\n Pericholecystic fluid\\n An impacted stone in the gallbladder neck\\n Tenderness on palpation of the gallbladder with the ultrasound probe (ultrasonographic Murphy's sign)\\nExtrahepatic obstruction\\n is indicated by dilated bile ducts. On transabdominal and endoscopic\\nultrasounds, bile ducts stand out as echo-free tubular structures. The diameter of the common duct is\\nnormally < 6 mm, increases slightly with age, and can reach 10 mm after cholecystectomy. Dilated ducts\\nare virtually pathognomonic for extrahepatic obstruction in the appropriate clinical setting.\\nUltrasonography can miss early or intermittent obstruction that does not dilate the ducts. Transabdominal\\nultrasonography may not reveal the level or cause of biliary obstruction (eg, sensitivity for common duct\\nstones is < 40%). Endoscopic ultrasonography has a better yield.\\nFocal liver lesions\\n > 1 cm in diameter can usually be detected by transabdominal ultrasonography. In\\ngeneral, cysts are echo-free; solid lesions (eg, tumors, abscesses) tend to be echogenic. Carcinoma\\nappears as a nonspecific solid mass. Ultrasonography has been used to screen for hepatocellular\\ncarcinoma in patients at high risk (eg, with chronic hepatitis B, cirrhosis, or hemochromatosis). Because\\nultrasonography can localize focal lesions, it can be used to guide aspiration and biopsy.\\nDiffuse disorders\\n (eg, cirrhosis, sometimes fatty liver) can be detected with ultrasonography. Ultrasound\\nelastography can measure liver stiffness as an index of hepatic fibrosis. In this procedure, the transducer\\nemits a vibration that induces an elastic shear wave. The rate at which the wave is propagated through\\nthe liver is measured; liver stiffness speeds this propagation.\\nDoppler ultrasonography:\\n This noninvasive method is used to assess direction of blood flow and\\npatency of blood vessels around the liver, particularly the portal vein. Clinical uses include\\n Detecting portal hypertension, (eg, indicated by significant collateral flow and the direction of flow)\\n Assessing the patency of liver shunts (eg, surgical portocaval, percutaneous transhepatic)\\n Evaluating portal vein patency before liver transplantation and detecting hepatic artery thrombosis after\\ntransplantation\\n Detecting unusual vascular structures (eg, cavernous transformation of the portal vein)\\n Assessing tumor vascularity before surgery\\nCT:\\n CT is commonly used to identify hepatic masses, particularly small metastases, with an accuracy of\\nabout 80%. It is considered the most accurate imaging technique. CT with IV contrast is accurate for\\ndiagnosing cavernous hemangiomas of the liver as well as differentiating them from other abdominal\\nmasses. Neither obesity nor intestinal gas obscures CT images. CT can detect fatty liver and the\\nincreased hepatic density that occurs with iron overload. CT is less helpful than ultrasonography in\\nidentifying biliary obstruction but often provides the best assessment of the pancreas.\\nCholescintigraphy:\\n After patients fast, an IV technetium-labeled iminodiacetic compound (eg, hydroxy or\\ndiisopropyl iminodiacetic acid [HIDA or DISIDA]) is injected; these substances are taken up by the liver\\nand excreted in bile, then enter the gallbladder.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n301\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 311, 'page_label': '302'}, page_content='In acute calculous cholecystitis, which is usually caused by impaction of a stone in the cystic duct, the\\ngallbladder does not appear on a scintigraphic scan because the radionuclide cannot enter the\\ngallbladder. Such nonvisualization is diagnostically quite accurate (except for false-positive results in\\nsome critically ill patients). However, cholescintigraphy is rarely needed clinically to diagnose acute\\ncholecystitis.\\nIf acalculous cholecystitis is suspected, the gallbladder is scanned before and after administration of\\ncholecystokinin (used to initiate gallbladder contraction). The decrease in scintigraphic counts indicates\\nthe gallbladder ejection fraction. Reduced emptying, measured as the ejection fraction, suggests\\nacalculous cholecystitis.\\nCholescintigraphy also detects bile leaks (eg, after surgery or trauma) and anatomic abnormalities (eg,\\ncongenital choledochal cysts, choledochoenteric anastomoses). After cholecystectomy, cholescintigraphy\\ncan quantitate biliary drainage; biliary drainage helps identify sphincter of Oddi dysfunction.\\nRadionuclide liver scanning:\\n Ultrasonography and CT have largely supplanted radionuclide scanning,\\nwhich had been used to diagnose diffuse liver disorders and mass lesions of the liver. Radionuclide\\nscanning shows the distribution of an injected radioactive tracer, usually technetium (\\n99m\\nTc sulfur\\ncolloid), which distributes uniformly within the normal liver. Space-occupying lesions > 4 cm, such as liver\\ncysts, abscesses, metastases, and tumors, appear as defects. Diffuse liver disorders (eg, cirrhosis,\\nhepatitis) decrease liver uptake of the tracer, with more appearing in the spleen and bone marrow. In\\nhepatic vein obstruction (Budd-Chiari syndrome), liver uptake is decreased except in the caudate lobe\\nbecause its drainage into the inferior vena cava is preserved.\\nPlain x-ray of the abdomen:\\n Plain x-rays are not usually useful for diagnosis of hepatobiliary disorders.\\nThey are insensitive for gallstones unless the gallstones are calcified and large. Plain x-rays can detect a\\ncalcified (porcelain) gallbladder. Rarely, in gravely ill patients, x-rays show air in the biliary tree, which\\nsuggests emphysematous cholangitis.\\nMRI:\\n MRI images blood vessels (without using contrast), ducts, and hepatic tissues. Its clinical uses are\\nstill evolving. MRI is superior to CT and ultrasonography for diagnosing diffuse liver disorders (eg, fatty\\nliver, hemochromatosis) and for clarifying some focal defects (eg, hemangiomas). MRI also shows blood\\nflow and therefore complements Doppler ultrasonography and CT angiography in the diagnosis of\\nvascular abnormalities and in vascular mapping before liver transplantation.\\nMagnetic resonance cholangiopancreatography (MRCP) is more sensitive than CT or ultrasonography in\\ndiagnosing common bile duct abnormalities, particularly stones. Its images of the biliary system and\\npancreatic ducts are comparable to those obtained with ERCP and percutaneous transhepatic\\ncholangiography, which are more invasive. Thus, \\nMRCP is a useful screening tool when biliary\\nobstruction is suspected and before therapeutic ERCP (eg, for simultaneous imaging and stone removal)\\nis done.\\nERCP:\\n ERCP combines endoscopy through the second portion of the duodenum with contrast imaging of\\nthe biliary and pancreatic ducts. The papilla of Vater is cannulated through an endoscope placed in the\\ndescending duodenum, and the pancreatic and biliary ducts are then injected with a contrast agent.\\nERCP provides detailed images of much of the upper GI tract and the periampullary area, biliary tract,\\nand pancreas. ERCP can also be used to obtain tissue for biopsy. ERCP is the best test for diagnosis of\\nampullary cancers. ERCP is as accurate as endoscopic ultrasonography for diagnosis of common duct\\nstones. Because it is invasive, ERCP is used more for treatment (including simultaneous diagnosis and\\ntreatment) than for diagnosis alone. ERCP is the procedure of choice for treating biliary and pancreatic\\nobstructing lesions, as for\\n Removal of bile duct stones\\n Stenting of strictures (inflammatory or malignant)\\n Sphincterotomy (eg, for sphincter of Oddi dysfunction)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n302'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 312, 'page_label': '303'}, page_content=\"Morbidity from a diagnostic ERCP with only injection of contrast material is about 1%. Adding\\nsphincterotomy raises morbidity to 4 to 9% (mainly due to pancreatitis and bleeding). ERCP with\\nmanometry to measure sphincter of Oddi pressure causes pancreatitis in up to 25% of patients.\\nPercutaneous transhepatic cholangiography (PTC):\\n With fluoroscopic or ultrasound guidance, the\\nliver is punctured with a needle, the peripheral intrahepatic bile duct system is cannulated above the\\ncommon hepatic duct, and a contrast agent is injected.\\nPTC is highly accurate in diagnosing biliary disorders and can be therapeutic (eg, decompression of the\\nbiliary system, insertion of an endoprosthesis). However, ERCP is usually preferred because PTC causes\\nmore complications (eg, sepsis, bleeding, bile leaks).\\nOperative cholangiography:\\n A contrast agent is directly injected during laparotomy to image the bile\\nduct system.\\nOperative cholangiography is indicated when jaundice occurs and noninvasive procedures are equivocal,\\nsuggesting common duct stones. The procedure can be followed by common duct exploration for removal\\nof biliary stones. Technical difficulties have limited its use, particularly during laparoscopic\\ncholecystectomy.\\nLiver Biopsy\\nLiver biopsy provides histologic information about liver structure and evidence of liver injury (type and\\ndegree, any fibrosis); this information can be essential not only to diagnosis but also to staging,\\nprognosis, and management. Although only a small core of tissue is obtained, it is usually representative,\\neven for focal lesions.\\nLiver biopsy is usually done percutaneously at the bedside or with ultrasound guidance. Ultrasound\\nguidance is preferred because its complication rate is slightly lower and it provides opportunity to\\nvisualize the liver and target focal lesions.\\nIndications:\\n Generally, biopsy is indicated for suspected liver abnormalities that are not identified by less\\ninvasive methods or that require histopathology for staging (see\\nTable 24-2\\n). Biopsy is especially valuable\\n[\\nTable 24-2.\\n Indications for Liver Biopsy*]\\nfor detecting TB or other granulomatous infiltrations and for clarifying graft problems (ischemic injury,\\nrejection, biliary tract disorders, viral hepatitis) after liver transplantation. Serial biopsies, commonly done\\nover years, may be necessary to monitor disease progression.\\nGross examination and histopathology are often definitive. Cytology (fine-needle aspiration), frozen\\nsection, and culture may be useful for selected patients. Metal content (eg, copper in suspected Wilson's\\ndisease, iron in hemochromatosis) can be measured in the biopsy specimen.\\nLimitations of liver biopsy include\\n Sampling error\\n Occasional errors or uncertainty in cases of cholestasis\\n Need for a skilled histopathologist (some pathologists have little experience with needle specimens)\\nContraindications:\\n Absolute contraindications to liver biopsy include\\n Patient's inability to remain still and to maintain brief expiration for the procedure\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n303\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 313, 'page_label': '304'}, page_content=' Suspected vascular lesion (eg, hemangioma)\\n Bleeding tendency (eg, INR > 1.2 despite receiving vitamin K, bleeding time > 10 min)\\n Severe thrombocytopenia (< 50,000/mL)\\nRelative contraindications include profound anemia, peritonitis, marked ascites, high-grade biliary\\nobstruction, and a subphrenic or right pleural infection or effusion. Nonetheless, percutaneous liver\\nbiopsy is sufficiently safe to be done on an outpatient basis. Mortality is 0.01%. Major complications (eg,\\nintra-abdominal hemorrhage, bile peritonitis, lacerated liver) develop in about 2% of patients.\\nComplications usually become evident within 3 to 4 hthe recommended period for monitoring patients.\\nOther routes:\\n Transjugular venous biopsy of the liver is more invasive than the percutaneous route; it is\\nreserved for patients with a severe coagulopathy. The procedure involves cannulating the right internal\\njugular vein and passing a catheter through the inferior vena cava into the hepatic vein. A fine needle is\\nthen advanced through the hepatic vein into the liver. Biopsy is successful in > 95% of patients.\\nComplication rate is low; 0.2% bleed from puncture of the liver capsule.\\nOccasionally, liver biopsy is done during surgery (eg, laparoscopy); a larger, more targeted tissue sample\\ncan then be obtained.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 24. Testing for Hepatic & Biliary Disorders\\n304'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 314, 'page_label': '305'}, page_content='Chapter 25. Drugs and the Liver\\nIntroduction\\nInteraction between drugs and the liver can be categorized as follows:\\n Effects of liver disease on drug metabolism\\n Liver injury caused by drugs\\n Effects of hepatic drug metabolism (eg, induction of hepatic enzymes, see p. \\n3177\\n)\\nThe number of possible interactions is vast.\\nEffects of Liver Disease on Drug Metabolism\\nLiver disease may have complex effects on drug clearance, biotransformation, and pharmacokinetics.\\nPathogenetic factors include alterations in intestinal absorption, plasma protein binding, hepatic extraction\\nratio, liver blood flow, portal-systemic shunting, biliary excretion, enterohepatic circulation, and renal\\nclearance. Sometimes alterations increase levels of bioavailable drug, causing normal drug doses to have\\ntoxic effects. However, levels and effects for an individual drug are unpredictable and do not correlate\\nwell with the type of liver injury, its severity, or liver function test results. Thus, no general rules are\\navailable for modifying drug dosage in patients with liver disease.\\nClinical effects can vary independent of drug bioavailability, especially in chronic liver disease; eg,\\ncerebral sensitivity to opioids and sedatives is often enhanced in patients with chronic liver disease.\\nThus, seemingly small doses of these drugs given to cirrhotic patients may precipitate encephalopathy.\\nThe mechanism of this effect probably involves alterations in cerebral drug receptors.\\nAdverse drug reactions do not appear to be more likely in patients with advanced liver disease; however,\\nsuch patients may tolerate any hepatic adverse effects of drugs less well.\\nLiver Injury Caused by Drugs\\nMany drugs (eg, statins) commonly cause asymptomatic elevation of hepatic enzymes (ALT, AST, alkaline\\nphosphatase). However, clinically significant liver injury (eg, with jaundice, abdominal pain, or pruritus) or\\nimpaired liver functionie, resulting in deficient protein synthesis (eg, with prolonged PT or with\\nhypoalbuminemia)is rare.\\nThe term drug-induced liver injury (DILI) may be used to mean clinically significant liver injury or all\\n(including asymptomatic) liver injury. DILI includes injury caused by medicinal herbs, plants, and nutritional\\nsupplements as well as drugs.\\nPathophysiology\\nThe pathophysiology of DILI varies depending on the drug (or other hepatotoxin) and, in many cases, is\\nnot entirely understood. Drug-induced injury mechanisms include covalent binding of the drug to cellular\\nproteins resulting in immune injury, inhibition of cell metabolic pathways, blockage of cellular transport\\npumps, induction of apoptosis, and interference with mitochondrial function.\\nIn general, the following are thought to increase risk of DILI:\\n Age  18 yr\\n Obesity\\n Pregnancy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 25. Drugs & the Liver\\n305'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 315, 'page_label': '306'}, page_content=\" Concomitant alcohol consumption\\n Genetic polymorphisms (increasingly recognized)\\nPatterns of liver injury:\\n DILI can be predictable (when injury usually occurs shortly after exposure and\\nis dose-related) or unpredictable (when injury develops after a period of latency and has no relation to\\ndose). Predictable DILI (commonly, acetaminophen-induced) is a common cause of acute jaundice and\\nacute liver failure in the US. Unpredictable DILI is a rare cause of severe liver disease. Subclinical DILI\\nmay be underreported.\\nBiochemically, 3 types of liver injury are generally noted (see\\nTable 25-1\\n):\\n \\nHepatocellular:\\n Hepatocellular hepatotoxicity generally manifests as malaise and\\n[\\nTable 25-1.\\n Potentially Hepatotoxic Drugs]\\n   \\nright upper quadrant abdominal pain, associated with marked elevation in aminotransferase levels (ALT,\\nAST, or both), which may be followed by hyperbilirubinemia in severe cases. Hyperbilirubinemia in this\\nsetting is known as hepatocellular jaundice and, according to Hy's law, is associated with mortality rates\\nas high as 50%. If hepatocellular liver injury is accompanied by jaundice, impaired hepatic synthesis,\\nand encephalopathy, chance of spontaneous recovery is low, and liver transplantation should be\\nconsidered. This type of injury can result from drugs such as acetaminophen and isoniazid.\\n \\nCholestatic:\\n Cholestatic hepatotoxicity is characterized by development of pruritus and jaundice\\naccompanied by marked elevation of serum alkaline phosphatase levels. Usually, this type of injury is\\nless serious than severe hepatocellular syndromes, but recovery may be protracted. Substances known\\nto lead to this type of injury include amoxicillin/clavulanate and chlorpromazine. Rarely, cholestatic\\nhepatotoxicity leads to chronic liver disease and vanishing bile duct syndrome (progressive destruction\\nof intrahepatic bile ducts).\\n \\nMixed:\\n In these clinical syndromes, neither aminotransferase nor alkaline phosphatase elevations are\\nclearly predominant. Symptoms may also be mixed. Drugs such as phenytoin can cause this type of\\ninjury.\\nDiagnosis\\n Identification of characteristic patterns of laboratory abnormalities\\n Exclusion of other causes\\nPresentation varies widely, ranging from absent or nonspecific symptoms (eg, malaise, nausea, anorexia)\\nto jaundice, impaired hepatic synthesis, and encephalopathy. Early recognition of DILI improves\\nprognosis.\\nIdentification of a potential hepatotoxin and a pattern of liver test abnormalities that is characteristic of the\\nsubstance (its signature) make the diagnosis likely.\\nBecause there is no confirmatory diagnostic test, other causes of liver disease, especially viral, biliary,\\nalcoholic, autoimmune, and metabolic causes, need to be excluded. Drug rechallenge, although it can\\nstrengthen evidence for the diagnosis, should usually be avoided. Suspected cases of DILI should be\\nreported to MedWatch (the FDA's adverse drug reaction monitoring program).\\nTreatment\\n Early drug withdrawal\\nManagement emphasizes drug withdrawal, which, if done early, usually results in recovery. In severe\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 25. Drugs & the Liver\\n306\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 316, 'page_label': '307'}, page_content='cases, consultation with a specialist is indicated, especially if patients have hepatocellular jaundice and\\nimpaired liver function, because liver transplantation may be required. Antidotes for DILI are available for\\nonly a few hepatotoxins; such antidotes include \\nN\\n-acetylcysteine for acetaminophen toxicity and silymarin\\nor penicillin for \\nAmanita phalloides\\n toxicity.\\nPrevention\\nEfforts to avoid DILI begin during the drug development process, although apparent safety in small\\npreclinical trials does not ensure eventual safety of the drug after it is in widespread use. Postmarketing\\nsurveillance, although often voluntary in the US, can call attention to potentially hepatotoxic drugs.\\nRoutine monitoring of liver enzymes has not been shown to decrease the incidence of hepatotoxicity. Use\\nof pharmacogenomics may allow tailoring of drug use and avoidance of potential toxicities in susceptible\\npatients.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 25. Drugs & the Liver\\n307'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 317, 'page_label': '308'}, page_content='Chapter 26. Alcoholic Liver Disease\\nAlcohol consumption is high in most Western countries. In the US, > 10% of people abuse or are\\ndependent on alcohol. The male:female ratio is about 2:1. Disorders that occur in alcohol abusers, often\\nin sequence, include\\n Fatty liver (in > 90%)\\n Alcoholic hepatitis (in 10 to 35%)\\n Cirrhosis (in 10 to 20%)\\nHepatocellular carcinoma may also develop, especially in association with iron accumulation.\\nRisk Factors\\nThe main causative factors in alcoholic liver disease are\\n Quantity and duration of alcohol use (usually > 8 yr)\\n Sex\\n Genetic and metabolic traits\\n Nutritional status\\nQuantity of alcohol:\\n Among susceptible people, a linear correlation generally exists between the amount\\nand duration of alcohol use and the development of liver disease.\\nAlcohol content is estimated to be the beverage volume (in mL) multiplied by its percentage of alcohol.\\nFor example, the alcohol content of 40 mL of an 80-proof (40% alcohol) beverage is 16 mL by volume.\\nEach mL contains about 0.79 g of alcohol. Although values can vary, the percentage of alcohol averages\\n2 to 7% for most beers and 10 to 15% for most wines. Thus, a 12-oz glass of beer contains about 3 to 10\\ng of alcohol, and an 8-oz glass of wine contains about 10 to 15 g.\\nRisk increases markedly for men who drink > 40 g, particularly > 80 g, of alcohol/day for > 10 yr (eg, 3 to\\n6 cans of beer, 3 to 6 shots of hard liquor, 4 to 8 glasses of wine). For cirrhosis to develop, consumption\\nmust usually be > 80 g/day for > 10 yr. If consumption exceeds 230 g/day for 20 yr, risk of cirrhosis is\\nabout 50%. But only some chronic alcohol abusers develop liver disease. Thus, variations in alcohol\\nintake do not fully explain variations in susceptibility, indicating that other factors are involved.\\nSex:\\n Women are more susceptible to alcoholic liver disease, even after adjustment for body size. Women\\nrequire only 20 to 40 g of alcohol to be at riskhalf of that for men. Risk in women may be increased\\nbecause they have less alcohol dehydrogenase in their gastric mucosa; thus, first-pass oxidation of\\nalcohol is decreased.\\nGenetic factors:\\n Alcoholic liver disease often runs in families, suggesting genetic factors (eg, deficiency\\nof cytoplasmic enzymes that eliminate alcohol).\\nNutritional status:\\n Undernutrition, particularly protein-energy undernutrition, increases susceptibility, as\\ndoes a diet high in unsaturated fat and obesity.\\nOther factors:\\n Other risk factors include iron accumulation in the liver (not necessarily related to iron\\nintake) and concomitant hepatitis C.\\nPathophysiology\\nAlcohol absorption and metabolism:\\n Alcohol (ethanol) is readily absorbed from the stomach, but most\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 26. Alcoholic Liver Disease\\n308'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 318, 'page_label': '309'}, page_content='is absorbed from the small intestine. Alcohol cannot be stored. A small amount is degraded in transit\\nthrough the gastric mucosa, but most is catabolized in the liver, primarily by alcohol dehydrogenase (ADH)\\nbut also by cytochrome P-450 2E1 (CYP2E1) and the microsomal enzyme oxidation system (MEOS).\\nMetabolism via the ADH pathway involves the following:\\n ADH, a cytoplasmic enzyme, oxidizes alcohol into acetaldehyde. Genetic polymorphisms in ADH account\\nfor some individual differences in blood alcohol levels after the same alcohol intake but not in\\nsusceptibility to alcoholic liver disease.\\n Acetaldehyde dehydrogenase (ALDH), a mitochondrial enzyme, then oxidizes acetaldehyde to acetate.\\nChronic alcohol consumption enhances acetate formation. Asians, who have lower levels of ALDH, are\\nmore susceptible to toxic acetaldehyde effects (eg, flushing); the effects are similar to those of\\ndisulfiram, which inhibits ALDH.\\n These oxidative reactions generate hydrogen, which converts nicotinamide-adenine dinucleotide (NAD)\\nto its reduced form (NADH), increasing the redox potential (NADH/NAD) in the liver.\\n The increased redox potential inhibits fatty acid oxidation and gluconeogenesis, promoting fat\\naccumulation in the liver.\\nChronic alcoholism induces the MEOS (mainly in endoplasmic reticulum), increasing \\nits activity. The main\\nenzyme involved is CYP2E1. When induced, the MEOS pathway can account for 20% of alcohol\\nmetabolism. This pathway generates harmful reactive O\\n2\\n species, increasing oxidative stress and\\nformation of O\\n2\\n-free radicals.\\nHepatic fat accumulation:\\n Fat (triglycerides) accumulates throughout the hepatocytes for the following\\nreasons:\\n Export of fat from the liver is decreased because hepatic fatty acid oxidation and lipoprotein production\\ndecrease.\\n Input of fat is increased because the decrease in hepatic fat export increases peripheral lipolysis and\\ntriglyceride synthesis, resulting in hyperlipidemia.\\nHepatic fat accumulation may predispose to subsequent oxidative damage.\\nEndotoxins in the gut:\\n Alcohol changes gut permeability, increasing absorption of endotoxins released\\nby bacteria in the gut. In response to the endotoxins (which the impaired liver can no longer detoxify), liver\\nmacrophages (Kupffer cells) release free radicals, increasing oxidative damage.\\nOxidative damage:\\n Oxidative stress is increased by\\n Liver hypermetabolism, caused by alcohol consumption\\n Free radical-induced lipid peroxidative damage\\n Reduction in protective antioxidants (eg, glutathione, vitamins A and E), caused by alcohol-related\\nundernutrition\\n Binding of alcohol oxidation products, such as acetaldehyde, to liver cell proteins, forming neoantigens\\nand resulting in inflammation\\n Accumulation of neutrophils and other WBCs, which are attracted by lipid peroxidative damage and\\nneoantigens\\n Inflammatory cytokines secreted by WBCs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 26. Alcoholic Liver Disease\\n309'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 319, 'page_label': '310'}, page_content=\"Accumulation of hepatic iron, if present, aggravates oxidative damage. Iron can accumulate in alcoholic\\nliver disease through ingestion of iron-containing fortified wines; most often, the iron accumulation is\\nmodest. This condition must be differentiated from hereditary hemochromatosis.\\nResultant inflammation, cell death, and fibrosis:\\n A vicious circle of worsening inflammation occurs:\\nCell necrosis and apoptosis result in hepatocyte loss, and subsequent attempts at regeneration result in\\nfibrosis. Stellate (Ito) cells, which line blood channels (sinusoids) in the liver, proliferate and transform into\\nmyofibroblasts, producing an excess of type I collagen and extracellular matrix. As a result, the sinusoids\\nnarrow, limiting blood flow. Fibrosis narrows the terminal hepatic venules, compromising hepatic perfusion\\nand thus contributing to portal hypertension. Extensive fibrosis is associated with an attempt at\\nregeneration, resulting in liver nodules. This process culminates in cirrhosis.\\nPathology\\nFatty liver, alcoholic hepatitis, and cirrhosis are often considered separate, progressive manifestations of\\nalcoholic liver disease. However, their features often overlap.\\nFatty liver\\n (steatosis) is the initial and most common consequence of excessive alcohol consumption.\\nFatty liver is potentially reversible. Macrovesicular fat accumulates as large droplets of triglyceride and\\ndisplaces the hepatocyte nucleus, most markedly in perivenular hepatocytes. The liver enlarges.\\nAlcoholic hepatitis\\n (steatohepatitis) is a combination of fatty liver, diffuse liver inflammation, and liver\\nnecrosis (often focal)all in various degrees of severity. The damaged hepatocytes are swollen with a\\ngranular cytoplasm (balloon degeneration) or contain fibrillar protein in the cytoplasm (Mallory or alcoholic\\nhyaline bodies). Severely damaged hepatocytes become necrotic. Sinusoids and terminal hepatic venules\\nare narrowed. Cirrhosis may also be present.\\nAlcoholic cirrhosis\\n is advanced liver disease characterized by extensive fibrosis that disrupts the normal\\nliver architecture. The amount of fat present varies. Alcoholic hepatitis may coexist. The feeble\\ncompensatory attempt at hepatic regeneration produces relatively small nodules (micronodular cirrhosis).\\nAs a result, the liver usually shrinks. In time, even with abstinence, fibrosis forms broad bands, separating\\nliver tissue into large nodules (macronodular cirrhosissee p. \\n241\\n).\\nSymptoms and Signs\\nSymptoms usually become apparent in patients during their 30s or 40s; severe problems appear about a\\ndecade later.\\nFatty liver\\n is often asymptomatic. In one third of patients, the liver is enlarged and smooth, but it is not\\nusually tender.\\nAlcoholic hepatitis\\n ranges from mild and reversible to life threatening. Most patients with moderate\\ndisease are undernourished and present with fatigue, fever, jaundice, right upper quadrant pain, tender\\nhepatomegaly, and sometimes a hepatic bruit. About 40% deteriorate soon after hospitalization, with\\nconsequences ranging from mild (eg, increasing \\njaundice) to severe (eg, ascites, portal-systemic\\nencephalopathy, variceal bleeding, liver failure with hypoglycemia, coagulopathy). Other manifestations of\\ncirrhosis may be present.\\nCirrhosis,\\n if compensated, may be asymptomatic. The liver is usually small; when the liver is enlarged,\\nfatty liver or hepatoma should be considered. Symptoms range from those of alcoholic hepatitis to the\\ncomplications of end-stage liver disease, such as portal hypertension (often with esophageal varices and\\nupper GI bleeding, splenomegaly, ascites, and portal-systemic encephalopathy). Portal hypertension may\\nlead to intrapulmonary arteriovenous shunting with hypoxemia (hepatopulmonary syndrome), which may\\ncause cyanosis and nail clubbing. Acute renal failure secondary to progressively decreasing renal blood\\nflow (hepatorenal syndrome) may develop. Hepatocellular carcinoma develops in 10 to 15% of patients\\nwith alcoholic cirrhosis.\\nChronic alcoholism,\\n rather than liver disease, causes Dupuytren's contracture of the palmar fascia,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 26. Alcoholic Liver Disease\\n310\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 320, 'page_label': '311'}, page_content=\"vascular spiders, and peripheral neuropathy. In men, chronic alcoholism causes signs of hypogonadism\\nand feminization (eg, smooth skin, lack of male-pattern baldness, gynecomastia, testicular atrophy,\\nchanges in pubic hair). Undernutrition may lead to multiple vitamin deficiencies (eg, of folate and thiamin),\\nenlarged parotid glands, and white nails. In alcoholics, Wernicke's encephalopathy and Korsakoff's\\npsychosis result mainly from thiamin deficiency. Hepatitis C occurs in > 25% of alcoholics; this\\ncombination markedly worsens the progression of liver disease.\\nRarely, patients with fatty liver or cirrhosis present with Zieve's syndrome (hyperlipidemia, hemolytic\\nanemia, and jaundice).\\nDiagnosis\\n Confirmed history of alcohol use\\n Liver function tests and CBC\\n Sometimes liver biopsy\\nAlcohol is suspected as the cause of liver disease in any patient who chronically consumes excess\\nalcohol, particularly > 80 g/day. History should be confirmed by family members. Patients can be\\nscreened for alcoholism using the CAGE questionnaire (need to \\nC\\nut down, \\nA\\nnnoyed by criticism, \\nG\\nuilty\\nabout drinking, and need for a morning \\nE\\nye-opener). There is no specific test for alcoholic liver disease,\\nbut if the diagnosis is suspected, liver function tests (PT; serum bilirubin, aminotransferase, and albumin\\nlevels) and CBC are done to detect signs of liver injury and anemia.\\nElevations of aminotransferases are moderate (< 300 IU/L) and do not reflect the extent of liver damage.\\nThe ratio of AST to ALT is  2. The basis for low ALT is a dietary deficiency of pyridoxal phosphate\\n(vitamin B\\n6\\n), which is needed for ALT to function. Its effect on AST is less pronounced. Serum \\n\\n-glutamyl\\ntranspeptidase (GGT) increases, more because ethanol induces this enzyme than because patients have\\ncholestasis or liver injury or use other drugs. Serum albumin may be low, usually reflecting undernutrition\\nbut occasionally reflecting otherwise obvious liver failure with deficient synthesis. Macrocytosis with an\\nMCV > 100 fL reflects the direct effect of alcohol on bone marrow as well as macrocytic anemia resulting\\nfrom folate deficiency, which is common among undernourished alcoholics. Indexes of the severity of liver\\ndisease are\\n Serum bilirubin, which represents secretory function\\n PT or INR, which reflects synthetic ability\\nThrombocytopenia can result from the direct toxic effects of alcohol on bone marrow or from\\nsplenomegaly, which accompanies portal hypertension. Neutrophilic leukocytosis may result from\\nalcoholic hepatitis, although coexisting infection (particularly pneumonia and spontaneous bacterial\\nperitonitis) should also be suspected.\\nImaging tests are not routinely needed for diagnosis. If done for other reasons, abdominal\\nultrasonography or CT may suggest fatty liver or show evidence of splenomegaly, portal hypertension, or\\nascites. Ultrasound elastrography measures liver stiffness and thus detects advanced fibrosis. This\\nvaluable adjunct can obviate the need for liver biopsy to check for cirrhosis and help assess prognosis. Its\\nexact role is under study.\\nIf abnormalities suggest alcoholic liver disease, screening tests for other treatable forms of liver disease,\\nespecially viral hepatitis, should be done. Because features of fatty liver, alcoholic hepatitis, and cirrhosis\\noverlap, describing the precise findings is more useful than assigning patients to a specific category,\\nwhich can only be determined by liver biopsy.\\nNot all experts agree on the indications for liver biopsy. Proposed indications include the following:\\n Unclear clinical diagnosis (eg, equivocal clinical and laboratory findings, unexplained persistent\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 26. Alcoholic Liver Disease\\n311\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 321, 'page_label': '312'}, page_content='elevations of aminotransferase levels)\\n Clinical suspicion of > 1 cause of liver disease (eg, alcohol plus viral hepatitis)\\n Desire for a precise prediction of prognosis\\nLiver biopsy confirms liver disease, helps identify excessive alcohol use as the likely cause, and\\nestablishes the stage of liver injury. If iron accumulation is observed, measurement of the iron content and\\ngenetic testing can eliminate hereditary hemochromatosis (see p. \\n1032\\n) as the cause.\\nFor stable patients with cirrhosis, \\n\\n-fetoprotein measurement and liver ultrasonography should be done to\\nscreen for hepatocellular carcinoma (see p. \\n265\\n).\\nPrognosis\\nPrognosis is determined by the degree of hepatic fibrosis and inflammation. Fatty liver and alcoholic\\nhepatitis without fibrosis are reversible if alcohol is avoided. With abstinence, fatty liver completely\\nresolves within 6 wk. Fibrosis and cirrhosis are irreversible.\\nCertain biopsy findings (eg, neutrophils, perivenular fibrosis) indicate a worse prognosis. Proposed\\nquantitative indexes to predict severity and mortality use primarily laboratory features of liver failure such\\nas prothrombin time, creatinine (for hepatorenal syndrome) and bilirubin levels. The Maddrey discriminant\\nfunction is calculated from the formula:\\n4.6  (PT - control PT)\\n+\\nserum bilirubin\\nFor this formula, bilirubin level is measured in mg/dL (converted from bilirubin in \\n\\nmol/L by dividing by 17).\\nA value of > 32 is associated with a high short-term mortality rate (eg, after 1 mo, 35% without\\nencephalopathy and 45% with encephalopathy). Other indexes include the Model for End-Stage Liver\\nDisease (MELD), Glasgow alcoholic hepatitis score, and Lille model.\\nOnce cirrhosis and its complications (eg, ascites, bleeding) develop, the 5-yr survival rate is about 50%;\\nsurvival is higher in patients who abstain and lower in patients who continue drinking.\\nCoexisting iron accumulation or chronic hepatitis C increases risk of hepatocellular carcinoma.\\nTreatment\\n Abstinence\\n Supportive care\\n Corticosteroids and enteral nutrition for severe alcoholic hepatitis\\n Sometimes transplantation\\nRestricting alcohol intake:\\n Abstinence is the mainstay of treatment; it prevents further damage from\\nalcoholic liver disease and thus prolongs life. Because compliance is problematic, a compassionate team\\napproach is essential. Behavioral and psychosocial interventions can help motivated patients; they\\ninclude rehabilitation programs and support groups (see p. \\n1521\\n), brief interventions by primary care\\nphysicians, and therapies that explore and clarify the motivation to abstain (motivational enhancement\\ntherapy).\\nDrugs, if used, should only supplement other interventions. Opioid antagonists (naltrexone or nalmefene)\\nand drugs that modulate \\n\\n-aminobutyric acid receptors (baclofen or acamprosate) appear to have a short-\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 26. Alcoholic Liver Disease\\n312'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 322, 'page_label': '313'}, page_content=\"term benefit by reducing the craving and withdrawal symptoms. Disulfiram inhibits aldehyde\\ndehydrogenase, allowing acetaldehyde to accumulate; thus, drinking alcohol within 12 h of taking\\ndisulfiram causes flushing and has other unpleasant effects. However, disulfiram has not been shown to\\npromote abstinence and consequently is recommended only for certain patients.\\nSupportive care:\\n General management emphasizes supportive care. A nutritious diet and vitamin\\nsupplements (especially B vitamins) are important during the first few days of abstinence. Alcohol\\nwithdrawal requires use of benzodiazepines (eg, diazepam). In patients with advanced alcoholic liver\\ndisease, excessive sedation can precipitate hepatic encephalopathy and thus must be avoided.\\nSevere acute alcoholic hepatitis commonly requires hospitalization, often in an intensive care unit, to\\nfacilitate enteral feeding (which can help manage nutritional deficiencies) and to manage specific\\ncomplications (eg, infection, bleeding from esophageal varices, specific nutritional deficiencies,\\nWernicke's encephalopathy, Korsakoff's psychosis, electrolyte abnormalities, portal hypertension, ascites,\\nportal-systemic encephalopathysee elsewhere in THE MANUAL).\\nSpecific treatment:\\n Corticosteroids (eg, prednisolone 40 mg/day po for 4 wk, followed by tapered doses\\nimprove outcome in patients who have severe acute alcoholic hepatitis and who do not have infection, GI\\nbleeding, renal failure, or pancreatitis.\\nOther than corticosteroids and enteral feeding, few specific treatments are clearly established.\\nAntioxidants (eg, \\nS\\n-adenosyl-L-methionine, phosphatidylcholine, metadoxine) show promise in\\nameliorating liver injury during early cirrhosis but require further study. Therapies directed at cytokines,\\nparticularly \\ntumor necrosis factor-\\n\\n (TNF-\\n\\n), and aiming to reduce inflammation have had mixed results in\\nsmall trials. Pentoxifylline, a phosphodiesterase inhibitor that inhibits TNF-\\n\\n synthesis, has some benefit.\\nIn contrast, when biologic agents that inhibit TNF-\\n\\n (eg, infliximab, etanercept) are used, risk of infection\\noutweighs benefit. Drugs given to decrease fibrosis (eg, colchicine, penicillamine) and drugs given to\\nnormalize the hypermetabolic state of the alcoholic liver (eg, propylthiouracil) have no proven benefit.\\nAntioxidant remedies, such as silymarin (milk thistle) and vitamins A and E, are ineffective.\\nLiver transplantation\\n can be considered if disease is severe. With transplantation, 5-yr survival rates\\nare comparable to those for nonalcoholic liver diseaseas high as 80% in patients without active liver\\ndisease and 50% in those with acute alcoholic hepatitis. Because up to 50% of patients resume drinking\\nafter transplantation, most programs require 6 mo of abstinence before transplantation is done.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 26. Alcoholic Liver Disease\\n313\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 323, 'page_label': '314'}, page_content='Chapter 27. Fibrosis and Cirrhosis\\nIntroduction\\nIn hepatic fibrosis, excessive connective tissue accumulates in the liver; this tissue represents scarring in\\nresponse to chronic, repeated liver cell injury. Commonly, fibrosis progresses, disrupting hepatic\\narchitecture and eventually function, as regenerating hepatocytes attempt to replace and repair damaged\\ntissue. When such disruption is widespread, cirrhosis is diagnosed. To develop, cirrhosis usually requires\\n> 6 mo of liver disease but can occur more rapidly (eg, during infancy with biliary atresia, after liver\\ntransplantation for severe liver disease secondary to chronic hepatitis B or C).\\nFibrosis\\nHepatic fibrosis is overly exuberant wound healing in which excessive connective tissue builds\\nup in the liver. The extracellular matrix is overproduced, degraded deficiently, or both. The\\ntrigger is chronic injury, especially if there is an inflammatory component. Fibrosis itself causes\\nno symptoms but can lead to portal hypertension (the scarring distorts blood flow through the\\nliver) or cirrhosis (the scarring results in disruption of normal hepatic architecture and liver\\ndysfunction). Diagnosis is based on liver biopsy. Treatment involves correcting the underlying\\ncondition when possible.\\nVarious types of chronic liver injury can cause fibrosis (see\\nTable 27-1\\n). Self-limited, acute liver injury (eg, acute viral hepatitis A), even when fulminant, does not\\nnecessarily distort the scaffolding architecture and hence does not cause fibrosis, despite loss of\\nhepatocytes. In its initial stages, hepatic fibrosis can regress if the cause is reversible (eg, with viral\\nclearance). After months or years of chronic or repeated injury, fibrosis becomes permanent. Fibrosis\\ndevelops even more rapidly in mechanical biliary obstruction.\\nPathophysiology\\nActivation of the hepatic perivascular stellate cells (Ito cells, which store fat) initiates fibrosis. These and\\nadjacent cells proliferate, becoming contractile cells termed myofibroblasts. These cells produce\\nexcessive amounts of abnormal matrix (consisting of collagen, other glycoproteins, and glycans) and\\nmatricellular proteins. Kupffer cells (resident macrophages), injured hepatocytes, platelets, and\\nleukocytes aggregate. As a result, reactive O\\n2\\n species and inflammatory mediators (eg, platelet-derived\\ngrowth factor, transforming growth factors, and connective tissue growth factor) are released. Thus,\\nstellate cell activation results in abnormal extracellular matrix, both in quantity and composition.\\nMyofibroblasts, stimulated by endothelin-1, contribute to increased portal vein resistance and increase\\nthe density of the abnormal matrix. Fibrous tracts join branches of afferent portal veins and efferent\\nhepatic veins, bypassing the hepatocytes and limiting their blood supply. Hence, fibrosis contributes both\\nto hepatocyte ischemia (causing hepatocellular dysfunction) and portal hypertension. The\\n[\\nTable 27-1.\\n Disorders and Drugs that Can Cause Hepatic Fibrosis]\\nextent of the ischemia and portal hypertension determines how the liver is affected. For example,\\ncongenital hepatic fibrosis affects portal vein branches, largely sparing the parenchyma. The result is\\nportal hypertension with sparing of hepatocellular function.\\nSymptoms and Signs\\nHepatic fibrosis itself does not cause symptoms. Symptoms may develop secondary to the primary\\ndisorder or to portal hypertension. Portal hypertension with splenomegaly is often asymptomatic unless\\ncomplications, such as variceal GI bleeding, ascites, or portal-systemic encephalopathy, develop.\\nEventually, cirrhosis supervenes.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 27. Fibrosis & Cirrhosis\\n314'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 324, 'page_label': '315'}, page_content=\" Biopsy\\nHepatic fibrosis is suspected in patients who have an underlying disorder or take a drug that could cause\\nfibrosis or who have unexplained abnormalities in liver function or enzymes. Noninvasive tests (eg,\\nserologic markers) are under study but are not yet ready for routine clinical use. Imaging tests such as\\nultrasonography, CT, and MRI may detect findings associated with fibrosis (eg, portal hypertension,\\nsplenomegaly, cirrhosis) but are not sensitive to parenchymal fibrosis itself. Liver biopsy is currently the\\nonly means of detecting hepatic fibrosis. Biopsy is indicated to clarify the diagnosis (eg, nonalcoholic\\nsteatohepatitis, primary biliary cirrhosis) and stage its progress (eg, in chronic hepatitis C to determine\\nwhether fibrosis is present or whether it has progressed to cirrhosis).\\nTreatment\\n Treatment of cause\\nBecause fibrosis represents a response to hepatic damage, primary treatment should focus on the cause\\n(removing the basis of the liver injury). Such treatment may include eliminating HBC or HCV in chronic\\nviral hepatitis, abstaining from alcohol in alcoholic liver disease, removing heavy metals such as iron in\\nhemochromatosis or copper in Wilson's disease, and decompressing bile ducts in biliary obstruction.\\nTreatments aimed at reversing the fibrosis are usually too toxic for long-term use (eg, corticosteroids,\\npenicillamine) or have no proven efficacy (eg, colchicine). Other antifibrotic treatments are under study.\\nSimultaneous use of multiple antifibrotic drugs may eventually prove most beneficial.\\nCirrhosis\\nCirrhosis is a late stage of hepatic fibrosis that has resulted in widespread distortion of normal\\nhepatic architecture. Cirrhosis is characterized by regenerative nodules surrounded by dense\\nfibrotic tissue. Symptoms may not develop for years and are often nonspecific (eg, anorexia,\\nfatigue, weight loss). Late manifestations include portal hypertension, ascites, and, when\\ndecompensation occurs, liver failure. Diagnosis often requires liver biopsy. Cirrhosis is usually\\nconsidered irreversible. Treatment is supportive.\\nCirrhosis is a leading cause of death worldwide. The causes of cirrhosis are the same as those of fibrosis\\n(see \\nTable 27-1\\n). In developed countries, most cases result from chronic alcohol abuse or chronic\\nhepatitis C. In parts of Asia and Africa, cirrhosis often results from chronic hepatitis B. Cirrhosis of\\nunknown etiology (cryptogenic cirrhosis) is becoming less common as many specific causes (eg, chronic\\nhepatitis C, steatohepatitis) are identified. Injury to the bile ducts also can result in cirrhosis, as occurs in\\nmechanical bile duct obstruction, primary biliary cirrhosis (see p. \\n244\\n), and primary sclerosing cholangitis\\n(see p. \\n278\\n).\\nPathophysiology\\nThere are 2 primary factors:\\n Hepatic fibrosis\\n Regenerating liver cells\\nIn response to injury and loss, growth regulators induce hepatocellular hyperplasia (producing\\nregenerating nodules) and arterial growth (angiogenesis). Among the growth regulators are cytokines and\\nhepatic growth factors (eg, epithelial growth factor, hepatocyte growth factor, transforming growth factor-\\n\\n, tumor necrosis factor). Insulin, glucagon, and patterns of intrahepatic blood flow determine how and\\nwhere nodules develop.\\nAngiogenesis produces new vessels within the fibrous sheath that surrounds nodules. These vessels\\nconnect the hepatic artery and portal vein to hepatic venules, restoring the intrahepatic circulatory\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 27. Fibrosis & Cirrhosis\\n315\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 325, 'page_label': '316'}, page_content=\"pathways. Such interconnecting vessels provide relatively low-volume, high-pressure venous drainage\\nthat cannot accommodate as much blood volume as normal. As a result, portal vein pressure increases.\\nSuch distortions in blood flow contribute to portal hypertension, which increases because the\\nregenerating nodules compress hepatic venules.\\nThe progression rate from fibrosis to cirrhosis and the morphology of cirrhosis vary from person to\\nperson. Presumably, the reason for such variation is the extent of exposure to the injurious stimulus and\\nthe individual's response.\\nComplications:\\n Portal hypertension (see p. \\n218\\n) is the most common serious complication; it can\\nmanifest as GI bleeding from esophageal, gastric, or rectal varices or portal hypertensive gastropathy.\\nPortal hypertension can be massive. Cirrhosis can cause other cardiovascular complications. Vasodilation\\nand intrapulmonary right-to-left shunting and ventilation/perfusion mismatch can result in hypoxia\\n(hepatopulmonary syndrome). A cardiac myopathy can also accompany cirrhosis.\\nAscites can develop, with a risk of spontaneous bacterial peritonitis. Splenic congestion with\\nhypersplenism may occur, resulting in splenomegaly, platelet sequestration, and consequent cytopenia.\\nProgressive loss of hepatic architecture impairs function, leading to hepatic insufficiency; it manifests as\\ncoagulopathy, renal failure (hepatorenal syndromesee p. \\n223\\n), and hepatic encephalopathy.\\nHepatocytes secrete less bile, contributing to cholestasis and jaundice. Less bile in the intestine causes\\nmalabsorption of dietary fat (triglycerides) and fat-soluble vitamins. Malabsorption of vitamin D may\\ncontribute to osteoporosis. Undernutrition is common. It may result from anorexia with reduced food intake\\nor, in patients with alcoholic liver disease, from malabsorption due to pancreatic insufficiency.\\nBlood disorders are common. Anemia results from hypersplenism, chronic GI bleeding, folate deficiency\\n(particularly in patients with alcoholism), and hemolysis. Clotting may be impaired because of\\ncoagulopathy or thrombocytopenia. Coagulopathy results from impaired hepatic synthesis of the factors\\nnecessary for clotting, malabsorption of vitamin K due to impaired bile secretion into the duodenum, or\\nboth. Thrombocytopenia may be caused by hypersplenism (platelet sequestration), alcohol excess\\n(directly inhibiting the bone marrow), or both. Pancytopenia also occurs with alcoholism.\\nHepatocellular carcinoma frequently complicates cirrhosis, particularly cirrhosis resulting from chronic\\nhepatitis B and C viruses, hemochromatosis, alcohol-related liver disease, \\n\\n1\\nantitrypsin deficiency, or\\nglycogen storage disease.\\nHistopathology:\\n Cirrhosis is characterized by regenerating nodules and fibrosis. Incompletely formed\\nliver nodules, nodules without fibrosis (nodular regenerative hyperplasia), and congenital hepatic fibrosis\\n(ie, widespread fibrosis without regenerating nodules) are not true cirrhosis.\\nCirrhosis can be micronodular or macronodular. Micronodular cirrhosis is characterized by uniformly small\\nnodules (< 3 mm in diameter) and thick regular bands of connective tissue. Typically, nodules lack lobular\\norganization; terminal (central) hepatic venules and portal triads are distorted. With time, macronodular\\ncirrhosis often develops. The nodules vary in size (3 mm to 5 cm in diameter) and have some rather\\nnormal lobular organization of portal triads and terminal hepatic venules. Broad fibrous bands of varying\\nthickness surround the large nodules. \\nCollapse of the normal hepatic architecture is suggested by the\\nconcentration of portal triads within the fibrous scars. Mixed cirrhosis (incomplete septal cirrhosis)\\ncombines elements of micronodular and macronodular cirrhosis. Differentiation between these\\nmorphologic types of cirrhosis has limited clinical value.\\nSymptoms and Signs\\nCirrhosis may be asymptomatic for years. One third of patients never develop symptoms. Often, the first\\nsymptoms are nonspecific; they include generalized fatigue (due to cytokine release), anorexia, malaise,\\nand weight loss (see\\nTable 27-2\\n). The liver is typically palpable and firm, with a blunt edge, but is sometimes small and difficult\\nto palpate. Nodules usually are not palpable.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 27. Fibrosis & Cirrhosis\\n316\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 326, 'page_label': '317'}, page_content=\"Clinical signs that suggest a chronic liver disorder or chronic alcohol use but are not specific for cirrhosis\\ninclude muscle wasting, palmar erythema, parotid gland enlargement, white nails, clubbing, Dupuytren's\\ncontracture, spider angiomas (< 10 may be normal), gynecomastia, axillary hair loss, testicular atrophy,\\nand peripheral neuropathy.\\nOnce complications of cirrhosis develop, decompensation inexorably ensues.\\nDiagnosis\\n Liver function tests, coagulation tests, CBC, and serologic tests for viral cause\\n Sometimes biopsy\\n Identification of cause based on clinical evaluation and selective testing\\nGeneral approach:\\n Cirrhosis is suspected in patients with manifestations of any of its complications (see\\nTable 27-2\\n), particularly portal hypertension or ascites. Early cirrhosis should be considered in patients\\nwith nonspecific\\n[\\nTable 27-2.\\n Common Symptoms and Signs Due to Complications of Cirrhosis]\\nsymptoms or characteristic laboratory abnormalities detected incidentally during laboratory testing,\\nparticularly in patients who have a disorder or take a drug that might cause fibrosis.\\nTesting seeks to detect cirrhosis and any complications and to determine its cause.\\nLaboratory tests:\\n Diagnostic testing begins with liver function tests, coagulation tests, CBC, and\\nserologic tests for viral causes (eg, hepatitis B and C). Laboratory tests alone may increase suspicion for\\ncirrhosis but cannot confirm or exclude it. Liver biopsy becomes necessary if a clear diagnosis would lead\\nto better management and outcome.\\nTest results may be normal or may indicate nonspecific abnormalities due to complications of cirrhosis or\\nalcoholism. ALT and AST levels are often modestly elevated. Alkaline phosphatase and \\n\\n-glutamyl\\ntranspeptidase (GGT) are often normal; elevated levels indicate cholestasis or biliary obstruction.\\nBilirubin is usually normal but increases when cirrhosis progresses, particularly in primary biliary cirrhosis\\n(see p. \\n244\\n). Decreased serum albumin and a prolonged PT directly reflect impaired hepatic synthesis\\nusually an end-stage event. Albumin can also be low when nutrition is poor. Serum globulin increases\\nin cirrhosis and in most liver disorders with an inflammatory component. Anemia is common and usually\\nnormocytic with a high RBC distribution width. Anemia is often multifactorial; contributing factors may\\ninclude chronic GI bleeding (usually causing microcytic anemia), folate nutritional deficiency (causing\\nmacrocytic anemia, especially in alcohol abuse), hemolysis, and hypersplenism. CBC may detect\\nleukopenia, thrombocytopenia, or pancytopenia.\\nDiagnostic imaging:\\n Imaging tests are not highly sensitive or specific for the diagnosis of cirrhosis by\\nthemselves, but they can often detect its complications. In advanced cirrhosis, ultrasonography shows a\\nsmall, nodular liver. Ultrasonography also detects portal hypertension and ascites.\\nCT can detect a nodular texture, but it has no advantage over ultrasonography. Radionuclide liver scans\\nusing technetium-99m sulfur colloid may show irregular liver uptake and increased spleen and bone\\nmarrow uptake. MRI is more expensive than other imaging tests and has little advantage.\\nIdentification of the cause:\\n Determining the specific cause of cirrhosis requires key clinical information\\nfrom the history and examination, as well as selective testing. Alcohol is the likely cause in patients with a\\ndocumented history of alcoholism and clinical findings such as gynecomastia, spider angiomas\\n(telangiectasia), and testicular atrophy plus laboratory confirmation of liver damage (AST elevated more\\nthan ALT) and liver enzyme induction (a greatly increased GGT). Fever, tender hepatomegaly, and\\njaundice suggest the presence of alcoholic hepatitis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 27. Fibrosis & Cirrhosis\\n317\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 327, 'page_label': '318'}, page_content=\"Detecting hepatitis B surface antigen (HBsAg) and IgG antibodies to hepatitis B (IgG anti-HBc) confirms\\nchronic hepatitis B. Identifying serum antibody to hepatitis C (anti-HCV) and HCV-RNA points to hepatitis\\nC.\\nIf common causes such as alcohol or viral hepatitis are not confirmed, other less common causes are\\nsought:\\n Presence of antimitochondrial antibodies (in 95%) suggests primary biliary cirrhosis.\\n Strictures and dilations of the intrahepatic and extrahepatic bile ducts seen on magnetic resonance\\ncholangiopancreatography (MRCP) suggest primary sclerosing cholangitis.\\n Increased serum Fe and transferrin and possibly results of genetic testing suggest hemochromatosis.\\n Decreased serum ceruloplasmin and characteristic copper test results suggest Wilson's disease.\\n Hypergammaglobulinemia and presence of autoantibodies (eg, antinuclear or anti-smooth muscle\\nantibodies) indicate autoimmune hepatitis.\\nLiver biopsy:\\n If clinical criteria and noninvasive testing are inconclusive, liver biopsy is usually done. Its\\nsensitivity approaches 100%. Nonalcoholic steatohepatitis (NASH), often associated with obesity,\\ndiabetes, or the metabolic syndrome, may be evident on ultrasound scans but requires liver biopsy for\\nconfirmation. In obvious cases of cirrhosis with a marked coagulopathy, portal hypertension, ascites, and\\nliver failure, biopsy is not required when results would not change management.\\nMonitoring:\\n Patients with cirrhosis, particularly if due to chronic viral hepatitis B or C or\\nhemochromatosis, should be screened for hepatocellular carcinoma (eg, measuring \\n\\n-fetoprotein levels\\nand ultrasonography every 6 to 12 mosee p. \\n266\\n).\\nPrognosis\\nPrognosis is often unpredictable. It depends on factors such as etiology, severity, presence of\\ncomplications, comorbid conditions, host factors, and effectiveness of therapy. Patients who continue to\\ndrink alcohol, even \\nsmall amounts, have a very poor prognosis. The Child-Turcotte-Pugh scoring system\\nuses clinical and laboratory information to stratify disease severity, surgical risk, and overall prognosis\\n(see\\nTables 27-3\\n and\\n27-4\\n).\\nTreatment\\n Supportive care\\nIn general, treatment is supportive and includes stopping injurious drugs, providing nutrition (including\\nsupplemental vitamins), and treating the underlying disorders and complications. Doses of drugs\\nmetabolized in the liver should be reduced. All alcohol and hepatotoxic substances must be avoided.\\nWithdrawal symptoms during hospitalization should be anticipated in patients who have cirrhosis and\\nhave continued to abuse alcohol.\\nPatients with varices need therapy to prevent bleeding (see p.\\n219\\n). Liver transplantation is indicated for end-stage liver failure in suitable candidates.\\nPrimary Biliary Cirrhosis\\nPrimary biliary cirrhosis (PBC) is an autoimmune liver disorder characterized by the\\nprogressive destruction of intrahepatic bile ducts, leading to cholestasis, cirrhosis, and liver\\nfailure. Patients usually are asymptomatic at presentation but may experience fatigue or have\\nsymptoms of cholestasis (eg, pruritus, steatorrhea) or cirrhosis (eg, portal hypertension,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 27. Fibrosis & Cirrhosis\\n318\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 328, 'page_label': '319'}, page_content=\"ascites). Laboratory tests reveal cholestasis, increased IgM, and, characteristically,\\nantimitochondrial antibodies in the serum. Liver biopsy may be necessary for diagnosis and\\nstaging. Treatment includes ursodeoxycholic acid, cholestyramine (for pruritus),\\n[\\nTable 27-3.\\n Child-Turcotte-Pugh Scoring System]\\n[\\nTable 27-4.\\n Interpretation of the Child-Turcotte-Pugh Scoring System]\\nsupplementary fat-soluble vitamins, and, ultimately for advanced disease, liver transplantation.\\nEtiology\\nPBC is the most common liver disease associated with chronic cholestasis in adults. Most (95%) cases\\noccur in women aged 35 to 70. PBC also clusters in families. A genetic predisposition, perhaps involving\\nthe X chromosome, probably contributes. There may be an inherited abnormality of immune regulation. An\\nautoimmune mechanism has been implicated; antibodies to antigens located on the inner mitochondrial\\nmembranes occur in > 95% of cases. These antimitochondrial antibodies (AMAs), the serologic hallmarks\\nof PBC, are not cytotoxic and are not involved in bile duct damage. PBC is associated with other\\nautoimmune disorders, such as RA, systemic sclerosis, Sjogren's syndrome, CREST syndrome,\\nautoimmune thyroiditis, and renal tubular acidosis.\\nT cells attack the small bile ducts. CD4 and CD8 T lymphocytes directly target biliary epithelial cells. The\\ntrigger for the immunologic attack on bile ducts is unknown. Exposure to foreign antigens, such as an\\ninfectious (bacterial or viral) or toxic agent, may be the instigating event. These foreign antigens might be\\nstructurally similar to endogenous proteins (molecular mimicry); then the subsequent immunologic\\nreaction would be autoimmune and self-perpetuating. Destruction and loss of bile ducts lead to impaired\\nbile formation and secretion (cholestasis). Retained toxic materials such as bile acids then cause further\\ndamage, particularly to hepatocytes. Chronic cholestasis thus leads to liver cell inflammation and scarring\\nin the periportal areas. Eventually, hepatic inflammation decreases as hepatic fibrosis progresses to\\ncirrhosis.\\nAutoimmune cholangitis is sometimes considered to be a separate disorder. It is characterized by\\nautoantibodies, such as antinuclear antibodies (ANAs), anti-smooth muscle antibodies, or both and has a\\nclinical course and response to treatment that are similar to PBC. However, in autoimmune cholangitis,\\nAMAs are absent.\\nSymptoms and Signs\\nAbout half of patients present without symptoms. Symptoms or signs may develop during any stage of the\\ndisease and may include fatigue or reflect cholestasis (and the resulting fat malabsorption, which may\\nlead to vitamin deficiencies and osteoporosis), hepatocellular dysfunction, or cirrhosis.\\nSymptoms usually develop insidiously. Pruritus, fatigue, and dry mouth and eyes are the initial symptoms\\nin > 50% of patients and can precede other symptoms by months or years. Other initial manifestations\\ninclude right upper quadrant discomfort (10%); an enlarged, firm, nontender liver (25%); splenomegaly\\n(15%); hyperpigmentation (25%); xanthelasmas (10%); and jaundice (10%). Eventually, all the features\\nand complications of cirrhosis occur. Peripheral neuropathy and other autoimmune disorders associated\\nwith PBC may also develop.\\nDiagnosis\\n Liver function tests\\n Antimitochondrial antibodies\\n Ultrasonography and often MRCP\\n Liver biopsy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 27. Fibrosis & Cirrhosis\\n319\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 329, 'page_label': '320'}, page_content='In asymptomatic patients, PBC is detected incidentally when liver function tests detect abnormalities,\\ntypically elevated levels of alkaline phosphatase and \\n\\n-glutamyl transpeptidase (GGT). PBC is suspected\\nin middle-aged women with classic symptoms (eg, unexplained pruritus, fatigue, right upper quadrant\\ndiscomfort, jaundice) or laboratory results suggesting cholestatic liver disease: elevated alkaline\\nphosphatase and GGT but minimally abnormal aminotransferases (ALT, AST). Serum bilirubin is usually\\nnormal in the early stages; elevation indicates disease progression and a worsening prognosis.\\nIf PBC is suspected, liver function tests and tests to measure serum IgM (increased in PBC) and AMA\\nshould be done. ELISA tests are 95% sensitive and 98% specific for PBC; false-positive results can occur\\nin autoimmune hepatitis (type 1). Other autoantibodies (eg, ANAs, anti-smooth muscle antibodies,\\nrheumatoid factor) may be present. Extrahepatic biliary obstruction should be ruled out. Ultrasonography\\nis often done first, but ultimately MRCP and sometimes ERCP are necessary. \\nUnless life expectancy is\\nshort or there is a contraindication, liver biopsy is usually done. Liver biopsy confirms the diagnosis; it\\nmay detect pathognomonic bile duct lesions, even in early stages. As PBC progresses, it becomes\\nmorphologically indistinguishable from other forms of cirrhosis. Liver biopsy also helps stage PBC, which\\nhas 4 histologic stages:\\n Stage 1: Inflammation, abnormal connective tissue, or both, confined to the portal areas\\n Stage 2: Inflammation, fibrosis, or both, confined to the portal and periportal areas\\n Stage 3: Bridging fibrosis\\n Stage 4: Cirrhosis\\nAutoimmune cholangitis is diagnosed when AMAs are absent in a patient who otherwise would be\\ndiagnosed with PBC.\\nPrognosis\\nUsually, PBC progresses to terminal stages over 15 to 20 yr, although the rate of progression varies. PBC\\nmay not diminish quality of life for many years. Patients who present without symptoms tend to develop\\nsymptoms over 2 to 7 yr but may not do so for 10 to 15 yr. Once symptoms develop, median life\\nexpectancy is 10 yr. Predictors of rapid progression include the following:\\n Rapid worsening of symptoms\\n Advanced histologic changes\\n Older patient age\\n Presence of edema\\n Presence of associated autoimmune disorders\\n Abnormalities in bilirubin, albumin, PT, or INR\\nThe prognosis is ominous when pruritus disappears, xanthomas shrink, jaundice develops, and serum\\ncholesterol decreases.\\nTreatment\\n Arresting or reversing liver damage\\n Treating complications (chronic cholestasis and liver failure)\\n Eventually, doing liver transplantation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 27. Fibrosis & Cirrhosis\\n320'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 330, 'page_label': '321'}, page_content='All alcohol use and hepatotoxic drugs should be stopped. Ursodeoxycholic acid (15 mg/kg po once/day)\\ndecreases liver damage, prolongs survival, and delays the need for liver transplantation. About 20% of\\npatients do not have biochemical improvement after  4 mo; they may have advanced disease and\\nrequire liver transplantation in a few years. Other drugs proposed to decrease liver damage have not\\nimproved overall clinical outcomes or are controversial.\\nPruritus may be controlled with cholestyramine 6 to 8 g po bid. This anionic-binding drug binds bile salts\\nand thus may aggravate fat malabsorption. If cholestyramine is taken long-term, supplements of fat-\\nsoluble vitamins should be considered. Cholestyramine can decrease absorption of ursodeoxycholic acid,\\nso these drugs should not be given simultaneously.\\nSome patients with pruritus respond to ursodeoxycholic acid and ultraviolet light; others may warrant a\\ntrial of rifampin or an opioid antagonist, such as naltrexone. Patients with fat malabsorption due to bile\\nsalt deficiency should be treated with vitamins A, D, E, and K. For osteoporosis, weight-bearing exercises,\\nbisphosphonates, or raloxifene may be needed in addition to Ca and vitamin D supplements. In later\\nstages, portal hypertension (see p. \\n218\\n) or complications of cirrhosis (see p. \\n241\\n) require treatment.\\nLiver transplantation has excellent results. The general indication is decompensated liver disease\\n(uncontrolled variceal bleeding, refractory ascites, intractable pruritus, and hepatic encephalopathy).\\nSurvival rates after liver transplantation are > 90% at 1 yr, > 80% at 5 yr, and > 65% at 10 yr. AMAs tend\\nto persist after transplantation. PBC recurs in 15% of patients in the first few years and in > 30% by 10 yr.\\nSo far, recurrent PBC after liver transplantation has a benign course. Cirrhosis rarely occurs.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 27. Fibrosis & Cirrhosis\\n321'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 331, 'page_label': '322'}, page_content='Chapter 28. Hepatitis\\nIntroduction\\nHepatitis is an inflammation of the liver characterized by diffuse or patchy necrosis. Major causes are\\nspecific hepatitis viruses, alcohol, and drugs. Less common causes include other viral infections (eg,\\ninfectious mononucleosis, yellow fever, cytomegalovirus infection) and leptospirosis. Parasitic infections\\n(eg, schistosomiasis, malaria, amebiasis), pyogenic infections, and abscesses that affect the liver are not\\nconsidered hepatitis. Liver \\ninvolvement with TB and other granulomatous infiltrations is sometimes called\\ngranulomatous hepatitis, but the clinical, biochemical, and histologic features differ from those of diffuse\\nhepatitis.\\nVarious systemic infections and other illnesses may produce small focal areas of hepatic inflammation or\\nnecrosis. This nonspecific reactive hepatitis can cause minor liver function abnormalities but is usually\\nasymptomatic.\\nSome types of infectious and noninfectious liver inflammation are summarized (see\\nTable 28-1\\n).\\nAcute Viral Hepatitis\\nAcute viral hepatitis is diffuse liver inflammation caused by specific hepatotropic viruses that\\nhave diverse modes of transmission and epidemiologies. A nonspecific viral prodrome is\\nfollowed by anorexia, nausea, and often fever or right upper quadrant pain. Jaundice often\\ndevelops, typically as other symptoms begin to resolve. Most cases resolve spontaneously, but\\nsome progress to chronic hepatitis. Occasionally, acute viral hepatitis progresses to acute\\nhepatic failure (fulminant hepatitis). Diagnosis is by liver function tests and serologic tests to\\nidentify the virus. Good hygiene can prevent acute viral hepatitis. Depending on the specific\\nvirus, preexposure and postexposure prophylaxis may be possible using vaccines or serum\\nglobulins. Treatment is usually supportive.\\n(See also Neonatal Hepatitis B Virus Infection on p. \\n2825\\n.)\\nAcute viral hepatitis is a common, worldwide disease that has different causes; each type shares clinical,\\nbiochemical, and morphologic features. Liver infections caused by nonhepatitis viruses (eg, Epstein-Barr\\nvirus, yellow fever virus, cytomegalovirus) generally are not termed acute viral hepatitis.\\nEtiology\\nAt least 5 specific viruses appear to be responsible (see\\nTable 28-2\\n). Other unidentified viruses probably also cause acute viral hepatitis.\\nHepatitis A virus (HAV):\\n HAV is a single-stranded RNA picornavirus. It is the most common cause of\\nacute viral hepatitis and is particularly common among children and young adults. In some countries, >\\n75% of adults have been exposed. HAV spreads primarily by fecal-oral contact and thus may occur in\\nareas of poor hygiene. Waterborne and food-borne epidemics occur, especially in underdeveloped\\ncountries. Eating contaminated raw shellfish is sometimes responsible. Sporadic cases are also common,\\nusually as a result of person-to-person contact. Fecal shedding of the virus occurs before symptoms\\ndevelop and usually ceases a few days after symptoms begin; thus, infectivity often has already ceased\\nwhen hepatitis becomes clinically evident. HAV has no known chronic carrier state and does not cause\\nchronic hepatitis or cirrhosis.\\nHepatitis B virus (HBV):\\n HBV is the most thoroughly characterized and complex hepatitis virus. The\\ninfective particle consists of a viral core plus an outer surface coat. The core contains circular double-\\nstranded DNA and DNA polymerase, and it replicates within the nuclei of infected hepatocytes. A surface\\ncoat is added in the cytoplasm and, for unknown reasons, is produced in great excess.\\nHBV is the 2nd most common cause of acute viral hepatitis. Prior unrecognized infection is common but is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n322'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 332, 'page_label': '323'}, page_content='much less widespread than that with HAV. HBV is often transmitted parenterally, typically by contaminated\\nblood or blood products. Routine screening of donor blood for hepatitis B surface antigen (HBsAg) has\\nnearly eliminated the previously common posttransfusion transmission, but transmission through needles\\nshared by drug users remains common. Risk of HBV is increased for patients in renal dialysis and\\noncology units and for hospital personnel in contact with blood. The virus may be spread through contact\\nwith other body fluids (eg, between sex partners, both heterosexual and homosexual; in closed\\ninstitutions, such as mental health institutions and prisons), but infectivity is far lower than that of HAV,\\nand the means of transmission is often unknown. The role of insect bites in transmission is unclear. Many\\ncases of acute hepatitis B occur sporadically without a known source.\\nHBV, for unknown reasons, is sometimes associated with several primarily extrahepatic disorders,\\nincluding polyarteritis nodosa, other connective tissue diseases, membranous glomerulonephritis, and\\nessential mixed cryoglobulinemia. The pathogenic role of HBV in these disorders is unclear, but\\nautoimmune mechanisms are suggested.\\nChronic HBV carriers provide a worldwide reservoir of infection. Prevalence varies widely according to\\nseveral factors, including geography (eg, < 0.5% in North America and northern Europe, > 10% in some\\nregions of the Far East). Vertical transmission from mother to infant is common (see p. \\n2644\\n).\\n[\\nTable 28-1.\\n Selected Diseases or Organisms Associated with Liver Inflammation]\\nHepatitis C virus (HCV):\\n HCV is a single-stranded RNA flavivirus. Six major HCV subtypes exist with\\nvarying amino acid sequences (genotypes); these subtypes vary geographically and in virulence and\\nresponse to therapy. HCV can also alter its amino acid pattern over time in an infected person, producing\\nquasispecies.\\nInfection is most commonly transmitted through blood, primarily when parenteral drug users share\\nneedles, but also through tattoos or body piercing. Sexual transmission and vertical transmission from\\nmother to infant are relatively rare. Transmission through blood transfusion has become very rare since\\nthe advent of screening tests for donated blood. Some sporadic cases occur in patients without apparent\\nrisk factors. HCV prevalence varies with geography and other risk factors.\\nHCV infection sometimes occurs simultaneously with specific systemic disorders, including essential\\nmixed cryoglobulinemia, porphyria cutanea tarda (about 60 to 80% of porphyria patients have HCV\\ninfection, but only a few patients infected with HCV develop porphyria), and glomerulonephritis; the\\nmechanisms are uncertain. In addition, up to 20% of patients with alcoholic liver disease harbor HCV. The\\nreasons for this high association are unclear because concomitant alcohol and drug use accounts for only\\na portion of cases. In these patients, HCV and alcohol act synergistically to exacerbate liver damage.\\nHepatitis D virus (HDV):\\n HDV, or delta agent, is a defective RNA virus that can replicate only in the\\npresence of HBV. It occurs uncommonly as a co-infection with acute hepatitis B or as a superinfection in\\nchronic \\nhepatitis B. Infected hepatocytes contain delta particles coated with HBsAg. Prevalence of HDV\\nvaries widely geographically, with endemic pockets in several countries. Parenteral drug users are at\\nrelatively high risk, but HDV (unlike HBV) has not widely permeated the homosexual community.\\nHepatitis E virus (HEV):\\n HEV is an enterically transmitted RNA virus. Outbreaks of acute HEV infection,\\noften waterborne and linked to fecal contamination of the water supply, have occurred in China, India,\\nMexico, Pakistan, Peru, Russia, and central and northern Africa. These outbreaks have epidemiologic\\ncharacteristics similar to HAV epidemics. Sporadic cases also occur. No outbreaks have occurred in the\\nUS or in Western Europe. Like HAV, HEV does not cause chronic hepatitis or cirrhosis, and there is no\\nchronic carrier state.\\nSymptoms and Signs\\nGeneral:\\n Acute infection tends to develop in predictable phases. Infection begins with an incubation\\nperiod (see \\nTable 28-2\\n), during which the virus multiplies and spreads without symptoms. The prodromal,\\nor pre-icteric, phase follows, causing nonspecific symptoms, such as profound anorexia, malaise, nausea\\nand vomiting, and often fever or right upper quadrant abdominal pain. Urticaria and arthralgias\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n323'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 333, 'page_label': '324'}, page_content='occasionally occur, especially in HBV infection. After 3 to 10 days, the urine darkens, followed by jaundice\\n(the icteric phase). Systemic symptoms often regress, and the patient feels better despite worsening\\njaundice. During the icteric phase, the liver is usually enlarged and tender, but the edge of the liver\\nremains soft and smooth. Mild splenomegaly occurs in 15 to 20% of patients. Jaundice usually peaks\\nwithin 1 to 2 wk and then fades during a 2- to 4-wk recovery phase. Appetite usually returns after the first\\nweek. Acute viral hepatitis usually resolves spontaneously 4 to 8 wk after symptom onset.\\nSometimes anicteric hepatitis, a minor flulike illness without jaundice, is the only manifestation. It occurs\\nmore often than icteric hepatitis in patients with HCV infection and in children with HAV infection.\\nRecrudescent hepatitis occurs in a few patients and is characterized by recurrent manifestations during\\nthe recovery phase. Manifestations of cholestasis may develop during the icteric phase (called cholestatic\\nhepatitis) but usually resolve. When they persist, they cause prolonged jaundice, elevated alkaline\\nphosphatase, and pruritus, despite general regression of inflammation.\\nVirus-specific:\\n HAV often does not cause jaundice and may not cause any symptoms. It almost\\ninvariably resolves after the acute infection, although there can be early recrudescence.\\nHBV causes a wide spectrum of liver diseases, from a subclinical carrier state to severe or fulminant\\nacute hepatitis, particularly in the elderly, in whom mortality can reach 10 to 15%. Five to 10% of all\\npatients with HBV develop chronic hepatitis or become inactive carriers. Cirrhosis can develop.\\nHepatocellular carcinoma can ultimately develop in chronic HBV infection, even without being preceded\\nby cirrhosis.\\nHCV may be asymptomatic during the acute infection. Its severity often fluctuates, sometimes with\\nrecrudescent hepatitis and\\n[\\nTable 28-2.\\n Characteristics of Hepatitis Viruses]\\nroller-coaster aminotransferase levels for many years or even decades. HCV has the highest rate of\\nchronicity (about 75%). The resultant chronic hepatitis is usually asymptomatic or benign but progresses\\nto cirrhosis in 20 to 30% of patients; cirrhosis often takes decades to appear. Hepatocellular carcinoma\\ncan result from HCV-induced cirrhosis but results only rarely from chronic infection without cirrhosis\\n(unlike in HBV infection).\\nAcute HDV infection typically manifests as unusually severe acute HBV infection (co-infection), an acute\\nexacerbation in chronic HBV carriers (superinfection), or a relatively aggressive course of chronic HBV\\ninfection.\\nHEV may be severe, especially in pregnant women.\\nDiagnosis\\n Liver function tests (AST and ALT elevated out of proportion to alkaline phosphatase, usually with\\nhyperbilirubinemia)\\n Viral serologic testing\\n PT measurement\\nInitial diagnosis:\\n Acute hepatitis must first be differentiated from other disorders that cause similar\\nsymptoms. In the prodromal phase, hepatitis mimics various nonspecific viral illnesses and is difficult to\\ndiagnose. Anicteric patients suspected of having hepatitis based on risk factors are tested initially with\\nnonspecific liver function tests, including aminotransferases, bilirubin, and alkaline phosphatase. Usually,\\nacute hepatitis is suspected only during the icteric phase. Thus, acute hepatitis should be differentiated\\nfrom other disorders causing jaundice (see\\nFig. 28-1\\n and p. \\n212\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n324'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 334, 'page_label': '325'}, page_content='Acute hepatitis can usually be differentiated from other causes of jaundice by its marked elevations of\\nAST and ALT (typically  400 IU/L). ALT is typically higher than AST, but absolute levels correlate poorly\\nwith clinical severity. Values increase early in the prodromal phase, peak before jaundice is maximal, and\\nfall slowly during the recovery phase. Urinary bilirubin usually precedes jaundice. Hyperbilirubinemia in\\nacute viral hepatitis varies in severity, and fractionation has no clinical value. Alkaline phosphatase is\\nusually only moderately elevated; marked elevation suggests extrahepatic cholestasis and prompts\\nimaging tests (eg, ultrasonography). Liver biopsy generally is not needed unless the diagnosis is\\nuncertain. If laboratory results suggest acute hepatitis, particularly if ALT and AST are > 1000 IU/L, PT is\\nmeasured. Manifestations of portal-systemic encephalopathy, bleeding diathesis, or prolongation of INR\\nsuggest fulminant hepatitis (see p. \\n254\\n).\\nIf acute hepatitis is suspected, efforts are next directed toward identifying its cause. A history of exposure\\nmay provide the only clue of drug-induced or toxic hepatitis. The history should also elicit risk factors for\\nviral hepatitis. Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather\\nthan viral hepatitis. Alcoholic hepatitis is suggested by a history of drinking, more gradual onset of\\nsymptoms, and presence of vascular spiders or signs of chronic alcohol use or chronic liver disease (see\\nalso p. \\n235\\n); aminotransferase levels rarely exceed 300 IU/L, even in severe cases. Also, unlike in viral\\nhepatitis, AST is typically higher than ALT, although this difference by itself does not reliably differentiate\\nthe two. In uncertain cases, liver biopsy usually distinguishes alcoholic from viral hepatitis.\\nSerology:\\n In patients with findings suggesting acute viral hepatitis, the following studies are done to\\nscreen for hepatitis viruses A, B, and C:\\n IgM antibody to HAV (IgM anti-HAV)\\n HBsAg\\n IgM antibody to hepatitis B core (IgM anti-HBc)\\n Antibody to HCV (anti-HCV)\\nIf any are positive, further serologic testing may be necessary to differentiate acute from past or chronic\\ninfection (see\\nTables 28-3\\n,\\n28-4\\n, and\\n28-5\\n). If serology suggests hepatitis B, testing for hepatitis B e antigen (HBeAg) and antibody to hepatitis\\nB e antigen (anti-HBe) is usually done to help determine the prognosis and to guide antiviral therapy. If\\nserologically confirmed HBV is severe, anti-HDV is measured. If the patient has recently traveled to an\\nendemic area, IgM anti-HEV should be measured if the test is available.\\nHAV\\n is present in serum only during acute infection and cannot be detected by clinically available tests.\\nIgM antibody typically develops early in the infection and peaks about 1 to 2 wk after the development of\\njaundice. It diminishes within several weeks, followed by the development of protective IgG antibody (IgG\\nanti-HAV), which persists usually for life. Thus, IgM antibody is a marker of acute infection, whereas IgG\\nanti-HAV indicates only previous exposure to HAV and immunity to recurrent infection.\\nHBV\\n has at least 3 distinct antigen-antibody systems that can be tested: HBsAg, hepatitis B core antigen\\n(HBcAg), and HBeAg. HBV-DNA can also be tested. HBV surface coat can be detected in serum as\\nHBsAg. HBsAg characteristically appears during the incubation period, usually 1 to 6 wk before clinical or\\nbiochemical\\n[\\nFig. 28-1.\\n Simplified diagnostic approach to possible acute viral hepatitis.]\\nillness develops, and implies infectivity of the blood. It disappears during convalescence. However,\\nHBsAg is occasionally transient. The corresponding protective antibody (anti-HBs) appears weeks or\\nmonths later, after clinical recovery, and usually persists for life; thus, its detection indicates past HBV\\ninfection and relative immunity. In 5 to 10% of patients, HBsAg persists and antibodies do not develop;\\nthese patients become asymptomatic carriers of the virus or develop chronic hepatitis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n325'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 335, 'page_label': '326'}, page_content='HBcAg reflects the viral core. It is detectable in infected liver cells but not in serum except by special\\ntechniques. Antibody to HBcAg (anti-HBc) generally appears at the onset of clinical illness; thereafter,\\ntiters gradually diminish, usually over years or life. Its presence with anti-HBs indicates recovery from\\nprevious HBV infection. Anti-HBc is also present in chronic HBsAg carriers, who do not mount an anti-HBs\\nresponse. In acute infection, anti-HBc is mainly of the IgM class, whereas in chronic infection, IgG anti-\\nHBc predominates. IgM anti-HBc is a sensitive marker of acute HBV infection and occasionally is the only\\nmarker of recent infection, reflecting a window between disappearance of HBsAg and appearance of\\nanti-HBs.\\nHBeAg is a protein derived from the viral core (not to be confused with hepatitis E virus).\\n[\\nTable 28-3.\\n Hepatitis A Serology]\\nPresent only in HBsAg-positive serum, HBeAg tends to suggest more active viral replication and greater\\ninfectivity. In contrast, presence of the corresponding antibody (anti-HBe) suggests lower infectivity. Thus,\\ne antigen markers are more helpful in prognosis than in diagnosis. Chronic liver disease develops more\\noften among patients with HBeAg and less often among patients with anti-HBe.\\nIn patients with active HBV infection, HBV-DNA can be detected in the serum with special testing,\\nalthough this testing is not routinely available.\\nIn \\nHCV\\n, serum antibody to HCV (anti-HCV) almost always implies active infection; it is not protective. Anti-\\nHCV usually appears within 2 wk of acute infection but is sometimes delayed; however, HCV-RNA is\\npositive. In a small proportion of patients, anti-HCV merely reflects prior exposure with clearance of the\\nvirus rather than active infection. In such cases, ALT and AST levels are usually normal. In unclear cases,\\nHCV-RNA is measured.\\n[\\nTable 28-4.\\n Hepatitis B Serology*]\\n[\\nTable 28-5.\\n Hepatitis C Serology]\\nIn \\nHDV\\n, anti-HDV implies active infection. It may not be detectable until weeks after the acute illness.\\nIn \\nHEV\\n, the test for IgM anti-HEV is not routinely available. In a patient with endemic exposure and\\ncompatible clinical findings, anti-HEV suggests acute HEV infection.\\nBiopsy:\\n Biopsy is usually unnecessary but, if done, usually reveals similar histopathology regardless of\\nthe specific virus: patchy cell dropout, acidophilic hepatocellular necrosis, mononuclear inflammatory\\ninfiltrate, histologic evidence of regeneration, and preservation of the reticulin framework. HBV can\\noccasionally be diagnosed based on the presence of ground-glass hepatocytes (caused by HBsAg-\\npacked cytoplasm) and using special immunologic stains for the viral components. However, these\\nfindings are unusual in acute HBV and are much more common in chronic HBV infection. HCV causation\\ncan sometimes be inferred from subtle morphologic clues. Liver biopsy may help predict prognosis in\\nacute hepatitis but is rarely done solely for this purpose. Complete histologic recovery occurs unless\\nextensive necrosis bridges entire acini (bridging necrosis). Most patients with bridging necrosis recover\\nfully. However, some cases progress to chronic hepatitis.\\nTreatment\\n Supportive care\\n Occasionally postexposure prophylaxis\\nNo treatments attenuate acute viral hepatitis except, occasionally, postexposure immunoprophylaxis.\\nAlcohol should be avoided because it \\ncan increase liver damage. Restrictions on diet or activity, including\\ncommonly prescribed bed rest, have no scientific basis. Most patients may safely return to work after\\njaundice resolves, even if AST or ALT levels are slightly elevated. For cholestatic hepatitis,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n326'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 336, 'page_label': '327'}, page_content='cholestyramine 8 g po once/day or bid can relieve itching. Viral hepatitis should be reported to the local or\\nstate health department.\\nPrevention\\nBecause treatments have limited efficacy, prevention of viral hepatitis is very important. Good personal\\nhygiene helps prevent transmission, particularly fecal-oral transmission, as occurs with HAV and HEV.\\nBlood and other body fluids (eg, saliva, semen) of patients with acute HBV and HCV and stool of patients\\nwith HAV are considered infectious. Barrier protection is recommended, but isolation of patients does little\\nto prevent spread of HAV and is of no value in HBV or HCV infection. Posttransfusion infection is\\nminimized by avoiding unnecessary transfusions and screening all donors for HBsAg and anti-HCV.\\nScreening has decreased the incidence of posttransfusion hepatitis, probably to about 1/100,000 units of\\nblood component transfused.\\nImmunoprophylaxis can involve active immunization using vaccines and passive immunization.\\nHAV:\\n Preexposure HAV prophylaxis should be provided for travelers to highly endemic areas. It should\\nalso be considered for military personnel, day-care center employees, diagnostic laboratory workers, and,\\nbecause they have an increased risk of fulminant hepatitis from HAV, patients with chronic liver disorders\\n(including chronic hepatitis C). Several vaccines against HAV are available, each with different doses and\\nschedules; they are safe, provide protection within about 4 wk, and provide prolonged protection\\n(probably for > 20 yr).\\nStandard immune globulin, formerly immune serum globulin, prevents or decreases the severity of HAV\\ninfection and should be given to family members and close contacts of patients for postexposure\\nprophylaxis; 0.02 mL/kg IM is generally recommended, but some experts advise 0.06 mL/kg (3 to 5 mL for\\nadults).\\nHBV:\\n Vaccination in endemic areas has dramatically reduced local prevalence. Pre-exposure\\nimmunization has long been recommended for people at high risk. However, selective vaccination of high-\\nrisk groups in the US and other nonendemic areas has not substantially decreased the incidence of HBV;\\nthus, vaccination is now recommended for all US residents < 18 beginning at birth. Universal worldwide\\nvaccination is desirable but is too expensive to be feasible.\\nTwo recombinant vaccines are available; both are safe, even during pregnancy. Three IM deltoid\\ninjections are given: at baseline, at 1 mo, and at 6 mo. Children are given lower doses, and\\nimmunosuppressed patients and patients receiving hemodialysis are given higher doses.\\nAfter vaccination, levels of anti-HBs remain protective for 5 yr in 80 to 90% of immunocompetent\\nrecipients and for 10 yr in 60 to 80%. Booster doses of vaccine are recommended for patients receiving\\nhemodialysis and immunosuppressed patients whose anti-HBs is < 10 mIU/mL.\\nHBV postexposure immunoprophylaxis combines vaccination with hepatitis B immune globulin (HBIG), a\\nproduct with high titers of anti-HBs. HBIG probably does not prevent infection but prevents or attenuates\\nclinical illness. For infants born to HBsAg-positive mothers, an initial dose of vaccine plus 0.5 mL of HBIG\\nis given IM in the thigh immediately after birth. For anyone having sexual contact with an HBsAg-positive\\nperson or percutaneous or mucous membrane exposure to HBsAg-positive blood, 0.06 mL/kg of HBIG is\\ngiven IM within days, along with vaccine. Any previously vaccinated patient sustaining a percutaneous\\nHBsAg-positive exposure is tested for anti-HBs; if titers are < 10 mIU/mL, a booster dose of vaccine is\\ngiven.\\nHCV, HDV, and HEV:\\n A vaccine is now available for hepatitis E; it appears to have about 95% efficacy in\\npreventing symptomatic infection in males and is safe. Efficacy in other groups, duration of protection,\\nand efficacy in preventing asymptomatic infection are unknown. No product exists for immunoprophylaxis\\nof HCV or HDV. However, prevention of HBV prevents HDV. The propensity of HCV for changing its\\ngenome hampers vaccine development.\\nFulminant Hepatitis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n327'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 337, 'page_label': '328'}, page_content=\"Fulminant hepatitis is a rare syndrome of massive necrosis of liver parenchyma and a decrease\\nin liver size (acute yellow atrophy) that usually occurs after infection with certain hepatitis\\nviruses, exposure to toxic agents, or drug-induced injury.\\nHBV is sometimes responsible, and up to 50% of cases of fulminant hepatitis B involve HDV coinfection.\\nFulminant hepatitis with HAV is rare but may be more likely in people with preexisting liver disorders. The\\nrole of HCV remains uncertain.\\nPatients rapidly deteriorate because portal-systemic encephalopathy develops, often followed by coma\\nwithin hours or a few days, sometimes with cerebral edema. Bleeding commonly results from hepatic\\nfailure or disseminated intravascular coagulation, and functional renal failure (hepatorenal syndrome\\nsee p. \\n223\\n) may develop. Increasing PT, portal-systemic encephalopathy, and particularly renal failure\\nare ominous.\\nMeticulous nursing care and aggressive treatment of complications improve the outcome. However,\\nemergency liver transplantation provides the best hope for survival. Survival in adults is uncommon\\nwithout transplantation; children tend to do better. Patients who survive usually recover fully.\\nChronic Hepatitis\\nChronic hepatitis is hepatitis that lasts > 6 mo. Common causes include hepatitis B and C\\nviruses, autoimmune mechanisms (autoimmune hepatitis), and drugs. Many patients have no\\nhistory of acute hepatitis, and the first indication is discovery of asymptomatic\\naminotransferase elevations. Some patients present with cirrhosis or its complications (eg,\\nportal hypertension). Biopsy is necessary to confirm the diagnosis and to grade and stage the\\ndisease. Treatment is directed toward complications and the underlying condition (eg,\\ncorticosteroids for autoimmune hepatitis, antiviral therapy for viral hepatitis). Liver\\ntransplantation is often indicated for end-stage disease.\\nEtiology\\nHepatitis lasting > 6 mo is generally defined as chronic, although this duration is arbitrary. Hepatitis B\\nvirus (HBV) and hepatitis C virus (HCV) are frequent causes of chronic hepatitis; 5 to 10% of cases of\\nHBV infection, with or without hepatitis D virus (HDV) co-infection, and about 75% of cases of HCV\\ninfection become chronic. Hepatitis A and E viruses are not causes. Although the mechanism of chronicity\\nis uncertain, liver injury is mostly determined by the patient's immune reaction to the infection.\\nMany cases are idiopathic. A high proportion of idiopathic cases have prominent features of immune-\\nmediated hepatocellular injury (autoimmune hepatitis), including the following:\\n The presence of serologic immune markers\\n An association with histocompatibility haplotypes common in autoimmune disorders (eg, HLA-B1, HLA-\\nB8, HLA-DR3, HLA-DR4)\\n A predominance of T lymphocytes and plasma cells in liver histologic lesions\\n Complex in vitro defects in cellular immunity and immunoregulatory functions\\n An association with other autoimmune disorders (eg, RA, autoimmune hemolytic anemia, proliferative\\nglomerulonephritis)\\n A response to therapy with corticosteroids or immunosuppressants\\nSometimes chronic hepatitis has features of both autoimmune hepatitis and another chronic liver disorder\\n(eg, primary biliary cirrhosis, chronic viral hepatitis). These conditions are called overlap syndromes.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n328\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 338, 'page_label': '329'}, page_content=\"Many drugs, including isoniazid, methyldopa, nitrofurantoin, and, rarely, acetaminophen, can cause\\nchronic hepatitis. The mechanism varies with the drug and may involve altered immune responses,\\ncytotoxic intermediate metabolites, or genetically determined metabolic defects.\\nOther causes of chronic hepatitis include alcoholic hepatitis and nonalcoholic steatohepatitis. Less often,\\nchronic hepatitis results from \\n\\n1\\n-antitrypsin deficiency or Wilson's disease.\\nCases were once classified histologically as chronic persistent, chronic lobular, or chronic active hepatitis.\\nA more useful recent classification system specifies the etiology, the intensity of histologic inflammation\\nand necrosis (grade), and the degree of histologic fibrosis (stage). Inflammation and necrosis are\\npotentially reversible; fibrosis generally is not.\\nSymptoms and Signs\\nClinical features vary widely. About one third of cases develop after acute hepatitis, but most develop\\ninsidiously de novo. Many patients are asymptomatic, especially in chronic HCV infection. However,\\nmalaise, anorexia, and fatigue are common, sometimes with low-grade fever and nonspecific upper\\nabdominal discomfort. Jaundice is usually absent. Often, particularly with HCV, the first findings are signs\\nof chronic liver disease (eg, splenomegaly, spider nevi, palmar erythema). A few patients with chronic\\nhepatitis develop manifestations of cholestasis. In the autoimmune variant, especially in young women,\\nmanifestations may involve virtually any body system and can include acne, amenorrhea, arthralgia,\\nulcerative colitis, pulmonary fibrosis, thyroiditis, nephritis, and hemolytic anemia.\\nChronic HCV is occasionally associated with lichen planus, mucocutaneous vasculitis, glomerulonephritis,\\nporphyria cutanea tarda, \\nand perhaps non-Hodgkin B-cell lymphoma. About 1% of patients develop\\nsymptomatic cryoglobulinemia with fatigue, myalgias, arthralgias, neuropathy, glomerulonephritis, and skin\\nrashes (urticaria, purpura, or leukocytoclastic vasculitis); asymptomatic cryoglobulinemia is more\\ncommon.\\nDiagnosis\\n Liver function test results compatible with hepatitis\\n Viral serologic tests\\n Possibly autoantibodies, immunoglobulins, \\n\\n1\\n-antitrypsin level, and other tests\\n Usually biopsy\\n Serum albumin and PT\\nThe diagnosis is suspected in patients with suggestive symptoms and signs, incidentally noted elevations\\nin aminotransferase levels, or previously diagnosed acute hepatitis. Liver function tests are needed if not\\npreviously done and include serum ALT, AST, alkaline phosphatase, and bilirubin. Aminotransferase\\nelevations are the most characteristic laboratory abnormalities. Although levels can vary, they are typically\\n100 to 500 IU/L. ALT is usually higher than AST. Amino-transferase levels can be normal during chronic\\nhepatitis if the disease is quiescent, particularly with HCV. Alkaline phosphatase is usually normal or only\\nslightly elevated but is occasionally markedly high. Bilirubin is usually normal unless the disease is severe\\nor advanced. However, abnormalities in these laboratory tests are not specific and can result from other\\ndisorders, such as alcoholic liver disease, recrudescent acute viral hepatitis, and primary biliary cirrhosis.\\nIf laboratory results are compatible with hepatitis, viral serologic tests are done to exclude HBV and HCV\\n(see \\nTables 28-4\\n and \\n28-5\\n). Unless these tests indicate viral etiology, further testing is required. The first\\ntests done include autoantibodies, immunoglobulins, and \\n\\n1\\n-antitrypsin level. Children and young adults\\nare screened for Wilson's disease with a ceruloplasmin level. Marked elevations in serum\\nimmunoglobulins suggest chronic autoimmune hepatitis but are not conclusive. Autoimmune hepatitis is\\nnormally diagnosed based on the presence of antinuclear (ANA), anti-smooth muscle, or anti-liver/kidney\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n329\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 339, 'page_label': '330'}, page_content=\"microsomal type 1 (anti-LKM1) antibodies at titers of 1:80 (in adults) or 1:20 (in children).\\nUnlike in acute hepatitis, biopsy is necessary. Mild cases may have only minor hepatocellular necrosis\\nand inflammatory cell infiltration, usually in portal regions, with normal acinar architecture and little or no\\nfibrosis. Such cases rarely develop into clinically important liver disease or cirrhosis. In more severe\\ncases, biopsy typically shows periportal necrosis with mononuclear cell infiltrates (piecemeal necrosis)\\naccompanied by variable periportal fibrosis and bile duct proliferation. The acinar architecture may be\\ndistorted by zones of collapse and fibrosis, and frank cirrhosis sometimes coexists with signs of ongoing\\nhepatitis. Biopsy is also used to grade and stage the disease.\\nIn most cases, the specific cause of chronic hepatitis cannot be discerned via biopsy alone, although\\ncases caused by HBV can be distinguished by the presence of ground-glass hepatocytes and special\\nstains for HBV components. Autoimmune cases usually have a more pronounced infiltration by\\nlymphocytes and plasma cells. In patients with histologic but not serologic criteria for chronic autoimmune\\nhepatitis, variant autoimmune hepatitis is diagnosed; many have overlap syndromes.\\nSerum albumin and PT should be measured to determine severity; hepatic insufficiency is suggested by\\nlow serum albumin or prolonged PT. If symptoms or signs of cryoglobulinemia develop during chronic\\nhepatitis, particularly with HCV, cryoglobulin levels and rheumatoid factor should be measured; high levels\\nof rheumatoid factor and low levels of complement suggest cryoglobulinemia.\\nPatients with chronic HBV infection should be screened annually for hepatocellular cancer with\\nultrasonography and serum \\n\\n-fetoprotein measurement, although the cost-effectiveness of this practice is\\ndebated. Patients with chronic HCV infection should be similarly screened only if cirrhosis is present.\\nPrognosis\\nPrognosis is highly variable. Chronic hepatitis caused by a drug often regresses completely when the\\noffending drug is withdrawn. Without treatment, cases caused by HBV can resolve (uncommon), progress\\nrapidly, or progress slowly to cirrhosis over decades. Resolution often begins with a transient increase in\\ndisease severity and results in seroconversion from hepatitis B e antigen (HBeAg) to antibody to hepatitis\\nB e antigen (anti-HBe). Co-infection with HDV causes the most severe form of chronic HBV infection;\\nwithout treatment, cirrhosis develops in up to 70% of patients. Untreated chronic hepatitis due to \\nHCV\\nproduces cirrhosis in 20 to 30% of patients, although development may take decades. Chronic\\nautoimmune hepatitis usually responds to therapy but sometimes causes progressive fibrosis and\\neventual cirrhosis.\\nChronic HBV infection increases the risk of hepatocellular cancer. The risk is also increased in chronic\\nHCV infection, but only if cirrhosis has already developed (see p. \\n265\\n).\\nTreatment\\n Supportive care\\n Treatment of cause (eg, corticosteroids for autoimmune hepatitis, antivirals for HBV, interferons for HCV)\\nTreatment goals include management of complications (eg, ascites, encephalopathy) and treatment of the\\ncause. Drugs that cause hepatitis should be stopped. Underlying disorders, such as Wilson's disease,\\nshould be treated. In chronic hepatitis due to HBV, prophylaxis for contacts of patients may be helpful\\n(see p. \\n254\\n); corticosteroids and immunosuppressive drugs should be avoided because they enhance\\nviral replication. No prophylactic measures are required for contacts of patients with HCV infection.\\nAutoimmune hepatitis:\\n Corticosteroids, with or without azathioprine, prolong survival. Prednisone is\\nusually started at 30 to 40 mg po once/day, then tapered to the lowest dose that maintains\\naminotransferases at normal or near-normal levels. Some experts give concomitant azathioprine 1 to 1.5\\nmg/kg po once/day; others add azathioprine only if low-dose prednisone fails to maintain suppression.\\nMost patients require long-term, low-dose maintenance treatment. Liver transplantation may be required\\nfor end-stage disease.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n330\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 340, 'page_label': '331'}, page_content='HBV:\\n Antiviral treatment is indicated for patients with elevated aminotransferase levels, clinical or biopsy\\nevidence of progressive disease, or both. The goal is to eliminate HBV-DNA. Treatment may need to be\\ncontinued indefinitely and thus may be very expensive; stopping treatment prematurely can lead to\\nrelapse, which may be severe. However, treatment may be stopped if HBeAg converts to anti-HBe or if\\ntests for HBsAg become negative. Drug resistance is also a concern. Six antiviral drugsentecavir,\\nadefovir, lamivudine, interferon-\\n\\n (INF-\\n\\n), pegylated INF-\\n\\n2a (peginterferon-\\n\\n2a), and telbivudineare\\navailable (see\\nTable 28-6\\n).\\nFirst-line treatment is usually with an oral antiviral drug, such as entecavir (a nucleoside analogue) or\\nadefovir (a nucleotide analogue). Combination therapy has not proved superior to monotherapy.\\nEntecavir appears to have higher antiviral potency than other commonly used drugs. Resistance to\\nentecavir is uncommon, but the drug has not been in widespread clinical use for very long. Dosage is 0.5\\nmg po once/day; however, patients who have previously taken\\n[\\nTable 28-6.\\n Comparison of Drugs Commonly Used to Treat Chronic Viral Hepatitis B*]\\na nucleoside analogue should take 1 mg po once/day. Dose reduction is required in patients with renal\\ninsufficiency. Serious adverse effects appear to be uncommon so far, although the drug can induce\\ntumors in animals.\\nAdefovir is also relatively potent. Dosage is 10 mg po once/day. Adefovir may cause renal dysfunction, so\\nserum creatinine level must be measured periodically and the dose reduced if necessary.\\nAlternatively, lamivudine (a nucleoside analogue) 100 mg po once/day is given. It has few adverse effects,\\nwhich is one of its advantages over other antiviral drugs used to treat chronic HBV infection. INF-\\n\\n(usually IFN-\\n\\n2b), formerly first-line treatment, can be used. Dosage is 5 million IU sc once/day or 10\\nmillion IU sc 3 times/wk for 4 mo. In about 40% of patients, this regimen eliminates HBV-DNA and causes\\nseroconversion to anti-HBe; a successful response is usually presaged by a temporary increase in\\naminotransferase levels. The drug must be given by injection and is often poorly tolerated. The first 1 or 2\\ndoses cause an influenza-like syndrome. Later, fatigue, malaise, depression, bone marrow suppression,\\nand, rarely, bacterial infections or autoimmune disorders can occur. In patients with advanced cirrhosis,\\nIFN-\\n\\n can precipitate hepatic failure and is therefore contraindicated. Other contraindications include\\nrenal failure, immunosuppression, solid organ transplantation, cytopenia, and substance abuse. In a few\\npatients, treatment must be stopped because of intolerable adverse effects. The drug should be given\\ncautiously or not at all to patients with ongoing substance abuse or a major psychiatric disorder.\\nPegylated IFN-\\n\\n2 can also be given. Dosage is 180 \\n\\ng sc once/wk. Adverse effects are similar to those of\\nINF-\\n\\n but may be less severe.\\nTelbivudine is a new drug that has greater efficacy than lamivudine but has high rates of resistance.\\nLiver transplantation should be considered for end-stage liver disease caused by HBV, but the infection\\naggressively attacks the graft, and prognosis is less favorable than when liver transplantation is done for\\nother indications. Long-term posttransplantation therapy with lamivudine improves the outcome.\\nHCV:\\n For chronic hepatitis due to HCV, treatment is indicated if aminotransferase levels are elevated and\\nbiopsy shows active inflammatory disease with evolving fibrosis. Treatment aims to permanently eliminate\\nHCV-RNA (sustained response), which is associated with permanent normalization of aminotransferase\\nand cessation of histologic progression.\\nCombination therapy with pegylated IFN-\\n\\n plus ribavirin has the best results. Pegylated IFN-\\n\\n2b 1.5 \\n\\ng/kg\\nsc once/wk and pegylated IFN-\\n\\n2a 180 \\n\\ng sc once/wk have comparable results. Ribavirin 500 to 600 mg\\npo bid is usually given, although 400 mg bid may be sufficient for viral genotypes 2 and 3.\\nHCV genotype and viral load are determined before treatment because results influence treatment.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n331'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 341, 'page_label': '332'}, page_content='Genotype 1 is the most common type but is relatively resistant to treatment. Combination therapy is given\\nfor 1 yr; a sustained response rate of about 45 to 50% overall occurs. Results are more favorable in\\npatients with early disease and less favorable in those who already have cirrhosis. HCV viral load should\\nbe measured at 3 mo and treatment stopped if RNA has not declined by at least 2 log levels compared\\nwith pretreatment values.\\nLess common genotypes 2 and 3 respond more favorably. Combination therapy is required for only 6 mo\\nand gives an overall sustained response rate of about 75%. Longer treatment does not improve the\\nresults.\\nAdverse effects of pegylated IFN are similar to those of IFN-\\n\\n but may be less severe; contraindications\\nare also similar (see above).\\nRibavirin is usually well tolerated but commonly causes anemia due to hemolysis; dosage should be\\ndecreased if hemoglobin falls to < 10 g/dL. Ribavirin is teratogenic for both men and women,\\nnecessitating contraception until 6 mo after completion of treatment. Patients who cannot tolerate ribavirin\\nshould be given pegylated IFN-\\n\\n, but results are not as good as with combination treatment. Ribavirin\\nmonotherapy is of no value.\\nIn most adult transplantation centers, advanced cirrhosis due to HCV is now the most common indication\\nfor liver transplantation. Although HCV recurs in the graft, the course is usually indolent, and long-term\\nsurvival rates are relatively high.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 28. Hepatitis\\n332'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 342, 'page_label': '333'}, page_content='Chapter 29. Vascular Disorders of the Liver\\nIntroduction\\nThe liver has a dual blood supply. The portal vein (which is rich in nutrients and relatively high in O\\n2\\n)\\nprovides two thirds of blood flow to the liver. The hepatic artery (which is O\\n2\\n-rich) supplies the rest. The\\nhepatic veins drain the liver into the inferior vena cava. When portal vein blood flow increases, hepatic\\nartery flow decreases and vice versa (the hepatic arterial buffer response). This dual, reciprocally\\ncompensatory blood supply provides some protection from hepatic ischemia in healthy people.\\nDespite its dual blood supply, the liver, a metabolically active organ, can be injured by\\n \\nIschemia:\\n Ischemia results from reduced blood flow, reduced O\\n2\\n delivery, increased metabolic activity,\\nor all three.\\n \\nInsufficient venous drainage:\\n The cause may be focal or diffuse obstruction. Manifestations of focal\\nvenous obstruction depend on the location. Diffuse venous congestion causes congestive hepatopathy.\\nReduced venous outflow from the liver (originating in the hepatic veins or within the liver itself, usually\\nfrom cirrhosis) results in portal hypertension.\\n \\nSpecific vascular lesions:\\n The hepatic artery, hepatic vein, or portal vein may be involved. In peliosis\\nhepatis, the vascular lesion occurs in the sinusoids (microvascular anastomoses between the portal\\nand hepatic veins).\\nHepatic Ischemia\\nDiffuse ischemia can cause ischemic hepatitis; focal ischemia can cause hepatic infarction or ischemic\\ncholangiopathy. Hepatic infarction results from hepatic artery disorders.\\nIschemic Hepatitis\\n(Acute Hepatic Infarction; Hypoxic Hepatitis; Shock Liver)\\nIschemic hepatitis is diffuse liver damage due to an inadequate blood or O\\n2\\n supply.\\nCauses are most often systemic:\\n Impaired hepatic perfusion (eg, due to heart failure or acute hypotension)\\n Hypoxemia (eg, due to respiratory failure or carbon monoxide toxicity)\\n Increased metabolic demand (eg, due to sepsis)\\nFocal lesions of the hepatic vasculature are less common causes. Ischemic hepatitis may develop when\\nhepatic artery thrombosis occurs during liver transplantation or when a sickle cell crisis is associated with\\nportal vein thrombosis (thus compromising the dual blood supply to the liver). Centrizonal necrosis\\ndevelops without liver inflammation (ie, not a true hepatitis).\\nSymptoms may include nausea, vomiting, and tender hepatomegaly.\\nDiagnosis\\n Clinical evaluation and liver function tests\\n Doppler ultrasonography, MRI, or arteriography\\nIschemic hepatitis is suspected in patients who have risk factors and laboratory abnormalities:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 29. Vascular Disorders of the Liver\\n333'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 343, 'page_label': '334'}, page_content=' Serum aminotransferase increases dramatically (eg, to 1000 to 3000 IU/L).\\n LDH increases within hours of ischemia (unlike acute viral hepatitis).\\n Serum bilirubin increases modestly, only to  4 times its normal level.\\n PT/INR increases.\\nDiagnostic imaging helps define the cause: Doppler ultrasonography, MRI, or arteriography can identify\\nan obstructed hepatic artery or portal vein thrombosis.\\nTreatment\\n Hepatic reperfusion\\nTreatment is directed at the cause, aiming to restore hepatic perfusion, particularly by improving cardiac\\noutput and reversing any hemodynamic instability.\\nIf perfusion is restored, aminotransferase decreases over 1 to 2 wk. In most cases, liver function is fully\\nrestored. Fulminant liver failure, although uncommon, can occur in patients with preexisting cirrhosis.\\nIschemic Cholangiopathy\\nIschemic cholangiopathy is focal damage to the biliary tree due to disrupted flow from the\\nhepatic artery via the peribiliary arterial plexus.\\nCommon causes of ischemic cholangiopathy include vascular injury during orthotopic liver transplantation\\nor laparoscopic cholecystectomy, graft-rejection injury, chemoembolization, radiation therapy, and\\nthrombosis resulting from hypercoagulability disorders. Bile duct injury (ischemic necrosis) results,\\ncausing cholestasis, cholangitis, or biliary strictures (often multiple).\\nSymptoms (eg, pruritus, dark urine, pale stools), laboratory tests, and imaging studies indicate\\ncholestasis.\\nThe diagnosis is suspected when cholestasis is evident in patients at risk, particularly after liver\\ntransplantation. Ultrasonography is the 1st-line diagnostic imaging test for cholestasis, but most patients\\nrequire magnetic resonance cholangiopancreatography, ERCP, or both to rule out other causes such as\\ncholelithiasis or cholangiocarcinoma.\\nTreatment is directed at the cause. After liver transplantation, such treatment includes antirejection\\ntherapy and possible retransplantation. Biliary strictures warrant endoscopic balloon dilation and stenting.\\nCongestive Hepatopathy\\n(Passive Hepatic Congestion)\\nCongestive hepatopathy is diffuse venous congestion within the liver that results from right-\\nsided heart failure (usually due to a cardiomyopathy, tricuspid regurgitation, mitral insufficiency,\\ncor pulmonale, or constrictive pericarditis).\\nModerate or severe right-sided heart failure increases central venous pressure, which is transmitted to\\nthe liver via the inferior vena cava and hepatic veins. Chronic congestion leads to atrophy of hepatocytes,\\ndistention of sinusoids, and centrizonal fibrosis, which, if severe, progresses to cirrhosis (cardiac\\ncirrhosis). The basis for liver cell death is probably sinusoidal thrombosis that propagates to the central\\nveins and branches of the portal vein, causing ischemia.\\nMost patients are asymptomatic. However, moderate congestion causes right upper quadrant discomfort\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 29. Vascular Disorders of the Liver\\n334'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 344, 'page_label': '335'}, page_content=\"(due to stretching of the liver capsule) and tender hepatomegaly. Severe congestion leads to massive\\nhepatomegaly and jaundice. Ascites may result from the transmitted central venous hypertension;\\ninfrequently, splenomegaly results. With transmitted central venous hypertension, the hepatojugular reflex\\nis present, unlike in hepatic congestion due to Budd-Chiari syndrome.\\nDiagnosis\\n Clinical evaluation\\nCongestive hepatopathy is suspected in patients who have right-sided heart failure, jaundice, and tender\\nhepatomegaly. Liver biochemistries are modestly abnormal: unconjugated hyperbilirubinemia (total\\nbilirubin < 3 mg/dL), elevated (usually < 2 to 3 fold) aminotransferases, and prolonged PT/INR. Any ascitic\\nfluid has a high albumin content (> 25 g/L) and serum ascites/albumin gradient. ( 1.1). Because the\\nlaboratory abnormalities are nonspecific, recognition of congestive hepatopathy is ultimately clinical. The\\nliver disorder is more important as an index of the severity of heart failure than as a diagnosis by itself.\\nTreatment\\nTreatment is directed at the underlying heart failure.\\nHepatic Artery Disorders\\nThe hepatic artery may be occluded. Uncommonly, aneurysms develop.\\nHepatic Artery Occlusion\\nCauses of hepatic artery occlusion include thrombosis (eg, due to hypercoagulability disorders, severe\\narteriosclerosis, or vasculitis), emboli (eg, due to endocarditis, tumors, therapeutic embolization, or\\nchemoembolization), iatrogenic causes (eg, ligation during surgery), vasculitis (via nonthrombotic\\nmechanisms), structural arterial abnormalities (eg, hepatic artery aneurysm), eclampsia, cocaine use, and\\nsickle cell crisis. Usually, the result is an hepatic infarct. In patients with a liver transplant or preexisting\\nportal vein thrombosis, hepatic artery thrombosis causes ischemic hepatitis (see p. \\n259\\n). Because of the\\nliver's dual blood supply, the liver is somewhat resistant to ischemic hepatitis and infarction.\\nHepatic artery occlusion does not elicit symptoms without hepatic infarction or ischemic hepatitis. Hepatic\\ninfarction may be asymptomatic or cause right upper quadrant pain, fever, nausea, vomiting, and\\njaundice. Leukocytosis and a high aminotransferase level are common.\\nDiagnosis\\n Vascular imaging\\nDiagnosis of hepatic artery occlusion is confirmed by imaging with Doppler ultrasonography, usually\\nfollowed by angiography. \\nThe choice between CT angiography, magnetic resonance angiography, and\\nceliac arteriography largely depends on availability and expertise. CT may detect a wedge-shaped area\\nof low attenuation.\\nTreatment\\nTreatment is directed at the cause.\\nAneurysms\\nAneurysms of the hepatic artery are uncommon. They tend to be saccular and multiple. Causes include\\ninfection, arteriosclerosis, trauma, and vasculitis. Untreated aneurysms may cause death by rupturing into\\nthe common bile duct (causing hemobilia), peritoneum (causing peritonitis), or adjacent hollow viscera.\\nHemobilia may cause jaundice, upper GI bleeding, and abdominal pain in the right upper quadrant.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 29. Vascular Disorders of the Liver\\n335\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 345, 'page_label': '336'}, page_content='Diagnosis is suspected if typical symptoms occur or if imaging tests detect an aneurysm. Doppler\\nultrasonography, followed by contrast CT, is required for confirmation.\\nTreatment is embolization or surgical ligation.\\nHepatic Vein Disorders\\nObstruction of hepatic venous outflow can occur in extrahepatic vessels (Budd-Chiari syndrome) or\\nintrahepatic vessels (veno-occlusive disease) but often occurs in both. Obstruction results in congestion\\nof the sinusoids, hepatomegaly, portal hypertension, reduced portal blood flow, ascites, and\\nsplenomegaly.\\nBudd-Chiari Syndrome\\nBudd-Chiari syndrome is obstruction of hepatic venous outflow that originates anywhere from\\nthe small hepatic veins inside the liver to the inferior vena cava and right atrium. Manifestations\\nrange from no symptoms to fulminant liver failure. Diagnosis is based on ultrasonography.\\nTreatment includes supportive medical therapy and measures to establish and maintain venous\\npatency, such as thrombolysis, decompression with shunts, and long-term anticoagulation.\\nEtiology\\nIn the Western world, the most common cause is a clot obstructing the hepatic veins and the adjacent\\ninferior vena cava. Clots commonly result from the following:\\n Thrombotic conditions (eg, protein C or S deficiency, antiphospholipid syndrome, antithrombin III\\ndeficiency, factor V Leiden mutation, pregnancy, oral contraceptive use)\\n Hematologic disorders (eg, myeloproliferative disorders such as polycythemia and paroxysmal nocturnal\\nhemoglobinopathy)\\n Inflammatory bowel disease\\n Connective tissue disorders\\n Trauma\\n Infection (eg, hydatid cyst, amebiasis)\\n Tumor invasion of the hepatic vein (eg, hepatocellular or renal cell carcinoma)\\nSometimes Budd-Chiari syndrome begins during pregnancy and unmasks a previously asymptomatic\\nhypercoagulability disorder.\\nThe cause of obstruction is often unknown. In Asia and South Africa, the basic defect is often a\\nmembranous obstruction (webs) of the inferior vena cava above the liver, likely representing\\nrecanalization of a prior thrombus in adults or a developmental flaw (eg, venous stenosis) in children.\\nThis type of obstruction is called obliterative hepatocavopathy.\\nBudd-Chiari syndrome usually develops over weeks or months. When it does, cirrhosis and portal\\nhypertension tend to develop.\\nSymptoms and Signs\\nManifestations range from none (asymptomatic) to fulminant liver failure or cirrhosis. Symptoms vary\\ndepending on whether the obstruction occurs acutely or over time.\\nAcute obstruction (in about 20%) causes fatigue, right upper quadrant pain, nausea, vomiting, mild\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 29. Vascular Disorders of the Liver\\n336'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 346, 'page_label': '337'}, page_content='jaundice, tender hepatomegaly, and ascites. It typically occurs during pregnancy. Fulminant liver failure\\nwith encephalopathy is rare. Aminotransferase levels are quite high\\nChronic outflow obstruction (developing over weeks to months) may be rather asymptomatic in some\\npatients until it progresses or may cause fatigue, abdominal pain, and hepatomegaly. Lower-extremity\\nedema and ascites may result from venous obstruction, even in the absence of cirrhosis. Cirrhosis may\\ndevelop, leading to variceal bleeding, massive ascites, splenomegaly, hepatopulmonary syndrome (see p.\\n1988\\n), or a combination. Complete obstruction of the inferior vena cava causes edema of the abdominal\\nwall and legs plus visibly tortuous superficial abdominal veins from the pelvis to the costal margin.\\nDiagnosis\\n Clinical evaluation and liver function tests\\n Vascular imaging\\nBudd-Chiari syndrome is suspected in patients with\\n Hepatomegaly, ascites, liver failure, or cirrhosis when there is no obvious cause (eg, alcohol abuse,\\nhepatitis) or when the cause is unexplained\\n Abnormal liver function test results and risk factors for thrombosis\\nLiver function tests are usually abnormal; the pattern is variable and nonspecific. Imaging usually begins\\nwith abdominal Doppler ultrasonography, which can show the direction of blood flow and the site of\\nobstruction. Magnetic resonance angiography and CT are useful if ultrasonography is not diagnostic.\\nConventional angiography (venography with pressure measurements and arteriography) is necessary if\\ntherapeutic or surgical intervention is planned. Liver biopsy is done occasionally to diagnose the acute\\nstages and determine whether cirrhosis has developed.\\nPrognosis\\nWithout treatment, most patients with complete venous obstruction die of liver failure within 3 yr. For\\npatients with incomplete obstruction, the course varies.\\nTreatment\\n Supportive care\\n Restoration and maintenance of adequate venous outflow\\nTreatment varies according to its onset (acute vs chronic) and severity (fulminant liver failure vs\\ndecompensated cirrhosis vs stable or asymptomatic). The cornerstones of management are\\n Giving supportive therapy directed at complications (eg, ascites, liver failure, esophageal varices)\\n Decompressing the congested liver (ie, maintaining venous outflow)\\n Preventing propagation of the clot\\nAggressive interventions (eg, thrombolysis, stents) are used when the disease is acute (eg, within 4 wk\\nand in the absence of cirrhosis). Thrombolysis can dissolve acute clots, allowing recanalization and so\\nrelieving hepatic congestion. Radiologic procedures have a major role using angioplasty, stenting, and\\nportosytemic shunts. For caval webs or hepatic venous stenosis, decompression via percutaneous\\ntransluminal balloon angioplasty with intraluminal stents can maintain hepatic outflow. When dilation of a\\nhepatic outflow narrowing is not technically feasible, transjugular intrahepatic portosystemic shunting\\n(TIPS) and various surgical shunts can provide decompression by diversion into the systemic circulation.\\nPortosystemic shunts are generally not used if hepatic encephalopathy is present; such shunts worsen\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 29. Vascular Disorders of the Liver\\n337'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 347, 'page_label': '338'}, page_content='liver function. Further, shunts tend to thrombose, especially when associated with hematologic disorders.\\nLong-term anticoagulation is often necessary to prevent recurrence. Liver transplantation may be\\nlifesaving in patients with fulminant disease or decompensated cirrhosis.\\nVeno-Occlusive Disease\\n(Sinusoidal Obstruction Syndrome)\\nHepatic veno-occlusive disease is caused by endothelial injury, leading to nonthrombotic\\nocclusion of the terminal hepatic venules and hepatic sinusoids, rather than of the hepatic veins\\nor inferior vena cava (as in Budd-Chiari syndrome).\\nVenous congestion causes portal hypertension and ischemic necrosis (which leads to cirrhosis).\\nCommon causes include\\n Irradiation\\n Graft-vs-host disease resulting from bone marrow or hematopoietic cell transplantation\\n Pyrrolizidine alkaloids in crotalaria and senecio plants (eg, medicinal bush teas) and other herbs (eg,\\ncomfrey)\\n Other hepatotoxins (eg, dimethylnitrosamine, aflatoxin, azathioprine, some anticancer drugs)\\nInitial manifestations include sudden jaundice, ascites, and tender, smooth hepatomegaly. Onset is within\\nthe first 3 wk of transplantation in bone marrow or hematopoietic cell recipients, who either recover\\nspontaneously within a few weeks (or sometimes, with mild cases, after an increase in\\nimmunosuppressant therapy) or die of fulminant liver failure. Other patients have recurrent ascites, portal\\nhypertension, splenomegaly, and, eventually, cirrhosis.\\nDiagnosis\\n Clinical evaluation and liver function tests\\n Ultrasonography\\n \\nSometimes invasive tests (eg, liver biopsy, measurement of portal-hepatic venous pressure gradient)\\nThe diagnosis is suspected in patients with unexplained clinical or laboratory evidence of liver disease,\\nparticularly in those with known risk factors, such as bone marrow or hematopoietic cell transplantation.\\nLaboratory results are nonspecific: elevated aminotransferase and conjugated bilirubin levels. PT/INR\\nbecomes abnormal when disease is severe. Ultrasonography shows retrograde flow in the portal vein. If\\nthe diagnosis is unclear, invasive tests become necessaryeg, liver biopsy or measurement of the portal-\\nhepatic venous pressure gradient (a pressure gradient > 10 mm Hg suggests veno-occlusive disease).\\nMeasuring the pressure across the liver entails inserting a catheter percutaneously into a hepatic vein\\nand then wedging it into the liver. This wedged pressure reflects portal vein pressure. (An exception is\\nportal vein thrombosis; in this case, the pressure is normal despite portal hypertension.)\\nTreatment\\n Supportive care\\n Treatment of cause\\n For progressive disease, transjugular intrahepatic portosystemic shunting or transplantation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 29. Vascular Disorders of the Liver\\n338'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 348, 'page_label': '339'}, page_content='Ursodeoxycholic acid helps prevent graft-vs-host disease in bone marrow or hematopoietic cell transplant\\nrecipients. Management includes withdrawing the causative agent (such as herbal teas) and providing\\nsupportive therapy. Most patients have mild to moderate disease and do quite well. Those that progress\\nmay require transjugular intrahepatic portosystemic shunting (TIPS) for relief of portal hypertension.\\nHowever, in 25%, veno-occlusive disease is severe, accompanied by fulminant liver failure. Liver\\ntransplantation is a last resort.\\nPortal Vein Disorders\\nNearly all portal vein disorders obstruct portal vein blood flow and cause portal hypertension (see p. \\n218\\n).\\nObstruction can be\\n Extrahepaticportal vein thrombosis due to a hypercoagulable state, vessel wall lesion (eg,\\npylephlebitis, omphalitis), an adjacent lesion (eg, pancreatitis, tumor), or congenital atresia of the portal\\nvein\\n Intrahepatic (eg, microvascular portal vein obstruction as in schistosomiasis, primary biliary cirrhosis,\\nsarcoidosis, noncirrhotic portal hypertension)\\nPortal Vein Thrombosis\\nPortal vein thrombosis causes portal hypertension and consequent GI bleeding from varices,\\nusually in the lower esophagus or stomach. Diagnosis is based on ultrasonography. Treatment\\ninvolves control of variceal bleeding (usually with endoscopic banding, IV octreotide, or both),\\nprevention of recurrence using \\n\\n-blockers and sometimes surgical shunts and thrombolysis for\\nacute thrombosis.\\nEtiology\\nCommon causes vary by age group (see\\nTable 29-1\\n).\\nSymptoms and Signs\\nAcute portal vein thrombosis is commonly asymptomatic unless associated with another event, such as\\npancreatitis (the cause), or another complication, such as mesenteric venous thrombosis. Most often,\\nclinical featuressplenomegaly (especially in children) and variceal hemorrhagedevelop chronically\\nsecondary to portal hypertension. Ascites is uncommon (10%) in postsinusoidal portal hypertension.\\nAscites may be precipitated when cirrhosis is also present or when serum albumin (and thus oncotic\\npressure) deceases after high-volume fluid resuscitation for a major GI bleed.\\nDiagnosis\\n Clinical evaluation and liver function tests\\n Doppler ultrasonography\\nPortal vein thrombosis is suspected in patients with the following:\\n Manifestations of portal hypertension without cirrhosis\\n Mild abnormalities in liver function or enzymes plus risk factors such as neonatal umbilical infection,\\nchildhood appendicitis, or a hypercoagulability disorder\\nDoppler ultrasonography is usually diagnostic, showing diminished or absent portal vein flow and\\nsometimes the thrombus. Difficult cases may require MRI or CT with contrast. Angiography may be\\nrequired to guide shunt surgery.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 29. Vascular Disorders of the Liver\\n339'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 349, 'page_label': '340'}, page_content='[\\nTable 29-1.\\n Common Causes of Portal Vein Thrombosis*]\\nTreatment\\n For some acute cases, thrombolysis\\n Long-term anticoagulation\\n Management of portal hypertension and its complications\\nIn acute cases, thrombolysis is sometimes successful, best reserved for recent occlusion, particularly in\\nhypercoagulable states. Anticoagulation does not lyse clots but has some value for long-term prevention\\nin hypercoagulable states despite the risk of variceal bleeding. In neonates and children, treatment is\\ndirected at the cause (eg, omphalitis, appendicitis). Otherwise, management is directed at the portal\\nhypertension and its complications (see p. \\n218\\n); treatment can include octreotide IV (a synthetic analog of\\nsomatostatin) and endoscopic banding to control variceal bleeding and nonselective \\n\\n-blockers to prevent\\nrebleeding. These therapies have decreased the use of surgical shunts (eg, mesocaval, splenorenal),\\nwhich can become occluded and have an operative mortality rate of 5 to 50%. Transjugular intrahepatic\\nportosytemic shunting (TIPS) is not recommended. TIPS requires monitoring (including frequent\\nangiography) to assess patency, may become blocked, and may not adequately decompress the liver.\\nPeliosis Hepatis\\nPeliosis hepatis is typically an asymptomatic disorder in which multiple blood-filled cystic\\nspaces develop randomly in the liver.\\nMeasuring a few millimeters to about 3 cm in diameter, the cysts of peliosis hepatis often lack a cell lining\\nand are surrounded by hepatocytes. Some have an endothelial cell lining, accompanied by dilated\\nhepatic sinusoids. The cause is probably damage to the sinusoidal lining cells. Peliosis hepatis is\\nassociated with use of hormones (eg, anabolic steroids, oral contraceptives, glucocorticoids), tamoxifen,\\nvinyl chloride, vitamin A, and, particularly in kidney transplant recipients, azathioprine.\\nPeliosis hepatis is usually asymptomatic, but occasionally cysts rupture, resulting in hemorrhage and\\nsometimes causing death. Some patients develop overt liver disease, characterized by jaundice,\\nhepatomegaly, and liver failure.\\nMild cases may be detected incidentally during imaging tests done because liver function test results are\\nslightly abnormal or for other reasons. Ultrasonography or CT can detect cysts.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 29. Vascular Disorders of the Liver\\n340'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 350, 'page_label': '341'}, page_content=\"Chapter 30. Liver Masses and Granulomas\\nIntroduction\\nLiver masses include cysts, benign tumors, primary liver cancers, and metastatic liver cancer. Certain\\ndrugs and disorders can result in granuloma formation in the liver.\\nHepatic Cysts\\nIsolated cysts are commonly detected incidentally on abdominal ultrasonography or CT. These cysts are\\nusually asymptomatic and have no clinical significance. The rare congenital polycystic liver is commonly\\nassociated with polycystic disease of the kidneys (see p. \\n2385\\n) and other organs. It causes progressive\\nnodular hepatomegaly (sometimes massive) in adults. Nevertheless, hepatocellular function is remarkably\\nwell preserved, and portal hypertension rarely develops.\\nOther hepatic cysts include the following:\\n Hydatid (echinococcal) cysts (see p. \\n1362\\n)\\n Caroli's disease, which is rare, autosomal recessive, and characterized by segmental cystic dilation of\\nintrahepatic bile ducts (often becoming symptomatic in adulthood, with stone formation, cholangitis, and\\nsometimes cholangiocarcinoma)\\n True cystic tumors (rare)\\nBenign Liver Tumors\\nBenign liver tumors are relatively common. Most are asymptomatic, but some cause hepatomegaly, right\\nupper quadrant discomfort, or intraperitoneal hemorrhage. Most are detected incidentally on ultrasound or\\nother scans. Liver function tests are usually normal or only slightly abnormal. Diagnosis is usually\\npossible with imaging tests but may require biopsy. Treatment is needed only in a few specific\\ncircumstances.\\nHepatocellular adenoma:\\n Hepatocellular adenoma is the most important benign tumor to recognize. It\\noccurs primarily in women of childbearing age, particularly those taking oral contraceptives, possibly via\\nestrogen's effects. Most adenomas are asymptomatic, but large ones may cause right upper quadrant\\ndiscomfort. Rarely, adenomas manifest as peritonitis and shock due to rupture and intraperitoneal\\nhemorrhage. Rarely, they become malignant.\\nDiagnosis is often suspected based on ultrasound or CT results, but biopsy is sometimes needed for\\nconfirmation.\\nAdenomas due to contraceptive use often regress if the contraceptive is stopped. If the adenoma does\\nnot regress or if it is subcapsular or > 5 cm, surgical resection is often recommended.\\nFocal nodular hyperplasia:\\n This localized hamartoma may resemble macronodular cirrhosis\\nhistologically. Diagnosis is usually based on MRI or CT with contrast, but biopsy may be necessary.\\nTreatment is rarely needed.\\nHemangiomas:\\n Hemangiomas are usually small and asymptomatic; they occur in 1 to 5% of adults.\\nThese tumors often have a characteristic highly vascular appearance. Rupture is rare, even when tumors\\nare large. Hemangiomas are found incidentally during ultrasonography, CT, or MRI. Treatment is usually\\nnot indicated.\\nIn infants, hemangiomas often regress spontaneously by age 2 yr. However, large hemangiomas\\noccasionally cause arteriovenous shunting sufficient to cause heart failure and sometimes consumption\\ncoagulopathy. In these cases, treatment may include high-dose corticosteroids, sometimes diuretics and\\ndigoxin to improve heart function, interferon-\\n\\n (given sc), surgical removal, selective hepatic artery\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 30. Liver Masses & Granulomas\\n341\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 351, 'page_label': '342'}, page_content=\"embolization, and, rarely, liver transplantation.\\nOther benign tumors:\\n Lipomas (usually asymptomatic) and localized fibrous tumors (eg, fibromas) rarely\\noccur in the liver.\\nBenign bile duct adenomas are rare, inconsequential, and usually detected incidentally. They are\\nsometimes mistaken for metastatic cancer.\\nPrimary Liver Cancer\\nPrimary liver cancer is usually hepatocellular carcinoma. The first manifestations of liver cancer are\\nusually nonspecific, delaying the diagnosis. Prognosis is usually poor.\\nHepatocellular Carcinoma\\nHepatocellular carcinoma (hepatoma) usually occurs in patients with cirrhosis and is common in\\nareas where infection with hepatitis B and C viruses is prevalent. Symptoms and signs are\\nusually nonspecific. Diagnosis is based on \\n\\n-fetoprotein (AFP) levels, imaging \\ntests, and\\nsometimes liver biopsy. Screening with periodic AFP measurement and ultrasonography is\\nsometimes recommended for high-risk patients. Prognosis is poor when cancer is advanced,\\nbut for small tumors that are confined to the liver, ablative therapies are palliative and surgical\\nresection or liver transplantation is sometimes curative.\\nHepatocellular carcinoma is the most common type of primary liver cancer and results in about 14,000\\ndeaths annually in the US. However, it is more common outside the US, particularly in East Asia and sub-\\nSaharan Africa; incidence generally parallels geographic prevalence of chronic hepatitis B virus (HBV)\\ninfection.\\nEtiology\\nHepatocellular carcinoma is usually a complication of cirrhosis.\\nThe presence of HBV increases risk of hepatocellular carcinoma by > 100-fold among HBV carriers.\\nIncorporation of HBV-DNA into the host's genome may initiate malignant transformation, even in the\\nabsence of chronic hepatitis or cirrhosis.\\nOther disorders that cause hepatocellular carcinoma include cirrhosis due to chronic hepatitis C virus\\n(HCV) infection, hemochromatosis, and alcoholic cirrhosis. Patients with cirrhosis due to other conditions\\nare also at increased risk.\\nEnvironmental carcinogens may play a role; eg, ingestion of food contaminated with fungal aflatoxins is\\nbelieved to contribute to the high incidence of hepatocellular carcinoma in subtropical regions.\\nSymptoms and Signs\\nMost commonly, previously stable patients with cirrhosis present with abdominal pain, weight loss, right\\nupper quadrant mass, and unexplained deterioration. Fever may occur. In a few patients, the first\\nmanifestation of hepatocellular carcinoma is bloody ascites, shock, or peritonitis, caused by hemorrhage\\nof the tumor. Occasionally, a hepatic friction rub or bruit develops.\\nOccasionally, systemic metabolic complications, including hypoglycemia, erythrocytosis, hypercalcemia,\\nand hyperlipidemia, occur. These complications may manifest clinically.\\nDiagnosis\\n \\n\\n-Fetoprotein (AFP) measurement\\n Imaging (CT, ultrasonography, or MRI)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 30. Liver Masses & Granulomas\\n342\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 352, 'page_label': '343'}, page_content='Diagnosis is based on AFP measurement and an imaging test. In adults, AFP signifies dedifferentiation of\\nhepatocytes, which most often indicates hepatocellular carcinoma; 40 to 65% of patients with the cancer\\nhave high AFP levels (> 400 \\n\\ng/L). High levels are otherwise rare, except in teratocarcinoma of the testis,\\na much less common tumor. Lower values are less specific and can occur with hepatocellular\\nregeneration (eg, in hepatitis). Other blood tests, such as AFP-L3 (an AFP isoform) and des-\\n\\n-\\ncarboxyprothrombin, are being studied as markers to be used for early detection of hepatocellular\\ncarcinoma.\\nDepending on local preferences and capabilities, the first imaging test may be contrast-enhanced CT,\\nultrasonography, or MRI. Hepatic arteriography is occasionally helpful in equivocal cases and can be\\nused to outline the vascular anatomy when ablation or surgery is planned.\\nIf imaging shows characteristic findings and AFP is elevated, the diagnosis is clear. Liver biopsy, often\\nguided by ultrasonography or CT, is sometimes indicated for definitive diagnosis.\\nStaging:\\n If a hepatocellular carcinoma is diagnosed, evaluation usually includes chest CT without\\ncontrast, imaging of the portal vein (if not already done) by MRI or CT with contrast to exclude\\nthrombosis, and sometimes bone scanning.\\nHepatocellular carcinoma is staged based on the following (American Cancer Society classification\\nsystemsee\\nTable 30-1\\n):\\n T: How many primary tumors, how big they are, and whether the cancer has spread to adjacent organs\\n N: Whether the cancer has spread to nearby lymph nodes\\n M: Whether the cancer has metastasized to other organs of the body\\nNumbers (0 to 4) are added after T, N, and M to indicate increasing severity. The letter X means no\\nassessment is possible.\\nScreening:\\n An increasing number of hepatocellular carcinomas are being detected through screening\\nprograms. Screening patients with cirrhosis is reasonable, although this measure is controversial and has\\nnot been shown to reduce mortality. One common screening method is AFP measurement and\\nultrasonography every 6 or 12 mo. Many experts advise screening patients with longstanding hepatitis B\\neven when cirrhosis is absent.\\nTreatment\\n Transplantation if tumors are small and few\\n[\\nTable 30-1.\\n Staging Hepatocellular Carcinoma*]\\nFor single tumors < 5 cm or  3 tumors  3 cm that are limited to the liver, liver transplantation results in\\nas good a prognosis as liver transplantation done for noncancerous disorders. Alternatively, surgical\\nresection may be done; however, the cancer usually recurs.\\nAblative treatments (eg, hepatic arterial chemoembolization, intratumoral ethanol injection, cryoablation,\\nradiofrequency ablation) provide palliation and slow tumor growth; they are used when patients are\\nawaiting liver transplantation.\\nIf the tumor is large (> 5 cm), is multifocal, has invaded the portal vein, or is metastatic (ie, stage III or\\nhigher), prognosis is much less favorable (eg, 5-yr survival rates of about 5% or less). Radiation therapy\\nis usually ineffective. Some newer chemotherapeutic regimens are promising.\\nPrevention\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 30. Liver Masses & Granulomas\\n343'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 353, 'page_label': '344'}, page_content='Use of vaccine against HBV eventually decreases the incidence, especially in endemic areas. Preventing\\nthe development of cirrhosis of any cause (eg, via treatment of chronic hepatitis C, early detection of\\nhemochromatosis, management of alcoholism) can also have a significant effect.\\nOther Primary Liver Cancers\\nOther primary liver cancers are uncommon or rare. Diagnosis usually requires biopsy. Prognosis is\\ntypically poor. Some cancers, if localized, can be resected. With resection or liver transplantation, survival\\nmay be prolonged.\\nFibrolamellar carcinoma:\\n This distinct variant of hepatocellular carcinoma has a characteristic\\nmorphology of malignant hepatocytes enmeshed in lamellar fibrous tissue. It usually occurs in young\\nadults and has no association with preexisting cirrhosis, HBV, HCV, or other known risk factors. AFP\\nlevels are rarely elevated. Prognosis is better than that for hepatocellular carcinoma, and many patients\\nsurvive several years after tumor resection.\\nCholangiocarcinoma:\\n This tumor originates in the biliary epithelium. It is common in China, where\\nunderlying infestation with liver flukes is believed to contribute. Elsewhere, it is less common than\\nhepatocellular carcinoma; histologically, the two may overlap. Primary sclerosing cholangitis greatly\\nincreases risk of cholangiocarcinoma.\\nHepatoblastoma:\\n Although rare, hepatoblastoma is one of the most common primary liver cancers in\\ninfants, particularly those with a family history of familial adenomatous polyposis (see p. \\n192\\n). It can also\\ndevelop in children. Some patients with hepatoblastoma present with precocious puberty caused by\\nectopic gonadotropin production, but the cancer is usually detected because of deteriorating general\\nhealth and a right upper quadrant mass. An elevated AFP level and abnormal imaging test results may\\nhelp in the diagnosis.\\nAngiosarcoma:\\n This rare cancer is associated with specific chemical carcinogens, including industrial\\nvinyl chloride.\\nMetastatic Liver Cancer\\nLiver metastases are common in many types of cancer, especially those of the GI tract, breast,\\nlung, and pancreas. The first symptoms of metastases are usually nonspecific (eg, weight loss,\\nright upper quadrant discomfort); they are sometimes the first symptoms of the primary cancer.\\nLiver metastases are suspected in patients with weight loss and hepatomegaly or with primary\\ntumors likely to spread to the liver. Diagnosis is usually supported by an imaging test, most\\noften ultrasonography, spiral CT with contrast, or MRI with contrast. Treatment usually involves\\npalliative chemotherapy.\\nMetastatic liver cancer is more common than primary liver cancer and is sometimes the initial clinical\\nmanifestation of cancer originating in the GI tract, breast, lung, or pancreas.\\nSymptoms and Signs\\nEarly liver metastases may be asymptomatic. Nonspecific symptoms of cancer (eg, weight loss, anorexia,\\nfever) often develop first. The liver may be enlarged, hard, or tender; massive hepatomegaly with easily\\npalpable nodules signifies advanced disease. Hepatic bruits and pleuritic-type pain with an overlying\\nfriction rub are uncommon but characteristic. Splenomegaly is occasionally present, especially when the\\nprimary cancer is pancreatic. Concomitant peritoneal tumor seeding may produce ascites, but jaundice is\\nusually absent or mild initially unless a tumor causes biliary obstruction.\\nIn the terminal stages, progressive jaundice and hepatic encephalopathy presage death.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 30. Liver Masses & Granulomas\\n344'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 354, 'page_label': '345'}, page_content=' CT with contrast or MRI with contrast\\n Sometimes biopsy\\nLiver metastases are suspected in patients with weight loss and hepatomegaly or with primary tumors\\nlikely to spread to the liver. If metastases are suspected, liver function tests are often done, but results\\nare usually not specific for the diagnosis. Alkaline phosphatase, \\n\\n-glutamyl transpeptidase, and\\nsometimes LDH typically increase earlier or to a greater degree than do other test results;\\naminotransferase levels vary. Imaging tests have good sensitivity and specificity. Ultrasonography is\\nusually helpful, but CT with contrast or MRI with contrast is often more accurate.\\nLiver biopsy guided by imaging provides the definitive diagnosis and is done if other tests are equivocal\\nor if histologic information (eg, cell type of the liver metastasis) may help determine the treatment plan.\\nTreatment\\nTreatment depends on the extent of metastasis. With solitary or very few metastases due to colorectal\\ncancer, surgical resection may prolong survival. Depending on characteristics of the primary tumor,\\nsystemic chemotherapy may shrink tumors and prolong life but is not curative; hepatic intra-arterial\\nchemotherapy sometimes has the same effect but with fewer or milder systemic adverse effects.\\nRadiation therapy to the liver occasionally alleviates severe pain due to advanced metastases but does\\nnot prolong life. Extensive disease is fatal and is best managed by palliation for the patient and support\\nfor the family (see p. \\n3480\\n).\\nHematologic Cancers and the Liver\\nThe liver is commonly involved in advanced leukemia and related blood disorders. Liver biopsy is not\\nneeded. In hepatic lymphoma, especially Hodgkin lymphoma, the extent of liver involvement determines\\nstaging and treatment but may be difficult to assess. Hepatomegaly and abnormal liver function tests may\\nreflect a systemic reaction to Hodgkin lymphoma rather than spread to the liver, and biopsy often shows\\nnonspecific focal mononuclear infiltrates or granulomas of uncertain significance. Treatment is directed at\\nthe hematologic cancer.\\nHepatic Granulomas\\nHepatic granulomas have numerous causes and are usually asymptomatic. However, the\\nunderlying disorder may cause extrahepatic manifestations, hepatic inflammation, fibrosis,\\nportal hypertension, or a combination. Diagnosis is based on liver biopsy, but biopsy is\\nnecessary only if a treatable underlying disorder (eg, infection) is suspected or if other liver\\ndisorders need to be ruled out. Treatment depends on the underlying disorder.\\nHepatic granulomas, although sometimes insignificant, more often reflect clinically relevant disease. The\\nterm granulomatous \\nhepatitis is often used to describe the condition, but the disorder is not true hepatitis,\\nand the presence of granulomas does not imply hepatocellular inflammation.\\nEtiology\\nHepatic granulomas have many causes (see\\nTable 30-2\\n.); drugs and systemic disorders (often infections) are more common causes than primary liver\\ndisorders. Infections must be identified because they require specific treatments. TB and schistosomiasis\\nare the most common infectious causes worldwide; fungal and viral causes are less common. Sarcoidosis\\nis the most common noninfectious cause; the liver is involved in about two thirds of patients, and\\noccasionally, clinical manifestations of sarcoidosis are predominantly hepatic.\\nGranulomas are much less common in primary liver disorders; primary biliary cirrhosis is the only\\nimportant cause. Small granulomas occasionally occur in other liver disorders but are not clinically\\nsignificant.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 30. Liver Masses & Granulomas\\n345'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 355, 'page_label': '346'}, page_content='Idiopathic granulomatous hepatitis\\n is a rare syndrome of hepatic granulomas with recurrent fever,\\nmyalgias, fatigue, and other systemic symptoms, which often occur intermittently for years. Some experts\\nbelieve it is a variant of sarcoidosis.\\nPathophysiology\\nA granuloma is a localized collection of chronic inflammatory cells with epithelioid cells and giant\\nmultinucleated cells. Caseation necrosis or foreign body tissue (eg, schistosome eggs) may be present.\\nMost granulomas occur in the parenchyma, but in primary biliary cirrhosis, granulomas may occur in the\\nhepatic triads.\\nGranuloma formation is incompletely understood. Granulomas may develop in response to poorly soluble\\nexogenous or endogenous irritants. Immunologic mechanisms are involved.\\nHepatic granulomas rarely affect hepatocellular function. However, when granulomas are part of a\\nbroader inflammatory reaction involving the liver (eg, drug reactions, infectious mononucleosis),\\nhepatocellular dysfunction is present. Sometimes inflammation causes progressive hepatic fibrosis and\\nportal hypertension, typically with schistosomiasis and occasionally with extensive sarcoidal infiltration.\\nSymptoms and Signs\\nGranulomas themselves are typically asymptomatic; even extensive infiltration usually causes only minor\\nhepatomegaly and little or no jaundice. Symptoms, if they occur, reflect the underlying condition (eg,\\nconstitutional symptoms in infections, hepatosplenomegaly in schistosomiasis).\\n[\\nTable 30-2.\\n Causes of Hepatic Granulomas]\\nDiagnosis\\n Liver function tests\\n Imaging\\n Biopsy\\nHepatic granulomas are suspected in patients with\\n Conditions that commonly cause granulomas\\n Unexplained hepatic masses found during imaging tests\\n Occasionally, when an imaging test is done to evaluate asymptomatic elevations in liver enzymes,\\nparticularly alkaline phosphatase\\nWhen granulomas are suspected, liver function tests are usually done, but results are nonspecific and are\\nrarely helpful in diagnosis. Alkaline phosphatase (and \\n\\n-glutamyltransferase) is often mildly elevated but\\noccasionally may be markedly elevated. Other test results may be normal or abnormal, reflecting\\nadditional hepatic damage (eg, widespread \\nhepatic inflammation due to a drug reaction). Usually, imaging\\ntests, such as ultrasonography, CT, or MRI, are not diagnostic; they may show calcification (if granulomas\\nare long-standing) or filling defects, particularly with confluent lesions.\\nDiagnosis is based on liver biopsy. However, biopsy is usually indicated only to diagnose treatable\\ncauses (eg, infections) or to rule out nongranulomatous disorders (eg, chronic viral hepatitis). Biopsy\\nsometimes detects evidence of the specific cause (eg, schistosome eggs, caseation of TB, fungal\\norganisms). However, other tests (eg, cultures, skin tests, laboratory tests, imaging tests, other tissue\\nspecimens) are often needed.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 30. Liver Masses & Granulomas\\n346'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 356, 'page_label': '347'}, page_content='In patients with constitutional or other symptoms suggesting infection (eg, FUO), specific measures are\\ntaken to increase the diagnostic sensitivity of biopsy for infections; eg, a portion of the fresh biopsy\\nspecimen is sent for culture, or special stains for acid-fast bacilli, fungi, and other organisms are used.\\nOften, cause cannot be established.\\nPrognosis\\nHepatic granulomas caused by drugs or infection regress completely after treatment. Sarcoid granulomas\\nmay disappear spontaneously or persist for years, usually without causing clinically important liver\\ndisease. Progressive fibrosis and portal hypertension (sarcoidal cirrhosis) rarely develop.\\nIn schistosomiasis, progressive portal scarring (pipestem fibrosis) is typical; liver function is usually\\npreserved, but marked splenomegaly and variceal hemorrhage can occur.\\nTreatment\\n Treatment of cause\\nTreatment is directed at the underlying disorder. When the cause is unknown, treatment is usually\\nwithheld, and follow-up with periodic liver function tests is instituted. However, if symptoms of TB (eg,\\nprolonged fever) and deteriorating health occur, empiric antituberculous therapy may be justified.\\nCorticosteroids may benefit patients with progressive hepatic sarcoidosis, although whether these drugs\\nprevent hepatic fibrosis is unclear. However, corticosteroids are not indicated for most patients with\\nsarcoidosis and are warranted only if TB and other infections can be excluded confidently.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 30. Liver Masses & Granulomas\\n347'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 357, 'page_label': '348'}, page_content='Chapter 31. Gallbladder and Bile Duct Disorders\\nIntroduction\\nThe liver produces about 500 to 600 mL of bile each day. Bile is isosmotic with plasma and consists\\nprimarily of water and electrolytes but also organic compounds: bile salts, phospholipids (mostly lecithin),\\ncholesterol, bilirubin, and other endogenously produced or ingested compounds, such as proteins that\\nregulate GI function and drugs or their metabolites. Bilirubin is a degradation product of heme compounds\\nfrom worn-out RBCs and is the pigment that gives bile its yellow-green color.\\nBile salts (bile acids) are the major organic component in bile. The liver uses active transport to secrete\\nbile salts into the canaliculus, the cleft between adjacent hepatocytes. Canalicular transport is the rate-\\nlimiting step in bile formation. Once secreted, bile salts draw other bile components (particularly Na\\n+\\n and\\nwater) into the canaliculus by osmosis. Bile salts are also biologic detergents that enable the body to\\nexcrete cholesterol and potentially toxic compounds (eg, bilirubin, drug metabolites). The function of bile\\nsalts in the duodenum is to solubilize ingested fat and fat-soluble vitamins, facilitating their digestion and\\nabsorption. From the liver, bile flows from the intrahepatic collecting system into the right or left hepatic\\nduct, then into the common hepatic duct.\\nDuring fasting, about 75% of the bile secreted passes from the common hepatic duct into the gallbladder\\nvia the cystic duct. The rest flows directly into the common bile duct (formed by the junction of the\\ncommon hepatic and cystic ducts) into the duodenum. During fasting, the gallbladder absorbs up to 90%\\nof bile water, concentrating and storing bile.\\nBile empties from the gallbladder into the common bile duct. The common bile duct joins with the\\npancreatic duct to form the ampulla of Vater, which empties into the duodenum. Before joining the\\npancreatic duct, the common bile duct tapers to a diameter of  0.6 cm.\\nThe sphincter of Oddi, which surrounds both the pancreatic duct and the common bile duct, includes a\\nsphincter for each duct. Bile does not normally flow retrograde into the pancreatic duct. These sphincters\\nare highly sensitive to cholecystokinin and other gut hormones (eg, gastrin-releasing peptide) and to\\nalterations in cholinergic tone (eg, by anticholinergic drugs).\\nEating releases gut hormones and stimulates cholinergic nerves, causing the gallbladder to contract and\\nthe sphincter of Oddi to relax. As a result, the gallbladder empties 50 to 75% of its contents into the\\nduodenum. Conversely, during fasting, an increase in sphincter tone facilitates gallbladder filling.\\nBile salts are poorly absorbed by passive diffusion in the proximal small bowel; most intestinal bile salts\\nreach the terminal ileum, which actively absorbs 90% into the portal venous circulation. Returned to the\\nliver, bile salts are efficiently extracted, promptly modified (eg, conjugated if they arrive in the free form),\\nand secreted back into bile. Bile salts circulate through this pathway from liver to gut to liverthe\\nenterohepatic circulation10 to 12 times/day.\\nCholelithiasis\\nCholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder. In\\ndeveloped countries, about 10% of adults and 20% of people > 65 yr have gallstones. Gallstones\\ntend to be asymptomatic. The most common symptom is biliary colic; gallstones do not cause\\ndyspepsia or fatty food intolerance. More serious complications include cholecystitis; biliary\\ntract obstruction (from stones in the bile ducts or choledocholithiasis), sometimes with infection\\n(cholangitis); and gallstone pancreatitis. Diagnosis is usually by ultrasonography. If\\ncholelithiasis causes symptoms or complications, cholecystectomy is necessary.\\nRisk factors for gallstones include female sex, obesity, increased age, American Indian ethnicity, a\\nWestern diet, and a family history. Most disorders of the biliary tract result from gallstones.\\nPathophysiology\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n348'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 358, 'page_label': '349'}, page_content='Biliary sludge\\n is often a precursor of gallstones. It consists of Ca bilirubinate (a polymer of bilirubin),\\ncholesterol microcrystals, and mucin. Sludge develops during gallbladder stasis, as occurs during\\npregnancy or use of TPN. Most sludge is asymptomatic and disappears when the primary condition\\nresolves. Alternatively, sludge can evolve into gallstones or migrate into the biliary tract, obstructing the\\nducts and leading to biliary colic, cholangitis, or pancreatitis.\\nThere are several types of gallstones.\\nCholesterol stones\\n account for > 85% of gallstones in the Western world. For cholesterol gallstones to\\nform, the following is required:\\n Bile must be supersaturated with cholesterol. Normally, water-insoluble cholesterol is made water\\nsoluble by combining with bile salts and lecithin to form mixed micelles. Supersaturation of bile with\\ncholesterol most commonly results from excessive cholesterol secretion (as occurs in obesity or\\ndiabetes) but may result from a decrease in bile salt secretion (eg, in cystic fibrosis because of bile salt\\nmalabsorption) or in lecithin secretion (eg, in a rare genetic disorder that causes a form of progressive\\nintrahepatic familial cholestasis).\\n The excess cholesterol must precipitate from solution as solid microcrystals. Such precipitation in the\\ngallbladder is accelerated by mucin, a glycoprotein, or other proteins in bile.\\n The microcrystals must aggregate and grow. This process is facilitated by the binding effect of mucin\\nforming a scaffold and by retention of microcrystals in the gallbladder with impaired contractility due to\\nexcess cholesterol in bile.\\nBlack pigment stones\\n are small, hard gallstones composed of Ca bilirubinate and inorganic Ca salts\\n(eg, Ca carbonate, Ca phosphate). Factors that accelerate stone development include alcoholic liver\\ndisease, chronic hemolysis, and older age.\\nBrown pigment stones\\n are soft and greasy, consisting of bilirubinate and fatty acids (Ca palmitate or\\nstearate). They form during infection, inflammation, and parasitic infestation (eg, liver flukes in Asia).\\nGallstones grow at about 1 to 2 mm/yr, taking 5 to 20 yr before becoming large enough to cause\\nproblems. Most gallstones form within the gallbladder, but brown pigment stones form in the ducts.\\nGallstones may migrate to the bile duct after cholecystectomy or, particularly in the case of brown pigment\\nstones, develop behind strictures as a result of stasis and infection.\\nSymptoms and Signs\\nAbout 80% of people with gallstones are asymptomatic. The remainder have symptoms ranging from\\nbiliary-type pain (biliary colic) \\nto cholecystitis to life-threatening cholangitis. Biliary colic is the most\\ncommon symptom.\\nStones occasionally traverse the cystic duct without causing symptoms. However, most gallstone\\nmigration leads to cystic duct obstruction, which, even if transient, causes biliary colic. Biliary colic\\ncharacteristically begins in the right upper quadrant but may occur elsewhere in the abdomen. It is often\\npoorly localized, particularly in diabetics and the elderly. The pain may radiate into the back or down the\\narm. Episodes begin suddenly, become intense within 15 min to 1 h, remain at a steady intensity (not\\ncolicky) for up to 12 h (usually < 6 h), and then gradually disappear over 30 to 90 min, leaving a dull ache.\\nThe pain is usually severe enough to send patients to the emergency department for relief. Nausea and\\nsome vomiting are common, but fever and chills do not occur unless cholecystitis has developed. Mild\\nright upper quadrant or epigastric tenderness may be present; peritoneal findings are absent. Between\\nepisodes, patients feel well.\\nAlthough biliary-type pain can follow a heavy meal, fatty food is not a specific precipitating factor.\\nNonspecific GI symptoms, such as gas, bloating, and nausea, have been inaccurately ascribed to\\ngallbladder disease. These symptoms are common, having about equal prevalence in cholelithiasis,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n349'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 359, 'page_label': '350'}, page_content='peptic ulcer disease, and functional GI disorders.\\nLittle correlation exists between the severity and frequency of biliary colic and pathologic changes in the\\ngallbladder. Biliary colic can occur in the absence of cholecystitis. If colic lasts > 12 h, particularly if it is\\naccompanied by vomiting or fever, acute cholecystitis or pancreatitis is likely.\\nDiagnosis\\n Ultrasonography\\nGallstones are suspected in patients with biliary colic. Abdominal ultrasonography is the method of choice\\nfor detecting gallbladder stones; sensitivity and specificity are 95%. Ultrasonography also accurately\\ndetects sludge. CT, MRI (see p. \\n230\\n), and oral cholecystography (rarely available now, although quite\\naccurate) are alternatives. Endoscopic ultrasonography accurately detects small gallstones (< 3 mm) and\\nmay be needed if other tests are equivocal. Laboratory tests usually are not helpful; typically, results are\\nnormal unless complications develop. Asymptomatic gallstones and biliary sludge are often detected\\nincidentally when imaging, usually ultrasonography, is done for other reasons. About 10 to 15% of\\ngallstones are calcified and visible on plain x-rays.\\nPrognosis\\nPatients with asymptomatic gallstones become symptomatic at a rate of about 2%/yr. The symptom that\\ndevelops most commonly is biliary colic rather than a major biliary complication. Once biliary symptoms\\nbegin, they are likely to recur; pain returns in 20 to 40% of patients/yr, and about 1 to 2% of patients/yr\\ndevelop complications such as cholecystitis, choledocholithiasis, cholangitis, and gallstone pancreatitis.\\nTreatment\\n Laparoscopic cholecystectomy for symptomatic stones\\n Expectant for asymptomatic stones; sometimes stone dissolution\\nMost asymptomatic patients decide that the discomfort, expense, and risk of elective surgery are not\\nworth removing an organ that may never cause clinical illness. However, if symptoms occur, gallbladder\\nremoval (cholecystectomy) is indicated because pain is likely to recur and serious complications can\\ndevelop.\\nSurgery:\\n Surgery can be done with an open or laparoscopic technique.\\nOpen cholecystectomy, which involves a large abdominal incision and direct exploration, is safe and\\neffective. Its overall mortality rate is about 0.1% when done electively during a period free of\\ncomplications.\\nLaparoscopic cholecystectomy is the treatment of choice. Using video endoscopy and instrumentation\\nthrough small abdominal incisions, the procedure is less invasive than open cholecystectomy. The result\\nis a much shorter convalescence, decreased postoperative discomfort, improved cosmetic results, yet no\\nincrease in morbidity or mortality. Laparoscopic cholecystectomy is converted to an open procedure in 2\\nto 5% of patients, usually because biliary anatomy cannot be identified or a complication cannot be\\nmanaged. Older age typically increases the risks of any type of surgery.\\nCholecystectomy effectively prevents future biliary colic but is less effective for preventing atypical\\nsymptoms such as dyspepsia. Cholecystectomy does not result in nutritional problems or a need for\\ndietary limitations. Some patients develop diarrhea, often because bile salt malabsorption in the ileum is\\nunmasked. Prophylactic cholecystectomy is \\nwarranted in asymptomatic patients with cholelithiasis only if\\nthey have large gallstones (> 3 cm) or a calcified gallbladder (porcelain gallbladder); these conditions\\nincrease the risk of gallbladder carcinoma.\\nStone dissolution:\\n For patients who decline surgery or who are at high surgical risk (eg, because of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n350'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 360, 'page_label': '351'}, page_content='concomitant medical disorders or advanced age), gallbladder stones can sometimes be dissolved by\\ningesting bile acids orally for many months. The best candidates for this treatment are those with small,\\nradiolucent stones (more likely to be composed of cholesterol) in a functioning nonobstructed gallbladder\\n(indicated by normal filling detected during cholescintigraphy or oral cholecystography or by absence of\\nstones in the neck).\\nUrsodeoxycholic acid 8 to 10 mg/kg/day po dissolves 80% of tiny stones < 0.5 cm in diameter within 6\\nmo. For larger stones (the majority), the success rate is much lower, even with higher doses of\\nursodeoxycholic acid. Further, after successful dissolution, stones recur in 50% within 5 yr. Most patients\\nare thus not candidates and prefer laparoscopic cholecystectomy. However, ursodeoxycholic acid can\\nhelp prevent stone formation in morbidly obese patients who are losing weight rapidly after bariatric\\nsurgery or while on a very low calorie diet.\\nStone fragmentation (extracorporeal shock wave lithotripsy) to assist stone dissolution and clearance is\\nnow unavailable.\\nCholecystitis\\nCholecystitis, which is inflammation of the gallbladder, can be acute or chronic.\\nAcute Cholecystitis\\nAcute cholecystitis is inflammation of the gallbladder that develops over hours, usually\\nbecause a gallstone obstructs the cystic duct. Symptoms include right upper quadrant pain and\\ntenderness, sometimes accompanied by fever, chills, nausea, and vomiting. Abdominal\\nultrasonography detects the gallstone and sometimes the associated inflammation. Treatment\\nusually involves antibiotics and cholecystectomy.\\nAcute cholecystitis is the most common complication of cholelithiasis. Conversely,  95% of patients with\\nacute cholecystitis have cholelithiasis. When a stone becomes impacted in the cystic duct and\\npersistently obstructs it, acute inflammation results. Bile stasis triggers release of inflammatory enzymes\\n(eg, phospholipase A, which converts lecithin to lysolecithin, which then may mediate inflammation). The\\ndamaged mucosa secretes more fluid into the gallbladder lumen than it absorbs. The resulting distention\\nfurther releases inflammatory mediators (eg, prostaglandins), worsening mucosal damage and causing\\nischemia, all of which perpetuate inflammation. Bacterial infection can supervene. The vicious circle of\\nfluid secretion and inflammation, when unchecked, leads to necrosis and perforation. If acute\\ninflammation resolves, the gallbladder becomes fibrotic and contracted and does not concentrate bile or\\nempty normallyfeatures of chronic cholecystitis.\\nAcute acalculous cholecystitis:\\n Acalculous cholecystitis is cholecystitis without stones. It accounts for\\n5 to 10% of cholecystectomies done for acute cholecystitis. Risk factors include the following:\\n Critical illness (eg, major surgery, burns, sepsis, or trauma)\\n Prolonged fasting or TPN (both predispose to bile stasis)\\n Shock\\n Immune deficiency\\n Vasculitis (eg, SLE, polyarteritis nodosa)\\nThe mechanism probably involves inflammatory mediators released because of ischemia, infection, or bile\\nstasis. Sometimes an infecting organism can be identified (eg, \\nSalmonella\\n sp or cytomegalovirus in\\nimmunodeficient patients). In young children, acute acalculous cholecystitis tends to follow a febrile\\nillness without an identifiable infecting organism.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n351'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 361, 'page_label': '352'}, page_content=\"Most patients have had prior attacks of biliary colic or acute cholecystitis. The pain of cholecystitis is\\nsimilar in quality and location to biliary colic but lasts longer (ie, > 6 h) and is more severe. Vomiting is\\ncommon, as is right subcostal tenderness. Within a few hours, Murphy's sign (deep inspiration\\nexacerbates the pain during palpation of the right upper quadrant and halts inspiration) develops along\\nwith involuntary guarding of upper abdominal muscles on the right side. Fever, usually low grade, is\\ncommon.\\nIn the elderly, the first or only symptoms may be systemic and nonspecific (eg, anorexia, vomiting,\\nmalaise, weakness, fever). Sometimes fever does not develop.\\nAcute cholecystitis begins to subside in 2 to 3 days and resolves within 1 wk in 85% of patients.\\nComplications:\\n Without treatment, 10% of patients develop localized perforation, and 1% develop free\\nperforation and peritonitis. Increasing abdominal pain, high fever, and rigors with rebound tenderness or\\nileus suggest empyema (pus in the gallbladder), gangrene, or perforation. When acute cholecystitis is\\naccompanied by jaundice or cholestasis, partial common duct obstruction is likely, usually due to stones\\nor inflammation. Other complications include the following:\\n Mirizzi's syndrome: Rarely, a gallstone becomes impacted in the cystic duct or Hartman's pouch and\\ncompresses and obstructs the common bile duct, causing cholestasis.\\n Gallstone pancreatitis: Gallstones pass from the gallbladder into the biliary tract and block the\\npancreatic duct.\\n Cholecystoenteric fistula: Infrequently, a large stone erodes the gallbladder wall, creating a fistula into\\nthe small bowel (or elsewhere in the abdominal cavity); the stone may pass freely or obstruct the small\\nbowel (gallstone ileus).\\nAcute acalculous cholecystitis:\\n The symptoms are similar to those of acute cholecystitis with\\ngallstones but may be difficult to identify because patients tend to be severely ill (eg, ICU setting) and\\nmay be unable to communicate clearly. Abdominal distention or unexplained fever may be the only clue.\\nUntreated, the disease can rapidly progress to gallbladder gangrene and perforation, leading to sepsis,\\nshock, and peritonitis; mortality approaches 65%.\\nDiagnosis\\n Ultrasonography\\n Cholescintigraphy if ultrasonography results are equivocal or if acalculous cholecystitis is suspected\\nAcute cholecystitis is suspected based on symptoms and signs.\\nTransabdominal ultrasonography is the best test to detect gallstones. The test may also elicit local\\nabdominal tenderness over the gallbladder (ultrasonographic Murphy's sign). Pericholecystic fluid or\\nthickening of the gallbladder wall indicates acute inflammation.\\nCholescintigraphy is useful when results are equivocal; failure of the radionuclide to fill the gallbladder\\nsuggests an obstructed cystic duct (ie, an impacted stone). False-positive results may be due to the\\nfollowing:\\n A critical illness\\n Receiving TPN and no oral foods (because gallbladder stasis prevents filling)\\n Severe liver disease (because the liver does not secrete the radionuclide)\\n Previous sphincterotomy (which facilitates exit into the duodenum rather than the gallbladder)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n352\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 362, 'page_label': '353'}, page_content=\"Morphine provocation, which increases tone in the sphincter of Oddi and enhances filling, helps eliminate\\nfalse-positive results.\\nAbdominal CT identifies complications such as gallbladder perforation or pancreatitis.\\nLaboratory tests are done but are not diagnostic. Leukocytosis with a left shift is common. In\\nuncomplicated acute cholecystitis, liver function tests are normal or only slightly elevated. Mild cholestatic\\nabnormalities (bilirubin up to 4 mg/dL and mildly elevated alkaline phosphatase) are common, probably\\nindicating inflammatory mediators affecting the liver rather than mechanical obstruction. More marked\\nincreases, especially if lipase (amylase is less specific) is elevated > 2-fold, suggest bile duct obstruction.\\nPassage of a stone through the biliary tract increases aminotransferases (ALT, AST).\\nAcute acalculous cholecystitis:\\n Acute acalculous cholecystitis is suggested if a patient has no\\ngallstones but has ultrasonographic Murphy's sign or a thickened gallbladder wall and pericholecystic\\nfluid. A distended gallbladder, biliary sludge, and a thickened gallbladder wall without pericholecystic fluid\\n(due to low albumin or ascites) may result simply from a critical illness. CT identifies extrabiliary\\nabnormalities. Cholescintigraphy is more helpful; failure of a radionuclide to fill may indicate edematous\\ncystic duct obstruction. Giving morphine helps eliminate a false-positive result due to gallbladder stasis.\\nTreatment\\n Supportive care (hydration, analgesics, antibiotics)\\n Cholecystectomy\\nManagement includes hospital admission, IV fluids, and analgesia with an NSAID (ketorolac) or an opioid.\\nNothing is given orally, and nasogastric suction is instituted if vomiting or an ileus is present. Parenteral\\nantibiotics are usually initiated to treat possible infection, but evidence of benefit is lacking. Empiric\\ncoverage, directed at gram-negative enteric organisms, involves IV regimens such as ceftriaxone 2 g q 24\\nh plus metronidazole 500 mg q 8 h, piperacillin/tazobactam 4 g q 6 h, or ticarcillin/clavulanate 4 g q 6 h.\\nCholecystectomy cures acute cholecystitis and relieves biliary pain. Early cholecystectomy \\nis generally\\npreferred, best done during the first 24 to 48 h in the following situations:\\n The diagnosis is clear and patients are at low surgical risk.\\n Patients are elderly or have diabetes and are thus at higher risk of infectious complications.\\n Patients have empyema, gangrene, perforation, or acalculous cholecystitis.\\nSurgery may be delayed when patients have an underlying severe chronic disorder (eg, cardiopulmonary)\\nthat increases the surgical risks. In such patients, cholecystectomy is deferred until medical therapy\\nstabilizes the comorbid disorders or until cholecystitis resolves. If cholecystitis resolves, cholecystectomy\\nmay be done  6 wk later. Delayed surgery carries the risk of recurrent biliary complications.\\nPercutaneous cholecystostomy is an alternative to cholecystectomy for patients at very high surgical risk,\\nsuch as the elderly, those with acalculous cholecystitis, and those in an ICU because of burns, trauma, or\\nrespiratory failure.\\nChronic Cholecystitis\\nChronic cholecystitis is long-standing gallbladder inflammation almost always due to gallstones.\\nChronic cholecystitis almost always results from gallstones and prior episodes of acute cholecystitis\\n(even if mild). Damage ranges from a modest infiltrate of chronic inflammatory cells to a fibrotic, shrunken\\ngallbladder. Extensive calcification due to fibrosis is called porcelain gallbladder.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n353\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 363, 'page_label': '354'}, page_content='Gallstones intermittently obstruct the cystic duct and so cause recurrent biliary colic. Such episodes of\\npain are not necessarily accompanied by overt gallbladder inflammation; the extent of inflammation does\\nnot correlate with the intensity or frequency of biliary colic. Upper abdominal tenderness may be present,\\nbut usually fever is not. Fever suggests acute cholecystitis. Once episodes begin, they are likely to recur.\\nDiagnosis\\n Ultrasonography\\nChronic cholecystitis is suspected in patients with recurrent biliary colic plus gallstones. Ultrasonography\\nor another imaging test usually shows gallstones and sometimes a shrunken, fibrotic gallbladder. The\\ndiagnosis is made in patients with a history of recurrent biliary colic and evidence of gallstones on\\nultrasonography. Cholescintigraphy may show nonvisualization of the gallbladder but is less accurate.\\nTreatment\\nLaparoscopic cholecystectomy is indicated to prevent symptom recurrence and further biliary\\ncomplications. This procedure is particularly valid for the porcelain gallbladder associated with gallbladder\\ncarcinoma.\\nAcalculous Biliary Pain\\nAcalculous biliary pain is biliary colic without gallstones, resulting from structural or functional\\ndisorders; it is sometimes treated with laparoscopic cholecystectomy.\\nBiliary colic can occur in the absence of gallstones, particularly in young women. Acalculous biliary pain\\naccounts for up to 15% of laparoscopic cholecystectomies. Common causes of such biliary pain include\\nthe following:\\n Microscopic stonesnot detected by routine abdominal ultrasonography\\n Abnormal gallbladder emptying\\n An overly sensitive biliary tract\\n Sphincter of Oddi dysfunction\\n Hypersensitivity of the adjacent duodenum\\n Possibly gallstones that have spontaneously passed\\nSome patients eventually develop other functional GI disorders.\\nDiagnosis\\nAcalculous biliary pain is suspected in patients with biliary colic when diagnostic imaging cannot detect\\ngallstones. Imaging should include ultrasonography and, where available, endoscopic ultrasonography\\n(for small stones < 1 cm). Abnormal laboratory tests may reveal evidence of a biliary tract abnormality (eg,\\nelevated alkaline phosphatase, bilirubin, ALT, or AST) or a pancreatic abnormality (eg, elevated lipase)\\nduring an episode of acute pain. Cholescintigraphy with cholecystokinin infusion measures gallbladder\\nemptying (ejection fraction); potentially interfering drugs such as Ca channel blockers, opioids, and\\nanticholinergics should not be used. ERCP with biliary manometry detects sphincter of Oddi dysfunction.\\nThe best diagnostic approach remains problematic.\\nTreatment\\nLaparoscopic cholecystectomy improves outcomes for patients with microscopic stones and possibly\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n354'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 364, 'page_label': '355'}, page_content=\"abnormal gallbladder motility. The role of laparoscopic cholecystectomy or endoscopic sphincterotomy\\nremains problematic. Drug therapies have no proven benefit.\\nPostcholecystectomy Syndrome\\nPostcholecystectomy syndrome is occurrence of abdominal symptoms after cholecystectomy.\\nPostcholecystectomy syndrome occurs in 5 to 40% of patients. It refers to presumed gallbladder\\nsymptoms that continue or that develop after cholecystectomy or to other symptoms that result from\\ncholecystectomy. Removal of the gallbladder, the storage organ for bile, normally has few consequences\\non biliary tract function or pressures. In about 10%, biliary colic appears to result from functional or\\nstructural abnormalities of the sphincter of Oddi, resulting in altered biliary pressures or heightened\\nsensitivity.\\nThe most common symptoms are dyspepsia or otherwise nonspecific symptoms rather than true biliary\\ncolic. Papillary stenosis, which is rare, is fibrotic narrowing around the sphincter, perhaps caused by\\ntrauma and inflammation due to pancreatitis, instrumentation (eg, ERCP), or prior passage of a stone.\\nOther causes include a retained bile duct stone, pancreatitis, and gastroesophageal reflux.\\nDiagnosis\\n ERCP with biliary manometry or biliary nuclear scanning\\n Exclusion of extrabiliary pain\\nPatients with postcholecystectomy pain should be evaluated as indicated for extra-biliary as well as biliary\\ncauses. If the pain suggests biliary colic, alkaline phosphatase, bilirubin, ALT, amylase, and lipase should\\nbe measured, and ERCP with biliary manometry or biliary nuclear scanning should be done. Elevated\\nliver enzymes suggest sphincter of Oddi dysfunction; elevated amylase and lipase suggest dysfunction of\\nthe sphincter's pancreatic portion.\\nDysfunction is best detected by biliary manometry done during ERCP, although ERCP has a risk of\\ninducing pancreatitis. Manometry shows increased pressure in the biliary tract when pain is reproduced. A\\nslowed hepatic hilum-duodenal transit time on a scan also suggests sphincter of Oddi dysfunction.\\nDiagnosis of papillary stenosis is based on a clear-cut history of recurrent episodes of biliary pain and\\nabnormal liver (or pancreatic) enzyme tests.\\nTreatment\\nEndoscopic sphincterotomy can relieve recurrent pain due to sphincter of Oddi dysfunction, especially if\\ndue to papillary stenosis. It is controversial for patients who have postcholecystectomy pain and no\\nobjective abnormalities.\\nCholedocholithiasis and Cholangitis\\nCholedocholithiasis is the presence of stones in bile ducts; the stones can form in the\\ngallbladder or in the ducts themselves. These stones cause biliary colic, biliary obstruction,\\ngallstone pancreatitis, or cholangitis (bile duct infection and inflammation). Cholangitis, in turn,\\ncan lead to strictures, stasis, and choledocholithiasis. Diagnosis usually requires visualization\\nby magnetic resonance cholangiopancreatography or ERCP. Early endoscopic or surgical\\ndecompression is indicated.\\nStones may be described as\\n Primary stones (usually brown pigment stones), which form in the bile ducts\\n Secondary stones (usually cholesterol), which form in the gallbladder but migrate to the bile ducts\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n355\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 365, 'page_label': '356'}, page_content=\" Residual stones, which are missed at the time of cholecystectomy (evident < 3 yr later)\\n Recurrent stones, which develop in the ducts > 3 yr after surgery\\nIn developed countries, > 85% of common duct stones are secondary; affected patients have additional\\nstones located in the gallbladder. Up to 10% of patients with symptomatic gallstones also have\\nassociated common bile duct stones. After cholecystectomy, brown pigment stones may result from stasis\\n(eg, due to a postoperative stricture) and the subsequent infection. The proportion of ductal stones that\\nare pigmented increases with time after cholecystectomy.\\nBile duct stones may pass into the duodenum asymptomatically. Biliary colic occurs when the ducts\\nbecome partially obstructed. More complete obstruction causes duct dilation, jaundice, and, eventually,\\ncholangitis (a bacterial infection). Stones that obstruct the\\n[\\nTable 31-1.\\n Causes of Bile Duct Obstruction]\\nampulla of Vater can cause gallstone pancreatitis. Some patients (usually the elderly) present with biliary\\nobstruction due to stones that have caused no symptoms previously.\\nIn \\nacute cholangitis,\\n bile duct obstruction allows bacteria to ascend from the duodenum. Most (85%)\\ncases result from common bile duct stones, but bile duct obstruction can result from tumors or other\\nconditions (see \\nTable 31-1\\n). Common infecting organisms include gram-negative bacteria (eg,\\nEscherichia coli, Klebsiella\\n sp, \\nEnterobacter\\n sp); less common are gram-positive bacteria (eg,\\nEnterococcus\\n sp) and mixed anaerobes (eg, \\nBacteroides\\n sp, \\nClostridia\\n sp). Symptoms include abdominal\\npain, jaundice, and fever or chills (Charcot's triad). The abdomen is tender, and often the liver is tender\\nand enlarged (often containing abscesses). Confusion and hypotension predict about a 50% mortality\\nrate and high morbidity.\\nRecurrent pyogenic cholangitis\\n (Oriental cholangiohepatitis, hepatolithiasis) is characterized by\\nintrahepatic brown pigment stone formation. This disorder occurs in Southeast Asia. It consists of sludge\\nand bacterial debris in the bile ducts. Undernutrition and parasitic infestation (eg, \\nClonorchis sinensis\\n,\\nOpisthorchis viverrini\\n) increase susceptibility. Parasitic infestation can cause obstructive jaundice with\\nintrahepatic ductal inflammation, proximal stasis, stone formation, and cholangitis. Repeating cycles of\\nobstruction, infection, and inflammation lead to bile duct strictures and biliary cirrhosis. The extrahepatic\\nducts tend to be dilated, but the intrahepatic ducts appear straight because of periductal fibrosis.\\nIn AIDS-related cholangiopathy or cholangitis, direct cholangiography may show abnormalities similar to\\nthose in primary sclerosing cholangitis or papillary stenosis (ie, multiple strictures and dilations involving\\nthe intrahepatic and extrahepatic bile ducts). Etiology is probably infection, most likely with\\ncytomegalovirus, \\nCryptosporidium\\n sp, or microsporidia.\\nDiagnosis\\n Liver function tests\\n Ultrasonography\\nCommon duct stones should be suspected in patients with jaundice and biliary colic. Fever and\\nleukocytosis further suggest acute cholangitis. Elevated levels of bilirubin, alkaline phosphatase, ALT, and\\n\\n-glutamyltransferase are consistent with extrahepatic obstruction, suggesting stones, particularly in\\npatients with features of acute cholecystitis or cholangitis.\\nUltrasonography may show stones in the gallbladder and occasionally in the common duct (less\\naccurate). The common duct is dilated (> 6 mm in diameter if the gallbladder is intact; > 10 mm after a\\ncholecystectomy). If the ducts are not dilated early in the presentation (eg, first day), stones have\\nprobably passed. If doubt exists, magnetic resonance cholangiopancreatography (MRCP) is highly\\naccurate for retained stones. ERCP is done if MRCP is equivocal; it can be therapeutic as well as\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n356\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 366, 'page_label': '357'}, page_content='diagnostic. CT, though less accurate than ultrasonography, can detect liver abscesses.\\nFor suspected acute cholangitis, CBC and blood cultures are essential. Leukocytosis is common, and\\naminotransferases may reach 1000 IU/L, suggesting acute hepatic necrosis, often due to\\nmicroabscesses. Blood cultures guide antibiotic choice.\\nTreatment\\n ERCP and sphincterotomy\\nIf biliary obstruction is suspected, ERCP and sphincterotomy are necessary to remove the stone.\\nSuccess rate exceeds 90%; up to 7% of patients have complications (eg, bleeding pancreatitis, infection\\nwith fibrosis and subsequent duct stricture). Laparoscopic cholecystectomy, which is not as well suited for\\noperative cholangiography or common duct exploration, can be done electively following ERCP and\\nsphincterotomy. Mortality and morbidity after open cholecystectomy with common duct exploration are\\nhigher. In patients at high risk of complications with cholecystectomy (eg, the elderly), sphincterotomy\\nalone is an alternative.\\nAcute cholangitis is an emergency requiring aggressive supportive care and urgent removal of the stones,\\nendoscopically or surgically. \\nAntibiotics are given, similar to those used for acute cholecystitis (see p. \\n274\\n)\\nAn alternative regimen for very ill patients is imipenem and ciprofloxacin, plus metronidazole to cover\\nanaerobes.\\nFor recurrent pyogenic cholangitis, management aims to provide supportive care (eg, broad-spectrum\\nantibiotics), eradicate any parasites, and mechanically clear the ducts of stones and debris\\nendoscopically (via ERCP) or surgically.\\nSclerosing Cholangitis\\nSclerosing cholangitis refers to chronic cholestatic syndromes characterized by patchy\\ninflammation, fibrosis, and strictures of the intrahepatic and extrahepatic bile ducts.\\nProgression obliterates the bile ducts and leads to cirrhosis, liver failure, and sometimes\\ncholangiocarcinoma.\\nSclerosing cholangitis may be primary (with no known cause) or secondary due to immune deficiencies\\n(congenital in children, acquired in adults as AIDS cholangiopathy) often associated with superimposed\\ninfections (eg, cytomegalovirus, \\nCryptosporidium\\n), histiocytosis X, or use of drugs (eg, intraarterial\\nfloxuridine). Both primary and secondary sclerosing cholangitis cause similar inflammatory and fibrosing\\nlesions scarring the bile ducts. Other causes of bile duct strictures are choledocholithiasis, postoperative\\nbiliary stricture, ischemic bile duct injury (during liver transplantation), congenital biliary abnormalities,\\ncholangiocarcinoma, and parasitic infestations.\\nDiagnosis of biliary strictures and dilations requires imaging techniques such as ultrasonography and\\ncholangiography. Treatment focuses on relieving biliary obstruction (eg, dilating and stenting strictures)\\nand, when possible, eradicating responsible organisms or treating the cause (eg, HIV).\\nPrimary Sclerosing Cholangitis\\nPrimary sclerosing cholangitis (PSC), the most common form of sclerosing cholangitis, has no\\nknown cause. However, 80% of patients have inflammatory bowel disease, most often\\nulcerative colitis. Other associated conditions include connective tissue disorders, alloimmune\\ndisorders, and immunodeficiency syndromes, sometimes complicated by opportunistic\\ninfections. Fatigue and pruritus develop insidiously and progressively. Diagnosis is by\\ncholangiography (magnetic resonance cholangiopancreatography or ERCP). Liver\\ntransplantation is indicated for advanced disease.\\nMost (70%) patients with PSC are men. Mean age at diagnosis is 40 yr.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n357'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 367, 'page_label': '358'}, page_content=\"Etiology\\nAlthough the cause is unknown, PSC is associated with inflammatory bowel disease, which is present in\\n80% of patients. About 5% of patients with ulcerative colitis and about 1% with Crohn's disease develop\\nPSC. This association and the presence of several autoantibodies (eg, anti-smooth muscle and\\nperinuclear antineutrophilic antibodies [pANCA]) suggest immune-mediated mechanisms. T cells appear\\nto be involved in the destruction of the bile ducts, implying disordered cellular immunity. A genetic\\npredisposition is suggested by a tendency for the disorder to develop in multiple family members and a\\nhigher frequency in people with HLAB8 and HLADR3, which are often correlated with autoimmune\\ndisorders. An unknown trigger (eg, bacterial infection, ischemic duct injury) probably causes PSC to\\ndevelop in genetically predisposed people.\\nSymptoms and Signs\\nOnset is usually insidious, with progressive fatigue and then pruritus. Jaundice tends to develop later.\\nAbout 10 to 15% of patients present with repeated episodes of right upper quadrant pain and fever,\\npossibly due to ascending bacterial cholangitis. Steatorrhea and deficiencies of fat-soluble vitamins can\\ndevelop. Persistent jaundice harbingers advanced disease. Symptomatic gallstones and\\ncholedocholithiasis tend to develop in about 75% of patients. Some patients, asymptomatic until late in\\nthe course, first present with hepatosplenomegaly or cirrhosis. PSC tends to slowly and inexorably\\nprogress. The terminal phase involves decompensated cirrhosis, portal hypertension, ascites, and liver\\nfailure. The time from diagnosis to liver failure is about 12 yr.\\nDespite the association between PSC and inflammatory bowel disease, the two diseases tend to run\\nseparate courses. Ulcerative colitis may appear years before PSC yet tends to have a milder course\\nwhen associated with PSC. Similarly, total colectomy does not change the course of PSC. The presence\\nof both diseases increases the risk of colorectal carcinoma, regardless of whether a liver transplantation\\nhas been done for PSC. Cholangiocarcinoma develops in 10 to 15% of patients.\\nDiagnosis\\n Magnetic resonance cholangiopancreatography (MRCP)\\nPSC is suspected in patients with unexplained abnormalities in liver biochemical tests, particularly in\\nthose with inflammatory bowel disease. A cholestatic pattern is typical: elevated alkaline phosphatase and\\n\\n-glutamyltransferase (GGT) rather than aminotransferases. Gamma globulin and IgM levels tend to be\\nincreased. Anti-smooth muscle antibodies and pANCA are usually positive. Antimitochondrial antibody,\\npositive in primary biliary cirrhosis, is characteristically negative.\\nImaging of the hepatobiliary system begins with ultrasonography to exclude extrahepatic biliary\\nobstruction. Although ultrasonography or CT can show ductal dilation, diagnosis requires\\ncholangiography to show multiple strictures and dilations in the intrahepatic and extrahepatic bile ducts.\\nImaging should begin with MRCP. ERCP is usually a 2nd choice because it is invasive. Liver biopsy is\\ngenerally not required for diagnosis; when done, it shows bile duct proliferation, periductal fibrosis,\\ninflammation, and loss of bile ducts. With disease progression, periductal fibrosis extends from the portal\\nregions and eventually leads to secondary biliary cirrhosis.\\nMeasurement of serum tumor markers and ERCP surveillance with brush cytology should be done\\nregularly to check for cholangiocarcinoma.\\nTreatment\\n Supportive care\\n ERCP dilation for major (dominant) strictures\\n Transplantation for recurrent bacterial cholangitis or complications of end-stage liver disease\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n358\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 368, 'page_label': '359'}, page_content='Asymptomatic patients usually require only monitoring (eg, physical examination and liver biochemical\\ntests twice/yr). Ursodeoxycholic acid (up to 15 mg/kg/day reduces itching and improve biochemical\\nmarkers but not survival. Chronic cholestasis (see p. \\n212\\n) and cirrhosis require supportive treatment.\\nEpisodes of bacterial cholangitis warrant antibiotics and therapeutic ERCP, as needed. If a single stricture\\nappears to be the major cause of obstruction (a dominant stricture, found in about 20% of patients),\\nERCP dilation (with brush cytology to check for tumors) and stenting can relieve symptoms.\\nLiver transplantation is the only treatment that improves life expectancy in patients with PSC and offers a\\ncure. Recurrent bacterial cholangitis or complications of end-stage liver disease (eg, intractable ascites,\\nportal-systemic encephalopathy, bleeding esophageal varices) are reasonable indications for liver\\ntransplantation.\\nAIDS Cholangiopathy\\nAIDS cholangiopathy is biliary obstruction secondary to biliary tract strictures caused by\\nvarious opportunistic infections.\\nBefore the advent of highly active antiretroviral therapy, cholangiopathy occurred in 25% of patients with\\nAIDS, especially in those with a low CD4 count (< 100/\\n\\nL). The most common pathogen is\\nCryptosporidium parvum\\n. Others include cytomegalovirus, microsporidia, and \\nCyclospora\\n sp. Papillary\\nstenosis or intrahepatic or extrahepatic sclerosing cholangitis develops in most patients. Over half have\\nboth.\\nCommon symptoms include right upper quadrant and epigastric pain and diarrhea. A few patients have\\nfever and jaundice. Severe pain usually indicates papillary stenosis. Milder pain suggests sclerosing\\ncholangitis. The diarrhea reflects small-bowel infection, often cryptosporidiosis.\\nDiagnosis\\n Usually ERCP and ultrasonography\\nERCP provides the diagnosis, identification of the causal organism by small-bowel biopsy, and a\\ntherapeutic opportunity to relieve strictures. Ultrasonography is noninvasive and very accurate (> 95%).\\nCT and magnetic resonance cholangiopancreatography likely have supportive roles.\\nLiver biochemistry is consistent with cholestasis, especially a high alkaline phosphatase level.\\nTreatment\\n Endoscopic procedures\\nEndoscopic sphincterotomy can markedly relieve pain, jaundice, and cholangitis in patients with papillary\\nstenosis. Isolated or dominant strictures can be stented endoscopically. Although the cause is an\\ninfectious agent, antimicrobial therapy alone does not relieve the biliary tract damage or its sequelae.\\nBecause of its use in primary sclerosing cholangitis, ursodeoxycholic acid may have a role in treating\\nintrahepatic ductal sclerosis and cholestasis.\\nTumors of the Gallbladder and Bile Ducts\\nGallbladder and bile duct tumors can cause extrahepatic biliary obstruction. Symptoms may be\\nabsent but often are constitutional or reflect biliary obstruction. Diagnosis is based on\\nultrasonography plus CT cholangiography or magnetic resonance cholangiopancreatography.\\nPrognosis is grim. Mechanical bile drainage can often relieve pruritus, recurrent sepsis, and\\npain due to biliary obstruction.\\nCholangiocarcinomas\\n and other bile duct tumors are rare (1 to 2/100,000 people) but are usually\\nmalignant. Cholangiocarcinomas occur predominantly in the extrahepatic bile ducts: 60 to 70% in the\\nperihilar region (Klatskin tumors), about 25% in the distal ducts, and the rest in the liver. Risk factors\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n359'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 369, 'page_label': '360'}, page_content=\"include primary sclerosing cholangitis, older age, infestation with liver flukes, and a choledochal cyst.\\nGallbladder carcinoma\\n is uncommon (2.5/100,000). It is more common among American Indians,\\npatients with large gallstones (> 3 cm), and those with extensive gallbladder calcification due to chronic\\ncholecystitis (porcelain gallbladder). Nearly all (70 to 90%) patients also have gallstones. Median survival\\nis 3 mo. Cure is possible when cancer is found early (eg, incidentally at cholecystectomy).\\nGallbladder polyps\\n are usually asymptomatic benign mucosal projections that develop in the lumen of\\nthe gallbladder. Most are < 10 mm in diameter and composed of cholesterol ester and triglycerides; the\\npresence of such polyps is called cholesterolosis. They are found in about 5% of people during\\nultrasonography. Other, much less common benign polyps include adenomas (causing adenomyomatosis)\\nand inflammatory polyps. Small gallbladder polyps are incidental findings that do not require treatment.\\nSymptoms and Signs\\nMost patients with cholangiocarcinomas present with pruritus and painless obstructive jaundice, typically\\nat age 50 to 70 yr. Early perihilar tumors may cause only vague abdominal pain, anorexia, and weight\\nloss. Other features include acholic stool, a palpable mass, hepatomegaly, or a distended gallbladder\\n(Courvoisier's sign, with distal cholangiocarcinoma). Pain may resemble that of biliary colic (reflecting\\nbiliary obstruction) or may be constant and progressive. Sepsis (acute cholangitis), though unusual, may\\nbe induced by ERCP.\\nManifestations of gallbladder carcinoma may range from incidental findings at cholecystectomy done for\\nbiliary pain to cholelithiasis to advanced disease with constant pain, weight loss, and an abdominal mass\\nor obstructive jaundice.\\nMost gallbladder polyps cause no symptoms.\\nDiagnosis\\nCholangiocarcinomas are suspected when extrahepatic biliary obstruction is unexplained. Laboratory test\\nresults reflect the degree of cholestasis. In patients with primary sclerosing cholangitis, serum\\ncarcinoembryonic antigen (CEA) and cancer antigen (CA) 19-9 levels are used for surveillance to detect\\nthe development of cholangiocarcinoma. Diagnosis is based on ultrasonography (or endoscopic\\nultrasonography) and CT cholangiography or magnetic resonance cholangiopancreatography. When\\nthese methods are inconclusive, ERCP with percutaneous transhepatic cholangiography (PTC) becomes\\nnecessary. ERCP not only detects the tumor but also, with brushings, can provide a tissue diagnosis,\\nsometimes making ultrasonography- or CT-guided needle biopsy unnecessary. Contrast-enhanced CT\\nassists in staging.\\nGallbladder carcinomas are better defined by CT than by ultrasonography. Open laparotomy is necessary\\nto determine disease extent, which guides treatment.\\nTreatment\\n For cholangiocarcinomas, stenting (or another bypass procedure) or occasionally resection\\nFor cholangiocarcinoma, stenting or surgically bypassing the obstruction relieves pruritus, jaundice, and\\nperhaps fatigue.\\nHilar cholangiocarcinomas with CT evidence of spread are stented via PTC or ERCP. Distal duct\\ncholangiocarcinomas are stented endoscopically with ERCP. If cholangiocarcinoma appears localized,\\nsurgical exploration determines resectability by hilar resection or pancreaticoduodenectomy. However,\\nsuccessful resection is uncommon.\\nLiver transplantation is not indicated because of the high recurrence rate. Effectiveness of adjuvant\\nchemotherapy and radiation therapy for cholangiocarcinomas is unproved as yet.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n360\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 370, 'page_label': '361'}, page_content='Many gallbladder carcinomas are treated symptomatically.The Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 31. Gallbladder & Bile Duct Disorders\\n361'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 371, 'page_label': '362'}, page_content=\"4 - Musculoskeletal and Connective Tissue Disorders\\nChapter 32. Approach to the Patient With Joint Disease\\nIntroduction\\nSome musculoskeletal disorders affect primarily the joints, causing arthritis. Others affect primarily the\\nbones (eg, fractures, Paget's disease, tumors), muscles or other extra-articular soft tissues (eg,\\nfibromyalgia), or periarticular soft tissues (eg, polymyalgia rheumatica, bursitis, tendinitis, sprain). Arthritis\\nhas myriad possible causes, including infection, autoimmune disorders, crystal-induced inflammation, and\\nnoninflammatory tissue degeneration (eg, osteoarthritis). Arthritis may affect single joints (monarthritis) or\\nmultiple joints (polyarthritis) in a symmetric or asymmetric manner. Joints may suffer fractures or sprains\\n(see elsewhere in THE MANUAL).\\nHistory\\nThe clinician should focus on systemic and extra-articular symptoms as well as joint symptoms. Many\\nsymptoms, including fever, chills, malaise, weight loss, Raynaud's syndrome, mucocutaneous symptoms\\n(eg, rash, eye irritation or pain, photosensitivity), and GI or cardiopulmonary symptoms, can be associated\\nwith various joint disorders.\\nPain is the most common symptom of joint disorders. The history should address the character, location,\\nseverity, factors that aggravate or relieve pain, and time frame (new-onset or recurrent). The clinician\\nmust determine whether pain is worse when first moving a joint or after prolonged use and whether it is\\npresent upon waking or develops during the day. Usually, pain originating from superficial structures is\\nbetter localized than pain originating from deeper structures. Pain originating in small distal joints tends to\\nbe better localized than pain originating in large proximal joints. Joint pain can be referred from extra-\\narticular structures or from other joints. Arthritis often causes aching pain, whereas neuropathies often\\ncause burning pain.\\nStiffness may mean weakness, fatigue, or fixed limitation of motion to patients. The clinician must\\nseparate the inability to move a joint from reluctance to move a joint because of pain. Characteristics of\\nstiffness may suggest a cause, as in the following:\\n Discomfort that occurs with motion when attempting to move a joint after a period of rest occurs in\\nrheumatic disease. Duration of stiffness after beginning joint motion reflects its severity.\\n The theater sign (stiffness upon standing that necessitates walking slowly after sitting for several hours)\\nis common in osteoarthritis.\\n Stiffness is more severe and prolonged in inflammatory joint disorders.\\n Morning stiffness in peripheral joints that lasts > 1 h can be an important early symptom of RA (see\\nTable 32-1\\n).\\n In the low back, morning stiffness that lasts > 1 h may reflect spondylitis.\\nFatigue is a desire to rest that reflects exhaustion. It differs from weakness, inability to move, and\\nreluctance to move due to pain with movement.\\nInstability (buckling of a joint) may suggest weakness of the ligaments or other structures that stabilize the\\njoint, which are assessed by stress testing. Buckling occurs most often in the knee and most often results\\nfrom an internal joint derangement.\\nPhysical Examination\\nEach involved joint should be inspected and palpated, and the range of motion should be estimated. With\\npolyarticular disease, certain nonarticular signs (eg, fever, wasting, rash) may reflect systemic disorders.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n362\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 372, 'page_label': '363'}, page_content='The rest position of joints is noted, along with any erythema, swelling, deformity, and skin abrasions or\\npunctures. Involved joints are compared with their uninvolved opposites or with those of the examiner.\\nJoints are gently palpated, noting the presence and location of tenderness, warmth, and swelling.\\nDetermining whether tenderness is present along the joint line or over tendon insertions or bursae is\\nparticularly important. Soft masses, bulges, or tissues that fill normal concavities or spaces (representing\\njoint effusion or synovial proliferation) are noted. Palpation of\\n[\\nTable 32-1.\\n Distinguishing Inflammatory vs Noninflammatory Features in Joint Disease by Features]\\nswollen joints can sometimes differentiate among joint effusion, synovial thickening, and capsular or bony\\nenlargement. Small joints (eg, the acromioclavicular, tibiofibular, radioulnar) can be the source of pain that\\nwas initially believed to arise from a nearby major joint. Bony enlargement (often due to osteophytes) is\\nnoted.\\nActive range of motion (the maximum range through which the patient can move the joint) is measured\\nfirst, using a goniometer; limitation may reflect weakness, pain, or stiffness as well as mechanical\\nabnormalities. Then passive range of motion (the maximum range through which the examiner can move\\nthe joint) is assessed; passive limitation generally reflects mechanical abnormalities (eg, scarring,\\nswelling, deformities) rather than weakness or pain. Active and passive movement of an inflamed joint\\n(eg, due to infection or gout) may be very painful.\\nPatterns of joint involvement should be noted. Symmetric involvement of multiple joints is common in\\nsystemic diseases (eg, RA); monarticular (involving one joint) or asymmetric oligoarticular (involving  4)\\njoint involvement is more common in osteoarthritis and psoriatic arthritis. Small peripheral joints are\\ncommonly affected in RA, and the larger joints and spine are affected more in spondyloarthropathies.\\nHowever, a pattern of involvement may not be apparent in early disease.\\nCrepitus, a palpable or audible grinding produced by motion, is noted. It may be caused by roughened\\narticular cartilage or by tendons; crepitus-causing motions should be determined and may suggest which\\nstructures are involved.\\nSpecific features should be sought at each joint.\\nElbow:\\n Synovial swelling and thickening caused by joint disease occur in the lateral aspect between the\\nradial head and olecranon, causing a bulge. Full 180 extension of the joint should be attempted.\\nAlthough full extension is possible with nonarthritic or extra-articular problems such as tendinitis, its loss is\\nan early change in arthritis. The area around the joint is examined for swellings. Rheumatoid nodules are\\nfirm, occurring especially along the extensor surface of the forearm. Tophi are sometimes visible under\\nthe skin as cream-colored aggregates and indicate gout. Swelling of the olecranon bursa occurs over the\\ntip of the olecranon, is cystic, and does not limit joint motion; infection, trauma, gout, and RA are possible\\ncauses. Epitrochlear nodes occur above the medial epicondyle; they can result from inflammation in the\\nhand but can also suggest sarcoidosis or lymphoma.\\nShoulder:\\n Because pain can be referred to areas around the shoulder, shoulder palpation should include\\nthe glenohumeral, acromioclavicular, and sternoclavicular joints, the coracoid process, clavicle, acromion\\nprocess, subacromial bursa, biceps tendon, and greater and lesser tuberosities of the humerus, as well\\nas the neck. Glenohumeral joint effusions may cause a bulge between the coracoid process and the\\nhumeral head. Possible causes include RA, osteoarthritis, septic arthritis, Milwaukee shoulder (see p.\\n355\\n), and other arthropathies.\\nLimited motion, weakness, pain, and other disturbances of mobility caused by rotator cuff impairment can\\nbe quickly identified by having the patient attempt to abduct and raise both arms above the head and then\\nto slowly lower them. Muscle atrophy and neurologic abnormalities should be sought.\\nKnee:\\n At the knee, gross deformities such as swelling (eg, joint effusion, popliteal cysts), quadriceps\\nmuscle atrophy, and joint instability may be obvious when the patient stands and walks. With the patient\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n363'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 373, 'page_label': '364'}, page_content=\"supine, the examiner should palpate the knee, identifying the patella, femoral condyles, tibial tuberosity,\\ntibial plateau, fibular head, medial and lateral joint lines, popliteal fossa, and quadriceps and patellar\\ntendons. The medial and lateral joint lines correspond to locations of the medial and lateral menisci and\\ncan be located by palpation while slowly flexing and extending the knee. Tender extra-articular bursae\\nsuch as the anserine bursa below the medial joint line should be differentiated from true intra-articular\\ndisturbances.\\nDetection of small knee effusions is often difficult and is best accomplished using the bulge sign. The\\nknee is fully extended and the leg slightly externally rotated while the patient is supine with muscles\\nrelaxed. The medial aspect of the knee is stroked to express any fluid away from this area. Placement of\\none hand on the suprapatellar pouch and gentle stroking or pressing on the lateral aspect of the knee\\ncan create a fluid wave or bulge, visible medially when an effusion is present. Larger effusions can be\\nidentified visually or by balloting the patella. Joint effusion can result from many joint diseases, including\\nRA, osteoarthritis, gout, and trauma.\\nFull 180 extension of the knee is attempted to detect flexion contractures. The patella is tested for free,\\npainless motion.\\nHip:\\n Examination begins with gait evaluation. A limp is common in patients with significant hip arthritis. It\\nmay be caused by pain, leg shortening, flexion contracture, muscle weakness, or knee problems. Loss of\\ninternal \\nrotation (often the earliest change in hip osteoarthritis or any hip synovitis), flexion, extension, or\\nabduction can usually be demonstrated. Placement of one hand on the patient's iliac crest detects pelvic\\nmovement that might be mistaken for hip movement. Flexion contracture can be identified by attempting\\nleg extension with the opposite hip maximally flexed to stabilize the pelvis. Tenderness over the femoral\\ngreater trochanter suggests bursitis (which is extra-articular) rather than an intra-articular disorder. Pain\\nwith passive range of motion (assessed by internal and external rotation with the patient supine and the\\nhip and knee flexed to 90) suggests intra-articular origin. However, patients may have simultaneous\\nintra-articular and extra-articular disorders.\\nOther:\\n Hand examination is discussed elsewhere (see p. \\n385\\n and \\nPolyarticular Joint Pain\\n on p. \\n292\\n).\\nFoot and ankle examination is discussed in \\nCh. 44\\n. Examination of the neck and back is discussed on p.\\n379\\n.\\nTesting\\nLaboratory testing and imaging studies often provide less information than do the history and physical\\nexamination. While some testing may be warranted in some patients, extensive testing is often not.\\nBlood tests:\\n Some tests, although not specific, can be helpful in supporting the possibility of certain\\nsystemic rheumatic diseases, as for the following:\\n Antinuclear antibodies (ANA) and complement in SLE\\n Rheumatoid factor and anticitrullinated peptide (CCP) in RA\\n HLA-B27 in spondyloarthropathy (occasionally useful)\\n Antineutrophil cytoplasmic antibodies (ANCA) in certain vasculitides (occasionally useful)\\nTests such as WBC count, ESR, and C-reactive protein may help determine the likelihood that arthritis is\\ninflammatory due to infectious or other systemic disorders, but these tests are not highly specific or\\nsensitive. For example, an elevated ESR or C-reactive protein level suggests inflammation or may be due\\nto aging or a large number of nonarticular inflammatory conditions (eg, infection, cancer). Also, such\\nmarkers may not be elevated in all inflammatory disorders.\\nImaging studies:\\n Imaging studies are often unnecessary. Plain x-rays in particular reveal mainly bony\\nabnormalities, and most joint disorders do not affect bone primarily. However, imaging may help in the\\ninitial evaluation of relatively localized, unexplained persistent or severe joint and particularly spine\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n364\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 374, 'page_label': '365'}, page_content=\"abnormalities; they may reveal primary or metastatic tumors, osteomyelitis, bone infarctions, periarticular\\ncalcifications (as in calcific tendinitis), or other changes in deep structures that may escape physical\\nexamination. If chronic RA, gout, or osteoarthritis is suspected, erosions, cysts, and joint space narrowing\\nwith osteophytes may be visible. In pseudogout, Ca pyrophosphate deposition may be visible in intra-\\narticular cartilage.\\nFor musculoskeletal imaging, plain x-rays may be obtained first, but they are often less sensitive,\\nparticularly during early disease, than MRI, CT, or ultrasonography. MRI is the most accurate study for\\nfractures not visible on plain x-rays, particularly in the hip and pelvis, and for soft tissues and internal\\nderangements of the knee. CT is useful if MRI is contraindicated or unavailable. Ultrasonography,\\narthrography, and bone scanning may help in certain conditions, as can biopsy of bone, synovium, or\\nother tissues.\\nArthrocentesis:\\n Arthrocentesis is the process of puncturing the joint with a needle to withdraw fluid. If\\nthere is an effusion and arthrocentesis is done correctly, fluid can generally be withdrawn. Examination of\\nsynovial fluid is the most accurate way to exclude infection, diagnose crystal-induced arthritis, and\\notherwise determine the cause of joint effusions. It is indicated in all patients with severe or unexplained\\nmonarticular joint effusions and in patients with unexplained polyarticular effusions.\\nArthrocentesis is done using strictly sterile technique. Infection or other rash over the site used to enter\\nthe joint is a contraindication. Preparations for collecting samples should be made before doing the\\nprocedure. Local anesthesia, with lidocaine or difluoroethane spray, is often used. Many joints are\\npunctured on the extensor surface to avoid nerves, arteries, and veins, which are usually on the joint's\\nflexor surface. A 20-gauge needle can be used for most larger joints. Smaller joints of the upper and lower\\nextremities are probably easier to access using a 22- or 23-gage needle. As much fluid as is possible\\nshould be removed. Specific anatomic landmarks are used (see\\nFigs. 32-1\\n,\\n32-2\\n, and\\n32-3\\n).\\nMetacarpophalangeal joints, metatarsophalangeal joints, and interphalangeal joints of the hands and feet\\nare punctured similarly to each other, using a 22- or 23-gauge needle. The needle is inserted dorsally, to\\neither side of the extensor tendon. Distraction of the joint is sometimes useful to open the joint space and\\nallow easier access.\\n[\\nFig. 32-1.\\n Arthrocentesis of the shoulder.]\\nSynovial fluid examination:\\n At the bedside, gross characteristics of the fluid are assessed, such as its\\ncolor, turbidity, and viscosity. Viscosity can be assessed using the string sign. The length of a viscous\\nstring of joint fluid dropped from the syringe is normally > 3 cm. Inflammation decreases viscosity,\\nshortening the length of the string.\\nGross characteristics allow many effusions to be tentatively classified as noninflammatory, inflammatory,\\nor infectious (see\\nTable 32-2\\n). Effusions can also be hemorrhagic. Each type of effusion suggests certain joint diseases\\n(see\\nTable 32-3\\n). So-called noninflammatory effusions are actually mildly inflammatory but tend to suggest\\ndiseases such as osteoarthritis, in which inflammation is not severe.\\nLaboratory tests commonly done on joint fluid include cell count, leukocyte differential, Gram stain and\\nculture (if infection is a concernsee p. \\n365\\n), and wet drop examination for cells and crystals. However,\\nthe exact tests often depend on which diagnoses are suspected.\\nMicroscopic examination of a wet drop preparation of synovial fluid for crystals (only a single drop of fluid\\nfrom a joint is needed), using polarized light, is essential for definitive diagnosis of gout, pseudogout, and\\nother crystal-induced arthritides (see p. \\n349\\n). A polarizer over the light source and another polarizer\\nbetween the specimen and the examiner's eye allow visualization of crystals with a shiny white\\nbirefringence. Compensated polarized light is provided by inserting a first-order red plate, as is found in\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n365\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 375, 'page_label': '366'}, page_content=\"commercially available microscopes. The effects of a compensator can be reproduced by placing 2 strips\\nof clear adhesive tape on a glass slide and placing this slide over the lower polarizer. Such a homemade\\nsystem should be tested against a commercial polarizing microscope. The most common crystals seen\\nare those diagnostic of gout (monosodium urate, negatively birefringent needle-shaped crystals) and\\npseudogout (Ca pyrophosphate, positively birefringent square-ended crystals). If crystals appear atypical\\nin a wet drop, several less common crystals (cholesterol, liquid lipid crystals, oxalate, cryoglobulins) or\\nartifacts (eg, depot corticosteroid crystals) should be considered.\\nOther synovial fluid findings that occasionally make or suggest a specific diagnosis include the following:\\n Specific organisms (identifiable by Gram or acid-fast stain)\\n Marrow spicules or fat globules (caused by fracture)\\n Reiter's cells (monocytes on Wright's-stained smears that have phagocytized PMNs), which appear most\\noften in reactive arthritis\\n Amyloid fragments (identifiable by Congo red stain)\\n Sickled RBCs (caused by sickle cell hemoglobinopathies)\\n[\\nFig. 32-2.\\n Arthrocentesis of the elbow.]\\n[\\nTable 32-2.\\n Classification of Synovial Effusions]\\nMonarticular Joint Pain\\nMonarticular pain may originate from the joint itself or surrounding structures. There may be pain\\n(arthralgia) or also inflammation (arthritis) with redness, warmth, and swelling. Pain may occur only with\\nuse, suggesting a mechanical problem (eg, osteoarthritis, tendinitis), or also at rest, suggesting\\ninflammation (eg, crystal disease, septic arthritis). There may or may not be fluid within the joint (effusion).\\nPrompt assessment is essential to exclude infection. It is important to remember that acute monarticular\\narthritis is sometimes the initial manifestation of some types of polyarticular arthritis (eg, psoriatic arthritis,\\nRA).\\nPathophysiology\\nMonarticular pain may originate\\n Within a joint (intra-articular)\\n Around a joint (periarticular)\\nIntra-articular disorders may be inflammatory (eg, infectious, rheumatoid, crystal deposition arthritis) or\\nnoninflammatory (eg, osteoarthritis, internal derangement).\\nPeriarticular disorders include bursitis and tendinitis.\\nCrystal-induced arthritis is usually caused by monosodium urate crystals (gout) or Ca pyrophosphate\\ndihydrate crystals (pseudogout).\\nEtiology\\nAt all ages, injury is the most common cause of acute monarticular joint pain; history of trauma is usually\\nobvious.\\n[\\nFig. 32-3.\\n Arthrocentesis of the knee.]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n366\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 376, 'page_label': '367'}, page_content='[\\nTable 32-3.\\n Differential Diagnosis Based on Synovial Fluid Classification*\\n]\\nAmong young adults, the most common nontraumatic causes are the following:\\n Disseminated gonococcal infection\\n Periarticular syndromes\\nAmong older adults, the most common nontraumatic causes are the following:\\n Osteoarthritis\\n Crystal-induced disease (gout or pseudogout)\\n Periarticular syndromes\\nThe most dangerous cause at any age is acute infectious arthritis, because it requires acute operative\\nintervention (saline washout of the joint) and antibiotics to minimize permanent damage to the joint and to\\nprevent sepsis and death.\\nAt all ages, rare causes include adjacent osteomyelitis, avascular necrosis, pigmented villonodular\\nsynovitis, hemarthrosis (eg, in hemophilia or coagulopathies), and tumors (see\\nTable 32-4\\n).\\nEvaluation\\nAcute monarticular joint pain requires especially rapid diagnosis because some of its causes, particularly\\ninfectious (septic) arthritis and crystal-induced arthritis, require rapid treatment.\\n[\\nTable 32-4.\\n Some Causes of Monarticular Joint Pain]\\nEvaluation should determine whether the joint or periarticular structures are the cause of symptoms and\\nwhether there is inflammation. If inflammation is present or the diagnosis is unclear, symptoms and signs\\nof polyarticular and systemic disorders should be sought and all joints should be examined.\\nHistory: History of present illness\\n should focus on the acuity of onset (eg, abrupt, gradual), whether\\nthe problem is new or recurrent, and whether other joints have caused pain in the past. Also, temporal\\npatterns (eg, diurnal variation, persistent vs intermittent), exacerbating and mitigating factors (eg, cold\\nweather, activity), and any recent or past trauma to the joint should be noted. Patients should be\\nspecifically asked about unprotected sexual contact (possible gonococcal infection), tick bites, \\nand\\nresidence in or travel to an area where Lyme disease is endemic.\\nReview of systems\\n should seek symptoms of causative disorders, including fever (infection), urethritis\\n(gonococcal arthritis), and previous unexplained illness with rash (Lyme arthritis).\\nPast medical history\\n should identify known joint disorders (particularly gout, osteoarthritis) and any\\nknown conditions that may cause monarticular joint pain (eg, coagulopathy, bursitis, tendinitis,\\nhemoglobinopathy). Drug history should be reviewed for any use of anticoagulants or diuretics and for\\nchronic corticosteroid use. A family history should also be obtained.\\nPhysical examination:\\n Vital signs are reviewed for fever. Examination of the head, neck, and skin\\nshould note any signs of conjunctivitis, psoriatic plaques, mucosal lesions, ecchymoses, or malar rash.\\nGenital examination should note any discharge or other findings consistent with sexually transmitted\\ndiseases.\\nJoints are inspected for deformities, erythema, and swelling. Range of motion is assayed, first actively\\nand then passively; any crepitus on joint motion is noted.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n367'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 377, 'page_label': '368'}, page_content=\"Palpation is done to detect warmth, identify any effusion, and localize the area of tenderness. Of\\nparticular importance is whether the tenderness is directly over the joint line or adjacent to it (helping to\\ndifferentiate an intra-articular from a periarticular disorder). Sometimes, compression of the joint without\\nflexing or extending it (eg, pushing on the end of the great toe for patients with pain in the 1st\\nmetatarsophalangeal joint), sometimes with slight rotation, also helps differentiate intra-articular from\\nperiarticular disorders; this maneuver is not particularly painful for patients with tendinitis or bursitis but is\\nquite painful for those with arthritis. If the patient can tolerate it, the joint is stressed with various\\nmaneuvers to identify disruption of cartilage or ligaments (eg, in the knee, valgus and varus tests, anterior\\nand posterior drawer tests, Lachman's test, and McMurray's test). Comparison with the contralateral\\nunaffected joint often helps detect more subtle changes.\\nLarge effusions in the knee are typically readily apparent. The examiner can check for minor knee\\neffusions by pushing the suprapatellar pouch inferiorly and then pressing medially on the lateral side of\\nthe patella on an extended knee. This maneuver causes swelling to appear on the medial side.\\nPeriarticular structures also should be examined to look for discrete soft swelling at the site of a bursa\\n(bursitis), point tenderness at the insertion of a tendon (tendinitis), and point tenderness over a tendon\\nwith fine crepitus (tenosynovitis).\\nRed flags:\\n The following findings are of particular concern:\\n Erythema, warmth, effusion, and decreased range of motion\\n Fever\\n Acute-onset joint pain in a sexually active young adult\\n Skin breaks with cellulitis adjacent to the affected joint\\n Underlying bleeding disorder, hemoglobinopathy, or anticoagulation\\n Extra-articular or systemic symptoms\\nInterpretation of findings:\\n Antecedent trauma suggests a fracture, meniscal tear, or hemarthrosis. In the\\nabsence of trauma, history and physical examination may suggest a cause, but testing is often necessary\\nto rule out serious causes.\\nAcuteness of onset is a very important feature. Severe joint pain that develops over hours suggests\\ncrystal-induced arthritis or, less often, infectious arthritis. A previous attack of crystal-induced arthritis with\\ndevelopment of similar symptoms suggests recurrence. Gradual onset of pain is typical of RA or\\nnoninfectious arthritis but can result from certain infectious arthritides (eg, mycobacterial, fungal).\\nPain during rest and on initiating activity suggests inflammatory arthritis, whereas pain worsened by\\nmovement and relieved by rest suggests mechanical disorders (eg, osteoarthritis).\\nPain worse with active than with passive joint motion may indicate tendinitis or bursitis; intra-articular\\ninflammation generally restricts active and passive range of joint motion severely.\\nIncreased warmth and erythema suggest inflammation, but erythema is often absent during inflammation.\\nTenderness or swelling at only one side of a joint, or away from the joint line, suggests an extra-articular\\norigin (eg, in ligaments, tendons, or bursae); findings on several aspects of the joint suggest an intra-\\narticular cause.\\nAlthough gout can involve many different single joints or combinations of joints, acute, painful\\nmonarticular arthritis of the metatarsophalangeal joint of a great toe (podagra) is especially suggestive.\\nThe presence of systemic findings can help narrow the diagnosis. Urethritis can suggest gonococcal\\ninfection (although gonococcal arthritis often develops in patients without symptoms of urethritis). Fever is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n368\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 378, 'page_label': '369'}, page_content='indicative of septic joint, crystal-induced arthropathy, or \\nosteomyelitis. Symptoms indicating dermatologic,\\ncardiac, or pulmonary involvement suggest diseases that are more commonly associated with\\npolyarticular joint pain.\\nTesting:\\n Joint aspiration (arthrocentesis) should be done in patients with an effusion or other signs of\\ninflammation (eg, erythema, warmth, fever). Studies of the joint fluid should include WBC count with\\ndifferential (to determine whether the effusion is bloody or inflammatory), Gram stain and cultures, and\\nmicroscopic examination for crystals. Finding crystals in synovial fluid confirms crystal-induced arthritis\\nbut does not rule out coexisting infection. A noninflammatory synovial fluid (eg, < 2000/\\n\\nL WBCs or <\\n75% neutrophils) should lead to consideration of osteoarthritis, soft-tissue injury, or viral infection.\\nX-rays usually are done unless the cause is clearly a flare-up of a known disorder (eg, gout) or is a\\nclinically obvious bursitis or tendinitis, which can often be diagnosed without further testing.\\nOther imaging tests (eg, CT, MRI, bone scan) are adjunctive and are done depending on what diagnoses\\nare being considered (see \\nTable 32-4\\n).\\nBlood tests (eg, ESR, antinuclear antibodies, rheumatoid factor, anticyclic citrullinated peptide [CCP]\\nantibody, HLA-B27 testing) may help support an early diagnosis of a noninfectious inflammatory arthritis.\\nTreatment\\nOverall treatment is directed at the underlying disorder.\\nJoint inflammation is usually treated symptomatically with NSAIDs. Pain without inflammation is usually\\nmore safely treated with acetaminophen. Joint immobilization with a splint or sling can sometimes relieve\\npain. Heat therapy may relieve muscle spasm around joints. Cold therapy may be analgesic in\\ninflammatory joint diseases.\\nPhysical therapy after the acute symptoms have lessened is useful to maintain range of motion and\\nstrengthen surrounding muscles.\\nKey Points\\n Atraumatic joint pain should prompt consideration of degenerative disease, crystal-induced arthropathy,\\ninfection, or cancer.\\n Arthrocentesis is mandatory to rule out infection in a joint that is red, warm, and swollen.\\n Disseminated gonococcal infection is the most common cause of acute nontraumatic monarthritis in\\nyoung adults, whereas osteoarthritis is the most common cause in older adults.\\n Crystals in synovial fluid confirm crystal-induced arthritis but do not rule out coexisting infection.\\n Joint pain that is still unexplained after arthrocentesis and x-ray should be evaluated with MRI to rule out\\nuncommon etiologies (eg, occult fracture, avascular necrosis, pigmented villonodular synovitis).\\nPolyarticular Joint Pain\\nJoints may simply be painful (arthralgia) or also inflamed (arthritis), with redness, warmth, and swelling.\\nPain may occur only with use or also at rest, and there may or may not be fluid within the joint (effusion).\\nA useful initial distinction is whether pain is present in one joint (monarticular) or multiple joints\\n(polyarticular). When multiple joints are affected, different terms can be used:\\n Arthritis involving  4 joints, particularly when it occurs in an asymmetric fashion, is oligoarticular or\\npauciarticular arthritis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n369'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 379, 'page_label': '370'}, page_content=' Arthritis involving > 4 joints, usually in a symmetric fashion, is polyarticular arthritis.\\nPathophysiology\\nPolyarticular arthralgia can originate from arthritis or from extra-articular disorders (eg, polymyalgia\\nrheumatica, fibromyalgia). Pain caused by intra-articular disorders may be secondary to an inflammatory\\narthritis (eg, infection, RA, crystal deposition) or a noninflammatory process (eg, osteoarthritis).\\nInflammatory arthritis may involve peripheral joints only (eg, hands, knees, feet) or both peripheral and\\naxial joints (eg, sacroiliac, apophyseal, discovertebral, costovertebral).\\nEtiology\\nPeripheral oligoarticular and polyarticular arthritis have specific, likely causes (see\\nTable 32-5\\n); the presence or absence of axial involvement helps limit possibilities. However, in many\\npatients, arthritis is often transient and resolves without diagnosis or may not fulfill the criteria for any\\ndefined rheumatic disease.\\nAcute polyarticular arthritis is most often due to the following:\\n Infection (usually viral)\\n Flare of a rheumatic disease\\n[\\nTable 32-5.\\n Some Causes of Polyarticular Joint Pain]\\nChronic polyarticular arthritis in adults is most often due to the following:\\n RA (inflammatory)\\n Osteoarthritis (noninflammatory)\\nChronic polyarticular arthritis in children is most often due to the following:\\n Juvenile idiopathic arthritis\\nEvaluation\\nEvaluation should determine whether the joints or periarticular structures are the cause of symptoms and\\nwhether there is inflammation or effusion. If inflammation is present or the diagnosis is unclear, symptoms\\nand signs of systemic disorders should be sought.\\nHistory: History of present illness\\n should identify the acuity of onset (eg, abrupt, gradual), temporal\\npatterns (eg, diurnal variation, persistent vs intermittent), chronicity (eg, acute vs longstanding), and\\nexacerbating factors (eg, cold weather, activity). Patients should be specifically asked about unprotected\\nsexual contact (possible gonococcal infection) and tick bites or residence in a Lyme-endemic area.\\nReview of systems\\n should seek symptoms and signs of causative disorders (see \\nTables 32-5\\n and\\n32-6\\n).\\n[\\nTable 32-6.\\n Some Suggestive Findings in Polyarticular Joint Pain]\\nPast medical history\\n and family history should identify known rheumatic disorders and other conditions\\ncapable of causing joint symptoms (see \\nTable 32-5\\n).\\nPhysical examination:\\n Vital signs are reviewed for fever.\\nExamination of the head, neck, and skin should note any signs of conjunctivitis, iritis, mucosal lesions,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n370'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 380, 'page_label': '371'}, page_content='sinonasal abnormalities, lymphadenopathy, ecchymoses, skin ulcers, psoriatic plaques, purpura, or malar\\nrash.\\nCardiopulmonary examination should note any signs of acute inflammatory disease or serositis (eg,\\nmurmur, pericardial rub, muffled heart sounds, bibasilar dullness consistent with pleural effusion).\\nGenital examination should note any discharge, ulcers, or other findings consistent with sexually\\ntransmitted diseases.\\nMusculoskeletal examination should note muscular point tenderness associated with fibromyalgia. Joint\\nexamination begins with inspection for deformities, erythema, swelling, or effusion and then proceeds to\\npalpation and estimation of pain and crepitus with active and passive range of motion. Comparison with\\nthe contralateral unaffected joint often helps detect more subtle changes. Examination should note\\nwhether the distribution of affected joints is symmetric.\\nPeriarticular structures also should be examined for discrete, soft swelling at the site of a bursa (bursitis),\\npoint tenderness at the insertion of a tendon (tendinitis), and point tenderness over a tendon with fine\\ncrepitus (tenosynovitis).\\nRed flags:\\n The following findings are of particular concern:\\n Hot, swollen, red joints\\n Any extra-articular symptoms (eg, fever, rash, plaques, ulcers, conjunctivitis, iritis, murmur, purpura)\\nInterpretation of findings:\\n An important initial element is whether pain originates in the joints, spine, or\\nboth or in other structures such as bones, tendons, bursae, muscles, other soft-tissue structures, or\\nnerves. Pain that worsens with active rather than passive joint motion may indicate tendinitis or bursitis;\\nintra-articular inflammation generally restricts active and passive range of joint motion severely.\\nTenderness or swelling at only one side of a joint, or away from the joint line, suggests an extra-articular\\norigin (eg, in ligaments, tendons, or bursae); findings on several aspects of the joint suggest an intra-\\narticular cause. Pain that is diffuse and described inconsistently or vaguely may result from fibromyalgia\\nor functional disorders.\\nIf the joints, spine, or both are involved, differentiating inflammatory from noninflammatory disorders may\\nhelp. Clinical findings of prominent morning stiffness, nontraumatic joint swelling, and fever or weight loss\\nare suggestive of an inflammatory disorder, but testing is often helpful.\\nExamination of the hand joints may yield other clues (see \\nTable 32-6\\n) and may help differentiate\\nosteoarthritis from RA (see\\nTable 32-7\\n).\\nBack pain with arthritis suggests ankylosing spondylitis a reactive or psoriatic arthritis, or fibromyalgia.\\n[\\nTable 32-7.\\n Differential Features of the Hand in RA and Osteoarthritis]\\nTesting:\\n The following tests are of particular importance:\\n Arthrocentesis\\n Serologic testing\\n Usually ESR\\nArthrocentesis is mandatory in most patients with a new effusion and can help rule out infection and\\ncrystal arthropathy as well as distinguish between an inflammatory and noninflammatory process. Other\\ntests may be needed to identify specific disorders (see \\nTable 32-5\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n371'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 381, 'page_label': '372'}, page_content='If the specific diagnosis cannot be established clinically and if determining whether arthritis is\\ninflammatory may help determine the diagnosis, ESR and C-reactive protein may be done. A low ESR\\nmakes inflammatory causes (eg, rheumatic disease, gout, infection, vasculitis) less likely but does not rule\\nthem out. Elevated results argue more strongly for inflammation, but they are very nonspecific, particularly\\nin older adults.\\nOnce a diagnosis of a systemic disease is thought to be most likely, supportive serologic testing for\\nantinuclear antibodies, double-stranded DNA, rheumatoid factor, anticyclic citrullinated peptide, and\\nantineutrophil cytoplasmic antibodies may assist in making the diagnosis.\\nTreatment\\nThe underlying disorder is treated. Systemic diseases may require either immunosuppression or\\nantibiotics as determined by the diagnosis. Joint inflammation is usually treated symptomatically with\\nNSAIDs. Pain without inflammation is usually more safely treated with acetaminophen. Joint\\nimmobilization with a splint or sling can sometimes relieve pain. Heat therapy may relieve muscle spasm\\naround joints, and cold therapy may be analgesic in inflammatory joint diseases. For cases of chronic\\narthritis, continued physical activity is encouraged.\\nGeriatrics Essentials\\nOsteoarthritis is by far the most common cause of arthritis in older people. RA most commonly begins\\nbetween ages 30 and 40, but in up to one third of patients, it develops after the age of 60. Because\\nparaneoplastic phenomena also can cause inflammatory polyarthritis, cancer should be considered in\\nolder adults in whom new-onset RA is suspected.\\nKey Points\\n The differential diagnosis of polyarticular joint pain can be narrowed by considering how many joints are\\naffected, whether inflammation is present, and whether any extra-articular signs are present.\\n Chronic arthritis is most often caused by juvenile idiopathic arthritis in children and osteoarthritis and RA\\nin adults.\\n Acute polyarticular arthritis is most often due to infection, gout, or a flare of rheumatic disease.\\n Arthrocentesis is mandatory in most cases of a new effusion and can help rule out infection and crystal-\\ninduced arthropathy as well as distinguish between an inflammatory and noninflammatory process.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 32. Approach to the Patient With Joint Disease\\n372'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 382, 'page_label': '373'}, page_content=\"Chapter 33. Autoimmune Rheumatic Disorders\\nIntroduction\\nAutoimmune rheumatic disorders include eosinophilic fasciitis, mixed connective tissue disease,\\npolymyositis and dermatomyositis, relapsing polychondritis, Sjogren's syndrome, SLE, and systemic\\nsclerosis. RA and the spondyloarthropathies and their variants (see \\nCh. 35\\n) are also immune mediated.\\nThe triggers and precise pathophysiology remain unknown for all these disorders, although many aspects\\nof pathogenesis are becoming clearer. Patients with most autoimmune rheumatic disorders are at\\nincreased risk of atherosclerosis.\\nEosinophilic Fasciitis\\nEosinophilic fasciitis (EF) is an uncommon disorder characterized by symmetric and painful\\ninflammation, swelling, and induration of the arms and legs. Diagnosis is by biopsy of skin and\\nfascia. Treatment is with corticosteroids.\\nThe cause of EF is unknown. The disorder occurs mostly in middle-aged men but can occur in women\\nand children.\\nSymptoms and Signs\\nThe disease often begins after strenuous physical activity (eg, chopping wood). The initial features are\\npain, swelling, and inflammation \\nof the skin and subcutaneous tissues, followed by induration, creating a\\ncharacteristic orange-peel configuration most evident over the anterior surfaces of the extremities. The\\nface and trunk are occasionally involved. Restriction of arm and leg movement usually develops\\ninsidiously. Contractures commonly evolve, secondary to induration and thickening of the fascia, but the\\nprocess may also involve tendons, synovial membranes, and muscle. Typically, EF does not involve the\\nfingers and toes (acral areas). Muscle strength is unimpaired, but myalgia and arthritis may occur. Carpal\\ntunnel syndrome may also occur.\\nFatigue and weight loss are common. Rarely, aplastic anemia, thrombocytopenia, and lymphoproliferative\\nprocesses develop.\\nDiagnosis\\n Biopsy\\nEF should be suspected in patients with typical symptoms. The cutaneous manifestations may suggest\\nsystemic sclerosis; however, patients with systemic sclerosis usually also have Raynaud's syndrome,\\nacral involvement, telangiectasia, and visceral changes (eg, esophageal dysmotility). All of these are\\nabsent in EF.\\nDiagnosis is confirmed by en bloc biopsy, which should be deep enough to include fascia and adjacent\\nmuscle fibers. Characteristic findings are inflammation of the fascia, with or without eosinophils.\\nBlood tests are not diagnostic, but CBC shows eosinophilia (in early active disease), and serum protein\\nelectrophoresis shows polyclonal hypergammaglobulinemia. CBC should be done in all patients because\\nthe presence of eosinophilia helps in the diagnosis. Autoantibodies are usually absent. MRI, although not\\nspecific, can show thickened fascia, the increased signal intensity in the superficial muscle fibers\\ncorrelating with the inflammation.\\nPrognosis\\nAlthough the long-term outcome varies, EF is often self-limited and uncomplicated.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n373\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 383, 'page_label': '374'}, page_content=\" Oral prednisone\\nMost patients respond rapidly to high doses of prednisone (40 to 60 mg po once/day followed by gradual\\nreduction to 5 to 10 mg/day as soon as the fascitis resolves). Continued low doses may be required for 2\\nto 5 yr. Some patients require longer courses and possibly other drugs (eg, hydroxychloroquine,\\ncyclosporine). NSAIDs and H\\n2\\n blockers (eg, cimetidine) also have been used to treat EF.\\nMonitoring with CBCs is advised because of the occasional hematologic complications.\\nMixed Connective Tissue Disease\\nMixed connective tissue disease (MCTD) is an uncommon, specifically defined, overlap\\nsyndrome characterized by clinical features of SLE, systemic sclerosis, and polymyositis with\\nvery high titers of circulating antinuclear antibody to a ribonucleoprotein antigen. Hand\\nswelling, Raynaud's syndrome, polyarthralgia, inflammatory myopathy, esophageal\\nhypomotility, and pulmonary dysfunction are common. Diagnosis is by the combination of\\nclinical features, antibodies to ribonucleoprotein, and absence of antibodies specific for other\\nautoimmune diseases. Treatment varies with disease severity and organ involvement but\\nusually includes corticosteroids and sometimes additional immunosuppressants.\\nMCTD occurs worldwide and in all races, with a peak incidence in the teens and 20s. About 80% of\\npeople who have this disease are women. The cause is unknown. In some patients, the disorder evolves\\ninto classic systemic sclerosis or SLE.\\nSymptoms and Signs\\nRaynaud's syndrome may precede other manifestations by years. Frequently, the first manifestations\\nresemble early SLE, systemic sclerosis, polymyositis, dermatomyositis, or even RA. Whatever the initial\\nmanifestation, limited disease tends to progress and become widespread, and the clinical pattern\\nchanges over time.\\nThe most frequent finding is swelling of the hands that eventually causes a sausage-like appearance of\\nthe fingers. Skin findings include lupus or dermatomyositis-like rashes. Diffuse systemic sclerosis-like skin\\nchanges and ischemic necrosis or ulceration of the fingertips may occasionally develop.\\nAlmost all patients have polyarthralgias, and 75% have frank arthritis. Often the arthritis is nondeforming,\\nbut erosive changes and deformities similar to those in RA (eg, boutonniere and swan-neck deformities)\\nmay be \\npresent. Proximal muscle weakness with or without tenderness is common.\\nRenal disease occurs in about 10% and is often mild but occasionally causes morbidity or mortality.\\nSometimes pulmonary involvement is the most serious complication. Heart failure can occur. Sjogren's\\nsyndrome may develop. A trigeminal sensory neuropathy develops more frequently in MCTD than in other\\nsystemic autoimmune diseases. It may be the presenting feature and is considered the most frequent\\nCNS manifestation.\\nDiagnosis\\n Testing for antinuclear antibodies (ANA), extractable nuclear antigen (ENA), and ribonucleoprotein\\n(RNP)\\n Organ involvement determined as clinically indicated\\nMCTD should be suspected when additional overlapping features are present in patients appearing to\\nhave SLE, systemic sclerosis, polymyositis, or RA.\\nTests for ANA and antibody to ENA and RNP antigen are done first. If results of these tests are\\ncompatible with MCTD (eg, RNP antibodies very high, positive ANA), tests for rheumatoid factors, anti Jo-\\n1 (anti-histidyl t-RNA synthetase), antibodies to the ribonuclease-resistant Smith (Sm) component of ENA,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n374\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 384, 'page_label': '375'}, page_content=\"and double-stranded DNA are done to exclude other possible diagnoses.\\nFurther evaluation depends on symptoms and signs; manifestations of myositis, renal involvement, or\\npulmonary involvement prompt tests of those organs (eg, CK, MRI, electromyogram, or muscle biopsy for\\ndiagnosis of myositis).\\nAlmost all patients have high titers (often > 1:1000) of fluorescent ANA that produce a speckled pattern.\\nAntibodies to ENA are usually present at very high titers (> 1:100,000). Antibody to RNP is present,\\nwhereas antibody to the ribonuclease-resistant Sm component of ENA is absent.\\nRheumatoid factors are frequently positive, and titers are often high. The ESR is frequently elevated.\\nPrognosis\\nThe overall 10-yr survival rate is 80%, but prognosis depends largely on which manifestations\\npredominate. Patients with features of systemic sclerosis and polymyositis have a worse prognosis.\\nPatients are at increased risk of atherosclerosis. Causes of death include pulmonary hypertension, renal\\nfailure, MI, colonic perforation, disseminated infection, and cerebral hemorrhage. Some patients have\\nsustained remissions for many years without treatment.\\nTreatment\\n NSAIDs or antimalarials for mild disease\\n Corticosteroids for moderate to severe disease\\n Sometimes other immunosuppressants\\nGeneral management and initial drug therapy are tailored to the specific clinical problem and are similar to\\nthose of SLE. Most patients with moderate or severe disease respond to corticosteroids, particularly if\\ntreated early. Mild disease is often controlled by NSAIDs, antimalarials, or sometimes low-dose\\ncorticosteroids. Severe major organ involvement usually requires higher doses of corticosteroids (eg,\\nprednisone 1 mg/kg po once/day) and additional immunosuppressants. If patients develop features of\\nmyositis or systemic sclerosis, treatment is as for those diseases.\\nAll patients should be closely monitored for atherosclerosis. Patients on long-term corticosteroid therapy\\nshould receive osteoporosis prophylaxis.\\nPolymyositis and Dermatomyositis\\nPolymyositis and dermatomyositis are uncommon systemic rheumatic disorders characterized\\nby inflammatory and degenerative changes in the muscles (polymyositis) or in the skin and\\nmuscles (dermatomyositis). The most specific skin signs are Gottron's papules over the\\nknuckles and a periorbital heliotropic rash. Manifestations include symmetric weakness, some\\ntenderness, and later atrophy, principally of the proximal limb girdle muscles. Complications\\ncan include visceral involvement and cancer. Diagnosis is by clinical findings and abnormalities\\non muscle tests, which may include muscle enzymes, MRI, electromyography, and muscle\\nbiopsy. Treatment is with corticosteroids, sometimes combined with immunosuppressants or IV\\nimmune globulin.\\nThe female:male ratio is 2:1. These disorders may appear at any age but occur most commonly from age\\n40 to 60 or, in children, from age 5 to 15.\\nEtiology\\nThe cause seems to be an autoimmune reaction to muscle tissue in genetically susceptible people.\\nFamilial clustering occurs, and HLA subtypes DR3, DR52, DR6 seem to be the genetic predisposition.\\nPossible inciting events include viral myositis and underlying cancer. Picornavirus-like structures have\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n375\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 385, 'page_label': '376'}, page_content=\"been found in muscle cells, but their significance is not known, and viruses can trigger similar disorders in\\nanimals. The association of cancer with dermatomyositis (much less so with polymyositis) suggests that a\\ntumor may incite myositis as the result of an autoimmune reaction against a common antigen in muscle\\nand tumor.\\nPathophysiology\\nPathologic changes in both disorders include cellular damage and atrophy, with variable degrees of\\ninflammation. Muscles in the hands, feet, and face are affected less than other skeletal muscles.\\nInvolvement of visceral muscles in the pharynx and upper esophagus and occasionally the heart,\\nstomach, or intestines can impair the functions of those organs. High blood levels of myoglobin from\\nrhabdomyolysis can damage the kidneys. Inflammation may occur in joints and lungs, especially in\\npatients with antisynthetase antibodies.\\nDermatomyositis is characterized by immune complex deposition in the vessels and is considered a\\ncomplement-mediated vasculopathy. In contrast, the main pathophysiologic abnormality in polymyositis is\\ndirect T cell-mediated muscle injury.\\nClassification\\nMyositis has been divided into several subtypes:\\n Primary idiopathic polymyositis can occur at any age and does not involve the skin.\\n Primary idiopathic dermatomyositis is similar to primary idiopathic polymyositis but also involves the skin.\\n Polymyositis or dermatomyositis associated with cancer can occur at any age but is most common\\namong older adults; the cancer can develop up to 2 yr before or after the myositis.\\n Childhood dermatomyositis can be associated with systemic vasculitis.\\n Polymyositis or dermatomyositis can occur with an associated disorder such as progressive systemic\\nsclerosis, mixed connective tissue disease, RA, SLE, or sarcoidosis.\\nInclusion body myositis is a separate disorder that has clinical manifestations similar to chronic idiopathic\\npolymyositis; however, it develops at an older age, frequently involves distal muscles (eg, hand and feet\\nmuscles), has a longer duration, responds poorly to therapy, and has a different histologic appearance.\\nSymptoms and Signs\\nOnset of polymyositis may be acute (particularly in children) or insidious (particularly in adults).\\nPolyarthralgias, Raynaud's syndrome, dysphagia, pulmonary symptoms, and constitutional complaints\\n(notably fever, fatigue, and weight loss) may also occur.\\nMuscle weakness\\n may progress over weeks to months. However, it takes destruction of 50% of muscle\\nfibers to cause symptomatic weakness (ie, muscle weakness indicates advanced myositis). Patients may\\nhave difficulty raising their arms above their shoulders, climbing steps, or rising from a sitting position.\\nPatients may become wheelchair-bound or bedridden because of weakness of pelvic and shoulder girdle\\nmuscles. The flexors of the neck may be severely affected, causing an inability to raise the head from the\\npillow. Involvement of pharyngeal and upper esophageal muscles may impair swallowing and predispose\\nto aspiration. Muscles of the hands, feet, and face escape involvement. Limb contractures may eventually\\ndevelop.\\nJoint manifestations\\n include polyarthralgia or polyarthritis, often with swelling, effusions, and other\\ncharacteristics of nondeforming arthritis, which occur in about 30% of patients. However, joint\\nmanifestations tend to be mild. They occur more often in a subset with Jo-1 or other antisynthetase\\nantibodies.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n376\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 386, 'page_label': '377'}, page_content=\"Visceral involvement\\n (except that of the pharynx and upper esophagus) is less common in polymyositis\\nthan in some other rheumatic disorders (eg, SLE, systemic sclerosis). Occasionally, and especially in\\npatients with antisynthetase antibodies, interstitial pneumonitis (manifested by dyspnea and cough) is the\\nmost prominent manifestation. Cardiac arrhythmias (including conduction disturbances and abnormal\\nsystolic time intervals) can occur but are often asymptomatic. GI symptoms, more common among\\nchildren with associated vasculitis, may include hematemesis, melena, and ischemic bowel perforation.\\nSkin changes\\n, which occur in dermatomyositis, tend to be dusky and erythematous. Periorbital edema\\nwith a purplish appearance \\n(heliotrope rash) is specific for dermatomyositis. The rash may be slightly\\nelevated and smooth or scaly; it may appear on the forehead, V of the neck and shoulders, chest and\\nback, forearms and lower legs, elbows and knees, medial malleoli, and radiodorsal aspects of the\\nproximal interphalangeal and metacarpophalangeal joints (Gottron's papulesalso a relatively specific\\nfinding). The base and sides of the fingernails may be hyperemic or thickened. Desquamating dermatitis\\nwith splitting of the skin may evolve over the radial aspects of the fingers. The primary skin lesions\\nfrequently fade completely but may be followed by secondary changes (eg, brownish pigmentation,\\natrophy, scarring, vitiligo). Subcutaneous calcification may occur, particularly in children.\\nDiagnosis\\n Clinical criteria\\n Muscle biopsy (definitive)\\nPolymyositis should be suspected in patients with proximal muscle weakness with or without muscle\\ntenderness. Dermatomyositis should be suspected in patients with a heliotropic rash or Gottron's papules,\\neven without polymyositis, and in patients with symptoms of polymyositis and any skin findings compatible\\nwith dermatomyositis. Polymyositis and dermatomyositis share certain clinical findings with systemic\\nsclerosis or, less frequently, with SLE or vasculitis. Establishing the diagnosis requires as many as\\npossible of the following 5 criteria:\\n Proximal muscle weakness\\n Characteristic rash\\n Elevated serum muscle enzymes (CK, or if this is not elevated, aminotransferases or aldolase)\\n Characteristic electromyographic or MRI abnormalities\\n Muscle biopsy changes (the definitive test)\\nMuscle biopsy\\n excludes some similar conditions such as inclusion body myositis and postviral\\nrhabdomyolysis. Biopsy findings can be variable, but chronic inflammation and muscle degeneration and\\nregeneration are typical. A definite diagnosis made by muscle biopsy is recommended before treatment of\\npolymyositis to exclude other muscle disorders. To increase the sensitivity of the biopsy results, the\\nbiopsy sample should be obtained from a muscle that has one or more of the following characteristics:\\n Weakness on clinical examination\\n Inflammation identified on MRI\\n Contralateral pair of a muscle shown to be abnormal on electromyography\\nLaboratory studies\\n can increase or decrease suspicion for the disorder, assess its severity, identify\\noverlaps, and help detect complications. Autoantibodies should be tested. Antinuclear antibodies are\\npositive in up to 80% of patients. Detailed testing of the antinuclear antibodies (ANA), when present, is\\nimportant in identifying other overlap syndromes, most often those with another autoimmune disorder.\\nAbout 30% of patients have myositis-specific autoantibodies: antibodies to aminoacyl-tRNA synthetases\\n(anti-synthetase antibodies), including anti-Jo-1; antibodies to signal recognition particle (SRPanti-SRP\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n377\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 387, 'page_label': '378'}, page_content=\"antibodies); and antibodies to Mi-2, a nuclear helicase. The relationship between these autoantibodies\\nand disease pathogenesis remains unclear, although antibody to Jo-1 is a significant marker for fibrosing\\nalveolitis, pulmonary fibrosis, arthritis, and Raynaud's syndrome.\\nPeriodic measurement of CK is helpful in monitoring treatment. However, in patients with widespread\\nmuscle atrophy, levels are occasionally normal despite chronic, active myositis. Muscle biopsy, MRI, or\\nhigh CK levels can often differentiate a relapse of polymyositis from corticosteroid-induced myopathy.\\nAldolase is a less specific marker for muscle injury than CK.\\nCancer screening\\n is recommended by some authorities for any adult who has dermatomyositis or for\\npatients  60 yr who have polymyositis because these patients often have unsuspected cancers.\\nScreening should include a physical examination that includes breast, pelvis, and rectum (with occult\\nblood testing); CBC; biochemical profile; mammogram; carcinoembryonic antigen; urinalysis; chest x-ray;\\nand any other tests appropriate based on patient's age. Additional investigation should be based on\\nhistory and physical examination findings. Some authorities recommend CT of the chest, abdomen, and\\npelvis. Younger patients without symptoms of cancer need not undergo screening.\\nPrognosis\\nLong remissions (even apparent recovery) occur in up to 50% of treated patients within 5 yr, more often in\\nchildren. Relapse, however, may still occur at any time. Overall 5-yr survival rate is 75% and is higher in\\nchildren. Death in adults is preceded by severe and progressive muscle weakness, dysphagia,\\nundernutrition, aspiration pneumonia, or respiratory \\nfailure with superimposed pulmonary infection.\\nPolymyositis tends to be more severe and resistant to treatment in patients with cardiac or pulmonary\\ninvolvement. Death in children may be a result of bowel vasculitis. Cancer, if present, generally\\ndetermines the overall prognosis.\\nTreatment\\n Corticosteroids\\n Sometimes immunosuppressants (eg, methotrexate, azathioprine, cyclosporine, IV immune globulin)\\nPhysical activities should be modestly curtailed until the inflammation subsides. Corticosteroids are the\\ndrugs of choice initially. For acute disease, adults receive prednisone  40 to 60 mg po once/day. Serial\\nmeasurements of CK provide the best early guide of therapeutic effectiveness, falling toward or reaching\\nnormal in most patients in 6 to 12 wk, followed by improved muscle strength. Once enzyme levels have\\nreturned to normal, prednisone can be gradually reduced. If muscle enzyme levels rise, the dose is\\nincreased. Patients who seem to recover can have treatment gradually withdrawn with close monitoring,\\nbut most adults require chronic maintenance with prednisone (up to 10 to 15 mg/day). Children require\\ninitial doses of prednisone of 30 to 60 mg/m\\n2\\n once/day. In children, it may be possible to stop prednisone\\nafter  1 yr of remission.\\nOccasionally, patients treated chronically with high-dose corticosteroids become increasingly weak\\nbecause of a superimposed corticosteroid myopathy.\\nIf a patient does not to respond to corticosteroids, depends on a high to moderate dose of corticosteroids,\\nor develops a corticosteroid myopathy or another complication that necessitates stopping or decreasing\\nprednisone, immunosuppressants (eg, methotrexate, azathioprine, cyclosporine, IV immune globulin)\\nshould be tried. Some patients have received only methotrexate (generally in higher doses than used for\\nRA) for  5 yr. IV immune globulins can be effective in some patients refractory to drug treatment, but the\\nprohibitive cost has precluded comparative trials. Some clinicians combine prednisone with an\\nimmunosuppressant. Other possible emerging therapies include anti-tumor necrosis factor (TNF) agents\\nand rituximab.\\nMyositis associated with tumors, metastatic disease, or inclusion body myositis usually is more refractory\\nto corticosteroids. Cancer-associated myositis may remit if the tumor is removed.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n378\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 388, 'page_label': '379'}, page_content='People with an autoimmune disorder are at higher risk of atherosclerosis and should be closely\\nmonitored. Patients on long-term corticosteroid therapy should receive osteoporosis prophylaxis.\\nRelapsing Polychondritis\\nRelapsing polychondritis is an episodic, inflammatory, and destructive disorder involving\\nprimarily cartilage of the ear and nose but also potentially affecting the eyes, tracheobronchial\\ntree, heart valves, kidneys, joints, skin, and blood vessels. Diagnosis is by a combination of\\nclinical, laboratory, imaging, and sometimes biopsy findings. Treatment usually requires\\nprednisone and other immunosuppressants.\\nRelapsing polychondritis affects men and women equally; onset typically is in middle age. An association\\nwith RA, systemic vasculitis, SLE, and other connective tissue disorders suggests an autoimmune\\netiology.\\nSymptoms and Signs\\nAcute pain, erythema, and swelling most commonly affect the pinna cartilage. Nasal cartilage\\ninflammation is the next most common, followed by arthritis that varies from arthralgias to symmetric or\\nasymmetric nondeforming arthritis involving large and small joints, with a predilection for the\\ncostochondral joints. The next most common manifestations, in decreasing order of frequency, are\\ninflammation of the eye (eg, conjunctivitis, scleritis, iritis, keratitis, chorioretinitis); cartilaginous tissue of\\nthe larynx, trachea, or bronchi (causing hoarseness, cough, and tenderness over the laryngeal cartilage);\\ninternal ear; cardiovascular system (eg, aortic regurgitation, mitral regurgitation, pericarditis, myocarditis,\\naortic aneurysms, aortitis); kidney; and skin. Bouts of acute inflammation heal over weeks to months, with\\nrecurrences over several years. Various rashes can develop.\\nAdvanced disease can lead to destruction of supporting cartilage, causing floppy ears; saddle nose;\\npectus excavatum; and visual, auditory, and vestibular abnormalities. Tracheal narrowing can lead to\\ndyspnea, pneumonia, or even tracheal collapse. Coexisting systemic vasculitis (leukocytoclastic vasculitis\\nor polyarteritis nodosa), myelodysplastic syndrome, or cancer is possible.\\nDiagnosis\\n Clinical criteria\\n Sometimes biopsy\\nDiagnosis is established if the patient develops at least 3 of the following:\\n Bilateral chondritis of the external ears\\n Inflammatory polyarthritis\\n Nasal chondritis\\n Ocular inflammation\\n Respiratory tract chondritis\\n Auditory or vestibular dysfunction\\nBiopsy of involved cartilage, most often the pinna, is helpful if clinical diagnosis is not clear-cut.\\nLaboratory tests are done. They are not specific but may help to exclude other disorders. Synovial fluid\\nanalysis reveals mild inflammatory changes that are nonspecific but help to rule out an infectious process.\\nBlood tests may show normocytic-normochromic anemia, leukocytosis, elevated ESR or \\n\\n-globulin levels,\\nand occasionally positive rheumatoid factor, antinuclear antibodies (ANA), or, in up to 25%, antineutrophil\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n379'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 389, 'page_label': '380'}, page_content=\"cytoplasmic antibodies (ANCA). Abnormal renal function may indicate an associated vasculitis. A positive\\nc-ANCA test (ANCA that are reactive mainly to proteinase-3) suggests Wegener's granulomatosis, which\\ncan cause similar findings (see p. \\n329\\n).\\nThe upper and lower airways should be evaluated, including complete spirometric testing and chest CT,\\nwhen the diagnosis is made.\\nPrognosis\\nMortality after 5 yr is 30%, from collapse of laryngeal and tracheal structures or from cardiovascular\\ncomplications such as large-vessel aneurysm, cardiac valvular insufficiency, or systemic vasculitis.\\nTreatment\\n NSAIDs or dapsone for mild ear disease\\n Corticosteroids\\n Sometimes methotrexate or other immunosuppressants (eg, cyclosporine, cyclophosphamide,\\nazathioprine)\\nMild recurrent ear disease may respond to NSAIDs in anti-inflammatory doses, or dapsone (50 to 100 mg\\npo once/day). However, most patients are treated with prednisone 30 to 60 mg po once/day, with tapering\\nof the dose as soon as there is a clinical response. Some patients require chronic use. In such patients,\\nmethotrexate 7.5 to 20 mg po once/wk can reduce the requirement for corticosteroids. Very severe cases\\nmay require other immunosuppressants, such as cyclosporine, cyclophosphamide, or azathioprine (see p.\\n337\\n). None of these therapies has been tested in controlled trials or has been shown to decrease\\nmortality. If tracheal narrowing causes stridor, a tracheostomy or stent may be needed. More extensive\\ntracheobronchial collapse may require tracheal reconstruction. Eye disease may sometimes be\\nrecalcitrant to treatment, especially when involving the sclera, and carries a poor prognosis.\\nAll patients should be closely monitored for atherosclerosis given the risk of premature atherosclerosis in\\nsystemic vasculitides. Patients on long-term corticosteroid therapy should receive osteoporosis\\nprophylaxis.\\nSjogren's Syndrome\\nSjogren's syndrome (SS) is a relatively common chronic, autoimmune, systemic, inflammatory\\ndisorder of unknown cause. It is characterized by dryness of the mouth, eyes, and other\\nmucous membranes due to lymphocytic infiltration of the exocrine gland and secondary gland\\ndysfunction. Sjogren's syndrome can affect various exocrine glands or other organs. Diagnosis\\nis by specific criteria relating to eye, mouth, and salivary gland involvement, autoantibodies,\\nand (occasionally) histopathology. Treatment is symptomatic.\\nSS occurs most frequently among middle-aged women. SS is classified as primary when there is no other\\nassociated disease. In about 30% of patients with autoimmune disorders such as RA, SLE, systemic\\nsclerosis, mixed connective tissue disease, Hashimoto's thyroiditis, primary biliary cirrhosis, or chronic\\nautoimmune hepatitis, SS develops and, in such cases, is classified as secondary. Genetic associations\\nhave been found (eg, HLADR3 antigens in whites with primary SS).\\nPathophysiology\\nSalivary, lacrimal, and other exocrine glands become infiltrated with CD4+ T cells and with some B cells.\\nThe T cells produce inflammatory cytokines (eg, IL-2, interferon-\\n\\n). Salivary duct cells also produce\\ncytokines, eventually damaging the secretory ducts. Atrophy of the secretory epithelium of the lacrimal\\nglands causes desiccation of the cornea and conjunctiva (keratoconjunctivitis siccasee p. \\n592\\n).\\nLymphocytic infiltration and intraductal cellular proliferation in the parotid gland cause luminal narrowing\\nand in some cases formation of compact cellular structures termed myoepithelial islands; atrophy of the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n380\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 390, 'page_label': '381'}, page_content=\"gland can result. Dryness and GI mucosal or submucosal atrophy and diffuse infiltration by plasma cells\\nand lymphocytes may cause symptoms (eg, dysphagia).\\nSymptoms and Signs\\nGlandular manifestations:\\n SS often affects the eyes or mouth initially and sometimes exclusively. Dry\\neyes can cause irritation and photosensitivity. In advanced cases, the cornea is severely damaged,\\nepithelial strands hang from the corneal surface (keratitis filiformis), and vision can be impaired.\\nDiminished saliva (xerostomia) results in difficulty chewing and swallowing, secondary \\nCandida\\n infection,\\ntooth decay, and calculi in the salivary ducts. Taste and smell may be diminished. Dryness may also\\ndevelop in the skin and in mucous membranes of the nose, throat, larynx, bronchi, vulva, and vagina.\\nDryness of the respiratory tract may cause cough. Alopecia may occur. Parotid glands enlarge in 33% of\\npatients and are usually firm, smooth, and mildly tender. Chronic salivary gland enlargement is rarely\\npainful unless there is obstruction or infection.\\nExtraglandular manifestations:\\n Joint disease in SS is typically nonerosive and nondeforming.\\nArthralgias occur in about 50% of patients. Arthritis occurs in about 33% of patients and is similar in\\ndistribution to RA but is not erosive.\\nOther common extraglandular manifestations include generalized lymphadenopathy, Raynaud's\\nsyndrome, parenchymal lung involvement (which is common but infrequently serious), and vasculitis.\\nVasculitis can occasionally affect the peripheral nerves (causing peripheral polyneuropathy or\\nmononeuritis multiplex) or CNS or cause rashes (including purpura) and glomerulonephritis. Kidney\\ninvolvement can cause renal tubular acidosis, impaired concentrating ability, kidney stones, or interstitial\\nnephritis. Pseudolymphoma, malignant lymphoma, or Waldenstrom's macroglobulinemia can develop;\\npatients develop non-Hodgkin lymphoma at 40 times the normal rate. Chronic hepatobiliary disease and\\npancreatitis (exocrine pancreatic tissue is similar to that of salivary glands) may also occur.\\nDiagnosis\\n Eye symptoms, oral symptoms, and eye and salivary gland testing\\n Autoantibodies\\n Sometimes salivary gland biopsy\\nSS should be suspected in patients with gritty or dry eyes or dry mouth, enlarged salivary glands,\\nperipheral neuropathy, purpura, or unexplained renal tubular acidosis. Such patients should receive\\ndiagnostic tests that can include evaluation of the eyes and salivary glands and serologic tests. Different\\ncriteria have been proposed for classification of SS. The latest modifications to the American-European\\nclassification criteria for SS were proposed in 2002. These criteria were not developed for use in routine\\nclinical practice, and not every patient who receives a clinical diagnosis of SS fulfills the proposed criteria\\n(usually > 3 of 6 manifestations). The 6 manifestations are eye symptoms, oral symptoms, positive eye\\ntests, salivary gland involvement, autoantibodies, and histopathology.\\nEye symptoms\\n are  3 mo of either dry eyes or use of tear substitutes  3 times/day; slit-lamp\\nexamination may also confirm dry eyes.\\nOral symptoms\\n are > 3 mo of daily dry mouth sensation, daily use of liquids to aid in swallowing, or\\nswollen salivary glands.\\nEye signs\\n include evaluation by Schirmer's test, which measures the quantity of tears secreted in 5 min\\nafter irritation from a filter paper strip placed under each lower eyelid. A young person normally moistens\\n15 mm of each paper strip. Most people with SS moisten < 5 mm, although about 15% of test results are\\nfalse-positive and 15% are false-negative. Ocular staining with an eyedrop of rose bengal or lissamine\\ngreen solution is highly specific. Slit-lamp examination showing a fluorescein tear breakup in < 10 sec is\\nalso suggestive.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n381\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 391, 'page_label': '382'}, page_content='Salivary gland involvement\\n can be confirmed by abnormally low saliva production ( 1.5 mL/15 min) as\\nmeasured by salivary flow, sialography, or salivary scintiscanning, although these tests are used less\\noften.\\nAutoantibodies\\n (serologic criteria) have limited sensitivity and specificity. They include antibodies to Ro\\n(SS-A autoantibodiessee \\nSystemic Lupus Erythematosus\\n on p. \\n305\\n) or to nuclear antigens (termed La\\nor SS-B autoantibodies), antinuclear antibodies, or an elevated level of antibodies against \\n\\n-globulin.\\nRheumatoid factor is present in > 70% of patients. ESR is elevated in 70%, 33% have anemia, and up to\\n25% have leukopenia.\\nHistopathology\\n is assessed by biopsy of minor salivary glands in the buccal mucosa. \\nSalivary gland\\nbiopsy is usually reserved for patients in whom the diagnosis cannot be established by autoantibody\\ntesting or when a major organ is involved. Histopathologic involvement is confirmed if labial minor salivary\\nglands show multiple large foci of lymphocytes with atrophy of acinar tissue.\\nMost common causes of dry eyes and dry mouth (sicca symptoms) are aging and drugs, but when parotid\\nenlargement occurs in addition to sicca symptoms, diseases such as hepatitis C, HIV, bulimia, and\\nsarcoidosis should be differentiated from SS.\\nPrognosis\\nSS is chronic, and death may occasionally result from pulmonary infection and, rarely, from renal failure or\\nlymphoma. Associated systemic autoimmune disorders may dictate prognosis.\\nTreatment\\n Symptomatic treatment for sicca symptoms\\n Avoidance of aggravating factors\\n Occasionally oral corticosteroids or cyclophosphamide\\nSS should be initially managed by topical therapy of dry eyes and dry mouth. Other systemic\\nmanifestations of SS should be treated depending on the severity and the involved organ. Recognition of\\ntherapies for other conditions that can exacerbate dryness complaints is crucial. Hydroxychloroquine 200\\nto 400 mg po once/day is usually given to halt the progression of the disease and for the treatment of\\narthralgias.\\nDry eyes should be treated with lubricating eye preparations (initially drops such as hypromellose or\\nmethylcellulose and an OTC ointment at bedtime). Other treatments include drainage (punctal) duct\\nclosure and topical cyclosporine. Skin and vaginal dryness can be treated with lubricants.\\nMouth dryness may be avoided by sipping fluids throughout the day, chewing sugarless gum, and using a\\nsaliva substitute containing carboxymethylcellulose as a mouthwash. Drugs that decrease salivary\\nsecretion (eg, antihistamines, antidepressants, other anticholinergics) should be avoided. Fastidious oral\\nhygiene and regular dental visits are essential. Stones must be promptly removed, preserving viable\\nsalivary tissue. The pain of suddenly enlarged salivary glands is generally best treated with warm\\ncompresses and analgesics. Pilocarpine 5 mg po tid to qid or cevimeline HCl 30 mg po tid can stimulate\\nsalivary production but should be avoided in patients with bronchospasm and closed-angle glaucoma.\\nAggressive systemic treatment is occasionally indicated. It is usually reserved for patients with associated\\ndiseases (eg, severe vasculitis or visceral involvement); corticosteroids (eg, prednisone 1 mg/kg po\\nonce/day) or cyclophosphamide 5 mg/kg po once/day may be used.\\nSystemic Lupus Erythematosus\\n(Disseminated Lupus Erythematosus)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n382'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 392, 'page_label': '383'}, page_content=\"Systemic lupus erythematosus (SLE) is a chronic, multisystem, inflammatory disorder of\\nautoimmune etiology, occurring predominantly in young women. Common manifestations may\\ninclude arthralgias and arthritis; malar and other skin rashes; pleuritis or pericarditis; renal or\\nCNS involvement; and hematologic cytopenias. Diagnosis requires clinical and serologic\\ncriteria. Treatment of severe ongoing active disease requires corticosteroids, often\\nhydroxychloroquine, and sometimes immunosuppressants.\\nOf all cases, 70 to 90% occur in women (usually of child-bearing age). SLE is more common among\\nblacks and Asians than whites. It can affect patients of any age, including neonates. Increased awareness\\nof mild forms has resulted in a worldwide rise in reported cases. In some countries, the prevalence of SLE\\nrivals that of RA. SLE may be precipitated by currently unknown environmental triggers that cause\\nautoimmune reactions in genetically predisposed people. Some drugs (eg, hydralazine, procainamide,\\nisoniazid) cause a reversible lupus-like syndrome.\\nSymptoms and Signs\\nClinical findings vary greatly. SLE may develop abruptly with fever or insidiously over months or years\\nwith episodes of arthralgias and malaise. Vascular headaches, epilepsy, or psychoses may be initial\\nfindings. Manifestations referable to any organ system may appear. Periodic exacerbations (flares) may\\noccur.\\nJoint manifestations:\\n Joint symptoms, ranging from intermittent arthralgias to acute polyarthritis, occur\\nin about 90% of patients and may precede other manifestations by years. Most lupus polyarthritis is\\nnondestructive and nondeforming. However, in long-standing disease, deformities without bone erosions\\nmay develop (eg, the metacarpophalangeal and interphalangeal joints may rarely develop ulnar drift or\\nswan-neck deformities without bony or cartilaginous erosions [Jaccoud's arthritis]).\\nSkin and mucous membrane manifestations\\n (see also p. \\n309\\n): Skin lesions include malar butterfly\\nerythema (flat or raised) that generally spares the nasolabial folds. The absence of papules and pustules\\nhelps distinguish SLE from rosacea. A variety of other erythematous, firm, maculopapular lesions can\\noccur elsewhere, including exposed areas of the face and neck, upper chest, and elbows. Skin blistering\\nand ulceration are rare, although recurrent ulcers on mucous membranes (particularly the central portion\\nof the hard palate near the junction of the hard and soft palate, the buccal and gum mucosa, and the\\nanterior nasal septum) are common. Generalized or focal alopecia is common during active phases of\\nSLE. Panniculitis can cause subcutaneous nodular lesions. Vasculitic skin lesions may include mottled\\nerythema on the palms and fingers, periungual erythema, nail-fold infarcts, urticaria, and palpable\\npurpura. Petechiae may develop secondary to thrombocytopenia. Photosensitivity occurs in most\\npatients.\\nCardiopulmonary manifestations:\\n Cardiopulmonary symptoms commonly include recurrent pleurisy,\\nwith or without pleural effusion. Pneumonitis is rare, although minor impairments in pulmonary function\\nare common. Severe pulmonary hemorrhage occasionally occurs. Prognosis has traditionally been poor\\nbut seems to be improving, possibly because of better early, aggressive, critical care. Other complications\\ninclude pulmonary emboli, pulmonary hypertension, and shrinking lung syndrome. Cardiac complications\\ninclude pericarditis (most commonly), pericardial effusion, and myocarditis. Serious, rare complications\\nare coronary artery vasculitis, valvular involvement, and Libman-Sacks endocarditis. Accelerated\\natherosclerosis is an increasing cause of morbidity and mortality. Congenital heart block can develop in\\nneonates.\\nAdenopathy and splenic manifestations:\\n Generalized adenopathy is common, particularly among\\nchildren, young adults, and blacks. Splenomegaly occurs in 10% of patients. The spleen may develop\\nperiarterial fibrosis.\\nNeurologic manifestations:\\n Neurologic symptoms can result from involvement of any part of the central\\nor peripheral nervous system or meninges. Mild cognitive impairment is common. There may also be\\nheadaches, personality changes, ischemic stroke, subarachnoid hemorrhage, seizures, psychoses,\\norganic brain syndrome, aseptic meningitis, peripheral neuropathies, transverse myelitis, or cerebellar\\ndysfunction.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n383\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 393, 'page_label': '384'}, page_content='Renal manifestations:\\n Renal involvement can develop at any time and may be the only manifestation of\\nSLE. It may be benign and asymptomatic or progressive and fatal. Renal lesions can range in severity\\nfrom a focal, usually benign, glomerulitis to a diffuse, potentially fatal, membranoproliferative\\nglomerulonephritis. Common manifestations include proteinuria (most often), an abnormal urinary\\nsediment manifested by RBC casts and leukocytes, hypertension, and edema.\\nObstetric manifestations:\\n Obstetric manifestations include early and late fetal loss. In patients with\\nantiphospholipid antibodies, the risk of recurrent miscarriages is increased. Pregnancy can be successful\\n(see p. \\n2636\\n), particularly after 6 to 12 mo of remission, but SLE flares are common during pregnancy.\\nPregnancy should be timed for when disease is in remission. During pregnancy, the patient should be\\nmonitored closely for any disease flare or thrombotic events by a multidisciplinary team that includes a\\nrheumatologist, an obstetrician who specializes in high-risk pregnancies, and a hematologist.\\nHematologic manifestations:\\n Hematologic manifestations include anemia (often autoimmune\\nhemolytic), leukopenia (usually lymphopenia, with < 1500 cells/\\n\\nL,), and thrombocytopenia (sometimes\\nlife-threatening autoimmune thrombocytopenia). Recurrent arterial or venous thrombosis,\\nthrombocytopenia, and a high probability of obstetric complications occur in patients with antiphospholipid\\nantibodies. Thromboses probably account for many of the complications of SLE, including obstetric\\ncomplications.\\nGI manifestations:\\n GI manifestations can result from bowel vasculitis or impaired bowel motility. In\\naddition, pancreatitis can result from SLE or from its treatment with corticosteroids or azathioprine.\\nManifestations may include abdominal pain from serositis, nausea, vomiting, manifestations of bowel\\nperforation, and pseudo-obstruction. SLE rarely causes parenchymal liver disease.\\nDiagnosis\\n Clinical criteria\\n Cytopenias\\n Autoantibodies\\nSLE should be suspected in patients, particularly young women, with any of the symptoms and signs.\\nHowever, early-stage SLE can mimic other connective (or nonconnective) tissue disorders, including RA if\\narthritic symptoms predominate. Mixed connective tissue disease can mimic SLE but also may involve\\nfeatures of systemic sclerosis, rheumatoid-like polyarthritis, and polymyositis or dermatomyositis.\\nInfections (eg, bacterial endocarditis, histoplasmosis) can mimic SLE and may develop as a result of\\ntreatment-caused immunosuppression. Disorders such as sarcoidosis and paraneoplastic syndromes can\\nalso mimic SLE.\\nLaboratory testing differentiates SLE from other connective tissue disorders. Routine testing should\\ninclude the following:\\n Antinuclear antibodies (ANA)\\n CBC\\n Urinalysis\\n Chemistry profile including renal and liver enzymes\\nThe diagnosis is especially likely if  4 of the criteria in\\nTable 33-1\\n are present at any time but is still possible if < 4 criteria are present. If the diagnosis is\\nsuspected but not established, additional testing for autoantibodies can be useful. Establishing the\\ndiagnosis may require repeated evaluations over months or years.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n384'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 394, 'page_label': '385'}, page_content='Fluorescent ANA:\\n The fluorescent test for ANA is the best screen for SLE; positive ANA tests (usually in\\nhigh titer: > 1:80) occur in > 98%. However, positive ANA tests can also occur in RA, other connective\\ntissue disorders, cancers, and even in the general population. The false-positive rate varies from about\\n3% for ANA titers of 1:320 to about 30% for ANA titers of 1:40 among healthy controls. Drugs such as\\nhydralazine, procainamide, and tumor necrosis factor (TNF)-\\n\\n antagonists can produce positive ANA\\nresults as well as a lupus-like syndrome; the ANA eventually becomes negative if the drug is stopped.\\nPositive ANA should prompt more specific testing such as anti-double-stranded DNA antibodies; high\\ntiters are highly specific for SLE but occur in only 25 to 30% of people with SLE.\\nOther ANA and anticytoplasmic antibodies:\\n The ANA test is very sensitive, but it is not specific for\\nSLE; thus, evidence of other autoantibodies is needed to establish the diagnosis. They include Ro [SSA],\\nLa [SSB], Smith [Sm], ribonucleoprotein [RNP], and double-stranded DNA. Ro is predominantly\\ncytoplasmic; anti-Ro antibodies are occasionally present in ANA-negative SLE patients presenting with\\nchronic cutaneous lupus. Anti-Ro is the causal antibody for neonatal lupus and congenital heart block.\\nAnti-Sm is highly specific for SLE but, like anti-double-stranded DNA, is not sensitive. Anti-RNP occurs in\\npatients with SLE, mixed connective tissue disease, and occasionally other systemic autoimmune\\ndisorders and systemic sclerosis.\\n[\\nTable 33-1.\\n Criteria for the Classification of SLE*]\\nOther blood tests:\\n Leukopenia (usually lymphopenia) is common. Hemolytic anemia may occur.\\nThrombocytopenia in SLE may be difficult or impossible to differentiate from idiopathic thrombocytopenic\\npurpura except that patients have other features of SLE. False-positive serologic tests for syphilis occur\\nin 5 to 10% of SLE patients. These test results may be associated with the lupus anticoagulant and a\\nprolonged PTT. Abnormal values in one or more of these assays suggest the presence of\\nantiphospholipid antibodies (eg, anticardiolipin antibodies), which should then be measured directly by\\nenzyme-linked immunosorbent assay (ELISA). Antiphospholipid antibodies are associated with arterial or\\nvenous thrombosis, thrombocytopenia, and, during pregnancy, spontaneous abortion or late fetal death\\nbut may be present in asymptomatic patients.\\nOther tests help monitor disease severity and determine the need for treatment. Serum complement levels\\n(C3, C4) are often depressed in active disease and are usually lowest in patients with active nephritis.\\nESR is elevated frequently during active disease. C-reactive protein levels are not necessarily elevated.\\nRenal involvement:\\n Screening for renal involvement begins with urinalysis. RBC and WBC casts\\nsuggest active nephritis. Urinalysis should be done at regular intervals, even for patients in apparent\\nremission, because kidney disease may be asymptomatic. Renal biopsy is usually not necessary for\\ndiagnosis of SLE or to confirm renal involvement but is helpful in evaluating the status of renal disease\\n(ie, active inflammation vs postinflammatory scarring) and guide therapy. Patients with chronic renal\\ninsufficiency and mostly sclerotic glomeruli are not likely to benefit from aggressive immunosuppressive\\ntherapy.\\nPrognosis\\nThe course is usually chronic, relapsing, and unpredictable. Remissions may last for years. If the initial\\nacute phase is controlled, even if very severe (eg, with cerebral thrombosis or severe nephritis), the long-\\nterm prognosis is usually good. The 10-yr survival in most developed countries is > 95%. Improved\\nprognosis is in part due to earlier diagnosis and more effective therapies. More severe disease requires\\nmore toxic therapies, which increase risk of mortality. Examples of such complications include infection\\nfrom immunosuppression or osteoporosis from long-term corticosteroid use. Increased risk of coronary\\nartery disease can contribute to premature death.\\nTreatment\\n NSAIDs and often antimalarials for mild disease\\n Corticosteroids and often immunosuppressants for severe disease\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n385'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 395, 'page_label': '386'}, page_content='To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, pericarditis, headache,\\nrash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial\\ninvolvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS\\ninvolvement).\\nMild or remittent disease:\\n Little or no therapy may be needed. Arthralgias are usually controlled with\\nNSAIDs. Antimalarials help, particularly when joint and skin manifestations are prominent.\\nHydroxychloroquine 200 mg po once/day or bid reduces the frequency of SLE flares. Alternatives include\\nchloroquine 250 mg po once/day and quinacrine 50 to 100 mg po once/day. Hydroxychloroquine can\\nrarely cause retinal toxicity. The eyes should be examined at 12-mo intervals.\\nSevere disease:\\n Corticosteroids are first-line therapy. A combination of prednisone and\\nimmunosuppressants is recommended in active, serious CNS lupus, vasculitis especially affecting viscera\\nor nerves, or active lupus nephritis. Prednisone is usually given in doses of 40 to 60 mg po once/day, but\\nthe dose may vary according to the manifestation of SLE. Oral azathioprine 1 to 2.5 mg/kg once/day or\\noral cyclophosphamide 1 to 4 mg/kg once/day can be used as an immunosuppressant. For renal\\ninvolvement, cyclophosphamide is usually given in intermittent IV pulses instead of daily oral doses; eg,\\nabout 500 mg to 1 g/m\\n2\\n IV (together with mesna and fluid loading to protect the bladder) monthly for 6 mo\\nand then once q 3 mo for 18 mo (less frequently if there is renal or hematologic toxicitysee\\nTable 33-2\\n).\\nIn CNS lupus or other critical crises, methylprednisolone 1 g by slow (1-h) IV infusion on 3 successive\\ndays is often the initial treatment, followed by IV cyclophosphamide, as mentioned previously.\\nMycophenolate mofetil is an alternative to cyclophosphamide therapy for patients with active kidney\\ndisease who have preserved kidney function. IgG 400 mg/kg IV once/day for 5 consecutive days may be\\nuseful for refractory thrombocytopenia. Patients\\n[\\nTable 33-2.\\n Protocol for Chemotherapy with Cyclophosphamide and IV Mesna]\\nwith end-stage renal disease can undergo kidney transplantation, as an alternative to dialysis, with a\\nsuccessful outcome, especially if their disease has been in remission.\\nImprovement of severe SLE often takes 4 to 12 wk. Thrombosis or embolism of cerebral, pulmonary, or\\nplacental vessels requires short-term treatment with heparin and longer treatment with warfarin, if the\\ndiagnosis of antiphospholipid syndrome is confirmed. The target INR is usually 3.\\nSuppressive therapy:\\n For most patients, the risk of flares can be decreased without prolonged high-\\ndose corticosteroids. Chronic disease should be treated with the lowest dose of corticosteroids and other\\ndrugs that control inflammation (eg, antimalarials, low-dose immunosuppressants). Treatment should be\\nguided by clinical features primarily, although anti-double-stranded DNA antibody titers or serum\\ncomplement levels may be followed. Other pertinent blood and urine tests may be used to assess specific\\norgan involvement. Anti-double-stranded DNA antibody titers or serum complement levels may not parallel\\nnonrenal disease flares. If a patient needs long-term high-dose corticosteroids, alternative oral\\nimmunosuppressants should be considered. Ca, vitamin D, and bisphosphonate therapy should be\\nconsidered in patients taking corticosteroids long term.\\nFocal complications and coexisting medical conditions:\\n All patients should be closely monitored for\\natherosclerosis. Long-term anticoagulation is vital in patients with antiphospholipid antibodies and\\nrecurrent thrombosis (see p. \\n2228\\n).\\nIf a pregnant patient has antiphospholipid antibodies, thrombotic complications can be limited with\\ncorticosteroids (prednisone  30 mg po once/day), low-dose aspirin, or anticoagulation with heparin. Daily\\nheparin given subcutaneously with or without one baby aspirin throughout the 2nd and 3rd trimesters may\\nbe the most successful prophylactic measure.\\nVariant Forms of Lupus\\nDiscoid lupus erythematosus (DLE):\\n DLE, also sometimes called chronic cutaneous lupus\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n386'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 396, 'page_label': '387'}, page_content=\"erythematosus, is a set of skin changes that can occur as part of lupus, with or without systemic\\ninvolvement. Skin lesions begin as erythematous plaques and progress to atrophic scars. They cluster in\\nlight-exposed areas of the skin, such as the face, scalp, and ears. Untreated, lesions extend and develop\\ncentral atrophy and scarring. There may be widespread scarring alopecia. Mucous membrane\\ninvolvement may be prominent, especially in the mouth.\\nPatients presenting with typical discoid lesions should be evaluated for SLE. Antibodies against double-\\nstranded DNA are almost invariably absent in DLE. Although it does not differentiate DLE from SLE,\\nbiopsy can rule out other disorders (eg, lymphoma or sarcoidosis). Biopsy should be done from the active\\nmargin of a skin lesion.\\nEarly treatment can prevent permanent atrophy. Exposure to sunlight or ultraviolet light should be\\nminimized (eg, using potent sunscreens when outdoors). Topical corticosteroid ointments (particularly for\\ndry skin) or creams (less greasy than ointments) tid to qid (eg, triamcinolone acetonide 0.1 or 0.5%,\\nfluocinolone 0.025 or 0.2%, flurandrenolide 0.05%, betamethasone valerate 0.1%, and, particularly\\nbetamethasone dipropionate 0.05%) usually cause involution of small lesions; they should not be used\\nexcessively or on the face (where they cause skin atrophy). Resistant lesions can be covered with plastic\\ntape coated with flurandrenolide. Alternatively, intradermal injection with triamcinolone acetonide 0.1%\\nsuspension (< 0.1 mL per site) may resolve lesions, but secondary atrophy frequently follows.\\nAntimalarials (eg, hydroxychloroquine 200 mg po once/day or bid) can help, including for facial lesions. In\\nresistant cases, combinations (eg, hydroxychloroquine 200 mg/day plus quinacrine 50 to 100 mg po\\nonce/day) may be required for months to years.\\nSubacute cutaneous lupus erythematosus (SCLE):\\n SCLE is a variant form of SLE in which skin\\ninvolvement is prominent. Patients with SCLE develop extensive recurring rashes. Annular or\\npapulosquamous lesions may develop on the face, arms, and trunk. Lesions are usually photosensitive\\nand can develop hypopigmentation but rarely scar. Arthritis and fatigue are common in SCLE, but\\nneurologic and renal manifestations are not. Patients may be ANA-positive or ANA-negative. Most have\\nantibodies to Ro (SSA). Infants whose mothers have Ro antibodies may have congenital SCLE or\\ncongenital heart block. SCLE should be treated similarly to SLE.\\nSystemic Sclerosis\\n(Scleroderma)\\nSystemic sclerosis (SSc) is a rare chronic disease of unknown cause characterized by diffuse\\nfibrosis, degenerative changes, and vascular \\nabnormalities in the skin, joints, and internal\\norgans (especially the esophagus, lower GI tract, lungs, heart, and kidneys). Common\\nsymptoms include Raynaud's syndrome, polyarthralgia, dysphagia, heartburn, and swelling and\\neventually skin tightening and contractures of the fingers. Lung, heart, and kidney involvement\\naccounts for most deaths. Diagnosis is clinical, but laboratory tests help with confirmation.\\nSpecific treatment is difficult, and emphasis is often on treatment of complications.\\nSSc is about 4 times more common among women than men. It is most common among people aged 20\\nto 50 and is rare in children. SSc can develop as part of mixed connective tissue disease.\\nEtiology\\nImmunologic mechanisms and heredity (certain HLA subtypes) play a role in etiology. SSc-like syndromes\\ncan result from exposure to vinyl chloride, bleomycin, pentazocine, epoxy and aromatic hydrocarbons,\\ncontaminated rapeseed oil, or L-tryptophan.\\nPathophysiology\\nPathophysiology involves vascular damage and activation of fibroblasts; collagen and other extracellular\\nproteins in various tissues are overproduced.\\nIn SSc, the skin develops more compact collagen fibers in the reticular dermis, epidermal thinning, loss of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n387\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 397, 'page_label': '388'}, page_content=\"rete pegs, and atrophy of dermal appendages. T cells may accumulate, and extensive fibrosis in the\\ndermal and subcutaneous layers develops. In the nail folds, capillary loops dilate and some microvascular\\nloops are lost. In the extremities, chronic inflammation and fibrosis of the synovial membrane and surfaces\\nand periarticular soft tissues occur.\\nEsophageal motility becomes impaired, and the lower esophageal sphincter becomes incompetent;\\ngastroesophageal reflux and secondary strictures can develop. The intestinal muscularis mucosa\\ndegenerates, leading to pseudodiverticula in the colon and ileum. Interstitial and peribronchial fibrosis or\\nintimal hyperplasia of small pulmonary arteries can develop; if long-standing, pulmonary hypertension can\\nresult. Diffuse myocardial fibrosis or cardiac conduction abnormalities occur. Intimal hyperplasia of\\ninterlobular and arcuate arteries can develop within the kidneys, causing renal ischemia and\\nhypertension.\\nSSc varies in severity and progression, ranging from generalized skin thickening with rapidly progressive\\nand often fatal visceral involvement (SSc with diffuse scleroderma) to isolated skin involvement (often just\\nthe fingers and face) and slow progression (often several decades) before visceral disease develops.\\nThe latter form is termed limited cutaneous scleroderma or CREST syndrome (calcinosis cutis, Raynaud's\\nsyndrome, esophageal dysmotility, sclerodactyly, telangiectasias). In addition, SSc can overlap with other\\nautoimmune rheumatic disorderseg, sclerodermatomyositis (tight skin and muscle weakness\\nindistinguishable from polymyositis) and mixed connective tissue disease.\\nSymptoms and Signs\\nThe most common initial symptoms and signs are Raynaud's syndrome and insidious swelling of the\\ndistal extremities with gradual thickening of the skin of the fingers. Polyarthralgia is also prominent. GI\\ndisturbances (eg, heartburn, dysphagia) or respiratory complaints (eg, dyspnea) are occasionally the first\\nmanifestations.\\nSkin and nail manifestations:\\n Swelling of the skin is usually symmetric and progresses to induration. It\\nmay be confined to the fingers (sclerodactyly) and hands, or it may affect most or all of the body. The skin\\neventually becomes taut, shiny, and hypopigmented or hyperpigmented; the face becomes masklike; and\\ntelangiectases may appear on the fingers, chest, face, lips, and tongue. Subcutaneous calcifications may\\ndevelop, usually on the fingertips (pulps) and over bony eminences. Trophic ulcers are common,\\nespecially on the fingertips, overlying the finger joints, or over calcinotic nodules. Abnormal capillary and\\nmicrovascular loops in the nails can be seen with an ophthalmoscope or dissecting microscope.\\nJoint manifestations:\\n Polyarthralgias or mild arthritis can be prominent. Flexion contractures may\\ndevelop in the fingers, wrists, and elbows. Friction rubs may develop over the joints, tendon sheaths, and\\nlarge bursae.\\nGI manifestations:\\n Esophageal dysfunction is the most frequent visceral disturbance and occurs in most\\npatients. Dysphagia (usually retrosternal) usually develops first. Acid reflux can cause heartburn and\\nstricture. Barrett's esophagus occurs in one third of patients and predisposes to complications (eg,\\nstricture, adenocarcinoma). Hypomotility of the small bowel causes anaerobic bacterial overgrowth that\\ncan lead to malabsorption. Air may penetrate the damaged bowel wall and be visible on x-rays\\n(pneumatosis intestinalis). Leakage \\nof bowel contents into the peritoneal cavity can cause peritonitis.\\nDistinctive wide-mouthed diverticula can develop in the colon. Biliary cirrhosis may develop in patients\\nwith CREST syndrome.\\nCardiopulmonary manifestations:\\n Lung involvement generally progresses indolently, with substantial\\nindividual variability, but is a common cause of death. Lung fibrosis can impair gas exchange, leading to\\nexertional dyspnea and restrictive disease with eventual respiratory failure. Acute alveolitis (potentially\\nresponsive to therapy) can develop. Esophageal dysfunction can lead to aspiration pneumonia.\\nPulmonary hypertension may develop, as can heart failure, both of which are poor prognostic findings.\\nPericarditis with effusion or pleurisy can occur. Cardiac arrhythmias are common.\\nRenal manifestations:\\n Severe, often sudden renal disease (renal crisis) may occur, most commonly in\\nthe first 4 to 5 yr and in patients with diffuse scleroderma. It is usually heralded by sudden, severe\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n388\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 398, 'page_label': '389'}, page_content=\"hypertension.\\nDiagnosis\\n Clinical evaluation\\n Usually antinuclear antibodies (ANA), Scl-70 (topoisomerase I), and anticentromere antibodies\\nSSc should be considered in patients with Raynaud's syndrome, typical musculoskeletal or skin\\nmanifestations, or unexplained dysphagia, malabsorption, pulmonary fibrosis, pulmonary hypertension,\\ncardiomyopathies, or conduction disturbances. Diagnosis can be obvious in patients with combinations of\\nclassic manifestations, such as Raynaud's syndrome, dysphagia, and tight skin. However, in some\\npatients, the diagnosis cannot be made clinically, and confirmatory laboratory tests can increase the\\nprobability of disease but do not rule it out.\\nSerum ANA and Scl-70 antibody should be obtained. ANA are present in  90%, often with an\\nantinucleolar pattern. Antibody to centromeric protein (anticentromere antibody) occurs in the serum of a\\nhigh proportion of patients with CREST syndrome and is detectable on the ANA. Scl-70 antigen is a DNA-\\nbinding protein sensitive to nucleases. Patients with diffuse scleroderma are more likely than those with\\nCREST to have anti-Scl-70 antibodies. Rheumatoid factor also is positive in one third of patients.\\nIf lung involvement is suspected, pulmonary function testing, chest CT, and echocardiography can begin\\nto define its severity. Acute alveolitis is often detected by high-resolution chest CT.\\nPrognosis\\nThe course depends on the type of SSc but is often unpredictable. Typically, progression is slow. Overall\\n10-yr survival is about 65%. Most patients with diffuse skin disease eventually develop visceral\\ncomplications, which are the usual causes of death. Prognosis is poor if cardiac, pulmonary, or renal\\nmanifestations are present early. Heart failure may be intractable. Ventricular ectopy, even if\\nasymptomatic, increases the risk of sudden death. Acute renal insufficiency, if untreated, progresses\\nrapidly and causes death within months. Patients with CREST syndrome may have disease that is limited\\nand nonprogressive for long periods; visceral changes (eg, pulmonary hypertension caused by vascular\\ndisease of the lung, a peculiar form of biliary cirrhosis) eventually develop, but the course is often\\nremarkably benign.\\nTreatment\\n Treatment directed at symptoms and dysfunctional organs\\nNo drug significantly influences the natural course of SSc overall, but various drugs are of value in\\ntreating specific symptoms or organ systems. NSAIDs can help arthritis. Corticosteroids may be helpful if\\nthere is overt myositis or mixed connective tissue disease but may predispose to renal crisis.\\nPenicillamine, long used for treatment of skin thickening, has not shown clear efficacy in recent trials.\\nVarious immunosuppressants, including methotrexate, azathioprine, and cyclophosphamide, may help\\npulmonary alveolitis. Successful lung transplantation has been reported. Epoprostenol (prostacyclin) and\\nbosentan may be helpful for pulmonary hypertension. Ca channel blockers, such as nifedipine 20 mg po\\ntid or as an extended-release formulation, or angiotensin receptor blockers, such as losartan 50 mg po\\nonce/day, may help Raynaud's syndrome. Patients should dress warmly. IV infusions of prostaglandin E1\\n(alprostadil) or epoprostenol or sympathetic blockers can be used for digital ischemia. Reflux esophagitis\\nis relieved by frequent small feedings, high-dose proton pump inhibitors, and sleeping with the head of\\nthe bed elevated. Esophageal strictures may require periodic dilation; gastroesophageal reflux may\\npossibly require gastroplasty. \\nTetracycline 500 mg po bid or another broad-spectrum antibiotic can\\nsuppress overgrowth of intestinal flora and may alleviate malabsorption symptoms. Physiotherapy may\\nhelp preserve muscle strength but is ineffective in preventing joint contractures. No treatment affects\\ncalcinosis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n389\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 399, 'page_label': '390'}, page_content='For acute renal crisis, prompt treatment with an ACE inhibitor can dramatically prolong survival. Blood\\npressure is usually, but not always, controlled. The mortality rate of renal crisis remains high. If end-stage\\nrenal disease develops, it may be reversible, but dialysis and transplantation may be necessary.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 33. Autoimmune Rheumatic Disorders\\n390'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 400, 'page_label': '391'}, page_content='Chapter 34. Vasculitis\\nIntroduction\\nVasculitis is inflammation of blood vessels, often with ischemia, necrosis, and occlusive changes. It can\\naffect any blood vesselarteries, arterioles, veins, venules, or capillaries. Most damage results when\\ninflammation narrows vessels and causes tissue necrosis. Clinical manifestations of specific vasculitic\\ndisorders are diverse and depend on the size of the involved vessels and the organs affected by\\nischemia.\\nEtiology\\nVasculitis may be primary or secondary. Primary vasculitis results from an inflammatory response that\\ntargets the vessel walls and has no known cause. Secondary vasculitis may be triggered by an infection,\\na drug, or a toxin or may occur as part of another inflammatory disorder or cancer.\\nPathophysiology\\nHistologic description of an affected vessel should include the following:\\n A description of vessel wall damage\\n The nature of the inflammatory infiltrate in the vessel wall (eg, granulomatous, nongranulomatous,\\nleukocytoclastic vasculitis)\\n A description of healing responses (eg, intimal hypertrophy, fibrosis)\\nCertain features (eg, predominant inflammatory cells, location of inflammation) suggest particular\\nvasculitic processes and may aid in the diagnosis (see\\nTable 34-1\\n). For example, in many acute lesions, the predominant inflammatory cells are PMNs; in chronic\\nlesions, lymphocytes predominate.\\nInflammation may be segmental or involve the entire vessel. At sites of inflammation, varying degrees of\\ncellular inflammation and necrosis or scarring occur in one or more layers\\n[\\nTable 34-1.\\n Histologic Clues to Diagnosis of Vasculitic Disorders]\\n[\\nTable 34-2.\\n Classification of Vasculitic Disorders]\\nof the vessel wall. Inflammation in the media of a muscular artery tends to destroy the internal elastic\\nlamina.\\nLeukocytoclastic vasculitis is a histopathologic term used to describe findings in small-vessel vasculitis. It\\nrefers to breakdown of inflammatory cells that leaves small nuclear fragments (nuclear debris) in and\\naround the vessels. Inflammation is transmural, rarely necrotizing, and nongranulomatous. PMNs\\npredominate early; later, lymphocytes predominate. Resolution of the inflammation tends to result in\\nfibrosis and intimal hypertrophy. Intimal hypertrophy or secondary clot formation can narrow the arterial\\nlumen and accounts for tissue ischemia or necrosis.\\nClassification\\nVasculitic disorders can be classified according to the size of the predominant vessel affected (see \\nTable\\n34-2\\n). However, there is often substantial overlap.\\nSymptoms and Signs\\nSize of the affected vessels helps determine clinical presentation (see \\nTable 34-2\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n391'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 401, 'page_label': '392'}, page_content=\"Regardless of the size of the vessels involved, patients can present with symptoms and signs of systemic\\ninflammation (eg, fever, night sweats, fatigue, anorexia, weight loss, arthralgias, arthritis). Some\\nmanifestations are life- or organ-threatening and require immediate treatment. They include alveolar\\nhemorrhage, rapidly progressive glomerulonephritis, mesenteric ischemia, orbital pseudotumor\\nthreatening the optic nerve (in Wegener's granulomatosis), and vision loss in patients with giant cell\\narteritis.\\nDiagnosis\\n Clinical evaluation\\n Antineutrophil cytoplasmic antibodies (ANCA) tests\\n Biopsy\\n Angiography\\nSystemic vasculitis is suspected in patients with the following:\\n Symptoms or signs characteristic of vasculitis (eg, mononeuritis multiplex, leukocytoclastic vasculitis)\\n Ischemic manifestations (eg, ischemic stroke, limb claudication, mesenteric ischemia) out of proportion\\nto a patient's risk factors for atherosclerosis\\n \\nUnexplained combinations of symptoms in more than one organ system that are compatible with\\nvasculitis (eg, hypertension, myalgias), particularly when symptoms of a systemic illness are present\\nPrimary vasculitic disorders are diagnosed based on the presence of characteristic symptoms, physical\\nfindings, compatible laboratory test results, and exclusion of other causes (ie, secondary vasculitis).\\nHistologic examination is done whenever possible and may point to a particular vasculitic disorder (see\\nTable 34-1\\n).\\nRoutine laboratory tests are done. Most results are nonspecific but can help support the diagnosis. Tests\\nusually include CBC, ESR or C-reactive protein, serum albumin and total protein, and tests for ANCA.\\nOften, patients present with elevated ESR or C-reactive protein, anemia due to chronic inflammation,\\nelevated platelets, and low serum albumin and total protein. Freshly voided urine must be tested for\\nRBCs, RBC casts, and protein to identify renal involvement. Serum creatinine levels should be checked\\nand monitored. Leukopenia and thrombocytopenia are uncommon.\\nDetection of ANCA may support the diagnosis of Wegener's granulomatosis, Churg-Strauss syndrome, or\\nmicroscopic polyangiitis. Standardized tests for ANCA include immunofluorescence staining and enzyme-\\nlinked immunosorbent assay (ELISA). Immunofluorescence staining of ethanol-fixed neutrophils can\\ndetect the cytoplasmic pattern of cANCA or the perinuclear pattern of pANCA. Then solid-phase ELISA is\\nused to check for antibodies specific for the major autoantigens: proteinase-3 (PR3), which correlates\\nwith the cANCA staining pattern, or myeloperoxidase (MPO), which correlates with the pANCA staining\\npattern. Because false-positives occur, ANCA should be measured only when one of these vasculitic\\ndisorders is clinically suspected.\\nOther useful laboratory tests include hepatitis B and C serologic testing, testing for the presence of\\ncryoglobulins, and complement levels to diagnose viral or cryoglobulinemic vasculitis. Further testing is\\ndetermined by clinical findings. A chest x-ray should be done to check for infiltrates, but high-resolution\\nnoncontrast CT of the chest may be needed to check for subtle findings, such as small nodules or\\ncavities. Bilateral diffuse infiltrates suggest possible alveolar hemorrhage, which requires immediate\\ndiagnosis and treatment. Other imaging tests may be required. For example, magnetic resonance\\nangiography of large blood vessels and the aorta is useful for diagnosis and monitoring when such\\nvessels appear affected. If symptoms suggest mononeuritis multiplex, electromyography is done.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n392\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 402, 'page_label': '393'}, page_content='Because vasculitic disorders are rare and treatment may have severe adverse effects, tissue biopsy is\\ndone to confirm the diagnosis whenever possible. Usually, clinical findings suggest the best site for\\nbiopsy. For example, if clinical and electromyographic findings suggest mononeuritis multiplex with\\ndysfunction of a specific peripheral nerve, tissue around arteries supplying the nerve is biopsied. Usually,\\nbiopsies of unaffected tissue are much less likely to provide positive results.\\nBecause vasculitis is often segmental or focal, biopsy may not show inflammation even when a vessel is\\naffected. Sampling from multiple areas or long segments of a vessel may increase diagnostic sensitivity.\\nTreatment\\n Corticosteroids and cyclophosphamide to induce remission of life- or organ-threatening disorders\\n Tapering or elimination of corticosteroids and substitution of methotrexate or azathioprine to maintain\\nremission\\nTreatment depends on the etiology and extent and severity of disease. For secondary vasculitic\\ndisorders, removing the cause (eg, infection, drug, cancer) can help.\\nFor primary vasculitic disorders, treatment aims to induce and maintain remission. Remission is induced\\nby using cytotoxic immunosuppressants and high-dose corticosteroids, usually for 3 to 6 mo, until\\nremission occurs or disease activity is acceptably reduced. Adjusting treatment to maintain remission\\nusually takes longer, on average > 1 or 2 yr. During this period, the goal is to eliminate corticosteroids or\\nreduce their dose and to use less potent immunosuppressants as long as needed.\\nInduction of remission:\\n For less severe forms of vasculitis, low doses of corticosteroids and less potent\\nimmunosuppressants (eg, methotrexate, azathioprine, mycophenolate mofetil) may be used.\\nSevere, rapidly progressive and life- or organ-threatening vasculitis (eg, causing alveolar hemorrhage,\\nrapidly progressive glomerulonephritis, or mesenteric ischemia) is a medical emergency requiring hospital\\nadmission and immediate treatment. Treatment consists of the following:\\n \\nCorticosteroids:\\n High-dose corticosteroids (also called pulse corticosteroids) are often prescribed.\\nMethylprednisolone 15 mg/kg \\nor 1 g IV once/day for 3 days may be used. Oral prednisone is given\\nconcurrently. A dose of 1 mg/kg once/day is given for about 4 wk until patients improve. The dose is\\nthen tapered slowly, as tolerated, usually by 10 mg every week to 40 mg/day, by 5 mg every 2 wk to 20\\nmg/day, by 2.5 mg every 2 wk to 10 mg/day, and by 1 mg every month from there on until the drug is\\nstopped. Changes in this tapering schedule may be necessary if the patient fails to improve or relapses.\\n \\nCyclophosphamide:\\n A dose of 2 mg/kg po once/day is usually recommended for at least 3 mo or until\\nremission occurs. The WBC count must be closely monitored, and the dose must be adjusted to avoid\\nleukopenia. (WBC count should be maintained at > 3500/\\n\\nL.) If patients cannot tolerate oral\\ncyclophosphamide, are unlikely to take oral drugs as directed, or have a high risk of bladder cancer, IV\\ncyclophosphamide may be used. The recommended cumulative dose of cyclophosphamide is 0.75 to 1\\ng/m\\n2\\n monthly. The dose should be reduced in patients with significant renal insufficiency. Patients\\ntaking cyclophosphamide should also be given prophylactic treatment against \\nPneumocystis jirovecii\\n.\\nAcrolein, a product of cyclophosphamide degradation, is toxic to the bladder epithelium and can lead to\\nhemorrhagic cystitis. For patients who have taken cyclophosphamide long term, risk of cystitis is\\nincreased, and some develop transitional cell carcinoma of the bladder. During cyclophosphamide\\ntherapy, careful hydration is needed to reduce the risk of bladder hemorrhage, cystitis, and bladder\\ncancer. Mesna binds acrolein and is mixed together with the IV cyclophosphamide infusion. One milligram\\nof mesna is added for each milligram of cyclophosphamide. Recurrence of hematuria, especially without\\ncasts and dysmorphic red cells, should prompt a referral for urologic evaluation. Cystoscopy and renal\\nimaging should be done to exclude cancer.\\nRemission maintenance:\\n Corticosteroids are tapered to zero or to the lowest dose that can maintain\\nremission. Usually, methotrexate (with folate) or azathioprine is prescribed to replace cyclophosphamide\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n393'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 403, 'page_label': '394'}, page_content=\"because these drugs have a better adverse effects profile. The duration of this treatment varies, from one\\nyear to several years. Patients with frequent relapses may need to take immunosuppressants indefinitely.\\nLong-term use of corticosteroids can have significant adverse effects. Patients who are taking such\\ntherapy should be given Ca and vitamin D supplements and bisphosphonates to help prevent or minimize\\nosteoporosis; bone density should be monitored yearly.\\nBehcet's Syndrome\\nBehcet's syndrome is a multisystem, relapsing, chronic vasculitic disorder with prominent\\nmucosal inflammation. Common manifestations include recurrent oral ulcers, ocular\\ninflammation, genital ulcers, and skin lesions. The most serious manifestations are blindness,\\nneurologic or GI manifestations, venous thromboses, and arterial aneurysms. Diagnosis is\\nclinical, using international criteria. Treatment is mainly symptomatic but may involve\\ncorticosteroids for acute severe ocular or neurologic manifestations or immunosuppressants\\nfor severe chronic lesions.\\nBehcet's syndrome involves small and large arteries and veins. Arterial thrombosis and superficial and\\ndeep venous thrombosis often occur.\\nThe syndrome occurs nearly equally in men and women, typically beginning during their 20s.\\nOccasionally, the syndrome develops in children. Incidence varies by location. Behcet's syndrome is most\\ncommon along the silk route from the Mediterranean to China; it is uncommon in the US.\\nThe cause is unknown. Immunologic (including autoimmune) and viral or bacterial triggers have been\\nsuggested, and HLA-B51 is associated with cases from Turkey, Iran, China, Korea, and Japan.\\nNeutrophil infiltration is detected in biopsy specimens from oral aphthous ulcers and erythema nodosum\\nand pathergy lesions, but no histologic changes are pathognomonic.\\nSymptoms and Signs\\nMucocutaneous:\\n Almost all patients have recurrent painful oral ulcers resembling those of aphthous\\nstomatitis; in most, these ulcers are the first manifestations. The ulcers are round or oval, 2 to 10 mm in\\ndiameter, and shallow or deep with a central yellowish necrotic center; they can occur anywhere in the\\noral cavity, often in clusters. Ulcers last 1 to 2 wk. Similar ulcers occur on the penis and scrotum, on the\\nvulva where they are painful, or in the vagina where they may cause little or no pain.\\nCutaneous lesions are common and may include acneiform lesions, nodules, erythema nodosum,\\nsuperficial thrombophlebitis, pyoderma gangrenosum-type lesions, and palpable purpura.\\nPathergy (an erythematous papular or pustular response to local skin injury) is defined as a papule > 2\\nmm that appears 24 to 48 h after oblique insertion of a 20- to 25-gauge needle into the skin. Pathergy has\\noccurred in many parts of the world but is less common among North American and northern European\\npatients than among Middle Eastern and Asian patients.\\nOcular:\\n The eyes are affected in 25 to 75% of patients. The following may occur:\\n Relapsing uveitis or iridocyclitis (most common) often manifests as pain, photophobia, and red eye.\\n Hypopyon (a layer of pus visible in the anterior chamber) may occur.\\n Uveitis is typically bilateral and episodic, often involves the entire uveal tract (panuveitis), and may not\\nresolve completely between episodes.\\n Choroiditis, retinal vasculitis, vascular occlusion, and optic neuritis may irreversibly impair vision and\\neven progress to blindness.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n394\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 404, 'page_label': '395'}, page_content=\"Musculoskeletal:\\n Relatively mild, self-limiting, and nondestructive arthralgias or frank arthritis, especially\\nin the knees and other large joints, occur in 50% of patients. Sacroiliac inflammation can occur.\\nVascular:\\n Superficial and deep venous thromboses are common. Large vessels are affected in about\\none third of patients. Perivascular and endovascular inflammation may lead to hemorrhage, stenosis,\\naneurysms, and thrombosis in arteries and veins. Superior and inferior vena cava occlusion, Budd-Chiari\\nsyndrome, and other venous obstructive lesions can also occur.\\nDisease of the aorta and large blood vessels may be life threatening. Hemoptysis may occur if fistulas\\nbetween the pulmonary artery and bronchus develop.\\nNeurologic and psychiatric:\\n CNS involvement is less common but is serious. Onset may be sudden or\\ngradual. The first manifestations may be parenchymal involvement with pyramidal signs, small-vessel\\ndisease with a multiple sclerosis-like pattern, aseptic meningitis or meningoencephalitis, or dural sinus\\nthrombosis.\\nPsychiatric disorders including personality changes and dementia may develop years later. Peripheral\\nneuropathy, common in other vasculitic disorders, is uncommon in Behcet's syndrome.\\nGI:\\n Abdominal discomfort, abdominal pain, and diarrhea with intestinal ulcers, occurring primarily in the\\nileum and colon and closely resembling Crohn's disease, may occur.\\nDiagnosis\\n Clinical criteria\\nBehcet's syndrome should be suspected in young adults with recurrent oral aphthous ulcers, unexplained\\nocular findings, or genital ulcers. Diagnosis is clinical and may require months because many of the\\nmanifestations are nonspecific and can be insidious.\\nInternational criteria\\n for diagnosis include recurrent oral ulcers (3 times in 1 yr) and 2 of the following:\\n Recurrent genital ulcers\\n Eye lesions\\n Skin lesions\\n Positive pathergy test with no other clinical explanation\\nLaboratory tests (eg, CBC, ESR or C-reactive protein, serum albumin and total protein levels) are done.\\nResults are nonspecific but characteristic of inflammatory disease (elevated ESR, C-reactive protein, and\\n\\n2\\n- and \\n\\n-globulins; mild leukocytosis).\\nDifferential diagnosis includes reactive arthritis, SLE, Crohn's disease, ulcerative colitis, ankylosing\\nspondylitis, and herpes simplex infection. Behcet's syndrome has no single pathognomonic finding but\\nmay be distinguished by its combinations of relapsing symptoms with spontaneous remissions and\\nmultiple organ involvement, particularly in patients with recurrent, deep mucosal ulcers.\\nPrognosis\\nBehcet's syndrome typically has a waxing and waning course characterized by exacerbations and\\nremissions. Mucocutaneous and ocular lesions and arthralgias are often worse early in the disease. CNS\\nand large-vessel manifestations, if they develop, typically occur later. Occasionally, the syndrome results\\nin death, usually due to neurologic, vascular (eg, aneurysms), or GI manifestations. Many patients\\neventually go into remission.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n395\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 405, 'page_label': '396'}, page_content=' Colchicine, thalidomide, etanercept, and interferon for mucosal disease\\n Azathioprine or cyclosporine for eye disease\\n Cyclophosphamide and chlorambucil for refractory or life-threatening disease\\nTreatment depends on the clinical manifestations.\\nMucosal disease can be managed symptomatically. Colchicine 0.6 mg po bid may decrease the frequency\\nand severity of oral or \\ngenital ulcers and may be effective for erythema nodosum and arthralgias.\\nThalidomide 100 to 300 mg po once/day may be used to treat oral, genital, and skin lesions, but lesions\\nmay recur when treatment is stopped. Etanercept 50 mg sc once/wk or 25 mg sc twice/wk may suppress\\nmucocutaneous lesions. Etanercept can be given if colchicine is ineffective. Interferon alfa-2a 6 million\\nunits sc 3 times/wk can also be given if colchicine is ineffective.\\nAzathioprine 2.5 mg/kg po once/day helps preserve visual acuity and prevent new eye lesions.\\nAzathioprine is also useful for mucocutaneous lesions and arthralgia. Cyclosporine 5 to 10 mg/kg po\\nonce/day may be reserved for patients with severe ocular manifestations and may be used with\\nazathioprine to treat refractory uveitis. Interferon alfa-2a 6 million units sc 3 times/wk and infliximab (a\\ntumor necrosis factor inhibitor) 3 to 10 mg/kg IV at 0, 2, 4, and then every 8 wk show promise for patients\\nwith ocular manifestations.\\nCyclophosphamide and chlorambucil are used in patients with refractory disease, life-threatening\\nconditions (eg, pulmonary aneurysms), or CNS manifestations.\\nThe efficacy of corticosteroids is unsubstantiated, despite their wide use. Topical corticosteroids may\\ntemporarily relieve ocular manifestations and most oral lesions. However, topical or systemic\\ncorticosteroids do not alter the frequency of relapses. A few patients with severe uveitis or CNS\\nmanifestations respond to high-dose systemic corticosteroids (eg, prednisone 60 to 80 mg po once/day).\\nWhether immunosuppressants should be added to anticoagulation therapy when patients have\\nthromboses has not been established.\\nChurg-Strauss Syndrome\\n(Allergic Angiitis and Granulomatosis)\\nChurg-Strauss syndrome is a pulmonary and systemic small-vessel necrotizing vasculitis,\\ncharacterized by extravascular granulomas, eosinophilia, and tissue infiltration by eosinophils.\\nIt tends to occur in people with adult-onset asthma, allergic rhinitis, nasal polyposis, or a\\ncombination. Diagnosis is best confirmed by biopsy. Treatment is primarily with corticosteroids\\nand, for severe disease, addition of other immunosuppressants.\\nChurg-Strauss syndrome occurs in about 3 people/million. Mean age at onset is 48.\\nChurg-Strauss syndrome is characterized by extravascular necrotizing granulomas (usually containing\\neosinophilic infiltrates), eosinophilia, and tissue infiltration by eosinophils. However, these abnormalities\\nrarely coexist. The vasculitis typically affects pulmonary and systemic arteries and veins. Any organ can\\nbe affected, but the lungs, skin, cardiovascular system (eg, as coronary artery vasculitis), kidneys,\\nperipheral nervous system, sinuses, joints, and GI tract are most commonly affected. Occasionally,\\npulmonary capillaritis may cause alveolar hemorrhage.\\nEtiology\\nThe cause is unknown. However, an allergic mechanism, with tissue directly injured by eosinophils and\\nneutrophil degranulation products, may be involved. Activation of T lymphocytes seems to help maintain\\neosinophilic inflammation. The syndrome occurs in patients who have adult-onset asthma, allergic rhinitis,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n396'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 406, 'page_label': '397'}, page_content=\"nasal polyposis, or a combination. Antineutrophil cytoplasmic autoantibodies (ANCA) are sometimes\\npresent.\\nSymptoms and Signs\\nThe syndrome has 3 phases, which may overlap:\\n Prodromal: This phase may persist for years. Patients have allergic rhinitis, nasal polyposis, asthma, or\\na combination.\\n 2nd phase: Peripheral blood and tissue eosinophilia is typical. Clinical presentation, which may\\nresemble Loffler's syndrome, includes chronic eosinophilic pneumonia and eosinophilic gastroenteritis.\\n 3rd phase: Potentially life-threatening vasculitis develops. Systemic symptoms (eg, fever, malaise,\\nweight loss, fatigue) are common.\\nHowever, the phases do not necessarily follow one another consecutively, and the time interval between\\nthem varies greatly.\\nVarious organs and systems may be affected:\\n \\nRespiratory:\\n Asthma, often with onset during adulthood, occurs in most patients. Sinusitis is common,\\ntypically without severe necrotizing inflammation. Sinusitis causes facial pain and increases nasal\\ndischarge. Patients may be short of breath. Cough and hemoptysis, due to alveolar hemorrhage, may\\nbe present. Transient patchy pulmonary infiltrates are common.\\n \\nNeurologic:\\n Neurologic manifestations are common. Mononeuritis multiplex occurs in \\nup to three\\nfourths of patients. CNS involvement is rare but can include confusion, seizures, and coma, with or\\nwithout cranial nerve palsies or evidence of cerebral infarction.\\n \\nCutaneous:\\n The skin is affected in about one half of patients. Nodules and papules appear on extensor\\nsurfaces of extremities. They are caused by extravascular palisading granulomatous lesions with\\ncentral necrosis. Purpura or erythematous papules, due to leukocytoclastic vasculitis with or without\\nprominent eosinophilic infiltration, may develop.\\n \\nMusculoskeletal:\\n Occasionally, arthralgias, myalgias, or even arthritis can occur, usually during the\\nvasculitic phase.\\n \\nCardiac:\\n Heart failure, MI, coronary artery vasculitis (possibly with MI), valvular disorders, or pericarditis\\nmay develop. The predominant histopathologic finding is eosinophilic myocarditis.\\n \\nGI:\\n Up to one third of patients present with GI symptoms (eg, abdominal pain, diarrhea, bleeding) due to\\neosinophilic gastroenteritis or mesenteric ischemia due to vasculitis.\\n \\nRenal:\\n The kidneys are affected less often than in other vasculitic disorders associated with ANCA.\\nTypically, pauci-immune (few if any immune complexes), focal segmental necrotizing glomerulonephritis\\nwith crescent formation is present; eosinophilic or granulomatous inflammation of the kidneys is rare.\\nRenal, cardiac, or neurologic involvement indicates a worse prognosis.\\nDiagnosis\\n Clinical criteria\\n Routine laboratory tests\\n Biopsy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n397\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 407, 'page_label': '398'}, page_content=\"Criteria for classification from the American College of Rheumatology consist of the following:\\n Asthma\\n Eosinophilia of > 10% in peripheral blood\\n Paranasal sinusitis\\n Pulmonary infiltrates, sometimes transient\\n Histologic evidence of vasculitis with extravascular eosinophils\\n Mononeuritis multiplex or polyneuropathy\\nIf  4 criteria are present, sensitivity is 85%, and specificity is 99.7%.\\nTesting aims to establish the diagnosis and the extent of organ involvement and to distinguish Churg-\\nStrauss syndrome from other eosinophilic disorders (eg, parasitic infections, drug reactions, acute and\\nchronic eosinophilic pneumonia, allergic bronchopulmonary aspergillosis, idiopathic hypereosinophilic\\nsyndrome). Diagnosis is suggested by clinical findings and results of routine laboratory tests but should\\nusually be confirmed by biopsy of lung or other affected tissue.\\nBlood tests and chest x-rays are done, but results are not diagnostic. CBC with differential is done to\\ncheck for eosinophilia. Peripheral blood eosinophilia is also a marker of disease activity. IgE and C-\\nreactive protein levels and ESR are determined periodically to evaluate inflammatory activity. Electrolyte\\nlevels are measured and urinalysis is done to check for evidence of renal involvement and to follow its\\nseverity.\\nSerologic testing is done. It detects ANCA in up to 50%; if ANCA is detected, enzyme-linked\\nimmunosorbent assay (ELISA) is done to check for specific antibodies. Perinuclear ANCA (p-ANCA) with\\nantibodies against myeloperoxidase is the most common result, but ANCA is not specific for Churg-\\nStrauss syndrome.\\nChest x-ray often shows transient patchy pulmonary infiltrates.\\nBiopsy of the most accessible affected tissue should be done if possible.\\nTreatment\\n Corticosteroids\\nSystemic corticosteroids are the mainstay of treatment. When to add other immunosuppressants is not\\nclear, but Churg-Strauss syndrome is generally treated the same way as Wegener's granulomatosis (see\\np. \\n329\\n) or microscopic polyangiitis (see p. \\n322\\n). Recombinant interferon alfa-2a 3 million units sc daily has\\nbeen used when the syndrome is refractory to other drugs or when eosinophilic inflammation is difficult to\\ncontrol.\\nCutaneous Vasculitis\\nCutaneous vasculitis affects small or medium-sized vessels in the skin and subcutaneous\\ntissue. This disorder may be limited to the skin or be part of systemic vasculitis. Purpura,\\nulcers, livedo reticularis, or nodules may develop. Diagnosis requires biopsy. Treatment\\ndepends on etiology and extent of disease.\\nCommon causes include serum sickness, infections (eg, hepatitis C), cancers, rheumatologic \\nor other\\nautoimmune disorders, and hypersensitivity to drugs.\\nVessel inflammation often results from immune complex deposition, but other pathogenetic mechanisms\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n398\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 408, 'page_label': '399'}, page_content='may be involved. Predominantly cutaneous vasculitis is a leukocytoclastic vasculitis, so-called because\\ninflammation disrupts leukocytes, resulting in deposition of nuclear debris (leukocytoclasis) in the vessel\\nwall.\\nSymptoms and Signs\\nPatients may present with skin symptoms such as lesions, including palpable purpura, urticaria, ulcers,\\nlivedo reticularis, and nodules. If cutaneous vasculitis occurs as part of a systemic vasculitis, symptoms\\nmay also include fever, arthralgias, other organ involvement, or a combination.\\nDiagnosis\\n Exclusion of systemic vasculitis clinically and by routine tests (eg, CBC, ESR, urinalysis, chest x-ray,\\nserum creatinine)\\n Biopsy\\n Tests for the cause of vasculitis (eg, cryoglobulins, antineutrophil cytoplasmic antibodies [ANCA],\\nhepatitis B and C antibodies, complement levels)\\nA diagnosis of vasculitis limited to the skin requires a complete history and physical examination, focusing\\non excluding manifestations of inflammation or vasculitis in other organs, as in the following:\\n Lungs: Shortness of breath, cough, hemoptysis, and signs of consolidation\\n Kidneys: New-onset hypertension or edema\\n Nerves: New-onset asymmetric weakness or paresthesias\\n Intestine: New-onset abdominal pain, diarrhea, and bloody stools\\nUrinalysis should exclude blood, protein, and RBC casts. A chest x-ray is needed to check for infiltrates\\n(suggesting alveolar hemorrhage). CBC and other blood tests are needed to check for anemia, to\\ndetermine platelet count and serum creatinine level, and to check for elevated levels of acute-phase\\nreactants (eg, ESR, C-reactive protein).\\nA skin biopsy is done, optimally within 24 to 48 h after vasculitic lesions appear. Diagnostic yield depends\\non the depth of the biopsy. Generally, punch biopsy or excision biopsy into the subcutis is preferred; these\\nbiopsies can sample small and medium-sized vessels. Shave biopsy is usually inadequate.\\nIf histologic examination detects the following, cutaneous vasculitis is confirmed:\\n Infiltration of the vessel wall by inflammatory cells, resulting in disruption and destruction of the vessel\\nwall\\n Intramural and intraluminal fibrin deposition (fibrinoid necrosis)\\n Extravasation of RBCs\\n Nuclear debris (leukocytoclasis)\\nDirect immunofluorescence staining is needed to check for IgA, IgM, and IgG and complement deposition\\nin and around the vessel wall, which suggests an immune complex-mediated process and supports the\\ndiagnosis. Further testing to establish the cause of vasculitis includes checking for cryoglobulins, ANCA,\\nand hepatitis B and C antibodies, measuring complement levels, and tests for any clinically suspected\\ndisorders that can cause vasculitis.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n399'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 409, 'page_label': '400'}, page_content=\" Antihistamines and sometimes low-dose corticosteroids to treat skin lesions\\n Trial of colchicine, hydroxychloroquine, or dapsone to prevent recurrences\\nTreatment is first directed at any identified cause. If no cause is identified and vasculitis is limited to the\\nskin, treatment is minimal and conservative. Support hose and antihistamines may be sufficient. If this\\ntreatment is ineffective, low-dose corticosteroids can be tried.\\nIf lesions recur, colchicine, hydroxychloroquine, or dapsone may prevent further recurrences. Rarely,\\nstronger immunosuppressants (eg, azathioprine, methotrexate) are used, particularly if lesions ulcerate.\\nGiant Cell Arteritis\\n(Temporal Arteritis; Cranial Arteritis; Horton's Disease)\\nGiant cell arteritis involves predominantly the thoracic aorta, large arteries emerging from the\\naorta in the neck, and extracranial branches of the carotid arteries. Simultaneous polymyalgia\\nrheumatica is common. Focal symptoms and signs may include headaches, visual\\ndisturbances, temporal artery tenderness, and pain in the jaw muscles during chewing. Fever,\\nweight loss, malaise, and fatigue are also common. ESR and C-reactive protein are typically\\nelevated. Diagnosis is clinical and confirmed by temporal artery biopsy. Treatment with high-\\ndose corticosteroids and aspirin is usually effective and prevents vision loss.\\nGiant cell arteritis is a relatively common form of vasculitis in the US and Europe. Incidence varies\\ndepending on ethnic background. Autopsy studies suggest that the disorder may be more common than is\\nclinically apparent. Women are affected more often. Mean age at onset is about 70, with a range of 50 to\\n> 90. About 40 to 60% of patients with giant cell arteritis have polymyalgia rheumatica. The intracranial\\nvessels are usually not affected.\\nPathophysiology\\nVasculitis may be localized, multifocal, or widespread. The disorder tends to affect arteries containing\\nelastic tissue, most often the temporal, cranial, or other carotid system arteries. The aortic arch branches,\\ncoronary arteries, and peripheral arteries can also be affected. Mononuclear cell infiltrates in the\\nadventitia form granulomas containing activated T cells and macrophages. Multinucleated giant cells,\\nwhen present, cluster near the disrupted elastic lamina. The intimal layer is markedly thickened, with\\nconcentric narrowing and occlusion of the lumen.\\nSymptoms and Signs\\nSymptoms may begin gradually over several weeks or abruptly.\\nPatients may present with systemic symptoms such as fever (usually low-grade), fatigue, malaise,\\nunexplained weight loss, and sweats. Some patients are initially diagnosed as having FUO. Eventually,\\nmost patients develop symptoms related to the affected arteries.\\nSevere, sometimes throbbing headache (temporal, occipital, frontal, or diffuse) is the most common\\nsymptom. It may be accompanied by scalp pain elicited by touching the scalp or combing the hair.\\nVisual disturbances include diplopia, scotomas, ptosis, blurred vision, and loss of vision (which is an\\nominous sign). Brief periods of partial or complete vision loss (amaurosis fugax) in one eye may be\\nrapidly followed by permanent irreversible loss of vision. If untreated, the other eye may also be affected.\\nHowever, complete bilateral blindness is uncommon. Vision loss is caused by arteritis of branches of the\\nophthalmic artery or posterior ciliary arteries, which leads to ischemia of the optic nerve. Funduscopic\\nfindings may include ischemic optic neuritis with pallor and edema of the optic disk, scattered cotton-wool\\npatches, and small hemorrhages. Later, the optic nerve atrophies. Rarely, central blindness results from\\ninfarction in the occipital cortex caused by arterial lesions in the distal cervical region or base of the brain.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n400\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 410, 'page_label': '401'}, page_content=\"Intermittent claudication (ischemic muscle pain) may occur in jaw muscles and muscles of the tongue or\\nextremities. Jaw claudication is noted especially when firm foods are chewed.\\nNeurologic manifestations, such as strokes and transient ischemic attacks, can result when the carotid or\\nvertebrobasilar arteries or branches are narrowed or occluded.\\nThoracic aortic aneurysms and dissection of the aorta are serious, often late, complications.\\nDiagnosis\\n ESR, C-reactive protein, and CBC\\n Biopsy, usually of the temporal artery\\nGiant cell arteritis is suspected in patients > 55 if any of the following develops, especially if they also\\nhave symptoms of systemic inflammation:\\n A new type of headache\\n Any new symptom or sign compatible with ischemia of an artery above the neck\\n Jaw pain during chewing\\n Temporal artery tenderness\\n Unexplained subacute fever or anemia\\nThe diagnosis is more likely if patients also have symptoms of polymyalgia rheumatica.\\nPhysical examination may detect swelling and tenderness, with or without nodularity or erythema, over\\nthe temporal arteries. Temporal arteries can become prominent. A temporal artery that rolls under the\\nexaminer's fingers, rather than collapses, is abnormal. The large arteries of the neck and limbs and the\\naorta should be evaluated for bruits.\\nIf the diagnosis is suspected, ESR, C-reactive protein, and CBC are determined. In most patients, ESR\\nand C-reactive protein are elevated; anemia of chronic disease is common. Occasionally, platelets are\\nelevated, and serum albumin and total protein, measured for other reasons, are low. Mild leukocytosis is\\ncommonly detected but is nonspecific.\\nIf the diagnosis is suspected, biopsy of an artery is recommended. Because inflamed segments often\\nalternate with normal segments, a segment that appears abnormal should be sampled if possible. Usually,\\nthe temporal artery is biopsied, but the occipital artery can also be biopsied if it appears abnormal. The\\noptimal length of the temporal artery to remove is unclear, but 5 cm is recommended if possible.\\nTreatment should not be delayed to do the biopsy. Biopsy can be done up to 2 wk or perhaps more after\\ntreatment is started because the inflammatory infiltrate is slow to resolve.\\nIf patients have pulse deficits, the aorta and its branches are imaged (see\\nTable 34-3\\n on p. \\n328\\n).\\nTreatment\\n Corticosteroids\\n Low-dose aspirin\\nTreatment should be started as soon as giant cell arteritis is suspected, even if biopsy is going to be\\ndelayed for several days.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n401\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 411, 'page_label': '402'}, page_content=\"Corticosteroids are the cornerstone of treatment. Corticosteroids rapidly reduce symptoms and prevent\\nvision loss in most patients. The optimal initial dose, tapering schedule, and total length of treatment are\\ndebated. For most patients, an initial dose of prednisone 40 to 60 mg po once/day (or equivalent) for 4\\nwk, followed by gradual tapering, is effective. If patients have visual disturbances, an initial dose of IV\\nmethylprednisolone 500 to 1000 mg once/day for 3 to 5 days can be tried in an attempt to help prevent\\nfurther decline in vision, particularly in the contralateral eye.\\nIf symptoms lessen, prednisone can be tapered gradually from doses of up to 60 mg/day based on the\\npatient's response, usually as follows: by 5 to 10 mg/day every week to 40 mg/day, by 2 to 5 mg/day\\nevery week to 10 to 20 mg/day, then by 1 mg/day every month thereafter until the drug is stopped. ESR\\nalone should not be used alone to evaluate patient response (and disease activity). Clinical symptoms\\nmust also be used.\\nMost patients require at least 2 yr of treatment with corticosteroids. Long-term use of corticosteroids can\\nhave significant adverse effects and thus should be limited if possible. More than one half of patients\\ntaking these drugs have drug-related complications. Consequently, alternative therapies are being\\nstudied. If patients cannot tolerate corticosteroids or if symptoms return when the dose is tapered,\\nmethotrexate 0.3 mg/kg/wk may be useful.\\nTumor necrosis factor inhibitors have not been shown to be effective.\\nLow-dose aspirin (100 mg po once/day) may help prevent ischemic events and should be prescribed for\\nall patients unless contraindicated.\\nHenoch-Schonlein Purpura\\nHenoch-Schonlein purpura is vasculitis that affects primarily small vessels. It occurs most often\\nin children. Common manifestations include palpable purpura, arthralgias, GI symptoms and\\nsigns, and glomerulonephritis. Diagnosis is clinical in children but usually warrants biopsy in\\nadults. Disease is usually self-limited. Corticosteroids can relieve arthralgias and GI symptoms\\nbut do not alter the course of the disease. Progressive glomerulonephritis may require high-\\ndose corticosteroids and cyclophosphamide.\\nIn Henoch-Schonlein purpura, IgA-containing immune complexes are deposited in small vessels of the\\nskin and other sites, with consequent activation of complement. Possible inciting antigens include viruses\\nthat cause URIs, streptococcal infection, drugs, foods, insect bites, and immunizations. Focal, segmental\\nproliferative glomerulonephritis is typical but mild.\\nSymptoms and Signs\\nThe disease begins with a sudden palpable purpuric rash typically occurring on the feet, legs, and arms\\nand as a strip across the buttocks. The purpura may start as small areas of urticaria that become\\nindurated and palpable. Crops of new lesions may appear over days to several weeks. Many patients\\nalso have fever and polyarthralgia with periarticular tenderness and swelling of the ankles, knees, hips,\\nwrists, and elbows.\\nGI symptoms are common and include colicky abdominal pain, abdominal tenderness, and melena.\\nIntussusception occasionally develops in children. Stool may test positive for occult blood.\\nSymptoms usually remit after about 4 wk but often recur at least once after a disease-free interval of\\nseveral weeks. In most patients, the disorder subsides without serious sequelae; however, some patients\\ndevelop chronic renal failure.\\nDiagnosis\\n Biopsy of skin lesions\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n402\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 412, 'page_label': '403'}, page_content=\"The diagnosis is suspected in patients, particularly children, with typical skin findings. It is confirmed by\\nbiopsy of skin lesions when leukocytoclastic vasculitis with IgA in the vessel walls is identified. Biopsy is\\nunnecessary if clinical diagnosis is clear in children. Urinalysis is done; hematuria, proteinuria, and RBC\\ncasts indicate renal involvement. CBC and renal function tests are done.\\nIf renal function is deteriorating, renal biopsy may help define the prognosis. Diffuse glomerular\\ninvolvement or crescent formation in most glomeruli predicts progressive renal failure.\\nTreatment\\n Primarily corticosteroids and symptomatic measures\\nIf the cause is a drug, it has to be stopped. Otherwise, treatment is primarily symptomatic. Corticosteroids\\n(eg, prednisone 2 mg/kg up to a total of 50 mg po once/day) may help control abdominal pain and are\\noccasionally needed to treat severe joint pain or renal disease. Pulse IV methylprednisolone followed by\\noral prednisone and cyclophosphamide can be given to attempt to control inflammation when the kidneys\\nare severely affected. However, the effects of corticosteroids on renal manifestations are not clear.\\nMicroscopic Polyangiitis\\nMicroscopic polyangiitis is a systemic pauci-immune necrotizing vasculitis that affects mainly\\nsmall vessels. It may begin as a pulmonary-renal syndrome with rapidly progressing\\nglomerulonephritis and alveolar hemorrhage, but the pattern of disease depends on the organs\\naffected. Diagnosis is by biopsy. Treatment, which depends on disease severity, includes\\ncorticosteroids and immunosuppressants.\\nMicroscopic polyangiitis is rare (about 13 to 19 cases/million). Pathogenesis is unknown. Like immune\\ncomplex-associated vasculitis (eg, SLE, cryoglobulinemia, serum sickness, Henoch-Schonlein purpura),\\nmicroscopic polyangiitis affects small vessels. Polyarteritis nodosa can cause some manifestations similar\\nto the small vessel vasculitides, such as mononeuritis multiplex and bowel ischemia. Microscopic\\npolyangiitis can be distinguished from immune complex-associated vasculitis and polyarteritis nodosa by\\nthe following:\\n Microscopic polyangiitis affects predominantly small vessels, unlike polyarteritis nodosa, which affects\\nmedium-sized muscular arteries.\\n Microscopic polyangiitis, unlike polyarteritis nodosa, may cause glomerulonephritis and may affect the\\nlungs and cause alveolar hemorrhage.\\n Immune complex deposits are scarce or absent (ie, pauci-immune) in contrast to immune complex-\\nassociated vasculitis.\\nClinical manifestations resemble those of Wegener's granulomatosis except that granulomatous\\ndestructive lesions are absent and the upper respiratory tract is usually not severely affected. In both\\ndisorders, antineutrophil cytoplasmic antibodies (ANCA) may be present. Microscopic polyangiitis can\\noccur in patients with viral hepatitis B or C.\\nSymptoms and Signs\\nUsually, a prodromal illness with systemic symptoms of fever, weight loss, myalgia, and arthralgia occurs.\\nOther symptoms depend on which organs and systems are affected:\\n \\nRenal:\\n The kidneys are affected in up to 90% of patients. Hematuria, proteinuria (sometimes > 3 g/24\\nh), and RBC casts are present. Without prompt diagnosis and treatment, renal failure may follow\\nrapidly.\\n \\nCutaneous:\\n About one third of patients have a purpuric rash at the time of the diagnosis. Nail bed\\ninfarcts and splinter hemorrhages may occur; digital ischemia occurs rarely.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n403\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 413, 'page_label': '404'}, page_content=\" \\nRespiratory:\\n If the lungs are affected, alveolar hemorrhage may occur, followed by pulmonary fibrosis.\\nRapid-onset dyspnea and anemia, with or without hemoptysis and bilateral patchy infiltrates (seen on\\nchest x-ray) may be due to alveolar hemorrhage, a medical emergency that requires immediate\\ntreatment. Mild symptoms of rhinitis, epistaxis, and sinusitis may occur; however, if the upper\\nrespiratory tract is severely affected, the cause is more likely to be Wegener's granulomatosis.\\n \\nGI:\\n GI symptoms include abdominal pain, nausea, vomiting, diarrhea, and bloody stools.\\n \\nNeurologic:\\n If the nervous system is affected, mononeuritis multiplex that affects peripheral or cranial\\nnerves usually occurs. Cerebral hemorrhage, infarction, seizures, or headache rarely results from\\ncerebral vasculitis.\\n \\nCardiac:\\n Rarely, the heart is affected.\\n \\nOcular:\\n If the eyes are affected, episcleritis usually results.\\nDiagnosis\\n Clinical findings\\n Tests for ANCA and C-reactive protein and routine laboratory tests\\n Biopsy\\nMicroscopic polyangiitis may mimic many other disorders because its manifestations vary. The disorder\\nshould be suspected in patients who have unexplained combinations of GI symptoms or signs, alveolar\\nhemorrhage, episcleritis, and peripheral neuropathy. Laboratory tests and sometimes x-rays are done, but\\nthe diagnosis is usually confirmed by biopsy.\\nTests include CBC, ESR, C-reactive protein, urinalysis, serum creatinine, and tests \\nfor ANCA. ESR, C-\\nreactive protein levels, and WBC and platelet counts are elevated, reflecting systemic inflammation.\\nAnemia of chronic disease is common. An acute drop in Hct suggests alveolar hemorrhage or hemorrhage\\nin the GI tract. Urinalysis (to check for hematuria, proteinuria, and cellular casts) should be done, and\\nserum creatinine should be measured periodically to check for renal involvement.\\nImmunofluorescence staining can detect ANCA; this test is followed by enzyme-linked immunosorbent\\nassay (ELISA) to check for specific antibodies. At least 60% of patients have ANCA, usually perinuclear\\nANCA (p-ANCA) with antibodies against myeloperoxidase.\\nBiopsy of the most accessible involved tissue should be done to confirm vasculitis. Renal biopsy may\\ndetect focal segmental pauci-immune necrotizing glomerulonephritis with fibrinoid necrosis of the\\nglomerular capillary wall, leading to formation of cellular crescents.\\nIn patients with respiratory symptoms, chest x-ray is done to check for infiltrates. Bilateral patchy infiltrates\\nsuggest alveolar hemorrhage even in patients without hemoptysis.\\nIf patients have dyspnea and bilateral infiltrates, bronchoscopy should be done immediately to check for\\nalveolar hemorrhages. Blood coming from both lungs and all bronchi, with more blood coming as the\\nbronchoscope goes deeper in the airways, indicates active alveolar hemorrhage. Hemosiderin-laden\\nmacrophages appear within 24 to 72 h after onset of hemorrhage and may persist for up to 2 mo.\\nTreatment\\n When vital organs are affected, corticosteroids plus cyclophosphamide\\n For less severe cases, corticosteroids plus azathioprine or methotrexate\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n404\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 414, 'page_label': '405'}, page_content=\"Treatment is similar to that of Wegener's granulomatosis. Cyclophosphamide given daily plus\\ncorticosteroids improves survival when vital organs are affected. However, induction and maintenance\\nregimens vary, and adjunctive therapies such as plasma exchange and pulse IV methylprednisolone may\\nor may not be used.\\nLess severe cases may be managed with corticosteroids plus azathioprine or methotrexate.\\nPolyarteritis Nodosa\\n(Polyarteritis; Periarteritis Nodosa)\\nPolyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-\\nsized muscular arteries and occasionally affects small muscular arteries, resulting in secondary\\ntissue ischemia. The kidneys, skin, joints, muscles, peripheral nerves, and GI tract are most\\ncommonly affected, but any organ can be. However, the lungs are usually spared. Patients\\ntypically present with systemic symptoms (eg, fever, fatigue). Diagnosis requires a biopsy or\\narteriography. Treatment with corticosteroids and immunosuppressants is often effective.\\nPAN is rare (about 2 to 33 cases/million). It affects mainly middle-aged adults, and incidence increases\\nwith aging, peaking in people in their 50s.\\nEtiology\\nMost cases are idiopathic. About 20% of patients have hepatitis B or C.\\nThe cause is unknown, but immune mechanisms appear to be involved. The variety of clinical and\\npathologic features suggests multiple pathogenic mechanisms. Drugs may be a cause. Usually, no\\npredisposing antigen is identified. Patients with certain lymphomas and leukemias, RA, or Sjogren's\\nsyndrome may develop a systemic vasculitis similar to PAN.\\nPathophysiology\\nPAN is characterized by segmental, transmural necrotizing inflammation of muscular arteries, most\\ncommonly at points of bifurcation. Unlike other vasculitic disorders, PAN does not involve postcapillary\\nvenules or veins. Lesions in all stages of development and healing are usually present. Early lesions\\ncontain PMNs and occasionally eosinophils; later lesions contain lymphocytes and plasma cells.\\nGranulomatous inflammation does not occur. Intimal proliferation with secondary thrombosis and\\nocclusion leads to organ and tissue infarction. Weakening of the muscular arterial wall may cause small\\naneurysms and arterial dissection. Healing can result in nodular fibrosis of the adventitia.\\nMostly commonly affected are the kidneys, skin, peripheral nerves, joints, muscles, and GI tract. Often\\naffected are the liver and heart. Renal ischemia and infarction occur, but glomerulonephritis is not a\\nfeature of PAN. Purpura is not a characteristic of PAN.\\nSymptoms and Signs\\nPAN mimics many disorders. The course may be acute and prolonged, subacute and fatal after several\\nmonths, or insidious, chronic, and debilitating. Symptoms depend mainly on location and severity of the\\narteritis and \\nextent of secondary ischemia. Only one organ or organ system may be affected.\\nPatients typically present with fever, fatigue, night sweats, loss of appetite, weight loss, and generalized\\nweakness. Myalgias with areas of focal ischemic myositis and arthralgias are common. Affected muscles\\nare tender and weak. Arthritis may occur.\\nSymptoms and signs vary, depending on organ or organ system predominantly affected:\\n \\nPeripheral nervous system:\\n Patients usually present with asymmetric peripheral neuropathy, such as\\nmononeuritis multiplex with signs of motor and sensory involvement of the peroneal, median, or ulnar\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n405\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 415, 'page_label': '406'}, page_content='nerves. As additional nerve branches are affected, patients may appear to have a distal symmetric\\npolyneuropathy.\\n \\nCNS:\\n Headache and seizures can result. In a few patients, ischemic stroke and cerebral hemorrhage\\noccur, sometimes resulting from hypertension.\\n \\nRenal:\\n If small and medium-sized arteries in the kidneys are affected, patients may have hypertension,\\noliguria, uremia, and a nonspecific urinary sediment with hematuria, proteinuria, and no cellular casts.\\nHypertension may worsen rapidly. Rupture of renal arterial aneurysms can cause perirenal hematomas.\\nIn severe cases, multiple renal infarcts with lumbar pain and gross hematuria may occur. Renal\\nischemia and infarction can lead to renal failure.\\n \\nGI:\\n Vasculitis of the liver or gallbladder causes right upper quadrant pain. Perforation of the gallbladder\\nwith acute abdomen may occur. Vasculitis of medium-sized mesenteric arteries causes abdominal pain,\\nnausea, vomiting (with or without bloody diarrhea), malabsorption, intestinal perforation, and acute\\nabdomen. Aneurysms may develop in hepatic or celiac arteries.\\n \\nCardiac:\\n Some patients have coronary artery disease, which is usually asymptomatic, but may cause\\nangina. Heart failure may result from ischemic or hypertensive cardiomyopathy\\n \\nCutaneous:\\n Livedo reticularis, skin ulcers, tender erythematous nodules, bullous or vesicular eruptions,\\ninfarction and gangrene of fingers or toes, or a combination may occur. The nodules in PAN resemble\\nerythema nodosum (inflammation of subcutaneous fat), but in PAN, necrotizing vasculitis occurs within\\nthe walls of medium-sized arteries, usually located in the deep dermis and subcutaneous fat.\\n \\nGenital:\\n Orchitis with testicular pain and tenderness can occur.\\nDiagnosis\\n Clinical findings\\n Biopsy\\n Arteriography if no clinically involved tissue is available for biopsy\\nPAN may be suspected in patients with unexplained fever, abdominal pain, renal failure, hypertension,\\narthralgia, muscle tenderness or weakness, subcutaneous nodules, skin ulcers, pain in the abdomen or\\nextremities, or rapidly developing hypertension. If patients have insidious, nonspecific symptoms,\\ndiagnosis is much more difficult. The diagnosis is further clarified when clinical findings are combined with\\ncertain laboratory results and other causes are excluded. PAN is also suspected in patients with systemic\\nsymptoms or signs and peripheral (usually multiple) neuritis involving major nerve trunks (eg, radial,\\nperoneal, sciatic) in a bilaterally symmetric or asymmetric fashion (mononeuritis multiplex).\\nDiagnosis is confirmed by biopsy showing necrotizing arteritis or by arteriography showing the typical\\naneurysms in medium-sized arteries. Magnetic resonance angiography may show microaneurysms, but\\nsome abnormalities may be too small for it to detect. Thus, magnetic resonance angiography is not the\\ntest used primarily for diagnosis. Biopsy of clinically uninvolved tissue is usually useless because the\\ndisease is focal; biopsy should target sites suggested by clinical evaluation. Samples of subcutaneous\\ntissue, sural nerve, and muscle, if thought to be involved, are preferred to samples from the kidneys or\\nliver. If clinical findings are absent or minimal, electromyography and nerve conduction studies may help\\nselect the site of muscle or nerve biopsy. If skin lesions are present, surgical skin biopsies that include\\ndeeper dermis and subcutaneous fat should be done. (Punch biopsies of the skin that sample the\\nepidermis and superficial dermis miss the lesions of PAN.) Even though microscopic lesions in the testes\\nare common, testicular biopsy should not be done if testicular symptoms are absent and if other possible\\nsites are accessible because the yield is low. Also, men may be reluctant to have testicular biopsy.\\nLaboratory tests are nonspecific. Leukocytosis up to 20,000 to 40,000/\\n\\nL, proteinuria, and microscopic\\nhematuria are the most common abnormalities. Patients may have thrombocytosis, markedly elevated\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n406'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 416, 'page_label': '407'}, page_content=\"ESR, anemia caused by blood loss or renal failure, hypoalbuminemia, and elevated serum\\nimmunoglobulins. AST and ALT are often mildly \\nelevated. Testing for hepatitis B and C should be done.\\nOther testing (eg, antineutrophil cytoplasmic antibodies [ANCA], rheumatoid factor, anticyclic citrullinated\\npeptides [CCP], antinuclear antibodies [ANA], C3 and C4 complement levels, cryoglobulin levels, nuclear\\nantigens and antibodies to extractable nuclear antigens such as anti-Smith, anti-Ro/SSA, anti-La/SSB,\\nand anti-RNP) is done if the clinical presentation suggests other diagnoses, such as RA, SLE, or\\nSjogren's syndrome.\\nPrognosis\\nWithout treatment, 5-yr survival is < 15%. With treatment, 5-yr survival is > 80% but may be lower for\\npatients with hepatitis B. Prognosis is better if disease remission is achieved within 18 mo after diagnosis.\\nThe following findings are associated with a poor prognosis:\\n Renal insufficiency\\n GI involvement\\n Neurologic involvement\\nTreatment\\n Corticosteroids alone or with cyclophosphamide, methotrexate, or azathioprine, depending on disease\\nseverity\\n Addition of lamivudine and plasma exchange for patients with hepatitis B\\nTreatment depends on the severity of the disease. For systemic symptoms but no serious neurologic,\\nrenal, GI, or cardiac manifestations, corticosteroids may be sufficient, at least initially. For severe disease\\nwith neurologic, renal, GI, or cardiac manifestations, cyclophosphamide plus corticosteroids may improve\\noutcome. For moderate disease, corticosteroids plus methotrexate or azathioprine can be used.\\nHypertension should be treated aggressively; ACE inhibitors are effective.\\nHepatitis B-related PAN:\\n Treatment aims at rapidly suppressing inflammation, then eliminating the virus\\nand inducing seroconversion via plasma exchange. A short course of corticosteroids is used for a few\\nweeks. Lamivudine 100 mg po once/day is given for a maximum of 6 mo. A lower dose is used in patients\\nwith renal insufficiency. Plasma exchanges are scheduled as follows: 3 times/wk for 3 wk, 2 times/wk for 2\\nwk and once/wk until hepatitis B e antigen (HBeAg) converts to hepatitis B e antibody (anti-HBe) or until\\nclinical recovery is sustained for 2 to 3 mo. Although this approach has not been proved to improve\\nsurvival when compared with immunosuppressive therapy only, it may reduce the risk of long-term\\ncomplications of hepatitis B and suppress the side effects of long-term treatment with corticosteroids and\\nimmunosuppressants.\\nTraditional treatment with corticosteroids, sometimes with cytotoxic immunosuppressants (mainly\\ncyclophosphamide), was often effective in the short term but did not prevent relapses and complications\\n(eg, chronic hepatitis, cirrhosis) due to persistence of the hepatitis B virus.\\nPolymyalgia Rheumatica\\nPolymyalgia rheumatica is a syndrome closely associated with giant cell (temporal) arteritis. It\\naffects adults > 55. It typically causes severe pain and stiffness in proximal muscles, without\\nweakness or atrophy, and nonspecific systemic symptoms. ESR is markedly elevated.\\nDiagnosis is clinical. Treatment with low-dose corticosteroids is effective.\\nPolymyalgia rheumatica affects adults > 55; the female:male ratio is 2:1.\\nBecause polymyalgia rheumatica is closely associated with giant cell arteritis (see p. \\n319\\n), some\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n407\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 417, 'page_label': '408'}, page_content='authorities consider the two disorders to be different phases of the same process. Polymyalgia\\nrheumatica appears to be more common. A few patients with polymyalgia rheumatica develop giant cell\\narteritis, but 40 to 60% of patients with giant cell arteritis have polymyalgia rheumatica. Polymyalgia\\nrheumatica may precede or occur simultaneously with giant cell arteritis.\\nEtiology and pathogenesis are unknown. Whether symptoms result from vasculitis is unclear; they\\nprobably result from low-grade axial synovitis and bursitis.\\nSymptoms and Signs\\nPolymyalgia rheumatica is characterized by bilateral proximal aching of the shoulder and hip girdle\\nmuscles and the back (upper and lower) and neck muscles. Stiffness in the morning is typical. Shoulder\\nsymptoms may reflect proximal bursitis (eg, subdeltoid, subacromial) and less often bicipital tenosynovitis\\nor joint synovitis. Discomfort is worse in the morning and is occasionally severe enough to prevent\\npatients from getting out of bed and from doing simple activities. The pain may \\nmake patients feel weak,\\nbut objective muscle weakness is not a feature of the disorder.\\nDiagnosis\\n Clinical findings\\n Exclusion of other causes\\nPolymyalgia rheumatica is suspected in elderly patients with typical symptoms, but other possible causes\\nmust be excluded. Tests include ESR, CBC, thyroid-stimulating hormone levels, and CK. In > 80 % of\\npatients, ESR is markedly elevated, often > 100 mm/h, usually > 50 mm/h (Westergren method).\\nElectromyography, biopsy, and other tests (eg, rheumatoid factor), which are normal in polymyalgia\\nrheumatica, are sometimes done to rule out other clinically suspected diagnoses.\\nThe following findings in polymyalgia rheumatica distinguish it:\\n From RA: Chronic small joint synovitis (although some joint swelling may be present), erosive or\\ndestructive lesions, rheumatoid nodules, and rheumatoid factor are absent.\\n From polymyositis: Pain rather than weakness predominates; muscle enzyme levels and\\nelectromyography and muscle biopsy results are normal.\\n From hypothyroidism: Thyroid function test results and muscle enzyme levels are normal.\\n From multiple myeloma: Monoclonal gammopathy is absent.\\n From fibromyalgia: Symptoms are more localized, and ESR is typically elevated.\\nTreatment\\n Prednisone\\nPrednisone started at 15 to 20 mg po once/day results in dramatic improvement. If giant cell arteritis is\\nthought to be present, the dose should be higher, and temporal artery biopsy should be done. As\\nsymptoms subside, corticosteroids are tapered to the lowest clinically effective dose, regardless of ESR.\\nSome patients are able to stop corticosteroids in  1 yr; others require small doses for years. NSAIDs are\\nrarely sufficient.\\nIn elderly patients, physicians should watch for and treat complications of corticosteroid use (eg,\\ndiabetes, hypertension). Patients taking prednisone long term should be given a bisphosphonate to\\nprevent osteoporosis.\\nBecause patients may develop giant cell arteritis, they should be instructed to immediately report\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n408'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 418, 'page_label': '409'}, page_content=\"headache, muscle pain during chewing, and, particularly, visual disturbances to their physician.\\nTakayasu's Arteritis\\n(Pulseless Disease; Occlusive Thromboaortopathy; Aortic Arch Syndrome)\\nTakayasu's arteritis is an inflammatory disease affecting the aorta, its branches, and pulmonary\\narteries. It occurs predominantly in young women. Etiology is unknown. Vascular inflammation\\nmay cause arterial stenosis, occlusion, dilation, or aneurysms. It causes asymmetric pulses and\\nsymptoms and signs of arterial obstruction. Diagnosis is by aortic arteriography or magnetic\\nresonance angiography. Treatment is with corticosteroids and, for organ-threatening ischemia,\\nvascular interventions such as bypass surgery.\\nTakayasu's arteritis is rare. It is more common among Asians but occurs worldwide. Female:male ratio is\\n8:1, and age at onset is typically 15 to 30. In North America, annual incidence is estimated to be 2.6\\ncases/million.\\nEtiology\\nThe cause is unknown. Cell-mediated immune mechanisms may be involved and may be similar to those\\nin giant cell arteritis.\\nPathophysiology\\nTakayasu's arteritis affects primarily large elastic arteries. The most commonly affected are the\\ninnominate and subclavian arteries, aorta (mainly the ascending aorta and the arch), common carotid\\narteries, and renal arteries. Most patients have stenoses or occlusions. Aneurysms occur in about one\\nthird of patients. Usually, the wall of the aorta or its branches thickens irregularly, with intimal wrinkling.\\nWhen the aortic arch is affected, orifices of the major arteries emerging from the aorta may be markedly\\nnarrowed or even obliterated by intimal thickening. In one half of patients, pulmonary arteries are also\\naffected.\\nHistologically, early changes consist of adventitial mononuclear infiltrate with perivascular cuffing of the\\nvasa vasorum. Later, intense mononuclear inflammation of the media may occur, sometimes accompanied\\nby granulomatous changes, giant cells, and patchy necrosis of the media. Morphologic changes may be\\nindistinguishable from those of giant cell arteritis. Panarteritic inflammatory infiltrates cause marked\\nthickening of the affected artery and subsequent luminal narrowing and occlusion.\\nSymptoms and Signs\\nMost patients present with only focal symptoms that reflect hypoperfusion of the \\naffected organ or limb.\\nTakayasu's arteritis may have 3 stages:\\n Systemic disease, usually with systemic, nonspecific symptoms (eg, fever, malaise, night sweats, weight\\nloss, arthralgias, fatigue)\\n Vascular inflammatory phase, with ischemic manifestations that may wax and wane\\n Inactive (burned-out) disease, sometimes with acute or progressive occlusion (including thrombosis)\\nOnly one third of patients have systemic symptoms at presentation or recall having had such symptoms.\\nRepetitive arm movements and sustained arm elevation may cause pain and fatigue. Arterial pulses in\\narms and legs may be diminished and asymmetric. Bruits are often audible over the subclavian arteries,\\nbrachial arteries, carotid arteries, abdominal aorta, or femoral arteries. Reduced BP in one or both arms is\\ncommon.\\nWhen the carotid and vertebral arteries are affected, cerebral blood flow decreases, leading to dizziness,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n409\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 419, 'page_label': '410'}, page_content=\"syncope, orthostatic hypotension, headaches, transient visual disturbances, transient ischemic attacks, or\\nstrokes. Stenotic lesions in a subclavian artery near the origin of a patent vertebral artery can cause\\nposterior circulation neurologic symptoms or syncope when the arm is used (called subclavian steal\\nsyndrome). Retrograde flow through the vertebral artery supplies the subclavian artery distal to the\\nstenosis, and vasodilation of the arterial bed in the upper limb during exercise compromises posterior\\ncerebral blood flow.\\nAngina pectoris or MI may result from narrowing of the coronary artery orifice due to aortitis or coronary\\narteritis. Aortic regurgitation may occur if the ascending aorta is markedly dilated. Heart failure can\\ndevelop.\\nObstruction of the descending thoracic aorta sometimes causes signs of aortic coarctation (eg,\\nhypertension, headache, leg claudication). Renovascular hypertension may develop if the abdominal\\naorta or renal arteries are narrowed.\\nPulmonary arteries are often affected, sometimes causing pulmonary hypertension. Because Takayasu's\\narteritis is chronic, collateral circulation can develop. Thus, ischemic ulcerations or gangrene due to\\nobstruction of the arteries to the extremities is rare.\\nDiagnosis\\n Aortic arteriography or magnetic resonance angiography\\n Monitoring of disease activity\\nThe diagnosis is suspected when symptoms suggest ischemia of organs supplied by the aorta or its\\nbranches or when peripheral pulses are decreased or absent in patients at low risk of atherosclerosis\\nand other aortic disorders, especially in young women. In these patients, arterial bruits and right-left or\\nupper extremity-lower extremity discrepancies in pulses or in BP also suggest the diagnosis. Confirmation\\nof the diagnosis requires aortic arteriography or magnetic resonance angiography to evaluate all\\nbranches of the aorta. Characteristic findings include stenosis, occlusion, irregularities in arterial lumens,\\npoststenotic dilation, collateral arteries around obstructed vessels, and aneurysms.\\nBP is measured in both arms. However, measurement can be difficult. If both subclavian arteries are\\nseverely affected, systemic BP can be accurately measured only in the legs. If the disorder affects both\\nsubclavian arteries in patients with coarctation of the descending aorta or involvement of both iliac or\\nfemoral arteries, BP cannot be accurately measured. Then, central arterial pressure must be measured\\nvia angiography to detect occult hypertension, which can cause complications.\\nLaboratory tests are nonspecific and not helpful in diagnosis. Common findings include anemia of chronic\\ndisease, elevated platelet levels, occasionally elevated WBC counts, and elevated ESR and C-reactive\\nprotein.\\nOnce Takayasu's arteritis is diagnosed, disease activity must be monitored to look for the following:\\n New systemic symptoms, which may reflect active arthritis or infection (secondary to\\nimmunosuppression therapy)\\n Evidence of inflammation detected by blood tests (although markers of inflammation may miss active\\narteritis)\\n Development of stenosis, aneurysms, or ischemic symptoms in previously unaffected arteries, as\\nassessed with periodic imaging (usually magnetic resonance angiography)\\nPeriodic imaging of the aorta and large arteries is important (see \\nTable 34-3\\n) because the disorder may\\nprogress silently, without clinical symptoms or evidence of inflammation in blood. Once the disorder is\\ndiagnosed, BP should be measured periodically in an unaffected limb because hypertension must be\\ncontrolled.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n410\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 420, 'page_label': '411'}, page_content=\"Disorders that mimic Takayasu's arteritis must be excluded. They include inherited connective tissue\\ndisorders (eg, Ehlers-Danlos or Marfan syndrome), vascular infections (tuberculous, fungal, or syphilitic),\\nfibromuscular\\n[\\nTable 34-3.\\n Imaging Tests Used in Takayasu's Arteritis]\\ndysplasias, disorders causing arterial thrombosis (eg, hypercoagulable states), and idiopathic\\ninflammatory conditions (eg, ankylosing spondylitis with aortitis, Cogan's or Behcet's syndrome, Kawasaki\\ndisease, sarcoidosis); all can affect large vessels.\\nPrognosis\\nFor 20% of patients, the course is monophasic. For the rest, the course is relapsing and remitting or\\nchronic and progressive. Even when symptoms and laboratory abnormalities suggest quiescence, new\\nlesions occur and are evident on imaging studies. A progressive course and the presence of\\ncomplications (eg, hypertension, aortic regurgitation, heart failure, aneurysms) predict a less favorable\\nprognosis.\\nTreatment\\n Corticosteroids\\n Sometimes immunosuppressants\\n Antihypertensives\\n Vascular interventions\\nDrugs:\\n Corticosteroids are the cornerstone of treatment. The optimal dose, tapering schedule, and\\nlength of treatment have not been determined. Treatment with corticosteroids alone induces remission in\\nmost patients. Prednisone is usually used. The starting dose is 1 mg/kg po once/day for 1 to 3 mo; the\\ndose is then tapered slowly over several months. Lower starting doses may also induce remission. About\\none half of patients relapse when the drug is tapered or stopped, despite initial response.\\nMethotrexate, cyclophosphamide, azathioprine, mycophenolate mofetil, and tumor \\nnecrosis factor\\ninhibitors (eg, etanercept, infliximab) have been used in some patients. They can be tried if\\ncorticosteroids are insufficiently effective or cannot be tapered. Methotrexate is given with a\\ncorticosteroid. Often, the starting dose is 0.3 mg/kg once/wk, which is increased up to 25 mg/wk.\\nMycophenolate mofetil can also be tried. Cyclophosphamide should be considered in patients with\\ncoronary vasculitis or other serious complications thought to be due to active arteritis.\\nAn antiplatelet drug (eg, aspirin 325 mg po once/day) is frequently used because platelet-mediated\\nocclusion cannot be excluded. Hypertension should be treated aggressively; ACE inhibitors may be\\neffective.\\nProcedures:\\n Vascular intervention, usually a bypass procedure, may be needed to reestablish blood flow\\nto ischemic tissues if drug therapy is ineffective. Indications include the following:\\n Severe hypertension that is refractory to medical management because renal artery stenosis is present\\n(although reocclusion and thrombosis of grafts is common)\\n Ischemia in the extremities that interferes with daily activities\\n Ischemia of cerebral arteries\\n New York Heart Association (NYHA) class II heart failure secondary to a discrete coronary artery\\nstenosis or occlusion\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n411\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 421, 'page_label': '412'}, page_content=\" Cardiac ischemia caused by stenosis of the coronary arteries\\n Coarctation of the aorta\\n Dissection or enlargement of an aortic aneurysm\\nBypass grafting preferably with an autologous graft has the best patency rates. The anastomosis should\\nbe made at disease-free sites of the affected arteries to help prevent aneurysm formation and occlusion.\\nPercutaneous transluminal coronary angioplasty (PTCA) has few risks and may be effective for short\\nlesions. But long-term restenosis rates seem much higher than those with bypass grafting. Vascular\\nstenting is usually not recommended because the restenosis rate is high.\\nFor aortic regurgitation, valvular surgery with aortic root replacement may be necessary.\\nWegener's Granulomatosis\\nWegener's granulomatosis is characterized by necrotizing granulomatous inflammation, small\\nand medium-sized vessel vasculitis, and focal necrotizing glomerulonephritis, often with\\ncrescent formation. Typically, the upper and lower respiratory tract and the kidneys are affected,\\nbut any organ may be. Symptoms vary depending on the organs and systems affected. Patients\\nmay present with upper and lower respiratory tract symptoms (eg, recurrent nasal discharge or\\nepistaxis, cough), followed by hypertension and edema, or with symptoms reflecting multiorgan\\ninvolvement. Diagnosis usually requires biopsy. Treatment is with corticosteroids plus an\\nimmunosuppressant. Remission is usually possible, although relapses are common.\\nWegener's granulomatosis occurs in about 1/25,000 people; it is most common among whites but can\\noccur in all ethnic groups and at any age. Mean age at onset is 40.\\nThe cause is unknown, although immunologic mechanisms play a role. Most patients with active\\ngeneralized disease have antineutrophil cytoplasmic antibodies (ANCA).\\nPathophysiology\\nCharacteristically, granulomas form with histiocytic epithelioid cells and often with giant cells. Plasma\\ncells, lymphocytes, neutrophils, and eosinophils are present. Inflammation affects tissues as well as\\nvessels; vasculitis may be a small or large component of the disease. Micronecrosis, usually with\\nneutrophils (microabscesses), occurs early. Micronecrosis progresses to macronecrosis. A central area of\\nnecrosis (called geographic necrosis) is rimmed by lymphocytes, plasma cells, macrophages, and giant\\ncells. A zone of fibroblastic proliferation with palisading histiocytes may surround the area.\\nNonspecific chronic inflammation and tissue necrosis occurs in the nose. The lungs are most likely to\\ndisplay the full spectrum of histopathologic abnormalities. In the kidneys, the most common finding is a\\nproliferative crescentic focal glomerulonephritis with necrosis and thrombosis of individual loops or larger\\nsegments of the glomerulus. Vasculitic lesions and disseminated granulomas occur only occasionally.\\nSymptoms and Signs\\nOnset may be insidious or acute; the full spectrum of the disease may take years to evolve. Some\\npatients present initially with upper and lower respiratory tract symptoms; at some point later, the kidneys\\nare affected. In other patients, onset of systemic manifestations is relatively acute; several organs and\\nsystems, such as the upper respiratory tract, \\nperipheral nervous system (causing mononeuritis multiplex),\\nkidneys (causing glomerulonephritis), and lower respiratory tract (causing hemorrhage, lung nodules,\\ncavities, or a combination), are simultaneously affected.\\n \\nUpper respiratory tract:\\n Sinus pain, serosanguineous or purulent discharge, and epistaxis may occur.\\nThe mucosa appears granular (like cobblestones) and is friable; ulcers, thick dark crusts, and septal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n412\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 422, 'page_label': '413'}, page_content=\"perforation are common. Nasal chondritis can occur with swelling, pain, and collapse of the nasal\\nbridge (saddle nose). Patients may report recurrent sinusitis that has responded inadequately to\\nmultiple antibiotic regimens and has required one or more sinus operations before diagnosis.\\nSecondary infections (eg, due to \\nStaphylococcus aureus\\n) may develop. Subglottic stenosis may\\ndevelop, causing symptoms such as pain in the larynx, hoarseness, dyspnea, wheezing, and stridor.\\n \\nEars:\\n Otitis, sensorineural hearing loss, vertigo, and chondritis may occur. The middle ear, inner ear,\\nand mastoids are often affected.\\n \\nEyes:\\n Eyes may appear red and swollen. Nasolacrimal duct inflammation and obstruction may affect the\\neye; conjunctivitis, scleritis, uveitis, or retinal vasculitis may also occur. Inflammatory infiltrates in the\\nretro-orbital space (orbital pseudotumor) can cause proptosis, compression of the optic nerve, and\\nblindness. Extension into the extraocular muscles leads to diplopia. If serious eye symptoms develop,\\nevaluation and treatment are required immediately to prevent permanent vision loss.\\n \\nLower respiratory tract:\\n Respiratory manifestations are common. Inflammation of the major bronchi\\nand branches can cause localized wheezing, postobstructive pneumonia, and atelectasis. Single or\\nmultiple pulmonary nodules, with or without cavitation, and parenchymal infiltrates, sometimes cause\\nsymptoms, such as chest pain, shortness of breath, and productive cough. Dyspnea with bilateral\\ninfiltrates, with or without hemoptysis, may indicate alveolar hemorrhage, and must be evaluated\\nimmediately.\\n \\nHeart:\\n Coronary artery disease may occur, but rarely.\\n \\nMusculoskeletal system:\\n Patients may present with myalgias, arthralgias, or nonerosive inflammatory\\narthritis.\\n \\nSkin:\\n Leukocytoclastic vasculitis, tender subcutaneous nodules, papules, livedo reticularis, or pyoderma\\ngangrenosum may develop.\\n \\nNervous system:\\n Vasculitis may cause ischemic peripheral neuropathy, brain lesions, or extension of\\nlesions from contiguous sites. Lesions that originate in the sinuses or middle ear may extend directly to\\nthe retropharyngeal area and base of the skull, leading to cranial neuropathy, proptosis, diabetes\\ninsipidus, or meningitis.\\n \\nKidneys:\\n Symptoms and signs of glomerulonephritis develop. Urinary sediment may be abnormal, and\\nserum creatinine may increase rapidly. Edema and hypertension may result. Rapidly progressive\\nglomerulonephritis, which is life threatening, can develop.\\n \\nOther organs:\\n Occasionally, an inflammatory mass occurs in the breasts, kidneys, prostate, or other\\norgans.\\nDiagnosis\\n Routine laboratory tests, including urinalysis\\n Tests for ANCA\\n Biopsy for definitive diagnosis\\nWegener's granulomatosis should be suspected in patients with chronic, unexplained respiratory\\nsymptoms and signs (including otitis media in adults), particularly if manifestations in other organ\\nsystems, especially the kidneys, also suggest the disorder. Routine laboratory tests are done, but ANCA\\ntesting and biopsy yield the most specific findings.\\nRoutine laboratory tests include ESR or C-reactive protein, CBC with differential, serum albumin and total\\nprotein, serum creatinine, urinalysis, 24-h urine protein, and chest x-ray. In most patients with active\\ndisease, ESR and C-reactive protein are elevated, and serum albumin and total protein are decreased;\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n413\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 423, 'page_label': '414'}, page_content=\"anemia, thrombocytosis, and mild to moderate eosinophilia are detected. Dysmorphic RBCs and RBC\\ncasts, detected during urinalysis, indicate glomerular involvement. Proteinuria may be detected. Serum\\ncreatinine may be increased.\\nSerologic testing to detect ANCA is followed by enzyme-linked immunosorbent assay (ELISA) to check for\\nspecific antibodies. Most patients with active disease have cytoplasmic ANCA (cANCA), with antibodies\\nagainst proteinase-3 (PR3); these findings plus characteristic clinical findings suggest Wegener's\\ngranulomatosis.\\nSome patients with other disorders (eg, bacterial endocarditis, TB) test positive for ANCA. If characteristic\\nclinical findings are absent, a positive ANCA result does not confirm Wegener's granulomatosis. ANCA\\ntesting should not be used to guide treatment. During apparent remission, ANCA may \\nincrease or ANCA\\ntest results may change from negative to positive. In some of these patients, symptoms do not recur; in\\nothers, symptoms recur or worsen soon after the test is done or during the next few weeks, months, or\\nsometimes years.\\nBiopsy should be done if possible to confirm the diagnosis. Clinically abnormal sites may be biopsied first,\\nbut lung biopsy is most likely to detect characteristic findings. Open thoracotomy provides the best access\\nto affected tissue. Biopsies of lung or sinus tissue are cultured to exclude infection. Renal biopsy may be\\nnecessary to confirm the diagnosis and to exclude other causes, especially if serum creatinine is\\nelevated. Biopsy results may also provide histologic information that can help guide treatment (eg, renal\\nfibrosis, which is irreversible with immunosuppressive treatment).\\nDifferential diagnosis includes other vasculitic disorders that affect small and medium-sized vessels.\\nPolyarteritis nodosa is unlikely if lung involvement is prominent and glomerulonephritis is present.\\nInfections, especially due to slow-growing fungi or acid-fast organisms should be ruled out by staining and\\nby culture of the sampled tissues. RA should not be diagnosed based only on the presence of rheumatoid\\nfactor, which is present in one half of patients with Wegener's granulomatosis.\\nPrognosis\\nPrognosis depends on the extent of the disorderwhether it is limited to nasal and pulmonary lesions,\\nwith little or no systemic involvement, or it affects many organs, causing severe systemic vasculitis.\\nUse of immunosuppressants for severe disease has dramatically improved prognosis. With treatment,\\ncomplete remission is possible for about 70% of patients, but about one half of them eventually relapse;\\nrelapse may occur when treatment is stopped or many years after it is stopped. Resuming or increasing\\ntreatment can usually control the disorder. However, the disease or treatment causes significant morbidity\\nin 90% of patients.\\nTreatment\\n Emergency treatment with corticosteroids and cyclophosphamide for severe disease\\n Corticosteroids and methotrexate for less severe disease\\n Kidney transplantation if necessary\\nTreatment depends on the severity of disease. A multidisciplinary approach is required for multiorgan\\ndisease; a rheumatologist, an otorhinolaryngologist, a pulmonologist, and sometimes a nephrologist may\\nbe included.\\nPatients who have severe life- or organ-threatening manifestations (eg, alveolar hemorrhage, rapidly\\nprogressive glomerulonephritis, mononeuritis multiplex with motor involvement) require immediate\\ntreatment and hospital admission. These patients require high-dose corticosteroids and\\ncyclophosphamide (see p. \\n314\\n). The role of rituximab in severe or refractory disease is under study.\\nFor less severe disease, corticosteroids and methotrexate are used. Methotrexate or azathioprine is used\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n414\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 424, 'page_label': '415'}, page_content='to maintain remission.\\nIrrigation of sinuses with saline, with or without mupirocin 2% nasal ointment, helps minimize crusting and\\nsecondary staphylococcal infections.\\nTreatment of subglottic stenosis is difficult. Systemic immunosuppressants may not be effective.\\nIntralesional injection of long-acting corticosteroids, with gentle progressive dilation, markedly improves\\noutcomes and helps prevent unnecessary tracheostomies.\\nPatients should be taught about the disorder so that relapses can be detected early. Patients should learn\\nhow to test their urine for blood and protein and be instructed to notify their physician at the first sign of\\nhematuria.\\nKidney transplantation has been successful; the risk of relapse after transplantation is reduced compared\\nwith maintenance dialysis treatment (possibly in part due to use of immunosuppressants to prevent\\nrejection).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 34. Vasculitis\\n415'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 425, 'page_label': '416'}, page_content='Chapter 35. Joint Disorders\\nIntroduction\\nJoint disorders may be inflammatory (RA, spondyloarthropathies, crystal-induced arthritis) or relatively\\nless inflammatory (osteoarthritis, neurogenic arthropathy). Crystal-induced arthritis and infectious arthritis\\nare discussed elsewhere in THE MANUAL.\\nRheumatoid Arthritis\\nRheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily involves the\\njoints. RA causes damage mediated by cytokines, chemokines, and metalloproteases.\\nCharacteristically, peripheral joints (eg, wrists, metacarpophalangeal joints) are symmetrically\\ninflamed, leading to progressive destruction of articular structures, usually accompanied by\\nsystemic symptoms. Diagnosis is based on specific clinical, laboratory, and imaging features.\\nTreatment involves drugs, physical measures, and sometimes surgery. Disease-modifying\\nantirheumatic drugs help control symptoms and slow disease progression.\\nRA affects about 1% of the population. Women are affected 2 to 3 times more often than men. Onset may\\nbe at any age, most often between 35 yr and 50 yr, but can be during childhood (see \\nJuvenile Idiopathic\\nArthritis\\n on p. \\n339\\n) or old age.\\nEtiology\\nAlthough RA involves autoimmune reactions, the precise cause is unknown; many factors may contribute.\\nA genetic predisposition has been identified and, in white populations, localized to a shared epitope in the\\nHLA-DR \\n\\n1\\n locus of class II histocompatibility antigens. Unknown environmental factors (eg, viral\\ninfections) are thought to play a role.\\nPathophysiology\\nProminent immunologic abnormalities include immune complexes produced by synovial lining cells and in\\ninflamed blood vessels. Plasma cells produce antibodies (eg, rheumatoid factor [RF]) that contribute to\\nthese complexes, but destructive arthritis can occur in the absence of RF. Macrophages also migrate to\\ndiseased synovium in early disease; increased macrophage-derived lining cells are prominent along with\\nvessel inflammation. Lymphocytes that infiltrate the synovial tissue are primarily CD4+ T cells.\\nMacrophages and lymphocytes produce pro-inflammatory cytokines and chemokines (eg, tumor necrosis\\nfactors [TNF], granulocyte-macrophage colony-stimulating factor [GM-CSF], various ILs, interferon-\\n\\n) in\\nthe synovium. Release of inflammatory mediators probably contributes to the systemic and joint\\nmanifestations of RA.\\nIn chronically affected joints, the normally thin synovium thickens and develops many villous folds. The\\nsynovial lining cells produce various materials, including collagenase and stromelysin, which contribute to\\ncartilage destruction, and IL-1 and TNF-\\n\\n, which stimulate cartilage destruction, osteoclast-mediated\\nbone absorption, synovial inflammation, and prostaglandins (which potentiate inflammation). Fibrin\\ndeposition, fibrosis, and necrosis are also present. Hyperplastic synovial tissue (pannus) releases these\\ninflammatory mediators, which erode cartilage, subchondral bone, articular capsule, and ligaments. PMNs\\non average make up about 60% of WBCs in the synovial fluid.\\nRheumatoid nodules develop in about 30% of patients with RA. They are granulomas consisting of a\\ncentral necrotic area surrounded by palisaded histiocytic macrophages, all enveloped by lymphocytes,\\nplasma cells, and fibroblasts. Nodules and vasculitis can also develop in visceral organs.\\nSymptoms and Signs\\nOnset is usually insidious, often beginning with systemic and joint symptoms. Systemic symptoms include\\nearly morning stiffness of affected joints, generalized afternoon fatigue and malaise, anorexia, generalized\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n416'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 426, 'page_label': '417'}, page_content=\"weakness, and occasionally low-grade fever. Joint symptoms include pain, swelling, and stiffness.\\nThe disease progresses most rapidly during the first 6 yr, particularly the first year; 80% of patients\\ndevelop some permanent joint abnormalities within 10 yr. The course is unpredictable in individual\\npatients.\\nJoint symptoms are characteristically symmetric. Typically, stiffness lasts > 60 min after rising in the\\nmorning but may occur after any prolonged inactivity. Involved joints become tender, with erythema,\\nwarmth, swelling, and limitation of motion. The joints involved include the following:\\n Wrists and the index and middle metacarpophalangeal joints (most commonly involved)\\n \\nProximal interphalangeal joints\\n Metatarsophalangeal joints\\n Shoulders\\n Elbows\\n Hips\\n Knees\\n Ankles\\nHowever, virtually any joint except uncommonly the distal interphalangeal (DIP) joints may be involved.\\nThe axial skeleton is rarely involved except for the upper cervical spine. Synovial thickening is detectable.\\nJoints are often held in flexion to minimize pain, which results from joint capsular distention.\\nFixed deformities, particularly flexion contractures, may develop rapidly; ulnar deviation of the fingers with\\nan ulnar slippage of the extensor tendons off the metacarpophalangeal joints is typical, as are swan-neck\\nand boutonniere deformities (see\\nFig. 43-2\\n on p. \\n387\\n). Joint instability can also occur. Carpal tunnel syndrome can result from wrist\\nsynovitis compressing the median nerve. Popliteal (Baker's) cysts can develop, causing calf swelling and\\ntenderness suggestive of deep venous thrombosis.\\nExtra-articular manifestations:\\n Subcutaneous rheumatoid nodules are not usually an early sign but\\neventually develop in up to 30% of patients, usually at sites of pressure and chronic irritation (eg, the\\nextensor surface of the forearm, metacarpophalangeal joints, occiput). Visceral nodules, usually\\nasymptomatic, are common in severe RA. Other extra-articular signs include vasculitis causing leg ulcers\\nor mononeuritis multiplex, pleural or pericardial effusions, pulmonary nodules, pulmonary infiltrates or\\nfibrosis, pericarditis, myocarditis, lymphadenopathy, Felty's syndrome, Sjogren's syndrome, scleromalacia,\\nand episcleritis. Involvement of the cervical spine can cause atlantoaxial subluxation (see p. \\n385\\n) and\\nspinal cord compression (see p. \\n1810\\n); it may worsen with extension of the neck (eg, during endotracheal\\nintubation).\\nDiagnosis\\n Clinical criteria\\n Serum rheumatoid factor (RF) or anticyclic citrullinated peptide antibody (anti-CCP)\\n X-rays\\nRA should be suspected in patients with polyarticular, symmetric arthritis, particularly if the wrists and 2nd\\nand 3rd metacarpophalangeal joints are involved. Criteria for the diagnosis of RA are listed in\\nTable 35-1\\n. The presence of  4 criteria suggests the diagnosis. Other causes of symmetric polyarthritis,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n417\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 427, 'page_label': '418'}, page_content=\"particularly hepatitis C, must be excluded. Patients should have a serum RF test, hand and wrist x-rays,\\nand baseline x-rays of affected joints to document future erosive changes.\\n[\\nTable 35-1.\\n Diagnosing Rheumatoid Arthritis*]\\nRFs, antibodies to human \\n\\n-globulin, are present in about 70% of patients with RA. However, RF, often in\\nlow titers, occurs in patients with other diseases, including other connective tissue diseases (eg, SLE),\\ngranulomatous diseases, chronic infections (eg, viral hepatitis, subacute bacterial endocarditis, TB), and\\ncancers. Low RF titers can also occur in 3% of the general population and 20% of the elderly. An RF titer\\nmeasured by latex agglutination of > 1:80 or a positive anti-CCP test supports the diagnosis of RA.\\nAnti-CCP antibodies have high specificity (90%) and sensitivity (96%) for RA and, like RF, predict a worse\\nprognosis.\\nX-rays show only soft-tissue swelling during the first months of disease. Subsequently, periarticular\\nosteoporosis, joint space (articular cartilage) narrowing, and marginal erosions may become visible.\\nErosions often develop within the first year but may occur any time. MRI seems to be more sensitive and\\ndetects earlier articular inflammation and erosions. In addition, abnormal subchondral bone signals (eg,\\nbone marrow lesions, bone marrow edema) around the knee suggest progressive disease.\\nIf RA is diagnosed, additional tests help detect complications and unexpected abnormalities. \\nCBC with\\ndifferential should be obtained. A normochromic (or slightly hypochromic)-normocytic anemia occurs in\\n80%; Hb is usually > 10 g/dL. If Hb is  10 g/dL, superimposed iron deficiency or other causes of anemia\\nshould be considered. Neutropenia occurs in 1 to 2% of cases, often with splenomegaly (Felty's\\nsyndrome). Acute-phase reactants (eg, thrombocytosis, elevated ESR, elevated C-reactive protein) reflect\\ndisease activity. A mild polyclonal hypergammaglobulinemia often occurs. ESR is elevated in 90% of\\npatients with active disease.\\nSynovial fluid examination is necessary with any new-onset effusion to rule out other disorders and\\ndifferentiate RA from other inflammatory arthritides (eg, septic and crystal-induced arthritis). In RA, during\\nactive joint inflammation, synovial fluid is turbid, yellow, and sterile, with reduced viscosity and usually\\n10,000 to 50,000 WBCs/\\n\\nL; PMNs typically predominate, but > 50% may be lymphocytes and other\\nmononuclear cells. Crystals are absent.\\nDifferential diagnosis:\\n Many disorders can simulate RA:\\n Crystal-induced arthritis\\n Osteoarthritis\\n SLE\\n Sarcoidosis\\n Reactive arthritis\\n Psoriatic arthritis\\n Ankylosing spondylitis\\nRF can be nonspecific and is often present in several autoimmune diseases; the presence of anti-CCP\\nantibodies is more specific for RA.\\nSome patients with crystal-induced arthritis may meet criteria for RA; however, synovial fluid examination\\nshould clarify the diagnosis. The presence of crystals makes RA unlikely. Joint involvement and\\nsubcutaneous nodules can result from gout, cholesterol, and amyloidosis as well as RA; aspiration or\\nbiopsy of the nodules may occasionally be needed.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n418\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 428, 'page_label': '419'}, page_content=\"SLE usually can be distinguished if there are skin lesions on light-exposed areas, hair loss, oral and\\nnasal mucosal lesions, absence of joint erosions in even long-standing arthritis, joint fluid that often has <\\n2000 WBCs/\\n\\nL (predominantly mononuclear cells), antibodies to double-stranded DNA, renal disease,\\nand low serum complement levels. In contrast to RA, deformities in SLE are usually reducible because of\\nthe lack of erosions and bone or cartilage damage. Arthritis similar to RA can also occur in other\\nrheumatic disorders (eg, polyarteritis, systemic sclerosis, dermatomyositis, or polymyositis) or there can\\nbe features of more than one disease, which suggests an overlap syndrome or mixed connective tissue\\ndisease.\\nSarcoidosis, Whipple's disease, multicentric reticulohistiocytosis, and other systemic diseases may\\ninvolve joints; other clinical features and tissue biopsy sometimes help differentiate these conditions.\\nAcute rheumatic fever has a migratory pattern of joint involvement and evidence of antecedent\\nstreptococcal infection (culture or changing antistreptolysin-O titer); in contrast, RA has an additive\\narthritis.\\nReactive arthritis (see p. \\n343\\n) can be differentiated by antecedent GI or GU symptoms; asymmetric\\ninvolvement and pain at the Achilles insertion of the heel, sacroiliac joints, and large joints of the leg;\\nconjunctivitis; iritis; painless buccal ulcers; balanitis circinata; or keratoderma blennorrhagicum on the\\nsoles and elsewhere.\\nPsoriatic arthritis (see p. \\n344\\n) tends to be asymmetric and is not usually associated with RF, but\\ndifferentiation may be difficult in the absence of nail or skin lesions. DIP joint involvement and severely\\nmutilating arthritis (arthritis mutilans) is strongly suggestive, as is the presence of a diffusely swollen\\n(sausage) digit. Ankylosing spondylitis (see p. \\n341\\n) may be differentiated by spinal and axial joint\\ninvolvement, absence of subcutaneous nodules, and negative RF test.\\nOsteoarthritis (see p. \\n345\\n) can be differentiated by the joints involved; the absence of rheumatoid\\nnodules, systemic manifestations, or significant amounts of RF; and synovial fluid WBC counts <\\n2000/\\n\\nL. Osteoarthritis of the hands most typically involves the DIP and proximal interphalangeal joints.\\nRA does not affect the DIP joints.\\nPrognosis\\nRA decreases life expectancy by 3 to 7 yr, with heart disease, infection, and GI bleeding accounting for\\nmost excess mortality; drug treatment, cancer, as well as the underlying disease may be responsible.\\nAt least 10% of patients eventually are severely disabled despite full treatment. Whites and women have\\na poorer prognosis, as do patients with subcutaneous nodules, advanced age at disease onset,\\ninflammation in  20 joints, early erosions, cigarette smoking, high ESR, and high levels of RF or anti-\\nCCP.\\nTreatment\\n Supportive measures (eg, nutrition, rest, physical measures, analgesics)\\n \\nNSAIDs\\n Drugs that modify disease progression\\nTreatment involves a balance of rest and exercise, adequate nutrition, physical measures, drugs, and\\nsometimes surgery.\\nRest and nutrition:\\n Complete bed rest is rarely indicated, even for a short time; however, a program\\nincluding judicious rest should be prescribed. An ordinary nutritious diet is generally sufficient. Rarely,\\npatients have food-associated exacerbations; no specific foods have been noted to exacerbate RA. Food\\nand diet quackery is common and should be discouraged. Substituting \\n\\n-3 fatty acids (in fish oils) for\\ndietary \\n\\n-6 fatty acids (in meats) may partially relieve symptoms by transiently decreasing production of\\ninflammatory prostaglandins.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n419\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 429, 'page_label': '420'}, page_content='Physical measures:\\n Joint splinting reduces local inflammation and may relieve severe symptoms. Cold\\nmay be applied to reduce pain from temporary worsening in one joint. Orthopedic or athletic shoes with\\ngood heel and arch support are frequently helpful; metatarsal supports placed posteriorly to painful\\nmetatarsophalangeal joints decrease the pain of weight bearing. Molded shoes may be needed for\\nsevere deformities. Self-help devices enable many patients with debilitating RA to perform activities of\\ndaily living.\\nExercise should proceed as tolerated. During acute inflammation, passive range-of-motion exercise helps\\nprevent flexion contractures. Heat therapy can be helpful. Range-of-motion exercises done in warm water\\nare helpful because heat improves muscle function by reducing stiffness and muscle spasm. However,\\ncontractures can be prevented and muscle strength can be restored more successfully after inflammation\\nbegins to subside; active exercise (including walking and specific exercises for involved joints) to restore\\nmuscle mass and preserve range of joint motion should not be fatiguing. Flexion contractures may require\\nintensive exercise, casting, or immobilization (eg, splinting) in progressively more stretched-open\\npositions. Paraffin baths can warm digits and facilitate finger exercise. Massage by trained therapists,\\ntraction, and deep heat treatment with diathermy or ultrasonography may be useful.\\nSurgery:\\n Surgery must always be considered in terms of the total disease and patient expectations. For\\nexample, deformed hands and arms limit crutch use during rehabilitation; seriously affected knees and\\nfeet limit benefit from hip surgery. Reasonable objectives for each patient must be determined, and\\nfunction must be considered. Surgery may be done while the disease is active.\\nArthroplasty with prosthetic joint replacement is indicated if damage severely limits function; total hip and\\nknee replacements are most consistently successful. Prosthetic hips and knees cannot tolerate vigorous\\nactivity (eg, competitive athletics). Excision of subluxed painful metatarsophalangeal joints may greatly aid\\nwalking. Thumb fusions may provide stability for pinch. Neck fusion may be needed for C1-2 subluxation\\nwith severe pain or potential for spinal cord compression. Arthroscopic or open synovectomy can relieve\\njoint inflammation but only temporarily unless disease activity can be controlled.\\nDrugs for RA\\nThe goal is to reduce inflammation as a means of preventing erosions and progressive deformity.\\nDisease-modifying antirheumatic drugs (DMARDs) are used early, often in combination. Other drug\\nclasses, including biologic agents, TNF-\\n\\n antagonists, and IL-1 receptor antagonists, seem to slow the\\nprogression of RA. NSAIDs are of some help for the pain of RA but do not prevent erosions or disease\\nprogression. Sometimes low-dose systemic corticosteroids (prednisone < 10 mg daily) are added to\\ncontrol severe polyarticular symptoms, usually with the objective of replacement with a DMARD. Intra-\\narticular depot corticosteroids can control severe monarticular or even oligoarticular symptoms. The\\noptimal combinations of drugs are not yet clear. However, some data suggest that certain combinations of\\ndrugs from different classes (eg, methotrexate plus other DMARDs, a rapidly tapered corticosteroid plus a\\nDMARD, methotrexate plus a TNF-\\n\\n antagonist or an IL-1 receptor antagonist, a TNF-\\n\\n antagonist or an\\nIL-1 receptor antagonist plus a DMARD) are more effective than using DMARDs alone sequentially or in\\ncombination.\\nNSAIDs:\\n Aspirin is no longer used for RA, as effective doses are often toxic. Only one NSAID should be\\ngiven at a time (see\\nTable 35-2\\n), although patients may also take aspirin at  325 mg/day for its antiplatelet cardioprotective\\neffect. Because the maximal response for NSAIDs can take up to 2 wk, doses should be increased no\\nmore frequently than this. Doses of drugs with flexible dosing can be increased until response is maximal\\nor maximum dosage is reached. All NSAIDs treat the symptoms of RA and decrease inflammation but do\\nnot alter the course of the disease.\\nNSAIDs inhibit cyclooxygenase (COX) enzymes and thus decrease production of prostaglandins. Some\\nprostaglandins under COX-1 control have important effects in\\n[\\nTable 35-2.\\n NSAID Treatment of Rheumatoid Arthritis]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n420'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 430, 'page_label': '421'}, page_content='many parts of the body (ie, they protect gastric mucosa and inhibit platelet adhesiveness). Other\\nprostaglandins are induced by inflammation and are produced by COX-2. Selective COX-2 inhibitors, also\\ncalled coxibs (eg, celecoxib), seem to have efficacy comparable to nonselective NSAIDs and are less\\nlikely to cause GI toxicity; however, they do not seem less likely to cause renal toxicity.\\nNSAIDs other than coxibs should be avoided in patients with previous peptic ulcer disease or dyspepsia.\\nOther possible adverse effects of all NSAIDs include headache, confusion and other CNS symptoms,\\nincreased BP, worsening of hypertension, edema, and decreased platelet function. The effect of NSAIDs\\non cardiovascular risk is still unclear. Creatinine levels can rise reversibly because of inhibited renal\\nprostaglandins; less frequently, interstitial nephritis can occur. Patients with urticaria, rhinitis, or asthma\\nfrom aspirin can have the same problems with these other NSAIDs.\\nTraditional DMARDs:\\n (See\\nTable 35-3\\n for specific dosage information and adverse effects of other drugs used to treat RA.)\\nThese drugs seem to slow the progression of RA and are indicated in nearly all patients with RA. They\\ndiffer from each other chemically and pharmacologically. Many take weeks or months to have an effect.\\nAbout two thirds of patients improve overall, but complete remissions are uncommon. Many result in\\nevidence of decreased damage on imaging studies, presumably reflecting decreased disease activity.\\nThey have minimal immediate analgesic effects, so NSAIDs or low-dose corticosteroids must often be\\ncontinued. Patients should be fully apprised of the risks of DMARDs and monitored carefully for evidence\\nof toxicity.\\nCombinations of DMARDs may be more effective than single drugs. For example, \\nhydroxychloroquine,\\nsulfasalazine, and methotrexate together are more effective than methotrexate alone or the other two\\ntogether. Also, combining a DMARD with another drug, such as methotrexate plus a TNF-\\n\\n antagonist or\\nan IL-1 receptor antagonist or a rapidly tapered corticosteroid, may be more effective than using DMARDs\\nalone.\\nMethotrexate\\n is a folate antagonist with immunosuppressive effects at high dose. It is anti-inflammatory\\nat doses used in RA. It is very effective and has a relatively rapid onset (clinical benefit often within 3 to 4\\nwk). Methotrexate should be used with caution, if at all, in patients with hepatic dysfunction or renal\\nfailure. Alcohol should be avoided. Supplemental folate, 1 mg po once/day, reduces the likelihood of\\nadverse effects. CBC, AST, ALT, and albumin and creatinine levels should be determined about every 8\\nwk. Rarely, a liver biopsy is needed if liver function test findings are persistently twice the upper limit of\\nnormal or more and the patient needs to continue to use methotrexate. Severe relapses of arthritis can\\noccur after withdrawal of methotrexate. Paradoxically, rheumatoid nodules may enlarge with methotrexate\\ntherapy.\\nHydroxychloroquine\\n can also control symptoms of mild RA. Funduscopic examination should be done\\nand visual fields should be assessed before and every 12 mo during treatment. The drug should be\\nstopped if no improvement occurs after 9 mo.\\nSulfasalazine\\n can alleviate symptoms and slow development of joint damage. It is usually given as\\nenteric-coated tablets. Benefit should occur within 3 mo. Enteric coating or dose reduction may increase\\ntolerability. CBCs should be obtained after 1 to 2 wk and then about every 12 wk during therapy. AST and\\nALT should be obtained at about 6-mo intervals and whenever the dose is increased.\\nLeflunomide\\n interferes with an enzyme involved with pyrimidine metabolism. It is about as effective as\\nmethotrexate but is less likely to suppress bone marrow, cause abnormal liver function, or cause\\npneumonitis.\\nParenteral \\ngold compounds\\n are not commonly used anymore.\\nCorticosteroids:\\n Systemic corticosteroids decrease inflammation and other symptoms more rapidly and\\nto a greater degree than other drugs. They also seem to slow bone erosion. However, they do not\\nprevent joint destruction, and their clinical benefit often diminishes with time. Furthermore, rebound often\\nfollows the withdrawal of corticosteroids in active disease. Because of their long-term adverse effects,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n421'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 431, 'page_label': '422'}, page_content='many doctors recommend that corticosteroids are given to maintain function only until another DMARD\\nhas taken effect.\\nCorticosteroids may be used for severe joint or systemic manifestations of RA (eg, vasculitis, pleurisy,\\npericarditis). Relative contraindications include peptic ulcer disease, hypertension, untreated infections,\\ndiabetes mellitus, and glaucoma. The risk of latent TB should be considered before corticosteroid therapy\\nis begun.\\nIntra-articular injections\\n of depot corticosteroids may temporarily help control pain and swelling in\\nparticularly painful joints. Triamcinolone hexacetonide may suppress inflammation for the longest time.\\nTriamcinolone acetonide and methylprednisolone acetate are also effective. No single joint should be\\ninjected with a corticosteroid more than 3 to 4 times a year, as too-frequent injections may accelerate joint\\ndestruction (although there are no specific data from humans to support this effect). Because injectable\\ncorticosteroid esters are crystalline, local inflammation transiently increases within a few hours in < 2% of\\ninjections. Although infection occurs in only < 1:40,000, it must be considered if pain occurs > 24 h after\\ninjection.\\nImmunomodulatory, cytotoxic, and immunosuppressive drugs:\\n Treatment with azathioprine,\\ncyclosporine (an immunomodulatory drug), or cyclophosphamide provides efficacy similar to DMARDs.\\nHowever, these drugs are more toxic, particularly cyclophosphamide. Thus, they are used only for\\npatients in whom treatment with DMARDs has failed or to decrease the need for corticosteroids. They are\\nused infrequently unless there are extra-articular complications. For maintenance therapy with\\nazathioprine, the lowest effective dose should be used. Low-dose cyclosporine may be effective alone or\\nwhen combined with methotrexate. It may be less toxic than azathioprine and cyclophosphamide.\\nBiologic agents:\\n Biologic response modifiers other than TNF-\\n\\n antagonists can be used to target B cells\\nor T cells.\\nRituximab\\n is an anti-CD 20 antibody that depletes B cells. It can be used in refractory patients.\\nResponse is often delayed but may last 6 mo. The course can be repeated in 6 mo. Mild adverse effects\\nare common, and analgesia, corticosteroids, diphenhydramine, or a combination may need to be given\\nconcomitantly. Rituximab is given only to patients who have not improved after using a TNF inhibitor and\\nmethotrexate.\\nAbatacept\\n, a soluble fusion cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) Ig, is indicated for\\npatients with RA with an inadequate response to other DMARDs.\\n[\\nTable 35-3.\\n Other Drugs Used to Treat RA]\\nOther agents: Anakinra\\n is a recombinant IL-1 receptor antagonist. IL-1 is heavily involved in the\\npathogenesis of RA. Infection and leukopenia can be a problem, particularly when given in combination\\nwith a TNF antagonist.\\nTNF-\\n\\n antagonists\\n (eg, adalimumab, etanercept, and infliximab) reduce the progression of erosions and\\nreduce the number of new erosions. Although not all patients respond, many have a prompt, dramatic\\nfeeling of well being, sometimes with the first injection. Inflammation is often dramatically reduced.\\nAlthough there are some differences among agents, the most serious problem is infection, particularly\\nwith reactivated TB. Patients should be screened for TB with PPD. Etanercept, infliximab, and\\nadalimumab can and probably should be used with methotrexate. High-dose infliximab should not be used\\nin patients with severe heart failure.\\nJuvenile Idiopathic Arthritis\\nJuvenile idiopathic arthritis (JIA) is a group of rheumatic diseases that begins at or before age\\n16. Arthritis, fever, rash, adenopathy, splenomegaly, and iridocyclitis are typical of some forms.\\nDiagnosis is clinical. Treatment involves NSAIDs and disease-modifying antirheumatic drugs.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n422'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 432, 'page_label': '423'}, page_content=\"JIA is uncommon. The cause is unknown, but there seems to be a genetic predisposition and an\\nautoimmune pathophysiology. JIA may be similar to adult RA (see p. \\n332\\n), but most forms are slightly\\ndifferent.\\nSymptoms and Signs\\nPatients with JIA can have joint stiffness, swelling, effusion, pain, and tenderness. JIA may interfere with\\ngrowth and development. Micrognathia (receded chin) due to early closure of mandibular epiphyses may\\noccur. Iridocyclitis may develop, which may cause conjunctival injection, pain, and photophobia but can\\nbe asymptomatic; scarring and glaucoma with band keratopathy can result. The initial symptoms and\\nsigns of JIA tend to fall into 3 possible patterns.\\nSystemic onset\\n (Still's disease) occurs in about 20% of patients. High fever, rash, splenomegaly,\\ngeneralized adenopathy, and serositis with pericarditis or pleuritis are common. These symptoms may\\nprecede the development of arthritis. Fever (quotidian) is often highest in the afternoon or evening and\\nmay persist for up to 2 wk. A typical transient rash often appears with the fever or may be diffuse and\\nmigratory, with urticarial or macular lesions.\\nPauciarticular onset\\n is characterized by involvement of  4 joints. It occurs in about 40% of patients,\\nusually young girls. Iridocyclitis is most common in pauciarticular JIA, developing in nearly 20%. Many\\naffected older boys have the HLA-B27 allele. Most of these boys subsequently develop classic features\\nof one of the spondyloarthropathies (eg, ankylosing spondylitis, psoriatic arthritis, reactive arthritis).\\nPolyarticular onset\\n involves  5 joints, often  20. It occurs in the remaining 40% of patients and is often\\nsimilar to adult RA. Arthritis tends to be symmetric and develop slowly.\\nDiagnosis\\n Clinical criteria\\n Rheumatoid factor (RF) and antinuclear antibodies (ANA)\\nJIA should be suspected in children with symptoms of arthritis, signs of iridocyclitis, generalized\\nadenopathy, splenomegaly, or unexplained rash or fever lasting more than a few days. Diagnosis is\\nprimarily clinical. Patients suspected of having JIA should be tested for RF, ANA, and ESR because these\\ntests may be helpful in diagnosing JIA and distinguishing its subtypes. In Still's disease, RF and ANA are\\nabsent. In pauciarticular-onset JIA, ANA are present in up to 75% and RF is absent. In polyarticular-onset\\nJIA, RF usually is negative, but in some patients, mostly adolescent girls, it can be positive.\\nTo diagnose iridocyclitis, slit-lamp examination should be done, even in the absence of ocular symptoms.\\nA recently diagnosed patient with pauciarticular onset should have an eye examination every 3 to 4 mo,\\nand a patient with polyarticular onset should have an eye examination about every 6 mo.\\nPrognosis\\nComplete remissions occur in 50 to 75% of treated patients. Patients with polyarticular onset and a\\npositive RF have a less favorable prognosis.\\nTreatment\\n Drugs that slow disease progression\\n Usually NSAIDs\\nSimilar to the therapy of patients with adult RA, disease-modifying antirheumatic drugs (DMARDs),\\nparticularly the biologic agents, have dramatically changed the therapeutic approach.\\nSymptoms may be reduced with NSAIDs. Naproxen 5 to 10 mg/kg po bid, ibuprofen 5 to 10 mg/kg po qid,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n423\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 433, 'page_label': '424'}, page_content=\"and indomethacin 0.5 to 1.0 mg/kg po tid are among the most useful. Salicylates are rarely used because\\nof their possible role in causing Reye's syndrome (see p. \\n2937\\n).\\nExcept for severe systemic disease, systemic corticosteroids can usually be avoided. When necessary,\\nthe lowest possible dose is used (eg, oral prednisone, 0.0125 to 0.5 mg/kg qid, or the same daily dose\\ngiven once or twice daily). Growth retardation, osteoporosis, and osteonecrosis are the major hazards of\\nprolonged corticosteroid use in children. Intra-articular depot corticosteroids can be given. The dosage for\\nchildren is adjusted based on weight. Children may need to be sedated for intra-articular injection.\\nMethotrexate is useful for pauciarticular and polyarticular disease. Adverse effects are monitored as in\\nadults. Bone marrow depression and hepatic toxicity are monitored with CBC, AST, ALT, and albumin.\\nOccasionally, sulfasalazine is used, especially in cases of suspected spondyloarthropathy. IM gold and\\npenicillamine are rarely used.\\nEtanercept, used as in adults, blocks tumor necrosis factor-\\n\\n (TNF-\\n\\n) and is often effective; 0.4 mg/kg sc\\n(up to a maximum of 25 mg) is given twice/wk. Anakinra is particularly effective in some patients with\\nsystemic-onset disease.\\nPhysical therapy, exercises, splints, and other supportive measures help prevent flexion contractures.\\nAdaptive devices can improve function and minimize unnecessary stresses on inflamed joints. Iridocyclitis\\nis treated with ophthalmic corticosteroid drops and mydriatics (see p. \\n609\\n).\\nSeronegative Spondyloarthropathies\\n(Seronegative Spondyloarthritides)\\nSeronegative spondyloarthropathies share certain clinical characteristics (eg, back pain, uveitis, GI\\nsymptoms, rashes). Some are strongly associated with the HLA-B27 allele. Clinical and genetic\\nsimilarities suggest that they also share similar causes or pathophysiologies. Rheumatoid factor (RF) is\\nnegative in the spondyloarthropathies (hence, why they are called seronegative spondyloarthropathies).\\nThey include ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and other disorders.\\nAnkylosing Spondylitis\\nAnkylosing spondylitis (AS) is a systemic disorder characterized by inflammation of the axial\\nskeleton, large peripheral joints, and digits; nocturnal back pain; back stiffness; accentuated\\nkyphosis; constitutional symptoms; aortitis; cardiac conduction abnormalities; and anterior\\nuveitis. Diagnosis requires showing sacroiliitis on x-ray. Treatment is with NSAIDs or tumor\\nnecrosis factor antagonists and physical measures that maintain joint flexibility.\\nAS is 3 times more frequent in men than in women and begins most often between ages 20 and 40. It is\\n10 to 20 times more common among 1st-degree relatives of AS patients than in the general population.\\nThe risk of AS in 1st-degree relatives with the HLA-B27 allele is about 20%. Increased prevalence of\\nHLA-B27 in whites or HLA-B7 in blacks supports a genetic predisposition. However, the concordance rate\\nin identical twins is only about 50%, suggesting that environmental factors contribute. The\\npathophysiology probably involves immune-mediated inflammation.\\nSymptoms and Signs\\nThe most frequent manifestation is back pain, but disease can begin in peripheral joints, especially in\\nchildren and women, and rarely with acute iridocyclitis (iritis or anterior uveitis). Other early symptoms and\\nsigns are diminished chest expansion from diffuse costovertebral involvement, low-grade fever, fatigue,\\nanorexia, weight loss, and anemia.\\nBack painoften nocturnal and of varying intensityeventually becomes recurrent. Morning stiffness,\\ntypically relieved by activity, and paraspinal muscle spasm develop. A flexed or bent-over posture eases\\nback pain and paraspinal muscle spasm; thus, kyphosis is common in untreated patients. Severe hip\\narthritis can eventually develop. In late stages, the patient has accentuated kyphosis, loss of lumbar\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n424\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 434, 'page_label': '425'}, page_content='lordosis, and fixed bent-forward posturing, with compromised pulmonary function and inability to lie flat.\\nThere may be peripheral potentially deforming joint involvement, sometimes involving the digits\\n(dactylitis). Achilles tendinitis can occur.\\nSystemic manifestations occur in one third of patients. Recurrent, acute anterior uveitis is common but\\nusually self-limited; uncommonly it becomes protracted and severe enough to impair vision. Neurologic\\nsigns occasionally result from compression radiculitis or sciatica, vertebral fracture or subluxation, or\\ncauda equina syndrome (see p.\\n1806\\n). Cardiovascular manifestations can include aortic insufficiency, aortitis, angina, pericarditis, and\\ncardiac conduction abnormalities (which may be asymptomatic). Dyspnea, cough, or hemoptysis can\\nresult from nontuberculous fibrosis or cavitation of an upper lobe of the lung; secondary infection with\\nAspergillus\\n can develop. Rarely, AS results in secondary amyloidosis. Subcutaneous nodules do not\\ndevelop.\\nDiagnosis\\n Lumbosacral spine imaging\\n Blood tests (ESR, C-reactive protein, and CBC) or explicit clinical criteria (modified New York criteria)\\nAS should be suspected in patients, particularly young men, with nocturnal back pain and kyphosis,\\ndiminished chest expansion, Achilles tendinitis, or unexplained anterior uveitis. A 1st-degree relative with\\nAS should heighten suspicion. Patients should generally be tested with ESR, C-reactive protein, and\\nCBC. IgM, RF, and antinuclear antibodies are needed only if peripheral arthritis suggests other\\ndiagnoses. No laboratory test is diagnostic, but results can increase suspicion for the disorder or rule out\\nother disorders than can simulate AS. If, after these tests, AS is still suspected, patients should undergo\\nimaging of the lumbosacral spine; demonstration of sacroiliitis on x-ray strongly supports the diagnosis.\\nAlternatively, AS can be diagnosed by the modified New York criteria. Using these criteria, the patient\\nmust have imaging study evidence of sacroiliitis and one of the following:\\n Restriction of lumbar spinal motion in both the sagittal (looking from the side) and frontal (looking from\\nthe back) planes\\n Restriction of chest expansion, adjusted for age\\n A history of inflammatory back pain\\nHistorical features that distinguish inflammatory back pain from noninflammatory back pain include onset\\nat  40 yr, gradual onset, morning stiffness, improvement with activity, and duration  3 mo before seeking\\nmedical attention.\\nESR and other acute-phase reactants (eg, C-reactive protein) are inconsistently elevated in patients with\\nactive AS. Tests for RF and antinuclear antibodies are negative. The HLA-B27 genetic marker is not of\\ndiagnostic value.\\nThe earliest x-ray abnormalities are pseudowidening from subchondral erosions, followed by sclerosis or\\nlater narrowing and eventually fusion in the sacroiliac joints. Changes are symmetric. Early changes in\\nthe spine are upper lumbar vertebral squaring with sclerosis at the corners; spotty ligamentous\\ncalcification; and one or two evolving syndesmophytes. Late changes result in a \"bamboo spine\"\\nappearance, resulting from prominent syndesmophytes, diffuse paraspinal ligamentous calcification, and\\nosteoporosis; these changes develop in some patients on average over 10 yr.\\nChanges typical of AS may not become visible on plain x-rays for years. CT and MRI show changes\\nearlier, but there is no consensus regarding their role in routine diagnosis.\\nA herniated intervertebral disk can cause back pain and radiculopathy similar to AS, but the pain is limited\\nto the spine, usually causes more sudden symptoms, and causes no systemic manifestations or\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n425'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 435, 'page_label': '426'}, page_content='laboratory test abnormalities. If necessary, CT or MRI can differentiate it from AS. Involvement of a single\\nsacroiliac joint suggests a different spondyloarthropathy, possibly infection. Tuberculous spondylitis can\\nsimulate AS (see p. \\n1313\\n).\\nDiffuse idiopathic skeletal hyperostosis (DISH)\\n occurs primarily in men > 50 yr and may resemble AS\\nclinically and on x-ray. Patients uncommonly have spinal pain, stiffness, and insidious loss of motion. X-\\nray findings in DISH include large ossifications anterior to spinal ligaments (the calcification appears as if\\nsomeone poured candle wax in front and on the sides of the vertebrae), bridging several vertebrae and\\nusually starting at the lower thoracic spine, eventually affecting the cervical and lumbar spine. There is\\noften subperiosteal bone growth along the pelvic brim and at insertion of tendons (such as the Achilles\\ntendon insertion). However, the anterior spinal ligament is intact and frequently bulging, and sacroiliac\\nand spinal apophyseal joints are not eroded. Additional differentiating features are stiffness that is not\\naccentuated in the morning and a normal ESR.\\nPrognosis\\nAS is characterized by mild or moderate flares of active inflammation alternating with periods of little or no\\ninflammation. Proper treatment in most patients results in minimal or no disability and in a full, productive\\nlife despite back stiffness. Occasionally, the course is severe and progressive, resulting in pronounced\\nincapacitating deformities.\\nTreatment\\n NSAIDs\\n Sulfasalazine, methotrexate, or tumor necrosis factor (TNF) antagonists\\n Exercises and supportive measures\\nThe goals of treatment are relieving pain, maintaining joint range of motion, and preventing end-organ\\ndamage. Because the condition may cause lung fibrosis, cigarette smoking is discouraged.\\nNSAIDs reduce pain and suppress joint inflammation and muscle spasm, thereby increasing range of\\nmotion, which facilitates exercise and prevents contractures. Most NSAIDs work in AS, and tolerance and\\ntoxicity dictate drug choice. The daily dose of NSAIDs should be as low as possible, but maximum doses\\nmay be needed with active disease. Drug withdrawal should be attempted only slowly, after systemic and\\njoint signs of active disease have been suppressed for several months.\\nSulfasalazine may help reduce peripheral joint symptoms and laboratory markers of inflammation. Dosage\\nshould be started at 500 mg/day and increased by 500 mg/day at 1-wk intervals to 1 to 1.5 g bid\\nmaintenance. Peripheral joint symptoms may also abate with methotrexate (see p. \\n337\\n). Systemic\\ncorticosteroids, immunosuppressants, and most disease-modifying antirheumatic drugs have no proven\\nbenefit and should generally not be used. TNF-\\n\\n antagonists (eg, etanercept, infliximab, adalimumab) are\\neffective treatments for inflammatory back pain.\\nFor proper posture and joint motion, daily exercise and other supportive measures (eg, postural training,\\ntherapeutic exercise) are vital to strengthen muscle groups that oppose the direction of potential\\ndeformities (ie, the extensor rather than flexor muscles). Reading while lying prone and pushing up on the\\nelbows or pillows and thus extending the back may help keep the back flexible. Because chest wall\\nmotion can be restricted, which impairs lung function, cigarette smoking, which also impairs lung function,\\nis strongly discouraged.\\nIntra-articular depot corticosteroids may be beneficial, particularly when one or two peripheral joints are\\nmore severely inflamed than others, thereby compromising exercise and rehabilitation. They may also\\nhelp if systemic drugs are ineffective. Corticosteroids injected into the sacroiliac joints may occasionally\\nhelp severe sacroiliitis.\\nFor acute uveitis, topical corticosteroids and mydriatics are usually adequate. If severe hip arthritis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n426'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 436, 'page_label': '427'}, page_content=\"develops, total hip arthroplasty may lessen pain and improve flexibility dramatically.\\nReactive Arthritis\\nReactive arthritis is an acute spondyloarthropathy that often seems precipitated by an infection,\\nusually GU or GI. Common manifestations include asymmetric arthritis of variable severity that\\ntends to affect the lower extremities, sausage-shaped deformities of fingers or toes or both,\\nconstitutional symptoms, enthesitis, tendinitis, and mucocutaneous ulcers, including\\nhyperkeratotic or crusted vesicular lesions (keratoderma blennorrhagicum). Diagnosis is\\nclinical. Treatment involves NSAIDs and sometimes sulfasalazine or immunosuppressants.\\nSpondyloarthropathy associated with urethritis or cervicitis, conjunctivitis, and mucocutaneous lesions\\n(previously called Reiter's syndrome) is one type of reactive arthritis.\\nEtiology\\nTwo forms of reactive arthritis are common: sexually transmitted and dysenteric. The sexually transmitted\\nform occurs primarily in men aged 20 to 40. Genital infections with \\nChlamydia trachomatis\\n are most often\\nimplicated. Men or women can acquire the dysenteric form after enteric infections, primarily \\nShigella\\n,\\nSalmonella\\n, \\nYersinia\\n, or \\nCampylobacter\\n. Reactive arthritis probably results from joint infection or\\npostinfectious inflammation. Although there is evidence of microbial antigens in the synovium, organisms\\ncannot be cultured from joint fluid.\\nEpidemiology:\\n The prevalence of the HLA-B27 allele in patients is 63 to 96% vs 6 to 15% in healthy\\nwhite controls, thus supporting a genetic predisposition.\\nSymptoms and Signs\\nReactive arthritis can range from transient monarticular arthritis to a severe, multisystem disorder.\\nConstitutional symptoms may include fever, fatigue, and weight loss. Arthritis may be mild or severe. Joint\\ninvolvement is generally asymmetric and oligoarticular or polyarticular, occurring predominantly in the\\nlarge joints of the lower extremities and in the toes. Back pain may occur, usually with severe disease.\\nEnthesopathy (inflammation at tendinous insertion into boneeg, plantar fasciitis, digital periostitis,\\nAchilles tendinitis) is common and characteristic. Mucocutaneous lesionssmall, transient, relatively\\npainless, superficial ulcerscommonly occur on the oral mucosa, tongue, and glans penis (balanitis\\ncircinata). Particularly characteristic are vesicles (sometimes identical to pustular psoriasis) of the palms\\nand soles and around the nails that become hyperkeratotic and form crusts (keratoderma\\nblennorrhagicum). Rarely, cardiovascular complications (eg, aortitis, aortic insufficiency, cardiac\\nconduction defects), pleuritis, and CNS or peripheral nervous system symptoms develop.\\nUrethritis may develop 7 to 14 days after sexual contact (or occasionally after dysentery); low-grade fever,\\nconjunctivitis, and arthritis develop over the next few weeks. Not all features may occur, so incomplete\\nforms need to be considered. In men, the urethritis is less painful and productive of purulent discharge\\nthan acute gonococcal urethritis and may be associated with hemorrhagic cystitis or prostatitis. In women,\\nurethritis and cervicitis may be mild (with dysuria or slight vaginal discharge) or asymptomatic.\\nConjunctivitis is the most common eye lesion. It usually causes eye redness and grittiness, but keratitis\\nand anterior uveitis can develop also, causing eye pain, photophobia, and tearing.\\nDiagnosis\\n Typical arthritis\\n Symptoms of GI or GU infection\\n One other extra-articular feature\\nReactive arthritis should be suspected in patients with acute, asymmetric arthritis affecting \\nthe large joints\\nof the lower extremities or toes, particularly if there is tendinitis or a history of an antecedent diarrhea or\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n427\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 437, 'page_label': '428'}, page_content='dysuria. Diagnosis is ultimately clinical and requires the typical peripheral arthritis with symptoms of GU\\nor GI infection or one of the other extra-articular features. Because these features may manifest at\\ndifferent times, definitive diagnosis may require several months. Serum and synovial fluid complement\\nlevels are high, but these findings are not usually diagnostic and need not be measured.\\nDisseminated gonococcal infection can closely simulate reactive arthritis (see p. \\n1472\\n). Arthrocentesis\\nmay fail to differentiate them, owing to inflammatory characteristics of synovial fluid in both disorders and\\nthe difficulty of culturing gonococci from this fluid. Clinical characteristics may help; disseminated\\ngonococcal infection tends to involve upper and lower extremities equally, be more migratory, and not\\nproduce back pain, and vesicles tend not to be hyperkeratotic. A positive gonococcal culture from blood\\nor skin lesions helps differentiate the two disorders, but a positive culture from the urethra or cervix does\\nnot. If differentiation is still difficult, ceftriaxone may be required for simultaneous diagnosis and treatment.\\nPsoriatic arthritis can simulate reactive arthritis, causing similar skin lesions, uveitis, and asymmetric\\narthritis. However, psoriatic arthritis often affects mostly the upper extremities and especially the distal\\ninterphalangeal joints, may be abrupt in onset but may also develop gradually, causes less enthesopathy,\\nand tends not to cause mouth ulcers or symptoms of GU or GI infection.\\nPrognosis\\nReactive arthritis often resolves in 3 to 4 mo, but up to 50% of patients experience recurrent or prolonged\\nsymptoms over several years. Joint, spinal, or sacroiliac inflammation or deformity may occur with chronic\\nor recurrent disease. Some patients are disabled.\\nTreatment\\n NSAIDs\\n Sometimes sulfasalazine, doxycycline, azathioprine or methotrexate, or a combination\\n Supportive measures\\nNSAIDs (eg, indomethacin 25 to 50 mg po tid) usually help relieve symptoms. If induced by infection with\\nC. trachomatis\\n, doxycycline 100 mg po bid for up to 3 mo may accelerate recovery, but this is\\ncontroversial. Sulfasalazine as used to treat RA may also be helpful (see p. \\n337\\n). If symptoms are severe\\ndespite NSAIDs and sulfasalazine, azathioprine or methotrexate may be considered. Systemic\\ncorticosteroids have no proven value.\\nLocal injection of depot corticosteroids for enthesopathy or resistant oligoarthritis may relieve symptoms.\\nPhysical therapy aimed at maintaining joint mobility is helpful during the recovery phase. Anterior uveitis is\\ntreated as usual, with corticosteroid and mydriatic eye drops to prevent scarring. Conjunctivitis and\\nmucocutaneous lesions require only symptomatic treatment.\\nPsoriatic Arthritis\\nPsoriatic arthritis is a chronic inflammatory arthritis that occurs in people with psoriasis of the\\nskin or nails. The arthritis is often asymmetric, and some forms involve the distal\\ninterphalangeal joints. Diagnosis is clinical. Treatment is usually similar to that of RA but can\\nalso involve phototherapy.\\nPsoriatic arthritis develops in 5 to 40% of patients with psoriasis. Prevalence is increased in patients with\\nAIDS. Risk of some involvement is increased in patients with HLA-B27 or some other specific alleles and\\nin family members. Etiology and pathophysiology are unknown.\\nSymptoms and Signs\\nPsoriasis of the skin or nails may precede or follow joint involvement. Skin lesions may be hidden in the\\nscalp, gluteal folds, or umbilicus and go unrecognized by the patient.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n428'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 438, 'page_label': '429'}, page_content=\"The distal interphalangeal (DIP) joints of fingers and toes are especially affected. Asymmetric involvement\\nof large and small joints, including the sacroiliacs and spine, is common. Joint and skin symptoms may\\nlessen or worsen simultaneously. Inflammation of the fingers, toes, or both may lead to sausage-shaped\\ndeformities. Rheumatoid nodules are absent. Arthritic remissions tend to be more frequent, rapid, and\\ncomplete than in RA, but progression to chronic arthritis and crippling may occur. There may be arthritis\\nmutilans (destruction of multiple hand joints with telescoping of the digits).\\nBack pain may be present. It is often accompanied by asymmetric syndesmophytes of the spine.\\nDiagnosis\\n Clinical evaluation\\n RF\\nPsoriatic arthritis should be suspected in patients with both psoriasis and arthritis. Because psoriasis may\\nbe overlooked or hidden or develop only after arthritis occurs, psoriatic arthritis should be considered in\\nany patient with seronegative inflammatory arthritis; these patients should be examined for psoriasis and\\nnail pitting and should be questioned about a family history of psoriasis. Patients suspected of having\\npsoriatic arthritis should be tested for rheumatoid factor, which can coexist. Psoriatic arthritis is diagnosed\\nclinically and by excluding other disorders that can cause such similar manifestations. X-ray findings\\ncommon in psoriatic arthritis include DIP involvement; resorption of terminal phalanges; arthritis mutilans;\\nand extensive destruction, proliferative bone reaction, and dislocation of large and small joints.\\nTreatment\\n Arthritis treated generally similarly to RA\\n Phototherapy\\nTreatment is directed at control of skin lesions (see p. \\n677\\n) and at joint inflammation. Drug therapy is\\nsimilar to that for RA, particularly methotrexate. Hydroxychloroquine is inconsistently of benefit and may\\ncause exfoliative dermatitis or aggravate underlying psoriasis. Benefit may be gained from NSAIDs,\\ncyclosporine, and TNF antagonists (see p. \\n335\\n under Drugs for RA); TNF antagonists have been\\nparticularly effective.\\nPhototherapy using long-wave psoralen plus ultraviolet A (PUVA) combined with oral methoxsalen 600\\n\\ng/kg po 2 h before PUVA twice/wk seems to be highly effective for psoriatic lesions and somewhat\\neffective for peripheral arthritis, but not for spine involvement.\\nOther Spondyloarthropathies\\nSpondyloarthropathy can develop in association with GI conditions (sometimes called enteropathic\\narthritis) such as inflammatory bowel disease, intestinal bypass surgery, or Whipple's disease.\\nJuvenile-onset spondyloarthropathy is an asymmetric, mostly lower extremity spondyloarthropathy that\\nbegins most commonly in boys aged 7 to 16.\\nSpondyloarthropathy can also develop in people without characteristics of other specific\\nspondyloarthropathy (undifferentiated spondyloarthropathy). Treatment of the arthritis of these other\\nspondyloarthropathies is similar to that of treatment of reactive arthritis (see p. \\n344\\n).\\nOsteoarthritis\\n(Degenerative Joint Disease; Osteoarthrosis; Hypertrophic Osteoarthritis)\\nOsteoarthritis (OA) is a chronic arthropathy characterized by disruption and potential loss of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n429\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 439, 'page_label': '430'}, page_content=\"joint cartilage along with other joint changes, including bone hypertrophy (osteophyte\\nformation). Symptoms include gradually developing pain aggravated or triggered by activity,\\nstiffness lasting < 30 min on awakening and after inactivity, and occasional joint swelling.\\nDiagnosis is confirmed by x-rays. Treatment includes physical measures (including\\nrehabilitation), patient education, and drugs.\\nOA, the most common joint disorder, often becomes symptomatic in the 40s and 50s and is nearly\\nuniversal (although not always symptomatic) by age 80. Only half of patients with pathologic changes of\\nOA have symptoms. Below age 40, most OA is in men and results from trauma. Women predominate from\\nage 40 to 70, after which men and women are equally affected.\\nClassification\\nOA is classified as primary (idiopathic) or secondary to some known cause.\\nPrimary OA may be localized to certain joints (eg, chondromalacia patellae is a mild OA that occurs in\\nyoung people). Primary OA is usually subdivided by the site of involvement (eg, hands and feet, knee,\\nhip). If primary OA involves multiple joints, it is classified as primary generalized OA.\\nSecondary OA results from conditions that change the microenvironment of the cartilage. These\\nconditions include significant trauma, congenital joint abnormalities, metabolic defects (eg,\\nhemochromatosis, Wilson's disease), infections (causing postinfectious arthritis), endocrine and\\nneuropathic diseases, and disorders that alter the normal structure and function of hyaline cartilage (eg,\\nRA, gout, chondrocalcinosis).\\nPathophysiology\\nNormal joints have little friction with movement and do not wear out with typical use, overuse, or trauma.\\nHyaline cartilage is avascular, aneural, and alymphatic. It is 95% water and extracellular cartilage matrix\\nand only 5% chondrocytes. Chondrocytes have the longest cell cycle in the body (similar to CNS and\\nmuscle cells). Cartilage health and function depend on compression and release of weight bearing and\\nuse (ie, compression pumps fluid from the cartilage into the joint \\nspace and into capillaries and venules,\\nwhereas release allows the cartilage to reexpand, hyperhydrate, and absorb necessary electrolytes and\\nnutrients).\\nOA begins with tissue damage from mechanical injury (eg, torn meniscus), transmission of inflammatory\\nmediators from the synovium into cartilage, or defects in cartilage metabolism. The tissue damage\\nstimulates chondrocytes to attempt repair, which increases production of proteoglycans and collagen.\\nHowever, efforts at repair also stimulate the enzymes that degrade cartilage, as well as inflammatory\\ncytokines, which are normally present in small amounts. Inflammatory mediators trigger an inflammatory\\ncycle that further stimulates the chondrocytes and synovial lining cells, eventually breaking down the\\ncartilage. Chondrocytes undergo programmed cell death (apoptosis). Once cartilage is destroyed,\\nexposed bone becomes eburnated and sclerotic.\\nAll articular and some periarticular tissues become involved in OA. Subchondral bone stiffens, then\\nundergoes infarction, and develops subchondral cysts. Attempts at bony repair cause subchondral\\nsclerosis and osteophytes at the joint margins. The osteophytes seem to develop in an attempt to\\nstabilize the joint. The synovium becomes inflamed and thickened and produces synovial fluid with less\\nviscosity and greater volume. Periarticular tendons and ligaments become stressed, resulting in tendinitis\\nand contractures. As the joint becomes less mobile, surrounding muscles thin and become less\\nsupportive. Menisci fissure and may fragment.\\nOA of the spine can, at the disk level, cause marked thickening and proliferation of the posterior\\nlongitudinal ligaments, which are posterior to the vertebral body but anterior to the spinal cord. The result\\ncan be transverse bars that encroach on the anterior spinal cord. Hypertrophy and hyperplasia of the\\nligamenta flava, which are posterior to the spinal cord, often compress the posterior canal, causing\\nlumbar spinal stenosis. In contrast, the anterior and posterior nerve roots, ganglia, and common spinal\\nnerve are relatively well protected in the intervertebral foramina, where they occupy only 25% of the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n430\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 440, 'page_label': '431'}, page_content=\"available and well-cushioned space.\\nSymptoms and Signs\\nOnset is most often gradual, usually beginning with one or a few joints. Pain is the earliest symptom,\\nsometimes described as a deep ache. Pain is usually worsened by weight bearing and relieved by rest\\nbut can eventually become constant. Stiffness follows awakening or inactivity but lasts < 30 min and\\nlessens with movement. As OA progresses, joint motion becomes restricted, and tenderness and crepitus\\nor grating sensations develop. Proliferation of cartilage, bone, ligament, tendon, capsules, and synovium,\\nalong with varying amounts of joint effusion, ultimately cause the joint enlargement characteristic of OA.\\nFlexion contractures may eventually develop. Acute and severe synovitis is uncommon.\\nTenderness on palpation and pain on passive motion are relatively late signs. Muscle spasm and\\ncontracture add to the pain. Mechanical block by intra-articular loose bodies or abnormally placed menisci\\ncan occur and cause locking or catching. Deformity and subluxations can also develop.\\nThe joints most often affected in generalized OA include the following:\\n Distal interphalangeal (DIP) and proximal interphalangeal (PIP) joints (causing Heberden's and\\nBouchard's nodes)\\n Thumb carpometacarpal joint\\n Intervertebral disks and zygapophyseal joints in the cervical and lumbar vertebrae\\n First metatarsophalangeal joint\\n Hip\\n Knee\\nCervical and lumbar spinal OA\\n may lead to myelopathy or radiculopathy. However, the clinical signs of\\nmyelopathy are usually mild. Lumbar spinal stenosis may cause lower back or leg pain that is worsened\\nby walking or back extension. Radiculopathy can be prominent but is less common because the nerve\\nroots and ganglia are well protected. Insufficiency of the vertebral arteries, infarction of the spinal cord,\\nand dysphagia due to esophageal impingement by osteophytes occasionally occur. Symptoms and signs\\nfrom OA in general may also derive from subchondral bone, ligamentous structures, synovium,\\nperiarticular bursae, capsules, muscles, tendons, disks, and periosteum, all of which are pain sensitive.\\nVenous pressure may increase within the subchondral bone marrow and cause pain (sometimes called\\nbone angina).\\nHip OA\\n causes gradual loss of range of motion. Pain may be felt in the inguinal area or greater\\ntrochanter or referred to the knee.\\nKnee OA\\n causes cartilage to be lost (medial loss occurs in 70% of cases). The ligaments become lax\\nand the joint becomes less stable, with local pain arising from the ligaments and tendons.\\nErosive OA\\n causes synovitis and cysts in the hand. It primarily affects the DIP or PIP \\njoints. The thumb\\ncarpometacarpal joints are involved in 20% of hand OA, but the metacarpophalangeal joints and wrists\\nare usually spared. At this time, it is uncertain whether erosive interphalangeal OA is a variant of hand OA\\nor whether it represents a separate entity.\\nOA is usually sporadically progressive but occasionally, with no predictability, stops or reverses.\\nDiagnosis\\n X-rays\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n431\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 441, 'page_label': '432'}, page_content='OA should be suspected in patients with gradual onset of symptoms and signs, particularly in older\\nadults. If OA is suspected, plain x-rays should be taken of the most symptomatic joints. X-rays generally\\nreveal marginal osteophytes, narrowing of the joint space, increased density of the subchondral bone,\\nsubchondral cyst formation, bony remodeling, and joint effusions. Standing x-rays of knees are more\\nsensitive in detecting joint space narrowing.\\nLaboratory studies are normal in OA but may be required to rule out other disorders (eg, RA) or to\\ndiagnose an underlying disorder causing secondary OA. If OA causes joint effusions, synovial fluid\\nanalysis can help differentiate it from inflammatory arthritides; in OA, synovial fluid is usually clear,\\nviscous, and has  2000 WBC/\\n\\nL.\\nOA involvement outside the usual joints suggests secondary OA; further evaluation may be required to\\ndetermine the underlying primary disorder (eg, endocrine, metabolic, neoplastic, biomechanical\\ndisorders).\\nTreatment\\n Rehabilitative and supportive measures\\n Adjunctive drug therapy\\nTreatment goals are relieving pain, maintaining joint flexibility, and optimizing joint and overall function.\\nPrimary treatments include physical measures that involve rehabilitation; support devices; exercise for\\nstrength, flexibility, and endurance; patient education; and modifications in activities of daily living.\\nAdjunctive therapies include drug treatment and surgery.\\nPhysical measures:\\n Rehabilitation techniques are best begun before disability develops. Exercises\\n(range of motion, isometric, isotonic, isokinetic, postural, strengtheningsee p. \\n3453\\n) maintain range of\\nmotion and increase the capacity for tendons and muscles to absorb stress during joint motion. Exercise\\ncan sometimes arrest or even reverse hip and knee OA. Stretching exercises should be done daily.\\nImmobilization for any prolonged period of time can promote contractures and worsen the clinical course.\\nHowever, a few minutes of rest (every 4 to 6 h in the daytime) can help if balanced with exercise and use.\\nModifying activities of daily living can help. For example, a patient with lumbar spine, hip, or knee OA\\nshould avoid soft deep chairs and recliners in which posture is poor and from which rising is difficult. The\\nregular use of pillows under the knees while reclining encourages contractures and should also be\\navoided. Patients should sit in straight-back chairs without slumping, sleep on a firm bed, perhaps with a\\nbed board, use a car seat shifted forward and designed for comfort, do postural exercises, wear well-\\nsupported shoes or athletic shoes, and continue employment and physical activity.\\nIn OA of the spine, knee, or thumb carpometacarpal joint, various supports can relieve pain and increase\\nfunction, but to preserve flexibility, they should be accompanied by specific exercise programs. In erosive\\nOA, range-of-motion exercises done in warm water can help prevent contractures.\\nDrugs:\\n Drug therapy is an adjunct to the physical program. Acetaminophen in doses of up to 1 g po qid\\nmay relieve pain and is safe. More potent analgesia may be required.\\nNSAIDs, including cyclooxygenase-2 (COX-2) inhibitors or coxibs, may be considered if patients have\\nrefractory pain or signs of inflammation (eg, redness, warmth). NSAIDs may be used simultaneously with\\nother analgesics (eg, tramadol, opioids) to provide better relief of symptoms.\\nMuscle relaxants (usually in low doses) occasionally relieve pain that arises from muscles strained by\\nattempting to support OA joints. In the elderly, however, they may cause more adverse effects than relief.\\nOral corticosteroids have no role. However, intra-articular depot corticosteroids help relieve pain and\\nincrease joint flexibility.\\nSynthetic hyaluronans (similar to hyaluronic acid, a normal component of the joint) can be injected into\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n432'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 442, 'page_label': '433'}, page_content='the knee, with pain relief for prolonged periods of time (up to a year). However, the effect seems to be\\nsmall. The treatment is a series of 3 to 5 weekly injections.\\nGlucosamine sulfate 1500 mg po once/day has been suggested to relieve pain and slow joint\\ndeterioration; chondroitin sulfate 1200 mg once/day has also been suggested for pain relief. Studies to\\ndate have shown mixed results in terms of pain relief.\\nOther adjunctive and experimental therapies:\\n Other adjunctive measures can relieve pain, including\\nmassage, heating pads, weight loss, acupuncture, transcutaneous electrical nerve stimulation, and local\\nrubs (eg, with capsaicin). Laminectomy, osteotomy, and total joint replacement should be considered if all\\nnonsurgical approaches fail. (See also the Agency for Healthcare Research and Quality\\'s Evidence-\\nBased Practice Program\\'s evidence report.)\\nExperimental therapies that may preserve cartilage or allow chondrocyte grafting are being studied. It is\\nnot clear whether using a lidocaine 5% patch relieves pain. Flavocoxid, a new drug, can be tried.\\nNeurogenic Arthropathy\\n(Neuropathic Arthropathy; Charcot\\'s Joints)\\nNeurogenic arthropathy is a rapidly destructive arthropathy due to impaired pain perception and\\nposition sense, which can result from various underlying disorders, most commonly diabetes\\nand stroke. Common manifestations include joint swelling, effusion, deformity, and instability.\\nPain may be disproportionately mild due to the underlying neuropathy. Diagnosis requires x-ray\\nconfirmation. Treatment consists of joint immobilization, which slows disease progression, and\\nsometimes surgery if the disease is advanced.\\nPathophysiology\\nMany conditions predispose to neurogenic arthropathy (see\\nTable 35-4\\n). Impaired deep pain sensation or proprioception affects the joint\\'s normal protective reflexes,\\noften allowing trauma (especially repeated minor episodes) and small periarticular fractures to go\\nunrecognized. Increased blood flow to bone from reflex vasodilation, resulting in active bone resorption,\\ncontributes to bone and joint damage. Each new injury sustained by the joint causes more distortion as it\\nheals. Hemorrhagic joint effusions and multiple small fractures can occur, accelerating disease\\nprogression. Ligamentous laxity, muscular hypotonia, and rapid destruction of joint cartilage are common,\\npredisposing to joint dislocations, which also accelerate disease progression. Advanced neurogenic\\narthropathy can cause hypertrophic changes, destructive changes, or both.\\n[\\nTable 35-4.\\n Conditions Underlying Neurogenic Arthropathy]\\nSymptoms and Signs\\nArthropathy does not usually develop until years after onset of the neurologic condition but can then\\nprogress rapidly and lead to complete joint disorganization in a few months. Pain is a common early\\nsymptom. However, because the ability to sense pain is commonly impaired, the degree of pain is often\\nunexpectedly mild for the degree of joint damage. A prominent, often hemorrhagic, effusion and\\nsubluxation and instability of the joint are usually present during early stages. Acute joint dislocation\\nsometimes occurs also.\\nDuring later stages, pain may be more severe if the disease has caused rapid joint destruction (eg,\\nperiarticular fractures or tense hematomas). During advanced stages, the joint is swollen from bony\\novergrowth and massive synovial effusion. Deformity results from dislocations and displaced fractures.\\nFractures and bony healing may produce many loose pieces of cartilage or bone that can slough into the\\njoint, causing a coarse, grating, often audible crepitus usually more unpleasant for the observer than for\\nthe patient. The joint may feel like a \"bag of bones.\"\\nAlthough many joints can be involved, the knee and the ankle are most often affected. \\nDistribution\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n433'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 443, 'page_label': '434'}, page_content=\"depends largely on the underlying disease. Thus, tabes dorsalis affects the knee and hip, and diabetes\\nmellitus affects the foot and ankle. Syringomyelia commonly affects the spine and upper limb joints,\\nespecially the elbow and shoulder. Frequently, only one joint is affected and usually no more than two or\\nthree (except for the small joints of the feet), in an asymmetric distribution.\\nInfectious arthritis may develop with or without systemic symptoms (eg, fever, malaise), particularly with\\ndiabetes. Structures such as blood vessels, nerves, and the spinal cord can become compressed due to\\nthe tissue overgrowth.\\nDiagnosis\\n X-rays\\nThe diagnosis should be considered in a patient with a predisposing neurologic disorder who develops a\\ndestructive but unexpectedly painless arthropathy, usually several years after the onset of the underlying\\nneurologic condition. If neurogenic arthropathy is suspected, x-rays should be taken. Diagnosis is\\nestablished by characteristic x-ray abnormalities in a patient with a predisposing condition and typical\\nsymptoms and signs.\\nX-ray abnormalities in early neurogenic arthropathy are often similar to those in osteoarthritis (OA). The\\ncardinal signs are bone fragmentation, bone destruction, new bone growth, and loss of joint space. There\\nmay also be synovial effusion and joint subluxation. Later, the bones are deformed, and new bone forms\\nadjacent to the cortex, starting within the joint capsule and often extending up the shaft, particularly in\\nlong bones. Rarely, calcification and ossification occur in the soft tissues. Large, bizarrely shaped\\nosteophytes may be present at the joint margins or within joints. Large curved (parrot's beak) osteophytes\\nfrequently develop in the spine in the absence of clinical spinal disease.\\nIn its early stages, neurogenic arthropathy can simulate OA. However, neurogenic arthropathy progresses\\nmore rapidly than OA and frequently causes proportionately less pain.\\nTreatment\\n Treatment of cause\\n Sometimes surgery\\nEarly diagnosis of asymptomatic or minimally symptomatic fractures facilitates early treatment;\\nimmobilization (with splints, special boots, or calipers) protects the joint from further injury, possibly\\nstopping disease evolution. Prevention of neurogenic arthropathy may even be possible in a patient at\\nrisk.\\nTreatment of the underlying neurologic condition may slow progression of the arthropathy and, if joint\\ndestruction is still in the early stages, partially reverse the process. For a grossly disorganized joint,\\narthrodesis using internal fixation, compression, and an adequate bone graft may be successful. For\\ngrossly disorganized hip and knee joints, if neurogenic arthropathy is not expected to be progressive,\\ngood results can be obtained with total hip and knee replacements. However, loosening and dislocation\\nof the prosthesis are major hazards.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 35. Joint Disorders\\n434\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 444, 'page_label': '435'}, page_content='Chapter 36. Crystal-Induced Arthritides\\nIntroduction\\nArthritis can result from intra-articular deposition of crystals: monosodium urate, Ca pyrophosphate\\ndihydrate, basic Ca phosphate (apatite), and, rarely, others such as Ca oxalate crystals. Diagnosis\\nrequires synovial fluid analysis (see p. \\n287\\n). Polarized light microscopy is used to specifically identify\\nmost crystals; basic Ca phosphate crystals are of ultramicroscopic size and require other methods.\\nCrystals may be engulfed in WBCs or may be extracellular. The presence of crystals does not exclude the\\npossibility of simultaneous infectious or other inflammatory forms of arthritis.\\nGout\\nGout is precipitation of monosodium urate crystals into tissue, usually in and around joints,\\nmost often causing recurrent acute or chronic arthritis. Acute arthritis is initially monarticular\\nand often involves the 1st metatarsophalangeal joint. Symptoms include acute pain,\\ntenderness, warmth, redness, and swelling. Diagnosis requires identification of crystals in\\nsynovial fluid. Treatment of acute attacks is with anti-inflammatory drugs. The frequency of\\nattacks can be reduced by regular use of NSAIDs, colchicine, or both and by treating\\nhyperuricemia with allopurinol or uricosuric drugs.\\nGout is more common among men than women. Usually, gout develops during middle age in men and\\nafter menopause in women. Gout is rare in younger people but is often more severe in people who\\ndevelop the disorder before age 30. Gout often runs in families.\\nPathophysiology\\nThe greater the degree and duration of hyperuricemia, the greater is the likelihood of gout and the more\\nsevere are the symptoms. Urate levels can be elevated because of\\n Decreased excretion\\n Increased production\\n Increased purine intake\\nWhy only some people with elevated serum uric acid (urate) levels develop gout is not known.\\nDecreased renal excretion\\n is by far the most common cause of hyperuricemia. It may be hereditary and\\nalso occurs in patients receiving diuretics and in those with diseases that decrease GFR. Ethanol\\nincreases purine catabolism in the liver and increases the formation of lactic acid, which blocks urate\\nsecretion by the renal tubules. Lead poisoning and cyclosporine, usually given to transplant patients,\\nirreversibly damage renal tubules, leading to urate retention.\\nIncreased production\\n of urate may be caused by increased nucleoprotein turnover in hematologic\\nconditions (eg, lymphoma, leukemia, hemolytic anemia) and in conditions with increased rates of cellular\\nproliferation and cell death (eg, psoriasis, cytotoxic cancer therapy, radiation therapy). Increased urate\\nproduction may also occur as a primary hereditary abnormality and in obesity, because urate production\\ncorrelates with body surface area. In most cases, the cause is unknown, but a few cases are attributable\\nto enzyme abnormalities; deficiency of hypoxanthine-guanine phosphoribosyltransferase (complete\\ndeficiency is Lesch-Nyhan syndrome) is a possible cause, as is overactivity of\\nphosphoribosylpyrophosphate synthetase.\\nIncreased intake\\n of purine-rich foods (eg, liver, kidney, anchovies, asparagus, consomme, herring, meat\\ngravies and broths, mushrooms, mussels, sardines, sweetbreads) can contribute to hyperuricemia.\\nHowever, a strict low-purine diet lowers serum urate by only about 1 mg/dL.\\nUrate precipitates as needle-shaped monosodium urate (MSU) crystals, which are deposited\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 36. Crystal-Induced Arthritides\\n435'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 445, 'page_label': '436'}, page_content=\"extracellularly in avascular tissues (eg, cartilage) or in relatively avascular tissues (eg, tendons, tendon\\nsheaths, ligaments, walls of bursae) and skin around cooler distal joints and tissues (eg, ears). In severe,\\nlongstanding hyperuricemia, MSU crystals may be deposited in larger central joints and in the\\nparenchyma of organs such as the kidney. At the acid pH of urine, urate precipitates readily as small\\nplatelike or irregular crystals that may aggregate to form gravel or stones, which may cause obstruction.\\nTophi are MSU crystal aggregates that most often develop in joint and cutaneous tissue.\\nAcute gouty arthritis may be triggered by trauma, medical stress (eg, pneumonia or other infection), and\\nespecially vascular occlusions (eg, stroke or MI), or by surgery, use of thiazide diuretics or drugs with\\nuricosuric activity (eg, allopurinol), or indulgence in purine-rich food or alcohol. Attacks are often\\nprecipitated by a sudden increase or, more commonly, a sudden decrease in serum urate levels. Why\\nacute attacks follow some of these precipitating conditions is unknown. Tophi in and around joints can\\nlimit motion and cause deformities, called chronic tophaceous gouty arthritis.\\nSymptoms and Signs\\nAcute gouty arthritis usually begins with sudden onset of pain (often nocturnal). The metatarsophalangeal\\njoint of a great toe is most often involved (podagra), but the instep, ankle, knee, wrist, and elbow are also\\ncommon sites. Rarely, the hip, shoulder, sacroiliac, sternoclavicular, or cervical spine joints are involved.\\nThe pain becomes progressively more severe, usually over a few hours, and is often excruciating.\\nSwelling, warmth, redness, and exquisite tenderness may suggest infection. The overlying skin may\\nbecome tense, warm, shiny, and red or purplish. Fever, tachycardia, chills, and malaise sometimes occur.\\nCoexisting hypertension, hyperlipidemia, and obesity are common.\\nCourse:\\n The first few attacks usually affect only a single joint and last only a few days. Later attacks may\\naffect several joints simultaneously or sequentially and persist up to 3 wk if untreated. Subsequent\\nattacks develop after progressively shorter symptom-free intervals. Eventually, several attacks may occur\\neach year.\\nTophi:\\n Tophi develop most often in patients with chronic gout, but they can occur in patients who have\\nnever had acute gouty arthritis. They are usually firm yellow or white papules or nodules, single or\\nmultiple. They can develop in \\nvarious locations, commonly the fingers, hands, feet, and around the\\nolecranon or Achilles tendon. Tophi can also develop in the kidneys and other organs and under the skin\\non the ears. Patients with osteoarthritic Heberden's nodes may develop tophi in the nodes. This\\ndevelopment occurs most often in elderly women taking diuretics. Normally painless, tophi, especially in\\nthe olecranon bursae, can become acutely inflamed and painful. Tophi may even erupt through the skin,\\ndischarging chalky masses of urate crystals. Tophi may eventually cause deformities.\\nChronic gout:\\n Chronic gouty arthritis can cause pain, deformity, and limited joint motion. Inflammation\\ncan be flaring in some joints while subsiding in others. About 20% of patients with gout develop\\nurolithiasis with uric acid stones or Ca oxalate stones. Complications include obstruction and infection,\\nwith secondary tubulointerstitial disease. Untreated progressive renal dysfunction, most often related to\\ncoexisting hypertension or, less often, some other cause of nephropathy, further impairs excretion of\\nurate, accelerating crystal deposition in tissues.\\nCardiovascular disease and the metabolic syndrome are common among patients with gout.\\nDiagnosis\\n Clinical criteria\\n Synovial fluid analysis\\nGout should be suspected in patients with acute monarticular or oligoarthritis, particularly older adults or\\nthose with other risk factors. Podagra and recurrent instep inflammation are particularly suggestive.\\nSimilar symptoms can result from\\n Ca pyrophosphate dihydrate (CPPD) crystal deposition disease (see p. \\n354\\n) (however, CPPD generally\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 36. Crystal-Induced Arthritides\\n436\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 446, 'page_label': '437'}, page_content=\"attacks larger joints and its clinical course is usually milder)\\n Acute rheumatic fever with joint involvement and juvenile RA (however, these disorders occur mostly in\\nyoung people, who rarely get gout)\\n RA (however, in RA, all affected joints flare and subside together, whereas in gout, inflammation is\\nusually flaring in some joints while subsiding in others)\\n Acute fracture in patients unable to provide a history of injury\\n Infectious arthritis (see pp. \\n365\\n and \\n369\\n; differentiation may require synovial fluid analysis)\\n Palindromic rheumatism\\nPalindromic rheumatism is characterized by acute, recurrent attacks of inflammation in or near one or\\noccasionally several joints with spontaneous resolution; pain and erythema can be as severe as in gout.\\nAttacks subside spontaneously and completely in 1 to 3 days. Such attacks may herald the onset of RA,\\nand rheumatoid factor tests can help in differentiation; they are positive in about 50% of patients (these\\ntests are positive in 10% of gouty patients also).\\nSynovial fluid analysis:\\n If acute gouty arthritis is suspected, arthrocentesis and synovial fluid analysis\\nshould be done at the initial presentation. A typical recurrence in a patient with known gout does not\\nmandate arthrocentesis, but it should be done if there is any question of the diagnosis or if the patient's\\nrisk factors or any clinical characteristics suggest infectious arthritis. Synovial fluid analysis can confirm\\nthe diagnosis by identifying needle-shaped, strongly negatively birefringent urate crystals that are free in\\nthe fluid or engulfed by phagocytes. Synovial fluid during attacks has inflammatory characteristics (see\\nTable 36-1\\n), usually 2,000 to 100,000 WBCs/\\n\\nL, with > 80% polymorphonuclear WBCs. These findings\\noverlap considerably with infectious arthritis, which must be excluded by Gram stain and culture.\\nSerum urate level:\\n An elevated serum urate level supports the diagnosis of gout but is neither specific\\nnor sensitive; at least 30% of patients have a normal serum urate level during an acute attack. However,\\nthe serum urate level reflects the size of the extracellular miscible urate pool. The level should be\\nmeasured on 2 or 3 occasions in patients with newly proven gout to establish a baseline; if elevated (> 7\\nmg/dL [> 0.41 mmol/L]), 24-h urinary urate excretion can also be measured. Normal 24-h excretion in\\npeople eating a regular diet is about 600 to 900 mg. Quantification of urinary uric acid can indicate\\nwhether hyperuricemia results from impaired excretion or increased production and help guide any serum\\nurate-lowering therapy. Patients with elevated urine excretion of urate are at increased risk of urolithiasis.\\nX-rays:\\n X-rays of the affected joint may be taken to look for bony tophi but are probably unnecessary if\\nthe diagnosis has been established by synovial fluid analysis. In CPPD, radiopaque deposits are present\\nin fibrocartilage, hyaline articular cartilage (particularly the knee), or both.\\nDiagnosis of chronic gouty arthritis:\\n Chronic gouty arthritis should be suspected in patients with\\npersistent joint disease or subcutaneous\\n[\\nTable 36-1.\\n Microscopic Examination of Crystals in Joints]\\nor bony tophi. Plain x-rays of the 1st metatarsophalangeal joint or other affected joint may be useful.\\nThese x-rays may show punched-out lesions of subchondral bone with overhanging bony margins, most\\ncommonly in the 1st metatarsophalangeal joint; lesions must be  5 mm in diameter to be visible on x-ray.\\nBone lesions are not specific or diagnostic but nearly always precede the appearance of subcutaneous\\ntophi.\\nPrognosis\\nWith early diagnosis, therapy enables most patients to live a normal life. For many patients with advanced\\ndisease, aggressive lowering of the serum urate level can resolve tophi and improve joint function. Gout\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 36. Crystal-Induced Arthritides\\n437\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 447, 'page_label': '438'}, page_content='is generally more severe in patients whose initial symptoms appear before age 30. The metabolic\\nsyndrome and cardiovascular disease probably increase mortality in patients with gout.\\nSome patients do not improve sufficiently with treatment. The usual reasons include nonadherence,\\nalcoholism, and undertreatment by physicians.\\nTreatment\\n Termination of an acute attack with NSAIDs or corticosteroids\\n Prevention of recurrent acute attacks with daily colchicine or an NSAID\\n Prevention of further deposition of MSU crystals and resolution of existing tophi by lowering the serum\\nurate level\\n Treatment of coexisting hypertension, hyperlipidemia, and obesity\\nTreatment of acute attacks: NSAIDs\\n are effective in treating acute attacks and are generally well\\ntolerated. However, they can still cause adverse effects, including GI upset, hyperkalemia, increases in\\ncreatinine, and fluid retention. Elderly and dehydrated patients are at particular risk, especially if there is\\na history of renal disease. Virtually any NSAID used in anti-inflammatory (high) doses is effective and is\\nlikely to exert an analgesic effect in a few hours (see\\nTable 35-2\\n on p. \\n336\\n). Treatment should be continued for several days after the pain and signs of\\ninflammation have resolved to prevent relapse.\\nOral colchicine\\n, a traditional therapy, often produces a dramatic response if begun soon after the onset\\nof symptoms. Joint pain generally begins to subside after 12 to 24 h of treatment and ceases within 3 to 7\\ndays. One regimen is colchicine 0.6 mg po q 1 h until symptoms abate to a maximum total dose of 4 to 5\\nmg or until diarrhea or vomiting occurs. However, diarrhea, sometimes severe, develops in up to 80% of\\npatients given this regimen of oral colchicine for an acute attack. If treatment is started very early,\\nregimens such as 0.6 to 1.2 mg bid to tid for 1 to 2 days are better tolerated and may be effective. If\\ncolchicine is tolerated, 0.6 to 1.2 mg once/day can be continued as the attack subsides.\\nIV colchicine\\n is much less likely to cause GI symptoms and provides an alternative, particularly for\\npostoperative patients. Colchicine 1 mg is diluted with 0.9% saline to 20 mL and injected slowly (over 2 to\\n5 min); a second 1-mg dose can be given in 12 h if needed; no more than 2 mg is given in 24 h (and no\\nmore than 4 mg over 7 days). \\nIV colchicine should not be given to patients with renal or liver disease\\nor those receiving prophylactic \\noral colchicine, because severe bone marrow suppression, shock, and\\ndeath may occur.\\n IV colchicine is also locally irritating, particularly if extravasated. Although effective and\\nperhaps the option of choice in certain specific situations, IV colchicine should only be used with careful\\nadherence to prescribing indications and contraindications.\\nCorticosteroids\\n are sometimes used to treat acute attacks; however, this use is controversial because\\ninflammation may continue while symptoms are masked. Aspiration of affected joints, followed by\\ninstillation of corticosteroid ester crystal suspension, is very effective, particularly for monarticular\\nsymptoms; prednisolone tebutate 4 to 40 mg or prednisolone acetate 5 to 25 mg can be used, with dose\\ndepending on the size of the affected joint. Oral prednisone (about 40 mg once/day), IM or IV\\ncorticosteroids, or single-dose ACTH 80 U IM is also very effective, particularly if multiple joints are\\ninvolved. As with NSAID therapy, corticosteroids should be continued until after the attack fully resolves to\\nprevent relapse.\\nIn addition to NSAIDs or corticosteroids, supplementary analgesics, rest, ice application, and splinting of\\nthe inflamed joint may be helpful. Because lowering the serum urate level during an attack prolongs the\\nattack or predisposes to recurrence, drugs that lower the serum urate level should not be initiated until\\nacute symptoms have been completely controlled.\\nPrevention of recurrent attacks:\\n The frequency of acute attacks is reduced by taking one to two 0.6-\\nmg tablets of colchicine daily (depending on tolerance and severity). An extra two or three 0.6-mg tablets\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 36. Crystal-Induced Arthritides\\n438'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 448, 'page_label': '439'}, page_content='of colchicine taken at the first suggestion of an attack may abort flares. A (reversible) neuropathy or\\nmyopathy can develop during chronic colchicine ingestion. This condition may occur in patients with renal\\ninsufficiency, in patients also receiving a statin or macrolide, or in patients with none of these risk factors.\\nAttack frequency can also be decreased with daily low-dose NSAIDs.\\nLowering the serum urate level:\\n Colchicine, NSAIDs, and corticosteroids do not retard the progressive\\njoint damage caused by tophi. Such damage can be prevented and, if present, reversed with urate-\\nlowering drugs. Tophaceous deposits are resorbed by lowering serum urate. Lowering serum urate may\\nalso decrease the frequency of acute arthritic attacks. This decrease is accomplished by\\n Blocking urate production with allopurinol\\n Increasing urate excretion with a uricosuric drug\\n Using both types of drugs together in severe tophaceous gout\\nUricase can also be given but is not yet routinely used. Uricase is an enzyme that converts urate to\\nallantoin, which is more soluble. IV uricase transiently lowers serum urate by a large amount.\\nHypouricemic therapy is indicated for patients with\\n Tophaceous deposits\\n Frequent or disabling attacks of gouty arthritis (eg, more than 2 attacks/yr or very severe attacks)\\ndespite prophylactic colchicine, an NSAID, or both\\n Gout with persistent serum urate  9 mg/dL\\n Urolithiasis\\n Multiple comorbidities (eg, peptic ulcer disease, chronic kidney disease) that are relative\\ncontraindications to the drugs used to treat acute attacks (NSAIDs or corticosteroids)\\nHyperuricemia is not usually treated in the absence of gout.\\nIf the goal of hypouricemic therapy is to dissolve tophi, the serum urate level should be lowered to 4.5\\nmg/dL (0.26 mmol/L), the saturation level at the normal temperature (31 C) of the bunion joint, or even\\nlower. If tophi do not need to be dissolved, a level of 5 to 6 mg/dL (0.30 to 0.36 mmol/L), which is below\\nthe level of saturation (> 7.0 mg/dL [> 0.41 mmol/L] at normal core body temperature and pH), is\\nacceptable. These target levels should be maintained indefinitely. Low levels are often difficult to\\nmaintain.\\nDrugs are effective in lowering serum urate; dietary restriction of purines is less effective, but high intake\\nof high-purine food and alcohol (beer in particular) should be avoided. Carbohydrate restriction and\\nweight loss can lower serum urate in patients with insulin resistance because high insulin levels suppress\\nurate excretion. Because acute attacks tend to develop during the first months of hypouricemic therapy,\\nsuch therapy should be started in conjunction with once or twice daily colchicine or NSAIDs and during a\\nsymptom-free period. Resolution of tophi may take many months even with maintenance of serum urate\\nat low levels. Serum urate should be measured periodically, usually monthly while determining required\\ndrug dosage and then yearly to confirm the effectiveness of therapy.\\nAllopurinol\\n, which inhibits urate synthesis, is the most commonly prescribed hypouricemic therapy. It is\\nespecially helpful in treating patients who repeatedly pass uric acid or Ca oxalate stones or who have\\nsevere renal dysfunction. Uric acid stones or gravel \\nmay dissolve during allopurinol treatment. Treatment\\nbegins with 100 mg po once/day and can be increased up to 800 mg po once/day, or even higher, to\\nachieve target urate levels; however, the dose must be decreased in patients with renal insufficiency. The\\nmost common daily dose is 300 mg. Adverse effects include mild GI distress and skin rash, which can be\\na harbinger of Stevens-Johnson syndrome, life-threatening hepatitis, vasculitis, or leukopenia. Adverse\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 36. Crystal-Induced Arthritides\\n439'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 449, 'page_label': '440'}, page_content='effects are more common among patients with renal dysfunction.\\nUricosuric therapy\\n is preferred to allopurinol as initial therapy for patients  60 yr with normal renal\\nfunction, no history of urolithiasis, and decreased renal urate excretion. Probenecid or sulfinpyrazone can\\nbe used. Probenecid treatment begins with 250 mg po bid, with doses increased as needed, to a\\nmaximum of 1 g po tid. Sulfinpyrazone treatment begins with 50 to 100 mg po bid, with doses increased\\nas needed, to a maximum of 100 mg po qid. Sulfinpyrazone is more potent than probenecid but is more\\ntoxic. Salicylates at low doses antagonize both drugs and can increase urate levels. Low doses may\\nworsen hyperuricemia, but a therapeutic trial of a cardioprotective dose while monitoring urate levels may\\nbe indicated for patients at high risk of cardiovascular disease. Acetaminophen provides comparable\\nanalgesia without interfering with drug efficacy.\\nOther treatments:\\n Fluid intake  3 L/day is desirable for all patients, especially those who chronically\\npass urate gravel or stones. Alkalinization of urine (with K citrate 20 to 40 mEq po bid or acetazolamide\\n500 mg po at bedtime) is also occasionally effective for patients with persistent uric acid urolithiasis\\ndespite hypouricemic therapy and adequate hydration. However, excessive urine alkalinization may cause\\ndeposition of Ca oxalate crystals. Extracorporeal shock wave lithotripsy may be needed to disintegrate\\nrenal stones. Large tophi in areas with healthy skin may be removed surgically; all others should slowly\\nresolve under adequate hypouricemic therapy. Losartan, which has uricosuric effects, can be considered\\nas an alternative to thiazide diuretics.\\nAsymptomatic Hyperuricemia\\nAsymptomatic hyperuricemia is elevation of serum urate > 7 mg/dL (> 0.42 mmol/L) in the absence of\\nclinical gout. Generally, treatment is not required. However, patients with overexcretion of urate who are\\nat risk of urolithiasis may receive allopurinol.\\nCalcium Pyrophosphate Dihydrate Crystal Deposition Disease\\n(Pseudogout)\\nCalcium pyrophosphate dihydrate (CPPD) crystal deposition disease involves intra-articular\\nand/or extra-articular deposition of CPPD crystals. Manifestations are protean and may be\\nminimal or include intermittent attacks of acute arthritis and a degenerative arthropathy that is\\noften severe. Diagnosis requires identification of CPPD crystals in synovial fluid. Treatment is\\nwith intra-articular corticosteroids or oral NSAIDs or colchicine.\\nCPPD crystal deposition (chondrocalcinosis), whether symptomatic and asymptomatic, becomes more\\ncommon with age.\\nThe incidence of radiologic (usually asymptomatic) chondrocalcinosis in patients aged 70 is about 3%,\\nreaching nearly 50% in patients aged 90. Asymptomatic chondrocalcinosis is common in the knee, hip,\\nanulus fibrosus, and symphysis pubis. Men and women are affected equally.\\nEtiology\\nThe cause is unknown. Frequent association with other conditions, such as trauma (including surgery),\\namyloidosis, myxedema, hypomagnesemia, hyperparathyroidism, gout, hemochromatosis, and old age,\\nsuggests that CPPD crystal deposits are secondary to degenerative or metabolic changes in the affected\\ntissues. Some cases are familial, usually transmitted in an autosomal dominant pattern, with complete\\npenetration by age 40.\\nSymptoms and Signs\\nAcute, subacute, or chronic arthritis can occur, usually in the knee or other large peripheral joints, which\\ncan mimic many other forms of arthritis. Attacks are sometimes similar to gout but are usually less severe.\\nThere may be no symptoms between attacks or continuous low-grade symptoms in multiple joints, similar\\nto RA or osteoarthritis. These patterns tend to persist for life.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 36. Crystal-Induced Arthritides\\n440'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 450, 'page_label': '441'}, page_content=\"Diagnosis\\n Synovial fluid analysis\\n Identification of crystals microscopically\\nCPPD crystal deposition disease should be suspected in older patients with arthritis, particularly\\ninflammatory arthritis. Diagnosis is established by identifying rhomboid or rod-shaped, weakly positively\\nbirefringent crystals on polarized light microscopy of synovial fluid (see \\nTable 36-1\\n). Coincident infectious\\narthritis must be ruled out by Gram stain and culture. X-rays are indicated if synovial fluid cannot be\\nobtained for analysis; findings of multiple linear or punctate calcification in articular cartilage, especially\\nfibrocartilages, support the diagnosis but do not exclude gout or infection.\\nPrognosis\\nThe prognosis for individual attacks is usually excellent. However, chronic arthritis can occur, and severe\\ndestructive arthropathy resembling neuropathic (Charcot's) joints occasionally occurs.\\nTreatment\\n Intra-articular corticosteroids\\n NSAIDs\\n Colchicine maintenance\\nSymptoms of acute synovial effusion abate with synovial fluid drainage and instillation of a\\nmicrocrystalline corticosteroid ester suspension into the joint space (eg, 40 mg prednisolone acetate or\\nprednisolone tertiary butylacetate into a knee). Indomethacin, naproxen, or another NSAID given at anti-\\ninflammatory doses (see \\nTable 35-2\\n on p. \\n336\\n) often stops acute attacks promptly. Colchicine 0.6 mg po\\nonce/day or bid may decrease the number of acute attacks.\\nBasic Calcium Phosphate and Calcium Oxalate Crystal Deposition Diseases\\nBasic Ca phosphate (apatite) and Ca oxalate crystal disorders tend to cause clinical manifestations\\nsimilar to other crystal-induced arthritides.\\nBasic Ca phosphate crystal deposition disease:\\n Most pathologic calcifications throughout the body\\ncontain mixtures of carbonate-substituted hydroxyapatite and octacalcium phosphate. Because these\\nultramicroscopic crystals are nonacidic Ca phosphates, the term basic Ca phosphate (BCP) is much more\\nprecise than apatite. These ultramicroscopic crystals occur in snowball-like clumps in rheumatic\\nconditions (eg, calcific tendinitis, calcific periarthritis, some cases of progressive systemic sclerosis and\\ndermatomyositis). They also occur in joint fluids of patients with all degenerative arthropathies sufficiently\\nadvanced to cause joint space narrowing on x-ray.\\nBCP crystals can destroy joints and can cause severe intra-articular or periarticular inflammation.\\nMilwaukee shoulder syndrome is one example, a profoundly destructive arthropathy affecting\\npredominantly elderly women that usually develops in the shoulders and (often) knees.\\nAcute podagra due to periarticular BCP deposition can mimic gout; it occurs as a discrete syndrome in\\nyoung women (less often in young men) and is treated the same as acute gout.\\nBesides synovial fluid analysis, x-rays should be taken of symptomatic joints. On x-ray, BCP crystals may\\nbe visible as periarticular cloudlike opacities. Definitive assay for BCP crystals in synovial fluid is not\\nreadily available. Clumped crystals can be identified only with transmission electron microscopy. The\\nclumps are not birefringent under polarized light.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 36. Crystal-Induced Arthritides\\n441\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 451, 'page_label': '442'}, page_content='Treatment with oral or IV colchicine, an NSAID, or, if a large joint is involved, intra-articular corticosteroid\\nester crystal suspension is helpful. Treatment is the same as that for acute gout (see p. \\n352\\n).\\nCa oxalate crystal deposition disease:\\n Ca oxalate crystal deposition is rare. It occurs most often in\\nazotemic patients receiving hemodialysis or peritoneal dialysis, particularly those treated with ascorbic\\nacid (vitamin C), which is metabolized to oxalate. Crystals may deposit in blood vessel walls and skin, as\\nwell as joints. The crystals appear as birefringent bipyramidal structures (see \\nTable 36-1\\n). Synovial fluid\\nmay have > 2000 WBC/\\n\\nL. On x-ray, Ca oxalate crystals are indistinguishable from BCP periarticular\\ncalcifications or Ca pyrophosphate dihydrate (CPPD) crystal deposits in cartilage. Treatment is the same\\nas that for CPPD crystals (see above).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 36. Crystal-Induced Arthritides\\n442'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 452, 'page_label': '443'}, page_content='Chapter 37. Osteoporosis\\nIntroduction\\nOsteoporosis is a progressive metabolic bone disease that decreases bone density (bone mass\\nper unit volume), with deterioration of bone structure. Skeletal weakness leads to fractures with\\nminor or inapparent trauma, particularly in the thoracic and lumbar spine, wrist, and hip. Acute\\nor chronic back pain is common. Diagnosis is by dual-energy x-ray absorptiometry. Prevention\\nand treatment involve Ca and vitamin D supplements, exercises to maximize bone and muscle\\nstrength and minimize the risk of falls, and drug therapy to preserve bone mass or stimulate\\nnew bone formation.\\nPathophysiology\\nNormally, bone formation and resorption are closely coupled. Osteoblasts (cells that make the organic\\nmatrix of bone and then mineralize bone) and osteoclasts (cells that resorb bone) are regulated by\\nparathyroid hormone (PTH), calcitonin, estrogen, vitamin D, various cytokines, and other local factors\\nsuch as prostaglandins.\\nPeak bone mass in men and women occurs by the mid 20s. Blacks reach higher bone mass than whites\\nand Asians, whereas Hispanics have intermediate values. Men have higher bone mass than women.\\nBone mass plateaus for about 10 yr, during which time bone formation approximately equals bone\\nresorption. After this, bone loss occurs at a rate of about 0.3 to 0.5%/yr. Beginning with menopause, bone\\nloss accelerates in women to about 3 to 5%/yr for about 5 to 7 yr.\\nOsteoporotic bone loss affects cortical and trabecular (cancellous) bone. Cortical thickness and the\\nnumber and size of trabeculae decrease, resulting in increased porosity. Trabeculae may be disrupted or\\nentirely absent.\\nClassification\\nOsteoporosis can develop as a primary disorder or secondarily due to some other factor.\\nPrimary osteoporosis:\\n More than 95% of osteoporosis in women and probably about 80% in men is\\nprimary. Most cases occur in postmenopausal women and older men. The terms postmenopausal,\\ninvolutional, senile, and age-related osteoporosis have been used to describe primary osteoporosis in\\nelderly patients. Estrogen deficiency is an important factor in men as well as women. Other contributing\\nfactors may include decreased Ca intake, low vitamin D levels, and secondary hyperparathyroidism.\\nThe major mechanism is increased bone resorption, which results in decreased bone mass and\\nmicroarchitectural deterioration, but other mechanisms also contribute not only in primary osteoporosis\\nbut also in the various secondary forms of osteoporosis. The mechanisms of bone loss may involve the\\nfollowing:\\n Local changes in the production of bone-resorbing cytokines, such as increases in cytokines that\\nstimulate bone resorption\\n Impaired formation response during bone remodeling (probably caused by age-related decline in the\\nnumber and activity of osteoblasts)\\n Other factors such as a decline in local and systemic growth factors\\nTrabecular bone loss occurs more rapidly than cortical bone loss because trabecular bone is more porous\\nand bone turnover is high. However, loss of both types contributes to skeletal fragility.\\nThe most common sites for fragility fractures are the distal radius (dorsally displaced fractures), spine\\n(vertebral compression fractures), femoral neck, and greater trochanter. Other sites include the proximal\\nhumerus and pelvis. Fragility fractures rarely occur in children or young adults with normal gonadal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 37. Osteoporosis\\n443'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 453, 'page_label': '444'}, page_content=\"function and no detectable secondary cause. This condition is called idiopathic osteoporosis.\\nSecondary osteoporosis:\\n Secondary osteoporosis accounts for < 5% of osteoporosis cases in women\\nbut probably more in men. The causes (see\\nTable 37-1\\n) may also aggravate bone loss and increase fracture risk in patients with primary\\nosteoporosis.\\nRisk Factors\\nBecause stress, including weight bearing, is necessary for bone growth, immobilization or extended\\nsedentary periods result in bone loss. Being thin predisposes to decreased bone mass. Insufficient\\ndietary intake of Ca, P, and vitamin D predisposes to bone loss, as does endogenous acidosis (eg, high-\\nprotein diets). Cigarette smoking and excessive caffeine or alcohol use also adversely affect bone mass.\\nWhites and Asians are at higher risk. A family history of osteoporosis also increases risk. Other risk\\nfactors (eg, decreasing\\n[\\nTable 37-1.\\n Causes of Secondary Osteoporosis]\\namounts of sex hormones) predispose to specific types of osteoporosis. Patients who have had one\\nfragility fracture are at increased risk of having other clinical (symptomatic) fractures as well as clinically\\nasymptomatic vertebral compression fractures.\\nSymptoms and Signs\\nMost of the chronic pain typical of osteoporosis results from fractures, which may develop after minimal,\\ninapparent, or no trauma. Patients may be asymptomatic for years, until fractures begin to occur.\\nEventually, patients often develop pain in the bones or muscles, particularly of the back. Vertebral\\ncompression fractures are common, usually in weight-bearing vertebrae (T6 and below). The pain begins\\nacutely, usually does not radiate, is aggravated by weight bearing, may cause local tenderness, and\\ngenerally begins to subside in 1 wk. However, residual pain may last for months or be constant.\\nMultiple thoracic compression fractures eventually cause dorsal kyphosis, with exaggerated cervical\\nlordosis (dowager's hump). Abnormal stress on the spinal muscles and ligaments may cause chronic, dull,\\naching pain, particularly in the lower back. Fractures can develop at other sites, commonly the hip or\\nwrist, usually from falls.\\nDiagnosis\\n Dual-energy x-ray absorptiometry (DEXA)\\nOsteoporosis should be suspected in patients who sustain fractures after only mild or trivial trauma; older\\nadults, particularly those with risk factors and unexplained back pain; patients with decreased bone\\ndensity that is incidentally noted on imaging studies; and patients at risk of secondary osteoporosis. If\\nimaging studies have been done or are necessary to evaluate symptoms (eg, back pain), osteoporosis\\nmay be obvious. However, imaging studies are often equivocal, and the diagnosis should be established\\nby bone density measurement.\\nPlain x-rays:\\n Bones show decreased radiodensity and loss of trabecular structure, but not until about\\n30% of bone has been lost. A loss of horizontally oriented trabeculae increases the prominence of the\\ncortical end plates and of vertically oriented, weight-bearing trabeculae. Loss of height and increased\\nbiconcavity characterize vertebral compression fractures. Thoracic vertebral fractures may cause anterior\\nwedging. In long bones, although the cortices may be thin, the periosteal surface remains smooth.\\nVertebral fractures at T4 or above suggest cancer rather than osteoporosis.\\nCorticosteroid-induced osteoporosis is likely to cause rib fractures and exuberant callus formation at sites\\nof healing fractures. Osteomalacia may cause abnormalities on imaging tests similar to those of\\nosteoporosis (see \\nSidebar 37-1\\n). Hyperparathyroidism can be differentiated when it causes subperiosteal\\nresorption or cystic bone lesions, but these are uncommon.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 37. Osteoporosis\\n444\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 454, 'page_label': '445'}, page_content='Bone density measurement:\\n DEXA is used to measure bone density. DEXA is diagnostic for\\nosteoporosis, predicts the risk of fracture, and can be used to follow treatment response. Bone density of\\nthe lumbar spine, hip, distal radius or ulna, or the entire body can be measured. (Quantitative CT\\nscanning can produce similar measurements in the spine or hip.) Usually, the lumbar spine, total proximal\\nfemur, or femoral neck is measured. DEXA results are reported as T scores. A T score corresponds to the\\nnumber of standard deviations by which bone density differs from a healthy, young person of the same\\nsex and race. A DEXA result of > 1 is defined as osteopenia and suggests an increased risk of\\nosteoporosis; > 2.5 is diagnostic for osteoporosis.\\nIf DEXA scanning of the central skeleton is unavailable, portable, less expensive systems such as\\nperipheral DEXA or quantitative ultrasonography of the heel can be used. However, monitoring the\\nresponse to treatment \\nwith serial measurements of bone density should be done only with central DEXA\\nscanning.\\nSidebar 37-1 Osteopenia: Differentiating Osteoporosis and Osteomalacia\\nOsteopenia is decreased bone mass. Two metabolic bone diseases decrease bone mass: osteoporosis\\nand osteomalacia. In osteoporosis, bone mass decreases, but the ratio of bone mineral to bone matrix is\\nnormal. In osteomalacia, the ratio of bone mineral to bone matrix is low.\\nOsteoporosis results from a combination of low peak bone mass, increased bone resorption, and\\nimpaired bone formation. Osteomalacia is due to impaired mineralization, usually because of severe\\nvitamin D deficiency or abnormal vitamin D metabolism (see p. \\n41\\n). Osteoporosis is much more common\\nthan osteomalacia in the US. The 2 disorders may coexist, and their clinical expression is similar;\\nmoreover, mild to moderate vitamin D deficiency can occur in osteoporosis.\\nCurrent central DEXA systems can also assess vertebral deformities in the lower thoracic and lumbar\\nspine, a procedure termed vertebral fracture analysis (VFA). Vertebral deformities, even those clinically\\nsilent, may indicate increased risk of future fractures. VFA is more likely to be useful in patients with loss\\nof  3 cm in height.\\nOther testing:\\n Once osteoporosis is diagnosed, patients should be checked for causes of secondary\\nosteoporosis. Serum Ca should be measured to rule out asymptomatic hyperparathyroidism. PTH levels\\nmay be increased in patients with decreased Ca absorption or hypercalciuria. Other tests such as thyroid-\\nstimulating hormone or free thyroxine to check for hyperthyroidism, vitamin D levels, measurements of\\nurinary free cortisol, and blood counts and other tests to rule out cancer, especially myeloma (eg, serum\\nprotein electrophoresis), should be considered depending on the clinical findings. Serum alkaline\\nphosphatase is usually normal but may be elevated by recent fracture.\\nPatients with weight loss should be screened for GI disorders as well as cancer. Bone biopsy is reserved\\nfor unusual cases (eg, young patients with pathologic fractures and no apparent cause). Levels of serum\\nor urine N-telopeptide crosslinks (NTX) or free deoxypyridinoline (DPYR) may reflect increased\\nbreakdown of collagen. These tests are not sufficiently accurate for routine clinical use but may be used\\nto assess the effectiveness of therapy.\\nScreening\\nDEXA screening is recommended for all women > 65. Bone density should also be measured in women\\nbetween 50 and 65 who have risk factors, including a family history of osteoporosis, a history of fragility\\nfractures, and low body weight. Screening is also recommended for both men and women who have had\\nfragility fractures, even at younger ages.\\nTreatment\\n Risk factor modification\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 37. Osteoporosis\\n445'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 455, 'page_label': '446'}, page_content=' Ca and vitamin D supplements\\n Bisphosphonates or sometimes other antiresorptive drugs\\nThe goals of treatment are to preserve bone mass, prevent fractures, decrease pain, and maintain\\nfunction.\\nPreserving bone mass:\\n The rate of bone loss can be slowed with drugs and, when possible,\\nmodification of risk factors. Ca and vitamin D intake and physical activity must be adequate for drug\\ntreatment to be effective.\\nRisk factor modification can include maintaining adequate body weight, increasing weight-bearing\\nexercise, minimizing caffeine and alcohol intake, and stopping smoking. The optimal amount of weight-\\nbearing exercise is not established, but an average of 30 min/day is recommended. A physical therapist\\ncan develop a safe exercise program.\\nAll men and women should consume at least 1000 mg of elemental Ca daily. An intake of 1200 to 1500\\nmg/day is recommended for postmenopausal women and older men and for periods of increased\\nrequirements, such as pubertal growth, pregnancy, and lactation. Diet alone is rarely adequate; Ca\\nsupplements are needed, most commonly as Ca carbonate or Ca citrate. Supplements differ in their\\nelemental Ca concentration. Ca citrate is better absorbed in patients with achlorhydria, but both are well\\nabsorbed when taken with meals. Ca should be taken in divided doses of 500 to 600 mg bid or tid.\\nVitamin D in doses of 800 U once/day is generally recommended, but up to 2000 U/day is safe and may\\nbe helpful in osteoporotic patients. Patients with vitamin D deficiency may need even higher doses.\\nSupplemental vitamin D is usually given as cholecalciferol, the natural form of vitamin D, although\\nergocalciferol, the synthetic plant derived form, is probably also acceptable.\\nBisphosphonates are first-line drug therapy. By inhibiting bone resorption, bisphosphonates preserve\\nbone mass and can decrease vertebral and hip fractures by 50%. To treat osteoporosis, bisphosphonates\\ncan be given orally. Alendronate can be given at doses of 10 mg po once/day or 70 mg po once/wk,\\nibandronate 2.5 mg po once/day or 150 mg once/mo, or risedronate at 5 mg po once/day or 35 mg\\nonce/wk. All increase bone mineral density and decrease risk of at least vertebral fractures. Oral\\nbisphosphonates must be taken on an empty stomach with a full glass of water, and the patient must\\nremain upright for  30 min. They can cause esophageal irritation. Esophageal disorders that delay transit\\ntime and symptoms of upper GI disorders are relative contraindications to oral bisphosphonates. Weekly\\nor monthly therapy is generally preferred for its greater convenience and probably fewer adverse effects.\\nParenteral zolendronate is an alternative to oral bisphosphonates. Doses of 5 mg IV once/year increase\\nbone mass and decrease risk of vertebral and nonvertebral fractures. Pamidronate can also be given IV\\nbut has not yet been shown to prevent fractures.\\nOsteonecrosis of the jaw has been associated with use of bisphosphonates; however, this condition is\\nrare in patients taking oral bisphosphonates. Risk factors include IV bisphosphonate use and cancer.\\nBisphosphonates may also be associated with atrial fibrillation, but the mechanism is not clear and there\\nhas been no association with increased cardiovascular mortality.\\nSalmon calcitonin is less effective than bisphosphonates for treating osteoporosis. The subcutaneous\\ndose is 100 IU/day or every other day; the nasal spray dose is 200 U/day in alternating nostrils (1 spray).\\nSalmon calcitonin may provide short-term analgesia after an acute fracture.\\nEstrogen can preserve bone density and prevent fractures. Most effective if started within 4 to 6 yr of\\nmenopause, estrogen may slow bone loss and possibly reduce fractures even when started much later. It\\nis usually given as conjugated estrogen 0.625 to 1.25 mg po once/day. However, 0.3 mg po once/day may\\nbe as effective. Use of estrogen increases the risk of thromboembolism and endometrial cancer and may\\nincrease the risk of breast cancer. The risk of endometrial cancer can be reduced in women with an intact\\nuterus by taking a progestin with estrogen (see p. \\n2519\\n). However, taking a combination of a progestin\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 37. Osteoporosis\\n446'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 456, 'page_label': '447'}, page_content='and estrogen increases the risk of breast cancer, coronary artery disease, stroke, and biliary disease.\\nRaloxifene is a selective estrogen receptor modulator (SERM) that may be appropriate for treatment of\\nosteoporosis in women who cannot take bisphosphonates. It reduces vertebral fractures by about 50%\\nbut has not been shown to reduce nonvertebral fractures. Raloxifene does not stimulate the uterus and\\nantagonizes estrogen effects in the breast, probably reducing the risk of breast cancer.\\nPTH, which stimulates new bone formation, is generally reserved for patients who have the following\\ncharacteristics:\\n Cannot tolerate antiresorptive drugs or have contraindications to their use\\n Fail to respond to antiresorptive drugs, as well as Ca, vitamin D, and exercise, developing new fractures\\nand loss of bone mineral density\\n Possibly have severe osteoporosis (eg, T score < 3.5)\\nWhen given daily by injection for an average of 20 mo, synthetic PTH (PTH 1-34; teriparatide) increases\\nbone mass and reduces risk of fractures.\\nPreventing fractures:\\n Many elderly patients are at risk of falls because of poor coordination, poor\\nvision, muscle weakness, confusion, and use of drugs that cause postural hypotension or alter the\\nsensorium. Educating patients about the risks of falls and fractures and developing individualized\\nprograms to increase physical stability and attenuate risk can help. Strengthening exercises may increase\\nstability. Hip pads can reduce the incidence of hip fracture despite continued falls.\\nTreating pain and maintaining function:\\n Acute back pain from a vertebral compression fracture should\\nbe treated with orthopedic support, analgesics, and (when muscle spasm is prominent) heat and massage\\n(see p.\\n3459\\n). Chronic backache may be relieved by an orthopedic garment and exercises to strengthen\\nparavertebral muscles. Avoiding heavy lifting can help. Bed rest should be minimized, and consistent,\\ncarefully designed weight-bearing exercise should be encouraged.\\nIn some cases, vertebroplasty, sometimes preceded by kyphoplasty, can relieve severe \\npain. In\\nvertebroplasty, methyl methacrylate is injected into the vertebral body. In kyphoplasty, the vertebral body\\nis expanded with a balloon. These procedures may reduce deformity in the injected vertebrae but do not\\nreduce and may even increase the risk of fractures in adjacent vertebrae. Other risks may include rib\\nfractures, cement leakage, and pulmonary edema or MI.\\nPrevention\\nThe goals of prevention are to preserve bone mass and prevent fractures. Preventive measures are\\nindicated in postmenopausal women and older men, patients taking long-term systemic corticosteroids,\\nand patients at high risk (eg, osteopenia with multiple risk factors or secondary causes).\\nPreventive measures are similar to treatment measures, including those aimed at preserving bone mass.\\nBisphosphonates and other drugs can be given as for treatment of osteoporosis, but alendronate is given\\nat a reduced dose (5 mg po once/day or 35 mg once/wk). Measures to prevent fractures are also\\nindicated.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 37. Osteoporosis\\n447'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 457, 'page_label': '448'}, page_content=\"Chapter 38. Paget's Disease of Bone\\nIntroduction\\n(Osteitis Deformans)\\nPaget's disease of bone is a chronic disorder of the adult skeleton in which bone turnover is\\naccelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The\\ndisease may be asymptomatic or cause gradual onset of bone pain or deformity. Diagnosis is by\\nx-ray. Treatment includes symptomatic measures and often drugs, usually bisphosphonates.\\nAbout 1% of adults in the US > 40 have Paget's disease, with a 3:2 male predominance. Prevalence\\nincreases with aging. However, overall prevalence seems to be decreasing. The disease is most common\\nin Europe (except Scandinavia), Australia, and New Zealand. It is particularly common in England.\\nEtiology\\nSeveral genetic abnormalities, many affecting osteoclast generation and activity, have been identified.\\nMutations of the \\nSequestrum 1\\n gene from chromosome 6 are commonly related to Paget's disease.\\nAppearance of involved bone on electron microscopy suggests a viral infection, but a viral cause has not\\nbeen established.\\nPathophysiology\\nAny bone can be involved. The bones most commonly affected are, in decreasing order, the pelvis, femur,\\nskull, tibia, vertebrae, clavicle, and humerus.\\nBone turnover is accelerated at involved sites. Pagetic lesions are metabolically active and highly\\nvascular. Excessively active osteoclasts are often large and contain many nuclei. Osteoblastic repair is\\nalso hyperactive, causing coarsely woven, thickened lamellae and trabeculae. This abnormal structure\\nweakens the bone, despite bone enlargement and heavy calcification.\\nComplications:\\n Overgrown bone may compress nerves and other structures passing through small\\nforamina. Spinal stenosis or spinal cord compression may develop. Osteoarthritis may develop in joints\\nadjacent to involved bone.\\nIn about 10 to 15% of patients, increased bone formation and Ca requirement leads to secondary\\nhyperparathyroidism; if this need is not matched by an increase in Ca intake, hypocalcemia may occur.\\nHypercalcemia (see p. \\n843\\n) occasionally develops in patients who are immobile. It also occurs in patients\\nwith Paget's disease who develop secondary hyperparathyroidism.\\nLarge or numerous lesions may lead to high-output heart failure.\\nSymptoms and Signs\\nThere are usually no symptoms for a prolonged period. If symptoms occur, they develop insidiously, with\\npain, stiffness, fatigue, and bone deformity. Bone pain is aching, deep, and occasionally severe,\\nsometimes worse at night. Pain also may arise from compression neuropathy or osteoarthritis. If the skull\\nis involved, there may be headaches and hearing impairment.\\nSigns may include skull enlargement bitemporally and frontally (frontal bossing); dilated scalp veins;\\nnerve deafness in one or both ears; angioid streaks in the fundus of the eye; a short kyphotic trunk with\\nsimian \\nappearance; hobbling gait; and anterolateral angulation (bowing) of the thigh or leg, often with\\nwarmth and tenderness. Deformities may develop from bowing of the long bones or osteoarthritis.\\nPathologic fractures may be the presenting manifestation. Sarcomatous degeneration develops in < 1%\\nand is often suggested by increasingly severe pain.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 38. Paget's Disease of Bone\\n448\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 458, 'page_label': '449'}, page_content=\"Diagnosis\\n Plain x-rays\\n Serum alkaline phosphatase, Ca, and PO\\n4\\n Bone scan after the diagnosis is established\\nPaget's disease should be suspected in patients with the following:\\n Unexplained bone pain or deformity\\n Suggestive findings on x-ray\\n Unexplained elevation of serum alkaline phosphatase on laboratory tests done for other reasons,\\nparticularly if \\n\\n-glutamyl-transpeptidase (GGT) is normal\\n Hypercalcemia that develops during bed rest, particularly among elderly patients\\n Bone sarcoma in elderly patients\\nIf Paget's disease is suspected, plain x-rays and serum alkaline phosphatase, Ca, and PO\\n4\\n levels should\\nbe obtained. Confirmation on x-ray is required to establish the diagnosis. Characteristic x-ray findings\\ninclude the following:\\n Increased bone sclerosis\\n Abnormal architecture with coarse cortical trabeculation or cortical thickening\\n Bowing\\n Bone enlargement\\nThere may be stress microfractures of the tibia or femur.\\nCharacteristic laboratory findings include elevated serum alkaline phosphatase (increased anabolic\\nactivity of bone) but usually normal GGT and serum PO\\n4\\n levels. Serum Ca is usually normal but can\\nincrease because of immobilization or hyperparathyroidism or decrease (often transiently) because of\\nincreased bone synthesis. If alkaline phosphatase is not elevated or it is unclear whether the increased\\nserum alkaline phosphatase is of bony origin (ie, if GGT is increased in proportion to alkaline\\nphosphatase), a bone-specific fraction can be measured.\\nOccasionally, increased catabolic activity of bone, as demonstrated by elevated urine markers of bone\\ncollagen turnover (eg, pyridinoline crosslinks), supplements the findings.\\nRadionuclide bone scan using technetium-labeled phosphonates should be done at baseline to determine\\nthe extent of bone involvement.\\nTreatment\\n Supportive care for symptoms and complications\\n Bisphosphonates\\nLocalized, asymptomatic disease requires no treatment. Symptomatic treatment includes\\n[\\nTable 38-1.\\n Drug Therapy for Paget's Disease]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 38. Paget's Disease of Bone\\n449\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 459, 'page_label': '450'}, page_content=\"analgesics or NSAIDs for pain. Orthotics help correct abnormal gait caused by bowed lower extremities.\\nSome patients require orthopedic surgery (eg, hip or knee replacement, decompression of the spinal\\ncord). Weight bearing should be encouraged, and bed rest should be avoided.\\nDrug therapy:\\n Drug therapy suppresses osteoclast activity. It is indicated for the following:\\n To prevent or reduce bleeding during orthopedic surgery\\n To prevent or retard progression of complications (eg, hearing loss, deformity, osteoarthritis, paraparesis\\nor paraplegia related to vertebral Paget's disease, or other neurologic deficits, particularly in a poor\\nsurgical candidate)\\n To treat pain clearly related to the pagetic process and not to another source (eg, osteoarthritis)\\n When serum alkaline phosphatase (of bony origin) is > 2 times the normal level, even in the absence of\\nsymptoms\\nAlthough disease progression can be retarded, existing deficits (eg, deformity, osteoarthritis, hearing loss,\\nneural impingement) are not reversed.\\nSeveral bisphosphonates are available and are the drugs of choice (see \\nTable 38-1\\n on p. \\n361\\n). Synthetic\\nsalmon calcitonin is an alternative to bisphosphonates for patients intolerant of or resistant to them. The\\nnewer bisphosphonates (amino-containing bisphosphonates, eg, zolendronate) seem to provide more\\nprolonged response.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 38. Paget's Disease of Bone\\n450\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 460, 'page_label': '451'}, page_content='Chapter 39. Osteonecrosis\\nIntroduction\\n(Avascular Necrosis; Aseptic Necrosis; Ischemic Necrosis of Bone)\\nOsteonecrosis (ON) is a focal infarct of bone that may be caused by specific etiologic factors or\\nmay be idiopathic. It can cause pain, limitation of motion, joint collapse, and osteoarthritis.\\nDiagnosis is by x-rays and MRI. In early stages, surgical procedures may slow or prevent\\nprogression. In later stages, joint replacement may be required for relief of pain and\\nmaintenance of function.\\nIn the US, ON affects about 20,000 new patients annually. The hip (femoral head) is most commonly\\naffected, followed by the knee and shoulder (humeral head). The wrist and ankle are less often involved.\\nIt is unusual for ON to involve the shoulder or other less commonly affected sites without the hip also\\nbeing involved.\\nEtiology\\nThe most common cause of ON is trauma. Nontraumatic ON affects men more often than women, is\\nbilateral in > 60% of cases, and occurs primarily in patients between ages 30 and 50.\\nTraumatic ON:\\n The most common cause of traumatic ON is a displaced subcapital fracture of the hip\\n(see p. \\n3211\\n); ON is uncommon after intertrochanteric fractures. The incidence of ON after hip dislocation\\nis high without prompt reduction; the sooner reduction occurs, the lower the incidence. Fracture or\\ndislocation may cause ON by grossly disrupting or compressing nearby blood vessels.\\nSpontaneous ON of the knee (SPONK) is localized ON of the femoral condyle or tibial plateau in elderly\\nwomen (occasionally men). SPONK is thought to be caused by an insufficiency fracture (a type of fragility\\nfracture caused by normal wear and tear on osteoporotic bone that occurs without direct trauma).\\nNontraumatic ON:\\n Factors causing or contributing to nontraumatic ON are listed in\\nTable 39-1\\n. The most common factors are the following:\\n Chronic corticosteroid use\\n Excessive alcohol consumption\\nThe risk of ON is increased when the dose of prednisone or an equivalent corticosteroid is > 25 mg/day\\nfor several weeks or months, resulting in a cumulative dose usually > 3000 mg. The risk of ON also is\\nincreased when > 3 drinks/day (> 500 mL ethanol/wk) are consumed for several years. Some genetic\\nfactors increase susceptibility to ON. Subtle clotting abnormalities due to deficiencies in protein C, protein\\nS, or antithrombin III or to anticardiolipin antibodies (see \\nCh. 110\\n) can be detected in a high percentage of\\npatients with ON. Some disorders that are themselves associated with ON are treated with corticosteroids\\n(eg, SLE), so it is not clear whether risk is increased because of corticosteroid use or the disorder. About\\n20% of cases are idiopathic.\\n[\\nTable 39-1.\\n Nontraumatic Risk Factors for Osteonecrosis]\\nON of the jaw has recently been reported in several patients who have received high-dose IV\\nbisphosphonate therapy (see \\nSidebar 39-1\\n). Nontraumatic ON of the hip is bilateral in 60% of patients.\\nPathophysiology\\nON involves the death of osteocytes and bone marrow. Mechanisms of nontraumatic ON may include\\nembolization by blood clots or lipid droplets, intravascular thrombosis, and extravascular compression.\\nAfter the vascular insult, the repair processes attempt to remove necrotic bone and marrow and replace\\nthem with viable tissue. If the infarct is small, particularly if it is not subject to major weight bearing, this\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 39. Osteonecrosis\\n451'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 461, 'page_label': '452'}, page_content='process may succeed. However, in about 80% of patients, the process is not successful and the infarct\\ngradually collapses. The overlying articular surface becomes flattened and irregular, causing increased\\npain and eventually leading to osteoarthritis.\\nSymptoms and Signs\\nGeneral symptoms:\\n Affected areas may remain asymptomatic for weeks to months after the vascular\\ninsult. Usually pain then develops gradually, although it may be acute. With progressive collapse of the\\njoint, pain increases and is exacerbated by motion and weight bearing and is relieved by rest.\\nJoint-specific symptoms:\\n ON of the hip causes groin pain that may radiate down the thigh or into the\\nbuttock. Motion becomes limited, and a limp usually develops. SPONK usually causes sudden knee pain\\nwithout preceding trauma. This pain is most often on the medial side of the femoral condyle or tibial\\nplateau and manifests with tenderness, joint effusion, painful motion, and a limp. ON of the humeral head\\noften causes less pain and disability than hip and knee involvement. With advanced disease, patients\\nhave pain and decreased motion, although passive range of motion is less affected than active range of\\nmotion.\\nSidebar 39-1 Osteonecrosis of the Jaw\\nOsteonecrosis of the jaw (ONJ) has no unanimously accepted definition but is generally held to be an\\noral lesion involving bare mandibular or maxillary bone, which usually manifests with pain and purulent\\ndischarge, although it may be asymptomatic. ONJ may occur spontaneously or after dental extraction or\\ntrauma, radiation therapy to the head and neck (osteoradionecrosis), or high-dose IV bisphosphonate\\ntherapy (eg, for cancer treatment). It is not clear whether routine use of oral bisphosphonates for\\ntreatment or prevention of osteoporosis increases risk of ONJ. Currently, otherwise appropriate\\nbisphosphonate use should not be discouraged. However, it seems reasonable to do any necessary oral\\nsurgery before beginning bisphosphonate therapy and to encourage good oral hygiene while patients are\\ntaking bisphosphonates.\\nOnce established, ONJ is challenging to treat and should be managed by an oral surgeon with\\nexperience treating ONJ. Treatment typically involves limited debridement, antibiotics, and oral rinses.\\nSurgical resection of the affected area may worsen the condition and should not be the initial treatment.\\nDiagnosis\\n X-rays\\n MRI\\nON should be suspected in patients with the following:\\n Fractures associated with an increased incidence of ON, particularly if pain persists or worsens\\n Persistent spontaneous hip, knee, or shoulder pain, particularly if risk factors for ON are present\\nPlain x-rays should be done initially. They may show no abnormalities for months. The earliest findings\\nare localized areas of sclerosis and lucency. Later, a subchondral crescent sign may appear. Then, gross\\ncollapse and flattening of the articular surface is seen, followed by advanced degenerative changes.\\nWhen x-rays are normal or nondiagnostic, an MRI, which is much more sensitive and more specific,\\nshould be done. Both hips should be imaged. Bone scans are less sensitive and less specific than MRI.\\nCT is rarely needed, although it may occasionally be of value to detect joint collapse, which does not\\nappear on plain x-rays.\\nLaboratory studies are usually normal and of little value in detecting ON. However, they might help detect\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 39. Osteonecrosis\\n452'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 462, 'page_label': '453'}, page_content='an underlying disorder (eg, coagulation defects, hemoglobinopathies, lipid abnormalities).\\nTreatment\\n Symptomatic measures (eg, rest, physical therapy, NSAIDs)\\n Surgical decompression or other procedures to stimulate healing\\n Hip replacement\\nNonsurgical treatments:\\n Small, asymptomatic lesions may heal spontaneously and may not need\\ntreatment.\\nLarger lesions, both symptomatic and asymptomatic, have a poor prognosis if untreated, especially when\\nin the femoral head. Therefore, early treatment to slow or prevent progression and save the joint is\\ndesirable. No completely effective treatment is yet available. Nonsurgical treatments include drugs (eg,\\nbisphosphonates) and physical modalities (eg, electromagnetic fields and acoustic waves). Drug therapy\\nand physical modalities have shown promise in limited studies but are not currently in general use.\\nSurgical treatments:\\n Surgical treatments are most effective when done before joint collapse. They have\\nbeen used most often in treating ON of the hip when the prognosis without treatment is worse than that\\nfor other regions. Core decompression is the procedure most frequently done; one or more cores of bone\\nare removed from the necrotic region or multiple small tracks or perforations are made in an attempt to\\ndecrease intraosseous pressure and stimulate repair. Core decompression is technically simple, and the\\ncomplication rate is very low if the procedure is done correctly. Protected weight bearing is needed for\\nabout 6 wk. Most reports indicate satisfactory or good results in 65% of patients, including those whose\\nhips have some degree of collapse, and in 80% of patients whose hips have small, early lesions. Other\\nestablished procedures include various proximal femoral osteotomies and bone grafting, both\\nvascularized and nonvascularized. These procedures are technically demanding, require protected\\nweight bearing for up to 6 mo, and have not been done often in the US. Reports vary as to their\\nindications and effectiveness. They should be done primarily at selected centers that have the surgical\\nexperience and facilities to achieve optimal results. An approach currently being evaluated is injection of\\nautologous marrow into the necrotic lesion.\\nIf extensive collapse of the femoral head and degenerative changes in the acetabulum cause sufficient\\npain and disability, an arthroplasty usually is the only way to effectively relieve pain and increase range of\\nmotion. The conventional approach is total hip replacement. Good to excellent results are achieved in\\n95% of total hip and total knee replacements, complication rates are low, and patients resume most\\nactivities of daily living within 3 mo. Most prosthetic hips and knees last > 15 to 20 yr.\\nTwo alternatives under investigation include surface replacement arthroplasty (SRA) and hemi-SRA. SRA,\\nwhich can be done instead of total hip replacement, involves the insertion of 2 metal caps, one into the\\nacetabulum and one onto the femoral head, producing a metal-on-metal articulation. Hemi-SRA involves\\nplacement of a metal cap onto only the femoral head. It is done only if disease is limited to the femoral\\nhead and is considered a temporizing procedure.\\nON of the knee and shoulder can be managed nonsurgically more often than ON of the hip. Limited\\nexperience with core decompression has been promising. In advanced stages, partial or total joint\\nreplacement may be indicated.\\nPrevention\\nRisk of ON caused by corticosteroids can be minimized by using them only when essential and by giving\\nthem in as low a dose as needed and for as short a duration as possible. To prevent ON caused by\\ndecompression sickness, people should follow accepted rules for decompression when diving and when\\nworking in pressurized environments. Excessive alcohol use and smoking should be discouraged. Various\\ndrugs (eg, anticoagulants, vasodilators, lipid-lowering drugs) are being evaluated for prevention of ON in\\npatients at high risk.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 39. Osteonecrosis\\n453'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 463, 'page_label': '454'}, page_content='The Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 39. Osteonecrosis\\n454'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 464, 'page_label': '455'}, page_content='Chapter 40. Infections of Joints and Bones\\nAcute Infectious Arthritis\\nAcute infectious arthritis is a joint infection that evolves over hours or days. The infection\\nresides in synovial or periarticular tissues and is usually bacterialin younger adults,\\nfrequently \\nNeisseria gonorrhoeae\\n. However, nongonococcal bacterial infections can also occur\\nand can rapidly destroy joint structures. Symptoms include rapid onset of pain, effusion, and\\nrestriction of both active and passive range of motion, usually within a single joint. Diagnosis\\nrequires synovial fluid analysis and culture. Treatment is IV antibiotics and drainage of pus from\\njoints.\\nAcute infectious arthritis may occur in children. About 50% of children with joint infection are < 3 yr.\\nHowever, routine childhood vaccination for \\nHaemophilus influenzae\\n and \\nStreptococcus pneumoniae\\n is\\ndecreasing the incidence in this age group.\\nRisk factors are listed in\\nTable 40-1\\n. Risk is substantially increased in patients with RA and other disorders causing chronic joint\\ndamage, a past history of joint infection, IV drug abuse, or a prosthetic joint (see p. \\n370\\n). RA patients are\\nat particular risk of bacterial arthritis (prevalence 0.3 to 3.0%; annual incidence 0.5%). Most children who\\ndevelop infectious arthritis do not have identified risk factors.\\nEtiology\\nInfectious organisms reach joints by direct penetration (eg, trauma, surgery, arthrocentesis, bites),\\nextension from an adjacent infection (eg, osteomyelitis, a soft-tissue abscess, an infected wound), or\\nhematogenous spread from a remote site of infection.\\n[\\nTable 40-1.\\n Risk Factors for Infectious Arthritis]\\nCommon organisms are listed in\\nTable 40-2\\n. In adults, most cases result from bacteria and are classified as gonococcal or nongonococcal.\\nIn adults overall, \\nStaphylococcus aureus\\n tends to be the most frequent cause of infectious arthritis.\\nMethicillin resistance has become more common among community isolates of \\nS. aureus\\n. In young adults\\nand adolescents, \\nNeisseria gonorrhoeae\\n is the most common cause and results when \\nN. gonorrhoeae\\n[\\nTable 40-2.\\n Organisms that Commonly Cause Acute Infectious Arthritis]\\nspreads from infected mucosal surfaces (cervix, urethra, rectum, pharynx) via the bloodstream. Affected\\npatients often have simultaneous genital infections with \\nChlamydia trachomatis\\n (see p. \\n1468\\n).\\nStreptococcus\\n species are also frequent causes, particularly in patients with polyarticular infections.\\nPathophysiology\\nInfecting organisms multiply in the synovial fluid and synovial lining. Some bacteria (eg, \\nS. aureus\\n)\\nproduce virulence factors (adhesins), which allow bacteria to penetrate, remain within, and infect joint\\ntissues. Other bacterial products (eg, endotoxin from gram-negative organisms, cell wall fragments,\\nexotoxins from gram-positive organisms, immune complexes formed by bacterial antigens and host\\nantibodies) augment the inflammatory reaction.\\nPMNs migrate into the joint and phagocytose the infecting organisms. Phagocytosis of bacteria also\\nresults in PMN autolysis with release of lysosomal enzymes into the joint, which damage synovia,\\nligaments, and cartilage. Therefore, PMNs are both the major host defense system and the cause of joint\\ndamage. Articular cartilage can be destroyed within hours or days. Inflammatory synovitis may\\noccasionally persist even after the infection has been eradicated by antibiotics. Particularly in gonococcal\\ncases, persistent antigen debris from bacteria or infection may alter cartilage, causing it to become\\nantigenic, andtogether with the adjuvant effects of bacterial componentsimmune-mediated, \"sterile\"\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 40. Infections of Joints & Bones\\n455'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 465, 'page_label': '456'}, page_content='chronic inflammatory synovitis results.\\nSymptoms and Signs\\nOver a few hours to a few days, patients develop moderate to severe joint pain, warmth, tenderness,\\neffusion, restricted active and passive motion, and sometimes redness. Systemic symptoms may be\\nminimal or absent. Infants and children may present with limited spontaneous movement of a limb\\n(pseudoparalysis), irritability, feeding disturbances, and a high, low-grade, or no fever.\\nGonococcal arthritis:\\n Gonococcal arthritis can cause a distinctive dermatitis-polyarthritistenosynovitis\\nsyndrome. Classic manifestations are fever (for 5 to 7 days); shaking chills; multiple skin lesions\\n(petechiae, papules, pustules, hemorrhagic vesicles or bullae, necrotic lesions) on mucosal surfaces and\\non the skin of the trunk, hands, or lower extremities; and migratory arthralgias, arthritis, and tenosynovitis,\\nwhich evolves into persistent inflammatory arthritis in one or more joints, most often the small joints of the\\nhands, wrists, elbows, knees, and ankles, and rarely the axial skeletal joints. Symptoms of the original\\nmucosal infection (eg, urethritis, cervicitis) may not be present.\\nNongonococcal bacterial arthritis:\\n Nongonococcal bacterial arthritis causes progressive moderate to\\nsevere joint pain that is markedly worsened by movement or palpation. Most infected joints are swollen,\\nred, and warm. Fever is absent or low grade in up to 50% of patients; 20% of patients report a shaking\\nchill. Virulent organisms (eg, \\nS. aureus, Pseudomonas aeruginosa\\n) generally cause a more fulminant\\narthritis, whereas less virulent organisms (eg, coagulase-negative staphylococci, \\nPropionibacterium\\nacnes\\n) cause a less fulminant arthritis. In 80% of adults, nongonococcal bacterial arthritis is monarticular\\nand usually occurs in a peripheral joint: knee, hip, shoulder, wrist, ankle, or elbow. In children,  90% is\\nmonarticular: knee (39%), hip (26%), and ankle (13%). Polyarticular \\ninvolvement is somewhat more\\ncommon among patients who are immunosuppressed or have an underlying chronic arthritis (eg, RA,\\nosteoarthritis). In IV drug users and patients with indwelling vascular catheters, axial joints (eg,\\nsternoclavicular, costochondral, hip, shoulder, vertebral, symphysis pubis, sacroiliac) are often involved.\\nInfectious arthritis secondary to bite wounds:\\n Infection due to human, dog, or cat bites usually\\ndevelops within 48 h. Rat bites cause systemic symptoms such as fever, rash, and joint pain or true\\narthritis with regional adenopathy within about 2 to 10 days.\\nViral infectious arthritis:\\n Viral infectious arthritis sometimes causes symptoms similar to acute\\nnongonococcal bacterial arthritis and is more likely to be polyarticular than bacterial arthritis.\\nBorrelia burgdorferi\\n arthritis:\\n Patients with \\nB. burgdorferi\\n arthritis may have other symptoms of Lyme\\ndisease (see p. \\n1269\\n) or present only with acute monarthritis or oligoarthritis.\\nDiagnosis\\n Arthrocentesis with synovial fluid examination and culture\\n Blood culture\\n Sometimes imaging studies\\n Often CBC and ESR (or C-reactive protein)\\nInfectious arthritis is suspected in patients with acute monarticular arthritis and in patients with other\\ncombinations of symptoms characteristic of particular infectious arthritis syndromes (eg, migratory\\npolyarthritis, tenosynovitis and skin lesions typical of disseminated gonococcal infection; erythema\\nmigrans or other symptoms and signs of Lyme diseasesee p. \\n1269\\n). Even mild monarticular joint\\nsymptoms should arouse suspicion in patients with risk factors (eg, RA), a prosthetic joint, or an extra-\\narticular infection capable of spreading to a joint (eg, genital gonococcal infection, bacteremia, any\\nanaerobic infection).\\nGeneral arthritis: Synovial fluid examination\\n is the cornerstone of diagnosis. Fluid is examined\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 40. Infections of Joints & Bones\\n456'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 466, 'page_label': '457'}, page_content='grossly and sent for cell count and differential, Gram stain, aerobic and anaerobic culture, and crystals.\\nFoul-smelling synovial fluid suggests anaerobic infection. Fluid from an acutely infected joint usually\\nreveals a WBC count > 20,000/\\n\\nL (often > 100,000/\\n\\nL) consisting of > 95% PMNs. WBC counts tend to\\nbe higher in nongonococcal bacterial than in gonococcal infectious arthritis. WBC counts may also be\\nlower in early or partially treated infections. Gram stain reveals organisms in only 50 to 75% of joints with\\nacute bacterial arthritis, most often with staphylococci. If positive, Gram stain is usually relatively specific,\\nbut cultures are definitive. The presence of crystals does not exclude infectious arthritis. Sometimes\\nsynovial fluid analysis cannot differentiate between infectious and other inflammatory synovial fluid. If\\ndifferentiation is impossible by clinical means or synovial fluid examination, infectious arthritis is assumed,\\npending culture results.\\nBlood tests\\n, such as blood cultures, CBC, and ESR (or C-reactive protein), are usually obtained.\\nHowever, normal results do not exclude infection. Likewise, WBC count, ESR, or C-reactive protein may\\nbe increased in noninfectious as well as infectious joint inflammation.\\nPlain x-rays\\n of the involved joint are not diagnostic of acute infection but can exclude other conditions\\nunder consideration (eg, fractures). Abnormalities in early acute bacterial arthritis are limited to soft-tissue\\nswelling and signs of synovial effusions. After 10 to 14 days of untreated bacterial infection, destructive\\nchanges of joint space narrowing (reflecting cartilage destruction) and erosions or foci of subchondral\\nosteomyelitis may appear. Gas visible within the joints suggests infection with \\nEscherichia coli\\n or\\nanaerobes.\\nMRI\\n is considered if the joint is not easily accessible for examination and aspiration (eg, an axial joint).\\nMRI or ultrasonography can identify sites of effusion or abscess that can be aspirated or drained for both\\ndiagnosis and therapy. MRI can provide early suggestion of associated osteomyelitis. Bone scans using\\ntechnetium-99m can be falsely negative in infectious arthritis. Also, because they show increased uptake\\nwith increased blood flow in inflamed synovial membranes and in metabolically active bone, they can be\\nfalsely positive in noninfectious inflammatory arthritis. Nuclear imaging and MRI do not distinguish\\ninfection from crystal-induced arthritis.\\nGonococcal arthritis:\\n If gonococcal arthritis is suspected, blood and synovial fluid samples should be\\nimmediately\\n plated on nonselective chocolate agar, and specimens from the urethra, endocervix, rectum,\\nand pharynx should be plated on selective Thayer-Martin medium. Genital chlamydial cultures are also\\ndone. Blood cultures are positive in 60 to 75% of cases during the first week and may be the only method\\nby which to identify the organism; cultures from joints with early tenosynovitis or arthritis are often\\nnegative. Synovial fluid cultures from joints with frank purulent arthritis are usually positive, and \\nfluid from\\nskin lesions may be positive. If disseminated gonococcal infection is suspected based on clinical criteria,\\nit is assumed to be present even if all gonococcal cultures are negative. Clinical response to antibiotics\\n(anticipated within 5 to 7 days) can help confirm the diagnosis.\\nPrognosis\\nAcute nongonococcal bacterial arthritis can destroy articular cartilage, permanently damaging the joint\\nwithin hours or days. Gonococcal arthritis does not usually damage joints permanently. Factors that\\nincrease susceptibility to infectious arthritis may also increase disease severity. In patients with RA,\\nfunctional outcome is particularly poor, and the mortality rate is increased.\\nTreatment\\n IV antibiotics\\n Drainage of pus from infected joints (for acute nongonococcal bacterial arthritis or any septic arthritis\\nwith persistent effusion\\nAntibiotic therapy:\\n Initial antibiotic selection is directed at the most likely pathogens. The regimen is\\nadjusted based on the results of culture and susceptibility testing.\\nGonococcal arthritis is treated with ceftriaxone 1 g IV once/day until at least 24 h after symptoms and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 40. Infections of Joints & Bones\\n457'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 467, 'page_label': '458'}, page_content='signs resolve, followed by cefixime 400 mg po bid for 7 days. Joint drainage and debridement may be\\nunnecessary. Coexisting genital infection with \\nC. trachomatis\\n is also treated, often with doxycycline 100\\nmg po bid for 7 days, and sexual contacts of the patient are treated as necessary (see p. \\n1470\\n).\\nIf nongonococcal gram-positive infection is suspected by Gram stain in an adult, the empiric choice is one\\nof the following: a semisynthetic penicillin (eg, nafcillin 2 g IV q 4 h), a cephalosporin (eg, cefazolin 2 g IV\\nq 8 h), or vancomycin 1 g IV q 12 h (if methicillin resistance is common among local community isolates of\\nS. aureus\\n). If gram-negative infection is suspected, empiric treatment includes a parenteral 3rd-\\ngeneration cephalosporin with antipseudomonal activity (eg, ceftazidime 2 g IV q 8 h) and, if infection is\\nsevere, an aminoglycoside.\\nParenteral antibiotics are continued until clinical improvement is clear (usually 2 to 4 wk), and oral\\nantibiotics should be given at high doses for another 2 to 6 wk according to the clinical response.\\nInfections caused by streptococci and \\nHaemophilus\\n are usually eradicated after 2 wk of oral antibiotics\\nafter IV treatment. Staphylococcal infections require at least 3 wk and often 6 wk or longer, especially in\\npatients with prior arthritis.\\nOther therapies:\\n In addition to antibiotics, acute nongonococcal bacterial arthritis requires large-bore\\nneedle aspiration of intra-articular pus at least once/day, or tidal irrigation lavage, arthroscopic lavage, or\\narthrotomy for debridement. Infected RA joints should generally undergo even earlier and more\\naggressive surgical debridement and drainage. For gonococcal arthritis with persistent effusion, pus is\\naspirated and drainage may need to be repeated as necessary. Acute bacterial arthritis requires joint\\nsplinting for the first few days to reduce pain, followed by passive and active range-of-motion exercises to\\nlimit contractures, with muscle strengthening as soon as tolerated. NSAIDs can help decrease pain and\\ninflammation.\\nViral arthritis and arthritis secondary to bite wounds:\\n Viral arthritis is treated supportively. Bite\\nwounds are treated with antibiotics and surgical drainage as necessary (see p. \\n3307\\n).\\nChronic Infectious Arthritis\\nChronic infectious arthritis develops over weeks and is usually caused by mycobacteria, fungi,\\nor bacteria with low pathogenicity.\\nChronic infectious arthritis accounts for 5% of infectious arthritis. It can develop in healthy people, but\\npatients at increased risk include those with\\n RA\\n HIV infection\\n Immunosuppression (eg, hematologic or other cancers, immunosuppressive drug use)\\n Prosthetic joints (see p. \\n370\\n)\\nExamples of possible causes are \\nMycobacterium tuberculosis, M. marinum, M. kansasii, Candida\\n sp,\\nCoccidioides immitis, Histoplasma capsulatum, Cryptococcus neoformans, Blastomyces dermatitidis,\\nSporothrix schenckii, Aspergillus fumigatus, Actinomyces israelii\\n, and \\nBrucella\\n sp. The arthritis of Lyme\\ndisease is usually acute but may be chronic and recurrent. Unusual opportunistic organisms are possible\\nin patients with hematologic cancers or HIV infection or who are taking immunosuppressive drugs. In\\nchronic infectious arthritis, the synovial membrane can proliferate and can erode articular cartilage and\\nsubchondral bone.\\nOnset is often indolent, with gradual swelling, mild warmth, minimal or no redness of the joint area, and\\naching pain that may be mild. Usually a single joint is involved. A prolonged duration and lack of response\\nto conventional antibiotics suggest a mycobacterial or fungal cause.\\nPatients should have fungal and mycobacterial cultures taken of synovial fluid or synovial tissue, as well\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 40. Infections of Joints & Bones\\n458'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 468, 'page_label': '459'}, page_content='as routine studies. Plain x-ray findings may differ from those of acute infectious arthritis in that joint space\\nis preserved longer, and marginal erosions and bony sclerosis may occur. Mycobacterial and fungal joint\\ninfections require prolonged treatment. Mycobacterial infections are often treated with multiple antibiotics,\\nguided by sensitivity testing results.\\nProsthetic Joint Infectious Arthritis\\nProsthetic joints are at risk of acute and chronic infection, which can cause sepsis, morbidity, or\\nmortality.\\nEtiology\\nInfections are more common in prosthetic joints. They are frequently caused by perioperative inoculations\\nof bacteria into the joint or by postoperative bacteremia resulting from skin infection, pneumonia, dental\\nprocedures, invasive instrumentation, UTI, or possibly falls. They develop within 1 yr of surgery in two\\nthirds of cases. During the first few months after surgery, the causes are \\nStaphylococcus aureus\\n in 50%\\nof cases, mixed flora in 35%, gram-negative organisms in 10%, and anaerobes in 5%.\\nSymptoms and Signs\\nThere is a history of a fall within 2 wk of symptom onset in about 25% of patients and of prior surgical\\nrevisions in about 20%. Some patients have had a postoperative wound infection that appeared to\\nresolve, satisfactory postoperative recovery for many months, and then development of persistent joint\\npain at rest and during weight bearing. Symptoms and signs may include pain, swelling, and limited\\nmotion; temperature may be normal.\\nDiagnosis\\n Clinical, microbiologic, pathologic, and radiographic criteria\\nThe diagnosis often uses a combination of clinical, microbiologic, pathologic, and radiographic criteria.\\nCommunication between a sinus tract and the prosthesis may also be considered diagnostic of infection.\\nSynovial fluid should be sampled for cell count and culture. X-rays may show loosening of the prosthesis\\nor periosteal reaction but are not diagnostic. Technetium-99m bone scanning and indium-labeled WBC\\nscanning are more sensitive than plain x-rays but may lack specificity in the immediate postoperative\\nperiod. Ultimately, periprosthetic tissue collected at the time of surgery may be sent for culture and\\nhistologic analysis.\\nTreatment\\n Arthrotomy with debridement\\n Long-term systemic antibiotic therapy\\nTreatment must be prolonged and usually involves arthrotomy for prosthesis removal with meticulous\\ndebridement of all cement, abscesses, and devitalized tissues. Debridement is followed by immediate\\nprosthesis revision or placement of an antibiotic-impregnated spacer and then delayed (2 to 4 mo)\\nimplantation of a new prosthesis using antibiotic-impregnated cement. Long-term systemic antibiotic\\ntherapy is used in either case; empiric therapy is initiated after intraoperative culture is done and usually\\ncombines coverage for methicillin-resistant gram-positive organisms (eg, vancomycin 1 g IV q 12 h) and\\naerobic gram-negative organisms (eg, piperacillin/tazobactam 3.375 g IV q 6 h or ceftazidime 2 g IV q 8 h)\\nand is revised based on results of culture and sensitivity testing. Infection develops in 38% of new\\nimplants, whether replaced immediately or after delay.\\nIf patients cannot tolerate surgery, long-term antibiotic therapy alone can be tried. Excision arthroplasty\\nwith or without fusion usually is reserved for patients with uncontrolled infection and insufficient bone\\nstock.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 40. Infections of Joints & Bones\\n459'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 469, 'page_label': '460'}, page_content='Prevention\\nIn the absence of other indications (eg, valvular heart disease), patients with prosthetic joints do not need\\nprophylactic antibiotics before procedures such as dental work and urologic instrumentation. Detailed\\nrecommendations are available at www.aaos.org\\n.\\nOsteomyelitis\\nOsteomyelitis is inflammation and destruction of bone caused by bacteria, mycobacteria, or\\nfungi. Common symptoms are localized bone pain and tenderness with constitutional\\nsymptoms (in acute osteomyelitis) or without constitutional symptoms (in chronic\\nosteomyelitis). Diagnosis is by imaging studies and cultures. Treatment is with antibiotics and\\nsometimes surgery.\\nEtiology\\nOsteomyelitis is caused by\\n Contiguous spread (from infected tissue or an infected prosthetic joint)\\n Bloodborne organisms (hematogenous osteomyelitis)\\n Open wounds (from contaminated open fractures or bone surgery)\\nTrauma, ischemia, and foreign bodies predispose to osteomyelitis. Osteomyelitis may form under deep\\ndecubitus ulcers.\\nAbout 80% of osteomyelitis results from contiguous spread or from open wounds; it is often polymicrobial.\\nStaphylococcus aureus\\n (including both methicillin-sensitive and methicillin-resistant strains) is present in\\n 50%; other common bacteria include streptococci, gram-negative enteric organisms, and anaerobic\\nbacteria. Osteomyelitis that results from contiguous spread is common in the feet (in patients with\\ndiabetes or peripheral vascular disease), at sites where bone was penetrated during trauma or surgery, at\\nsites damaged by radiation therapy, and in bones contiguous to decubitus ulcers, such as the hips and\\nsacrum. A sinus, gum, or tooth infection may spread to the skull.\\nHematogenously spread osteomyelitis usually results from a single organism. In children, gram-positive\\nbacteria are most common, usually affecting the metaphyses of the tibia, femur, or humerus.\\nHematogenously spread osteomyelitis in adults usually affects the vertebrae. Risk factors in adults are\\nolder age, debilitation, hemodialysis, sickle cell disease, and IV drug use. Common infecting organisms\\ninclude \\nS. aureus\\n (methicillin-resistant \\nS. aureus\\n [MRSA] is common) and enteric gram-negative bacteria\\n(in adults who are older, debilitated, or receiving hemodialysis); \\nS. aureus\\n, \\nPseudomonas aeruginosa\\n,\\nand \\nSerratia\\n sp (in IV drug users); and \\nSalmonella\\n sp (in patients with sickle cell disease). Fungi and\\nmycobacteria can cause hematogenous osteomyelitis, usually in immunocompromised patients or in\\nareas of endemic infection with histoplasmosis, blastomycosis, or coccidioidomycosis. The vertebrae are\\noften involved.\\nPathophysiology\\nOsteomyelitis tends to occlude local blood vessels, which causes bone necrosis and local spread of\\ninfection. Infection may expand through the bone cortex and spread under the periosteum, with formation\\nof subcutaneous abscesses that may drain spontaneously through the skin. In vertebral osteomyelitis,\\nparavertebral or epidural abscess can develop.\\nIf treatment of acute osteomyelitis is only partially successful, low-grade chronic osteomyelitis develops.\\nSymptoms and Signs\\nPatients with acute osteomyelitis of peripheral bones usually experience weight loss, fatigue, fever, and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 40. Infections of Joints & Bones\\n460'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 470, 'page_label': '461'}, page_content='localized warmth, swelling, erythema, and tenderness.\\nVertebral osteomyelitis causes localized back pain and tenderness with paravertebral muscle spasm that\\nis unresponsive to conservative treatment. Patients are usually afebrile.\\nChronic osteomyelitis causes intermittent (months to many years) bone pain, tenderness, and draining\\nsinuses.\\nDiagnosis\\n ESR or C-reactive protein\\n X-rays, MRI, or radioisotopic bone scanning\\n Culture of bone, abscess, or both\\nAcute osteomyelitis is suspected in patients with localized peripheral bone pain, fever, and malaise or with\\nlocalized refractory vertebral pain, particularly in patients with recent risk factors for bacteremia. Chronic\\nosteomyelitis is suspected in patients with persistent localized bone pain, particularly if they have risk\\nfactors.\\nIf osteomyelitis is suspected, CBC and ESR or C-reactive protein, as well as plain x-rays of the affected\\nbone, are obtained. The WBC count may not be elevated, but the ESR and C-reactive protein usually\\nare. X-rays become abnormal after 2 to 4 wk, showing periosteal elevation, bone destruction, soft-tissue\\nswelling, and, in the vertebrae, loss of vertebral body height or narrowing of the adjacent infected\\nintervertebral disk space and destruction of the end plates above and below the disk.\\nIf x-rays are equivocal or symptoms are acute, CT and MRI are the current imaging techniques of choice\\nto define abnormalities and reveal abscesses (eg, paravertebral or epidural abscesses). Alternatively, a\\nradioisotope bone scan with technetium-99m can be done. The bone scan shows abnormalities earlier\\nthan plain x-rays but does not distinguish among infection, fractures, and tumors. A white blood cell scan\\nusing indium-111-labeled cells may help to better identify areas of infection seen on bone scan.\\nBacteriologic diagnosis is necessary for optimal therapy of \\nosteomyelitis; bone biopsy with a needle or\\nsurgical excision and aspiration or debridement of abscesses provides tissue for culture and antibiotic\\nsensitivity testing. Culture of sinus drainage does not necessarily reveal the bone pathogen. Biopsy and\\nculture should precede antibiotic therapy unless the patient is in shock or has neurologic dysfunction.\\nTreatment\\n Antibiotics\\n Surgery for abscess, constitutional symptoms, potential spinal instability, or much necrotic bone\\nAntibiotics effective against both gram-positive and gram-negative organisms are given until culture\\nresults and sensitivities are available. Initial antibiotic treatment for acute hematogenous osteomyelitis\\nshould include a penicillinase-resistant semisynthetic penicillin (eg, nafcillin or oxacillin 2 g IV q 4 h) or\\nvancomycin 1 g IV q 12 h (when MRSA is prevalent in a community) and a 3rd- or 4th-generation\\ncephalosporin (such as ceftazidime 2 g IV q 8 h or cefepime 2 g IV q 12 h). Empiric treatment of chronic\\nosteomyelitis arising from a contiguous soft-tissue focus, particularly in patients with diabetes, must be\\neffective against anaerobic organisms in addition to gram-positive and gram-negative aerobes.\\nAmpicillin/sulbactam 3 g IV q 6 h or piperacillin/tazobactam 3.375 g IV q 6 h is commonly used;\\nvancomycin 1 g IV q 12 h is added when infection is severe or MRSA is prevalent. Antibiotics must be\\ngiven parenterally for 4 to 8 wk and tailored to results of appropriate cultures. If any constitutional findings\\n(eg, fever, malaise, weight loss) persist or if large areas of bone are destroyed, necrotic tissue is debrided\\nsurgically. Surgery may also be needed to drain coexisting paravertebral or epidural abscesses or to\\nstabilize the spine to prevent injury. Skin or pedicle grafts may be needed to close large surgical defects.\\nBroad-spectrum antibiotics should be continued for > 3 wk after surgery. In chronic osteomyelitis, long-\\nterm antibiotic therapy may be needed.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 40. Infections of Joints & Bones\\n461'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 471, 'page_label': '462'}, page_content='The Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 40. Infections of Joints & Bones\\n462'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 472, 'page_label': '463'}, page_content=\"Chapter 41. Bursa, Muscle, and Tendon Disorders\\nIntroduction\\nOften, muscles, bursae, and tendons are injured during sports activities. Injury, overuse, infection, and\\noccasionally disease can temporarily or permanently damage these structures. Damage can cause pain,\\nlimit control of movement, and reduce range of motion.\\nBursitis\\nBursitis is acute or chronic inflammation of a bursa. The cause is usually unknown, but trauma,\\nrepetitive or acute, may contribute, as may infection and crystal-induced disease. Symptoms\\ninclude pain (particularly with motion or pressure), swelling, and tenderness. Diagnosis is\\nusually clinical; however, ultrasonography may be needed to evaluate deep bursae. Diagnosis\\nof infection and crystal-induced disease requires analysis of bursal fluid. Treatment includes\\nsplinting, NSAIDs, sometimes corticosteroid injections, and treatment of the cause.\\nBursae are fluid-filled sac-like cavities or potential cavities that are located where friction occurs (eg,\\nwhere tendons or muscles pass over bony prominences). Bursae minimize friction between moving parts\\nand facilitate movement. Some communicate with joints.\\nBursitis may occur in the shoulder (subacromial or subdeltoid bursitis), particularly in patients with rotator\\ncuff tendinitis, which is usually the primary lesion in the shoulder. Other commonly affected bursae\\ninclude olecranon (miners' or barfly's elbow), prepatellar (housemaid's knee), suprapatellar,\\nretrocalcaneal, iliopectineal (iliopsoas), ischial (tailor's or weaver's bottom), greater trochanteric, pes\\nanserine, and first metatarsal head (bunion) bursae. Occasionally, bursitis causes inflammation in a\\ncommunicating joint.\\nEtiology\\nBursitis may be caused by the following:\\n Injury\\n Chronic overuse\\n Inflammatory arthritis (eg, gout, RA)\\n Acute or chronic infection (eg, pyogenic organisms, particularly \\nStaphylococcus aureus\\n)\\nIdiopathic and traumatic causes are by far the most common. Acute bursitis may follow unusual exercise\\nor strain and usually causes bursal effusion. Infection most often affects olecranon and prepatellar\\nbursae.\\nChronic bursitis may develop after previous attacks of bursitis or repeated trauma. The bursal wall is\\nthickened, with proliferation of its synovial lining; bursal adhesions, villus formation, tags, and chalky\\ndeposits may develop.\\nSymptoms and Signs\\nAcute bursitis causes pain, particularly when the bursa is compressed or stretched during motion.\\nSwelling, sometimes with other signs of inflammation, is common if the bursa is superficial (eg,\\nprepatellar, olecranon). Swelling may be more prominent than pain in olecranon bursitis. Crystal- or\\nbacterial-induced bursitis is usually accompanied by erythema, pitting edema, pain, and warmth in the\\narea over the bursa.\\nChronic bursitis may last for several months and may recur frequently. Bouts may last a few days to\\nseveral weeks. If inflammation persists near a joint, the joint's range of motion may be limited. Limited\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 41. Bursa, Muscle & Tendon Disorders\\n463\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 473, 'page_label': '464'}, page_content=\"several weeks. If inflammation persists near a joint, the joint's range of motion may be limited. Limited\\nmotion may lead to muscle atrophy.\\nDiagnosis\\n Clinical evaluation\\n Ultrasonography or MRI for deep bursitis\\n Aspiration for suspected infection or crystal-induced bursitis\\nSuperficial bursitis should be suspected in patients with swelling or signs of inflammation over bursae.\\nDeep bursitis is suspected in patients with unexplained pain worsened by motion in a location compatible\\nwith bursitis. Usually, bursitis can be diagnosed clinically. Ultrasonography or MRI can help confirm the\\ndiagnosis when deep bursae are not readily accessible for inspection, palpation, or aspiration. These\\ntests are done to confirm or exclude a suspected diagnosis. These imaging techniques increase the\\naccuracy of identifying the involved structures.\\nIf bursal swelling is particularly painful, red, or warm or if the olecranon or prepatellar bursa is affected,\\ninfection and crystal-induced disease should be excluded by bursal aspiration. After a local anesthetic is\\ninjected, fluid is withdrawn from the bursa using sterile techniques; analysis includes cell count, Gram\\nstain and culture, and microscopic search for crystals. Gram stain, although helpful, may not be specific,\\nand WBC counts in infected bursae are usually lower than those in septic joints. Urate crystals are easily\\nseen with polarized light, but the apatite crystals typical of calcific tendinitis appear only as shiny chunks\\nthat are not birefringent. X-rays should be taken if bursitis is persistent or if calcification is suspected.\\nAcute bursitis should be distinguished from hemorrhage into a bursa, which can cause similar\\nmanifestations because blood is inflammatory. Fluid in traumatic bursitis is serosanguineous. Cellulitis can\\ncause signs of inflammation but does not normally cause bursal effusion; cellulitis overlying the bursa is a\\nrelative contraindication to bursal puncture through the cellulitis, but if septic bursitis is strongly\\nsuspected, aspiration must occasionally be done.\\nTreatment\\n Rest\\n High-dose NSAIDs\\n Treatment of crystal-induced disease or infection\\nCrystal-induced disease (see p. \\n349\\n) or infection should be treated if present. For infection, choice of\\nantibiotic is determined by results of Gram stain and culture. Empiric antibiotics effective against \\nS.\\naureus\\n should be given. Infectious bursitis requires drainage or excision in addition to antibiotics.\\nAcute nonseptic bursitis is treated with temporary rest or immobilization and high-dose NSAIDs and\\nsometimes with other analgesics. Voluntary movement should be increased as pain subsides. Pendulum\\nexercises are helpful for the shoulder joint.\\nIf oral drugs and rest are inadequate, aspiration and intrabursal injection of depot corticosteroids 0.5 to 1\\nmL (eg, triamcinolone acetonide 40 mg/mL) are the treatment of choice. About 1 mL of local anesthetic\\n(eg, 2% lidocaine) can be injected before the corticosteroid injection. The same needle is used; it is kept\\nin place and the syringes are changed. Dose and volume of the corticosteroid may vary according to the\\nsize of the bursa. Infrequently, a flare-up occurs within several hours of injection of a depot corticosteroid;\\nthe flare-up is probably a form of crystal-induced synovitis. It usually lasts  24 h and responds to cold\\ncompresses plus analgesics. Oral corticosteroids (eg, prednisone) can be used if a local injection is not\\nfeasible.\\nChronic bursitis is treated the same as acute bursitis, except that splinting and rest are less likely to help\\nand range-of-motion exercises are especially important. Rarely, the bursa needs to be excised.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 41. Bursa, Muscle & Tendon Disorders\\n464\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 474, 'page_label': '465'}, page_content=\"Tendinitis and Tenosynovitis\\nTendinitis is inflammation of a tendon, often developing after degeneration (tendinopathy);\\ntenosynovitis is tendinitis with inflammation of the tendon sheath lining. Symptoms usually\\ninclude pain with motion and tenderness with palpation. Chronic deterioration or inflammation\\ncan cause scars that restrict motion. Diagnosis is clinical, sometimes supplemented with\\nimaging. Treatment includes rest, NSAIDs, and sometimes corticosteroid injections.\\nTendinopathy usually results from repeated small tears or degenerative changes (sometimes with Ca\\ndeposit) that occur over years in the tendon.\\nTendinitis and tenosynovitis most commonly affect tendons associated with the shoulder (rotator cuff), the\\ntendon of the long head of the biceps muscle (bicipital tendon), flexor carpi radialis or ulnaris, flexor\\ndigitorum (for infectious flexor tenosynovitis, see p. \\n390\\n), popliteus tendon, Achilles tendon (see p. \\n3304\\n),\\nand the abductor pollicis longus and extensor pollicis brevis, which share a common fibrous sheath (the\\nresulting disorder is de Quervain's syndromesee p. \\n393\\n).\\nEtiology\\nThe cause of tendinitis is often unknown. It usually occurs in people who are middle-aged or older as the\\nvascularity of tendons decreases; repetitive microtrauma may contribute. Repeated or extreme trauma\\n(short of rupture), strain, and excessive or unaccustomed exercise probably also contribute. Some\\nquinolone antibiotics may increase the risk of tendinopathy and tendon rupture.\\nRisk of tendinitis may be increased by certain systemic disordersmost commonly RA, systemic\\nsclerosis, gout, reactive arthritis, and diabetes or, very rarely, amyloidosis or markedly elevated blood\\ncholesterol levels. In younger adults, particularly women, disseminated gonococcal infection may cause\\nacute migratory tenosynovitis.\\nSymptoms and Signs\\nAffected tendons are usually painful when moved. Occasionally, tendon sheaths become swollen and fluid\\naccumulates, usually when patients have infection, RA, or gout. Swelling may be visible or only palpable.\\nAlong the tendon, palpation elicits localized tenderness of varying severity.\\nIn systemic sclerosis, the tendon sheath may remain dry, but movement of the tendon in its sheath causes\\nfriction, which can be felt, or heard with a stethoscope.\\nDiagnosis\\n Clinical evaluation\\n Sometimes imaging\\nUsually, the diagnosis can be based on symptoms and physical examination, including palpation or\\nspecific maneuvers to assess pain. MRI or ultrasonography may be done to confirm the diagnosis or rule\\nout other disorders. MRI can detect tendon tears and inflammation (as can ultrasonography).\\n \\nRotator cuff tendinitis:\\n This disorder is the most common cause of shoulder pain. Active abduction in\\nan arc of 40 to 120 and internal rotation cause pain (see p. \\n3298\\n). Passive abduction causes less\\npain. Ca deposits in the tendon just below the acromion are sometimes visible on x-ray.\\nUltrasonography or MRI may help with further evaluation and with treatment decisions.\\n \\nBicipital tendinitis:\\n Pain in the biceps tendon is aggravated by shoulder flexion or resisted supination\\nof the forearm. Examiners can elicit tenderness proximally over the bicipital groove of the humerus by\\nrolling (flipping) the bicipital tendon under their thumb.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 41. Bursa, Muscle & Tendon Disorders\\n465\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 475, 'page_label': '466'}, page_content=' \\nVolar flexor tenosynovitis\\n (digital tendinitis): This common musculoskeletal disorder is often\\noverlooked (see p. \\n393\\n). Pain occurs in the palm on the volar aspect of the thumb or other digits and\\nmay radiate distally. Palpation of the tendon and sheath elicits tenderness; swelling and sometimes a\\nnodule are present. In later stages, the digit may lock when it is flexed, then extend suddenly with a\\nsnap (trigger finger).\\n \\nGluteus medius tendinitis:\\n Patients with trochanteric bursitis almost always have gluteus medius\\ntendinitis. In patients with trochanteric bursitis, palpation over the lateral prominence of the greater\\ntrochanter elicits tenderness. Patients often have a history of chronic pressure on the joint, trauma, a\\nchange in gait (eg, due to osteoarthritis, stroke, or leg-length discrepancy), or inflammation at this site\\n(eg, in RA).\\nTreatment\\n Rest or immobilization, heat or cold, followed by exercise\\n High-dose NSAIDs\\n Sometimes corticosteroid injection\\nSymptoms are relieved by rest or immobilization (splint or sling) of the tendon, application of heat (usually\\nfor chronic inflammation) or cold (usually for acute inflammation), and high-dose NSAIDs (see\\nTable 35-2\\n on p. \\n336\\n) for 7 to 10 days. Indomethacin or colchicine may be helpful if gout is the cause (see\\np. \\n349\\n). After inflammation is controlled, exercises that gradually increase range of motion should be done\\nseveral times a day, especially for the shoulder, which can develop contractures rapidly.\\nInjecting a sustained-release corticosteroid (eg, betamethasone 6 mg/mL, triamcinolone 40 mg/mL,\\nmethylprednisolone 20 to 40 mg/mL) in the tendon sheath may help; injection is usually indicated if pain is\\nsevere or if the problem has been chronic. Injection volume may range from 0.3 mL to 1 mL, depending\\non the site. An injection through the same needle of an equal or double volume of local anesthetic (eg, 1\\nto 2% lidocaine) confirms the diagnosis if pain is relieved immediately. Clinicians should be careful not to\\ninject the tendon (which can be recognized by marked resistance to injection); doing so may weaken it,\\nincreasing risk of rupture. Patients are advised to rest the injected joint to reduce the slight risk of rupture.\\nInfrequently, symptoms can worsen for up to 24 h after the injection.\\nRepeat injections and symptomatic treatment may be required. Rarely, for persistent cases, particularly\\nrotator cuff tendinitis, surgical exploration with removal of Ca deposits or tendon repair, followed by\\ngraded physical therapy, is needed. Occasionally, patients require surgery to release scars that limit\\nfunction or tenosynovectomy to relieve chronic inflammation.\\nFibromyalgia\\n(Myofascial Pain Syndrome; Fibrositis; Fibromyositis)\\nFibromyalgia is a common nonarticular disorder of unknown cause characterized by\\ngeneralized aching (sometimes severe); widespread tenderness of muscles, areas around\\ntendon insertions, and adjacent soft tissues; muscle stiffness; fatigue; and poor sleep.\\nDiagnosis is clinical. Treatment includes exercise, local heat, stress management, drugs to\\nimprove sleep, and analgesics.\\nIn fibromyalgia, any fibromuscular tissues may be involved, especially those of the occiput, neck,\\nshoulders, thorax, low back, and thighs. There is no specific histologic abnormality. Symptoms and signs\\nare generalized, in contrast to localized soft-tissue pain and tenderness (myofascial pain syndromesee\\nalso p. \\n533\\n), which is often related to overuse or microtrauma.\\nFibromyalgia is common; it is about 7 times more common among women, usually young or middle-aged\\nwomen, but can occur in men, children, and adolescents. Because of the sex difference, it is sometimes\\noverlooked in men. It sometimes occurs in patients with systemic rheumatic disorders.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 41. Bursa, Muscle & Tendon Disorders\\n466'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 476, 'page_label': '467'}, page_content='The cause is unknown, but disruption of stage 4 sleep may contribute, as can emotional stress. Patients\\nmay tend to be perfectionists. Fibromyalgia may be precipitated by a viral or other systemic infection (eg,\\nLyme disease) or a traumatic event.\\nSymptoms and Signs\\nStiffness and pain frequently begin gradually and diffusely and have an achy quality. Symptoms can be\\nexacerbated by environmental or emotional stress, poor sleep, trauma, or exposure to dampness or cold\\nor by a physician who implies that the disorder is \"all in the head.\"\\nPatients tend to be stressed, tense, anxious, fatigued, ambitious, and sometimes depressed. Many\\npatients also have irritable bowel syndrome symptoms or migraine or tension headaches. Pain may\\nworsen with fatigue, muscle strain, or overuse. Specific, discrete areas of muscle (tender points) may be\\ntender when palpated.\\nDiagnosis\\n Clinical criteria\\nFibromyalgia is suspected in patients with the following:\\n Generalized pain and tenderness, especially if disproportionate to physical findings\\n Negative laboratory results despite widespread symptoms\\n Fatigue as the predominant symptom\\nTests should include ESR or C-reactive protein, CK, and probably tests for hypothyroidism and hepatitis\\nC (which can cause fatigue and generalized myalgias). The diagnosis is based on clinical criteria,\\nincluding tenderness at some of the 18 specified tender points (see\\nFig. 41-1\\n). Most experts no longer require a specific number of tender points to make the diagnosis, as\\noriginally proposed ( 11 of 18). Patients with only some of the specified features may still have\\nfibromyalgia.\\n[\\nFig. 41-1.\\n Diagnosing fibromyalgia.]\\nTo avoid potential pitfalls, clinicians should consider the following:\\n Fibromyalgia is often overlooked in men, children, and adolescents.\\n Chronic fatigue syndrome (see p. \\n3442\\n) can cause similar generalized myalgias and fatigue and typically\\nproduces normal laboratory test results.\\n Polymyalgia rheumatica (see p. \\n325\\n) can cause generalized myalgias, particularly in older adults; it can\\nbe distinguished because it tends to affect proximal muscles selectively and ESR is high.\\n In patients with systemic rheumatic disorders, diagnosing fibromyalgia may be difficult. For example,\\nfibromyalgia may be misinterpreted as an exacerbation of RA or SLE.\\nPrognosis\\nFibromyalgia tends to be chronic but may remit spontaneously if stress decreases. It can also recur at\\nfrequent intervals. Functional prognosis is usually favorable for patients being treated with a\\ncomprehensive, supportive program, although symptoms tend to persist to some degree.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 41. Bursa, Muscle & Tendon Disorders\\n467'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 477, 'page_label': '468'}, page_content=\" Stretching and aerobic exercise, local heat, and massage\\n Stress management\\n Tricyclic antidepressants or cyclobenzaprine to improve sleep\\n Analgesics\\nStretching exercises, aerobic exercises, sufficient sound sleep, local applications of heat, and gentle\\nmassage may provide relief. Overall stress management (eg, deep breathing exercises, meditation,\\npsychologic support, counseling if necessary) is important.\\nExercises to gently stretch the affected muscles should be done daily; stretches should be held for about\\n30 sec and repeated about 5 times. Aerobic exercise (eg, fast walking, swimming, exercise bicycle) can\\nlessen symptoms.\\nImproving sleep is critical. Low-dose oral tricyclic antidepressants at bedtime (eg, amitriptyline 10 to 50\\nmg, trazodone 50 to 150 mg, doxepin 10 to 25 mg) or the pharmacologically similar cyclobenzaprine 10 to\\n40 mg may promote deeper sleep and decrease muscle pain. The lowest effective dose should be used.\\nDrowsiness, dry mouth, and other adverse effects may make some or all of these drugs intolerable,\\nparticularly for the elderly.\\nNonopioid analgesics (eg, tramadol, propoxyphene, acetaminophen, NSAIDs) may help some patients but\\non average are not effective. Opioids should be avoided. Pregabalin, used as an adjunct to exercise,\\nmeasures to improve sleep, and stress management, may help reduce pain.\\nRarely, injections of 0.5% bupivacaine or 1% lidocaine 1 to 5 mL are used to treat incapacitating areas of\\nfocal tenderness, but such injections should not be relied on as primary treatment.\\nDrugs taken by the patient should be reviewed to identify those that may aggravate sleep problems. Such\\ndrugs should be stopped, and future use should be avoided. Anxiety or depression, if present, may\\nrequire treatment.\\nMuscle Cramps\\nA muscle cramp is a sudden, brief, painful contraction of a muscle or group of muscles.\\nCramps (charley horses) can occur in healthy people (usually middle-aged and elderly people),\\nsometimes during rest, but particularly during or after exercise. Leg cramps can occur during sleep,\\ncausing pain and plantar flexion of the foot and toes.\\nTight calf muscles (eg, from lack of stretching, inactivity, or sometimes chronic lower leg edema) are a\\ncommon cause of leg cramps. Cramps may also be caused by electrolyte abnormalities (eg,\\nhypokalemia). Exertional muscle pain from ischemia due to peripheral arterial disease (claudication) may\\ncause similar calf pain, but this pain is due to inadequate blood flow to muscles and not to a muscle\\ncontraction as with a cramp.\\nTreatment\\n Stretching\\nIf a cramp occurs, stretching the affected muscle often relieves the cramp. For example, for a calf cramp,\\nthe person could use a hand to pull the foot and toes upward (dorsiflexion) or do the runner's stretch.\\nPrevention\\nMeasures to prevent cramps include the following:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 41. Bursa, Muscle & Tendon Disorders\\n468\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 478, 'page_label': '469'}, page_content=\" Not exercising immediately after eating\\n Gently stretching the muscles before exercising or going to bed\\n Drinking plenty of fluids (particularly beverages that contain potassium) after exercise\\n Not consuming stimulants (eg, caffeine, nicotine, ephedrine, pseudoephedrine)\\nThe runner's stretch is most useful. A person stands with one leg forward and bent at the knee and the\\nother leg behind and the knee straighta lunge position. The hands can be placed on the wall for\\nbalance. Both heels remain on the floor. The knee of the front leg is bent further until a stretch is felt\\nalong the back of the other leg. The greater the distance between the two feet and the more the front\\nknee is bent, the greater the stretch. The stretch is held for 30 sec and repeated 5 times. The set of\\nstretches is repeated on the other side.\\nMost of the drugs prescribed to prevent cramps (eg, quinine, magnesium, benzodiazepines) have no\\ndemonstrated efficacy and are not recommended. Mexiletine sometimes helps, but whether using it is\\nworth the risk of adverse effects is unclear. These adverse effects include nausea, vomiting, heartburn,\\ndizziness, and tremor. Ca supplements are safe and have few adverse effects but have not proved\\neffective.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 41. Bursa, Muscle & Tendon Disorders\\n469\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 479, 'page_label': '470'}, page_content='Chapter 42. Neck and Back Pain\\nIntroduction\\nNeck pain and back pain are among the most common reasons for physician visits. This discussion\\ncovers neck pain involving the posterior neck (not pain limited to the anterior neck) and does not cover\\nmost major traumatic injuries (eg, fractures, dislocations, subluxations).\\nPathophysiology\\nDepending on the cause, neck or back pain may be accompanied by neurologic symptoms.\\nIf a nerve root is affected, pain may radiate distally along the distribution of that root (called radicular pain\\nor, in the low back, sciatica). Strength, sensation, and reflexes of the area innervated by that root may be\\nimpaired.\\nIf the spinal cord is affected, strength, sensation, and reflexes may be impaired at the affected spinal cord\\nlevel and all levels below (called segmental neurologic deficits).\\nIf the cauda equina is affected, segmental deficits develop in the lumbosacral region, typically with loss of\\nbowel and bladder function, loss of perianal sensation, erectile dysfunction, urinary retention, and loss of\\nrectal tone and sphincter (eg, bulbocavernosus, anal wink) reflexes.\\nAny painful disorder of the spine may also cause reflex tightening (spasm) of paraspinal muscles, which\\ncan be excruciating.\\nEtiology\\nMost neck and back pain is caused by disorders of the spine. Fibromyalgia is also a common cause.\\nOccasionally, pain is referred from extraspinal disorders (particularly vascular, GI, or GU disorders). Some\\nuncommon causesspinal and extraspinalare serious.\\nMost spinal disorders are mechanical. Only a few involve infection, inflammation, or cancer (considered\\nnonmechanical).\\nCommon causes:\\n Most mechanical spine disorders that cause neck or back pain involve a nonspecific\\nmechanical derangement:\\n Muscle strain, ligament sprain, spasm, or a combination\\nOnly about 15% involve specific structural lesions that clearly cause the symptoms, primarily the\\nfollowing:\\n Disk herniation\\n Compression fracture\\n Lumbar spinal stenosis\\n Osteoarthritis\\n Spondylolisthesis\\nIn the other mechanical disorders, there are no specific lesions, or the findings (eg, disk bulging or\\ndegeneration, osteophytes, spondylolysis, congenital facet abnormalities) are common among people\\nwithout neck or back pain, and thus are questionable as the etiology of pain. However, etiology of back\\npain, particularly if mechanical, is often multifactorial, with an underlying disorder exacerbated by fatigue,\\nphysical deconditioning, and sometimes psychosocial stress or psychiatric abnormality. Thus, identifying\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n470'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 480, 'page_label': '471'}, page_content=\"a single cause is often difficult or impossible.\\nSerious uncommon causes:\\n Serious causes may require timely treatment to prevent disability or death.\\nSerious \\nextraspinal\\n disorders include the following:\\n Abdominal aortic aneurysm\\n Aortic dissection\\n Carotid or vertebral artery dissection\\n Acute meningitis\\n Angina or MI\\n Certain GI disorders (eg, cholecystitis, diverticulitis, diverticular abscess, pancreatitis, penetrating peptic\\nulcer, retrocecal appendicitis)\\n Certain pelvic disorders (eg, ectopic pregnancy, ovarian cancer, salpingitis)\\n Certain pulmonary disorders (eg, pleuritis, pneumonia)\\n Certain urinary tract disorders (eg, prostatitis, pyelonephritis)\\nSerious \\nspinal\\n disorders include the following:\\n Infections (eg, diskitis, epidural abscess, osteomyelitis)\\n Primary tumors (of spinal cord or vertebrae)\\n Metastatic vertebral tumors (most often from breasts, lungs, or prostate)\\nMechanical spine disorders can be serious if they compress the spinal nerve roots or, particularly, the\\nspinal cord. Spinal cord compression may result from disorders such as tumors and spinal epidural\\nabscess or hematoma.\\nOther uncommon causes:\\n Neck or back pain can result from many other disorders, such as Paget's\\ndisease of bone, torticollis, thoracic outlet syndrome, temporomandibular joint syndrome, herpes zoster,\\nand \\nspondyloarthropathies (ankylosing spondylitis most often, but also enteropathic arthritis, psoriatic\\narthritis, reactive arthritis, and undifferentiated spondyloarthropathy).\\nEvaluation\\nGeneral:\\n Because the cause is often multifactorial, a definitive diagnosis cannot be established in many\\npatients. However, clinicians should determine the following if possible:\\n Whether pain has a spinal or extraspinal cause\\n Whether the cause is a serious disorder\\nHistory: History of present illness\\n should include quality, onset, duration, severity, location, radiation,\\nand time course of pain, as well as modifying factors such as rest, activity, changes in position, weight\\nbearing, and time of day (eg, at night, when awakening). Accompanying symptoms to note include\\nstiffness, numbness, paresthesias, weakness, urinary retention, and incontinence.\\nReview of systems\\n should note symptoms suggesting a cause, including fever and chills (infection);\\nweight loss and poor appetite (infection or cancer); fatigue, depressive symptoms, and headaches\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n471\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 481, 'page_label': '472'}, page_content=\"(multifactorial mechanical back pain); worsening of neck pain during swallowing (esophageal disorders);\\nanorexia, nausea, vomiting, and change in bowel function or stool (GI disorders); urinary symptoms and\\nflank pain (urinary tract disorders); cough, dyspnea, and worsening during inspiration (pulmonary\\ndisorders); vaginal bleeding or discharge and pain related to menstrual cycle phase (pelvic disorders).\\nPast medical history\\n includes known neck or back disorders (including osteoporosis, osteoarthritis, disk\\ndisorders, recent or remote injury) and surgery, risk factors for back disorders (eg, cancer, osteoporosis),\\nrisk factors for aneurysm (eg, smoking, hypertension), and risk factors for infection (eg,\\nimmunosuppression; IV drug use; recent surgery, penetrating trauma, or bacterial infection).\\nPhysical examination:\\n Temperature and general appearance are noted. When possible, patients\\nshould be unobtrusively observed as they move into the examination room, undress, and climb onto the\\ntable. If symptoms are exacerbated by psychologic issues, true functional level can be assessed more\\naccurately when patients are not aware they are being evaluated.\\nThe examination focuses on the spine and the neurologic examination. If no mechanical spinal source of\\npain is obvious, patients are checked for sources of referred pain.\\nIn the spinal examination, the back and neck are inspected for any visible deformity, area of erythema, or\\nvesicular rash. The spine and paravertebral muscles are palpated for tenderness and muscle spasm.\\nGross range of motion is tested.\\nIn the neurologic examination, strength and deep tendon reflexes are tested. In patients with neurologic\\nsymptoms, sensation and sacral nerve function (eg, rectal tone, anal wink reflex, bulbocavernosus reflex)\\nare tested. These tests are among the most reliable physical tests for confirming normal spinal cord\\nfunction. Corticospinal tract dysfunction is indicated by the extensor plantar response and Hoffman's sign.\\nTo test for Hoffman's sign, clinicians tap the nail or flick the volar surface of the 3rd finger; if the distal\\nphalanx of the thumb flexes, the test is positive, usually indicating corticospinal tract dysfunction caused\\nby stenosis of the cervical cord. Sensory findings are subjective and may be unreliable.\\nThe straight leg raise test helps confirm sciatica. The patient is supine with both knees extended and the\\nankles dorsiflexed. The clinician raises the affected leg, keeping the knee extended. If sciatica is present,\\n10 to 60 of elevation typically causes symptoms. For the crossed straight leg raise test, the unaffected\\nleg is raised; the test is positive if sciatica occurs in the affected leg. A positive straight leg test is\\nsensitive but not specific for herniated disk; the crossed straight leg raise test is less sensitive but 90%\\nspecific. The seated straight leg raise test is done while patients are seated with the hip joint flexed at\\n90; the lower leg is slowly raised until the knee is fully extended. If sciatica is present, the pain occurs as\\nthe leg is extended.\\nIn the general examination, the lungs are auscultated. The abdomen is checked for tenderness, masses,\\nand, particularly in patients > 55, a pulsatile mass (which suggests abdominal aortic aneurysm). With a\\nfist, clinicians percuss the costovertebral angle for tenderness, suggesting pyelonephritis.\\nRectal examination, including stool testing for occult blood and, in men, prostate examination, is done. In\\nwomen with symptoms suggesting a pelvic disorder or with unexplained fever, pelvic examination is done.\\nLower-extremity pulses are checked.\\nRed flags:\\n The following findings are of particular concern:\\n Abdominal aorta that is > 5 cm (particularly if tender) or lower-extremity pulse deficits\\n Acute, tearing mid-back pain\\n Cancer, diagnosed or suspected\\n Duration of pain > 6 wk\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n472\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 482, 'page_label': '473'}, page_content=' Neurologic deficit\\n \\nFever\\n GI findings such as localized abdominal tenderness, peritonitis, melena, or hematochezia\\n Infection risk factors (eg, immunosuppression; IV drug use; recent surgery, penetrating trauma, or\\nbacterial infection)\\n Meningismus\\n Severe nocturnal or disabling pain\\n Unexplained pain after age 55\\n Unexplained weight loss\\nInterpretation of findings:\\n Although serious extraspinal disorders (eg, cancers, aortic aneurysms,\\nepidural abscesses, osteomyelitis) are uncommon causes of back pain, they are not rare, particularly in\\nhigh-risk groups.\\nA spinal cause is more likely (but not definitive) than referred pain from an extraspinal cause when\\n Pain is worsened by movement or weight bearing and is relieved by rest or recumbency\\n Vertebral or paravertebral tenderness is present\\nRed flag findings should heighten suspicion of a serious cause (see\\nTable 42-1\\n).\\nOther findings are also helpful. Erythema and tenderness over the spine suggests infection, particularly in\\npatients with risk factors. Worsening of pain with flexion is consistent with intervertebral disk disease;\\nworsening with extension suggests spinal stenosis, arthritis affecting the facet joints, or retroperitoneal\\ninflammation or infiltration (eg, pancreatic or kidney inflammation or tumor). Tenderness over certain\\nspecific trigger points suggests fibromyalgia. Deformities of the proximal interphalangeal (PIP) and distal\\ninterphalangeal (DIP) finger joints and stiffness that lessens within 30 min after awakening suggest\\nosteoarthritis. Neck pain that is unrelated to swallowing and is exertional may indicate angina.\\nTesting:\\n Usually, if duration of pain is short (< 4 to 6 wk), no testing is required unless red flag findings\\nare present, patients have had a serious injury (eg, vehicular crash, fall from a height, penetrating\\ntrauma), or evaluation suggests a specific nonmechanical cause (eg, pyelonephritis).\\nPlain x-rays can identify most osteoporotic fractures and osteoarthritis. However, they do not identify\\nabnormalities in soft tissue (the most common cause of back and neck pain) or nerve tissue (as occurs in\\nmany serious disorders). Thus, x-rays are usually unnecessary and do not change management.\\nSometimes\\n[\\nTable 42-1.\\n Interpretation of Red Flag Findings in Patients with Back Pain]\\nx-rays are done to identify obvious bone abnormalities (eg, those due to infection or tumors) and to avoid\\nMRI and CT, which are harder to obtain but which are much more accurate and usually necessary.\\nTesting is guided by findings and suspected cause:\\n Neurologic deficits, particularly those consistent with spinal cord compression: MRI or CT myelography,\\ndone as soon as possible\\n Possible infection: WBC count, ESR, imaging (usually MRI or CT), and culture of infected tissue\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n473'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 483, 'page_label': '474'}, page_content=' Possible cancer: CT or MRI and possibly biopsy\\n Possible aneurysm: CT, angiography, or sometimes ultrasonography\\n Possible aortic dissection: Angiography, CT, or MRI\\n Symptoms that are disabling or that persist > 6 wk: Imaging (usually MRI or CT) and, if infection is\\nsuspected, WBC count and ESR\\n Other extraspinal disorders: Testing as appropriate (eg, chest x-ray for pulmonary disorders, urinalysis\\nfor urinary tract disorders)\\nTreatment\\nUnderlying disorders are treated.\\nAcute musculoskeletal pain (with or without radiculopathy) is treated with\\n Analgesics\\n Heat and cold\\n Early mobilization followed by stabilization exercises\\nAcetaminophen or NSAIDs are the initial choice of analgesics, but opioids may be necessary for severe\\npain. Adequate analgesia is important immediately after acute injury to help limit the cycle of pain and\\nspasm.\\nAcute muscle spasms may also be relieved by cold or heat. Cold is usually preferred to heat during the\\nfirst 2 days after an injury. Ice and cold packs should not be applied directly to the skin. They should be\\nenclosed (eg, in plastic) and placed over a towel or cloth. The ice is removed after 20 min, then later\\nreapplied for 20 min over a period of 60 to 90 min. This process can be repeated several times during the\\nfirst 24 h. Heat, using a heating pad, can be applied for the same periods of time. Because the skin on\\nthe back may be insensitive to heat, heating pads must be used cautiously to prevent burns. Patients are\\nadvised not to use a heating pad at bedtime to avoid prolonged exposure due to falling asleep with the\\npad still on their back. Diathermy may help reduce muscle spasm and pain after the acute stage.\\nOral muscle relaxants (eg, cyclobenzaprine, methocarbamol, metaxalone) are controversial. Benefits of\\nthese drugs should be weighed against their CNS and other adverse effects, particularly in elderly\\npatients, who may have more severe adverse effects.\\nAlthough a brief initial period (eg, 1 to 2 days) of decreased activity is sometimes needed for comfort,\\nprolonged bed rest, spinal traction, and corsets are not beneficial. Patients with severe torticollis may\\nbenefit from a cervical collar and contour pillow until pain is relieved and they can participate in a\\nstabilization program.\\nSpinal manipulation may help relieve pain caused by muscle spasm or an acute neck or back injury;\\nhowever, some forms of manipulation may have risks for patients with disk disorders or osteoporosis.\\nWhen acute pain decreases enough that motion is possible, a lumbar stabilization program is begun. This\\nprogram includes exercises that strengthen abdominal and low back muscles plus instruction in work\\nposture; the aim is to strengthen the supporting structures of the back and reduce the likelihood of the\\ncondition becoming chronic or recurrent.\\nClinicians should reassure patients with acute nonspecific musculoskeletal back pain that the prognosis is\\ngood and that activity and exercise are safe even when they cause some discomfort. Clinicians should be\\nthorough, kind, firm, and nonjudgmental. If depression or secondary gain persists for several months,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n474'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 484, 'page_label': '475'}, page_content='psychologic evaluation should be considered.\\nGeriatrics Essentials\\nLow back pain affects 50% of adults > 60.\\nAbdominal aortic aneurysm (and CT or ultrasonography to detect it) should be considered in elderly\\npatients with atraumatic low back pain, even if no physical findings suggest this diagnosis.\\nImaging of the spine may be appropriate for elderly patients (eg, to rule out cancer) even when the cause\\nappears to be uncomplicated musculoskeletal back pain.\\nOral muscle relaxants (eg, cyclobenzaprine, methocarbamol, metaxalone) are controversial;\\nanticholinergic, CNS, and other adverse effects may outweigh potential benefits in elderly patients.\\nKey Points\\n Most neck and back pain is caused by mechanical spinal disorders, usually nonspecific, self-limited\\nmusculoskeletal derangements.\\n \\nMost mechanical disorders are treated with analgesics, early mobilization, and exercises; prolonged bed\\nrest and immobilization are avoided.\\n Back pain is often multifactorial, making diagnosis difficult.\\n Serious spinal or extraspinal disorders are unusual causes.\\n Red flag findings often indicate a serious disorder and the need for testing.\\n Patients with segmental neurologic deficits suggesting spinal cord compression require MRI or CT\\nmyelography as soon as possible.\\n Normal spinal cord function during physical examination is best confirmed by tests of sacral nerve\\nfunction (eg, rectal tone, anal wink reflex, bulbocavernosus reflex).\\n Pain not worsened by movement is often extraspinal, particularly if no vertebral or paravertebral\\ntenderness is detected.\\n Abdominal aortic aneurysm should be considered in any elderly patient with low back pain, even if no\\nphysical findings suggest this diagnosis.\\nSpasmodic Torticollis\\nSpasmodic torticollis is characterized by involuntary tonic contractions or intermittent spasms\\nof neck muscles. The cause is unknown. Diagnosis is clinical. Treatment can include physical\\ntherapy, drugs, and selective denervation of neck muscles with surgery or locally injected\\nbotulinum toxin.\\nIn torticollis, contraction of the neck muscles causes the neck to turn from its usual position. It is the most\\ncommon dystonia (see p.\\n1760\\n).\\nSpasmodic (or adult-onset) torticollis is usually idiopathic. About 5% of patients with spasmodic torticollis\\nhave a family history. One third of these patients have other dystonias (eg, eyelids, face, jaw, hand).\\nTorticollis can also be congenital or secondary to other conditions such as lesions of the brain stem and\\nbasal ganglia.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n475'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 485, 'page_label': '476'}, page_content='Symptoms may begin at any age but usually begin between age 20 and 60, with a peak between age 30\\nand 50.\\nSymptoms usually begin gradually but may begin suddenly. Painful tonic contractions or intermittent\\nspasms of the sternocleidomastoid, trapezius, and other neck muscles occur, usually unilaterally, and\\nresult in abnormal head position. Sternocleidomastoid muscle contraction causes the head to rotate to the\\nopposite side and the neck to flex laterally to the same side. Rotation may involve any plane but almost\\nalways has a horizontal component. Besides rotational tilting (torticollis), the head can tilt laterally\\n(laterocollis), forward (anterocollis), or backward (retrocollis). During sleep, muscle spasms disappear.\\nSpasmodic torticollis ranges from mild to severe. Usually, it progresses slowly for 1 to 5 yr, then plateaus.\\nAbout 10 to 20% of patients recover spontaneously within 5 yr of onset (usually in milder cases with\\nyounger age onset). However, it may persist for life and can result in restricted movement and postural\\ndeformity.\\nDiagnosis\\n Clinical evaluation\\nThe diagnosis is based on characteristic symptoms and signs and exclusion of alternative diagnoses,\\nsuch as the following:\\n Tardive dyskinesia can cause torticollis but can usually be distinguished by a history of chronic\\nantipsychotic use and involuntary movements in muscles outside of the neck.\\n Basal ganglia disease and occasionally CNS infections can cause movement disorders but usually also\\ninvolve other muscles. Also, CNS infections are usually acute and cause other symptoms.\\n Neck infections or tumors are usually differentiated by features of the primary process.\\n Antipsychotics and other drugs can cause acute torticollis, but the symptoms usually develop in hours\\nand resolve within days.\\nTreatment\\n Physical measures\\n Sometimes botulinum toxin or oral drugs\\nSpasms can sometimes be temporarily inhibited by physical therapy and massage, including sensory\\nbiofeedback techniques (slight tactile pressure to the jaw on the same side as head rotation) and any\\nlight touch.\\nInjections of botulinum toxin type A into the dystonic muscles can reduce painful spasms for 1 to 3 mo in\\nabout 70% of patients, restoring a more neutral position of the head. However, this treatment can lose\\neffectiveness with repeated injections because antibodies develop against the toxin. Drugs can usually\\nrelieve pain, but they suppress dystonic movements in only about 25 to 33% of patients. Anticholinergics\\nsuch as trihexyphenidyl 10 to 25 mg po once/day or bid may help, but adverse \\neffects may limit their use;\\nbenzodiazepines (particularly clonazepam 0.5 mg po bid) and baclofen and carbamazepine may help. All\\ndrugs should be started in low doses. Doses should be increased until symptoms are controlled or\\nintolerable adverse effects (particularly likely in the elderly) develop.\\nSurgery is controversial. The most successful surgical approach selectively severs nerves to affected\\nneck muscles, permanently weakening or paralyzing them. Results are favorable when the procedure is\\ndone at centers with extensive experience.\\nRarely, an emotional problem contributes to spasmodic torticollis; psychiatric treatment is indicated.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n476'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 486, 'page_label': '477'}, page_content=\"Psychiatric prognosis is best if symptom onset coincided with exogenous stress.\\nSciatica\\nSciatica is pain along the sciatic nerve. It usually results from compression of nerve roots in the\\nlower back. Common causes include intervertebral disk herniation, osteophytes, and narrowing\\nof the spinal canal (spinal stenosis). Symptoms include pain radiating from the buttocks down\\nthe leg. Diagnosis sometimes involves MRI or CT. Electromyography and nerve conduction\\nstudies can identify the affected level. Treatment includes symptomatic measures and\\nsometimes surgery, particularly if there is a neurologic deficit.\\nEtiology\\nSciatica is typically caused by nerve root compression, usually due to intervertebral disk herniation (see\\np. \\n1810\\n), bony irregularities (eg, osteoarthritic osteophytes, spondylolisthesis), or, much less often,\\nintraspinal tumor or abscess. Compression may occur within the spinal canal or intervertebral foramen.\\nThe nerves can also be compressed outside the vertebral column, in the pelvis or buttocks. L5-S1, L4-L5,\\nand L3-L4 nerve roots are most often affected (see\\nTable 186-1\\n on p. \\n1805\\n).\\nSymptoms and Signs\\nPain radiates along the course of the sciatic nerve, most often down the buttocks and posterior aspect of\\nthe leg to below the knee. The pain is typically burning, lancinating, or stabbing. It may occur with or\\nwithout low back pain. The Valsalva maneuver or coughing may worsen pain due to disk herniation.\\nPatients may complain of numbness and sometimes weakness in the affected leg.\\nNerve root compression can cause sensory, motor, or, the most objective finding, reflex deficits see p.\\n1810\\n). L5-S1 disk herniation may affect the ankle jerk reflex; L3-L4 herniation may affect the knee jerk.\\nStraight leg raising may cause pain that radiates down the leg when the leg is raised above 60 and\\nsometimes less. This finding is sensitive for sciatica; pain radiating down the affected leg when the\\ncontralateral leg is lifted (crossed straight leg raising) is more specific for sciatica.\\nDiagnosis\\n Clinical evaluation\\n Sometimes MRI, electrodiagnostic studies, or both\\nSciatica is suspected based on the characteristic pain. If it is suspected, strength, reflexes, and sensation\\nshould be tested. If there are neurologic deficits or if symptoms persist for > 6 wk, imaging and\\nelectrodiagnostic studies should be done. Structural abnormalities causing sciatica (including spinal\\nstenosis) are most accurately diagnosed by MRI or CT. Electrodiagnostic studies can confirm the\\npresence and degree of nerve root compression and can exclude conditions that may mimic sciatica,\\nsuch as polyneuropathy. These studies may help determine whether the lesion involves single or multiple\\nnerve levels and whether the clinical findings correlate with MRI abnormalities (especially valuable before\\nsurgery). However, abnormalities may not be evident on electrodiagnostic studies for up to a few weeks\\nafter symptoms begin.\\nTreatment\\n Bed rest (brief), analgesics, and sometimes drugs that relieve neuropathic pain\\n Surgery for severe cases\\nAcute pain relief can come from 24 to 48 h of bed rest in a recumbent position with the head of the bed\\nelevated about 30 (semi-Fowler's position). Measures used to treat low back pain, including nonopioid\\nanalgesics (eg, NSAIDs, acetaminophen), can be tried for up to 6 wk. Drugs that decrease neuropathic\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n477\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 487, 'page_label': '478'}, page_content=\"pain (see p. \\n1633\\n), such as gabapentin or other anticonvulsants or low-dose tricyclic antidepressants (no\\ntricyclic is superior to another), may relieve symptoms. Gabapentin 100 to 300 mg po at bedtime is used\\ninitially, but doses typically have to be much higher, up to 3600 mg/day. As with all sedating drugs, care\\nshould be taken in the elderly, patients at risk of falls, and those with arrhythmias.\\nMuscle spasm may be relieved with therapeutic heat or cold (see p.\\n3459\\n), and physical therapy may be useful. Whether corticosteroids should be used to treat acute\\nradicular pain is controversial. Given epidurally, corticosteroids may accelerate pain relief, but they\\nprobably should not be used unless pain is severe or persistent.\\nSurgery is indicated only for unequivocal disk herniation plus one of the following:\\n Muscular weakness\\n Progressive neurologic deficit\\n Intolerable, intractable pain that interferes with job or personal functions in an emotionally stable patient\\nand that has not lessened after 6 wk of conservative treatment\\nSome of these patients benefit from epidural corticosteroids instead of surgery.\\nClassic diskectomy with limited laminotomy for intervertebral disk herniation is the standard procedure. If\\nherniation is localized, microdiskectomy may be done; with it, the skin incision and laminotomy can be\\nsmaller. Chemonucleolysis, using intradiskal injection of chymopapain, is no longer used.\\nPredictors of poor surgical outcome include\\n Prominent psychiatric factors\\n Persistence of symptoms for > 6 mo\\n Heavy manual labor\\n Prominence of back pain (nonradicular)\\n Secondary gain (ie, litigation and compensability)\\nLumbar Spinal Stenosis\\nLumbar spinal stenosis (LSS) is narrowing of the lumbar spinal canal, which puts pressure on\\nthe sciatic nerve roots (or sometimes the cord) before their exit from the foramina. It causes\\npositional back pain, symptoms of nerve root compression, and lower-extremity pain during\\nwalking or weight bearing.\\nSpinal stenosis can be congenital or acquired. It may involve the cervical or lumbar spine. Acquired LSS\\nis a common cause of sciatica in middle-aged or elderly patients. The most common causes of LSS are\\nosteoarthritis, degenerative disk disorders, and spondylolisthesis with compression of the cauda equina.\\nOther causes include Paget's disease of bone, RA, and ankylosing spondylitis.\\nSymptoms and Signs\\nPain occurs in the buttocks, thighs, or calves during walking, running, climbing stairs, or even standing.\\nThe pain is not relieved by standing still but by flexing the back or by sitting (although paresthesias may\\ncontinue). Walking up hills is less painful than walking down because the back is slightly flexed. Patients\\nmay have pain, paresthesias, weakness, and diminished reflexes in the affected nerve root distribution.\\nRarely, spinal cord compression may cause cauda equina syndrome (see p.\\n1806\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n478\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 488, 'page_label': '479'}, page_content='Diagnosis\\n Clinical evaluation\\n Sometimes MRI, electrodiagnostic studies, or both\\nSpinal stenosis is suspected based on characteristic symptoms. Diagnostic tests are the same as for\\nsciatica (see p. \\n383\\n). Calf symptoms may simulate those of intermittent claudication. Claudication can be\\ndifferentiated by relief with rest (not position change), skin atrophy, and abnormalities in pulses, capillary\\nrefill, and vascular tests.\\nTreatment\\n Bed rest (brief), analgesics, and sometimes drugs that relieve neuropathic pain\\n Surgery for severe cases\\nConservative treatments and indications for surgery are similar to those for sciatica. For advanced spinal\\nstenosis, surgery involves decompression of nerve root entrapment by vertebral canal and foraminal\\nencroachments, which sometimes requires laminectomy at 2 or 3 levels plus foraminotomies.\\nSpinal stability must be preserved. Spinal fusion is indicated if there is instability or severe, well-localized\\narthritic changes in 1 or 2 vertebral interspaces.\\nNontraumatic Subluxation\\nSpinal dislocation and subluxation (partial dislocation) are usually due to trauma. For example,\\natlantoaxial subluxation and spondylolisthesis can result from obvious major trauma, such as a high-\\nspeed deceleration injury. However, these disorders can occur with minimal, unrecognized, or no trauma.\\nRarely, cervical disk disorders can cause nontraumatic spinal subluxation.\\nAtlantoaxial Subluxation\\n(C1-C2 Subluxation)\\nAtlantoaxial subluxation is misalignment of the 1st and 2nd cervical vertebrae, which may occur\\nonly with neck flexion.\\nAtlantoaxial subluxation can result from major trauma or can occur without trauma in patients with RA,\\njuvenile RA, or ankylosing spondylitis.\\nAtlantoaxial subluxation is usually asymptomatic but may cause vague neck pain, occipital headache, or\\noccasionally intermittent (and potentially fatal) cervical spinal cord compression.\\nDiagnosis\\n Plain x-rays\\n MRI if cord compression suspected\\nIt is usually diagnosed with plain cervical x-rays; however, flexion views may be required to show\\nintermittent subluxation. Views during flexion, done by the patient, show dynamic instability of the entire\\ncervical spine. If x-rays are normal and subluxation is still suspected, MRI, which is more sensitive, should\\nbe done. MRI also provides the most sensitive evaluation of spinal cord compression and is done\\nimmediately if cord compression is suspected.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n479'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 489, 'page_label': '480'}, page_content='Indications for treatment include pain, neurologic deficits, and potential spinal instability. Treatment\\nincludes symptomatic measures and cervical immobilization, usually beginning with a rigid cervical collar.\\nSurgery may be needed to stabilize the spine.\\nSpondylolisthesis\\nSpondylolisthesis is subluxation of lumbar vertebrae, usually occurring during adolescence. It\\nusually results from a congenital defect in the pars interarticularis (spondylolysis).\\nSpondylolisthesis is usually fixed. It usually involves the L3-L4, L4-L5, or L5-S1 vertebrae.\\nSpondylolisthesis often occurs in adolescents or young adults who are athletes and who have had only\\nminimal trauma; the cause is a lumbar vertebra weakened by a congenital defect in the pars\\ninterarticularis. This defect is easily fractured; separation of the fracture fragments causes the\\nsubluxation. Spondylolisthesis can also occur with minimal trauma in patients who are > 60 and have\\nosteoarthritis. If mild to moderate (subluxation of  50%), spondylolisthesis, particularly in the young, may\\ncause little or no pain. Spondylolisthesis can predispose to later development of spinal stenosis. If due to\\nmajor trauma, spondylolisthesis can cause spinal cord compression or other neurologic deficits (see p.\\n1810\\n); these deficits rarely occur.\\nSpondylolisthesis is staged according to the degree of subluxation of adjacent vertebral bodies:\\n Stage I: 0 to 25%\\n Stage II: 25 to 50%\\n Stage III: 50 to 75%\\n Stage IV: 75 to 100%\\nSpondylolisthesis is evident on plain lumbar x-rays. The lateral view is usually used for staging.\\nTreatment is usually symptomatic.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 42. Neck & Back Pain\\n480'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 490, 'page_label': '481'}, page_content=\"Chapter 43. Hand Disorders\\nIntroduction\\nCommon hand disorders include a variety of deformities, ganglia, infections, Kienbock's disease, nerve\\ncompression syndromes, noninfectious tenosynovitis, and osteoarthritis. Complex regional pain syndrome\\n(reflex sympathetic dystrophy) is discussed on p. \\n1633\\n, and hand injuries are discussed in \\nCh. 323\\n.\\nEvaluation\\nHistory and physical examination findings are often diagnostic in hand disorders.\\nHistory:\\n The history should include information about the trauma or other events that may be associated\\nwith symptoms. The presence and duration of deformity and difficulty with motion are noted. The\\npresence, duration, severity, and factors that exacerbate or relieve pain are elicited. Associated\\nsymptoms, such as fever, swelling, rashes, Raynaud's syndrome (see p. \\n2221\\n), paresthesias, and\\nweakness, are also recorded.\\nPhysical examination:\\n Examination should include inspection for redness, swelling, or deformity and\\npalpation for tenderness. Active \\nrange of motion should be tested for any possible tendon injury. Passive\\nrange of motion can assess whether specific motions aggravate pain. Sensation is tested most accurately\\nby 2-point discrimination, using 2 ends of a paper clip. Motor function testing involves muscles innervated\\nby the radial, median, and ulnar nerves. Vascular examination should include evaluation of capillary refill,\\nradial and ulnar pulses, and Allen's test (see p. \\n1856\\n). Stress testing is helpful when specific ligament\\ninjuries are suspected (eg, ulnar collateral ligament in gamekeeper's thumbsee p. \\n3216\\n). Provocative\\ntesting can aid in the diagnosis of tenosynovitis and nerve compression syndromes.\\nLaboratory testing:\\n Laboratory testing has a limited role. Plain x-rays and MRI are helpful for injuries,\\narthritis, and Kienbock's disease or to rule out hidden foreign bodies that could be sources of infections.\\nNerve conduction testing can help diagnose nerve compression syndromes. Bone scans may assist in\\ndiagnosing occult fractures and reflex sympathetic dystrophy.\\nDeformities\\nDeformities can result from generalized disorders (eg, arthritis) or dislocations, fractures, and other\\nlocalized disorders. Most nontraumatic localized disorders can be diagnosed by physical examination.\\nOnce a hand deformity becomes firmly established, it cannot be significantly altered by splinting, exercise,\\nor other nonsurgical treatment.\\nMallet Finger\\nMallet finger is a flexion deformity of the distal interphalangeal joint preventing extension (see\\nFig. 43-1\\n).\\nThis deformity results from an extensor tendon rupture or an avulsion fracture of the distal phalanx. The\\ndeformity may not be obvious immediately after injury, but on examination, patients cannot fully extend the\\ndistal interphalangeal (DIP) joint. Closed injuries may be treated with splinting that holds the DIP joint in\\nextension and leaves the proximal interphalangeal (PIP) joint free. Avulsion fractures are usually united\\nafter 6 wk, but pure tendon injuries require an additional 2 to 4 wk of nighttime splinting. Surgery may be\\nrequired if there is a fracture that involves a large proportion of the articular surface or if the joint is\\nsubluxated.\\nSwan-Neck Deformity\\nA swan-neck deformity consists of hyperextension of the PIP joint, flexion of the DIP joint, and\\nsometimes flexion of the metacarpophalangeal joint (see\\nFig. 43-2\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n481\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 491, 'page_label': '482'}, page_content='Although characteristic in RA, swan-neck deformity has several causes, including untreated mallet finger,\\nlaxity of the ligaments of the volar aspect of the PIP joint, spasticity of intrinsic hand muscles, rupture of\\nthe flexor tendon of the PIP joint, and malunion of a fracture of the middle or proximal phalanx. The\\ninability to correct or compensate for hyperextension of the PIP joint makes finger closure impossible and\\ncan cause severe disability. Treatment is aimed at correcting the underlying disorder when possible (eg,\\ncorrecting the mallet finger or any bony malalignment, releasing spastic intrinsic muscles). Mild\\ndeformities in patients with RA may be treated with a functional ring splint.\\nTrue swan-neck deformity does not affect the thumb, which has only one interphalangeal\\n[\\nFig. 43-1.\\n Mallet finger.]\\n[\\nFig. 43-2.\\n Boutonniere and swan-neck deformities.]\\njoint. However, severe hyperextension of the interphalangeal joint of the thumb with flexion of the\\nmetacarpophalangeal (MCP) joint can occur; this is called a duck bill, Z (zigzag) type, or 90-angle\\ndeformity. With simultaneous thumb instability, pinch is greatly impaired. This deformity can usually be\\ncorrected by interphalangeal arthrodesis along with tendon reconstruction at the MCP joint.\\nBoutonniere Deformity\\n(Buttonhole Deformity)\\nA boutonniere deformity consists of flexion of the PIP joint accompanied by hyperextension of\\nthe DIP joint (see \\nFig. 43-2\\n).\\nThis deformity can result from tendon laceration, dislocation, fracture, osteoarthritis, or RA. Classically,\\nthe deformity is caused by disruption of the central slip attachment of the extensor tendon to the base of\\nthe middle phalanx, allowing the proximal phalanx to protrude (\"buttonhole\") between the lateral bands of\\nthe extensor tendon. Initial treatment consists of splinting, but it must occur before scarring and fixed\\ndeformities develop. Surgical reconstruction often cannot restore normal motion but may decrease the\\ndeformity and improve hand function.\\nDupuytren\\'s Contracture\\n(Palmar Fibromatosis)\\nDupuytren\\'s contracture is progressive contracture of the palmar fascial bands, causing flexion\\ndeformities of the fingers.\\nDupuytren\\'s contracture is one of the more common hand deformities; the incidence is higher among men\\nand increases after age 45. This autosomal dominant condition with variable penetrance may occur more\\ncommonly among patients with diabetes, alcoholism, or epilepsy. However, the specific factor that causes\\nthe palmar fascia to thicken and contract is unknown.\\nSymptoms and Signs\\nThe earliest manifestation is usually a tender nodule in the palm, most often near the middle or ring finger;\\nit gradually becomes painless. Next, a superficial cord forms and contracts the MCP joints and\\ninterphalangeal joints of the fingers. The hand eventually becomes arched. The disease is occasionally\\nassociated with fibrous thickening of the dorsum of the PIP joints (Garrod\\'s pads), Peyronie\\'s disease\\n(penile fibromatosis) in about 7 to 10% of patients, and rarely nodules on the plantar surface of the feet\\n(plantar fibromatosis). Other types of flexion deformities of the fingers can also occur in diabetes,\\nsystemic sclerosis, and chronic reflex sympathetic dystrophy, which need to be differentiated.\\nTreatment\\n Corticosteroid injection (before contractures develop)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n482'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 492, 'page_label': '483'}, page_content=\" Surgery for disabling contractures\\nInjection of a corticosteroid suspension into the nodule can relieve local tenderness if begun before\\ncontractures develop. If the hand cannot be placed flat on a table or, especially, when significant\\ncontracture develops at the \\nPIP joints, surgery is usually indicated. Excision of the diseased fascia must\\nbe meticulous because it surrounds neurovascular bundles and tendons. Incomplete excision or new\\ndisease results in recurrent contracture, especially in patients who are young at disease onset or who\\nhave a family history, Garrod's pads, Peyronie's disease, or plantar foot involvement. Injectable\\ncollagenase may reverse some contractures, although this treatment is not yet in widespread clinical use.\\nGanglia\\n(Ganglion Cysts)\\nGanglia are cystic swellings occurring usually on the hands, especially on the dorsal aspect of\\nthe wrists. Aspiration or excision is indicated for symptomatic ganglia.\\nGanglia constitute about 60% of chronic soft-tissue swellings affecting the hand and wrist. They usually\\ndevelop spontaneously in adults aged 20 to 50, with a female:male preponderance of 3:1.\\nEtiology\\nThe cause of most ganglia is unknown. The cystic structures are near or attached (often by a pedicle) to\\ntendon sheaths and joint capsules. The wall of the ganglion is smooth, fibrous, and of variable thickness.\\nThe cyst is filled with clear gelatinous, sticky, or mucoid fluid of high viscosity. The fluid in the cyst is\\nsometimes almost pure hyaluronic acid.\\nMost ganglia are isolated abnormalities. The dorsal wrist ganglion arises from the scapholunate joint and\\nconstitutes about 65% of ganglia of the wrist and hand. The volar wrist ganglion arises over the distal\\naspect of the radius and constitutes about 20 to 25% of ganglia. Flexor tendon sheath ganglia and\\nmucous cysts (arising from dorsal distal interphalangeal joint) make up the remaining 10 to 15%. Ganglia\\nmay spontaneously regress.\\nDiagnosis\\n Examination\\nGanglia are evident on examination. Another type of ganglion on the dorsal wrist occurs in patients with\\nRA; it is easily differentiated by its soft irregular appearance and association with proliferative rheumatoid\\nextensor tenosynovitis.\\nTreatment\\n Aspiration or excision if troublesome\\nMost ganglia do not require treatment. However, if the patient is disturbed by its appearance or if the\\nganglion is painful or tender, a single aspiration with a large-bore needle is effective in about 50% of\\npatients. Attempting to rupture the ganglion by hitting it with a hard object risks local injury without likely\\nbenefit. Nonsurgical treatment fails in about 40 to 70% of patients, necessitating surgical excision.\\nRecurrence rates after surgical removal are about 5 to 15%.\\nInfections\\nCommon bacterial hand infections include paronychia (see p. \\n735\\n), infected bite wounds, felon, palm\\nabscess, and infectious flexor tenosynovitis. Herpetic whitlow is a viral hand infection. Infections often\\nbegin with constant, intense, throbbing pain and are usually diagnosed by physical examination. X-rays\\nare taken in some infections (eg, bite wounds, infectious flexor tenosynovitis) to detect occult foreign\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n483\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 493, 'page_label': '484'}, page_content='bodies but may not detect small or radiolucent objects.\\nTreatment\\n Surgical measures and antibiotics\\nThe increased incidence of community-acquired and nosocomial methicillin-resistant \\nStaphylococcus\\naureus\\n (MRSA) should be taken into consideration. Uncomplicated MRSA infections are best treated with\\nincision and drainage. If there is a high incidence of MRSA and the infection is severe, hospitalization and\\nvancomycin or daptomycin (for IV therapy) are recommended, as is consultation with an infectious\\ndisease specialist. For outpatients, trimethoprim/sulfamethoxazole, clindamycin, doxycycline, or linezolid\\n(for oral therapy) can be given. Once culture and sensitivity results rule out MRSA, nafcillin, cloxacillin,\\ndicloxacillin, or a 1st- or 2nd-generation cephalosporin can be given.\\nInfected Bite Wounds\\nA small puncture wound, particularly from a human or cat bite, may involve significant injury to the tendon,\\njoint capsule, or articular cartilage. The most common cause of human bites is a tooth-induced injury to\\nthe metacar-pophalangeal\\n[\\nFig. 43-3.\\n Splint in the functional position (20 wrist extension, 60 metacarpophalangeal joint flexion,\\nslight interphalangeal joint flexion).]\\njoint as a result of a punch to the mouth (clenched fist injury). The oral flora of humans includes \\nEikenella\\ncorrodens\\n, staphylococci, streptococci, and anaerobes. Patients with clenched fist injuries tend to wait\\nhours or days after the wound occurs before seeking medical attention, which increases the severity of\\nthe infection. Animal bites usually contain multiple potential pathogens, including \\nPasteurella multocida\\n(particularly in cat bites), staphylococci, streptococci, and anaerobes. Serious complications include\\ninfectious arthritis and osteomyelitis.\\nDiagnosis\\n Clinical evaluation\\n X-rays\\nErythema and pain localized to the bite suggest infection. Tenderness along the course of a tendon\\nsuggests spread to the tendon sheath. Pain worsening significantly with motion suggests infection of a\\njoint or tendon sheath.\\nThe diagnosis is clinical, but if the skin is broken, x-rays should be taken to detect fracture or teeth or\\nother foreign bodies that could be a nidus of continuing infection.\\nTreatment\\n Debridement\\n Antibiotics\\nTreatment includes surgical debridement, with the wound left open, and antibiotics. For outpatient\\ntreatment, empiric antibiotics usually include monotherapy with amoxicillin/clavulanate 500 mg po tid or\\ncombined therapy with a penicillin 500 mg po qid (for \\nE. corrodens\\n, \\nP. multocida\\n, streptococci, and\\nanaerobes) plus a cephalosporin (eg, cephalexin 500 mg po qid) or semisynthetic penicillin (eg,\\ndicloxacillin 500 mg po qid) for staphylococci. In areas where MRSA is prevalent,\\ntrimethoprim/sulfamethoxazole, clindamycin, doxycycline, or linezolid should be used instead of a\\ncephalosporin. If the patient is allergic to penicillin, clindamycin 300 mg po q 6 h can be used. The hand\\nshould be splinted in the functional position and elevated (see \\nFig. 43-3\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n484'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 494, 'page_label': '485'}, page_content=\"Noninfected bites may require surgical debridement and prophylaxis with 50% of the dose of antibiotic\\nused to treat infected wounds.\\nFelon\\nA felon is an infection of the pulp space of the fingertip, usually with staphylococci and\\nstreptococci.\\nThe most common site is the distal pulp, which may be involved centrally, laterally, or apically. The septa\\nbetween pulp spaces ordinarily limit the spread of infection, resulting in an abscess, which creates\\npressure and necrosis of adjacent tissues. The underlying bone, joint, or flexor tendons may become\\ninfected. There is intense throbbing pain and a swollen, warm, extremely tender pulp. Treatment involves\\nprompt incision and drainage (using a mid-lateral incision that adequately divides the fibrous septa) and\\noral antibiotic therapy. Empiric treatment with a cephalosporin is adequate. In areas where MRSA is\\nprevalent, trimethoprim/sulfamethoxazole, clindamycin, doxycycline, or linezolid should be used instead of\\na cephalosporin.\\nPalm Abscess\\nA palm abscess is a purulent infection of deep spaces in the palm, typically with staphylococci\\nor streptococci.\\nPalm abscesses can include collar-button abscesses, thenar space abscesses, and midpalmar space\\nabscesses. An abscess can occur in any of the deep palmar compartments and spread \\nbetween the\\nmetacarpals, from the midpalmar space to the dorsum, manifesting as an infection on the dorsum of the\\nhand. Intense throbbing pain occurs with swelling and severe tenderness on palpation. X-rays should be\\ntaken to detect occult foreign bodies. Incision and drainage in the operating room (with cultures), with\\ncare to avoid the many important anatomic structures, and antibiotics (eg, a cephalosporin) are required.\\nIn areas where MRSA is prevalent, trimethoprim/sulfamethoxazole, clindamycin, doxycycline, or linezolid\\nshould be used instead of a cephalosporin.\\nInfectious Flexor Tenosynovitis\\nInfectious flexor tenosynovitis is an acute infection within the flexor tendon sheath.\\nThe usual cause is a penetration and bacterial inoculation of the sheath.\\nDiagnosis\\n Kanavel's signs\\n X-rays\\nInfectious flexor tenosynovitis causes Kanavel's signs:\\n Flexed resting position of the digit\\n Fusiform swelling\\n Tenderness along the flexor tendon sheath\\n Pain with passive extension of the digit\\nX-rays should be taken to detect occult foreign bodies. Acute calcific tendinitis and RA can restrict motion\\nand cause pain in the tendon sheath but can usually be differentiated from infectious flexor tenosynovitis\\nby a more gradual onset and the absence of some of Kanavel's signs. Disseminated gonococcal infection\\ncan cause tenosynovitis but often involves multiple joints (particularly those of the wrists, fingers, ankles,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n485\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 495, 'page_label': '486'}, page_content=\"and toes), and patients often have recent fever, rash, polyarthralgias, and often risk factors for an STD.\\nInfection of the tendon sheath may involve atypical mycobacteria, but these infections are usually indolent\\nand chronic.\\nTreatment\\n Surgical drainage and antibiotics\\nTreatment is surgical drainage (eg, irrigation of the tendon sheath by inserting a cannula into one end\\nand allowing the irrigating fluid to pass along the tendon sheath to the other end). Antibiotic therapy\\n(beginning empirically with a cephalosporin) and cultures are also required. In areas where MRSA is\\nprevalent, trimethoprim/sulfamethoxazole, clindamycin, doxycycline, or linezolid should be used instead of\\na cephalosporin.\\nHerpetic Whitlow\\nHerpetic whitlow is a cutaneous infection of the distal aspect of the finger caused by herpes\\nsimplex virus.\\nHerpetic whitlow may cause intense pain. The digital pulp is not very tense. Vesicles develop on the volar\\nor dorsal distal phalanx but often not until 2 to 3 days after pain begins. The intense pain can simulate a\\nfelon, but herpetic whitlow can usually be differentiated by the absence of tenseness in the pulp or the\\npresence of vesicles. The condition is self-limited but may recur. Incision and drainage are\\ncontraindicated. Topical acyclovir 5% can shorten the duration of a first episode. Oral acyclovir (800 mg\\npo bid) may prevent recurrences if given immediately after onset of recurrent symptoms. Open or draining\\nvesicles should be covered to prevent transmission.\\nKienbock's Disease\\nKienbock's disease is avascular necrosis of the lunate bone.\\nKienbock's disease occurs most commonly in the dominant hand of men aged 20 to 45, usually in workers\\ndoing heavy manual labor. Overall, Kienbock's disease is relatively rare. Its cause is unknown. The lunate\\ncan eventually collapse and cause fixed rotation of the scaphoid and subsequent degeneration of the\\ncarpal joints.\\nSymptoms and Signs\\nSymptoms generally start with insidious onset of wrist pain, localized to the region of the lunate carpal\\nbone; patients have no recollection of trauma. Kienbock's disease is bilateral in 10% of cases. There is\\nlocalized tenderness in the lunate bone.\\nDiagnosis\\n Imaging\\nMRI and CT are the most sensitive; plain x-rays show abnormalities later, usually beginning with a\\nsclerotic lunate, then later cystic changes, fragmentation, and collapse.\\nTreatment\\n Surgical procedures\\nTreatment is aimed at relieving pressure on the lunate by surgically shortening the radius or lengthening\\nthe ulna. Alternative treatments attempt to revascularize the lunate (eg, implanting a blood vessel or bone\\ngraft on a vascular pedicle). Salvage procedures (eg, proximal row carpectomy or intercarpal fusions)\\nmay help preserve some wrist function if the carpal joints have degenerated. Total wrist arthrodesis can\\nbe done as a last resort to relieve pain. Nonsurgical treatments are not effective.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n486\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 496, 'page_label': '487'}, page_content=\"Nerve Compression Syndromes\\nCommon nerve compression syndromes include carpal tunnel syndrome, cubital tunnel syndrome, and\\nradial tunnel syndrome. Compression of nerves often causes paresthesias; these paresthesias can often\\nbe reproduced by tapping the compressed nerve, usually with the examiner's fingertip (Tinel's sign).\\nSuspected nerve compression can be confirmed by testing nerve conduction velocity and distal latencies,\\nwhich accurately measure motor and sensory nerve conduction. Initial treatment is usually conservative,\\nbut surgical decompression may be necessary if conservative measures fail or if there are significant\\nmotor or sensory deficits.\\nCarpal Tunnel Syndrome\\nCarpal tunnel syndrome is compression of the median nerve as it passes through the carpal\\ntunnel in the wrist. Symptoms include pain and paresthesias in the median nerve distribution.\\nDiagnosis is suggested by symptoms and signs and is confirmed by nerve conduction velocity\\ntesting. Treatments include ergonomic improvements, analgesia, splinting, and sometimes\\ncorticosteroid injection or surgery.\\nCarpal tunnel syndrome is very common and most often occurs in women aged 30 to 50. Risk factors\\ninclude RA or other wrist arthritis (sometimes the presenting manifestation), diabetes mellitus,\\nhypothyroidism, acromegaly, amyloidosis, hemodialysis, and pregnancy-induced edema in the carpal\\ntunnel. Activities or jobs that require repetitive flexion and extension of the wrist may contribute, but rarely.\\nMost cases are idiopathic.\\nSymptoms and Signs\\nSymptoms include pain of the hand and wrist associated with tingling and numbness, classically\\ndistributed along the median nerve (the palmar side of the thumb, the index and middle fingers, and the\\nradial half of the ring finger) but possibly involving the entire hand. Typically, the patient wakes at night\\nwith burning or aching pain and with numbness and tingling and shakes the hand to obtain relief and\\nrestore sensation. Thenar atrophy and weakness of thumb opposition and abduction may develop late.\\nDiagnosis\\n Clinical evaluation\\n Nerve conduction testing\\nThe diagnosis is strongly suggested by Tinel's sign, in which median nerve paresthesias are reproduced\\nby tapping at the volar surface of the wrist over the site of the median nerve in the carpal tunnel.\\nReproduction of tingling with wrist flexion (Phalen's sign) is also suggestive. However, clinical\\ndifferentiation from other types of peripheral neuropathy may sometimes be difficult. If symptoms are\\nsevere or the diagnosis is uncertain, nerve conduction testing should be done on the affected arm for\\ndiagnosis and to exclude a more proximal neuropathy.\\nTreatment\\n Splinting\\n Sometimes corticosteroid/anesthetic injection\\n Sometimes surgical decompression\\nChanging the position of computer keyboards and making other ergonomic corrections may occasionally\\nprovide relief. Otherwise, treatment includes wearing a lightweight neutral wrist splint (see\\nFig. 43-4\\n), especially at night, and taking mild analgesics (eg, acetaminophen, NSAIDs). If these\\nmeasures do not control symptoms, a mixture of a corticosteroid and an anesthetic (eg, 1.5 mL of a 4-\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n487\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 497, 'page_label': '488'}, page_content=\"mg/mL dexamethasone solution mixed with 1.5 mL of 1% lidocaine) should be injected into the carpal\\ntunnel at a site just ulnar to the palmaris longus tendon and proximal to the distal crease at the wrist. If\\nbothersome symptoms persist or recur or if hand weakness and thenar wasting develop, the carpal tunnel\\ncan be surgically decompressed by using an open or endoscopic technique.\\n[\\nFig. 43-4.\\n Neutral wrist splint.]\\nCubital Tunnel Syndrome\\n(Ulnar Neuropathy)\\nCubital tunnel syndrome is compression or traction of the ulnar nerve at the elbow.\\nThe ulnar nerve is commonly irritated at the elbow or, rarely, the wrist. Cubital tunnel syndrome is most\\noften caused by leaning on the elbow or by prolonged and excessive elbow flexion. It is less common\\nthan carpal tunnel syndrome. Baseball pitching (particularly sliders), which can injure the medial elbow\\nligaments, confers risk.\\nSymptoms and Signs\\nSymptoms include numbness and paresthesia along the ulnar nerve distribution (in the ring and little\\nfingers and the ulnar aspect of the hand) and elbow pain. In advanced stages, weakness of the intrinsic\\nmuscles of the hand and the flexors of the ring and little fingers may develop. Weakness interferes with\\npinch between the thumb and index finger and with hand grip.\\nDiagnosis\\n Clinical evaluation\\n Sometimes nerve conduction studies\\nDiagnosis is often possible clinically. However, if clinical diagnosis is equivocal and when surgery is being\\nconsidered, nerve conduction studies are done. Cubital tunnel syndrome is differentiated from ulnar nerve\\nentrapment at the wrist (in Guyon's canal) by the presence of sensory deficits (on sensory testing or with\\nTinel's sign) over the ulnar dorsal hand and by the presence of ulnar nerve deficits proximal to the wrist\\non muscle testing or nerve conduction velocity testing.\\nTreatment\\nTreatment involves splinting at night, with the elbow extended at 45, and use of an elbow pad during the\\nday. Surgical decompression can help if conservative treatment fails.\\nRadial Tunnel Syndrome\\n(Posterior Interosseous Nerve Syndrome)\\nRadial tunnel syndrome is compression of the radial nerve in the proximal forearm.\\nCompression at the elbow can result from trauma, ganglia, lipomas, bone tumors, or radiocapitellar\\n(elbow) synovitis.\\nSymptoms and Signs\\nSymptoms include lancinating pain in the dorsum of the forearm and lateral elbow. Pain is precipitated by\\nattempted extension of the wrist and fingers and forearm supination. Sensory loss is rare because the\\nradial nerve is principally a motor nerve at this level. This disorder is sometimes confused with backhand\\ntennis elbow (lateral epicondylitis). When weakness of the extensor muscles is the primary finding, the\\ncondition is referred to as posterior interosseus nerve palsy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n488\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 498, 'page_label': '489'}, page_content='Diagnosis\\n Clinical evaluation\\nLateral epicondylitis can cause similar tenderness around the lateral epicondyle but does not cause\\nTinel\\'s sign or tenderness along the course of the radial nerve.\\nTreatment\\n Splinting\\nSplinting allows avoidance of the forceful or repeated motion of supination or wrist dorsiflexion, reducing\\npressure on the nerve. If wristdrop or weakened digital extension develops, or conservative treatment\\nfails to provide relief after 3 mo, surgical decompression may be needed.\\nNoninfectious Tenosynovitis\\n(See also p. \\n374\\n.)\\nAlthough the digital flexor tendons and extensor pollicis brevis are commonly affected, tenosynovitis may\\ninvolve any of the tendons in or around the hand.\\nDigital Flexor Tendinitis and Tenosynovitis\\n(Trigger Finger)\\nDigital flexor tendinitis and tenosynovitis are inflammation, sometimes with subsequent\\nfibrosis, of tendons and tendon sheaths of the digits.\\nThese conditions are idiopathic but are common among patients with RA or diabetes mellitus. Repetitive\\nuse of the hands (as may occur when using heavy gardening shears) may contribute. In diabetes, they\\noften coexist with carpal tunnel syndrome and occasionally with fibrosis of the palmar fascia. Pathologic\\nchanges begin with a thickening or nodule within the tendon; when located at the site of the tight first\\nannular pulley, the thickening or nodule blocks smooth extension or flexion of the finger. The finger may\\nlock in flexion, or \"trigger,\" suddenly extending with a snap.\\nTreatment\\n Conservative measures\\n Sometimes corticosteroid injection\\nTreatment of acute inflammation and pain includes splinting, moist heat, and anti-inflammatory doses of\\nNSAIDs (see p. \\n335\\n). If these measures fail, injection of a corticosteroid suspension into the flexor tendon\\nsheath, along with splinting, may provide safe, rapid relief of pain and triggering. Operative release can\\nbe done if corticosteroid therapy fails.\\nDe Quervain\\'s Syndrome\\n(Washerwoman\\'s Sprain)\\nDe Quervain\\'s syndrome is stenosing tenosynovitis of the short extensor (extensor pollicis\\nbrevis) and long abductor tendon (abductor pollicis longus) of the thumb within the first\\nextensor compartment.\\nDe Quervain\\'s syndrome usually occurs after repetitive use (especially wringing) of the wrist, although it\\noccasionally occurs in association with RA. The major symptom is aching pain at the wrist and thumb,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n489'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 499, 'page_label': '490'}, page_content=\"aggravated by motion. Tenderness can be elicited just proximal to the radial styloid process over the site\\nof the involved tendon sheaths. Diagnosis is highly suggested by the Finkelstein test. The patient\\nadducts the involved thumb into the palm and wraps the fingers over the thumb. The test is positive if\\ngentle passive ulnar deviation of the wrist provokes severe pain at the affected tendon sheaths.\\nTreatment\\n Corticosteroid injection\\n Thumb spica splint\\nRest, warm soaks, and NSAIDs may help in very mild cases. Local corticosteroid injections and a thumb\\nspica splint help 70 to 80% of cases. Tendon rupture is a rare complication of injection and can be\\nprevented by confining infiltration to the tendon sheath and avoiding injection of the corticosteroid into the\\ntendon. Intratendinous location of the needle is likely if injection is met with moderate or severe\\nresistance. Surgical release of the first extensor compartment is very effective when conservative therapy\\nfails.\\nOsteoarthritis of the Hand\\nHand involvement is extremely common in osteoarthritis.\\nOsteoarthritis affecting the hand may be asymptomatic enlargement of nodules at the proximal\\ninterphalangeal joint (Bouchard's nodules) or distal interphalangeal joint (Heberden's nodes) or\\nangulation at these joints. Pain and stiffness of these joints and the base of the thumb are also common.\\nThe wrist usually is spared, and there is usually minimal or no metacarpophalangeal joint involvement\\nunless the patient also has a metabolic disorder (eg, hemochromatosis). Differentiation of hand changes\\nin osteoarthritis from those in RA is discussed in\\nTable 32-7\\n on p. \\n296\\n.\\nTreatment\\n Conservative measures\\n Occasionally corticosteroid injection or surgery\\nTreatment is symptomatic with analgesics, appropriate rest, splinting, and occasionally corticosteroid\\ninjection as needed. Surgical procedures can help relieve pain and correct deformity for severe changes\\nat the base of the thumb and, less commonly, for advanced degeneration of the interphalangeal joints.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 43. Hand Disorders\\n490\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 500, 'page_label': '491'}, page_content='Chapter 44. Foot and Ankle Disorders\\nIntroduction\\nMost foot problems result from anatomic disorders or abnormal function of articular or extra-articular\\nstructures (see\\nFig. 44-1\\n). Less commonly, foot problems reflect a systemic disorder (see\\nTable 44-1\\n).\\nIn people with diabetes and people with peripheral vascular disease, careful examination of the feet, with\\nevaluation of vascular sufficiency and neurologic integrity, should be done at least twice/yr. People with\\nthese diseases should examine their own feet at least once/day.\\nThe feet are also common sites for corns and calluses (see p. \\n660\\n) and infections by fungus (see \\nTinea\\nPedis\\n on p. \\n708\\n), bacteria (see p. \\n694\\n), and viruses (see \\nWarts\\n on p. \\n715\\n).\\nTable 44-2\\n lists foot and ankle disorders according to anatomic site.\\nTable 44-3\\n lists common causes of heel pain according to location.\\nTibialis Posterior Tendinosis\\nTibialis posterior tendinosis, degeneration of the tibialis posterior tendon, is the most common\\ncause of pain behind the medial malleolus.\\nThe posterior tibial tendon lies immediately behind the medial malleolus. Degeneration results from long-\\nstanding biomechanical problems, such as excessive pronation often in obese people. The tendon can\\nalso be involved by primary inflammatory disorders, such as RA or gout.\\nSymptoms and Signs\\nEarly on, patients experience occasional pain behind the medial malleolus. Over time, the pain becomes\\nsevere, with painful swelling behind the medial malleolus. Normal standing, walking, and standing on the\\ntoes become difficult.\\n[\\nFig. 44-1.\\n Bones of the foot.]\\n[\\nTable 44-1.\\n Foot Manifestations of Systemic Disorders]\\nDiagnosis\\n MRI\\nClinical findings suggest the diagnosis. Palpation of the tendon in an inverted-plantar flexed position\\nusually elicits pain. Standing on the toes is usually painful and may not be possible if the tendon is\\nruptured. Pain and swelling behind the medial malleolus, especially with tibialis posterior tendon pain on\\n[\\nTable 44-2.\\n Common Foot and Ankle Disorders by Anatomic Site]\\npalpation, are highly suggestive. MRI or ultrasonography can confirm injury to the tendon and its extent.\\nTreatment\\n Orthotics and braces or surgery\\nComplete rupture requires surgery if normal function is the goal. Surgery is especially important in young\\nactive patients with acute tears. Conservative therapy consists of mechanically off-loading the tendon by\\nusing orthotics and ankle braces. Corticosteroid injections exacerbate the degenerative process (see\\nSidebar 44-1\\n). If the tendon is inflamed, rest and aggressive anti-inflammatory therapy are warranted.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n491'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 501, 'page_label': '492'}, page_content=\"Tarsal Tunnel Syndrome\\n(Posterior Tibial Nerve Neuralgia)\\nTarsal tunnel syndrome is pain along the course of the posterior tibial nerve, usually resulting\\nfrom nerve compression within the tarsal tunnel.\\nAt the level of the ankle, the posterior tibial nerve passes through a fibro-osseous canal and divides into\\nthe medial and lateral plantar nerves. Tarsal tunnel syndrome refers to compression of the nerve within\\nthis canal, but the term has been loosely applied to neuralgia of the posterior tibial nerve resulting from\\nany cause. Synovitis of the flexor tendons of the ankle caused by abnormal foot function, inflammatory\\narthritis (eg, RA), fracture, and ankle venous stasis edema are contributing factors. Patients with\\nhypothyroidism may develop tarsal tunnel-like symptoms as a result of perineural mucin deposition.\\nSymptoms and Signs\\nPain (occasionally burning and tingling) is usually retromalleolar and sometimes in the plantar medial heel\\nand may extend along the plantar surface as far as the toes. Although the pain is worse during standing\\nand walking, pain at rest may occur as the disorder progresses.\\nDiagnosis\\n Examination and electrodiagnostic testing\\nTapping or palpating the posterior tibial nerve below the medial malleolus at a site of compression or\\ninjury often causes distal tingling (Tinel's sign). While false-negative results on electrodiagnostic tests are\\nsomewhat common, a positive history combined with supportive physical findings and positive\\nelectrodiagnostic results makes the diagnosis of tarsal tunnel syndrome highly likely. The cause of any\\nswelling near the nerve should be determined.\\nTreatment\\n Foot inversion, injection, surgery, or a combination\\nStrapping the foot in a neutral or slightly inverted position or wearing an orthotic that keeps the foot\\ninverted reduces nerve tension. Local infiltration of a mixture of an insoluble corticosteroid and an\\nanesthetic may be effective if the cause is inflammation or fibrosis. Surgical decompression may be\\nnecessary to relieve suspected fibro-osseus compression with recalcitrant symptoms.\\n[\\nTable 44-3.\\n Disorders Associated with Heel Pain According to Location]\\nMetatarsalgia\\nMetatarsalgia is a general term for pain in the area of the metatarsophalangeal joints (ball of the\\nfoot). Most common causes include Freiberg's disease, interdigital nerve pain (Morton's\\nneuroma), metatarsophalangeal joint pain, and sesamoiditis.\\nFreiberg's Disease\\nFreiberg's disease is avascular necrosis of the metatarsal head.\\nFreiberg's disease is caused by microtrauma at the metaphysis and growth plate. Avascular necrosis\\nflattens the metatarsal head. The 2nd metatarsal head is most often affected. Freiberg's disease occurs\\nmore frequently among pubertal females and among people who have a short 1st metatarsal bone, which\\nincreases stress on the 2nd metatarsal head and joint.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n492\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 502, 'page_label': '493'}, page_content=\"The pain is most pronounced in the forefoot at the metatarsal head with weight bearing, particularly when\\npushing off or when wearing high-heeled footwear. The metatarsophalangeal joint may also be swollen\\nand have limited and painful passive range of motion.\\nDiagnosis\\n X-rays\\nThe diagnosis is confirmed with x-rays. Typically, the head of the 2nd metatarsal is widened and\\nflattened, and the metatarsal joint is sclerotic and irregular.\\nSidebar 44-1 Considerations for Using Corticosteroid Injections\\nCorticosteroid injections should be used judiciously to avoid adverse effects. Injectable corticosteroids\\nshould be reserved for inflammation, which is not present in most foot disorders. Because the tarsus,\\nankle, retrocalcaneal space, and dorsum of the toes have little connective tissue between the skin and\\nunderlying bone, injection of insoluble corticosteroids into these structures may cause depigmentation,\\natrophy, or ulceration, especially in elderly patients with peripheral arterial disease.\\nInsoluble corticosteroids can be given deeply rather than superficially with greater safety (eg, in the heel\\npad, tarsal canal, or metatarsal interspaces). The foot should be immobilized for a few days after tendon\\nsheaths are injected. Unusual resistance to injection suggests injection into a tendon. Repeated injection\\ninto a tendon should be avoided because the tendon may weaken (partially tear), predisposing to\\nsubsequent rupture.\\nTreatment\\n Immobilization and weight unloading if acute, then modification of footwear\\nCorticosteroid injections and immobilization may help to alleviate acutely painful flare-ups. Long-term\\nmanagement may require orthoses with metatarsal bars and low-heeled footwear to reduce stress on the\\n2nd metatarsal head and joint. Corticosteroid injections can be tried, and, rarely, surgical excision of the\\nmetatarsal head may be necessary to relieve recalcitrant pain.\\nInterdigital Nerve Pain\\n(Morton's Neuroma/Neuralgia)\\nInterdigital nerve irritation (neuralgia) or persistent benign enlargement of the perineurium\\n(neuroma) can cause pain, which may be nonspecific, burning, or lancinating, or a foreign body\\nsensation. Diagnosis is usually clinical. Treatment may involve correction of footwear, local\\ninjection, or sometimes surgical excision.\\nThe interdigital nerves of the foot travel beneath and between the metatarsals, extending distally to\\ninnervate the toes. Neuralgia of the interdigital nerve along its distal innervation near the ball of the foot\\ndevelops primarily as a result of improper or constrictive footwear or, less commonly, nerve traction\\nresulting from abnormal foot structure. As a result of chronic repetitive trauma, a benign thickening of the\\nnerve develops (Morton's neuroma).\\nSymptoms and Signs\\nInterdigital neuralgia is characterized by pain around the metatarsal heads or the toes. Early interdigital\\nneuralgia often causes an occasional mild ache or discomfort in the ball of the foot, usually when wearing\\na specific shoe, such as those that are too narrow at the front. Neuralgia is usually unilateral. As the\\ncondition progresses, the nerve thickens. The pain becomes worse, often with a burning or lancinating\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n493\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 503, 'page_label': '494'}, page_content=\"quality or paresthesias. In time, patients are unable to wear most shoes. While walking, patients often\\nfalsely sense a pebble in their shoes, which they take off for relief. Neuroma most frequently affects the\\n3rd interspace. Only slightly less common is involvement of the 2nd interspace. Sometimes both\\ninterspaces or feet are involved simultaneously.\\nDiagnosis\\n Clinical evaluation\\nThe symptoms are often specific, and the diagnosis is confirmed by tenderness on plantar palpation of\\nthe interdigital space and reproduction of the radiating burning pain by squeezing the space. Although\\nMRI does not usually confirm neuroma, it may be useful to rule out other interspace lesions or arthritis\\ncausing similar symptoms.\\nTreatment\\n Modification of footwear and injection\\nNeuralgia of recent onset usually resolves quickly with properly fitting shoes and insoles or with local\\nanesthetic injection. In contrast, neuromas may require one or more perineural infiltrations of long-acting\\ncorticosteroids with a local anesthetic. Injection is at a 45 angle to the foot, into the interspace at the\\nlevel of the dorsal aspect of the metatarsophalangeal joints. An appropriate orthotic often relieves\\nsymptoms. If conservative therapy is ineffective, excision often brings complete relief. However, another\\nneuroma occasionally develops at the site of nerve excision (amputation or stump neuroma).\\nMetatarsophalangeal Joint Pain\\nMetatarsophalangeal joint pain usually results from tissue changes due to aberrant foot\\nbiomechanics. Symptoms and signs include pain with walking and tenderness. Diagnosis is\\nclinical; however, infection or systemic rheumatic diseases (eg, RA) may need to be excluded\\nby testing. Treatment includes orthotics, sometimes local injection, and occasionally surgery.\\nMetatarsophalangeal joint pain most commonly results from misalignment of the joint surfaces with altered\\nfoot biomechanics, causing joint subluxations, capsular impingement, and joint cartilage destruction\\n(osteoarthrosis). Misaligned joints may cause synovial impingement, with minimal if any heat and swelling\\n(osteoarthritic synovitis).\\nMetatarsophalangeal joint subluxations also occur as a result of inflammatory arthropathy, particularly RA.\\nInflammatory synovitis and interosseous muscle atrophy in RA lead to subluxations of the lesser\\nmetatarsophalangeal joints as well, resulting in hammer toe deformities. Consequently, the metatarsal fat\\npad, which usually cushions the stress between the metatarsals and interdigital nerves during walking,\\nmoves distally under the toes; interdigital neuralgia or Morton's neuroma may result. To compensate for\\nthe loss of cushioning, adventitial calluses and bursae may develop.\\nMetatarsophalangeal joint pain may also result from functional hallux limitus, which limits passive and\\nactive joint motion and usually occurs at the 1st metatarsophalangeal joint. Patients usually have foot\\npronation disorders that result in elevation of the 1st ray with lowering of the medial longitudinal arch\\nduring weight bearing. As a result of the 1st ray elevation, the proximal phalanx of the great toe cannot\\nfreely extend on the 1st metatarsal head; the result is jamming at the dorsal joint leading to osteoarthritic\\nchanges and loss of joint motion. Over time, pain may develop, and the joint may become less mobile with\\nan arthrosis (hallux rigidus), which can be debilitating.\\nSymptoms and Signs\\nSymptoms include pain on walking. Dorsal and plantar joint tenderness is usually present on palpation\\nand during passive range of motion. Mild swelling with minimal heat occurs in osteoarthritic synovitis.\\nSignificant warmth, swelling, or redness suggests inflammatory arthropathies or infection.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n494\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 504, 'page_label': '495'}, page_content='Diagnosis\\n Mainly clinical evaluation\\n Exclusion of infection or arthropathy if signs of inflammation\\nMetatarsophalangeal joint pain can usually be differentiated from neuralgia or neuroma of the interdigital\\nnerves by the absence of burning, numbness, and tingling and interspace pain, although these symptoms\\nmay develop from joint inflammation; if so, palpation can help with differentiation.\\nMonarticular heat, redness, and swelling indicate infection until proven otherwise, although gout is more\\nlikely. When warmth, redness, and swelling involve multiple joints, evaluation for a systemic cause of joint\\ninflammation (eg, gout, RA, viral-associated arthritis, enteropathic arthritis) with a rheumatic disease\\nassessment (eg, antinuclear antibodies, rheumatoid factor, ESR) is indicated.\\nTreatment\\n Orthoses\\nFoot orthoses may help to redistribute and relieve pressure from the noninflamed joints. With excess\\nsubtalar eversion or when the feet are highly arched, an orthotic that corrects these abnormal motions\\nshould be prescribed. For functional hallux limitus, orthosis modifications may further help to plantarflex\\nthe 1st ray to improve metatarsophalangeal joint motion and reduce pain. For more severe limitation of\\n1st metatarsophalangeal motion or pain, the use of rigid orthoses, carbon fiber plates, or external shoe\\nbars or rocker soles may be necessary to reduce motion at the joint. Surgery may be needed if\\nconservative therapies are ineffective. If inflammation (synovitis) is present, injection of a local\\ncorticosteroid/anesthetic mixture may be useful.\\nSesamoiditis\\nSesamoiditis is pain at the sesamoid bones beneath the head of the 1st metatarsal, with or\\nwithout inflammation or fracture. Diagnosis is usually clinical. Treatment is usually modification\\nof footwear.\\nThe 2 semilunar-shaped sesamoid bones aid the foot in locomotion. The medial bone is the tibial\\nsesamoid, and the lateral bone is the fibular sesamoid. Direct trauma or positional change of the\\nsesamoids due to alterations in foot structure (eg, lateral displacement of a sesamoid due to lateral\\ndeviation of the great toe) can make the sesamoids painful. Sesamoiditis is particularly common among\\ndancers, joggers, and those who have high-arched feet or wear high heels. Many people with\\nsesamoiditis have bunions.\\nSymptoms and Signs\\nThe pain of sesamoiditis is beneath the head of the 1st metatarsal; the pain is usually made worse by\\nwalking and may be worse when wearing certain shoes. Occasionally, inflammation occurs, causing mild\\nwarmth and swelling or occasionally redness that may extend medially and appear to involve the 1st\\nmetatarsophalangeal joint. Sesamoid fracture can also cause pain, moderate swelling, and possibly\\ninflammation.\\nDiagnosis\\n Clinical evaluation\\n Imaging if fracture, infection, or gout is suspected\\nWith the foot and 1st (big) toe dorsiflexed, the examiner inspects the metatarsal head and palpates each\\nsesamoid. Tenderness is localized to a sesamoid, usually the tibial sesamoid. Hyperkeratotic tissue may\\nindicate that a wart or corn is causing pain. If inflammation causes swelling around the 1st\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n495'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 505, 'page_label': '496'}, page_content='metatarsophalangeal joint, arthrocentesis is usually indicated to exclude gout and infectious arthritis. If\\nfracture, osteoarthritis, or displacement is suspected, x-rays are taken. Sesamoids separated by cartilage\\nor fibrous tissue (bipartite \\nsesamoids) may appear fractured on x-rays. If plain x-rays are equivocal, MRI\\nmay be ordered.\\nTreatment\\n New shoes, orthotics, or both\\nSimply not wearing the shoes that cause pain may be sufficient. If symptoms persist, shoes with a thick\\nsole and orthotics are prescribed and help by reducing sesamoid pressure. If fracture without\\ndisplacement is present, conservative therapy may be sufficient and may also involve immobilization of\\nthe joint with the use of a flat, rigid, surgical shoe. NSAIDs and injections of a corticosteroid/local\\nanesthetic solution can be helpful. Although surgery may help in recalcitrant cases, it is controversial\\nbecause of the potential for disturbing biomechanics and locomotion of the foot. If inflammation is\\npresent, treatment includes conservative measures plus local infiltration of a corticosteroid/anesthetic\\nsolution to help reduce symptoms.\\nPlantar Fasciosis\\n(Plantar Fasciitis)\\nPlantar fasciosis is pain at the site of the attachment of the plantar fascia and the calcaneus,\\nwith or without accompanying pain along the medial band of the plantar fascia. Diagnosis is\\nmainly clinical. Treatment involves calf muscle and plantar soft-tissue foot-stretching exercises,\\nnight splints, and orthotics.\\nSyndromes of pain in the plantar fascia have been called plantar fasciitis; however, because there is\\nusually no inflammation, plantar fasciosis is more correct. Other terms used include calcaneal\\nenthesopathy pain or calcaneal spur syndrome; however, there may be no bone spurs on the calcaneus.\\nPlantar fasciosis may involve acute or chronic stretching, tearing, and degeneration of the fascia at its\\nattachment site.\\nEtiology\\nRecognized causes include shortening or contracture of the calf muscles and plantar fascia. Risk factors\\nfor such shortening include a sedentary lifestyle, occupations requiring sitting, very high or low arches in\\nthe feet, and wearing high-heel shoes. The disorder is also common among runners and dancers and\\nmay occur in people whose occupations involve standing or walking on hard surfaces for prolonged\\nperiods. Disorders that may be associated with plantar fasciosis are obesity, RA, reactive arthritis, and\\npsoriatic arthritis. Multiple injections of corticosteroids may contribute by causing degenerative changes\\nof the fascia and possible loss of the cushioning subcalcaneal fat pad.\\nSymptoms and Signs\\nPlantar fasciosis is characterized by pain at the bottom of the heel on weight bearing, particularly when\\nfirst arising in the morning; pain usually improves within 5 to 10 min, only to return later in the day. It is\\noften worse when pushing off of the heel (the propulsive phase of gait). Acute severe heel pain,\\nespecially with mild local puffiness, may indicate an acute tear. Some patients describe burning or sticking\\npain along the plantar medial border of the foot when walking.\\nDiagnosis\\n Pain reproduced by calcaneal pressure during dorsiflexion\\nOther disorders causing heel pain can mimic plantar fasciosis:\\n Throbbing heel pain, particularly when the shoes are removed or when mild heat and puffiness are\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n496'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 506, 'page_label': '497'}, page_content=\"present, is more suggestive of calcaneal bursitis (see p. \\n401\\n).\\n Acute severe retrocalcaneal pain, with redness and heat, may indicate gout.\\n Pain that radiates from the low back to the heel may be an S1 radiculopathy due to an L5 disk\\nherniation.\\nPlantar fasciosis is confirmed if firm thumb pressure applied to the calcaneus when the foot is dorsiflexed\\nelicits pain. Fascial pain along the plantar medial border of the fascia may also be present. If findings are\\nequivocal, demonstration of a heel spur on x-ray may support the diagnosis; however, absence does not\\nrule out the diagnosis, and visible spurs are not generally the cause of symptoms. Also, infrequently,\\ncalcaneal spurs appear ill defined on x-ray, exhibiting fluffy new bone formation, suggesting\\nspondyloarthropathy (eg, ankylosing spondylitis, reactive arthritis). If an acute fascial tear is suspected,\\nMRI is done.\\nTreatment\\n Splinting, stretching, and cushioning or orthotics\\nTo alleviate the stress and pain on the fascia, the person can take shorter steps and avoid walking\\nbarefoot. Activities that involve foot impact, such as jogging, should be avoided. The most effective\\ntreatments include the use \\nof in-shoe heel and arch cushioning with calf-stretching exercises and night\\nsplinting devices that stretch the calf and plantar fascia while the patient sleeps. Prefabricated or custom-\\nmade foot orthotics may also alleviate fascial tension and symptoms. Other treatments may include\\nactivity modifications, NSAIDs, weight loss in obese patients, cold and ice massage therapy, and\\noccasional corticosteroid injections. However, because corticosteroid injections can predispose to plantar\\nfasciosis, many clinicians limit these injections. For recalcitrant cases, physical medicine, oral\\ncorticosteroids, and cast immobilization should be used before surgical intervention is considered.\\nInferior Calcaneal Bursitis\\nBursitis can develop at the inferior calcaneus, near the insertion of the plantar fascia. Symptoms and\\nsigns include throbbing heel pain, particularly when the shoes are removed; mild warmth; and swelling.\\nThe pain is most pronounced when the heel first contacts the ground during walking or running activity.\\nTreatment is injection of a local anesthetic/corticosteroid mixture and soft-soled shoes with added\\nprotective heel cushion padding.\\nAchilles Tendon Enthesopathy\\nAchilles tendon enthesopathy is pain at the insertion of the Achilles tendon at the\\nposterosuperior aspect of the calcaneus.\\nThe cause is chronic traction of the Achilles tendon on the calcaneus. Contracted or shortened calf\\nmuscles (resulting from a sedentary lifestyle and obesity) and athletic overuse are factors. Enthesopathy\\nmay be caused by a spondyloarthropathy.\\nPain at the posterior heel below the top of the shoe counter during ambulation is characteristic. Pain on\\npalpation of the tendon at its insertion is diagnostic. Manual dorsiflexion of the ankle during palpation\\nusually exacerbates the pain. Recurrent and especially multifocal enthesitis should prompt evaluation\\n(history and examination) for a spondyloarthropathy.\\nTreatment\\n Stretching, splinting, and heel lifts\\nPhysical therapy aimed at calf muscle stretching should be done 10 min three times/day. The patient can\\nexert pressure posteriorly to stretch the calf muscle while facing a wall at arms' length, with knees\\nextended and foot dorsiflexed. To minimize stress to the Achilles tendon with weight bearing, the patient\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n497\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 507, 'page_label': '498'}, page_content=\"should move the foot and ankle actively through their range of motion for about 1 min when rising after\\nextended periods of rest. Night splints may also be prescribed to provide passive stretch during sleep and\\nhelp prevent contractures. Heel lifts should be used temporarily to decrease tendon stress during weight\\nbearing and relieve pain. Heel lifts should be used bilaterally to prevent gait disturbance even if pain is\\nonly in one heel.\\nAnterior Achilles Tendon Bursitis\\n(Albert's Disease; Retromalleolar Bursitis)\\nAnterior Achilles tendon bursitis is inflammation of the retromalleolar (retrocalcaneal) bursa,\\nlocated anterior (deep) to the attachment of the Achilles tendon to the calcaneus.\\nBursitis is due to trauma (eg, from rigid or poorly fitting shoes) or inflammatory arthritis (eg, RA, gout). On\\noccasion, small calcaneal erosions may develop from severe inflammation.\\nSymptoms and Signs\\nSymptoms and signs caused by trauma or gout develop rapidly; those caused by another systemic\\ndisorder develop gradually. Pain, swelling, and warmth around the heel are common, as are difficulty\\nwalking and wearing shoes. The bursa is tender. Initially, the swelling is localized anterior to the Achilles\\ntendon but in time extends medially and laterally.\\nUsing the thumb and index finger, side-to-side compression anterior to the Achilles tendon causes pain.\\nDiagnosis\\n Clinical evaluation and x-rays\\nFracture of the posterolateral talar tubercle also causes tenderness anterior to the insertion of the\\nAchilles tendon. Bursitis is often differentiated from the fracture by the localization of warmth and swelling\\ncontiguous to the tendon and pain localized primarily in the soft tissue. Also, x-rays are taken to rule out\\nfracture as well as erosive calcaneal changes characteristic of chronic RA or other rheumatic disorders.\\nTreatment\\n Intrabursal injection of a soluble corticosteroid/anesthetic solution\\nA corticosteroid/anesthetic injection, NSAIDs, and warm or cold compresses may be effective. Care must\\nbe taken to inject only the bursal sac and not the tendon proper because tendon injection may lead to\\ntendon weakening or tearing, predisposing to subsequent rupture.\\nPosterior Achilles Tendon Bursitis\\nPosterior Achilles tendon bursitis is inflammation of a bursa that forms in response to shoe\\npressure and is located at the top edge of the posterior shoe counter between the skin and\\nAchilles tendon.\\nThis disorder occurs mainly in young women. Wearing high-heeled shoes is a risk factor. Many patients\\nhave a bony prominence (Haglund's deformity) on the calcaneus.\\nSymptoms and Signs\\nSymptoms and signs develop at the top edge of the posterior shoe counter. Early symptoms may be\\nlimited to redness, pain, and warmth. Later, superficial skin erosion may occur. After months or longer, a\\nfluctuant, tender, cystic nodule 1- to 3-cm in diameter develops. It is red or flesh-colored. In chronic cases,\\nthe bursa becomes fibrotic.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n498\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 508, 'page_label': '499'}, page_content=\"Diagnosis\\n Symptoms and a small, tender, flesh-colored or red nodule\\nThe presence of the small, tender, flesh-colored or red nodule in a patient with compatible symptoms is\\ndiagnostic. Rarely, an Achilles tendon xanthoma develops at the top edge of the posterior shoe counter\\nbut tends to be pink and asymptomatic. Achilles tendon enthesopathy causes pain mainly at the tendon's\\ninsertion but may also cause pain at the top edge of the posterior shoe counter. Enthesopathy is\\ndifferentiated by the absence of a soft-tissue lesion.\\nTreatment\\n Modification of footwear\\nProperly fitting shoes with low heels are essential. A foam rubber or felt heel pad may be needed to lift the\\nheel high enough so that the bursa does not hit the shoe counter. Padding around the bursa or the\\nwearing of a backless shoe until inflammation subsides is indicated. Foot orthotics may enhance rear foot\\nstability and help reduce irritating motion on the posterior calcaneus while walking. Warm or cool\\ncompresses, NSAIDs, and intrabursal injection of a local anesthetic/corticosteroid solution offer temporary\\nrelief; the Achilles tendon itself must not be injected. Surgical removal of a portion of the underlying bone\\nmay rarely be necessary to reduce soft-tissue impingement.\\nEpiphysitis of the Calcaneus\\n(Sever's Disease)\\nEpiphysitis of the calcaneus is painful disruption between the calcaneal apophysis and the body\\nof the heel that occurs before calcaneal ossification is complete.\\nThe calcaneus develops from two centers of ossification: one begins at birth, the other usually after age\\n8. Ossification is usually complete by age 15. The cartilaginous disruption in calcaneal epiphysitis may\\nresult from an excessive pull on the apophysis by contracted or shortened calf muscles. Bone growth\\nspurts without adaptive calf muscle lengthening may play a role.\\nPain develops in a patient (usually aged 9 to 14) with a history of athletic activity; it affects the sides or\\nmargins of the heel and is aggravated by standing on tip toes or running. Warmth and swelling are\\noccasionally present.\\nThe diagnosis is clinical. X-rays are not helpful.\\nTreatment\\n Heel pads and splinting or casting\\nHeel pads relieve symptoms by reducing the pull of the Achilles tendon on the heel. Night splints may be\\nused to passively stretch the calf muscles, helping maintain flexibility. In more severe or recalcitrant\\ncases, cast immobilization may be used to relieve pain and stretch the calf muscles. Reassurance is\\nimportant because symptoms may last several months.\\nMedial Plantar Nerve Entrapment\\nMedial plantar nerve entrapment is symptomatic compression of the medial branch of the\\nposterior tibial nerve at the medial heel.\\nSymptoms include almost constant pain, with and without weight bearing. Simple standing is often\\ndifficult. Burning, numbness, and paresthesias are usually absent.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n499\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 509, 'page_label': '500'}, page_content=' Clinical evaluation\\nMedial plantar nerve entrapment may be confused with plantar fasciosis and heel spur pain as well as\\ntarsal tunnel syndrome. In medial plantar nerve entrapment, the following are present:\\n Tenderness is at the medial heel.\\n Other signs of tarsal tunnel syndrome are absent.\\n Symptoms can be reproduced by palpation over the proximal aspect of the abductor hal-lucis, the origin\\nof the plantar fascia, or both at the medial tubercle of the calcaneus.\\nTreatment\\n Orthoses, immobilization, and physical therapy\\nImmobilization and foot orthoses to prevent irritating motion and pressure may be helpful, as may physical\\ntherapy and cryotherapy. If these treatments are ineffective, injection with a sclerosing agent that contains\\nalcohol or careful surgical decompression of the nerve may help relieve pain.\\nPlantar Fibromatosis\\nPlantar fibromatosis is a benign proliferative neoplasia of the plantar fascia.\\nIn plantar fibromatosis, nodules are displayed most easily when the foot is dorsiflexed against the leg.\\nMost patients also have palmar nodules, usually located at the 4th metacarpophalangeal joint. Reported\\nassociations with diabetes, epilepsy, and alcoholism may be anecdotal. Treatment is usually not indicated\\nunless the nodules become large enough to cause pressure-related pain with weight bearing. If so,\\northoses can help redistribute pressure away from the fibrotic nodular lesions. Surgery usually results in\\nrecurrence and may also result in unintentional instability of the foot when fascial removal is excessive.\\nHammer Toe Deformity\\nHammer toe is a C-shaped deformity caused by dorsal subluxation at the metatarsophalangeal\\njoint.\\n[\\nFig. 44-2.\\n Hammer toe.]\\nThe usual cause is misalignment of the joint surfaces due to a genetic predisposition toward aberrant foot\\nbiomechanics and tendon contractures. RA and neurologic disorders such as Charcot-Marie-Tooth\\ndisease are other causes. The 2nd toe is the most common digit to develop a hammer toe deformity (see\\nFig. 44-2\\n). Second toe hammer toes commonly result from an elongated 2nd metatarsal and from\\npressure due to an excessively abducted great toe (hallux valgus deformity) causing a bunion (see\\nbelow). Painful corns (see p. \\n660\\n) often develop in hammer toe deformity, particularly of the 5th toe.\\nReactive adventitial bursas often develop beneath corns, which may become inflamed.\\nSymptoms include pain while wearing shoes, especially shoes with low and narrow toe boxes, and\\nsometimes metatarsalgia. Diagnosis is clinical. Joints are examined for coexistent arthritis (eg, RA).\\nTreatment\\n Wide toe box, toe pads, orthotics, or a combination\\nShoes should have a wide toe box. Toe pads sold in pharmacies also help by shielding the affected toes\\nfrom the overlying shoe. If these measures are ineffective, surgical correction of the deformity often\\nrelieves symptoms. If there is accompanying metatarsalgia, OTC or prescription orthotic devices with\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n500'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 510, 'page_label': '501'}, page_content=\"metatarsal pads and cushioning may help alleviate the pain.\\nBunion\\nBunion is a prominence of the medial portion of the head of the 1st metatarsal bone. The cause\\nis often variations in position of the 1st \\nmetatarsal bone or great toe, such as lateral angulation\\nof the great toe (hallux valgus). Secondary osteoarthritis and spur formation are common.\\nSymptoms may include pain and redness, bursitis medial to the joint, and mild synovitis.\\nDiagnosis is usually clinical. Treatment is usually a shoe with a wide toe box, protective pads,\\nand orthotics. For bursitis or synovitis, corticosteroid injection may be helpful.\\nContributing factors may include excessive turning in (pronation) of the ankles, wearing tight and pointed-\\ntoe shoes, and occasionally trauma. Joint misalignment causes osteoarthritis with cartilage erosion and\\nexostosis formation, resulting in joint motion being limited (hallux limitus) or eliminated (hallux rigidus). In\\nlate stages, synovitis occurs, causing joint swelling. In reaction to pressure from tight shoes, an\\nadventitious bursa can develop medial to the joint prominence, which can become painful, swollen, and\\ninflamed (see\\nFig. 44-3\\n).\\nSymptoms and Signs\\nThe initial symptom may be pain at the joint prominence when wearing certain shoes. The joint capsule\\nmay be tender at any stage. Later symptoms may include a painful, warm, red, cystic, movable, fluctuant\\nswelling located medially (adventitial bursitis) and swellings and mild inflammation affecting the entire joint\\n(osteoarthritic synovitis), which is more circumferential. With hallux limitus or rigidus, there is restriction of\\npassive joint motion, tenderness of the lateral aspect of the joint, and increased dorsiflexion of the distal\\nphalanx.\\n[\\nFig. 44-3.\\n Bunion.]\\nDiagnosis\\n Clinical evaluation\\nClinical findings are usually specific. Acute circumferential intense pain, warmth, swelling, and redness\\nsuggest gouty arthritis or infectious arthritis, mandating examination of synovial fluid. If multiple joints are\\naffected, gout or another systemic rheumatic disease should be considered. If clinical diagnosis of\\nosteoarthritic synovitis is equivocal, x-rays are taken. Suggestive findings include joint space narrowing\\nand bony spurs extending from the metatarsal head or sometimes from the base of the proximal phalanx.\\nPeriarticular erosions (Martel's sign) seen on imaging studies suggest gout.\\nTreatment\\n Wide toe box, bunion pads, orthotics, or a combination\\n Treatment of complications\\nMild discomfort may lessen by wearing a shoe with a wide toe box. If not, bunion pads purchased in most\\npharmacies can shield the painful area. Orthotics can also be prescribed to redistribute and relieve\\npressure from the affected articulation. If conservative therapy fails or if the patient is unwilling to wear\\nlarge, wide shoes and orthotics because they are unattractive, surgery aimed at correcting abnormal bony\\nalignments and restoring joint mobility should be strongly considered. For bursitis, bursal aspiration and\\ninjection of a corticosteroid are indicated. For osteoarthritic synovitis, oral NSAIDs or an intra-articular\\ninjection of a corticosteroid/anesthetic solution reduces symptoms. For hallux limitus or hallux rigidus,\\ntreatment aims to preserve joint mobility by using passive stretching exercises, which occasionally require\\ninjection of a local anesthetic to relieve muscle spasm. Sometimes surgical release of contractures is\\nnecessary.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 44. Foot & Ankle Disorders\\n501\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 511, 'page_label': '502'}, page_content=\"Chapter 45. Tumors of Bones and Joints\\nIntroduction\\nBone tumors may be primary or metastatic and benign or malignant.\\nIn children, most bone tumors are primary and benign; some are malignant primary tumors (eg,\\nosteosarcoma, Ewing's sarcoma). Very few are metastatic tumors (eg, neuroblastoma, Wilms' tumor).\\nBone also can be affected by childhood leukemia and lymphomas.\\nIn adults, especially those over age 40, metastatic tumors are about 100 times more common than primary\\nmalignant tumors. Excluding marrow cell tumors (eg, multiple myeloma), there are only about 2500 cases\\nof primary malignant bone tumors in the US each year among children and adults.\\nSynovial tumors are extremely rare in both children and adults. Pigmented villonodular synovitis is a\\nbenign but at times destructive tumor of synovial cells. Synovial sarcoma (often with both spindle cell and\\nglandular-like components) is a malignant soft-tissue tumor not of synovial origin, which seldom occurs\\ninside of a joint.\\nSymptoms and Signs\\nBone tumors typically cause unexplained, progressive pain and swelling. Pain can occur without weight\\nbearing or bone stress and can occur at rest and at night.\\nDiagnosis\\n Plain x-rays\\n MRI usually and sometimes CT\\n Bone scan if multicentric or metastatic tumors are suspected\\n Biopsy unless imaging studies clearly show benign characteristics\\nThe most common reason that diagnosis of bone tumors is delayed is that physicians fail to suspect the\\ntumor and order appropriate imaging studies. Persistent or progressive unexplained pain of the trunk or\\nextremities, particularly if associated with a mass, is suggestive. Plain x-rays are the first test. Tumors\\nshould also be suspected if a radiographic study shows an unexplained abnormality consistent with a\\ntumor. Lesions suggestive of tumors usually require further assessment, often with additional imaging\\nstudies and a biopsy.\\nCharacteristic findings:\\n Some tumors (eg, Paget's disease, nonossifying fibroma, fibrous dysplasia,\\nenchondromas) may have characteristic radiographic findings and can be diagnosed without biopsy.\\nRadiographic findings that suggest cancer include the following:\\n A lytic, destructive, or permeative appearance\\n Irregular tumor borders\\n Areas, especially multiple areas, of bone destruction (moth-eaten appearance)\\n Cortical destruction\\n Soft-tissue extension\\n Pathologic fracture\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 45. Tumors of Bones & Joints\\n502\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 512, 'page_label': '503'}, page_content=\"A lytic appearance is characterized by clear areas of bone destruction that are sharply demarcated. A\\npermeative appearance is characterized by a faint, gradual loss of bone or an infiltrating pattern without\\nclear borders. Certain tumors have a characteristic appearance (eg, Ewing's sarcoma typically shows\\npermeative-type bone destruction, including a large soft-tissue mass with periosteal onion-skin reactive\\nbone often before there is an extensive, lytic, destructive appearance; giant cell tumor has a cystic\\nappearance without a sclerotic interface between the tumor and normal bone). The tumor's location may\\nnarrow diagnostic possibilities (eg, Ewing's sarcoma commonly appears in the shaft of a long bone;\\nosteosarcoma usually appears in the metaphyseal-diaphyseal region toward the end of a long bone; giant\\ncell tumor usually occurs in the epiphysis).\\nSome benign conditions, however, can mimic a malignant tumor:\\n Heterotopic ossification (myositis ossificans) and exuberant callus formation after fracture can cause\\nmineralization around bony cortices and in adjacent soft tissues, mimicking malignant tumors.\\n Langerhans' cell histiocytosis (histiocytosis X, Letterer-Siwe disease, Hand-Schuller-Christian disease,\\neosinophilic granuloma) can cause solitary or multiple bone lesions that are usually distinguishable on\\nx-ray. In solitary lesions, there may be periosteal new bone formation, suggesting a malignant bone\\ntumor.\\n Osteopoikilosis (spotted bones) is an asymptomatic condition of no clinical consequence but can\\nsimulate osteoblastic bone metastases of breast cancer. It is characterized by multiple small, round, or\\noval foci of bony sclerosis, usually in the tarsal, carpal, or pelvic bones or the metaphyseal-epiphyseal\\nregions of tubular bones.\\nOther testing:\\n CT and MRI may help define the location and extent of a bone tumor and sometimes\\nsuggest a specific diagnosis. MRI is usually done if cancer is suspected. If tumors are suspected of being\\nmetastatic or involving multiple foci (multicentric), then radioisotopic technetium bone scanning should be\\ndone to search for all tumors.\\nBiopsy is usually essential for diagnosis of malignant tumors, unless the imaging studies have a\\nclassically benign appearance. The pathologist should be given pertinent details of the clinical history\\nand should review imaging studies. Histopathologic diagnosis may be difficult and requires sufficient\\nviable tissue from a representative portion of the tumor (usually the soft portion). The best results are\\nobtained in centers with extensive experience in bone biopsies. Immediate, accurate, definitive diagnosis\\nis possible in > 90% of cases. If a malignant diagnosis is suspected on frozen section histology, often the\\nsurgeon will wait upon permanent histology before treating definitively. Mistakes occur more frequently in\\nhospitals that infrequently encounter patients with malignant primary tumors.\\nBenign Bone Tumors\\nOsteochondroma:\\n Osteochondromas (osteocartilaginous exostoses), the most common benign bone\\ntumors, may arise from any bone but tend to occur near the ends of long bones. These tumors manifest\\nmost often in people aged 10 to 20 and may be single or multiple. Multiple osteochondromas tend to run\\nin families. Secondary malignant chondrosarcoma develops in about 10% of patients with multiple\\nosteochondromas and in well < 1% of those with single osteochondromas. Osteochondromas rarely\\ncause the bone to fracture.\\nOn imaging studies, the lesion appears as a bony prominence with a cartilage cap (< 2 cm) off the\\nsurface of the bone with no underlying cortex under the prominence.\\nExcision is needed if the tumor is compressing a large nerve; causes pain (especially when impinging on\\nmuscle and creating an inflammatory bursa); disturbs growth; or on imaging study has a destructive\\nappearance, soft-tissue mass, or thickened cartilaginous cap (> 2 cm) suggesting transformation into\\nmalignant chondrosarcoma.\\nEnchondroma:\\n Enchondromas may occur at any age but tend to be recognized in patients aged 10 to\\n40. They are usually located within the medullary bone metaphyseal-diaphyseal region. These tumors are\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 45. Tumors of Bones & Joints\\n503\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 513, 'page_label': '504'}, page_content='usually asymptomatic but may enlarge and become painful. They are often found when x-rays are taken\\nfor another reason.\\nOn x-ray, the tumor may appear as a lobulated calcified area within bone; some lesions are less calcified,\\nwith areas of stippled calcification either on plain films or CT. If adjacent to the cortex, enchondromas\\nshow minor endosteal scalloping. Almost all enchondromas have increased uptake on a bone scan and\\nthus create concern of cancer. X-ray findings, including MRI and CT, may be diagnostic; if they are not,\\nand especially if the tumor (not the associated joint) is painful, the diagnosis should be confirmed by\\nbiopsy. To help differentiate bone pain from joint pain, the joint can be injected, usually with a long-lasting\\nanesthetic (eg, bupivacaine); if pain persists, it may be caused by the bone lesion.\\nAn asymptomatic enchondroma does not need biopsy, excision, or other treatment (usually curettage);\\nhowever, follow-up imaging studies are indicated to rule out disease progression. These are done at 6 mo\\nand again at 1 yr or whenever symptoms develop.\\nChondroblastoma:\\n Chondroblastoma is rare and occurs most commonly among people aged 10 to 20.\\nArising in the epiphysis, this tumor may continue to grow and destroy bone and the joint. It appears on\\nimaging studies as a sclerotic marginated cyst containing spots of punctate calcification. MRI can help\\ndiagnostically by showing characteristic changes well away from the lesion.\\nThe tumor must be surgically removed by curettage, and the cavity must be bone grafted. Local\\nrecurrence rate is about 10 to 20%, and recurrent lesions often resolve with repeat bone curettage and\\nbone grafting.\\nChondromyxofibroma:\\n Chondromyxofibroma is very rare and usually occurs before age 30. The\\nappearance on imaging studies (usually eccentric, sharply circumscribed, lytic, and located near the end\\nof long bones) suggests the diagnosis. Treatment after biopsy is surgical excision or curettage.\\nOsteoid osteoma:\\n Osteoid osteoma, which tends to affect young people (commonly aged 10 to 35), can\\noccur in any bone but is most common among long bones. It can cause pain (usually worse at night) that\\nis typically relieved by mild analgesics, particularly aspirin or other NSAIDs. In growing children, the\\ninflammatory response and associated hyperemia, if close to the open growth plate, may cause\\novergrowth and limb length discrepancy. Physical examination may reveal atrophy of regional muscles\\nbecause the pain causes muscle disuse.\\nCharacteristic appearance on imaging studies is a small radiolucent zone surrounded by a larger sclerotic\\nzone. If a tumor is suspected, a technetium-99m bone scan should be done; an osteoid osteoma appears\\nas an area of increased uptake. CT with fine image sequences is also done and is most helpful in\\ndistinguishing the lesion.\\nRemoval of the small radiolucent zone with percutaneous radiofrequency ablation provides permanent\\nrelief. Most osteoid osteomas are treated by an interventional musculoskeletal radiologist using\\npercutaneous techniques and anesthesia. Less often, osteoid osteomas are surgically curetted or\\nexcised.\\nBenign giant cell tumor:\\n These tumors, which most commonly affect people in their 20s and 30s, occur\\nin the epiphyses and may eventually erode the rest of the bone and extend into the soft tissues. They\\nmay cause pain. Giant cell tumors are notorious for their tendency to recur. Rarely, a giant cell tumor may\\nmetastasize to the lung, even though it remains histologically benign.\\nBenign giant cell tumors appear as expansile lytic lesions on imaging. On imaging studies, there is a\\nmargin without a sclerotic rim where the tumor ends and normal trabecular bone begins.\\nMost benign giant cell tumors are treated by curettage and packing with methyl methacrylate or by bone\\ngraft. To reduce recurrence rate, surgeons often prefer using an adjuvant such as thermal heat (provided\\nby the hardening of methyl methacrylate) or chemically by phenol or freezing with liquid nitrogen. If a\\ntumor is very large and destructive to the joint, complete excision with joint reconstruction may be\\nnecessary.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 45. Tumors of Bones & Joints\\n504'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 514, 'page_label': '505'}, page_content=\"Primary Malignant Bone Tumors\\n(See also \\nCh. 117\\n.)\\nMultiple myeloma:\\n Multiple myeloma is the most common primary malignant bone tumor but is often\\nconsidered a marrow cell tumor within the bone rather than a bone tumor. It is of hematopoietic derivation\\n(see also p. \\n1029\\n) and occurs mostly in older adults. The neoplastic process is usually multicentric and\\noften involves the bone marrow so diffusely that bone marrow aspiration is diagnostic. Imaging studies\\nusually show sharply circumscribed lytic lesions or diffuse demineralization. Rarely, the lesion can appear\\nas sclerotic or as diffuse osteopenia, especially in a vertebral body. An isolated single myeloma lesion\\nwithout systemic marrow involvement is called a plasmacytoma.\\nOsteosarcoma:\\n Osteosarcoma (osteogenic sarcoma) is the 2nd most common primary bone tumor and\\nis highly malignant. It is most common among people aged 10 to 25, although it can occur at any age.\\nOsteosarcoma produces malignant osteoid (immature bone) from tumor bone cells. Osteosarcoma usually\\ndevelops around the knee (distal femur more often than proximal tibia) or in other long bones, particularly\\nthe metaphyseal-diaphyseal area, and may metastasize, usually to lung or other bone. Pain and swelling\\nare the usual symptoms.\\nFindings on imaging studies vary and may include sclerotic or lytic features. Diagnosis requires biopsy.\\nPatients need a chest x-ray and CT to detect lung metastases and a bone scan to detect bone\\nmetastases.\\nTreatment is a combination of chemotherapy and surgery. Use of adjuvant chemotherapy increases\\nsurvival from < 20% to > 65% at 5 yr. Chemotherapy usually begins before any surgery. Decreased tumor\\nsize on x-ray, decreased pain level, and decreased serum alkaline phosphatase indicate some response,\\nbut the desired response is for > 95% tumor necrosis on mapping of the resected specimen. After several\\ncourses of chemotherapy (over several months), limb-sparing surgery and limb reconstruction can\\nproceed. In limb-sparing surgery, the tumor is resected en bloc, including all surrounding reactive tissue\\nand a rim of surrounding normal tissue; to avoid microscopic spillage of tumor cells, the tumor is not\\nviolated. More than 80% of patients can be treated with limb-sparing surgery without decreasing long-\\nterm survival rate. Continuation of chemotherapy after surgery is usually necessary. If there is nearly\\ncomplete tumor necrosis (about 99%) from preoperative chemotherapy, 5-yr survival rate is > 90%.\\nFibrosarcoma:\\n Fibrosarcomas have similar characteristics to osteosarcomas but produce fibrous tumor\\ncells (rather than bone tumor cells), affect the same age group, and pose similar problems.\\nMalignant fibrous histiocytoma:\\n This tumor is clinically similar to osteosarcoma and fibrosarcoma,\\nalthough malignant fibrous histiocytomas have been classified as different from the osteosarcoma group\\nbecause of a different histology (no tumor bone production). Malignant fibrous histiocytomas tend to\\noccur in children and teenagers but can also occur in older adults as secondary lesions in bone infarcts\\nand radiation fields. Treatment is similar to that of osteosarcoma.\\nChondrosarcoma:\\n Chondrosarcomas are malignant tumors of cartilage. They differ from osteosarcomas\\nclinically, therapeutically, and prognostically. Of chondrosarcomas, 90% are primary tumors.\\nChondrosarcomas arise in other pre-existing conditions, particularly multiple osteochondromas and\\nmultiple enchondromatosis (eg, in Ollier's disease and Maffucci's syndrome). Chondrosarcomas tend to\\noccur in older adults. They often develop in flat bones (eg, pelvis, scapula) but can develop in any portion\\nof any bone and can implant in surrounding soft tissues.\\nX-rays often reveal punctate calcifications. Primary chondrosarcomas often also exhibit cortical bone\\ndestruction and loss of normal bone trabeculae. Secondary chondrosarcoma may be suggested by the\\nappearance of punctate calcifications or an increase in size of an osteochondroma. Technetium-99m\\nbone scintigraphy is a helpful screening study; all cartilaginous lesions show increased uptake on the\\nscan, although chondrosarcomas exhibit particularly high uptake. Biopsy is required for diagnosis and can\\nalso determine the tumor's grade (probability of metastasizing).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 45. Tumors of Bones & Joints\\n505\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 515, 'page_label': '506'}, page_content=\"Low-grade chondrosarcomas (grade 1/2 or grade 1) are often treated intralesionally (wide curettage) with\\naddition of an adjuvant (often freezing liquid nitrogen; argon beam; heat of methyl methacrylate;\\nradiofrequency; or phenol). Other tumors are treated with total surgical resection. When surgical resection\\nwith maintenance of function is impossible, amputation may be necessary. Because of the potential to\\nimplant the tumor, meticulous care must be taken to avoid spillage of tumor cells into the soft tissues\\nduring biopsy or surgery. Recurrence is inevitable if tumor cells spill. If no spillage occurs, the cure rate\\ndepends on the tumor grade. Low-grade tumors are nearly all cured with adequate treatment. Because\\nthese tumors have limited vascularity, chemotherapy and radiation therapy have little efficacy.\\nEwing's sarcoma of bone:\\n Ewing's sarcoma is a round-cell bone tumor with a peak incidence between\\n10 and 25 yr. Most develop in the extremities, but any bone may be involved. Ewing's sarcoma tends to\\nbe extensive, sometimes involving the entire bone shaft, most often the diaphyseal region. About 15 to\\n20% occur around the metaphyseal region. Pain and swelling are the most common symptoms.\\nLytic destruction, particularly a permeative infiltrating pattern without clear borders, is the most common\\nfinding on imaging, but multiple layers of subperiosteal reactive new bone formation may give an onion-\\nskin appearance. X-rays do not usually reveal the full extent of bone involvement, and a large soft-tissue\\nmass usually surrounds the affected bone. MRI better defines disease extent, which can help guide\\ntreatment. Many other benign and malignant tumors can appear very similar, so diagnosis is made by\\nbiopsy. At times this tumor may be confused with an infection. Accurate histologic diagnosis can be\\naccomplished with molecular markers, including evaluation for a typical clonal chromosomal abnormality.\\nTreatment includes various combinations of surgery, chemotherapy, and radiation therapy. Currently, >\\n60% of patients with primary localized Ewing's sarcoma may be cured by this multimodal approach. Cure\\nis sometimes possible even with metastatic disease. Chemotherapy in conjunction with surgical en bloc\\nresection, if applicable, often yields better long-term results.\\nLymphoma of bone:\\n Lymphoma of bone (previously known as reticulum cell sarcoma) affects adults,\\nusually in their 40s and 50s. It may arise in any bone. The tumor consists of small round cells, often with\\na mixture of reticulum cells, lymphoblasts, and lymphocytes. It can develop as an isolated primary bone\\ntumor, in association with similar tumors in other tissues, or as a metastasis from known soft-tissue\\nlymphomatous disease. Pain and swelling are the usual symptoms. Pathologic fracture is common.\\nImaging studies reveal bone destruction, which may be in a mottled or patchy or even infiltrating,\\npermeative pattern, often with a clinical and radiographic large soft-tissue mass. In advanced disease, the\\nentire outline of the affected bone may be lost.\\nIn isolated primary bone lymphoma, the 5-yr survival rate is  50%. Combination radiation therapy and\\nchemotherapy is as curative as amputation or other extensive ablative surgery. Stabilization of long bones\\nis often necessary to prevent pathologic fracture. Amputation is indicated only rarely, when function is lost\\nbecause of pathologic fracture or extensive soft-tissue involvement that cannot be managed otherwise.\\nMalignant giant cell tumor:\\n Malignant giant cell tumor, which is rare, is usually located at the extreme\\nend of a long bone. X-ray reveals classic features of malignant destruction (predominantly lytic\\ndestruction, cortical destruction, soft-tissue extension, and pathologic fracture). A malignant giant cell\\ntumor that develops in a previously benign giant cell tumor is characteristically radioresistant. Treatment\\nis similar to that of osteosarcoma, but the cure rate is low.\\nChordoma:\\n Chordoma, which is rare, develops from the remnants of the primitive notochord. \\nIt tends to\\noccur at the ends of the spinal column, usually in the middle of the sacrum or near the base of the skull. A\\nchordoma in the sacrococcygeal region causes nearly constant pain. A chordoma in the base of the skull\\ncan cause deficits in a cranial nerve, most commonly in nerves to the eye.\\nSymptoms may exist for months to several years before diagnosis. A chordoma appears on imaging\\nstudies as an expansile, destructive bone lesion that may be associated with a soft-tissue mass.\\nMetastasis is unusual, but local recurrence is not. Chordomas in the sacrococcygeal region may be cured\\nby radical en bloc excision. Chordomas in the base of the skull are usually inaccessible to surgery but\\nmay respond to radiation therapy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 45. Tumors of Bones & Joints\\n506\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 516, 'page_label': '507'}, page_content='Metastatic Bone Tumors\\nAny cancer may metastasize to bone, but metastases from carcinomas are the most common, particularly\\nthose arising in the following areas:\\n Breast\\n Lung\\n Prostate\\n Kidney\\n Thyroid\\n Colon\\nProstate cancer in men and breast cancer in women are the most common types of cancers. Lung cancer\\nis the most common cause of cancer death in both sexes. Breast cancer is the most common cancer to\\nmetastasize to bone. Any bone may be involved with metastases. Metastatic disease does not commonly\\nspread to bone below the mid forearm or mid calf, but when it occurs in those sites, it results most often\\nfrom lung or sometimes kidney cancer.\\nSymptoms and Signs\\nMetastases manifest as bone pain, although they may remain asymptomatic for some time. Bone\\nmetastases may cause symptoms before the primary tumor is suspected or may appear in patients with a\\nknown diagnosis of cancer.\\nDiagnosis\\n X-ray\\n Radionuclide scanning to identify all metastases\\n Clinical evaluation and testing to diagnose the primary tumor (if unknown)\\n Often biopsy if the primary tumor is unknown after assessment\\nMetastatic bone tumors are considered in all patients with unexplained bone pain, but particularly in\\npatients who have\\n Known cancer\\n Pain at more than one site\\n Findings on imaging studies that suggest metastases\\nProstate cancer is most often blastic, lung cancer is most often lytic, and breast cancer may be blastic or\\nlytic.\\nCT and MRI are highly sensitive for specific metastases. However, if metastases are suspected, a\\nradionuclide whole-body scan, which is not quite as sensitive, is usually done. Bone scan is more\\nsensitive for early and asymptomatic metastases than plain x-rays and can be used to scan the entire\\nbody. Lesions on the scan are usually presumed to be metastases if the patient has a known primary\\ncancer. Metastases should be suspected in patients who have multiple lesions on bone scan. Although\\nmetastases are suspected in patients with known cancer and a single bone lesion, the lesion may not be\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 45. Tumors of Bones & Joints\\n507'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 517, 'page_label': '508'}, page_content=\"a metastasis; thus, a needle biopsy of the lesion is often done to confirm the diagnosis of a metastasis.\\nPET for almost whole-body scanning is now often used for some tumors.\\nIf bone metastases are suspected because multiple lytic lesions are found, assessment for the primary\\ntumor can begin with clinical evaluation for primary cancers (particularly focused on the breast, prostate,\\nand thyroid), chest x-ray, mammography, and measurement of prostate-specific antigen level. Initial CT of\\nthe chest, abdomen, and pelvis may also reveal the primary tumor. However, bone biopsy, especially fine-\\nneedle or core biopsy, is necessary if metastatic tumor is suspected and the primary tumor has not been\\notherwise diagnosed. Biopsy with use of immunohistologic stains may give clues to the primary tumor\\ntype.\\nTreatment\\n Usually radiation therapy\\n Surgery to stabilize bone at risk of pathologic fracture\\n Kyphoplasty or vertebraplasty for certain painful vertebral fractures\\nTreatment depends on the type of tissue involved (which organ tissue type). Radiation therapy, combined\\nwith selected chemotherapeutic or hormonal drugs, is the most common treatment modality. Early use of\\nradiation (30 Gy) and bisphosphonates (eg, zoledronate, pamidronate) slows bone destruction. Some\\ntumors are more likely to heal after radiation \\ntherapy; for example, blastic lesions of prostate and breast\\ncancer are more likely to heal than lytic destructive lesions of lung cancer and renal cell carcinoma.\\nIf bone destruction is extensive, resulting in imminent or actual pathologic fracture, surgical fixation or\\nresection and reconstruction may be required to provide stabilization and help minimize morbidity. When\\nthe primary cancer has been removed and only a single bone metastasis remains (especially if the\\nmetastatic lesion appears  1 yr after the primary tumor), en bloc excision sometimes combined with\\nradiation therapy, chemotherapy, or both rarely may be curative. Insertion of methyl methacrylate into the\\nspine (kyphoplasty or vertebraplasty) relieves pain and expands and stabilizes compression fractures that\\ndo not have epidural soft-tissue extension.\\nOther Bone Lesions\\nMany nonneoplastic conditions of bone may clinically or radiologically mimic solitary bone tumors.\\nUnicameral bone cyst:\\n Simple unicameral bone cysts occur in the long bones starting distal to the\\nepiphyseal plate in children. The cyst causes the cortex to thin and predisposes the area to a buckle-like\\npathologic fracture, which is usually how the cyst is recognized. Cysts < 5 cm may heal and may\\ndisappear as the fracture heals. Cysts > 5 cm, particularly in children, may require excision or curettage\\nand bone grafting; however, many respond to injections of corticosteroids, demineralized bone matrix, or\\nsynthetic bone substitutes. The response may be variable and may require multiple injections.\\nRegardless of treatment, cysts persist in about 10 to 15% of patients.\\nFibrous dysplasia:\\n Fibrous dysplasia involves abnormal bone development during childhood. It may\\naffect one or several bones. Cutaneous pigmentation and endocrine abnormalities may be present\\n(Albright's syndrome). The abnormal bone lesions of fibrous dysplasia commonly stop developing at\\npuberty. They rarely undergo malignant degeneration. On x-ray, the lesions can appear cystic and may be\\nextensive and deforming. Calcitonin may help relieve pain. Progressive deformities, fractures that do not\\nheal with immobilization, or intractable pain may be effectively treated with orthopedic surgery.\\nAneurysmal bone cyst:\\n An aneurysmal bone cyst is an idiopathic expansile lesion that usually develops\\nbefore age 25 yr. This cystic lesion usually occurs in the metaphyseal region of the long bones, but\\nalmost any bone may be affected. It tends to grow slowly. A periosteal new bone shell forms around the\\nexpansile lesion and is often wider than the original bone. Pain and swelling are common. The lesion may\\nbe present for a few weeks to a year before diagnosis. The appearance on x-ray is often characteristic:\\nThe rarefied area is usually well circumscribed and eccentric; the periosteum bulges, extending into the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 45. Tumors of Bones & Joints\\n508\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 518, 'page_label': '509'}, page_content='soft tissues, and may be surrounded by new bone formation.\\nSurgical removal of the entire lesion is the most successful treatment; regression after incomplete\\nremoval sometimes occurs. Radiation should be avoided when possible because sarcomas occasionally\\ndevelop. However, radiation may be the treatment of choice in completely surgically inaccessible\\nvertebral lesions that are compressing the spinal cord.\\nJoint Tumors\\nTumors rarely affect joints, unless by direct extension of an adjacent bone or soft-tissue tumor. However,\\n2 conditionssynovial chondromatosis and pigmented villonodular synovitisoccur in the lining\\n(synovium) of joints. These conditions are benign but locally aggressive. Both usually affect one joint,\\nmost often the knee and second most often the hip, and can cause pain and effusion. Both are treated by\\nsynovectomy and removal of any intra-articular bodies.\\nSynovial chondromatosis:\\n Synovial chondromatosis (previously called synovial osteochondromatosis)\\nis considered metaplastic. It is characterized by numerous calcified cartilaginous bodies in the synovium,\\nwhich often become loose. Each body may be no larger than a grain of rice, in a swollen, painful joint.\\nMalignant change is very rare. Recurrence is common.\\nPigmented villonodular synovitis:\\n Pigmented villonodular synovitis is considered neoplastic. The\\nsynovium becomes thickened and contains hemosiderin, which gives the tissue its blood-stained\\nappearance and characteristic appearance on MRI. This tissue tends to invade adjacent bone, causing\\ncystic destruction and damage to the cartilage. Pigmented villonodular synovitis is usually monarticular\\nbut may be polyarticular. Late management, especially after recurrence, may require total joint\\nreplacement. On rare occasions after several synovectomies, radiation therapy can be used.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 45. Tumors of Bones & Joints\\n509'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 519, 'page_label': '510'}, page_content='5 - Ear, Nose, Throat, and Dental Disorders\\nChapter 46. Approach to the Patient With Ear Problems\\nIntroduction\\nEarache, hearing loss, otorrhea, tinnitus, and vertigo are the principal symptoms of ear problems. Hearing\\nloss is discussed in \\nCh. 47\\n.\\nIn addition to the ears, nose, nasopharynx, and paranasal sinuses, the teeth, tongue, tonsils,\\nhypopharynx, larynx, salivary glands, and temporomandibular joint are examined; pain and discomfort\\nmay be referred from them to the ears. It is important to examine cranial nerve function (see pp. \\n1587\\n and\\n1745\\n) and to perform tests of hearing (see p. \\n431\\n) and of the vestibular apparatus. The patient is also\\nexamined for nystagmus (a rhythmic movement of the eyessee \\nSidebar 46-1\\n).\\nTesting\\nPatients with abnormal hearing on history or physical examination or with tinnitus or vertigo undergo an\\naudiogram (see p. \\n433\\n). Patients with nystagmus or altered vestibular function may benefit from\\ncomputerized electronystagmography (ENG), which quantifies spontaneous, gaze, or positional\\nnystagmus that might not be visually detectable. Computerized ENG caloric testing quantifies the strength\\nof response of the vestibular system to cool and warm irrigations in each ear, enabling the physician to\\ndiscriminate unilateral weakness. Different components of the vestibular system can be tested by varying\\nhead and body position or by presenting visual stimuli.\\nSidebar 46-1 Nystagmus\\nNystagmus is a rhythmic movement of the eyes that can have various causes. Vestibular disorders can\\nresult in nystagmus because the vestibular system and the oculomotor nuclei are interconnected. The\\npresence of vestibular nystagmus helps identify vestibular disorders and sometimes distinguishes central\\nfrom peripheral vertigo. Vestibular nystagmus has a slow component caused by the vestibular input and a\\nquick, corrective component that causes movement in the opposite direction. The direction of the\\nnystagmus is defined by the direction of the quick component because it is easier to see. Nystagmus may\\nbe rotary, vertical, or horizontal and may occur spontaneously, with gaze, or with head motion.\\nInitial inspection for nystagmus is done with the patient lying supine with unfocused gaze (+30 diopter or\\nFrenzel lenses can be used to prevent gaze fixation). The patient is then slowly rotated to a left and then\\nto a right lateral position. The direction and duration of nystagmus are noted. If nystagmus is not\\ndetected, the Dix-Hallpike (or Barany) maneuver is done. In this maneuver, the patient sits erect on a\\nstretcher so that when lying back, the head extends beyond the end. With support, the patient is rapidly\\nlowered to horizontal, and the head is extended back 45 below horizontal and rotated 45 to the left.\\nDirection and duration of nystagmus and development of vertigo are noted. The patient is returned to an\\nupright position, and the maneuver is repeated with rotation to the right. Any position or maneuver that\\ncauses nystagmus should be repeated to see whether it fatigues.\\nNystagmus secondary to peripheral nervous system disorders has a latency period of 3 to 10 sec and\\nfatigues rapidly, whereas nystagmus secondary to CNS has no latency period and does not fatigue.\\nDuring induced nystagmus, the patient is instructed to focus on an object. Nystagmus caused by\\nperipheral disorders is inhibited by visual fixation. Because Frenzel lenses prevent visual fixation, they\\nmust be removed to assess visual fixation.\\nCaloric stimulation of the ear canal induces nystagmus in a person with an intact vestibular system.\\nFailure to induce nystagmus or > 20% difference in duration between sides suggests a lesion on the side\\nof the decreased response. Quantification of caloric response is best done with formal (computerized)\\nelectronystagmography.\\nAbility of the vestibular system to respond to peripheral stimulation can be assessed at the bedside. Care\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n510'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 520, 'page_label': '511'}, page_content='should be taken not to irrigate an ear with a known tympanic membrane perforation or chronic infection.\\nWith the patient supine and the head elevated 30\\n, each ear is irrigated sequentially with 3 mL of ice\\nwater. Alternatively, 240 mL of warm water (40 to 44C) may be used, taking care not to burn the patient\\nwith overly hot water. Cold water causes nystagmus to the opposite side; warm water causes nystagmus\\nto the same side. A mnemonic device is COWS (\\nC\\nold to the \\nO\\npposite and \\nW\\narm to the \\nS\\name).\\nPrimary imaging tests include CT of the temporal bone with or without radiopaque dye and gadolinium-\\nenhanced MRI of the brain, with attention paid to the internal auditory canals to rule out an acoustic\\nneuroma. These tests may be indicated in cases of trauma to the ear, head, or both; chronic infection;\\nhearing loss; vertigo; facial paralysis; and otalgia of obscure origin.\\nEarache\\n(Otalgia)\\nEarache may occur in isolation or along with discharge or, rarely, hearing loss.\\nPathophysiology\\nPain may come from a process within the ear itself or may be referred to the ear from a nearby\\nnonotologic disorder.\\nPain from the ear itself\\n may result from a pressure gradient between the middle ear and outside air,\\nfrom local inflammation, or both. A middle ear pressure gradient usually involves eustachian tube\\nobstruction, which inhibits equilibration between middle ear pressure and atmospheric pressure and also\\nallows fluid to accumulate in the middle ear. Otitis media causes painful inflammation of the tympanic\\nmembrane (TM) as well as pain from increased middle ear pressure (causing bulging of the TM).\\nReferred pain\\n can result from disorders in areas innervated by cranial nerves responsible for sensation\\nin the external and middle ear (5th, 9th, and 10th). Specific areas include the nose, paranasal sinuses,\\nnasopharynx, teeth, gingiva, temporomandibular joint (TMJ), mandible, parotid glands, tongue, palatine\\ntonsils, pharynx, larynx, trachea, and esophagus. Disorders in these areas sometimes also obstruct the\\neustachian tube, causing pain from a middle ear pressure gradient.\\nEtiology\\nEarache results from otologic causes (involving the middle ear or external ear) or from nonotologic causes\\nreferred to the ear from nearby disease processes (see\\nTable 46-1\\n).\\nWith \\nacute pain\\n, the most common causes are\\n Middle ear infection\\n External ear infection\\nWith \\nchronic pain\\n (> 2 to 3 wk), the most common causes are\\n TMJ dysfunction\\n Chronic eustachian tube dysfunction\\n Chronic otitis externa\\nAlso with chronic pain, a tumor must be considered, particularly in elderly patients and if the pain is\\nassociated with ear drainage. People with diabetes or in other immunocompromised states may develop a\\nparticularly severe form of external otitis termed malignant or necrotizing external otitis. In this situation, if\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n511'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 521, 'page_label': '512'}, page_content='abnormal soft tissue is found on examination of the ear canal, the tissue must be biopsied to rule out\\ncancer.\\nTMJ dysfunction is a common cause of earache in patients with a normal ear examination.\\nEvaluation\\nHistory: History of present illness\\n should assess the location, duration, and severity of pain and\\nwhether it is constant or intermittent. If intermittent, it is important to determine whether it is random or\\noccurs mainly with swallowing or jaw movement. Important associated symptoms include ear drainage,\\nhearing loss, and sore throat. The patient should be asked about any attempts at cleaning the ear canal\\n(eg, with cotton swab) or other recent instrumentation, foreign bodies, recent air travel or scuba diving,\\nand swimming or other recurrent water exposure to ears.\\nReview of systems\\n should ask about symptoms of chronic illness, such as weight loss and fevers.\\nPast medical history\\n should ask about known diabetes or other immunocompromised state, previous\\near disorders (particularly infections), and amount and duration of tobacco and alcohol use.\\nPhysical examination:\\n Vital signs should be checked for fever.\\nExamination focuses on the ears, nose, and throat.\\nThe pinna and area over the mastoid process should be inspected for redness and swelling. The ear\\ncanal should be examined for redness, discharge, cerumen or foreign body, and any other lesions. The\\nTM should be examined for redness, perforation, and signs of middle ear fluid collection (eg, bulging,\\ndistortion, change in normal light reflex). A brief bedside test of hearing (see p. \\n431\\n) should be conducted.\\nThe throat should be examined for erythema, tonsillar exudate, peritonsillar swelling, and any mucosal\\nlesions suggesting cancer.\\nTMJ function should be assessed by palpation of the joints on opening and closing of the mouth, and\\nnotation should be made of trismus or evidence of bruxism.\\nThe neck should be palpated for lymphadenopathy. In-office fiberoptic examination of the pharynx and\\nlarynx should be considered, particularly if no cause for the pain is identified on routine examination and if\\nnonotologic symptoms such as hoarseness, difficulty swallowing, or nasal obstruction are reported.\\nRed flags:\\n The following findings are of particular concern:\\n Diabetes or immunocompromised state\\n Redness and fluctuance over mastoid and protrusion of auricle\\n Severe swelling at external auditory canal meatus\\n Chronic pain, especially if associated with other head/neck symptoms\\nInterpretation of findings:\\n An important differentiator is whether the ear examination\\n[\\nTable 46-1.\\n Some Causes of Earache]\\nis normal; middle and external ear disorders cause abnormal physical findings, which, when combined\\nwith history, usually suggest an etiology (see \\nTable 46-1\\n). For example, those with chronic eustachian\\ntube dysfunction have abnormalities of the TM, typically a retraction pocket.\\nThose with a normal ear examination may have a visible oropharyngeal cause, such as tonsillitis or\\nperitonsillar abscess. Ear pain due to neuralgia has a classic manifestation as brief (usually seconds,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n512'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 522, 'page_label': '513'}, page_content='always < 2 min) episodes of extremely severe, sharp pain. Chronic ear pain without abnormality on ear\\nexamination might be due to a TMJ disorder, but patients should have a thorough head and neck\\nexamination (including fiberoptic examination) to rule out cancer.\\nTesting:\\n Most cases are clear after history and physical examination. Depending on clinical findings,\\nnonotologic causes may require testing (see \\nTable 46-1\\n). Those with a normal ear examination,\\nparticularly with chronic or recurrent pain, may warrant evaluation with an MRI to rule out cancer.\\nTreatment\\nUnderlying disorders are treated.\\nPain is treated with oral analgesics; usually an NSAID or acetaminophen is adequate, but sometimes a\\nbrief course of an oral opioid is necessary, particularly for cases of severe otitis externa. In cases of\\nsevere otitis externa, effective treatment requires suction of debris from the ear canal and insertion of a\\nwick to allow for delivery of antibiotic ear drops to the infected tissue. Topical analgesics (eg, antipyrine-\\nbenzocaine combinations) are generally not very effective but can be used on a limited basis.\\nPatients should be instructed to avoid digging in their ears with any objects (no matter how soft the\\nobjects are or how careful the patient claims to be). Also, patients should not irrigate their ears unless\\ninstructed by a physician to do so, and then only gently. An oral irrigator should never be used to irrigate\\nthe ear.\\nKey Points\\n Most cases are due to infection of the middle or external ear.\\n History and physical examination are usually adequate for diagnosis.\\n Nonotologic causes should be considered when ear examination is normal.\\nOtorrhea\\nEar discharge (otorrhea) is drainage exiting the ear. It may be serous, serosanguineous, or purulent.\\nAssociated symptoms may include ear pain, fever, pruritus, vertigo, tinnitus, and hearing loss.\\nEtiology\\nCauses may originate from the ear canal, the middle ear, or the cranial vault. Certain causes tend to\\nmanifest acutely because of the severity of their symptoms or associated conditions. Others usually have\\na more indolent, chronic course but sometimes manifest acutely (see\\nTable 46-2\\n).\\nOverall, the most common causes are\\n Acute otitis media with perforation\\n Chronic otitis media (with a perforation of the eardrum, cholesteatoma, or both)\\n Otitis externa\\nThe most serious causes are necrotizing external otitis and cancer of the ear.\\nEvaluation\\nHistory: History of present illness\\n should cover duration of symptoms and whether symptoms have\\nbeen recurrent. Important associated symptoms include pain, itching, decreased hearing, vertigo, and\\ntinnitus. Patients are questioned about activities that can affect the canal or tympanic membrane (TM\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n513'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 523, 'page_label': '514'}, page_content=\"eg, swimming; insertion of objects, including cotton swabs; use of ear drops). Head trauma sufficient to\\ncause a CSF leak is readily apparent.\\nReview of systems\\n should seek symptoms of cranial nerve deficit and systemic symptoms suggesting\\nWegener's granulomatosis (eg, nasal discharge, cough, joint pains).\\nPast medical history\\n should note any previous known ear disorders, ear surgery (particularly\\ntympanostomy tube placement), and diabetes or immunodeficiency.\\nPhysical examination:\\n Examination begins with a review of vital signs for fever.\\nEar and surrounding tissues (particularly the area over the mastoid) are inspected for erythema and\\nedema. The pinna is pulled and the tragus is pushed gently to see whether pain is worsened. The ear\\ncanal is inspected with an otoscope; the character of discharge and presence of canal lesions,\\ngranulation tissue, or foreign body are noted. Edema and discharge may block visualization of all but the\\ndistal canal (irrigation should not be used in case there is a TM perforation), but when\\n[\\nTable 46-2.\\n Some Causes of Ear Discharge]\\npossible, the TM is inspected for inflammation, perforation, distortion, and signs of cholesteatoma (eg,\\ncanal debris, polypoid mass from TM).\\nWhen the ear canal is severely swollen at the meatus (eg, as with severe otitis externa) or there is\\ncopious drainage, careful suctioning can permit an adequate examination and also allow treatment (eg,\\napplication of drops, with or without a wick).\\nThe cranial nerves are tested. The nasal mucosa is examined for raised, granular lesions, and the skin is\\ninspected for vasculitic lesions, both of which may suggest Wegener's granulomatosis.\\nRed flags:\\n The following findings are of particular concern:\\n Recent major head trauma\\n Any cranial nerve dysfunction (including sensorineural hearing loss)\\n Fever\\n Erythema of ear or periauricular tissue\\n Diabetes or immunodeficiency\\nInterpretation of findings:\\n Otoscopic examination can usually diagnose perforated TM, external otitis\\nmedia, foreign body, or other uncomplicated sources of otorrhea. Some findings are highly suggestive\\n(see \\nTable 46-2\\n). Other findings are less specific but indicate a more serious problem that involves more\\nthan a localized external ear or middle ear disorder:\\n Vertigo and tinnitus (disorder of the inner ear)\\n Cranial nerve deficits (disorder involving the skull base)\\n Erythema and tenderness of ear, surrounding tissues, or both (significant infection)\\nTesting:\\n Many cases are clear after clinical evaluation.\\nIf CSF leakage is in question, discharge can be tested for glucose or \\n\\n2\\n-transferrin; these substances are\\npresent in CSF but not in other types of discharge.\\nPatients without an obvious etiology on examination require audiogram and CT of the temporal bone or\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n514\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 524, 'page_label': '515'}, page_content='gadolinium-enhanced MRI. Biopsy should be considered when auditory canal granulation tissue is\\npresent.\\nTreatment\\nTreatment is directed at the cause. Most physicians do not treat a suspected CSF leak with antibiotics\\nwithout a definitive diagnosis because drugs might mask the onset of meningitis.\\nKey Points\\n Acute discharge in a patient without chronic ear problems or immunodeficiency is likely the result of otitis\\nexterna or perforated otitis media.\\n Severe otitis externa may require specialty referral for more extensive cleaning and possible wick\\nplacement.\\n Those with recurrent ear symptoms (diagnosed or undiagnosed), cranial nerve findings, or systemic\\nsymptoms should have specialty referral.\\nTinnitus\\nTinnitus is a noise in the ears. It is experienced by 10 to 15% of the population.\\nSubjective tinnitus\\n is perception of sound in the absence of an acoustic stimulus and is \\nheard only by\\nthe patient. Most tinnitus is subjective.\\nObjective tinnitus\\n is uncommon and results from noise generated by structures near the ear. Sometimes\\nthe tinnitus is loud enough to be heard by the examiner.\\nCharacteristics:\\n Tinnitus may be described as buzzing, ringing, roaring, whistling, or hissing and is\\nsometimes variable and complex. Objective tinnitus typically is pulsatile (synchronous with the heartbeat)\\nor intermittent. Tinnitus is most noticeable in quiet environments and in the absence of distracting stimuli\\nand, thus, frequently seems worse at bedtime.\\nTinnitus may be intermittent or continuous. Continuous tinnitus is at best annoying and is often quite\\ndistressing. Some patients adapt to its presence better than others; depression occasionally results.\\nStress generally exacerbates tinnitus.\\nPathophysiology\\nSubjective tinnitus\\n is thought to be caused by abnormal neuronal activity in the auditory cortex. This\\nactivity results when input from the auditory pathway (cochlea, auditory nerve, brain stem nuclei, auditory\\ncortex) is disrupted or altered in some manner. This disruption may cause loss of suppression of intrinsic\\ncortical activity and perhaps creation of new neural connections. Some believe the phenomenon is similar\\nto the development of phantom limb pain after amputation. Conductive hearing loss (eg, caused by\\ncerumen impaction, otitis media, or eustachian tube dysfunction) may also be associated with subjective\\ntinnitus, by altering sound input to the central auditory system.\\nObjective tinnitus\\n represents actual noise generated by physiologic phenomena occurring near the\\nmiddle ear. Usually the noise comes from blood vessels, either normal vessels in conditions of increased\\nor turbulent flow (eg, caused by atherosclerosis) or abnormal vessels (eg, in tumors or vascular\\nmalformations). Sometimes muscle spasms or myoclonus of palatal muscles or muscles in the middle ear\\n(stapedius, tensor tympani) cause clicking sounds.\\nEtiology\\nCauses may be considered by whether they cause subjective or objective tinnitus (see\\nTable 46-3\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n515'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 525, 'page_label': '516'}, page_content=\"Subjective tinnitus:\\n Subjective tinnitus may occur with almost any disorder affecting the auditory\\npathways.\\nThe most common disorders are those that involve sensorineural hearing loss, particularly\\n Acoustic trauma (noise-induced sensorineural hearing loss)\\n Aging (presbycusis)\\n Ototoxic drugs\\n Meniere's disease\\nInfections and CNS lesions (eg, caused by tumor, stroke, multiple sclerosis) that affect auditory pathways\\nalso may be responsible.\\nDisorders causing conductive hearing loss also may cause tinnitus. These include obstruction of the ear\\ncanal by cerumen, a foreign body, or external otitis. Otitis media, barotrauma, eustachian tube\\ndysfunction, and otosclerosis may also be associated with tinnitus.\\nTemporomandibular joint dysfunction may be associated with tinnitus in some patients.\\nObjective tinnitus:\\n Objective tinnitus usually involves noise from vascular flow, which causes an audible\\npulsating sound synchronous with the pulse. Causes include\\n Turbulent flow through the carotid artery or jugular vein\\n Highly vascular middle ear tumors\\n Dural arteriovenous malformations (AVMs)\\nMuscle spasms or myoclonus of palatal muscles or those of the middle ear (stapedius, tensor tympani)\\nmay cause perceptible noise, typically a rhythmic clicking. Such spasms may be idiopathic or caused by\\ntumors, head trauma, and infectious or demyelinating diseases (eg, multiple sclerosis). Palatal myoclonus\\ncauses visible movement of the palate, tympanic membrane, or both that coincides with tinnitus.\\nEvaluation\\nHistory: History of present illness\\n should note duration of tinnitus, whether it is in one or both ears,\\nand whether it is a constant tone or intermittent. If intermittent, the clinician should determine whether it is\\nregular and whether it is about the rate of the pulse or sporadic. Any exacerbating or relieving factors (eg,\\nswallowing, head position) should be noted. Important associated symptoms include hearing loss, vertigo,\\near pain, and ear discharge.\\nReview of systems\\n should seek symptoms of possible causes, including diplopia and difficulty\\nswallowing or speaking (lesions of the brain stem) and focal weakness and sensory changes (peripheral\\nnervous system disorders). The impact of the tinnitus on the patient also should be assessed. Whether\\nthe tinnitus is sufficiently distressing to cause significant anxiety, depression, or sleeplessness should be\\nnoted.\\nPast medical history\\n should ask about risk factors for tinnitus, including exposure to loud noise, sudden\\npressure change (from diving or air travel), history of ear or CNS infections or trauma, radiation therapy to\\nthe head, and recent major weight loss (risk of eustachian dysfunction). Drug use should be ascertained,\\nparticularly any salicylates, aminoglycosides, or loop diuretics.\\nPhysical examination:\\n Physical examination focuses on the ear and the nervous system.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n516\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 526, 'page_label': '517'}, page_content='The ear canal should be inspected for discharge, foreign body, and cerumen. The tympanic membrane\\nshould be inspected for signs of acute infection (eg, redness, bulging), chronic infection (eg, perforation,\\ncholesteatoma), and tumor (red or bluish mass). A bedside hearing test should be done.\\nCranial nerves, particularly vestibular function (see p. \\n423\\n), are tested along with peripheral strength,\\nsensation, and reflexes. A stethoscope is used to listen for vascular noise over the course of the carotid\\narteries and jugular veins and over and adjacent to the ear.\\nRed flags:\\n The following findings are of particular concern:\\n Bruit, particularly over the ear or skull\\n Accompanying neurologic symptoms or signs (other than hearing loss)\\n Unilateral tinnitus\\nInterpretation of findings:\\n In some cases, tinnitus may indicate retrocochlear pathology, such as an\\nacoustic neuroma (benign but invasive tumor originating from the vestibular portion of the 8th cranial\\nnerve in the internal auditory canal).\\nIt is important to note whether the tinnitus is unilateral because acoustic neuromas may manifest only with\\nunilateral tinnitus. This diagnosis is more likely if there is also unilateral sensorineural hearing loss or\\nasymmetric hearing loss with worse hearing in the ear with tinnitus.\\nIt also is important to distinguish the uncommon cases of objective tinnitus from the more common cases\\nof subjective tinnitus. Tinnitus that is pulsatile or intermittent is almost always objective (although not\\nalways detectable by the examiner), as is that associated with a bruit. Pulsatile tinnitus is nearly always\\nbenign. Continuous tinnitus is usually subjective (except perhaps for that caused by a venous hum, which\\nmay be identified by presence of a bruit and often by a change in tinnitus with head rotation or jugular\\nvein compression).\\nSpecific causes can often be suspected by findings on examination (see \\nTable 46-3\\n). In particular,\\nexposure to loud noise, barotrauma, or certain drugs before onset suggests those factors as the cause.\\nTesting:\\n All patients with significant tinnitus should be referred for comprehensive audiologic evaluation\\nto determine the presence, degree, and type of hearing loss.\\nIn patients with unilateral tinnitus and hearing loss, acoustic neuroma should be ruled out by gadolinium-\\nenhanced MRI. In those with unilateral tinnitus and normal hearing and physical examination, MRI is not\\nnecessary unless tinnitus persists > 6 mo.\\nOther testing depends on patient presentation (see \\nTable 46-3\\n).\\nThose with visible evidence of a vascular tumor in the middle ear require CT, gadolinium-enhanced MRI,\\nand referral to a subspecialist if the diagnosis is confirmed.\\nThose with pulsatile, objective tinnitus and no ear abnormalities on examination or audiology require\\nfurther investigation of the vascular system (carotid, vertebral, and intracranial vessels). The usual test\\nsequence is to begin with magnetic resonance angiography (MRA). However, because MRA is not very\\nsensitive for dural AVMs, many clinicians then consider doing an arteriogram. However, because dural\\nAVMs are rare, the significant risks of arteriography must be weighed against the potential benefit of\\ndiagnosis and treatment (with embolization) of this vascular anomaly.\\nTreatment\\nTreatment of the underlying disorder may lessen tinnitus. Correcting hearing loss (eg, with a hearing aid)\\nrelieves tinnitus in about 50% of patients.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n517'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 527, 'page_label': '518'}, page_content='Because stress and other mental factors (eg, depression) can exacerbate symptoms, efforts to recognize\\nand treat these factors may help. Many patients are reassured by learning that their tinnitus does not\\nrepresent a serious medical problem. Tinnitus also can be worsened by caffeine and other stimulants, so\\npatients should try eliminating use of these substances.\\nAlthough no specific medical or surgical therapy is available, many patients find that background sound\\nmasks the tinnitus and may help them fall asleep. Some patients benefit from a tinnitus masker, a device\\nworn like a hearing aid that provides a low-level sound that can cover up the tinnitus. Tinnitus retraining\\ntherapy, offered by programs that specialize in tinnitus treatment, are helpful for many patients. Electrical\\nstimulation of the inner ear, as with a cochlear implant, occasionally\\n[\\nTable 46-3.\\n Some Causes of Tinnitus]\\nreduces the tinnitus but is appropriate only for patients who are profoundly deaf.\\nGeriatrics Essentials\\nOne out of 4 people > 65 yr have significant hearing impairment. Because tinnitus is common in people\\nwith sensorineural hearing loss, tinnitus is a common complaint among the elderly.\\nKey Points\\n Subjective tinnitus is caused by an abnormality somewhere in the auditory pathway.\\n Objective tinnitus is caused by an actual noise produced in a vascular structure near the ear.\\n Loud noise, aging, Meniere\\'s disease, and drugs are the most common causes of subjective tinnitus.\\n Unilateral tinnitus with hearing loss or dizziness/dysequilibrium warrants gadolinium-enhanced MRI to\\nrule out acoustic neuroma.\\n Any tinnitus accompanied by a neurologic deficit is of concern.\\nDizziness and Vertigo\\nDizziness\\n is an imprecise term patients often use to describe various related sensations, including\\n Faintness (a feeling of impending syncope)\\n Light-headedness\\n Feeling of imbalance or unsteadiness\\n A vague spaced-out or swimmy-headed feeling\\nVertigo\\n is a false sensation of movement of the self or the environment. Usually the perceived movement\\nis rotarya spinning or wheeling sensationbut some patients simply feel pulled to one side. Vertigo is\\nnot a diagnosisit is a description of a sensation.\\nBoth sensations may be accompanied by nausea and vomiting or difficulty with balance, gait, or both.\\nPerhaps because these sensations are hard to describe in words, patients often use \"dizziness,\" \"vertigo,\"\\nand other terms interchangeably and inconsistently. Different patients with the same underlying disorder\\nmay describe their symptoms very differently. A patient may even give different descriptions of the same\\n\"dizzy\" event during a given visit depending on how the question is asked. Because of this discrepancy,\\neven though vertigo seems to be a clearly delineated subset of dizziness, many clinicians prefer to\\nconsider the two symptoms together.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n518'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 528, 'page_label': '519'}, page_content=\"However they are described, dizziness and vertigo may be disturbing and even incapacitating, particularly\\nwhen accompanied by nausea and vomiting. Symptoms cause particular problems for people doing an\\nexacting or dangerous task, such as driving, flying, or operating heavy machinery.\\nDizziness accounts for about 5 to 6% of physician visits. It may occur at any age but becomes more\\ncommon with increasing age; it affects about 40% of people over 40 yr at some time. Dizziness may be\\ntemporary or chronic. Chronic dizziness, defined as lasting > 1 mo, is more common among elderly\\npeople.\\nPathophysiology\\nThe \\nvestibular system\\n is the main neurologic system involved in balance. This system includes\\n \\nThe vestibular apparatus of the inner ear\\n The 8th (vestibulocochlear) cranial nerve, which conducts signals from the vestibular apparatus to the\\ncentral components of the system\\n The vestibular nuclei in the brain stem and cerebellum\\nDisorders of the inner ear and 8th cranial nerve are considered peripheral disorders. Those of the\\nvestibular nuclei and their pathways in the brain stem and cerebellum are considered central disorders.\\nThe sense of balance also incorporates visual input from the eyes and proprioceptive input from the\\nperipheral nerves (via the spinal cord). The cerebral cortex receives output from the lower centers and\\nintegrates the information to produce the perception of motion.\\nVestibular apparatus:\\n Perception of stability, motion, and orientation to gravity originates in the\\nvestibular apparatus, which consists of\\n The 3 semicircular canals\\n The 2 otolith organsthe saccule and utricle\\nRotary motion causes flow of endolymph in the semicircular canal oriented in the plane of motion.\\nDepending on the direction of flow, endolymph movement either stimulates or inhibits neuronal output\\nfrom hair cells lining the canal. Similar hair cells in the saccule and utricle are embedded in a matrix of Ca\\ncarbonate crystals (otoliths). Deflection of the otoliths by gravity stimulates or inhibits neuronal output\\nfrom the attached hair cells.\\nEtiology\\nThere are numerous structural (trauma, tumors, degenerative), vascular, infectious, toxic (including drug-\\nrelated), and idiopathic causes (see\\nTable 46-4\\n), but only about 5% of cases are caused by a serious disorder.\\n[\\nTable 46-4.\\n Some Causes of Dizziness and Vertigo]\\nThe \\nmost common causes of dizziness with vertigo\\n involve some component of the peripheral\\nvestibular system:\\n Benign positional vertigo\\n Meniere's disease\\n Vestibular neuronitis\\n Labyrinthitis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n519\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 529, 'page_label': '520'}, page_content='Less often, the cause is a central vestibular disorder (most commonly migraine), a disorder with a more\\nglobal effect on cerebral function, a psychiatric disorder, or a disorder affecting visual or proprioceptive\\ninput. Sometimes, no cause can be found.\\nThe \\nmost common causes of dizziness without vertigo\\n are less clear cut, but they are usually not\\notologic and probably are\\n Drug effects\\n Multifactorial or idiopathic\\nNonneurologic disorders with a more global effect on cerebral function sometimes manifest as dizziness\\nand rarely as vertigo. These disorders typically involve inadequate substrate (eg, O\\n2\\n, glucose) delivery\\ncaused by hypotension, hypoxemia, anemia, or hypoglycemia; when severe, some of these disorders may\\nmanifest as syncope. Additionally, certain hormonal changes (eg, as with thyroid disease, menstruation,\\npregnancy) can cause dizziness. Numerous CNS-active drugs can cause dizziness independent of any\\ntoxic effect on the vestibular system.\\nOccasionally, dizziness and vertigo may be psychogenic. Patients with panic disorder, hyperventilation\\nsyndrome, anxiety, or depression may present with complaints of dizziness.\\nIn elderly patients, dizziness is often multifactorial secondary to drug adverse effects and age-diminished\\nvisual, vestibular, and proprioceptive abilities. Two of the most common specific causes are disorders of\\nthe inner ear: benign paroxysmal positional vertigo and Meniere\\'s disease.\\nEvaluation\\nHistory: History of present illness\\n should cover the sensations felt; an open-ended question is best\\n(eg, \"Different people use the word \\'dizziness\\' differently. Can you please describe as thoroughly as you\\ncan what you feel?\"). Brief, specific questioning as to whether the feeling is faintness, light-headedness,\\nloss of balance, or vertiginous may bring some clarity, but persistent efforts to categorize a patient\\'s\\nsensations are unnecessary. Other elements are more valuable and clear-cut:\\n Severity of initial episode\\n Severity and characteristics of subsequent episodes\\n Symptoms continuous or episodic\\n If episodic, frequency and duration\\n Triggers and relievers (ie, triggered by head/body position change)\\n Associated aural symptoms (eg, hearing loss, ear fullness, tinnitus)\\n Severity and related disability\\nIs the patient having a single, sudden, acute event, or has dizziness been chronic and recurrent? Was the\\nfirst episode the most severe (vestibular crisis)? How long do episodes last, and what seems to trigger\\nand worsen them? The patient should be asked specifically about movement of the head, arising, being\\nin anxious or stressful situations, and menses. Important associated symptoms include headache, hearing\\nloss, tinnitus, nausea and vomiting, impaired vision, focal weakness, and difficulty walking. The severity\\nof impact on the patient\\'s life should be estimated: Has the patient fallen? Is the patient reluctant to drive\\nor leave the house? Has the patient missed work days?\\nReview of systems\\n should seek symptoms of causative disorders, including URI symptoms (inner ear\\ndisorders); chest pain, palpitations, or both (heart disease); dyspnea (lung disease); dark stools (anemia\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n520'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 530, 'page_label': '521'}, page_content=\"caused by GI blood loss); and weight change or heat or cold intolerance (thyroid disease).\\nPast medical history\\n should note presence of recent head trauma (usually obvious), migraine, diabetes,\\nheart or lung disease, and drug and alcohol abuse. In addition to identifying all current drugs, drug history\\nshould assess recent changes in drugs, doses, or both.\\nPhysical examination:\\n Examination begins with a review of vital signs, including presence of fever,\\nrapid or irregular pulse, and supine and standing BP, noting any drop in BP on standing up (orthostatic\\nhypotension) and whether standing provokes symptoms. If standing does provoke symptoms, postural\\nsymptoms should be distinguished from those triggered by head movement by returning the patient\\nsupine until symptoms dissipate and then rotating the head.\\nThe ENT and neurologic examinations are fundamental. Specifically, with the patient supine, the eyes are\\nchecked for presence, direction, and duration of spontaneous nystagmus (for full description of\\nexamination for nystagmus, see \\nSidebar 46-1\\n). Direction and duration of nystagmus and development of\\nvertigo are noted.\\nA gross bedside hearing test is done, the ear canal is inspected for discharge and foreign body, and the\\ntympanic membrane is checked for signs of infection or perforation.\\nCerebellar function is tested by assessing gait and doing a finger-nose test and Romberg's test. The\\nremainder of the neurologic examination is done, including testing the rest of the cranial nerves.\\nRed flags:\\n The following findings are of particular concern:\\n Head or neck pain\\n Ataxia\\n Loss of consciousness\\n Focal neurologic deficit\\nInterpretation of findings:\\n Traditionally, differential diagnosis has been based on the exact nature of the\\nchief complaint (ie, distinguishing dizziness from light-headedness from vertigo). However, the\\ninconsistency of patients' descriptions and the poor specificity of symptoms make this unreliable. A better\\napproach places more weight on the onset and timing of symptoms, the triggers, and associated\\nsymptoms and findings, particularly otologic and neurologic ones.\\nSome constellations of findings are highly suggestive (see \\nTable 46-4\\n), particularly those that help\\ndifferentiate peripheral from central vestibular disorders.\\n Peripheral: Ear symptoms (eg, tinnitus, fullness, hearing loss) usually indicate a peripheral disorder.\\nThey are typically associated with vertigo and not generalized dizziness (unless caused by\\nuncompensated peripheral vestibular weakness). Symptoms are usually paroxysmal, severe, and\\nepisodic; continuous dizziness is rarely due to peripheral vertigo. Loss of consciousness is not\\nassociated with dizziness due to peripheral vestibular pathology.\\n Central: Ear symptoms are rarely present, but gait/balance disturbance is common. Nystagmus is not\\ninhibited by visual fixation.\\nTesting:\\n Patients with a sudden, ongoing attack should have pulse oximetry and finger-stick glucose test.\\nWomen should have a pregnancy test. Most clinicians also do an ECG. Other tests are done based on\\nfindings (see \\nTable 46-4\\n), but generally gadolinium-enhanced MRI is indicated for patients with acute\\nsymptoms who have headache, neurologic abnormalities, or any other findings suggestive of a CNS\\netiology.\\nPatients with chronic symptoms should have gadolinium-enhanced MRI to look for evidence of stroke,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n521\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 531, 'page_label': '522'}, page_content=\"multiple sclerosis, or other CNS lesions.\\nPatients for whom results of bedside tests of hearing and vestibular function are abnormal or equivocal\\nshould undergo formal testing with audiometry and electronystagmography.\\nLaboratory tests are rarely helpful, except for patients with chronic vertigo and bilateral hearing loss, for\\nwhom syphilis serology is indicated.\\nTreatment\\nTreatment is directed at the cause, including stopping, reducing, or switching any causative drugs.\\nIf a vestibular disorder is present and thought to be secondary to active Meniere's disease or vestibular\\nneuronitis or labyrinthitis, the most effective vestibular nerve suppressants are diazepam (2 to 5 mg po q\\n6 to 8 h, with higher doses given under supervision for severe vertigo) or oral\\nantihistamine/anticholinergic drugs (eg, meclizine 25 to 50 mg tid). All of these drugs can cause\\ndrowsiness, thereby limiting their use for certain patients. Nausea can be treated with prochlorperazine 10\\nmg IM qid or 25 mg rectally bid. Vertigo associated with benign paroxysmal positional vertigo is treated\\nwith the Epley maneuver (otolith repositioning) done by an experienced practitioner (see\\nFig. 48-1\\n on p. \\n443\\n). Meniere's disease is best managed by an otolaryngologist with training in\\nmanagement of this chronic disorder, but initial management consists of a low-salt diet and a K-sparing\\ndiuretic.\\nPatients with persistent or recurrent vertigo secondary to unilateral vestibular weakness (such as\\nsecondary to vestibular neuronitis) usually benefit from vestibular rehabilitation therapy done by an\\nexperienced physical therapist. Most patients compensate well, although some, especially the elderly,\\nhave more difficulty. Physical therapy can also provide important safety information for elderly or\\nparticularly disabled patients.\\nGeriatrics Essentials\\nAs people age, organs involved in balance function less well. For example, seeing in dim light becomes\\nmore difficult, inner ear structures deteriorate, proprioception becomes less sensitive, and mechanisms\\nthat control BP become less responsive (eg, to postural changes, postprandial demands). Older people\\nalso are more likely to have cardiac or cerebrovascular disorders that can contribute to dizziness. They\\nalso are more likely to be taking drugs that can cause dizziness, including those for hypertension, angina,\\nheart failure, seizures, and anxiety, as well as certain antibiotics, antihistamines, \\nand sleep aids. Thus,\\ndizziness in elderly patients usually has more than one cause.\\nAlthough unpleasant at any age, the consequences of dizziness and vertigo are a particular problem for\\nelderly patients. Those with frailty are at significant risk of falling with consequent fractures; their fear of\\nmoving and falling often significantly decreases their ability to do daily activities.\\nIn addition to treatment of specific causes, elderly patients with dizziness or vertigo may benefit from\\nphysical therapy and exercises to strengthen muscles and help maintain independent ambulation as long\\nas possible.\\nKey Points\\n Vague or inconsistently described symptoms may still be associated with a serious condition.\\n Cerebrovascular disease and drug effects should be sought, particularly in elderly patients.\\n Peripheral vestibular system disorders should be differentiated from central vestibular system disorders.\\n Immediate neuroimaging should be done when symptoms are accompanied by headache, focal\\nneurologic abnormalities, or both.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 46. Approach to the Patient With Ear Problems\\n522\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 532, 'page_label': '523'}, page_content='Chapter 47. Hearing Loss\\nIntroduction\\nNearly 10% of people in the US have some degree of hearing loss. About 1/800 to 1/1000 neonates are\\nborn with severe to profound hearing loss. Two to 3 times as many are born with lesser hearing loss.\\nDuring childhood, another 2 to 3/1000 children acquire moderate to severe hearing loss. Adolescents are\\nat risk from excessive exposure to noise, head trauma, or both. Older adults typically experience a\\nprogressive decrease in hearing (presbycusissee p. \\n438\\n), which is probably related to aging and noise\\nexposure.\\nHearing deficits in early childhood can result in lifelong impairments in receptive and expressive language\\nskills. The severity of the handicap is determined by the age at which the hearing loss occurred; the\\nnature of the loss (its duration, the frequencies affected, and the degree); and the susceptibilities of the\\nindividual child (eg, coexisting visual impairment, intellectual disability, primary language deficits,\\ninadequate linguistic environment). Children who have other sensory, linguistic, or cognitive deficiencies\\nare affected most severely.\\nPathophysiology\\nHearing loss can be classified as conductive, sensorineural, or both (mixed loss).\\nConductive hearing loss\\n occurs secondary to lesions in the external auditory canal, tympanic\\nmembrane (TM), or middle ear. These lesions prevent sound from being effectively conducted to the inner\\near.\\nSensorineural hearing loss\\n is caused by lesions of either the inner ear (sensory) or the auditory (8th)\\nnerve (neuralsee\\nTable 47-1\\n). This distinction is important because sensory\\n[\\nTable 47-1.\\n Differences Between Sensory and Neural Hearing Losses]\\nhearing loss is sometimes reversible and is seldom life threatening. A neural hearing loss is rarely\\nrecoverable and may be due to a potentially life-threatening brain tumorcommonly a cerebellopontine\\nangle tumor.\\nMixed loss\\n may be caused by severe head injury with or without fracture of the skull or temporal bone,\\nby chronic infection, or by one of many genetic disorders. It may also occur when a transient conductive\\nhearing loss, commonly due to otitis media, is superimposed on a sensorineural hearing loss.\\nEtiology\\nHearing loss can be congenital (see\\nTable 47-2\\n) or acquired (see\\nTable 47-3\\n), progressive or sudden (see also p. \\n438\\n), temporary or permanent, unilateral or bilateral, and\\nmild or profound. Drug-induced ototoxicity is discussed elsewhere (see p. \\n443\\n).\\nThe \\nmost common causes\\n overall are the following:\\n Cerumen accumulation\\n Noise\\n Aging\\n Infections (particularly among children and young adults)\\nCerumen\\n (earwax) accumulation is the most common cause of treatable hearing loss, especially in the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n523'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 533, 'page_label': '524'}, page_content=\"elderly. Foreign bodies obstructing the canal are sometimes a problem in children, both because of their\\npresence and because of any damage inadvertently caused during their removal.\\nNoise\\n can cause sudden or gradual sensorineural hearing loss. In acoustic trauma, hearing loss results\\nfrom exposure to a single, extreme noise (eg, a nearby gunshot or explosion); some patients have tinnitus\\nas well. The loss is usually temporary (unless there is also blast damage, which may destroy the TM,\\nossicles, or both). In noise-induced hearing loss, the loss develops over time because of chronic\\nexposure to noise > 85 decibels (dBsee \\nSidebar 47-1\\n on p. \\n434\\n). Although people vary somewhat in\\nsusceptibility to noise-induced hearing loss, nearly everyone loses some hearing if they are exposed to\\nsufficiently intense noise for an adequate time. Repeated exposure to loud noise ultimately results in loss\\nof hair cells in the organ of Corti. Hearing loss typically occurs first at 4 kHz and gradually spreads to the\\nlower and higher frequencies as exposure continues. In contrast to most other causes of sensorineural\\nhearing losses, noise-induced hearing loss may be less severe at 8 kHz than at 4 kHz.\\n[\\nTable 47-2.\\n Congenital Causes of Hearing Loss*]\\nAcute otitis media\\n (AOMsee p. \\n448\\n) is a common cause of transient mild to moderate hearing loss\\n(mainly in children). However, without treatment, AOM sequelae and chronic otitis media (and the rarer\\npurulent labyrinthitis) can cause permanent loss, particularly if a cholesteatoma forms.\\nSecretory otitis media\\n (SOMsee p. \\n450\\n) occurs in several ways. Almost all episodes of AOM are\\nfollowed by a period of 2 to 4 wk of SOM. SOM can also be caused by eustachian \\ntube dysfunction (eg,\\nresulting from cleft palate, benign or malignant tumors of the nasopharynx, or rapid changes in external\\nair pressure as occur during descent from high altitudes or rapid ascent while scuba diving).\\nAutoimmune disorders\\n can cause sensorineural hearing loss at all ages and can cause other\\nsymptoms and signs as well.\\nEvaluation\\nEvaluation consists of detecting and quantifying hearing loss and determining etiology (particularly\\nreversible causes).\\nScreening:\\n Most adults and older children notice a sudden hearing loss, and caregivers may suspect\\nthat a neonate has a severe hearing loss within the first week of life when the neonate does not respond\\nto voices or other sounds. However, progressive losses and nearly all losses in infants and young\\nchildren must be detected by screening. Screening should begin at birth (see p. \\n2717\\n) so that linguistic\\ninput can allow optimal language development. Suspected hearing loss at any time should prompt referral\\nto a specialist. If screening is not done, severe bilateral losses may not be recognized until age 2 yr, and\\nmild to moderate or severe unilateral losses are often not recognized until children reach school age.\\nHistory: History of present illness\\n should note how long hearing loss has been perceived, how it\\nbegan (eg, gradual, acute), whether it is unilateral or bilateral, and whether sound is distorted (eg, music\\nis offdull or lifeless) or there is difficulty with speech discrimination. The patient should be asked\\nwhether the loss followed any acute event (eg, head injury, barotrauma [particularly a diving injury],\\nstarting of a drug). Important accompanying symptoms include other otologic symptoms (eg, ear pain,\\ntinnitus, ear discharge), vestibular symptoms (eg, disorientation in the dark, vertigo), and other neurologic\\nsymptoms (eg, headache, weakness or asymmetry of the face, an abnormal sense of taste, fullness of\\nthe ear). In children, important associated symptoms include presence of delays in speech or language\\ndevelopment and delayed motor development.\\nReview of systems\\n should seek to determine the impact of hearing difficulty on the patient's life.\\nPast medical history\\n should note previous possibly causative disorders, including CNS infection,\\nrepeated ear infections, chronic exposure to loud noise, head trauma, rheumatic disorders (eg, RA,\\nlupus), and a family history of hearing loss. Drug history should specifically query current or previous use\\nof ototoxic drugs (see \\nTable 47-3\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n524\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 534, 'page_label': '525'}, page_content=\"Physical examination:\\n The focus is examination of the ears and hearing and the neurologic\\nexamination. The external ear is inspected for obstruction, infection, congenital malformations, and other\\nlesions. The TM is examined for perforation, drainage, otitis media, and cholesteatoma. During the\\nneurologic examination, particular attention needs to be paid to the 2nd through 7th cranial nerves as well\\nas to vestibular and cerebellar function because abnormalities in these areas often occur with tumors of\\nthe brain stem and cerebellopontine angle. Weber's test and the Rinne test require a tuning fork to\\ndifferentiate conductive from sensorineural hearing loss.\\nIn \\nWeber's test\\n, the stem of a vibrating 512-Hz or 1024-Hz tuning fork is placed on the midline of the\\nhead, and the patient indicates in which ear the tone is louder. In unilateral conductive hearing loss, the\\ntone is louder in the ear with hearing loss. In unilateral sensorineural hearing loss, the tone is louder in\\nthe normal ear because the tuning fork stimulates both inner ears equally and the patient perceives the\\nstimulus with the unaffected ear.\\nIn the \\nRinne test\\n, hearing by bone and by air conduction is compared. Bone conduction bypasses the\\nexternal and middle ear and tests the integrity of the inner ear, 8th cranial nerve, and central auditory\\npathways. The stem of a vibrating tuning fork is held against the mastoid (for bone conduction); as soon\\nas the sound is no longer perceived, the fork is removed from the mastoid, and the still-vibrating tines are\\nheld close to the pinna (for air conduction). Normally, the fork can once more be heard, indicating that air\\nconduction is better than bone conduction. With conductive hearing loss, the relationship is reversed;\\nbone conduction is louder than air conduction. With sensorineural hearing loss, both air and bone\\nconduction are reduced, but air conduction remains louder.\\nRed flags:\\n Findings of particular concern are\\n Unilateral sensorineural hearing loss\\n Abnormalities of cranial nerves (other than hearing loss)\\nInterpretation of findings:\\n Many causes of hearing loss (eg, cerumen, injury, significant noise exposure,\\ninfectious sequelae, drugs) are readily apparent based on results of the examination (see \\nTable 47-3\\n).\\nAssociated findings are helpful in diagnosing the remaining small number of patients in\\n[\\nTable 47-3.\\n Some Causes of Acquired Hearing Loss]\\nwhom no clear cause can be found. Those who have focal neurologic abnormalities are of particular\\nconcern. The 5th or 7th cranial nerve or both are often affected by tumors that involve the 8th nerve, so\\nloss of facial sensation and weak jaw clench (5th) and hemifacial weakness and taste abnormalities (7th)\\npoint to a lesion in that area. Signs of autoimmune disorders, maxillofacial malformations, and renal\\ndysfunction may suggest these disorders as a cause.\\nAny child with delays in speech or language development or difficulty in school should be evaluated for\\nhearing loss. Intellectual disability, aphasia, and autism must also be considered. Delayed motor\\ndevelopment may signal vestibular deficit, which is often associated with a sensorineural hearing loss.\\nTesting:\\n Testing includes\\n Audiologic tests\\n Sometimes MRI or CT\\nAudiologic tests\\n are required for all people who have hearing loss; these tests usually include\\n Measurement of pure-tone thresholds with air and bone conduction\\n Speech reception threshold\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n525\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 535, 'page_label': '526'}, page_content=\" Speech discrimination\\n Tympanometry\\n Acoustic reflex testing\\nInformation gained from these tests helps determine whether more definitive differentiation of sensory\\nfrom neural hearing loss is needed.\\nPure-tone audiometry quantifies hearing loss. An audiometer delivers sounds of specific frequencies\\n(pure tones) at different intensities to determine the patient's hearing threshold (how loud a sound must\\nbe to be perceived) for each frequency. Hearing in each ear is tested from 125 or 250 to 8000 Hz by air\\nconduction (using earphones) and up to 4 kHz by bone conduction (using an oscillator in contact with the\\nmastoid process or forehead). Test results are plotted on graphs called audiograms (see\\nFig. 47-1\\n), which show the difference between the patient's hearing threshold and normal hearing at each\\nfrequency. The difference is measured in dB (see \\nSidebar 47-1\\n). The normal threshold is considered 0 dB\\nhearing level (Hl); hearing loss is considered present if the patient's threshold is > 25 dB Hl. When\\nhearing loss is such as to require loud test tones, intense tones presented to one ear may be heard in the\\nother ear. In such cases, a masking sound, usually narrow band noise, is presented to the ear not being\\ntested to isolate it.\\nSpeech audiometry includes the speech reception threshold (SRT) and the word recognition score. The\\nSRT is a measure of the intensity at which speech is recognized. To \\ndetermine the SRT, the examiner\\npresents the patient with a list of words at specific sound intensities. These words usually have 2 equally\\naccented syllables (spondees), such as railroad, staircase, and baseball. The examiner notes the\\nintensity at which the patient repeats 50% of the words correctly. The SRT approximates the average\\nhearing level at speech frequencies (eg, 500 Hz, 1000 Hz, 2000 Hz).\\nSidebar 47-1 Sound Levels\\nSound intensity and pressure (the physical correlates of loudness) are measured in decibels (dB). A dB is\\na unitless figure that compares 2 values and is defined as the logarithm of the ratio of a measured value\\nto a reference value, multiplied by a constant:\\ndB = k log (V\\nmeasured\\n/V\\nref\\n)\\nBy convention, the reference value for sound pressure level (SPL) is taken as the quietest 1000-Hz\\nsound detectable by young, healthy human ears.\\n*\\n The sound may be measured in terms of pressure\\n(N/m\\n2\\n) or intensity (watts/m\\n2\\n).\\nBecause sound intensity equals the square of sound pressure, the constant (k) for SPL is 20; for sound\\nintensity, 10. Thus, each 20-dB increase represents a 10-fold increase in SPL but a 100-fold increase in\\nsound intensity.\\nThe dB values in the table below give only a rough idea of the risk of hearing loss. Some of them are dB\\nSPL values (referenced to N/m\\n2\\n), whereas others represent peak dB or dB on the A-scale (a scale that\\nemphasizes the frequencies that are most hazardous to human hearing).\\nDb\\nExample\\n0\\nFaintest sound heard by human ear\\n30\\nWhisper, quiet library\\n60\\nNormal conversation, sewing machine, typewriter\\n90\\nLawnmower, shop tools, truck traffic (8 h/day is the maximum exposure without protection\\n)\\n100\\nChain saw, pneumatic drill, snowmobile (2 h/day is the maximum exposure without protection)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n526\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 536, 'page_label': '527'}, page_content=\"115\\nSandblasting, loud rock concert, automobile horn (15 min/day is the maximum exposure without\\nprotection)\\n140\\nGun muzzle blast, jet engine (noise causes pain and even brief exposure injures unprotected ears;\\ninjury may occur even with hearing protectors)\\n180\\nRocket launching pad\\n*In audiometric testing, because human ears respond differently at different frequencies, the reference\\nvalue changes for each frequency tested. Threshold values reported on audiograms take this into\\naccount; the normal threshold is always 0 dB, regardless of the actual SPL.\\nMandatory federal standard, but protection is recommended for more than brief exposure to sound levels\\n> 85 db.\\nThe word recognition score tests the ability to discriminate among the various speech sounds or\\nphonemes. It is determined by presenting 50 phonetically balanced one-syllable words at an intensity of\\n35 to 40 dB above the patient's SRT. The word list contains phonemes in the same relative frequency\\nfound in conversational English. The score is the percentage of words correctly repeated by the patient\\nand reflects the ability to understand speech\\n[\\nFig. 47-1.\\n Audiogram of right ear in a patient with normal hearing.]\\nunder optimal listening conditions. A normal score ranges from 90 to 100%. The word recognition score is\\nnormal with conductive hearing loss, albeit at a higher intensity level, but can be reduced at all intensity\\nlevels with sensorineural hearing loss. Discrimination is even poorer in neural than in sensory hearing\\nloss.\\nTympanometry measures the impedance of the middle ear to acoustic energy and does not require\\npatient participation. It is commonly used to screen children for middle ear effusions. A probe containing a\\nsound source, microphone, and air pressure regulator is placed snugly with an airtight seal into the ear\\ncanal. The probe microphone records the reflected sound from the TM while pressure in the canal is\\nvaried. Normally, maximal compliance of the middle ear occurs when the pressure in the ear canal equals\\natmospheric pressure. Abnormal compliance patterns suggest specific anatomic disruptions. In eustachian\\ntube obstruction and middle ear effusion, maximal compliance occurs with a negative pressure in the ear\\ncanal. When the ossicular chain is disrupted, as in necrosis or dislocation of the long process of the\\nincus, the middle ear is excessively compliant. When the ossicular chain is fixed, as in stapedial ankylosis\\nin otosclerosis, compliance may be normal or reduced.\\nThe acoustic reflex is contraction of the stapedius muscle in response to loud sounds, \\nwhich changes the\\ncompliance of the TM, protecting the middle ear from acoustic trauma. The reflex is tested by presenting\\na tone and measuring what intensity provokes a change in middle ear impedance as noted by movement\\nof the TM. An absent reflex could indicate middle ear disease or a tumor of the auditory nerve.\\nAdvanced testing\\n is sometimes needed. Gadolinium-enhanced MRI of the head to detect lesions of the\\ncerebellopontine angle may be needed in patients with an abnormal neurologic examination or those\\nwhose audiologic testing shows poor word recognition, asymmetric sensorineural hearing loss, or a\\ncombination when the etiology is not clear.\\nCT is done if bony tumors or bony erosion is suspected. Magnetic resonance angiography is done if\\nvascular abnormalities such as glomus tumors are suspected.\\nThe auditory brain stem response uses surface electrodes to monitor brain wave response to acoustic\\nstimulation in people who cannot otherwise respond.\\nElectrocochleography measures the activity of the cochlea and the auditory nerve with an electrode\\nplaced on or through the eardrum. It can be used to assess and monitor patients with dizziness, can be\\nused in patients who are awake, and is useful in intraoperative monitoring.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n527\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 537, 'page_label': '528'}, page_content=\"Otoacoustic emissions testing measures sounds produced by outer hair cells of the cochlea in response\\nto a sound stimulus usually placed in the ear canal. It is used to screen neonates and infants for hearing\\nloss and to monitor the hearing of patients who are using ototoxic drugs (eg, gentamicin, cisplatin).\\nCertain patients, such as children with a reading or other learning problem and elderly people who seem\\nto hear but do not comprehend, should undergo a central auditory evaluation. It measures discrimination\\nof degraded or distorted speech, discrimination in the presence of a competing message in the opposite\\near, the ability to fuse incomplete or partial messages delivered to each ear into a meaningful message,\\nand the capacity to localize sound in space when acoustic stimuli are delivered simultaneously to both\\nears.\\nTreatment\\nThe causes of a hearing loss should be determined and treated. Ototoxic drugs should be stopped or the\\ndose should be lowered unless the severity of the disease being treated (usually cancer or a severe\\ninfection) requires that the risk of additional ototoxic hearing loss be accepted. Attention to peak and\\ntrough drug levels may help minimize risk.\\nFluid from middle ear effusion can be drained by myringotomy and prevented with the insertion of a\\ntympanostomy tube. Benign growths (eg, enlarged adenoids, nasal polyps) and malignant tumors (eg,\\nnasopharyngeal cancers, sinus cancers) blocking the eustachian tube or ear canal can be removed.\\nHearing loss caused by autoimmune disorders may respond to corticosteroids.\\nDamage to the TM or ossicles or otosclerosis may require reconstructive surgery. Brain tumors causing\\nhearing loss may in some cases be removed and hearing preserved.\\nMany causes of hearing loss have no cure, and treatment involves compensating for the hearing loss with\\nhearing aids and, for severe to profound loss, a cochlear implant. In addition, various coping mechanisms\\nmay help.\\nHearing aids:\\n Amplification of sound with a hearing aid helps many people. Although hearing aids do not\\nrestore hearing to normal, they can significantly improve communication. Physicians should encourage\\nhearing aid use and help patients overcome a sense of social stigma that continues to obstruct use of\\nthese devices, perhaps by making the analogy that a hearing aid is to hearing as eye glasses are to\\nseeing.\\nAll hearing aids have a microphone, amplifier, speaker, earpiece, and volume control, although they differ\\nin the location of these components. An audiologist should be involved in selection and fitting of a hearing\\naid.\\nThe best models are adjusted to a person's particular pattern of hearing loss. People with mainly high-\\nfrequency hearing loss do not benefit from simple amplification, which merely makes the garbled speech\\nthey hear sound louder. They usually need a hearing aid that selectively amplifies the high frequencies.\\nSome hearing aids contain vents in the ear mold, which facilitate the passage of high-frequency sound\\nwaves. Some use digital sound processing with multiple frequency channels so that amplification more\\nprecisely matches hearing loss as measured on the audiogram.\\nTelephone use can be difficult for people with hearing aids. Typical hearing aids cause squealing when\\nthe ear is placed next to the phone handle. Some hearing aids have a phone coil with a switch that turns\\nthe microphone off and links the phone coil electromagnetically to the speaker magnet in the phone.\\nFor moderate to severe hearing loss, a postauricular (ear-level) aid, which fits behind the pinna and is\\ncoupled to the ear mold with \\nflexible tubing, is appropriate. An in-the-ear aid is contained entirely within\\nthe ear mold and fits less conspicuously into the concha and ear canal; it is appropriate for mild to\\nmoderate hearing loss. Some people with mild hearing loss limited to high frequencies are most\\ncomfortably fitted with postauricular aids and completely open ear canals. Canal aids are contained\\nentirely within the ear canal and are cosmetically acceptable to many people who would otherwise refuse\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n528\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 538, 'page_label': '529'}, page_content=\"to use a hearing aid, but they are difficult for some people (especially the elderly) to manipulate. The\\nCROS aid (contralateral routing of signals) is occasionally used for severe unilateral hearing loss; a\\nhearing-aid microphone is placed in the nonfunctioning ear, and sound is routed to the functioning ear\\nthrough a wire or radio transmitter. This device enables the wearer to hear sounds from the\\nnonfunctioning side, allowing for some limited capacity to localize sound. If the better ear also has some\\nhearing loss, the sound from both sides can be amplified with the binaural CROS (BiCROS) aid. The\\nbody aid type is appropriate for profound hearing loss. It is worn in a shirt pocket or a body harness and\\nconnected by a wire to the earpiece (the receiver), which is coupled to the ear canal by a plastic insert\\n(ear mold).\\nA bone conduction aid may be used when an ear mold or tube cannot be used, as in atresia of the ear\\ncanal or persistent otorrhea. An oscillator is held against the head, usually over the mastoid, with a spring\\nband, and sound is conducted through the skull to the cochlea. Bone conduction hearing aids require\\nmore power, introduce more distortion, and are less comfortable to wear than air conduction hearing aids.\\nSome bone conduction aids (bone-anchored hearing aids or BAHAs) are surgically implanted in the\\nmastoid process, avoiding the discomfort and prominence of the spring band.\\nCochlear implants:\\n Profoundly deaf patients, including those with some hearing but who even with a\\nhearing aid cannot understand speech without the assistance of vision (lip-reading or speech-reading),\\nmay benefit from a cochlear implant. This device provides electrical signals directly into the auditory nerve\\nvia multiple electrodes implanted in the cochlea. An external microphone and processor convert sound\\nwaves to electrical impulses, which are transmitted through the skin electromagnetically from an external\\ninduction coil to an internal coil implanted in the skull above and behind the ear. The internal coil\\nconnects to electrodes inserted in the scala tympani.\\nCochlear implants help with speech-reading by providing information about the intonation of words and\\nthe rhythm of speech. Many if not most adults with cochlear implants can discriminate words without\\nvisual clues, allowing them to talk on the telephone. Cochlear implants enable deaf people to hear and\\ndistinguish environmental sounds and warning signals. They also help deaf people modulate their voice\\nand make their speech more intelligible.\\nBrain stem implants:\\n Patients who have had both acoustic nerves destroyed (eg, by bilateral temporal\\nbone fractures or neurofibromatosis) can have some hearing restored by means of brain stem implants\\nthat have electrodes connected to sound-detecting and sound-processing devices similar to those used\\nfor cochlear implants.\\nCoping mechanisms:\\n Alerting systems that use light let people know when the doorbell is ringing, a\\nsmoke detector is sounding, or a baby is crying. Special sound systems transmitting infrared or FM radio\\nsignals help people hear in theaters, churches, or other places where competing noise exists. Many\\ntelevision programs carry closed captioning. Telephone communication devices are also available.\\nLip-reading or speech-reading is particularly important for people who can hear but have trouble\\ndiscriminating sounds. Most people get useful speech information from lip-reading even without formal\\ntraining. Even people with normal hearing can better understand speech in a noisy place if they can see\\nthe speaker. To use this information the listener must be able to see the speaker's mouth. Health care\\npersonnel should be sensitive to this issue and always position themselves appropriately when speaking\\nto the hearing-impaired. Observing the position of a speaker's lips allows recognition of the consonant\\nbeing spoken, thereby improving speech comprehension in patients with high-frequency hearing loss. Lip-\\nreading may be learned in aural rehabilitation sessions in which a group of age-matched peers meets\\nregularly for instruction and supervised practice in optimizing communication.\\nPeople can gain control over their listening environment by modifying or avoiding difficult situations. For\\nexample, people can visit a restaurant during off-peak hours, when it is quieter. They can ask for a booth,\\nwhich blocks out some extraneous sounds. In direct conversations, people may ask the speaker to face\\nthem. At the beginning of a telephone conversation, they can identify themselves as being hearing-\\nimpaired. At a conference, the \\nspeaker can be asked to use an assistive listening system, which makes\\nuse of either inductive loop, infrared, or FM technology that sends sound through the microphone to a\\npatient's hearing aid.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n529\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 539, 'page_label': '530'}, page_content='People with profound hearing loss often communicate by using sign language. American Sign Language\\n(ASL) is the most common version in the US. Other forms include Signed English, Signing Exact English,\\nand Cued Speech.\\nTreatment in Children\\nIn addition to treatment of any cause and the provision of hearing aids, children with hearing loss require\\nsupport of language development with appropriate therapy. Because children must hear language to learn\\nit spontaneously, most deaf children develop language only with special training, ideally beginning as\\nsoon as the hearing loss is identified (an exception would be a deaf child growing up with deaf parents\\nwho are fluent sign language users). Deaf infants must be provided with a form of language input. For\\nexample, a visually based sign language can provide a foundation for later development of oral language\\nif a cochlear implant is not available.\\nIf infants as young as 1 mo have profound bilateral hearing loss and cannot benefit from hearing aids,\\nthey can be a candidate for a cochlear implant. Although cochlear implants allow auditory communication\\nin many children with either congenital or acquired deafness, they are, in the main, more effective in\\nchildren who already have developed language. Children who have postmeningitic deafness develop an\\nossified inner ear; they should receive cochlear implants early to maximize effectiveness. Children whose\\nacoustic nerves have been destroyed by tumors may be helped by implantation of brain stem auditory-\\nstimulating electrodes. Children with cochlear implants may have a slightly greater risk of meningitis than\\nchildren without cochlear implants or adults with cochlear implants.\\nChildren with unilateral deafness should be allowed to use a special system in the classroom, such as an\\nFM auditory trainer. With these systems, the teacher speaks into a microphone that sends signals to a\\nhearing aid in the child\\'s nonaffected ear, improving the child\\'s greatly impaired ability to hear speech\\nagainst a noisy background.\\nGeriatrics Essentials\\nElderly people typically experience a progressive decrease in hearing (presbycusis). The prevalence of\\nhearing impairment is 30% in people > 65 and is 40 to 50% in those > 75. Nonetheless, hearing loss in\\nthe elderly should be evaluated and not ascribed to aging; elderly patients may have a tumor, a\\nneurologic or autoimmune disorder, or an easily correctible conductive hearing loss. Also, hearing loss in\\nthe elderly facilitates dementia (which can be mitigated by properly correcting hearing loss).\\nPresbycusis:\\n Presbycusis is sensorineural hearing loss that probably results from a combination of age-\\nrelated deterioration and cell death in various components of the hearing system and the effects of\\nchronic noise exposure.\\nHearing loss usually affects the highest frequencies (18 to 20 kHz) early on and gradually affects the\\nlower frequencies; it usually becomes clinically significant when it affects the critical 2- to 4-kHz range at\\nabout age 55 to 65 (sometimes sooner). The loss of high-frequency hearing significantly affects speech\\ncomprehension. Although the loudness of speech seems normal, certain consonant sounds (eg, C, D, K,\\nP, S, T) become hard to hear. Consonant sounds are the most important sounds for speech recognition.\\nFor example, when \"shoe,\" \"blue,\" \"true,\" \"too,\" or \"new\" is spoken, many people with presbycusis can\\nhear the \"oo\" sound, but most have difficulty recognizing which word has been spoken because they\\ncannot distinguish the consonants. This inability to distinguish consonants causes affected people to\\noften think the speaker is mumbling. A speaker attempting to speak louder usually accentuates vowel\\nsounds (which are low frequency), doing little to improve speech recognition. Speech comprehension is\\nparticularly difficult when background noise is present.\\nScreening:\\n A screening tool is often helpful for elderly people because many do not complain of hearing\\nloss. One tool is the Hearing Handicap Inventory for the Elderly-Screening Version, which asks\\n Does a hearing problem cause you to feel embarrassed when you meet people?\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n530'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 540, 'page_label': '531'}, page_content=' Does a hearing problem cause you to feel frustrated when talking to a family member?\\n Do you have difficulty hearing when someone whispers?\\n Do you feel handicapped by a hearing problem?\\n Does a hearing problem cause you difficulty when visiting friends, relatives, or neighbors?\\n Does a hearing problem cause you to attend religious services less often than you would like?\\n \\nDoes a hearing problem cause you to have arguments with family members?\\n Does a hearing problem cause you difficulty when listening to the television or radio?\\n Do you feel that any difficulty with your hearing hampers your personal or social life?\\n Does a hearing problem cause you difficulty when in a restaurant with relatives or friends?\\nScoring is \"no\" = 0 points, \"sometimes\" = 2 points, and \"yes\" = 4 points. Scores > 10 suggest significant\\nhearing impairment and necessitate follow-up.\\nPrevention\\nPrevention of hearing loss consists mainly of limiting duration and intensity of noise exposure. People\\nrequired to expose themselves to loud noise must wear ear protectors (eg, plastic plugs in the ear canals\\nor glycerin-filled muffs over the ears). The Occupational Safety and Health Administration (OSHA) of the\\nUS Department of Labor and similar agencies in many other countries have standards regarding the\\nlength of time that a person can be exposed to a noise. The louder the noise, the shorter the permissible\\ntime of exposure.\\nKey Points\\n Cerumen, genetic disorders, infections, aging, and noise exposure are the most common causes.\\n All patients with hearing loss should have audiologic testing.\\n Cranial nerve deficits and other neurologic deficits should raise concern and warrant imaging tests.\\nSudden Deafness\\nSudden deafness is severe sensorineural hearing loss that develops within a few hours or is noticed on\\nawakening. It affects about 1/5000 people each year. Initial hearing loss is typically unilateral (unless\\ndrug-induced) and may range in severity from mild to profound. Many also have tinnitus, and some have\\ndizziness, vertigo, or both.\\nSudden deafness has some causes that differ from chronic hearing loss and must be addressed urgently.\\nEtiology\\nThe following are common characteristics of sudden deafness:\\n Most cases (see\\nTable 47-4\\n) are idiopathic.\\n Some occur in the course of an obvious explanatory event.\\nA few represent the initial manifestation of an occult but identifiable disorder.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n531'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 541, 'page_label': '532'}, page_content=\"Idiopathic:\\n There are numerous theories for which some evidence (although conflicting and incomplete)\\nexists. The most promising possibilities include viral infections (particularly involving herpes simplex),\\nautoimmune attacks, and acute microvascular occlusion.\\nObvious event:\\n Some causes of sudden deafness are readily apparent.\\nBlunt head trauma\\n with temporal bone fracture or severe concussion involving the cochlea can cause\\nsudden hearing loss.\\nLarge ambient pressure changes\\n (eg, caused by diving) or strenuous activities (eg, weightlifting) can\\ninduce a perilymphatic fistula between the middle and inner ear, causing sudden, severe symptoms.\\nPerilymphatic fistula can also be congenital; it can spontaneously cause a sudden loss or loss may occur\\nafter trauma or pressure changes.\\n[\\nTable 47-4.\\n Some Causes of Sudden Deafness]\\nOtotoxic drugs\\n can result in hearing loss occurring sometimes within a day, especially with an overdose\\n(systemically or when applied to a large wound area, such as a burn). There is a rare genetic\\nmitochondrial-transmitted disorder that increases the susceptibility to aminoglycoside ototoxicity.\\nA number of \\ninfections\\n cause sudden deafness during or immediately after acute illness. Common\\ncauses include bacterial meningitis, Lyme disease, and many viral infections that affect the cochlea (and\\nsometimes the vestibular apparatus). The most common viral causes in the developed world are mumps\\nand herpes. Measles is a very rare cause because most of the population is immunized.\\nOccult disorders:\\n Sudden deafness rarely can be an isolated first manifestation of some disorders that\\nusually have other initial symptoms. Sudden deafness rarely may be the first manifestation of an acoustic\\nneuroma, multiple sclerosis, Meniere's disease, or a small cerebellar stroke. Syphilis reactivation in HIV-\\ninfected patients rarely can cause sudden deafness.\\nCogan's syndrome is a rare autoimmune reaction directed against an unknown common autoantigen in\\nthe cornea and inner ear; > 50% of patients present with vestibuloauditory symptoms. About 10 to 30% of\\npatients also have a severe systemic vasculitis, which may include life-threatening aortitis.\\nSome vasculitic disorders can cause hearing loss, some of which is acute. Hematologic disorders, such\\nas Waldenstrom's macroglobulinemia, sickle cell disease, and some forms of leukemia, rarely can cause\\nsudden deafness.\\nEvaluation\\nEvaluation consists of detecting and quantifying hearing loss and determining etiology (particularly\\nreversible causes).\\nHistory: History of present illness\\n should verify that loss is sudden and not chronic. The history\\nshould also note whether loss is unilateral or bilateral and whether there is a current acute event (eg,\\nhead injury, barotrauma [particularly a diving injury], infectious illness). Important accompanying\\nsymptoms include other otologic symptoms (eg, tinnitus, ear discharge), vestibular symptoms (eg,\\ndisorientation in the dark, vertigo), and other neurologic symptoms (eg, headache, weakness or\\nasymmetry of the face, abnormal sense of taste).\\nReview of systems\\n should seek symptoms of possible causes, including transient, migratory neurologic\\ndeficits (multiple sclerosis) and eye irritation and redness (Cogan's syndrome).\\nPast medical history\\n should ask about known HIV or syphilis infection and risk factors for them (eg,\\nmultiple sex partners, unprotected intercourse). Family history should note close relatives with hearing\\nloss (suggesting a congenital fistula). Drug history should specifically query current or previous use of\\nototoxic drugs (see \\nTable 47-4\\n) and whether the patient has known renal insufficiency or renal failure.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n532\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 542, 'page_label': '533'}, page_content=\"Physical examination:\\n The examination focuses on the ears and hearing and on the neurologic\\nexamination.\\nThe tympanic membrane is inspected for perforation, drainage, or other lesions. During the neurologic\\nexamination, attention should be paid to the cranial nerves (particularly the 5th, 7th, and 8th) and to\\nvestibular and cerebellar function because abnormalities in these areas often occur with tumors of the\\nbrain stem and cerebellopontine angle.\\nWeber's test and the Rinne test require a tuning fork to differentiate conductive from sensorineural\\nhearing loss (see p. \\n429\\n).\\nAdditionally, the eyes are examined for redness and photophobia (possible Cogan's syndrome), and the\\nskin is examined for rash (eg, viral infection, syphilis).\\nRed flags:\\n Findings of particular concern are\\n Abnormalities of cranial nerves (other than hearing loss)\\nInterpretation of findings:\\n Traumatic, ototoxic, and some infectious causes are usually apparent\\nclinically. A patient with perilymphatic fistula may hear an explosive sound in the affected ear when the\\nfistula occurs and may also have sudden vertigo, nystagmus, and tinnitus.\\nFocal neurologic abnormalities are of particular concern. The 5th cranial nerve, 7th cranial nerve, or both\\nare often affected by tumors that involve the 8th cranial nerve, so loss of facial sensation and weak jaw\\nclench (5th) and hemifacial weakness and taste abnormalities (7th) point to a lesion in that area.\\nUnilateral hearing loss accompanied by tinnitus and vertigo also suggests Meniere's disease. Systemic\\nsymptoms suggesting inflammation (eg, fevers, rash, joint pains, mucosal lesions) should raise suspicion\\nof an occult infection or autoimmune disorder.\\nTesting:\\n Typically, patients should have an audiogram, and unless the diagnosis is clearly an acute\\ninfection or drug toxicity, most clinicians do gadolinium-enhanced MRI to diagnose \\ninapparent causes.\\nPatients with an acute traumatic cause also should have MRI. If a perilymphatic fistula is suspected\\nclinically, it may be confirmed by tympanometry and electronystagmography (ENG); CT is usually done to\\nshow the bony characteristics of the inner ear.\\nPatients who have risk factors for or symptoms that suggest causes should have appropriate tests (eg,\\nserologic tests for possible HIV infection or syphilis, CBC and coagulation profile for hematologic\\ndisorders, ESR and antinuclear antibodies for vasculitis).\\nTreatment\\nTreatment focuses on the causative disorder when known. Fistulas are explored and repaired surgically.\\nIn viral and idiopathic cases, hearing returns to normal in about 50% of patients and is partially recovered\\nin others.\\nIn patients who recover their hearing, improvement usually occurs within 10 to 14 days.\\nFor patients with idiopathic loss, many clinicians empirically give a short course of glucocorticoids and\\nantiviral drugs effective against herpes simplex (eg, valacyclovir, famciclovir). Glucocorticoids can be\\ngiven orally or by transtympanic injection; it is unclear which route is more effective.\\nKey Points\\n Most cases are idiopathic.\\n A few cases have an obvious cause (eg, major trauma, acute infection, drugs).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n533\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 543, 'page_label': '534'}, page_content=' A very few cases represent unusual manifestations of treatable disorders.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 47. Hearing Loss\\n534'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 544, 'page_label': '535'}, page_content='Chapter 48. Inner Ear Disorders\\nIntroduction\\n(See also \\nHearing Loss\\n on p. \\n429\\n.)\\nThe inner ear is in the petrous area of the temporal bone. Within the bone is the osseous labyrinth, which\\nencases the membranous labyrinth. The osseous labyrinth includes the vestibular system (made up of\\nthe semicircular canals and the vestibule) and the cochlea. The vestibular system is responsible for\\nbalance and posture; the cochlea, for hearing.\\nAcoustic Neuroma\\n(Acoustic Neurinoma; 8th Nerve Tumor; Vestibular Schwannoma)\\nAn acoustic neuroma is a Schwann cell-derived tumor of the 8th cranial nerve. Symptoms\\ninclude unilateral hearing loss. Diagnosis is based on audiology and confirmed by MRI.\\nTreatment is surgical removal, stereotactic radiation therapy, or both.\\nAcoustic neuromas almost always arise from the vestibular division of the 8th cranial nerve and account\\nfor about 7% of all intracranial tumors. As the tumor expands, it projects from the internal auditory meatus\\ninto the cerebellopontine angle and compresses the cerebellum and brain stem. The 5th cranial nerve\\nand later the 7th cranial nerve are affected.\\nBilateral acoustic neuromas are common in neurofibromatosis type 2.\\nSymptoms and Signs\\nSlowly progressive unilateral sensorineural hearing loss is the hallmark symptom. However, the onset of\\nhearing loss may be abrupt, and the degree of impairment may fluctuate. Other early symptoms include\\nunilateral tinnitus, dizziness and dysequilibrium, headache, sensation of pressure or fullness in the ear,\\notalgia, trigeminal neuralgia, and numbness or weakness of the facial nerve.\\nDiagnosis\\n Audiogram\\n If positive, gadolinium-enhanced MRI\\nAn audiogram is the first test done (see p. \\n433\\n). It usually reveals an asymmetric sensorineural hearing\\nloss and a greater impairment of speech discrimination than would be expected for the degree of hearing\\nloss. Acoustic reflex decay, the absence of waveforms, and increased latency of the 5th waveform in\\nauditory brain stem response testing are further evidence of a neural lesion. Although not usually required\\nin the routine evaluation of a patient with asymmetric sensorineural hearing loss, caloric testing shows\\nmarked vestibular hypoactivity (canal paresis). Such findings indicate the \\nneed for imaging tests,\\npreferably gadolinium-enhanced MRI.\\nTreatment\\n Surgical removal\\n Sometimes stereotactic radiation therapy\\nSmall tumors may be removed with microsurgery that preserves the facial nerve. A middle cranial fossa or\\nretrosigmoid approach may preserve remaining hearing; a translabyrinthine route may be used if no\\nuseful hearing remains. Large tumors are removed with the translabyrinthine approach regardless of the\\nremaining hearing. Stereotactic radiation therapy as the sole treatment modality is used predominantly in\\nthe management of small tumors in older patients; its long-term efficacy and adverse effects are under\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 48. Inner Ear Disorders\\n535'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 545, 'page_label': '536'}, page_content=\"study.\\nBenign Paroxysmal Positional Vertigo\\n(Benign Postural or Positional Vertigo)\\nIn benign paroxysmal positional vertigo (BPPV), short (< 60 sec) episodes of vertigo occur with\\ncertain head positions. Nausea and nystagmus develop. Diagnosis is clinical. Treatment\\ninvolves canalith repositioning maneuvers. Drugs and surgery are rarely, if ever, indicated.\\nBPPV is the most common cause of relapsing otogenic vertigo. It affects people increasingly as they age\\nand can severely affect balance in the elderly, leading to potentially injurious falls.\\nEtiology\\nThe condition is thought to be caused by displacement of otoconial crystals (Ca carbonate crystals\\nnormally embedded in the saccule and utricle). This displaced material stimulates hair cells in the\\nposterior semicircular canal, creating the illusion of motion. Etiologic factors include spontaneous\\ndegeneration of the utricular otolithic membranes, labyrinthine concussion, otitis media, ear surgery,\\nrecent viral infection (eg, viral neuronitis), head trauma, prolonged anesthesia or bed rest, previous\\nvestibular disorders (eg, Meniere's disease), and occlusion of the anterior vestibular artery.\\nSymptoms and Signs\\nVertigo is triggered when the patient's head moves (eg, when rolling over in bed or bending over to pick\\nup something). Acute vertigo lasts only a few seconds to minutes; episodes tend to peak in the morning\\nand abate throughout the day. Nausea and vomiting may occur, but hearing loss and tinnitus do not.\\nDiagnosis\\n Clinical evaluation\\n Gadolinium-enhanced MRI if findings suggest CNS lesion\\nDiagnosis is based on characteristic symptoms, on nystagmus as determined by the Dix-Hallpike\\nmaneuver (a provocative test for positional nystagmussee \\nSidebar 46-1\\n on p. \\n414\\n), and on absence of\\nother abnormalities on neurologic examination. Such patients require no further testing. Patients with\\nnystagmus suggesting a CNS lesion undergo gadolinium-enhanced MRI. Unlike the positional nystagmus\\nof BPPV, the positional nystagmus of CNS lesions lacks latency, fatigability, and severe subjective\\nsensation and may continue for as long as the position is maintained. Nystagmus caused by a CNS lesion\\nmay be vertical or change direction and, if rotary, is likely to be in the unexpected direction.\\nTreatment\\n Provocative maneuvers to fatigue symptoms\\n Canalith repositioning maneuvers\\n Drug treatment typically not recommended\\nBPPV usually subsides spontaneously in several weeks or months but may continue for months or years.\\nBecause the condition can be long-lasting, drug treatment (like that used in Meniere's diseasesee p.\\n445\\n) is not recommended. Often, the adverse effects of drugs worsen dysequilibrium.\\nBecause BPPV is fatigable, one therapy is to have the patient perform provocative maneuvers early in the\\nday in a safe environment. Symptoms are then minimal for the rest of the day.\\nCanalith repositioning maneuvers (Epley maneuversee\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 48. Inner Ear Disorders\\n536\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 546, 'page_label': '537'}, page_content=\"Fig. 48-1\\nand Semont maneuver) involve moving the head through a series of specific positions\\nintended to return the errant canalith to the utricle. After performing these maneuvers, the patient should\\nremain erect or semi-erect for 1 to 2 days. Both maneuvers can be repeated as necessary.\\n[\\nFig. 48-1.\\n The Epley maneuver.]\\nFor the Semont maneuver, the patient is seated upright in the middle of a stretcher. The patient's head is\\nrotated toward the unaffected ear; this rotation is maintained throughout the maneuver. Next, the torso is\\nlowered laterally onto the stretcher so that the patient is lying on the side of the affected ear with the nose\\npointed up. After 3 min in this position, the patient is quickly moved through the upright position without\\nstraightening the head and is lowered laterally to the other side now with the nose pointed down. After 3\\nmin in this position, the patient is slowly returned to the upright position, and the head is rotated back to\\nnormal.\\nDrug-Induced Ototoxicity\\nA wide variety of drugs can be ototoxic (see\\nTable 48-1\\n).\\nFactors affecting ototoxicity include dose, duration of therapy, concurrent renal failure,\\n[\\nTable 48-1.\\n Some Drugs that Cause Ototoxicity]\\ninfusion rate, lifetime dose, co-administration with other drugs having ototoxic potential, and genetic\\nsusceptibility. Ototoxic drugs should not be used for otic topical application when the tympanic membrane\\nis perforated because the drugs might diffuse into the inner ear.\\nStreptomycin tends to cause more damage to the vestibular portion than to the auditory portion of the\\ninner ear. Although vertigo and difficulty maintaining balance tend to be temporary, severe loss of\\nvestibular sensitivity may persist, sometimes permanently. Loss of vestibular sensitivity causes difficulty\\nwalking, especially in the dark, and oscillopsia (a sensation of bouncing of the environment with each\\nstep). About 4 to 15% of patients who receive 1 g/day for > 1 wk develop measurable hearing loss, which\\nusually occurs after a short latent period (7 to 10 days) and slowly worsens if treatment is continued.\\nComplete, permanent deafness may follow.\\nNeomycin has the greatest cochleotoxic effect of all antibiotics. When large doses are given orally or by\\ncolonic irrigation for intestinal sterilization, enough may be absorbed to affect hearing, particularly if\\nmucosal lesions are present. Neomycin should not be used for wound irrigation or for intrapleural or\\nintraperitoneal irrigation, because massive amounts of the drug may be retained and absorbed, causing\\ndeafness. Kanamycin and amikacin are close to neomycin in cochleotoxic potential and are both capable\\nof causing profound, permanent hearing loss while sparing balance. Viomycin has both cochlear and\\nvestibular toxicity. Gentamicin and tobramycin have vestibular and cochlear toxicity, causing impairment in\\nbalance and hearing.\\nVancomycin can cause hearing loss, especially in the presence of renal insufficiency.\\nChemotherapeutic (antineoplastic) drugs, particularly those containing platinum (cisplatin and\\ncarboplatin), can cause tinnitus and hearing loss. Hearing loss can be profound and permanent, occurring\\nimmediately after the first dose, or can be delayed until several months after completion of treatment.\\nSensorineural hearing loss strikes bilaterally, progresses decrementally, and is permanent.\\nEthacrynic acid and furosemide given IV have caused profound, permanent hearing loss in patients with\\nrenal failure who had been receiving aminoglycoside antibiotics.\\nSalicylates in high doses (> 12 325-mg tablets of aspirin per day) cause temporary hearing loss and\\ntinnitus. Quinine and its synthetic substitutes can also cause temporary hearing loss.\\nPrevention\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 48. Inner Ear Disorders\\n537\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 547, 'page_label': '538'}, page_content=\"Ototoxic antibiotics should be avoided during pregnancy. The elderly and people with preexisting hearing\\nloss should not be treated with ototoxic drugs if other effective drugs are available. The lowest effective\\ndosage of ototoxic drugs should be used and levels should be closely monitored. If possible before\\ntreatment with an ototoxic drug, hearing should be measured and then monitored during treatment;\\nsymptoms are not reliable warning signs.\\nHerpes Zoster Oticus\\n(Geniculate Herpes; Ramsay Hunt Syndrome; Viral Neuronitis)\\nHerpes zoster oticus is infection of the 8th cranial nerve ganglia and the geniculate ganglion of\\nthe facial nerve by the herpes zoster virus.\\nRisk factors for herpes infection include immunodeficiency secondary to cancer, chemotherapy, radiation\\ntherapy, and HIV infection.\\nSymptoms and Signs\\nSymptoms include severe ear pain, transient or permanent facial paralysis (resembling Bell's palsy),\\nvertigo lasting days to weeks, and hearing loss (which may be permanent or which may resolve partially\\nor completely). Vesicles occur on the pinna and in the external auditory canal along the distribution of the\\nsensory branch of the facial nerve. Symptoms of meningoencephalitis (eg, headache, confusion, stiff\\nneck) are uncommon. Sometimes other cranial nerves are involved.\\nDiagnosis\\nDiagnosis usually is clinical. If there is any question about viral etiology, vesicular scrapings may be\\ncollected for direct immunofluorescence or for viral cultures, and MRI is done.\\nTreatment\\n Perhaps corticosteroids, antivirals, and surgical decompression\\nAlthough there is no reliable evidence that corticosteroids, antiviral drugs, or surgical decompression\\nmakes a difference, they are the only possibly useful treatments. Corticosteroids are started with\\nprednisone 60 mg po once/day for 4 days, followed by gradual tapering of the dose over the next 2 wk.\\nAcyclovir 800 mg po q 4 h 5 times/day or valacyclovir 1 g po bid for 10 days may shorten the clinical\\ncourse. Vertigo is effectively suppressed with diazepam 2 to 5 mg po q 4 to 6 h. Pain may require oral\\nopioids. Postherpetic neuralgia may be treated with amitriptyline. Surgical decompression of the fallopian\\ncanal may be indicated if the facial palsy is complete (no visible facial movement). Before surgery,\\nhowever, electroneurography is done and should show a > 90% decrement.\\nMeniere's Disease\\n(Endolymphatic Hydrops)\\nMeniere's disease is an inner ear disorder that causes vertigo, fluctuating sensorineural hearing\\nloss, and tinnitus. There is no diagnostic test. Vertigo and nausea are treated with\\nanticholinergics or benzodiazepines. Diuretics and a low-salt diet may decrease frequency and\\nseverity of episodes. For severe cases, the vestibular system can be ablated with topical\\ngentamicin or surgery.\\nIn Meniere's disease, pressure and volume changes of the labyrinthine endolymph affect inner ear\\nfunction. The etiology of endolymphatic fluid buildup is unknown. Risk factors include a family history of\\nMeniere's disease, preexisting autoimmune disorders, allergies, trauma to the head or ear, and, rarely,\\nsyphilis (even several decades previously). Peak incidence is between ages 20 and 50.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 48. Inner Ear Disorders\\n538\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 548, 'page_label': '539'}, page_content=\"Symptoms and Signs\\nPatients have sudden attacks of vertigo lasting up to 24 h, usually with nausea and vomiting.\\nAccompanying symptoms include diaphoresis, diarrhea, and gait unsteadiness. Tinnitus may be constant\\nor intermittent, buzzing or roaring; it is not related to position or motion. Hearing impairment, typically\\naffecting low frequencies, may follow. Before an episode, most patients sense fullness or pressure in the\\naffected ear. In 50% of patients, only one ear is affected.\\nDuring the early stages, symptoms remit between episodes; symptom-free interludes may last > 1 yr. As\\nthe disease progresses, however, hearing impairment persists and gradually worsens, and tinnitus may\\nbe constant.\\nDiagnosis\\n Clinical evaluation\\n Audiogram and gadolinium-enhanced MRI to rule out other causes\\nThe diagnosis, made clinically, is primarily one of exclusion. Similar symptoms can result from viral\\nlabyrinthitis or neuritis, a cerebellopontine angle tumor (eg, acoustic neuroma), or a brain stem stroke.\\nPatients with suggestive symptoms should have an audiogram and an MRI (with gadolinium\\nenhancement) of the CNS with attention to the internal auditory canals to exclude other causes.\\nAudiogram typically shows a low-frequency sensorineural hearing loss in the affected ear.\\nOn examination during an acute attack, the patient has nystagmus and falls to the affected side. Between\\nattacks, the Fukada stepping test (marching in place with eyes closed) can be used; a patient with\\nMeniere's disease often turns away from the affected ear, consistent with a unilateral labyrinthine lesion.\\nAdditionally, the Rinne test and Weber's test may indicate sensorineural hearing loss (see p. \\n431\\n).\\nTreatment\\n Symptom relief with antiemetics, antihistamines, or benzodiazepines\\n Diuretics and low-salt diet\\n Rarely vestibular ablation by drugs or surgery\\nMeniere's disease tends to be self-limited. Treatment of an acute attack is aimed at symptom relief.\\nAnticholinergics (eg, prochlorperazine or promethazine 25 mg rectally or 10 mg po q 6 to 8 h) can\\nminimize vagal-mediated GI symptoms. Antihistamines (eg, diphenhydramine, meclizine, or cyclizine 50\\nmg po q 6 h) or benzodiazepines (eg, diazepam 5 mg po q 6 to 8 h) are used to sedate the vestibular\\nsystem. Some physicians also use a corticosteroid burst (eg, prednisone 60 mg once/day for 1 wk,\\ntapered over another wk) for an acute episode.\\nA low-salt (< 1.5 g/day) diet, avoidance of alcohol and caffeine, and a diuretic (eg, \\nhydrochlorothiazide 25\\nmg po once/day) may help prevent vertigo and are useful for many patients.\\nIntratympanic gentamicin (chemical labyrinthectomy) may be used when medical management is\\nunsuccessful. Typical dose is 1 mL (at a 30 mg/mL concentration, made by diluting the commercial 40\\nmg/mL preparation with bicarbonate) injected through the tympanic membrane. Follow-up with serial\\naudiometry is recommended to distinguish hearing loss from cochleotoxicity. The injection can be\\nrepeated in 4 wk if vertigo persists without hearing loss.\\nSurgery is reserved for patients with frequent, severely debilitating episodes who are unresponsive to\\nother modalities. Endolymphatic sac decompression relieves vertigo in some patients and poses minimal\\nrisk of hearing loss. Vestibular neurectomy (an intracranial procedure) relieves vertigo in about 95% of\\npatients and usually preserves hearing. A surgical labyrinthectomy is done only if preexisting hearing loss\\nis profound.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 48. Inner Ear Disorders\\n539\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 549, 'page_label': '540'}, page_content=\"Unfortunately, there is no known way to prevent the natural progression of hearing loss. Most patients\\nsustain moderate to severe sensorineural hearing loss in the affected ear within 10 to 15 yr.\\nPurulent Labyrinthitis\\nPurulent (suppurative) labyrinthitis is bacterial infection of the inner ear, often causing deafness\\nand loss of vestibular function.\\nPurulent labyrinthitis usually occurs when bacteria spread to the inner ear during the course of severe\\nacute otitis media, purulent meningitis, or an enlarging cholesteatoma.\\nSymptoms include severe vertigo and nystagmus, nausea and vomiting, tinnitus, and varying degrees of\\nhearing loss. Pain and fever are common.\\nPurulent labyrinthitis is suspected if vertigo, nystagmus, sensorineural hearing loss, or a combination\\noccurs during an episode of acute otitis media. CT of the temporal bone is done to identify erosion of the\\notic capsule bone or other complications of acute otitis media, such as coalescent mastoiditis. MRI may\\nbe indicated if symptoms of meningitis or brain abscess, such as altered mental status, meningismus, or\\nhigh fever, are present; in such cases, a lumbar puncture and blood cultures also are done.\\nTreatment is with IV antibiotics appropriate for meningitis (eg, ceftriaxone 50 to 100 mg/kg IV once/day to\\nmaximum 2 g) adjusted according to results of culture and sensitivity testing. A myringotomy (and\\nsometimes tympanostomy tube placement) is done to drain the middle ear. Mastoidectomy may be\\nrequired.\\nVestibular Neuronitis\\nVestibular neuronitis causes a self-limited episode of vertigo, presumably due to inflammation\\nof the vestibular division of the 8th cranial nerve; some vestibular dysfunction may persist.\\nAlthough etiology is unclear, a viral cause is suspected.\\nSymptoms and Signs\\nSymptoms include a single attack of severe vertigo, with nausea and vomiting and persistent nystagmus\\ntoward the affected side, which lasts 7 to 10 days. The nystagmus is unidirectional, horizontal, and\\nspontaneous, with fast-beat oscillations in the direction of the unaffected ear. The absence of\\nconcomitant tinnitus or hearing loss is a hallmark of vestibular neuronitis. The condition slowly subsides\\nafter this initial episode. Some patients have residual dysequilibrium, especially with rapid head\\nmovements, probably due to permanent vestibular injury.\\nDiagnosis\\n Audiology, electronystagmography, and MRI\\nPatients undergo an audiologic assessment, electronystagmography with caloric testing, and gadolinium-\\nenhanced MRI of the head, with attention to the internal auditory canals to exclude other diagnoses, such\\nas cerebellopontine angle tumor, brain stem hemorrhage, or infarction. MRI may show enhancement of\\nthe vestibular nerves, consistent with inflammatory neuritis.\\nTreatment\\n Symptom relief with antiemetics, antihistamines, or benzodiazepines\\nSymptoms are addressed as in Meniere's disease (see p. \\n445\\n), ie, with anticholinergics, antiemetics (eg,\\nprochlorperazine or promethazine 25 mg rectally or 10 mg po q 6 to 8 h), antihistamines or\\nbenzodiazepines, and a corticosteroid burst with rapid taper. If vomiting is prolonged, IV fluids and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 48. Inner Ear Disorders\\n540\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 550, 'page_label': '541'}, page_content='electrolytes may be required. Vestibular rehabilitation (usually given by a physical therapist) helps\\ncompensate for any residual vestibular deficit.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 48. Inner Ear Disorders\\n541'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 551, 'page_label': '542'}, page_content=\"Chapter 49. Middle Ear and Tympanic Membrane Disorders\\nIntroduction\\n(See also \\nOtic Tumors\\n on p. \\n493\\n)\\nMiddle ear disorders may be secondary to infection, eustachian tube obstruction, or trauma. Information\\nabout objects placed in the ear and symptoms such as rhinorrhea, nasal obstruction, sore throat, URI,\\nallergies, headache, systemic symptoms, and fever aid diagnosis. The appearance of the external\\nauditory canal and tympanic membrane (see\\nFig. 49-1\\n) often yields a diagnosis. The nose, nasopharynx, and oropharynx are examined for signs of\\ninfection and allergy and for evidence of tumors. Middle ear function is evaluated with use of pneumatic\\notoscopy, Weber's tuning fork test and the Rinne tuning fork test, tympanometry, and audiologic tests (see\\np. \\n431\\n).\\nMastoiditis\\nMastoiditis is a bacterial infection of the mastoid air cells, which typically occurs after acute\\notitis media. Symptoms include redness, tenderness, swelling, and fluctuation over the mastoid\\nprocess, with displacement of the pinna. Diagnosis is clinical. Treatment is with antibiotics, such\\nas ceftriaxone, and mastoidectomy if drug therapy is not effective.\\nIn acute purulent otitis media, inflammation often extends into the mastoid antrum and air cells, resulting in\\nfluid accumulation. In a few patients, bacterial infection develops in the collected fluid, typically with the\\nsame organism causing the otitis media; pneumococcus is most common. Mastoid infection can cause\\nosteitis of the septae, leading to coalescence of the air cells. The infection may decompress through a\\nperforation in the tympanic membrane or extend through the lateral mastoid cortex, forming a\\npostauricular subperiosteal abscess. Rarely, it extends centrally, causing a temporal lobe abscess or a\\nseptic thrombosis of the lateral sinus. Occasionally, the infection may erode through the tip of the mastoid\\nand drain into the neck (called a Bezold abscess).\\nSymptoms and Signs\\nSymptoms begin days to weeks after onset of acute otitis media and include fever and persistent,\\nthrobbing otalgia. Nearly all patients have signs of otitis media (see p. \\n448\\n) and purulent otorrhea.\\nRedness, swelling,\\n[\\nFig. 49-1.\\n Tympanic membrane of right ear (A); tympanic cavity with tympanic membrane removed (B).]\\ntenderness, and fluctuation may develop over the mastoid process; the pinna is typically displaced\\nlaterally and inferiorly.\\nDiagnosis\\n Clinical evaluation\\n Rarely CT\\nDiagnosis is clinical. CT is rarely necessary but can confirm the diagnosis and show the extent of the\\ninfection. Any middle ear drainage is sent for culture and sensitivity. Tympanocentesis for culture\\npurposes can be done if no spontaneous drainage occurs. CBC and ESR may be abnormal but are\\nneither sensitive nor specific and add little to the diagnosis.\\nTreatment\\n IV ceftriaxone\\nIV antibiotic treatment is initiated immediately with a drug that provides CNS penetration, such as\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 49. Middle Ear & Tympanic Membrane Disorders\\n542\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 552, 'page_label': '543'}, page_content='ceftriaxone 1 to 2 g (children, 50 to 75 mg/kg) once/day continued for  2 wk. Oral treatment with a\\nquinolone may be acceptable. Subsequent antibiotic choice is guided by culture and sensitivity test\\nresults.\\nA subperiosteal abscess usually requires a simple mastoidectomy, in which the abscess is drained, the\\ninfected mastoid cells are removed, and drainage is established from the antrum of the mastoid to the\\nmiddle ear cavity.\\nMyringitis\\n(Bullous Myringitis)\\nMyringitis is a form of acute otitis media in which vesicles develop on the tympanic membrane.\\nMyringitis can develop with viral, bacterial (particularly \\nStreptococcus pneumoniae\\n), or mycoplasmal otitis\\nmedia. Pain occurs suddenly and persists for 24 to 48 h. Hearing loss and fever suggest a bacterial\\norigin. Diagnosis is based on otoscopic visualization of vesicles on the tympanic membrane.\\nBecause differentiation among a viral, bacterial, and mycoplasmal cause is difficult, antibiotics effective\\nagainst organisms causing otitis media are prescribed (see\\nTable 49-1\\n). Severe, continued pain may be relieved by rupturing the vesicles with a myringotomy knife or\\nby oral analgesics (eg, oxycodone with acetaminophen). Topical analgesics (eg, benzocaine, antipyrine)\\nmay also be beneficial.\\nAcute Otitis Media\\nAcute otitis media (AOM) is a bacterial or viral infection of the middle ear, usually accompanying\\na URI. Symptoms include otalgia, often with systemic symptoms (eg, fever, nausea, vomiting,\\ndiarrhea), especially in the very young. Diagnosis is based on otoscopy. Treatment is with\\nanalgesics and sometimes antibiotics.\\nAlthough AOM can occur at any age, it is most common between ages 3 mo and 3 yr. At this age, the\\neustachian tube is structurally and functionally immature; the angle of the eustachian tube is more\\nhorizontal; and the angle of the tensor veli palatini muscle and the cartilaginous eustachian tube renders\\nthe opening mechanism less efficient.\\nThe etiology may be viral or bacterial. Viral infections are often complicated by secondary bacterial\\ninfection. In neonates, gram-negative enteric bacilli, particularly \\nEscherichia coli\\n, and \\nStaphylococcus\\naureus\\n cause AOM. In older infants and children < 14 yr, the most common organisms are \\nStreptococcus\\npneumoniae\\n, \\nMoraxella (Branhamella) catarrhalis\\n, and nontypeable \\nHaemophilus influenzae\\n; less\\ncommon causes are group A \\n\\n-hemolytic streptococci and \\nS. aureus\\n. In patients > 14 yr, \\nS. pneumoniae\\n,\\ngroup A \\n\\n-hemolytic streptococci, and \\nS. aureus\\n are most common, followed by \\nH. influenzae\\n.\\nIn rare cases, bacterial middle ear infection spreads locally, resulting in acute mastoiditis, petrositis, or\\nlabyrinthitis. Intracranial spread is extremely rare and usually causes meningitis, but brain abscess,\\nsubdural empyema, epidural abscess, lateral sinus thrombosis, or otitic hydrocephalus may occur. Even\\nwith antibiotic treatment, intracranial complications are slow to resolve, especially in immunocompromised\\npatients.\\nSymptoms and Signs\\nThe usual initial symptom is earache, often with hearing loss. Infants may simply be cranky or have\\ndifficulty sleeping. Fever, nausea, vomiting, and diarrhea often occur in young children. Otoscopic\\nexamination can show a bulging, erythematous tympanic membrane (TM) with indistinct landmarks and\\ndisplacement of the light reflex. Air insufflation (pneumatic otoscopy) shows poor mobility of the TM.\\nSpontaneous perforation of the TM causes serosanguineous or purulent otorrhea.\\nSevere headache, confusion, or focal neurologic signs may occur with intracranial spread of infection.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 49. Middle Ear & Tympanic Membrane Disorders\\n543'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 553, 'page_label': '544'}, page_content=\"Facial paralysis or vertigo suggests local extension to the fallopian canal or labyrinth.\\n[\\nTable 49-1.\\n Antibiotics for Otitis Media]\\nDiagnosis\\nDiagnosis usually is clinical. Except for fluid obtained during myringotomy, cultures are not generally\\ndone.\\nTreatment\\n Analgesics\\n Sometimes antibiotics\\n Rarely myringotomy\\nAlthough 80% of cases resolve spontaneously, in the US, antibiotics are often given (see \\nTable 49-1\\n).\\nAntibiotics relieve symptoms quicker (although results after 1 to 2 wk are similar) and may reduce the\\nchance of residual hearing loss and labyrinthine or intracranial sequelae. However, with the recent\\nemergence of resistant organisms, pediatric organizations have strongly recommended initial antibiotics\\nonly for those at highest risk (eg, those who are younger or more severely illsee\\nTable 49-2\\n) or for those with recurrent AOM (eg,  4 episodes in 6 mo). Others, provided there is good\\nfollow-up, can safely\\n[\\nTable 49-2.\\n Guidelines for Using Antibiotics in Acute Otitis Media]\\nbe observed for up to 72 h and given antibiotics only if no improvement is seen; if follow-up by phone is\\nplanned, a prescription can be given at the initial visit to save time and expense.\\nAll patients receive analgesics (eg, acetaminophen, ibuprofen). In adults, topical intranasal\\nvasoconstrictors, such as phenylephrine 0.25% 3 drops q 3 h, improve eustachian tube function. To avoid\\nrebound congestion, these preparations should not be used > 4 days. Systemic decongestants (eg,\\npseudoephedrine 30 to 60 mg po q 6 h prn) may be helpful. Antihistamines (eg, chlorpheniramine 4 mg po\\nq 4 to 6 h for 7 to 10 days) may improve eustachian tube function in people with allergies but should be\\nreserved for the truly allergic. For children, neither vasoconstrictors nor antihistamines are of benefit.\\nMyringotomy may be done for a bulging TM, particularly if severe or persistent pain, fever, vomiting, or\\ndiarrhea is present. The patient's hearing, tympanometry, and TM appearance and movement are\\nmonitored until normal.\\nPrevention\\nRoutine childhood vaccination against pneumococci (with pneumococcal conjugate vaccine), \\nH.\\ninfluenzae\\n type B, and influenza decreases the incidence of AOM. Infants should not sleep with a bottle,\\nand elimination of household smoking may decrease incidence.\\nSecretory Otitis Media\\n(Serous Otitis Media)\\nSecretory otitis media is an effusion in the middle ear resulting from incomplete resolution of\\nacute otitis media or obstruction of the eustachian tube without infection. Symptoms include\\nhearing loss and a sense of fullness or pressure in the ear. Diagnosis is based on appearance of\\nthe tympanic membrane and sometimes on tympanometry. Most cases resolve in 2 to 3 wk. If\\nthere is no improvement in 1 to 3 mo, some form of myringotomy is indicated, usually with\\ninsertion of a tympanostomy tube. Antibiotics and decongestants are not effective.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 49. Middle Ear & Tympanic Membrane Disorders\\n544\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 554, 'page_label': '545'}, page_content=\"Normally, the middle ear is ventilated 3 to 4 times/min as the eustachian tube opens during swallowing,\\nand O\\n2\\n is absorbed by blood in the vessels of the middle ear mucous membrane. If patency of the\\neustachian tube is impaired, a relative negative pressure develops within the middle ear, which can lead\\nto fluid accumulation. This fluid may cause hearing loss.\\nSecretory otitis media is a common sequela to acute otitis media in children (often identified on routine\\near recheck) and may persist for weeks to months. In other cases, eustachian tube obstruction may be\\nsecondary to inflammatory processes in the nasopharynx, allergies, hypertrophic adenoids or other\\nobstructive lymphoid aggregations on the torus of the eustachian tube and in Rosenmuller's fossa, or\\nbenign or malignant tumors. The effusion may be sterile or (more commonly) contain pathogenic bacteria\\nsometimes as a biofilm, although inflammation is not observed.\\nSymptoms and Signs\\nPatients may report no symptoms, but some (or their family members) note hearing loss. Patients may\\nexperience a feeling of fullness, pressure, or popping in the ear with swallowing. Otalgia is rare.\\nVarious possible changes to the tympanic membrane (TM) include an amber or gray color, displacement\\nof the light reflex, mild to severe retraction, and accentuated landmarks. On air insufflation, the TM may\\nbe immobile. An air-fluid level or bubbles of air may be visible through the TM.\\nDiagnosis\\nDiagnosis is clinical. Tympanometry may be done to confirm middle ear effusion. Adults and adolescents\\nmust undergo nasopharyngeal examination to exclude malignant or benign tumors.\\nTreatment\\n Observation\\n If unresolved, myringotomy with tympanostomy tube insertion\\n If recurrent in childhood, sometimes adenoidectomy\\nFor most patients, watchful waiting is all that is required. Antibiotics and decongestants are not helpful.\\nFor patients in whom allergies are clearly involved, antihistamines and topical corticosteroids may be\\nhelpful.\\nIf no improvement occurs in 1 to 3 mo, myringotomy may be done for aspiration of fluid and insertion of a\\ntympanostomy tube, which allows ventilation of the middle ear and temporarily ameliorates eustachian\\ntube obstruction, regardless of cause. Tympanostomy tubes may be inserted for persistent conductive\\nhearing loss or to help prevent recurrence of acute otitis media.\\nOccasionally, the middle ear is temporarily ventilated with the Valsalva maneuver or politzerization. To do\\nthe Valsalva maneuver, patients keep their mouth closed and try to forcibly blow air out through their\\npinched nostrils (ie, popping the ear). To do politzerization, the physician blows air with a special syringe\\n(middle ear inflator) into one of the patient's nostrils and blocks the other while the patient swallows. This\\nforces the air into the eustachian tube and middle ear. Neither procedure should be done if the patient\\nhas a cold and rhinorrhea.\\nPersistent, recurrent secretory otitis media may require correction of underlying nasopharyngeal\\nconditions. Children may benefit from adenoidectomy, including the removal of the central adenoid mass\\nas well as lymphoid aggregations on the torus of the eustachian tube and in Rosenmuller's fossa.\\nAntibiotics should be given for bacterial rhinitis, sinusitis, and nasopharyngitis. Demonstrated allergens\\nshould be eliminated from the patient's environment and immunotherapy should be considered.\\nChronic Otitis Media\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 49. Middle Ear & Tympanic Membrane Disorders\\n545\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 555, 'page_label': '546'}, page_content=\"Chronic otitis media is a persistent, chronically draining (> 6 wk), suppurative perforation of the\\ntympanic membrane. Symptoms include painless otorrhea with conductive hearing loss.\\nComplications include development of aural polyps, cholesteatoma, and other infections.\\nTreatment requires complete cleaning of the ear canal several times daily, careful removal of\\ngranulation tissue, and application of topical corticosteroids and antibiotics. Systemic antibiotics\\nand surgery are reserved for severe cases.\\nChronic otitis media can result from acute otitis media, eustachian tube obstruction, mechanical trauma,\\nthermal or chemical burns, blast injuries, or iatrogenic causes (eg, after tympanostomy tube placement).\\nFurther, patients with craniofacial abnormalities (eg, Down syndrome, cri du chat syndrome, cleft lip\\nand/or cleft palate, velocardiofacial syndrome [Shprintzen's syndrome]) have an increased risk.\\nChronic otitis media may become exacerbated after a URI or when water enters the middle ear through a\\ntympanic membrane (TM) perforation during bathing or swimming. Infections often are caused by gram-\\nnegative bacilli or \\nStaphylococcus aureus\\n, resulting in painless, purulent, sometimes foul-smelling\\notorrhea. Persistent chronic otitis media may result in destructive changes in the middle ear (such as\\nnecrosis of the long process of the incus) or aural polyps (granulation tissue prolapsing into the ear canal\\nthrough the TM perforation). Aural polyps are a serious sign, almost invariably suggesting cholesteatoma.\\nA cholesteatoma is an epithelial cell growth that forms in the middle ear, mastoid, or epitympanum after\\nchronic otitis media (see\\nPlate 1\\n). Lytic enzymes, such as collagenases, produced by the cholesteatoma can destroy adjacent\\nbone and soft tissue. The cholesteatoma is also a nidus for infection; purulent labyrinthitis, facial\\nparalysis, or intracranial abscess may develop.\\nSymptoms and Signs\\nChronic otitis media usually manifests with conductive hearing loss and otorrhea. Pain is uncommon\\nunless an associated osteitis of the temporal bone occurs. The TM is perforated and draining, and the\\nauditory canal is macerated and littered with granulation tissue.\\nA patient with cholesteatoma has white debris in the middle ear, a draining polypoid mass protruding\\nthrough the TM perforation, and an ear canal that appears clogged with mucopurulent granulation tissue.\\nDiagnosis\\nDiagnosis is usually clinical. Drainage is cultured. When cholesteatoma or other complications are\\nsuspected (as in a febrile patient \\nor one with vertigo or otalgia), CT or MRI is done. These tests may\\nreveal intratemporal or intracranial processes (eg, labyrinthitis, ossicular or temporal erosion, abscesses).\\nTreatment\\n Irrigation and topical antibiotic drops\\n Removal of granulation tissue\\nThe ear canal is irrigated with a bulb syringe 3 times/day with a slightly warmed solution of half vinegar\\nand half sterile water. After the ear drains, 10 drops topical ofloxacin solution are instilled in the affected\\near 2 times/day for 14 days.\\nWhen granulation tissue is present, it is removed with microinstruments or cauterization with silver nitrate\\nsticks. Ciprofloxacin 0.3% and dexamethasone 0.1% is then instilled into the ear canal for 7 to 10 days.\\nSevere exacerbations require systemic antibiotic therapy with amoxicillin 250 to 500 mg po q 8 h for 10\\ndays or a 3rd-generation cephalosporin, subsequently modified by culture results and response to\\ntherapy.\\nTympanoplasty is indicated for patients with marginal or attic perforations and chronic central TM\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 49. Middle Ear & Tympanic Membrane Disorders\\n546\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 556, 'page_label': '547'}, page_content='perforations. A disrupted ossicular chain may be repaired during tympanoplasty as well.\\nCholesteatomas must be removed surgically. Because recurrence is common, reconstruction of the\\nmiddle ear is usually deferred until a 2nd-look operation is done 6 to 8 mo later.\\nOtic Barotrauma\\n(Barotitis Media or Aerotitis Media)\\nOtic barotrauma is ear pain or damage to the tympanic membrane caused by rapid changes in\\npressure.\\nTo maintain equal pressure on both sides of the tympanic membrane (TM), gas must move freely\\nbetween the nasopharynx and middle ear. When a URI, allergy, or other mechanism interferes with\\neustachian tube functioning during changes in environmental pressure, the pressure in the middle ear\\neither falls below ambient pressure, causing retraction of the TM, or rises above it, causing bulging. With\\nnegative middle ear pressure, a transudate of fluid may form in the middle ear. As the pressure differential\\nincreases, ecchymosis and subepithelial hematoma may develop in the mucous membrane of the middle\\near and the TM. A very large pressure differential may cause bleeding into the middle ear, TM rupture,\\nand the development of a perilymph fistula through the oval or round window.\\nSymptoms are severe pain, conductive hearing loss, and, if there is a perilymph fistula, sensory neural\\nloss. Symptoms usually worsen during rapid increase in external air pressures, such as a rapid ascent\\n(eg, during scuba diving) or descent (eg, during air travel). Sensorineural hearing loss or vertigo during\\ndescent suggests the development of a perilymph fistula; the same symptoms during ascent from a deep-\\nsea dive can additionally suggest an air bubble formation in the inner ear.\\nTreatment\\n Methods to equalize pressure (eg, yawning, swallowing, chewing gum)\\nRoutine self-treatment of pain associated with changing pressure in an aircraft includes chewing gum,\\nattempting to yawn and swallow, blowing against closed nostrils, and using decongestant nasal sprays.\\nIf hearing loss is sensorineural and vertigo is present, a perilymph fistula is suspected and middle ear\\nexploration to close a fistula is considered. If pain is severe and hearing loss is conductive, myringotomy\\nis helpful.\\nPrevention\\nA person with nasal congestion due to URI or allergies should avoid flying and diving. When these\\nactivities are unavoidable, a topical nasal vasoconstrictor (eg, phenylephrine 0.25 to 1.0%) is applied 30\\nto 60 min before descent or ascent.\\nOtosclerosis\\nOtosclerosis is a disease of the bone of the otic capsule that causes an abnormal accumulation\\nof new bone within the oval window.\\nIn otosclerosis, the new bone traps and restricts the movement of the stapes, causing conductive hearing\\nloss (see p. \\n429\\n). Otosclerosis also may cause a sensorineural hearing loss, particularly when the foci of\\notosclerotic bone are adjacent to the scala media. Half of all cases are inherited. The measles virus plays\\nan inciting role in patients with a genetic predisposition for otosclerosis.\\nAlthough about 10% of white adults have some otosclerosis (compared with 1% of blacks), only about\\n10% of affected people develop conductive hearing loss. Hearing loss caused by otosclerosis may\\nmanifest as early as age 7 or 8, but most cases do not become \\nevident until the late teen or early adult\\nyears, when slowly progressive, asymmetric hearing loss is diagnosed. Fixation of the stapes may\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 49. Middle Ear & Tympanic Membrane Disorders\\n547'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 557, 'page_label': '548'}, page_content='progress rapidly during pregnancy.\\nA hearing aid may restore hearing. Alternatively, microsurgery to remove some or all of the stapes and to\\nreplace it with a prosthesis may be beneficial.\\nTraumatic Perforation of the Tympanic Membrane\\nTraumatic perforation of the tympanic membrane (TM) can cause pain, bleeding, hearing loss,\\ntinnitus, and vertigo. Diagnosis is based on otoscopy. Treatment often is unnecessary.\\nAntibiotics may be needed for infection. Surgery may be needed for perforations persisting > 2\\nmo, disruption of the ossicular chain, or injuries affecting the inner ear.\\nTraumatic causes of TM perforation include\\n Insertion of objects into the ear canal purposely (eg, cotton swabs) or accidentally\\n Concussion caused by an explosion or open-handed slap across the ear\\n Head trauma (with or without basilar fracture)\\n Sudden negative pressure (eg, strong suction applied to the ear canal)\\n Barotrauma (eg, during air travel or scuba diving)\\n Iatrogenic perforation during irrigation or foreign body removal\\nPenetrating injuries of the TM may result in dislocations of the ossicular chain, fracture of the stapedial\\nfootplate, displacement of fragments of the ossicles, bleeding, a perilymph fistula from the oval or round\\nwindow resulting in leakage of perilymph into the middle ear space, or facial nerve injury.\\nSymptoms and Signs\\nTraumatic perforation of the TM causes sudden severe pain sometimes followed by bleeding from the\\near, hearing loss, and tinnitus. Hearing loss is more severe if the ossicular chain is disrupted or the inner\\near is injured. Vertigo suggests injury to the inner ear. Purulent otorrhea may begin in 24 to 48 h,\\nparticularly if water enters the middle ear.\\nDiagnosis\\n Otoscopy\\n Audiometry\\nPerforation is generally evident on otoscopy. Any blood obscuring the ear canal is carefully suctioned.\\nIrrigation and pneumatic otoscopy are avoided. Extremely small perforations may require otomicroscopy\\nor middle ear impedance studies for definitive diagnosis. If possible, audiometric studies are done before\\nand after treatment to avoid confusion between trauma-induced and treatment-induced hearing loss.\\nPatients with marked hearing loss or severe vertigo are evaluated by an otolaryngologist as soon as\\npossible. Exploratory tympanotomy may be needed to assess and repair damage. Patients with a large\\nTM defect should also be evaluated, because the displaced flaps may need to be repositioned.\\nTreatment\\n Ear kept dry\\n Oral or topical antibiotics if dirty injury\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 49. Middle Ear & Tympanic Membrane Disorders\\n548'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 558, 'page_label': '549'}, page_content='Often, no specific treatment is needed. The ear should be kept dry; routine antibiotic eardrops are\\nunnecessary. However, prophylaxis with oral broad-spectrum antibiotics or antibiotic eardrops is\\nnecessary if contaminants may have entered through the perforation as occurs in dirty injuries.\\nIf the ear becomes infected, amoxicillin 500 mg po q 8 h is given for 7 days.\\nAlthough most perforations close spontaneously, surgery is indicated for a perforation persisting > 2 mo.\\nPersistent conductive hearing loss suggests disruption of the ossicular chain, necessitating surgical\\nexploration and repair.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 49. Middle Ear & Tympanic Membrane Disorders\\n549'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 559, 'page_label': '550'}, page_content=\"Chapter 50. External Ear Disorders\\nIntroduction\\nThe external ear (pinna and external auditory canal) can be affected by congenital, dermatologic,\\ninfectious, neoplastic, obstructive, and traumatic disorders. Congenital defects are discussed on p.\\n2971\\n. Ear trauma is discussed on p. \\n3231\\n.\\nDermatitis\\nDermatitis is inflammation of the ear canal involving itching and skin changes that are caused\\nby exposure to allergens (contact dermatitis) or are spontaneous occurrences (aural\\neczematoid dermatitis).\\nCommon contact allergens include nickel-containing earrings and numerous beauty products (eg,\\nhairsprays, lotions, hair dye). Aural eczematoid dermatitis is more common among people with a\\npredisposition toward atopy and with other similar dermatitides (eg, seborrhea, psoriasis).\\nBoth contact dermatitis and aural eczematoid dermatitis cause itching, redness, discharge, desquamation,\\nhyperpigmentation, and, sometimes, fissuring. A secondary infection can occur.\\nContact dermatitis requires avoidance or withdrawal of allergic triggers. Trial and error may be needed to\\nidentify the offending agent. Topical corticosteroids (eg, 1% hydrocortisone cream) can decrease\\ninflammation and itching.\\nAural eczematoid dermatitis can be treated with dilute aluminum acetate solution (Burow's solution), which\\ncan be applied as often as required for comfort. Itching and inflammation can be reduced with topical\\ncorticosteroids. If diffuse external otitis ensues, antibiotic therapy may be required (see p. \\n455\\n).\\nExternal Otitis\\nExternal otitis is infection of the ear canal, typically by bacteria. Symptoms include itching, pain,\\nand discharge. Diagnosis is based on inspection. Treatment is with topical drugs, including\\nantibiotics, corticosteroids, and acetic acid or a combination.\\nExternal otitis may manifest as a localized furuncle or as a diffuse infection of the entire canal\\n(generalized or diffuse external otitis). This condition is often called swimmer's ear because it sometimes\\nafflicts people who swim. Malignant external otitis (see p. \\n455\\n) is a severe \\nPseudomonas\\n infection of the\\ntemporal bone and is especially dangerous in diabetics.\\nEtiology\\nDiffuse external otitis is usually caused by bacteria, such as \\nPseudomonas aeruginosa\\n, \\nProteus vulgaris\\n,\\nStaphylococcus aureus\\n, or \\nEscherichia coli\\n. Fungal external otitis (otomycosis), typically caused by\\nAspergillus niger\\n or \\nCandida albicans\\n, is less common. Furuncles usually are due to \\nS. aureus\\n.\\nPredisposing conditions include allergies, psoriasis, eczema, seborrheic dermatitis, decreased canal\\nacidity (possibly due to the repeated presence of water), irritants (eg, hair spray, hair dye), and\\ninadvertent injury to the canal caused by excessive cleaning with cotton swabs or other objects. Attempts\\nto clean the ear canal may push debris and cerumen deeper into the canal; these accumulated\\nsubstances tend to trap water, resulting in skin maceration that sets the stage for bacterial infection.\\nSymptoms and Signs\\nPatients have itching and pain. Sometimes, a foul-smelling discharge and hearing loss occur if the canal\\nbecomes swollen or filled with purulent debris. Exquisite tenderness accompanies traction of the pinna or\\npressure over the tragus. Otoscopic examination is painful and difficult to conduct. It shows the ear canal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 50. External Ear Disorders\\n550\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 560, 'page_label': '551'}, page_content=\"to be red, swollen, and littered with moist, purulent debris. Otomycosis caused by \\nA. niger\\n usually\\nmanifests with grayish black or yellow dots (fungal conidiophores) surrounded by a cottonlike material\\n(fungal hyphae). Infection caused by \\nC. albicans\\n does not show any visible fungi but usually contains a\\nthickened, creamy white exudate.\\nFuruncles cause severe pain and may drain sanguineous, purulent material. They appear as a focal,\\nerythematous swelling.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is based on inspection. When discharge is copious, external otitis can be difficult to\\ndifferentiate from perforated otitis media; pain with pulling on the pinna may indicate an external otitis.\\nFungal infection is diagnosed by appearance or culture.\\nTreatment\\n Topical acetic acid and corticosteroids\\n Sometimes topical antibiotics\\nIn diffuse external otitis, topical antibiotics and corticosteroids are effective. First, the infected debris\\nshould be gently and thoroughly removed from the canal with suction or dry cotton wipes. Mild external\\notitis can be treated by altering the ear canal's pH with 2% acetic acid and by relieving inflammation with\\ntopical hydrocortisone; these are given as 5 drops tid for 7 days. Moderate external otitis requires the\\naddition of an antibacterial solution or suspension, such as neomycin, polymyxin, ciprofloxacin, or\\nofloxacin. When inflammation of the ear canal is relatively severe, an ear wick should be placed into the\\near canal and wetted with the necessary drugs 4 times/day. The wick is left in place for 24 to 72 h, after\\nwhich time the swelling may have receded enough to allow the instillation of drops directly into the canal.\\nSevere external otitis or the presence of cellulitis extending beyond the ear canal may require systemic\\nantibiotics, such as cephalexin 500 mg po tid for 10 days or ciprofloxacin 500 mg po bid for 10 days. An\\nanalgesic, such as an NSAID or even an oral opioid, may be necessary for the first 24 to 48 h. Fungal\\nexternal otitis requires thorough cleaning of the ear canal and application of an antimycotic solution (eg,\\ngentian violet, cresylate acetate, nystatin, clotrimazole). Repeated cleanings and treatments may be\\nneeded.\\nA furuncle, if obviously pointing, should be incised and drained. Incision is of little value, however, if the\\npatient is seen at an early stage. Topical antibiotics are ineffective; oral antistaphylococcal antibiotics\\nshould be given. Analgesics, such as oxycodone with acetaminophen, may be necessary for pain relief.\\nDry heat can also lessen pain and hasten resolution.\\nPrevention\\nExternal otitis often can be prevented by irrigating the ears with a 1:1 mixture of rubbing alcohol and\\nvinegar immediately after swimming. The alcohol helps remove water, and the vinegar alters the pH of the\\ncanal.\\nMalignant External Otitis\\nMalignant external otitis is typically a \\nPseudomonas\\n osteomyelitis of the temporal bone.\\nSoft tissue, cartilage, and bone are all affected. The osteomyelitis spreads along the base of the skull and\\nmay cross the midline.\\nMalignant external otitis occurs mainly in elderly patients with diabetes or in immunocompromised patients\\nand is often initiated by \\nPseudomonas\\n external otitis. It is characterized by persistent and severe earache,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 50. External Ear Disorders\\n551\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 561, 'page_label': '552'}, page_content=\"foul-smelling purulent otorrhea, and granulation tissue in the ear canal (usually at the junction of the bony\\nand cartilaginous portions of the canal). Varying degrees of conductive hearing loss may occur. In severe\\ncases, facial nerve paralysis may ensue.\\nDiagnosis is based on a CT scan of the temporal bone, which may show increased radiodensity in the\\nair-cell system and middle ear radiolucency (demineralization) in some areas. Cultures are done, and the\\near canal is biopsied to differentiate the granulation tissue of this disorder from a malignant tumor.\\nTreatment is with a 6-wk IV course of a fluoroquinolone or an aminoglycoside-semisynthetic penicillin\\ncombination. Extensive bone disease may require more prolonged antibiotic therapy. Careful control of\\ndiabetes is essential. Surgery usually is not necessary.\\nObstructions\\nThe ear canal may be obstructed by cerumen (earwax), insertion of a foreign object, or an\\ninsect. Itching, pain, and temporary conductive hearing loss may result. Most causes of\\nobstruction are readily apparent during otoscopic examination. Treatment is manual removal.\\nCerumen:\\n Cerumen may get pushed further into the ear canal and accumulate during ill-advised\\nattempts to clean the ear canal with cotton swabs, resulting in obstruction. Cerumen solvents (hydrogen\\nperoxide, carbamide peroxide, glycerin, triethanolamine) may be used to soften very hard wax before\\nirrigation or direct removal. However, the prolonged use of these agents may lead to canal skin irritation\\nor allergic reactions. Although cerumen may be removed by irrigation, rolling the cerumen out of the ear\\ncanal with a blunt curet or loop or removing it with a suction tip (eg, Baron, size 7 French) is quicker,\\nneater, safer, and more comfortable for the patient. Irrigation is contraindicated if the patient has a history\\nof otorrhea or perforation of the tympanic membrane; water entering the middle ear through a perforation\\nmay exacerbate chronic otitis media.\\nForeign bodies:\\n Foreign bodies are common, particularly among children, who often insert objects,\\nparticularly beads, erasers, and beans, into the ear canal. Foreign bodies may remain unnoticed until they\\nprovoke an inflammatory response, causing pain, itching, infection, and foul-smelling, purulent drainage. A\\nforeign body in the ear canal is best removed by reaching behind it and rolling it out with a blunt hook.\\nForceps tend to push smooth objects deeper into the canal. Unfortunately, a foreign body lying medial to\\nthe isthmus (the bony cartilaginous junction of the external auditory canal) is difficult to remove without\\ninjuring the tympanic membrane and ossicular chain. Metal and glass beads can sometimes be removed\\nby irrigation, but hygroscopic foreign bodies (eg, beans or other vegetable matter) swell when water is\\nadded, complicating removal. A general anesthetic may be needed when a child cannot remain still or\\nwhen removal is difficult, threatening injury to the tympanic membrane or ossicles. Further, if manipulating\\na presumed foreign object results in bleeding, immediate otolaryngologic consultation should be sought.\\nBleeding may indicate a mucosal polyp originating in the middle ear, which may be attached to the\\nossicles or facial nerve.\\nInsects in the canal are most annoying while alive. Filling the canal with viscous lidocaine kills the insect,\\nwhich provides immediate relief and allows the immobilized insect to be removed with forceps.\\nPerichondritis\\nPerichondritis is infection of the perichondrium of the pinna in which pus accumulates between\\nthe cartilage and the perichondrium.\\nCauses of perichondritis include trauma, insect bites, body piercings, and incision of superficial infections\\nof the pinna. Because the cartilage's blood supply is provided by the perichondrium, separation of the\\nperichondrium from both sides of the cartilage may lead to avascular necrosis and a deformed pinna.\\nSeptic necrosis may also ensue, often with infection by gram-negative bacilli. Symptoms include redness,\\npain, and swelling. The course of perichondritis tends to be indolent, long-term, and destructive.\\nThe affected area is incised, and a drain is left in place for 24 to 72 h. Systemic antibiotics are initiated\\nwith an aminoglycoside and semisynthetic penicillin. Subsequent antibiotic choice is guided by culture\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 50. External Ear Disorders\\n552\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 562, 'page_label': '553'}, page_content='and sensitivity tests. Warm compresses may help.The Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 50. External Ear Disorders\\n553'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 563, 'page_label': '554'}, page_content=\"Chapter 51. Approach to the Patient With Nasal and Pharyngeal Symptoms\\nIntroduction\\nThe nose and pharynx (consisting of the nasopharynx, oropharynx, and hypopharynx) may be affected by\\ninflammation, infection, trauma, tumors, and several miscellaneous conditions.\\nAnatomy\\nThroat:\\n The uvula hangs in the midline at the far end of the soft palate. It varies greatly in length. A long\\nuvula and loose or excess velopharyngeal tissue may cause snoring and occasionally contribute to\\nobstructive sleep apnea.\\nTonsils and adenoids are patches of lymphoid tissue surrounding the posterior pharynx in an area termed\\nWaldeyer's ring. Their role is to combat infection.\\nThe larynx is discussed in \\nCh. 54\\n.\\nNose:\\n The nasal cavity is covered with a highly vascular mucosa that warms and humidifies incoming air.\\nEach lateral wall of the cavity has 3 turbinates, which are bony shelves that increase the surface area,\\nthereby allowing more effective heat and moisture exchange. Nasal mucus traps incoming particulate\\nmatter. The space between the middle and inferior turbinate is the middle meatus, into which the maxillary\\nand most of the ethmoid sinuses drain. Polyps may develop between the turbinates, often in association\\nwith asthma, allergy, aspirin use, and cystic fibrosis.\\nSinuses:\\n The paranasal sinuses are mucus-lined bony cavities that connect to the nasopharynx. The 4\\ntypes are maxillary, frontal, ethmoid, and sphenoid sinuses. They are located in the facial and cranial\\nbones (see\\nFig. 51-1\\n). The physiologic role of the sinuses is unclear.\\n[\\nFig. 51-1.\\n Paranasal sinuses.]\\nEvaluation\\nExamination of the nose and pharynx is part of every general physical examination.\\nHistory:\\n General information includes use of alcohol or tobacco (both major risk factors for head and\\nneck cancer) and systemic symptoms, such as fever and weight loss. Oropharyngeal symptoms include\\npain, ulcers, and difficulty swallowing or speaking. Nasal and sinus symptoms include presence and\\nduration of congestion, discharge, or bleeding.\\nPhysical examination:\\n Most physicians use a head-mounted light. However, because the light cannot\\nbe precisely aligned on the axis of vision, it is difficult to avoid shadowing in narrow areas (eg, nasal\\ncavity). Better illumination results with a head-mounted convex mirror; the physician looks through a hole\\nin the center of the mirror, so the illumination is always on-axis. The head mirror reflects light from a\\nsource (any incandescent light) placed behind the patient and slightly to one side and requires practice to\\nuse effectively.\\nThe nose is examined using a nasal speculum, which is held so that the 2 blades open in an\\nanteroposterior (or slightly oblique) direction and do not press against the septum. The physician notes\\ncrusting, discharge, septal deviation, or perforation; whether mucosa is erythematous, boggy, or swollen;\\nand presence of polyps. The skin over the frontal and maxillary sinuses is examined for erythema and\\ntenderness, suggesting sinus inflammation.\\nIf necessary, the nasopharynx and hypopharynx can be examined with mirrors, which should be warmed\\nbefore use to avoid fogging. A small mirror is used for the nasopharynx. It is held just below the uvula,\\nangling upward; the tongue is pushed down with a tongue blade. A larger mirror is used for the\\nhypopharynx and larynx. The tongue is retracted by grasping it with a gauze pad, and the mirror is placed\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n554\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 564, 'page_label': '555'}, page_content=\"against the soft palate, angling downward. If patients do not tolerate mirror examination, a flexible\\nfiberoptic nasopharyngoscope is helpful. A topical anesthetic (eg, lidocaine 4%) is sprayed in the nose\\nand throat, and the nose is also sprayed with a decongestant (eg, phenylephrine 0.5%). After several\\nminutes, the scope is gently passed through the nares, and the nasal cavity, hypopharynx, and larynx are\\ninspected.\\nNeck examination consists of inspection and palpation for masses. If masses are found, the physician\\nnotes whether they are tender; fluctuant, firm, or stony hard; and movable or fixed. Masses caused by\\ninfection are tender and mobile; cancers tend to be nontender, hard, and fixed. Particular attention is paid\\nto the cervical lymph nodes and thyroid and parotid glands.\\nEpistaxis\\nEpistaxis is nose bleeding. Bleeding can range from a trickle to a strong flow, and the\\nconsequences can range from a minor annoyance to life-threatening hemorrhage. Swallowed\\nblood is a gastric irritant, so patients also may describe vomiting blood.\\nPathophysiology\\nMost nasal bleeding is anterior, originating from a plexus of vessels in the anteroinferior septum\\n(Kiesselbach's area).\\nLess common but more serious are posterior nosebleeds, which originate in the posterior septum\\noverlying the vomer bone, or laterally on the inferior or middle turbinate. Posterior nosebleeds tend to\\noccur in patients who have preexisting atherosclerotic vessels or bleeding disorders and have undergone\\nnasal or sinus surgery.\\nEtiology\\nThe most common causes of epistaxis are\\n Local trauma (eg, nose blowing and picking)\\n Drying of the nasal mucosa\\nThere are a number of less common causes (see\\nTable 51-1\\n). Hypertension may contribute to the persistence of a nosebleed that has already begun but is\\nunlikely to be the sole etiology.\\nEvaluation\\nHistory: History of present illness\\n should try to determine which side began bleeding first; although\\nmajor epistaxis quickly involves both nares, most patients can localize the initial flow to one side, which\\nfocuses the physical examination. Also, the duration of bleeding should be established, as well as any\\ntriggers (eg, sneezing, nose blowing, picking) and attempts by the patient to stop the bleeding. Important\\nassociated symptoms prior to onset include symptoms of a URI, sensation of nasal obstruction, and nasal\\nor facial pain. The time and number of previous nose-bleeding episodes and their resolution should be\\nidentified.\\n[\\nTable 51-1.\\n Some Causes of Epistaxis]\\nReview of systems\\n should ask about symptoms of excessive bleeding, including easy bruising; bloody\\nor tarry stools; hemoptysis; blood in urine; and excess bleeding with toothbrushing, phlebotomy, or minor\\ntrauma.\\nPast medical history\\n should note presence of known bleeding disorders (including a family history) and\\nconditions associated with defects in platelets or coagulation, particularly cancer, cirrhosis, HIV, and\\npregnancy. Drug history should specifically query about use of drugs that may promote bleeding,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n555\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 565, 'page_label': '556'}, page_content='including aspirin and other NSAIDs, other antiplatelet drugs (eg, clopidogrel), heparin, and warfarin.\\nPhysical examination:\\n Vital signs should be reviewed for indications of intravascular volume depletion\\n(tachycardia, hypotension) and marked hypertension. With active bleeding, treatment takes place\\nsimultaneously with evaluation.\\nDuring active bleeding, inspection is difficult, so attempts are first made to stop the bleeding as described\\nbelow. The nose is then examined using a nasal speculum and a bright head lamp or head mirror, which\\nleaves one hand free to manipulate suction or an instrument.\\nAnterior bleeding sites are usually apparent on direct examination. If no site is apparent and there have\\nbeen only 1 or 2 minor nosebleeds, further examination is not needed. If bleeding is severe or recurrent\\nand no site is seen, fiberoptic endoscopy may be necessary.\\nThe general examination should look for signs of bleeding disorders, including petechiae, purpura, and\\nperioral and oral mucosal telangiectasias as well as any intranasal masses.\\nRed flags:\\n The following findings are of particular concern:\\n Signs of hypovolemia or hemorrhagic shock\\n Anticoagulant drug use\\n Cutaneous signs of a bleeding disorder\\n Bleeding not stopped by direct pressure or vasoconstrictor-soaked pledgets\\n Multiple recurrences, particularly with no clear cause\\nInterpretation of findings:\\n Many cases have a clear-cut trigger (particularly nose blowing or picking) as\\nsuggested by findings (see \\nTable 51-1\\n).\\nTesting:\\n Routine laboratory testing is not required. Patients with symptoms or signs of a bleeding\\ndisorder and those with severe or recurrent epistaxis should have CBC, PT, and PTT.\\nCT may be done if a foreign body, a tumor, or sinusitis is suspected.\\nTreatment\\nPresumptive treatment for actively bleeding patients is that for anterior bleeding. The need for blood\\nreplacement is determined by the Hb level, symptoms of anemia, and vital signs. Any identified bleeding\\ndisorders are treated.\\nAnterior epistaxis:\\n Bleeding can usually be controlled by pinching the nasal alae together for 10 min\\nwhile the patient sits upright (if possible). If this maneuver fails, a cotton pledget impregnated with a\\nvasoconstrictor (eg, phenylephrine 0.25%) and a topical anesthetic (eg, lidocaine 2%) is inserted and the\\nnose pinched for another 10 min. The bleeding point may then be cauterized with electrocautery or silver\\nnitrate on an applicator stick. Cauterizing 4 quadrants immediately adjacent to the bleeding vessel is most\\neffective. Care must be taken to avoid burning the mucous membrane too deeply; therefore, silver nitrate\\nis the preferred method. Alternatively, a nasal tampon of expandable foam may be inserted. Coating the\\ntampon with a topical ointment, such as bacitracin or mupirocin, may help. If these methods are\\nineffective, various commercial nasal balloons can be used to compress bleeding sites. Alternatively, an\\nanterior nasal pack consisting of 1/2-in petrolatum gauze may be inserted; up to 72 in of gauze may be\\nrequired. This procedure is painful, and analgesics usually are needed; it should be used only when other\\nmethods fail or are not available.\\nPosterior epistaxis:\\n Posterior bleeding may be difficult to control. Commercial nasal balloons are quick\\nand convenient; a gauze posterior pack is effective but more difficult to position. Both are very\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n556'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 566, 'page_label': '557'}, page_content='uncomfortable; IV sedation and analgesia may be needed, and hospitalization is required.\\nCommercial balloons are inserted according to the instructions accompanying the product.\\nThe posterior gauze pack consists of 4-in gauze squares folded, rolled, tied into a tight bundle with 2\\nstrands of heavy silk suture, and coated with antibiotic ointment. The ends of one suture are tied to a\\ncatheter that has been introduced through the nasal cavity on the side of the bleeding and brought out\\nthrough the mouth. As the catheter is withdrawn from the nose, the postnasal pack is pulled into place\\nabove the soft palate in the nasopharynx. The 2nd suture hangs down the back of the throat and is\\ntrimmed below the level of the soft palate so that it can be used to remove the pack. The nasal cavity\\nanterior to this pack is firmly packed with 1/2-in petrolatum gauze, and the \\n1st suture is tied over a roll of\\ngauze at the anterior nares to secure the postnasal pack. The packing remains in place for 4 to 5 days.\\nAn antibiotic (eg, amoxicillin/clavulanate 875 mg po bid for 7 to 10 days) is given to prevent sinusitis and\\notitis media. Posterior nasal packing lowers the arterial PO\\n2\\n, and supplementary O\\n2\\n is given while the\\npacking is in place.\\nRarely, the internal maxillary artery and its branches must be ligated to control the bleeding. The arteries\\nmay be ligated with clips using endoscopic or microscopic guidance and a surgical approach through the\\nmaxillary sinus. Alternatively, angiographic embolization may be done by a skilled radiologist.\\nBleeding disorders:\\n In Rendu-Osler-Weber syndrome, a split-thickness skin graft (septal dermatoplasty)\\nreduces the number of nosebleeds and allows the anemia to be corrected. Laser (Nd:YAG)\\nphotocoagulation can be done in the operating room. Selective embolization also is very effective,\\nparticularly in patients who cannot tolerate general anesthesia or for whom surgical intervention has not\\nbeen successful. New endoscopic sinus devices have made transnasal surgery more effective.\\nBlood may be swallowed in large amounts and, in patients with liver disease, should be eliminated\\npromptly with enemas and cathartics to prevent hepatic encephalopathy. The GI tract should be sterilized\\nwith nonabsorbable antibiotics (eg, neomycin 1 g po qid) to prevent the breakdown of blood and the\\nabsorption of ammonia.\\nKey Points\\n Most nosebleeds are anterior and stop with direct pressure.\\n Screening (by history and physical examination) for bleeding disorders is important.\\n Patients should always be asked about aspirin or ibuprofen use.\\nNasal Congestion and Rhinorrhea\\nNasal congestion and rhinorrhea (runny nose) are extremely common problems that commonly occur\\ntogether but occasionally occur alone.\\nEtiology\\nThe most common causes (see\\nTable 51-2\\n) are the following:\\n Viral infections\\n Allergic reactions\\nDry air may provoke congestion. Acute sinusitis is slightly less common, and a nasal foreign body is\\nunusual (and occurs predominantly in children).\\nPatients who use topical decongestants for > 1 day often experience significant rebound congestion\\nwhen the effects of the drug wear off, causing them to continue using the decongestant in a vicious circle\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n557'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 567, 'page_label': '558'}, page_content='of persistent, worsening congestion. This situation (rhinitis medicamentosa) may persist for some time\\nand may be misinterpreted as a continuation of the original problem rather than a consequence of\\ntreatment.\\nEvaluation\\nHistory: History of present illness\\n should determine the nature of the discharge (eg, watery, mucoid,\\npurulent, bloody) and whether discharge is chronic or recurrent. If recurrent, any relation to patient\\nlocation, season, or exposure to potential triggering allergens (numerous) should be determined.\\nReview of systems\\n should seek symptoms of possible causes, including fever and facial pain\\n(sinusitis); watery, itchy eyes (allergies); and sore throat, malaise, fever, and cough (viral URI).\\nPast medical history\\n should seek known allergies and existence of diabetes or immunocompromise.\\nDrug history should ask specifically about topical decongestant use.\\nPhysical examination:\\n Vital signs are reviewed for fever.\\nExamination focuses on the nose and area over the sinuses. The face is inspected for focal erythema\\nover the frontal and maxillary sinuses; these areas are also palpated for tenderness. Nasal mucosa is\\ninspected for color (eg, red or pale), swelling, color and nature of discharge, and (particularly in children)\\npresence of any foreign body.\\nRed flags:\\n The following findings are of particular concern:\\n Unilateral discharge, particularly if purulent or bloody\\n Facial pain, tenderness, or both\\nInterpretation of findings:\\n Symptoms and examination are often enough to suggest a diagnosis (see\\nTable 51-2\\n).\\nIn children, unilateral foul-smelling discharge suggests a nasal foreign body. If no foreign body is seen,\\nsinusitis is suspected when purulent rhinorrhea persists for > 10 days along with fatigue and cough.\\nTesting:\\n Testing is generally not indicated for acute nasal symptoms unless invasive sinusitis is\\nsuspected in a diabetic or immunocompromised patient; these patients usually should undergo CT.\\n[\\nTable 51-2.\\n Some Causes of Nasal Congestion and Rhinorrhea]\\nTreatment\\nSpecific conditions are treated. Symptomatic relief of congestion can be achieved with topical or oral\\ndecongestants. Topical decongestants include oxymetazoline, 2 sprays each nostril once/day or bid for 3\\ndays. Oral decongestants include pseudoephedrine 60 mg bid. Prolonged use should be avoided.\\nViral rhinorrhea can be treated with oral antihistamines (eg, diphenhydramine 25 to 50 mg po bid), which\\nare recommended because of their anticholinergic properties unrelated to their H\\n2\\n-blocking properties.\\nAllergic congestion and rhinorrhea can be treated with antihistamines; in such cases, nonanticholinergic\\nantihistamines (eg, fexofenadine 60 mg po bid) as needed provoke fewer adverse effects. Nasal\\ncorticosteroids (eg, mometasone 2 sprays each nostril daily) also help allergic conditions.\\nAntihistamines and decongestants are not recommended for children < 6 yr.\\nGeriatrics Essentials\\nAntihistamines and can have sedating and anticholinergic effects and should be given in decreased\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n558'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 568, 'page_label': '559'}, page_content='dosage in the elderly. Similarly, sympathomimetics should be used with the lowest dosage that is clinically\\neffective.\\nKey Points\\n Most nasal congestion and rhinorrhea are caused by URI or allergies.\\n A foreign body should be considered in children.\\n Rebound from topical decongestant overuse should also be considered.\\nNeck Mass\\nPatients or their family members may notice a mass on the neck, or one may be discovered during routine\\nexamination. A neck mass may be painless or painful depending on the cause. When a neck mass is\\npainless, much time may pass before patients seek medical care.\\nEtiology\\nThere are many causes of neck mass, including infectious, cancerous, and congenital causes (see\\nTable 51-3\\n).\\nThe most common causes in younger patients include the following:\\n Reactive adenitis\\n Primary bacterial lymph node infection\\n Systemic infections\\n[\\nTable 51-3.\\n Some Causes of Neck Mass]\\nReactive adenitis occurs in response to viral or bacterial infection somewhere in the oropharynx. Some\\nsystemic infections (eg, mononucleosis, HIV, TB) cause cervical lymph node enlargementusually\\ngeneralized rather than isolated.\\nCongenital disorders may cause a neck mass, typically longstanding. The most common are thyroglossal\\nduct cysts, branchial cleft cysts, and dermoid or sebaceous cysts.\\nCancerous masses are more common among older patients but may occur in younger ones. These\\nmasses may represent a local primary tumor or lymph node involvement from a local, regional, or distant\\nprimary cancer. About 60% of supraclavicular triangle masses are metastases from distant primary sites.\\nElsewhere in the neck, 80% of cancerous cervical adenopathy originates in the upper respiratory or\\nalimentary tract. Likely sites of origin are the posterior-lateral border of the tongue and the floor of the\\nmouth followed by the nasopharynx, palatine tonsil, laryngeal surface of the epiglottis, and hypopharynx,\\nincluding the pyriform sinuses.\\nThe thyroid gland may enlarge in various disorders, including simple nontoxic goiter, subacute thyroiditis,\\nand, less often, thyroid cancer.\\nEvaluation\\nHistory: History of present illness\\n should note how long the mass has been present and whether it is\\npainful. Important associated acute symptoms include sore throat, URI symptoms, and toothache.\\nReview of systems\\n should ask about difficulty swallowing or speaking and symptoms of chronic\\ndisease (eg, fever, weight loss, malaise). Regional and distant cancers causing metastases to the neck\\noccasionally cause symptoms in their system of origin (eg, cough in lung cancer, swallowing difficulty in\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n559'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 569, 'page_label': '560'}, page_content='esophageal cancer). Because numerous cancers can metastasize to the neck, a complete review of\\nsystems is important to help identify a source.\\nPast medical history\\n should inquire about known HIV or TB and risk factors for them. Risk factors for\\ncancer are assessed, including consumption of alcohol or use of tobacco (particularly snuff or chewing\\ntobacco), ill-fitting dental appliances, and chronic oral candidiasis. Poor oral hygiene also may be a risk.\\nPhysical examination:\\n The neck mass is palpated to determine consistency (ie, whether soft and\\nfluctuant, rubbery, or hard) and presence and degree of tenderness. Whether the mass is freely mobile or\\nappears fixed to the skin or underlying tissue also needs to be determined.\\nThe scalp, ears, nasal cavities, oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx are closely\\ninspected for signs of infection and any other visible lesions. Teeth are percussed to detect the exquisite\\ntenderness of root infection. The base of the tongue, floor of the mouth, and the thyroid and salivary\\nglands are palpated for masses.\\nThe breasts and prostate gland are palpated for masses, and the spleen is palpated for enlargement.\\nStool is checked for occult blood, suggestive of a GI cancer.\\nOther lymph nodes are palpated (eg, axillary, inguinal).\\nRed flags:\\n The following findings are of particular concern:\\n Hard, fixed mass\\n Older patient\\n Presence of oropharyngeal lesions (other than simple pharyngitis or dental infection)\\n A history of persistent hoarseness or dysphagia\\nInterpretation of findings:\\n Important differentiating factors for a neck mass (see also \\nTable 51-3\\n)\\ninclude acuity, pain and tenderness, and consistency and mobility.\\nA new mass (ie, developing over only a few days), particularly after symptoms of a URI or pharyngitis,\\nsuggests benign reactive lymphadenopathy. An acute tender mass suggests lymphadenitis or an infected\\ndermoid cyst.\\nA chronic mass in younger patients suggests a cyst. A non-midline mass in older patients, particularly\\nthose with risk factors, should be considered cancer until proven otherwise; a midline mass is likely of\\nthyroid origin (benign or malignant).\\nPain, tenderness, or both in the mass suggest inflammation (particularly infectious), whereas a painless\\nmass suggests a cyst or tumor. A hard, fixed, nontender mass suggests cancer, whereas rubbery\\nconsistency and mobility suggest otherwise.\\nGeneralized adenopathy and splenomegaly suggest infectious mononucleosis or a lymphoreticular\\ncancer. Generalized adenopathy alone may suggest HIV infection, particularly in those with risk factors.\\nRed and white mucosal patches (erythroplakia and leukoplakia) in the oropharynx may be malignant\\nlesions responsible for the neck mass.\\nDifficulty swallowing may be noted with thyroid enlargement or cancer originating in various sites in the\\nneck. Difficulty speaking \\nsuggests a cancer involving the larynx or recurrent laryngeal nerve.\\nTesting:\\n If the nature of the mass is readily apparent (eg, lymphadenopathy caused by recent\\npharyngitis) or is in a healthy young patient with a recent, tender swelling and no other findings, then no\\nimmediate testing is required. However, the patient is reexamined regularly; if the mass fails to resolve,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n560'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 570, 'page_label': '561'}, page_content='further evaluation is needed.\\nMost other patients should have a CBC and chest x-ray. Those with findings suggesting specific causes\\nshould also have testing for those disorders (see \\nTable 51-3\\n).\\nIf examination reveals an oral or nasopharyngeal lesion that fails to begin resolving within 2 wk, testing\\nmay include CT or MRI and fine-needle biopsy of that lesion.\\nIn young patients with no risk factors for head and neck cancer and no other apparent lesions, the neck\\nmass may be biopsied.\\nOlder patients, particularly those with risk factors for cancer, should first undergo further testing to identify\\nthe primary site; biopsy of the neck mass may simply reveal undifferentiated squamous cell carcinoma\\nwithout illuminating the source. Such patients should have direct laryngoscopy, bronchoscopy, and\\nesophagoscopy with biopsy of all suspicious areas. CT of the head, neck, and chest and possibly a\\nthyroid scan are done. If a primary tumor is not found, fine-needle aspiration biopsy of the neck mass\\nshould be done, which is preferable to an incisional biopsy because it does not leave a transected mass\\nin the neck. If the neck mass is cancerous and a primary tumor has not been identified, random biopsy of\\nthe nasopharynx, palatine tonsils, and base of the tongue should be considered.\\nTreatment\\nTreatment is directed at the cause.\\nKey Points\\n An acute neck mass in younger patients is usually benign.\\n Neck mass in an elderly patient raises concern of cancer.\\n Thorough oropharyngeal examination is important.\\nPharyngitis\\nPharyngitis (sore throat) is pain in the posterior pharynx that occurs with or without swallowing.\\nPain can be severe; many patients refuse oral intake.\\nEtiology\\nSore throat results from infection; the most common cause is\\n Tonsillopharyngitis\\nRarely, an abscess or epiglottitis is involved; although uncommon, these are of particular concern\\nbecause they may compromise the airway.\\nTonsillopharyngitis:\\n Tonsillopharyngitis is predominantly a viral infection; a lesser number of cases are\\ncaused by bacteria.\\nThe respiratory viruses (rhinovirus, adenovirus, influenza, coronavirus, respiratory syncytial virus) are the\\nmost common viral causes, but occasionally Epstein-Barr virus (the cause of mononucleosis), herpes\\nsimplex, cytomegalovirus, or primary HIV infection is involved.\\nThe main bacterial cause is group A \\n\\n-hemolytic streptococcus (GABHS), which, although estimates vary,\\ncauses perhaps 10% of cases in adults and slightly more in children. GABHS is a concern because of the\\npossibility of the poststreptococcal sequelae of rheumatic fever, glomerulonephritis, and abscess.\\nUncommon bacterial causes include gonorrhea, diphtheria, mycoplasma, and chlamydia.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n561'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 571, 'page_label': '562'}, page_content='Abscess:\\n An abscess in the pharyngeal area (peritonsillar, parapharyngeal, and, in children,\\nretropharyngeal) is uncommon but causes significant throat pain. The usual causative organism is\\nGABHS.\\nEpiglottitis:\\n Epiglottitis, perhaps better termed supraglottitis, used to occur primarily in children and\\nusually was caused by \\nHaemophilus influenzae\\n type B (HiB). Now, because of widespread childhood\\nvaccination against HiB, supraglottitis/epiglottitis has been almost eradicated in children (more cases\\noccur in adults). Causal organisms in children and adults include \\nStreptococcus pneumoniae\\n,\\nStaphylococcus aureus\\n, nontypeable \\nH. influenzae\\n, \\nHaemophilus parainfluenzae\\n, \\n\\n-hemolytic\\nstreptococci, \\nBranhamella catarrhalis\\n, and \\nKlebsiella pneumoniae\\n. HiB is still a cause in adults and\\nunvaccinated children.\\nEvaluation\\nHistory: History of present illness\\n should note the duration and severity of sore throat.\\nReview of systems\\n should seek important associated symptoms, such as runny nose, cough, and\\ndifficulty swallowing, speaking, or breathing. The presence and duration of any preceding weakness and\\nmalaise (suggesting mononucleosis) are noted.\\nPast medical history\\n should seek history of previous documented mononucleosis (recurrence is highly\\nunlikely). Social history should inquire about close contact with people with documented GABHS\\ninfection, risk factors for gonorrhea transmission (eg, recent oral-genital sexual contact), and risk factors\\nfor HIV acquisition (eg, unprotected intercourse, multiple sex partners, IV drug abuse).\\nPhysical examination:\\n General examination should note fever and signs of respiratory distress, such as\\ntachypnea, dyspnea, stridor, and, in children, the tripod position (sitting upright, leaning forward with neck\\nhyperextended and jaw thrust forward).\\nPharyngeal examination should not be done in children if supraglottitis/epiglottitis is suspected, because it\\nmay trigger complete airway obstruction. Adults with no respiratory distress may be examined but with\\ncare. Erythema, exudates, and any signs of swelling around the tonsils or retropharyngeal area should be\\nnoted. Whether the uvula is in the midline or appears pushed to one side should also be noted.\\nThe neck is examined for presence of enlarged, tender lymph nodes. The abdomen is palpated for\\npresence of splenomegaly.\\nRed flags:\\n The following findings are of particular concern:\\n Stridor or other sign of respiratory distress\\n Drooling\\n Muffled, \"hot potato\" voice\\n Visible bulge in pharynx\\nInterpretation of findings:\\n Supraglottitis/epiglottitis and pharyngeal abscess pose a threat to the airway\\nand must be differentiated from simple tonsillopharyngitis, which is uncomfortable but not acutely\\ndangerous. Clinical findings help make this distinction.\\nWith supraglottitis/epiglottitis, there is abrupt onset of severe throat pain and dysphagia, usually with no\\npreceding URI symptoms. Children often have drooling and signs of toxicity. Sometimes (more often in\\nchildren), there are respiratory manifestations, with tachypnea, dyspnea, stridor, and sitting in the tripod\\nposition. If examined, the pharynx almost always appears unremarkable.\\nPharyngeal abscess and tonsillopharyngitis both may cause pharyngeal erythema, exudate, or both.\\nHowever, some findings are more likely in one condition or another:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n562'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 572, 'page_label': '563'}, page_content=' Pharyngeal abscess: Muffled, \"hot potato\" voice (speaking as if a hot object is being held in the mouth);\\nvisible focal swelling in the posterior pharyngeal area (often with deviation of the uvula)\\n Tonsillopharyngitis: Accompanied by URI symptoms (eg, runny nose, cough)\\nAlthough tonsillopharyngitis is easily recognized clinically, its cause is not. Manifestations of viral and\\nGABHS infection overlap significantly, although URI symptoms are more common with a viral cause. In\\nadults, clinical criteria that increase suspicion of GABHS as a cause include\\n Tonsillar exudate\\n Tender lymphadenopathy\\n Fever (including history)\\n Absence of cough\\nThose with  1 criterion reasonably may be presumed to have viral illness. If  2 criteria are present, the\\nlikelihood of GABHS is high enough to warrant testing but probably not high enough to warrant\\nantibiotics, but this decision needs to be patient-specific (ie, threshold for testing and treatment may be\\nlower in those at risk because of diabetes or immunocompromise). In children, testing usually is done.\\nRegarding rarer causes of tonsillopharyngitis, infectious mononucleosis should be considered when there\\nis posterior cervical or generalized adenopathy, hepatosplenomegaly, and fatigue and malaise for > 1 wk.\\nThose with no URI symptoms but recent oral-genital contact may have pharyngeal gonorrhea. A dirty-\\ngray, thick, tough membrane on the posterior pharynx that bleeds if peeled away indicates diphtheria (rare\\nin the US). HIV infection should be considered in patients with risk factors.\\nTesting:\\n If supraglottitis/epiglottitis is considered possible after evaluation, testing is required. Patients\\nwho do not appear seriously ill and have no respiratory symptoms may have plain lateral neck x-rays to\\nlook for an edematous epiglottis. However, a child who appears seriously ill or has stridor or any other\\nrespiratory symptoms should not be transported to the x-ray suite. Such patients (and those with positive\\nor equivocal x-ray findings) usually should have flexible fiberoptic laryngoscopy. (CAUTION: \\nExamination\\nof the pharynx and larynx may precipitate complete respiratory obstruction in children, and the pharynx\\nand larynx should not be directly examined except in the operating room, where the most advanced\\nairway intervention is available\\n.)\\nMany abscesses are managed clinically, but if location and extent are unclear, immediate CT of the neck\\nshould be done.\\nIn tonsillopharyngitis, throat culture is the only reliable way to differentiate viral infection \\nfrom GABHS. To\\nbalance timeliness of diagnosis, cost, and accuracy, one strategy in children is to do a rapid strep screen\\nin the office, treat if positive, and send a formal culture if negative. In adults, because other bacterial\\npathogens may be involved, throat culture for all bacterial pathogens is appropriate for those meeting\\nclinical criteria described previously.\\nTesting for mononucleosis, gonorrhea, or HIV is done only when clinically suspected.\\nTreatment\\nSpecific conditions are treated. Those with severe symptoms of tonsillopharyngitis may be started on a\\nbroad-spectrum antibiotic (eg, amoxicillin/clavulanate) pending culture results.\\nSymptomatic treatments such as warm saltwater gargles and topical anesthetics (eg, benzocaine,\\nlidocaine, dyclonine) may help temporarily relieve pain in tonsillopharyngitis. Patients in severe pain (even\\nfrom tonsillopharyngitis) may require short-term use of opioids.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n563'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 573, 'page_label': '564'}, page_content=\"Key Points\\n Most sore throats are caused by viral tonsillopharyngitis.\\n It is difficult to clinically distinguish viral from bacterial causes of tonsillopharyngitis.\\n Abscess and epiglottitis are rare but serious causes.\\n Severe sore throat in a patient with a normal-appearing pharynx should raise suspicion of epiglottitis.\\nSmell and Taste Abnormalities\\nBecause distinct flavors depend on aromas to stimulate the olfactory chemoreceptors, smell and taste are\\nphysiologically interdependent. Dysfunction of one often disturbs the other. Disorders of smell and taste\\nare rarely incapacitating or life threatening, so they often do not receive close medical attention, although\\ntheir effect on quality of life can be severe.\\nTaste:\\n Although abnormal taste sensations may be due to mental disorders, local causes should always\\nbe sought. Glossopharyngeal and facial nerve integrity can be determined by testing taste on both sides\\nof the dorsum of the tongue with sugar, salt, vinegar (acid), and quinine (bitter).\\nDrying of the oral mucosa caused by heavy smoking, Sjogren's syndrome, radiation therapy of the head\\nand neck, or desquamation of the tongue can impair taste, and various drugs (eg, those with\\nanticholinergic properties and vincristine) alter taste. In all instances, the gustatory receptors are diffusely\\ninvolved. When limited to one side of the tongue (eg, in Bell's palsy), ageusia (loss of the sense of taste)\\nis rarely noticed.\\nSmell:\\n The inability to detect certain odors, such as gas or smoke, may be dangerous, and several\\nsystemic and intracranial disorders should be excluded before dismissing symptoms as harmless.\\nWhether brain stem disease (involvement of the nucleus solitarius) can cause disorders of smell and\\ntaste is uncertain, because other neurologic manifestations usually take precedence.\\nAnosmia (loss of the sense of smell) is probably the most common abnormality. Hyperosmia (increased\\nsensitivity to odors) usually reflects a neurotic or histrionic personality but can occur intermittently with\\nseizure disorders. Dysosmia (disagreeable or distorted sense of smell) may occur with infection of the\\nnasal sinuses, partial damage to the olfactory bulbs, or mental depression. Some cases, accompanied by\\na disagreeable taste, result from poor dental hygiene. Uncinate epilepsy can produce brief, vivid,\\nunpleasant olfactory hallucinations. Hyposmia (diminished sense of smell) and hypogeusia (diminished\\nsense of taste) can follow acute influenza, usually temporarily.\\nRarely, idiopathic dysgeusia (distorted sense of taste), hypogeusia, and dysosmia respond to zinc\\nsupplementation.\\nAnosmia\\nAnosmia is complete loss of smell. Hyposmia is partial loss of smell. Most patients with anosmia have\\nnormal perception of salty, sweet, sour, and bitter substances but lack flavor discrimination, which largely\\ndepends on olfaction. Therefore, they often complain of losing the sense of taste (ageusia) and of not\\nenjoying food. If unilateral, anosmia is often unrecognized.\\nEtiology\\nAnosmia occurs when intranasal swelling or other obstruction prevents odors from gaining access to the\\nolfactory area; when the olfactory neuroepithelium is destroyed; or when the olfactory nerve fila, bulbs,\\ntracts, or central connections are destroyed (see\\nTable 51-4\\n).\\nMajor causes include\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n564\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 574, 'page_label': '565'}, page_content=\" Head trauma (young adults)\\n Viral infections and Alzheimer's disease (older adults)\\n[\\nTable 51-4.\\n Some Causes of Anosmia]\\nPrior URI, especially influenza infection, is implicated in 14 to 26% of all presenting cases of hyposmia or\\nanosmia.\\nDrugs can contribute to anosmia in susceptible patients. Other causes include prior head and neck\\nradiation, recent nasal or sinus surgery, nasal and brain tumors, and toxins. The role of tobacco is\\nuncertain.\\nEvaluation\\nHistory: History of present illness\\n should assess the time course of symptoms and their relation to\\nany URI or head injury. Important associated symptoms are nasal congestion, rhinorrhea, or both. The\\nnature of rhinorrhea should be assessed (eg, watery, mucoid, purulent, bloody).\\nReview of systems\\n should assess neurologic symptoms, particularly those involving mental status (eg,\\ndifficulty with recent memory) and cranial nerves (eg, diplopia, difficulty speaking or swallowing, tinnitus,\\nvertigo).\\nPast medical history\\n should include history of sinus disorders, cranial trauma or surgery, allergies,\\ndrugs used, and exposure to chemicals or fumes.\\nPhysical examination:\\n The nasal passages should be inspected for swelling, inflammation, discharge,\\nand polyps. Having the patient breathe through each nostril sequentially (while the other is manually\\noccluded) may help identify obstruction.\\nA complete neurologic examination, particularly of mental status and cranial nerves, is done.\\nRed flags:\\n The following findings are of particular concern:\\n Previous head injury\\n Neurologic symptoms or signs\\n Sudden onset\\nInterpretation of findings:\\n Sudden onset after significant head trauma or toxin exposure strongly\\nimplicates that event as the cause.\\nA history of chronic rhinosinusitis is suggestive, particularly when significant congestion, polyps, or both\\nare visible on examination. However, because these findings are common in the population, the physician\\nshould be wary of missing another disorder. Progressive confusion and recent memory loss in an elderly\\npatient suggest Alzheimer's disease as a cause. Waxing and waning neurologic symptoms affecting\\nmultiple areas suggest a neurodegenerative disease such as multiple sclerosis. Slowly progressive\\nanosmia in an elderly patient with no other symptoms or findings suggests normal aging as the cause.\\nTesting:\\n An in-office test of olfaction can help confirm olfactory dysfunction. Commonly, one nostril is\\npressed shut, and a pungent odor such as from a vial containing coffee, cinnamon, or tobacco is placed\\nunder the open nostril; if the patient can identify the substance, olfaction is presumed intact. The test is\\nrepeated on the other nostril to determine whether the response is bilateral. Unfortunately, the test is\\ncrude and unreliable.\\nIf anosmia is present and no cause is readily apparent on clinical evaluation (see \\nTable 51-4\\n), patients\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n565\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 575, 'page_label': '566'}, page_content='should have CT of the head (including sinuses) with contrast to rule out a tumor or unsuspected fracture\\nof the floor of the anterior cranial fossa. MRI is also used to evaluate intracranial disease and may be\\nneeded as well, particularly in those patients with no nasal or sinus pathology on CT.\\nA psychophysical assessment of odor and taste identification and threshold detection is done as well.\\nThis assessment commonly involves use of one or several commercially available testing kits. One kit\\nuses a scratch-and-sniff battery of odors, whereas another kit involves sequential dilutions of an odorous\\nchemical.\\nTreatment\\nSpecific causes are treated, although smell does not always recover even after successful treatment of\\nsinusitis.\\nThere are no treatments for anosmia. Patients who retain some sense of smell may find adding\\nconcentrated flavoring agents to food improves their enjoyment of eating. Smoke alarms, important in all\\nhomes, are even more essential for patients with anosmia. Patients should be cautioned about\\nconsumption of stored food and use of natural gas for cooking or heating, because they have difficulty\\ndetecting food spoilage or gas leaks.\\nGeriatrics Essentials\\nThere is a significant loss of olfactory receptor neurons with normal aging, leading to a marked diminution\\nof the sense of smell. Changes are usually noticeable by age 60 and can be marked after age 70.\\nKey Points\\n Anosmia may be part of normal aging.\\n Common causes include URI, sinusitis, and head trauma.\\n Cranial imaging is typically required unless the cause is obvious.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 51. Approach to the Patient With Nasal & Pharyngeal Symptoms\\n566'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 576, 'page_label': '567'}, page_content=\"Chapter 52. Oral and Pharyngeal Disorders\\nIntroduction\\nOral and pharyngeal disorders include adenoid disorders, epiglottitis, parapharyngeal abscess,\\nperitonsillar abscess and cellulitis, retropharyngeal abscess, salivary stones, sialadenitis, submandibular\\nspace infection, tonsillopharyngitis, Tornwaldt's cyst, and velopharyngeal insufficiency. Oral, pharyngeal,\\nand salivary gland tumors are discussed in \\nCh. 55\\n.\\nSialadenitis\\nSialadenitis is bacterial infection of a salivary gland, usually due to an obstructing stone or\\ngland hyposecretion. Symptoms are swelling, pain, redness, and tenderness. Diagnosis is\\nclinical. CT, ultrasound, and MRI may help identify the cause. Treatment is with antibiotics.\\nEtiology\\nSialadenitis usually occurs after hyposecretion or duct obstruction but may develop without an obvious\\ncause. The major salivary glands are the parotid, submandibular, and sublingual glands. Sialadenitis is\\nmost common in the parotid gland and typically occurs in patients in their 50s and 60s, in chronically ill\\npatients with xerostomia, in those with Sjogren's syndrome, and in those who have had radiation therapy\\nto the oral cavity. Teenagers and young adults with anorexia are also prone to this disorder. The most\\ncommon causative organism is \\nStaphylococcus aureus\\n; others include streptococci, coliforms, and\\nvarious anaerobic bacteria.\\nSymptoms and Signs\\nFever, chills, and unilateral pain and swelling develop. The gland is firm and diffusely tender, with\\nerythema and edema of the overlying skin. Pus can often be expressed from the duct by compressing the\\naffected gland and should be cultured. Focal enlargement may indicate an abscess.\\nDiagnosis\\nCT, ultrasound, and MRI can confirm sialadenitis or abscess that is not obvious clinically, although MRI\\nmay miss an obstructing stone.\\nTreatment\\n Antistaphylococcal antibiotics\\n Local measures (eg, sialagogues, warm compresses)\\nInitial treatment is with antibiotics active against \\nS. aureus\\n (eg, dicloxacillin, 250 mg po qid, a 1st-\\ngeneration cephalosporin, or clindamycin), modified according to culture results. With the increasing\\nprevalence of methicillin-resistant \\nS. aureus\\n, especially among the elderly living in extended-care nursing\\nfacilities, vancomycin is often required. Hydration, sialagogues (eg, lemon juice, hard candy, or some\\nother substance that triggers saliva flow), warm compresses, gland massage, and good oral hygiene are\\nalso important. Abscesses require drainage. Occasionally, a superficial parotidectomy or submandibular\\ngland excision is indicated for patients with chronic or relapsing sialadenitis.\\nOther Salivary Gland Infections\\nMumps often cause parotid swelling (see\\nTable 155-1\\n on p. \\n1462\\n). Patients with HIV infection often have parotid enlargement secondary to one or\\nmore lymphoepithelial cysts. Cat-scratch disease caused by \\nBartonella\\n infection often invades periparotid\\nlymph nodes and may infect the parotid glands by contiguous spread. Although cat-scratch disease is\\nself-limited, antibiotic therapy is often provided, and incision and drainage are necessary if an abscess\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n567\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 577, 'page_label': '568'}, page_content=\"develops.\\nAtypical mycobacterial infections in the tonsils or teeth may spread contiguously to the major salivary\\nglands. The PPD may be negative, and the diagnosis may require biopsy and tissue culture for acid-fast\\nbacteria. Treatment recommendations are controversial. Options include surgical debridement with\\ncurettage, complete excision of the infected tissue, and use of anti-TB drug therapy (rarely necessary).\\nSalivary Stones\\n(Sialolithiasis)\\nStones composed of Ca salts often obstruct salivary glands, causing pain, swelling, and\\nsometimes infection. Diagnosis is made clinically or with CT, ultrasonography, or sialography.\\nTreatment involves stone expression with saliva stimulants, manual manipulation, a probe, or\\nsurgery.\\nThe major salivary glands are the paired parotid, submandibular, and sublingual glands. Stones in the\\nsalivary glands are most common among adults. Eighty percent of stones originate in the submandibular\\nglands and obstruct Wharton's duct. Most of the rest originate in the parotid glands and block Stensen's\\nduct. Only about 1% originate in the sublingual glands. Multiple stones occur in about 25% of patients.\\nEtiology\\nMost salivary stones are composed of Ca phosphate with small amounts of Mg and carbonate. Patients\\nwith gout may have uric acid stones. Stone formation requires a nidus on which salts can precipitate\\nduring salivary stasis. Stasis occurs in patients who are debilitated, dehydrated, have reduced food\\nintake, or take anticholinergics. Persisting or recurrent stones predispose to infection of the involved\\ngland (sialadenitissee p. \\n469\\n).\\nSymptoms and Signs\\nObstructing stones cause glandular swelling and pain, particularly after eating, which stimulates saliva\\nflow. Symptoms may subside after a few hours. Relief may coincide with a gush of saliva. Some stones\\ncause intermittent or no symptoms. If a stone is lodged distally, it may be visible or palpable at the duct's\\noutlet.\\nDiagnosis\\n Clinical evaluation\\n Sometimes imaging (eg, CT, ultrasonography, sialography)\\nIf a stone is not apparent on examination, the patient can be given a sialagogue (eg, lemon juice, hard\\ncandy, or some other substance that triggers saliva flow). Reproduction of symptoms is almost always\\ndiagnostic of a stone. CT, ultrasonography, and sialography are highly sensitive and are used if clinical\\ndiagnosis is equivocal. Contrast sialography may be done through a catheter inserted into the duct and\\ncan differentiate between stone, stenosis, and tumor. This technique is occasionally therapeutic. Because\\n90% of submandibular calculi are radiopaque and 90% of parotid calculi are radiolucent, plain x-rays are\\nnot always accurate. MRI is not indicated.\\nTreatment\\n Local measures (eg, sialagogues, massage)\\n Sometimes manual expression or surgical removal\\nAnalgesics, hydration, and massage can relieve symptoms. Antistaphylococcal antibiotics can be used to\\nprevent acute sialadenitis if started early. Stones may pass spontaneously or when salivary flow is\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n568\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 578, 'page_label': '569'}, page_content=\"stimulated by sialagogues; patients are encouraged to suck a lemon wedge or sour candy every 2 to 3 h.\\nStones right at the duct orifice can sometimes be expressed manually by squeezing with the fingertips.\\nDilation of the duct with a small probe may facilitate expulsion. Surgical removal of stones succeeds if\\nother methods fail. Stones at or near the orifice of the duct may be removed transorally, whereas those in\\nthe hilum of the gland often require complete excision of the salivary gland.\\nSubmandibular Space Infection\\n(Ludwig's Angina)\\nSubmandibular space infection is acute cellulitis of the soft tissues below the mouth.\\nSymptoms include pain, dysphagia, and potentially fatal airway obstruction. Diagnosis usually is\\nclinical. Treatment includes airway management, surgical drainage, and IV antibiotics.\\nSubmandibular space infection is a rapidly spreading, bilateral, indurated cellulitis occurring in the\\nsuprahyoid soft tissues, the floor of the mouth, and both sublingual and submaxillary spaces without\\nabscess formation. Although not a true abscess, it resembles one clinically and is treated similarly.\\nThe condition usually develops from an odontogenic infection, especially of the 2nd and 3rd mandibular\\nmolars, or as an extension of peritonsillar cellulitis. Contributing factors may include poor dental hygiene,\\ntooth extractions, and trauma (eg, fractures of the mandible, lacerations of the floor of the mouth).\\nSymptoms and Signs\\nEarly manifestations are pain in any involved teeth, with severe, tender, localized submental and\\nsublingual induration. Board-like firmness of the floor of the mouth and brawny induration of the\\nsuprahyoid soft tissues may develop rapidly. Drooling, trismus, dysphagia, stridor caused by laryngeal\\nedema, and elevation of the posterior tongue against the palate may be present. Fever, chills, and\\ntachycardia are usually present as well. The condition can cause airway obstruction within hours and\\ndoes so more often than do other neck infections.\\nDiagnosis\\nThe diagnosis usually is obvious. If not, CT is done.\\nTreatment\\n Maintenance of airway patency\\n Surgical incision and drainage\\n Antibiotics active against oral flora\\nMaintaining airway patency is of the highest priority. Because swelling makes oral endotracheal intubation\\ndifficult, fiberoptic nasotracheal intubation done with topical anesthesia in the operating room or ICU with\\nthe patient awake is preferable. Some patients require a tracheotomy. Patients without immediate need\\nfor intubation require intense observation and may benefit temporarily from a nasal trumpet.\\nIncision and drainage with placement of drains deep into the mylohyoid muscles relieve the pressure.\\nAntibiotics should be chosen to cover both oral anaerobes and aerobes (eg, clindamycin,\\nampicillin/sulbactam, high-dose penicillin).\\nAdenoid Disorders\\nHypertrophy or inflammation of the adenoids is common among children. Symptoms include\\nnasal obstruction, sleep disturbances, and middle ear effusions with hearing loss. Diagnosis is\\nenhanced by flexible fiberoptic nasopharyngoscopy. Treatment often includes intranasal\\ncorticosteroids, antibiotics, and, for significant nasal obstruction or persistent recurrent acute\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n569\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 579, 'page_label': '570'}, page_content='otitis media or middle ear effusion, adenoidectomy.\\nThe adenoids are a rectangular mass of lymphatic tissue in the posterior nasopharynx. They are largest\\nin children 2 to 6 yr. Enlargement may be physiologic or secondary to viral or bacterial infection, allergy,\\nirritants, and, possibly, gastroesophageal reflux. Other risk factors include ongoing exposure to bacterial\\nor viral infection (eg, to multiple children at a child care center). Severe hypertrophy can obstruct the\\neustachian tubes (causing otitis media), posterior choanae (causing sinusitis), or both.\\nSymptoms and Signs\\nAlthough patients with adenoid hypertrophy may not complain of symptoms, they usually have chronic\\nmouth breathing, snoring, sleep disturbance, halitosis, recurrent acute otitis media, conductive hearing\\nloss (secondary to recurrent otitis media or persistent middle ear effusions), and a hyponasal voice\\nquality. Chronic adenoiditis can also cause chronic or recurrent nasopharyngitis, rhinosinusitis, epistaxis,\\nhalitosis, and cough.\\nDiagnosis\\n Flexible nasopharyngoscopy\\nAdenoid hypertrophy is suspected in children and adolescents with characteristic symptoms, persistent\\nmiddle ear effusions, or recurrent acute otitis media or rhinosinusitis. Similar symptoms and signs in a\\nmale adolescent may result from an angiofibroma. The gold standard for office assessment of the\\nnasopharynx is flexible nasopharyngoscopy. X-ray imaging and sleep tape recording, although also often\\nused, are not as accurate. A sleep study may help define the severity of any sleep disturbance due to\\nchronic obstruction.\\nTreatment\\n Treatment of cause\\n Sometimes adenoidectomy\\nUnderlying allergy is treated with intranasal corticosteroids, and underlying bacterial infection is treated\\nwith antibiotics. In children with persistent middle ear effusions or frequent otitis media, adenoidectomy\\noften limits recurrence. Children > 4 yr who require tympanostomy tubes often undergo adenoidectomy\\nwhen tubes are placed. Surgery is also recommended for younger children with recurrent epistaxis or\\nsignificant nasal obstruction (eg, sleep disturbance, voice change). Although it requires general\\nanesthesia, adenoidectomy usually can be done on an outpatient basis with recovery in 48 to 72 h.\\nRetropharyngeal Abscess\\nRetropharyngeal abscesses, most common among young children, can cause sore throat, fever,\\nneck stiffness, and stridor. Diagnosis requires lateral neck x-ray or CT. Treatment is with\\nendotracheal intubation, drainage, and antibiotics.\\nRetropharyngeal abscesses develop in the retropharyngeal lymph nodes at the back of the pharynx,\\nadjacent to the vertebrae. They can be seeded by infection of the pharynx, sinuses, adenoids, or nose.\\nThey occur mainly in children 1 to 8 yr, as the retropharyngeal lymph nodes begin to recede by 4 to 5 yr.\\nHowever, adults may develop infection after foreign body ingestion or after instrumentation. Common\\norganisms include aerobic \\n(\\nStreptococcus\\n and \\nStaphylococcus\\n sp) and anaerobic (\\nBacteroides\\n and\\nFusobacterium\\n) bacteria and, increasingly in adults and children, HIV and TB.\\nThe most serious consequences include airway obstruction, septic shock, rupture of the abscess into the\\nairway resulting in aspiration pneumonia or asphyxia, mediastinitis, carotid rupture, and suppurative\\nthrombophlebitis of the internal jugular veins (Lemierre syndrome).\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n570'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 580, 'page_label': '571'}, page_content=\"Symptoms and signs are usually preceded in children by an acute URI and in adults by foreign body\\ningestion or instrumentation. Children may have odynophagia, dysphagia, fever, cervical\\nlymphadenopathy, nuchal rigidity, stridor, dyspnea, snoring or noisy breathing, and torticollis. Adults may\\nhave severe neck pain but less often have stridor. The posterior pharyngeal wall may bulge to one side.\\nDiagnosis\\n CT\\nDiagnosis is suspected in patients with severe, unexplained sore throat and neck stiffness; stridor; or\\nnoisy breathing. Lateral soft-tissue x-rays of the neck, taken in the maximum possible hyperextension and\\nduring inspiration, may show focal widening of the prevertebral soft tissues, reversal of normal cervical\\nlordosis, air in the prevertebral soft tissues, or erosion of the adjacent vertebral body. CT can help\\ndiagnose questionable cases, help differentiate cellulitis from an abscess, and assess extent of the\\nabscess.\\nTreatment\\n Antibiotics (eg, ceftriaxone, clindamycin)\\n Usually surgical drainage\\nAntibiotics, such as a broad-spectrum cephalosporin (eg, ceftriaxone 50 to 75 mg/kg IV once/day) or\\nclindamycin, may occasionally be sufficient for children with small abscesses. However, most patients\\nalso require drainage through an incision in the posterior pharyngeal wall. Endotracheal intubation is\\ndone preoperatively and maintained for 24 to 48 h.\\nTornwaldt's Cyst\\n(Pharyngeal Bursa)\\nTornwaldt's cyst is a rare cyst in the midline of the nasopharynx that may become infected.\\nTornwaldt's cyst is a remnant of the embryonal notochord superficial to the superior constrictor muscle of\\nthe pharynx and is covered by the mucous membrane of the nasopharynx. It may become infected,\\ncausing persistent purulent drainage with a foul taste and odor, eustachian tube obstruction, and sore\\nthroat.\\nPurulent exudate may be seen at the opening of the cyst. Diagnosis is based on nasopharyngoscopy\\nsupplemented by CT or MRI when the diagnosis is in doubt. Treatment consists of marsupialization or\\nexcision.\\nVelopharyngeal Insufficiency\\nVelopharyngeal insufficiency is incomplete closure of a sphincter between the oropharynx and\\nnasopharynx, often resulting from anatomic abnormalities of the palate and causing hypernasal\\nspeech. Treatment is with speech therapy and surgery.\\nVelopharyngeal insufficiency is incomplete closure of the velopharyngeal sphincter between the\\noropharynx and the nasopharynx. Closure, normally achieved by the sphincteric action of the soft palate\\nand the superior constrictor muscle, is impaired in patients with cleft palate, repaired cleft palate,\\ncongenitally short palate, submucous cleft palate, palatal paralysis, and, sometimes, enlarged tonsils. The\\ncondition may also result when adenoidectomy or uvulopalatopharyngoplasty is done in a patient with a\\ncongenital underdevelopment (submucous cleft) or paralysis of the palate.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n571\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 581, 'page_label': '572'}, page_content='Speech in a patient with velopharyngeal insufficiency is characterized by hypernasal resonant voice,\\nnasal emission of air, nasal turbulence, and inability to produce sounds requiring oral pressure (plosives).\\nSevere velopharyngeal insufficiency results in regurgitation of solid foods and fluids through the nose.\\nInspection of the palate during phonation may reveal palatal paralysis.\\nDiagnosis\\n Direct inspection with a fiberoptic nasoendoscope\\nThe diagnosis is suspected in patients with the typical speech abnormalities. Palpation of the midline of\\nthe soft palate may reveal an \\noccult submucous cleft. Direct inspection with a fiberoptic nasoendoscope is\\nthe primary diagnostic technique. Multiview videofluoroscopy during connected speech and swallowing\\n(modified barium swallow), done in conjunction with a speech pathologist, can also be used.\\nTreatment\\n Surgical repair and speech therapy\\nTreatment consists of speech therapy and surgical correction by a palatal elongation pushback\\nprocedure, posterior pharyngeal wall implant, pharyngeal flap, or pharyngoplasty, depending on the\\nmobility of the lateral pharyngeal walls, the degree of velar elevation, and the size of the defect.\\nTonsillopharyngitis\\n(See also p.\\n1232\\n.)\\nTonsillopharyngitis is acute infection of the pharynx, palatine tonsils, or both. Symptoms may\\ninclude sore throat, dysphagia, cervical lymphadenopathy, and fever. Diagnosis is clinical,\\nsupplemented by culture or rapid antigen test. Treatment depends on symptoms and, in the\\ncase of group A\\n \\n\\n-hemolytic streptococcus, involves antibiotics.\\nThe tonsils participate in systemic immune surveillance. In addition, local tonsillar defenses include a\\nlining of antigen-processing squamous epithelium that involves B- and T-cell responses.\\nTonsillopharyngitis of all varieties constitutes about 15% of all office visits to primary care physicians.\\nEtiology\\nTonsillopharyngitis is usually viral, most often caused by the common cold viruses (adenovirus, rhinovirus,\\ninfluenza, coronavirus, respiratory syncytial virus), but occasionally by Epstein-Barr virus, herpes simplex\\nvirus, cytomegalovirus, or HIV.\\nIn about 30% of patients, the cause is bacterial. Group A \\n\\n-hemolytic streptococcus (GABHS) is most\\ncommon (see p. \\n1232\\n), but \\nStaphylococcus aureus\\n, \\nStreptococcus pneumoniae\\n, \\nMycoplasma\\npneumoniae\\n, and \\nChlamydia pneumoniae\\n are sometimes involved. Rare causes include pertussis,\\nFusobacterium\\n, diphtheria, syphilis, and gonorrhea.\\nGABHS occurs most commonly between ages 5 and 15 and is uncommon before age 3.\\nSymptoms and Signs\\nPain with swallowing is the hallmark and is often referred to the ears. Very young children who are not\\nable to complain of sore throat often refuse to eat. High fever, malaise, headache, and GI upset are\\ncommon, as are halitosis and a muffled voice. A scarlatiniform or nonspecific rash may also be present.\\nThe tonsils are swollen and red and often have purulent exudates. Tender cervical lymphadenopathy may\\nbe present. Fever, adenopathy, palatal petechiae, and exudates are somewhat more common with\\nGABHS than with viral tonsillopharyngitis, but there is much overlap. GABHS usually resolves within 7\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n572'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 582, 'page_label': '573'}, page_content='days. Untreated GABHS may lead to local suppurative complications (eg, peritonsillar abscess or\\ncellulitis) and sometimes to rheumatic fever or glomerulonephritis.\\nDiagnosis\\n Clinical evaluation\\n GABHS ruled out by rapid antigen test, culture, or both\\nPharyngitis itself is easily recognized clinically. However, its cause is not. Rhinorrhea and cough usually\\nindicate a viral cause. Infectious mononucleosis is suggested by posterior cervical or generalized\\nadenopathy, hepatosplenomegaly, fatigue, and malaise for > 1 wk; a full neck with petechiae of the soft\\npalate; and thick tonsillar exudates. A dirty gray, thick, tough membrane that bleeds if peeled away\\nindicates diphtheria (rare in the US).\\nBecause GABHS requires antibiotics, it must be diagnosed early. Criteria for testing are controversial.\\nMany authorities recommend testing with a rapid antigen test or culture for all children. Rapid antigen\\ntests are specific but not sensitive and may need to be followed by a culture, which is about 90% specific\\nand 90% sensitive. In adults, many authorities recommend using the following 4 criteria:\\n History of fever\\n Tonsillar exudates\\n Absence of cough\\n Tender anterior cervical lymphadenopathy\\nPatients who meet 1 or no criteria are unlikely to have GABHS and should not be tested. Patients who\\nmeet 2 criteria can be tested. Patients who meet 3 or 4 criteria can be tested or treated empirically for\\nGABHS.\\nTreatment\\n Symptomatic treatment\\n Antibiotics for GABHS\\n Tonsillectomy considered for recurrent GABHS\\nSupportive treatments include analgesia, hydration, and rest. Penicillin V is usually considered the drug of\\nchoice for GABHS tonsillopharyngitis; dose is 250 mg po bid for 10 days for patients < 27 kg and 500 mg\\nfor those > 27 kg (see also p. \\n1234\\n). Amoxicillin is effective and more palatable if a liquid preparation is\\nrequired. If adherence is a concern, a single dose of benzathine penicillin 1.2 million units IM (600,000\\nunits for children  27 kg) is effective. Other oral drugs include macrolides for patients allergic to\\npenicillin, a 1st-generation cephalosporin, and clindamycin.\\nTreatment may be started immediately or delayed until culture results are known. If treatment is started\\npresumptively, it should be stopped if cultures are negative. Follow-up throat cultures are not done\\nroutinely. They are useful in patients with multiple GABHS recurrences or if pharyngitis spreads to close\\ncontacts at home or school.\\nTonsillectomy:\\n Tonsillectomy should be considered if GABHS tonsillitis recurs repeatedly (> 6\\nepisodes/yr, > 4 episodes/yr for 2 yr, > 3 episodes/yr for 3 yr) or if acute infection is severe and persistent\\ndespite antibiotics. Other criteria for tonsillectomy include obstructive sleep disorder, recurrent\\nperitonsillar abscess, and suspicion of cancer.\\nNumerous effective surgical techniques are used to perform tonsillectomy, including electrocautery,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n573'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 583, 'page_label': '574'}, page_content='microdebrider, radiofrequency coblation, and sharp dissection. Significant intraoperative or postoperative\\nbleeding occurs in < 2% of patients, usually within 24 h of surgery or after 7 days, when the eschar\\ndetaches. Patients with bleeding should go to the hospital. If bleeding continues on arrival, patients\\ngenerally are examined in the operating room, and hemostasis is obtained. Any clot present in the tonsillar\\nfossa is removed, and patients are observed for 24 h. Postoperative IV rehydration is necessary in  3%\\nof patients, possibly in fewer patients with use of optimal preoperative hydration, perioperative antibiotics,\\nanalgesics, and corticosteroids. Postoperative airway obstruction occurs most frequently in children < 2 yr\\nwho have preexisting severe obstructive sleep disorders and in patients who are morbidly obese or have\\nneurologic disorders, craniofacial anomalies, or significant preoperative obstructive sleep apnea.\\nComplications are generally more common and serious among adults.\\nPeritonsillar Abscess and Cellulitis\\nPeritonsillar abscess and cellulitis are acute pharyngeal infections most common among\\nadolescents and young adults. Symptoms are severe sore throat, trismus, \"hot potato\" voice,\\nand uvular deviation. Diagnosis requires needle aspiration. Treatment includes broad-spectrum\\nantibiotics, drainage of any pus, hydration, analgesics, and, occasionally, acute tonsillectomy.\\nEtiology\\nAbscess (quinsy) and cellulitis probably represent a spectrum of the same process in which bacterial\\ninfection of the tonsils and pharynx spreads to the soft tissues. Infection is virtually always unilateral and\\nis located between the tonsil and the superior pharyngeal constrictor muscle. It usually involves multiple\\nbacteria. \\nStreptococcus\\n and \\nStaphylococcus\\n are the most frequent aerobic pathogens, whereas\\nBacteroides\\n sp is the predominant anaerobic pathogen.\\nSymptoms and Signs\\nSymptoms include gradual onset of severe unilateral sore throat, dysphagia, fever, otalgia, and\\nasymmetric cervical adenopathy. Trismus, \"hot potato\" voice (speaking as if a hot object was in the\\nmouth), a toxic appearance (see \\nEpiglottitis\\n on p. \\n475\\n), drooling, severe halitosis, tonsillar erythema, and\\nexudates are common. Abscess and cellulitis both have swelling above the affected tonsil, but with\\nabscess there is more of a discrete bulge, with deviation of the soft palate and uvula and pronounced\\ntrismus.\\nDiagnosis\\n Needle aspiration\\n Sometimes CT\\nPeritonsillar cellulitis is recognized in patients with severe sore throat who have trismus, \"hot potato\"\\nvoice, and uvular deviation. All such patients require needle aspiration of the tonsillar mass and cultures.\\nAspiration of pus differentiates abscess from cellulitis. CT or ultrasound of the neck can help confirm the\\ndiagnosis when the physical examination is difficult or the diagnosis is in doubt, particularly when the\\ncondition must be differentiated from a parapharyngeal infection or other deep neck infection.\\nTreatment\\n Antibiotics\\n Drainage of abscess\\nCellulitis subsides, usually within 48 h, with hydration and high-dose penicillin (eg, 2 million units IV q 4 h\\nor 1 g po qid); alternative drugs \\ninclude a 1st-generation cephalosporin or clindamycin. Culture-directed\\nantibiotics are then prescribed for 10 days. Abscesses are incised and drained in the emergency\\ndepartment using thorough local anesthesia and sometimes procedural sedation; many clinicians believe\\nneedle aspiration alone provides adequate drainage. Although most patients can be treated as\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n574'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 584, 'page_label': '575'}, page_content='outpatients, some need brief hospitalization for parenteral antibiotics, IV hydration, and airway monitoring.\\nRarely, an immediate tonsillectomy is done, particularly in a young or uncooperative patient who has other\\nindications for elective tonsillectomy (eg, history of frequently recurrent tonsillitis or obstructive sleep\\napnea). Otherwise, elective tonsillectomy is done 4 to 6 wk out to prevent abscess recurrence.\\nParapharyngeal Abscess\\nA parapharyngeal abscess is a deep neck abscess treated with antibiotics and surgical\\ndrainage.\\nThe parapharyngeal (pharyngomaxillary) space is lateral to the superior pharyngeal constrictor and\\nmedial to the masseter muscle. This space connects to every other major fascial neck space and is\\ndivided into anterior and posterior compartments by the styloid process. The posterior compartment\\ncontains the carotid artery, internal jugular vein, and numerous nerves. Infections in the parapharyngeal\\nspace usually originate in the tonsils or pharynx, although local spread from odontogenic sources and\\nlymph nodes may occur.\\nAbscess swelling can compromise the airway. Posterior space abscess can erode into the carotid artery\\nor cause septic thrombophlebitis of the internal jugular vein (Lemierre syndrome).\\nSymptoms and Signs\\nMost patients have fever, sore throat, odynophagia, and swelling in the neck down to the hyoid bone.\\nAnterior space abscesses cause trismus and induration along the angle of the mandible, with medial\\nbulging of the tonsil and lateral pharyngeal wall. Posterior space abscesses cause swelling that is more\\nprominent in the posterior pharyngeal wall. Trismus is minimal. Posterior abscesses may involve\\nstructures within the carotid sheath, possibly causing rigors, high fever, bacteremia, neurologic deficits,\\nand massive hemorrhage caused by carotid artery rupture.\\nDiagnosis\\n CT\\nDiagnosis is suspected in patients with poorly defined deep neck infection or other typical symptoms and\\nis confirmed by using contrast-enhanced CT.\\nTreatment\\n Broad-spectrum antibiotics (eg, ceftriaxone, clindamycin)\\n Surgical drainage\\nTreatment may require airway control. Parenteral broad-spectrum antibiotics (eg, ceftriaxone,\\nclindamycin) and surgical drainage are generally needed. Posterior abscesses are drained externally\\nthrough the submaxillary fossa. Anterior abscesses can often be drained through an intra-oral incision.\\nSeveral days of parenteral culture-determined antibiotics are required after drainage, followed by 10 to 14\\ndays of oral antibiotics. Occasionally, small abscesses can be treated with IV antibiotics alone.\\nEpiglottitis\\n(Supraglottitis)\\nEpiglottitis is a rapidly progressive bacterial infection of the epiglottis and surrounding tissues\\nthat may lead to sudden respiratory obstruction and death. Symptoms include severe sore\\nthroat, dysphagia, high fever, drooling, and inspiratory stridor. Diagnosis requires direct\\nvisualization of the supraglottic structures, which is not to be done until full respiratory support\\nis available. Treatment includes airway protection and antibiotics.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n575'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 585, 'page_label': '576'}, page_content='Epiglottitis used to be primarily a disease of children and usually was caused by \\nHaemophilus influenzae\\ntype B. Now, because of widespread vaccination, it has been almost eradicated in children (more cases\\noccur in adults). Causal organisms in children and adults include \\nStreptococcus pneumoniae\\n,\\nStaphylococcus aureus\\n, nontypeable \\nH. influenzae\\n, \\nHaemophilus parainfluenzae\\n, \\n\\n-hemolytic\\nstreptococci, \\nBranhamella catarrhalis\\n, and \\nKlebsiella pneumoniae\\n. \\nH. influenzae\\n type B is still a cause in\\nadults and unvaccinated children.\\nBacteria that have colonized the nasopharynx spread locally to cause supraglottic cellulitis with marked\\ninflammation of the epiglottis, vallecula, aryepiglottic folds, arytenoids, and laryngeal ventricles. With \\nH.\\ninfluenzae\\n type B, infection may spread hematogenously.\\nThe inflamed supraglottic structures mechanically obstruct the airway, increasing the work of breathing,\\nultimately causing respiratory failure. Clearance of inflammatory secretions is also impaired.\\nSymptoms and Signs\\nIn children, sore throat, odynophagia, and dysphagia develop abruptly. Fatal asphyxia may occur within a\\nfew hours of onset. Drooling is very common. Additionally, the child has signs of toxicity (poor or absent\\neye contact, failure to recognize parents, cyanosis, irritability, inability to be consoled or distracted) and is\\nfebrile and anxious. Dyspnea, tachypnea, and inspiratory stridor may be present, often causing the child\\nto sit upright, lean forward, and hyperextend the neck with the jaw thrust forward and mouth open in an\\neffort to enhance air exchange (tripod position). Relinquishing this position may herald respiratory failure.\\nSuprasternal, supraclavicular, and subcostal inspiratory retractions may be present.\\nIn adults, symptoms are similar to those of children, including sore throat, fever, dysphagia, and drooling,\\nbut peak symptoms usually take > 24 h to develop. Because of the larger diameter of the adult airway,\\nobstruction is less common and less fulminant. Often, there is no visible oropharyngeal inflammation.\\nHowever, severe throat pain with a normal-appearing pharynx raises suspicion of epiglottitis.\\nDiagnosis\\n Direct inspection (typically in operating room)\\n X-ray in milder cases with low suspicion\\nEpiglottitis is suspected in patients with severe sore throat and no pharyngitis and also in patients with\\nsore throat and inspiratory stridor. Stridor in children may also result from croup (viral laryngotracheal\\nbronchitissee\\nTable 52-1\\n and p. \\n2879\\n), bacterial tracheitis, and airway foreign body. The tripod position may also occur\\nwith peritonsillar or retropharyngeal abscess.\\nThe patient is hospitalized if epiglottitis is suspected. Diagnosis requires direct examination, usually with\\nflexible fiberoptic laryngoscopy. (CAUTION: \\nExamination of the pharynx and larynx may precipitate\\ncomplete respiratory obstruction in children, and the pharynx and larynx should not be directly\\nexamined except in the operating room, where the most advanced airway intervention is available.\\n)\\nAlthough plain x-rays may be helpful, a child with stridor should not be transported to the x-ray suite.\\nDirect laryngoscopy that reveals a beefy-red, stiff, edematous epiglottis is diagnostic. Cultures from the\\nsupraglottic tissues and blood can then be taken to search for the causative organism.\\n[\\nTable 52-1.\\n Differentiating Epiglottitis from Croup]\\nAdults may, in some cases, safely undergo flexible fiberoptic laryngoscopy.\\nTreatment\\n Adequate airway ensured\\n Antibiotics (eg, ceftriaxone)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n576'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 586, 'page_label': '577'}, page_content='In children, the airway must be secured immediately, preferably by nasotracheal intubation. Securing the\\nairway can be quite difficult and should, if possible, be done by experienced personnel in the operating\\nroom. An endotracheal tube is usually required until the patient has been stabilized for 24 to 48 h (usual\\ntotal intubation time is < 60 h). Alternatively, a tracheotomy is done. If respiratory arrest occurs before an\\nairway is established, bag-mask ventilation may be a life-saving temporary measure. For emergency care\\nof children with epiglottitis, each institution should have a protocol that involves critical care,\\notolaryngology, anesthesia, and pediatrics.\\nAdults whose airway is severely obstructed can be endotracheally intubated during flexible fiberoptic\\nlaryngoscopy. Other adults may not require immediate intubation but should be observed for airway\\ncompromise in an ICU with an intubation set and cricothyrotomy tray at the bedside.\\nA \\n\\n-lactamase-resistant antibiotic, such as ceftriaxone 50 to 75 mg/kg IV once/day (maximum 2 g), should\\nbe used empirically, pending culture and sensitivity test results.\\nEpiglottitis caused by \\nH. influenzae\\n type B can be effectively prevented with the \\nH. influenzae\\n type B\\n(Hib) conjugate vaccine.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 52. Oral & Pharyngeal Disorders\\n577'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 587, 'page_label': '578'}, page_content=\"Chapter 53. Nose and Paranasal Sinus Disorders\\nIntroduction\\n(See \\nCh. 51\\n for a detailed description of the anatomy of the nose and sinuses.)\\nBacterial Infections\\nNasal vestibulitis\\n is bacterial infection of the nasal vestibule, typically with \\nStaphylococcus aureus\\n. It\\nmay result from nose picking or excessive nose blowing and causes annoying crusts and bleeding when\\nthe crusts slough off. Bacitracin or mupirocin ointment applied topically bid for 14 days is effective.\\nFuruncles\\n of the nasal vestibule are usually staphylococcal; they may develop into spreading cellulitis of\\nthe tip of the nose. Systemic antistaphylococcal antibiotics (eg, cephalexin 500 mg po qid) are given and\\nwarm compresses and topical mupirocin are applied. Furuncles are incised and drained to prevent local\\nthrombophlebitis and subsequent cavernous sinus thrombosis.\\nForeign Bodies\\nNasal foreign bodies are found occasionally in young children, the intellectually impaired, and psychiatric\\npatients. Common objects pushed into the nose include beads, beans, seeds, nuts, insects, and button\\nbatteries (which may cause chemical burns). When mineral salts are deposited on a long-retained foreign\\nbody, the object is called a rhinolith.\\nA nasal foreign body is suspected in any patient with a unilateral, foul-smelling, bloody, purulent\\nrhinorrhea. Diagnosis is often made through another party's observation of the item being pushed into the\\nnose or through visualization with a nasal speculum.\\nNasal foreign bodies can sometimes be removed in the office with a nasal speculum and Hartmann's\\nnasal forceps. Pretreatment with topical phenylephrine may aid visualization and removal. To avoid\\npushing a slippery, round object deeper, it is better to reach behind the object with the bent tip of a blunt\\nprobe and pull it forward. Sometimes, general anesthesia is necessary if a rhinolith has formed or if the\\nforeign body may be displaced dorsally and then aspirated, resulting in airway obstruction.\\nNasal Polyps\\nNasal polyps are fleshy outgrowths of the nasal mucosa that form at the site of dependent\\nedema in the lamina propria of the mucous membrane, usually around the ostia of the maxillary\\nsinuses (see\\nPlate 2\\n).\\nAllergic rhinitis, acute and chronic infections, and cystic fibrosis all predispose to the formation of nasal\\npolyps. Bleeding polyps occur in rhinosporidiosis. Unilateral polyps occasionally occur in association with\\nor represent benign or malignant tumors of the nose or paranasal sinuses. They can also occur in\\nresponse to a foreign body. Nasal polyps are strongly associated with aspirin allergy, sinus infections, and\\nasthma.\\nSymptoms include obstruction and postnasal drainage, congestion, sneezing, rhinorrhea, anosmia,\\nhyposmia, facial pain, and ocular itching.\\nDiagnosis generally is based on physical examination. A developing polyp is teardrop-shaped; when\\nmature, it resembles a peeled seedless grape.\\nTreatment\\n Topical corticosteroid spray\\n Sometimes surgical removal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 53. Nose & Paranasal Sinus Disorders\\n578\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 588, 'page_label': '579'}, page_content=\" Sometimes surgical removal\\nCorticosteroids (eg, mometasone [30 \\n\\ng/spray], beclomethasone [42 \\n\\ng/spray], flunisolide [25 \\n\\ng/spray]\\naerosols), given as 1 or 2 sprays bid in each nasal cavity, may shrink or eliminate polyps, as may a 1-wk\\ntapered course of oral corticosteroids. Surgical removal is still required in many cases. Polyps that\\nobstruct the airway or promote sinusitis are removed, as are unilateral polyps that may be obscuring\\nbenign or malignant tumors. However, polyps tend to recur unless the underlying allergy or infection is\\ncontrolled. After removal of nasal polyps, topical beclomethasone or flunisolide therapy tends to retard\\nrecurrence. In severe recurrent cases, maxillary sinusotomy or ethmoidectomy may be indicated. These\\nprocedures are usually done endoscopically.\\nRhinitis\\n(See also \\nAllergic Rhinitis\\n on p. \\n1117\\n.)\\nRhinitis is inflammation of the nasal mucous membrane, with resultant nasal congestion,\\nrhinorrhea, and variable associated symptoms depending on etiology (eg, itching, sneezing,\\npurulence, anosmia, ozena). The cause is usually viral, although irritants can cause it. Diagnosis\\nis usually clinical. Treatment includes humidification of room air, sympathomimetic amines, and\\nantihistamines. Bacterial superinfection requires appropriate antibiotic treatment.\\nThere are several forms of rhinitis.\\nAcute rhinitis:\\n This form of rhinitis, manifesting with edema and vasodilation of the nasal mucous\\nmembrane, rhinorrhea, and obstruction, is usually the result of a common cold (see p. \\n1404\\n); other\\ncauses include streptococcal, pneumococcal, and staphylococcal infections.\\nChronic rhinitis:\\n This form of rhinitis is generally a prolongation of subacute inflammatory or infectious\\nviral rhinitis but may also occur in syphilis, TB, rhinoscleroma, rhinosporidiosis, leishmaniasis,\\nblastomycosis, histoplasmosis, and leprosyall of which are characterized by granuloma formation and\\ndestruction of soft tissue, cartilage, and bone. Nasal obstruction, purulent rhinorrhea, and frequent\\nbleeding result. Rhinoscleroma causes progressive nasal obstruction from indurated inflammatory tissue\\nin the lamina propria. Rhinosporidiosis is characterized by bleeding polyps. Both low humidity and\\nairborne irritants can result in chronic rhinitis.\\nAtrophic rhinitis:\\n This form of rhinitis results in atrophy and sclerosis of mucous membrane; the mucous\\nmembrane changes from ciliated pseudostratified columnar epithelium to stratified squamous epithelium,\\nand the lamina propria is reduced in amount and vascularity. Atrophic rhinitis is associated with advanced\\nage, Wegener's granulomatosis, and iatrogenically induced excessive nasal tissue extirpation. Although\\nthe exact etiology is unknown, bacterial infection frequently plays a role. Nasal mucosal atrophy often\\noccurs in the elderly.\\nVasomotor rhinitis:\\n This form of rhinitis is a chronic condition in which intermittent vascular\\nengorgement of the nasal mucous membrane leads to watery rhinorrhea and sneezing. Etiology is\\nuncertain, and no allergy can be identified. A dry atmosphere seems to aggravate the condition.\\nSymptoms and Signs\\nAcute rhinitis results in cough, low-grade fever, nasal congestion, rhinorrhea, and sneezing. Symptoms\\nand signs of chronic rhinitis are similar but may include purulent rhinorrhea and bleeding.\\nAtrophic rhinitis results in abnormal patency of the nasal cavities, crust formation, anosmia, and epistaxis\\nthat may be recurrent and severe.\\nVasomotor rhinitis results in sneezing and watery rhinorrhea. The turgescent mucous membrane varies\\nfrom bright red to purple. The condition is marked by periods of remission and exacerbation. Vasomotor\\nrhinitis is differentiated from specific viral and bacterial infections of the nose by the lack of purulent\\nexudate and crusting. It is differentiated from allergic rhinitis by the absence of an identifiable allergen.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 53. Nose & Paranasal Sinus Disorders\\n579\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 589, 'page_label': '580'}, page_content=\"Diagnosis\\nThe different forms of rhinitis are diagnosed clinically. Testing is unnecessary.\\nTreatment\\n For viral rhinitis, decongestants, antihistamines, or both\\n For atrophic rhinitis, topical treatment\\n For vasomotor rhinitis, humidification and sometimes topical corticosteroids and oral pseudoephedrine\\nViral rhinitis may be treated symptomatically with decongestants (either topical vasoconstriction with a\\nsympathomimetic amine, such as \\noxymetazoline q 8 to 12 h or phenylephrine 0.25% q 3 to 4 h for not\\nmore than 7 days, or systemic sympathomimetic amines, such as pseudoephedrine 30 mg po q 4 to 6 h).\\nAntihistamines (see\\nTable 127-2\\n on p. \\n1111\\n) may be helpful. Those with anticholinergic properties dry mucous membranes and\\ntherefore may increase irritation. Decongestants also may relieve symptoms of acute bacterial rhinitis and\\nchronic rhinitis, whereas an underlying bacterial infection requires culture or biopsy, pathogen\\nidentification, antibiotic sensitivities, and appropriate antimicrobial treatment.\\nTreatment of atrophic rhinitis is directed at reducing the crusting and eliminating the odor with topical\\nantibiotics (eg, bacitracin), topical or systemic estrogens, and vitamins A and D. Occluding or reducing the\\npatency of the nasal cavities surgically decreases the crusting caused by the drying effect of air flowing\\nover the atrophic mucous membrane.\\nTreatment of vasomotor rhinitis is by trial and error and is not always satisfactory. Patients benefit from\\nhumidified air, which may be provided by a humidified central heating system or a vaporizer in the\\nworkroom or bedroom. Systemic sympathomimetic amines (eg, for adults, pseudoephedrine 30 mg po q 4\\nto 6 h prn) relieve symptoms but are not recommended for long-term use. Topical vasoconstrictors are\\navoided because they cause the vasculature of the nasal mucous membrane to lose its sensitivity to\\nother vasoconstrictive stimulieg, the humidity and temperature of inspired air. Topical corticosteroids\\n(eg, mometasone 2 sprays bid) can be of some benefit.\\nSeptal Deviation and Perforation\\nDeviations of the nasal septum\\n due to developmental abnormalities or trauma are common but often\\nare asymptomatic and require no treatment. Symptomatic septal deviation causes nasal obstruction and\\npredisposes the patient to sinusitis (particularly if the deviation obstructs the ostium of a paranasal sinus)\\nand to epistaxis due to drying air currents. Other symptoms may include facial pain, headaches, and noisy\\nnight breathing. Septal deviation is usually evident on examination, although a flashlight and examination\\nof the anterior nasal passage may not be sufficient. Treatment consists of septoplasty (septal\\nreconstruction).\\nSeptal ulcers and perforations\\n may result from nasal surgery; repeated trauma, such as chronic nose\\npicking; cosmetic piercing; toxic exposures (eg, acids, chromium, phosphorus, copper vapor); chronic\\ncocaine use; chronic nasal spray use (including corticosteroids and OTC phenylephrine or oxymetazoline\\nsprays); transnasal O\\n2\\n use; or diseases such as TB, syphilis, leprosy, SLE, and Wegener's\\ngranulomatosis. Crusting around the margins and repeated epistaxis, which can be severe, may result.\\nSmall perforations may whistle. Anterior rhinoscopy or fiberoptic endoscopy can be used to view septal\\nperforations. Topical bacitracin or mupirocin ointment reduces crusting, as may saline nasal spray.\\nSymptomatic septal perforations are occasionally repaired with buccal or septal mucous membrane flaps;\\nclosing the perforation with a silicone septal button is a reliable option.\\nSinusitis\\nSinusitis is inflammation of the paranasal sinuses due to viral, bacterial, or fungal infections or\\nallergic reactions. Symptoms include nasal obstruction and congestion, purulent rhinorrhea,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 53. Nose & Paranasal Sinus Disorders\\n580\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 590, 'page_label': '581'}, page_content='cough, facial pain, malaise, and sometimes fever. Treatment is with antibiotics, such as\\namoxicillin, penicillin, erythromycin, or trimethoprim/sulfamethoxazole, given for 12 to 14 days\\nfor acute sinusitis and for up to 6 wk for chronic sinusitis. Decongestants and application of heat\\nand humidity may help relieve symptoms and improve sinus drainage. Recurrent sinusitis may\\nrequire surgery to improve sinus drainage.\\nSinusitis may be classified as acute (completely resolved in < 30 days); subacute (completely resolved in\\n30 to 90 days); recurrent (multiple discrete acute episodes, each completely resolved in < 30 days but\\nrecurring in cycles, with at least 10 days between complete resolution of symptoms and initiation of a new\\nepisode); and chronic (lasting > 90 days).\\nEtiology\\nAcute sinusitis\\n is usually precipitated by viral URI, followed by secondary bacterial colonization with\\nstreptococci, pneumococci, \\nHaemophilus influenzae\\n, \\nMoraxella catarrhalis\\n, or staphylococci. In a URI,\\nthe swollen nasal mucous membrane obstructs the ostium of a paranasal sinus, and the O\\n2\\n in the sinus is\\nabsorbed into the blood vessels of the mucous membrane. The resulting relative negative \\npressure in the\\nsinus (vacuum sinusitis) is painful. If the vacuum is maintained, a transudate from the mucous membrane\\ndevelops and fills the sinus; the transudate serves as a medium for bacteria that enter the sinus through\\nthe ostium or through a spreading cellulitis or thrombophlebitis in the lamina propria of the mucous\\nmembrane. An outpouring of serum and leukocytes to combat the infection results, and painful positive\\npressure develops in the obstructed sinus. The mucous membrane becomes hyperemic and edematous.\\nChronic sinusitis\\n may be exacerbated by gram-negative bacilli or anaerobic micro-organisms. In a few\\ncases, chronic maxillary sinusitis is secondary to dental infection or exposure to environmental pollution.\\nFungal infections (\\nAspergillus\\n, \\nSporothrix\\n, \\nPseudallescheria\\n) tend to strike the immunocompromised\\npatient, whereas hospital-acquired infections complicate cystic fibrosis, nasogastric and nasotracheal\\nintubation, and debilitated patients. Typical organisms include \\nStaphylococcus aureus\\n, \\nKlebsiella\\npneumoniae\\n, \\nPseudomonas aeruginosa\\n, \\nProteus mirabilis\\n, and \\nEnterobacter\\n.\\nAllergic fungal sinusitis\\n is characterized by diffuse nasal congestion, markedly viscid nasal secretions,\\nand, often, nasal polyps. It is an allergic response to the presence of topical fungi, often \\nAspergillus\\n, and\\nis not caused by an invasive infection.\\nSymptoms and Signs\\nAcute and chronic sinusitis cause similar symptoms and signs, including purulent rhinorrhea, pressure\\nand pain in the face, nasal congestion and obstruction, hyposmia, halitosis, and productive cough\\n(especially at night). Often the pain is more severe in acute sinusitis. The area over the affected sinus\\nmay be tender, swollen, and erythematous. Maxillary sinusitis causes pain in the maxillary area,\\ntoothache, and frontal headache. Frontal sinusitis causes pain in the frontal area and frontal headache.\\nEthmoid sinusitis causes pain behind and between the eyes, frontal headache often described as\\nsplitting, periorbital cellulitis, and tearing. Pain caused by sphenoid sinusitis is less well localized and is\\nreferred to the frontal or occipital area. Malaise may be present. Fever and chills suggest an extension of\\nthe infection beyond the sinuses.\\nThe nasal mucous membrane is red and turgescent; yellow or green purulent rhinorrhea may be present.\\nSeropurulent or mucopurulent exudate may be seen in the middle meatus with maxillary, anterior ethmoid,\\nor frontal sinusitis and in the area medial to the middle turbinate with posterior ethmoid or sphenoid\\nsinusitis.\\nDiagnosis\\n Clinical evaluation\\n Sometimes CT\\nSinus infections are usually diagnosed clinically. Absence or dullness of light on transillumination may\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 53. Nose & Paranasal Sinus Disorders\\n581'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 591, 'page_label': '582'}, page_content=\"suggest fluid-filled maxillary or frontal sinuses. In acute and chronic sinusitis, the swollen mucous\\nmembranes and retained exudate cause the affected sinus to appear opaque on 4-view x-rays. Plain x-\\nrays are not as valuable as CT, which provides better definition of the extent and degree of sinusitis. X-\\nrays of the apices of the teeth may be required in chronic maxillary sinusitis to exclude a periapical\\nabscess. When questions persist (eg, regarding intracranial extension, treatment failure, or hospital-\\nacquired causes of sinusitis), culture and sensitivity tests can be done on sinus secretions obtained\\nthrough endoscopy or sinus puncture and aspiration.\\nSinusitis in children is suspected when purulent rhinorrhea persists for > 10 days along with fatigue and\\ncough. Fever is uncommon. Local facial pain or discomfort may be present. Nasal examination discloses\\npurulent drainage; CT is confirmatory. CT is of limited cuts in the coronal projection to limit radiation\\nexposure.\\nTreatment\\n Local measures to enhance drainage (eg, steam, topical vasoconstrictors)\\n Antibiotics (eg, amoxicillin, erythromycin, trimethoprim/sulfamethoxazole)\\nIn acute sinusitis, improved drainage and control of infection are the aims of therapy. Steam inhalation;\\nhot, wet towels over the affected sinuses; and hot beverages alleviate nasal vasoconstriction and\\npromote drainage. Topical vasoconstrictors, such as phenylephrine 0.25% spray q 3 h, are effective but\\nshould be used for a maximum of 5 days or for a repeating cycle of 3 days on and 3 days off until the\\nsinusitis is resolved. Systemic vasoconstrictors, such as pseudoephedrine 30 mg po (for adults) q 4 to 6\\nh, are less effective.\\nIn acute and chronic sinusitis, antibiotics are given for at least 10 days and often for 14 days. In acute\\nsinusitis, amoxicillin 500 mg po q 8 h with or without clavulanate is primary therapy. Erythromycin 250 mg\\npo q 6 h or trimethoprim/sulfamethoxazole 80/400 mg \\nq 6 h can be given to patients allergic to penicillin.\\nSecond-line therapy includes cefuroxime 500 mg q 12 h or moxifloxacin 400 mg once/day. For children,\\nsimilar antibiotics are used, adjusted for the child's weight. Fluoroquinolones, however, are not used in\\nchildren because of concerns of premature epiphyseal growth plate closure.\\nIn exacerbations of chronic sinusitis in children or adults, a broad-spectrum antibiotic, such as\\namoxicillin/clavulanate 875 mg po q 12 h (12.5 to 25 mg/kg q 12 h in children), cefuroxime, or, in adults,\\nmoxifloxacin, is used. In chronic sinusitis, prolonged antibiotic therapy for 4 to 6 wk often brings complete\\nresolution. The sensitivities of pathogens isolated from the sinus exudate and the patient's response\\nguide subsequent therapy.\\nSinusitis unresponsive to antibiotic therapy may require surgery (maxillary sinusotomy, ethmoidectomy, or\\nsphenoid sinusotomy) to improve ventilation and drainage and to remove inspissated mucopurulent\\nmaterial, epithelial debris, and hypertrophic mucous membrane. These procedures usually are done\\nintranasally with the aid of an endoscope. Chronic frontal sinusitis may be managed either with\\nosteoplastic obliteration of the frontal sinuses or endoscopically in selected patients. The use of\\nintraoperative computer-aided surgery to localize disease and prevent injury to surrounding contiguous\\nstructures (such as the eye and brain) has become common.\\nSinusitis in Immunocompromised Patients\\nAggressive and even fatal fungal or bacterial sinusitis can occur in patients who are immunocompromised\\nbecause of poorly controlled diabetes, neutropenia, or HIV infection.\\nMucormycosis:\\n Mucormycosis (phycomycosis)a mycosis due to fungi of the order Mucorales,\\nincluding species of \\nMucor\\n, \\nAbsidia\\n, and \\nRhizopus\\nmay develop in patients with poorly controlled\\ndiabetes. It is characterized by black, devitalized tissue in the nasal cavity and neurologic signs\\nsecondary to retrograde thromboarteritis in the carotid arterial system. Diagnosis is based on\\nhistopathologic demonstration of mycelia in the avascularized tissue. Treatment requires control of the\\nunderlying condition (such as reversal of ketoacidosis in diabetes) and IV amphotericin B therapy. Prompt\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 53. Nose & Paranasal Sinus Disorders\\n582\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 592, 'page_label': '583'}, page_content='biopsy of intranasal tissue for histology and culture is warranted.\\nAspergillosis and candidiasis:\\n \\nAspergillus\\n and \\nCandida\\n spp may infect the paranasal sinuses of\\npatients who are immunocompromised secondary to therapy with cytotoxic drugs or to\\nimmunosuppressive diseases, such as leukemia, lymphoma, multiple myeloma, and AIDS. These\\ninfections can appear as polypoid tissue in the nose as well as thickened mucosa; tissue is required for\\ndiagnosis. Aggressive paranasal sinus surgery and IV amphotericin B therapy are used to control these\\noften-fatal infections.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 53. Nose & Paranasal Sinus Disorders\\n583'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 593, 'page_label': '584'}, page_content='Chapter 54. Laryngeal Disorders\\nIntroduction\\nThe larynx contains the vocal cords and serves as the opening to the tracheobronchial tree. Laryngeal\\ndisorders include various benign and malignant tumors, contact ulcers, granulomas, laryngitis,\\nlaryngoceles, spasmodic dysphonia, vocal cord paralysis, and vocal cord polyps and nodules. For acute\\nlaryngotracheobronchitis, see \\nCroup\\n on p. \\n2879\\n.\\nLaryngeal cancer is discussed on p. \\n489\\n.\\nMost laryngeal disorders cause dysphonia, which is impairment of the voice (see \\nSidebar 54-1\\n). A\\npersistent change in the voice (eg, > 3 wk) requires visualization of the vocal cords, including their\\nmobility. Although the voice changes with advancing age, becoming breathy and aperiodic, acute or\\nprominent changes in the elderly should not be presumed to result from aging, and evaluation is required.\\nThe voice should be assessed and recorded, particularly if surgical procedures are planned. Examination\\nof the larynx includes external inspection and palpation of the neck and internal visualization of the\\nepiglottis, false cords, true cords, arytenoids, pyriform sinuses, and subglottic region below the cords.\\nInternal visualization is accomplished by either indirect mirror examination (see\\nFig. 54-1\\n) or direct flexible fiberoptic laryngoscopy in an outpatient setting with a topical anesthetic. Rigid\\nlaryngoscopy with the patient under general anesthesia allows for biopsy when necessary or assessment\\nof passive mobility of the vocal cords when immobilized by either paralysis or fixation.\\nSidebar 54-1 The Professional Voice\\nPeople who use their voice professionally for public speaking and singing often experience voice\\ndisorders manifesting as hoarseness or breathiness, lowered vocal pitch, vocal fatigue, nonproductive\\ncough, persistent throat clearing, and/or throat ache. These symptoms often have benign causes, such\\nas vocal nodules, vocal fold edema, polyps, or granulomas. Such disorders are usually caused by vocal\\nfold hyperfunction (excessive laryngeal muscular tension when speaking) and possibly laryngopharyngeal\\nreflux.\\nTreatment in most cases includes the following:\\n Voice evaluation by a speech pathologist or experienced physician, including, when available, use of a\\ncomputer-assisted program to assess pitch and intensity and to determine parameters of vocal\\nacoustics\\n Behavioral treatment (decreasing musculoskeletal laryngeal tension when speaking) using the same\\ncomputer program for visual and auditory biofeedback\\n A vocal hygiene program to eliminate vocally abusive behaviors, such as excessive loudness, long\\nduration, vocal tension, and habitual throat clearing\\n An antireflux regimen, when appropriate\\n Adequate hydration to promote an adequate glottal mucosal wave\\n Diet modification before vocal performances, which may include avoidance of dairy products, caffeine,\\nand ambient tobacco smoke and other inhaled irritants\\nBenign Tumors\\nBenign laryngeal tumors include juvenile papillomas hemangiomas, fibromas, chondromas, myxomas, and\\nneurofibromas. They may appear in any part of the larynx. Symptoms include hoarseness, breathy voice,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 54. Laryngeal Disorders\\n584'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 594, 'page_label': '585'}, page_content=\"dyspnea, aspiration, dysphagia, pain, otalgia (pain referred to the ear), and hemoptysis. Diagnosis is\\nbased on direct or indirect visualization of the larynx, supplemented by CT. Removal restores the voice,\\nthe functional integrity of the laryngeal sphincter, and the airway. Smaller lesions may be excised\\nendoscopically by using a CO\\n2\\n laser and general anesthesia. Larger lesions extending beyond the\\nlaryngeal framework often require pharyngotomy or laryngofissure.\\nCancerous tumors are discussed in \\nCh. 55\\n.\\nContact Ulcers\\nContact ulcers are unilateral or bilateral erosions of the mucous membrane over the vocal\\nprocess of the arytenoid cartilage.\\nContact ulcers are usually caused by voice abuse in the form of repeated sharp glottal attacks (abrupt\\nloudness at the onset of phonation), often experienced by singers. They may also occur after\\nendotracheal intubation if an oversized tube erodes the mucosa overlying the cartilaginous vocal\\nprocesses. Gastroesophageal reflux may also cause or aggravate contact ulcers. Symptoms include\\nvarying degrees of hoarseness and mild pain with phonation and swallowing. Biopsy to exclude\\ncarcinoma or TB is important. Prolonged ulceration leads to nonspecific granulomas that also cause\\nvarying degrees of hoarseness.\\nTreatment consists of  6 wk of voice rest. Patients must recognize the limitations of their voice and learn\\nto adjust their postrecovery vocal activities to avoid recurrence. Granulomas tend to recur after surgical\\nremoval. Risk of recurrence is reduced through vigorous treatment of gastroesophageal reflux (see p.\\n125\\n). Suppression of bacterial flora by antibiotics during postoperative healing is also recommended.\\nLaryngitis\\nLaryngitis is inflammation of the larynx, usually the result of a virus or overuse. The result is\\nacute change in the voice, with decreased volume and hoarseness. Diagnosis is based on\\nclinical findings. Laryngoscopy is required for symptoms persisting > 3 wk. Viral laryngitis is\\nself-limited. Other infectious or irritating causes may require specific treatment.\\nThe most common cause of acute laryngitis is a viral URI. Coughing-induced laryngitis may also occur in\\nbronchitis, pneumonia, influenza, pertussis, measles, and diphtheria.\\n[\\nFig. 54-1.\\n Laryngeal disorders.]\\nExcessive use of the voice (especially with loud speaking or singing), allergic reactions,\\ngastroesophageal reflux, bulimia, or inhalation of irritating substances (eg, cigarette smoke or certain\\naerosolized drugs) can cause acute or chronic laryngitis. Bacterial laryngitis is extremely rare. Smoking\\ncan cause Reinke's edema, which is a watery swelling of both vocal cords.\\nSymptoms and Signs\\nAn unnatural change of voice is usually the most prominent symptom. Volume is typically greatly\\ndecreased; some patients have aphonia. Hoarseness, a sensation of tickling, rawness, and a constant\\nurge to clear the throat may occur. Symptoms vary with the severity of the inflammation. Fever, malaise,\\ndysphagia, and throat pain may occur in more severe infections. Laryngeal edema, although rare, may\\ncause dyspnea.\\nDiagnosis\\n Clinical evaluation\\n Sometimes direct or indirect laryngoscopy\\nDiagnosis is based on symptoms. Indirect or direct flexible laryngoscopy is recommended for symptoms\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 54. Laryngeal Disorders\\n585\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 595, 'page_label': '586'}, page_content='persisting > 3 wk; findings in laryngitis include mild to marked erythema of the mucous membrane, which\\nmay also be edematous. With reflux, there is swelling of the inner lining of the larynx and redness of the\\nvocal cords that extends above and below the edges of the back part of the cords. If a pseudomembrane\\nis present, diphtheria is suspected.\\nTreatment\\n Symptomatic treatment (eg, cough suppressants, voice rest, steam inhalations)\\nNo specific treatment is available for viral laryngitis. Cough suppressants, voice rest, and steam\\ninhalations relieve symptoms and promote resolution of acute laryngitis. Smoking cessation and treatment\\nof acute or chronic bronchitis may relieve laryngitis. Depending on the presumed cause, specific\\ntreatments to control gastroesophageal reflux, bulimia, or drug-induced laryngitis may be beneficial.\\nLaryngoceles\\nLaryngoceles are evaginations of the mucous membrane of the laryngeal ventricle.\\nInternal laryngoceles displace and enlarge the false vocal cords, resulting in hoarseness and airway\\nobstruction. External laryngoceles extend through the thyrohyoid membrane, causing a mass in the neck.\\nLaryngoceles tend to occur in musicians who play wind instruments. Laryngoceles are filled with air and\\ncan be expanded by the Valsalva maneuver. They appear on CT as smooth, ovoid, low-density masses.\\nLaryngoceles may become infected (laryngopyocele) or filled with mucoid fluid. Treatment is excision.\\nSpasmodic Dysphonia\\nSpasmodic dysphonia (vocal cord spasms) is intermittent spasm of laryngeal muscles that\\ncauses an abnormal voice.\\nCause is unknown. Patients often describe the onset of symptoms following a URI, a period of excessive\\nvoice use, or occupational or emotional stress. As a localized form of movement disorder, spasmodic\\ndysphonia has an onset between ages 30 and 50 yr, and about 60% of patients are women.\\nIn the adductor type of spasmodic dysphonia, patients attempt to speak through the spasmodic closure\\nwith a voice that sounds squeezed, effortful, or strained. These spasmodic episodes usually occur when\\nvowel sounds are being formed, particularly at the beginning of words. The less common abductor form\\nresults in sudden interruptions of sound caused by momentary abduction of the vocal cords accompanied\\nby audible escape of air during connected speech.\\nSurgery has been more successful than other approaches for adductor spasmodic dysphonia. The use of\\nbotulinum toxin injection has restored a normal voice in 70% of patients for up to 3 mo. Because the effect\\nis temporary, injections may be repeated. There is no known temporary alleviation of the abductor form of\\nthis disorder.\\nVocal Cord Paralysis\\nVocal cord paralysis has numerous causes and can affect speaking, breathing, and swallowing.\\nThe left vocal cord is affected twice as often as the right, and females are affected more often\\nthan males (3:2). Diagnosis is based on direct visualization. An extensive assessment may be\\nnecessary to determine the cause. Several direct surgical approaches are available if treating\\nthe cause is not curative.\\nVocal cord paralysis may result from lesions at the nucleus ambiguus, its supranuclear tracts, the main\\ntrunk of the vagus, or the recurrent laryngeal nerves.\\nParalysis is usually unilateral. About one third of unilateral vocal cord paralyses are neoplastic in origin,\\none third are traumatic, and one third are idiopathic. Intracranial tumors, vascular accidents, and\\ndemyelinating diseases cause nucleus ambiguus paralysis. Tumors at the base of the skull and trauma to\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 54. Laryngeal Disorders\\n586'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 596, 'page_label': '587'}, page_content='the neck cause vagus paralysis. Recurrent laryngeal nerve paralysis is caused by neck or thoracic\\nlesions (eg, aortic aneurysm; mitral stenosis; mediastinal tuberculous adenitis; tumors of the thyroid\\ngland, esophagus, lung, or mediastinal structures), trauma, thyroidectomy, neurotoxins (eg, lead, arsenic,\\nmercury), neurotoxic infections (eg, diphtheria), cervical spine injury or surgery, Lyme disease, and viral\\nillness. Viral neuronitis probably accounts for most idiopathic cases.\\nBilateral vocal cord paralysis is a life-threatening disorder caused by thyroid and cervical surgery, tracheal\\nintubation, trauma, and neurodegenerative and neuromuscular diseases.\\nSymptoms and Signs\\nVocal cord paralysis results in loss of vocal cord abduction and adduction. Paralysis may affect\\nphonation, respiration, and deglutition, and food and fluids may be aspirated into the trachea. The\\nparalyzed cord generally lies 2 to 3 mm lateral to the midline. In recurrent laryngeal nerve paralysis, the\\ncord may move with phonation but not with inspiration. In unilateral paralysis, the voice may be hoarse\\nand breathy, but the airway is usually not obstructed because the normal cord abducts sufficiently. In\\nbilateral paralysis, both cords generally lie within 2 to 3 mm of the midline, and the voice is of good quality\\nbut of limited intensity. The airway, however, is inadequate, resulting in stridor and dyspnea with moderate\\nexertion as each cord is drawn to the midline glottis by an inspiratory Bernoulli effect. Aspiration is also a\\ndanger.\\nDiagnosis\\n Laryngoscopy\\n Various tests for possible causes\\nDiagnosis is based on laryngoscopy. The cause must always be sought. Evaluation is guided by\\nabnormalities identified on history and physical examination. During the history, the physician asks about\\nall possible causes of peripheral neuropathy, including chronic heavy metal exposure (arsenic, lead,\\nmercury), drug effects from phenytoin and vincristine, and history of connective tissue disorders, Lyme\\ndisease, sarcoidosis, diabetes, and alcoholism. Further evaluation may include enhanced CT or MRI of\\nthe head, neck, and chest; thyroid scan; barium swallow or bronchoscopy; and esophagoscopy.\\nCricoarytenoid arthritis, which may cause fixation of the cricoarytenoid joint, must be differentiated from a\\nneuromuscular etiology. Fixation is best documented by absence of passive mobility during rigid\\nlaryngoscopy under general anesthesia. Cricoarytenoid arthritis may complicate such conditions as RA,\\nexternal blunt trauma, and prolonged endotracheal intubation.\\nTreatment\\n For unilateral paralysis, surgical procedures to move cords closer together\\n For bilateral paralysis, surgical procedures and measures to maintain airway\\nIn unilateral paralysis, treatment is directed at improving voice quality through augmentation,\\nmedialization, or reinnervation.\\nAugmentation involves injecting a paste of plasticized particles, collagen, micronized dermis, or\\nautologous fat into the paralyzed cord, bringing the cords closer together to improve the voice and\\nprevent aspiration.\\nMedialization is shifting the vocal cord toward the midline by inserting an adjustable spacer laterally to the\\naffected cord. This can be done with a local anesthetic, allowing the position of the spacer to be \"tuned\"\\nto the patient\\'s voice. Unlike augmentation with plasticized particles, which permanently fixes the cord, the\\nspacer is both adjustable and removable.\\nReinnervation has only rarely been successful.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 54. Laryngeal Disorders\\n587'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 597, 'page_label': '588'}, page_content='In bilateral paralysis, an adequate airway must be reestablished. Tracheotomy may be needed\\npermanently or temporarily during a URI. An arytenoidectomy with lateralization of the true vocal cord\\nopens the glottis and improves the airway but may adversely affect voice quality. Posterior laser\\ncordectomy opens the posterior glottis and may be preferred to endoscopic or open arytenoidectomy.\\nSuccessful laser establishment of a posterior glottic airway usually obviates the need for long-term\\ntracheotomy while preserving a serviceable voice quality.\\nVocal Cord Polyps and Nodules\\nAcute trauma or chronic irritation causes changes in the vocal cords that can lead to polyps or\\nnodules. Both cause hoarseness and a breathy voice. Persistence of these symptoms for > 3\\nwk dictates visualization of the vocal cords. Diagnosis is based on laryngoscopy and on biopsy\\nto rule out cancer. Surgical removal restores the voice, and removal of the irritating source\\nprevents recurrence.\\nEtiology\\nPolyps and nodules result from injury to the lamina propria of the true vocal cords. Polyps may occur at\\nthe mid third of the membranous cords and are more often unilateral. They frequently result from an\\ninitiating acute phonatory injury. Nodules usually occur bilaterally at the junction of the anterior and middle\\nthird of the cords. Their main cause is chronic voice abuseyelling, shouting, singing loudly, or using an\\nunnaturally low frequency. Polyps may have several other causes, including gastric reflux, untreated\\nhypothyroid states, chronic laryngeal allergic reactions, or chronic inhalation of irritants, such as industrial\\nfumes or cigarette smoke. Polyps tend to be larger and more protuberant than nodules and often have a\\ndominant surface blood vessel.\\nSymptoms and Signs\\nBoth result in slowly developing hoarseness and a breathy voice.\\nDiagnosis\\n Laryngoscopy\\n Sometimes biopsy\\nDiagnosis is based on direct or indirect visualization of the larynx with a mirror or laryngoscope. Biopsy of\\ndiscrete lesions to exclude carcinoma is done by microlaryngoscopy.\\nTreatment\\n Avoidance of cause\\n For polyps, usually surgical removal\\nCorrection of the underlying voice abuse cures most nodules and prevents recurrence. Removal of the\\noffending irritants allows healing, and voice therapy with a speech therapist \\nreduces the trauma to the\\nvocal cords caused by improper singing or protracted loud speaking. Nodules usually regress with voice\\ntherapy alone.\\nMost polyps must be surgically removed to restore a normal voice. Cold-knife microsurgical excision\\nduring direct microlaryngoscopy is preferable to laser excision, which is more likely to cause collateral\\nthermal injury if improperly applied.\\nIn microlaryngoscopy, an operating microscope is used to examine, biopsy, and operate on the larynx.\\nImages can be recorded on video as well. The patient is anesthetized, and the airway is secured by high-\\npressure jet ventilation through the laryngoscope, endotracheal intubation, or, for an inadequate upper\\nairway, tracheotomy. Because the microscope allows observation with magnification, tissue can be\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 54. Laryngeal Disorders\\n588'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 598, 'page_label': '589'}, page_content='removed precisely and accurately, minimizing damage (possibly permanent) to the vocal mechanism.\\nLaser surgery can be done through the optical system of the microscope to allow for precise cuts.\\nMicrolaryngoscopy is preferred for almost all laryngeal biopsies, for procedures involving benign tumors,\\nand for many forms of phonosurgery.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 54. Laryngeal Disorders\\n589'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 599, 'page_label': '590'}, page_content='Chapter 55. Tumors of the Head and Neck\\nIntroduction\\nThe most common noncutaneous tumor of the head and neck is squamous cell carcinoma of the larynx,\\nfollowed by squamous cell carcinomas of the tongue, palatine tonsil, and floor of the mouth. Less\\ncommon are tumors of the salivary glands, jaw, nose and paranasal sinuses, and ear. Tumors of the\\nthyroid gland, eye, and skin are discussed elsewhere in THE MANUAL.\\nExcluding the skin and thyroid gland, > 90% of head and neck cancers are squamous cell (epidermoid)\\ncarcinomas, and 5% are melanomas, lymphomas, and sarcomas. Patients with sarcomas or carcinomas\\nof the salivary glands or paranasal sinuses are often younger than patients with squamous cell\\ncarcinoma, who are more commonly in their mid-50s and older.\\nEtiology\\nThe vast majority of patients, 85% or more, with cancer of the head and neck have a history of alcohol\\nuse, smoking, or both. Other suspected causes include use of snuff or chewing tobacco, sunlight\\nexposure, previous x-rays of the head and neck, certain viral infections, ill-fitting dental appliances,\\nchronic candidiasis, and poor oral hygiene. In India, oral cancer is extremely common, probably because\\nof chewing betel quid (a mixture of substances, also called paan). Long-term exposure to sunlight and the\\nuse of tobacco products are the primary causes of squamous cell carcinoma of the lower lip.\\nPatients who in the past were treated with radiation for acne, excess facial hair, enlarged thymus, or\\nhypertrophic tonsils and adenoids are predisposed to thyroid and salivary gland cancers and benign\\nsalivary tumors.\\nEpstein-Barr virus plays a role in the pathogenesis of nasopharyngeal cancer, and serum measures of\\ncertain Epstein-Barr virus proteins may be biomarkers of recurrence. Human papillomavirus seems to be\\nassociated with head and neck squamous cell carcinoma, particularly oropharyngeal cancer. The\\nmechanism for viral-mediated tumor genesis may be distinct from tobacco-related pathways and seem to\\nhave a different, better, prognosis.\\nSymptoms and Signs\\nMost head and neck cancers first manifest as an asymptomatic neck mass, painful mucosal ulceration, or\\nvisible mucosal lesion (eg, leukoplakia, erythroplakia). Subsequent symptoms depend on location and\\nextent of the tumor and include pain, paresthesia, nerve palsies, trismus, and halitosis. Otalgia is an often\\noverlooked symptom usually representing referred pain from the primary tumor. Weight loss caused by\\nperturbed eating and odynophagia is also common.\\nDiagnosis\\n Clinical evaluation\\n Biopsy\\n Imaging tests and endoscopy to evaluate extent of disease\\nRoutine physical examination (including a thorough oral examination) is the best way to detect cancers\\nearly before they become symptomatic. Commercially available brush biopsy kits help screen for oral\\ncancers. Any head and neck symptom (eg, sore throat, hoarseness, \\notalgia) lasting > 2 to 3 wk should\\nprompt referral to a head and neck specialist.\\nDefinitive diagnosis usually requires a biopsy. Additional important information is obtained from a\\ncombination of imaging tests (eg, CT, MRI, PET/CT), endoscopy, and fine-needle aspiration of any neck\\nmass.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n590'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 600, 'page_label': '591'}, page_content='Staging\\nHead and neck cancers may remain localized for months to years. Local tissue invasion eventually is\\nfollowed by metastasis to regional lymph nodes, related in large part to tumor size and extent, and\\nreduces overall survival by nearly half. Distant metastases tend to occur late, usually in patients with\\nadvanced tumor and nodal stages. Metastases occur more commonly among immunocompromised\\npatients. Common sites of distant metastases are the lungs, liver, bone, and brain.\\nHead and neck cancers are staged (see\\nTable 55-1\\n) according to size and site of the primary tumor (T), number and size of metastases to the\\ncervical lymph nodes (N), and evidence of distant metastases (M). Staging usually requires imaging with\\nCT, MRI, or both, and often PET.\\nPrognosis\\nPrognosis is favorable if diagnosis is early and treatment is timely and appropriate. In general, the more\\npoorly differentiated the cancer, the greater the chance of regional and distant metastases. The presence\\nof regional nodal spread reduces overall survival by nearly half. Distant metastasis greatly reduces\\nsurvival, having only rare cures. Local invasion, a criterion for advanced T stage, with invasion of muscle,\\nbone, or cartilage, also significantly decreases cure rate. Perineural spread, as evidenced by pain,\\nparalysis, or numbness, indicates a highly aggressive tumor, is associated with nodal metastasis, and has\\na less favorable prognosis than a similar lesion without perineural invasion.\\nWith appropriate treatment, 5-yr survival can be as high as 90% for stage I, 75 to 80% for stage II, 45 to\\n75% for stage III, and up to 40% for stage IV. The survival rates vary greatly depending on the primary\\nsite. Stage I laryngeal cancers have an excellent survival rate when compared to other sites.\\nTreatment\\n Surgery, radiation therapy, or both\\n Sometimes chemotherapy\\nMany stage I tumors, regardless of location, respond similarly to surgery and to radiation therapy, allowing\\nother factors (eg, patient preference) to determine choice of therapy. Thus, the treating physician should\\ncarefully review risks and benefits with the patient. However, at certain locations, there is clear superiority\\nof one modality over another. For\\n[\\nTable 55-1.\\n Staging of Head and Neck Cancer]\\nexample, surgery is the better treatment for early-stage disease involving the oral cavity. In select head\\nand neck cancers, endoscopic surgery has cure rates similar to those of open surgery or radiation, and\\nmorbidity is significantly less. However, many physicians still recommend radiation for early-stage\\nlaryngeal cancer.\\nIf radiation therapy is chosen for primary therapy, it is delivered to the primary site and sometimes\\nbilaterally to the cervical lymph nodes. The treatment of lymphatics, whether by radiation or surgery, is\\ndetermined by the primary site, histologic criteria, and risk of nodal disease.\\nAdvanced-stage disease (stages III and IV) often requires multimodality treatment, incorporating some\\ncombination of chemotherapy, radiation therapy, and surgery. Bone or cartilage invasion requires surgical\\nresection of the primary site and usually regional lymph nodes because of the high risk of nodal spread. If\\nthe primary site is treated surgically, then postoperative radiation to the cervical lymph nodes is delivered\\nif there are high-risk features, such as multiple lymph nodes with cancer or extracapsular extension.\\nPostoperative radiation usually is preferred over preoperative radiation, because radiated tissues heal\\npoorly. Recent studies have shown that adding chemotherapy to adjuvant radiation therapy to the neck\\nimproves regional control of the cancer and improves survival. There are significant risks to this\\napproach, so the decision to add chemotherapy should be carefully considered.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n591'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 601, 'page_label': '592'}, page_content=\"Advanced squamous cell carcinoma without bony invasion often is treated with concomitant\\nchemotherapy and radiation therapy. Although advocated as organ-sparing, combining chemotherapy with\\nradiation therapy doubles the rate of acute toxicities, particularly severe dysphagia. Radiation may be\\nused alone for debilitated patients with advanced disease who cannot tolerate the sequelae of\\nchemotherapy and are too high a risk for general anesthesia.\\nPrimary chemotherapy is reserved for chemosensitive tumors, such as Burkitt's lymphoma, or for patients\\nwho have widespread metastases (eg, hepatic or pulmonary involvement). Several drugscisplatin,\\nfluorouracil, bleomycin, and methotrexateprovide palliation for pain and shrink the tumor in patients who\\ncannot be treated with other methods. Response may be good initially but is not durable, and the cancer\\nwill return.\\nTumor recurrence:\\n Managing recurrent tumors after therapy is complex and has potential complications.\\nA palpable mass or ulcerated lesion with edema or pain at the primary site after therapy strongly suggests\\na persistent tumor. Such patients require CT (with thin cuts) or MRI. For local recurrence after surgical\\ntreatment, all scar planes and reconstructive flaps are excised along with residual cancer. Radiation\\ntherapy, chemotherapy, or both may be done but have limited effectiveness. Patients with recurrence after\\nradiation therapy should not receive additional radiation and are best treated with surgery.\\nSymptom control:\\n Pain is a common symptom in patients with head and neck cancer and must be\\nadequately addressed. Palliative surgery or radiation may temporarily alleviate pain, and in 30 to 50% of\\npatients, chemotherapy can produce improvement that lasts a mean of 3 mo. A stepwise approach to pain\\nmanagement, as recommended by the WHO, is critical to controlling pain. Severe pain is best managed in\\nassociation with a pain and palliative care specialist.\\nPain, difficulty eating, choking on secretions, and other problems make adequate symptomatic treatment\\nessential. Patient directives regarding such care should be clarified early (see p. \\n3471\\n).\\nAdverse effects of treatment:\\n All cancer treatments have potential complications and expected\\nsequelae. Because many treatments have similar cure rates, the choice of modality is based largely on\\nreal, or perceived, differences in sequelae.\\nAlthough it is commonly thought that surgery requires rehabilitation for swallowing and speaking, many\\nprocedures do not require such rehabilitation. Increasingly complex reconstructive procedures and\\ntechniques, including prostheses, grafts, regional pedicle flaps, and complex free flaps, can restore\\nfunction and appearance often to near normal.\\nToxic effects of chemotherapy include malaise, severe nausea and vomiting, mucositis, transient hair\\nloss, gastroenteritis, hematopoietic and immune suppression, and infection.\\nTherapeutic radiation for head and neck cancers has several adverse effects. The function of any\\nsalivary gland within the beam is permanently destroyed by a dose of about 40 Gy, resulting in\\nxerostomia, which markedly increases the risk of dental caries. Newer radiation techniques, such as\\nintensity-modulated radiation therapy, can minimize or eliminate toxic doses to the parotid glands in\\ncertain patients. Radioprotectant drugs (eg, amifostine) also can help protect salivary function. In addition,\\nthe blood supply of bone, particularly in the mandible, is compromised by doses of > 60 Gy, and\\nosteoradionecrosis may occur \\n(see also p. \\n505\\n). In this condition, tooth extraction sites break down,\\nsloughing bone and soft tissue. Therefore, any needed dental treatment, including scaling, fillings, and\\nextractions, should be done before radiation therapy. Any teeth in poor condition that cannot be\\nrehabilitated should be extracted. Radiation therapy may also cause oral mucositis and dermatitis in the\\noverlying skin, which may result in dermal fibrosis. Loss of taste (ageusia) and impaired smell (dysosmia)\\noften occur but are usually transient.\\nPrevention\\nRemoving risk factors is critical, and all patients should cease tobacco use and limit alcohol consumption.\\nRemoving risk factors also helps prevent disease recurrence in those treated for cancer. A new primary\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n592\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 602, 'page_label': '593'}, page_content=\"cancer develops in about 5% of patients/yr (to a maximum risk of about 20%); risk is lower in those who\\nstop.\\nCancer of the lower lip may be prevented by sunscreen use and tobacco cessation. Because 60% of\\nhead and neck cancers are well advanced (stage III or IV) at the time of diagnosis, the most promising\\nstrategy for reducing morbidity and mortality is diligent routine examination of the oral cavity.\\nJaw Tumors\\nNumerous tumor types, both benign and malignant, originate in the jaw. Symptoms are\\nswelling, pain, tenderness, and unexplained tooth mobility; some tumors are discovered on\\nroutine dental x-rays, whereas others are found on routine examinations of the oral cavity and\\nteeth. Treatment depends on location and tumor type. Benign tumors may be observed and\\nmay not need surgical excision, although most tumors require resection with possible\\nreconstruction.\\nIf not initially detected on x-ray, jaw tumors are diagnosed clinically because their growth causes swelling\\nof the face, palate, or alveolar ridge (the part of the jaw supporting the teeth). They can also cause bone\\ntenderness and severe pain.\\nBony outgrowths (torus palatinus, torus mandibularis) may develop on the palate or mandible. These are\\ncommon growths and may prompt concerns about cancer, although they are benign and of concern only\\nif they interfere with dental care or function of the submandibular gland. When on the palate, they are in\\nthe midline and have intact, smooth mucosa. Multiple osteomas seen on dental x-ray may suggest\\nGardner's syndrome.\\nThe most common tumor of the mandible and maxilla is squamous cell carcinoma invading the bone\\nthrough dental sockets. These can involve any portion of the intraoral mandible or maxilla.\\nAmeloblastoma, the most common epithelial odontogenic tumor, usually arises in the posterior mandible. It\\nis slowly invasive and rarely metastatic. On x-ray, it typically appears as multiloculated or soap-bubble\\nradiolucency. Treatment is wide surgical excision and reconstruction if appropriate.\\nOdontoma, the most common odontogenic tumor, affects the dental follicle or the dental tissues and\\nusually appears in the mandibles of young people. Odontomas include fibrous odontomas and\\ncementomas. A clinically absent molar tooth suggests a composite odontoma. Typically, no treatment is\\nindicated. These tumors may be excised when the diagnosis is in doubt.\\nOsteosarcoma, giant cell tumor, Ewing's tumor, multiple myeloma, and metastatic tumors may affect the\\njaw. Treatment is the same as for those tumors in other bony sites.\\nLaryngeal Cancer\\nNinety percent of laryngeal cancer is squamous cell carcinoma. Smoking, alcohol abuse, lower\\nsocioeconomic status, and being male and > 60 yr increase risk. Early diagnosis is common\\nwith vocal cord tumors because vocal, swallowing, or respiratory symptoms develop early.\\nHowever, supraglottic tumors (above the vocal cords) and subglottic tumors (below the vocal\\ncords) are often very large and at an advanced stage when diagnosed because they are\\nasymptomatic until obstructive symptoms develop. Diagnosis is based on laryngoscopy and\\nbiopsy. Treatment of early-stage tumors is with surgery or radiation. Advanced-stage tumors are\\nmost often treated with chemotherapy and radiation therapy. Surgery is reserved for salvage\\ntreatment or lesions with significant extralaryngeal extension or cartilage destruction.\\nReestablishment of speaking ability is needed if a total laryngectomy is done.\\nSquamous cell carcinoma is the most common cancer of the larynx. In the US, it is 4 times more common\\namong men and is more common among those of lower socioeconomic status. Over 95% of patients are\\nsmokers; 15 pack-years of smoking increase the risk 30-fold. \\nThe incidence of larynx cancer is\\ndecreasing, particularly among men, most likely due to changes in smoking habits.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n593\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 603, 'page_label': '594'}, page_content='Sixty percent of patients present with localized disease alone; 25% present with local disease and\\nregional nodal metastatic disease; and 15% present with advanced disease, distant metastases, or both.\\nDistant metastases occur most frequently in the lungs and liver.\\nCommon sites of origin are the true vocal cords (glottis) and the supraglottic larynx. The least common\\nsite is the subglottic larynx, where only 1% of primary laryngeal cancers originate. Verrucous carcinoma, a\\nrare variant of squamous cell carcinoma, usually arises in the glottic area and has a better survival rate\\nthan standard squamous cell carcinoma.\\nSymptoms and Signs\\nSymptoms and signs differ based on the involved portion of the larynx. Hoarseness is common early in\\nglottic cancers but is a late symptom for supraglottic and subglottic cancers. Supraglottic cancer is often\\nasymptomatic until it manifests as a mass lesion (eg, with airway obstruction, dysphagia, otalgia, or a \"hot\\npotato\" voice) or with weight loss. Such patients should be referred for indirect laryngoscopy without\\ndelay.\\nDiagnosis\\n Laryngoscopy\\n Operative endoscopy and biopsy\\n Imaging tests for staging\\nAll patients who have hoarseness for > 2 to 3 wk should have their larynx examined by a head and neck\\nspecialist. Any lesions discovered require further evaluation, usually with operative endoscopy and\\nbiopsy, with concomitant evaluation of the upper airway and GI tract for coexisting cancers. The incidence\\nof a synchronous second primary tumor may be as high as 10%.\\nPatients with confirmed carcinoma typically have neck CT with contrast and a chest x-ray or chest CT.\\nMost clinicians also do PET of the neck and chest at the time of diagnosis.\\nTreatment\\n Early-stage: Surgery or radiation therapy\\n Advanced: Radiation therapy and sometimes chemotherapy\\nFor early-stage glottic carcinoma, laser excision, radiation therapy, or occasionally open laryngeal surgery\\nresults in a 5-yr survival rate of 85 to 95%. Endoscopic laser resection and radiation therapy usually\\npreserve a normal voice and post-treatment function and have similar cure rates.\\nFor advanced glottic carcinoma, defined by a lack of vocal cord mobility, thyroid cartilage invasion, or\\nextension into the tongue, most patients are treated with chemotherapy and radiation therapy. Surgery\\n(followed by radiation therapy) is reserved for salvage situations; most such cases require total\\nlaryngectomy, although endoscopic or open partial laryngectomy may sometimes be used. Extensive local\\ninvasion, however, usually requires an initial total laryngectomy rather than nonsurgical therapy.\\nEarly supraglottic carcinoma can be effectively treated with radiation therapy or partial laryngectomy.\\nLaser resection has shown considerable success on early-stage supraglottic squamous cell carcinomas\\nand minimizes functional changes after surgery. If the carcinoma is more advanced but does not affect the\\ntrue vocal cords, a supraglottic partial laryngectomy can be done to preserve the voice and glottic\\nsphincter. If the true vocal cords also are affected, a supracricoid laryngectomy or a total laryngectomy is\\nrequired if surgery is chosen. As with glottic carcinoma, most advanced-stage supraglottic cancers initially\\nare treated with chemotherapy and radiation therapy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n594'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 604, 'page_label': '595'}, page_content='Treatment of hypopharyngeal carcinomas is similar to that of laryngeal cancer. Early-stage lesions\\nusually are treated with radiation alone, although endoscopic resection is an option. However, the\\nmajority of patients with hypopharyngeal cancer have advanced-stage disease, because of the silent\\nnature of the disease and frequent regional lymphatic spread; such patients are treated with\\nchemotherapy and radiation therapy primarily, with surgical salvage.\\nRehabilitation:\\n Rehabilitation may be required after either surgical or nonsurgical treatment. Significant\\nswallowing problems are common after chemotherapy and radiation therapy and may require esophageal\\ndilation, swallowing therapy, or, in severe cases, surgical replacement of the pharynx or gastrostomy tube\\nfeedings. Swallowing also is affected by surgery and may require swallowing therapy or dilation as well.\\nSpeech, on the other hand, is more significantly affected by surgery. After total laryngectomy, the patient\\nrequires creation of a new voice by way of\\n Esophageal speech\\n A tracheoesophageal puncture\\n An electrolarynx\\nIn all 3 techniques, sound is articulated into speech by the pharynx, palate, tongue, teeth, and lips.\\nEsophageal speech involves taking air into the esophagus during inspiration and gradually eructating the\\nair through the pharyngoesophageal junction to produce a sound.\\nA tracheoesophageal puncture involves placement of a one-way valve between the trachea and\\nesophagus to facilitate phonation. This valve forces air into the esophagus during expiration to produce a\\nsound. Patients receive physical rehabilitation, speech therapy, and appropriate training in the\\nmaintenance and use of this valve and must be cautioned against the possible aspiration of food, fluids,\\nand secretions.\\nAn electrolarynx is a battery-powered sound source that is held against the neck to produce sound.\\nAlthough it carries a great deal of social stigma for many patients, it has the advantage of being functional\\nimmediately with little or no training.\\nNasopharyngeal Cancer\\nNasopharyngeal cancers are rare in the US but common in the South China Sea region.\\nSymptoms develop late, including unilateral bloody nasal discharge, nasal obstruction, facial\\nswelling, and numbness. Diagnosis is based on inspection and biopsy, with CT, MRI, or PET to\\nevaluate extent. Treatment is with radiation, chemotherapy, and, rarely, surgery.\\nSquamous cell carcinoma is the most common malignant tumor of the nasopharynx. It can occur in any\\nage group and is rare in North America. It is one of the most common cancers among people of Chinese,\\nespecially southern Chinese, and Southeast Asian ancestry, including Chinese immigrants to North\\nAmerica. Over several generations, the prevalence among Chinese-Americans gradually decreases to\\nthat among non-Chinese Americans, suggesting an environmental component to etiology. Dietary\\nexposure to nitrites and salted fish also is thought to increase risk. Epstein-Barr virus is a significant risk\\nfactor, and there is hereditary predisposition. Other nasopharyngeal cancers include adenoid cystic and\\nmucoepidermoid carcinomas, malignant mixed tumors, adenocarcinomas, lymphomas, fibrosarcomas,\\nosteosarcomas, chondrosarcomas, and melanomas.\\nSymptoms and Signs\\nThe first symptom is often nasal or eustachian tube obstruction causing hearing loss due to a middle ear\\neffusion. Other symptoms include purulent bloody rhinorrhea, frank epistaxis, cranial nerve palsies, and\\ncervical lymphadenopathy. Cranial nerve palsies most often involve the 6th, 4th, and 3rd cranial nerves\\ndue to their location in the cavernous sinus, in close proximity to the foramen lacerum, which is the most\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n595'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 605, 'page_label': '596'}, page_content='common route of intracranial spread for these tumors. Because lymphatics of the nasopharynx\\ncommunicate across the midline, bilateral metastases are common.\\nDiagnosis\\n Nasopharyngeal endoscopy and biopsy\\n Imaging tests for staging\\nPatients suspected of having nasopharyngeal cancer must undergo examination with a nasopharyngeal\\nmirror or endoscope, and lesions are biopsied. Open cervical node biopsy should not be done as the\\ninitial procedure (see \\nNeck Mass\\n on p. \\n461\\n), although a needle biopsy is acceptable and often\\nrecommended. Gadolinium-enhanced MRI (with fat suppression) of the head with attention to the\\nnasopharynx and skull base is done; the skull base is involved in about 25% of patients. CT also is\\nrequired to accurately assess skull base bony changes, which are less visible on MRI. A PET scan also\\ncommonly is done to assess the extent of disease as well as the cervical lymphatics.\\nTreatment\\n Chemotherapy plus radiation therapy\\nBecause of the location and extent of involvement, nasopharyngeal cancers often are not amenable to\\nsurgical resection. They are typically treated with chemotherapy and radiation therapy, which are often\\nfollowed by adjuvant chemotherapy.\\nRecurrent tumors can be treated with another course of radiation, commonly with brachytherapy;\\nradionecrosis of the skull base is a risk. An alternative to radiation is skull base resection.\\nOral Squamous Cell Carcinoma\\nOral squamous cell carcinoma affects about 30,000 Americans each year. Over 95% smoke,\\ndrink alcohol, or both. Early, curable lesions are rarely symptomatic; thus, preventing fatal\\ndisease requires early detection by screening. Treatment is with surgery, radiation, or both. The\\noverall 5-yr survival rate (all sites and stages combined) is > 50%.\\nIn the US, 3% of cancers in men and 2% in women are oral squamous cell carcinomas, most of which\\noccur after age 50. Squamous cell carcinoma is the most common oral or pharyngeal cancer (and the\\nmost common at head and neck sites in general).\\nThe chief risk factors for oral squamous cell carcinoma are smoking (especially > 2 packs/day) and\\nalcohol use. Risk increases dramatically when alcohol use exceeds 6 oz of distilled liquor, 6 oz of wine, or\\n12 oz of beer/day. The combination of heavy smoking and alcohol abuse is estimated to raise the risk\\n100-fold in women and 38-fold in men. Squamous cell carcinoma of the tongue may also result from any\\nchronic irritation, such as dental caries, overuse of mouthwash, chewing tobacco, or the use of betel\\nquid. Oral human papillomavirus (HPV), typically acquired via oral-genital contact, may have a role in\\netiology.\\nAbout 40% of intraoral squamous cell carcinomas begin on the floor of the mouth or on the lateral and\\nventral surfaces of the tongue. About 38% of all oral squamous cell carcinomas occur on the lower lip;\\nthese are usually solar-related cancers on the external surface. About 11% begin in the palate and\\ntonsillar area. Squamous cell carcinoma of the tonsil (an oropharyngeal cancer), 2nd in frequency only to\\ncarcinoma of the larynx among cancers of the upper respiratory tract, occurs predominantly in males.\\nSymptoms and Signs\\nOral lesions are asymptomatic initially, highlighting the need for oral screening. Most dental professionals\\ncarefully examine the oral cavity and oropharynx during routine care and may do a brush biopsy of\\nabnormal areas. The lesions may appear as areas of erythroplakia or leukoplakia and may be exophytic\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n596'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 606, 'page_label': '597'}, page_content='or ulcerated. Cancers are often indurated and firm with a rolled border. Tonsillar carcinoma usually\\nmanifests as an asymmetric swelling and sore throat, with pain often radiating to the ipsilateral ear. A\\nmetastatic mass in the neck may be the first symptom, particularly in tonsillar cancer.\\nDiagnosis\\n Biopsy\\n Endoscopy to detect second primary cancer\\n Chest x-ray and CT of head and neck\\nBiopsy of suspect areas is done. Direct laryngoscopy, bronchoscopy, and esophagoscopy are done to\\nexclude a simultaneous second primary cancer. Head and neck CT usually is done. Chest x-ray is done;\\nchest CT is done if an advanced stage is suspected or confirmed.\\nPrognosis\\nIf carcinoma of the tongue is localized (no lymph node involvement), 5-yr survival is > 50%. For localized\\ncarcinoma of the floor of the mouth, 5-yr survival is 65%. Lymph node metastasis decreases survival rate\\nby about 50%. Metastases reach the regional lymph nodes first and later the lungs.\\nFor lower lip lesions, 5-yr survival is 90%, and metastases are rare. Carcinoma of the upper lip tends to\\nbe more aggressive and metastatic. For carcinoma of the palate and tonsillar area, 5-yr survival is 68% if\\npatients are treated before lymph node involvement but only 17% after involvement. The prognosis for\\ntonsillar carcinoma is often better stage for stage than that for oral cancers. Oropharyngeal cancer\\nassociated with HPV infection may have a better prognosis.\\nTreatment\\n Surgery or radiation therapy\\nSurgery and radiation therapy are the treatments of choice. Regional or distant disease necessitates a\\nmore radical treatment approach.\\nFor tongue lesions, surgery is usually the initial treatment, particularly for early-stage disease. Selective\\nneck dissection is indicated if the risk of nodal disease exceeds 15 to 20%. Routine surgical\\nreconstruction is the key to reducing postoperative oral disabilities; procedures range from local tissue\\nflaps to free tissue transfers. Speech and swallowing therapy may be required after significant resections.\\nRadiation therapy is an alternative treatment. Chemotherapy is not used routinely but is recommended on\\nan individual basis; rare distant metastases are present in sites where chemotherapy may be of some\\npalliative value (eg, lung, bone, heart, pericardium).\\nTreatment of squamous cell carcinoma of the lip is surgical excision with reconstruction to maximize\\npostoperative function. When large areas of the lip exhibit premalignant change, the lip can be surgically\\nshaved, or a laser can remove all affected mucosa. Thereafter, appropriate sunscreen application is\\nrecommended.\\nTreatment of tonsillar carcinoma usually consists of concomitant chemotherapy and radiation therapy.\\nAnother option includes radical resection of the tonsillar fossa, sometimes with partial mandibulectomy\\nand neck dissection.\\nOtic Tumors\\nA number of malignant and benign otic tumors occur, usually manifesting with hearing loss.\\nThey may also manifest with dizziness, vertigo, or imbalance. These tumors are rare and can be\\ndifficult to diagnose.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n597'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 607, 'page_label': '598'}, page_content='Malignant otic tumors:\\n Basal cell and squamous cell carcinomas may arise in the ear canal. Persistent\\ninflammation caused by chronic otitis media may predispose to the development of squamous cell\\ncarcinoma. Extensive resection is indicated, followed by radiation therapy. En bloc resection of the ear\\ncanal with sparing of the facial nerve is done when lesions are limited to the canal and have not invaded\\nthe middle ear. Deeper invasion requires a more significant temporal bone resection.\\nRarely, squamous cell carcinoma originates in the middle ear. The persistent otorrhea of chronic otitis\\nmedia may be a predisposing factor. Resection of the temporal bone and postoperative radiation therapy\\nare necessary.\\nNonchromaffin paragangliomas (chemodectomas) arise in the temporal bone from glomus bodies in the\\njugular bulb (glomus jugulare tumors) or the medial wall of the middle ear (glomus tympanicum tumors).\\nThey appear as a pulsatile red mass in the middle ear. The first symptom often is tinnitus that is\\nsynchronous with the pulse. Hearing loss develops, followed by vertigo. Cranial nerve palsies of the 9th,\\n10th, or 11th nerve may accompany glomus jugulare tumors that extend through the jugular foramen.\\nExcision is the treatment of choice, and radiation is used for nonsurgical candidates.\\nBenign otic tumors:\\n Sebaceous cysts, osteomas, and keloids may arise in and occlude the ear canal,\\ncausing retention of cerumen and conductive hearing loss. Excision is the treatment of choice for all\\nbenign otic tumors.\\nCeruminomas occur in the outer third of the ear canal. These tumors appear benign histologically and do\\nnot metastasize regionally or distantly but they are locally invasive and potentially destructive and should\\nbe excised widely.\\nSalivary Gland Tumors\\nMost salivary gland tumors are benign and occur in the parotid glands. A painless salivary mass\\nis the most common sign and is evaluated by fine-needle aspiration biopsy. Imaging with CT\\nand MRI can be helpful. For malignant tumors, treatment is with excision and radiation. Long-\\nterm results are related to the grade of the cancer.\\nAbout 85% of salivary gland tumors occur in the parotid glands, followed by the submandibular and minor\\nsalivary glands, and about 1% occur in the sublingual glands. About 75 to 80% are benign, slow-growing,\\nmovable, painless, usually solitary nodules beneath normal skin or mucosa. Occasionally, when cystic,\\nthey are soft but most often they are firm.\\nBenign tumors:\\n The most common type is a pleomorphic adenoma (mixed tumor). Malignant\\ntransformation is possible, resulting in carcinoma ex mixed tumor, but this usually occurs only after the\\nbenign tumor has been present for 15 to 20 yr. If malignant transformation occurs, the cure rates are very\\nlow, despite adequate surgery and adjuvant therapy.\\nOther benign tumors include monomorphic adenoma, oncocytoma, and papillary cystadenoma\\nlymphomatosum (previously known as cylindroma). These tumors rarely recur and rarely become\\nmalignant.\\nMalignant salivary gland tumors:\\n Malignant tumors are less common and are characterized by rapid\\ngrowth or a sudden growth spurt. They are firm, nodular, and can be fixed to adjacent tissue, often with a\\npoorly defined periphery. Pain and neural involvement are common. Eventually, the overlying skin or\\nmucosa may become ulcerated or the adjacent tissues may become invaded. Surgery, followed by\\nradiation therapy, is the treatment of choice for resectable disease. Currently, there is no effective\\nchemotherapy for salivary cancer.\\nMucoepidermoid carcinoma is the most common salivary gland cancer, typically occurring in people in\\ntheir 20s to 50s. It can manifest in any salivary gland, often in a minor salivary gland of the palate, or it\\ncan occur deep within the bone, such as in the wall of a dentigerous cyst. Intermediate and high-grade\\nmucoepidermoid carcinomas may metastasize to the regional lymphatics, which must be addressed with\\nsurgical dissection or postoperative radiation therapy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n598'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 608, 'page_label': '599'}, page_content='Adenoid cystic carcinoma is the most common malignant tumor of minor salivary glands (and of the\\ntrachea). It is a slowly growing malignant transformation of a much more common benign cylindroma. Its\\npeak incidence is between ages 40 and 60, and symptoms include severe pain and, often, facial nerve\\nparalysis. It has a propensity for perineural invasion and spread, with disease potentially extending many\\ncentimeters from the main tumor mass. Lymphatic spread is not a common feature of this tumor, so\\nelective nodal treatment is less common. Although the 5- and 10-yr survival rates are quite good, the \\n15-\\nand 20-yr rates are quite poor, with most patients developing distant metastases. Pulmonary metastases\\nare common, although patients can live quite long with them.\\nAcinic cell carcinoma, a common parotid tumor, occurs in people in their 40s and 50s. This carcinoma has\\na more indolent course, as well as an incidence of multifocality.\\nCarcinoma ex mixed tumor is adenocarcinoma arising in a preexisting benign carcinoma ex mixed tumor.\\nOnly the carcinomatous element metastasizes.\\nSymptoms and Signs\\nMost benign and malignant tumors manifest as a painless mass. However, malignant tumors may invade\\nnerves, causing localized or regional pain, numbness, paresthesia, causalgia, or a loss of motor function.\\nDiagnosis\\n Biopsy\\n CT and MRI for extent of disease\\nCT and MRI locate the tumor and describe its extent. Biopsy confirms the cell type. A search for spread to\\nregional nodes or distant metastases in the lung, liver, bone, or brain may be indicated before treatment is\\nselected.\\nTreatment\\n Surgery, sometimes plus radiation therapy\\nTreatment of benign tumors is surgery. The recurrence rate is high when excision is incomplete.\\nTreatment of mucoepidermoid carcinoma consists of wide excision and postoperative radiation. The 5-yr\\nsurvival rate is 95% with the low-grade type, primarily affecting mucus cells, and 50% with the high-grade\\ntype, primarily affecting epidermoid cells. Treatment of adenoid cystic carcinoma is wide surgical excision,\\nbut local recurrence is common. Lung metastases and death are likely, although many years, to a decade\\nor more, after the initial diagnosis and treatment. The prognosis for acinic cell carcinoma is favorable after\\nwide excision. All surgeries are designed to spare the facial nerve, which is sacrificed only in cases of\\ndirect tumor involvement with the nerve.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 55. Tumors of the Head & Neck\\n599'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 609, 'page_label': '600'}, page_content=\"Chapter 56. Approach to Dental and Oral Symptoms\\nIntroduction\\nA physician should always examine the mouth and be able to recognize major oral disorders, particularly\\npossible cancers. However, consultation with a dentist is needed to evaluate nonmalignant changes as\\nwell as patients with tooth problems. Likewise, patients with xerostomia or unexplained swelling or pain in\\nthe mouth, face, or neck require a dental consultation. Children with abnormal facies (who also may have\\ndental malformations requiring correction) should be evaluated by a dentist. In FUO or a systemic\\ninfection of unknown cause, a dental disorder should be considered. A dental consultation is necessary\\nbefore head and neck radiation therapy and is advisable before chemotherapy.\\nClues suggesting systemic disease may be found in the mouth and adjacent structures (see\\nTable 56-1\\n). A dentist should consult a physician when a systemic disorder is suspected, when the patient\\nis taking certain drugs (eg, warfarin, bisphosphonates), and when a patient's ability to withstand general\\nanesthesia or extensive oral surgery must be evaluated. Patients with certain heart valve abnormalities\\nmay require antibiotic prophylaxis to help prevent bacterial endocarditis before undergoing certain dental\\nprocedures (see\\nTables 215-3\\n and\\n215-4\\n on pp. \\n2199\\n and \\n2200\\n).\\nCommon dental disorders are discussed in \\nCh. 57\\n. Dental emergencies, including toothache, are\\ndiscussed in \\nCh. 58\\n.\\nAnatomy and Development\\nTeeth:\\n The teeth are categorized as incisors, canines, premolars, and molars and conventionally are\\nnumbered beginning with the maxillary right 3rd molar (see\\nFig. 56-1\\n).\\nEach tooth has a crown and a root. The canines have the largest and strongest roots. An inner pulp\\ncontains blood vessels, lymphatics, and nerves, surrounded by the hard but porous dentin, a very hard\\nenamel coating that covers the crown. The bonelike cementum is over the root, which, when healthy, is\\ncovered by gingiva (see\\nFig. 56-2\\n). Twenty deciduous\\n[\\nTable 56-1.\\n Oral Findings in Systemic Disorders]\\nteeth normally begin appearing at close to age 6 mo and should all be in place by age 30 mo (see\\nTable 271-1\\n on p. \\n2757\\n). These teeth are followed by 32 permanent teeth that begin to appear by about\\nage 6. The period from age 6 to 11 is called the mixed dentition stage, in which both deciduous and\\npermanent teeth are present. Timing of tooth eruption is one indicator of skeletal age and may identify\\ngrowth retardation or establish age for forensic purposes.\\nSupporting tissues:\\n The gingiva surrounds the teeth at the base of their crown. The alveolar ridges are\\ntrabecular bone containing sockets for the teeth. The periodontium consists of the tissues that support\\nthe teeththe gingiva, epithelial attachment, connective tissue attachment, periodontal ligament, and\\nalveolar bone. The mandible and maxilla support the alveolar ridges and house the teeth. Saliva from the\\nsalivary glands bathes and protects the teeth. The tongue directs food between the grinding surfaces and\\nhelps clean the teeth. The maxilla receives innervation from the maxillary nerve, the 2nd division of the\\ntrigeminal nerve (the 5th cranial nerve). The mandibular nerve, which is the 3rd and most inferior division\\nof the trigeminal nerve, innervates the mandible.\\nIn the elderly, or in some periodontal diseases, gingival recession exposes the dental root adjacent to the\\ncrown, making root caries common. If tooth destruction results and the tooth must be removed, the\\nmechanical stimulation necessary for maintaining bone integrity ceases. Consequently, atrophy of the\\nalveolar ridge (senile atrophy) begins when teeth are absent.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n600\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 610, 'page_label': '601'}, page_content=\"Mouth:\\n Normally, keratinized epithelium occurs on the facial aspect of the lips, dorsum of the tongue,\\nhard palate, and gingiva around the teeth. When healthy, the gingiva extends\\n[\\nFig. 56-1.\\n Identifying the teeth.]\\n5 to 7 mm from the tooth. Nonkeratinized mucosa occurs over alveolar bone further from the teeth, inside\\nthe lips and cheeks, on the sides and undersurface of the tongue, on the soft palate, and covering the\\nfloor of the mouth. The skin and mucosa of the lips are demarcated by the vermilion border.\\nThe buccal mucosa, including the vestibule and nonkeratinized alveolar mucosa, is usually smooth, moist,\\nand more red than pink (as compared to healthy gingiva). Innocuous entities in this region include linea\\nalba (a thin white line, typically bilateral, on the level of the occlusal plane, where the cheek is bitten),\\nFordyce's granules (aberrant sebaceous glands appearing as < 1 mm light yellow spots that also may\\noccur on the lips), and white sponge nevus (bilateral thick white folds over most of the buccal mucosa).\\nRecognizing these avoids needless biopsy and apprehension. The orifices of the parotid (Stensen's)\\nducts are opposite the maxillary 1st molar on the inside of each cheek and should not be mistaken for an\\nabnormality.\\nThe dorsal surface of the tongue is covered with numerous whitish elevations called the filiform papillae.\\nInterspersed among them are isolated reddish prominences called the fungiform papillae, occurring mostly\\non the anterior part of the tongue. The circumvallate papillae, numbering 8 to 12, are considerably larger\\nand lie posteriorly in a V pattern. The circumvallate papillae do not project from the tongue but instead are\\nsurrounded by a trench. The foliate papillae appear as a series of parallel, slitlike folds on the lateral\\nborders of the tongue, near the anterior pillars of the fauces. They vary in length and can easily be\\nconfused with malignant lesions, as may the foramen cecum, median rhomboid glossitis, and, rarely, a\\nlingual thyroid nodule. Lingual tonsils are components of Waldeyer's ring, are at the back of the tongue,\\nand should not be mistaken for lesions. If an apparent abnormality is bilateral, it is almost always a normal\\nvariant.\\nInnervation is supplied by the lingual nerves (branches of the 5th cranial nerves), for general sensory\\ninnervation, and the chorda tympani fibers (of the 7th cranial nerve), which innervate the taste buds of the\\nanterior two thirds of the tongue. Behind the circumvallate papillae, the glossopharyngeal nerves (9th\\ncranial nerves) provide the sensations of touch and taste. The tongue has taste receptors for sweet,\\nsalty, sour, bitter, and umami (a savory\\n[\\nFig. 56-2.\\n Section of a canine tooth.]\\ntaste triggered by natural glutamic acid and glutamates such as the flavoring agent monosodium\\nglutamate). Although previously thought to be isolated to particular portions of the tongue, these receptors\\nare now known to be distributed over the surface of the tongue. The hypoglossal nerves (12th cranial\\nnerves) control movement of the tongue.\\nThe major salivary glands are the paired parotid, submandibular, and sublingual glands. Most oral\\nmucosal surfaces contain many minor mucus-secreting salivary glands. Anteriorly and near the midline on\\neach side of the floor of the mouth are the openings of Wharton's ducts, which drain the ipsilateral\\nsubmandibular and sublingual glands. The parotid glands drain into the cheeks via Stensen's ducts.\\nEvaluation\\nThe first routine dental examination should take place by age 1 yr or when the first tooth erupts.\\nSubsequent evaluations should take place at 6-mo intervals or whenever symptoms develop. Examination\\nof the mouth is part of every general physical examination. Oral findings in many systemic diseases are\\nunique, sometimes pathognomonic, and may be the first sign of disease. Oral cancer may be detected at\\nan early stage.\\nHistory:\\n Important dental symptoms include bleeding, pain, malocclusion, new growths, numbness or\\nparesthesias, and chewing problems (which may lead to weight losssee\\nTable 56-2\\n). General information includes use of alcohol or tobacco (both major risk factors for head and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n601\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 611, 'page_label': '602'}, page_content=\"neck cancer) and systemic symptoms, such as fever and weight loss.\\nPhysical examination:\\n A thorough inspection requires good illumination, a tongue blade, gloves, and a\\ngauze pad. Complete or partial dentures are removed so that underlying soft tissues can be seen.\\nMost physicians use a head-mounted light. However, because the light cannot be precisely aligned on the\\naxis of vision, it is difficult to avoid shadowing in narrow areas. Better illumination results with a head-\\nmounted convex mirror; the physician looks through a hole in the center of the mirror, so the illumination is\\nalways on-axis. The head mirror reflects light from a source (any incandescent light) placed behind the\\npatient and slightly to one side and requires practice to use effectively.\\nThe examiner initially looks at the face for asymmetry, masses, and skin lesions. Slight facial asymmetry is\\nuniversal, but more marked asymmetry may indicate an underlying disorder, either congenital or acquired\\n(see\\nTable 56-3\\n).\\nTeeth are inspected for shape, alignment, defects, mobility, color, and presence of adherent plaque,\\nmateria alba (dead bacteria, food debris, desquamated epithelial cells), and calculus (tartar).\\nTeeth are gently tapped with a tongue depressor or mirror handle to assess tenderness (percussion\\nsensitivity). Tenderness to percussion suggests deep caries that has caused a necrotic pulp with\\nperiapical abscess or severe periodontal disease. Percussion sensitivity or pain on biting also can\\nindicate an incomplete (green stick) fracture of a tooth. Percussion tenderness in multiple adjacent\\nmaxillary teeth may result from maxillary sinusitis. Tenderness to palpation around the apices of the teeth\\nalso may indicate an abscess.\\nLoose teeth usually indicate severe periodontal disease but can be caused by bruxism (clenching or\\ngrinding of teethsee p. \\n506\\n) or trauma that damages periodontal tissues. Rarely, teeth become loose\\nwhen alveolar bone is eroded by an underlying mass (eg, ameloblastoma, eosinophilic granuloma). A\\ntumor or systemic cause of alveolar bone loss (eg, diabetes mellitus, hyperparathyroidism, osteoporosis,\\nCushing's syndrome) is suspected when teeth are loose and heavy plaque and calculus are absent.\\nCalculus is mineralized bacterial plaquea concretion of bacteria, food residue, saliva,\\n[\\nTable 56-2.\\n Some Oral Symptoms and Possible Causes]\\nand mucus with Ca and phosphate salts. After a tooth is cleaned, a mucopolysaccharide coating (pellicle)\\nis deposited almost immediately. After about 24 h, bacterial colonization turns the pellicle into plaque. After\\nabout 72 h, the plaque starts calcifying, becoming calculus. When present, calculus is deposited most\\nheavily on the lingual (inner, or tongue) surfaces of the mandibular anterior teeth near the submandibular\\nand sublingual duct orifices (Wharton's ducts) and on the buccal (cheek) surfaces of the maxillary molars\\nnear the parotid duct orifices (Stensen's ducts).\\nCaries (tooth decaysee p. \\n516\\n) first appears as defects in the tooth enamel. Caries then appears as\\nwhite spots, later becoming brown.\\nAttrition (wearing of biting surfaces) can result from chewing abrasive foods or tobacco or from the wear\\nthat accompanies aging, but it usually indicates bruxism. Another common cause is abrasion of a\\nporcelain crown occluding against opposing enamel, because porcelain is considerably harder than\\nenamel. Attrition makes chewing less effective and causes noncarious teeth to become\\n[\\nTable 56-3.\\n Some Disorders of the Oral Region by Predominant Site of Involvement]\\npainful when the eroding enamel exposes the underlying dentin. Dentin is sensitive to touch and to\\ntemperature changes. A dentist can desensitize such teeth or restore the dental anatomy by placing\\ncrowns or onlays over badly worn teeth. In minor cases of root sensitivity, the exposed root may be\\ndesensitized by fluoride application or dentin-bonding agents.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n602\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 612, 'page_label': '603'}, page_content='Deformed teeth may indicate a developmental or endocrine disorder. In Down syndrome, teeth are small.\\nIn congenital syphilis, the incisors may be small at the incisal third, causing a pegged or screwdriver\\nshape with a notch in the center of the incisal edge (Hutchinson\\'s incisors), and the 1st molar is small,\\nwith a small occlusal surface and roughened, lobulated, often hypoplastic enamel (mulberry molar). In\\nectodermal dysplasia, teeth are absent or conical, so that dentures are needed from childhood.\\nDentinogenesis imperfecta, an autosomal dominant disorder, causes abnormal dentin that is dull bluish\\nbrown and opalescent and does not cushion the overlying enamel adequately. Such teeth cannot\\nwithstand occlusal stresses and rapidly become worn. People with pituitary dwarfism or with congenital\\nhypoparathyroidism have small dental roots; people with gigantism have large ones. Acromegaly causes\\nexcess cementum in the roots as well as enlargement of the jaws, so teeth may become widely spaced.\\nAcromegaly also can cause an open bite to develop in adulthood. Congenitally narrow lateral incisors\\noccur in the absence of systemic disease. The most commonly congenitally absent teeth are the 3rd\\nmolars, followed in frequency by the maxillary lateral incisors and 2nd mandibular premolars.\\nDefects in tooth color must be differentiated from the darkening or yellowing that is caused by food\\npigments, aging, and, most prominently, smoking. A tooth may appear gray because of pulpal necrosis,\\nusually due to extensive caries penetrating the pulp or because of hemosiderin deposited in the dentin\\nafter trauma, with or without pulpal necrosis. Children\\'s teeth darken appreciably and permanently after\\neven short-term use of tetracyclines by the mother during the 2nd half of pregnancy or by the child during\\nodontogenesis (tooth development), specifically calcification of the crowns, which lasts until age 9.\\nTetracyclines rarely cause permanent discoloration of fully formed teeth in adults. However, minocycline\\ndarkens bone, which can be seen in the mouth when the overlying gingiva and mucosa are thin. Affected\\nteeth fluoresce with distinctive colors under ultraviolet light corresponding to the specific tetracycline\\ntaken. In congenital porphyria, both the deciduous and permanent teeth may have red or brownish\\ndiscoloration but always fluoresce red from the pigment deposited in the dentin. Congenital\\nhyperbilirubinemia causes a yellowish tooth discoloration. Teeth can be whitened (see\\nTable 56-4\\n).\\nDefects in tooth enamel may be caused by rickets, which results in a rough, irregular band in the enamel.\\nAny prolonged febrile illness during odontogenesis can cause a permanent narrow zone of chalky, pitted\\nenamel or simply white discoloration visible after the tooth erupts. Thus, the age at which the disease\\noccurred and its duration can be estimated from the location and height of the band. Amelogenesis\\nimperfecta, an autosomal dominant disease, causes severe enamel hypoplasia. Chronic vomiting and\\nesophageal reflux can decalcify the dental crowns, primarily the lingual surfaces of the maxillary anterior\\nteeth. Chronic snorting of cocaine can result in widespread decalcification of teeth, because the drug\\ndissociates in saliva into a base and HCl. Chronic use of methamphetamines markedly increases dental\\ncaries (\"meth mouth\").\\nSwimmers who spend a lot of time in over-chlorinated pools may lose enamel from the outer facial/buccal\\nside of the teeth, especially the maxillary incisors, canines, and 1st premolars. If Na carbonate has been\\nadded to the pool water to correct pH, then brown calculus develops but can be removed by a dental\\ncleaning.\\nFluorosis is mottled enamel that may develop in children who drink water containing > 1 ppm of fluoride\\nduring tooth development. Fluorosis depends on the amount of fluoride ingested. Enamel changes range\\nfrom irregular whitish opaque areas to severe brown discoloration of the entire crown with a roughened\\nsurface. Such teeth are highly resistant to dental caries.\\nThe lips are palpated. With the patient\\'s mouth open, the buccal mucosa and vestibules are examined\\nwith a tongue blade; then the hard and soft palates, uvula, and oropharynx are viewed. The patient is\\nasked to extend the tongue as far as possible, exposing the dorsum, and to move the extended tongue as\\nfar as possible to each side, so that its posterolateral surfaces can be seen. If a patient does not extend\\nthe tongue far enough to expose the circumvallate papillae, the examiner grasps the tip of the tongue with\\na gauze pad and extends it. Then the tongue is raised to view the ventral surface and the floor of the\\nmouth. The teeth and gingiva are viewed. An abnormal distribution of keratinized or nonkeratinized oral\\nmucosa demands attention. Keratinized tissue that occurs in normally nonkeratinized areas appears\\nwhite. This abnormal condition, called leukoplakia, requires a biopsy because it may be cancerous or\\nprecancerous. More ominous, however, are thinned areas of mucosa. These\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n603'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 613, 'page_label': '604'}, page_content=\"[\\nTable 56-4.\\n Tooth Whitening Procedures]\\nred areas, called erythroplakia, if present for at least 2 wk, especially on the ventral tongue and floor of\\nthe mouth, suggest dysplasia, carcinoma in situ, or cancer.\\nWith gloved hands, the examiner palpates the vestibules and the floor of the mouth, including the\\nsublingual and submandibular glands. To make palpation more comfortable, the examiner asks the patient\\nto relax the mouth, keeping it open just wide enough to allow access.\\nThe temporomandibular joint (TMJ) is assessed by looking for jaw deviation on opening and by palpating\\nthe head of the condyle anterior to the external auditory meatus. Examiners then place their little fingers\\ninto the external ear canals with the pads of the fingertips lightly pushing anteriorly while patients open\\nwidely and close 3 times. Patients also should be able to comfortably open wide enough to fit 3 of their\\nfingers vertically between the incisors (typically 4 to 5 cm). Trismus, the inability to open the mouth, may\\nindicate temporomandibular disease (the most common cause), pericoronitis, scleroderma, arthritis,\\nankylosis of the TMJ, dislocation of the temporomandibular disk, tetanus, or peritonsillar abscess.\\nUnusually wide opening suggests subluxation or type III Ehlers-Danlos syndrome.\\nTesting:\\n For a new patient or for someone who requires extensive care, the dentist takes a full mouth x-\\nray series. This series consists of 14 to 16 periapical films to show the roots and bone plus 4 bite-wing\\nfilms to detect early caries between posterior teeth. Modern techniques reduce radiation exposure to a\\nnear-negligible level. Patients at high risk of caries (ie, those who have had caries detected during the\\nclinical examination, have many restorations, or have recurrent caries on teeth previously restored)\\nshould undergo bite-wing x-rays every 12 mo. Otherwise, bite-wings are indicated every 2 to 3 yr. A\\npanoramic x-ray can yield useful information about tooth development, cysts or tumors of the jaws,\\nsupernumerary or congenitally absent teeth, 3rd molar impaction, Eagle's syndrome (less frequently), and\\ncarotid plaques.\\nGeriatrics Essentials\\nWith aging, resting salivary secretion diminishes and can be further diminished by drugs, although meal-\\nstimulated salivary flow is usually adequate. The flattened cusps of worn teeth and weakness of the\\nmasticatory muscles may make chewing tiresome, impairing food intake. Loss of bone mass in the jaws\\n(particularly the alveolar portion), dryness of \\nthe mouth, thinning of the oral mucosa, and impaired\\ncoordination of lip, cheek, and tongue movements may make denture retention difficult. The taste buds\\nbecome less sensitive, so the elderly may add abundant seasonings, particularly salt (which is harmful for\\nsome), or they may desire very hot foods for more taste, sometimes burning the often atrophic oral\\nmucosa. Gingival recession and xerostomia contribute to development of root caries. Despite these\\nchanges, improved dental hygiene has greatly decreased the prevalence of tooth loss, and most older\\npeople can expect to retain their teeth.\\nPoor oral health contributes to poor nutritional intake, which impairs general health. Dental disease\\n(particularly periodontitis) is associated with a 2-fold increased risk of coronary artery disease.\\nEdentulous patients cannot have periodontitis (because they do not have a periodontium), although\\nperiodontitis may have resulted in their tooth loss. Aspiration pneumonia in patients with periodontitis can\\ninvolve anaerobic organisms and has a high mortality rate. Severe bacteremias secondary to acute or\\nchronic dental infection may contribute to brain abscesses, cavernous sinus thrombosis, endocarditis,\\nprosthetic joint infections, and unexplained fevers.\\nDental Care of Patients With Systemic Disorders\\nCertain medical conditions (and their treatment) predispose patients to dental problems or affect dental\\ncare.\\nHematologic disorders:\\n People who have disorders that interfere with coagulation (eg, hemophilia,\\nacute leukemia, thrombocytopenia) require medical consultation before undergoing dental procedures\\nthat might cause bleeding (eg, extraction, mandibular block). Hemophiliacs should have clotting factors\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n604\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 614, 'page_label': '605'}, page_content=\"given before, during, and after an extraction. Such oral surgery should be done in the hospital in\\nconsultation with a hematologist. All patients with bleeding disorders should maintain a lifelong routine of\\nregular dental visits, which includes cleanings, fillings, topical fluoride, and preventative sealants, to avoid\\nthe need for extractions.\\nCardiovascular disorders:\\n After an MI, dental procedures should be avoided for 6 mo, if possible, to\\nallow damaged myocardium to become less electrically labile. Patients with pulmonary or cardiac disease\\nwho require inhalation anesthesia for dental procedures should be hospitalized.\\nEndocarditis prophylaxis\\n is required before dental procedures only in patients with\\n Prosthetic cardiac valves\\n Previous history of bacterial endocarditis\\n Cyanotic congenital defects of the heart or great vessels (if unrepaired, if completely repaired during\\nfirst 6 mo after surgery, or if repaired but with residual defects)\\n Cardiac transplantation recipients with a valvulopathy\\nThe heart is better protected against low-grade bacteremias, which occur in chronic dental conditions,\\nwhen dental treatment is received (with prophylaxis) than when it is not received. Patients who are to\\nundergo cardiac valve surgery or repair of congenital heart defects should have any necessary dental\\ntreatment completed before surgery.\\nAlthough probably of marginal benefit, antibiotic prophylaxis is sometimes recommended for patients with\\nhemodialysis shunts and within 2 yr of receipt of a major prosthetic joint (hip, knee, shoulder, elbow). The\\norganisms causing infections at these sites are almost invariably of dermal rather than oral origin.\\nEpinephrine and levonordefrin are added to local anesthetics to increase the duration of anesthesia. In\\nsome cardiovascular patients, excess amounts of these drugs cause arrhythmias, myocardial ischemia, or\\nhypertension. Plain anesthetic can be used for procedures requiring < 45 min, but in longer procedures or\\nwhere hemostasis is needed, up to 0.04 mg epinephrine (2 dental cartridges with 1:100,000 epinephrine)\\nis considered safe. Generally, no healthy patient should receive > 0.2 mg epinephrine at any one\\nappointment. Absolute contraindications to epinephrine (any dose) are uncontrolled hyperthyroidism;\\npheochromocytoma; BP > 200 mm Hg systolic or > 115 mm Hg diastolic; uncontrolled arrhythmias despite\\ndrug therapy; and unstable angina, MI, or stroke within 6 mo.\\nSome electrical dental equipment, such as an electrosurgical cautery, a pulp tester, or an ultrasonic\\nscaler, can interfere with early-generation pacemakers.\\nCancer:\\n Extracting a tooth adjacent to a carcinoma of the gingiva, palate, or antrum facilitates invasion of\\nthe alveolus (tooth socket) by the tumor. Therefore, a tooth should be extracted only during the course of\\ndefinitive treatment. In patients with leukemia or agranulocytosis, infection may follow an extraction\\ndespite the use of antibiotics.\\nImmunosuppression:\\n People with impaired immunity are prone to severe mucosal and periodontal\\ninfections by fungi, herpes and other viruses, and, less commonly, bacteria. The infections may cause\\nhemorrhage, delayed healing, or sepsis. Dysplastic or neoplastic oral lesions may develop after a few\\nyears of immunosuppression. People with AIDS may develop Kaposi's sarcoma, non-Hodgkin lymphoma,\\nhairy leukoplakia, candidiasis, aphthous ulcers, or a rapidly progressive form of periodontal disease.\\nEndocrine disorders:\\n Dental treatment may be complicated by some endocrine disorders. For example,\\npeople with hyperthyroidism may develop tachycardia and excessive anxiety as well as thyroid storm if\\ngiven epinephrine. Insulin requirements may be reduced on elimination of oral infection in diabetics;\\ninsulin dose may require reduction when food intake is limited because of pain after oral surgery. In\\npeople with diabetes, hyperglycemia with resultant polyuria may lead to dehydration, resulting in\\ndecreased salivary flow (xerostomia), which, along with elevated salivary glucose levels, contributes to\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n605\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 615, 'page_label': '606'}, page_content=\"caries.\\nPatients receiving corticosteroids and those with adrenocortical insufficiency may require supplemental\\ncorticosteroids during major dental procedures. Patients with Cushing's syndrome or who are taking\\ncorticosteroids may have alveolar bone loss, delayed wound healing, and increased capillary fragility.\\nNeurologic disorders:\\n Patients with seizures who require dental appliances should have nonremovable\\nappliances that cannot be swallowed or aspirated. Patients unable to brush or floss effectively may use\\nchlorhexidine 12% rinses in the morning and at bedtime.\\nObstructive sleep apnea:\\n Patients with obstructive sleep apnea who are unable to tolerate treatment\\nwith a positive airway pressure (CPAP, biPAP) mask are sometimes treated with an intraoral device that\\nexpands the oropharynx. This treatment is not as effective as CPAP, but more patients tolerate using it.\\nDrugs:\\n Certain drugs, such as corticosteroids, immunosuppressants, and antineoplastics, compromise\\nhealing and host defenses. When possible, dental procedures should not be done while these drugs are\\nbeing given.\\nSome antineoplastics (eg, doxorubicin, 5-fluorouracil, bleomycin, dactinomycin, cytosine, arabinoside,\\nmethotrexate) cause stomatitis, which is worse in patients with preexisting periodontal disease. Before\\nsuch drugs are prescribed, oral prophylaxis should be completed, and patients should be instructed in\\nproper toothbrushing and flossing.\\nDrugs that interfere with clotting may need to be reduced or stopped before oral surgery. Patients taking\\naspirin, NSAIDs, or clopidogrel should stop doing so 4 days before undergoing dental surgery and can\\nresume taking these drugs after bleeding stops. Warfarin should be stopped 2 to 3 days before oral\\nsurgery. PT is obtained; INR of 1.5 is considered safe for surgery. For people receiving hemodialysis,\\ndental procedures should be done the day after dialysis, when heparinization has subsided.\\nPhenytoin and Ca channel blockers, particularly nifedipine, contribute to gingival hyperplasia; however,\\nthis hyperplasia is minimized with excellent oral hygiene and frequent oral prophylaxes (cleanings).\\nBisphosphonates, primarily when given parenterally for treatment of bone cancer, and to a much lesser\\ndegree when used orally to prevent osteoporosis, can result in osteonecrosis after an extraction (see\\nSidebar 39-1\\n on p.\\n363\\n).\\nRadiation therapy:\\n (CAUTION: \\nExtraction of teeth from irradiated tissues [particularly if the total dose\\nwas\\n > \\n65 Gy, especially in the mandible] is commonly followed by osteoradionecrosis of the jaw. This\\nis a catastrophic complication in which extraction sites break down, frequently sloughing bone and soft\\ntissue.\\n) Thus, if possible, patients should have any necessary dental treatment completed before\\nundergoing radiation therapy of the head and neck region, with time allowed for healing. Teeth that may\\nnot survive should be extracted. Necessary sealants and topical fluoride should be applied. After\\nradiation, extraction should be avoided, if possible, by using dental restorations and root canal treatment\\ninstead.\\nHead and neck radiation often damages salivary glands, causing xerostomia, which promotes caries.\\nPatients must therefore practice lifelong good oral hygiene. A fluoride gel and fluoride mouth rinse should\\nbe used daily. Rinsing with 0.12% chlorhexidine for 30 to 60 sec, if tolerated, can be done in the morning\\nand at bedtime. Viscous lidocaine may enable a patient with sensitive oral tissues to brush and floss the\\nteeth and eat. A dentist must be seen at 3-, 4-, or 6-mo intervals, depending on findings at the last\\nexamination. Irradiated tissue under dentures is likely to break down, so dentures should be checked and\\nadjusted whenever discomfort is noted. Early caries may also be reversed by Ca phosphopeptides and\\namorphous Ca phosphate, which can be applied by a dentist or prescribed to a patient for at-home use.\\nPatients who undergo radiation therapy may develop oral mucosal inflammation and diminished taste as\\nwell as trismus due to fibrosis of \\nthe masticatory muscles. Trismus may be minimized by such exercises\\nas opening and closing the mouth widely 20 times 3 or 4 times/day. Extractions of teeth in irradiated bone\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n606\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 616, 'page_label': '607'}, page_content=\"should be avoided (because of possible osteoradionecrosis). Sometimes root canal therapy is done, and\\nthe tooth is ground down to the gum line. If extraction is required after radiation, 10 to 20 treatments in a\\nhyperbaric O\\n2\\n chamber may forestall or prevent osteoradionecrosis.\\nBruxism\\nBruxism is clenching or grinding of teeth. Bruxism can abrade and eventually wear down dental crowns\\nand loosen teeth. In many people, headaches, jaw pain, or both actually are the result of bruxism. The\\nmost severe and extensive grinding and clenching occurs during sleep, so the person may be oblivious to\\nit, but family members might notice.\\nTreatment requires that the patient consciously try to reduce bruxism while awake. Plastic oral appliances\\n(night guards) that prevent occlusal contact by fitting between the teeth can be used while sleeping.\\nWhen symptoms are severe, a guard can be used also during the day. Usually, such devices are made by\\ndentists. However, if the only problem is tooth wear, OTC heat-moldable devices, fitted at home, are\\navailable. Mild anxiolytics, particularly benzodiazepines, may help until a night guard is available but\\nshould not be used for extended periods.\\nHalitosis\\n(Fetor Oris; Oral Malodor)\\nHalitosis is a frequent or persistent unpleasant odor to the breath.\\nPathophysiology\\nHalitosis most often results from fermentation of food particles by anaerobic gram-negative bacteria in the\\nmouth, producing volatile sulfur compounds such as hydrogen sulfide and methyl mercaptan. Causative\\nbacteria may be present in areas of gingival or periodontal disease, particularly when ulceration or\\nnecrosis is present. The causative organisms reside deep in periodontal pockets around teeth. In patients\\nwith healthy periodontal tissue, these bacteria may deposit on the dorsal posterior tongue.\\nFactors contributing to the overgrowth of causative bacteria include decreased salivary flow (eg, due to\\nparotid disease, Sjogren's syndrome, use of anticholinergicssee p. \\n513\\n), salivary stagnation, and\\nincreased salivary pH.\\nCertain foods or spices, after digestion, release the odor of that substance to the lungs; the exhaled odor\\nmay be unpleasant to others. For example, the odor of garlic is noted on the breath by others 2 or 3 h\\nafter consumption, long after it is gone from the mouth.\\nEtiology\\nAbout 85% of cases result from oral conditions. A variety of systemic and extraoral conditions account for\\nthe remainder (see\\nTable 56-5\\n).\\nThe \\nmost common causes\\n overall are the following:\\n Gingival or periodontal disease\\n Smoking\\n Ingested foods that have a volatile component\\nGI disorders rarely cause halitosis because the esophagus is normally collapsed. It is a fallacy that breath\\nodor reflects the state of digestion and bowel function.\\nOther breath odors:\\n Several systemic diseases produce volatile substances detectable on the breath,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n607\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 617, 'page_label': '608'}, page_content=\"although not the particularly foul, pungent odors typically considered halitosis. Diabetic ketoacidosis\\nproduces a sweet or fruity odor of acetone; liver failure produces a mousy or sometimes faintly sulfurous\\nodor; and renal failure produces an odor of urine or ammonia.\\nEvaluation\\nHistory: History of present illness\\n should ascertain duration and severity of halitosis (including\\nwhether other people have noticed or complained), adequacy of patient's oral hygiene, and the\\nrelationship of halitosis to ingestion of causative foods (see \\nTable 56-5\\n).\\nReview of systems\\n should seek symptoms of causative disorders, including nasal discharge and face\\nor head pain (sinusitis, nasal foreign body); productive cough and fevers (pulmonary infection); and\\nregurgitation of undigested food when lying down or bending over (Zenker's diverticulum). Predisposing\\nfactors such as dry mouth, dry eyes, or both (Sjogren's syndrome) should be noted.\\nPast medical history\\n should ask about duration and amount of use of alcohol and tobacco. Drug history\\nshould specifically ask about use of those that can cause dry mouth.\\n[\\nTable 56-5.\\n Some Causes of Halitosis]\\nPhysical examination:\\n Vital signs are reviewed, particularly for presence of fever.\\nThe nose is examined for discharge and foreign body.\\nThe mouth is examined for signs of gum disease, dental infection, and cancer. Signs of apparent dryness\\nare noted (eg, whether the mucosa is dry, sticky, or moist; whether saliva is foamy, stringy, or normal in\\nappearance).\\nThe pharynx is examined for signs of infection and cancer.\\nSniff test:\\n A sniff test of exhaled air is conducted. In general, oral causes result in a putrefying, pungent\\nsmell, whereas systemic conditions result in a more subtle, abnormal odor. Ideally, for 48 h before the\\nexamination, the patient avoids eating garlic or onions, and for 2 h before, the patient abstains from\\neating, \\nchewing, drinking, gargling, rinsing, or smoking. During the test, the patient exhales 10 cm away\\nfrom the examiner's nose, first through the mouth and then with the mouth closed. A worse odor through\\nthe mouth suggests an oral etiology. A worse odor through the nose suggests a nasal or sinus etiology.\\nSimilar odor through both nose and mouth suggests a systemic or pulmonary cause. If site of origin is\\nunclear, the posterior tongue is scraped with a plastic spoon. After 5 sec, the spoon is sniffed 5 cm from\\nthe examiner's nose.\\nRed flags:\\n The following findings are of particular concern:\\n Fever\\n Purulent nasal discharge or sputum\\n Visible or palpable oral lesions\\nInterpretation of findings:\\n Because oral causes are by far the most common, any visible oral disease\\nmay be presumed to be the cause in patients with no extraoral symptoms or signs. When other disorders\\nare involved, clinical findings often suggest a diagnosis (see \\nTable 56-5\\n).\\nIn patients whose symptoms seem to be related to intake of certain substances and who have no other\\nfindings, a trial of avoidance may clarify the diagnosis.\\nTesting:\\n Extensive diagnostic evaluation should not be undertaken unless the history and physical\\nexamination suggest an underlying disease (see \\nTable 56-5\\n). Portable sulfur monitors, gas\\nchromatography, and chemical tests of tongue scrapings are available but best left to research protocols\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n608\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 618, 'page_label': '609'}, page_content='or the occasional dental office that focuses on halitosis.\\nTreatment\\nUnderlying diseases are treated.\\nIf the cause is oral, the patient should see a dentist for professional cleaning and treatment of gingival\\ndisease and caries. Home treatment involves enhanced oral hygiene, including thorough flossing,\\ntoothbrushing, and brushing of the tongue with the toothbrush or a scraper. Mouthwashes are of limited\\nbenefit except to mask odor for about 20 min. Psychogenic halitosis may require psychiatric consultation.\\nGeriatrics Essentials\\nElderly patients are more likely to take drugs that cause dry mouth, which leads to difficulties with oral\\nhygiene and hence to halitosis, but are otherwise not more likely to have halitosis. Also, oral cancers are\\nmore common with aging and are more of a concern among elderly than younger patients.\\nKey Points\\n Most halitosis comes from fermentation of food particles by anaerobic gram-negative bacteria in the\\nmouth.\\n Extraoral disorders may cause halitosis but are often accompanied by suggestive findings.\\n It is a fallacy that breath odor reflects the state of digestion and bowel function.\\n Mouthwashes provide only brief benefit.\\nMalocclusion\\nMalocclusion is abnormal contact between the maxillary and mandibular teeth.\\nNormally, each dental arch consists of teeth in side-by-side contact, forming a smooth curve, with the\\nmaxillary anterior teeth overlying the upper third of the mandibular anterior teeth. The buccal (outer)\\ncusps of the maxillary posterior teeth are external to the corresponding cusps of the mandibular posterior\\nteeth. On each side of the mouth, the anterior buccal cusp of the maxillary 1st permanent molar fits into\\nthe anterior buccal groove of the mandibular 1st molar. Because the outer parts of all maxillary teeth are\\nnormally external to the mandibular teeth, the lips and cheeks are displaced from between the teeth so\\nthat they are not bitten. The lingual (inner) surfaces of the lower teeth form a smaller arc than those of the\\nupper teeth, confining the tongue and minimizing the likelihood of its being bitten. All the maxillary teeth\\nshould contact the corresponding mandibular teeth, so that the masticatory forces (which may be > 150 lb\\nin the molar region and 250 lb when clenching during sleep) are widely distributed. If these forces are\\napplied to only a few teeth, those teeth will eventually loosen.\\nEtiology\\nMalocclusion often results from jaw and tooth size discrepancies (ie, the jaw is too small or the teeth are\\ntoo large for the jaw to accommodate them in proper alignment) but may be caused by a number of\\ncongenital deformities and disorders or by tooth loss. When permanent teeth are lost, adjacent teeth shift\\nand opposing teeth extrude, causing malocclusion unless a bridge, implant, or partial denture is worn to\\nprevent these movements. When children lose deciduous teeth prematurely, the teeth more posterior in\\nthe arch or the permanent 1st molars often drift forward, leaving insufficient space for other permanent\\nteeth to erupt. Malocclusion after \\nfacial trauma may indicate tooth displacement or jaw fracture. In\\nectodermal dysplasia, malocclusion results from having too few teeth.\\nEvaluation\\nOcclusion is checked on both sides of the mouth by retracting each cheek with a tongue depressor while\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n609'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 619, 'page_label': '610'}, page_content='telling the patient to close on the back teeth. Malocclusion sometimes is identified as early as the first\\ndental visit. Early identification may make later treatment easier and more effective.\\nTreatment\\nMalocclusions are corrected primarily for aesthetic and psychologic reasons. However, in some cases,\\ntreatment may increase resistance to caries (in specific teeth), to anterior tooth fracture, and, possibly, to\\nperiodontal disease or stripping of the gingiva on the palate. Treatment may improve speech and\\nmastication as well. Occlusion can be improved by aligning teeth properly, by selectively grinding teeth\\nand restorations that contact prematurely, and by inserting crowns or onlays to build up tooth surfaces\\nthat are below the plane of occlusion.\\nOrthodontic appliances (braces) apply a continuous mild force to teeth to gradually remodel the\\nsurrounding alveolar bone. Extraction of one or more permanent teeth (usually a 1st premolar) may be\\nneeded to allow other teeth to be repositioned or to erupt into a stable alignment. After the teeth are\\nproperly aligned, the patient wears a plastic-and-wire retainer 24 h/day initially, then only at night for 2 to\\n3 yr.\\nWhen orthodontic treatment alone is insufficient, surgical correction of jaw abnormalities contributing to\\nmalocclusion (orthognathic surgery) may be indicated.\\nStomatitis\\nOral inflammation and ulcers, known as stomatitis, may be mild and localized or severe and widespread.\\nThey are invariably painful. Stomatitis may involve swelling and redness of the oral mucosa or discrete,\\npainful ulcers (single or multiple). Less commonly, whitish lesions form, and, rarely, the mouth appears\\nnormal (burning mouth syndrome) despite significant symptoms. Symptoms hinder eating, sometimes\\nleading to dehydration and malnutrition. Secondary infection occasionally occurs. Some conditions are\\nrecurrent.\\nEtiology\\nStomatitis may be caused by local infection, systemic disease, a physical or chemical irritant, or an\\nallergic reaction (see\\nTable 56-6\\n); many cases are idiopathic. Because the normal flow of saliva protects the mucosa against\\nmany insults, xerostomia predisposes the mouth to stomatitis of any cause.\\nThe \\nmost common specific causes\\n overall include\\n Recurrent aphthous stomatitis (RAS)also called recurrent aphthous ulcers (RAU)\\n Viral infections, particularly herpes simplex and herpes zoster\\n Other infectious agents (\\nCandida albicans\\n and bacteria)\\n Trauma\\n Tobacco\\n Chemotherapy and radiation therapy\\nEvaluation\\nHistory: History of present illness\\n should ascertain the duration of symptoms and whether the patient\\never had them previously. Presence and severity of pain should be noted. The relation of symptoms to\\nfood, drugs, and other substances (particularly occupational exposure to chemicals, metals, fumes, or\\ndust) is sought.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n610'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 620, 'page_label': '611'}, page_content=\"Review of systems\\n seeks symptoms of possible causes, including chronic diarrhea and weakness\\n(inflammatory bowel disease, celiac sprue); genital lesions (Behcet's syndrome, syphilis); eye irritation\\n(Behcet's syndrome); and weight loss, malaise, and fever (nonspecific chronic illness).\\nPast medical history\\n should ascertain known conditions that cause oral lesions, including herpes\\nsimplex, Behcet's syndrome, inflammatory bowel disease, and risk factors for oral lesions, including\\nimmunocompromised state (eg, cancer, diabetes, organ transplant, use of immunosuppressants, HIV\\ninfection). Whether chemotherapy or radiation therapy has ever been used to manage cancer needs to be\\ndetermined. Drug history should note all recent drugs used. History of tobacco use should be noted.\\nSocial history should include sexual contact, particularly oral sex, unprotected sex, and sex with multiple\\npartners.\\nPhysical examination:\\n Vital signs are reviewed for fever. The patient's general appearance is noted for\\nlethargy, discomfort, or other signs of significant systemic illness.\\nThe mouth is inspected for the location and nature of any lesions.\\nThe skin and other mucosal surfaces (including the genitals) are inspected for any lesions,\\n[\\nTable 56-6.\\n Some Causes of Stomatitis]\\nrash, petechiae, or desquamation. Any bullous lesions are rubbed for Nikolsky's sign (peeling of\\nepithelium with lateral pressure).\\nRed flags:\\n The following findings are of particular concern:\\n Fever\\n Cutaneous bullae\\n Ocular inflammation\\n Immunocompromise\\nInterpretation of findings:\\n Occasionally, causes are obvious in the history (eg, cytotoxic chemotherapy;\\nsignificant occupational exposure to chemicals, fumes, or dust). Recurrent episodes of oral lesions occur\\nwith RAS, herpes simplex, and Behcet's syndrome. History of diabetes, HIV infection or other\\nimmunocompromise, or recent antibiotic use should increase suspicion of \\nCandida\\n infection. Recent drug\\nuse (particularly sulfa drugs, other antibiotics, and antiepileptics) should increase suspicion of Stevens-\\nJohnson syndrome (SJS).\\nSome causes typically have \\nextraoral, noncutaneous findings\\n, some of which suggest a cause.\\nRecurrent GI symptoms suggest inflammatory bowel disease or celiac sprue. Ocular symptoms can occur\\nwith Behcet's syndrome and SJS. Genital lesions may occur with Behcet's syndrome and primary syphilis.\\nSome causes usually also have \\nextraoral, cutaneous findings\\n.\\nCutaneous bullae suggest SJS, pemphigus vulgaris, or bullous pemphigoid. Prodrome of malaise, fever,\\nconjunctivitis, and generalized macular target lesions suggests SJS. Pemphigus vulgaris starts with oral\\nlesions, then progresses to flaccid cutaneous bullae. Bullous pemphigoid has tense bullae on normal-\\nappearing skin. Nikolsky's sign is usually positive in SJS and pemphigus vulgaris.\\nCutaneous vesicles are typical with chickenpox or herpes zoster. Unilateral lesions in a band after a\\ndermatome suggest herpes zoster. Diffuse, scattered vesicular and pustular lesions in different stages\\nsuggest chickenpox.\\nKawasaki disease usually has a macular rash, desquamation of hands and feet, and conjunctivitis; it\\noccurs in children, usually those < 5 yr. Oral findings include erythema of the lips and oral mucosa.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n611\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 621, 'page_label': '612'}, page_content='Other cutaneous lesions may implicate erythema multiforme, hand-foot-and-mouth disease (from\\ncoxsackievirus), or secondary syphilis.\\nSome causes have \\nisolated oral findings\\n, including RAS, most viral infections, acute necrotizing\\nulcerative gingivitis, primary syphilis, gonorrhea, and \\nCandida\\n.\\nLocation of oral lesions may help identify the cause. Interdental ulcers occur with primary herpes simplex\\nor acute necrotizing ulcerative gingivitis. Lesions on keratinized surfaces suggest herpes simplex, RAS, or\\nphysical injury. Physical injury typically has an irregular appearance and occurs near projections of teeth,\\ndental appliances, or where biting can injure the mucosa. An aspirin burn next to a tooth and pizza burn\\non the palate are common.\\nPrimary herpes simplex infection causes multiple vesicular lesions on the intraoral mucosa on both\\nkeratinized and nonkeratinized surfaces and always includes the gingiva. These lesions rapidly ulcerate.\\nClinical manifestation occurs most often in children. Subsequent reactivations (secondary herpes simplex,\\ncold sore) usually appear starting in puberty on the lip at the vermilion border and, rarely, on the hard\\npalate.\\nAcute necrotizing ulcerative gingivitis causes severe inflammation and punched-out ulcers on the dental\\npapillae and marginal gingivae. A severe variant called noma (gangrenous stomatitis) can cause full-\\nthickness tissue destruction (sometimes involving the lips or cheek), typically in a debilitated patient. It\\nbegins as a gingival, buccal, or palatal (midline lethal granuloma) ulcer that becomes necrotic and\\nspreads rapidly. Tissue sloughing may occur.\\nIsolated oral gonorrhea very rarely causes burning ulcers and erythema of the gingiva and tongue, as\\nwell as the more common pharyngitis. Primary syphilis chancres may appear in the mouth. Tertiary\\nsyphilis may cause oral gummas or a generalized glossitis and mucosal atrophy. The site of a gumma is\\nthe only time that squamous cell carcinoma develops on the dorsum of the tongue. A common sign of HIV\\nbecoming AIDS is hairy leukoplakia (vertical white lines on the lateral border of the tongue).\\nC. albicans\\n and related species, which are normal oral flora, can overgrow in people who have taken\\nantibiotics or corticosteroids or who are immunocompromised, such as patients with AIDS. \\nC. albicans\\ncan cause whitish, cheesy plaques that leave erosions when wiped off. Sometimes only flat,\\nerythematous areas appear (erosive form of \\nCandida\\n).\\nTesting:\\n Patients with acute stomatitis and no symptoms, signs, or risk factors for systemic illness\\nprobably require no testing.\\nIf stomatitis is recurrent, viral and bacterial cultures, CBC, serum iron, ferritin, vitamin B\\n12\\n, folate, zinc,\\nand endomysial antibody (for sprue) are done. Biopsy at the periphery of \\nnormal and abnormal tissue can\\nbe done for persistent lesions that do not have an obvious etiology.\\nSystematically eliminating foods from the diet can be useful, as can changing brands of toothpaste,\\nchewing gum, or mouthwash.\\nTreatment\\nSpecific disorders are treated, and any causative substances or drugs are avoided.\\nMeticulous oral hygiene (using a soft toothbrush) may help prevent secondary infection. A soft diet that\\ndoes not include acidic or salty foods is followed.\\nTopical measures:\\n Numerous topical treatments, alone or in combination, are used to ease symptoms.\\nThese treatments include\\n Anesthetics\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n612'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 622, 'page_label': '613'}, page_content=' Protective coatings\\n Corticosteroids\\n Antibiotics\\n Physical measures (eg, cautery)\\nFor topical anesthesia of discomfort that may interfere with eating and drinking, the following may be\\neffective:\\n Lidocaine rinse\\n Sucralfate plus aluminum-magnesium antacid rinse\\nA 2-min rinse is done with 15 mL (1 tbsp) 2% viscous lidocaine q 3 h prn; patient expectorates when done\\n(no rinsing with water and no swallowing unless the pharynx is involved). A soothing coating may be\\nprepared with sucralfate (1-g pill dissolved in 15 mL water) plus 30 mL of aluminum-magnesium liquid\\nantacid; the patient should rinse with or without swallowing. Many institutions and pharmacies have their\\nown variation of this formulation (magic mouthwash), which sometimes also contains an antihistamine.\\nIf the physician is certain the inflammation is not caused by an infectious organism, the patient can\\n Rinse and expectorate after meals with dexamethasone elixir 0.5 mg/5 mL (1 tsp)\\n Apply a paste of 0.1% triamcinolone in an oral emollient\\n Wipe amlexanox over the ulcerated area with the tip of a finger\\nChemical or physical cautery can ease pain of localized lesions. Silver nitrate sticks are not as effective\\nas low-power (2- to 3-watt), defocused, pulsed-mode CO\\n2\\n laser treatments, after which pain relief is\\nimmediate and lesions tend not to recur locally.\\nKey Points\\n Isolated stomatitis in patients with no other symptoms and signs or risk factors for systemic illness is\\nusually caused by a viral infection or RAS.\\n Extraoral symptoms, skin rash, or both suggest more immediate need for diagnosis.\\nRecurrent Aphthous Stomatitis\\nRecurrent aphthous stomatitis is a common condition in which round or ovoid painful ulcers\\nrecur on the oral mucosa. Etiology is unclear. Diagnosis is clinical. Treatment is symptomatic\\nand usually includes topical corticosteroids.\\nRecurrent aphthous stomatitis (RAS) affects 20 to 30% of adults and a greater percentage of children at\\nsome time in their life.\\nEtiology\\nEtiology is unclear, but RAS tends to run in families. The damage is predominately cell-mediated.\\nCytokines, such as IL-2, IL-10, and, particularly, tumor necrosis factor-\\n\\n, play a role.\\nPredisposing factors\\n include\\n Oral trauma\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n613'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 623, 'page_label': '614'}, page_content=\" Stress\\n Foods, particularly chocolate, coffee, peanuts, eggs, cereals, almonds, strawberries, cheese, and\\ntomatoes\\nAllergy does not seem to be involved.\\nFactors that may, for unknown reasons, be \\nprotective\\n include oral contraceptives, pregnancy, and\\ntobacco, including smokeless tobacco and nicotine-containing tablets.\\nSymptoms and Signs\\nSymptoms and signs usually begin in childhood (80% of patients are < 30 yr) and decrease in frequency\\nand severity with aging. Symptoms may involve as few as one ulcer 2 to 4 times/yr or almost continuous\\ndisease, with new ulcers forming as old ones heal. A prodrome of pain or burning for 1 to 2 days\\nprecedes ulcers, but there are no antecedent vesicles or bullae. Severe pain, disproportionate to the size\\nof the lesion, can last from 4 to 7 days.\\nUlcers are well-demarcated, shallow, ovoid, or round and have a necrotic center with a yellow-gray\\npseudomembrane, a red halo, and slightly raised red margins.\\nMinor aphthae\\n (Mikulicz's disease) account for 85% of cases. They occur on the floor of \\nthe mouth,\\nlateral and ventral tongue, buccal mucosa, and pharynx; are < 8 mm (typically 2 to 3 mm); and heal in 10\\ndays without scarring.\\nMajor aphthae\\n (Sutton's disease, periadenitis mucosa necrotica recurrens) constitute 10% of cases.\\nAppearing after puberty, the prodrome is more intense and the ulcers are deeper, larger (> 1 cm), and\\nlonger lasting (weeks to months) than minor aphthae. They appear in the lips, soft palate, and throat.\\nFever, dysphagia, malaise, and scarring may occur.\\nHerpetiform ulcers\\n (morphologically resembling but unrelated to herpesvirus) account for 5% of cases.\\nThey begin as multiple (up to 100) 1- to 3-mm crops of small, painful clusters of ulcers on an\\nerythematous base. They coalesce to form larger ulcers that last 2 wk. They tend to occur in women and\\nat a later age of onset than do other forms of RAS.\\nDiagnosis\\n Clinical evaluation\\nEvaluation proceeds as described previously under stomatitis (see p. \\n509\\n). Diagnosis is based on\\nappearance and on exclusion, because there are no definitive histologic features or laboratory tests.\\nPrimary oral herpes simplex may mimic RAS but usually occurs in younger children, always involves the\\ngingiva and may affect any keratinized mucosa (hard palate, attached gingiva, dorsum of tongue), and is\\nassociated with systemic symptoms. Viral culture can be done to identify herpes simplex. Recurrent\\nherpetic lesions are usually unilateral.\\nSimilar recurrent episodes can occur with Behcet's syndrome, inflammatory bowel disease, sprue, HIV\\ninfection, and nutritional deficiencies; these conditions generally have systemic symptoms and signs.\\nIsolated recurrent oral ulcers can occur with herpes infection, HIV, and, rarely, nutritional deficiency. Viral\\ntesting and serum hematologic tests can identify these conditions.\\nDrug reactions may mimic RAS but are usually temporally related to ingestion. However, reactions to\\nfoods or dental products may be difficult to identify; sequential elimination may be necessary.\\nTreatment\\n Topical chlorhexidine and corticosteroids\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n614\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 624, 'page_label': '615'}, page_content=\"General treatments for stomatitis (see p. \\n512\\n) may help patients with RAS. Chlorhexidine gluconate\\nmouthwashes and topical corticosteroids, the mainstays of therapy, should be used during the prodrome,\\nif possible. The corticosteroid can be dexamethasone 0.5 mg/5 mL tid used as a rinse and then\\nexpectorated or clobetasol ointment 0.05% or fluocinonide ointment 0.05% in carboxymethylcellulose\\nmucosal protective paste (1:1) applied tid. Patients using these corticosteroids should be monitored for\\ncandidiasis. If topical corticosteroids are ineffective, prednisone (eg, 40 mg po once/day) may be needed\\nfor  5 days. Continuous or particularly severe RAS is best treated by a specialist in oral medicine.\\nTreatment may require prolonged use of systemic corticosteroids, azathioprine or other\\nimmunosuppressants, pentoxifylline, or thalidomide. Intralesional injections can be done with\\nbetamethasone, dexamethasone, or triamcinolone. Supplemental B\\n1\\n, B\\n2\\n, B\\n6\\n, B\\n12\\n, folate, or iron lessens\\nRAS in some patients.\\nXerostomia\\nXerostomia is dry mouth caused by reduced or absent flow of saliva. This condition can result in\\ndiscomfort, interfere with speech and swallowing, make wearing dentures difficult, cause halitosis, and\\nimpair oral hygiene by causing a decrease in oral pH and an increase in bacterial growth. Longstanding\\nxerostomia can result in severe tooth decay and oral candidiasis. Xerostomia is a common complaint\\namong older adults, affecting about 20% of the elderly.\\nPathophysiology\\nStimulation of the oral mucosa signals the salivatory nuclei in the medulla, triggering an efferent\\nresponse. The efferent nerve impulses release acetylcholine at salivary gland nerve terminals, activating\\nmuscarinic receptors (M\\n3\\n), which increase saliva production and flow. Medullary signals responsible for\\nsalivation may also be modulated by cortical inputs from other stimuli (eg, taste, smell, anxiety).\\nEtiology\\nXerostomia is usually caused by the following:\\n Drugs\\n Radiation to the head and neck (for cancer treatment)\\nSystemic disorders are less commonly the cause, but xerostomia is common in Sjogren's syndrome and\\nmay occur in HIV/AIDS, uncontrolled diabetes, and certain other disorders.\\nDrugs:\\n Drugs are the most common cause (see\\nTable 56-7\\n); about 400 prescription drugs\\n[\\nTable 56-7.\\n Some Causes of Xerostomia]\\nand many OTC drugs cause decreased salivation. The most common include the following:\\n Anticholinergics\\n Antiparkinsonians\\n Antineoplastics (chemotherapy)\\nChemotherapy drugs cause severe dryness and stomatitis while they are being taken; these problems\\nusually end after therapy is stopped.\\nOther common drug classes that cause xerostomia include antihypertensives, anxiolytics, and\\nantidepressants (less severe with SSRIs than with tricyclics).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n615\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 625, 'page_label': '616'}, page_content=\"The rise of illicit methamphetamine use has resulted in an increasing incidence of meth mouth, which is\\nsevere tooth decay caused by methamphetamine-induced xerostomia. The damage is exacerbated by the\\nbruxing and clenching caused by the drug. This combination causes very rapid destruction of teeth.\\nTobacco use usually causes a decrease of saliva.\\nRadiation:\\n Incidental radiation to the salivary glands during radiation therapy for head and neck cancer\\noften causes severe xerostomia (5200 cGy causes severe, permanent dryness, but even low doses can\\ncause temporary drying).\\nEvaluation\\nHistory: History of present illness\\n should include acuity of onset, temporal patterns (eg, constant vs\\nintermittent, presence only on awakening), provoking factors, including situational or psychogenic factors\\n(eg, whether xerostomia occurs only during periods of psychologic stress or certain activities),\\nassessment of fluid status (eg, fluid intake habits, recurrent vomiting or diarrhea), and sleeping habits.\\nUse of recreational drugs should be specifically elicited.\\nReview of systems\\n should seek symptoms of causative disorders, including dry eyes, dry skin, rashes,\\nand joint pain (Sjogren's syndrome).\\nPast medical history\\n should inquire about conditions associated with xerostomia, including Sjogren's\\nsyndrome, history of radiation treatment, head and neck trauma, and a diagnosis of or risk factors for HIV\\ninfection. Drug profiles should be reviewed for potential offending drugs (see \\nTable 56-7\\n).\\nPhysical examination:\\n Physical examination is focused on the oral cavity, specifically any apparent\\ndryness (eg, whether the mucosa is dry, sticky, or moist; whether saliva is foamy, stringy, or normal in\\nappearance), the presence of any lesions caused by \\nCandida albicans\\n, and the condition of the teeth.\\nThe presence and severity of xerostomia can be assessed at the bedside in several ways. For example, a\\ntongue blade can be held against the buccal mucosa for 10 sec. If the tongue blade falls off immediately\\nwhen released, salivary flow is normal. The more difficulty encountered removing the tongue blade, the\\nmore severe the xerostomia. In women, the lipstick sign, where lipstick adheres to the front teeth, may be\\na useful indicator of xerostomia.\\nIf there appears to be dryness, the submandibular, sublingual, and parotid glands should be palpated\\nwhile observing the ductal openings for saliva flow. The openings are at the base of the tongue anteriorly\\nfor the submandibular glands and on the middle of the inside \\nof the cheek for the parotid glands. Drying\\nthe duct openings with a gauze square before palpation aids observation. If a graduated container is\\navailable, the patient can expectorate once to empty the mouth and then expectorate all saliva into the\\ncontainer. Normal production is 0.3 to 0.4 mL/min. Significant xerostomia is 0.1 mL/min.\\nDental caries may be sought at the margins of restorations or in unusual places (eg, at the neck or tip of\\nthe tooth).\\nThe most common manifestation of \\nC. albicans\\n infection is areas of erythema and atrophy (eg, on the\\ndorsum of the tongue). Less common is the better-known white, cheesy curd that bleeds when wiped off.\\nRed flags:\\n The following findings are of particular concern:\\n Extensive tooth decay\\n Concomitant dry eyes, dry skin, rash, or joint pain\\n Risk factors for HIV\\nInterpretation of findings:\\n Xerostomia is diagnosed by symptoms, appearance, and absence of salivary\\nflow when massaging the salivary glands.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n616\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 626, 'page_label': '617'}, page_content=\"No further assessment is required when xerostomia occurs after initiation of a new drug and stops after\\ncessation of that drug or when symptoms appear within several weeks of irradiation of the head and\\nneck. Xerostomia that occurs with abrupt onset after head and neck trauma is caused by nerve damage.\\nConcomitant presence of dry eyes, dry skin, rash, or joint pain, particularly in a female patient, suggests a\\ndiagnosis of Sjogren's syndrome. Severe tooth decay, out of proportion to expected findings, may be\\nindicative of illicit drug use, particularly methamphetamines. Xerostomia that occurs only during nighttime\\nor that is noted only on awakening may be indicative of excessive mouth breathing in a dry environment.\\nTesting:\\n For those in whom the presence of xerostomia is unclear, sialometry can be conducted by\\nplacing collection devices over the major duct orifices and then stimulating salivary production with citric\\nacid or by chewing paraffin. Normal parotid flow is 0.4 to 1.5 mL/min/gland. Flow monitoring can also help\\ndetermine response to therapy.\\nThe cause of xerostomia is often apparent, but if the etiology is unclear and systemic disease is\\nconsidered possible, further assessment should be pursued with biopsy of a minor salivary gland (for\\ndetection of Sjogren's syndrome, sarcoidosis, amyloidosis, TB, or cancer) and HIV testing.\\nTreatment\\nWhen possible, the cause of xerostomia should be addressed and treated.\\nFor patients with drug-related xerostomia whose therapy cannot be changed to another drug, drug\\nschedules should be modified to achieve maximum drug effect during the day, because nighttime\\nxerostomia is more likely to cause caries. For all drugs, easy-to-take formulations, such as liquids, should\\nbe considered, and sublingual dosage forms should be avoided. The mouth and throat should be\\nlubricated with water before swallowing capsules and tablets or before using sublingual nitroglycerin.\\nPatients should avoid decongestants and antihistamines.\\nPatients using continuous positive airway pressure for obstructive sleep apnea may benefit from\\nhumidifying the source air (room humidifier for those using oral appliance therapy).\\nSymptom control:\\n Symptomatic treatment consists of measures that do the following:\\n Increase existing saliva\\n Replace lost secretions\\n Control caries\\nDrugs that augment saliva production include cevimeline and pilocarpine, both cholinergic agonists.\\nCevimeline (30 mg po tid) has less M\\n2\\n (cardiac) receptor activity than pilocarpine and a longer half-life.\\nThe main adverse effect is nausea. Pilocarpine (5 mg po tid) may be given after ophthalmologic and\\ncardiorespiratory contraindications are excluded; adverse effects include sweating, flushing, and polyuria.\\nSipping sugarless fluids frequently, chewing xylitol-containing gum, and using an OTC saliva substitute\\ncontaining carboxymethylcellulose or hydroxyethylcellulose may help. Petroleum jelly can be applied to\\nthe lips and under dentures to relieve drying, cracking, soreness, and mucosal trauma. A cold-air\\nhumidifier may aid mouth breathers who typically have their worst symptoms at night.\\nMeticulous oral hygiene is essential. Patients should brush and floss regularly and use fluoride rinses or\\ngels daily; using newer toothpastes with added Ca and phosphorous also may help avoid rampant caries.\\nAn increased frequency of preventive dental visits with plaque removal is advised. The most effective way\\nto prevent caries is to sleep with individually fitted carriers containing 1.1% Na fluoride or 0.4% stannous\\nfluoride. If 2 carriers cannot be worn at once, then each arch should be covered every other night. In\\naddition, a dentist can apply a 5% Na fluoride varnish 2 to 4 times/yr.\\nPatients should avoid sugary or acidic foods and beverages and any irritating foods that are dry, spicy,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n617\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 627, 'page_label': '618'}, page_content=\"astringent, or excessively hot or cold.\\nGeriatrics Essentials\\nAlthough dry mouth becomes more common among the elderly, this is probably due to the many drugs\\ntypically used by the elderly rather than aging itself.\\nKey Points\\n Drugs are the most common cause, but systemic diseases (most commonly Sjogren's syndrome or HIV)\\nand radiation therapy also can cause xerostomia.\\n Symptomatic treatment includes increasing existing saliva flow with stimulants or drugs, and artificial\\nsaliva replacement. Xylitol-containing gum and candy may be useful.\\n Patients with xerostomia are at high risk of tooth decay; meticulous oral hygiene and professionally\\napplied fluorides are essential.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 56. Approach to Dental & Oral Symptoms\\n618\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 628, 'page_label': '619'}, page_content='Chapter 57. Common Dental Disorders\\nIntroduction\\nCommon dental disorders include caries, gingivitis, periodontitis, and pulpitis. Dental emergencies, such\\nas toothache, fractured or avulsed teeth, and postextraction complications, are discussed in \\nCh. 58\\n.\\nCaries\\nCaries is tooth decay, commonly called cavities. The symptomstender, painful teethappear\\nlate. Diagnosis is based on inspection, probing of the enamel surface with a fine metal\\ninstrument, and dental x-rays. Treatment involves removing affected tooth structure and\\nrestoring it with various materials. Fluoride, diligent dental hygiene, sealants, and proper diet\\ncan prevent virtually all caries.\\nEtiology\\nCaries is caused by acids produced by bacteria in dental plaque. Plaque is, at first, a soft, thin film of\\nbacteria, mucin, dead epithelial cells, and food debris that develops on the tooth surface within about 24 h\\nafter the tooth is cleaned. \\nMutans streptococci\\n is a group of related bacteria that grow in plaque and can\\ncause caries. Some strains are more cariogenic than others. Eventually (commonly, after 72 h), soft\\nplaque mineralizes, mainly with Ca, phosphate, and other minerals, becoming calculus (hard plaque or\\ntartar), which cannot easily be removed with a toothbrush.\\nRisk factors:\\n There are several risk factors for caries:\\n Dental defects\\n High-acid or low-fluoride environment\\n Reduced salivary flow\\nMany teeth have open enamel pits, fissures, and grooves, which may extend from the surface to the\\ndentin. These defects may be wide enough to harbor bacteria but too narrow to clean effectively. They\\npredispose teeth to caries. Large amounts of sugar in the diet provide nutrients for plaque-forming\\nbacteria.\\nA tooth surface is more susceptible to caries when it is poorly calcified, has low fluoride exposure, or is in\\nan acidic environment. Typically, decalcification begins when the pH at the tooth falls below 5.5 (eg, when\\nlactic acid-producing bacteria colonize the area or when people drink cola beverages, which contain\\nphosphoric acid).\\nRampant caries in deciduous teeth suggests prolonged contact with infant formula, milk, or juice, typically\\nwhen an infant goes to bed with a bottle (baby or nursing bottle caries). Thus, bedtime bottles should\\ncontain only water.\\nThe elderly often take drugs that reduce salivary flow, predisposing to caries. The elderly also have a\\nhigher incidence of root caries because of gingival recession, exposure of root surfaces, and declining\\nmanual dexterity.\\nComplications:\\n Untreated caries leads to tooth destruction, infections, and the need for extractions and\\nreplacement prostheses. Premature loss of deciduous teeth may shift the adjacent teeth, hindering\\neruption of their permanent successors.\\nSymptoms and Signs\\nCaries initially involves only the enamel and causes no symptoms. A cavity that invades the dentin causes\\npain, first when hot, cold, or \\nsweet foods or beverages contact the involved tooth, and later with chewing\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n619'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 629, 'page_label': '620'}, page_content='pain, first when hot, cold, or \\nsweet foods or beverages contact the involved tooth, and later with chewing\\nor percussion. Pain can be intense and persistent when the pulp is severely involved (see \\nPulpitis\\n on p.\\n522\\n).\\nDiagnosis\\n Direct inspection\\n Sometimes use of x-rays or special testing instruments\\nRoutine, frequent (q 6 to 12 mo) clinical evaluation identifies early caries at a time when minimal\\nintervention prevents its progression. A thin probe, sometimes special dyes, and transillumination by\\nfiberoptic lights are used, frequently supplemented by new devices that detect caries by changes in\\nelectrical conductivity or laser reflectivity. However, x-rays are still important for detecting caries,\\ndetermining the depth of involvement, and identifying caries under existing restorations.\\nTreatment\\n Restorative therapy\\n Sometimes a root canal and crown\\nIncipient caries (which is confined to the enamel) should be remineralized through improved home care\\n(brushing and flossing), cleanings, prescriptions for high-fluoride toothpastes, and multiple fluoride\\napplications at the dental office.\\nThe primary treatment of caries that has entered dentin is removal by drilling, followed by filling of the\\nresultant defect. For very deep cavities, a temporary filling may be left in place 6 to 10 wk in the hope that\\na tooth will deposit reparative dentin, preventing exposure of the pulp, which necessitates root canal\\ntreatment.\\nFillings for occlusal surfaces of posterior teeth, which bear the brunt of mastication, must be composed of\\nstrong materials. The most common material has been silver amalgam, which combines silver, mercury,\\ncopper, tin, and, occasionally, zinc, palladium, or indium. Amalgam is inexpensive and lasts an average of\\n14 yr. However, if oral hygiene is good and if amalgam was placed using a rubber dam for isolation from\\nsaliva, many amalgam fillings last > 40 yr. Although concern has been raised about mercury poisoning,\\nthe number of amalgam fillings a person has bears no relationship to blood mercury levels. Replacing\\namalgam is not recommended because it is expensive, damages tooth structure, and actually increases\\npatient exposure to mercury.\\nComposite resins, which have a more acceptable appearance, have long been used in anterior teeth,\\nwhere aesthetics are primary and the forces of chewing are minimal. Some patients request them in\\nposterior teeth as well, and they are becoming common there. However, composite resins under high\\nocclusal stress generally last less than half as long as amalgam and tend to develop recurrent decay\\nbecause the composite resin shrinks when it hardens and expands and contracts with heat and cold more\\nthan the tooth or other filling materials. The current generation of composites also closely resemble\\nenamel but do not appear to have the same incidence of recurrent caries as earlier materials and may\\nalso last longer. However, although long-term results with these newer amalgam substitutes appear good,\\ndata equivalent in numbers and duration to those with amalgam are not yet available.\\nIf decay leaves too little dentin to hold a restoration, a dentist replaces the missing dentin with cement,\\namalgam, composite, or other materials. Sometimes a post must be inserted into one or more roots to\\nsupport a gold, silver, or composite core, which replaces the coronal dentin. This procedure necessitates\\na root canal filling, in which an opening is made in the tooth and the pulp is removed. The root canal\\nsystem is thoroughly debrided, shaped, and then filled with gutta-percha. The outer tooth surfaces (what\\nwould have been the enamel) are then reduced so that an artificial crown, usually made of gold,\\nporcelain, or both, can be placed. Crowns for anterior teeth consist of, or are covered with, porcelain.\\nPrevention\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n620'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 630, 'page_label': '621'}, page_content=\" Regular brushing and flossing\\n Fluoride in water, toothpaste, or both\\n Regular professional cleanings\\n Rarely chlorhexidine rinses and topical fluoride applications\\nFor most people, caries is preventable. Cavities first form on permanent teeth in the early teens to late\\n20s. Caries-prone people typically have low exposure to fluoride and a relatively cariogenic microflora\\nacquired from their mothers and through social contact. Maintaining good oral hygiene and minimizing\\nsugar intake are especially important.\\nRemoval of plaque at least q 24 h, usually by brushing and flossing, helps prevent dental caries. The\\ngingival third of the tooth is the most important area to clean but is the area most often neglected. Electric\\nand electronic toothbrushes are excellent, but a manual soft \\ntoothbrush, used for an average of 3 to 4\\nmin, suffices. Using excess toothpaste, particularly an abrasive type, may erode the teeth. Dental floss is\\nplaced between each of the teeth, curved against the side of each tooth, and moved up and down 3\\ntimes, going just beneath the gingival margin. Flosses that are very thin (dental tape) or coated with wax\\nor polytetraethylene can be used for exceptionally tight contacts between teeth or rough filling margins.\\nTeeth with fluoride incorporated into their enamel are more resistant to acidic decalcification and more\\nreadily recalcify when pH increases. If drinking water is not adequately fluoridated, fluoride supplements\\nare recommended for children from shortly after birth through age 8 yr and for pregnant women beginning\\nat 3 mo gestation (when teeth are forming in the fetus). The dose must be selected according to the\\namount of fluoride present in the drinking water and the age of the child. The total dose should not be so\\nhigh as to cause dental fluorosis (see p. \\n52\\n). Fluoridated toothpaste should also be used by people of all\\nages.\\nFluoridation offers less protection against caries in pits and fissures than against those on smooth\\nsurfaces. Pits and fissures require use of sealants (plastic materials that adhere tightly to the surface of\\nthe enamel) to prevent nutrients from reaching bacteria, reducing their growth and acid production.\\nIf these measures do not decrease cavity formation, more intensive therapy is aimed at changing the\\nflora. After cavities are treated, pits and fissures, which can harbor \\nM. streptococci\\n, are sealed. This\\ntreatment is followed by 60-sec mouth rinses using 0.12% chlorhexidine bid for 2 wk, which may reduce\\nthe cariogenic bacteria in plaque and allow repopulation with less cariogenic strains of \\nM. streptococci\\n.\\nTo encourage this repopulation, xylitol in the form of hard candy or chewing gum is used for 5 min tid.\\nAdditionally, topical fluoride may be applied by a dentist or used at night in a custom-made fluoride carrier.\\nFor pregnant women with a history of severe caries, the above regimen may be used before the child's\\nteeth erupt. If this is not feasible, the mother can use xylitol, as mentioned above, from the time of the\\nbaby's birth to the age at which the mother no longer samples the child's food (the hypothesized mode of\\ntransfer).\\nFor prevention of caries in deciduous teeth (once they have erupted) in infants, bedtime bottles should\\ncontain only water.\\nGingivitis\\nGingivitis is inflammation of the gingivae, causing bleeding with swelling, redness, exudate, a\\nchange of normal contours, and, occasionally, discomfort. Diagnosis is based on inspection.\\nTreatment involves professional teeth cleaning and intensified home dental hygiene. Advanced\\ncases may require antibiotics or surgery.\\nNormally, the gingivae are firm, tightly adapted to the teeth, and contoured to a point. Keratinized gingiva\\nnear the crowns is pink stippled tissue. This tissue should fill the entire space between the crowns. The\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n621\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 631, 'page_label': '622'}, page_content=\"gingiva farther from the crowns, called alveolar mucosa, is nonkeratinized, highly vascular, red, movable,\\nand continuous with the buccal mucosa. A tongue depressor should express no blood or pus from normal\\ngingiva.\\nInflammation, or gingivitis, the most common gingival problem, may evolve into periodontitis (see p. \\n520\\n).\\nEtiology\\nThe most common cause of gingivitis is poor oral hygiene.\\nPoor oral hygiene allows plaque to accumulate between the gingiva and the teeth; gingivitis does not\\noccur in edentulous areas. Irritation due to plaque deepens the normal crevice between the tooth and\\ngingiva, creating gingival pockets. These pockets contain bacteria that may cause both gingivitis and root\\ncaries. Other local factors, such as malocclusion, dental calculus, food impaction, faulty dental\\nrestorations, and xerostomia, play a secondary role.\\nSystemic causes:\\n Gingivitis also commonly occurs at puberty, during menstruation and pregnancy, and\\nat menopause, presumably because of hormonal changes. Similarly, oral contraceptives may exacerbate\\ninflammation.\\nGingivitis may be an early sign of a systemic disorder, particularly those that affect the response to\\ninfection (eg, diabetes, AIDS, vitamin deficiency, leukopenia), particularly if it occurs in patients with\\nminimal dental plaque. Some patients with Crohn's disease have a cobblestone area of granulomatous\\ngingival hypertrophy when intestinal flare-ups occur. Exposure to heavy metals (eg, lead, bismuth) may\\ncause gingivitis and a dark line at the gingival margin. Severe deficiency of niacin or vitamin C can cause\\ngingivitis.\\nSymptoms and Signs\\nSimple gingivitis first causes a deepening of the sulcus (gingival crevice) between the tooth \\nand the\\ngingiva, followed by a band of red, inflamed gingiva along one or more teeth, with swelling of the\\ninterdental papillae and easy bleeding. Pain is usually absent. It may resolve, remain superficial for years,\\nor occasionally progress to periodontitis.\\nPericoronitis is acute, painful inflammation of the gingival flap over a partly erupted tooth, usually around\\nmandibular 3rd molars (wisdom teeth). Infection is common, and an abscess may develop. Pericoronitis\\noften recurs as food gets trapped beneath the flap. The gingival flap disappears when the tooth is fully\\nerupted.\\nDesquamative gingivitis may occur during menopause. It is characterized by deep red, painful gingival\\ntissue that bleeds easily. Vesicles may precede desquamation. The gingivae are soft because the\\nkeratinized cells that resist abrasion by food particles are absent. A similar gingival lesion may be\\nassociated with pemphigus vulgaris, bullous pemphigoid, benign mucous membrane pemphigoid, or\\natrophic lichen planus.\\nDuring pregnancy, swelling, especially of the interdental papillae, is likely to occur. Pedunculated gingival\\ngrowths often arise in the interdental papillae during the 1st trimester, may persist throughout pregnancy,\\nand may or may not subside after delivery. Pregnancy tumors are soft reddish masses that are,\\nhistologically, pyogenic granulomas. They develop rapidly and then remain static. An underlying irritant is\\ncommon, such as calculus or a restoration with a rough margin.\\nUncontrolled diabetes can exaggerate the effects of gingival irritants, making secondary infections and\\nacute gingival abscesses common.\\nIn leukemia, the gingivae may become engorged with a leukemic infiltrate, exhibiting clinical symptoms of\\nedema, pain, and easily induced bleeding.\\nIn scurvy (vitamin C deficiency), the gingivae are inflamed, hyperplastic, and engorged, bleeding easily.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n622\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 632, 'page_label': '623'}, page_content=\"Petechiae and ecchymoses may appear throughout the mouth.\\nIn pellagra (niacin deficiency), the gingivae are inflamed, bleed easily, and are susceptible to secondary\\ninfection. Additionally, the lips are reddened and cracked, the mouth feels scalded, the tongue is smooth\\nand bright red, and the tongue and mucosa may have ulcerations.\\nDiagnosis\\n Clinical evaluation\\nFinding erythematous, friable tissue at the gum lines confirms the diagnosis. To detect early gingival\\ndisease, some dentists frequently measure the depth of the pocket around each tooth. Depths < 3 mm\\nare normal; deeper pockets are at high risk of gingivitis and periodontitis.\\nTreatment\\n Regular oral hygiene and professional cleaning\\nSimple gingivitis is controlled by proper oral hygiene with or without an antibacterial mouth rinse.\\nThorough scaling (professional cleaning with hand or ultrasonic instruments) should be done. If\\nappropriate, poorly contoured restorations are reshaped or replaced and local irritants are removed.\\nExcess gingiva, if present, can be excised. Drugs causing gingival hyperplasia should be stopped if\\npossible; if not, improved home care and more frequent professional cleanings (at least every 3 mo)\\nusually reduce the hyperplasia. Pregnancy tumors are excised.\\nTreatment of pericoronitis consists of\\n Removal of debris from under the gingival flap\\n Irrigation with saline, 1.5% hydrogen peroxide, or 0.12% chlorhexidine\\n Particularly when episodes recur, extraction\\nIf severe infection develops, antibiotics may be given for a day before extraction and continued during\\nhealing. A common regimen is amoxicillin 500 mg po q 6 h for 10 days (or until 3 days after all\\ninflammation has subsided). Abscesses associated with pericoronitis require localized incision and\\ndrainage, a periodontal flap and root debridement, or extraction.\\nIn gingivitis caused by systemic disorders, treatment is directed at the cause. In desquamative gingivitis\\nduring menopause, sequential administration of estrogens and progestins may be beneficial, but adverse\\neffects of this therapy (see p. \\n2519\\n) limit recommendations for its use. Otherwise, dentists may prescribe\\na corticosteroid rinse or a corticosteroid paste that is applied directly to the gums. Gingivitis caused by\\npemphigus vulgaris (see p. \\n658\\n) and similar mucocutaneous conditions may require systemic\\ncorticosteroid therapy.\\nPrevention\\nDaily removal of plaque with dental floss and a toothbrush and routine cleaning by a dentist or hygienist\\nat 6-mo to 1-yr intervals can help minimize gingivitis. Patients with systemic disorders predisposing to\\ngingivitis require more frequent professional cleanings (from q 2 wk to 4 times/yr).\\nAcute Necrotizing Ulcerative Gingivitis\\n(Fusospirochetosis; Trench Mouth; Vincent's Infection or Angina)\\nAcute necrotizing ulcerative gingivitis is a painful infection of the gums. Symptoms are acute\\npain, bleeding, and foul breath. Diagnosis is based on clinical findings. Treatment is gentle\\ndebridement, improved oral hygiene, mouth rinses, supportive care, and, if debridement must\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n623\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 633, 'page_label': '624'}, page_content='be delayed, antibiotics.\\nAcute necrotizing ulcerative gingivitis occurs most frequently in smokers and debilitated patients who are\\nunder stress. Other risk factors are poor oral hygiene, nutritional deficiencies, and sleep deprivation.\\nSymptoms and Signs\\nThe usually abrupt onset may be accompanied by malaise or fever. The chief manifestations are acutely\\npainful, bleeding gingivae; excessive salivation; and overwhelmingly foul breath (fetor oris). Ulcerations,\\nwhich are pathognomonic, are present on the dental papillae and marginal gingiva; these have a\\ncharacteristically punched-out appearance and are covered by a gray pseudomembrane. Similar lesions\\non the buccal mucosa and tonsils are rare. Swallowing and talking may be painful. Regional\\nlymphadenopathy often is present.\\nDiagnosis\\n Clinical evaluation\\nRarely, tonsillar or pharyngeal tissues are affected, and diphtheria or infection due to agranulocytosis\\nmust be ruled out by throat culture and CBC.\\nTreatment\\n Debridement\\n Rinses (eg, hydrogen peroxide, chlorhexidine)\\n Improved oral hygiene\\n Sometimes oral antibiotics\\nTreatment consists of gentle debridement with a hand scaler or ultrasonic device. Debridement is done\\nover several days. The patient uses a soft toothbrush to wipe the teeth. Rinses at hourly intervals with\\nwarm normal saline or twice/day with 1.5% hydrogen peroxide or 0.12% chlorhexidine may help during\\nthe first few days after initial debridement. Essential supportive measures include improved oral hygiene\\n(done gently at first), adequate nutrition, high fluid intake, rest, analgesics as needed, and avoiding\\nirritation (eg, caused by smoking or hot or spicy foods). Marked improvement usually occurs within 24 to\\n48 h, after which debridement can be completed. If debridement is delayed (eg, if a dentist or the\\ninstruments necessary for debridement are unavailable), oral antibiotics (eg, amoxicillin 500 mg,\\nerythromycin 250 mg, or tetracycline 250 mg q 6 h) provide rapid relief and can be continued until 72 h\\nafter symptoms resolve. If the gingival contour inverts (ie, if the tips of papillae are lost) during the acute\\nphase, surgery is eventually required to prevent subsequent periodontitis.\\nOther Gingival Disorders\\nHyperplasia of gingival tissues may occur without inflammation in response to various drugs, particularly\\nphenytoin, cyclosporine, and nifedipine or, less commonly, other Ca channel blockers. Hyperplasia is\\ncharacterized by diffuse, relatively avascular smooth or nodular enlargement of the gingiva, which may\\nalmost cover some teeth. The hypertrophied tissue is often excised. If possible, substitutions are made for\\nthe offending drugs. Scrupulous oral hygiene may minimize recurrence.\\nCarcinoma can also originate in the gingiva and spread to regional lymph nodes.\\nPeriodontitis\\nPeriodontitis is an infection of the periodontiumcausing inflammation of the periodontal\\nligament, gingiva, cementum, and alveolar bone. It usually manifests as a worsening of\\ngingivitis. Symptoms are rare except with HIV or when abscesses develop, in which case pain\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n624'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 634, 'page_label': '625'}, page_content=\"and swelling are common. Diagnosis is based on inspection, periodontal probing, and x-rays.\\nTreatment involves dental cleaning that extends under the gums and a vigorous home hygiene\\nprogram. Advanced cases may require antibiotics and surgery.\\nEtiology\\nPeriodontitis usually develops when gingivitis, usually with abundant plaque and calculus beneath the\\ngingival margin, has not been adequately treated. In periodontitis, the deep pockets can harbor anaerobic\\norganisms \\nthat do more damage than those usually present in simple gingivitis. The gingiva progressively\\nloses its attachment to the teeth, periodontal pockets deepen, and bone loss begins. With progressive\\nbone loss, teeth may loosen, and gingiva recedes. Tooth migration is common in later stages.\\nSystemic causes:\\n Systemic diseases that predispose patients to periodontitis include diabetes\\n(especially type 1); acquired, familial, and cyclic neutropenia; leukemia; Down syndrome; leukocyte\\nadhesion deficiency syndromes; Papillon-Lefevre syndrome; Crohn's disease; histiocytosis syndromes;\\nagranulocytosis; lazy leukocyte syndrome; hypogammaglobulinemia; Chediak-Higashi syndrome;\\nglycogen storage disease; infantile genetic agranulocytosis; Ehlers-Danlos syndrome (types IV and VIII);\\nvitamin C deficiency (scurvy); and hypophosphatasia. Faulty occlusion, causing an excessive functional\\nload on teeth, may contribute to progression of a particular type of periodontitis characterized by angular\\nbony defects.\\nPathophysiology\\nPeriodontitis is usually chronic and characterized by periods of exacerbation and remission. Chronic\\nperiodontitis (formerly adult periodontitis) occurs in localized and generalized forms, and people with\\nsignificant disease tend to be > 35 yr. About 85% of the population is affected to a mild degree, but the\\nmost advanced cases are seen in less than 5% of the population.\\nAggressive periodontitis:\\n Several more rapidly progressive subtypes of chronic periodontitis exist,\\ncollectively known as aggressive periodontitis. Aggressive periodontitis may develop as early as\\nchildhood, sometimes before age 3 yr. Patients may have severe bone loss, even tooth loss, by age 20.\\nNeutrophil function may be defective in aggressive periodontitis; its clinical significance is unknown.\\nIn one type of aggressive periodontitis that occurs in healthy adolescents (formerly called localized\\njuvenile periodontitis), patients often have significant colonization of \\nActinobacillus\\nactinomycetemcomitans\\n. Typically, the signs of inflammation are minor. The disease is detected by\\nperiodontal probing or x-rays, which show localized, deep (vertical) bone loss, commonly limited to the 1st\\nmolars and incisors. Bone loss progresses faster than in adult periodontitis, often at a rate of 3 to 4\\n\\nm/day.\\nAn uncommon type of aggressive periodontitis (formerly called prepubertal periodontitis) affects\\ndeciduous teeth, usually shortly after eruption. Generalized acute proliferative gingivitis and rapid alveolar\\nbone destruction are its hallmarks. Patients also have frequent bouts of otitis media and are usually\\ndiagnosed by age 4 yr. In some patients, the disease resolves before the permanent teeth erupt.\\nTreatment regimens are under study.\\nPrototypical aggressive periodontitis (formerly called rapidly progressive periodontitis) occurs in patients\\naged 20 to 35 yr. It is often associated with \\nA. actinomycetemcomitans\\n, \\nPorphyromonas gingivalis\\n,\\nEikenella corrodens\\n, and many gram-negative bacilli, but cause and effect are not clear. Some cases\\nresult from undiagnosed localized juvenile periodontitis or prepubertal periodontitis, but others appear\\nindependently.\\nHIV-associated periodontitis is a particularly virulent, rapidly progressing disease. Clinically, it resembles\\nacute necrotizing ulcerative gingivitis (see p. \\n520\\n) combined with rapidly progressive periodontitis.\\nPatients may lose 9 to 12 mm of attachment in as little as 6 mo.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n625\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 635, 'page_label': '626'}, page_content='Pain is usually absent unless an acute infection forms in one or more periodontal pockets or if HIV-\\nassociated periodontitis is present. Impaction of food in the pockets can cause pain at meals. Abundant\\nplaque along with redness, swelling, and exudate are characteristic. Gums may be tender and bleed\\neasily, and breath may be foul.\\nDiagnosis\\n Clinical evaluation\\n Sometimes dental x-rays\\nInspection of the teeth and gingiva combined with probing of the pockets and measurement of their depth\\nare usually sufficient for diagnosis. Pockets deeper than 4 mm indicate periodontitis. Dental x-rays reveal\\nalveolar bone loss adjacent to the periodontal pockets.\\nTreatment\\n Scaling and root planing\\n Sometimes oral antibiotics, antibiotic packs, or both\\n Surgery or extraction\\nFor all forms of periodontitis, the first phase of treatment consists of thorough scaling and root planing (ie,\\nremoval of diseased or toxin-affected cementum and dentin followed by smoothing of the root) to remove\\nplaque and \\ncalculus deposits. Thorough home oral hygiene is necessary. The patient is reevaluated after\\n3 wk. If pockets are no deeper than 4 mm at this point, the only treatment needed is regular cleanings.\\nIf deeper pockets persist, systemic antibiotics can be used. A common regimen is amoxicillin 500 mg po\\nqid for 10 days. In addition, a gel containing doxycycline or microspheres of minocycline can be placed\\ninto isolated recalcitrant pockets. These are resorbed in 2 wk.\\nAnother approach is to surgically eliminate the pocket and recontour the bone so that the patient can\\nclean the depth of the sulcus (pocket reduction/elimination surgery). In selected situations, regenerative\\nsurgery and bone grafting are done to encourage alveolar bone growth. Splinting of loose teeth and\\nselective reshaping of tooth surfaces to eliminate traumatic occlusion may be necessary. Extractions are\\noften necessary in advanced disease. Contributing systemic factors should be controlled before initiating\\nperiodontal therapy.\\nNinety percent of patients with HIV-associated periodontitis respond to irrigation of the sulcus with\\npovidone-iodine (which the dentist applies with a syringe), regular use of chlorhexidine mouth rinses, and\\nsystemic antibiotics, usually metronidazole 250 mg po tid for 14 days.\\nLocalized juvenile periodontitis requires periodontal surgery plus oral antibiotics (eg, amoxicillin 500 mg\\nqid or metronidazole 250 mg tid for 14 days).\\nPulpitis\\nPulpitis is inflammation of the dental pulp resulting from untreated caries, trauma, or multiple\\nrestorations. Its principal symptom is pain. Diagnosis is based on clinical findings and is\\nconfirmed by x-ray. Treatment involves removing decay, restoring the damaged tooth, and\\nsometimes doing root canal therapy or extracting the tooth.\\nPulpitis can occur when\\n Caries progresses deeply into the dentin\\n A tooth requires multiple invasive procedures\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n626'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 636, 'page_label': '627'}, page_content=' Trauma disrupts the lymphatic and blood supply to the pulp\\nPulpitis begins as a reversible condition in which the tooth can be saved by a simple filling. It becomes\\nirreversible as swelling inside the rigid encasement of the dentin compromises circulation, making the\\npulp necrotic, which predisposes to infection.\\nComplications:\\n Infectious sequelae of pulpitis include apical periodontitis, periapical abscess, cellulitis,\\nand osteomyelitis of the jaw. Spread from maxillary teeth may cause purulent sinusitis, meningitis, brain\\nabscess, orbital cellulitis, and cavernous sinus thrombosis. Spread from mandibular teeth may cause\\nLudwig\\'s angina, parapharyngeal abscess, mediastinitis, pericarditis, empyema, and jugular\\nthrombophlebitis.\\nSymptoms and Signs\\nIn reversible pulpitis, pain occurs when a stimulus (usually cold or sweet) is applied to the tooth. When\\nthe stimulus is removed, the pain ceases within 1 to 2 sec.\\nIn irreversible pulpitis, pain occurs spontaneously or lingers minutes after the stimulus is removed. A\\npatient may have difficulty locating the tooth from which the pain originates, even confusing the maxillary\\nand mandibular arches (but not the left and right sides of the mouth). The pain may then cease for\\nseveral days because of pulpal necrosis. As infection develops and extends through the apical foramen,\\nthe tooth becomes exquisitely sensitive to pressure and percussion. A periapical (dentoalveolar) abscess\\nelevates the tooth from its socket and feels \"high\" when the patient bites down.\\nDiagnosis\\n Clinical evaluation\\n Sometimes dental x-rays\\nDiagnosis is based on the history and physical examination, which makes use of provoking stimuli\\n(application of heat, cold, percussion). X-rays help determine whether inflammation has extended beyond\\nthe tooth apex and help exclude other conditions.\\nTreatment\\n Drilling and filling for reversible pulpitis\\n Root canal and crown or extraction for irreversible pulpitis\\n Antibiotics (eg, amoxicillin) for infection\\nIn reversible pulpitis, pulp vitality can be maintained if the tooth is treated, usually by caries removal, and\\nthen restored.\\nIrreversible pulpitis and its sequelae require endodontic (root canal) therapy or tooth extraction. In\\nendodontic therapy, an opening is made in the tooth and the pulp is removed. The root canal system is\\nthoroughly debrided, shaped, and then filled with gutta-percha. After root canal therapy, adequate healing\\nis \\nmanifested clinically by resolution of symptoms and radiographically by bone filling in the radiolucent\\narea at the root apex over a period of months. If patients have systemic signs of infection (eg, fever), an\\noral antibiotic is prescribed (amoxicillin 500 mg q 8 h; for patients allergic to penicillin, clindamycin 150 mg\\nor 300 mg q 6 h). If symptoms persist or worsen, root canal therapy is usually repeated in case a root\\ncanal was missed, but alternative diagnoses (eg, temporomandibular disorder, occult tooth fracture,\\nneurologic disorder) should be considered.\\nVery rarely, subcutaneous or mediastinal emphysema develops after compressed air or a high-speed air\\nturbine dental drill has been used during root canal therapy or extraction. These devices can force air into\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n627'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 637, 'page_label': '628'}, page_content='the tissues around the tooth socket that dissects along fascial planes. Acute onset of jaw and cervical\\nswelling with characteristic crepitus of the swollen skin on palpation is diagnostic. Treatment usually is\\nnot required, although prophylactic antibiotics are sometimes given.\\nDental Appliances\\nTeeth may be lost to dental caries, periodontal disease, or trauma or may be removed when treatment\\nfails. Missing teeth may cause cosmetic, phonation, and occlusal problems and may allow movement of\\nremaining teeth.\\nTypes:\\n Dental appliances include fixed bridges, removable partial or complete dentures, and osseo-\\nintegrated implants.\\nA \\nbridge\\n (fixed partial denture) is composed of false teeth cast or soldered to each other and, at each\\nend, to a crown that is cemented to natural (abutment) teeth, which bear all stress of biting. A bridge is\\nnot removed. A bridge is smaller than a removable partial denture, but one or multiple bridges can be\\nmade to replace many of the teeth in a dental arch.\\nA \\nremovable partial denture\\n, typically an appliance with clasps that snap over abutment teeth, may be\\nremoved for cleaning and during sleep. Part of the occlusal stress may be borne by the soft tissues under\\nthe denture, often on both sides of the jaw. This appliance commonly is used when many teeth have to be\\nreplaced and bridges or implants are not feasible or affordable.\\nComplete dentures\\n are removable appliances used when no teeth remain. They help a patient chew\\nand improve speech and appearance but do not provide the efficiency or sensation of natural dentition.\\nWhen teeth are absent, the mandible slowly resorbs, resulting in ill-fitting dentures that require revision\\n(called reline or rebase) or replacement. Alternatives are oral surgical procedures to enlarge the alveolar\\nridge or dental implants to replace missing teeth.\\nAn \\nimplant\\n is typically a titanium cylinder or screw that replaces a tooth root. One or more implants are\\nplaced into the alveolar bone, where they ankylose. After 4 to 6 mo, artificial teeth are attached to the\\nimplants. Implants are not readily removable, although the prostheses they support can be. The potential\\nfor infection at these sites warrants scrupulous attention to oral hygiene.\\nDental appliances and surgery:\\n Generally, all removable dental appliances are removed before general\\nanesthesia, throat surgery, or convulsive therapy to prevent their breakage or aspiration. They are stored\\nin water to prevent changes in shape. However, some anesthesiologists believe that leaving appliances in\\nplace aids the passage of an airway tube, keeps the face in a more normal shape so that the anesthetic\\nmask fits better, prevents natural teeth from injuring the opposing gingiva of a completely edentulous jaw,\\nand does not interfere with laryngoscopy.\\nDenture problems:\\n Occasionally, the mucosa beneath a denture becomes inflamed (denture sore\\nmouth, inflammatory papillary hyperplasia). Contributing factors to this usually painless condition include\\ncandidal infections, poor denture fit, poor hygiene, excessive movement of the denture, and, most\\nfrequently, wearing a denture 24 h/day. The mucosa appears red and velvety. Candidal overgrowth may\\nbe indicated by adherent cottonlike patches or, more commonly, erosive lesions on the mucosa. The\\npresence of \\nCandida\\n can be confirmed by the microscopic appearance of typical branching hyphae.\\nWithout \\nCandida,\\n inflammatory papillary hyperplasia is unlikely.\\nA new well-made denture almost always improves the situation. Other treatments consist of improving\\noral and denture hygiene, refitting the existing denture, removing the denture for extended periods, and\\nusing anti-fungal therapy (nystatin rinses for the mouth and overnight nystatin soaks for the denture).\\nSoaking the denture in a commercial cleanser is sometimes helpful. Other options are applying nystatin\\nsuspension to the tissue surface of the denture and clotrimazole troches 10 mg 5 times/day. Ketoconazole\\n200 mg po once/day may be required. If inflammation persists, biopsy is indicated, and systemic\\nconditions should be ruled out.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 57. Common Dental Disorders\\n628'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 638, 'page_label': '629'}, page_content='Chapter 58. Dental Emergencies\\nIntroduction\\nEmergency dental treatment by a physician is sometimes required when a dentist is unavailable.\\nOral analgesics effective for most dental problems include acetaminophen 650 to 1000 mg q 6 h and\\nNSAIDs such as ibuprofen 400 to 800 mg q 6 h. For severe pain, these drugs may be combined with\\nopioids such as codeine 60 mg; hydrocodone 5 mg, 7.5 mg, or 10 mg; or oxycodone 5 mg.\\nAntibiotics for dental infections include penicillin VK 500 mg po q 6 h and clindamycin 300 mg po q 8 h.\\nProphylactic antibiotics:\\n Current American Heart Association guidelines (2007) recommend far fewer\\npeople use prophylactic antibiotics for prevention of infective endocarditis (IEsee p. \\n2199\\n).\\nCoverage for dental procedures is recommended only for patients with prosthetic cardiac valves, previous\\nIE, specific congenital heart diseases, and for cardiac transplant recipients with heart valve problems\\n(valvulopathy). Dental procedures requiring prophylaxis are those that require manipulation or perforation\\nof gingival or oral mucosa or that involve the root end area of the teeth (ie, those most likely to cause\\nbacteremia). The preferred drug is amoxicillin 2 g po 30 to 60 min before the procedure. For those who\\ncannot tolerate penicillins, alternatives include clindamycin 600 mg or cephalexin 2 g.\\nFractured and Avulsed Teeth\\nTooth fracture:\\n Fractures are divided by depth into those that\\n Affect only the enamel\\n Expose the dentin\\n Expose the pulp\\nIf the fracture involves only the enamel, patients notice rough or sharp edges but are asymptomatic.\\nDental treatment to smooth the edges and improve appearance is elective.\\nIf dentin is exposed but not the dental pulp, patients usually exhibit sensitivity to cold air and water.\\nTreatment is a mild analgesic and referral to a dentist. Dental treatment consists of restoration of the\\ntooth by a composite (white filling) or, if the fracture is extensive, a dental crown, to cover the exposed\\ndentin.\\nIf the pulp is exposed (indicated by bleeding from the tooth) or if the tooth is mobile, dental referral is\\nurgent. Dental treatment usually involves a root canal.\\nRoot fractures and alveolar fractures are not visible, but the tooth (or several teeth) may be mobile.\\nDental referral is also urgent for stabilization by bonding an orthodontic arch wire or polyethylene line\\nonto several adjacent teeth.\\nTooth avulsion:\\n Avulsed primary teeth are not replaced because they typically become necrotic, then\\ninfected. They may also become ankylosed and do not exfoliate, thereby interfering with the eruption of\\nthe permanent tooth.\\nIf a secondary tooth is avulsed, the patient should replace it in its socket immediately and seek dental\\ncare to stabilize it. If this cannot be done, the tooth should be kept immersed in milk or wrapped in a\\nmoistened paper towel and brought to a dentist for replacement and stabilization. The tooth should not be\\nscrubbed, because scrubbing may remove viable periodontal ligament fibers, which aid in reattachment. A\\npatient with an avulsed tooth should take an antibiotic for several days. If the avulsed tooth cannot be\\nfound, it may have been aspirated, embedded in soft tissue, or swallowed. A chest x-ray may be needed\\nto rule out aspiration, but a swallowed tooth is harmless.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 58. Dental Emergencies\\n629'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 639, 'page_label': '630'}, page_content=\"A partially avulsed tooth that is repositioned and stabilized quickly usually is permanently retained. A\\ncompletely avulsed tooth may be permanently retained if replaced in the socket with minimal handling\\nwithin 30 min to 1 h. Both partial and complete avulsions usually ultimately require root canal therapy\\nbecause the pulp tissue becomes necrotic. When replacement of the tooth is delayed, the long-term\\nretention rate drops, and root resorption eventually occurs. Nevertheless, a patient may be able to use\\nthe tooth for several years.\\nMandibular Dislocation\\nSpontaneous mandibular dislocation usually occurs in people with a history of such dislocations. Although\\na dislocated mandible is occasionally caused by trauma, the initiating episode is typically a wide opening\\nfollowed by biting pressure (eg, biting into a large\\n[\\nFig. 58-1.\\n Mandibular reduction.]\\nsandwich with hard bread), a wide yawn, or a dental procedure. People prone to dislocation may have\\nnaturally loose temporomandibular joint (TMJ) ligaments.\\nPatients present with a wide-open mouth that they are unable to close. Pain is secondary to patients'\\nattempts to close the mouth. If the mandibular midline deviates to one side, the dislocation is unilateral.\\nAlthough rarely used, a local anesthetic (eg, 2% lidocaine 2 to 5 mL) injected into the ipsilateral joint and\\ninto the adjacent area of insertion of the lateral pterygoid muscle may allow the mandible to reduce\\nspontaneously.\\nManual reduction may be necessary (see \\nFig. 58-1\\n). Premedication may be used (eg, diazepam 5 to 10\\nmg IV at 5 mg/min or midazolam 3 to 5 mg IV at 2 mg/min and an opioid such as meperidine 25 mg IV or\\nfentanyl 0.5 to 1 \\n\\ng/kg IV) but is usually unnecessary, especially if time will be lost preparing the IV. The\\nlonger the mandible is dislocated, the more difficult it is to reduce and the greater the likelihood that\\ndislocation will recur.\\nBarton's bandage may be needed for 2 or 3 days. Most importantly, the patient must avoid opening the\\nmouth wide for at least 6 wk. When anticipating a yawn, the patient should place a fist under the chin to\\nprevent wide opening. Food must be cut into small pieces. If the patient suffers from chronic dislocations\\nand more conservative treatment modalities have been exhausted, an oral and maxillofacial surgeon may\\nbe consulted. As last-resort treatments, the ligaments around the TMJ can be surgically tightened\\n(shortened) in an attempt to stabilize the joint or the articular eminence can be reduced (eminectomy).\\nPostextraction Problems\\nPain and swelling:\\n Swelling is normal after oral surgery and is proportional to the degree of\\nmanipulation and trauma. If swelling does not begin to subside by the 3rd postoperative day, infection is\\nlikely and an antibiotic may be given (eg, penicillin VK 500 mg po q 6 h until 72 h after symptoms\\nsubside).\\nPostoperative pain varies from moderate to severe and is treated with analgesics (see p. \\n1623\\n).\\nAlveolitis and osteomyelitis:\\n Postextraction alveolitis (dry socket) is pain emanating from bare bone if\\nthe socket's clot lyses. Although assumed to be due to bacterial action, it is much more common among\\nsmokers and oral contraceptive users. It is peculiar to the removal of mandibular molars, usually wisdom\\nteeth. Typically, the pain begins on the 2nd or 3rd postoperative day, is referred to the ear, and lasts from\\na few days to many weeks. Alveolitis is best treated with topical analgesics: a 1- to 2-in iodoform gauze\\nstrip saturated in eugenol or coated with an anesthetic ointment, such as lidocaine 2.5% or tetracaine\\n0.5%, is placed in the socket. The gauze is changed every 1 to 3 days until symptoms do not return after\\nthe gauze is left out for a few hours. This procedure eliminates the need for systemic analgesics.\\nOsteomyelitis, which in rare cases is confused with alveolitis, is differentiated by fever, local tenderness,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 58. Dental Emergencies\\n630\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 640, 'page_label': '631'}, page_content='and swelling. If symptoms last a month, a sequestrum, which is diagnostic of osteomyelitis, should be\\nsought by x-ray. Osteomyelitis requires long-term treatment with antibiotics effective against \\nboth gram-\\npositive and gram-negative organisms and referral for definitive care.\\nOsteonecrosis of the jaw (ONJ):\\n ONJ (see also \\nSidebar 39-1\\n on p. \\n363\\n) is an oral lesion involving\\npersistent exposure of mandibular or maxillary bone, which usually manifests with pain, loosening of\\nteeth, and purulent discharge. ONJ may occur after dental extraction but also may develop after trauma or\\nradiation therapy to the head and neck. Recently, an association has been discovered between IV\\nbisphosphonate (BP) use and ONJ. However, oral BP therapy seems to pose very low risk of ONJ.\\nStopping oral BP therapy is unlikely to reduce this already low rate of ONJ, and maintaining good oral\\nhygiene is a more effective preventative measure than stopping oral BP before dental procedures.\\nManagement of ONJ is challenging and typically involves limited debridement, antibiotics, and oral rinses.\\nBleeding:\\n Postextraction bleeding usually occurs in the small vessels. Any clots extending out of the\\nsocket are removed with gauze, and a 4-in gauze pad (folded) or a tea bag is placed over the socket.\\nThen the patient is instructed to apply continuous pressure by biting for 1 h. The procedure may have to\\nbe repeated 2 or 3 times. Patients are told to wait at least 1 h before checking the site so as not to disrupt\\nclot formation. They also are informed that a few drops of blood diluted in a mouth full of saliva appear to\\nbe more blood than is actually present. If bleeding continues, the site may be anesthetized by nerve block\\nor local infiltration with 2% lidocaine containing 1:100,000 epinephrine. The socket is then curetted to\\nremove the existing clot and to freshen the bone and is irrigated with normal saline. Then the area is\\nsutured under gentle tension. Local hemostatic agents, such as oxidized cellulose, topical thrombin on a\\ngelatin sponge, or microfibrillar collagen, may be placed in the socket before suturing.\\nIf possible, patients taking low-dose anticoagulants (eg, aspirin, clopedigrol, warfarin) should stop therapy\\n3 to 4 days before surgery. Therapy can be reinstated that evening. If these measures fail, a systemic\\ncause (eg, bleeding diathesis) is sought.\\nToothache and Infection\\nPain in and around the teeth is a common problem, particularly among those with poor oral hygiene. Pain\\nmay be constant, felt after stimulation (eg, heat, cold, sweet food or drink, chewing, brushing), or both.\\nEtiology\\nThe most common causes of toothache (see\\nTable 58-1\\n) are\\n Dental caries\\n Pulpitis\\n Trauma\\n Erupting wisdom tooth (causing pericoronitis)\\nToothache is usually caused by dental caries and its consequences.\\nCaries causes pain when the lesion extends through the enamel into dentin. Pain usually occurs after\\nstimulation from cold, heat, sweet food or drink, or brushing; these stimuli cause fluid to move along\\ndentinal tubules to the pulp. As long as the discomfort does not persist after the stimulus is removed, the\\npulp is likely healthy enough to be maintained. This is referred to as normal dentinal sensitivity, reversible\\npulpalgia, or reversible pulpitis.\\nPulpitis is inflammation of the pulp, typically due to advancing caries, cumulative minor pulp damage from\\nprevious large restorations, a defective restoration, or trauma. It may be reversible or irreversible.\\nPressure necrosis frequently results from pulpitis, because the pulp is encased in a rigid compartment.\\nPain may be spontaneous or in response to stimulation. In both cases, pain lingers for a minute or longer.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 58. Dental Emergencies\\n631'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 641, 'page_label': '632'}, page_content=\"Once the pulp becomes necrotic, pain ends briefly (hours to weeks). Subsequently, periapical\\ninflammation (apical periodontitis) or an abscess develops. The tooth is exquisitely sensitive to\\npercussion (tapped with a metal dental probe or tongue blade) and chewing.\\nPeriapical abscess may follow untreated caries or pulpitis. The abscess may point intraorally and\\neventually drain or may become a cellulitis.\\nTooth trauma can damage the pulp. The damage may manifest soon after the injury or up to decades\\nlater.\\nPericoronitis is inflammation and infection of the tissue between the tooth and its overlying flap of gingiva\\n(operculum). It usually occurs in an erupting wisdom tooth (almost always a lower one).\\nComplications:\\n Rarely, sinusitis results from untreated maxillary dental infection. More commonly, pain\\nfrom a sinus infection is perceived as originating in the (unaffected) teeth, mistakenly creating the\\nimpression of a dental origin.\\nRarely, cavernous sinus thrombosis (see p. \\n624\\n) or Ludwig's angina (submandibular space infectionsee\\np. \\n470\\n) develops; these conditions are life threatening and require immediate intervention.\\n[\\nTable 58-1.\\n Some Causes of Toothache]\\nEvaluation\\nHistory: History of present illness\\n should identify the location and duration of the pain and whether it\\nis constant or present only after stimulation. Specific triggering factors to review include heat, cold, sweet\\nfood or drink, chewing, and brushing. Any preceding trauma or dental work should be noted.\\nReview of systems\\n should seek symptoms of complications, including face pain, swelling, or both\\n(dental abscess, sinusitis); pain below the tongue and difficulty swallowing (submandibular space\\ninfection); pain with bending forward (sinusitis); and retro-orbital headache, fever, and vision symptoms\\n(cavernous sinus thrombosis).\\nPast medical history\\n should note previous dental problems and treatment.\\nPhysical examination:\\n Vital signs are reviewed for fever.\\nThe examination focuses on the face and mouth. The face is inspected for swelling and is palpated for\\ninduration and tenderness.\\nThe oral examination includes inspection for gum inflammation and caries and any localized swelling at\\nthe base of a tooth that may represent a pointing apical abscess. If no tooth is clearly involved, teeth in\\nthe area of pain are percussed for tenderness with a tongue depressor. Also, an ice cube can be applied\\nbriefly to each tooth, removing it immediately once pain is felt. In healthy teeth, the pain stops almost\\nimmediately. Pain lingering more than a few seconds indicates pulp damage (eg, irreversible pulpitis,\\nnecrosis). The floor of the mouth is palpated for induration and tenderness, suggesting a deep space\\ninfection.\\nNeurologic examination, concentrating on the cranial nerves, should be done in those with fever,\\nheadache, or facial swelling.\\nRed flags:\\n Findings of particular concern are\\n Headache\\n Fever\\n Swelling or tenderness of floor of the mouth\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 58. Dental Emergencies\\n632\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 642, 'page_label': '633'}, page_content=\" Cranial nerve abnormalities\\nInterpretation of findings:\\n Red flag finding of headache suggests sinusitis, particularly if multiple upper\\nmolar and premolar (back) teeth are painful. However, presence of vision symptoms or abnormalities of\\nthe pupils or of ocular motility suggests cavernous sinus thrombosis.\\nFever is unusual with routine dental infection unless there is significant local extension. Bilateral\\ntenderness of the floor of the mouth suggests Ludwig's angina.\\n[\\nTable 58-2.\\n Characteristics of Pain in Toothache]\\nDifficulty opening the mouth (trismus) can occur with any lower molar infection but is common only with\\npericoronitis.\\nIsolated dental condition:\\n Patients without red flag findings or facial swelling likely have an isolated\\ndental condition, which, although uncomfortable, is not serious. Clinical findings, particularly the nature of\\nthe pain, help suggest a cause (see \\nTables 58-1\\n and \\n58-2\\n). Because of its innervation, the pulp can\\nperceive stimuli (eg, heat, cold, sweets) only as pain. An important distinction is whether there is\\ncontinuous pain or pain only on stimulation and, if pain is only on stimulation, whether the pain lingers\\nafter the stimulus is removed.\\nSwelling at the base of a tooth, on the cheek, or both indicates infection, either cellulitis or abscess. A\\ntender, fluctuant area at the base of a tooth suggests a pointing abscess.\\nTesting:\\n Dental x-rays are the mainstay of testing but can be deferred to a dentist.\\nThe rare cases in which cavernous sinus thrombosis or Ludwig's angina are suspected require imaging\\nstudies, typically CT or MRI.\\nTreatment\\nAnalgesics\\n (see p. \\n1623\\n) are given pending dental evaluation and definitive treatment. A patient who is\\nseen frequently for emergencies but who never receives definitive dental treatment despite availability\\nmay be seeking opioids.\\nAntibiotics\\n directed at oral flora are given for most disorders beyond irreversible pulpitis (eg, necrotic\\npulp, apical periodontitis, abscess, cellulitis). The patient with pericoronitis \\nalso should receive an\\nantibiotic. However, antibiotics can be deferred if the patient can be seen the same day by a dentist, who\\nmay be able to treat the infection by removing the source (eg, by extraction, pulpectomy, or curettage).\\nWhen antibiotics are used, penicillin is preferred, with clindamycin the alternative.\\nAn \\nabscess\\n associated with well-developed (soft) fluctuance is typically drained through an incision with\\na #15 scalpel blade at the most dependent point of the swelling. A rubber drain, held by a suture, is often\\nplaced.\\nPericoronitis\\n or erupting 3rd molars are treated with chlorhexidine 0.12% rinses or hypertonic saltwater\\nsoaks (1 tbsp salt mixed in a glass of hot waterno hotter than the coffee or tea a patient normally\\ndrinks). The salt water is held in the mouth on the affected side until it cools and then is expectorated and\\nimmediately replaced with another mouthful. Three or 4 glasses of salt water a day usually control\\ninflammation and pain pending dental evaluation.\\nTeething pain\\n in young children may be treated with weight-based doses of acetaminophen or ibuprofen.\\nTopical treatments can include chewing hard crackers (eg, biscotti), applying 7.5% or 10% benzocaine\\ngel qid (provided there is no family history of methemoglobinemia), and chewing on anything cold (eg,\\ngel-containing teething rings).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 58. Dental Emergencies\\n633\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 643, 'page_label': '634'}, page_content=\"The rare patient with cavernous sinus thrombosis or Ludwig's angina requires immediate hospitalization,\\nremoval of the infected tooth, and culture-guided parenteral antibiotics.\\nGeriatrics Essentials\\nThe elderly are more prone to caries of the root surfaces, usually because of gingival recession.\\nPeriodontitis often begins in young adulthood; if untreated, tooth pain and loss are common in old age.\\nKey Points\\n Most toothache involves dental caries or its complications (eg, pulpitis, abscess).\\n Symptomatic treatment and dental referral are usually adequate.\\n Antibiotics are given if signs of a necrotic pulp or more severe conditions are present.\\n Very rare but serious complications include extension of dental infection to the floor of the mouth or to\\nthe cavernous sinus.\\n Dental infections rarely cause sinusitis, but sinus infection may cause pain perceived as originating in\\nthe teeth.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 58. Dental Emergencies\\n634\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 644, 'page_label': '635'}, page_content='Chapter 59. Temporomandibular Disorders\\nIntroduction\\n(See also \\nMandibular Dislocation\\n on p. \\n524\\n, \\nTemporal Bone Fractures\\n on p. \\n3234\\n, and \\nJaw Tumors\\n on p.\\n489\\n.)\\nThe term temporomandibular disorders is an umbrella term for conditions causing dysfunction of the jaw\\njoint or pain in the jaw and face, often in or around the temporomandibular joint (TMJ), including\\nmasticatory and other muscles of the head and neck, the fascia, or both. A person is considered to have a\\ntemporomandibular disorder only if pain or limitation of motion is severe enough to require professional\\ncare.\\nTemporomandibular disorders typically are multifactorial, but most are related to problems with muscles or\\njoints. Internal derangements of the TMJ cause disturbed movement of the mandibular condyle in the\\nglenoid fossa or against the cartilaginous articular disk (see\\nFig. 59-1\\n). This disk, shaped like a donut with a closed hole or like a mature red blood cell, serves as a\\ncushion between joint surfaces. Causes for this disturbed movement include clenching and grinding of\\nthe teeth, trauma, arthritis, and malocclusion and missing teeth. Even the trauma of persistent gum\\nchewing can be enough to damage the joint.\\nDiagnosis\\nDisorders of the TMJ must be distinguished from the many conditions that mimic them (see\\nTable 59-1\\n). Pain exacerbated by finger pressure on the joint when the mouth is opened implicates the\\nTMJ.\\nPatients are asked to describe the pain and designate painful areas. The cervical and occipital muscles\\nand each of the major muscle groups involved in mastication are palpated for general tenderness and\\ntrigger points (spots\\n[\\nFig. 59-1.\\n The temporomandibular joint.]\\nthat radiate pain to another area). Patients are observed opening the mouth as wide as is comfortable.\\nWhen patients open and close their mouth with the junction of the maxillary and mandibular central\\nincisors (normally in the midline) lined up against a vertical straight edge, the mandibular midline typically\\ndeviates toward the painful side. Palpation and auscultation of the joint during opening and closing may\\nreveal tenderness, catching, clicking, or popping. Condylar motion can best be palpated by placing the\\n5th fingers into the external ear canals and exerting very gentle forward pressure as patients move the\\njaw. The average-sized patient can open the mouth at least 40 to 45 mm (measured between upper and\\nlower central incisors). To account for differences in patient size, a patient should be able to fit 3 fingers\\n(index, middle, ring) in the mouth on top of each other.\\nAnkylosis of the Temporomandibular Joint\\nAnkylosis of the TMJ is immobility or fusion of the joint.\\nAnkylosis of the TMJ most often results from trauma or infection, but it may be congenital or a result of\\nRA. Chronic, painless limitation of motion occurs. When ankylosis leads to arrest of condylar growth,\\nfacial asymmetry is common (see \\nCondylar Hyperplasia\\n on p. \\n532\\n). Intra-articular (true) ankylosis must be\\ndistinguished from extra-articular (false) ankylosis, which may be caused by enlargement of the coronoid\\nprocess, depressed fracture of the zygomatic arch, or scarring resulting from surgery, irradiation, or\\ninfection. In most cases of true ankylosis, x-rays of the joint show loss of normal bony architecture.\\nTreatment may include a condylectomy if the ankylosis is intra-articular or an ostectomy of part of the\\nramus if the coronoid process and zygomatic arch are also affected. Jaw-opening exercises must be done\\nfor months to years to maintain the surgical correction, but forced opening of the jaws without surgery is\\ngenerally ineffective because of bony fusion.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 59. Temporomandibular Disorders\\n635'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 645, 'page_label': '636'}, page_content='Arthritis of the Temporomandibular Joint\\nInfectious arthritis, traumatic arthritis, osteoarthritis, RA, and secondary degenerative arthritis\\ncan affect the TMJ.\\nInfectious arthritis:\\n Infection of the TMJ may result from direct extension of adjacent infection or\\nhematogenous spread of blood-borne organisms (see also \\nAcute Infectious Arthritis\\n on p. \\n365\\n). The area\\nis inflamed, and jaw movement is limited. Local signs of infection associated with evidence of a systemic\\ndisease or with an adjacent infection suggest the diagnosis. X-ray results are negative in the early stages\\nbut may show bone destruction later. If suppurative arthritis is suspected, the joint is aspirated to confirm\\nthe diagnosis and to identify the causative organism. Diagnosis must be made rapidly to prevent\\npermanent joint damage.\\n[\\nTable 59-1.\\n Some Conditions that Mimic Temporomandibular Disorders]\\nTreatment includes antibiotics, proper hydration, pain control, and motion restriction. Parenteral penicillin\\nG is the drug of choice until a specific bacteriologic diagnosis can be made on the basis of culture and\\nsensitivity testing. Suppurative infections are aspirated or incised. Once the infection is controlled, jaw-\\nopening exercises help prevent scarring and limitation of motion.\\nTraumatic arthritis:\\n Rarely, acute injury (eg, due to difficult tooth extraction or endotracheal intubation)\\nmay lead to arthritis of the TMJ. Pain, tenderness, and limitation of motion occur. Diagnosis is based\\nprimarily on history. X-ray results are negative except when intra-articular edema or hemorrhage widens\\nthe joint space. Treatment includes NSAIDs, application of heat, a soft diet, and restriction of jaw\\nmovement.\\nOsteoarthritis:\\n The TMJ may be affected, usually in people > 50 yr. Occasionally, patients complain of\\nstiffness, grating, or mild pain. Crepitus results from a hole worn through the disk, causing bone to grate\\non bone. Joint involvement is generally bilateral. X-rays or CT may show flattening and lipping of the\\ncondyle, suggestive of dysfunctional change. Treatment is symptomatic.\\nRheumatoid arthritis:\\n The TMJ is affected in > 17% of adults and children with RA, but it is usually\\namong the last joints involved. Pain, swelling, and limited movement are the most common findings. In\\nchildren, destruction of the condyle results in mandibular growth disturbance and facial deformity.\\nAnkylosis may follow. X-rays of the TMJ are usually negative in early stages but later show bone\\ndestruction, which may result in an anterior open-bite deformity. The diagnosis is suggested by TMJ\\ninflammation associated with polyarthritis and is confirmed by other findings typical of the disease.\\nTreatment is similar to that of RA in other joints. In the acute stage, NSAIDs may be given, and jaw\\nfunction should be restricted. A night guard or splint is often helpful. When symptoms subside, mild jaw\\nexercises help prevent excessive loss of motion. Surgery is necessary if ankylosis develops but should\\nnot be done until the condition is quiescent.\\nSecondary degenerative arthritis:\\n This type of arthritis usually develops in people aged 20 to 40 after\\ntrauma or in people with persistent myofascial pain syndrome (see p. \\n533\\n). It is characterized by limited\\nopening of the mouth, unilateral pain during jaw movement, joint tenderness, and crepitus. When it is\\nassociated with the myofascial pain syndrome, symptoms wax and wane. Diagnosis is based on x-rays,\\nwhich generally show condylar flattening, lipping, spurring, or erosion. Unilateral joint involvement helps\\ndistinguish secondary degenerative arthritis from osteoarthritis.\\nTreatment is conservative, as it is for myofascial pain syndrome, although arthroplasty or high\\ncondylectomy may be necessary. An occlusal splint (mouth guard) usually relieves symptoms. The splint\\nis worn constantly, except during meals, oral hygiene, and appliance \\ncleaning. When symptoms resolve,\\nthe length of time that the splint is worn each day is gradually reduced. Intra-articular injection of\\ncorticosteroids may relieve symptoms but may harm the joint if repeated often.\\nCondylar Hyperplasia\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 59. Temporomandibular Disorders\\n636'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 646, 'page_label': '637'}, page_content='Condylar hyperplasia is a disorder of unknown etiology characterized by persistent or\\naccelerated growth of the condyle when growth should be slowing or ended. Growth eventually\\nstops without treatment.\\nSlowly progressive unilateral enlargement of the head and neck of the condyle causes crossbite\\nmalocclusion, facial asymmetry, and shifting of the midpoint of the chin to the unaffected side. The patient\\nmay appear prognathic. The lower border of the mandible is often convex on the affected side.\\nChondroma and osteochondroma may cause similar symptoms and signs, but they grow more rapidly and\\nmay cause even greater asymmetric condylar enlargement.\\nDiagnosis\\n Plain x-rays\\n Usually CT\\nOn x-ray, the temporomandibular joint may appear normal, or the condyle may be proportionally enlarged\\nand the mandibular neck elongated. CT is usually done to determine whether bone growth is generalized,\\nwhich confirms the diagnosis, or localized to part of the condylar head. If growth is localized, a biopsy\\nmay be necessary to distinguish between tumor and hyperplasia.\\nTreatment\\n During active growth, usually condylectomy\\n After growth cessation, orthodontics or surgical mandibular repositioning\\nTreatment usually includes condylectomy during the period of active growth. If growth has stopped,\\northodontics and surgical mandibular repositioning are indicated. If the height of the mandibular body is\\ngreatly increased, facial symmetry can be further improved by reducing the inferior border.\\nCondylar Hypoplasia\\nCondylar hypoplasia is facial deformity caused by a short mandibular ramus.\\nThis condition usually results from trauma, infection, or irradiation occurring during the growth period but\\nmay be idiopathic. The deformity involves fullness of the face, deviation of the chin to the affected side,\\nan elongated mandible, and flatness of the face on the unaffected side. (The side to which the ramus is\\nshort causes muscles to appear fuller; the muscles on the unaffected side are stretched so that side\\nappears flatter.) Mandibular deviation causes malocclusion.\\nDiagnosis is based on a history of progressive facial asymmetry during the growth period, x-ray evidence\\nof condylar deformity and antegonial notching (a depression in the inferior border of the mandible just\\nanterior to the angle of the mandible), and, frequently, a causative history.\\nTreatment consists of surgical shortening of the unaffected side of the mandible or lengthening of the\\naffected side. Presurgical orthodontic therapy helps optimize results.\\nInternal Joint Derangement\\nThe most common form of internal joint derangement is anterior misalignment or displacement\\nof the articular disk above the condyle. Symptoms are localized joint pain and popping on jaw\\nmovement. Diagnosis is based on history and physical examination. Treatment is with\\nanalgesics, jaw rest, muscle relaxation, physical therapy, and bite splinting. If these methods\\nfail, surgery may be necessary. Early treatment greatly improves results.\\nThe superior head of the lateral pterygoid muscle may pull the articular disk out of place when abnormal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 59. Temporomandibular Disorders\\n637'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 647, 'page_label': '638'}, page_content=\"jaw mechanics place unusual stress on the joint. Abnormal jaw mechanics can be due to congenital or\\nacquired asymmetries or to the sequelae of trauma or arthritis. If the disk remains anterior, the\\nderangement is said to be without reduction. Restricted jaw opening (locked jaw) and pain in the ear and\\naround the temporomandibular joint result. If at some point in the joint's excursion the disk returns to the\\nhead of the condyle, it is said to be with reduction. Derangement with reduction occurs in about one third\\nof the population at some point. All types of derangement can cause capsulitis (or synovitis), which is\\ninflammation of the tissues surrounding the joint (eg, tendons, ligaments, connective tissue, synovium).\\nCapsulitis can also occur spontaneously or result from arthritis, trauma, or infection.\\nSymptoms and Signs\\nDerangement with reduction often causes a clicking or popping sound when the mouth is opened. Pain\\nmay be present, particularly when chewing hard foods. Patients are often embarrassed because they\\nthink others can hear noise when they chew. Indeed, although the sound seems louder to the patient,\\nothers can sometimes hear it.\\nDerangement without reduction usually causes no sound, but maximum opening between the tips of the\\nupper and lower incisors is reduced from the normal 40 to 45 mm to  30 mm. Pain and a change in the\\npatients' perception of their bite generally result.\\nCapsulitis results in localized joint pain, tenderness, and, sometimes, restricted opening.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis of derangement with reduction requires observation of the jaw when the mouth is opened.\\nWhen the jaw is opened > 10 mm (measured between upper and lower incisors), a click or pop is heard\\nor a catch is felt as the disk pops back over the head of the condyle. The condyle remains on the disk\\nduring further opening. Usually, another click is heard during closing when the condyle slips over the\\nposterior rim of the disk and the disk slips forward (reciprocal clicking).\\nDiagnosis of derangement without reduction requires that the patient open as wide as possible. The\\nopening is measured, and gentle pressure is then exerted to open the mouth a little wider. Normally, the\\njaw opens about 45 to 50 mm; if the disk is deranged, it will open about 20 mm. Closing or protruding the\\njaw against resistance worsens the pain.\\nMRI is usually done to confirm presence of derangement or to determine why a patient is not responding\\nto treatment.\\nCapsulitis is often diagnosed based on a history of injury or infection along with exquisite tenderness over\\nthe joint and by exclusion when pain remains after treatment for myofascial pain syndrome, disk\\nderangement, arthritis, and structural asymmetries. However, capsulitis may be present with any of these\\nconditions.\\nTreatment\\n Analgesics as needed\\n Sometimes repositioning splint or surgery\\n Sometimes corticosteroid injection for capsulitis\\nDerangement with reduction does not require treatment if the patient can open reasonably wide (about 40\\nmm or the width of the index, middle, and ring fingers) without discomfort. If pain occurs, mild analgesics,\\nsuch as NSAIDs (ibuprofen 400 mg po q 6 h), can be used. If onset is < 6 mo, an anterior repositioning\\nsplint may be used to position the mandible forward and on the disk. The splint is a horseshoe-shaped\\nappliance of hard, transparent acrylic (plastic) made to fit snugly over the teeth of one arch. Its chewing\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 59. Temporomandibular Disorders\\n638\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 648, 'page_label': '639'}, page_content=\"surface is designed to hold the mandible forward when the patient closes on the splint. In this position,\\nthe disk is always on the head of the condyle. The splint is gradually adjusted to allow the mandible to\\nmove posteriorly. If the disk stays with the condyle as the superior head of the external pterygoid\\nstretches, the disk is said to be captured. The longer the disk is displaced, the more deformed it becomes\\nand the less likely repositioning will succeed. Surgical plication of the disk may be done, with variable\\nsuccess.\\nDerangement without reduction may not require treatment other than analgesics. Splints may help if the\\narticular disk has not been significantly deformed, but long-term use may result in irreversible changes in\\noral architecture. In some cases, the patient is instructed to slowly stretch the disk out of position, which\\nallows the jaw to open normally. Various arthroscopic and open surgical procedures are available when\\nconservative treatment fails.\\nCapsulitis is initially treated with NSAIDs, jaw rest, and muscle relaxation. If these treatments are\\nunsuccessful, corticosteroids may be injected into the joint, or arthroscopic joint lavage and debridement\\nare used.\\nMyofascial Pain Syndrome\\nMyofascial pain syndrome can occur in patients with a normal temporomandibular joint. It is\\ncaused by tension, fatigue, or spasm in the masticatory muscles (medial or internal and lateral\\nor external pterygoids, temporalis, and masseter). Symptoms include bruxism, pain and\\ntenderness in and around the masticatory apparatus or referred to other locations in the head\\nand neck, and, often, abnormalities of jaw mobility. Diagnosis is based on history and physical\\nexamination. Conservative treatment, including analgesics, muscle relaxation, habit\\nmodification, and bite splinting, usually is effective.\\nThis syndrome is the most common disorder affecting the temporomandibular region. It is \\nmore common\\namong women and has a bimodal age distribution in the early 20s and around menopause. The muscle\\nspasm causing the disorder usually is the result of nocturnal bruxism (clenching or grinding of the teeth).\\nWhether bruxism is caused by irregular tooth contacts, emotional stress, or sleep disorders is\\ncontroversial. Bruxism usually has a multifactorial etiology. Myofascial pain syndrome is not limited to the\\nmuscles of mastication. It can occur anywhere in the body, most commonly involving muscles in the neck\\nand back.\\nSymptoms and Signs\\nSymptoms include pain and tenderness of the masticatory muscles and often pain and limitation of jaw\\nexcursion. Nocturnal bruxism may lead to headache that is more severe on awakening and that gradually\\nsubsides during the day. Such pain should be distinguished from temporal arteritis. Daytime symptoms,\\nincluding headache, may worsen if bruxism continues throughout the day.\\nThe jaw deviates when the mouth opens but usually not as suddenly or always at the same point of\\nopening as it does with internal joint derangement (see p. \\n532\\n). Exerting gentle pressure, the examiner\\ncan open the patient's mouth another 1 to 3 mm beyond unaided maximum opening.\\nDiagnosis\\n Clinical evaluation\\nA simple test may aid the diagnosis: Tongue blades of 2 or 3 thicknesses are placed between the rear\\nmolars on each side, and the patient is asked to bite down gently. The distraction produced in the joint\\nspace may ease the symptoms. X-rays usually do not help except to rule out arthritis. If temporal arteritis\\nis suspected, ESR is measured.\\nTreatment\\n Mild analgesics\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 59. Temporomandibular Disorders\\n639\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 649, 'page_label': '640'}, page_content=' Splint or mouth guard\\n An anxiolytic at bedtime considered\\n Physical therapy modalities considered\\nA plastic splint or mouth guard from the dentist can keep teeth from contacting each other and prevent the\\ndamages of bruxism. Comfortable, heat-moldable splints are available from many sporting goods stores or\\ndrugstores. Low doses of a benzodiazepine at bedtime are often effective for acute exacerbations and\\ntemporary relief of symptoms. Mild analgesics, such as NSAIDs or acetaminophen, are indicated.\\nCyclobenzaprine may help muscle relaxation in some people. Because the condition is chronic, opioids\\nshould not be used, except perhaps briefly for acute exacerbations. The patient must learn to stop\\nclenching the jaw and grinding the teeth. Hard-to-chew foods and chewing gum should be avoided.\\nPhysical therapy, biofeedback to encourage relaxation, and counseling help some patients. Physical\\nmodalities include transcutaneous electric nerve stimulation and \"spray and stretch,\" in which the jaw is\\nstretched open after the skin over the painful area has been chilled with ice or sprayed with a skin\\nrefrigerant, such as ethyl chloride. Botulinum toxin has recently been used successfully to relieve muscle\\nspasm in myofascial pain syndrome. Most patients, even if untreated, stop having significant symptoms\\nwithin 2 to 3 yr.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 59. Temporomandibular Disorders\\n640'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 650, 'page_label': '641'}, page_content=\"6 - Eye Disorders\\nChapter 60. Approach to the Ophthalmologic Patient\\nIntroduction\\nThe eye can be examined with routine equipment, including a standard ophthalmoscope; thorough\\nexamination requires special equipment and evaluation by an ophthalmologist. (See\\nFig. 60-1\\n for a cross-section of the eye.)\\nHistory\\nHistory includes location, speed of onset, and duration of current symptoms and history of previous\\nocular symptoms; the presence and nature of pain, discharge, or redness; and changes in visual acuity.\\nWorrisome symptoms besides vision loss and eye pain include flashing lights, showers of floaters (both of\\nwhich may be symptoms of retinal detachment), diplopia, and loss of peripheral vision.\\nPhysical Examination\\nVisual acuity:\\n The first step is to record visual acuity. Many patients do not give a full effort. Providing\\nadequate time and coaxing patients tend to yield more accurate results. Visual acuity is measured with\\nand without the patient's own glasses. If patients do not have their glasses, a pinhole refractor is used. If\\na commercial pinhole refractor is unavailable, one can be made at the bedside by poking holes through a\\npiece of cardboard using an 18-gauge needle and varying the diameter of each hole slightly. Patients\\nchoose the hole that corrects vision the most. If acuity corrects with pinhole refraction, the problem is a\\nrefractive error. Pinhole refraction is a rapid, efficient way to diagnose refractive errors, which are the\\nmost common cause of blurred vision. However, with pinhole refraction, best correction is usually to only\\nabout 20/30, not 20/20.\\n[\\nFig. 60-1.\\n Cross-section of the eye.]\\nVisual acuity in each eye is tested as the opposite eye is covered with a solid object (not the patient's\\nfingers, which may separate during testing). Patients look at an eye chart 20 ft (6 m) away. If this test\\ncannot be done, acuity can be measured using a chart held about 36 cm (14 in) from the eye. Normal and\\nabnormal vision is quantified by Snellen notation. A Snellen notation of 20/40 (6/12) indicates that the\\nsmallest letter that can be read by someone with normal vision at 40 ft (12 m) has to be brought to 20 ft (6\\nm) before it is recognized by the patient. Vision is recorded as the smallest letter patients read correctly,\\neven if patients feel that the letter is blurry or they have to guess. If the patient cannot read the top line of\\nthe Snellen chart at 20 ft (6 m), acuity is tested at 10 ft (3 m). If nothing can be read from a chart even at\\nthe closest distance, the examiner holds up different numbers of fingers to see whether the patient can\\naccurately count them. If not, the examiner tests whether the patient can perceive hand motion. If not, a\\nlight is shined into the eye to see whether light is perceived.\\nNear vision is checked by asking patients to read a standard near card or newsprint at 14 in (35 cm);\\npatients > 40 yr who require corrective lenses (reading glasses) should wear them during near vision\\ntesting.\\nRefractive error can be estimated roughly with a handheld ophthalmoscope by noting the lens necessary\\nfor the examiner to focus on the retina; this procedure requires examiners to use their own corrective\\nlenses and is never a substitute for a comprehensive assessment of refraction. More commonly, refractive\\nerror is measured with a standard phoropter or an automated refractor (a device that measures changes\\nin light projected and reflected by the patient's eye). These devices also measure astigmatism (see p.\\n571\\n).\\nEyelid and conjunctival examination:\\n Eyelid margins and periocular cutaneous tissues are examined\\nunder a focal light and magnification (eg, provided by loupe, slit lamp, or ophthalmoscope focused at the\\nexaminer's working distance). In cases of suspected dacryocystitis or canaliculitis, the lacrimal sacs are\\npalpated and an attempt is made to express any contents through the canaliculi and puncta. After eyelid\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n641\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 651, 'page_label': '642'}, page_content=\"eversion, the palpebral and bulbar conjunctivae and the fornices can be inspected for foreign bodies,\\nsigns of inflammation (eg, follicular hypertrophy, exudate, hyperemia, edema), or other abnormalities.\\nCorneal examination:\\n Indistinct or blurred edges of the corneal light reflex (reflection of light from the\\ncornea when illuminated) suggest the corneal surface is not intact or is roughened, as occurs with a\\ncorneal abrasion or keratitis. Fluorescein staining reveals abrasions and ulcers. Before staining, a drop of\\ntopical anesthetic (eg, proparacaine 0.5%, tetracaine 0.5%) may be added to facilitate examination if the\\npatient is in pain or if it is necessary to touch the cornea or conjunctiva (eg, to remove a foreign body or\\nmeasure intraocular pressure). A sterile, individually packaged fluorescein strip is moistened with 1 drop\\nof sterile saline or topical anesthetic and, with the patient's eye turned upward, is touched momentarily to\\nthe inside of the lower eyelid. The patient blinks several times to spread the dye into the tear film, and\\nthen the eye is examined under magnification and cobalt blue illumination. Areas where corneal or\\nconjunctival epithelium is absent (abraded or ulcerated) fluoresce green.\\nPupil examination:\\n The size and shape of the pupils are noted, and pupillary reaction to light is tested\\nin each eye, one at a time, while the patient looks in the distance. Then the swinging flashlight test is\\ndone with a penlight to compare direct and consensual pupillary response. There are 3 steps:\\n1.\\n One pupil is maximally constricted by being exposed to light from the penlight for 1 to 3 sec.\\n2.\\n The penlight is rapidly moved to the other eye for 1 to 3 sec.\\n3.\\n The light is moved back to the first eye.\\nNormally, a pupil constricts similarly when light is shone on it (direct response) and when light is shone on\\nthe other eye (consensual response). However, if one eye has less light perception than the other, as\\ncaused by dysfunction of the afferent limb (from the optic nerve to the optic chiasm) or extensive retinal\\ndisease, then the \\nconsensual\\n response in the affected eye is stronger than the \\ndirect\\n response. Thus, on\\nstep 3 of the swinging light test, when the light is shined back on the affected eye, it paradoxically\\nappears to dilate. This finding indicates a relative afferent pupillary defect (RAPD, or Marcus Gunn pupil).\\nExtraocular muscles:\\n The examiner guides the patient to look in 8 directions (up, up and right, right,\\ndown and right, down, down and left, left, left and up) with a moving finger, penlight, or transillumination\\nlight, observing for gaze deviation, limitation of movement, disconjugate gaze, or a combination consistent\\nwith cranial nerve palsy, orbital disease, or other abnormalities that restrict movement.\\nOphthalmoscopy:\\n Ophthalmoscopy can be done directly by using a handheld ophthalmoscope or\\nindirectly by using a head-mounted \\nophthalmoscope with a handheld lens. With handheld\\nophthalmoscopy, the examiner dials the ophthalmoscope to zero diopters, then increases or decreases\\nthe setting until the fundus comes into focus. The view of the retina is limited with a handheld\\nophthalmoscope, whereas indirect ophthalmoscopy gives a 3-dimensional view and is better for\\nvisualizing the peripheral retina, where retinal detachment most commonly occurs. The view of the fundus\\ncan be improved by dilating the pupils. Before dilation, the anterior chamber depth is estimated because\\nmydriasis can precipitate an attack of acute angle-closure glaucoma if the anterior chamber is shallow.\\nDepth can be estimated with a slit lamp (see below) or less accurately with a penlight held at the temporal\\nlimbus parallel to the plane of the iris and pointed toward the nose. If the medial iris is in shadow, the\\nchamber is shallow and dilation should be avoided. Other contraindications to dilation include head\\ntrauma, suspicion of a ruptured globe, a narrow angle, and angle-closure glaucoma.\\nPupils can be dilated using 1 drop of tropicamide 1%, phenylephrine 2.5%, or both (repeated in 5 to 10\\nmin if necessary); for longer action, a larger dilated pupil, or both, cyclopentolate 1% can be substituted\\nfor tropicamide.\\nOphthalmoscopy can detect lens or vitreous opacities, assess the optic cup-to-disk ratio, and identify\\nretinal and vascular changes. The optic cup is the central depression, and the optic disk is the entire area\\nof the optic nerve head. The normal ratio of the cup-to-nerve diameters is 0 to 0.4. A ratio of  0.5 may\\nsignify loss of ganglion cells and may be a sign of glaucoma. Retinal changes include hemorrhage,\\nmanifested as small or large areas of blood, and drusen (small subretinal yellow-white spots that may\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n642\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 652, 'page_label': '643'}, page_content=\"signify dry age-related macular degeneration). Vascular changes include arteriovenous nicking, a sign of\\nchronic hypertension in which retinal veins are compressed by arteries where the two cross; copper\\nwiring, a sign of arteriosclerosis in which thickened arteriolar walls increase the thickness of the light\\nreflex; silver wiring, a sign of hypertension in which thin, fibrotic arteriolar walls decrease the thickness of\\nthe light reflex; and loss of venous pulsations, a sign of increased intracranial pressure in patients known\\nto have had pulsations.\\nSlit-lamp examination:\\n A slit lamp focuses the height and width of a beam of light for a precise\\nstereoscopic view of the eyelids, conjunctiva, cornea, anterior chamber, iris, lens, and anterior vitreous. It\\nis especially useful for the following:\\n Identifying corneal foreign bodies and abrasions\\n Measuring depth of the anterior chamber\\n Detecting cells (RBCs or WBCs) and flare (evidence of protein) in the anterior chamber\\n Identifying ciliary flush (dilation of blood vessels localized to the limbal region overlying the ciliary body),\\nwhich occurs with uveitis\\n Identifying scleral edema, which is seen as a bowing forward of the slit beam when it is focused beneath\\nthe conjunctiva and which is usually a sign of scleritis\\nTonometry (see p. \\n540\\n) and gonioscopy, which quantifies the iridocorneal angle and requires the use of a\\nspecial lens, may be done.\\nVisual field testing:\\n Visual fields may be impaired by lesions anywhere in the neural visual pathways\\nfrom the optic nerves to the occipital lobes (see\\nTable 60-1\\n and\\nFig. 69-1\\n on p. \\n620\\n). Glaucoma causes loss of peripheral vision. Fields can be assessed grossly by direct\\nconfrontation testing or by more precise, detailed testing.\\nIn \\ndirect confrontation\\n, patients maintain a fixed gaze at the examiner's eye or nose. The examiner\\nbrings a small target (eg, a match or a finger) from the patients' visual periphery into each of the 4 visual\\nquadrants and asks patients to indicate when they first see the object. Wiggling the small target helps\\npatients separate and define it. Another method of direct confrontation visual field testing is to hold a\\nnumber of fingers in each quadrant and ask patients how many they see. For both methods, each eye is\\ntested separately. Abnormalities in target detection should prompt detailed testing with more precise\\ninstruments.\\nMore detailed methods include use of a tangent screen, Goldmann perimeter, or computerized automated\\nperimetry (in which the visual field is mapped out in detail based on patient response to a series of\\nflashing lights in different locations controlled by a standardized computer program). The Amsler grid is\\nused to test central vision. Distortion of the grid (metamorphopsia) or a missing area (central scotoma)\\nmay indicate disease of the macula (eg, choroidal neovascularization), as occurs in age-related macular\\ndegeneration.\\nColor vision testing:\\n Twelve to 24 Ishihara color plates, which have colored numbers or symbols hidden\\nin a field of colored dots, are commonly used to test color vision. Colorblind patients or patients with\\nacquired color deficiency (eg, in optic nerve diseases) cannot see some or all of the hidden numbers.\\nMost\\n[\\nTable 60-1.\\n Types of Field Defects]\\ncongenital color blindness is red-green; most acquired (eg, caused by glaucoma or optic nerve disease)\\nis blue-yellow.\\nTesting\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n643\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 653, 'page_label': '644'}, page_content='Tonometry:\\n Tonometry measures intraocular pressure by determining the amount of force needed to\\nindent the cornea. Handheld pen-type tonometers are used for screening. This test requires topical\\nanesthesia (eg, proparacaine 0.5%). Office-based screening with noncontact air-puff tonometry also can\\nbe used; it requires less training because it makes no direct corneal contact. Goldmann \\napplanation\\ntonometry is the most accurate method but requires more training and typically is used only by\\nophthalmologists. Measurement of intraocular pressure alone is not adequate screening for glaucoma;\\nthe optic nerve also should be examined.\\nFluorescein angiography:\\n After IV injection of fluorescein solution, the retinal, choroidal, optic disk, or\\niris vasculature is photographed in rapid sequence. Fluorescein angiography is used to investigate\\nunderperfusion and neovascularization in conditions such as diabetes, age-related macular degeneration,\\nretinal vascular occlusion, and ocular histoplasmosis. It is also useful in preoperative assessment for\\nretinal laser procedures.\\nElectroretinography:\\n Electrodes are placed on each cornea and on the surrounding skin, and electrical\\nactivity in the retina is recorded. This technique evaluates retinal function in patients with retinal\\ndegeneration. It does not evaluate vision.\\nUltrasonography:\\n B-mode ultrasonography provides 2-dimensional structural information even in the\\npresence of opacities of the cornea and lens. Examples of ophthalmologic applications include\\nassessment of retinal tumors, detachments, and vitreous hemorrhages; location of foreign bodies;\\ndetection of posterior scleral edema characteristic of posterior scleritis; and distinction of choroidal\\nmelanoma from metastatic carcinoma and subretinal hemorrhage.\\nA-mode ultrasonography is 1-dimensional ultrasonography used to determine the axial length of the eye,\\na measurement needed to calculate the power of an intraocular lens for implantation as a part of cataract\\nsurgery.\\nUltrasonic pachymetry is use of ultrasonography to measure the thickness of the cornea before refractive\\nsurgery (eg, LASIK) and in patients with corneal dystrophies.\\nCT and MRI:\\n These imaging techniques most often are used for evaluation of ocular trauma, particularly\\nif an intraocular foreign body is suspected, and in the evaluation of orbital tumors, optic neuritis, and optic\\nnerve tumors. MRI should not be done when there is suspicion of a metallic intraocular foreign body.\\nElectronystagmography:\\n See p. \\n414\\n.\\nAcute Vision Loss\\nLoss of vision is usually considered acute if it develops within a few minutes to a couple of days. It may\\naffect one or both eyes and all or part of a visual field. Patients with small visual field defects (eg, caused\\nby a small retinal detachment) may describe their symptoms as blurred vision.\\nPathophysiology\\nAcute loss of vision has 3 general causes:\\n Opacification of normally transparent structures through which light rays pass to reach the retina (eg,\\ncornea, vitreous)\\n Retinal abnormalities\\n Abnormalities affecting the optic nerve or visual pathways\\nEtiology\\nThe most common causes of acute loss of vision are\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n644'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 654, 'page_label': '645'}, page_content=\" Vascular occlusions of the retina (central retinal artery occlusion, central retinal vein occlusion)\\n Ischemic optic neuropathy (often in patients with temporal arteritis)\\n Vitreous hemorrhage (caused by diabetic retinopathy or trauma)\\n Trauma\\nIn addition, sudden recognition of loss of vision (pseudo-sudden loss of vision) may manifest initially as\\nsudden onset. For example, a patient with long-standing reduced vision in one eye (possibly caused by a\\ndense cataract) suddenly is aware of the reduced vision in the affected eye when covering the unaffected\\neye.\\nPresence or absence of pain helps categorize loss of vision (see\\nTable 60-2\\n).\\nMost disorders that cause total loss of vision when they affect the entire eye may affect only part of the\\neye and cause only a visual field defect (eg, branch occlusion of the retinal artery or retinal vein, focal\\nretinal detachment).\\nLess common causes of acute loss of vision include\\n Anterior uveitis (a common disorder, but one that usually causes eye pain severe enough to trigger\\nevaluation before vision is lost)\\n Highly aggressive retinitis\\n Certain drugs (eg, methanol, salicylates, ergot alkaloids, quinine)\\nEvaluation\\nHistory: History of present illness\\n should describe loss of vision in terms of onset, duration,\\nprogression, and location (whether it is monocular or binocular and whether it involves the entire visual\\nfield or a specific part and which part). Important associated visual symptoms include floaters, flashing\\nlights, halos around lights, distorted color vision,\\n[\\nTable 60-2.\\n Some Disorders that Cause Acute Vision Loss]\\nand jagged or mosaic patterns (scintillating scotomata). The patient should be asked about eye pain and\\nwhether it is constant or occurs only with eye movement.\\nReview of systems\\n should seek extraocular symptoms of possible causes, including jaw or tongue\\nclaudication, temporal headache, proximal muscle pain, and stiffness (giant cell arteritis); and headaches\\n(ocular migraine).\\nPast medical history\\n should seek known risk factors for eye disorders (eg, contact lens use, severe\\nmyopia, recent eye surgery or injury), risk factors for vascular disease (eg, diabetes, hypertension), and\\nhematologic disorders (eg, sickle cell anemia or disorders such as Waldenstrom's macroglobulinemia or\\nmultiple myeloma that could cause a hyperviscosity syndrome).\\nFamily history should note any family history of migraine headaches.\\nPhysical examination:\\n Vital signs, including temperature, are measured.\\nIf the diagnosis of a transient ischemic attack is under consideration, a complete neurologic examination\\nis done. The facial skin is inspected for vesicles or ulcers in the V\\n1\\n distribution (ophthalmic division of the\\ntrigeminal nerve), and the temples are palpated for pulses, tenderness, or nodularity over the course of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n645\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 655, 'page_label': '646'}, page_content=\"the temporal artery. However, most of the examination focuses on the eye.\\nEye examination includes the following:\\n Visual acuity is measured.\\n Peripheral visual fields are assessed by confrontation.\\n Central visual fields are assessed by Amsler grid.\\n Direct and consensual pupillary light reflexes are examined using the swinging flashlight test.\\n Ocular motility is assessed.\\n Color vision is tested with color plates.\\n The eyelids, sclera, and conjunctiva are examined using a slit lamp if possible.\\n The cornea is examined with fluorescein staining.\\n The anterior chamber is examined for cells and flare in patients who have eye pain or conjunctival\\ninjection.\\n The lens is checked for cataracts using a direct ophthalmoscope, slit lamp, or both.\\n Intraocular pressure is measured.\\n Ophthalmoscopy is done, preferably after dilating the pupil with a drop of a sympathomimetic (eg, 2.5%\\nphenylephrine), cycloplegic (eg, 1% cyclopentolate or 1% tropicamide), or both; dilation is nearly full\\nafter about 20 min. The entire fundus, including the retina, macula, fovea, vessels, and optic disk and\\nits margins, is examined.\\n If pupillary light responses are normal and functional loss of vision is suspected (rarely),\\n[\\nFig. 60-2.\\n Evaluation of acute vision loss.]\\n   optokinetic nystagmus is checked. If an optokinetic drum is unavailable, a mirror can be held near the\\npatient's eye and slowly moved. If the patient can see, the eyes usually track movement of the mirror.\\nRed flags:\\n Acute loss of vision is itself a red flag; most causes are serious.\\nInterpretation of findings:\\n Diagnosis can be begun systematically. \\nFig. 60-2\\n describes a simplified,\\ngeneral approach. Specific patterns of visual field deficit help suggest a cause (see \\nTable 60-1\\n). Other\\nclinical findings also help suggest a cause (see \\nTable 60-2\\n):\\n Difficulty seeing the red reflex during ophthalmoscopy suggests opacification of transparent structures\\n(eg, caused by corneal ulcer, vitreous hemorrhage, or severe endophthalmitis).\\n Retinal abnormalities that are severe enough to cause acute loss of vision are detectable \\nduring\\nophthalmoscopy, particularly if the pupils are dilated. Retinal detachment may show retinal folds; retinal\\nvein occlusion may show marked retinal hemorrhages; and retinal artery occlusion may show a pale\\nretina with cherry-red fovea.\\n An afferent pupillary defect (absence of a direct pupillary light response but a normal consensual\\nresponse) with an otherwise normal examination (except sometimes an abnormal optic disk) suggests\\nan abnormality of the optic nerve or retina (ie, anterior to the chiasm).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n646\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 656, 'page_label': '647'}, page_content='In addition, the following facts may help:\\n Monocular symptoms suggest a lesion anterior to the optic chiasm.\\n Bilateral, symmetric visual field defects suggest a lesion posterior to the chiasm.\\n Constant eye pain suggests a corneal lesion (ulcer or abrasion), anterior chamber inflammation, or\\nincreased intraocular pressure, whereas eye pain with movement suggests optic neuritis.\\n Temporal headaches suggest giant cell arteritis or migraine.\\nTesting:\\n ESR is done for all patients with symptoms (eg, temporal headaches, jaw claudication, proximal\\nmyalgias, stiffness) or signs (eg, temporal artery tenderness or induration, pale retina, papilledema)\\nsuggesting optic nerve or retinal ischemia to exclude giant cell arteritis.\\nOther testing is listed in \\nTable 60-2\\n. The following are of particular importance:\\n Ultrasonography is done to view the retina if the retina is not clearly visible with pupillary dilation and\\nindirect ophthalmoscopy done by an ophthalmologist.\\n Gadolinium-enhanced MRI is done for patients who have eye pain with movement or afferent pupillary\\ndefect, particularly with optic nerve swelling on ophthalmoscopy, to diagnose multiple sclerosis.\\nTreatment\\nCausative disorders are treated. Treatment should usually commence immediately if the cause is\\ntreatable. In many cases (eg, vascular disorders), treatment is unlikely to salvage the affected eye but can\\ndecrease the risk of the same process occurring in the contralateral eye.\\nKey Points\\n Diagnosis and treatment should occur as rapidly as possible.\\n Acute monocular loss of vision with an afferent pupillary defect indicates a lesion of the eye or of the\\noptic nerve anterior to the optic chiasm.\\n Optic nerve lesion, particularly ischemia, is considered in patients with acute monocular loss of vision or\\nafferent pupillary defect and in those with or without optic nerve abnormalities on ophthalmoscopy but\\nno other abnormalities on eye examination.\\n Corneal ulcer, acute angle-closure glaucoma, endophthalmitis, or severe anterior uveitis is considered in\\npatients with acute monocular loss of vision, afferent pupillary defect, eye pain, and conjunctival\\ninjection.\\nAnisocoria\\n(Unequal Pupils)\\nAnisocoria is unequal pupil sizes. Anisocoria itself does not cause symptoms.\\nEtiology\\nThe most common cause of anisocoria is\\n Physiologic (present in about 20% of people)\\nSee\\nTable 60-3\\n for other causes of anisocoria.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n647'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 657, 'page_label': '648'}, page_content=\"Many disorders are accompanied by anisocoria due to iris or neurologic dysfunction but usually manifest\\nwith other, more bothersome symptoms (eg, uveitis, optic neuritis, stroke, subarachnoid hemorrhage,\\nacute angle-closure glaucoma).\\nEvaluation\\nThe goal of evaluation is to elucidate the physiologic mechanism of anisocoria. By identifying certain\\nmechanisms (eg, Horner's syndrome, 3rd cranial nerve palsy), clinicians can diagnose the occasional\\nserious occult disorder (eg, tumor, aneurysm) manifesting with anisocoria.\\nHistory: History of present illness\\n includes the presence, nature, and duration of symptoms. Any\\nhistory of head or ocular trauma is noted.\\nReview of systems\\n seeks symptoms that may suggest a cause, such as birth defects or chromosomal\\nabnormalities (congenital defects); droopy eyelid, cough, chest pain, or dyspnea (Horner's syndrome);\\ngenital lesions, adenopathy, rashes, or fever (syphilis); and headaches or other neurologic symptoms\\n(Horner's syndrome or 3rd cranial nerve palsy).\\nPast medical history\\n includes known ocular disorders and surgeries and exposure to drugs.\\n[\\nTable 60-3.\\n Some Common Causes of Anisocoria]\\nPhysical examination:\\n Pupillary size and light responses should be examined in lighted and dark\\nrooms. Accommodation and extraocular movements should be tested. Ocular structures are inspected by\\nusing a slit lamp or other magnification to identify structural abnormalities and ptosis. Other ocular\\nsymptoms are evaluated by eye examination as clinically indicated. An old photograph of the patient or\\nthe patient's driver's license should be examined (under magnification if possible) to see whether\\nanisocoria was present previously.\\nTesting:\\n Testing is usually unnecessary but is indicated for clinically suspected disorders. Patients with\\nHorner's syndrome or 3rd cranial nerve palsy usually require brain MRI or CT.\\nRed flags:\\n The following findings are of particular concern:\\n Ptosis\\n Anhidrosis\\n Pupils that respond more to accommodation than light\\n Impaired extraocular movements\\nInterpretation of findings:\\n If the difference in size is greater in the dark, the smaller pupil is abnormal.\\nCommon causes include Horner's syndrome and physiologic anisocoria. An ophthalmologist can\\ndifferentiate them because the small pupil in Horner's syndrome does not dilate after instillation of an\\nocular dilating drop (eg, 10% cocaine).\\nIf the difference in pupillary sizes is greater in light, the larger pupil is abnormal. If extraocular movements\\nare impaired, particularly with ptosis, 3rd cranial nerve palsy is likely. If extraocular movements are intact,\\nan ophthalmologist can further differentiate among causes by instilling a drop of a pupillary constrictor\\n(eg, 0.1% pilocarpine). If the large pupil constricts, the cause is probably Adie's tonic pupil; if the large\\npupil does not constrict, the cause is probably drugs or structural (eg, traumatic, surgical) damage to the\\niris.\\nTreatment\\nTreatment of anisocoria is unnecessary.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n648\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 658, 'page_label': '649'}, page_content='Key Points\\n Physiologic anisocoria is very common and causes < 1 mm of difference between the pupils in size.\\n Examining the pupils in light and dark and inspecting an old photograph or the \\ndriver\\'s license of the\\npatient provide a great deal of diagnostic information.\\n Serious disorders should be considered in patients with Horner\\'s syndrome or 3rd cranial nerve palsy.\\nBlurred Vision\\nBlurred vision is the most common visual symptom. It usually refers to decreased visual acuity of gradual\\nonset. For sudden, complete loss of vision in one or both eyes (blindness), see p. \\n541\\n. Patients with small\\nvisual field defects (eg, caused by a small retinal detachment) may describe their symptoms as blurring.\\nEtiology\\nThe most common causes of blurred vision (see\\nTable 60-4\\n) include\\n Refractive errors (the most common cause overall)\\n Age-related macular degeneration\\n Cataracts\\n Diabetic retinopathy\\n Glaucoma\\nBlurred vision has 4 general mechanisms:\\n Opacification of normally transparent ocular structures (cornea, lens, vitreous) through which light rays\\nmust pass to reach the retina\\n Disorders affecting the retina\\n Disorders affecting the optic nerve or its connections\\n Refractive errors\\nCertain disorders can have more than one mechanism. For example, refraction can be impaired by early\\ncataracts or the reversible lens swelling caused by poorly controlled diabetes.\\nPatients with certain disorders that cause blurred vision (eg, acute corneal lesions [such as abrasions],\\nulcers, herpes simplex keratitis, herpes zoster ophthalmicus, acute angle-closure glaucoma) are more\\nlikely to present with other symptoms such as eye pain and red eye.\\nRare disorders that can cause blurred vision include hereditary optic neuropathies (eg, dominant optic\\natrophy, Leber\\'s hereditary optic neuropathy) and corneal scarring due to vitamin A deficiency or\\namiodarone toxicity.\\nEvaluation\\nHistory: History of present illness\\n should ascertain the onset, duration, and progression of symptoms,\\nas well as whether they are bilateral or unilateral. The symptom should be defined as precisely as\\npossible by asking an open-ended question or request (eg, \"Please describe what you mean by blurred\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n649'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 659, 'page_label': '650'}, page_content='vision\"). For example, loss of detail is not the same as loss of contrast. Also, visual field defects may not\\nbe recognized as such by patients, who may instead describe symptoms such as missing steps or the\\ninability to see words when reading. Important associated symptoms include eye redness, photophobia,\\nfloaters, sensation of lightning-like flashes of light (photopsias), and pain at rest or with eye movement.\\nThe effects of darkness (night vision), bright lights (ie, causing blur, star bursts, halos, photophobia),\\ndistance from an object, and corrective lenses and whether central or peripheral vision seems to be more\\naffected should be ascertained.\\nReview of systems\\n includes questions about symptoms of possible causes, such as increased thirst\\nand polyuria (diabetes).\\nPast medical history\\n should note previous eye injury or other diagnosed eye disorders and ask about\\ndisorders known to be risk factors for eye disorders (eg, hypertension, diabetes, HIV/AIDS, SLE, sickle\\ncell anemia, disorders that could cause hyperviscosity syndrome such as multiple myeloma or\\nWaldenstrom\\'s macroglobulinemia). Drug history should include questions about use of drugs that could\\naffect vision (eg, amiodarone, corticosteroids) and treatments for disorders affecting vision (eg, diabetic\\nretinopathy).\\nPhysical examination:\\n Nonvisual symptoms are evaluated as needed; however, examination of the\\neyes may be all that is necessary.\\nTesting \\nvisual acuity\\n is key. Many patients do not give a full effort. Providing adequate time and coaxing\\npatients tend to yield more accurate results.\\nAcuity ideally is measured while the patient stands 6 m (about 20 ft) from a Snellen chart posted on a\\nwall. If this test cannot be done, acuity can be measured using a chart held about 36 cm (14 in) from the\\neye. Measurement of near vision should be done with reading correction in place for patients > age 40.\\nEach eye is measured separately while the other eye is covered with a solid object (not the patient\\'s\\nfingers, which may separate during testing). If the patient cannot read the top line of the Snellen chart at\\n6 m, acuity is tested at 3 m. If nothing can be read from a chart even at the closest distance, the examiner\\nholds up different numbers of fingers to see whether the patient can accurately count them. If not, the\\nexaminer tests whether the patient can perceive hand motion. If not, a light is shined into the eye to see\\nwhether light is perceived.\\nVisual acuity is measured with and without the patients\\' own glasses. If acuity is corrected\\n[\\nTable 60-4.\\n Some Causes of Blurred Vision]\\nwith glasses, the problem is a refractive error. If patients do not have their glasses, a pinhole refractor is\\nused. If a commercial pinhole refractor is unavailable, one can be made at the bedside by poking holes\\nthrough a piece of cardboard using an 18-gauge needle and varying the diameter of each hole slightly.\\nPatients choose the hole that corrects vision the most. If acuity corrects with pinhole refraction, the\\nproblem is a refractive error. Pinhole refraction is a rapid, efficient way to diagnose refractive errors,\\nwhich are the most common cause of blurred vision. However, with pinhole refraction, best correction is\\nusually to only about 20/30, not 20/20.\\nEye examination\\n is also important. Direct and consensual pupillary light responses are examined using\\nthe swinging flashlight test. Visual fields are checked using confrontation and an Amsler grid.\\nThe cornea is examined for opacification, ideally using a slit lamp. The anterior chamber is examined for\\ncells and flare using a slit lamp if possible, although results of this examination are unlikely to explain\\nvisual blurring in patients without eye pain or redness.\\nThe lens is examined for opacities using an ophthalmoscope, slit lamp, or both.\\nOphthalmoscopy is done using a direct ophthalmoscope. More detail is visible if the eyes are dilated for\\nophthalmoscopy with a drop of a sympathomimetic (eg, 2.5% phenylephrine), cycloplegic (eg, 1%\\ntropicamide or 1% cyclopentolate), or both; dilation is nearly full after about 20 min. As much of the fundus\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n650'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 660, 'page_label': '651'}, page_content=\"as is visible, including the retina, macula, fovea, vessels, and optic disk and its margins, is examined. To\\nsee the entire fundus (ie, to see a peripheral retinal detachment), the examiner, usually an\\nophthalmologist, must use an indirect ophthalmoscope.\\nIntraocular pressure is measured.\\nRed flags:\\n The following findings are of particular concern:\\n Sudden change in vision\\n Eye pain (with or without eye movement)\\n Visual field defect (by history or examination)\\n Visible abnormality of the retina or optic disk\\n HIV/AIDS or other immunosuppressive disorder\\n A systemic disorder that could cause retinopathy (eg, sickle cell anemia, possible hyperviscosity\\nsyndrome, diabetes, hypertension)\\nInterpretation of findings:\\n Symptoms and signs help suggest a cause (see \\nTable 60-4\\n).\\nIf visual acuity is corrected with glasses or a pinhole refractor, simple refractive error is the cause of\\nblurring. Loss of contrast or glare may still be caused by cataract, which should be considered.\\nHowever, red flag findings suggest a more serious ophthalmologic disorder (see\\nTable 60-5\\n) and need for a complete examination, including slit-lamp examination, tonometry,\\nophthalmoscopic examination with pupillary dilation, and, depending on findings, possibly immediate or\\nurgent ophthalmologic referral.\\nSpecific retinal findings help suggest a cause (see\\nTable 60-6\\n).\\n[\\nTable 60-5.\\n Interpretation of Some Red Flag Findings]\\n[\\nTable 60-6.\\n Interpretation of Retinal Findings]\\nTesting:\\n If acuity corrects appropriately with refraction, patients are referred to an optometrist or\\nophthalmologist for routine formal refraction. If visual acuity is not corrected with refraction but there are\\nno red flag findings, patients are referred to an ophthalmologist for routine evaluation. With certain red\\nflag findings, patients are referred for immediate or urgent ophthalmologic evaluation.\\nPatients with symptoms or signs of systemic disorders should have appropriate testing:\\n Diabetes: Fingerstick or random glucose measurement\\n Poorly controlled hypertension and acute hypertensive retinopathy (hemorrhages, exudates, or\\npapilledema): Urinalysis, renal function testing, BP monitoring, and possibly ECG\\n HIV/AIDS and retinal abnormalities: HIV serology and CD4+ count\\n SLE and retinal abnormality: Antinuclear antibodies, ESR, and CBC\\n Waldenstrom's macroglobulinemia, multiple myeloma, or sickle cell anemia: CBC with differential count\\nand other testing (eg, serum protein electrophoresis) as clinically indicated\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n651\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 661, 'page_label': '652'}, page_content='Underlying disorders are treated. Corrective lenses may be used to improve visual acuity, even when the\\ndisorder causing blurring is not purely a refractive error (eg, early cataract).\\nGeriatrics Essentials\\nAlthough some decrease in visual acuity normally occurs with aging, acuity normally is correctable to\\n20/20 with refraction, even in very elderly patients.\\nKey Points\\n If visual acuity is corrected with pinhole refraction, refractive error is the problem.\\n Because glaucoma is common, intraocular pressure should be measured.\\n If pinhole refraction does not correct acuity and there is no obvious cataract or corneal abnormality,\\nophthalmoscopy should be done after pupillary dilation.\\n Many abnormalities on ophthalmoscopy, particularly if symptoms are recently worsening, require urgent\\nor immediate ophthalmologic referral.\\nDiplopia\\n(Double Vision)\\nDiplopia is the perception of 2 images of a single object. Diplopia may be monocular or binocular.\\nMonocular diplopia is present when only one eye is open. Binocular diplopia disappears when either eye\\nis closed.\\nEtiology\\nMonocular diplopia\\n can occur when something distorts light transmission through the eye to the retina.\\nThere may be > 2 images. One of the images is of normal quality (eg, brightness, contrast, clarity); the\\nrest are of inferior quality. The most common causes of monocular diplopia are\\n \\nCataract\\n Corneal shape problems, such as keratoconus or surface irregularity\\n Uncorrected refractive error, usually astigmatism\\nOther causes include corneal scarring and dislocated lens. Complaints also may represent malingering.\\nBinocular diplopia\\n suggests disconjugate alignment of the eyes. There are only 2 images, and they are\\nof equal quality. There are many possible causes of binocular diplopia (see\\nTable 60-7\\n). The most common are\\n Cranial nerve (3rd, 4th, or 6th) palsy\\n Myasthenia gravis\\n Orbital infiltration (eg, thyroid infiltrative ophthalmopathy, orbital pseudotumor)\\nMost commonly, the eyes are misaligned because of a disorder affecting the cranial nerves innervating\\nthe extraocular muscles (3rd, 4th, or 6th cranial nerves). These palsies may be isolated and idiopathic or\\nthe result of various disorders involving the cranial nerve nuclei or the infranuclear nerve or nerves. Other\\ncauses involve mechanical interference with ocular motion or a generalized disorder of neuromuscular\\ntransmission.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n652'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 662, 'page_label': '653'}, page_content=\"Evaluation\\nHistory: History of present illness\\n should determine whether diplopia involves one or both eyes,\\nwhether diplopia is intermittent or constant, and whether the images are separated vertically, horizontally,\\nor both. Any associated pain is noted, as well as whether it occurs with or without eye movement.\\nReview of systems\\n should seek symptoms of other cranial nerve dysfunction, such as vision\\nabnormalities (2nd cranial nerve); numbness of forehead and cheek (5th cranial nerve); facial weakness\\n(7th cranial nerve); dizziness, hearing loss, or gait difficulties (8th cranial nerve); and swallowing or\\nspeech difficulties (9th and 12th cranial nerves). Other neurologic symptoms, such as weakness and\\nsensory abnormalities, should be sought noting whether these are intermittent or constant. Nonneurologic\\nsymptoms of potential causes are ascertained; they include nausea, vomiting, and diarrhea (botulism);\\npalpitations, heat sensitivity, and weight loss (Graves' disease); and difficulty with bladder control (multiple\\nsclerosis).\\nPast medical history\\n should seek presence of known hypertension, diabetes, or both; atherosclerosis,\\nparticularly including cerebrovascular disease; and alcohol abuse.\\nPhysical examination:\\n Examination begins with a review of vital signs for fever and general\\nappearance for signs of toxicity (eg, prostration, confusion).\\nEye examination begins with measuring visual acuity (with correction) in each eye and both together,\\nwhich also helps determine whether diplopia is monocular or binocular. Eye examination should note\\npresence of bulging of one or both eyes, eyelid droop, pupillary abnormalities, and disconjugate eye\\nmovement and nystagmus during ocular motility testing. Ophthalmoscopy should be done, particularly\\nnoting any abnormalities of the lens (eg, cataract, displacement) and retina (eg, detachment).\\nOcular motility is tested by having the patient hold the head steady and track the examiner's finger, which\\nis moved to extreme gaze to the right, left, upward, downward, diagonally to either side, and finally inward\\ntoward the patient's nose (convergence). However, mild paresis of ocular motility sufficient to cause\\ndiplopia may escape detection by such examination.\\nIf diplopia occurs in one direction of gaze, the eye that produces each image can be determined by\\nrepeating the examination with a red glass placed over one of the patient's eyes. The image that is more\\nperipheral originates in the paretic eye; ie, if the more peripheral image is red, the red glass is covering\\nthe paretic eye. If a red glass is not available, the paretic eye can sometimes be identified by having the\\npatient close each eye. The paretic eye is the eye that when closed eliminates the more peripheral image.\\nThe other cranial nerves are tested, and the remainder of the neurologic examination, including strength,\\nsensation, reflexes, cerebellar function, and observation of gait, is completed.\\nRelevant nonneurophthalmologic components of the examination include palpation of the neck for goiter\\nand inspection of the shins for pretibial myxedema (Graves' disease).\\nRed flags:\\n The following findings are of particular concern:\\n More than one cranial nerve deficit\\n Pupillary involvement of any degree\\n Any neurologic symptoms or signs besides diplopia\\n Pain\\n Proptosis\\nInterpretation of findings:\\n Findings sometimes suggest which nerve is involved.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n653\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 663, 'page_label': '654'}, page_content=\" Nerve III: Eyelid droop, eye deviated laterally and down, sometimes pupillary dilation\\n[\\nTable 60-7.\\n Some Causes of Binocular Diplopia]\\n Nerve IV: Vertical diplopia worse on downward gaze (patient tilts head to improve vision)\\n Nerve VI: Eye deviated medially, diplopia worse on lateral gaze (patient turns head to improve vision)\\nOther findings help suggest a cause (see \\nTable 60-7\\n).\\nIntermittent diplopia suggests a waxing and waning neurologic disorder, such as myasthenia gravis or\\nmultiple sclerosis, or unmasking of a latent phoria (eye deviation). Patients with latent phoria do not have\\nany other neurologic manifestations.\\nInternuclear ophthalmoplegia (INO) results from a brain stem lesion in the medial longitudinal fasciculus\\n(MLF). INO manifests on horizontal gaze testing with diplopia, weak adduction on the affected side\\n(usually cannot adduct eye past midline), and nystagmus of the contralateral eye. However, the affected\\neye adducts normally on convergence testing (which does not require an intact MLF).\\nPain suggests a compressive lesion or inflammatory disorder.\\nTesting:\\n Patients with monocular diplopia are referred to an ophthalmologist to evaluate for ocular\\npathology; no other tests are required beforehand.\\nFor binocular diplopia, patients with a unilateral, single cranial nerve palsy, a normal pupillary light\\nresponse, and no other symptoms or signs can usually be observed without testing for a few weeks.\\nMany cases resolve spontaneously. Ophthalmologic evaluation may be done to monitor the patient and\\nhelp further delineate the deficit.\\nMost other patients require neuroimaging with MRI to detect orbital, cranial, or CNS abnormalities. CT\\nmay be substituted if there is concern about a metallic intraocular foreign body or if MRI is otherwise\\ncontraindicated or unavailable. Imaging should be done immediately if findings suggest infection,\\naneurysm, or acute (< 3 h) stroke.\\nPatients with manifestations of Graves' disease should have thyroid tests (serum thyroxine [T\\n4\\n] and\\nthyroid-stimulating hormone [TSH] levels). Testing for myasthenia gravis and multiple sclerosis should be\\nstrongly considered for those with intermittent diplopia.\\nTreatment\\nTreatment is management of the underlying disorder.\\nKey Points\\n Isolated, pupil-sparing nerve palsy in patients with no other symptoms may resolve spontaneously.\\n Imaging is required for those with red flag findings.\\n Focal weakness (in any muscle) may indicate a disorder of neuromuscular transmission.\\nEyelid Swelling\\nEyelid swelling can be unilateral or bilateral. It may be asymptomatic or accompanied by itching or pain.\\nEtiology\\nEyelid swelling has many causes (see\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n654\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 664, 'page_label': '655'}, page_content='Table 60-8\\n). It usually results from an eyelid disorder but may result from disorders in and around the orbit\\nor from systemic disorders that cause generalized edema.\\nThe most common causes are allergic, including\\n Local allergy (contact sensitivity)\\n Systemic allergy (eg, angioedema, systemic allergy accompanying allergic rhinitis)\\nFocal swelling of one eyelid is most often caused by a chalazion.\\nThe most immediately dangerous causes are orbital cellulitis and cavernous sinus thrombosis (rare).\\n[\\nTable 60-8.\\n Some Causes of Eyelid Swelling]\\nIn addition to the disorders listed in \\nTable 60-8\\n, eyelid swelling may result from the following:\\n Disorders that may involve the eyelid but do not cause swelling unless very advanced (eg, eyelid\\ntumors, including squamous cell carcinomas and melanoma)\\n Disorders (eg, dacryocystitis, canaliculitis) that cause swelling that begins and is usually most severe in\\nstructures near, but not part of, the eyelids\\n Disorders in which swelling occurs but is not the presenting symptom (eg, basilar skull fracture, burns,\\ntrauma, postsurgery)\\nEvaluation\\nHistory: History of present illness\\n should ascertain how long swelling has been present, whether it is\\nunilateral or bilateral, and whether it has been preceded by any trauma (including insect bites). Important\\naccompanying symptoms to identify include itching, pain, headache, change in vision, fever, and eye\\ndischarge.\\nReview of systems\\n should seek symptoms of possible causes, including runny nose, itching, rash, and\\nwheezing (systemic allergic reaction); headache, nasal congestion, and purulent nasal discharge\\n(sinusitis); toothache (dental infection); dyspnea, orthopnea, and paroxysmal nocturnal dyspnea (heart\\nfailure); cold intolerance and changes in skin texture (hypothyroidism); and heat intolerance, anxiety, and\\nweight loss (hyperthyroidism).\\nPast medical history\\n should include recent eye injury or surgery; known heart, liver, renal, or thyroid\\ndisease; and allergies and exposure to possible allergens. Drug history should specifically include use of\\nACE inhibitors.\\nPhysical examination:\\n Vital signs should be assessed for fever and tachycardia.\\nEye inspection should assess the location and color of swelling (erythematous or pale), including whether\\nit is present on one eyelid, both eyelids, or both eyes and whether it is tender, warm, or both. The\\nexaminer should observe whether the finding represents edema of the eyelids, protrusion of the globe\\n(proptosis), or both. Eye examination should particularly note visual acuity and range of extraocular\\nmotion (full or limited). This examination can be difficult when swelling is marked but is important because\\ndeficits suggest an orbital or retro-orbital disorder rather than an eyelid disorder; an assistant may be\\nrequired to hold the \\neyelids open. Conjunctivae are examined for injection and discharge. Any eyelid or\\neye lesions are evaluated using a slit lamp.\\nGeneral examination should assess signs of toxicity, suggesting a serious infection, and signs of a\\ncausative disorder. Facial skin is inspected for dryness and scales (which may suggest hypothyroidism)\\nand greasy scales or other signs of seborrheic dermatitis. Extremities and the presacral area are\\nexamined for edema, which suggests a systemic cause. If a systemic cause is suspected, see p. \\n2031\\n for\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n655'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 665, 'page_label': '656'}, page_content='further discussion of the evaluation.\\nRed flags:\\n The following findings are of particular concern:\\n Fever\\n Loss of visual acuity\\n Impaired extraocular movements\\n Proptosis\\nInterpretation of findings:\\n Some findings help distinguish among categories of disorders. The first\\nimportant distinction is between inflammation or infection and allergy or fluid overload. Pain, redness,\\nwarmth, and tenderness suggest inflammation or infection. Painless, pale swelling suggests angioedema.\\nItching suggests allergic reaction, and absence of itching suggests cardiac or renal dysfunction.\\nSwelling localized to one eyelid in the absence of other signs is rarely caused by a dangerous disorder.\\nMassive swelling of the eyelids of one or both eyes should raise suspicion of a serious problem. Signs of\\ninflammation, proptosis, loss of vision, and impaired extraocular movements suggest an orbital disorder\\n(eg, orbital cellulitis, cavernous sinus thrombosis) that may be pushing the globe forward or affecting the\\nnerves or muscles. Other suggestive and specific findings are listed in \\nTable 60-8\\n.\\nTesting:\\n In most cases, diagnosis can be established clinically and no testing is necessary. If orbital\\ncellulitis or cavernous sinus thrombosis is suspected, diagnosis and treatment should proceed as rapidly\\nas possible. Immediate imaging with CT or MRI should be done. If cardiac, liver, renal, or thyroid\\ndysfunction is suspected, organ function is evaluated with laboratory tests and imaging as appropriate for\\nthat system.\\nTreatment\\nTreatment is directed at the underlying disorder. There is no specific treatment for the swelling.\\nKey Points\\n Proptosis with impaired vision or extraocular movements suggests orbital cellulitis or cavernous sinus\\nthrombosis, and diagnosis and treatment should proceed as rapidly as possible.\\n Eyelid disorders should be differentiated from orbital and systemic causes of swelling.\\nEye Pain\\nEye pain may be described as sharp, aching, or throbbing and should be distinguished from superficial\\nirritation or a foreign body sensation. In some disorders, pain is worsened by bright light. Eye pain may be\\ncaused by a serious disorder and requires prompt evaluation. Many causes of eye pain also cause a red\\neye.\\nPathophysiology\\nThe cornea is richly innervated and highly sensitive to pain. Many disorders that affect the cornea or\\nanterior chamber (eg, uveitis) also cause pain via ciliary muscle spasm; when such spasm is present,\\nbright light causes muscle contraction, worsening pain.\\nEtiology\\nDisorders that cause eye pain can be divided into those that affect primarily the cornea, other ocular\\ndisorders, and disorders that cause pain referred to the eye (see\\nTable 60-9\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n656'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 666, 'page_label': '657'}, page_content=\"The most common causes overall are\\n Corneal abrasion\\n Foreign bodies\\nHowever, most corneal disorders can cause eye pain.\\nA feeling of scratchiness or of a foreign body may be caused by either a conjunctival or a corneal\\ndisorder.\\nEvaluation\\nHistory: History of present illness\\n should address the onset, quality, and severity of pain and any\\nhistory of prior episodes (eg, daily episodes in clusters). Important associated symptoms include true\\nphotophobia (shining a light into the unaffected eye causes pain in the affected eye when the affected\\neye is shut), decreased visual acuity, foreign body sensation and pain when blinking, and pain when\\nmoving the eye.\\nReview of systems\\n should seek symptoms suggesting a cause, including presence of an aura\\n(migraine); fever and chills (infection); \\nand pain when moving the head, purulent rhinorrhea, productive or\\nnocturnal cough, and halitosis (sinusitis).\\nPast medical history\\n should include known disorders that are risk factors for eye pain, including\\nautoimmune disorders, multiple sclerosis, migraine, and sinus infections. Additional risk factors to assess\\ninclude use (and overuse) of contact lenses (contact lens keratitis), exposure to excessive sunlight or to\\nwelding (UV keratitis), hammering or drilling metal (foreign body), and recent eye injury or surgery\\n(endophthalmitis).\\nPhysical examination:\\n Vital signs are checked for the presence of fever. The nose is inspected for\\npurulent rhinorrhea, and the face is palpated for tenderness. If the eye is red, the preauricular region is\\nchecked for adenopathy. Hygiene during examination must be scrupulous when examining patients who\\nhave chemosis, preauricular adenopathy, punctate corneal staining, or a combination; these findings\\nsuggest epidemic keratoconjunctivitis, which is highly contagious.\\nEye examination should be as complete as possible for patients with eye pain. Best corrected visual\\nacuity is checked. Visual fields are typically tested by confrontation in patients with eye pain, but this test\\ncan be insensitive (particularly for small defects) and unreliable because of poor patient cooperation. A\\nlight is moved from one eye to the other to check for pupillary size and direct and consensual pupillary\\nlight responses. In patients who have unilateral eye pain, a light is shined in the unaffected eye while the\\naffected eye is shut; pain in the affected eye represents true photophobia. Extraocular movements are\\nchecked. The orbital and periorbital structures are inspected. Conjunctival injection that seems most\\nintense and confluent around the cornea and limbus is called ciliary flush.\\nSlit-lamp examination is done if possible. The cornea is stained with fluorescein and examined under\\nmagnification with cobalt blue light. If a slit lamp is unavailable, the cornea can be examined after\\nfluorescein staining with a Wood's light using magnification. Ophthalmoscopy is done, and ocular\\npressures are measured (tonometry). In patients with a foreign body sensation or unexplained corneal\\nabrasions, the eyelids are everted and examined for foreign bodies.\\nRed flags:\\n The following findings are of particular concern:\\n Vomiting, halos around lights, or corneal edema\\n Signs of systemic infection (eg, fever, chills)\\n Decreased visual acuity\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n657\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 667, 'page_label': '658'}, page_content=' Proptosis\\n Impaired extraocular motility\\nInterpretation of findings:\\n Suggestive findings are listed in \\nTable 60-9\\n. Some findings suggest\\ncategories of disorders.\\nScratchiness or a foreign body sensation is most often caused by disorders of the eyelids, conjunctivae,\\nor superficial cornea. Photosensitivity is possible.\\nSurface pain with photophobia is often accompanied by a foreign body sensation and pain when blinking;\\nit suggests a corneal lesion, most often a foreign body or abrasion.\\nDeeper painoften described as aching or throbbingusually indicates a serious disorder such as\\nglaucoma, uveitis, scleritis, endophthalmitis, orbital cellulitis, or orbital pseudotumor. Within this group,\\neyelid swelling, proptosis, or both and impaired extraocular movements or visual acuity suggest orbital\\npseudotumor, orbital cellulitis, or possibly severe endophthalmitis. Fever, chills, and tenderness suggest\\ninfection (eg, orbital cellulitis, sinusitis).\\nA red eye suggests that the disorder causing pain is ocular rather than referred.\\nIf pain develops in the affected eye in response to shining light in the unaffected eye when the affected\\neye is shut (true photophobia), the cause is most often a corneal lesion or uveitis.\\nIf topical anesthetic drops (eg, proparacaine) abolish pain in a red eye, the cause is probably a corneal\\ndisorder.\\nSome findings are more suggestive of particular disorders. Pain and photophobia days after blunt eye\\ntrauma suggest uveitis. Hammering or drilling metal is a risk factor for occult metal intraocular foreign\\nbody. Pain with movement of extraocular muscles and loss of pupillary light response that is\\ndisproportionate to loss of visual acuity suggest optic neuritis.\\nTesting:\\n Testing is not usually necessary, with some exceptions (see \\nTable 60-9\\n). Gonioscopy is done if\\nglaucoma is suspected based on increased intraocular pressure. Imaging, usually with CT or MRI, is done\\nif orbital pseudotumor or orbital cellulitis is suspected or if sinusitis is suspected but the diagnosis is not\\nclinically clear. MRI is often done when optic neuritis is suspected, looking for demyelinating lesions in the\\nbrain suggesting multiple sclerosis.\\nIntraocular fluids (vitreous and aqueous humor) may be cultured for suspected endophthalmitis. Viral\\ncultures can be used to confirm herpes zoster ophthalmicus or herpes\\n[\\nTable 60-9.\\n Some Causes of Eye Pain]\\nsimplex keratitis if the diagnosis is not clear clinically.\\nTreatment\\nThe cause of pain is treated. Pain itself is also treated. Systemic analgesics are used as needed. Pain\\ncaused by uveitis and many corneal lesions is also relieved with cycloplegic eye drops (eg, homatropine\\n5% qid).\\nKey Points\\n Most diagnoses can be made by clinical evaluation.\\n Infection precautions should be maintained when examining patients with bilateral red eyes.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n658'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 668, 'page_label': '659'}, page_content=\" Important danger signs are vomiting, halos around lights, fever, decreased visual acuity, proptosis, and\\nimpaired extraocular motility.\\n Pain in the affected eye in response to shining light in the unaffected eye when the affected eye is shut\\n(true photophobia) suggests a corneal lesion or uveitis.\\n If a topical anesthetic (eg, proparacaine) relieves pain, the cause of pain is a corneal lesion.\\n \\nHammering or drilling on metal is a risk factor for occult intraocular foreign body.\\nProptosis\\n(Exophthalmos)\\nProptosis is protrusion of the eyeball. Exophthalmos means the same thing, and this term is usually used\\nwhen describing proptosis due to Grave's disease. Disorders that may cause changes in the appearance\\nof the face and eyes that resemble proptosis but are not include hyperthyroidism without infiltrative eye\\ndisease, Cushing's disease, and severe obesity.\\nEtiology\\nThe \\nmost common cause\\n is Graves' disease (see\\nTable 60-10\\n), which causes edema and lymphoid infiltration of the orbital tissues.\\nEvaluation\\nRate of onset may provide a clue to diagnosis. Sudden unilateral onset suggests intraorbital hemorrhage\\n(which can occur after surgery, retrobulbar injection, or trauma) or inflammation of the orbit or paranasal\\nsinuses. A 2- to 3-wk onset suggests chronic inflammation or orbital inflammatory pseudotumor (non-\\nneoplastic cellular infiltration and proliferation); slower onset suggests an orbital tumor.\\nOcular examination findings typical of hyperthyroidism but unrelated to infiltrative eye disease include\\neyelid retraction, eyelid lag, temporal flare of the upper eyelid, and staring. Other signs include eyelid\\nerythema and conjunctival hyperemia. Prolonged exposure of larger-than-usual areas of the eyeball to air\\ncauses corneal drying and can lead to infection and ulceration.\\nTesting:\\n Proptosis can be confirmed with exophthalmometry, which measures the distance between the\\nlateral angle of the bony orbit and the cornea; normal values are < 20 mm in whites and < 22 mm in\\nblacks. CT or MRI is often useful to confirm the diagnosis and to identify structural causes of unilateral\\nproptosis. Thyroid function testing is indicated when Graves' disease is suspected.\\n[\\nTable 60-10.\\n Some Causes of Proptosis]\\nTreatment\\nLubrication to protect the cornea is required in severe cases. When lubrication is not sufficient, surgery to\\nprovide better coverage of the eye surface or to reduce proptosis may be required. Systemic\\ncorticosteroids (eg, prednisone 1 mg/kg po once/day for 1 wk, tapered over  1 mo) are often helpful in\\ncontrolling edema and orbital congestion due to thyroid eye disease or inflammatory orbital pseudotumor.\\nOther interventions vary by etiology. Graves' exophthalmos is not affected by treatment of the thyroid\\ncondition but may lessen over time. Tumors must be surgically removed. Selective embolization or, rarely,\\ntrapping procedures may be effective in cases of arteriovenous fistulas involving the cavernous sinus.\\nFloaters\\nFloaters are opacities that move across the visual field and do not correspond to external visual objects.\\nPathophysiology\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n659\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 669, 'page_label': '660'}, page_content='With aging, the vitreous humor can contract and separate from the retina. The age at which this change\\noccurs varies but most often is between 50 and 75 yr. During this separation, the vitreous can\\nintermittently tug on the retina. The mechanical traction stimulates the retina, which sends a signal that is\\nperceived by the brain and interpreted as light. Complete separation of the vitreous leads to an increase\\nin floaters, which may last for years.\\nHowever, traction on the retina may create a hole (retinal tear), and if fluid leaks behind the tear, the\\nretina may detach. Retinal detachment may also be caused by other factors (eg, trauma, primary retinal\\ndisorders). Lightning-like flashes, common in retinal detachment, are called \\nphotopsias\\n. Photopsias can\\nalso occur when rubbing the eyes or when looking around after awakening.\\nEtiology\\nThe most common cause of vitreous floaters is\\n Contraction of the vitreous humor that occurs for unknown reasons (idiopathic)\\nLess common causes are listed in\\nTable 60-11\\n.\\nRare causes of floaters include intraocular tumors (eg, lymphoma). Intraocular foreign bodies can cause\\nfloaters but usually manifest with other symptoms, such as loss of vision, eye pain, or redness.\\nEvaluation\\nThe most important goal is to identify serious vitreous and retinal disorders. If these disorders cannot be\\nruled out, patients should be examined by an ophthalmologist using an indirect ophthalmoscope after\\npupillary dilation. Recognizing ocular migraine is also helpful.\\nHistory: History of present illness\\n should ascertain onset and duration of symptoms and the shape\\nand volume of floaters, as well as whether they are unilateral or bilateral and whether they have been\\npreceded by trauma. The patient should try to distinguish floaters from lightning-like flashes of light (as in\\nphotopsias) or jagged lines across the visual field (as in migraine). Important associated symptoms\\ninclude loss of vision (and its distribution in the visual field) and eye pain.\\nReview of systems\\n should seek symptoms of possible causes, such as headaches (ocular migraine)\\nand eye redness (vitreous inflammation).\\nPast medical history\\n should note diabetes (including diabetic retinopathy), migraine headaches, eye\\nsurgery, severe myopia, and any disorders that could affect the immune system (eg, AIDS).\\nPhysical examination:\\n Eye examination should be reasonably complete. Best corrected visual acuity is\\nmeasured. The eyes are inspected for redness. Visual fields are assessed in all patients. However,\\nrecognition of visual field defects by bedside examination is very insensitive, so inability to show such a\\ndefect is not evidence that the patient has full visual fields. Extraocular movements and pupillary light\\nresponses are assessed. If patients have a red eye or eye pain, the corneas are examined under\\nmagnification after fluorescein staining, and slit-lamp examination is done if possible. Ocular pressure is\\nmeasured (tonometry).\\nOphthalmoscopy is the most important part of the examination. It is done using a direct ophthalmoscope\\nand after dilating the pupils. To dilate the pupils, the physician first makes sure to record pupillary size\\nand light responses, then instills drops, usually 1 drop each of a short-acting \\n\\n-adrenergic agonist (eg,\\n2.5% phenylephrine) and a cycloplegic (eg, 1% tropicamide or 1% cyclopentolate). The pupils are fully\\ndilated about 20 min after these drops are instilled.\\nRed flags:\\n The following findings are of particular concern:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n660'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 670, 'page_label': '661'}, page_content='[\\nTable 60-11.\\n Some Causes of Floaters]\\n \\nSudden increase in floaters\\n Lightning-like flashes (photopsias)\\n Loss of vision, diffuse or focal (visual field defect)\\n Recent eye surgery or eye trauma\\n Eye pain\\n Loss of red reflex\\n Abnormal retinal findings\\nInterpretation of findings:\\n Retinal detachment is suggested by sudden increases in floaters,\\nphotopsias, or any of its other, more specific characteristics (eg, visual field defects, retinal\\nabnormalities). Bilateral synchronous symptoms suggest ocular migraine, although patients often have\\ndifficulty deciphering the laterality of their symptoms (eg, they often interpret scintillating scotoma of the\\nleft field of both eyes as left-eyed). Loss of red reflex suggests opacification of the vitreous (eg, vitreous\\nhemorrhage or inflammation), but it also can be caused by advanced cataracts. Loss of vision suggests a\\nserious disorder causing dysfunction of the vitreous or retina.\\nTesting:\\n Patients who require evaluation by an ophthalmologist may need testing. However, tests can be\\nselected by or in conjunction with the ophthalmologist. For example, patients suspected of having\\nchorioretinitis may require microbiologic testing.\\nTreatment\\nIdiopathic vitreous floaters require no treatment. Other disorders causing symptoms are treated.\\nKey Points\\n Floaters by themselves rarely indicate a serious disorder.\\n Patients with any abnormal findings on examination require ophthalmologic referral.\\n If floaters are accompanied by any other symptoms (eg, persistent flashing lights, visual deficit,\\nsensation of a moving curtain of vision loss), patients require ophthalmologic referral, regardless of\\nexamination findings.\\nRed Eye\\n(Pink Eye)\\nRed eye refers to a red appearance of the opened eye, reflecting dilation of the superficial ocular\\nvessels.\\nPathophysiology\\nDilation of superficial ocular vessels can result from\\n Infection\\n Allergy\\n Inflammation (noninfectious)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n661'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 671, 'page_label': '662'}, page_content=' Elevated intraocular pressure\\nSeveral ocular components may be involved, most commonly the conjunctiva, but also the uveal tract,\\nepisclera, and sclera.\\nEtiology\\nThe most common causes of red eye include\\n Infectious conjunctivitis\\n Allergic conjunctivitis\\nCorneal abrasions and foreign bodies are common causes (see\\nTable 60-12\\n). Although the eye is red, patients usually present with a complaint of injury, eye pain, or\\nboth. However, in young children and infants, this information may be unavailable.\\nEvaluation\\nMost disorders can be diagnosed by a general health care practitioner.\\nHistory: History of present illness\\n should note the onset and duration of redness and presence of any\\nchange in vision, itching, scratchy sensation, pain, or discharge. Nature and severity of pain, including\\nwhether pain is worsened by light (photophobia), are noted. The clinician should determine whether\\ndischarge is watery or purulent. Other questions assess history of injury, including exposure to irritants\\nand use of contact lenses (eg, possible overuse, such as wearing them while sleeping). Prior episodes of\\neye pain or redness and their time patterns are elicited.\\nReview of systems\\n should seek symptoms suggesting possible causes, including headache, nausea,\\nvomiting, and halos around lights (acute angle-closure glaucoma); runny nose and sneezing (allergies,\\nURI); and cough, sore throat, and malaise (URI).\\nPast medical history\\n includes questions about known allergies and autoimmune disorders. Drug history\\nshould specifically ask about recent use of topical ophthalmic drugs (including OTC drugs), which might\\nbe sensitizing.\\nPhysical examination:\\n General examination should include head and neck examination for signs of\\nassociated disorders (eg, URI, allergic rhinitis, zoster rash).\\nEye examination involves a formal measure of visual acuity and usually requires a penlight, fluorescein\\nstain, and slit lamp.\\nBest corrected visual acuity is measured. Pupillary size and reactivity to light are assessed. True\\nphotophobia (sometimes called\\n[\\nTable 60-12.\\n Some Causes of Red Eye]\\nconsensual photophobia) is present if shining light into an unaffected eye causes pain in the affected eye\\nwhen the affected eye is shut. Extraocular movements are assessed, and the eye and periorbital tissues\\nare inspected for lesions and swelling. The tarsal surface is inspected for follicles. The corneas are\\nstained with fluorescein and examined with magnification. If a corneal abrasion is found, the eyelid is\\neverted and examined for hidden foreign bodies. Inspection of the ocular structures and cornea is best\\ndone using a slit lamp. A slit lamp is also used to examine the anterior chamber for cells, flare, and pus\\n(hypopyon). Ocular pressure is measured using tonometry, although it may be permissible to omit this test\\nif there are no symptoms or signs suggesting a disorder other than conjunctivitis.\\nRed flags:\\n The following findings are of particular concern:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n662'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 672, 'page_label': '663'}, page_content=' Sudden, severe pain and vomiting\\n Zoster skin rash\\n Decreased visual acuity\\n Corneal crater\\n Branching, dendritic corneal lesion\\n Ocular pressure > 40 mm Hg\\n Failure to blanch with phenylephrine eye drop\\nInterpretation of findings: Conjunctival disorders\\n and \\nepiscleritis\\n are differentiated from other\\ncauses of red eye by the absence of pain, photophobia, and corneal staining. Among these disorders,\\nepiscleritis is differentiated by its focality, and subconjunctival hemorrhage is usually differentiated by the\\nabsence of lacrimation, itching, and photosensitivity. Clinical criteria do not accurately differentiate viral\\nfrom bacterial conjunctivitis.\\nCorneal disorders\\n are differentiated from other causes of red eye (and usually from each other) by\\nfluorescein staining. These disorders also tend to be characterized by pain and photophobia. If instillation\\nof an ocular anesthetic drop (eg, proparacaine 0.5%), which is done before tonometry and ideally before\\nfluorescein instillation, completely \\nrelieves pain, the cause is probably limited to the cornea. If pain is\\npresent and is not relieved by an ocular anesthetic, the cause may be anterior uveitis, glaucoma, or\\nscleritis. Because patients may have anterior uveitis secondary to corneal lesions, persistence of pain\\nafter instillation of the anesthetic does not exclude a corneal lesion.\\nAnterior uveitis, glaucoma, acute angle-closure glaucoma\\n, and \\nscleritis\\n can usually be\\ndifferentiated from other causes of red eye by the presence of pain and the absence of corneal staining.\\nAnterior uveitis is likely in patients with pain, true photophobia, absence of corneal fluorescein staining,\\nand normal intraocular pressure; it is definitively diagnosed based on the presence of cells and flare in\\nthe anterior chamber. However, these findings may be difficult for general health care practitioners to\\ndiscern. Acute angle-closure glaucoma can usually be recognized by the sudden onset of its severe and\\ncharacteristic symptoms, but tonometry is definitive.\\nInstillation of phenylephrine 2.5% causes blanching in a red eye unless the cause is scleritis.\\nPhenylephrine is instilled to dilate the pupil in patients needing a thorough retinal examination. However, it\\nshould not be used in patients who have the following:\\n Suspected acute angle-closure glaucoma\\n A history of angle-closure glaucoma\\n A narrow anterior chamber\\nTesting:\\n Testing is usually unnecessary. Viral cultures may help if herpes simplex or herpes zoster is\\nsuspected and the diagnosis is not clear clinically. Corneal ulcers are cultured by an ophthalmologist.\\nGonioscopy is done in patients with glaucoma. Testing for autoimmune disorders may be worthwhile in\\npatients with uveitis and no obvious cause (eg, trauma). Patients with scleritis undergo further testing as\\ndirected by an ophthalmologist.\\nTreatment\\nThe cause is treated. Red eye itself does not require treatment. Topical vasoconstrictors are not\\nrecommended.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n663'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 673, 'page_label': '664'}, page_content='Key Points\\n Most cases are caused by conjunctivitis.\\n Pain and true photophobia suggest other, more serious diagnoses.\\n In patients with pain, slit-lamp examination with fluorescein staining and tonometry are key.\\n Persistence of pain despite an ocular anesthetic in a patient with a normal fluorescein examination\\nsuggests anterior uveitis, scleritis, or acute angle-closure glaucoma. These diagnoses should not be\\nmissed.\\nTearing\\n(Epiphora)\\nExcess tearing may cause a sensation of watery eyes or result in tears falling down the cheek (epiphora).\\nPathophysiology\\nTears are produced in the lacrimal gland and drain through the upper and lower puncta into the canaliculi\\nand then into the lacrimal sac and nasolacrimal duct (see\\nFig. 60-3\\n). Obstruction of tear drainage can lead to stasis and infection. Recurrent infection of the\\nlacrimal sac (dacryocystitis) can sometimes spread, potentially leading to orbital cellulitis.\\nEtiology\\nOverall, the most common causes of tearing are\\n URI\\n Allergic rhinitis\\nTearing can be caused by increased tear production or decreased nasolacrimal drainage.\\nIncreased tear production:\\n The most common causes are\\n URI\\n Allergic rhinitis\\n Allergic conjunctivitis\\n Dry eyes (reflex tearing produced in response to dryness of the ocular surface)\\n Trichiasis\\nAny disorder causing conjunctival or corneal irritation can increase tear production (see\\nTable 60-13\\n). However, most patients with corneal disorders that cause excess tearing (eg, corneal\\nabrasion, corneal ulcer, corneal foreign body, keratitis) or with primary angle-closure glaucoma or anterior\\nuveitis present with eye symptoms other than tearing (eg, eye pain, redness). Most people who have\\nbeen crying do not present for evaluation of tearing.\\nDecreased nasolacrimal drainage:\\n The most common causes are\\n Idiopathic age-related nasolacrimal duct stenosis\\n Dacryocystitis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n664'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 674, 'page_label': '665'}, page_content=\" Ectropion\\n[\\nFig. 60-3.\\n Anatomy of the lacrimal system.]\\nNasolacrimal drainage system obstruction may be caused by strictures, tumors, or foreign bodies (eg,\\nstones, often associated with subclinical infection by \\nActinomyces\\n). Obstruction can also be a congenital\\nmalformation. Many disorders and drugs can cause stricture or obstruction of nasolacrimal drainage.\\nOther causes of nasolacrimal drainage stricture or obstruction include\\n Burns\\n Chemotherapy drugs\\n Eye drops (particularly echothiophate iodide, epinephrine, and pilocarpine)\\n Infection, including canaliculitis (eg, caused by \\nStaphylococcus aureus\\n, \\nActinomyces\\n, \\nStreptococcus\\n,\\nPseudomonas\\n, herpes zoster virus, herpes simplex conjunctivitis, infectious mononucleosis, human\\npapillomavirus, \\nAscaris\\n, leprosy, TB)\\n Inflammatory disorders (sarcoidosis, Wegener's granulomatosis)\\n Injuries (eg, nasoethmoid fractures; nasal, orbital, or endoscopic sinus surgery)\\n Obstruction of nasal outlet despite an intact nasolacrimal system (eg, URI, allergic rhinitis, sinusitis)\\n Radiation therapy\\n Stevens-Johnson syndrome\\n Tumors (eg, primary lacrimal sac tumors, benign papillomas, squamous and basal cell carcinoma,\\ntransitional cell carcinoma, fibrous histiocytomas, midline granuloma, lymphoma)\\nEvaluation\\nHistory: History of present illness\\n addresses the duration, onset, and severity of symptoms, including\\nwhether tears drip down the cheek (true epiphora). The effects of weather, environmental humidity, and\\ncigarette smoke are ascertained.\\nReview of symptoms\\n should seek symptoms of possible causes, including itching, rhinorrhea, or\\nsneezing, particularly when occurring perennially or after exposure to specific potential allergens (allergic\\nreaction); eye irritation or pain (blepharitis, corneal abrasion, irritant chemicals); and pain near the medial\\ncanthus (dacryocystitis). Other symptoms are of lower yield but should be sought; they include positional\\nheadache, purulent rhinorrhea, nocturnal cough, and fever (sinusitis, Wegener's granulomatosis); rash\\n(Stevens-Johnson syndrome); cough, dyspnea, and chest pain (sarcoidosis); and epistaxis, hemoptysis,\\npolyarthralgias, and myalgias (Wegener's granulomatosis).\\nPast medical history\\n asks about known disorders that can cause tearing, including Wegener's\\ngranulomatosis, sarcoidosis, and\\n[\\nTable 60-13.\\n Some Causes of Tearing]\\ncancer treated with chemotherapy drugs; disorders that cause dry eyes (eg, RA, sarcoidosis, Sjogren's\\nsyndrome); and drugs, such as echothiophate, epinephrine, and pilocarpine. Previous ocular and nasal\\nhistory, including infections, injuries, surgical procedures, and radiation exposure, is ascertained.\\nPhysical examination:\\n Examination focuses on the eye and surrounding structures.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n665\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 675, 'page_label': '666'}, page_content=\"The face is inspected; asymmetry suggests congenital or acquired obstruction of nasolacrimal duct\\ndrainage. When available, a slit lamp should be used to examine the eyes. The conjunctivae and corneas\\nare inspected for lesions, including punctate spots, and redness. The cornea is stained with fluorescein\\nand examined. The lids are everted to detect hidden foreign bodies. The eyelids, including the lacrimal\\npuncta, are closely inspected for foreign bodies, blepharitis, hordeola, ectropion, entropion, and trichiasis.\\nThe lacrimal sac (near the medial canthus) is palpated for warmth, tenderness, and swelling. Any\\nswellings are palpated for consistency and to see whether pus is expressed.\\nThe nose is examined for congestion, purulence, and bleeding.\\nRed flags:\\n The following findings are of particular concern:\\n Repeated, unexplained episodes of tearing\\n Hard mass in or near the nasolacrimal drainage structures\\nInterpretation of findings:\\n Findings that suggest obstruction of nasolacrimal drainage include\\n Tears running down the cheek (true epiphora)\\n Absence of signs of a specific cause\\nA cause is often evident from the clinical evaluation (see\\nTable 60-14\\n).\\n[\\nTable 60-14.\\n Findings that Suggest the Cause of Nasolacrimal Obstruction]\\nTesting:\\n Testing is often unnecessary because the cause is usually evident from the examination.\\nSchirmer's test with a large amount of wetting (eg, > 25 mm) suggests an evaporative dry eye as the\\netiology of tearing. Schirmer's test with very little wetting (< 5.5 mm) suggests an aqueous teardeficient\\ndry eye. Usually, Schirmer's test is done by an ophthalmologist to ensure it is done and interpreted\\ncorrectly.\\nProbing and saline irrigation of the lacrimal drainage system can help detect anatomic obstruction of\\ndrainage, as well as stenosis due to complete obstruction of the nasolacrimal drainage system. Irrigation\\nis done with and without fluorescein dye. Reflux through the opposite punctum or canaliculus signals fixed\\nobstruction; reflux and nasal drainage signify stenosis. This test is considered adjunctive and is done by\\nophthalmologists.\\nImaging tests and procedures (dacryocystography, CT, nasal endoscopy) are sometimes useful to\\ndelineate abnormal anatomy when surgery is being considered or occasionally to detect an abscess.\\nTreatment\\nUnderlying disorders (eg, allergies, foreign bodies, conjunctivitis) are treated.\\nThe use of artificial tears lessens tearing when dry eyes or corneal epithelial defects are the cause.\\nCongenital nasolacrimal duct obstruction often resolves spontaneously. In patients < 1 yr, manual\\ncompression of the lacrimal sac 4 or 5 times/day may relieve the distal obstruction. After 1 yr, the\\nnasolacrimal duct may need probing with the patient under general anesthesia. If obstruction is recurrent,\\na temporary drainage tube may be inserted.\\nIn acquired nasolacrimal duct obstruction, irrigation of the nasolacrimal duct may be therapeutic when\\nunderlying disorders do not respond to treatment. As a last resort, a passage between the lacrimal sac\\nand the nasal cavity can be created surgically (dacryocystorhinostomy).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n666\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 676, 'page_label': '667'}, page_content=\"In cases of punctal or canalicular stenosis, dilation is usually curative. If canalicular stenosis is severe\\nand bothersome, a surgical procedure that places a glass tube leading from the caruncle into the nasal\\ncavity can be considered.\\nGeriatrics Essentials\\nIdiopathic age-related nasolacrimal duct stenosis is the most common cause of unexplained epiphora in\\nelderly patients; however, tumors should also be considered.\\nKey Points\\n If tears do not run down the cheek, dry eyes is often the cause.\\n If tears run down the cheek, obstruction of nasolacrimal drainage is likely.\\n \\nTesting is often unnecessary but is needed in cases of recurrent infectious dacryocystitis, which can\\nprogress to more serious conditions such as orbital cellulitis.\\nOther Eye Symptoms\\nDry eyes are discussed under Keratoconjunctivitis sicca (see p. \\n592\\n) The disorder is most often idiopathic\\nor associated with older age but can also be caused by connective tissue diseases (eg, Sjogren's\\nsyndrome, RA, SLE).\\nEye discharge:\\n Discharge is often accompanied by a red eye (see p. \\n563\\n) and commonly is caused by\\nallergic or infectious conjunctivitis, blepharitis, and, in infants, ophthalmia neonatorum (neonatal\\nconjunctivitis). Infectious discharge may be purulent in bacterial infection, such as staphylococcal\\nconjunctivitis or gonorrhea. Less common causes include dacryocystitis and canaliculitis.\\nDiagnosis is usually made clinically. Allergic conjunctivitis can often be distinguished from infectious by\\npredominance of itching, clear discharge, and presence of other allergic symptoms (eg, runny nose,\\nsneezing). Clinical differentiation between viral and bacterial conjunctivitis is difficult. Cultures are not\\nusually done, but are indicated for patients with the following:\\n Clinically suspected gonococcal or chlamydial conjunctivitis\\n Severe symptoms\\n Immunocompromise\\n A vulnerable eye (eg, after a corneal transplant, in exophthalmos due to Graves' disease)\\n Ineffective initial therapy\\nHalos:\\n Halos around light may result from cataracts; conditions that result in corneal edema, such as\\nacute angle-closure glaucoma or disorders that cause bullous keratopathy; corneal haziness; mucus on\\nthe cornea; or drugs, such as digoxin or chloroquine.\\nBlue hues:\\n Certain conditions may cause a blue tint to the visual field (cyanopsia). Cyanopsia may occur\\nfor a few days after cataract removal or as an adverse effect of sildenafil and possibly other\\nphosphodiesterase-5 (PDE5) inhibitors.\\nScotomata:\\n Scotomata are visual field deficits and are divided into\\n Negative scotomata (blind spots)\\n Positive scotomata (light spots or scintillating flashes)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n667\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 677, 'page_label': '668'}, page_content='Negative scotomata may not be noticed by patients unless they involve central vision and interfere\\nsignificantly with visual acuity; the complaint is most often decreased visual acuity (see p. \\n541\\n). Negative\\nscotomata have multiple causes that can sometimes be distinguished by the specific type of field deficit\\n(see \\nTable 60-1\\n) as identified by use of a tangent screen, Goldmann perimeter, or computerized\\nautomated perimetry (in which the visual field is mapped out in detail based on patient response to a\\nseries of flashing lights in different locations controlled by a standardized computer program).\\nPositive scotomata represent a response to abnormal stimulation of some portion of the visual system, as\\noccurs in migraines.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 60. Approach to the Ophthalmologic Patient\\n668'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 678, 'page_label': '669'}, page_content=\"Chapter 61. Refractive Error\\nIntroduction\\nIn the emmetropic (normally refracted) eye, entering light rays are focused on the retina by the cornea\\nand the lens, creating a sharp image that is transmitted to the brain. The lens is elastic, more so in\\nyounger people. During accommodation, the ciliary muscles adjust lens shape to properly focus images.\\nRefractive errors are failure of the eye to focus images sharply on the retina, causing blurred vision (see\\nFig. 61-1\\n).\\nIn \\nmyopia\\n (nearsightedness), the point of focus is in front of the retina because the cornea is too steeply\\ncurved, the axial length of the eye is too long, or both. Distant objects are blurred, but near objects can be\\nseen clearly. To correct myopia, a concave (minus) lens is used. Myopic refractive errors in children\\nfrequently increase until the child stops growing.\\nIn \\nhyperopia\\n (farsightedness), the point of focus is behind the retina because the cornea is too flatly\\ncurved, the axial length is too short, or both. In adults, both near and distant objects are blurred. Children\\nand young adults with mild hyperopia may be able to see clearly because of their ability to accommodate.\\nTo correct hyperopia, a convex (plus) lens is used.\\n[\\nFig. 61-1.\\n Errors of refraction.]\\nIn \\nastigmatism,\\n nonspherical (variable) curvature of the cornea or lens causes light rays of different\\norientations (eg, vertical, oblique, horizontal) to focus at different points. To correct astigmatism, a\\ncylindric lens (a segment cut from a cylinder) is used. Cylindric lenses have no refractive power along one\\naxis and are concave or convex along the other axis.\\nPresbyopia\\n is loss of the lens' ability to change shape to focus on near objects due to aging. Typically,\\npresbyopia becomes noticeable by the time a person reaches the early or mid 40s. A convex (plus) lens is\\nused for correction when viewing near objects. These lenses may be supplied as separate glasses or\\nbuilt into a lens as bifocals or variable focus lenses.\\nAnisometropia\\n is a significant difference between the refractive errors of the 2 eyes (usually > 3\\ndiopters). When corrected with eyeglasses, a difference in image size (aniseikonia) is produced; it can\\nlead to difficulties with fusion of the 2 differently sized images and even to suppression of one of the\\nimages.\\nSymptoms and Signs\\nThe primary symptom of refractive errors is blurred vision for distant objects, near objects, or both.\\nSometimes the excessive ciliary muscle tone can cause headaches. Occasionally, excessive staring can\\nlead to ocular surface desiccation, causing eye irritation, itching, visual fatigue, foreign body sensation,\\nand redness. Frowning when reading and excessive blinking or rubbing of the eyes are symptoms in\\nchildren.\\nDiagnosis\\nRefraction should be checked every 1 or 2 yr. Screening children helps detect refractive errors before\\nthey interfere with learning. A comprehensive eye examination (see p. \\n537\\n) should accompany refraction\\ntesting, whether done by an ophthalmologist or an optometrist.\\nContact Lenses\\nContact lenses often provide better visual acuity and peripheral vision than do eyeglasses and can be\\nprescribed to correct myopia, hyperopia, astigmatism, anisometropia, aniseikonia, aphakia (absence of\\nthe lens) after cataract removal, and keratoconus (a conical-shaped cornea). Either soft or rigid lenses\\nare used to correct myopia and hyperopia. Toric soft contact lenses (which have different curvatures\\nmolded onto the front lens surface) or rigid lenses are used to correct significant astigmatism; they are\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 61. Refractive Error\\n669\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 679, 'page_label': '670'}, page_content='satisfactory in many cases but require expert fitting.\\nPresbyopia can also be corrected with contact lenses. In one approach, termed monovision, the\\nnondominant eye is corrected for reading and the dominant eye is corrected for distant vision. Rigid and\\nsoft bifocal and multifocal contact lenses can also be successful, but the fitting procedure is time-\\nconsuming because precise alignment is essential.\\nNeither rigid nor soft contact lenses offer the eyes the protection against blunt or sharp injury that\\neyeglasses do.\\nCare and Complications\\nInstructions for hygiene and handling lenses must be strictly observed. Poor contact lens hygiene may\\nlead to persistent inflammation or infection of the cornea.\\nContact lenses occasionally cause painless superficial corneal changes. Contact lenses can be painful\\nwhen\\n The corneal epithelium is abraded (see p. \\n3236\\n); the cornea becomes red and inflamed and stains with\\nfluorescein.\\n The lenses fit poorly (eg, too tight, too loose, poorly centered).\\n There is too little moisture to keep the lens floating above the cornea.\\n The lenses are worn in a nonideal environment (eg, O\\n2\\n-poor, smoky, windy).\\n A lens is improperly inserted or removed.\\n A small foreign particle (eg, soot, dust) becomes trapped between the lens and the cornea.\\n The lenses are worn for a long time (overwear syndrome).\\nIn overwear syndrome, spontaneous healing may occur in a day or so if lenses are not worn. In some\\ncases, active treatment is requiredeg, topical antibiotic eyedrops or ointments and dilation of the pupil\\nwith a mydriatic to ease photophobia. (Mydriatics work by paralyzing the muscles of the iris and ciliary\\nbody [movement of the inflamed muscles causes pain].) Recovery is usually rapid, complete, and without\\nvision impairment. An ophthalmologist should be consulted before lenses are worn again.\\nRisk factors for contact lens-related corneal infection (keratitis) include the following:\\n Poor lens hygiene\\n Overnight or extended wear\\n Use of tap water in the cleaning regimen\\n Eyes with a compromised ocular surface (eg, dryness, poor corneal sensation)\\nInfections require rapid management by an ophthalmologist.\\nCorneal ulcer:\\n A corneal ulcer, which is a potentially vision-threatening infection of the cornea, is\\nsuspected when a contact lens wearer experiences intense eye pain (both foreign body sensation and\\nache), redness, photophobia, and tearing (see also p. \\n588\\n).\\nDiagnosis is by slit-lamp examination and fluorescein staining. A corneal infiltrate (collection of WBCs in\\nthe corneal stroma) is present. At times, the corneal infiltrate is large and dense enough to be seen with\\nhandheld magnification or even with the naked eye as a white spot on the cornea. Microbiologic analysis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 61. Refractive Error\\n670'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 680, 'page_label': '671'}, page_content='of cultures and smears of the corneal infiltrate, contact lens, and contact lens case is indicated.\\nTreatment includes cessation of contact lens wear and antibiotic drops. Initial therapy includes broad-\\nspectrum antibiotic coverage using a fluoroquinolone antibiotic drop q 15 to 60 min around the clock for\\n24 to 72 h, then at gradually longer intervals. Drops of an additional antibiotic, such as cefazolin,\\nvancomycin, or concentrated tobramycin, are used if the ulcer is large, deep, or close to the visual axis.\\nThe antibiotic may be changed later based on culture results. Neglected cases may respond poorly or not\\nat all to treatment, and severe vision loss may result.\\nRigid Corneal Contact Lenses\\nOlder polymethyl methacrylate rigid contact lenses have been replaced by gas-permeable contact lenses\\n(GPCLs) made of fluorocarbon and polymethyl methacrylate admixtures. GPCLs are 6.5 to 10 mm in\\ndiameter and cover part of the cornea, floating on the tear layer overlying it.\\nRigid contact lenses can improve vision for people with myopia, hyperopia, and astigmatism. If the\\ncorneal surface is irregular, rigid lenses often provide a smooth refracting surface and thus improve visual\\nacuity noticeably more than soft contact lenses or eyeglasses.\\nFor complete wearing comfort, rigid contact lenses require an adaptation period, sometimes as long as 1\\nwk. During this time, the wearer gradually increases the number of hours the lenses are worn each day.\\nImportantly, no pain should occur at any time. Pain is a sign of an ill-fitting contact lens or corneal\\nirritation. Wearers usually experience temporary (< 2 h) blurred vision (spectacle blur) when wearing\\neyeglasses after removing rigid contact lenses.\\nSoft Hydrophilic Contact Lenses\\nSoft contact lenses are made of poly-2-hydroxyethyl methacrylate and other flexible plastics and are 30 to\\n79% water. They are 13 to 15 mm in diameter and cover the entire cornea. Soft contact lenses can\\nimprove vision for people with myopia and hyperopia. Because soft contact lenses mold to the existing\\ncorneal curvature, anything greater than minimal astigmatism cannot be treated unless a special toric\\nlens, which has different curvatures molded onto the front lens surface, is used. Weighting the lower\\naspect of the lens maintains its orientation.\\nSoft contact lenses are also prescribed for treatment of recurrent corneal erosions and other corneal\\ndisorders (called bandage or therapeutic contact lenses). Prophylactic antibiotic eyedrops (eg,\\nfluoroquinolone qid) may be advisable with a bandage lens. Extended wearing of contact lenses,\\nespecially in aphakia after cataract surgery, is practical, but an ophthalmologist should examine the\\npatient at least 4 times/yr. The patient should clean the lenses once/wk.\\nBecause of their larger size, soft contact lenses are easier to handle, are not as likely as rigid lenses to\\neject spontaneously, and are less likely to allow foreign bodies to lodge beneath them. Immediate wearing\\ncomfort allows for a brief adaptation period.\\nSoft contact lenses have a higher incidence of corneal infections, which increases for every night a\\nperson wears them during sleep. When dry, soft contact lenses are brittle and break easily. They absorb a\\ncertain amount of moisture (based on the water content) from the tear film to retain adequate shape and\\npliability. Therefore, patients with dry eye are usually more comfortable wearing lenses that have a low\\nwater content.\\nRefractive Surgery\\nCorneal refractive surgery alters the curvature of the cornea to focus light more precisely on the retina.\\nThe goal of refractive surgery is to decrease dependence on eyeglasses or contact lenses. Most people\\nwho undergo refractive surgery achieve this goal; about 95% do not need corrective lenses for distance\\nvision. Ideal candidates for refractive surgery are people with healthy eyes who are not satisfied wearing\\neyeglasses or contact lenses. Preoperative examination excludes people with active ocular diseases,\\nincluding severe dry eye. Candidates should not have a history of autoimmune or connective tissue\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 61. Refractive Error\\n671'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 681, 'page_label': '672'}, page_content='disease because of potential problems with wound healing. Latent herpes simplex virus may be\\nreactivated after surgery; patients should be advised accordingly. Refraction should be stable for at least\\n1 yr, and candidates should be > 18 yr. Another contraindication is use of isotretinoin or amiodarone.\\nAdverse effects of refractive surgery include temporary foreign body sensation, glare, halos, and dryness;\\noccasionally, these symptoms persist. Potential complications include overcorrection and undercorrection,\\ninfection, and irregular astigmatism. In excimer laser procedures performed on the superficial corneal\\nstroma, haze formation is possible. If infection, irregular astigmatism, or haze formation causes permanent\\nchanges in the central cornea, best-corrected acuity could be lost. The overall complication rate is low;\\nchance of vision loss is < 1% if the patient is considered a good candidate for refractive surgery\\npreoperatively.\\nLaser In Situ Keratomileusis\\nIn laser in situ keratomileusis (LASIK), a flap of corneal tissue is created with a laser or mechanical\\nmicrokeratome and turned back, the underlying stromal bed is sculpted (photo-ablated) with the excimer\\nlaser, and the flap is replaced without suturing. Because surface epithelium is not disrupted centrally,\\nvision returns rapidly. Most people notice a significant improvement the next day. LASIK can be used to\\ntreat myopia, astigmatism, and hyperopia.\\nAdvantages of LASIK over photorefractive keratectomy (PRK) include the desirable lack of healing\\nresponse (the central corneal epithelium is not removed, thereby decreasing the risk of central haze\\nformation that occurs during healing), the shorter visual rehabilitation period, and minimal postoperative\\npain. Disadvantages include possible intraoperative and postoperative flap-related complications, such as\\nirregular flap formation, flap dislocation, and the need for adequate corneal thickness to prevent long-term\\ncorneal ectasia. Ectasia occurs when the cornea has become so thin that intraocular pressure causes\\ninstability and bulging of the thinned and weakened corneal stroma. Blurring, increasing myopia, and\\nirregular astigmatism can result.\\nPhotorefractive Keratectomy\\nIn PRK, the excimer laser is used to sculpt (photoablate) the anterior curvature of the corneal stromal bed\\nto treat myopia, hyperopia, and astigmatism. The corneal epithelium is removed before photoablation and\\ngenerally takes 3 to 4 days to regenerate; during this time a bandage contact lens is worn. Unlike LASIK,\\nno corneal flap is created.\\nPRK may be more suitable for patients with thin corneas or anterior basement membrane dystrophy.\\nAdvantages of PRK include an overall thicker residual stromal bed (thereby reducing risk of ectasia) and\\nlack of flap-related complications. Disadvantages include potential for corneal haze formation if a large\\namount of corneal tissue is ablated and the need for postoperative corticosteroid drops for 3 to 4 mo.\\nMore than 95% of patients see 20/40 or better without eyeglasses after surgery.\\nIntracorneal Ring Segments\\nIntracorneal ring segments (INTACS) are thin arc-shaped segments of biocompatible plastic that are\\ninserted in pairs through a small radial corneal incision into the peripheral corneal stroma at two-thirds\\ndepth. After INTACS are inserted, the central corneal curvature is flattened, reducing myopia. INTACS are\\nused for mild myopia (< 3 diopters) and minimal astigmatism (< 1 diopter). INTACS maintain a central,\\nclear, optical zone because the 2 segments are placed in the corneal periphery. INTACS can be replaced\\nor removed if desired.\\nRisks include induced astigmatism, undercorrection and overcorrection, infection, glare, halo, and\\nincorrect depth placement. Vision results are very good; in US clinical studies, 97% of patients saw 20/40\\nor better and 74% of patients saw 20/20 or better.\\nConductive Keratoplasty\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 61. Refractive Error\\n672'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 682, 'page_label': '673'}, page_content=\"Conductive keratoplasty (CK) is a thermal technique that can treat spherical hyperopia (ie, hyperopia\\nwithout associated astigmatism) and presbyopia. CK uses radiofrequency energy applied with a fine\\nprobe in a ring pattern to the peripheral cornea to contract the periphery and steepen the center, thereby\\nincreasing the refractive power of the cornea. For presbyopic patients who wear only reading glasses, CK\\nis typically done in the nondominant eye (monovision) to induce myopia in that eye and enable the patient\\nto regain reading vision. As the presbyopia progresses, additional rings of treatment are added. Risks of\\nCK include induced astigmatism and regression of effect.\\nPhakic Intraocular Lenses\\nPhakic intraocular lenses (IOLs) are lens implants that are used to treat severe myopia in patients who\\nare not suitable candidates for laser vision correction. Unlike in cataract surgery, the patient's natural lens\\nis not removed. The phakic IOL is inserted directly anterior or posterior to the iris through an incision in\\nthe eye. This procedure is intraocular surgery and must be done in an operating room.\\nRisks include cataract formation, glaucoma, infection, and loss of corneal endothelial cells.\\nBecause phakic IOLs do not correct astigmatism, patients can undergo subsequent laser vision correction\\nto refine refractive results in a technique known as bioptics. Because the bulk of the myopia is corrected\\nwith the phakic IOL, less corneal tissue is removed with LASIK, and the risk of ectasia is thus low.\\nClear Lensectomy\\nClear lensectomy can be considered in patients with high hyperopia who are already presbyopic. This\\nprocedure is identical to cataract surgery except the patient's lens is clear and not cataractous. A\\nmultifocal intraocular lens, which allows the patient to focus over a wide range of distances without\\nexternal lens correction, can be inserted.\\nThe main risks of clear lensectomy are infection and rupture of the posterior capsule of the lens, which\\nwould necessitate further surgery. Clear lensectomy should be done with great caution in young myopic\\npatients because they have an increased risk of retinal detachment.\\nRadial and Astigmatic Keratotomy\\nRadial and astigmatic keratotomy procedures change the shape of the cornea by making deep corneal\\nincisions using a diamond blade.\\nRadial keratotomy has been replaced by laser vision correction and is rarely used because it offers no\\nclear advantages over laser vision correction, has a greater need for subsequent retreatment, leads to\\nvisual and refractive results that change through the day, and tends to cause hyperopia in the long term.\\nAstigmatic keratotomy is used to treat astigmatism at the time of cataract surgery or after corneal\\ntransplantation.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 61. Refractive Error\\n673\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 683, 'page_label': '674'}, page_content='Chapter 62. Eyelid and Lacrimal Disorders\\nIntroduction\\nCommon eyelid and lacrimal disorders include blepharitis, blepharospasm, canaliculitis, chalazion and\\nhordeolum, dacryocystitis, dacryostenosis, entropion and ectropion, trichiasis, and tumors.\\nBlepharitis\\nBlepharitis is inflammation of the eyelid margins that may be acute or chronic. Symptoms and\\nsigns include itching and burning of the eyelid margins with redness and edema. Diagnosis is\\nby history and examination. Acute ulcerative blepharitis is usually treated with topical\\nantibiotics or systemic antivirals. Acute nonulcerative blepharitis is occasionally treated with\\ntopical corticosteroids. Chronic disease is treated with tear supplements, warm compresses,\\nand occasionally oral antibiotics (eg, a tetracycline) for meibomian gland dysfunction or with\\neyelid hygiene and tear supplements for seborrheic blepharitis.\\nEtiology\\nBlepharitis may be acute (ulcerative or nonulcerative) or chronic (meibomian gland dysfunction,\\nseborrheic blepharitis).\\nAcute:\\n Acute ulcerative blepharitis is usually caused by bacterial infection (usually staphylococcal) of the\\neyelid margin at the origins of the eyelashes; the lash follicles and meibomian glands are also involved. It\\nmay also be due to a virus (eg, herpes simplex, varicella zoster).\\nAcute nonulcerative blepharitis is usually caused by an allergic reaction involving the same area (eg,\\natopic blepharodermatitis and seasonal allergic blepharoconjunctivitis, which cause intense itching,\\nrubbing, and a rash; contact sensitivity [dermatoblepharo-conjunctivitis]).\\nChronic:\\n Chronic blepharitis is noninfectious inflammation of unknown cause. Meibomian glands in the\\neyelid produce lipids (meibum) that reduce tear evaporation by forming a lipid layer on top of the aqueous\\ntear layer. In meibomian gland dysfunction, the lipid composition is abnormal, and gland ducts and orifices\\nbecome inspissated with hard, waxy plugs. Many patients have rosacea (see p. \\n654\\n) and recurrent\\nhordeola or chalazia.\\nMany patients with seborrheic blepharitis have seborrheic dermatitis of the face and scalp (see p. \\n671\\n) or\\nacne rosacea. Secondary bacterial colonization often occurs on the scales that develop on the eyelid\\nmargin. Meibomian glands can become obstructed.\\nMost patients with meibomian gland dysfunction or seborrheic blepharitis have increased tear evaporation\\nand secondary keratoconjunctivitis sicca.\\nSymptoms and Signs\\nSymptoms common to all forms of blepharitis include itching and burning of the eyelid margins and\\nconjunctival irritation with lacrimation, photosensitivity, and foreign body sensation.\\nAcute:\\n In acute ulcerative blepharitis, small pustules may develop in eyelash follicles and eventually\\nbreak down to form shallow marginal ulcers. Tenacious adherent crusts leave a bleeding surface when\\nremoved. During sleep, eyelids can become glued together by dried secretions. Recurrent ulcerative\\nblepharitis can cause eyelid scars and loss of eyelashes.\\nIn acute nonulcerative blepharitis, eyelid margins become edematous and erythematous; eyelashes may\\nbecome crusted with dried serous fluid.\\nChronic:\\n In meibomian gland dysfunction, examination reveals dilated, inspissated gland orifices that,\\nwhen pressed, exude a waxy, thick, yellowish secretion with pressure. In seborrheic blepharitis, greasy,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 62. Eyelid & Lacrimal Disorders\\n674'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 684, 'page_label': '675'}, page_content=\"easily removable scales develop on eyelid margins. Most patients with seborrheic blepharitis and\\nmeibomian gland dysfunction have symptoms of keratoconjunctivitis sicca, such as foreign body\\nsensation, grittiness, eye strain and fatigue, and blurring with prolonged visual effort.\\nDiagnosis\\nDiagnosis is usually by slit-lamp examination. Chronic blepharitis that does not respond to treatment may\\nrequire biopsy to exclude eyelid tumors that can simulate the condition.\\nPrognosis\\nAcute blepharitis most often responds to treatment but may recur, develop into chronic blepharitis, or\\nboth. Chronic blepharitis is indolent, recurrent, and resistant to treatment. Exacerbations are\\ninconvenient, uncomfortable, and cosmetically unappealing but do not usually result in corneal scarring or\\nvision loss.\\nTreatment\\nAcute:\\n Acute ulcerative blepharitis is treated with an antibiotic ointment (eg, bacitracin/polymyxin B,\\nerythromycin, or gentamicin 0.3% qid for 7 to 10 days). Acute viral ulcerative blepharitis is treated with\\nsystemic antivirals (eg, for herpes simplex, acyclovir 400 mg po tid for 7 days; for varicella zoster,\\nfamciclovir 500 mg po tid or valacyclovir 1 g po tid for 7 days).\\nTreatment of acute nonulcerative blepharitis begins with avoiding the offending action (eg, rubbing) or\\nsubstance (eg, new eye drops). Warm compresses over the closed eyelid may relieve symptoms and\\nspeed resolution. If swelling persists > 24 h, topical corticosteroids (eg, fluorometholone ophthalmic\\nointment 0.1% tid for 7 days) can be used.\\nChronic:\\n The initial treatment for both meibomian gland dysfunction and seborrheic blepharitis is directed\\ntoward the secondary keratoconjunctivitis sicca (see p. \\n592\\n). Tear supplements, bland ointments at night,\\nand, if necessary, punctal plugs (inserts that obstruct the puncta and thus decrease tear drainage) are\\neffective in most patients.\\nIf needed, additional treatment for meibomian gland dysfunction includes warm compresses to melt the\\nwaxy plugs and occasionally eyelid massage to extrude trapped secretions and coat the ocular surface. A\\ntetracycline (eg, doxycycline 100 mg po bid tapered over 3 to 4 mo) may also be effective because it\\nchanges the composition of meibomian gland secretions.\\nIf needed, additional treatment for seborrheic blepharitis includes gentle cleansing of the eyelid margin 2\\ntimes a day with a cotton swab dipped in a dilute solution of baby shampoo (2 to 3 drops in 1/2 cup of\\nwarm water). A topical antibiotic ointment (bacitracin/polymyxin B or sulfacetamide 10% bid for up to 3 mo)\\nmay be added to reduce bacterial counts on the eyelid margin when cases are unresponsive to weeks of\\neyelid hygiene.\\nBlepharospasm\\nBlepharospasm is spasm of muscles around the eye causing involuntary blinking and eye\\nclosing.\\nThe cause of blepharospasm is most often unknown. It affects women more than men and tends to occur\\nin families. Blepharospasm may be secondary to eye disorders, including those that cause ocular irritation\\n(eg, trichiasis, corneal foreign body, keratoconjunctivitis sicca) and systemic neurologic diseases that\\ncause spasm (eg, Parkinson's disease).\\nSymptoms are involuntary blinking and closing of the eyes; in severe cases, people cannot open their\\neyes. Spasms may be made worse by fatigue, bright light, and anxiety.\\nTreatment involves injecting botulinum toxin type A into the eyelid muscles; treatment must be repeated in\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 62. Eyelid & Lacrimal Disorders\\n675\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 685, 'page_label': '676'}, page_content=\"most instances. Anxiolytics may help. Surgery to cut the periorbital muscles is also effective but, because\\nof potential complications, is considered only if botulinum toxin is ineffective. Sunglasses help decrease\\nthe light sensitivity that may cause or accompany blepharospasm.\\nCanaliculitis\\nCanaliculitis is inflammation of the canaliculus (see\\nFig. 60-3\\n on p. \\n567\\n).\\nThe most common cause is infection with \\nActinomyces israelii\\n, a gram-positive bacillus with fine\\nbranching filaments, but other bacteria, fungi (eg, \\nCandida albicans\\n), and viruses (eg, herpes simplex)\\nmay be causative. Symptoms and signs are tearing, discharge, red eye (especially nasally), and mild\\ntenderness over the involved side.\\nDiagnosis is suspected based on symptoms and signs, expression of turbid secretions with pressure over\\nthe lacrimal sac, and a gritty sensation caused by necrotic material that can be felt during probing of the\\nlacrimal system. Canaliculitis can be differentiated from dacryocystitis. In canaliculitis, the punctum and\\ncanaliculus are red and swollen; in dacryocystitis, the punctum and canaliculus are normal, but a red,\\nswollen, tender mass is located in or near the lacrimal sac.\\nTreatment is warm compresses, irrigation of the canaliculus with antibiotic solution (by an\\nophthalmologist), and removal of any concretions, which usually requires surgery. Antibiotic selection is\\nusually empiric with a 1st-generation cephalosporin or penicillinase-resistant synthetic penicillin but may\\nbe guided by irrigation samples.\\nChalazion and Hordeolum\\nChalazia and hordeola are sudden-onset localized swellings of the eyelid. A chalazion is caused\\nby noninfectious meibomian gland occlusion, whereas a hordeolum is caused by infection. Both\\nconditions initially cause eyelid hyperemia and edema, swelling, and pain. With time, a\\nchalazion becomes a small nontender nodule in the eyelid center, whereas a \\nhordeolum\\nremains painful and localizes to an eyelid margin. Diagnosis is clinical. Treatment is with hot\\ncompresses. Both conditions improve spontaneously, but incision or, for chalazia, intralesional\\ncorticosteroids may be used to hasten resolution.\\nChalazion:\\n A chalazion is noninfectious obstruction of a meibomian gland causing extravasation of\\nirritating lipid material in the eyelid soft tissues with focal secondary granulomatous inflammation (see\\nPlate 7\\n). Disorders that cause abnormally thick meibomian gland secretions (eg, meibomian gland\\ndysfunction, acne rosacea) increase the risk of meibomian gland obstruction.\\nHordeolum:\\n A hordeolum (stye) is an acute, localized, pyogenic (usually staphylococcal) infection or\\nabscess of the eyelid that may be external or internal (see\\nPlate 16\\n). Most hordeola are external and result from obstruction and infection of an eyelash follicle and\\nadjacent glands of Zeis or Moll's glands. Follicle obstruction may be associated with blepharitis. An\\ninternal hordeolum, which is very rare, results from infection of a meibomian gland. Sometimes cellulitis\\naccompanies hordeola.\\nSymptoms and Signs\\nChalazia and hordeola each cause eyelid redness, swelling, and pain.\\nChalazion:\\n After 1 or 2 days, a chalazion localizes to the body of the eyelid. Typically, a small nontender\\nnodule or lump develops. A chalazion usually drains through the inner surface of the eyelid or is absorbed\\nspontaneously over 2 to 8 wk; rarely, it persists longer. Vision may be slightly blurred.\\nHordeolum:\\n After 1 to 2 days, an external hordeolum localizes to the eyelid margin. There may be\\ntearing, photophobia, and a foreign body sensation. Typically, a small yellowish pustule develops at the\\nbase of an eyelash, surrounded by hyperemia, induration, and diffuse edema. Within 2 to 4 days, the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 62. Eyelid & Lacrimal Disorders\\n676\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 686, 'page_label': '677'}, page_content='lesion ruptures and discharges pus, thereby relieving pain and resolving the lesion.\\nSymptoms of an internal hordeolum are the same as those of a chalazion, with pain, redness, and edema\\nlocalized to the posterior tarsal conjunctival surface. Inflammation may be severe, sometimes with fever or\\nchills. Inspection of the tarsal conjunctivae shows a small elevation or yellow area at the site of the\\naffected gland. Later, an abscess forms. Spontaneous rupture is rare; however, when it does occur, it\\nusually occurs on the conjunctival side of the eyelid and sometimes erupts through the skin side.\\nRecurrence is common.\\nDiagnosis\\n Clinical assessment\\nDiagnosis of chalazion and both kinds of hordeola is clinical; however, during the first 2 days, they may\\nbe clinically indistinguishable. Because internal hordeola are so rare, they are not usually suspected\\nunless inflammation is severe or fever or chills are present. If the chalazion or hordeolum lies near the\\ninner canthus of the lower eyelid, it must be differentiated from dacryocystitis (see below), which can\\nusually be excluded by noting the location of maximum induration and tenderness (eg, eyelid for a\\nchalazion, under the medial canthus near the side of the nose for dacryocystitis). Chronic chalazia that do\\nnot respond to treatment require biopsy to exclude tumor of the eyelid.\\nTreatment\\n Hot compresses\\n Sometimes drainage or drug therapy\\nHot compresses for 5 to 10 min 2 or 3 times a day can be used to hasten resolution of chalazia and\\nexternal hordeola.\\nChalazion:\\n Incision and curettage or intrachalazion corticosteroid therapy (0.05 to 0.2 mL triamcinolone\\n25 mg/mL) may be indicated if chalazia are large, unsightly, and persist for more than several weeks\\ndespite conservative therapy.\\nHordeolum:\\n An external hordeolum that does not respond to hot compresses can be incised with a\\nsharp, fine-tipped blade. Systemic antibiotics (eg, dicloxacillin or erythromycin 250 mg po qid) are\\nindicated when cellulitis accompanies a hordeolum.\\nTreatment of internal hordeola is oral antibiotics and incision and drainage if needed. Topical antibiotics\\nare usually ineffective.\\nDacryocystitis\\nDacryocystitis is infection of the lacrimal sac, usually with staphyloccocal or streptococcal\\nspecies and usually as a consequence of nasolacrimal duct obstruction.\\nIn acute dacryocystitis, the patient presents with pain, redness, and edema around the lacrimal sac.\\nDiagnosis is suspected based on symptoms and signs and when pressure over the lacrimal sac causes\\nreflux of mucoid material through the puncta. Initial treatment is with warm compresses and oral antibiotics\\nfor mild cases or IV antibiotics for more severe cases. \\nThe antibiotic is usually a 1st-generation\\ncephalosporin or penicillinase-resistant synthetic penicillin. If the infection does not respond as expected,\\nconsideration should be given to methicillin-resistant \\nStaphylococcus aureus\\n (MRSA), and antibiotics\\nchanged accordingly. The abscess can be drained and the antibiotics can be changed based on culture\\nresults if the initial antibiotic proves ineffective.\\nPatients with chronic dacryocystitis usually present with a mass under the medial canthal tendon and\\nchronic conjunctivitis. Definitive treatment for resolved acute dacryocystitis or chronic conjunctivitis is\\nusually surgery that creates a passage between the lacrimal sac and the nasal cavity\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 62. Eyelid & Lacrimal Disorders\\n677'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 687, 'page_label': '678'}, page_content=\"(dacryocystorhinostomy).\\nDacryostenosis\\nDacryostenosis is obstruction or stenosis of the nasolacrimal duct, causing excess tearing.\\nNasolacrimal obstruction may be congenital or acquired. One cause of congenital obstruction is\\ninadequate development of any part of the nasolacrimal ducts. Typically, a membrane at the distal end of\\nthe nasolacrimal duct persists. There is tearing and purulent discharge; the condition may manifest as\\nchronic conjunctivitis, usually beginning after the age of 2 wk (most often at age 3 to 12 wk).\\nCauses of acquired nasolacrimal duct obstruction are listed in\\nTable 62-1\\n. The cause is most often age-related stenosis of the nasolacrimal duct. Other causes include\\npast nasal or facial bone fractures and sinus surgery, which disrupt the nasolacrimal duct; inflammatory\\ndiseases (eg, sarcoidosis, Wegener's granulomatosis); and dacryocystitis.\\nCauses of punctal or canalicular stenosis include chronic conjunctivitis (especially herpetic), certain types\\nof chemotherapy, adverse reactions to eye drops (especially topical echothiophate iodide), and radiation.\\nDiagnosis\\nDiagnosis is usually based on clinical criteria. Sometimes ophthalmologists probe and irrigate the lacrimal\\ndrainage system with saline, with or without fluorescein dye. Reflux indicates stenosis.\\nTreatment\\nCongenital nasolacrimal duct obstruction often resolves spontaneously by about age 6 to 9 mo; before 1\\nyr, manual compression of the lacrimal sac 4 or 5 times/day may relieve the obstruction. After 1 yr, the\\nnasolacrimal duct may need probing, usually under general anesthesia; if obstruction is recurrent, a\\ntemporary silastic tube may be inserted.\\n[\\nTable 62-1.\\n Causes of Acquired Nasolacrimal Duct Obstruction]\\nIn acquired nasolacrimal duct obstruction, the underlying disorder is treated when possible. If treatment is\\nnot possible or is ineffective, a passage between the lacrimal sac and the nasal cavity can be created\\nsurgically (dacryocystorhinostomy).\\nIn cases of punctal or canalicular stenosis, dilation is usually curative. If canalicular stenosis is severe\\nand bothersome, a surgical procedure that places a glass tube (Jones tube) leading from the caruncle\\ninto the nasal cavity can be considered.\\nEntropion and Ectropion\\nEntropion is inversion of an eyelid. Ectropion is eversion of the lower eyelid.\\nEntropion:\\n Entropion (inversion of an eyelid) is caused by age-related tissue relaxation, postinfectious or\\nposttraumatic changes, or blepharospasm. Eyelashes rub against the eyeball and may lead to corneal\\nulceration and scarring. Symptoms can include foreign body sensation, tearing, and red eye. Diagnosis is\\nclinical. Definitive treatment is surgery.\\nEctropion:\\n Ectropion (eversion of the lower eyelidsee\\nPlate 12\\n) is caused by age-related tissue relaxation, cranial nerve VII palsy, and posttraumatic or\\npostsurgical changes. Symptoms are tearing (due to poor drainage of tears through the nasolacrimal\\nsystem, which may no longer contact the eyeball) and symptoms of dry eyes (see p. \\n592\\n), possibly due to\\ninadequate blinking. Diagnosis is clinical. Symptomatic treatment can include tear supplements and, at\\nnight, ocular lubricants; definitive treatment is surgery.\\nTrichiasis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 62. Eyelid & Lacrimal Disorders\\n678\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 688, 'page_label': '679'}, page_content=\"Trichiasis is an anatomic misalignment of eyelashes, which rub against the eyeball, in a patient\\nwith no entropion.\\nTrichiasis is most often idiopathic, but known causes include blepharitis, posttraumatic and postsurgical\\nchanges, conjunctival scarring (eg, secondary to cicatricial pemphigoid, atopic keratoconjunctivitis,\\nStevens-Johnson syndrome, or chemical injury), epiblepharon (an extra lower eyelid skinfold that directs\\nlashes into a vertical position), and distichiasis (a congenital extra row of eyelashes). Corneal ulceration\\nand scarring can occur in chronic cases. Symptoms are foreign body sensation, tearing, and red eye.\\nDiagnosis is usually clinical. Trichiasis differs from entropion in that the eyelid position is normal.\\nEvaluation includes fluorescein staining to exclude corneal abrasion or ulceration. Treatment is eyelash\\nremoval with forceps. If eyelashes grow back, electrolysis or cryosurgery is more effective at permanently\\npreventing recurrence.\\nTumors\\nThe skin of the eyelids is a common site for growth of benign and malignant tumors.\\nXanthelasma:\\n Xanthelasma is a common, benign deposit of yellow-white flat plaques of lipid material\\nthat occur subcutaneously on the upper and lower eyelids. Although some people with xanthelasmas\\nhave dyslipidemias, most do not. Diagnosis is by appearance. No treatment is necessary, although\\nxanthelasmas can be removed for cosmetic reasons, and underlying dyslipidemias should be treated.\\nBasal cell carcinoma:\\n This skin cancer frequently occurs at the eyelid margins, at the inner canthus,\\nand on the upper cheek (see also p. \\n749\\n). Metastasis is rare. Biopsy establishes the diagnosis.\\nTreatment is surgical excision using conventional techniques or by Mohs' surgery.\\nOther malignant tumors:\\n These types of tumors are less common; they include squamous cell\\ncarcinoma, meibomian gland carcinoma, and melanomas. Eyelid tumors may simulate chronic blepharitis\\nor chronic chalazion. Therefore, chronic blepharitis, chronic chalazion, or similar lesions should be\\nbiopsied if unresponsive to initial treatment.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 62. Eyelid & Lacrimal Disorders\\n679\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 689, 'page_label': '680'}, page_content='Chapter 63. Conjunctival and Scleral Disorders\\nIntroduction\\nThe conjunctiva lines the back of the eyelids (palpebral or tarsal conjunctiva), crosses the space between\\nthe lid and the globe (forniceal conjunctiva), then folds back on itself as it spreads over the sclera to the\\ncornea (bulbar conjunctiva). The conjunctiva helps maintain the tear film and protect the eye from foreign\\nobjects and infection.\\nThe sclera is the thick white sphere of dense connective tissue that encloses the eye and maintains its\\nshape. Anteriorly, the sclera fuses with the cornea, and posteriorly it blends with the meninges where the\\noptic nerve penetrates the globe.\\nThe episclera is a thin vascular membrane between the conjunctiva and the sclera.\\nThe most common disorders are inflammatory (eg, conjunctivitis, episcleritis, scleritis). Conjunctivitis can\\nbe acute or chronic and is infectious, allergic, or irritant in origin. Scleritis usually results from immune-\\nmediated disease and episcleritis often does as well. Episcleritis usually does not threaten vision, but\\nscleritis can destroy vision and the eye. Major symptoms of conjunctivitides (eg, conjunctival hyperemia)\\nare similar. Early, accurate diagnosis is important.\\nSelect eye findings in conjunctival disorders:\\n Edema of the bulbar conjunctiva results in a\\ntranslucent, bluish, thickened conjunctiva. Gross edema with ballooning of the conjunctiva, often leading\\nto prolapse of conjunctiva, is known as chemosis.\\nEdema of the tarsal conjunctiva (typical of allergic conjunctivitis) results in fine, minute projections\\n(papillae), giving the conjunctiva a velvety appearance.\\nHyperplasia of lymphoid follicles in the conjunctiva can occur in viral or chlamydial conjunctivitis. It\\nappears as small bumps with pale centers, resembling cobblestones. It occurs most commonly in the\\ninferior tarsal conjunctiva.\\nCicatricial Pemphigoid\\n(Benign Mucous Membrane Pemphigoid; Mucous Membrane Pemphigoid; Ocular Cicatricial Pemphigoid)\\nCicatricial pemphigoid is a chronic, bilateral, progressive scarring and shrinkage of the\\nconjunctiva with opacification of the cornea. Early \\nsymptoms are hyperemia, discomfort,\\nitching, and discharge; progression leads to eyelid and corneal damage and sometimes\\nblindness. Diagnosis may be confirmed by biopsy, but biopsy is often not necessary. Treatment\\nmay require systemic immunosuppression.\\nCicatricial pemphigoid is an autoimmune disease in which binding of anticonjunctival basement\\nmembrane antibodies results in conjunctival inflammation. It is unrelated to bullous pemphigoid.\\nSymptoms and Signs\\nUsually beginning as a chronic conjunctivitis, the condition progresses to symblepharon (adhesion\\nbetween the tarsal and bulbar conjunctiva); trichiasis (in-turning eyelashes); keratoconjunctivitis sicca;\\ncorneal neovascularization, opacification, and keratinization; and conjunctival shrinkage and\\nkeratinization. Chronic corneal epithelial defects can lead to secondary bacterial ulceration, scarring, and\\nblindness. Oral mucous membrane involvement with ulceration and scarring is common, but skin\\ninvolvement, characterized by scarring bullae and erythematous plaques, is uncommon.\\nDiagnosis\\n Unexplained symblepharon or biopsy findings\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n680'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 690, 'page_label': '681'}, page_content='Diagnosis is suspected clinically in patients with conjunctival scarring plus corneal changes,\\nsymblepharon, or both. The differential diagnosis of progressive conjunctival scarring includes\\npostradiation and atopic disease. Therefore, the clinical diagnosis of cicatricial pemphigoid is made when\\nthere is progression of symblepharon without a history of local radiation or severe perennial allergic\\nconjunctivitis. Diagnosis can be confirmed by conjunctival biopsy showing antibody deposition on the\\nbasement membrane.\\nTreatment\\n Epilation of in-turning lashes\\n Sometimes systemic immunosuppression\\nTear substitutes and epilation, cryoepilation, or electroepilation of the in-turning eyelashes may increase\\npatient comfort and reduce the risk of ocular infection and secondary scarring. For progressive scarring\\nor corneal opacification or for nonhealing corneal epithelial defects, systemic immunosuppression with\\ndapsone or cyclophosphamide is indicated.\\nConjunctivitis\\nConjunctival inflammation typically results from infection, allergy, or irritation. Symptoms are\\nconjunctival hyperemia and ocular discharge and, depending on the etiology, discomfort and\\nitching. Diagnosis is clinical; sometimes cultures are indicated. Treatment depends on etiology\\nand may include topical antibiotics, antihistamines, mast cell stabilizers, and corticosteroids.\\nInfectious conjunctivitis is most commonly viral or bacterial and is contagious. Rarely, mixed or\\nunidentifiable pathogens are present. Numerous allergens can cause allergic conjunctivitis (see p. \\n584\\n).\\nNonallergic conjunctival irritation can result from foreign bodies; wind, dust, smoke, fumes, chemical\\nvapors, and other types of air pollution; and intense ultraviolet light of electric arcs, sunlamps, and\\nreflection from snow.\\nConjunctivitis is typically acute, but both infectious and allergic conditions can be chronic. Conditions that\\ncause chronic conjunctivitis include ectropion, entropion, blepharitis, and chronic dacryocystitis.\\nSymptoms and Signs\\nAny source of inflammation causes lacrimation or discharge and diffuse conjunctival vascular dilation.\\nDischarge may cause the eyes to crust overnight. Thick discharge may blur vision, but once discharge is\\ncleared, visual acuity should be unaffected.\\nItching and watery discharge predominate in allergic conjunctivitis. Chemosis and papillary hyperplasia\\nalso suggest allergic conjunctivitis. Irritation or foreign body sensation, photophobia, and discharge\\nsuggest infectious conjunctivitis; purulent discharge suggests a bacterial cause. Severe eye pain\\nsuggests scleritis (see p. \\n587\\n).\\nDiagnosis\\n Clinical evaluation\\n Sometimes culture\\nUsually, diagnosis is made by history and examination (see also\\nTable 63-1\\n), usually \\nincluding slit-lamp examination with fluorescein staining of the cornea and, if\\nglaucoma is suspected, measurement of intraocular pressure.\\nOther disorders can cause a red eye (see p. \\n563\\n). Deep pain in the affected eye when a light is shone in\\nthe unaffected eye (true photophobia) does not occur in uncomplicated conjunctivitis and suggests a\\ndisorder of the cornea or anterior uveal tract. Circumcorneal conjunctival hyperemia (sometimes\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n681'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 691, 'page_label': '682'}, page_content=\"described as ciliary flush) is caused by dilated, fine, straight, deep vessels that radiate out 1 to 3 mm from\\nthe limbus, without significant hyperemia of the bulbar and tarsal conjunctivae. Ciliary flush occurs with\\nuveitis, acute glaucoma, and some types of keratitis.\\nThe cause of conjunctivitis is suggested by clinical findings. However, cultures are indicated for patients\\nwith severe symptoms, immunocompromise, a vulnerable eye (eg, after a corneal transplant, in\\nexophthalmos due to Graves' disease), or ineffective initial therapy.\\nClinical differentiation between viral and bacterial infectious conjunctivitis is not highly accurate. However,\\ntemporarily missing some cases of mild bacterial conjunctivitis is not likely to be harmful because the\\ninfection often resolves spontaneously and antibiotics can be prescribed if symptoms persist.\\nTreatment\\n Prevention of spread\\n Treatment of symptoms\\nMost infectious conjunctivitis is highly contagious and spreads by droplet, fomites, and hand-to-eye\\ninoculation. To avoid transmitting infection, physicians must wash their hands thoroughly and disinfect\\nequipment after examining patients. Patients should wash their hands thoroughly after touching their eyes\\nor nasal secretions, avoid touching the noninfected eye after touching the infected eye, avoid sharing\\ntowels or pillows, and avoid swimming in pools. Eyes should be kept free of discharge and should not be\\npatched. Small children with conjunctivitis should be kept home from school to avoid spread. Cool wash-\\ncloths applied to the eyes may help relieve local burning and itching. Antimicrobials are used for certain\\ninfections.\\nViral Conjunctivitis\\nViral conjunctivitis is a highly contagious acute conjunctival infection usually caused by\\nadenovirus. Symptoms include irritation, photophobia, and watery discharge. Diagnosis is\\nclinical. Infection is self-limited, but severe cases sometimes require topical corticosteroids.\\nEtiology\\nConjunctivitis may accompany the common cold and other systemic viral infections (especially measles,\\nbut also chickenpox, rubella, and mumps). Isolated viral conjunctivitis usually results from adenoviruses\\nand sometimes enteroviruses.\\nEpidemic keratoconjunctivitis usually results from adenovirus serotypes Ad 5, 8, 11, 13, 19, and 37.\\nPharyngoconjunctival fever usually results from serotypes Ad 3, 4, and 7. Outbreaks of acute\\nhemorrhagic conjunctivitis, a rare conjunctivitis associated with infection by enterovirus type 70, have\\noccurred in Africa and Asia.\\nSymptoms and Signs\\nAfter an incubation period of about 5 to 12 days, conjunctival hyperemia, watery discharge, and ocular\\nirritation usually begin in one eye and spread rapidly to the other. Follicles may be present on the\\npalpebral conjunctiva. A preauricular lymph node is often enlarged and painful. Many patients have had\\ncontact with someone with conjunctivitis, a recent URI, or both.\\n[\\nTable 63-1.\\n Differentiating Features in Acute Conjunctivitis]\\nIn severe adenoviral conjunctivitis, patients may have photophobia and foreign body sensation. Chemosis\\nmay be present. Pseudomembranes of fibrin and inflammatory cells on the tarsal conjunctiva, focal\\ncorneal inflammation, or both may blur vision. Even after conjunctivitis has resolved, residual corneal\\nsubepithelial opacities (multiple, coin-shaped, 0.5 to 1.0 mm in diameter) may be visible with a slit lamp for\\nup to 2 yr. Corneal opacities occasionally result in decreased vision and significant glare.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n682\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 692, 'page_label': '683'}, page_content='Diagnosis\\n Clinical evaluation\\nDiagnosis of conjunctivitis and differentiation between bacterial, viral, and noninfectious conjunctivitis are\\nusually clinical; special tissue cultures are necessary for growth of the virus but are rarely indicated.\\nFeatures that may help differentiate between viral and bacterial conjunctivitis can include purulence of\\neye discharge, presence of preauricular lymphadenopathy, and, in epidemic keratoconjunctivitis,\\nchemosis. Patients with photophobia are stained with fluorescein and examined with a slit lamp. Epidemic\\nkeratoconjunctivitis may cause punctate corneal staining. Secondary bacterial infection of viral\\nconjunctivitis is rare. However, if any signs suggest bacterial conjunctivitis (eg, purulent discharge),\\nsmears from the eye may be examined microscopically and cultured for bacteria.\\nTreatment\\n Supportive measures\\nViral conjunctivitis is highly contagious, and transmission precautions must be followed (as described\\npreviously). Children should generally be kept out of school until resolution.\\nViral conjunctivitis is self-limiting, lasting 1 wk in mild cases to up to 3 wk in severe cases. It requires only\\nwarm or cool compresses for symptomatic relief. However, patients who have severe photophobia or\\nwhose vision is affected may benefit from topical corticosteroids (eg, 1% prednisolone acetate q 6 to 8 h).\\nCorticosteroids, if prescribed, are usually prescribed by an ophthalmologist. Herpes simplex keratitis (see\\np. \\n589\\n) must be ruled out first (by fluorescein staining and slit-lamp examination) because corticosteroids\\ncan exacerbate it.\\nAcute Bacterial Conjunctivitis\\nAcute conjunctivitis can be caused by numerous bacteria. Symptoms are hyperemia,\\nlacrimation, irritation, and discharge. Diagnosis is clinical. Treatment is with topical antibiotics,\\naugmented by systemic antibiotics in more serious cases.\\nMost bacterial conjunctivitis is acute; chronic bacterial conjunctivitis may be caused by \\nChlamydia\\n and\\nrarely \\nMoraxella\\n. Chlamydial conjunctivitis includes trachoma and adult or neonatal inclusion\\nconjunctivitis.\\nEtiology\\nBacterial conjunctivitis is usually caused by \\nStaphylococcus aureus\\n, \\nStreptococcus pneumoniae\\n,\\nHaemophilus\\n sp, or, less commonly, \\nChlamydia trachomatis\\n (see p. \\n583\\n). \\nNeisseria gonorrhoeae\\n causes\\ngonococcal conjunctivitis, which usually results from sexual contact with a person who has a genital\\ninfection.\\nOphthalmia neonatorum (see also p. \\n2824\\n) is conjunctivitis that occurs in 20 to 40% of neonates\\ndelivered through an infected birth canal. It can be caused by maternal gonococcal or chlamydial\\ninfection.\\nSymptoms and Signs\\nSymptoms are typically unilateral but frequently spread to the opposite eye within a few days. Discharge\\nis typically purulent.\\nThe bulbar and tarsal conjunctivae are intensely hyperemic and edematous. Petechial subconjunctival\\nhemorrhages, chemosis, photophobia, and an enlarged preauricular lymph node are typically absent.\\nEyelid edema is often moderate.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n683'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 693, 'page_label': '684'}, page_content=\"With adult gonococcal conjunctivitis, symptoms develop 12 to 48 h after exposure. Severe eyelid edema,\\nchemosis, and a profuse purulent exudate are typical. Rare complications include corneal ulceration,\\nabscess, perforation, panophthalmitis, and blindness.\\nOphthalmia neonatorum caused by gonococcal infection appears 2 to 5 days after delivery. With\\nophthalmia neonatorum caused by a chlamydial infection, symptoms appear within 5 to 14 days.\\nSymptoms of both are bilateral, intense papillary conjunctivitis with lid edema, chemosis, and\\nmucopurulent discharge.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis of conjunctivitis and differentiation between bacterial, viral, and noninfectious conjunctivitis are\\nusually clinical. Smears and bacterial cultures should be done in patients with severe symptoms,\\nimmunocompromise, ineffective initial \\ntherapy, or a vulnerable eye (eg, after a corneal transplant, in\\nexophthalmos due to Graves' disease). Smears and conjunctival scrapings should be examined\\nmicroscopically and stained with Gram stain to identify bacteria and stained with Giemsa stain to identify\\nthe characteristic epithelial cell basophilic cytoplasmic inclusion bodies of chlamydial conjunctivitis.\\nTreatment\\n Antibiotics (topical for all causes except gonococcal)\\nBacterial conjunctivitis is very contagious, and standard infection control measures (see p. \\n581\\n) should be\\nfollowed.\\nIf neither gonococcal nor chlamydial infection is suspected, most clinicians treat presumptively with\\nmoxifloxacin 0.5% drops tid for 7 to 10 days or another fluoroquinolone or trimethoprim/polymyxin B qid. A\\npoor clinical response after 2 or 3 days indicates that the cause is resistant bacteria, a virus, or an allergy.\\nCulture and sensitivity studies determine subsequent treatment.\\nAdult gonococcal conjunctivitis requires a single dose of ceftriaxone 1 g IM. Fluoroquinolones are no\\nlonger recommended because resistance is now widespread. Bacitracin 500 U/g or gentamicin 0.3%\\nophthalmic ointment instilled into the affected eye q 2 h may be used in addition to systemic treatment.\\nSex partners should also be treated. Because chlamydial genital infection is often present in patients with\\ngonorrhea, patients should also receive a single dose of azithromycin 1 g or doxycycline 100 mg po bid\\nfor 7 days.\\nOphthalmia neonatorum is prevented by the routine use of silver nitrate eye drops or erythromycin\\nointment at birth. Infections that develop despite this treatment require systemic treatment. For\\ngonococcal infection, ceftriaxone 25 to 50 mg/kg IV or IM is given once/day for 7 days. Chlamydial\\ninfection is treated with erythromycin 12.5 mg/kg po or IV qid for 14 days. The parents should also be\\ntreated.\\nAdult Inclusion Conjunctivitis\\n(Adult Chlamydial Conjunctivitis; Swimming Pool Conjunctivitis)\\nAdult inclusion conjunctivitis is caused by sexually transmitted \\nChlamydia trachomatis\\n.\\nSymptoms include chronic unilateral hyperemia and mucopurulent discharge. Diagnosis is\\nclinical. Treatment is with systemic antibiotics.\\nAdult inclusion conjunctivitis is caused by \\nChlamydia trachomatis\\n serotypes D through K. In most\\ninstances, adult inclusion conjunctivitis results from sexual contact with a person who has a genital\\ninfection. Usually, patients have acquired a new sex partner in the preceding 2 mo. Rarely, adult inclusion\\nconjunctivitis is acquired from contaminated, incompletely chlorinated swimming pool water.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n684\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 694, 'page_label': '685'}, page_content='Symptoms and Signs\\nAdult inclusion conjunctivitis has an incubation period of 2 to 19 days. Most patients have a unilateral\\nmucopurulent discharge. The tarsal conjunctiva is often more hyperemic than the bulbar conjunctiva.\\nCharacteristically, there is a marked tarsal follicular response. Occasionally, superior corneal opacities\\nand vascularization occur. Preauricular lymph nodes may be swollen on the side of the involved eye.\\nOften, symptoms have been present for many weeks or months and have not responded to topical\\nantibiotics.\\nDiagnosis\\n Clinical evaluation\\n Laboratory testing\\nChronicity, mucopurulent discharge, marked tarsal follicular response, and failure of topical antibiotics\\ndifferentiate adult inclusion conjunctivitis from other bacterial conjunctivitides. Smears, bacterial cultures,\\nand chlamydial studies should be done. Immunofluorescent staining techniques, PCR, and special\\ncultures are used to detect \\nC. trachomatis\\n. Smears and conjunctival scrapings should be examined\\nmicroscopically and stained with Gram stain to identify bacteria and stained with Giemsa stain to identify\\nthe characteristic epithelial cell basophilic cytoplasmic inclusion bodies of chlamydial conjunctivitis.\\nTreatment\\n Antibiotics\\nAzithromycin 1 g po once only or either doxycycline 100 mg po bid or erythromycin 500 mg po qid for 1 wk\\ncures the conjunctivitis and concomitant genital infection. Sex partners also require treatment.\\nTrachoma\\n(Egyptian Ophthalmia; Granular Conjunctivitis)\\nTrachoma is a chronic conjunctivitis caused by \\nChlamydia trachomatis\\n and is characterized by\\nprogressive exacerbations and remissions. \\nIt is the leading cause of preventable blindness\\nworldwide. Initial symptoms are conjunctival hyperemia, eyelid edema, photophobia, and\\nlacrimation. Later, corneal neovascularization and scarring of the conjunctiva, cornea, and\\neyelids occur. Diagnosis is usually clinical. Treatment is with topical or systemic antibiotics.\\nTrachoma is endemic in poverty-stricken parts of North Africa, the Middle East, the Indian subcontinent,\\nAustralia, and Southeast Asia. The causative organism is \\nChlamydia trachomatis\\n (serotypes A, B, Ba,\\nand C). In the US, trachoma is rare, occurring occasionally among Native Americans and immigrants. The\\ndisease occurs mainly in children, particularly those between the ages of 3 and 6. Older children and\\nadults are much less susceptible because of increased immunity and better personal hygiene. Trachoma\\nis highly contagious in its early stages and is transmitted by eye-to-eye contact, hand-to-eye contact, eye-\\nseeking flies, or the sharing of contaminated articles (eg, towels, handkerchiefs, eye makeup).\\nSymptoms and Signs\\nTrachoma usually affects both eyes. After an incubation period of about 7 days, conjunctival hyperemia,\\neyelid edema, photophobia, and lacrimation gradually appear, usually bilaterally. Small follicles develop in\\nthe upper tarsal conjunctiva 7 to 10 days later and gradually increase in size and number for 3 or 4 wk\\n(see\\nPlate 20\\n). Inflammatory papillae appear on the upper tarsal conjunctiva, and corneal neovascularization\\nbegins during this stage, with invasion of the upper half of the cornea by loops of vessels from the limbus\\n(called pannus). The stage of follicular/papillary hypertrophy and corneal neovascularization may last\\nfrom several months to > 1 yr, depending on response to therapy. The entire cornea may ultimately be\\ninvolved, reducing vision.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n685'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 695, 'page_label': '686'}, page_content='Without treatment, a cicatricial (scarring) stage follows. The follicles and papillae gradually shrink and are\\nreplaced by scar tissue that often causes entropion and lacrimal duct obstruction. Entropion leads to\\nfurther corneal scarring and neovascularization. Secondary bacterial infection is common, contributing to\\nscarring and disease progression. The corneal epithelium becomes dull and thickened, and lacrimation is\\ndecreased. Small corneal ulcers may appear at the site of peripheral corneal infiltrates, stimulating further\\nneovascularization.\\nWith treatment and healing, the conjunctiva becomes smooth and grayish white. Rarely, corneal\\nneovascularization regresses completely without treatment, and corneal transparency is restored.\\nImpaired vision or blindness occurs in about 5% of people with trachoma.\\nDiagnosis\\n Clinical findings (eg, tarsal lymphoid follicles, linear conjunctival scars, corneal pannus)\\nDiagnosis is usually clinical because testing is rarely available in endemic areas. Lymphoid follicles on the\\ntarsal plate or along the corneal limbus, linear conjunctival scarring, and corneal pannus are considered\\ndiagnostic in the appropriate clinical setting. If diagnosis is uncertain, \\nC. trachomatis\\n can be isolated in\\nculture or identified by PCR and immunofluorescence techniques. In the early stage, minute basophilic\\ncytoplasmic inclusion bodies within conjunctival epithelial cells in Giemsa-stained conjunctival scrapings\\ndifferentiate trachoma from nonchlamydial conjunctivitis. Inclusion bodies are also found in adult inclusion\\nconjunctivitis (see p. \\n583\\n), but the setting and developing clinical picture distinguish it from trachoma.\\nPalpebral vernal conjunctivitis appears similar to trachoma in its follicular hypertrophic stage, but\\nsymptoms are different, milky flat-topped papillae are present, and eosinophils (not basophilic inclusion\\nbodies) are found in the scrapings.\\nTreatment\\n Oral azithromycin\\nFor individual or sporadic cases, azithromycin 20 mg/kg (maximum 1 g) po as a single dose is 78%\\neffective. Alternatives are doxycycline 100 mg bid or tetracycline 250 mg qid for 4 wk. In hyperendemic\\nareas, tetracycline or erythromycin ophthalmic ointment applied bid for 5 consecutive days each month for\\n6 mo has been effective as treatment and prophylaxis. Endemic trachoma has been dramatically reduced\\nby using community-wide oral azithromycin in a single dose or in repeated doses. Reinfection due to re-\\nexposure is common among endemic areas. Better personal hygiene and environmental measures (eg,\\naccess to potable water) can reduce reinfection.\\nEyelid deformities (eg, entropion) should be treated surgically.\\nAllergic Conjunctivitis\\n(Atopic Conjunctivitis; Atopic Keratoconjunctivitis; Hay Fever Conjunctivitis; Perennial Allergic\\nConjunctivitis; Seasonal Allergic Conjunctivitis; Vernal Keratoconjunctivitis)\\nAllergic conjunctivitis is an acute, intermittent, or chronic conjunctival inflammation usually\\ncaused by airborne allergens. Symptoms include itching, lacrimation, discharge, and\\nconjunctival hyperemia. Diagnosis is clinical. Treatment is with topical antihistamines and mast\\ncell stabilizers.\\nEtiology\\nAllergic conjunctivitis is due to a type I hypersensitivity reaction to a specific antigen.\\nSeasonal allergic conjunctivitis\\n (hay fever conjunctivitis) is caused by airborne pollen of trees,\\ngrasses, or weeds. It tends to peak during the spring, late summer, or early fall and disappear during the\\nwinter monthscorresponding to the life cycle of the causative plant.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n686'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 696, 'page_label': '687'}, page_content=\"Perennial allergic conjunctivitis\\n (atopic conjunctivitis, atopic keratoconjunctivitis) is caused by dust\\nmites, animal dander, and other nonseasonal allergens. These allergens, particularly those in the home,\\ntend to cause symptoms year-round.\\nVernal keratoconjunctivitis\\n is a more severe type of conjunctivitis most likely allergic in origin. It is most\\ncommon among males aged 5 to 20 who also have eczema, asthma, or seasonal allergies. Vernal\\nconjunctivitis typically reappears each spring and subsides in the fall and winter. Many children outgrow\\nthe condition by early adulthood.\\nSymptoms and Signs\\nGeneral:\\n Patients report bilateral mild to intense ocular itching, conjunctival hyperemia, photosensitivity\\n(photophobia in severe cases), eyelid edema, and watery or stringy discharge. Concomitant rhinitis is\\ncommon. Many patients have other atopic diseases, such as eczema, allergic rhinitis, or asthma.\\nFindings characteristically include conjunctival edema and hyperemia and a discharge. The bulbar\\nconjunctiva may appear translucent, bluish, and thickened. Chemosis and a characteristic boggy\\nblepharedema of the lower eyelid are common. Chronic itching can lead to chronic eyelid rubbing,\\nperiocular hyperpigmentation, and dermatitis.\\nSeasonal and perennial conjunctivitis:\\n Fine papillae on the upper tarsal conjunctiva give it a velvety\\nappearance. In more severe forms, larger tarsal conjunctival papillae, conjunctival scarring, corneal\\nneovascularization, and corneal scarring with variable loss of visual acuity can occur.\\nVernal keratoconjunctivitis:\\n Usually, the palpebral conjunctiva of the upper eyelid is involved, but the\\nbulbar conjunctiva is sometimes affected. In the palpebral form, square, hard, flattened, closely packed,\\npale pink to grayish cobblestone papillae are present, chiefly in the upper tarsal conjunctiva (see\\nPlate 8\\n). The uninvolved tarsal conjunctiva is milky white. In the bulbar (limbal) form, the circumcorneal\\nconjunctiva becomes hypertrophied and grayish. Discharge may be tenacious and mucoid, containing\\nnumerous eosinophils.\\nOccasionally, a small, circumscribed loss of corneal epithelium occurs, causing pain and increased\\nphotophobia. Other corneal changes (eg, central plaques) and white limbal deposits of eosinophils\\n(Trantas' dots) may be seen.\\nDiagnosis\\nThe diagnosis is usually clinical. Eosinophils are present in conjunctival scrapings, which may be taken\\nfrom the lower or upper tarsal conjunctiva; however, such testing is rarely indicated.\\nTreatment\\n Symptomatic measures\\n Topical antihistamines, vasoconstrictors, NSAIDs, mast cell stabilizers, or a combination\\n Topical corticosteroids or cyclosporine for recalcitrant cases\\nAvoidance of known allergens and use of tear supplements can reduce symptoms; antigen\\ndesensitization is occasionally helpful. Topical OTC antihistamine/vasoconstrictors (eg,\\nnaphazoline/pheniramine) are useful for mild cases. If these drugs are insufficient, topical prescription\\nantihistamines (eg, olopatadine, ketotifen), NSAIDs (eg, ketorolac), or mast cell stabilizers (eg, pemirolast,\\nnedocromil, azelastine) can be used separately or in combination. Topical corticosteroids (eg, loteprednol,\\nfluorometholone 0.1%, prednisolone acetate 0.12% to 1% drops tid) can be useful in recalcitrant cases.\\nBecause topical corticosteroids can exacerbate ocular herpes simplex virus infections, possibly leading to\\ncorneal ulceration and perforation and, with long-term use, to glaucoma and possibly cataracts, their use\\nshould be initiated and monitored by an ophthalmologist. Topical cyclosporine may be indicated when\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n687\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 697, 'page_label': '688'}, page_content=\"corticosteroids are needed but cannot be used.\\nSeasonal allergic conjunctivitis is less likely to require multiple drugs or intermittent topical corticosteroids.\\nOther Conjunctival Disorders\\nPinguecula and pterygium:\\n These lesions are benign growths of the conjunctiva that can \\nresult from\\nchronic actinic irritation. Both typically appear adjacent to the cornea at the 3-o'clock position, the 9-\\no'clock position, or both (see\\nFig. 63-1\\n).\\nA \\npinguecula\\n is a raised yellowish white mass on the bulbar conjunctiva, adjacent to the cornea. It does\\nnot tend to grow onto the cornea. However, it may cause irritation or cosmetic blemish and, although\\nrarely necessary, can easily be removed.\\nA \\npterygium\\n is a fleshy triangular growth of bulbar conjunctiva that may spread across and distort the\\ncornea, induce astigmatism, and change the refractive power of the eye. Symptoms may include\\ndecreased vision and foreign body sensation. It is more common in hot, dry climates. Removal is often\\nindicated for cosmesis, to reduce irritation, and to improve or preserve vision.\\nSubconjunctival hemorrhages:\\n These extravasations of blood beneath the conjunctiva usually result\\nfrom minor trauma, straining, sneezing, or coughing; rarely, they occur spontaneously. The extent and\\nlocation of hyperemia can help determine etiology. Diffuse hyperemia of the bulbar and tarsal\\nconjunctivae is typical of conjunctivitis. Subconjunctival hemorrhages alarm the patient but are of no\\npathologic significance except when associated with blood dyscrasia, which is rare, or other facial or\\nocular injuries. They are absorbed spontaneously, usually within 2 wk. Topical corticosteroids, antibiotics,\\nvasoconstrictors, and compresses do not speed reabsorption; reassurance is adequate therapy.\\nEpiscleritis\\nEpiscleritis is self-limiting, recurring, idiopathic inflammation of the episcleral tissue that does\\nnot threaten vision. Symptoms are a localized area of hyperemia of the globe, irritation, and\\nlacrimation. Diagnosis is clinical. Treatment is symptomatic.\\nEpiscleritis occurs in young adults, more commonly among women. It is usually idiopathic; it can be\\nassociated with connective tissue diseases and rarely with serious systemic diseases.\\nMild irritation occurs. Additionally, a bright red patch is present just under the bulbar conjunctiva (simple\\nepiscleritis). A hyperemic, edematous, raised nodule (nodular episcleritis) may also be present. The\\npalpebral conjunctiva is normal.\\nEpiscleritis is distinguished from conjunctivitis because hyperemia is localized to a limited area of the\\nglobe and lacrimation is much less. It is distinguished from scleritis by lack of photophobia and lack of\\nsevere pain.\\nThe condition is self-limited, and a diagnostic assessment for systemic disorders is not routinely\\nwarranted. A topical corticosteroid (eg, prednisolone acetate, 1% drops qid for 5 days, gradually reduced\\nover 3 wk) or an oral NSAID usually shortens the attack; corticosteroids are usually prescribed by an\\nophthalmologist. Topical vasoconstrictors (eg, tetrahydrozoline) to improve appearance are optional.\\n[\\nFig. 63-1.\\n Pinguecula and pterygium.]\\nScleritis\\nScleritis is a severe, destructive, vision-threatening inflammation involving the deep episclera\\nand sclera. Symptoms are moderate to marked pain, hyperemia of the globe, lacrimation, and\\nphotophobia. Diagnosis is clinical. Treatment is with systemic corticosteroids and possibly\\nimmunosuppressants.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n688\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 698, 'page_label': '689'}, page_content=\"Scleritis is most common among women aged 30 to 50 yr, and many have connective tissue diseases,\\nsuch as RA, SLE, polyarteritis nodosa, Wegener's granulomatosis, or relapsing polychondritis. A few\\ncases are infectious in origin. About half of the cases of scleritis have no known cause. Scleritis most\\ncommonly involves the anterior segment and occurs in 3 typesdiffuse, nodular, and necrotizing\\n(scleromalacia perforans).\\nSymptoms and Signs\\nPain (often characterized as a deep, boring ache) is severe enough to interfere with sleep and appetite.\\nPhotophobia and lacrimation may occur. Hyperemic patches develop deep beneath the bulbar conjunctiva\\nand are more violaceous than those of episcleritis or conjunctivitis. The palpebral conjunctiva is normal.\\nThe involved area may be focal (usually one quadrant of the globe) or involve the entire globe and may\\ncontain a hyperemic, edematous, raised nodule (nodular scleritis) or an avascular area (necrotizing\\nscleritis). Posterior scleritis is less common and is less likely to cause red eye but more likely to cause\\nblurred or decreased vision.\\nIn severe cases of necrotizing scleritis, perforation of the globe and loss of the eye may result.\\nConnective tissue disease occurs in 20% of patients with diffuse or nodular scleritis and in 50% of\\npatients with necrotizing scleritis. Necrotizing scleritis in patients with connective tissue disease signals\\nunderlying systemic vasculitis.\\nDiagnosis\\nDiagnosis is made clinically and by slit-lamp examination. Smears or rarely biopsies are necessary to\\nconfirm infectious scleritis. CT or ultrasonography may be needed for posterior scleritis.\\nPrognosis\\nOf patients with scleritis, 14% lose significant visual acuity within 1 yr, and 30% lose significant visual\\nacuity within 3 yr. Patients with necrotizing scleritis and underlying systemic vasculitis have a mortality\\nrate of up to 50% in 10 yr (mostly due to MI).\\nTreatment\\n Systemic corticosteroids\\nOccasionally, NSAIDs are sufficient for mild cases. However, usually a systemic corticosteroid (eg,\\nprednisone 1 mg/kg po once/day) is the initial therapy. If patients are unresponsive to or intolerant of\\nsystemic corticosteroids or have necrotizing scleritis and connective tissue disease, systemic\\nimmunosuppression with cyclophosphamide or azathioprine is indicated, but only in consultation with a\\nrheumatologist. Scleral grafts may be indicated for threatened perforation.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 63. Conjunctival & Scleral Disorders\\n689\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 699, 'page_label': '690'}, page_content=\"Chapter 64. Corneal Disorders\\nIntroduction\\nThe cornea is subject to infection, noninfectious inflammation, ulceration, mechanical damage, and\\nenvironmental injury. Infection (keratitis), frequently with secondary conjunctivitis, can be due to viruses,\\nbacteria, \\nAcanthamoeba\\n, or fungi. Ulceration usually represents progression of keratitis. Symptoms that\\nsuggest corneal involvement rather than simple conjunctivitis include pain, particularly with exposure to\\nlight, and slight impairment of vision. Evaluation of the cornea requires slit-lamp examination and\\nsometimes microbial studies.\\nBullous Keratopathy\\nBullous keratopathy is the presence of corneal epithelial bullae, resulting from corneal\\nendothelial disease.\\nBullous keratopathy is caused by edema of the cornea, resulting from failure of the corneal endothelium\\nto maintain the normally dehydrated state of the cornea. Most frequently, it is due to Fuchs' corneal\\nendothelial \\ndystrophy or corneal endothelial trauma. Fuchs' dystrophy causes bilateral, progressive\\ncorneal endothelial cell loss, sometimes leading to symptomatic bullous keratopathy by age 50 to 60.\\nCorneal endothelial trauma can occur during intraocular surgery (eg, cataract removal) or after placement\\nof a poorly designed or malpositioned intraocular lens implant, leading to bullous keratopathy. Bullous\\nkeratopathy after cataract removal is called pseudophakic (if an intraocular lens implant is present) or\\naphakic (if no intraocular lens implant is present) bullous keratopathy.\\nSubepithelial fluid-filled bullae form on the corneal surface as the corneal stroma swells, leading to eye\\ndiscomfort, decreased visual acuity, loss of contrast, glare, and photophobia. Sometimes bullae rupture,\\ncausing pain and foreign body sensation. Bacteria can invade a ruptured bulla, leading to a corneal ulcer.\\nThe bullae and swelling of the corneal stroma can be seen on slit-lamp examination.\\nTreatment requires an ophthalmologist and includes topical dehydrating agents (eg, hypertonic saline),\\nintraocular pressure-lowering agents, soft contact lenses for some mild to moderate cases, and treatment\\nof any secondary microbial infection. Corneal transplantation is usually curative.\\nCorneal Ulcer\\nA corneal ulcer is a corneal epithelial defect with underlying inflammation (which soon results in\\nnecrosis of corneal tissue) due to invasion by bacteria, fungi, viruses, or \\nAcanthamoeba\\n. It can\\nbe initiated by mechanical trauma or nutritional deficiencies. Symptoms are progressive\\nredness, foreign body sensation, ache, photophobia, and lacrimation. Diagnosis is by slit-lamp\\nexamination, fluorescein staining, and microbial studies. Treatment with topical antimicrobials\\nand often dilating drops is urgent and requires an ophthalmologist.\\nEtiology\\nCorneal ulcers have many causes (see\\nTable 64-1\\n). Bacterial ulcers (most commonly due to contact lens wear) may complicate herpes simplex\\nkeratitis and be particularly refractory to treatment. Ulcers caused by \\nAcanthamoeba\\n (also most\\ncommonly due to contact lens wear) and fungi (most commonly due to trauma with vegetable material) are\\nindolent but progressive; those caused by \\nPseudomonas aeruginosa\\n (seen almost exclusively in contact\\nlens wearers) develop rapidly, causing deep and extensive corneal necrosis. Wearing contact lenses\\nwhile sleeping or wearing inadequately disinfected contact lenses can cause corneal ulcers (see p. \\n572\\n).\\nPathophysiology\\nUlcers are characterized by corneal epithelial defects with underlying inflammation, and soon necrosis of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n690\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 700, 'page_label': '691'}, page_content='the corneal stroma develops. Corneal ulcers tend to heal with scar tissue, resulting in opacification of the\\ncornea and decreased visual acuity. Uveitis, corneal perforation with iris prolapse, pus in the anterior\\nchamber (hypopyon), panophthalmitis, and destruction of the eye may occur with or without treatment.\\nMore severe symptoms and complications tend to occur with deeper ulcers.\\nSymptoms and Signs\\nConjunctival redness, eye ache, foreign body sensation, photophobia, and lacrimation may be minimal\\ninitially.\\nA corneal ulcer begins as a corneal epithelial defect that stains with fluorescein and an underlying dull,\\ngrayish, circumscribed superficial opacity. Subsequently, the ulcer suppurates and necroses to form an\\nexcavated ulcer. Considerable circumcorneal conjunctival hyperemia is usual (see\\nPlate 9\\n). In long-standing\\n[\\nTable 64-1.\\n Causes of Corneal Ulcers]\\ncases, blood vessels may grow in from the limbus (corneal neovascularization). The ulcer may spread to\\ninvolve the width of the cornea, may penetrate deeply, or both. Hypopyon (layered WBCs in the anterior\\nchamber) may occur.\\nCorneal ulcers due to \\nAcanthamoeba\\n are often intensely painful and may show transient corneal\\nepithelial defects, multiple corneal stromal infiltrates, and, later, a large ringshaped infiltrate. Fungal\\nulcers, which are more chronic than bacterial ulcers, are densely infiltrated and show occasional discrete\\nislands of infiltrate (satellite lesions) at the periphery.\\nDiagnosis\\n Slit-lamp examination\\nDiagnosis is made by slit-lamp examination; a corneal infiltrate with an epithelial defect that stains with\\nfluorescein is diagnostic. All but small ulcers should be cultured by scraping with a sterile platinum spatula\\n(typically by an ophthalmologist). Microscopic examination of scrapings can identify \\nAcanthamoeba\\n.\\nTreatment\\n Empiric topical broad-spectrum antibiotic therapy\\n More specific antimicrobial therapy directed at the cause\\nTreatment for corneal ulcers, regardless of cause, begins with moxifloxacin 0.5% or gatifloxacin 0.3% for\\nsmall ulcers and fortified (higher than stock concentration) antibiotic drops, such as tobramycin 15 mg/mL\\nand cefazolin 50 mg/mL, for more significant ulcers, particularly those that are near the center of the\\ncornea. Frequent dosing (eg, q 15 min for 4 doses, followed by q 1 h around the clock) is necessary\\ninitially. Patching is contraindicated because it creates a stagnant, warm environment that favors bacterial\\ngrowth and prevents the administration of topical drugs.\\nHerpes simplex (see below) is treated with trifluridine 1% drops q 2 h while the patient is awake or\\nacyclovir 400 mg po 5 times/day for about 14 days.\\nFungal infections are treated with one of many topical antifungal drops (eg, natamycin 5%, amphotericin\\nB 0.15%), initially q 1 h during the day and q 2 h overnight. Deep infections may require addition of oral\\nketoconazole, fluconazole, or itraconazole.\\nIf \\nAcanthamoeba\\n is identified, traditional therapy is propamidine and neomycin supplemented with\\nmiconazole, clotrimazole, or oral ketoconazole. Additional treatments include polyhexamethylene\\nbiguanide 0.02% or chlorhexidine 0.02% q 1 to 2 h until clinical improvement is evident, then gradually\\nreduced to 4 times/day and continued for a number of months until all inflammation has resolved.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n691'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 701, 'page_label': '692'}, page_content='Polyhexamethylene biguanide and chlorhexidine are not commercially available as ocular agents but can\\nbe prepared by a compounding pharmacy. Topical propamidine 0.1% q 1 to 2 h is often added for 3 days.\\nFor all ulcers, treatment may also include a cycloplegic, such as atropine 1% or scopolamine 0.25% 1\\ndrop tid, to decrease the ache of a corneal ulcer and to reduce the formation of posterior synechiae. In\\nsevere cases, debridement of the infected epithelium or even penetrating keratoplasty may be required.\\nPatients who are poorly compliant or who have large, central, or refractory ulcers may need to be\\nhospitalized.\\nHerpes Simplex Keratitis\\n(Herpes Simplex Keratoconjunctivitis)\\nHerpes simplex keratitis is corneal infection with herpes simplex virus (see also p. \\n1417\\n). It may\\ninvolve the iris. Symptoms and signs include foreign body sensation, lacrimation, photophobia,\\nand conjunctival hyperemia. Recurrences are common and may lead to corneal hypoesthesia,\\nulceration, and permanent scarring. Diagnosis is based on the characteristic dendritic corneal\\nulcer and sometimes viral culture. Treatment is with topical and occasionally systemic antiviral\\ndrugs.\\nHerpes simplex usually affects the corneal surface but sometimes involves the deeper layers of the\\ncornea (corneal stroma). Stromal involvement is probably an immunologic response to the virus.\\nAs with all herpes simplex virus infections, there is a primary infection, followed by a latent phase, in\\nwhich the virus goes into the nerve roots. Latent virus may reactivate, causing recurrent symptoms.\\nSymptoms and Signs\\nPrimary infection:\\n The initial (primary) infection is usually nonspecific self-limiting conjunctivitis, often in\\nearly childhood and sometimes without corneal involvement. If the cornea is involved, early symptoms\\ninclude foreign body sensation, lacrimation, photophobia, and conjunctival hyperemia. Sometimes\\nvesicular blepharitis (blisters on the eyelid) follows, symptoms worsen, vision blurs, and blisters break\\ndown and ulcerate, then resolve without scarring in about a week.\\nRecurrent infection:\\n Recurrences usually take the form of epithelial keratitis (also called dendritic\\nkeratitis) with tearing, foreign body sensation, and a characteristic branching (dendritic or serpentine)\\nlesion of the corneal epithelium with knoblike terminals that stain with fluorescein (see\\nPlate 14\\n). Multiple recurrences may result in corneal hypoesthesia or anesthesia, ulceration, and\\npermanent scarring.\\nStromal involvement:\\n Most patients with disciform keratitis, which involves the corneal stroma, have a\\nhistory of epithelial keratitis. Disciform keratitis is a deeper, disk-shaped, localized area of corneal edema\\nand haze accompanied by anterior uveitis. This form may cause pain and vision loss.\\nStromal keratitis can cause necrosis of the stroma and severe ache, photophobia, foreign body\\nsensation, and decreased vision.\\nDiagnosis\\nSlit-lamp examination is mandatory. Finding a dendrite is enough to confirm the diagnosis in most cases.\\nWhen the appearance is not conclusive, viral culture of the lesion can confirm the diagnosis.\\nTreatment\\n Topical trifluridine\\n Sometimes oral or IV acyclovir\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n692'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 702, 'page_label': '693'}, page_content=' For stromal involvement or uveitis, topical corticosteroids in addition to antiviral drugs\\nMost patients are managed by an ophthalmologist. If stromal or uveal involvement occurs, treatment is\\nmore involved and referral to an ophthalmologist is mandatory.\\nTopical therapy (eg, trifluridine 1% drops 9 times/day) is usually effective. Occasionally, acyclovir 400 mg\\npo 5 times/day is indicated. Immunocompromised patients may require IV antivirals (eg, acyclovir 5 mg/kg\\nIV q 8 h for 7 days). If the epithelium surrounding the dendrite is loose and edematous, debridement by\\ngentle swabbing with a cotton-tipped applicator before beginning drug therapy may speed healing.\\nTopical corticosteroids are contraindicated in epithelial keratitis\\n but may be effective when used with an\\nantiviral drug to manage later-stage stromal involvement (disciform or stromal keratitis) or uveitis. In such\\ncases, patients may be given prednisolone acetate 1% instilled q 2 h initially, lengthening the interval to q\\n4 to 8 h as symptoms improve. Topical drugs to relieve photophobia include atropine 1% or scopolamine\\n0.25% tid.\\nHerpes Zoster Ophthalmicus\\n(Herpes Zoster Virus Ophthalmicus; Ophthalmic Herpes Zoster; Varicella-Zoster Virus Ophthalmicus)\\nHerpes zoster ophthalmicus is reactivation of a varicella-zoster virus infection (shingles) (see\\nalso p. \\n1420\\n) involving the eye. Symptoms and signs, which may be intense, include\\ndermatomal forehead rash and painful inflammation of all the tissues of the anterior and, rarely,\\nposterior structures of the eye. Diagnosis is based on the characteristic appearance of the\\nanterior structures of the eye plus zoster dermatitis of the first branch of the trigeminal nerve.\\nTreatment is with oral antiviral drugs, mydriatics, and topical corticosteroids.\\nHerpes zoster of the forehead involves the globe in three fourths of cases when the nasociliary nerve is\\naffected (as indicated by a lesion on the tip of the nose) and in one third of cases not involving the tip of\\nthe nose. Overall, the globe is involved in half of patients.\\nSymptoms and Signs\\nA prodrome of tingling of the forehead may occur. During acute disease, in addition to the forehead rash,\\nsymptoms and signs may include severe pain; marked eyelid edema; conjunctival, episcleral, and\\ncircumcorneal conjunctival hyperemia; corneal edema; and photophobia (see\\nPlate 15\\n).\\nComplications:\\n Keratitis accompanied by uveitis may be severe and followed by scarring. Late sequelae\\nglaucoma, cataract, chronic or recurrent uveitis, corneal scarring, corneal neovascularization, and\\nhypesthesiaare common and may threaten vision. Postherpetic neuralgia may develop late.\\nDiagnosis\\n Zoster rash on the forehead or eyelid plus eye findings\\nDiagnosis is based on a typical acute herpes zoster rash on the forehead, eyelid, or both or on a\\ncharacteristic history plus signs of previous zoster rash. Vesicular or bullous lesions in this distribution\\nthat do not yet involve the eye suggest significant risk and should prompt an ophthalmologic consultation\\nto determine whether the eye is involved. Culture and immunologic or PCR studies of skin at initial\\nevaluation or serial serologic tests are done only when lesions are atypical and the diagnosis uncertain.\\nTreatment\\n Oral antivirals (eg, acyclovir, famciclovir, valacyclovir)\\n Sometimes topical corticosteroids\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n693'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 703, 'page_label': '694'}, page_content=\"Early treatment with acyclovir 800 mg po 5 times/day or famciclovir 500 mg or valacyclovir 1 g po tid for 7\\ndays reduces ocular complications. Patients with keratitis or uveitis require topical corticosteroids (eg,\\nprednisolone acetate 1% instilled qid initially, lengthening the interval as symptoms lessen). The pupil\\nshould be dilated with atropine 1% or scopolamine 0.25% 1 drop tid. Intraocular pressure must be\\nmonitored and treated if it rises significantly above normal values.\\nUse of a brief course of high-dose oral corticosteroids to prevent postherpetic neuralgia in patients > 60\\nyr who are in good general health remains controversial.\\nInterstitial Keratitis\\n(Parenchymatous Keratitis)\\nInterstitial keratitis is chronic, nonulcerative inflammation of the middle layers of the cornea (ie,\\nmid-stroma) that is sometimes associated with uveitis. The cause is usually infectious.\\nSymptoms are photophobia, pain, lacrimation, and vision blurring. Diagnosis is by slit-lamp\\nexamination and serologic tests to determine the cause. Treatment is directed at the cause and\\nmay require topical corticosteroids.\\nInterstitial keratitis, a manifestation of certain corneal infections, is rare in the US. Most cases occur in\\nchildren or adolescents as a late complication of congenital syphilis (see p. \\n2821\\n). Ultimately, both eyes\\nmay be involved. A similar but less dramatic bilateral keratitis occurs in Cogan's syndrome, Lyme disease,\\nand Epstein-Barr virus infection. Rarely, acquired syphilis, herpes simplex, herpes zoster, or TB may\\ncause a unilateral form in adults.\\nSymptoms and Signs\\nPhotophobia, pain, lacrimation, and vision blurring are common. The lesion begins as patches of\\ninflammation in the middle corneal layers (ie, mid-stroma) that cause opacification. Typically with syphilis\\nand occasionally with other causes, the entire cornea develops a ground-glass appearance, obscuring\\nthe iris. New blood vessels grow in from the limbus (neovascularization) and produce orange-red areas\\n(salmon patches). Anterior uveitis and choroiditis are common in syphilitic interstitial keratitis. Inflammation\\nand neovascularization usually begin to subside after 1 to 2 mo. Some corneal opacity usually remains,\\ncausing mild to moderate vision impairment.\\nDiagnosis\\n Corneal opacification and other typical findings on slit-lamp examination\\n Serologic testing to determine etiology\\nThe specific etiology must be determined. The stigmas of congenital syphilis, vestibuloauditory\\nsymptoms, history of an expanding rash, and tick exposure support a specific etiology. However, all\\npatients should have serologic testing, including all of the following:\\n Fluorescent treponemal antibody absorption test or the microhemagglutination assay for \\nTreponema\\npallidum\\n Lyme titer\\n Epstein-Barr virus panel\\nPatients with negative serologic test results may have Cogan's syndrome, an idiopathic syndrome\\nconsisting of interstitial keratitis and vestibular and auditory deficits. To prevent permanent\\nvestibuloauditory damage, symptoms of hearing loss, tinnitus, or vertigo require referral to an\\notolaryngologist.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n694\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 704, 'page_label': '695'}, page_content=\" Sometimes topical corticosteroids\\nKeratitis may resolve with treatment of the underlying condition. Additional topical treatment with a\\ncorticosteroid, such as prednisolone 1% qid, is often advisable. An ophthalmologist should be consulted.\\nCogan's Syndrome\\nCogan's syndrome is a rare autoimmune disease involving the eye and the inner ear.\\nCogan's syndrome affects young adults, with 80% of patients between 14 and 47 yr. The disease\\nappears to result from an autoimmune reaction directed against an unknown common autoantigen in the\\ncornea and inner ear. About 10 to 30% of patients also have severe systemic vasculitis, which may\\ninclude life-threatening aortitis.\\nSymptoms and Signs\\nThe presenting symptoms involve the ocular system in 38% of patients, the vestibuloauditory system in\\n46%, and both in 15%. \\nBy 5 mo, 75% of patients have both ocular and vestibuloauditory symptoms.\\nNonspecific systemic complaints include fever, headache, joint pain, and myalgia.\\nOcular:\\n Ocular involvement includes any combination of the following:\\n Bilateral interstitial keratitis or other corneal stromal keratitis\\n Episcleritis or scleritis\\n Uveitis\\n Papillitis\\n Other orbital inflammation (eg, vitritis, choroiditis)\\nOcular symptoms include irritation, pain, photophobia, and decreased vision. Ocular examination shows a\\npatchy corneal stromal infiltrate typical of interstitial keratitis (see p. \\n591\\n), ocular redness, optic nerve\\nedema, proptosis, or a combination of these symptoms.\\nVestibuloauditory:\\n Vestibuloauditory symptoms include sensorineural hearing loss, tinnitus, and vertigo.\\nVascular:\\n A diastolic heart murmur may be present when aortitis is significant. Claudication may be\\npresent if limb vessels are affected.\\nDiagnosis\\nDiagnosis is based on clinical findings and exclusion of other causes (eg, syphilis, Lyme disease,\\nEpstein-Barr virus infection) by appropriate serologic tests. Evaluation by an ophthalmologist and\\notolaryngologist is important.\\nTreatment\\n Initially topical and sometimes systemic corticosteroids\\nUntreated disease may lead to corneal scarring and visual loss and, in 60 to 80% of patients, permanent\\nhearing loss. Keratitis, episcleritis, and anterior uveitis can usually be treated with topical prednisolone\\nacetate 1% q 1 h to qid. To treat deeper ocular inflammation and especially to treat vestibuloauditory\\nsymptoms before they become permanent, prednisone 1 mg/kg po once/day is begun as soon as possible\\nand continued for 2 to 6 mo. Some clinicians add cyclophosphamide, methotrexate, or cyclosporine for\\nrecalcitrant cases.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n695\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 705, 'page_label': '696'}, page_content=\"Keratoconjunctivitis Sicca\\n(Dry Eyes; Keratitis Sicca)\\nKeratoconjunctivitis sicca is chronic, bilateral desiccation of the conjunctiva and cornea due to\\nan inadequate tear film. Symptoms include itching, burning, irritation, and photophobia.\\nDiagnosis is clinical; the Schirmer test may be helpful. Treatment is with topical tear\\nsupplements and sometimes blockage of the nasolacrimal openings.\\nEtiology\\nThere are 2 main types:\\n Aqueous tear-deficient keratoconjunctivitis sicca is caused by inadequate tear volume.\\n Evaporative keratoconjunctivitis sicca (more common) is caused by accelerated tear evaporation due to\\npoor tear quality.\\nAqueous tear-deficient keratoconjunctivitis sicca is most commonly an isolated idiopathic condition in\\npostmenopausal women. It is also commonly part of Sjogren's syndrome (see p. \\n303\\n), RA, or SLE. Less\\ncommonly, it is secondary to other conditions that scar the lacrimal ducts (eg, cicatricial pemphigoid,\\nStevens-Johnson syndrome, trachoma). It may result from a damaged or malfunctioning lacrimal gland\\ndue to graft-vs-host disease, HIV (diffuse infiltrative lymphocytosis syndrome), local radiation therapy, or\\nfamilial dysautonomia.\\nEvaporative keratoconjunctivitis sicca is caused by loss of the tear film due to abnormally rapid\\nevaporation caused by an inadequate oil layer on the surface of the aqueous layer of tears. Symptoms\\nmay result from abnormal oil quality (ie, meibomian gland dysfunction) or a degraded normal oil layer (ie,\\nseborrheic blepharitis). Patients frequently have acne rosacea.\\nDrying can also result from exposure due to inadequate eye closure at night (nocturnal lagophthalmos) or,\\nrarely, from inadequate tear volume due to an insufficient blink rate.\\nSymptoms and Signs\\nPatients report itching; burning; a gritty, pulling, or foreign body sensation; or photophobia. A sharp\\nstabbing pain, eye strain or fatigue, and blurred vision may also occur. Some patients note a flood of\\ntears after severe irritation. Typically, symptoms fluctuate in intensity and may be intermittent. Certain\\nfactors can worsen symptoms:\\n Prolonged visual efforts (eg, reading, working on the computer, driving, watching television)\\n Local environments that are dry, windy, dusty, or smoky\\n Certain systemic drugs, including isotretinoin, sedatives, diuretics, antihypertensives, oral\\ncontraceptives, and all anticholinergics (including antihistamines and many GI drugs)\\nSymptoms lessen on cool, rainy, or foggy days or in other high-humidity environments, such as in the\\nshower. Recurrent and prolonged blurring and frequent intense irritation can impair daily function.\\nHowever, permanent impairment of vision is rare.\\nWith both forms, the conjunctiva is hyperemic, and there is often scattered, fine, punctate loss of corneal\\nepithelium (superficial punctate keratitis), conjunctival epithelium, or both. When the condition is severe,\\nthe involved areas, mainly between the eyelids (the intrapalpebral or exposure zone), stain with\\nfluorescein. Patients often blink at an accelerated rate because of irritation.\\nWith the aqueous tear-deficient form, the conjunctiva can appear dry and lusterless with redundant folds.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n696\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 706, 'page_label': '697'}, page_content=\"With the evaporative form, abundant tears may be present as well as foam at the eyelid margin. Very\\nrarely, severe, advanced, chronic drying leads to significant vision loss due to keratinization of the ocular\\nsurface or loss of corneal epithelium, leading to sequelae such as scarring, neovascularization, infections,\\nulceration, and perforation.\\nDiagnosis\\n Schirmer test and tear breakup tests\\nDiagnosis is based on characteristic symptoms and clinical appearance. The Schirmer test and tear\\nbreakup test may differentiate type.\\nThe Schirmer test determines whether tear production is normal. After blotting the closed eye to remove\\nexcess tears, a strip of filter paper is placed, without topical anesthesia, at the junction of the middle and\\nlateral third of the lower eyelid. If < 5.5 mm of wetting occurs after 5 min on 2 successive occasions, the\\npatient has aqueous tear-deficient keratoconjunctivitis sicca.\\nWith evaporative keratoconjunctivitis sicca, the Schirmer test is usually normal. The tear film can be made\\nvisible under cobalt blue light at the slit lamp by instillation of a small volume of highly concentrated\\nfluorescein (made by wetting a fluorescein strip with saline and shaking the strip to remove any excess\\nmoisture). Blinking several times reapplies a complete tear film. The patient then stares, and the length of\\ntime until the first dry spot develops is determined (tear breakup test, or TBUT). An accelerated rate of\\nintact tear film breakup (< 10 sec) is characteristic of evaporative keratoconjunctivitis sicca.\\nIf aqueous tear-deficient keratoconjunctivitis sicca is diagnosed, Sjogren's syndrome (see p. \\n303\\n) should\\nbe suspected, especially if xerostomia is also present. Serologic tests and labial salivary gland biopsy are\\nused for diagnosis. Patients with primary or secondary Sjogren's syndrome are at increased risk of\\nseveral serious diseases (eg, primary biliary cirrhosis, non-Hodgkin lymphoma). Therefore, proper\\nevaluation and monitoring are essential.\\nTreatment\\n Artificial tears\\n Sometimes occlusion of nasolacrimal punctum or tarsorrhaphy\\nFrequent use of artificial tears can be effective for both forms. More viscous artificial tears coat the ocular\\nsurface longer, and artificial tears that contain polar lipids such as glycerin reduce evaporation; both types\\nare particularly useful in evaporative keratoconjunctivitis sicca. Artificial tear ointments applied before\\nsleep are particularly useful when patients have nocturnal lagophthalmos or irritation on waking. Most\\ncases are treated adequately throughout the patient's life with such supplementation. Staying hydrated,\\nusing humidifiers, and avoiding dry, drafty environments can often help. Not smoking and avoiding\\nsecondary smoke are important. In recalcitrant cases, occlusion of the nasolacrimal punctum may be\\nindicated. In severe cases, a partial tarsorrhaphy can reduce tear loss through evaporation. Topical\\ncyclosporine and \\n\\n-3 fatty acid dietary supplements may be a useful adjunct in some patients.\\nPatients with evaporative keratoconjunctivitis sicca often benefit from treatment of concomitant blepharitis\\nand associated rosacea with measures such as warm compresses, eyelid margin scrubs, and intermittent\\ntopical eyelid antibiotic ointments (eg, bacitracin at bedtime), systemic doxycycline 50 to 100 mg po once\\nor twice/day (contraindicated in pregnant or nursing patients), or both.\\nCyclosporine drops that decrease the inflammation associated with dryness of the eye are available.\\nThey lead to meaningful improvement but only in a fraction of patients. These drops sting and take\\nmonths before an effect is noticed.\\nKeratoconus\\nKeratoconus is a bulging distortion of the cornea, leading to loss of visual acuity.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n697\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 707, 'page_label': '698'}, page_content=\"Keratoconus is a slowly progressive thinning and bulging of the cornea, usually bilateral, beginning\\nbetween ages 10 and 25. Its cause is unknown.\\nThe distorted cone shape of the cornea causes major changes in the refractive characteristics of the\\ncornea (irregular astigmatism) that cannot be fully corrected with glasses. Progressing keratoconus\\nnecessitates frequent change of eyeglasses. Contact lenses may provide better vision correction and\\nshould be tried when eyeglasses are not satisfactory. Corneal transplant surgery may be necessary if\\nvisual acuity with contact lenses is inadequate, contact lenses are not tolerated, or a visually significant\\ncorneal scar (caused by tearing of stromal fibers) is present.\\nNewer treatments seem promising. Implantation of corneal ring segments appears to have the potential to\\nsave selected patients from transplantation. Corneal cross-linking, an ultraviolet light treatment that\\nstrengthens the cornea, has had positive results in European studies and may become more common.\\nKeratomalacia\\n(Xerotic Keratitis; Xerophthalmia)\\nKeratomalacia is degeneration of the cornea caused by nutritional deficiency.\\nKeratomalacia is caused by vitamin A deficiency typically in patients with protein-calorie undernutrition. It\\nis characterized by a hazy, dry cornea. Corneal ulceration with secondary infection is common. The\\nlacrimal glands and conjunctiva are also affected. Lack of tears causes extreme dryness of the eyes, and\\nfoamy spots appear on the temporal and often nasal bulbar conjunctiva (Bitot's spots). Night blindness\\nmay occur. For further details, including specific therapy, see Vitamin A Deficiency on p. \\n34\\n.\\nPeripheral Ulcerative Keratitis\\n(Marginal Keratolysis; Peripheral Rheumatoid Ulceration)\\nPeripheral ulcerative keratitis is inflammation and ulceration of the cornea that often occurs\\nwith chronic connective tissue diseases. Irritation and decreased vision result.\\nPeripheral ulcerative keratitis is a serious corneal ulceration; it often occurs with autoimmune diseases\\nthat are active, long-standing, or both, such as RA, Wegener's granulomatosis, and relapsing\\npolychondritis.\\nPatients often have decreased visual acuity, photophobia, and foreign body sensation. A crescentic area\\nof opacification in the periphery of the cornea, due to infiltration by WBCs and ulceration, stains with\\nfluorescein. Infectious causes, such as bacteria, fungi, and herpes simplex virus, must be ruled out by\\nculturing the ulcer and eyelid margins.\\nAmong patients with rheumatic disease and peripheral ulcerative keratitis, the 10-yr mortality rate is about\\n40% (usually due to MI) without treatment and about 8% with systemic cytotoxic therapy.\\nAny patient with peripheral ulcerative keratitis should be promptly referred to an ophthalmologist.\\nSystemic cyclophosphamide or other immunosuppressants treat the keratitis, life-threatening vasculitis,\\nand underlying autoimmune disease. Treatment also includes local approaches to control inflammation\\n(eg, tissue adhesive and bandage contact lenses) and repair damage (eg, patch grafts). Other possibly\\nhelpful drugs include collagenase inhibitors, such as systemic tetracycline or topical 20% \\nN\\n-\\nacetylcysteine.\\nPhlyctenular Keratoconjunctivitis\\n(Phlyctenular Conjunctivitis; Phlyctenulosis)\\nPhlyctenular keratoconjunctivitis, a hypersensitivity reaction of the cornea and conjunctiva to\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n698\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 708, 'page_label': '699'}, page_content='bacterial antigens, is characterized by discrete nodular areas of corneal or conjunctival\\ninflammation.\\nPhlyctenular keratoconjunctivitis results from a hypersensitivity reaction to bacterial antigens, primarily\\nstaphylococcal, but TB, \\nChlamydia\\n, and other agents have been implicated. It is more common in\\nchildren. Many patients also have blepharitis.\\nPatients have multiple lesions, consisting of small yellow-gray nodules (phlyctenules) that appear at the\\nlimbus, on the cornea, or on the bulbar conjunctiva and persist from several days to 2 wk. On the\\nconjunctiva, these nodules ulcerate but heal without a scar. When the cornea is affected, severe\\nlacrimation, photophobia, blurred vision, aching, and foreign body sensation may be prominent. Frequent\\nrecurrence, especially with secondary infection, may lead to corneal opacity and neovascularization with\\nloss of visual acuity.\\nDiagnosis is by characteristic clinical appearance. Testing for TB may be indicated (eg, for patients at\\nrisk).\\nTreatment for nontuberculous cases is with a topical corticosteroid-antibiotic combination. If patients have\\nseborrheic blepharitis, eyelid scrubs may help prevent recurrence.\\nSuperficial Punctate Keratitis\\nSuperficial punctate keratitis is corneal inflammation of diverse causes characterized by\\nscattered, fine, punctate corneal epithelial loss or damage. Symptoms are redness, lacrimation,\\nphotophobia, and slightly decreased vision. Diagnosis is by slit-lamp examination. Treatment\\ndepends on the cause.\\nSuperficial punctate keratitis is a nonspecific finding. Causes may include any of the following:\\n Viral conjunctivitis (most commonly adenovirus)\\n Blepharitis\\n Keratoconjunctivitis sicca\\n Trachoma\\n Chemical burns\\n Ultraviolet (UV) light exposure (eg, welding arcs, sunlamps, snow glare)\\n Contact lens overwear\\n Systemic drugs (eg, adenine arabinoside)\\n Topical drug or preservative toxicity.\\nSymptoms include photophobia, foreign body sensation, lacrimation, redness, and slightly decreased\\nvision. Slit-lamp or ophthalmoscope examination of the cornea reveals a characteristic hazy appearance\\nwith multiple punctate speckles that stain with fluorescein. With viral conjunctivitis, preauricular\\nadenopathy is common and chemosis may occur.\\nKeratitis that accompanies adenovirus conjunctivitis resolves spontaneously in about 3 wk. Blepharitis\\n(see p. \\n575\\n), keratoconjunctivitis sicca (see p. \\n592\\n), and trachoma (see p. \\n583\\n) require specific therapy.\\nWhen caused by overwearing contact lenses, keratitis is treated with discontinuation of the contact lens\\nand an antibiotic ointment (eg, ciprofloxacin 0.3% qid), but the eye is not patched because serious\\ninfection may result. Contact lens wearers with superficial punctate keratitis should be examined the next\\nday. Suspected causative topical drugs (active ingredient or preservative) should be stopped.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n699'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 709, 'page_label': '700'}, page_content=\"Ultraviolet keratitis:\\n UVB light (wavelength < 300 nm) can burn the cornea, causing keratitis or\\nkeratoconjunctivitis. Arc welding is a common cause; even a brief, unprotected glance at a welding arc\\nmay result in a burn. Other causes include high-voltage electric sparks, artificial sun lamps, and sunlight\\nreflected off snow at high altitudes. UV radiation increases 4 to 6% for every 1000-ft (305-m) increase in\\naltitude above sea level, and snow reflects 85% of UVB.\\nSymptoms are usually not apparent for 8 to 12 h after exposure and last 24 to 48 h. Patients have\\nlacrimation, pain, redness, swollen eyelids, photophobia, headache, foreign body sensation, and\\ndecreased vision. Permanent vision loss is rare.\\nDiagnosis is by history, presence of superficial punctate keratitis, and absence of a foreign body or\\ninfection.\\nTreatment consists of an antibiotic ointment (eg, bacitracin or gentamicin 0.3% ointment q 8 h) and\\noccasionally a short-acting cycloplegic drug (eg, cyclopentolate 1% drop q 4 h). Severe pain may require\\nsystemic analgesics. The corneal surface regenerates spontaneously in 24 to 48 h. The eye must be\\nrechecked in 24 h. Dark glasses or welder's helmets that block UV light are preventive.\\nCorneal Transplantation\\n(Corneal Graft; Penetrating Keratoplasty)\\nIndications:\\n Corneal transplantations are done for several reasons:\\n To reconstruct the cornea (eg, replacing a perforated cornea)\\n To relieve intractable pain (eg, severe foreign body sensation due to recurrent ruptured bullae in bullous\\nkeratopathy)\\n To treat a disorder unresponsive to medical management (eg, severe, uncontrolled fungal corneal ulcer)\\n To improve the optical qualities of the cornea and thus improve vision (eg, replacing a cornea that is\\nscarred after a corneal ulcer, is clouded because of edema as occurs in Fuchs' dystrophy or after\\ncataract surgery, is opaque because of deposits of nontransparent abnormal corneal stromal proteins\\nas occurs in hereditary corneal stromal dystrophy, or has irregular astigmatism as occurs with\\nkeratoconus)\\nThe most common indications are the following:\\n Bullous keratopathy (pseudophakic or aphakic, Fuchs' endothelial dystrophy)\\n Keratoconus\\n Repeat graft\\n \\nKeratitis or postkeratitis (caused by viral, bacterial, fungal, or \\nAcanthamoeba\\n infection or perforation)\\n Corneal stromal dystrophies\\nProcedure:\\n Tissue matching is not routinely done. Cadaveric donor tissue cannot be used from anyone\\nsuspected of having a communicable disease.\\nCorneal transplantation can be done using general anesthesia or local anesthesia plus IV sedation.\\nTopical antibiotics are used for several weeks postoperatively and topical corticosteroids for several\\nmonths. To protect the eye from inadvertent trauma after transplantation, the patient wears shields,\\nglasses, or sunglasses. If transplantation involves the full thickness of the cornea (as in penetrating\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n700\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 710, 'page_label': '701'}, page_content=\"keratoplasty, or PKP), achievement of full visual potential may take up to 18 mo because of changing\\nrefraction with wound healing and after suture removal. If only the endothelium is replaced (as in\\nDescemet's stripping endothelial keratoplasty), achievement of full visual potential usually occurs by 6\\nmo. In many patients, earlier and better vision is attained by wearing a rigid contact lens over the corneal\\ntransplant.\\nComplications:\\n Complications include the following:\\n Graft rejection\\n Infection (intraocular and corneal)\\n Wound leak\\n Glaucoma\\n Graft failure\\n High refractive error (especially astigmatism, myopia, or both)\\n Recurrence of disease (with herpes simplex or hereditary corneal stromal dystrophy)\\nGraft rejection rates are usually < 10% but may be up to 68% in higher-risk patients. Rejection symptoms\\ninclude decreased vision, photosensitivity, ocular ache, and ocular redness. Graft rejection is treated with\\ntopical corticosteroids (eg, prednisolone 1% hourly), sometimes with a supplemental periocular injection\\n(eg, triamcinolone acetonide 40 mg). If graft rejection is severe or if graft function is marginal, additional\\ncorticosteroids are given orally (eg, prednisone 1 mg/kg once/day) and occasionally IV (eg,\\nmethylprednisolone 3 to 5 mg/kg once). Typically, the rejection episode reverses, and graft function\\nreturns fully. The graft may fail if the rejection episode is unusually severe or long-standing or if multiple\\nepisodes of graft rejection occur. Regraft is possible, but the long-term prognosis is worse than for the\\noriginal graft.\\nPrognosis\\nThe chance of long-term transplant success is\\n > 90% for keratoconus, corneal scars, early bullous keratopathy, or hereditary corneal stromal\\ndystrophies\\n 80 to 90% for more advanced bullous keratopathy or inactive viral keratitis\\n 50% for active corneal infection\\n 0 to 50% for chemical or radiation injury\\nThe generally high rate of success of corneal transplantation is attributable to many factors, including the\\navascularity of the cornea and the fact that the anterior chamber has venous drainage but no lymphatic\\ndrainage. These conditions promote low-zone tolerance (an immunologic tolerance that results from\\nconstant exposure to low doses of an antigen) and a process termed anterior chamber-associated\\nimmune deviation, in which there is active suppression of intraocular lymphocytes and delayed-type\\nhypersensitivity to transplanted intraocular antigens. Another important factor is the effectiveness of the\\ncorticosteroids used topically, locally, and systemically to treat graft rejection.\\nCorneal Limbal Stem Cell Transplantation\\nCorneal limbal stem cell transplantation surgically replaces critical stem cells at the limbus (the area\\nwhere the conjunctiva meets the cornea). Host stem cells normally reside in this area. Transplantation is\\ndone when the host stem cells have been too severely damaged to recover from disease or injury.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n701\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 711, 'page_label': '702'}, page_content=\"Conditions such as severe chemical burns, Stevens-Johnson syndrome, and severe contact lens\\noverwear may cause persistent nonhealing corneal epithelial defects. These defects result from failure of\\ncorneal epithelial stem cells to produce sufficient epithelial cells to repopulate the cornea. If untreated,\\npersistent nonhealing corneal epithelial defects are vulnerable to infection, which can lead to scarring,\\nperforation, or both. Under these circumstances, a corneal transplant, which replaces only the central\\ncornea and not the limbus, is insufficient; stem cells are needed to produce new cells that repopulate the\\ncornea, restoring the regenerative capacity of the ocular surface.\\nCorneal limbal stem cells can be transplanted from the patient's healthy eye or from a cadaveric donor\\neye. The patient's damaged \\ncorneal epithelial stem cells are removed by a partial-thickness dissection of\\nthe limbus (ie, all the epithelium and the superficial stroma of the limbus). Donor limbal tissue, which is\\nprepared by a similar dissection, is sutured into the prepared bed.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 64. Corneal Disorders\\n702\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 712, 'page_label': '703'}, page_content='Chapter 65. Glaucoma\\nIntroduction\\nGlaucomas are a group of eye disorders characterized by progressive optic nerve damage at least partly\\ndue to increased intraocular pressure (IOP). Glaucoma is the 3rd most common cause of blindness\\nworldwide and the 2nd most common cause of blindness in the US, where it is the leading cause of\\nblindness for blacks and Hispanics. About 3 million Americans and 14 million people worldwide have\\nglaucoma, but only half are aware of it. Glaucoma can occur at any age but is 6 times more common\\namong people > 60 yr.\\nGlaucomas are categorized as open-angle or closed-angle (angle-closure)see\\nTables 65-1\\n,\\n65-2\\n, and\\n65-3\\n. The \"angle\" refers to the angle formed by the junction of the iris and cornea at the periphery of the\\nanterior chamber (see\\nFig. 65-1\\n). The angle is where > 98% of the aqueous humor exits the eye via either the trabecular\\nmeshwork and Schlemm\\'s canal (the major pathway, particularly in the elderly) or the ciliary body face and\\nchoroidal vasculature. These outflow pathways are not simply a mechanical filter and drain but instead\\ninvolve active physiologic processes.\\nGlaucomas are further subdivided into primary (cause of outflow resistance or angle closure is unknown)\\nand secondary (outflow resistance results from another disorder), accounting for > 20 adult types.\\nPathophysiology\\nAxons of retinal ganglion cells travel through the optic nerve carrying images from the eye to the brain.\\nDamage to these axons causes ganglion cell death with resultant optic nerve atrophy and patchy vision\\nloss. Elevated IOP (in unaffected eyes, the average range is 11 to 21 mm Hg) plays a role in axonal\\ndamage, either by direct nerve compression or diminution of blood flow. However, the relationship\\nbetween pressure and nerve damage is variable. Of people with IOP > 21 mm Hg (ie, ocular\\nhypertension), only about 1 to 2%/yr (about 10% over 5 yr) develop glaucoma. Additionally, about one\\nthird of patients with glaucoma do not have IOPs > 21 mm Hg (known as lowtension glaucoma or normal-\\ntension glaucoma).\\nIOP is determined by the balance of aqueous secretion and drainage. Elevated IOP is caused by inhibited\\nor obstructed outflow, not oversecretion. In open-angle glaucoma, IOP is elevated because outflow is\\ninadequate despite an angle that appears unobstructed. In angle-closure glaucoma, IOP is elevated when\\na physical distortion of the peripheral iris mechanically blocks outflow.\\nSymptoms and Signs\\nSymptoms and signs vary with the type of glaucoma, but the defining characteristic is optic nerve damage\\nas evidenced by an abnormal optic disk (see p. \\n601\\n and\\nPlate 13\\n) and certain types of visual field deficits (see p. \\n601\\n).\\nIOP may be elevated or within the average range. (For techniques of measurement, see p.\\n540\\n)\\nDiagnosis\\n Characteristic visual field defects\\n Exclusion of other causes\\n IOP usually > 21 mm Hg (but not required for the diagnosis)\\nGlaucoma should be suspected in a patient with any of the following:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 65. Glaucoma\\n703'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 713, 'page_label': '704'}, page_content=' Typical visual field defects\\n Abnormal optic nerve on ophthalmoscopy\\n Elevated IOP\\nSuch patients (and those with any risk factors) should be referred to an ophthalmologist for a\\ncomprehensive examination that includes a thorough history, family history, examination of the optic disks\\n(preferably using a binocular examination technique), formal visual field examination, IOP measurement,\\nand gonioscopy (visualization of the anterior chamber angle with a special mirrored contact lens prism).\\nGlaucoma is diagnosed when characteristic findings of optic nerve damage are present and other causes\\n(eg, multiple sclerosis)\\n[\\nTable 65-1.\\n Open-Angle Glaucoma: Classification Based on Mechanisms of Outflow Obstruction*]\\nhave been excluded. Elevated IOP makes the diagnosis more likely but is not essential.\\nScreening:\\n Screening can be done by primary physicians by checking visual fields with frequency-\\ndoubling technology (FDT) perimetry and ophthalmoscopic evaluation of the optic nerve. FDT perimetry\\ninvolves use of a desktop device that can screen for visual field abnormalities suggestive of glaucoma in\\n2 to 3 min per eye. Although IOP should be measured, screening based only on IOP has low sensitivity,\\nlow specificity, and low positive\\n[\\nTable 65-2.\\n Angle-Closure Glaucoma: Classification Based on Mechanisms of Outflow Obstruction*]\\npredictive value. Patients > 40 yr and those who have risk factors for open-angle or angle-closure\\nglaucoma should receive a comprehensive eye examination every 1 to 2 yr.\\nTreatment\\n Decreasing IOP by using drugs or laser or incisional surgery\\n[\\nTable 65-3.\\n Developmental Abnormalities of the Anterior Chamber Angle Causing Glaucoma:\\nClassification Based on Mechanisms of Outflow Obstruction*]\\nPatients with characteristic optic nerve and corresponding visual field changes are treated regardless of\\nIOP. Lowering the IOP is the only clinically proven treatment. For chronic adult and juvenile glaucomas,\\nthe initial target IOP is at least 20% below pretreatment readings.\\nThree methods are available: drugs, laser surgery, and incisional surgery. The type of glaucoma\\ndetermines the appropriate method. Drugs and most laser surgeries (trabeculoplasty) modify the existing\\naqueous secretion and drainage system. Most incisional surgeries (eg, guarded filtration procedures\\n[trabeculectomy], glaucoma drainage implant devices [tube shunts]) create a new drainage system.\\nProphylactic IOP lowering in patients with ocular hypertension delays the onset of glaucoma. However,\\nbecause the rate of conversion from ocular hypertension to glaucoma in untreated people is low, the\\ndecision to treat prophylactically should be individualized based on the presence of risk factors,\\nmagnitude of IOP elevation, and patient factors (ie, preference for drugs vs surgery, drug adverse\\neffects). Generally, treatment is recommended for patients with IOP > 30 mm Hg even if the visual field is\\nfull and the optic nerve disk appears healthy because the likelihood of damage is significant at that IOP\\nlevel.\\n[\\nFig. 65-1.\\n Aqueous humor production and flow.]\\nPrimary Open-Angle Glaucoma\\nPrimary open-angle glaucoma is a syndrome of optic nerve damage associated with an open\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 65. Glaucoma\\n704'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 714, 'page_label': '705'}, page_content=\"anterior chamber angle and an elevated or sometimes average intraocular pressure (IOP).\\nSymptoms occur late and involve visual field loss. Diagnosis is by ophthalmoscopy,\\ngonioscopy, visual field examination, and measurement of IOP. Treatment includes topical drugs\\n(eg, prostaglandin analogs, \\n\\n-blockers) and often requires laser or incisional surgery to increase\\naqueous drainage.\\nEtiology\\nAlthough open-angle glaucomas can have numerous causes (see \\nTable 65-1\\n), 60 to 70% of cases have\\nno identifiable cause and are termed primary open-angle glaucoma. Both eyes usually are affected, but\\ntypically not equally.\\nRisk factors include older age, positive family history, black race, thinner central corneal thickness,\\nsystemic hypertension, diabetes, and myopia. In blacks, glaucoma is more severe \\nand develops at an\\nearlier age, and blindness is 6 to 8 times more likely.\\nPathophysiology\\nIOP can be elevated or within the average range.\\nElevated-pressure glaucoma:\\n Two thirds of patients with glaucoma have elevated (> 21 mm Hg) IOP.\\nAqueous humor drainage is inadequate, whereas production by the ciliary body is normal. Identifiable\\nmechanisms (ie, secondary open-angle glaucomas) are not present. These mechanisms include\\ndevelopmental anomalies, scarring caused by trauma or infection, and plugging of channels by detached\\niris pigment (ie, pigment dispersion syndrome) or abnormal protein deposits (eg, pseudoexfoliation\\nsyndrome).\\nNormal- or low-pressure glaucoma:\\n In at least one third of patients with glaucoma, IOP is within the\\naverage range, but optic nerve damage and visual field loss typical of glaucoma are present. These\\npatients have a higher incidence of vasospastic diseases (eg, migraines, Raynaud's syndrome) than the\\ngeneral population, suggesting that a vascular disorder compromising blood flow to the optic nerve may\\nplay a role.\\nSymptoms and Signs\\nEarly symptoms are uncommon. Usually, the patient becomes aware of visual field loss only when optic\\nnerve atrophy is marked; the typically asymmetric deficits contribute to delay in recognition. However,\\nsome patients have complaints, such as missing stairs if their inferior visual field has been lost, noticing\\nportions of words missing when reading, or having difficulty with driving.\\nExamination findings include an unobstructed open angle on gonioscopy and characteristic optic nerve\\nappearance and visual field defects. IOP may be normal or high but is almost always higher in the eye\\nwith more optic nerve damage.\\nOptic nerve appearance:\\n The optic nerve head (ie, disk) is normally a slightly vertically elongated circle\\nwith a centrally located depression called the cup. The neurosensory rim is the tissue between the margin\\nof the cup and the edge of the disk and is composed of the ganglion cell axons from the retina.\\nCharacteristic optic nerve changes include\\n Increased cup:disk ratio\\n Thinning of the neurosensory rim\\n Pitting or notching of the rim\\n Nerve fiber layer hemorrhage that crosses the disk margin (ie, Drance hemorrhage or splinter\\nhemorrhages)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 65. Glaucoma\\n705\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 715, 'page_label': '706'}, page_content=\" Vertical elongation of the cup\\n Quick angulations in the course of the exiting blood vessels\\nThinning of the neurosensory rim over time alone can be diagnostic of glaucoma regardless of the IOP or\\nvisual field. However, most initial diagnoses of glaucoma involve some visual field change.\\nVisual field defects:\\n Visual field changes caused by lesions of the optic nerve include\\n Nasal step defects (which do not cross the horizontal meridianan imaginary horizontal line between\\nthe upper and lower parts of the visual field)\\n Arcuate (arc-shaped) scotomata extending nasally from the blind spot\\n Temporal wedge defects\\n Paracentral scotomata\\nIn contrast, deficits of the more proximal visual pathways (ie, from the lateral geniculate nucleus to the\\noccipital lobe) involve quadrants or hemispheres of the visual field; thus, deficits do not cross the vertical\\nmeridian.\\nDiagnosis\\n Visual field testing\\n Ophthalmoscopy\\n Measurement of IOP\\n Exclusion of other optic neuropathies\\nDiagnosis is suggested by the examination, but similar findings can result from other optic neuropathies\\n(eg, caused by ischemia, cytomegalovirus infection, or vitamin B\\n12\\n deficiency).\\nBefore a diagnosis of normal-pressure glaucoma can be established, the following factors may need to be\\nruled out: inaccurate IOP readings, large diurnal fluctuations (causing intermittent normal readings), optic\\nnerve damage caused by previously resolved glaucoma (eg, a previously elevated IOP due to\\ncorticosteroid use or uveitis), intermittent angle-closure glaucoma, and other ocular or neurologic\\ndisorders that cause similar visual field defects.\\nOptic disk photography or a detailed optic disk drawing is helpful for future comparison. The frequency of\\nfollow-up examinations varies from weeks to years, depending on the patient's reliability, severity of the\\nglaucoma, and response to treatment.\\nTreatment\\n Decreasing IOP 20 to 40%\\n Initially, drugs (eg, prostaglandin analogs, \\n\\n-blockers such as timolol)\\n Sometimes surgery, such as laser trabeculoplasty or guarded filtration procedure\\nVision lost by glaucoma cannot be recovered. The goal is to prevent further optic nerve and visual field\\ndamage by lowering IOP. The target level is 20 to 40% below pretreatment readings. In general, the\\ngreater the damage caused by glaucoma, the lower the IOP must be to prevent further damage. If\\ndamage progresses, the IOP goal is lowered further and additional therapy is initiated.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 65. Glaucoma\\n706\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 716, 'page_label': '707'}, page_content=\"Initial treatment is usually drug therapy, proceeding to laser therapy and then incisional surgery if the\\ntarget IOP is not met. Surgery may be the initial treatment if IOP is extremely high.\\nDrug therapy:\\n Multiple drugs are available (see\\nTable 65-4\\n). Topical agents are preferred. The most popular are prostaglandin analogs, followed by \\n\\n-\\nblockers (particularly timolol). Other drugs include \\n\\n2\\n-selective adrenergic agonists, cholinergic agonists,\\nand carbonic anhydrase inhibitors. Oral carbonic anhydrase inhibitors are effective, but adverse effects\\nlimit their use.\\nPatients taking topical glaucoma drugs should be taught passive lid closure with punctal occlusion to help\\nreduce systemic absorption and associated adverse effects, although the effectiveness of these\\nmaneuvers is controversial. Patients who have difficulty instilling drops directly onto the conjunctiva may\\nplace the drop on the nose just medial to the medial canthus, then roll the head slightly toward the eye so\\nthat the liquid flows into the eye.\\nTypically, to gauge effectiveness, clinicians start drugs in only one eye (one-eye trial); once improvement\\nin the treated eye has been confirmed at a subsequent visit (typically 1 to 4 wk later), both eyes are\\ntreated.\\nSurgery:\\n Surgery for primary open-angle and normal-pressure glaucoma includes laser trabeculoplasty,\\na guarded filtration procedure, and possibly tube shunts or ciliodestructive procedures.\\nArgon laser trabeculoplasty\\n (ALT) may be the initial treatment for patients who do not respond to or\\nwho cannot tolerate drug therapy. Laser energy is applied to either 180 or 360 of the trabecular\\nmeshwork to improve the drainage of aqueous humor. Within 2 to 5 yr, about 50% of patients require\\nadditional drug therapy or surgery because of insufficient IOP control.\\nSelective laser trabeculoplasty\\n (SLT) uses a pulsed double-frequency neodymium:yttrium-aluminum-\\ngarnet laser. SLT and ALT are equally effective initially, but SLT may have greater effectiveness in\\nsubsequent treatments.\\nA \\nguarded filtration procedure\\n is the most commonly used filtration procedure. A hole is made in the\\nlimbal sclera (trabeculectomy), which is covered by a partial-thickness scleral flap that controls egress of\\naqueous from the eye to the subconjunctival space, forming a filtration bleb. Adverse effects of glaucoma\\nfiltration surgery include acceleration of cataract growth, pressures that are too low, and transient\\nswelling during the perioperative period. Patients with trabeculectomies are at increased risk of bacterial\\nendophthalmitis and should be instructed to report any symptoms or signs of bleb infection (blebitis) or\\nendophthalmitis immediately.\\nViscocanalostomy, canaloplasty, and Trabectome surgery are newer filtration procedures that do not\\ninvolve creating a fistula between the anterior chamber and subconjunctival space. Viscocanalostomy and\\ncanaloplasty involve dilating Schlemm's canal. Trabectome surgery uses a proprietary device to remove\\na portion of the inner aspect of one of the drains of the eye (trabecular meshwork). More long-term\\nstudies with these procedures are needed and are on-going. Currently, these new procedures do not\\nappear as effective as trabeculectomy but seem to offer greater safety.\\nAngle-Closure Glaucoma\\nAngle-closure glaucoma is glaucoma associated with a physically obstructed anterior chamber\\nangle, which may be chronic or, rarely, acute. Symptoms of acute angle closure are severe\\nocular pain and redness, decreased vision, colored halos around lights, headache, nausea, and\\nvomiting. Intraocular pressure (IOP) is elevated. Immediate treatment of the acute condition\\nwith multiple topical and systemic drugs is required to prevent permanent vision loss, followed\\nby the definitive treatment, iridotomy.\\nAngle-closure glaucoma accounts for about 10% of all glaucomas in the US.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 65. Glaucoma\\n707\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 717, 'page_label': '708'}, page_content='Etiology\\nAngle-closure glaucoma is caused by factors that either pull or push the iris up into the angle (ie, junction\\nof the iris and cornea at the periphery of the anterior chamber), physically blocking drainage of aqueous\\nand raising IOP (see \\nTable 65-2\\n). Elevated IOP damages the optic nerve.\\nPathophysiology\\nAngle closure may be primary (cause is unknown) or secondary to another condition (see \\nTable 65-2\\n) and\\ncan be acute, subacute (intermittent), or chronic.\\n[\\nTable 65-4.\\n Drugs Used to Treat Glaucoma]\\nPrimary angle-closure glaucoma:\\n Narrow angles are not present in young people. As people age, the\\nlens of the eye continues to grow. In some but not all people, this growth pushes the iris forward,\\nnarrowing the angle. Risk factors for developing narrow angles include Asian ethnicity, hyperopia, family\\nhistory, and advanced age.\\nIn people with narrow angles, the distance between the pupillary iris and the lens is also very narrow.\\nWhen the iris dilates, forces pull it centripetally and posteriorly causing iris-lens contact, which prevents\\naqueous from passing between the lens and iris into the anterior chamber (this mechanism is termed\\npupillary block). Pressure from the continued secretion \\nof aqueous into the posterior chamber by the\\nciliary body pushes the peripheral iris anteriorly (causing a forward-bowing iris called iris bombe), closing\\nthe angle. This closure blocks aqueous outflow, resulting in rapid (within hours) and severe (> 40 mm Hg)\\nelevation of IOP. Because of the rapid onset, this condition is called primary acute angle-closure\\nglaucoma and is an ophthalmic emergency requiring immediate treatment.\\nIntermittent angle-closure glaucoma occurs if the episode of pupillary block resolves spontaneously after\\nseveral hours, usually after sleeping supine.\\nChronic angle-closure glaucoma occurs if the angle narrows slowly, allowing scarring between the\\nperipheral iris and trabecular meshwork; IOP elevation is slow.\\nPupillary dilation (mydriasis) can push the iris into the angle and precipitate acute angle-closure glaucoma\\nin any person with narrow angles. This development is of particular concern when applying topical agents\\nto dilate the eye for examination (eg, cyclopentolate, phenylephrine) or for treatment (eg, homatropine) or\\nwhen giving systemic drugs that have the potential to dilate the pupils (eg, scopolamine, \\n\\n-adrenergic\\nagonists commonly used to treat urinary incontinence, drugs with anticholinergic effects).\\nSecondary angle-closure glaucomas:\\n The mechanical obstruction of the angle is due to a coexisting\\ncondition, such as proliferative diabetic retinopathy (PDR), ischemic central vein occlusion, uveitis, or\\nepithelial down-growth. Contraction of a neovascular membrane (eg, in PDR) or inflammatory scarring\\nassociated with uveitis can pull the iris into the angle.\\nSymptoms and Signs\\nAcute angle-closure glaucoma:\\n Patients have severe ocular pain and redness, decreased vision,\\ncolored halos around lights, headache, nausea, and vomiting. The systemic complaints may be so severe\\nthat patients are misdiagnosed as having a neurologic or GI problem. Examination typically reveals\\nconjunctival hyperemia, a hazy cornea, a fixed mid-dilated pupil, and anterior chamber inflammation.\\nVision is decreased. IOP is usually 40 to 80 mm Hg. The optic nerve is difficult to visualize because of\\ncorneal edema, and visual field testing is not done because of discomfort.\\nChronic angle-closure glaucoma:\\n This type of glaucoma manifests similarly to open-angle glaucoma\\n(see p. \\n600\\n). Some patients have ocular redness, discomfort, blurred vision, or headache that lessens\\nwith sleep (perhaps because of sleep-induced miosis and posterior displacement of the lens by gravity).\\nOn gonioscopy, the angle is narrow, and peripheral anterior synechiae (PAS) may be seen. IOP may be\\nnormal but is usually higher in the affected eye.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 65. Glaucoma\\n708'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 718, 'page_label': '709'}, page_content='Diagnosis\\n \\nAcute:\\n Measurement of IOP and clinical findings\\n \\nChronic:\\n Gonioscopy showing peripheral anterior synechiae and characteristic optic nerve and visual\\nfield abnormalities\\nDiagnosis of acute angle-closure glaucoma is clinical and by measurement of IOP. Gonioscopy may be\\ndifficult to perform in the involved eye because of a clouded cornea with friable corneal epithelium.\\nHowever, examination of the other eye reveals a narrow or occludable angle. If the other eye has a wide\\nangle, a diagnosis other than primary angle-closure glaucoma should be considered.\\nDiagnosis of chronic angle-closure glaucoma is based on the presence of PAS on gonioscopy and\\ncharacteristic optic nerve and visual field changes (see p. \\n601\\n).\\nTreatment\\n \\nAcute:\\n Timolol, pilocarpine, and apraclonidine drops and a systemic osmotic drug followed promptly by\\nlaser peripheral iridotomy\\n \\nChronic:\\n Similar to primary open-angle glaucoma except that laser peripheral iridotomy may be done if\\nthe clinician feels that the procedure may slow the mechanical closing of the angle\\nAcute angle-closure glaucoma:\\n Treatment must be initiated immediately because vision can be lost\\nquickly and permanently. The patient should receive several drugs at once. A suggested regimen is\\ntimolol 0.5% one drop q 30 min for 2 doses; pilocarpine 2 to 4% one drop q 15 min for the first 1 to 2 h;\\napraclonidine 0.5 to 1% one drop q 30 min for 2 doses; acetazolamide 500 mg po initially followed by 250\\nmg q 6 h; and an osmotic agent, such as oral glycerol 1 mL/kg diluted with an equal amount of cold water,\\nmannitol 1.0 to 1.5 mg/kg IV, or isosorbide 100 g po (220 mL of a 45% solution [NOTE: This form of\\nisosorbide is not isosorbide dinitrate.]). Response is evaluated by measuring IOP. Miotics are generally\\nnot effective when IOP is > 40 or 50 mm Hg because of an anoxic pupillary sphincter.\\nDefinitive treatment is with laser peripheral iridotomy (LPI), which opens another pathway for fluid to pass\\nfrom the posterior to the anterior chamber, breaking the pupillary \\nblock. It is done as soon as the cornea is\\nclear and inflammation has subsided. In some cases the cornea clears within hours of lowering the IOP;\\nin other cases, it can take 1 to 2 days. Because the chance of having an acute attack in the other eye is\\n80%, LPI is done on both eyes.\\nThe risk of complications with LPI is extremely low compared with its benefits. Glare, which can be\\nbothersome, may occur if the iridotomy is not placed superiorly enough for the upper lid to cover it.\\nChronic angle-closure glaucoma:\\n Patients with chronic, subacute, or intermittent angle-closure\\nglaucoma should also have LPI. Additionally, patients with a narrow angle, even in the absence of\\nsymptoms, should undergo prompt LPI to prevent angle-closure glaucoma.\\nThe drug and surgical treatments are the same as with open-angle glaucoma. Laser trabeculoplasty is\\nrelatively contraindicated if the angle is so narrow that additional PAS may form after the laser procedure.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 65. Glaucoma\\n709'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 719, 'page_label': '710'}, page_content='Chapter 66. Cataract\\n(For developmental or congenital cataracts, see p. \\n2920\\n.)\\nA cataract is a congenital or degenerative opacity of the lens. The main symptom is gradual,\\npainless vision blurring. Diagnosis is by ophthalmoscopy and slit-lamp examination. Treatment\\nis surgical removal and placement of an intraocular lens.\\nLens opacity can develop in several locations:\\n Central lens nucleus (nuclear cataract)\\n Beneath the posterior lens capsule (posterior subcapsular cataract)\\nEtiology\\nCataracts occur with aging. Other risk factors may include the following:\\n Trauma (sometimes causing cataracts years later)\\n Smoking\\n Alcohol use\\n Exposure to x-rays\\n Heat from infrared exposure\\n Systemic disease (eg, diabetes)\\n Uveitis\\n Systemic drugs (eg, corticosteroids)\\n Undernutrition\\n Dark eyes\\n Possibly chronic ultraviolet exposure\\nMany people have no risk factors other than age. Some cataracts are congenital, associated with\\nnumerous syndromes and diseases.\\nSymptoms and Signs\\nCataracts generally develop slowly over years. Early symptoms may be loss of contrast, glare (halos and\\nstarbursts around lights), needing more light to see well, and problems distinguishing dark blue from\\nblack. Painless blurring eventually occurs. The degree of blurring depends on the location and extent of\\nthe opacity. Double vision occurs rarely.\\nWith a nuclear cataract (see\\nPlate 4\\n), distance vision worsens. Near vision may improve in the early stages because of changes in the\\nrefractive index of the lens; presbyopic patients may be temporarily able to read without glasses (second\\nsight).\\nA posterior subcapsular cataract disproportionately affects vision because the opacity is located at the\\ncrossing point of incoming light rays. Such cataracts reduce visual acuity more when the pupil constricts\\n(eg, in bright light, during reading). They are also the type most likely to cause loss of contrast as well as\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 66. Cataract\\n710'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 720, 'page_label': '711'}, page_content='glare, especially from bright lights or from car headlights while driving at night.\\nRarely, the cataract swells, occluding the trabecular drainage meshwork and causing secondary closed-\\nangle glaucoma and pain.\\nDiagnosis\\n Ophthalmoscopy followed by slit-lamp examination\\nDiagnosis is best made with the pupil dilated. Well-developed cataracts appear as gray, white, or yellow-\\nbrown opacities in the lens. Examination of the red reflex through the dilated pupil with the\\nophthalmoscope held about 30 cm away usually discloses subtle opacities. Small cataracts stand out as\\ndark defects in the red reflex. A large cataract may obliterate the red reflex. Slit-lamp examination provides\\nmore details about the character, location, and extent of the opacity.\\nTreatment\\n Surgical removal of the cataract\\n Placement of an intraocular lens\\nFrequent refractions and corrective lens prescription changes may help maintain useful vision during\\ncataract development. Occasionally, long-term pupillary dilation (with phenylephrine 2.5% q 4 to 8 h) is\\nhelpful for small centrally located cataracts. Indirect lighting while reading minimizes pupillary constriction\\nand may optimize vision for close tasks. Polarized lenses reduce glare.\\nUsual indications for surgery include the following:\\n Best vision obtained with glasses is worse than 20/40 (< 6/12), or vision is significantly decreased under\\nglare conditions (eg, oblique lighting while trying to read a chart) in a patient with bothersome halos or\\nstarbursts.\\n Patients sense that vision is limiting (eg, by preventing activities of daily living such as driving, reading,\\nhobbies, and occupational activities).\\n Vision could potentially be meaningfully improved if the cataract is removed (ie, a significant portion of\\nthe vision loss must be caused by the cataract).\\nFar less common indications include cataracts that cause glaucoma or that obscure the fundus in patients\\nwho need periodic fundus examinations for management of diseases such as diabetic retinopathy and\\nglaucoma. There is no advantage to removing a cataract early.\\nCataract extraction is usually done using a topical or local anesthetic and IV sedation. There are 3\\nextraction techniques. In \\nintracapsular cataract extraction\\n, the cataract and lens capsule are removed\\nin one piece; this technique is rarely used. In \\nextracapsular cataract extraction\\n, the hard central\\nnucleus is removed in one piece and then the soft cortex is removed in multiple small pieces. In\\nphacoemulsification\\n, the hard central nucleus is dissolved by ultrasound and then the soft cortex is\\nremoved in multiple small pieces. Phacoemulsification requires the smallest incision, thus enabling the\\nfastest healing, and is usually the preferred procedure. In extracapsular extraction and\\nphacoemulsification, the lens capsule is not removed.\\nA plastic or silicone lens is almost always implanted intraocularly to replace the optical focusing power\\nlost by removal of the crystalline lens. The lens implant is usually placed on or within the lens capsule\\n(posterior chamber lens). The lens can also be placed in front of the iris (anterior chamber lens) or\\nattached to the iris and within the pupil (iris plane lens). Iris plane lenses are rarely used in the US\\nbecause many designs led to a high frequency of postoperative complications. Multifocal intraocular\\nlenses are newer and have different focusing zones that may reduce dependence on glasses after\\nsurgery. Patients occasionally experience glare or halos with these lenses, especially under low-light\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 66. Cataract\\n711'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 721, 'page_label': '712'}, page_content=\"conditions.\\nIn most cases, a tapering schedule of topical antibiotics (eg, moxifloxacin 0.5% 1 drop qid) and topical\\ncorticosteroids (eg, prednisolone acetate 1% 1 drop qid) is used for up to 4 wk postsurgery. Patients often\\nwear an eye shield while sleeping and should avoid the Valsalva maneuver, heavy lifting, excessive\\nforward bending, and eye rubbing for several weeks.\\nMajor complications of cataract surgery are rare. Complications include the following:\\n Intraoperative: Bleeding beneath the retina, causing the intraocular contents to extrude through the\\nincision (choroidal hemorrhage), vitreous prolapsing out of the incision (vitreous loss), fragments of the\\ncataract dislocating into the vitreous, incisional burn, and detachment of corneal endothelium and its\\nbasement membrane (Descemet's membrane)\\n Within the first week: Endophthalmitis (infection within the eye) and glaucoma\\n Within the first month: Cystoid macular edema\\n Months later: Bullous keratopathy (ie, swelling of the cornea due to damage to the corneal pump cells\\nduring cataract surgery), retinal detachment, and posterior capsular opacification (common, but\\ntreatable with laser)\\nAfter surgery, vision returns to 20/40 (6/12) or better in 95% of eyes if there are no preexisting disorders\\nsuch as amblyopia, retinopathy, macular degeneration, and glaucoma. If an intraocular lens is not\\nimplanted, contact lenses or thick glasses are needed to correct the resulting hyperopia.\\nPrevention\\nMany ophthalmologists recommend ultraviolet-coated eyeglasses or sunglasses as a preventive\\nmeasure. Reducing risk factors such as alcohol, tobacco, and corticosteroids and controlling blood\\nglucose in diabetes delay onset. A diet high in vitamin C, vitamin A, and carotenoids (contained in\\nvegetables such as spinach and kale) may protect against cataracts.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 66. Cataract\\n712\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 722, 'page_label': '713'}, page_content='Chapter 67. Uveitis\\nIntroduction\\nUveitis is inflammation of the uveal tractthe iris, ciliary body, and choroid. Most cases are\\nidiopathic, but identifiable causes include various infections and systemic diseases, many of\\nwhich are autoimmune. Symptoms include decreased vision, ocular ache, redness,\\nphotophobia, and floaters. Although intraocular inflammation is identified clinically, identifying\\nthe cause of the inflammation typically requires testing. Treatment depends on cause but\\ntypically includes topical, locally injected, or systemic corticosteroids with a topical cycloplegic-\\nmydriatic drug. Noncorticosteroid immunosuppressive drugs may be used in severe and\\nrefractory cases. Infectious causes require antimicrobial therapy.\\nInflammation of the uvea (uveitis) may occur with or without vitreitis, retinitis, papillitis, or optic neuritis.\\nUveitis is classified anatomically as anterior, intermediate, or posterior uveitis or panuveitis.\\nAnterior uveitis\\n is localized primarily to the anterior segment of the eye and includes iritis (inflammation\\nin the anterior chamber alone) and iridocyclitis (inflammation in the anterior chamber and anterior\\nvitreous).\\nIntermediate uveitis\\n (peripheral uveitis or chronic cyclitis) occurs in the vitreous.\\nPosterior uveitis\\n refers to any form of retinitis, choroiditis, or inflammation of the optic disk.\\nPanuveitis\\n (also called diffuse uveitis) implies inflammation in both the anterior and posterior chambers.\\nEtiology\\nMost cases are idiopathic and presumed to be autoimmune in origin. Identifiable causes include\\n Trauma\\n Ocular and systemic infections\\n Systemic autoimmune disorders\\nThe most common cause of anterior uveitis is trauma (traumatic iridocyclitis). Other causes are\\nspondyloarthropathies (20 to 25%), juvenile idiopathic arthritis, and herpesvirus (herpes simplex and\\nvaricella-zoster) infection. Half of all cases of anterior uveitis are idiopathic.\\nMost intermediate uveitis is idiopathic. Uncommon identifiable causes include multiple sclerosis,\\nsarcoidosis, TB, syphilis, and, in endemic regions, Lyme disease.\\nMost posterior uveitis (retinitis) is idiopathic. The most commonly recognized cause of posterior uveitis in\\nimmunocompetent patients is toxoplasmosis; the most commonly recognized cause in patients with\\nHIV/AIDS is cytomegalovirus (CMV).\\nThe most commonly identified cause of panuveitis is sarcoidosis, but most cases remain idiopathic\\ndespite appropriate testing.\\nInfrequently, systemic drugs cause uveitis (usually anterior). Examples are sulfonamides, pamidronate (an\\ninhibitor of bone resorption), rifabutin, and cidofovir.\\nSystemic diseases causing uveitis and their treatment are discussed elsewhere in THE MANUAL.\\nSymptoms and Signs\\nSymptoms and signs may be subtle and vary depending on the site and severity of inflammation.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 67. Uveitis\\n713'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 723, 'page_label': '714'}, page_content='Anterior uveitis\\n tends to be the most symptomatic, usually manifesting with pain (ocular ache), redness,\\nphotophobia, and, to a variable degree, decreased vision. Signs include hyperemia of the conjunctiva\\nadjacent to the cornea (ciliary flush or limbal injection). Slit-lamp findings include cells and flare (a haze)\\nin the anterior chamber (aqueous humor), keratic precipitates (WBC clumps on the inner corneal surface),\\nand posterior synechiae. With severe anterior uveitis, WBCs may layer in the anterior chamber\\n(hypopyon).\\nIntermediate uveitis\\n is typically painless and manifests with floaters and decreased vision. The primary\\nsign is cells in the vitreous humor. Aggregates and condensations of inflammatory cells often occur over\\nthe pars plana (near the junction of the iris and sclera), forming snowballs. Vision may be decreased\\nbecause of floaters or cystoid macular edema, which results from fluid leakage from blood vessels in the\\nmacula. Confluent and condensed vitreous cells and snowballs over the pars plana may cause a classic\\nsnowbank appearance, which can be associated with neovascularization of the retinal periphery.\\nPosterior uveitis\\n may give rise to diverse symptoms but most commonly causes floaters and decreased\\nvision as occurs in intermediate uveitis. Signs include cells in the vitreous humor; white or yellow-white\\nlesions in the retina (retinitis), underlying choroid (choroiditis), or both; exudative retinal detachments;\\nretinal vasculitis; and optic disk edema.\\nPanuveitis\\n may cause any combination of the previously mentioned symptoms and signs.\\nConsequences:\\n Consequences of uveitis include profound and irreversible vision loss, especially when\\nuveitis is unrecognized, inadequately treated, or both. The most frequent complications include cataract;\\nglaucoma; retinal detachment; neovascularization of the retina, optic nerve, or iris; and cystoid macular\\nedema (the most common cause of decreased vision in patients with uveitis).\\nDiagnosis\\n Slit-lamp examination\\n Ophthalmoscopy after pupil dilation\\nUveitis should be suspected in any patient who has ocular ache, redness, photophobia, floaters, or\\ndecreased vision. Patients with anterior uveitis have ocular ache in the affected eye if light is shined in\\nthe unaffected eye (true photophobia), which is uncommon in conjunctivitis. Diagnosis of anterior uveitis\\nis by recognizing cells and flare in the anterior chamber. Cells and flare are seen with a slit lamp and are\\nmost evident when using a narrow, intensely bright light focused on the anterior chamber in a dark room.\\nFindings of intermediate and posterior uveitis are most easily seen after dilating the pupil (see p. \\n538\\n).\\nIndirect ophthalmoscopy (usually done by an ophthalmologist) is more sensitive than direct\\nophthalmoscopy. (NOTE: If uveitis is suspected, patients should be referred immediately for complete\\nophthalmologic evaluation.)\\nMany conditions that cause intraocular inflammation can mimic uveitis and should be considered in the\\nappropriate clinical settings. Such conditions include intraocular cancers in the very young (typically\\nretinoblastoma and leukemia) and in the elderly (intraocular lymphoma). Less commonly, retinitis\\npigmentosa (see p. \\n618\\n) can manifest with mild inflammation, which may be confused with uveitis.\\nTreatment\\n Corticosteroids (usually topical)\\n Cycloplegic-mydriatic drugs\\nTreatment of active inflammation usually involves corticosteroids given topically or by periocular or\\nintraocular injection along with a cycloplegic-mydriatic drug (eg, homatropine 2% or 5% drops bid to qid\\ndepending on severity). Antimicrobial drugs are used to treat infectious uveitis. Particularly severe or\\nchronic cases may require systemic corticosteroids, systemic noncorticosteroid immunosuppressive\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 67. Uveitis\\n714'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 724, 'page_label': '715'}, page_content=\"drugs, laser phototherapy, cryotherapy applied transsclerally to the retinal periphery, or surgical removal\\nof the vitreous (vitrectomy).\\nUveitis Caused by Connective Tissue Disease\\nA number of connective tissue diseases cause inflammation of the uveal tract.\\nSpondyloarthropathies:\\n The seronegative spondyloarthropathies (see p. \\n341\\n) are a common cause of\\nanterior uveitis. RA, in contrast, is not associated with uveitis. Ocular inflammation is most common with\\nankylosing spondylitis but also occurs with reactive arthritis, inflammatory bowel disease (ulcerative colitis\\nand Crohn's disease), and psoriatic arthritis. Uveitis is classically unilateral, but recurrences are common\\nand active inflammation may alternate between eyes. Men are affected more commonly than women.\\nMost patients, regardless of sex, are HLA-B27 positive.\\nTreatment requires a topical corticosteroid and a cycloplegic-mydriatic drug. Occasionally, periocular\\ncorticosteroids are required.\\nJuvenile idiopathic arthritis (JIA, also known as juvenile RA):\\n JIA characteristically causes chronic\\nbilateral iridocyclitis in children, particularly those with the pauciarticular variety (see p. \\n339\\n). Unlike most\\nforms of anterior uveitis, however, JIA tends not to cause pain, photophobia, and conjunctival injection but\\nonly blurring and meiosis and is, therefore, often referred to as white iritis. JIA-associated uveitis is more\\ncommon among girls.\\nRecurrent bouts of inflammation are best treated with a topical corticosteroid and a cycloplegic-mydriatic\\ndrug. Long-term control often requires use of a noncorticosteroid immunosuppressive drug (eg,\\nmethotrexate, mycophenolate mofetil).\\nSarcoidosis:\\n Sarcoidosis (see also p. \\n1965\\n) accounts for 10 to 20% of cases of uveitis, and about 25%\\nof patients with sarcoidosis develop uveitis. Sarcoid uveitis is more common among blacks and the\\nelderly.\\nVirtually any symptoms and signs of anterior, intermediate, posterior, or panuveitis can occur. Suggestive\\nfindings include conjunctival granulomas, large keratic precipitates on the corneal endothelium (so-called\\ngranulomatous or mutton fat precipitates), iris granulomas, and retinal vasculitis. Biopsy of suggestive\\nlesions, which provides the most secure diagnosis, is usually done on the conjunctiva; it is rarely done on\\nintraocular tissues because of the risk associated with the procedure.\\nTreatment usually involves topical, periocular, intraocular, or systemic corticosteroids, or a combination,\\nalong with a topical cycloplegic-mydriatic drug. Patients with moderate to severe inflammation may require\\na noncorticosteroid immunosuppressive drug (eg, methotrexate, mycophenolate mofetil, azathioprine).\\nBehcet's syndrome:\\n This condition is rare in North America but is a fairly common cause of uveitis in\\nthe Middle East and Far East (see also p. \\n315\\n).\\nTypical findings include severe anterior uveitis with hypopyon, retinal vasculitis, and optic disk\\ninflammation. The clinical course is usually severe with multiple recurrences.\\nDiagnosis requires the presence of associated systemic manifestations, such as oral aphthous or genital\\nulcers; dermatitis, including erythema nodosum; thrombophlebitis; or epididymitis. Oral aphthae may be\\nbiopsied to show an occlusive vasculitis. There are no laboratory tests for Behcet's syndrome.\\nTreatment with local and systemic corticosteroids and a cycloplegic-mydriatic drug may alleviate acute\\nexacerbations, but most patients eventually require systemic corticosteroids and a noncorticosteroid\\nimmunosuppressive drug (eg, cyclosporine, chlorambucil) to control the inflammation and avoid the\\nserious complications of long-term corticosteroid treatment. Biologic agents such as interferons and tumor\\nnecrosis factor inhibitors have been effective in selected patients unresponsive to other therapies.\\nVogt-Koyanagi-Harada (VKH) syndrome:\\n VKH syndrome is an uncommon systemic disorder\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 67. Uveitis\\n715\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 725, 'page_label': '716'}, page_content='characterized by uveitis accompanied by cutaneous and neurologic abnormalities. VKH syndrome is\\nparticularly common among people of Asian, Asian Indian, and American Indian descent. Women in their\\n20s and 30s are affected more often than men. The etiology is unknown, although an autoimmune\\nreaction directed against melanin-containing cells in the uveal tract, skin, inner ear, and meninges is\\nstrongly suspected.\\nNeurologic symptoms tend to occur early and include tinnitus, dysacusis (auditory agnosia), vertigo,\\nheadache, and meningismus. Cutaneous findings frequently occur later and include patchy vitiligo\\n(especially common on the eyelids, low back, and buttocks), poliosis (a localized patch of white hair), and\\nalopecia, often involving the head and neck. Common findings include serous retinal detachment, optic\\ndisk edema, and choroiditis. Long-term complications include cataracts, glaucoma, subretinal fibrosis, and\\nchoroidal neovascularization.\\nEarly treatment includes local and systemic corticosteroids and a cycloplegic-mydriatic drug. Many\\npatients also require a noncorticosteroid immunosuppressive drug (eg, methotrexate, azathioprine,\\nmycophenolate mofetil).\\nEndophthalmitis\\nEndophthalmitis is an acute panuveitis resulting most often from bacterial infection.\\nMost cases of endophthalmitis are caused by gram-positive bacteria, such as \\nStaphylococcus\\nepidermidis\\n or \\nS. aureus\\n. Gram-negative organisms can also cause endophthalmitis, tend to be more\\nvirulent, and predict a poorer prognosis. Fungal and protozoan causes of endophthalmitis are rare. Most\\ncases occur after penetrating ocular trauma or intraocular surgery (exogenous). Less commonly, infection\\nreaches the eye via the bloodstream after systemic surgery or dental procedures or when IV lines or IV\\ndrugs are used (endogenous).\\nEndophthalmitis is a medical emergency because vision prognosis is directly related to the time from\\nonset to treatment. Rarely, untreated intraocular infections extend beyond the confines of the eye to\\ninvolve the orbit and CNS.\\nExogenous endophthalmitis typically causes severe ocular ache and decreased vision. Signs include\\nintense conjunctival hyperemia and intraocular inflammation within the anterior chamber and vitreous,\\noccasionally with eyelid edema.\\nDiagnosis requires a high index of suspicion in at-risk patients, especially those with recent eye surgery\\nor trauma. Gram stain and culture of aspirates from the anterior chamber and vitreous are standard.\\nPatients with suspected endogenous endophthalmitis should also have blood and urine cultures.\\nInitial treatment includes broad-spectrum intravitreal antibiotics, most commonly vancomycin and\\nceftazidime. Patients with endogenous endophthalmitis should receive both intravitreal and IV antibiotics.\\nTherapy is modified based on culture and sensitivity results.\\nVision prognosis is often poor, even with early and appropriate treatment. Patients with count-fingers or\\nworse vision at presentation should be considered for vitrectomy and use of intraocular corticosteroids.\\nCorticosteroids are, however, contraindicated in fungal endophthalmitis.\\nInfectious Uveitis\\nA number of infectious diseases cause uveitis (see\\nTable 67-1\\n). The most common are\\n[\\nTable 67-1.\\n Infectious Causes of Uveitis]\\nherpes simplex virus, varicella-zoster virus, and CMV infection and toxoplasmosis. Different organisms\\naffect different parts of the uveal tract.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 67. Uveitis\\n716'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 726, 'page_label': '717'}, page_content='Herpesvirus:\\n Herpes simplex virus (see also p. \\n1417\\n) causes anterior uveitis. Varicellazoster virus does\\nso less commonly, although the prevalence of zoster-associated anterior uveitis increases with age.\\nSymptoms include ocular ache, photophobia, and decreased vision. Signs include redness; conjunctival\\ninjection and anterior chamber inflammation (cells and flare), often accompanied by corneal inflammation\\n(keratitis); decreased corneal sensation; and patchy or sectorial iris atrophy. Intraocular pressure may be\\nelevated as well; elevation can be detected by using applination tonometry with a Schiotz tonometer, a\\nGoldmann tonometer, or a pneumotonometer.\\nTreatment should generally be initiated by an ophthalmologist and should include a topical corticosteroid\\nand a cycloplegic-mydriatic drug. Acyclovir (400 mg po 5 times/day for herpes simplex virus and 800 mg\\npo 5 times/day for herpes zoster virus) may also be given. Drops to lower intraocular pressure may be\\nrequired in patients with ocular hypertension.\\nMuch less commonly, varicella-zoster and herpes simplex viruses cause a rapidly progressing form of\\nretinitis called acute retinal necrosis (ARN), which typically manifests as confluent retinitis, occlusive\\nretinal vasculitis, and moderate to severe vitreous inflammation. One third of ARN cases become bilateral,\\nand in three fourths of eyes, retinal detachment occurs. ARN may also occur in patients with HIV/AIDS,\\nbut severely immunocompromised patients can have less prominent vitreous inflammation. Vitreous\\nbiopsy for culture and PCR analysis may be useful in diagnosing ARN. Treatment options include IV\\nacyclovir, IV ganciclovir or foscarnet, intravitreal ganciclovir or foscarnet, and oral valacyclovir or\\nvalganciclovir.\\nToxoplasmosis:\\n Toxoplasmosis (see also p. \\n1390\\n) is the most common cause of retinitis in\\nimmunocompetent patients. Most cases are transmitted congenitally, although acquired cases occur.\\nSymptoms of floaters and decreased vision may be due to cells in the vitreous humor or to retinal lesions\\nor scars. Concurrent anterior segment involvement can occur and may cause ocular ache, redness, and\\nphotophobia. Laboratory testing should include serum anti-\\nToxoplasma\\n antibody titers.\\nTreatment is recommended for patients with posterior lesions that threaten vital visual structures, such as\\nthe optic disk or macula, and for immunocompromised patients. Multidrug therapy is commonly\\nprescribed; it includes pyrimethamine, sulfonamides, clindamycin, and, in select cases, systemic\\ncorticosteroids. Corticosteroids should not, however, be used without concurrent antimicrobial coverage.\\nLong-acting periocular and intraocular corticosteroids (eg, triamcinolone acetonide) should be avoided.\\nPatients with small peripheral lesions that do not directly threaten vital visual structures may be observed\\nwithout treatment and should begin to show slow improvement in 1 to 2 mo.\\nCytomegalovirus:\\n CMV (see also p. \\n1416\\n) is the most common cause of retinitis in\\nimmunocompromised patients, affecting  5% of patients with HIV/AIDS receiving highly active\\nantiretroviral therapy (HAART). Most affected patients have a CD4+ count < 100 cells/\\n\\nL. CMV retinitis\\nmay also occur in neonates and in pharmacologically immunosuppressed patients but is uncommon.\\nThe diagnosis is largely clinical based on direct or indirect ophthalmoscopic examination; serologic tests\\nare of limited use. Treatment in patients with HIV/AIDS is with systemic or local (implant) ganciclovir,\\nsystemic foscarnet, or valganciclovir. Therapy is typically continued indefinitely, unless immune\\nreconstitution is achieved with combination antiretroviral therapy (typically a CD4+ count > 100 cells/\\n\\nL\\nfor at least 3 mo).\\nSympathetic Ophthalmia\\nSympathetic ophthalmia is inflammation of the uveal tract after trauma or surgery to the other\\neye.\\nSympathetic ophthalmia is a rare granulomatous uveitis that occurs after penetrating trauma or surgery to\\nthe other eye. Sympathetic ophthalmia has been estimated to occur in up to 0.5% of nonsurgical and in <\\n0.1% of surgical penetrating eye wounds. The underlying mechanism is thought to be an autoimmune\\nreaction directed against melanin-containing cells in the uvea. Uveitis appears within 2 to 12 wk after\\ninjury in about 80% of cases. Isolated cases of sympathetic ophthalmia have occurred as early as 1 wk or\\nas late as 30 yr after the initial injury or surgery.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 67. Uveitis\\n717'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 727, 'page_label': '718'}, page_content='Symptoms typically include floaters and decreased vision. Choroiditis, often with overlying exudative\\nretinal detachment, is common.\\nTreatment typically requires oral corticosteroids plus a long-term noncorticosteroid immunosuppressive\\ndrug. Prophylactic enucleation of a severely injured eye should be considered within 2 wk of vision loss\\nto minimize the risk of sympathetic ophthalmia developing in the other eye, but only when the injured eye\\nhas no vision potential.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 67. Uveitis\\n718'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 728, 'page_label': '719'}, page_content='Chapter 68. Retinal Disorders\\nIntroduction\\n(For Retinopathy of Prematurity, see p. \\n2781\\n.)\\nThe retina is the light-sensing layer of tissue at the back of the eye; it contains the rods, cones, and\\nnerve endings that transform light into neural impulses. Retinal disorders may be inherited or caused by\\nvascular disease, inflammation, infection, cancer, or trauma. Visual rehabilitation is indicated for all\\npatients who have severe vision loss.\\nAge-Related Macular Degeneration\\n(Senile Macular Degeneration)\\nAge-related macular degeneration (AMD) is the most common cause of irreversible central\\nvision loss in elderly patients. Funduscopic findings are diagnostic; fluorescein angiography\\nand optical coherence tomography assist in directing treatment. Treatment is with dietary\\nsupplements, intravitreal injection of anti-vascular endothelial growth factor, laser\\nphotocoagulation, photodynamic therapy, and low-vision devices.\\nAMD is a leading cause of permanent, irreversible vision loss in the elderly. It is more common among\\nwhites.\\nEtiology\\nRisk factors include the following:\\n Genetic variants (eg, abnormal complement factor H)\\n Smoking\\n Cardiovascular disease\\n Hypertension\\n A diet low in \\n\\n-3 fatty acids and dark green leafy vegetables\\n Age\\nPathophysiology\\nTwo different forms occur:\\n Dry (atrophic), in about 90% of cases\\n Wet (exudative or neovascular), in about 10% of cases\\nNinety percent of the blindness caused by AMD occurs in patients who have the wet form.\\nDry AMD\\n causes retinal pigmentation changes, yellow spots (drusensee\\nPlate 3\\n), and areas of chorioretinal atrophy (referred to as geographic atrophy). There is no elevated\\nmacular scar, edema, hemorrhage, or exudation.\\nWet AMD\\n begins as dry AMD. Choroidal neovascularization (abnormal new vessel formation) occurs\\nunder the retina. Localized macular edema or hemorrhage may elevate an area of the macula or cause a\\nlocalized retinal pigment epithelial detachment. Eventually, neovascularization causes an elevated scar\\nunder the macula.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n719'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 729, 'page_label': '720'}, page_content='Symptoms and Signs\\nDry AMD:\\n The loss of central vision is slow, painless, and usually mild. Central blind spots (scotomas)\\nusually occur late and can sometimes become severe. Symptoms are usually bilateral.\\nFunduscopic changes include the following:\\n Pigment changes\\n Drusen\\n Areas of chorioretinal atrophy\\nWet AMD:\\n Rapid vision loss is more typical of wet AMD. The first symptom is usually visual distortion,\\nsuch as a central blind spot (scotoma) or curving of straight lines (metamorphopsia). Peripheral vision\\nand color vision are generally unaffected; however, the patient may become legally blind (< 20/200 vision)\\nin the affected eye or eyes, particularly if AMD is not treated. Wet macular degeneration usually affects\\none eye at a time; thus, symptoms of wet AMD are often unilateral.\\nFunduscopic changes include the following:\\n Subretinal hemorrhage in or around the macula\\n Localized retinal elevation\\n Retinal edema\\n Gray discoloration of the subretinal space\\n Exudates in or around the macula\\n Detachment of retinal pigment epithelium\\nDiagnosis\\n Funduscopic examination\\n Fluorescein angiography\\n Optical coherence tomography\\nBoth forms of AMD are diagnosed by funduscopic examination. Visual changes can often be detected\\nwith an Amsler grid (see p. \\n539\\n). Fluorescein angiography is done when findings suggest wet AMD.\\nAngiography demonstrates and characterizes subretinal choroidal neovascular membranes and can\\ndelineate areas of geographic atrophy. Optical coherence tomography (OCT) aids in identifying\\nintraretinal and subretinal fluid and can help assess response to treatment.\\nTreatment\\n Dietary supplements for dry or unilateral wet AMD\\n Intravitreal anti-vascular endothelial growth factor drugs or laser treatments for wet AMD\\n Supportive measures\\nDry AMD:\\n There is no way to reverse damage caused by dry AMD, but patients with extensive drusen,\\npigment changes, or geographic atrophy benefit from daily supplements of the following:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n720'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 730, 'page_label': '721'}, page_content=' Zinc oxide 80 mg\\n Copper 2 mg\\n Vitamin C 500 mg\\n Vitamin E 400 IU\\n \\n\\n-Carotene 15 mg (or vitamin A 28,000 IU)\\nVitamin A is sometimes substituted for \\n\\n-carotene. In smokers, \\n\\n-carotene and vitamin A can increase the\\nrisk of lung cancer. For this reason, they are contraindicated in patients who have smoked in the previous\\n7 yr. Reducing cardiovascular risk factors, including eating foods high in \\n\\n-3 fatty acids and dark green\\nleafy vegetables may help.\\nWet AMD:\\n Patients with wet AMD in one eye may benefit from daily supplements that are recommended\\nfor dry AMD. The choice of other treatment depends on the size, location, and type of neovascularization.\\nIntravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs (usually ranibizumab or\\nbevacizumab or, occasionally, pegaptanib) can substantially reduce the risk of vision loss and can help\\nrestore reading vision in up to one third of patients. Thermal laser photocoagulation of neovascularization\\noutside the fovea may prevent severe vision loss. Photodynamic therapy, a type of laser treatment, helps\\nunder specific circumstances. Corticosteroids (eg, triamcinolone) are sometimes injected intraocularly\\nalong with an anti-VEGF drug. Other treatments, including transpupillary thermotherapy, subretinal\\nsurgery, and macular translocation surgery, are seldom used.\\nSupportive measures:\\n For patients who have lost central vision, low-vision devices such as magnifiers,\\nhigh-power reading glasses, computer monitors, and telescopic lenses, are available. Also, certain types\\nof software can display computer data in large print or read information aloud in a synthetic voice. Low-\\nvision counseling is advised.\\nCentral Retinal Artery Occlusion\\n(Retinal Artery Occlusion)\\nCentral retinal artery occlusion is blockage of the central retinal artery, usually due to an\\nembolism. Its symptom is sudden, painless, unilateral blindness. Diagnosis is by history and\\ncharacteristic retinal findings on funduscopy. Decreasing intraocular pressure can be attempted\\nwithin the first 24 h of occlusion. If patients present within the first few hours of occlusion,\\nsome centers catheterize the carotid artery and selectively inject thrombolytic drugs.\\nEtiology\\nRetinal artery occlusion may be due to embolism or thrombosis.\\nEmboli may come from any of the following:\\n Atherosclerotic plaques\\n Endocarditis\\n \\nFat\\n Atrial myxoma\\nGiant cell arteritis (see p. \\n319\\n) is another important cause of arterial occlusion.\\nOcclusion can affect a branch of the retinal artery as well as the central retinal artery.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n721'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 731, 'page_label': '722'}, page_content='Neovascularization (abnormal new vessel formation) of the retina or iris (rubeosis iridis) with secondary\\n(neovascular) glaucoma can occur weeks to months after occlusion. Vitreous hemorrhage may result from\\nretinal neovascularization.\\nSymptoms and Signs\\nRetinal artery occlusion causes sudden, painless blindness or visual field defect, usually unilaterally.\\nThe pupil may respond poorly to direct light but constricts briskly when the other eye is illuminated\\n(relative afferent pupillary defect). In acute cases, funduscopy discloses a pale, opaque fundus with a red\\nfovea (cherry-red spotsee\\nPlate 5\\n). Typically, the arteries are attenuated and may even appear bloodless. An embolic obstruction is\\nsometimes visible. If a major branch is occluded rather than the entire artery, fundus abnormalities and\\nvision loss are limited to that sector of the retina.\\nPatients who have giant cell arteritis often have headache, a tender and palpable temporal artery, jaw\\nclaudication, fatigue, or a combination.\\nDiagnosis\\n Clinical evaluation\\n Sometimes fluorescein angiography\\nThe diagnosis is suspected when a patient has acute, painless vision loss. Funduscopy is usually\\nconfirmatory. Fluorescein angiography is often done and shows obstruction clearly.\\nOnce the diagnosis is made, carotid Doppler ultrasonography and echocardiography should be done to\\nlocate any embolic source so that further embolization can be prevented.\\nIf giant cell arteritis is suspected, ESR, C-reactive protein, and platelet count are done.\\nPrognosis\\nPatients with a branch artery occlusion often maintain good to fair vision, but vision loss is often profound\\nwith central artery occlusion, even with treatment. Once retinal infarction occurs (possibly in < 2 h, almost\\nalways by 24 h), vision loss is permanent.\\nTreatment\\n Sometimes reduction of intraocular pressure\\nImmediate treatment is indicated if occlusion occurred within 24 h of presentation. Reduction of\\nintraocular pressure by ocular hypotensive drugs (eg, topical timolol 0.5%, acetazolamide 500 mg IV or\\npo), intermittent digital massage over the closed eyelid, or anterior chamber paracentesis may dislodge\\nan embolus and allow it to enter a smaller branch of the artery, thus reducing the area of retinal ischemia.\\nSome centers have tried infusing thrombolytics into the carotid artery to dissolve the obstructing clot.\\nNonetheless, treatments for retinal artery occlusions rarely improve visual acuity. Surgical or laser-\\nmediated embolectomy is available but not commonly done.\\nPatients with occlusion secondary to temporal arteritis should receive high-dose systemic corticosteroids.\\nCentral Retinal Vein Occlusion\\n(Retinal Vein Occlusion)\\nCentral retinal vein occlusion is a blockage of the central retinal vein by a thrombus. It causes\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n722'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 732, 'page_label': '723'}, page_content='painless vision loss, usually suddenly. Diagnosis is by funduscopy. Most treatments are\\nineffective.\\nEtiology\\nMajor risk factors include\\n Hypertension\\n Age\\nOther risk factors include\\n Glaucoma\\n Diabetes\\n Increased blood viscosity\\nOcclusion may also be idiopathic. The condition is uncommon among young people. Occlusion may affect\\na branch of the retinal vein or the central retinal vein.\\nNeovascularization of the retina or iris (rubeosis iridis) with secondary (neovascular) glaucoma can occur\\nweeks to months after occlusion. Vitreous hemorrhage may result from retinal neovascularization.\\nSymptoms and Signs\\nPainless visual loss is usually sudden, but it can also occur gradually over a period of days to weeks.\\nFunduscopy reveals hemorrhages throughout the retina, engorgement and tortuousness of the retinal\\nveins, and, usually, significant retinal edema (see\\nPlate 6\\n). These \\nchanges are limited to one quadrant if obstruction involves only a branch of the central\\nretinal vein.\\nDiagnosis\\n Funduscopy\\nThe diagnosis is suspected in patients with painless visual loss, particularly those at risk. Funduscopy\\nconfirms the diagnosis. Patients with a central retinal vein occlusion are evaluated for hypertension and\\nglaucoma and tested for diabetes. Young patients are tested for increased blood viscosity (with a CBC\\nand other coagulable factors as deemed necessary).\\nPrognosis\\nMost patients have some visual deficit. In mild cases, there can be spontaneous improvement to near-\\nnormal vision over a variable period of time. Visual acuity at presentation is a good indicator of final\\nvision. If visual acuity is at least 20/40, visual acuity will likely remain good, occasionally near normal. If\\nvisual acuity is worse than 20/200, it will remain at that level or worsen in 80% of patients.\\nTreatment\\n Panretinal photocoagulation if neovascularization develops\\nThere is no generally accepted medical therapy for occlusion itself. However, if neovascularization\\ndevelops, panretinal photocoagulation should be initiated because it may decrease vitreous hemorrhages\\nand prevent neovascular glaucoma.\\nClinical trials are investigating intravitreal injection of corticosteroids and anti-vascular endothelial growth\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n723'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 733, 'page_label': '724'}, page_content='factor drugs.\\nDiabetic Retinopathy\\nDiabetic retinopathy includes microaneurysms, intraretinal hemorrhage, exudates, macular\\nedema, macular ischemia, neovascularization, vitreous hemorrhage, and traction retinal\\ndetachment. Symptoms may not develop until late in the disease. Diagnosis is by funduscopy;\\nfurther details are elucidated by fluorescein angiography and optical coherence tomography.\\nTreatment includes control of diabetes and BP and ocular laser photocoagulation, intravitreal\\ninjection of drugs, vitrectomy, or a combination.\\nPathophysiology\\nDiabetic retinopathy is a major cause of blindness. The degree of retinopathy is highly correlated with\\n Duration of diabetes\\n Blood glucose levels\\n BP levels\\nPregnancy can impair blood glucose control and thus worsen retinopathy.\\nNonproliferative retinopathy:\\n (also called background retinopathy) develops first and causes increased\\ncapillary permeability, microaneurysms, hemorrhages, exudates, macular ischemia, and macular edema\\n(thickening of the retina caused by fluid leakage from capillaries).\\nProliferative retinopathy:\\n develops after nonproliferative retinopathy and is more severe; it may lead to\\nvitreous hemorrhage and traction retinal detachment. Proliferative retinopathy is characterized by\\nabnormal new vessel formation (neovascularization), which occurs on the inner (vitreous) surface of the\\nretina and may extend into the vitreous cavity and cause vitreous hemorrhage. The neovascularization is\\noften accompanied by preretinal fibrous tissue, which, along with the vitreous humor, can contract,\\nresulting in traction retinal detachment. Neovascularization may also occur in the anterior segment of the\\neye on the iris; neovascular membrane growth in the angle of the eye at the peripheral margin of the iris\\ncan result, leading to neovascular glaucoma. Vision loss with proliferative retinopathy may be severe.\\nClinically significant macular edema can occur with nonproliferative or proliferative retinopathy and is the\\nmost common cause of vision loss due to diabetic retinopathy.\\nSymptoms and Signs\\nNonproliferative retinopathy:\\n Vision symptoms accompany macular edema or macular ischemia.\\nHowever, patients may be unaware of vision loss. The first signs of nonproliferative retinopathy are\\n Capillary microaneurysms\\n Dot and blot retinal hemorrhages\\n Hard exudates\\n Cotton-wool spots (soft exudates)\\nHard exudates are discrete, yellow, and generally deeper than retinal vessels and suggest retinal edema.\\nCotton-wool spots are areas of microinfarction that lead to retinal opacification; they are fuzzy-edged and\\nwhite and obscure underlying vessels (see\\nPlate 10\\n).\\nSigns in later stages are\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n724'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 734, 'page_label': '725'}, page_content=' Macular edema (seen on slit-lamp biomicroscopy as elevation and blurring of retinal layers)\\n \\nVenous dilation and intraretinal microvascular abnormalities\\nProliferative retinopathy:\\n Symptoms may include blurred vision, black spots or flashing lights in the\\nfield of vision, and sudden, severe painless vision loss. Some of these symptoms may be caused by\\nvitreous hemorrhage or traction retinal detachment.\\nProliferative retinopathy, unlike nonproliferative retinopathy, causes fine preretinal capillaries (newly\\ndeveloped capillaries) to appear on the optic nerve or retinal surface (see\\nPlates 11\\n and\\n23\\n). Macular edema or retinal hemorrhage may be visible on funduscopy.\\nDiagnosis\\n Funduscopy\\n Fluorescein angiography\\n Sometimes optical coherence tomography\\nDiagnosis is by funduscopy. Fluorescein angiography is used to determine the extent of damage, to\\ndevelop a treatment plan, and to monitor the results of treatment. Optical coherence tomography is also\\nuseful to assess severity of macular edema and treatment response.\\nScreening:\\n Because early detection is important, all patients with diabetes should have an annual\\ndilated ophthalmologic examination. Pregnant patients with diabetes should be examined every trimester.\\nVision symptoms are indications for ophthalmologic referral.\\nTreatment\\n Control of blood glucose and BP\\n For macular edema, focal laser and possibly vitrectomy or intravitreal drugs\\n For high-risk or complicated proliferative retinopathy, panretinal laser photocoagulation and sometimes\\nvitrectomy\\nControl of blood glucose and BP are critical; intensive control of blood glucose slows progression of\\nretinopathy. Clinically significant diabetic macular edema is treated with focal laser. Intravitreal injection of\\ntriamcinolone, as well as anti-vascular endothelial growth factor (VEGF) drugs, may help in more severe\\ncases. Vitrectomy can help in recalcitrant diabetic macular edema. In select cases of severe\\nnonproliferative retinopathy, panretinal laser photocoagulation may be used; however, most patients can\\nbe followed closely until proliferative retinopathy develops.\\nProliferative diabetic retinopathy with high-risk characteristics of vitreous hemorrhage, extensive\\npreretinal neovascularization, or anterior segment neovascularization/neovascular glaucoma, should be\\ntreated with panretinal laser photocoagulation. This treatment reduces the risk of severe vision loss\\nsignificantly.\\nVitrectomy can help preserve and often restore lost vision in patients with any of the following:\\n Vitreous hemorrhage that persists for 3 mo\\n Extensive preretinal membrane formation\\n Traction retinal detachment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n725'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 735, 'page_label': '726'}, page_content='Prevention\\nControl of blood glucose and BP is critical; intensive control of blood glucose delays onset of retinopathy.\\nHypertensive Retinopathy\\nHypertensive retinopathy is retinal vascular damage caused by hypertension. Symptoms\\ndevelop late. Funduscopic examination shows arteriolar constriction, arteriovenous nicking,\\nvascular wall changes, flame-shaped hemorrhages, cotton-wool spots, yellow hard exudates,\\nand papilledema. Treatment is directed at controlling BP and, when vision loss occurs, treating\\nthe retina.\\nPathophysiology\\nAcute BP elevation typically causes reversible vasoconstriction in retinal blood vessels, and hypertensive\\ncrisis may cause papilledema. More prolonged or severe hypertension leads to exudative vascular\\nchanges, a consequence of endothelial damage and necrosis. Other changes (eg, arteriole wall\\nthickening) typically require years of elevated BP to develop. Smoking compounds the adverse effects of\\nhypertension on the retina.\\nHypertension is a major risk factor for other retinal disorders (eg, retinal artery or vein occlusion, diabetic\\nretinopathy). Also, hypertension combined with diabetes greatly increases risk of vision loss. Patients with\\nhypertensive retinopathy are at high risk of hypertensive damage to other end organs.\\nSymptoms and Signs\\nSymptoms usually do not develop until late in the disease.\\nIn the early stages, funduscopy identifies arteriolar constriction, with a decrease in the ratio of the width\\nof the retinal arterioles to the retinal venules.\\nChronic, poorly controlled hypertension causes the following:\\n \\nPermanent arterial narrowing\\n Arteriovenous crossing abnormalities (arteriovenous nicking)\\n Arteriosclerosis with moderate vascular wall changes (copper wiring) to more severe vascular wall\\nhyperplasia and thickening (silver wiring)\\nSometimes total vascular occlusion occurs. Arteriovenous nicking is a major predisposing factor to the\\ndevelopment of a branch retinal vein occlusion.\\nIf acute disease is severe, the following can develop:\\n Superficial flame-shaped hemorrhages\\n Small white superficial foci of retinal ischemia (cotton-wool spotssee\\nPlate 18\\n)\\n Yellow hard exudates\\n Optic disk edema (papilledema)\\nYellow hard exudates represent intraretinal lipid deposition from leaking retinal vessels. These exudates\\ncan form a star-shaped lesion in the macula, particularly when hypertension is severe (see\\nPlate 17\\n). In severe hypertension, the optic disk becomes congested and edematous (papilledema\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n726'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 736, 'page_label': '727'}, page_content='indicating hypertensive crisis).\\nDiagnosis\\nDiagnosis is by history (duration and severity of hypertension) and funduscopy.\\nTreatment\\nHypertensive retinopathy is managed primarily by controlling hypertension. Other vision-threatening\\nconditions should also be aggressively controlled. If vision loss occurs, treatment of the retinal edema\\nwith laser or with intravitreal injection of corticosteroids or anti-vascular endothelial growth factor (VEGF)\\ndrugs may be useful.\\nRetinal Detachment\\nRetinal detachment is separation of the neural retina from the underlying retinal pigment\\nepithelium. The most common cause is a retinal tear. Symptoms are decreased peripheral or\\ncentral vision, often described as a curtain or dark cloud coming across the field of vision.\\nAssociated symptoms can include painless vision disturbances, including flashing lights and\\nexcessive floaters. Traction and serous retinal detachments cause either central or peripheral\\nvision loss. Diagnosis is by funduscopy; ultrasonography may help determine the presence and\\ntype of retinal detachment if it cannot be seen with funduscopy. Immediate treatment is\\nimperative if rhegmatogenous retinal detachment is acute and threatens central vision.\\nTreatment of rhegmatogenous detachment may include sealing retinal holes (by laser,\\ndiathermy, or cryotherapy), supporting the holes with scleral buckling, pneumatic retinopexy,\\nand vitrectomy.\\nEtiology\\nThere are 3 types of detachment: rhegmatogenous, which involves a retinal tear, and traction and serous\\n(exudative) detachment, which do not involve a tear (nonrhegmatogenous).\\nRhegmatogenous detachment\\n is the most common. Risk factors include the following:\\n Myopia\\n Previous cataract surgery\\n Ocular trauma\\nTraction retinal detachment\\n can be caused by vitreoretinal traction due to preretinal fibrous membranes\\nas may occur in proliferative diabetic or sickle cell retinopathy.\\nSerous detachment\\n results from transudation of fluid into the subretinal space. Causes include severe\\nuveitis, especially in Vogt-Koyanagi-Harada syndrome, choroidal hemangiomas, and primary or metastatic\\nchoroidal cancers (see p. \\n619\\n).\\nSymptoms and Signs\\nRetinal detachment is painless. Early symptoms of rhegmatogenous detachment may include dark or\\nirregular vitreous floaters (particularly in large numbers), flashes of light (photopsias), and blurred vision.\\nAs detachment progresses, the patient notices a curtain, veil, or grayness in the field of vision. If the\\nmacula is involved, central vision becomes poor. Patients may have simultaneous vitreous hemorrhage.\\nTraction and exudative (serous) retinal detachments can cause blurriness of vision, but they may not\\ncause any symptoms in the early stages.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n727'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 737, 'page_label': '728'}, page_content=' Indirect funduscopy with pupillary dilation\\nRetinal detachment should be suspected in patients, particularly those at risk, who have any of the\\nfollowing:\\n Sudden increase or change in floaters\\n Photopsias\\n Curtain or veil across the visual field\\n Any sudden, unexplained loss of vision\\n Vitreous hemorrhage that obscures the retina\\nFunduscopy shows the retinal detachment and can differentiate the subtypes of retinal detachment in\\nnearly all cases. Direct funduscopy using a handheld ophthalmoscope can \\nmiss some retinal\\ndetachments, which may be peripheral. Peripheral fundus examination, using either indirect\\nophthalmoscopy with scleral depression or using a 3-mirror lens, should be done.\\nIf vitreous hemorrhage (which may be due to a retinal tear), cataract, corneal opacification, or traumatic\\ninjury obscures the retina, retinal detachment should be suspected and B-scan ultrasonography should\\nbe done.\\nTreatment\\n Sealing retinal holes\\n Scleral buckling\\n Pneumatic retinopexy\\n Vitrectomy\\nAlthough often localized, retinal detachments due to retinal tears can expand to involve the entire retina if\\nthey are not treated promptly. \\nAny patient with a suspected or established retinal detachment should be\\nexamined urgently by an ophthalmologist\\n.\\nRhegmatogenous detachment\\n is treated with one or more methods, depending on the cause and\\nlocation of the lesion. One method involves sealing the retinal holes by laser, diathermy, or cryotherapy.\\nThe eye may be treated by scleral buckling (which indents the sclera, pushing the retina inward and\\nthereby relieving vitreous traction on the retina); during this procedure, fluid may be drained from the\\nsubretinal space. Pneumatic retinopexy (intravitreal injection of gas) and vitrectomy are other treatments.\\nRetinal tears without detachment can be sealed by laser photocoagulation or transconjunctival cryopexy.\\nNearly all rhegmatogenous detachments can be reattached surgically.\\nNonrhegmatogenous detachments\\n due to vitreoretinal traction may be treated by surgical vitrectomy;\\ntransudative detachments due to uveitis may respond to systemic corticosteroids, systemic corticosteroid-\\nsparing drugs (eg, methotrexate, azathioprine, anti-tumor necrosis factor drugs), or a slow-release\\ncorticosteroid implant, which is surgically implanted into the eye. Primary and metastatic choroidal\\ncancers also require treatment. Choroidal hemangiomas may respond to localized photocoagulation.\\nRetinitis Pigmentosa\\nRetinitis pigmentosa is a slowly progressive, bilateral degeneration of the retina and retinal\\npigment epithelium caused by various genetic mutations. Symptoms include night blindness\\nand loss of peripheral vision. Diagnosis is by funduscopy, which demonstrates pigmentation in\\na bone-spicule configuration in the equatorial retina, narrowing of the retinal arterioles, a waxy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n728'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 738, 'page_label': '729'}, page_content='pallor of the optic disk, posterior subcapsular cataracts, and cells in the vitreous.\\nElectroretinography helps confirm the diagnosis.\\nAbnormal gene coding for retinal proteins appears to be the cause of retinitis pigmentosa; several genes\\nhave been identified. Transmission may be autosomal recessive, autosomal dominant, or, infrequently, X-\\nlinked. It may occur as part of a syndrome (eg, Bassen-Kornzweig, Laurence-Moon). Some of these\\nsyndromes include congenital hearing loss as well.\\nSymptoms and Signs\\nRetinal rods are affected, causing defective night vision that becomes symptomatic at varying ages,\\nsometimes in early childhood. Night vision may eventually be lost. A peripheral ring scotoma (detectable\\nby visual field testing) widens gradually, so that central vision may also be affected in advanced cases.\\nThe most conspicuous funduscopic finding is hyperpigmentation in a bone-spicule configuration in the\\nmidperipheral retina. Other findings include the following:\\n Narrowing of the retinal arterioles\\n Cystoid macular edema\\n Waxy yellow appearance of the disk\\n Posterior subcapsular cataracts\\n Cells in the vitreous (less commonly)\\n Myopia\\nDiagnosis\\n Funduscopy\\n Electroretinography\\nThe diagnosis is suspected in patients with poor night vision or a family history. Diagnosis is by\\nfunduscopy, usually supplemented with electroretinography. Other retinopathies that can simulate retinitis\\npigmentosa should be excluded; they include retinopathies associated with syphilis, rubella,\\nphenothiazine or chloroquine toxicity, and nonocular cancer. Family members should be examined and\\ntested as necessary or desired to establish the hereditary pattern. Patients with a hereditary syndrome\\nmay wish to seek genetic counseling before having children.\\nTreatment\\n Vitamin A\\nThere is no way to reverse damage caused by retinitis pigmentosa, but vitamin A palmitate 20,000 units\\npo once/day may help slow disease progression in some patients. Patients taking vitamin A palmitate\\nshould have regular liver function tests. Vision decreases as the macula becomes increasingly involved\\nand can evolve to legal blindness.\\nEpiretinal Membrane\\n(Macular Pucker; Cellophane Maculopathy; Premacular Fibrosis)\\nEpiretinal membrane is formation of a thin membrane over the retina, which interferes with\\nvision.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n729'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 739, 'page_label': '730'}, page_content='Epiretinal membrane typically occurs after age 50 and is most common among people > 75. An epiretinal\\nmembrane is a thin fibrotic membrane that forms over the retina and contracts, wrinkling the retina\\nunderneath.\\nRisk factors for epiretinal membrane are the following:\\n Diabetic retinopathy\\n Uveitis\\n Retinal detachment\\n Ocular injury\\nMost cases are idiopathic.\\nSymptoms may include blurred vision or distorted vision (eg, straight lines may appear wavy). Many\\npatients say that it seems like they are looking through plastic wrap or cellophane. Diagnosis is by\\nfunduscopy. Fluorescein angiography and optical coherence tomography may also be helpful.\\nMost people need no treatment. If problems with vision are significant, the membrane can be removed\\nsurgically (membrane peel).\\nCancers Affecting the Retina\\nCancers affecting the retina usually begin in the choroid. Because the retina depends on the choroid for\\nits support and half of its blood supply, damage to the choroid by a cancer is likely to affect vision.\\nChoroidal melanoma:\\n Choroidal melanoma originates in the choroidal melanocytes. Choroidal\\nmelanoma is the most common cancer originating in the eye, with an incidence of about 1 in 2500 whites.\\nIt is less common among darker-skinned people. It occurs most frequently at age 55 to 60. It may spread\\nlocally or metastasize and be fatal.\\nSymptoms tend to develop late and include loss of vision and symptoms of retinal detachment (see p.\\n617\\n).\\nDiagnosis is by funduscopy, supplemented, when indicated, by other tests, such as ultrasonography, CT,\\nfluorescein angiography, and serial photographs.\\nSmall cancers are treated with laser, radiation, or radioactive implants, which may preserve vision and\\nsave the eye. Rarely, local resection is used. Large cancers require enucleation.\\nChoroidal metastases:\\n Choroidal metastases are common because the choroid is highly vascular. The\\nmost common primary cancers are those of the breast in women and of the lung and prostate in men.\\nSymptoms tend to develop late and include loss of vision and symptoms of retinal detachment.\\nDiagnosis is often incidental during routine ophthalmoscopy. Ultrasonography is usually done, and the\\ndiagnosis is confirmed using fine-needle biopsy.\\nTreatment is usually with chemotherapy, radiation therapy, or both.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 68. Retinal Disorders\\n730'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 740, 'page_label': '731'}, page_content=\"Chapter 69. Optic Nerve Disorders\\nIntroduction\\nThe optic pathway includes the retina, optic nerve, optic chiasm, optic radiations, and occipital cortex (see\\nFig. 69-1\\n). Damage along the optic pathway causes a variety of visual field changes (see\\nTable 60-1\\n on p. \\n540\\n).\\nHereditary Optic Neuropathies\\nHereditary optic neuropathies are genetic defects that cause vision loss, occasionally with\\ncardiac or neurologic abnormalities. There is no effective treatment.\\nHereditary optic neuropathies typically manifest in childhood or adolescence with\\n[\\nFig. 69-1.\\n Higher visual pathwayslesion sites and corresponding visual field defects.]\\nbilateral, symmetric central vision loss. Optic nerve damage is usually permanent and in some cases\\nprogressive. By the time optic atrophy is detected, substantial optic nerve injury has already occurred.\\nDominant optic atrophy:\\n This disorder is inherited in an autosomal dominant fashion. It is believed to be\\nthe most common of the hereditary optic neuropathies, with prevalence in the range of 1:10,000 to\\n1:50,000. It is thought to be optic abiotrophy, premature degeneration of the optic nerve leading to\\nprogressive vision loss. Onset is in the 1st decade of life.\\nLeber's hereditary optic neuropathy:\\n This disorder involves a mitochondrial DNA abnormality that\\naffects cellular respiration. Although mitochondrial DNA throughout the body is affected, vision loss is the\\nprimary manifestation. Most cases (80 to 90%) occur in males. The disease is inherited with a maternal\\ninheritance pattern, meaning that all offspring of a woman with the abnormality inherit the abnormality, but\\nonly females can pass on the abnormality because the zygote receives mitochondria only from the\\nmother.\\nSymptoms and Signs\\nDominant optic atrophy:\\n Most patients have no associated neurologic abnormalities, although\\nnystagmus and hearing loss have been reported. The only symptom is slowly progressive bilateral vision\\nloss, usually mild until late in life. The entire optic disk or, at times, only the temporal part is pale without\\nvisible vessels. A blue-yellow color vision deficit is characteristic.\\nLeber's hereditary optic neuropathy:\\n Vision loss typically begins between 15 and 35 yr (range, 1 to 80\\nyr). Painless central vision loss \\nin one eye is usually followed weeks to months later by loss in the other\\neye. Simultaneous vision loss has been reported. Most patients lose vision to worse than 20/200 acuity.\\nOphthalmoscopic examination may show telangiectatic microangiopathy, swelling of the nerve fiber layer\\naround the optic disk, and an absence of leakage on fluorescein angiography. Eventually, optic atrophy\\nsupervenes.\\nSome patients with Leber's hereditary optic neuropathy have cardiac conduction defects. Other patients\\nhave minor neurologic abnormalities, such as a postural tremor, loss of ankle reflexes, dystonia,\\nspasticity, or a multiple sclerosis-like illness.\\nDiagnosis\\nMolecular genetic testing is available to confirm the diagnosis of dominant optic atrophy.\\nDiagnosis of Leber's hereditary optic atrophy is mainly clinical. ECG should be done to diagnose occult\\ncardiac conduction defects.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 69. Optic Nerve Disorders\\n731\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 741, 'page_label': '732'}, page_content=\" Symptomatic treatment\\nThere is no effective treatment for the hereditary optic neuropathies. Low-vision aids (eg, magnifiers,\\nlarge-print devices, talking watches) may be helpful. Genetic counseling is suggested.\\nLeber's hereditary optic neuropathy:\\n Corticosteroids, vitamin supplements, and antioxidants have\\nbeen tried without success. A small study found benefits from quinone analogs (ubiquinone and\\nidebenone) during the early phase. Suggestions to avoid agents that might stress mitochondrial energy\\nproduction (eg, alcohol) have no proven benefit but are theoretically reasonable. Patients should avoid\\ntobacco products and excessive alcohol intake. Cardiac and neurologic abnormalities should be referred\\nto a specialist.\\nIschemic Optic Neuropathy\\nIschemic optic neuropathy is infarction of the optic disk. The only constant symptom is painless\\nvision loss. Diagnosis is clinical. Treatment is ineffective.\\nTwo varieties of optic nerve infarction exist: nonarteritic and arteritic. The nonarteritic variant occurs more\\nfrequently, typically affecting people about 50 yr and older. Vision loss tends not to be as severe as in the\\narteritic variant, which typically affects an older group, typically about 70 yr and older.\\nMost ischemic optic neuropathy is unilateral. Bilateral, sequential cases occur in about 20%, but bilateral\\nsimultaneous involvement is uncommon. Atherosclerotic narrowing of the posterior ciliary arteries may\\npredispose to nonarteritic optic nerve infarction, particularly after a hypotensive episode. Any of the\\ninflammatory arteritides, especially giant cell arteritis (see p. \\n319\\n), can precipitate the arteritic form.\\nAcute ischemia causes nerve edema, which further worsens ischemia. A small optic cup to optic disk ratio\\nis a risk factor for nonarteritic ischemic optic neuropathy but not for the arteritic variety. Usually, no\\nmedical condition is apparent to cause the nonarteritic variety, although diabetes and hypertension are\\npresent in some patients and are thought to be risk factors. Vision loss on awakening leads investigators\\nto suspect nocturnal hypotension as a potential cause of the nonarteritic variety.\\nSymptoms and Signs\\nVision loss with both varieties is typically rapid (over minutes, hours, or days) and painless. Some patients\\nnotice the loss on awakening. Symptoms such as general malaise, muscle aches and pains, headaches\\nover the temple, pain when combing hair, jaw claudication, and tenderness over the temporal artery may\\nbe present with temporal arteritis; however, such symptoms may not occur until after vision is lost. Visual\\nacuity is reduced, and an afferent pupillary defect is present. The optic disk is swollen with surrounding\\nhemorrhages. Visual field examination often shows a defect in the inferior and central visual fields.\\nDiagnosis\\n ESR\\n CT or MRI if vision loss is progressive\\nDiagnosis is based mainly on a clinical evaluation, but ancillary testing may be needed. Most important is\\nto exclude the arteritic variety because the other eye is at risk if treatment is not started quickly. ESR is\\nusually dramatically elevated in the arteritic variety and is normal in the nonarteritic variety. C-reactive\\nprotein is also a useful monitoring test. If temporal arteritis is suspected, temporal artery biopsy should be\\ndone. For isolated cases of progressive vision loss, CT or MRI should be done to rule out compressive\\nlesions.\\nPrognosis\\nThere is no effective treatment, and most lost vision is not recovered; however, in the \\nnonarteritic variety,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 69. Optic Nerve Disorders\\n732\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 742, 'page_label': '733'}, page_content=\"up to 40% of patients spontaneously recover some useful vision.\\nTreatment\\n Corticosteroids for the arteritic variety\\nThe arteritic variety is treated with oral corticosteroids (prednisone 80 mg po once/day and tapered based\\non ESR) to protect the other eye. Treatment should not be delayed while awaiting biopsy results.\\nTreatment of the nonarteritic variety with aspirin or corticosteroids has not been helpful. Risk factors are\\ncontrolled. Low-vision aids (eg, magnifiers, large-print devices, talking watches) may be helpful in both\\ntypes.\\nOptic Neuritis\\nOptic neuritis is inflammation of the optic nerve. Symptoms are usually unilateral, with eye pain\\nand partial or complete vision loss. Diagnosis is primarily clinical. Treatment is directed at the\\nunderlying condition; most cases resolve spontaneously.\\nEtiology\\nOptic neuritis is most common among adults 20 to 40 yr. Most cases result from demyelinating disease,\\nparticularly multiple sclerosis (see p. \\n1779\\n), in which case there may be recurrences. Optic neuritis is\\noften the presenting manifestation of multiple sclerosis. Other causes include the following:\\n Infectious diseases (eg, viral encephalitis [particularly in children], sinusitis, meningitis, TB, syphilis, HIV)\\n Tumor metastasis to the optic nerve\\n Chemicals and drugs (eg, lead, methanol, quinine, arsenic, antibiotics)\\nRare causes include diabetes, pernicious anemia, Graves' disease, bee stings, and trauma. Often, the\\ncause remains obscure despite thorough evaluation.\\nSymptoms and Signs\\nThe main symptom is vision loss, frequently maximal within 1 or 2 days and varying from a small central or\\nparacentral scotoma to complete blindness. Most patients have mild eye pain, which often feels worse\\nwith eye movement.\\nIf the optic disk is swollen, the condition is called papillitis. Otherwise, it is called retrobulbar neuritis. The\\nmost characteristic findings include reduced visual acuity, a visual field deficit, and disturbed color vision\\n(often out of proportion to loss of visual acuity). An afferent pupillary defect is usually detectable if the\\ncontralateral eye is unaffected or involved to a lesser degree. Testing of color vision is a useful adjunct. In\\nabout two thirds of patients, inflammation is entirely retrobulbar, causing no visible changes in the optic\\nfundus. In the rest, disk hyperemia, edema in or around the disk, vessel engorgement, or a combination is\\npresent. A few exudates and hemorrhages may be present near or on the optic disk.\\nDiagnosis\\n Clinical evaluation\\n MRI\\nOptic neuritis is suspected in patients with characteristic pain and vision loss. Neuroimaging, preferably\\nwith gadolinium-enhanced MRI, is usually done and may show an enlarged, enhancing optic nerve. MRI\\nmay also help diagnose multiple sclerosis. Fluid attenuating inversion recovery (FLAIR) MRI sequences\\nmay show typical demyelinating lesions in a periventricular location if optic neuritis is related to\\ndemyelination.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 69. Optic Nerve Disorders\\n733\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 743, 'page_label': '734'}, page_content='Prognosis\\nPrognosis depends on the underlying condition. Most episodes resolve spontaneously, with return of\\nvision in 2 to 3 mo. Most patients with a typical history of optic neuritis and no underlying systemic\\ndisease, such as a connective tissue disease, recover vision, but > 25% have a recurrence in the same\\neye or in the other eye. MRI is used to determine future risk of demyelinating disease.\\nTreatment\\n Corticosteroids\\nCorticosteroids are an option, especially if multiple sclerosis is suspected. Treatment with\\nmethylprednisolone (500 mg to 1000 mg IV once/day) for 3 days followed by prednisone (1 mg/kg po\\nonce/day) for 11 days may speed recovery, but ultimate vision results are no different from those with\\nobservation alone. IV corticosteroids have been reported to delay onset of multiple sclerosis for at least 2\\nyr. Treatment with oral prednisone alone does not improve vision outcome and may increase the rate of\\nrecurrent episodes. Low-vision aids (eg, magnifiers, large-print devices, talking watches) may be helpful.\\nPapilledema\\nPapilledema is swelling of the optic disk due to increased intracranial pressure. All other causes\\nof optic disk swelling, such as that \\ncaused by malignant hypertension or thrombosis of the\\ncentral retinal vein, do not involve increased intracranial pressure and therefore are not causes\\nof papilledema. There are no early symptoms, although vision may be disturbed for a few\\nseconds. Papilledema requires an immediate search for the cause. Diagnosis is by\\nophthalmoscopy with further tests, usually brain imaging, to determine cause. Treatment is\\ndirected at the underlying condition.\\nPapilledema is a sign of elevated intracranial pressure and is almost always bilateral. Causes include the\\nfollowing:\\n Brain tumor or abscess\\n Cerebral trauma or hemorrhage\\n Meningitis\\n Arachnoidal adhesions\\n Cavernous or dural sinus thrombosis\\n Encephalitis\\n Idiopathic intracranial hypertension (pseudotumor cerebri), a condition with elevated CSF pressure and\\nno mass lesion\\nSymptoms and Signs\\nVision is usually not affected initially, but seconds-long graying out of vision, flickering, or blurred or\\ndouble vision may occur. Patients may have symptoms of increased intracranial pressure, such as\\nheadache or nausea and vomiting.\\nOphthalmoscopic examination reveals engorged and tortuous retinal veins, a hyperemic and swollen optic\\ndisk (optic nerve head), and retinal hemorrhages around the disk but not into the retinal periphery (see\\nPlate 19\\n). Isolated disk edema (eg, caused by optic neuritis or ischemic optic neuropathy) without\\nelevated CSF pressure is not considered papilledema.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 69. Optic Nerve Disorders\\n734'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 744, 'page_label': '735'}, page_content=\"In the early stages, visual acuity and pupillary response to light are usually normal and become abnormal\\nonly after the condition is well advanced. Visual field testing may detect an enlarged blind spot. Later,\\nnerve fiber bundle defects may be apparent.\\nDiagnosis\\n Clinical evaluation\\n Immediate neuroimaging\\nThe degree of disk swelling can be quantified by comparing the plus lens numbers needed to focus an\\nophthalmoscope on the most elevated portion of the disk and on the unaffected portion of the retina.\\nDifferentiating papilledema from other causes of a swollen optic disk, such as optic neuritis, ischemic\\noptic neuropathy, hypotony, central retinal vein occlusion, uveitis, or pseudo swollen disks (eg, optic nerve\\ndrusen), requires a thorough ophthalmologic evaluation. If papilledema is suspected clinically, MRI with\\ngadolinium contrast or CT with contrast is done immediately to exclude causes such as an intracranial\\nmass. Lumbar puncture and measurement of CSF pressure should be done if a mass lesion has been\\nruled out. Lumbar puncture in patients with intracranial mass lesions can result in brain stem herniation.\\nB-scan ultrasonography is the best diagnostic tool for the pseudo disk edema of optic nerve drusen.\\nTreatment\\n Treatment of underlying disorder\\nUrgent treatment of the underlying disorder is indicated to decrease intracranial pressure. If intracranial\\npressure is not reduced, secondary optic nerve atrophy and vision loss eventually occur, along with other\\nserious neurologic sequelae.\\nToxic Amblyopia\\n(Nutritional Amblyopia)\\nToxic amblyopia is reduction in visual acuity believed to be the result of a toxic reaction in the\\norbital portion (papillomacular bundle) of the optic nerve. It can be caused by various toxic and\\nnutritional factors and probably unknown factors. The main symptom is painless vision loss.\\nDiagnosis is by history and visual field examination. Treatment is avoiding suspected toxic\\nagents and improving nutrition.\\nEtiology\\nToxic amblyopia is usually bilateral and symmetric. In alcoholics, undernutrition may be the cause. True\\ntobacco-induced amblyopia is rare. Lead, methanol, chloramphenicol, digoxin, ethambutol, and many\\nother chemicals can damage the optic nerve. Deficiencies of protein and antioxidants are likely risk\\nfactors. Toxic amblyopia may occur with other nutritional disorders, such as Strachan's syndrome\\n(polyneuropathy and orogenital dermatitis).\\nSymptoms and Signs\\nVision blurring and dimness typically develop over days to weeks. An initially small central or pericentral\\nscotoma slowly enlarges, typically involving both the fixation and the blind spot (centrocecal scotoma),\\nand progressively interferes with vision. Total blindness \\nmay occur in methanol ingestion, but other\\nnutritional causes typically do not cause profound vision loss. Retinal abnormalities do not usually occur,\\nbut temporal disk pallor may develop late.\\nDiagnosis\\n Mainly clinical evaluation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 69. Optic Nerve Disorders\\n735\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 745, 'page_label': '736'}, page_content='A history of undernutrition or toxic or chemical exposure combined with typical bilateral scotomata on\\nvisual field testing justifies treatment. Laboratory testing for lead, methanol, and other suspected toxins is\\ndone.\\nPrognosis\\nVision may improve if the cause is treated or removed quickly. Once the optic nerve has atrophied, vision\\nusually does not recover.\\nTreatment\\nThe cause is treated. Exposure to toxic substances should stop immediately. Chelation therapy is\\nindicated in lead poisoning. Dialysis, fomepizole, ethanol, or a combination is used for methanol\\npoisoning. Treatment with oral or parenteral B vitamins before vision loss becomes severe may reverse\\nthe condition when undernutrition is the presumed cause.\\nLow-vision aids (eg, magnifiers, large-print devices, talking watches) may be helpful.\\nThe role of antioxidants has not been fully characterized. Their use could be justified on a theoretic basis;\\nhowever, there is no proof of efficacy, and the at-risk population that should receive such supplements\\nhas not been defined.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 69. Optic Nerve Disorders\\n736'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 746, 'page_label': '737'}, page_content=\"Chapter 70. Orbital Diseases\\nIntroduction\\nOrbital diseases may be vascular, thyroid-related (Graves' disease), infectious, inflammatory, or\\nneoplastic. Cavernous sinus thrombosis causes many of the same symptoms and signs as orbital\\ndiseases. Infiltrative ophthalmopathy due to Graves' disease, the most frequent cause of orbital disease,\\nis discussed on p. \\n780\\n. Orbital fractures are discussed on p. \\n3232\\n. (See\\nFig. 60-1\\n on p. \\n537\\n for anatomy of the orbit.)\\nCavernous Sinus Thrombosis\\nCavernous sinus thrombosis (CST) is a very rare, typically septic thrombosis of the cavernous\\nsinus, usually caused by bacterial sinusitis. Symptoms and signs include pain, proptosis,\\nophthalmoplegia, vision loss, papilledema, and fever. Diagnosis is confirmed by CT or MRI.\\nTreatment is with IV antibiotics. Complications are common, and prognosis is poor.\\nEtiology\\nThe cavernous sinuses are trabeculated sinuses located at the base of the skull that drain venous blood\\nfrom facial veins. CST is an extremely rare complication of common facial infections, most notably nasal\\nfuruncles (50%), sphenoidal or ethmoidal sinusitis (30%), and dental infections (10%). Most common\\npathogens are \\nStaphylococcus aureus\\n (70%), followed by \\nStreptococcus\\n sp; anaerobes are more\\ncommon when the underlying condition is dental or sinus infection.\\nThrombosis of the lateral sinus (related to mastoiditis) and thrombosis of the superior sagittal sinus\\n(related to bacterial meningitis) occur but are rarer than CST.\\nPathophysiology\\nThe 3rd, 4th, and 6th cranial nerves and the ophthalmic and maxillary branches of the 5th cranial nerve\\nare adjacent to the cavernous sinus and are commonly affected. Complications include\\nmeningoencephalitis, brain abscess, stroke, blindness, and pituitary insufficiency.\\nSymptoms and Signs\\nInitial symptoms are progressively severe headache or facial pain, usually unilateral and localized to retro-\\norbital and frontal regions. High fever is common. Later, ophthalmoplegia (initially the 6th cranial nerve,\\nlateral gaze), proptosis, and lid edema develop and often become bilateral. Facial sensation may be\\ndiminished or absent. Decreased level of consciousness, confusion, seizures, and focal neurologic\\ndeficits are signs of CNS spread. Patients may also have anisocoria or mydriasis (3rd cranial nerve\\ndysfunction), papilledema, and vision loss.\\nDiagnosis\\n MRI or CT\\nCST is often misdiagnosed because it is rare. It should be considered in patients who have signs\\nconsistent with orbital cellulitis. Features that distinguish CST from orbital cellulitis include cranial nerve\\ndysfunction, bilateral eye involvement, and mental status changes.\\nDiagnosis is based on neuroimaging. MRI is the better study, but CT is also helpful. Useful adjunct testing\\nmay include blood cultures and lumbar puncture. Lumbar puncture may show inflammatory cells (PMNs,\\nlymphocytes, monocytes); other possible abnormalities include low glucose, high protein, and positive\\nCSF cultures. Cultures of any suspected source infections are also done.\\nPrognosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 70. Orbital Diseases\\n737\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 747, 'page_label': '738'}, page_content='Mortality is 30% in all patients and 50% in those with underlying sphenoid sinusitis. An additional 30%\\ndevelop serious sequelae (eg, ophthalmoplegia, blindness, disability due to stroke, pituitary insufficiency),\\nwhich may be permanent.\\nTreatment\\n IV high-dose antibiotics\\n Sometimes corticosteroids\\nInitial antibiotics can include nafcillin or oxacillin 1 to 2 g q 4 to 6 h combined with a 3rd-generation\\ncephalosporin (eg, ceftriaxone 1 g q 12 h). In areas where methicillin-resistant \\nS. aureus\\n is prevalent,\\nvancomycin 1 g IV q 12 h should be substituted for nafcillin or oxacillin. A drug for anaerobes (eg,\\nmetronidazole 500 mg q 8 h) should be added if an underlying sinusitis or dental infection is present.\\nIn cases with underlying sphenoid sinusitis, surgical sinus drainage is indicated, especially if there is no\\nclinical response to antibiotics within 24 h.\\nSecondary treatment may include corticosteroids (eg, dexamethasone 10 mg po q 6 h) for cranial nerve\\ndysfunction; anticoagulation is controversial because most patients respond to antibiotics, and adverse\\neffects may exceed benefits.\\nInflammatory Orbital Disease\\nOrbital inflammation (inflammatory orbital pseudotumor) can affect any or all structures within the orbit.\\nThe inflammatory response can be nonspecific, granulomatous, or vasculitic. The inflammation can be\\npart of an underlying medical disorder or can exist in isolation. Patients of all ages can be affected. The\\nprocess can be acute or chronic and can recur.\\nSymptoms and Signs\\nSymptoms and signs typically include a sudden onset of pain along with swelling and erythema of the\\neyelids. Proptosis, diplopia, and vision loss are also possible.\\nDiagnosis\\n CT or MRI\\nSimilar findings occur with orbital infection, but there is no history of trauma or adjacent focus of infection\\n(eg, sinusitis). Neuroimaging with CT or MRI is required. For chronic or recurrent disease, biopsy may be\\nused to find evidence of an underlying medical condition.\\nTreatment\\nTreatment depends on the type of inflammatory response and may include oral corticosteroids, radiation\\ntherapy, and one of several immunomodulating drugs. In difficult cases, some initial success has occurred\\nwith monoclonal antibodies against tumor necrosis factor \\n\\n or with another monoclonal antibody that\\ncauses lymphocyte depletion.\\nPreseptal and Orbital Cellulitis\\nPreseptal cellulitis (periorbital cellulitis) is infection of the eyelid and surrounding skin anterior\\nto the orbital septum. Orbital cellulitis (postseptal cellulitis) is infection of the orbital tissues\\nposterior to the orbital septum. Either can be caused by an external focus of infection (eg, a\\nwound), infection that extends from the nasal sinuses or teeth, or metastatic spread from\\ninfection elsewhere. Symptoms include eyelid pain, discoloration, and swelling; orbital cellulitis\\nalso causes fever, malaise, proptosis, impaired ocular movement, and impaired vision.\\nDiagnosis is based on history, examination, and CT or MRI. Treatment is with antibiotics and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 70. Orbital Diseases\\n738'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 748, 'page_label': '739'}, page_content='sometimes surgical drainage.\\nPreseptal cellulitis and orbital cellulitis are 2 distinct diseases that share a few clinical symptoms and\\nsigns. Preseptal cellulitis usually begins superficial to the orbital septum. Orbital cellulitis usually begins\\ndeep to the orbital septum. Both are more common among \\nchildren; preseptal cellulitis is far more\\ncommon than orbital cellulitis.\\nEtiology\\nPreseptal cellulitis is caused by contiguous spread of infection from local facial or eyelid injuries, insect or\\nanimal bites, conjunctivitis, chalazion, or sinusitis.\\nOrbital cellulitis is most often caused by extension of infection from adjacent sinuses, especially the\\nethmoid sinus (75 to 90%); it is less commonly caused by direct infection accompanying local trauma (eg,\\ninsect or animal bite, penetrating eyelid injuries) or contiguous spread of infection from the face or teeth\\nor by hematogenous spread.\\nPathogens vary by etiology and patient age. \\nStreptococcus pneumoniae\\n is the most frequent pathogen\\nassociated with sinus infection, whereas \\nStaphylococcus aureus\\n and \\nStreptococcus pyogenes\\npredominate when infection arises from local trauma. \\nHaemophilus influenzae\\n type b, once a common\\ncause, is now less common because of widespread vaccination. Fungi are uncommon pathogens,\\ncausing orbital cellulitis in diabetic or immunosuppressed patients. Infection in children < 9 yr is typically\\nwith a single aerobic organism; patients > 15 yr typically have polymicrobial mixed aerobic and anaerobic\\n(\\nBacteroides\\n, \\nPeptostreptococcus\\n) infections.\\nPathophysiology\\nBecause orbital cellulitis originates from large adjacent foci of fulminant infection (eg, sinusitis) separated\\nby only a thin bone barrier, orbital infection can be extensive and severe. Subperiosteal fluid collections,\\nsome quite large, can accumulate; they are called subperiosteal abscesses, but many are sterile initially.\\nComplications include vision loss (3 to 11%) due to ischemic retinopathy and optic neuropathy caused by\\nincreased intraorbital pressure; restricted ocular movements (ophthalmoplegia) caused by soft-tissue\\ninflammation; and intracranial sequelae from central spread of infection, including cavernous sinus\\nthrombosis, meningitis, and cerebral abscess.\\nSymptoms and Signs\\nSymptoms and signs of preseptal cellulitis include tenderness, swelling, warmth, and redness or\\ndiscoloration (violaceous in the case of \\nH. influenzae\\n) of the eyelid. Patients may be unable to open their\\neyes because of swelling, but visual acuity is not affected.\\nSymptoms and signs of orbital cellulitis include swelling and redness of the eyelid and surrounding soft\\ntissues, conjunctival hyperemia and chemosis, decreased ocular motility, pain with eye movements,\\ndecreased visual acuity, and proptosis caused by orbital swelling. Signs of the primary infection are also\\noften present (eg, nasal discharge and bleeding with sinusitis, periodontal pain and swelling with\\nabscess). Fever, malaise, and headache should raise suspicion of associated meningitis. Some or all of\\nthese findings may be absent early in the course of the infection.\\nSubperiosteal abscesses, if large enough, can contribute to symptoms of orbital cellulitis such as swelling\\nand redness of the eyelid, decreased ocular motility, proptosis, and decreased visual acuity.\\nDiagnosis\\n Mainly clinical evaluation\\n CT or MRI if orbital cellulitis is possible\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 70. Orbital Diseases\\n739'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 749, 'page_label': '740'}, page_content='Diagnosis is suspected clinically. Other disorders to consider include trauma, insect or animal bites\\nwithout cellulitis, retained foreign bodies, allergic reactions, tumors, and inflammatory orbital\\npseudotumor.\\nEyelid swelling may require the use of lid retractors for evaluation of the globe, and initial signs of\\ncomplicated infection may be subtle. An ophthalmologist should be consulted when orbital cellulitis is\\nsuspected.\\nPreseptal cellulitis and orbital cellulitis are often distinguishable clinically. Preseptal cellulitis is likely if eye\\nfindings are normal except for eyelid swelling. The presence of a local nidus of infection on the skin\\nmakes preseptal cellulitis even more likely.\\nIf findings are equivocal, if the examination is difficult (as in young children), or if nasal discharge is\\npresent (suggesting sinusitis), CT or MRI should be done to confirm orbital cellulitis, to exclude tumor and\\npseudotumor, and to diagnose sinusitis if present. MRI is better than CT if cavernous sinus thrombosis is\\nbeing considered.\\nThe direction of proptosis may be a clue to the site of infection; eg, extension from the frontal sinus\\npushes the globe down and out, and extension from the ethmoid sinus pushes the globe laterally and out.\\nBlood cultures are often done (ideally before beginning antibiotics) in patients with orbital cellulitis but are\\npositive in less than one third. Lumbar puncture is done if meningitis is suspected. Cultures of the\\nparanasal sinus fluid are done if sinusitis is the suspected source. Other laboratory tests are not\\nparticularly helpful.\\nTreatment\\n Antibiotics\\nPreseptal cellulitis:\\n Initial therapy should be directed against sinusitis pathogens (\\nS. pneumoniae\\n,\\nnontypable \\nH. influenzae\\n, \\nS. aureus\\n, \\nMoraxella catarrhalis\\n); however, in areas where methicillin-resistant\\nS. aureus\\n is prevalent, clinicians should add appropriate antibiotics (eg, clindamycin,\\ntrimethoprim/sulfamethoxazole, or doxycycline for oral treatment and vancomycin for inpatient treatment).\\nIn patients with dirty wounds, gram-negative infection must be considered.\\nOutpatient treatment is an option if orbital cellulitis has been definitively excluded; children should have\\nno signs of systemic infection and should be in the care of responsible parents or guardians. Patients\\nshould be closely followed by an ophthalmologist. Outpatient treatment options include\\namoxicillin/clavulanate 30 mg/kg po q 8 h (for children < 12 yr) or 500 mg po tid or 875 mg po bid (for\\nadults) for 10 days.\\nFor inpatients, ampicillin/sulbactam 50 mg/kg IV q 6 h (for children) or 1.5 to 3 g (for adults) IV q 6 h\\n(maximum 8 g ampicillin/day) for 7 days is an option.\\nOrbital cellulitis:\\n Patients with orbital cellulitis should be hospitalized and treated with meningitis-dose\\nantibiotics. A 2nd- or 3rd-generation cephalosporin, such as cefotaxime 50 mg/kg IV q 6 h (for children <\\n12 yr) or 1 to 2 g IV q 6 h (for adults) for 14 days, is an option when sinusitis is present; imipenem,\\nceftriaxone, and piperacillin/tazobactam are other options. If cellulitis is related to trauma or foreign body,\\ntreatment should cover gram-positive (vancomycin 1 g IV q 12 h) and gram-negative (eg, ertapenem 100\\nmg IV once/day) pathogens and be taken for 7 to 10 days or until clinical improvement.\\nSurgery to decompress the orbit, drain an abscess, open infected sinuses, or a combination is indicated\\nin any of the following circumstances:\\n Vision is compromised.\\n Suppuration or foreign body is suspected.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 70. Orbital Diseases\\n740'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 750, 'page_label': '741'}, page_content=' Imaging shows orbital or large subperiosteal abscess.\\n The infection does not resolve with antibiotics.\\nTumors of the Orbit\\nOrbital tumors can be benign or malignant and arise primarily within the orbit or secondarily\\nfrom an adjacent source, such as the eyelid, paranasal sinus, or intracranial compartment.\\nCauses differ by age group. The more common benign pediatric tumors include dermoid tumors and\\nvascular lesions such as capillary hemangioma and lymphangioma. In adults, cavernous hemangiomas\\npredominate.\\nSome orbital tumors usually cause proptosis and displacement of the globe in a direction opposite the\\ntumor. Pain, diplopia, and vision loss may also be present. Diagnosis, in most cases, is based on the\\nhistory, examination, and neuroimaging (CT, MRI, or both).\\nTreatment\\nTreatment varies by tumor type. Treatment of dermoid tumors is excision. Capillary hemangiomas tend to\\nspontaneously involute and therefore do not need any treatment; however, especially when located on\\nthe upper eyelid, they may affect vision and require treatment with interlesional injection of corticosteroids\\nor surgical debulking.\\nChildren:\\n The common pediatric malignant tumors include rhabdomyosarcoma and metastatic lesions\\nrelated to leukemia or neuroblastoma. If rhabdomyosarcoma is resectable, surgery is done, followed by\\nchemotherapy and orbital radiation therapy. Leukemic disease is usually managed by orbital radiation\\ntherapy, chemotherapy, or both.\\nAdults:\\n The most common benign tumors are meningiomas, mucoceles, and cavernous hemangiomas.\\nWhen symptomatic, sphenoid wing meningiomas are treated with debulking via craniotomy, sometimes\\nfollowed by a course of radiation therapy. Because meningioma cells infiltrate bone of the skull base,\\ncomplete resection usually is not possible. Mucoceles are treated by draining them into the nose because\\nthey most commonly arise from the ethmoid or frontal sinus. Cavernous hemangiomas are excised.\\nCommon malignant tumors include lymphoma, squamous cell carcinoma, and metastatic disease.\\nLymphomas involving the orbit are typically B-cell and characteristically low grade. Lymphomas can be\\nbilateral and simultaneous and can be part of a systemic process or exist in the orbit in isolation.\\nRadiation therapy effectively treats orbital lymphomas with few adverse effects, although the addition of\\nmonoclonal antibodies against a surface receptor (CD20) on the lymphocyte is also effective. Most\\nsquamous cell carcinomas arise from the adjacent paranasal sinuses. Surgery, radiation therapy, or both\\nform the backbone of therapy. Metastatic disease is usually treated with radiation therapy. Metastatic\\ndisease involving the orbit is usually an unfavorable prognostic sign; carcinoid tumors are a notable\\nexception.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 70. Orbital Diseases\\n741'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 751, 'page_label': '742'}, page_content='7 - Dermatologic Disorders\\nChapter 71. Approach to the Dermatologic Patient\\nIntroduction\\nHistory and physical examination are adequate for diagnosing many skin lesions. Some require biopsy or\\nother testing.\\nImportant information to obtain from history includes\\n Personal or family history of atopy (suggesting atopic dermatitis)\\n Occupational exposures (contact dermatitis)\\n Long-term exposure to sunlight or other forms of radiation (benign and malignant skin tumors)\\n Systemic disease (diabetes and \\nCandida\\n or tinea, hepatitis C and cryoglobulinemia)\\n Sexual history (syphilis and gonorrhea)\\n Use of drugs (Stevens-Johnson syndrome, toxic epidermal necrolysis)\\n Travel history (Lyme disease, skin infections)\\nA negative history is as important as a positive history. The history of the particular skin lesions is also\\nimportant, including time and site of initial appearance, spread, change in appearance, and triggering\\nfactors.\\nVisual inspection is the central evaluation tool; many skin disorders are diagnosed by the characteristic\\nappearance or morphology of the lesions.\\nDescription of Skin Lesions\\nAn extensive language has been developed to standardize the description of skin lesions, including\\n Primary morphology (lesion type)\\n Secondary morphology (configuration)\\n Texture\\n Distribution\\n Color\\nRash is a general term for a temporary skin eruption.\\nPrimary Morphology\\nMacules\\n are flat, nonpalpable lesions usually < 10 mm in diameter. Macules represent a change in color\\nand are not raised or depressed compared to the skin surface. A patch is a large macule. Examples\\ninclude freckles, flat moles, tattoos, port-wine stains, and the rashes of rickettsial infections, rubella,\\nmeasles, and some allergic drug eruptions.\\nPapules\\n are elevated lesions usually < 10 mm in diameter that can be felt or palpated. Examples include\\nnevi, warts, lichen planus, insect bites, seborrheic and actinic keratoses, some lesions of acne, and skin\\ncancers. The term maculopapular is often loosely and improperly used to describe many red skin \\nrashes;\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n742'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 752, 'page_label': '743'}, page_content='cancers. The term maculopapular is often loosely and improperly used to describe many red skin \\nrashes;\\nbecause this term is nonspecific and easily misused, it should be avoided.\\nPlaques\\n are palpable lesions > 10 mm in diameter that are elevated or depressed compared to the skin\\nsurface. Plaques may be flat topped or rounded. Lesions of psoriasis and granuloma annulare commonly\\nform plaques.\\nNodules\\n are firm papules or lesions that extend into the dermis or subcutaneous tissue. Examples\\ninclude cysts, lipomas, and fibromas.\\nVesicles\\n are small, clear, fluid-filled blisters < 10 mm in diameter. Vesicles are characteristic of herpes\\ninfections, acute allergic contact dermatitis, and some autoimmune blistering disorders (eg, dermatitis\\nherpetiformis).\\nBullae\\n are clear fluid-filled blisters > 10 mm in diameter. These may be caused by burns, bites, irritant or\\nallergic contact dermatitis, and drug reactions. Classic autoimmune bullous diseases include pemphigus\\nvulgaris and bullous pemphigoid. Bullae also may occur in inherited disorders of skin fragility.\\nPustules\\n are vesicles that contain pus. Pustules are common in bacterial infections and folliculitis and\\nmay arise in some inflammatory disorders including pustular psoriasis.\\nUrticaria\\n (wheals or hivessee\\nPlate 53\\n) is characterized by elevated lesions caused by localized edema. Wheals are a common\\nmanifestation of hypersensitivity to drugs, stings or bites, autoimmunity, and, less commonly, physical\\nstimuli including temperature, pressure, and sunlight. The typical wheal lasts < 24 h.\\nScales\\n are heaped-up accumulations of horny epithelium that occur in disorders such as psoriasis,\\nseborrheic dermatitis, and fungal infections. Pityriasis rosea and chronic dermatitis of any type may be\\nscaly.\\nCrusts (scabs)\\n consist of dried serum, blood, or pus. Crusting can occur in inflammatory or infectious\\nskin diseases (eg, impetigo).\\nErosions\\n are open areas of skin that result from loss of part or all of the epidermis. Erosions can be\\ntraumatic or can occur with various inflammatory or infectious skin diseases. An excoriation is a linear\\nerosion caused by scratching, rubbing, or picking.\\nUlcers\\n result from loss of the epidermis and at least part of the dermis. Causes include venous stasis\\ndermatitis, physical trauma with or without vascular compromise (eg, from decubitus ulcers, peripheral\\narterial disease), infections, and vasculitis.\\nPetechiae\\n are nonblanchable punctate foci of hemorrhage. Causes include platelet abnormalities (eg,\\nthrombocytopenia, platelet dysfunction), vasculitis, and infections (eg, meningococcemia, Rocky Mountain\\nspotted fever, other rickettsioses).\\nPurpura\\n is a larger area of hemorrhage that may be palpable. Palpable purpura is considered the\\nhallmark of leukocytoclastic vasculitis. Purpura may indicate a coagulopathy. Large areas of purpura may\\nbe called ecchymoses or, colloquially, bruises.\\nAtrophy\\n is thinning of the skin, which may appear dry and wrinkled, resembling cigarette paper. Atrophy\\nmay be caused by chronic sun exposure, aging, and some inflammatory and neoplastic skin diseases,\\nincluding cutaneous T-cell lymphoma and lupus erythematosus. Atrophy also may result from long-term\\nuse of potent topical corticosteroids.\\nScars\\n are areas of fibrosis that replace normal skin after injury. Some scars become hypertrophic or\\nthickened and raised. Keloids are hypertrophic scars that extend beyond the original wound margin.\\nTelangiectases\\n are foci of small, permanently dilated blood vessels that are most often idiopathic but\\nmay occur in rosacea, systemic diseases (especially systemic sclerosis), or inherited diseases (eg,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n743'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 753, 'page_label': '744'}, page_content=\"ataxia-telangiectasia, hereditary hemorrhagic telangiectasia) or after long-term therapy with topical\\nfluorinated corticosteroids.\\nSecondary Morphology (Configuration)\\nConfiguration is the shape of single lesions and the arrangement of clusters of lesions.\\nLinear lesions\\n take on the shape of a straight line and are suggestive of some forms of contact\\ndermatitis, linear epidermal nevi, and lichen striatus.\\nAnnular lesions\\n are rings with central clearing. Examples include granuloma annulare, some drug\\neruptions, some dermatophyte infections (eg, ringworm), and secondary syphilis.\\nNummular lesions\\n are circular or coin-shaped; an example is nummular eczema.\\nTarget (bull's-eye or iris) lesions\\n appear as rings with central duskiness and are classic for erythema\\nmultiforme.\\nSerpiginous lesions\\n have linear, branched, and curving elements. Examples include some fungal and\\nparasitic infections (eg, cutaneous larva migrans).\\nReticulated lesions\\n have a lacy or networked pattern. Examples include cutis marmorata and livedo\\nreticularis.\\nHerpetiform\\n describes grouped papules or vesicles arranged like those of a herpes simplex infection.\\nZosteriform\\n describes lesions clustered in a dermatomal distribution similar to herpes zoster.\\nTexture\\nSome skin lesions have visible or palpable texture that suggests a diagnosis.\\nVerrucous lesions\\n have an irregular, pebbly, or rough surface. Examples include warts and seborrheic\\nkeratoses.\\nLichenification\\n is thickening of the skin with accentuation of normal skin markings; it results from\\nrepeated rubbing.\\nInduration\\n, or deep thickening of the skin, can result from edema, inflammation, or infiltration, including\\nby cancer. Indurated skin has a hard, resistant feeling. Induration is characteristic of panniculitis, some\\nskin infections, and cutaneous metastatic cancers.\\nUmbilicated lesions\\n have a central indentation and are usually viral. Examples include molluscum\\ncontagiosum and herpes simplex.\\nXanthomas\\n, which are yellowish, waxy lesions, may occur in lipid disorders.\\nLocation and Distribution\\nIt is important to note whether\\n Lesions are single or multiple\\n Particular body parts are affected (eg, palms or soles, scalp, mucosal membranes)\\n Distribution is random or patterned, symmetric or asymmetric\\n Lesions are on sun-exposed or protected skin\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n744\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 754, 'page_label': '745'}, page_content=\"Although few patterns are pathognomonic, some are consistent with certain diseases.\\nPsoriasis\\n frequently affects the scalp, extensor surfaces of the elbows and knees, umbilicus, and the\\ngluteal cleft.\\nLichen planus\\n frequently arises on the wrists, forearms, genitals, and lower legs.\\nVitiligo\\n may be patchy and isolated or may group around the distal extremities and face.\\nChronic cutaneous lupus erythematosus\\n has characteristic lesions on sun-exposed skin of the face,\\nespecially the forehead, nose, and the conchal bowl of the ear.\\nHidradenitis suppurativa\\n involves skin containing a high density of apocrine glands, including the\\naxillae, groin, and under the breasts.\\nColor\\nRed skin\\n (erythema) can result from many different inflammatory or infectious diseases. Cutaneous\\ntumors are often pink or red. Superficial vascular lesions such as port-wine stains may appear red.\\nOrange skin\\n is most often seen in hypercarotenemia, a usually benign condition of carotene deposition\\nafter excess dietary ingestion of \\n\\n-carotene.\\nYellow skin\\n is typical of jaundice, xanthelasmas and xanthomas, and pseudoxanthoma elasticum.\\nGreen fingernails\\n suggest \\nPseudomonas aeruginosa\\n infection.\\nViolet skin\\n may result from cutaneous hemorrhage or vasculitis. Vascular lesions or tumors, such as\\nKaposi's sarcoma and hemangiomas, can appear purple. A lilac color of the eyelids or heliotrope eruption\\nis characteristic of dermatomyositis.\\nShades of blue, silver, and gray\\n can result from deposition of drugs or metals in the skin, including\\nminocycline, amiodarone, and silver (argyria). Ischemic skin appears purple to gray in color. Deep dermal\\nnevi appear blue.\\nBlack skin\\n lesions may be melanocytic, including nevi and melanoma. Black eschars are collections of\\ndead skin that can arise from vascular infarction, which may be caused by infection (eg, anthrax,\\nangioinvasive fungi including \\nRhizopus\\n, meningococcemia), calciphylaxis, arterial insufficiency, or\\nvasculitis.\\nOther Clinical Signs\\nDermatographism\\n is the appearance of an urticarial wheal after focal pressure (eg, stroking or\\nscratching the skin) in the distribution of the pressure. Up to 5% of normal patients may exhibit this sign,\\nwhich is a form of physical urticaria.\\nDarier's sign\\n refers to rapid swelling of a lesion when stroked. It occurs in patients with urticaria\\npigmentosa or mastocytosis.\\nNikolsky's sign\\n is epidermal shearing that occurs with gentle lateral pressure on seemingly uninvolved\\nskin in patients with toxic epidermal necrolysis and some autoimmune bullous diseases.\\nAuspitz sign\\n is the appearance of pinpoint bleeding after scale is removed from plaques in psoriasis.\\nKoebner phenomenon\\n describes the development of lesions within areas of trauma (eg, caused by\\nscratching, rubbing, injury). Psoriasis frequently exhibits this phenomenon, as may lichen planus.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n745\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 755, 'page_label': '746'}, page_content=\"Diagnostic Tests\\nDiagnostic tests are indicated when the cause of a skin lesion or disease is not obvious from history and\\nphysical examination alone (for patch testing, see p.\\n667\\n).\\nBiopsy:\\n A skin biopsy can be done by a primary care physician. One procedure is a punch \\nbiopsy, in\\nwhich a tubular punch (diameter usually 4 mm) is inserted into deep dermal or subcutaneous tissue to\\nobtain a specimen, which is snipped off at its base. More superficial lesions may be biopsied by shaving\\nwith a scalpel or razor blade. Bleeding is controlled by aluminum chloride solution or electrodesiccation;\\nlarge incisions are closed by sutures. Larger or deeper biopsies can be done by excising a wedge of skin\\nwith a scalpel. All pigmented lesions should be excised deeply for histologic evaluation of depth;\\nsuperficial biopsies are often inadequate. Diagnosis and cure are achieved simultaneously for most small\\ntumors by complete excision that includes a small border of normal skin.\\nScrapings:\\n Skin scrapings help diagnose fungal infections and scabies. For fungal infection, scales are\\ntaken from the border of the lesion and placed onto a microscope slide. Then a drop of 10 to 20%\\npotassium hydroxide (KOH) is added. Hyphae, budding yeast, or both confirm the diagnosis of tinea or\\ncandidiasis. For scabies, scrapings are taken from suspected burrows and placed directly under a\\ncoverslip with mineral oil; findings of mites, feces, or eggs confirm the diagnosis.\\nWood's light:\\n Wood's light (black light) can help distinguish hypopigmentation from depigmentation\\n(depigmentation of vitiligo fluoresces ivory-white and hypopigmented lesions do not). Erythrasma\\nfluoresces bright orangered. Tinea capitis caused by \\nMicrosporum canis\\n and \\nMicrosporum audouinii\\nfluoresces a light, bright green. (NOTE: Most tinea capitis in the US is caused by \\nTrichophyton\\n species,\\nwhich do not fluoresce.) The earliest clue to cutaneous \\nPseudomonas\\n infection (eg, in burns) may be\\ngreen fluorescence.\\nTzanck testing:\\n Tzanck testing can be used to diagnose viral disease, such as herpes simplex and\\nherpes zoster, and is done when active intact vesicles are present. Tzanck testing cannot distinguish\\nbetween herpes simplex and herpes zoster infections. An intact blister is the preferred lesion for\\nexamination. The blister roof is removed with a sharp blade, and the base of the unroofed vesicle is\\nscraped with a #15 scalpel blade. The scrapings are transferred to a slide and stained with Wright's stain\\nor Giemsa stain. Multinucleated giant cells are a sign of herpes infection.\\nDiascopy:\\n Diascopy is used to determine whether a lesion is vascular (inflammatory) or nonvascular\\n(nevus) or hemorrhagic (petechia or purpura). A microscope slide is pressed against a lesion to see\\nwhether it blanches. Hemorrhagic lesions and nonvascular lesions do not blanch; inflammatory lesions\\ndo. Diascopy is sometimes used to identify sarcoid skin lesions, which, when tested, turn an apple jelly\\ncolor.\\nItching\\n(Pruritus)\\nItching is a symptom that can cause significant discomfort and is one of the most common reasons for\\nconsultation with a dermatologist. Itching leads to scratching, which can cause inflammation, skin\\ndegradation, and possible secondary infection. The skin can become lichenified, scaly, and excoriated.\\nPathophysiology\\nItch can be prompted by diverse stimuli, including light touch, vibration, and wool fibers. There are a\\nnumber of chemical mediators as well as different mechanisms by which the sensation of itch occurs.\\nMediators:\\n Histamine is one of the most significant mediators. It is synthesized and stored in mast cells\\nin the skin and is released in response to various stimuli. Other mediators (eg, neuropeptides) can either\\ncause the release of histamine or act as pruritogens themselves, thus explaining why antihistamines\\nameliorate some cases of itching and not others. Opioids have a central pruritic action as well as\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n746\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 756, 'page_label': '747'}, page_content='stimulating the peripherally mediated histamine itch.\\nMechanisms:\\n There are 4 mechanisms of itch:\\n Dermatologictypically caused by inflammatory or pathologic processes (eg, urticaria, eczema)\\n Systemicrelated to diseases of organs other than skin (eg, cholestasis)\\n Neuropathicrelated to disorders of the CNS or peripheral nervous system (eg, multiple sclerosis)\\n Psychogenicrelated to psychiatric conditions\\nIntense itching stimulates vigorous scratching, which in turn can cause secondary skin conditions (eg,\\ninflammation, excoriation, infection), which can lead to more itching. However, scratch can temporarily\\nreduce the sensation of itch by activating inhibitory neuronal circuits.\\nEtiology\\nItching can be a symptom of a primary skin disease or, less commonly, a systemic disease (see\\nTable 71-1\\n).\\n[\\nTable 71-1.\\n Some Causes of Itching]\\nSkin disorders:\\n Many skin disorders cause itching. The most common include\\n Dry skin\\n Atopic dermatitis (eczema)\\n Contact dermatitis\\n Fungal skin infections\\nSystemic disorders:\\n In systemic disorders, itching may occur with or without skin lesions. However,\\nwhen itching is prominent without any identifiable skin lesions, systemic disorders and drugs should be\\nconsidered more strongly. Systemic disorders are less \\noften a cause of itching than skin disorders, but\\nsome of the more common causes include\\n Allergic reaction (eg, to foods, drugs, bites and stings)\\n Cholestasis\\n Chronic renal failure\\nLess common systemic causes of itching include hyperthyroidism, hypothyroidism, diabetes, iron\\ndeficiency, dermatitis herpetiformis, and polycythemia vera.\\nDrugs:\\n Drugs can cause itching as an allergic reaction or by directly triggering histamine release (most\\ncommonly morphine, some IV contrast agents).\\nEvaluation\\nHistory: History of present illness\\n should determine onset of itching, initial location, course, duration,\\npatterns of itching (eg, nocturnal or diurnal, intermittent or persistent, seasonal variation), and whether\\nany rash is present. A careful drug history should be obtained; both oral (eg, opioids, cocaine, aspirin,\\nprescription and OTC) and topical (eg, hydrocortisone, benadryl, moisturizers) drugs are included. History\\nalso should include any factors that make the itching better or worse.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n747'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 757, 'page_label': '748'}, page_content=\"Review of systems\\n should seek symptoms of causative disorders, including steatorrhea and right upper\\nquadrant pain (cholestasis); constitutional symptoms of fever, weight loss, and night sweats (cancer);\\nintermittent weakness, numbness, tingling, and visual disturbances or loss (multiple sclerosis); irritability,\\nsweating, weight loss, and palpitations (hyperthyroidism) or depression, dry skin, and weight gain\\n(hypothyroidism); urinary frequency, excessive thirst, and weight loss (diabetes); and headache, pica, hair\\nthinning, and exercise intolerance (iron deficiency anemia).\\nPast medical history\\n should identify known causative disorders (eg, renal disease, cholestatic disorder,\\ncancer being treated with chemotherapy) and the patient's emotional state. Social history should focus on\\nfamily members with similar itching and skin symptoms (eg, scabies, pediculosis); relationship of itching to\\noccupation or exposures to plants, animals, or chemicals; and history of recent travel.\\nPhysical examination:\\n Physical examination begins with a review of clinical appearance for signs of\\njaundice, weight loss or gain, and fatigue. Close examination of the skin should be done, taking note of\\npresence, morphology, extent, and distribution of lesions. Cutaneous examination also should make note\\nof signs of secondary infection (eg, erythema, swelling, warmth, yellow or honey-colored crusting).\\nThe examination should make note of significant adenopathy suggestive of cancer. Abdominal\\nexamination should focus on organomegaly, masses, and tenderness (cholestatic disorder or cancer).\\nNeurologic examination focuses on weakness, spasticity, or numbness (multiple sclerosis).\\nRed flags:\\n The following findings are of particular concern:\\n Constitutional symptoms of weight loss, fatigue, and night sweats\\n Extremity weakness, numbness, or tingling\\n Abdominal pain and jaundice\\n Urinary frequency, excessive thirst, and weight loss\\nInterpretation of findings:\\n Generalized itching that begins shortly after use of a drug is likely caused by\\nthat drug. Localized itching (often with rash) that occurs in the area of contact with a substance is likely\\ncaused by that substance. However, many systemic allergies can be difficult to identify because patients\\ntypically have consumed multiple different foods and have been in contact with many substances before\\ndeveloping itching. Similarly, identifying a drug cause in a patient taking several drugs may be difficult.\\nSometimes the patient has been taking the offending drug for months or even years before developing a\\nreaction.\\nIf an etiology is not immediately obvious, the appearance and location of skin lesions can suggest a\\ndiagnosis (see \\nTable 71-1\\n).\\nIn the minority of patients in whom no skin lesions are evident, a systemic disorder should be considered.\\nSome disorders that cause itching are readily apparent on evaluation (eg, chronic renal failure,\\ncholestatic jaundice). Other systemic disorders that cause itching are suggested by findings (see \\nTable\\n71-1\\n). Rarely, itching is the first manifestation of significant systemic disorders (eg, polycythemia vera,\\ncertain cancers, hyperthyroidism).\\nTesting:\\n Many dermatologic disorders are diagnosed clinically. However, when itching is accompanied by\\ndiscrete skin lesions of uncertain etiology, biopsy can be appropriate. When an allergic reaction is\\nsuspected but the substance is unknown, skin testing (either prick or patch testing depending on\\nsuspected etiology) is often done. When a systemic disorder is suspected, testing is directed by the\\nsuspected cause and usually involves CBC; liver, renal, and thyroid function measurements; and\\nappropriate evaluation for underlying cancer.\\nTreatment\\nAny underlying disorder is treated. Supportive treatment involves the following (see also\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n748\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 758, 'page_label': '749'}, page_content='Table 71-2\\n):\\n Local skin care\\n Topical treatment\\n Systemic treatment\\nSkin care:\\n Itching due to any cause benefits from use of cool or lukewarm (but not hot) water when\\nbathing, mild or moisturizing soap, limited bathing duration and frequency, frequent lubrication,\\nhumidification of dry air, and avoidance of irritating or tight clothing. Avoidance of contact irritants (eg,\\nwool clothing) also may be helpful.\\nTopical drugs:\\n Topical drugs may help localized itching. Options include lotions or creams that contain\\ncamphor and/or menthol, pramoxine, or corticosteroids. Corticosteroids are effective in relieving itch\\ncaused by inflammation but should be avoided for conditions that have no evidence of inflammation.\\nTopical diphenhydramine and doxepin should be avoided because they may sensitize the skin.\\nSystemic drugs:\\n Systemic drugs are indicated for generalized itching or local itching resistant to topical\\nagents. Antihistamines, most notably hydroxyzine, are effective, especially for nocturnal itch, and are most\\ncommonly used. Sedating antihistamines must be used cautiously in elderly patients during the day\\nbecause they can lead to falls; newer nonsedating antihistamines such as loratadine, fexofenadine, and\\ncetirizine can be useful for daytime itching. Other drugs include doxepin (typically taken at night due to\\nhigh level of sedation), cholestyramine (for renal failure, cholestasis, polycythemia vera), opioid\\nantagonists such as naltrexone (for biliary pruritus), and possibly gabapentin (for uremic pruritus).\\nPhysical agents that may be effective for itching include ultraviolet phototherapy.\\nGeriatrics Essentials\\nXerotic eczema is very common among elderly patients. It is especially likely if itching is primarily on the\\nlower extremities.\\nSevere, diffuse itching in the elderly should raise concern for cancer, especially if another etiology is not\\nimmediately apparent.\\nWhen treating the elderly, sedation can be a significant problem with antihistamines. Use of nonsedating\\nantihistamines during the day and sedating antihistamines at night, liberal use of topical ointments and\\ncorticosteroids (when appropriate), and consideration of ultraviolet phototherapy can help avoid the\\ncomplications of sedation.\\nKey Points\\n Itching is usually a symptom of a skin disorder or systemic allergic reaction but can result from a\\nsystemic disorder.\\n If skin lesions are not evident, systemic causes should be investigated.\\n Skin care (eg, limiting bathing, avoiding irritants, moisturizing regularly, humidifying environment) should\\nbe observed.\\n Symptoms can be relieved by topical or systemic drugs.\\nUrticaria\\n(Hives; Wheals)\\nUrticaria is migratory, well-circumscribed, erythematous, pruritic plaques on the skin (see \\nPlate 53\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n749'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 759, 'page_label': '750'}, page_content='Urticaria also may be accompanied by angioedema, which results from mast cell and basophil activation\\nin the deeper dermis and subcutaneous tissues and manifests as edema of the face and lips, extremities,\\nor genitals. Angioedema can be life-threatening if airway obstruction occurs because of laryngeal edema\\nor tongue swelling.\\nPathophysiology\\nUrticaria results from the release of histamine, bradykinin, kallikrein, and other vasoactive substances\\nfrom mast cells and basophils in the superficial dermis, resulting in intradermal edema caused by capillary\\nand venous vasodilation and occasionally caused by leukocyte infiltration.\\nThe process can be immune mediated or nonimmune mediated.\\nImmune-mediated mast cell activation\\n includes\\n Type I hypersensitivity reactions, in which allergen-bound IgE antibodies bind to high-affinity cell surface\\nreceptors on mast cells and basophils\\n Autoimmune disorders, in which antibodies to an IgE receptor functionally cross-link IgE receptors and\\ncause mast cell degranulation\\nNonimmune-mediated mast cell activation\\n includes\\n Direct nonallergic activation of mast cells by certain drugs\\n Drug-induced cyclooxygenase inhibition that activates mast cells by poorly understood mechanisms\\n[\\nTable 71-2.\\n Some Therapeutic Approaches to Itching]\\n \\nActivation by physical or emotional stimuli; mechanism is poorly understood but possibly involves the\\nrelease of neuropeptides that interact with mast cells\\nEtiology\\nUrticaria is classified as acute (< 6 wk) or chronic (> 6 wk); acute cases (70%) are more common than\\nchronic (30%).\\nAcute urticaria\\n (see\\nTable 71-3\\n) most often results from\\n Type I hypersensitivity reactions\\nA presumptive trigger (eg, drug, food ingestion, insect sting, infection) occasionally can be identified.\\nChronic urticaria\\n most often results from\\n Idiopathic causes\\n Autoimmune disorders\\nChronic urticaria often lasts months to years, eventually resolving without a cause being found.\\nEvaluation\\nBecause there are no definitive diagnostic tests for urticaria, evaluation largely relies on history and\\nphysical examination.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n750'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 760, 'page_label': '751'}, page_content=\"History: History of present illness\\n should include a detailed account of the individual episodes of\\nurticaria, including distribution, size, and appearance of lesions; frequency of occurrence; duration of\\nindividual lesions; and any prior episodes. Activities and exposures during, immediately before, and within\\nthe past 24 h of the appearance of urticaria should be noted. Clinicians specifically should ask about\\nrecent exercise; exposure to potential allergens (see \\nTable 71-3\\n), insects, or animals; new laundry\\ndetergent or soaps; new foods; recent infections; or recent stressful life events. The patient should be\\nasked about the duration between any suspected trigger and the appearance of urticaria and which\\nparticular triggers are suspected. Important associated symptoms include pruritus, rhinorrhea, swelling of\\nthe face and tongue, and dyspnea.\\nReview of systems\\n should seek symptoms of causative disorders, including fever, fatigue, abdominal\\npain, and diarrhea (infection); heat or cold intolerance, tremor, or weight change (autoimmune thyroiditis);\\njoint pain (cryoglobulinemia, SLE); malar rash (SLE); dry eyes and dry mouth (Sjogren's syndrome);\\ncutaneous ulcers and hyperpigmented lesions after resolution of urticaria (urticarial vasculitis); small\\npigmented papules (mastocytosis); lymphadenopathy (viral illness, cancer, serum sickness); acute or\\nchronic diarrhea (viral or parasitic enterocolitis); and fevers, night sweats, or weight loss (cancer).\\nPast medical history\\n should include a detailed allergy history, including known atopic conditions (eg,\\nallergies, asthma, eczema) and known possible causes (eg, autoimmune disorders, cancer). All drug use\\nshould be reviewed, including OTC drugs and herbal products, specifically any agents particularly\\nassociated with urticaria (see \\nTable 71-3\\n). Family history should elicit any history of rheumatoid disease,\\nautoimmune disorders, or cancer. Social history should cover any recent travel and any risk factors for\\ntransmission of infectious disease (eg, hepatitis, HIV).\\nPhysical examination:\\n Vital signs should note the presence of bradycardia or tachycardia and\\ntachypnea. General examination should immediately seek any signs of respiratory distress and also note\\ncachexia, jaundice, or agitation.\\nExamination of the head should note any swelling of the face, lips, or tongue; scleral icterus; malar rash;\\ntender and enlarged thyroid; lymphadenopathy; or dry eyes and dry mouth. The oropharynx should be\\ninspected and the sinuses should be palpated and transilluminated for signs of occult infection (eg, sinus\\ninfection, tooth abscess).\\nAbdominal examination should note any masses, hepatomegaly, splenomegaly, or tenderness. Neurologic\\nexamination should note any tremor or hyperreflexia or hyporeflexia. Musculoskeletal examination should\\nnote the presence of any inflamed or deformed joints.\\nSkin examination should note the presence and distribution of urticarial lesions as well as any cutaneous\\nulceration, hyperpigmentation, small papules, or jaundice. Urticarial lesions usually appear as well-\\ndemarcated transient swellings involving the dermis. These swellings are typically red and vary in size\\nfrom pinprick to covering wide areas. Some lesions can be very large. In other cases, smaller urticarial\\nlesions may become confluent. However, skin lesions also may be absent at the time of the visit.\\nManeuvers to evoke physical urticaria can be done during the examination, including exposure to\\nvibration (tuning fork), warmth (tuning fork held under warm water), cold (stethoscope or chilled tuning\\nfork), water, or pressure (lightly scratching an unaffected area with a fingernail).\\nRed flags:\\n The following findings are of particular concern:\\n Angioedema (swelling of the face, lips, or tongue)\\n[\\nTable 71-3.\\n Some Causes of Urticaria]\\n \\nStridor, wheezing, or other respiratory distress\\n Hyperpigmented lesions, ulcers, or urticaria that persist > 48 h\\n Signs of systemic illness (eg, fever, lymphadenopathy, jaundice, cachexia)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n751\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 761, 'page_label': '752'}, page_content='Interpretation of findings: Acute urticaria\\n is nearly always due to some defined exposure to a drug or\\nphysical stimulus or an acute infectious illness. However, the trigger is not always clear from the history,\\nparticularly because allergy may develop without warning to a previously tolerated substance.\\nMost \\nchronic urticaria\\n is idiopathic. The next most common cause is an autoimmune disorder. The\\ncausative autoimmune disorder is sometimes clinically apparent. Urticarial vasculitis sometimes is\\nassociated with connective tissue disorders (particularly SLE or Sjogren\\'s syndrome). In urticarial\\nvasculitis, urticaria is accompanied by findings of cutaneous vasculitis; it should be considered when the\\nurticaria are painful rather than pruritic, last > 48 h, do not blanch, or are accompanied by vesicles or\\npurpura.\\nTesting:\\n Usually, no testing is needed for an isolated episode of urticaria unless symptoms and signs\\nsuggest a specific disorder (eg, infection).\\nUnusual, recurrent, or persistent cases warrant further evaluation. Referral for allergy skin testing should\\nbe done, and routine laboratory tests should consist of CBC, blood chemistries, liver function tests, and\\nthyroid-stimulating hormone (TSH). Further testing should be guided by symptoms and signs (eg, of\\nautoimmune disorders) and any abnormalities on the screening tests (eg, hepatitis serologies and\\nultrasonography for abnormal liver function tests; ova and parasites for eosinophilia; cryoglobulin titer for\\nelevated liver function tests or elevated creatinine; thyroid autoantibodies for abnormal TSH).\\nSkin biopsy should be done if there is any uncertainty as to the diagnosis or if wheals persist > 48 h (to\\nrule out urticarial vasculitis).\\nClinicians should not recommend the patient do an empiric challenge (eg, \"Try such and such again and\\nsee whether you get a reaction\") because subsequent reactions may be more severe.\\nTreatment\\nAny identified causes are treated or remedied. Implicated drugs or foods should be stopped.\\nNonspecific symptomatic treatment (eg, taking cool baths, avoiding hot water and scratching, and wearing\\nloose clothing) may be helpful.\\nDrugs:\\n Antihistamines remain the mainstay of treatment. They must be taken on a regular basis, rather\\nthan as needed. Newer oral antihistamines often are preferred because of once-daily dosing and\\nbecause some are less sedating. Appropriate choices include\\n Cetirizine 10 mg once/day\\n Fexofenadine 180 mg once/day\\n Desloratadine 5 mg once/day\\n Levocetirizine 5 mg once/day\\nOlder oral antihistamines (eg, hydroxyzine 10 to 25 mg q 4 to 6 h; diphenhydramine 25 to 50 mg q 6 h)\\nare sedating but inexpensive and also quite effective.\\nSystemic corticosteroids (eg, prednisone 30 to 40 mg po once/day) are given for severe symptoms but\\nshould not be used long term. Topical corticosteroids or antihistamines are not beneficial.\\nAngioedema:\\n Patients who have angioedema involving the oropharynx or any involvement of the airway\\nshould receive epinephrine 0.3 mL of 1:1000 solution sc and be admitted to the hospital. On discharge,\\npatients should be supplied with and trained in the use of an auto-injectable epinephrine pen.\\nGeriatrics Essentials\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n752'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 762, 'page_label': '753'}, page_content=\"The older oral antihistamines (eg, hydroxyzine, diphenhydramine) are sedating and can cause confusion,\\nurinary retention, and delirium. They should be used cautiously to treat urticaria in elderly patients.\\nKey Points\\n Urticaria can be caused by allergic or nonallergic mechanisms.\\n Most acute cases are caused by an allergic reaction to a specific substance.\\n Most chronic cases are idiopathic or result from autoimmune disease.\\n Treatment is based on severity; nonsedating antihistamines and avoidance of triggers are first-line\\noptions.\\n Topical corticosteroids and antihistamines are not beneficial.\\n Concomitant systemic symptoms require a thorough evaluation for the etiology.\\nSkin Manifestations of Internal Disease\\nThe skin frequently serves as a marker for underlying internal disease. The type of lesion typically relates\\nto a specific disease or type of disease.\\nInternal cancer:\\n Of patients with dermatomyositis, about 50% have associated breast, lung, ovarian,\\nand GI cancers.\\nAcute onset of multiple seborrheic keratoses (Leser-Trelat sign) may indicate underlying internal cancer,\\nparticularly adenocarcinoma. However, because of the high prevalence of seborrheic keratoses in\\nhealthy adults, this sign may be overdiagnosed.\\nAcute febrile neutrophilic dermatosis is associated with hematologic cancer.\\nAcanthosis nigricans (see\\nPlate 24\\n) that is associated with cancer can be of rapid onset and particularly widespread. Pruritus\\nwithout a clearly associated dermatitis may indicate occult cancer, often lymphoma.\\nParaneoplastic pemphigus is a relatively rare autoimmune blistering disease that has been associated\\nwith various cancers, including leukemias.\\nThe carcinoid syndrome (flushing and erythema of the neck) is associated with carcinoid tumor.\\nErythema gyratum repens is a rare eruption consisting of concentric erythematous lesions, resembling\\nwood grain, which has been associated with various cancers.\\nEndocrinopathies:\\n Many skin findings are associated with endocrinopathies but are not specific.\\nPatients with diabetes mellitus may have acanthosis nigricans, necrobiosis lipoidica, perforating\\ndisorders, and scleredema adultorum.\\nThyroid disease, both hypothyroidism and hyperthyroidism, can affect hair, nails, and skin.\\nCushing's disease causes striae distensae, moon facies, and skin fragility.\\nAddison's disease is characterized by hyperpigmentation that is accentuated in skin creases and areas of\\ntrauma.\\nGI disorders:\\n Skin conditions commonly associated with GI disorders include\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n753\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 763, 'page_label': '754'}, page_content=' Pyoderma gangrenosum: Inflammatory bowel disease\\n Lichen planus and porphyria cutanea tarda: Hepatitis C infection\\n Diffuse hyperpigmentation, or bronze diabetes: Hemochromatosis\\n Erythema nodosum: Inflammatory bowel disease, sarcoidosis, and various infections\\n Eruptive xanthomas: Elevated serum triglycerides\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 71. Approach to the Dermatologic Patient\\n754'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 764, 'page_label': '755'}, page_content=\"Chapter 72. Principles of Topical Dermatologic Therapy\\nIntroduction\\nTopical dermatologic treatments include\\n Cleansing agents\\n Absorbents\\n Anti-infective agents\\n Anti-inflammatory agents\\n Astringents (drying agents that precipitate protein and shrink and contract the skin)\\n Emollients (skin hydrators and softeners)\\n Keratolytics (agents that soften, loosen, and facilitate exfoliation of the squamous cells of the epidermis)\\nVehicles\\nTopical therapies can be delivered in various vehicles, which include\\n Powders\\n Liquids\\n Combinations of liquid and oil\\nThe vehicle influences a therapy's effectiveness and may itself cause adverse effects (eg, contact or\\nirritant dermatitis). Generally, aqueous preparations are drying (because the liquid evaporates) and are\\nused in acute inflammatory conditions. Oil-based preparations are moisturizing and are preferred for\\nchronic inflammation.\\nPowders:\\n Inert powders may be mixed with active agents (eg, antifungals) to deliver therapy. They are\\nprescribed for lesions in moist or intertriginous areas.\\nLiquids:\\n Liquid vehicles include\\n Baths and soaks\\n Solutions\\n Lotions\\n Gels\\nBaths and soaks are used when therapy must be applied to large areas, such as with extensive contact\\ndermatitis or atopic dermatitis.\\nSolutions are ingredients dissolved in a solvent, usually ethyl alcohol, propylene glycol, polyethylene\\nglycol, or water. Solutions are convenient to apply (especially to the scalp \\nfor disorders such as psoriasis\\nor seborrhea) but tend to be drying. Two common solutions are Burow's solution and Domeboro's\\nsolution.\\nLotions are water-based emulsions. They are easily applied to hairy skin. Lotions cool and dry acute\\ninflammatory and exudative lesions, such as contact dermatitis, tinea pedis, and tinea cruris.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 72. Principles of Topical Dermatologic Therapy\\n755\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 765, 'page_label': '756'}, page_content=\"Gels are ingredients suspended in a solvent thickened with polymers. Gels are often more effective for\\ncontrolled release of topical agents. They are often used in acne, rosacea, and psoriasis of the scalp.\\nCombination vehicles:\\n Combinations include\\n Creams\\n Ointments\\nCombination vehicles usually contain oil and water but may also contain propylene or polyethylene glycol.\\nCreams are semi-solid emulsions of oil and water. They are used for moisturizing and cooling and when\\nexudation is present. They vanish when rubbed into skin.\\nOintments are oil based (eg, petrolatum) with little if any water. Ointments are optimal lubricants and\\nincrease drug penetration because of their occlusive nature; a given concentration of drug is generally\\nmore potent in an ointment. They are preferred for lichenified lesions and lesions with thick crusts or\\nheaped-up scales, including psoriasis and lichen simplex chronicus. Ointments are less irritating than\\ncreams for erosions or ulcers.\\nDressings\\nDressings protect open lesions, facilitate healing, increase drug absorption, and protect the patient's\\nclothing.\\nNonocclusive dressings:\\n The most common are gauze dressings. They maximally allow air to reach\\nthe wound, which is often preferred in healing, and allow the lesion to dry. Nonocclusive dressings wetted\\nwith solution, usually saline, are used to help cleanse and debride thickened or crusted lesions. The\\ndressings are applied wet and removed after the solution has evaporated (wet-to-dry dressings);\\nmaterials from the skin then adhere to the dressing.\\nOcclusive dressings:\\n Occlusive dressings increase the absorption and effectiveness of topical therapy.\\nMost common are transparent films such as polyethylene (plastic household wrap) or flexible, transparent,\\nsemi-permeable dressings. Hydrocolloid dressings can be applied with a gauze cover in patients with\\ncutaneous ulceration. Zinc oxide gelatin (Unna's paste boot) is an effective occlusive dressing for patients\\nwith stasis dermatitis and ulcers. Plastic tape impregnated with flurandrenolide, a corticosteroid, can be\\nused for isolated or recalcitrant lesions.\\nOcclusive dressings applied over topical corticosteroids to increase absorption are sometimes used to\\ntreat psoriasis, atopic dermatitis, skin lesions of lupus erythematosus, and chronic hand dermatitis,\\namong other conditions. Systemic absorption of topical corticosteroids may occur and cause\\n Development of miliaria\\n Skin atrophy\\n Striae\\n Bacterial or fungal infections\\n Adrenal suppression\\n Acneiform eruptions\\nOther occlusive dressings are used to protect and help heal open wounds, such as burns (see p. \\n3242\\n).\\nCategories and Indications\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 72. Principles of Topical Dermatologic Therapy\\n756\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 766, 'page_label': '757'}, page_content='Major categories of topical agents include\\n Cleansing\\n Moisturizing\\n Drying\\n Anti-inflammatory\\n Antimicrobial\\n Keratolytic\\n Astringent\\n Antipruritic\\nCleansing agents:\\n The principal cleansing agents are soaps, detergents, and solvents. Soap is the\\nmost popular cleanser, but synthetic detergents are also used. Baby shampoos are usually well tolerated\\naround the eyes and for cleansing wounds and abrasions; they are useful for removing crusts and scales\\nin psoriasis, eczema, and other forms of dermatitis. However, acutely irritated, weeping, or oozing lesions\\nare most comfortably cleansed with water or isotonic saline.\\nWater is the principal solvent for cleansing. Organic solvents (eg, acetone, petroleum products, propylene\\nglycol) are very drying, can be irritating, and cause irritant or, less commonly, allergic contact dermatitis.\\nRemoval of hardened tar and dried paint from the skin may require a petrolatum-based ointment or\\ncommercial waterless cleanser.\\nMoisturizing agents:\\n Moisturizers (emollients) restore water and oils to the skin and help to maintain\\nskin hydration. They typically contain glycerin, mineral oil, or petrolatum and are available as lotions,\\ncreams, ointments, and bath oils. Stronger moisturizers contain urea \\n2%, lactic acid 5 to 12%, and\\nglycolic acid 10% (higher concentrations are used as keratinolytics, eg, for ichthyosis). They are most\\neffective when applied to already moistened skin (ie, after a bath or shower).\\nDrying agents:\\n Excessive moisture in intertriginous areas (eg, between the toes; in the intergluteal cleft,\\naxillae, groin, and inframammary areas) can cause irritation and maceration. Powders dry macerated skin\\nand reduce friction by absorbing moisture. However, some powders tend to clump and can be irritating if\\nthey become moist. Cornstarch and talc are most often used. Although talc is more effective, talc may\\ncause granulomas if inhaled and is no longer used in baby powders. Cornstarch may promote fungal\\ngrowth. Aluminum chloride solutions are another type of drying agent (often useful in hyperhidrosis).\\nAnti-inflammatory agents:\\n Topical anti-inflammatory agents are either corticosteroids or\\nnoncorticosteroids.\\nCorticosteroids\\n are the mainstay of treatment for most noninfectious inflammatory dermatoses. Lotions\\nare useful on intertriginous areas and the face. Gels are useful on the scalp and in management of\\ncontact dermatitis. Creams are useful on the face and in intertriginous areas and for management of\\ninflammatory dermatoses. Ointments are useful for dry scaly areas and when increased potency is\\nrequired. Corticosteroid-impregnated tape is useful to protect an area from excoriation. It also increases\\ncorticosteroid absorption and therefore potency.\\nTopical corticosteroids range in potency from mild (class VII) to superpotent (class Isee\\nTable 72-1\\n). Intrinsic differences in potency are attributable to fluorination or chlorination (halogenation) of\\nthe compound.\\nTopical corticosteroids are generally applied 2 to 3 times daily, but high-potency formulations may require\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 72. Principles of Topical Dermatologic Therapy\\n757'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 767, 'page_label': '758'}, page_content='application only once/day or even less frequently. Most dermatoses are treated with mid-potency to high-\\npotency formulations; mild formulations are better for mild inflammation and for use on the face or\\nintertriginous areas, where systemic absorption is more likely. All agents can cause skin atrophy, striae,\\nand acneiform eruptions when used for > 1 mo. This effect is particularly problematic on the thinner skin\\nof the face or genitals. Corticosteroids also promote fungal growth. Contact dermatitis in reaction to\\npreservatives and additives is also common with prolonged use. Contact dermatitis to the corticosteroid\\nitself may also occur. Perioral dermatitis occurs with mid-potency or high-potency formulations used on\\nthe face but is uncommon with mild formulations. High-potency formulations may cause adrenal\\nsuppression when used in children, over extensive skin surfaces, or for long periods. Relative\\ncontraindications include conditions in which infection plays an underlying role and acneiform disorders.\\nNoncorticosteroid anti-inflammatory agents\\n include tar preparations. Tar comes in the form of crude\\ncoal tar and is indicated for psoriasis. Adverse effects include irritation, folliculitis, staining of clothes and\\nfurniture, and photosensitization. Contraindications include infected skin. Several herbal products are\\ncommonly used in commercial products, although their effectiveness has not been well established.\\nAmong the most popular are chamomile and calendula.\\nAntimicrobials:\\n Topical antimicrobials include\\n Antibiotics\\n Antifungals\\n Insecticides\\n Nonspecific antiseptic agents\\nAntibiotics\\n have few indications. Topical clindamycin and erythromycin are used as primary or adjunctive\\ntreatment for acne vulgaris in patients who do not warrant or tolerate oral antibiotics. Mupirocin has\\nexcellent gram-positive (\\nStaphylococcus aureus\\n, streptococci) coverage and can be used to treat\\nimpetigo when deep tissues are not affected. OTC antibiotics such as bacitracin and polymyxin are often\\nused in postoperative care of a skin biopsy site and to prevent infection in scrapes, minor burns, and\\nexcoriations. Topical neomycin causes contact dermatitis more frequently than other antibiotics. The use\\nof topical antibiotics and washing with antiseptic soaps in healing wounds may, however, actually slow\\nhealing.\\nAntifungals\\n are used to treat candidiasis, a wide variety of dermatophytoses, and other fungal infections\\n(see\\nTable 82-1\\n on p. \\n704\\n).\\nInsecticides\\n (eg, permethrin, malathion) are used treat lice infestation and scabies (see\\nTable 83-1\\n on p. \\n712\\n).\\nNonspecific antiseptic agents\\n include iodine solutions (eg, povidone iodine, clioquinol), gentian violet,\\nsilver preparations (eg, silver nitrate, silver sulfadiazine), and zinc pyrithione. Iodine is indicated for\\npresurgical skin preparation. Gentian violet is used when an inexpensive chemically and physically stable\\nantiseptic/antimicrobial is needed. Silver preparations are effective in treating burns and ulcers and have\\nstrong antimicrobial\\n[\\nTable 72-1.\\n Relative Potency of Selected Topical Corticosteroids]\\nproperties; several wound dressings are impregnated with silver. Zinc pyrithione is an antifungal and a\\ncommon ingredient in shampoos used to treat dandruff due to psoriasis or seborrheic dermatitis. Healing\\nwounds should generally not be treated with topical antiseptics other than silver because they are\\nirritating and tend to kill fragile granulation tissue.\\nKeratolytics:\\n Keratolytics soften and facilitate exfoliation of epidermal cells. Examples include 3 to 6%\\nsalicylic acid and urea. Salicylic acid is used to treat psoriasis, seborrhea, acne, and warts. Adverse\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 72. Principles of Topical Dermatologic Therapy\\n758'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 768, 'page_label': '759'}, page_content=\"effects are burning and systemic toxicity if large areas are covered. It should rarely be used in children\\nand infants. Urea is used to treat plantar keratodermas and ichthyosis. Adverse effects are irritation and\\nintractable burning. It should not be applied to large areas.\\nAstringents:\\n Astringents are drying agents that precipitate protein and shrink and contract the skin. The\\nmost commonly used astringents are aluminum acetate (Burow's solution) and aluminum sulfate plus Ca\\nacetate (Domeboro's solution). Usually applied with dressings or as soaks, astringents are used to treat\\ninfectious eczema, exudative skin lesions, and pressure ulcers. Witch hazel is a popular OTC astringent.\\nAntipruritics:\\n Doxepin is a topical antihistamine that is effective in treating itching of atopic dermatitis,\\nlichen simplex chronic dermatitis, and nummular dermatitis. Topical benzocaine and diphenhydramine\\n(present in certain OTC lotions) are sensitizing and not recommended. Other antipruritics include\\ncamphor 0.5 to 3%, menthol 0.1 to 0.2%, pramoxine hydrochloride, and eutectic mixture of local\\nanesthetics (EMLA), which contain equal parts lidocaine and prilocaine in an oil-in-water vehicle. Topical\\nantipruritics are preferred over systemic drugs (eg, oral antihistamines) when smaller surface areas of\\nskin are affected and pruritus is not intractable. Calamine lotion is soothing but not specifically antipruritic.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 72. Principles of Topical Dermatologic Therapy\\n759\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 769, 'page_label': '760'}, page_content=\"Chapter 73. Acne and Related Disorders\\nIntroduction\\nAcne vulgaris is a common skin problem, affecting most adolescents and many adults. Perioral dermatitis\\nand rosacea can produce similar lesions.\\nAcne Vulgaris\\nAcne vulgaris (acne) is the formation of comedones, papules, pustules, nodules, and/or cysts as\\na result of obstruction and inflammation of pilosebaceous units (hair follicles and their\\naccompanying sebaceous gland). It most often affects adolescents. Diagnosis is by\\nexamination. Treatment is a variety of topical and systemic agents intended to reduce sebum\\nproduction, infection, and inflammation and to normalize keratinization.\\nPathophysiology\\nAcne occurs when pilosebaceous units become obstructed with plugs of sebum and desquamated\\nkeratinocytes, then colonized and sometimes infected with the normal skin anaerobe \\nPropionibacterium\\nacnes\\n. Manifestations differ depending on whether \\nP. acnes\\n stimulates inflammation in the follicle; acne\\ncan be noninflammatory or inflammatory.\\nComedones, uninfected sebaceous plugs impacted within follicles, are the signature of noninflammatory\\nacne. Comedones are termed open or closed depending on whether the follicle is dilated or closed at the\\nskin surface. Inflammatory acne comprises papules, pustules, nodules, and cysts.\\nPapules appear when lipases from \\nP. acnes\\n metabolize triglycerides into free fatty acids (FFA), which\\nirritate the follicular wall. Pustules occur when active \\nP. acnes\\n infection causes inflammation within the\\nfollicle. Nodules and cysts occur when rupture of follicles due to inflammation, physical manipulation, or\\nharsh scrubbing releases FFAs, bacteria, and keratin into tissues, triggering soft-tissue inflammation.\\nEtiology\\nThe most common trigger is puberty, when surges in androgen stimulate sebum production and\\nhyperproliferation of keratinocytes. Other triggers include hormonal changes that occur with pregnancy or\\nthroughout the menstrual cycle; occlusive cosmetics, cleansing agents, and clothing; and humidity and\\nsweating. Associations between acne exacerbation and diet (eg, chocolate), inadequate face washing,\\nmasturbation, and sex are unfounded. Some studies question an association with milk products. Acne\\nmay improve in summer months because of sunlight's anti-inflammatory effects. \\nProposed associations\\nbetween acne and hyperinsulinism require further investigation.\\nSymptoms and Signs\\nCystic acne can be painful; other types cause no physical symptoms but can be a source of significant\\nemotional distress. Lesion types frequently coexist at different stages.\\nComedones appear as whiteheads or blackheads. Whiteheads (closed comedones) are flesh-colored or\\nwhitish palpable lesions 1 to 3 mm in diameter; blackheads (open comedones) are similar in appearance\\nbut with a dark center.\\nPapules and pustules are red lesions 2 to 5 mm in diameter. In both, the follicular epithelium becomes\\ndamaged with accumulation of neutrophils and then lymphocytes. When the epithelium ruptures, the\\ncomedo contents elicit an intense inflammatory reaction in the dermis. Relatively deep inflammation\\nproduces papules. Pustules are more superficial.\\nNodules are larger, deeper, and more solid than papules. Such lesions resemble inflamed epidermoid\\ncysts, although they lack true cystic structure.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 73. Acne & Related Disorders\\n760\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 770, 'page_label': '761'}, page_content='Cysts are suppurative nodules. Rarely cysts become infected and form abscesses. Long-term cystic acne\\ncan cause scarring that manifests as tiny, deep pits (icepick scars), larger pits, shallow depressions, or\\nareas of hypertrophic scar.\\nAcne conglobata is the most severe form of acne vulgaris, affecting men more than women. Patients have\\nabscesses, draining sinuses, fistulated comedones, and keloidal and atrophic scars. The back and chest\\nare severely involved. The arms, abdomen, buttocks, and even the scalp may be affected.\\nAcne fulminans is acute, febrile, ulcerative acne, characterized by the sudden appearance of confluent\\nabscesses leading to hemorrhagic necrosis. Leukocytosis and joint pain and swelling may also be\\npresent.\\nPyoderma faciale (also called rosacea fulminans) occurs suddenly on the midface of young women. It\\nmay be analogous to acne fulminans. The eruption consists of erythematous plaques and pustules,\\ninvolving the chin, cheeks, and forehead.\\nDiagnosis\\n Assessment for contributing factors (eg, hormonal, mechanical, or drug-related)\\n Determination of severity (mild, moderate, severe)\\n Assessment of psychosocial impact\\nDiagnosis is by examination. Differential diagnosis includes rosacea (in which no comedones are seen),\\ncorticosteroid-induced acne (which lacks comedones and in which pustules are usually in the same stage\\nof development), perioral dermatitis (usually with a more perioral and periorbital distribution), and\\nacneiform drug eruptions. Acne severity is graded mild, moderate, or severe based on the number and\\ntype of lesions; a standardized system is outlined in\\nTable 73-1\\n.\\nPrognosis\\nAcne of any severity usually remits spontaneously by the early to mid-20s, but a substantial minority of\\npatients, usually women, may have acne into their 40s; options for treatment may be limited because of\\nchild-bearing. Many adults occasionally develop mild, isolated acne lesions. Noninflammatory and mild\\ninflammatory acne usually heals without scars. Moderate to severe inflammatory acne heals but often\\nleaves scarring. Scarring is not only physical; acne may be a huge emotional stressor for adolescents\\nwho may withdraw, using the acne as an excuse to avoid difficult personal adjustments. Supportive\\ncounseling for patients and parents may be indicated in severe cases.\\nTreatment\\n Comedones: Topical tretinoin\\n Mild inflammatory acne: Topical antibiotics, benzoyl peroxide, or both\\n Moderate acne: Oral antibiotics\\n Severe acne: Oral isotretinoin\\n Cystic acne: Intralesional triamcinolone\\nTreatments are directed at reducing sebum production, comedone formation, inflammation, and infection\\n(see\\nFig. 73-1\\n). Selection of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 73. Acne & Related Disorders\\n761'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 771, 'page_label': '762'}, page_content='[\\nTable 73-1.\\n Classification of Acne Severity]\\n[\\nFig. 73-1.\\n How various drugs work in treating acne.]\\ntreatment is generally based on severity; options are summarized in\\nTable 73-2\\n. Affected areas should be cleansed daily, but extra washing, use of antibacterial soaps, and\\nscrubbing confer no added benefit. Changes in diet are also unnecessary and ineffective, although\\nmoderation of milk intake might be considered for treatment-resistant adolescent acne. Peeling agents\\nsuch as sulfur, salicylic acid, and resorcinol are minor therapeutic adjuncts.\\nTreatment should involve educating the patient and tailoring the plan to one that is realistic for the patient.\\nTreatment failure can frequently be attributed to lack of adherence to the plan and also to lack of follow-\\nup. Consultation with a specialist may be necessary.\\nMild acne:\\n Single-agent therapy is generally sufficient for comedonal acne; papulopustular acne\\ngenerally requires dual therapy (eg, the combination of tretinoin with benzoyl peroxide or topical\\nantibiotics). Treatment should be continued for 6 wk or until lesions respond. Maintenance treatment may\\nbe necessary to maintain control.\\nA mainstay of treatment for comedones is daily topical tretinoin as tolerated. Daily adapalene gel,\\ntazarotene cream or gel, azelaic acid cream, and glycolic or salicylic acid in propylene glycol are\\nalternatives for patients who cannot tolerate topical tretinoin. Adverse effects include erythema, burning,\\nstinging, and peeling. Adapalene and tazarotene are retinoids; like tretinoin, they tend to be somewhat\\nirritating and photosensitizing. Azelaic acid has comedolytic and antibacterial properties by an unrelated\\nmechanism and may be synergistic with retinoids.\\nMild inflammatory acne should be treated with topical benzoyl peroxide, topical antibiotics (eg,\\nerythromycin, clindamycin), glyolic acid, or a combination. Combination preparations of these agents may\\nhelp limit development of resistance. None have significant adverse effects other than drying and irritation\\n(and rare allergic reactions to benzoyl peroxide). Topical retinoids are often used concomitantly.\\nPhysical extraction of comedones using a comedo extractor is an option for patients unresponsive to\\ntopical treatment. Comedo extraction may be done by a physician, nurse, or physician assistant. One end\\nof the comedo extractor is like a blade or bayonet that punctures the closed comedo. The other end\\nexerts pressure to extract the comedo.\\nOral antibiotics (eg, tetracycline, minocycline, doxycycline, erythromycin) can be used when wide\\ndistribution of lesions makes topical therapy impractical.\\nModerate acne:\\n Moderate acne responds best to oral systemic therapy with antibiotics. Antibiotics\\neffective for acne include tetracycline, minocycline, erythromycin, and doxycycline. Full benefit takes  12\\nwk. Topical therapy as for mild acne is usually used concomitantly with oral antibiotics.\\nTetracycline is usually a good first choice: 250 or 500 mg bid (between meals and at bedtime) for 4 wk or\\nuntil lesions respond, after which it may be reduced to the lowest effective dose. Rarely, dosage must be\\nincreased to\\n[\\nTable 73-2.\\n Drugs Used to Treat Acne]\\n500 mg qid. After control is achieved, it is reasonable to attempt to taper and discontinue the oral\\nantibiotic and continue topical therapy for control. Because relapse often follows short-term treatment,\\ntherapy may need to be continued for months to years, although for maintenance tetracycline 250 or 500\\nmg once/day is often sufficient. Minocycline 50 or 100 mg bid causes fewer GI adverse effects, is easier\\nto take, and is less likely to cause photosensitization, but it is the most costly option. Erythromycin and\\ndoxycycline are considered 2nd-line drugs because both can cause GI adverse effects, and doxycycline\\nis a frequent photosensitizer. Subantimicrobial doses of doxycycline have also been proven effective for\\nacne and rosacea.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 73. Acne & Related Disorders\\n762'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 772, 'page_label': '763'}, page_content=\"Long-term use of antibiotics may cause a gram-negative pustular folliculitis around the nose and in the\\ncenter of the face. This uncommon superinfection may be difficult to clear and is best treated with oral\\nisotretinoin after discontinuing the oral antibiotic. Ampicillin is an alternative treatment for gram-negative\\nfolliculitis. In women, prolonged antibiotic use can cause candidal vaginitis; if local and systemic therapy\\ndoes not eradicate this problem, antibiotic therapy for acne must be stopped.\\nSevere acne:\\n Oral isotretinoin is the best treatment for patients with moderate acne in whom antibiotics\\nare unsuccessful and for those with severe inflammatory acne. Dosage of isotretinoin is usually 1 mg/kg\\nonce/day for 16 to 20 wk, but the dosage may be increased to 2 mg/kg once/day. If adverse effects make\\nthis dosage intolerable, it may be reduced to 0.5 mg/kg once/day. After therapy, acne may continue to\\nimprove. Most patients do not require a 2nd course of treatment; when needed, it should be resumed only\\nafter the drug has been stopped for 4 mo. Retreatment is required more often if the initial dosage is low\\n(0.5 mg/kg). With this dosage (which is very popular in Europe), fewer adverse effects occur, but\\nprolonged therapy is usually required.\\nIsotretinoin is nearly always effective, but use is limited by adverse effects, including dryness of\\nconjunctivae and mucosae of the genitals, chapped lips, arthralgias, depression, elevated lipid levels, and\\nthe risk of birth defects if treatment occurs during pregnancy. Hydration with water followed by petrolatum\\napplication usually alleviates mucosal and cutaneous dryness. Arthralgias (mostly of large joints or the\\nlower back) occur in about 15% of patients. Increased risk for depression \\nand suicide is much publicized\\nbut probably rare. CBC; liver function; and fasting glucose, triglyceride, and cholesterol levels should be\\ndetermined before treatment. Each should be reassessed at 4 wk and, unless abnormalities are noted,\\nneed not be repeated until the end of treatment. Triglycerides rarely increase to a level at which the drug\\nshould be stopped. Liver function is seldom affected. Because isotretinoin is teratogenic, women of\\nchildbearing age are urged to use 2 methods of contraception for 1 mo before treatment, during\\ntreatment, and for at least 1 mo after stopping treatment. Pregnancy tests should be done before\\nbeginning therapy and monthly until 1 mo after therapy stops.\\nIntralesional injection of 0.1 mL triamcinolone acetonide suspension 2.5 mg/mL (the 10 mg/mL\\nsuspension must be diluted) is indicated for patients with firm (cystic) acne who seek quick clinical\\nimprovement and to reduce scarring. Local atrophy may occur but is usually transient. For isolated, very\\nboggy lesions, incision and drainage are often beneficial but may result in residual scarring.\\nOther forms of acne:\\n Pyoderma faciale is treated with oral corticosteroids and isotretinoin. Acne\\nfulminans is treated with oral corticosteroids and systemic antibiotics. Acne conglobata is treated with oral\\nisotretinoin if systemic antibiotics fail. For acne with endocrine abnormalities, antiandrogens are indicated.\\nSpironolactone, which has some antiandrogen effects, is sometimes prescribed to treat acne at a dose of\\n50 to 100 mg po once/day. Cyproterone acetate is used in Europe. When other measures fail, an\\nestrogen-progesterone-containing contraceptive may be tried; therapy  6 mo is needed to evaluate\\neffect.\\nScarring:\\n Small scars can be treated with chemical peels, laser resurfacing, or dermabrasion. Deeper,\\ndiscrete scars can be excised. Wide, shallow depressions can be treated with subcision or collagen\\ninjection. Collagen implants are temporary and must be repeated every few years.\\nPerioral Dermatitis\\nPerioral dermatitis is an erythematous, papulopustular facial eruption that resembles acne\\nand/or rosacea but typically starts around the mouth.\\nA variety of causes have been proposed, including exposure to topical corticosteroids and/or fluoride in\\nwater and toothpaste, but the etiology is unknown. Despite its name, perioral dermatitis is not a true\\ndermatitis. It primarily affects women of childbearing age and children. The eruption classically starts at\\nthe nasolabial folds and spreads periorally sparing a zone around the vermilion border of the lips. But the\\neruption can also spread periorbitally and to the forehead.\\nDiagnosis is by appearance; perioral dermatitis is distinguished from acne by the absence of comedones\\nand from rosacea by the latter's lack of lesions around the mouth and eyes. Seborrheic dermatitis and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 73. Acne & Related Disorders\\n763\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 773, 'page_label': '764'}, page_content=\"contact dermatitis must be excluded. Biopsy, which is generally not clinically necessary, shows spongiosis\\nand a lymphohistiocytic infiltrate affecting vellus hair follicles. In the lupoid variant, granulomas may be\\npresent.\\nTreatment is to stop fluorinated dental products and topical corticosteroids (if being used) and then either\\nuse topical antibiotics (eg, erythromycin 2% or metronidazole 0.75% gel or cream bid), or oral tetracycline\\n250 to 500 mg po bid (between meals) for 4 wk, tapered to the lowest effective dose. Alternative oral\\nantibiotics include doxycycline 50 to 100 mg bid and minocycline 50 to 100 mg bid. In contrast to acne,\\nantibiotics can usually be stopped. Reasons for efficacy of antibiotics are unclear given the absence of\\nevidence of infection. Isotretinoin has been successfully used to treat granulomatous perioral dermatitis.\\nRosacea\\nRosacea (acne rosacea) is a chronic inflammatory disorder characterized by facial flushing,\\ntelangiectasias, erythema, papules, pustules, and in severe cases, rhinophyma (see\\nPlate 43\\n). Diagnosis is based on the characteristic appearance and history. Treatment depends\\non severity and includes topical metronidazole, topical and oral antibiotics, rarely isotretinoin,\\nand, for severe rhinophyma, surgery.\\nRosacea most commonly affects patients aged 30 to 50 with fair complexions, most notably those of Irish\\nand Northern European descent, but it affects and is probably under-recognized in darker-skinned\\npatients.\\nEtiology\\nThe etiology is unknown, although associations with abnormal vasomotor control, impaired facial venous\\ndrainage, an increase in follicle mites (\\nDemodex folliculorum\\n), and \\nHelicobacter pylori\\n infection have\\nbeen \\nproposed. People with rosacea may have elevated levels of small antimicrobial peptides that are\\npart of the body's natural defense system. People with rosacea may also have higher than normal levels\\nof cathelicidin as well as another group of enzymes called stratum corneum tryptic enzymes.\\nSymptoms and Signs\\nRosacea is limited to the face and scalp and manifests in 4 phases:\\n Prerosacea phase\\n Vascular phase\\n Inflammatory phase\\n Late stage\\nIn the prerosacea phase, patients describe embarrassing flushing and blushing, often accompanied by\\nuncomfortable stinging. Common reported triggers for these flares include sun exposure, emotional\\nstress, cold or hot weather, alcohol, spicy foods, exercise, wind, cosmetics, and hot baths or hot drinks.\\nThese symptoms persist throughout other phases of the disorder.\\nIn the vascular phase, patients develop facial erythema and edema with multiple telangiectases, possibly\\nas a result of persistent vasomotor instability.\\nAn inflammatory phase often follows, in which sterile papules and pustules (leading to the designation of\\nrosacea as adult acne) develop.\\nSome patients go on to develop late-stage rosacea, characterized by coarse tissue hyperplasia of the\\ncheeks and nose (rhinophyma) caused by tissue inflammation, collagen deposition, and sebaceous gland\\nhyperplasia.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 73. Acne & Related Disorders\\n764\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 774, 'page_label': '765'}, page_content='The phases of rosacea are usually sequential. Some patients go directly into the inflammatory stage,\\nbypassing the earlier stages. Treatment may cause rosacea to return to an earlier stage. Progression to\\nthe late stage is not inevitable.\\nOcular rosacea often accompanies facial rosacea and manifests as some combination of\\nblepharoconjunctivitis, iritis, scleritis, and keratitis, causing itching, foreign body sensation, erythema, and\\nedema of the eye.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is based on the characteristic appearance; there are no specific diagnostic tests. The age of\\nonset and absence of comedones help distinguish rosacea from acne. Differential diagnosis includes\\nacne vulgaris, SLE, sarcoidosis, photodermatitis, drug eruptions (particularly from iodides and bromides),\\ngranulomas of the skin, and perioral dermatitis.\\nTreatment\\n Avoidance of triggers\\n Consideration of topical or oral antibiotics\\n Consideration of isotretinoin if antibiotics are unsuccessful\\n Consideration of dermabrasion and tissue excision for rhinophyma\\nPrimary initial treatment of rosacea involves avoidance of triggers (including use of sunscreen).\\nAntibiotics may be used for inflammatory disease. The objective of treatment is control of symptoms, not\\ncure.\\nMetronidazole cream 1%, lotion (0.75%), or gel (0.75%) and azelaic acid 20% cream, applied bid, are\\nequally effective; 2.5% benzoyl peroxide, applied once/day or bid, can be added for improved control.\\nLess effective alternatives include sodium sulfacetamide 10%/sulfur 5% lotion; clindamycin 1% solution,\\ngel, or lotion; and erythromycin 2% solution, all applied bid. Many patients require indefinite treatment for\\nchronic control.\\nOral antibiotics are indicated for patients with multiple papules or pustules and for those with ocular\\nrosacea; options include tetracycline 250 to 500 mg bid, doxycycline 50 to 100 mg bid, minocycline 50 to\\n100 mg bid, and erythromycin 250 to 500 mg bid. Dose should be reduced to the lowest one that controls\\nsymptoms once a beneficial response is achieved. Recalcitrant cases may respond to oral isotretinoin.\\nSubantimicrobial doses of doxycycline are also effective for acne and rosacea.\\nTechniques for treatment of rhinophyma include dermabrasion and tissue excision; cosmetic results are\\ngood.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 73. Acne & Related Disorders\\n765'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 775, 'page_label': '766'}, page_content=\"Chapter 74. Bullous Diseases\\nIntroduction\\nBullae are elevated, fluid-filled blisters  5 mm in diameter. Bullous diseases include bullous pemphigoid,\\ndermatitis herpetiformis, epidermolysis bullosa acquisita, herpes gestationis (pemphigoid gestationissee\\np. \\n2666\\n), linear IgA disease, pemphigus vulgaris, and pemphigus foliaceus. Staphylococcal scalded skin\\nsyndrome (see p. \\n701\\n) and toxic epidermal necrolysis (see p. \\n689\\n) also cause bullae.\\nBullous Pemphigoid\\nBullous pemphigoid is an autoimmune skin disorder causing chronic, pruritic bullous eruptions\\nin elderly patients. Diagnosis is by skin biopsy. Corticosteroids are used initially. Most patients\\nrequire long-term maintenance therapy, for which a variety of drugs can be used.\\nIn bullous pemphigoid, antibodies are directed against the basement membrane zone of the epidermis,\\ncausing separation between the epidermis and dermis. Bullous pemphigoid must be distinguished from\\npemphigus vulgaris (see p. \\n658\\n), a much more serious disease.\\nSymptoms and Signs\\nCharacteristic tense bullae develop on normal-appearing or erythematous skin, most often in flexural\\nareas. Nikolsky's sign, in which lateral pressure on skin adjacent to a blister causes epidermal\\ndetachment, is negative. Bullous pemphigoid can manifest initially as hives with annular, dusky-red,\\nedematous lesions, with or without peripheral vesicles. Itching is common, usually without other\\nsymptoms. Oral lesions occur in about one third of patients but heal rapidly.\\nDiagnosis\\n Skin biopsy and antibody titers\\nPatients should have a skin biopsy and serum antibody titers for hemidesmosomal BP antigens BP230\\n(BPAg1) and BP180 (BPAg2).\\nBullous pemphigoid must be differentiated from pemphigus vulgaris (see\\nTable 74-1\\n), linear IgA disease, erythema multiforme, drug-induced eruptions, benign mucous membrane\\npemphigoid, paraneoplastic pemphigoid, dermatitis herpetiformis, and epidermolysis bullosa acquisita.\\nPrognosis\\nPrognosis is good, and the disorder usually subsides within months to years; however, the disorder is\\npotentially fatal, especially in the elderly and debilitated patients, with death being caused by infection\\nand sepsis or the effects of the drugs.\\nTreatment\\n Corticosteroids, topical or oral\\n Anti-inflammatory drugs\\nMild bullous pemphigoid sometimes resolves without treatment, but resolution usually\\n[\\nTable 74-1.\\n Distinguishing Pemphigoid from Pemphigus Vulgaris]\\ntakes months or years. Patients with more severe disease receive prednisone 60 to 80 mg po once/day,\\nwhich can be tapered to a maintenance level of  10 to 20 mg/day after several weeks. Most patients\\nachieve remission after 2 to 10 mo. Occasional new lesions in elderly patients do not require increasing\\nthe prednisone dosage.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 74. Bullous Diseases\\n766\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 776, 'page_label': '767'}, page_content='The disorder occasionally responds to a combination of tetracycline or minocycline and nicotinamide.\\nOther treatment options include dapsone, sulfapyridine, erythromycin, and tetracycline used alone for\\ntheir anti-inflammatory rather than their antibiotic properties. IV immune globulin has been used\\noccasionally. For patients with generalized and recalcitrant disease, immunosuppressants such as\\nazathioprine, cyclophosphamide, rituximab, and cyclosporine may be used. However, use of\\nimmunosuppressants for bullous pemphigoid is controversial.\\nDermatitis Herpetiformis\\nDermatitis herpetiformis is a cutaneous manifestation associated with gluten sensitivity. It\\nproduces a chronic eruption characterized by clusters of intensely pruritic vesicles, papules,\\nand urticaria-like lesions. The cause is autoimmune. Diagnosis is by skin biopsy with direct\\nimmunofluorescence testing. Treatment is usually with dapsone or sulfapyridine and a gluten-\\nfree diet.\\nThis disease usually manifests in patients 30 to 40 yr old (but may occur from age 2 to 90 yr) and is rare\\nin blacks and Asians.\\nMore than 90% of affected patients have a gluten-sensitive enteropathy, which is often asymptomatic.\\nDermatitis herpetiformis develops in 15 to 25% of patients with celiac sprue. Patients have a slightly\\nhigher incidence of other autoimmune disorders, including type 1 diabetes mellitus, sarcoidosis, SLE, and\\nthyroid abnormalities. The incidence of enteropathy-associated T-cell lymphoma is also increased.\\nThe term herpetiformis refers to the clustered appearance of the lesions rather than a relationship to\\nherpesvirus.\\nSymptoms and Signs\\nOnset is usually gradual. Vesicles, papules, and urticaria-like lesions are usually distributed symmetrically\\non extensor aspects (elbows, knees, sacrum, buttocks, occiput). Vesicles and papules occur in about one\\nthird of patients. Itching and burning are severe, and scratching often obscures the primary lesions with\\neczematization of nearby skin, leading to an erroneous diagnosis of eczema. NSAIDs and iodides may\\nworsen the rash.\\nDiagnosis\\n Skin biopsy\\nDiagnosis is based on skin biopsy and direct immunofluorescence testing of a lesion and adjacent\\nnormal-appearing skin. Granular IgA deposition in the dermal papillary tips is invariably present and\\nimportant for diagnosis. Patients should be evaluated for celiac sprue (see p. \\n158\\n).\\nTreatment\\n Gluten-free diet\\n Dapsone\\nStrict adherence to a gluten-free diet for a prolonged time (eg, 6 to 12 mo) controls the disease in some\\npatients, obviating or reducing the need for drug therapy. When drugs are needed, dapsone generally\\nresults in remarkable improvement. Initial dosages of dapsone are 25 to 50 mg po once/day in adults and\\n0.5 mg/kg in children. Usually, this dose dramatically relieves symptoms, including itching, within 1 to 3\\ndays; if it does, the dose is continued. If no improvement occurs, the dose can be increased every week,\\nup to 300 mg/day. Most patients can be maintained on 50 to 150 mg/day, and some require as little as 25\\nmg/wk. After initial therapy and stabilization of the disease, the majority of patients can be maintained on\\na strict gluten-free diet. Although less effective, sulfapyridine may be used as an alternative for patients\\nwho cannot tolerate dapsone. Initial oral dosage is 500 mg bid, increasing by 1 g/day q 1 to 2 wk until\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 74. Bullous Diseases\\n767'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 777, 'page_label': '768'}, page_content='disease is controlled. Maintenance dosage varies from 500 mg twice/wk to 1000 mg once/day. Colchicine\\nis another treatment option. Treatment continues until lesions resolve.\\nIn patients with G6PD deficiency, dapsone may cause severe hemolysis. Patients receiving dapsone or\\nsulfapyridine should have a baseline CBC; CBC is then done weekly for 4 wk, then every 2 to 3 wk for 8\\nwk, and every 12 to 16 wk thereafter. Hemolytic anemia and methemoglobinemia are the most frequently\\nencountered adverse effects. CNS or liver toxicity is rare. If dapsone therapy causes \\nconsiderable\\nhemolysis, significant cardiopulmonary problems, or peripheral neuropathy, sulfapyridine may be used.\\nSulfapyridine usually does not induce significant hemolysis.\\nEpidermolysis Bullosa Acquisita\\nEpidermolysis bullosa acquisita is a chronic autoimmune mucocutaneous disease causing\\nblistering and skin fragility.\\nEpidermolysis bullosa acquisita usually appears in adults. Bullous lesions may develop on normal-\\nappearing skin spontaneously or may be caused by minor trauma. The trauma-prone areas of the skin,\\nsuch as the extensor surfaces of elbows, knees, ankles, and buttocks, are most commonly affected. Pain\\nand scarring are common. Because the hands and feet are often involved, disability can be significant.\\nOccasionally, mucosa of eyes, mouth, or genitals is involved. Laryngeal and esophageal involvement also\\noccurs. Diagnosis is by skin biopsy. Lesions respond poorly to corticosteroids. Mild disease may be\\ntreated with colchicine, but more severe disease may require cyclosporine or immune globulin.\\nLinear Immunoglobulin A Disease\\nLinear immunoglobulin A (IgA) disease is an uncommon bullous disease distinguished from\\nbullous pemphigoid and dermatitis herpetiformis by the linear deposits of IgA in the basement\\nmembrane zone.\\nLinear IgA disease occurs in adults and children. The childhood form is most frequently termed chronic\\nbullous disease of childhood.\\nIn linear IgA disease, vesicular or bullous skin lesions occur frequently in a clustered (herpetiform)\\narrangement. There is a predilection for flexural areas (eg, inguinal crease). As in dermatitis herpetiformis,\\nsevere burning and pruritus of cutaneous lesions are prominent features. It was previously considered a\\nform of dermatitis herpetiformis but has no concomitant gluten-sensitive enteropathy and\\nimmunopathology. Also, genetic studies indicate that linear IgA disease is a separate disorder. Drug-\\ninduced linear IgA disease, most commonly associated with vancomycin, has been reported.\\nDiagnosis is by skin biopsy. Dapsone is the treatment of choice. Doses should be similar to those used\\nfor dermatitis herpetiformis (see p. \\n657\\n), and CBC monitoring should follow the same parameters. Other\\ntreatment options include glucocorticoids (systemic, topical, and intralesional), cyclophosphamide,\\nazathioprine, colchicine, tetracycline and nicotinamide, and cyclosporine.\\nPemphigus Vulgaris\\nPemphigus vulgaris is an uncommon, potentially fatal, autoimmune disorder characterized by\\nintraepidermal blisters and extensive erosions on apparently healthy skin and mucous\\nmembranes. Diagnosis is by skin biopsy with direct immunofluorescence testing. Treatment is\\nwith corticosteroids and sometimes immunosuppressants.\\nPemphigus vulgaris usually occurs in middle-aged or elderly patients and is rare in children. One variant,\\nparaneoplastic pemphigus, occurs in older patients with cancer (primarily lymphoreticular); outcome is\\npoor.\\nThe disorder is characterized by the presence of autoantibodies directed against intercellular adhesion\\nmolecules desmoglein-1 and desmoglein-3 in the epidermis. They are Ca-dependent cadherins, involved\\nin adhesion and cell signaling between epidermal cells. Acantholysis results from either direct inhibition of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 74. Bullous Diseases\\n768'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 778, 'page_label': '769'}, page_content=\"function of the desmogleins by autoantibody binding or from autoantibody-induced cell signaling that\\nresults in down-regulation of cell-cell adhesion and formation of blisters. These autoantibodies are\\npresent in both serum and skin during active disease. Any area of stratified squamous epithelium may be\\naffected, including mucosal surfaces.\\nSymptoms and Signs\\nThe primary lesions are flaccid bullae of various sizes (see\\nPlate 41\\n), but often skin or mucosa just shears off, leaving painful erosions. Lesions typically occur first in\\nthe mouth, where they rupture and remain as chronic, often painful, erosions for variable periods before\\nthe skin is affected; dysphagia and poor oral intake are common. Lesions also may occur in the \\nupper\\nesophagus. Cutaneous bullae typically arise from normal-appearing skin, rupture, and leave a raw area\\nand crusting. Itching is usually absent. Open skin lesions often become infected. If large portions of the\\nbody are affected, fluid and electrolyte loss may be significant.\\nDiagnosis\\n Clinical evaluation\\n Biopsy with direct immunofluorescence testing\\n Sometimes titers of antibodies against desmoglein-3 or desmoglein-1\\nPemphigus vulgaris should be suspected in patients with any bullous disorder or chronic mucosal\\nulceration. It must be differentiated from other chronic oral ulcers and from other bullous dermatoses (eg,\\npemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, drug eruptions, toxic epidermal\\nnecrolysis, erythema multiforme, dermatitis herpetiformis, bullous contact dermatitis). Two physical signs\\nin pemphigus vulgaris are helpful:\\n Lateral pressure on skin adjacent to a blister causes epidermal detachment (Nikolsky's sign).\\n Pressure on a blister can cause the blister to extend to adjacent skin (Asboe-Hansen sign).\\nBiopsy of the edge of a fresh lesion and of a nearby area of normal skin is required; light microscopy and\\ndirect immunofluorescence testing are usually diagnostic. Serum antibodies (eg, to desmoglein-3) can be\\nused for diagnosis and for differentiating from pemphigus foliaceus; serial titers can help follow disease\\nactivity.\\nPrognosis\\nBefore systemic corticosteroids were used, pemphigus vulgaris was usually fatal; most patients died\\nwithin 5 yr of disease onset. Even with treatment, pemphigus vulgaris is a serious disorder with an\\ninconsistent and unpredictable response to treatment, a prolonged course, and virtually inevitable\\nadverse drug effects.\\nTreatment\\n Corticosteroids, oral or IV\\n Sometimes immunosuppressants\\n Sometimes plasmapheresis and IV immune globulin (IVIG)\\nReferral to a dermatologist with expertise in treating this disorder is recommended. Hospitalization is\\nrequired initially for all but the most minor cases. Cleansing and dressing of open skin lesions is similar to\\nthat done for partial-thickness burns (eg, reverse isolation, hydrocolloid or silver sulfadiazine dressings\\nsee p. \\n3246\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 74. Bullous Diseases\\n769\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 779, 'page_label': '770'}, page_content='Drug treatment aims to decrease the production of autoantibodies and stop the eruption of new lesions.\\nThe mainstay is systemic corticosteroids. Some patients with few lesions may respond to oral prednisone\\n20 to 30 mg once/day, but most require 1.0 mg/kg once/day as an initial dose. Some clinicians begin with\\neven higher doses, which may slightly hasten initial response but does not appear to improve outcome. If\\nnew lesions continue to appear after 5 to 7 days, IV pulse therapy with methylprednisolone 1 g once/day\\ncan be tried.\\nImmunosuppressants such as methotrexate, cyclophosphamide, azathioprine, gold, mycophenolate\\nmofetil, cyclosporine, or rituximab can reduce the need for corticosteroids and thus minimize the\\nundesirable effects of long-term corticosteroid use. Plasmapheresis and high-dose IVIG to reduce\\nantibody titers have also been effective.\\nOnce no new lesions have appeared for 7 to 10 days, corticosteroid dose should be tapered monthly by\\nabout 10 mg/day (tapering continues more slowly once 20 mg/day is reached). A relapse requires a return\\nto the starting dose. If the patient has been stable after a year, a trial without treatment can be attempted\\nbut must be closely monitored.\\nPemphigus Foliaceus\\nPemphigus foliaceus is a generally benign blistering disorder. It is characterized by splitting\\nhigh in the epidermis, causing erosions to form on the skin.\\nPemphigus foliaceus usually occurs in middle-aged patients. Foci of high incidence occur in South\\nAmerica, especially Brazil.\\nThe primary lesion is a flaccid bulla. However, because splitting occurs high in the epidermis, bullae are\\nrarely seen; the blisters are so fragile that they rupture. Clinically, scaly, crusted cutaneous erosions, often\\non an erythematous base, can be seen. Mucosal surfaces are not usually involved. In one variant,\\npemphigus erythematosus, lesions occur on \\nlight-exposed skin and are often similar to those of\\ncutaneous lupus erythematosus.\\nDiagnosis is by biopsy of a lesion and neighboring normal skin and by serum antibody titers against the\\ncell adhesion molecule desmoglein 1 (160 kd). Because the disorder is much more benign than\\npemphigus vulgaris, treatment is generally less aggressive. Superpotent topical corticosteroids may be\\nsufficient in some patients. Others require oral prednisone and additional immunosuppressants. A\\ncombination of tetracycline 500 mg qid and nicotinamide 1.5 g/day has been effective in some patients.\\nPlasmapheresis is an option for severe disease.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 74. Bullous Diseases\\n770'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 780, 'page_label': '771'}, page_content='Chapter 75. Cornification Disorders\\nIntroduction\\nCornification disorders include calluses, corns, ichthyosis, and keratosis pilaris.\\nCalluses and Corns\\n(Tylomas; Helomas; Clavi)\\nCalluses and corns are circumscribed areas of hyperkeratosis at a site of intermittent pressure\\nor friction. Calluses are more superficial, cover broader areas of skin, and usually\\nasymptomatic. Corns are deeper, more focal, and frequently painful. Diagnosis is by\\nappearance. Treatment is with manual abrasion with or without keratolytics. Prevention\\ninvolves altering biomechanics, such as changing footwear. Rarely, surgery is required.\\nCalluses and corns are caused by intermittent pressure or friction, usually over a bony prominence (eg,\\nheel, metatarsal heads).\\nCorns\\n consist of a sharply circumscribed keratinous plug, pea-sized or slightly larger, which extends\\nthrough most of the underlying dermis. An underlying adventitial bursitis may develop. Hard corns occur\\nover prominent bony protuberances, especially on the toes and plantar surface. Soft corns occur between\\nthe toes. Most corns result from poorly fitting footwear, but small seed-sized corns on non-weight-bearing\\naspects of the soles and palms may represent inherited keratosis punctata.\\nCalluses\\n lack a central plug and have a more even appearance. They usually occur on the hands or feet\\nbut may occur elsewhere, especially in a person whose occupation entails repeated trauma to a particular\\narea (eg, the mandible and clavicle of a violinist).\\nSymptoms and Signs\\nCalluses are usually asymptomatic but, if friction is extreme, may become irritated, causing mild burning\\ndiscomfort. At times, the discomfort may mimic that of interdigital neuralgia.\\nCorns may be painful or tender when pressure is applied. A bursa or fluid-filled pocket sometimes forms\\nbeneath a corn.\\nDiagnosis\\n Clinical evaluation\\nA corn may be differentiated from a plantar wart or callus by paring away the horny skin. After paring, a\\ncallus shows smooth translucent skin, whereas a wart (see p. \\n715\\n) appears sharply circumscribed,\\nsometimes with soft macerated tissue or with central black dots (bleeding points) representing\\nthrombosed capillaries. A corn, when pared, shows a sharply outlined yellowish to tan translucent core\\nthat interrupts the normal architecture of the papillary dermis. Interdigital neuralgia can be ruled out by the\\nabsence of interspace pain on palpation.\\nTreatment\\n Manual removal\\n Keratolytics\\n Cushioning\\n Altering foot biomechanics\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 75. Cornification Disorders\\n771'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 781, 'page_label': '772'}, page_content=\"A nail file, emery board, or pumice stone used immediately after bathing is often a practical way to\\nmanually remove hyperkeratotic tissue. Keratolytics (eg, 17% salicylic acid in collodion, 40% salicylic acid\\nplasters, 40% urea) can also be used, taking care to avoid applying the agents to normal skin. Normal\\nskin may be protected by covering it with petrolatum before application of the keratolytic.\\nCushioning and altering foot biomechanics can help prevent corns and help treat existing corns. Although\\ndifficult to eliminate, pressure on the affected surface should be reduced and redistributed. For foot\\nlesions, soft, well-fitting shoes are important; they should have a roomy toe box so that toes can move\\nfreely in the shoe. Stylish shoes often prevent this freedom of motion. Shoes that increase discomfort of a\\nlesion should be eliminated from the wardrobe. Pads or rings of suitable shapes and sizes, moleskin or\\nfoam-rubber protective bandages, arch inserts (orthotics), or metatarsal plates or bars may help\\nredistribute the pressure. For corns and calluses on the ball of the foot, an orthotic should not be full\\nlength but should extend only to the ball or part of the shoe immediately behind the corn or callus.\\nSurgical off-loading or removal of the offending bone is rarely necessary.\\nPatients who have a tendency to develop calluses and corns may need the regular services of a\\npodiatrist. Patients with impaired peripheral circulation, especially if associated with diabetes, require\\nexpert care.\\nIchthyosis\\nIchthyosis is scaling and flaking of skin ranging from mild but annoying dryness (xeroderma) to\\nsevere disfiguring disease (inherited ichthyosis). Ichthyosis can also be a sign of systemic\\ndisease. Diagnosis is clinical. Treatment involves emollients and sometimes oral retinoids.\\nXeroderma:\\n Xeroderma (xerosis), or dry skin, is neither inherited nor associated with systemic\\nabnormalities. Dry skin results from loss of the water content of the skin, resulting in fine white scales.\\nRisk factors for xerosis include the following:\\n Residence in a dry, cold climate\\n Older age\\n Atopic dermatitis\\n Frequent bathing, particularly if using harsh soaps\\nInherited ichthyoses:\\n Inherited ichthyoses, which are characterized by excessive accumulation of scale\\non the skin surface, are classified according to clinical and genetic criteria (see\\nTable 75-1\\n). Some occur in isolation without\\n[\\nTable 75-1.\\n Clinical and Genetic Features of Some Inherited Ichthyoses]\\nassociated abnormalities (eg, ichthyosis vulgaris, X-linked ichthyosis, lamellar ichthyosis, epidermolytic\\nhyperkeratosis [bullous congenital ichthyosiform erythroderma]). Other ichthyoses are part of a syndrome\\nthat involves multiple organs. For instance, Refsum's disease (see p. \\n3024\\n) and Sjogren-Larsson\\nsyndrome (hereditary intellectual disability and spastic paralysis caused by a defect in fatty aldehyde\\ndehydrogenase) are autosomal recessive conditions with skin and extracutaneous organ involvement. A\\ndermatologist should assist in diagnosis and management, and a medical geneticist should be consulted\\nfor genetic counseling.\\nAcquired ichthyosis:\\n Ichthyosis may be an early manifestation of some systemic disorders (eg, leprosy,\\nhypothyroidism, lymphoma, AIDS). Some drugs cause ichthyosis (eg, nicotinic acid, triparanol,\\nbutyrophenones). The dry scaling may be fine and localized to the trunk and legs, or it may be thick and\\nwidespread. Biopsy of ichthyotic skin is usually not diagnostic of the systemic disorder; however, there\\nare exceptions, most notably sarcoidosis, in which a thick scaling may appear on the legs, and biopsy\\nusually shows the typical granulomas.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 75. Cornification Disorders\\n772\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 782, 'page_label': '773'}, page_content='Treatment\\n Minimization of exacerbating factors\\n Moisturization and keratolytics\\n Sometimes infection prophylaxis\\nWhen ichthyosis is caused by a systemic disorder, abatement is greatest if the primary disorder can be\\ncorrected. Otherwise, treatment is symptomatic, including using emollients and keratolytics and avoiding\\ndrying.\\nMoisturization and keratolytics:\\n In any ichthyosis, there is impaired epidermal barrier function, and\\nmoisturizers should be applied immediately after bathing. Substances that are applied to the skin may\\nhave increased absorption. For example, hexachlorophene products should not be used because of\\nincreased absorption and toxicity.\\nAn emollient, preferably plain petrolatum, mineral oil, or lotions containing urea or \\n\\n-hydroxy acids (eg,\\nlactic, glycolic, and pyruvic acids), should be applied twice daily, especially after bathing while the skin is\\nstill wet. Blotting with a towel removes excess applied material.\\nIchthyosis typically responds well to propylene glycol. To remove scale (eg, if ichthyosis is severe),\\npatients can apply a preparation containing 40 to 60% propylene glycol in water under occlusion (eg, a\\nthin plastic film or bag), every night after hydrating the skin (eg, by bathing or showering); in children, the\\npreparation should be applied twice daily without occlusion. Occlusion should be maintained overnight.\\nAfter scaling has decreased, less frequent application is required. Other useful keratolytics include\\nceramide-based creams, 6% salicylic acid gel, hydrophilic petrolatum and water (in equal parts), and the\\n\\n-hydroxy acids in various bases. Topical calcipotriol cream has been used with success; however, this\\nvitamin D derivative can result in hypercalcemia when used over broad areas, especially in small children.\\nRetinoids\\n are effective in treating ichthyosis. Oral synthetic retinoids are effective for most ichthyoses.\\nAcitretin (see p. \\n679\\n) is effective in treating most forms of inherited ichthyosis. In lamellar ichthyosis, 0.1%\\ntretinoin cream or oral isotretinoin may be effective. The lowest effective dose should be used. Long-term\\n(1 yr) treatment with oral isotretinoin has resulted in bony exostoses in some patients, and other long-term\\nadverse effects may arise. (CAUTION: \\nOral retinoids are contraindicated in pregnancy because of their\\nteratogenicity, and acitretin should be avoided in women of childbearing potential because of its\\nteratogenicity and long half-life.)\\nInfection prophylaxis:\\n Patients with epidermolytic hyperkeratosis may need long-term treatment with\\ncloxacillin 250 mg po tid or qid or erythromycin 250 mg po tid or qid, as long as thick intertriginous scaling\\nis present, to prevent bacterial superinfection from causing painful, foul-smelling pustules. Regularly using\\nsoaps containing chlorhexidine may also reduce the bacteria, but these soaps tend to dry the skin.\\nKeratosis Pilaris\\nKeratosis pilaris is a disorder of keratinization in which horny plugs fill the openings of hair\\nfollicles.\\nKeratosis pilaris is common. The cause is unknown, but there is often an autosomal dominant inheritance.\\nMultiple small, pointed, keratotic follicular papules appear mainly on the lateral aspects of the upper arms,\\nthighs, and buttocks. Facial lesions may also occur, particularly in children. Lesions are most prominent in\\ncold weather and sometimes abate in the summer. Skin may appear red. The problem is mainly cosmetic,\\nbut the disorder may cause itching or, rarely, follicular pustules.\\nTreatment is usually unnecessary and often unsatisfactory. Hydrophilic petrolatum \\nand water (in equal\\nparts), cold cream, or petrolatum with 3% salicylic acid may help flatten the lesions. Buffered lactic acid\\n(ammonium lactate) lotions or creams, urea creams, 6% salicylic acid gel, or 0.1% tretinoin cream may\\nalso be effective. Acid creams should be avoided in young children because of burning and stinging.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 75. Cornification Disorders\\n773'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 783, 'page_label': '774'}, page_content='Pulse-dye laser has been used successfully to treat facial redness.The Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 75. Cornification Disorders\\n774'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 784, 'page_label': '775'}, page_content='Chapter 76. Dermatitis\\nIntroduction\\nDermatitis is superficial inflammation of the skin characterized by redness, edema, oozing, crusting,\\nscaling, and sometimes vesicles. Pruritus is common. Eczema is a term often used interchangeably with\\ndermatitis.\\nAtopic Dermatitis\\nAtopic dermatitis (AD) is an immune-mediated inflammation of the skin arising from an\\ninteraction between genetic and environmental factors. Recent research suggests that a\\nheritable epidermal barrier defect is a primary cause, and defects in the \\nfilaggrin\\n gene have\\nbeen specifically implicated. Pruritus is the primary symptom; skin lesions range from mild\\nerythema to severe lichenification. Diagnosis is by history and examination. Treatment is\\nmoisturizers, avoidance of allergic and irritant triggers, and often topical corticosteroids. Atopic\\ndermatitis frequently resolves completely by age 30.\\nEtiology\\nAD primarily affects children in urban areas or developed countries; at least 5% of children in the US are\\naffected. Like asthma, it may be linked to proallergic/proinflammatory T-cell immune responses. Such\\nresponses are becoming more common in developed countries because trends toward smaller families,\\ncleaner indoor environments, and early use of vaccinations and antibiotics deprive children of the early\\nexposure to infections and allergens that otherwise suppress proallergic T cells and thereby induce\\ntolerance to various antigens.\\nPathophysiology\\nAD can be divided into 2 forms:\\n Extrinsic: IgE-mediated (70 to 80% of cases)\\n Intrinsic: Non-IgE-mediated (20 to 30% of cases)\\nExtrinsic AD:\\n This form occurs when environmental exposures trigger immunologic, usually allergic (ie,\\nIgE-mediated), reactions in genetically susceptible people. Common environmental triggers include\\n Foods (eg, milk, eggs, soy, wheat, peanuts, fish)\\n Airborne allergens (eg, dust mites, molds, dander)\\n \\nStaphylococcus aureus\\n colonization on skin due to deficiencies in endogenous antimicrobial peptides\\n Topical products (eg, cosmetics)\\nAD is common within families, suggesting a genetic component. Many patients with AD have a mutation in\\nthe gene encoding for the filaggrin protein, which is a component of the cornified cell envelope produced\\nby differentiating keratinocytes. Also, research has shown that skin affected by AD is deficient in\\nceramides, which increases transepidermal water loss.\\nIntrinsic AD:\\n This form is not mediated by IgE. Intrinsic AD is nonfamilial and idiopathic, and its\\npathophysiology is generally not well understood.\\nSymptoms and Signs\\nManifestations of intrinsic and extrinsic AD are similar. AD usually appears in infancy, typically by 3 mo. In\\nthe acute phase, lasting 1 to 2 mo (see\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n775'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 785, 'page_label': '776'}, page_content=\"the acute phase, lasting 1 to 2 mo (see\\nPlate 27\\n), red, weeping, crusted lesions appear on the face and spread to the neck, scalp, extremities,\\nand abdomen. In the chronic phase (see\\nPlate 28\\n), scratching and rubbing create skin lesions (typically erythematous macules and papules that\\nlichenify with continued scratching). Lesions typically appear in antecubital and popliteal fossae and on\\nthe eyelids, neck, and wrists and may occasionally become generalized. Lesions slowly resolve to dry\\nscaly macules (xerosis) that can fissure and facilitate exposure to irritants and allergens. In older children\\nand adults, intense pruritus is the key feature. Patients have a reduced threshold for perceiving itch, and\\nitch \\nworsens with allergen exposures, dry air, sweating, local irritation, wool garments, and emotional\\nstress.\\nComplications:\\n Secondary bacterial infections, especially staphylococcal and streptococcal, and\\nregional lymphadenitis are common.\\nEczema herpeticum (Kaposi's varicelliform eruption) is a diffuse herpes simplex infection occurring in\\npatients with AD. It manifests as grouped vesicles in areas of active or recent dermatitis, although normal\\nskin can be involved. High fever and adenopathy may develop after several days. Occasionally, this\\ninfection can become systemic, which may be fatal. Sometimes the eye is involved, causing a painful\\ncorneal lesion.\\nFungal and nonherpetic viral skin infections (eg, common warts, molluscum contagiosum) can also occur.\\nPatients with long-standing AD may develop cataracts in their 20s or 30s.\\nFrequent use of topical products exposes the patient to many potential allergens, and contact dermatitis\\nmay aggravate and complicate AD, as may the generally dry skin that is common among these patients.\\nDiagnosis\\n Clinical evaluation\\n Sometimes testing for allergic triggers with skin prick testing or radioallergosorbent testing levels\\nDiagnosis is clinical (see\\nTable 76-1\\n). AD is often hard to differentiate from other dermatoses (eg, seborrheic dermatitis, contact\\ndermatitis, nummular dermatitis, psoriasis), although a family history of atopy and the distribution of\\nlesions are helpful. For example, psoriasis is usually extensor rather than flexurally distributed, may\\ninvolve the fingernails, and has a shinier (micaceous) scale. Seborrheic dermatitis affects the face (eg,\\nnasolabial folds, eyebrows, glabellar region, scalp) most commonly. Nummular dermatitis is not flexural,\\nand lichenification is rare. Because patients can still develop other skin disorders, not all subsequent skin\\nproblems should be attributed to AD.\\nThere is no definitive laboratory test for AD. However, allergic precipitants of AD can be identified with\\nskin testing, measurement of allergen-specific IgE levels, or both.\\nPrognosis\\nAD in children often abates by age 5 yr, although exacerbations are common throughout adolescence and\\ninto adulthood. Girls and patients with severe disease, early age of onset, family history, and associated\\nrhinitis or asthma are more likely to have prolonged disease. Even in these patients, AD frequently\\nresolves completely by age 30. AD may have long-term psychologic sequelae as children confront many\\nchallenges of living with a visible, sometimes disabling, skin disease during formative years.\\n[\\nTable 76-1.\\n Clinical Findings in Atopic Dermatitis*]\\nTreatment\\n Supportive care (eg, moisturizers, symptomatic treatment for pruritus)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n776\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 786, 'page_label': '777'}, page_content=' Avoidance of precipitating factors\\n Topical corticosteroids\\n Sometimes immune modulators (most often topical but sometimes oral)\\n Sometimes ultraviolet (UV) therapy\\nTreatment can usually be given at home, but patients who have exfoliative dermatitis (see p. \\n668\\n),\\ncellulitis, or eczema herpeticum may need to be hospitalized.\\nSupportive care:\\n Skin care involves moisturizing. Bathing and hand washing should be infrequent, and\\nlukewarm (not hot) water should be used; soap use should be minimized on dermatitic areas because it\\nmay be drying and irritating. Colloidal oatmeal baths can be helpful. When toweling dry, the skin should\\nbe blotted or patted dry rather than rubbed.\\nBody oils or emollients such as white petrolatum, vegetable oil, or hydrophilic petrolatum (unless the\\npatient is allergic to lanolin) applied immediately after bathing may help retain skin moisture and reduce\\nitching. Continuously wet dressings (not wet-to-dry) are an alternative for severe lesions. Coal tar cream\\nor oil can be an effective topical anti-pruritic but also can be inconvenient because it stains clothing.\\nAntihistamines can help relieve pruritus. Options include hydroxyzine 25 mg po tid or qid (for children, 0.5\\nmg/kg q 6 h or 2 mg/kg in a single bedtime dose) and diphenhydramine 25 to 50 mg po at bedtime. Low-\\nsedating H\\n1\\n receptor blockers, such as loratadine 10 mg po once/day, fexofenadine 60 mg po bid or 180\\nmg po once/day, and cetirizine 5 to 10 mg po once/day, may be useful, although their efficacy has not\\nbeen defined. Doxepin (a tricyclic antidepressant also with H\\n1\\n and H\\n2\\n receptor blocking activity) 25 to 50\\nmg po at bedtime may also help, but its use is not recommended for children < 12 yr. Fingernails should\\nbe cut short to minimize excoriations and secondary infections.\\nAvoidance of precipitating factors:\\n Household antigens can be controlled by using synthetic fiber\\npillows and impermeable mattress covers; washing bedding in hot water; removing upholstered furniture,\\nsoft toys, carpets, and pets (to reduce dust mites and animal dander); using air circulators equipped with\\nhigh-efficiency particulate air (HEPA) filters in bedrooms and other frequently occupied living areas; and\\nusing dehumidifiers in basements and other poorly aerated damp rooms (to reduce molds). Reduction of\\nemotional stress is useful but often difficult. Antistaphylococcal antibiotics, both topical (eg, mupirocin,\\nfusidic acid) and oral (eg, dicloxacillin, cephalexin, erythromycin [all 250 mg qid]), can control \\nS. aureus\\nnasal colonization and are indicated in patients with severe disease unresponsive to specific therapies\\nand positive nasal cultures. Extensive dietary changes intended to eliminate exposure to allergenic foods\\nare unnecessary and probably ineffective; food hypersensitivities rarely persist beyond childhood.\\nCorticosteroids:\\n Corticosteroids are the mainstay of therapy. Creams or ointments applied twice daily\\nare effective for most patients with mild or moderate disease. Emollients are applied between\\ncorticosteroid applications and can be mixed with them to decrease the corticosteroid amount required to\\ncover an area. Systemic corticosteroids (prednisone 60 mg or, for children 1 mg/kg, po once/day for short\\ncourses of 7 to 14 days) are indicated for extensive or refractory disease but should be avoided\\nwhenever possible, because disease often recurs and topical therapy is safer. Prolonged, widespread\\nuse of high-potency corticosteroid creams or ointments should be avoided in infants because adrenal\\nsuppression may ensue.\\nOther therapies:\\n Tacrolimus and pimecrolimus are T-cell inhibitors effective for AD. They should be used\\nwhen patients do not respond to corticosteroids and tar or when corticosteroid adverse effects such as\\nskin atrophy, striae formation, or adrenal suppression is a concern. Tacrolimus or pimecrolimus cream is\\napplied twice daily. Burning or stinging after application is usually transient and abates after a few days.\\nFlushing is less common.\\nRepair of the stratum corneum and barrier function may help alleviate AD. Research has shown that skin\\naffected by AD is particularly deficient in ceramides and that a deficiency in ceramides increases\\ntransepidermal water loss. Several ceramide-containing emollient products are considered helpful for AD\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n777'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 787, 'page_label': '778'}, page_content='control.\\nPhototherapy is helpful for extensive AD. Natural sun exposure ameliorates disease in many patients,\\nincluding children. Alternatively, therapy with ultraviolet A (UVA) or B (UVB) may be used. Narrowband\\nUVB therapy is proving more effective than traditional broadband UVB therapy and is also effective in\\nchildren. Psoralen plus UVA (PUVAsee p. \\n679\\n) therapy is reserved for extensive, refractory AD. Adverse\\neffects include sun damage (eg, PUVA lentigines, nonmelanoma skin cancer). Because of these adverse\\neffects, PUVA is rarely indicated for children or young adults.\\nSystemic immune modulators effective in at least some patients include cyclosporine, interferon gamma,\\nmycophenolate, methotrexate, and azathioprine. All downregulate or inhibit T-cell function and have anti-\\ninflammatory properties. These agents are indicated for widespread, recalcitrant, or disabling AD that fails\\nto abate with topical therapy and phototherapy.\\nEczema herpeticum is treated with acyclovir. Infants receive 10 to 20 mg/kg IV q 8 h; older children and\\nadults with mild illness may receive 200 mg po 5 times/day. Involvement of the eye is considered an\\nophthalmic emergency, and if eye involvement is suspected, an ophthalmology consult should be\\nobtained.\\nContact Dermatitis\\nContact dermatitis (CD) is acute inflammation of the skin caused by irritants or allergens. The\\nprimary symptom is pruritus. Skin changes range from erythema to blistering and ulceration,\\noften on or near the hands but occurring on any exposed skin surface. Diagnosis is by exposure\\nhistory, examination, and sometimes skin patch testing. Treatment entails antipruritics, topical\\ncorticosteroids, and avoidance of causes.\\nPathophysiology\\nCD is caused by irritants or allergens.\\nIrritant contact dermatitis (ICD):\\n ICD accounts for 80% of all cases of CD. It is a nonspecific\\ninflammatory reaction to substances contacting the skin; the immune system is not activated. Numerous\\nsubstances are involved, including\\n Chemicals (eg, acids, alkalis, solvents, metal salts)\\n Soaps (eg, abrasives, detergents)\\n Plants (eg, poinsettias, peppers)\\n Body fluids (eg, urine, saliva)\\nProperties of the irritant (eg, extreme pH, solubility in the lipid film on skin), environment (eg, low humidity,\\nhigh temperature, high friction), and patient (eg, very young or old) influence the likelihood of developing\\nICD. ICD is more common among patients with atopic disorders, in whom ICD also may initiate\\nimmunologic sensitization and hence allergic CD.\\nPhototoxic dermatitis\\n (see p. \\n675\\n) is a variant in which topical (eg, perfumes, coal tar) or ingested (eg,\\npsoralens) agents generate damaging free radicals and inflammatory mediators only after absorption of\\nultraviolet light.\\nAllergic contact dermatitis (ACD):\\n ACD is a type IV cell-mediated hypersensitivity reaction that has 2\\nphases:\\n Sensitization to an antigen\\n Allergic response after reexposure\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n778'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 788, 'page_label': '779'}, page_content='In the sensitization phase, allergens are captured by Langerhans\\' cells (dendritic epidermal cells), which\\nmigrate to regional lymph nodes where they process and present the antigen to T cells. The process may\\nbe brief (6 to 10 days for strong sensitizers such as poison ivy) or prolonged (years for weak sensitizers\\nsuch as sunscreens, fragrances, and glucocorticoids). Sensitized T cells then migrate back to the\\nepidermis and activate on any reexposure to the allergen, releasing cytokines, recruiting inflammatory\\ncells, and leading to the characteristic symptoms and signs of ACD.\\nIn \\nautoeczematization\\n, epidermal T cells activated by an allergen migrate locally or through the\\ncirculation to cause dermatitis at sites remote from the initial trigger. However, contact with fluid from\\nvesicles or blisters cannot trigger a reaction elsewhere on the patient or on another person.\\nMultiple allergens cause ACD (see\\nTable 76-2\\n), and cross-sensitization among agents is common (eg, between benzocaine and\\nparaphenylenediamine). Cross-sensitization means that exposure to one substance can result in an\\nallergic response after exposure to a different but related substance.\\nACD variants include photoallergic CD and systemically induced ACD. In photoallergic CD (see p. \\n675\\n), a\\nsubstance becomes sensitizing only after it undergoes structural change triggered by ultraviolet light.\\nTypical causes include aftershave lotions, sunscreens, and topical sulfonamides. Reactions may extend\\nto non-sun-exposed skin. In systemically induced ACD, ingestion of an allergen after topical sensitization\\ncauses diffuse dermatitis (eg, oral diphenhydramine after sensitization with topical diphenhydramine).\\nSymptoms and Signs\\nICD:\\n ICD is more painful than pruritic. Signs range from mild erythema to hemorrhage, crusting, erosion,\\npustules, bullae, and edema.\\nACD:\\n In ACD, the primary symptom is intense pruritus; pain is usually the result of excoriation or infection.\\nSkin changes range from transient erythema through vesiculation to severe swelling with bullae,\\nulceration, or both. Changes often occur in a pattern, distribution, or combination that suggests a specific\\nexposure, such as linear streaking on an arm or leg (eg, from brushing against poison ivy) or\\ncircumferential erythema (under a wristwatch or waistband). Any surface may be involved, but hands are\\nthe most common surface due to handling and touching potential allergens. With airborne exposure (eg,\\n[\\nTable 76-2.\\n Causes of Allergic Contact Dermatitis]\\nperfume aerosols), areas not covered by clothing are predominantly affected. The dermatitis is typically\\nlimited to the site of contact but may later spread due to scratching and autoeczematization. In\\nsystemically induced ACD, skin changes may be distributed over the entire body.\\nDiagnosis\\n Clinical evaluation\\n Sometimes patch testing\\nCD can often be diagnosed by skin changes and exposure history. The patient\\'s occupation, hobbies,\\nhousehold duties, vacations, clothing, topical drug use, cosmetics, and spouse\\'s activities must be\\nconsidered. The \"use\" test, in which a suspected agent is applied far from the original area of dermatitis,\\nusually on the flexor forearm, is useful when perfumes, shampoos, or other home agents are suspected.\\nPatch testing is indicated when ACD is suspected and does not respond to treatment. In patch testing,\\nstandard contact allergens are applied to the upper back using adhesive-mounted patches containing\\nminute amounts of allergen or plastic (Finn) chambers containing allergen held in place with porous tape.\\nThin-layer rapid use epicutaneous (TRUE) patch testing involves 2 adhesive strips that can be applied\\nand interpreted by any provider. Skin under the patches is evaluated 48 and 96 h after application. False-\\npositive results occur when concentrations provoke an irritant rather than an allergic reaction, when\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n779'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 789, 'page_label': '780'}, page_content=\"reaction to one antigen triggers a nonspecific reaction to others, or with cross-reacting antigens. False-\\nnegative results occur when patch allergens do not include the offending antigen. Definitive diagnosis\\nrequires a history of exposure to the test agent in the original area of dermatitis.\\nPrognosis\\nResolution may take up to 3 wk. Reactivity is usually lifelong. Patients with photoallergic CD can have\\nflares for years when exposed to sun (persistent light reaction).\\nTreatment\\n Avoidance of offending agents\\n Supportive care (eg, cool compresses, dressings, antihistamines)\\n Corticosteroids (most often topical but sometimes oral)\\nCD is prevented by avoiding the trigger; patients with photosensitive CD should avoid exposure to sun.\\nTopical treatment includes cool compresses (saline or Burow's solution) and corticosteroids; patients with\\nmild to moderate ACD are given mid-potency topical corticosteroids (eg, triamcinolone 0.1% ointment or\\nbetamethasone valerate cream 0.1%). Oral corticosteroids (eg, prednisone 60 mg once/day for 7 to 14\\ndays) can be used for severe blistering or extensive disease. Systemic antihistamines (eg, hydroxyzine,\\ndiphenhydramine) help pruritus; antihistamines with low anticholinergic potency, such as low-sedating H\\n1\\nblockers, are not as effective. Wet-to-dry dressings can soothe oozing blisters, dry the skin, and promote\\nhealing.\\nExfoliative Dermatitis\\n(Erythroderma)\\nExfoliative dermatitis is widespread erythema and scaling of the skin caused by preexisting\\nskin disorders, drugs, cancer, or unknown causes. Symptoms and signs are pruritus, diffuse\\nerythema, and epidermal sloughing. Diagnosis is clinical. Treatment involves corticosteroids\\nand correction of the cause.\\nExfoliative dermatitis is a manifestation of rapid epidermal cell turnover. Its cause is unknown, but it most\\noften occurs in the context of preexisting skin disorders (eg, atopic dermatitis, contact dermatitis,\\nseborrheic dermatitis, psoriasis, pityriasis rubra pilaris), use of drugs (eg, penicillin, sulfonamides,\\nisoniazid, phenytoin, barbiturates), and cancer (eg, mycosis fungoides, leukemia, and, rarely, ade-\\nnocarcinomas). Up to 25% of patients have no identifiable underlying disease.\\nSymptoms and Signs\\nSymptoms include pruritus, malaise, and chills. Diffuse erythema initially occurs in patches but spreads\\nand involves all or nearly all of the body. Extensive epidermal sloughing leads to abnormal\\nthermoregulation, nutritional deficiencies because of extensive protein losses, increased metabolic rate\\nwith a hypercatabolic state, and hypovolemia due to transdermal fluid losses.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is by history and examination. Preexisting skin disease may underlie the extensive erythema\\nand suggest a cause. Biopsy is often nonspecific but is indicated when mycosis fungoides is suspected.\\nBlood tests may reveal hypoproteinemia, hypocalcemia, and iron deficiency, each a consequence of\\nextensive protein, electrolyte, and RBC loss; however, these findings are not diagnostic.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n780\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 790, 'page_label': '781'}, page_content='Treatment\\n Supportive care (eg, rehydration)\\n Topical care (eg, emollients, colloidal oatmeal baths)\\n Systemic corticosteroids for severe disease\\nThe disease may be life threatening; hospitalization is often necessary. Any known cause is treated.\\nSupportive care consists of correction of dehydration, correction of electrolyte abnormalities and\\nnutritional deficiencies, and comprehensive wound care and dressings to prevent bacterial superinfection.\\nBecause drug eruptions and contact dermatitis cannot be ruled out by history alone, all drugs should be\\nstopped if possible or changed. Skin care is with emollients and colloidal oatmeal baths. Weak topical\\ncorticosteroids (eg, 1 to 2.5% hydrocortisone ointment) may be used. Corticosteroids (prednisone 40 to\\n60 mg po once/day for 10 days, then tapered) are used for severe disease.\\nPrognosis depends on the cause. Cases related to drug reactions have the shortest duration, lasting 2 to\\n6 wk after the drug is withdrawn.\\nHand and Foot Dermatitis\\nHand and foot dermatitis is not a single disorder. Rather, it is a categorization of dermatitis that\\naffects the hands and feet selectively due to one of several causes.\\nPatients often present with isolated dermatitis of the hands or feet. Causes include\\n Contact dermatitis\\n Fungal infection\\n Psoriasis\\n Scabies\\nOther causes include systemic viral infection in children (hand-foot-and-mouth diseasesee p. \\n1426\\n) or\\ncertain chemotherapies (hand-foot syndrome). Some cases are idiopathic.\\nDiagnosis can sometimes be inferred from location and appearance of the skin lesions (see\\nTable 76-3\\n).\\nTreatment of all forms of hand and foot dermatitis should be directed at the cause when possible. Topical\\ncorticosteroids or antifungals may be tried empirically. Patients should also avoid prolonged contact with\\nwater that would otherwise remove protective oils and lead to paradoxical drying of the skin.\\nDyshidrotic dermatitis:\\n Pruritic vesicles or bullae on the palms, sides of the fingers, or soles are\\ncharacteristic of this disorder. Scaling, redness, and oozing often follow vesiculation. Pompholyx is a\\nsevere form with bullae. The cause is unknown, but fungal infection, contact dermatitis, and id reactions\\nto tinea pedis can cause a similar clinical appearance and should be ruled out. Treatment includes topical\\ncorticosteroids, tacrolimus or pimecrolimus, oral antibiotics, and ultraviolet light.\\nKeratolysis exfoliativa:\\n Painless patchy peeling of the palms, soles, or both is characteristic of this\\ndisorder. The cause is unknown; treatment is unnecessary because the condition is self-resolving.\\nHyperkeratotic eczema:\\n Thick yellow-brown plaques on the palms and sometimes soles are\\ncharacteristic of this disorder. The cause is unknown. Treatment is with topical corticosteroids and\\nkeratolytics, oral psoralen plus ultraviolet A (PUVA), and retinoids.\\nId reaction:\\n The appearance of vesicles usually on the sides of the fingers in response to active\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n781'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 791, 'page_label': '782'}, page_content=\"dermatitis elsewhere is characteristic of this disorder. The cause may be an allergic reaction.\\nHousewives' eczema:\\n This irritant contact dermatitis affects people whose hands are frequently\\nimmersed in water. It is worsened by washing dishes, clothes, and babies because repeated exposure to\\neven mild detergents and water or prolonged sweating under rubber gloves may irritate dermatitic skin or\\ncause an irritant contact dermatitis.\\nHand-foot syndrome:\\n This disorder (also called acral erythema or palmar-plantar eryth-rodysesthesia)\\nrepresents cutaneous toxicity caused by certain systemic chemotherapies (eg, capecitabine, cytarabine,\\nfluorouracil, idarubicin, doxorubicin, taxanes, methotrexate, cisplatin, tegafur). Manifestations include\\npain, swelling, numbness, tingling, redness, and sometimes flaking or blistering of the palms or soles.\\nTreatment is with oral or topical corticosteroids, topical dimethylsulfoxide, oral vitamin B\\n6\\n (pyridoxine),\\nOTC analgesics (eg, acetaminophen, ibuprofen), and supportive measures (eg, cool compresses,\\nminimizing manual tasks).\\nLichen Simplex Chronicus\\n(Neurodermatitis)\\nLichen simplex chronicus is eczema caused by repeated scratching; by several mechanisms,\\nchronic scratching causes further itching, creating a vicious circle. Diagnosis is by examination.\\n[\\nTable 76-3.\\n Differential Diagnosis of Hand Dermatitis]\\nTreatment is through education and behavioral techniques to prevent scratching and\\ncorticosteroids and antihistamines.\\nEtiology\\nLichen simplex chronicus is thickening of the skin with variable scaling that arises secondary to repetitive\\nscratching or rubbing. Lichen simplex chronicus is not a primary process. Perceived pruritus in a specific\\narea of skin (with or without underlying pathology) provokes rubbing and mechanical trauma, resulting in\\nsecondary lichenification and further pruritus. Lichen simplex chronicus frequently occurs in people with\\nanxiety disorders and nonspecific emotional stress as well as in patients with any type of underlying\\nchronic dermatitis.\\nPathophysiology\\nThe underlying pathophysiology is unknown but may involve alterations in the way the nervous system\\nperceives and processes itchy sensations. Skin that tends toward eczematous conditions (eg, atopic\\ndermatitis) is more prone to lichenification.\\nSymptoms and Signs\\nLichen simplex chronicus is characterized by pruritic, dry, scaling, hyperpigmented, lichenified plaques in\\nirregular, oval, or angular shapes. It involves easily reached sites, most commonly the legs, arms, neck,\\nand upper trunk.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is by examination. A fully developed plaque has an outer zone of discrete, brownish papules\\nand a central zone of confluent papules covered with scales. Look-alike conditions include tinea corporis,\\nlichen planus, and psoriasis; lichen simplex chronicus can be distinguished from these by potassium\\nhydroxide wet mount and biopsy.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n782\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 792, 'page_label': '783'}, page_content=' Education and behavioral techniques\\n Corticosteroids (most often topical but sometimes intralesional)\\n Antihistamines\\nPrimary treatment is patient education about the effects of scratching and rubbing. Secondary treatment\\nis topical corticosteroids (eg, triamcinolone acetonide, fluocinonide); surgical tape impregnated with\\nflurandrenolide (applied in the morning and replaced in the evening) may be preferred because occlusion\\nprevents scratching. Small areas may be locally infiltrated (intralesional injections) with a long-acting\\ncorticosteroid such as triamcinolone acetonide 2.5 mg/mL (diluted with saline), 0.3 mL/cm\\n2\\n of lesion;\\ntreatment can be repeated every 3 to 4 wk. Oral H\\n1\\n-blocking antihistamines may be useful. Emollients\\nmay also be helpful.\\nNummular Dermatitis\\nNummular (discoid) dermatitis is inflammation of the skin characterized by coin-shaped or disc-\\nshaped lesions. Diagnosis is clinical. Treatment may include antibiotics, corticosteroids, and\\nultraviolet light therapy.\\nNummular dermatitis is most common among middle-aged patients and is often associated with dry skin,\\nespecially during the winter. The cause is unknown.\\nSymptoms and Signs\\nDiscoid lesions often start as patches of confluent vesicles and papules that later ooze serum and form\\ncrusts. Lesions are eruptive, widespread, and pruritic. They are often more prominent on the extensor\\naspects of the extremities and on the buttocks but also appear on the trunk. Exacerbations and\\nremissions may occur, and when they do, new lesions tend to reappear at the sites of healed lesions.\\nDiagnosis\\nDiagnosis is clinical based on the characteristic appearance and distribution of the skin lesions.\\nTreatment\\n Supportive care\\n Antibiotics\\n Corticosteroids (most often topical, but sometimes intralesional or oral)\\n Ultraviolet light therapy\\nNo treatment is uniformly effective. Oral antibiotics (eg, dicloxacillin or cephalexin 250 mg qid) may be\\ngiven, along with use of tap water compresses, especially when weeping and pus are present. Less\\ninflamed lesions may respond to tetracycline 250 mg po qid, which has a beneficial (although not\\nnecessarily antibacterial) effect. Corticosteroid cream or ointment should be rubbed in 3 times daily. An\\nocclusive dressing with a corticosteroid cream under polyethylene film or with flurandrenolide-\\nimpregnated \\ntape can be applied at bedtime. Intralesional corticosteroid injections may be beneficial for\\nthe few lesions that do not respond to therapy. In more widespread, resistant, and recurrent cases,\\nultraviolet B radiation alone or oral psoralen plus ultraviolet A (PUVA) radiation may be helpful.\\nOccasionally, oral corticosteroids are required, but long-term use should be avoided; a reasonable\\nstarting dose is prednisone 40 mg every other day.\\nSeborrheic Dermatitis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n783'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 793, 'page_label': '784'}, page_content=\"Seborrheic dermatitis (SD) is inflammation of skin that has a high density of sebaceous glands\\n(eg, face, scalp, upper trunk). The cause is unknown, but \\nPityrosporum ovale\\n, a normal skin\\norganism, plays some role. SD occurs with increased frequency in patients with HIV and in\\nthose with certain neurologic disorders. SD causes occasional pruritus, dandruff, and yellow,\\ngreasy scaling along the hairline and on the face. Diagnosis is made by examination. Treatment\\nis tar or other medicated shampoo and topical corticosteroids and antifungals.\\nDespite the name, the composition and flow of sebum are usually normal. The pathogenesis of SD is\\nunclear, but its activity has been linked to the number of \\nPityrosporum\\n yeasts present on the skin. The\\nincidence and severity of disease seem to be affected by genetic factors, emotional or physical stress,\\nand climate (usually worse in cold weather). SD may precede or be associated with psoriasis (called\\nseborrhiasis). SD may be more common and more severe among patients with neurologic disorders\\n(especially Parkinson's disease) or HIV/AIDS. Very rarely, the dermatitis becomes generalized.\\nSymptoms and Signs\\nSymptoms develop gradually, and the dermatitis is usually apparent only as dry or greasy diffuse scaling\\nof the scalp (dandruff) with variable pruritus. In severe disease, yellow-red scaling papules appear along\\nthe hairline, behind the ears, in the external auditory canals, on the eyebrows, in the axillae, on the bridge\\nof the nose, in the nasolabial folds, and over the sternum. Marginal blepharitis with dry yellow crusts and\\nconjunctival irritation may develop. SD does not cause hair loss.\\nNeonates may develop SD with a thick, yellow, crusted scalp lesion (cradle cap); fissuring and yellow\\nscaling behind the ears; red facial papules; and stubborn diaper rash. Older children may develop thick,\\ntenacious, scaly plaques on the scalp that may measure 1 to 2 cm in diameter.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is made by physical examination. SD may occasionally be difficult to distinguish from other\\ndisorders, including psoriasis, atopic dermatitis or contact dermatitis, tinea, and rosacea.\\nTreatment\\n Topical therapy\\nAdults:\\n In adults, zinc pyrithione, selenium sulfide, sulfur and salicylic acid, or tar shampoo should be\\nused daily or every other day until dandruff is controlled and twice/wk thereafter. A corticosteroid lotion\\n(eg, 0.01% fluocinolone acetonide solution, 0.025% triamcinolone acetonide lotion) can be rubbed into\\nthe scalp or other hairy areas twice daily until scaling and redness are controlled. For SD of the\\npostauricular areas, nasolabial folds, eyelid margins, and bridge of the nose, 1% hydrocortisone cream is\\nrubbed in 2 or 3 times daily, decreasing to once/day when SD is controlled; hydrocortisone cream is the\\nsafest corticosteroid for the face because fluorinated corticosteroids may cause adverse effects (eg,\\ntelangiectasia, atrophy, perioral dermatitis). In some patients, 2% ketoconazole cream or other topical\\nimidazoles applied twice daily for 1 to 2 wk induce a remission that lasts for months. For eyelid margin\\nseborrhea, a dilution of 1 part baby shampoo to 9 parts water is applied with a cotton swab.\\nInfants and children:\\n In infants, a baby shampoo is used daily, and 1% hydrocortisone cream is rubbed\\nin twice daily. For thick lesions on the scalp of a young child, 2% salicylic acid in olive oil or a\\ncorticosteroid gel is applied at bedtime to affected areas and rubbed in with a toothbrush. The scalp is\\nshampooed daily until the thick scale is gone.\\nStasis Dermatitis\\nStasis dermatitis is inflammation of the skin of the lower legs caused by chronic venous\\ninsufficiency. Symptoms are itching, scaling, hyperpigmentation, and sometimes ulceration.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n784\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 794, 'page_label': '785'}, page_content=\"Diagnosis is clinical. Treatment is directed at the chronic venous insufficiency and preventing\\noccurrence or progression of associated ulcers.\\nStasis dermatitis occurs in patients with chronic venous insufficiency (see p. \\n2231\\n) because pooled\\nvenous blood in the legs compromises the endothelial integrity in the microvasculature, resulting in fibrin\\nleakage, local inflammation, and local cell necrosis.\\nSymptoms and Signs\\nInitially, hyperpigmentation and red-brown discoloration from RBC extravasation appear. Later,\\neczematous changes develop and manifest as erythema, scaling, weeping, and crusting (see\\nPlate 46\\n), all of which can be made worse by bacterial superinfection or by contact dermatitis caused by\\nthe many topical treatments often applied. When chronic venous insufficiency and stasis dermatitis are\\nboth inadequately treated, stasis dermatitis progresses to frank skin ulceration (see\\nPlate 47\\n), chronic edema, thickened fibrotic skin, or lipodermatosclerosis (a painful induration resulting\\nfrom panniculitis, which, if severe, gives the lower leg an inverted bowling pin shape with enlargement of\\nthe calf and narrowing at the ankle).\\nDiagnosis\\nDiagnosis is clinical based on the characteristic appearance of the skin lesions and other signs of chronic\\nvenous insufficiency.\\nTreatment\\n Elevation, compression, and dressings\\n Sometimes topical or oral antibiotics\\nChronic venous insufficiency must be adequately treated with leg elevation and compression stockings\\n(see p. \\n2232\\n). For acute stasis dermatitis (characterized by crusts, exudation, and superficial ulceration),\\ncontinuous and then intermittent tap water compresses should be applied. For a weeping lesion, a\\nhydrocolloid dressing may be best. For less acute dermatitis, a corticosteroid cream or ointment should be\\napplied 3 times/day or incorporated into zinc oxide paste.\\nUlcers are best treated with compresses and bland dressings (eg, zinc oxide paste); other dressings (eg,\\nhydrocolloids) are also effective (see also p.\\n740\\n). Ulcers in ambulatory patients may be healed with Unna's paste boot (zinc gelatin), the less messy\\nzinc gelatin bandage, or a colloid dressing (all are available commercially). Colloid-type dressings used\\nunder elastic support are more effective than Unna's paste boot. It may be necessary to change the\\ndressing every 2 or 3 days, but as edema recedes and the ulcer heals, once or twice/wk is sufficient. After\\nthe ulcer heals, an elastic support should be applied before the patient rises in the morning. Regardless\\nof the dressing used, reduction of edema (usually with compression) is paramount for healing.\\nOral antibiotics (eg, cephalosporins, dicloxacillin) are used to treat superimposed cellulitis. Topical\\nantibiotics (eg, mupirocin, silver sulfadiazine) are useful for treating erosions and ulcers. When edema\\nand inflammation subside, split-thickness skin grafts may be needed for large ulcers.\\nComplex or multiple topical drugs or OTC remedies should not be used. The skin in stasis dermatitis is\\nmore vulnerable to direct irritants and to potentially sensitizing topical agents (eg, antibiotics; anesthetics;\\nvehicles of topical drugs, especially lanolin or wool alcohols).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 76. Dermatitis\\n785\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 795, 'page_label': '786'}, page_content='Chapter 77. Reactions to Sunlight\\nIntroduction\\nThe skin may respond to excessive sunlight in several ways: various chronic changes (eg,\\ndermatoheliosis, actinic keratoses), photosensitivity, or sunburn.\\nUltraviolet (UV) radiation:\\n Although the sun emits a wide range of UV electromagnetic radiation (ie,\\nUVA, 320 to 400 nm; UVB, 280 to 320 nm; UVC, 100 to 280 nm), only UVA and UVB reach the earth\\'s\\nsurface. The character and amount of such radiation vary greatly with the seasons and with changing\\natmospheric conditions. Exposure of skin to sunlight depends on multiple lifestyle factors, (eg, clothing,\\noccupation), geographic factors (eg, altitude, latitude), and time of year (UV intensity is higher in\\nsummer).\\nSunburn-producing rays (primarily wavelengths < 320 nm) are filtered out by glass and to a great extent\\nby smoke and smog. Sunburn-producing rays may pass through light clouds, fog, or 30 cm of clear water,\\ncausing severe burns in unsuspecting people. Snow, sand, and water enhance exposure by reflecting the\\nrays. Stratospheric ozone, which filters out shorter wavelengths of UV, is depleted by man-made\\nchlorofluorocarbons (eg, in refrigerants \\nand aerosols). A decreased ozone layer increases inadvertent\\nexposure to UVA and UVB.\\nSun-tanning lamps use artificial light that is more UVA than UVB. This UVA use is often advertised as a\\n\"safer\" way to tan; however, many of the same long-term deleterious effects may occur as with UVB\\nexposure, including photoaging and skin cancer. Quite simply, there is no \"safe tan.\"\\nPathophysiology\\nAfter exposure to sunlight, the epidermis thickens, and melanocytes produce the pigment melanin at an\\nincreased rate, causing tanning. Tanning provides some natural protection against future exposure.\\nExposure leads to both inactivation and loss of epidermal Langerhans\\' cells, which are immunologically\\nimportant.\\nPeople differ greatly in their sensitivity and response to sunlight based on the amount of melanin in their\\nskin. Skin is classified into 6 types (I to VI) in decreasing order of susceptibility to sun injury. Classification\\nis based on skin color, UV sensitivity, and response to sun exposure. Skin type I is white to lightly\\npigmented, very sensitive to UV light, has no immediate pigment darkening, always burns easily, and\\nnever tans. Skin type VI is dark brown or black, least sensitive to UV light, has significant immediate\\npigment darkening, and tans profusely (deep black). Dark-skinned people are not immune to the effects\\nof the sun and can become sunburned with strong or prolonged exposure. Long-term effects of UV\\nexposure in dark-skinned people are the same as those in light-skinned people but are often delayed and\\nless severe. People with blonde or red hair are especially susceptible to the acute and chronic effects of\\nUV radiation. Uneven melanocyte activation occurs in many fair-haired people and results in freckling.\\nThere is no skin pigmentation in people with albinism (see p. \\n719\\n) because of a defect in melanin\\nmetabolism. Patchy areas of depigmentation are present in patients with vitiligo (see p. \\n720\\n) because of\\nimmunologic destruction of melanocytes.\\nPrevention\\nAvoidance:\\n Simple precautions help prevent sunburn and the chronic effects of sunlight. These\\nprecautions are recommended for people of all skin types, particularly those who are fair skinned and\\nburn easily. Exposure to bright midday sun should not be > 30 min, even for people with dark skin. In\\ntemperate zones, exposure is less hazardous before 10 AM and after 3 PM because more sunburn-\\nproducing wavelengths are filtered out. Fog and clouds do not reduce risk, and risk is increased at high\\naltitude.\\nClothing:\\n Skin should be covered. Fabrics with a tight weave block the sun better than do those with a\\nloose weave. Special clothing that provides high sun protection is commercially available. Broad-brimmed\\nhats protect the face, ears, and neck. Regular use of UV-protective, wrap-around sunglasses helps shield\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 77. Reactions to Sunlight\\n786'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 796, 'page_label': '787'}, page_content='the eyes.\\nSunscreens:\\n Although sunscreens help protect the skin from sunburn and chronic sun damage, they do\\nnot always prevent damage. Older sunscreens tended to filter only UVB light, but many newer\\nsunscreens are now \"full spectrum\" and effectively filter UVA light as well. In the US, the FDA rates\\nsunscreens by sun protection factor (SPF): the higher the number, the greater the protection. Agents with\\nSPF  15 are recommended. The SPF, however, only quantifies the protection against UVB exposure;\\nthere is no scale for UVA protection.\\nSunscreens are available in a wide variety of formulations, including creams, gels, foams, sprays, and\\nsticks. Self-tanning products do not provide significant protection from UV exposure.\\nMost sunscreens contain several agents that function as chemical screens, absorbing light or providing a\\nphysical screen that reflects or scatters light. Common chemical sunscreen agents mostly absorb UVB\\nrays and include the aminobenzoates, which include \\np\\n-aminobenzoic acid (PABA), salicylates,\\ncinnamates, benzophenones (eg, avobenzone), and the anthrilates (an aminobenzoate derivative). Of\\nthese, the benzophenones are particularly effective at screening UVA rays.\\nOther sunscreens, called sunblocks, contain zinc oxide and titanium dioxide, which physically block both\\nUVB and UVA rays. Micronized formulations of these products have significantly improved their cosmetic\\nacceptability.\\nSunscreen failure is common and usually results from insufficient application of the product, application\\ntoo late (sunscreens should optimally be applied 30 min before exposure), or failure to reapply after\\nswimming or exercise.\\nAllergic or photoallergic reactions to sunscreens must be distinguished from other photosensitive skin\\neruptions. Patch or photopatch testing with sunscreen components may be necessary to make the\\ndiagnosis. This testing is usually done by dermatologists with a particular expertise in allergic contact\\ndermatitis.\\nChronic Effects of Sunlight\\nAging:\\n Chronic exposure to sunlight ages the skin (dermatoheliosis, extrinsic aging), producing both fine\\nand coarse wrinkles, rough leathery texture, mottled pigmentation, and telangiectasia. The atrophic\\neffects in some people may resemble those seen after x-ray therapy (chronic radiation dermatitis).\\nActinic keratoses:\\n Actinic keratoses are precancerous changes in skin cells (keratinocytes) that are a\\nfrequent, disturbing consequence of many years of sun exposure. People with blonde or red hair, blue\\neyes, and skin type I or II are particularly susceptible.\\nThe keratoses are usually pink or red, poorly marginated, and scaly on palpation, although some are light\\ngray or pigmented, giving them a brown appearance. They should be differentiated from seborrheic\\nkeratoses (see p. \\n746\\n), which increase in number and size with aging. Seborrheic keratoses tend to\\nappear waxy and stuck-on but can often take on an appearance similar to actinic keratoses. Close\\ninspection usually reveals distinguishing characteristics of the lesion. Unlike actinic keratoses, seborrheic\\nkeratoses also occur on non-sun-exposed areas of the body and are not premalignant.\\nSkin cancers\\n (see p. \\n748\\n)\\n:\\n The incidence of squamous cell carcinoma and basal cell carcinoma in fair,\\nlight-skinned people is directly proportional to the total annual sunlight in the area. Such lesions are\\nespecially common among people who were extensively exposed to sunlight as children and adolescents\\nand among those who are chronically exposed to the sun as part of their profession or recreational\\nactivities (eg, athletes, farmers, ranchers, sailors, frequent sunbathers). Sun exposure also substantially\\nincreases the risk of malignant melanomas.\\nTreatment\\nVarious combination therapies, including chemical peels, 5-fluorouracil (5-FU), topical \\n\\n-hydroxy acids,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 77. Reactions to Sunlight\\n787'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 797, 'page_label': '788'}, page_content='imiquimod, photodynamic therapy, and tretinoin, have been used to reduce carcinogenic changes and\\nimprove the cosmetic appearance of chronically sun-damaged skin. These therapies are often effective in\\nameliorating superficial skin changes (eg, coarse and fine wrinkles, irregular pigmentation, sallowness,\\nroughness, minor laxity) but have a much less pronounced effect on deeper changes (eg,\\ntelangiectasias). Lasers are capable of treating both superficial and deep changes in the dermis and are\\nused to treat cosmetic and precancerous skin changes. Many chemicals are used in OTC cosmetic\\nproducts without significant evidence that they improve chronic changes of the skin caused by sunlight.\\nActinic keratoses:\\n There are several options, depending on the number and location of lesions.\\n Liquid nitrogen\\n Topical 5-FU\\n Topical imiquimod\\nIf only a few actinic keratoses are present, cryotherapy (freezing with liquid nitrogen) is the most rapid\\nand satisfactory treatment.\\nIf there are too many lesions to freeze, topical 5-FU applied to the affected area nightly or twice daily for 2\\nto 6 wk often clears the majority of lesions. Several strengths and formulations of 5-FU are commercially\\navailable. Many patients tolerate 0.5% 5-FU cream applied once/day for 4 wk on the face better than\\nstronger concentrations. Actinic keratoses on the arms may require stronger concentrations, such as 5%\\ncream. Topical 5-FU produces a brisk reaction, with redness, scaling, and burning, often affecting areas\\nwith no visible actinic keratoses. If the reaction is too brisk, application may be suspended for 1 to 3 days.\\nTopical 5-FU has few significant adverse effects except for this unsightly and uncomfortable reaction,\\nwhich can be masked by cosmetics and, when necessary, suppressed with topical corticosteroids. 5-FU\\nshould not be used to treat basal cell carcinomas, except those shown by biopsy to be of the superficial\\ntype.\\nA relatively new drug, imiquimod, is often used for treatment of actinic keratoses and superficial basal cell\\ncarcinomas. It stimulates the immune system to recognize and destroy cancerous skin lesions. For\\ntreatment of skin cancers, see \\nCh. 90\\n.\\nPhotosensitivity\\nPhotosensitivity is a poorly understood cutaneous reaction to sunlight probably involving the\\nimmune system. It may be idiopathic or occur after exposure to certain drugs or chemicals, and\\nit is sometimes a feature of systemic disorders (eg, SLE, porphyria, pellagra, xeroderma\\npigmentosum). Diagnosis is clinical. Treatment varies by type.\\nIn addition to the acute and chronic effects of sunlight, a variety of unusual reactions may \\noccur soon\\nafter only a brief sun exposure. Unless the cause is obvious, patients with pronounced photosensitivity\\nshould be evaluated for systemic or cutaneous disorders associated with light sensitivity such as SLE\\n(see p. \\n305\\n) and porphyria (see p. \\n807\\n). Treatment for chemical photosensitivity is topical corticosteroids\\nand avoidance of the causative substance.\\nSolar urticaria:\\n In certain patients, urticaria develops at a site of sun exposure within a few minutes.\\nRarely, if large areas are involved, syncope, dizziness, wheezing, and other systemic symptoms may\\ndevelop. Etiology is unclear but may involve endogenous skin constituents functioning as photoallergens,\\nleading to mast cell degranulation as in other types of urticaria. Solar urticaria can be distinguished from\\nother types of urticaria in that wheals in solar urticaria occur only on exposed skin after ultraviolet (UV)\\nlight exposure. Solar urticaria can be classified based on the component of the UV spectrum (UVA, UVB,\\nand visible light) that produces them. Treatment can be difficult and may include H\\n1\\n blockers, antimalarial\\ndrugs, topical corticosteroids, sunscreens, and psoralen UV light (PUVA). The wheals of solar urticaria\\nusually last just minutes to hours, but the disorder is chronic and can wax and wane over years.\\nChemical photosensitivity:\\n Over 100 substances, ingested or applied topically, are known to\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 77. Reactions to Sunlight\\n788'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 798, 'page_label': '789'}, page_content='predispose to cutaneous reactions following sun exposure. A limited number are responsible for most\\nreactions (see\\nTable 77-1\\n). Reactions are divided into phototoxicity and photoallergy.\\nIn \\nphototoxicity\\n, light-absorbing compounds directly generate free radicals and inflammatory mediators,\\ncausing tissue damage manifesting as pain and erythema (like sunburn). This reaction does not require\\nprior sun exposure and can appear in any person, although reaction is highly variable. Typical causes of\\nphototoxic reactions include topical (eg, perfumes, coal tar) or ingested (eg, tetracyclines, psoralen-\\ncontaining plants) agents. Phototoxic reactions do not generalize to non-sun-exposed skin.\\nPhotoallergy\\n is a type IV (cell-mediated) immune response; light absorption causes structural changes in\\nthe drug or substance, allowing it to bind to tissue protein and function as a hapten. Prior exposure is\\nrequired. Typical causes of photoallergic reactions include aftershave lotions, sunscreens, and\\nsulfonamides. Reaction may extend to non-sun-exposed skin. Symptoms include erythema, pruritus, and\\nsometimes vesicles.\\n[\\nTable 77-1.\\n Some Substances that Sensitize the Skin to Sunlight]\\nPolymorphous light eruption:\\n These eruptions are unusual reactions to light that do not seem to be\\nassociated with systemic disease or drugs. Eruptions appear on sun-exposed areas, usually 30 min to\\nseveral hours after exposure. Lesions are pruritic, erythematous, and often papular but may be\\npapulovesicular or plaquelike. They are most common among women and people from northern climates\\nwhen first exposed to spring or summer sun than among those exposed to sun year-round. Lesions\\nsubside within several days to 1 wk or so. Actinic prurigo is a similar (perhaps related) phenomenon with\\nmore nodular-appearing lesions that may persist year-round, worsening with sun exposure.\\nDiagnosis is made by history, skin findings, and exclusion of other sun-sensitivity disorders. Diagnosis\\nsometimes requires reproduction of the lesions with artificial or natural \\nsunlight when the patient is not\\nusing any potentially sensitizing drugs.\\nOften, lesions are self-limited and spontaneously improve as summer progresses. Treatment is by\\nmoderating sun exposure and applying topical corticosteroids. More severely affected patients may\\nbenefit from desensitization by graduated exposure to UV light with PUVA (see p. \\n679\\n) or narrow band\\nUVB (312 nm) phototherapy. Patients with disabling disease may require a course of oral\\nimmunosuppressive therapy such as prednisone, azathioprine, cyclosporine, or hydroxychloroquine.\\nSunburn\\nSunburn is characterized by erythema and sometimes pain and blisters caused by exposure to\\nsolar ultraviolet radiation. Treatment is similar to that for thermal burns, including cool\\ncompresses, NSAIDs, and, for severe cases, sterile dressings and topical antimicrobials.\\nPrevention by sun avoidance and use of sunscreens is crucial.\\nSunburn results from overexposure of the skin to ultraviolet (UV) radiation; wavelengths in the UVB\\nspectrum (280 to 320 nm) cause the most pronounced effects.\\nSymptoms and Signs\\nSymptoms and signs appear in 1 to 24 h and, except in severe reactions, peak within 72 h. Skin changes\\nrange from mild erythema, with subsequent superficial scaling, to pain, swelling, skin tenderness, and\\nblisters. Constitutional symptoms (eg, fever, chills, weakness, shock), similar to a thermal burn, may\\ndevelop if a large portion of the body surface is affected; these symptoms may be caused by the release\\nof inflammatory cytokines such as IL-1.\\nSecondary infection, blotchy pigmentation, and miliaria-like eruptions are the most common late\\ncomplications. Exfoliated skin may be extremely vulnerable to sunlight for several weeks.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 77. Reactions to Sunlight\\n789'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 799, 'page_label': '790'}, page_content=' Supportive measures\\nFurther exposure should be avoided until sunburn has completely subsided. Cold tap water compresses\\nand oral NSAIDs help relieve symptoms, as may topical aloe vera. Topical corticosteroids are no more\\neffective than cool compresses. Blistered areas should be managed similarly to other partial-thickness\\nburns (see p. \\n3246\\n), with sterile dressings and topical bacitracin or silver sulfadiazine. Ointments or\\nlotions containing local anesthetics (eg, benzocaine) should be avoided because of the risk of allergic\\ncontact dermatitis.\\nEarly treatment of extensive, severe sunburn with a systemic corticosteroid (eg, prednisone 20 to 30 mg\\npo bid for 4 days for adults or teenagers) may decrease the discomfort, but this use is controversial.\\nPrevention\\nSimple precautions (eg, avoiding the sun especially during midday, wearing tightly woven clothing, using\\nsunscreens) usually prevent most cases of sunburn (see p. \\n673\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 77. Reactions to Sunlight\\n790'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 800, 'page_label': '791'}, page_content='Chapter 78. Psoriasis and Scaling Diseases\\nIntroduction\\nPsoriasis, parapsoriasis, pityriasis rosea, pityriasis rubra pilaris, pityriasis lichenoides, lichen planus, and\\nlichen sclerosus are dissimilar disorders grouped together because their primary lesions have similar\\ncharacteristics: sharply marginated, scaling papules or plaques without wetness, crusts, fissures, and\\nexcoriations. Lesion appearance and distribution distinguish these diseases from each other.\\nPsoriasis\\nPsoriasis is an inflammatory disease that manifests most commonly as well-circumscribed,\\nerythematous papules and plaques covered with silvery scales. Cause is unclear but seems to\\ninvolve the immune system. Common triggers include trauma, infection, and certain drugs.\\nSymptoms are usually minimal with occasional mild itching, but cosmetic implications may be\\nmajor. Some people develop severe disease with painful arthritis. Diagnosis is based on\\nappearance and distribution of lesions. Treatment is with emollients, vitamin D analogs,\\nretinoids, tar, anthralin, corticosteroids, phototherapy, and, when severe, methotrexate,\\nretinoids, immunomodulatory agents (biologics), or immunosuppressants.\\nPsoriasis is hyperproliferation of epidermal keratinocytes combined with inflammation of the epidermis\\nand dermis. It affects about 1 \\nto 5% of the population worldwide; light-skinned people are at greater risk.\\nPeak onset is roughly bimodal, most often at ages 16 to 22 and at ages 57 to 60, but the disorder can\\noccur at any age.\\nEtiology\\nThe cause is unclear but involves immune stimulation of epidermal keratinocytes; T cells seem to play a\\ncentral role. Family history is common, and certain genes and HLA antigens (Cw6, B13, B17) are\\nassociated with psoriasis. An environmental trigger is thought to evoke an inflammatory response and\\nsubsequent hyperproliferation of keratinocytes.\\nWell-identified triggers include\\n Injury (Koebner phenomenon)\\n Sunburn\\n HIV\\n \\n\\n-Hemolytic streptococcal infection\\n Drugs (especially \\n\\n-blockers, chloroquine, lithium, ACE inhibitors, indomethacin, terbinafine, and\\ninterferon alfa)\\n Emotional stress\\n Alcohol consumption\\nSymptoms and Signs\\nLesions are either asymptomatic or pruritic and are most often localized on the scalp, extensor surfaces of\\nthe elbows and knees, sacrum, buttocks, and penis. The nails, eyebrows, axillae, umbilicus, and perianal\\nregion may also be affected. The disease can be widespread, involving confluent areas of skin extending\\nbetween these regions. Lesions differ in appearance depending on type.\\nAmong the various subtypes (see\\nTable 78-1\\n), plaque psoriasis (psoriasis vulgaris or chronic plaque psoriasis) is the most common pattern;\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 78. Psoriasis & Scaling Diseases\\n791'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 801, 'page_label': '792'}, page_content=\"lesions are discrete, erythematous papules or plaques covered with thick, silvery, shiny scales. Lesions\\nappear gradually and remit and recur either spontaneously or with appearance and resolution of triggers.\\nArthritis develops in 5 to 30% of patients and can be disabling (see p. \\n344\\n); joint destruction may\\nultimately occur.\\nPsoriasis is rarely life-threatening but can affect a patient's self-image. Besides image, the sheer amount\\nof time required to treat extensive skin or scalp lesions and to maintain clothing and bedding may\\nadversely affect quality of life.\\nDiagnosis\\n Clinical evaluation\\n Rarely biopsy\\nDiagnosis is most often by clinical appearance and distribution of lesions. Differential diagnosis includes\\nseborrheic dermatitis, dermatophytoses, cutaneous lupus erythematosus, eczema, lichen planus,\\npityriasis rosea, squamous cell carcinoma in situ (Bowen's disease, especially when on the trunk), lichen\\nsimplex chronicus, and secondary syphilis. Biopsy is rarely necessary and may not be diagnostic.\\nDisease is graded as mild, moderate, or severe based on the body surface area affected and how the\\nlesions affect patients' quality of life. There are many more complex scoring systems for disease severity\\n(eg, the Psoriasis Area and Severity Index), but these systems are useful mainly in research protocols.\\nTreatment\\n Topical treatments\\n Systemic treatments\\n Ultraviolet (UV) light therapy\\nTreatment options are extensive and include emollients, salicylic acid, coal tar, anthralin, corticosteroids,\\nvitamin D\\n3\\n analogs, methotrexate, topical and oral retinoids, topical and oral calcineurin inhibitors,\\nimmunosuppressants, immunomodulatory agents (biologics), and ultraviolet light therapy.\\nTopical treatments: Emollients\\n include emollient creams, ointments, petrolatum, paraffin, and even\\nhydrogenated vegetable (cooking) oils. They reduce scaling and are most effective when applied twice\\ndaily and immediately after bathing. Lesions may appear redder as scaling decreases or becomes more\\ntransparent. Emollients are safe and should probably always be used for mild to moderate plaque\\npsoriasis.\\nSalicylic acid\\n is a keratinolytic that softens scales, facilitates their removal, and increases absorption of\\nother topical agents. It is especially useful as a component of scalp treatments; scalp scale can be quite\\nthick.\\nCoal tar\\n ointments, solutions, or shampoos are anti-inflammatory and decrease keratinocyte\\nhyperproliferation via an unknown mechanism. They are typically applied at night and washed off in the\\nmorning. They can be used in combination with topical corticosteroids or with exposure to natural or\\nartificial broad-band UVB light (280 to 320 nm) in slowly increasing increments (Goeckerman regimen).\\nAnthralin\\n is a topical antiproliferative, anti-inflammatory agent. Its mechanism is unknown. Effective dose\\nis 0.1% cream or ointment increased to 1% as tolerated. Anthralin may be irritating and should be used\\nwith caution in intertriginous areas; it also stains. Irritation and staining can be avoided\\n[\\nTable 78-1.\\n Subtypes of Psoriasis]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 78. Psoriasis & Scaling Diseases\\n792\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 802, 'page_label': '793'}, page_content='by washing off the anthralin 20 to 30 min after application. Using a liposome-encapsulated preparation\\nmay also avoid some disadvantages of anthralin.\\nCorticosteroids\\n are usually used topically but may be injected into small or recalcitrant lesions.\\n(CAUTION: \\nSystemic corticosteroids may precipitate exacerbations or development of pustular\\npsoriasis and should not be used to treat psoriasis\\n.) Topical corticosteroids are used twice daily,\\nsometimes with anthralin or coal tar applied at bedtime. Corticosteroids are most effective when used\\novernight under occlusive polyethylene coverings or incorporated into tape; a corticosteroid cream is\\napplied without occlusion during the day. Corticosteroid \\npotency (see p. \\n647\\n) is selected according to the\\nextent of involvement. As lesions abate, the corticosteroid should be applied less frequently or at a lower\\npotency to minimize local atrophy, striae formation, and telangiectases. Ideally, after about 3 wk, an\\nemollient should be substituted for the corticosteroid for 1 to 2 wk (as a rest period); this substitution limits\\ncorticosteroid dosage and prevents tachyphylaxis. Topical corticosteroid use can be expensive because\\nlarge quantities (about 1 oz or 30 g) are needed for each application when a large body surface area is\\naffected. Topical corticosteroids applied for long duration to large areas of the body may cause systemic\\neffects and exacerbate psoriasis. For small, thick, localized, or recalcitrant lesions, high-potency\\ncorticosteroids are used with an occlusive dressing or flurandrenolide tape; these dressings are left on\\novernight and changed in the morning. Relapse after topical corticosteroids are stopped is often faster\\nthan with other agents.\\nVitamin D\\n3\\n analogs\\n (eg, calcipotriol, calcitriol) are topical vitamin D analogs that induce normal\\nkeratinocyte proliferation and differentiation; they can be used alone or in combination with topical\\ncorticosteroids. Some clinicians have patients apply calcipotriol on weekdays and corticosteroids on\\nweekends.\\nCalcineurin inhibitors\\n (eg, tacrolimus, pimecrolimus) are available in topical form and are generally well-\\ntolerated. They are not as effective as corticosteroids but may avoid the complications of corticosteroids\\nwhen treating facial and intertriginous psoriasis. They may be associated with an increased risk of\\nlymphoma and skin cancer.\\nTazarotene\\n is a topical retinoid. It is less effective than corticosteroids as monotherapy but is a useful\\nadjunct.\\nSystemic treatments: Methotrexate\\n taken orally is the most effective treatment for severe disabling\\npsoriasis, especially severe psoriatic arthritis or widespread erythrodermic or pustular psoriasis\\nunresponsive to topical agents or psoralen plus ultraviolet A (PUVA) light therapy. Methotrexate seems to\\ninterfere with the rapid proliferation of epidermal cells. Hematologic, renal, and hepatic function should be\\nmonitored. Dosage regimens vary, so only physicians experienced in its use for psoriasis should\\nundertake methotrexate therapy.\\nSystemic retinoids\\n (eg, acitretin, isotretinoin) may be effective for severe and recalcitrant cases of\\npsoriasis vulgaris, pustular psoriasis (in which isotretinoin may be preferred), and hyperkeratotic\\npalmoplantar psoriasis. Because of the teratogenic potential and long-term retention of acitretin in the\\nbody, women who use it must not be pregnant and should be warned against becoming pregnant for at\\nleast 2 yr after treatment ends. Pregnancy restrictions also apply to isotretinoin, but the agent is not\\nretained in the body beyond 1 mo. Long-term treatment may cause diffuse idiopathic skeletal hyperostosis\\n(DISHsee p. \\n342\\n).\\nImmunosuppressants\\n can be used for severe psoriasis. Cyclosporine is a commonly used\\nimmunosuppressant. It should be limited to courses of several months (rarely, up to 1 yr) and alternated\\nwith other therapies. Its effect on the kidneys and potential long-term effects on the immune system\\npreclude more liberal use. Other immunosuppressants (eg, hydroxyurea, 6-thioguanine, mycophenolate\\nmofetil) have narrow safety margins and are reserved for severe, recalcitrant psoriasis.\\nImmunomodulatory agents\\n (biologicssee p.\\n1086\\n) include tumor necrosis factor (TNF)-\\n\\n inhibitors (etanercept, adalimumab, infliximab) and the T-cell\\nmodulator alefacept. TNF-\\n\\n inhibitors lead to clearing of psoriasis, but their safety profile is still under\\nstudy. Efalizumab is no longer available in the US due to increased risk of progressive multifocal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 78. Psoriasis & Scaling Diseases\\n793'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 803, 'page_label': '794'}, page_content='leukoencephalopathy.\\nPhototherapy: UV light therapy\\n is typically used in patients with extensive psoriasis. The mechanism\\nof action is unknown, although UVB light reduces DNA synthesis and can induce mild systemic\\nimmunosuppression. In PUVA, oral methoxypsoralen, a photosensitizer, is followed by exposure to long-\\nwave UVA light (330 to 360 nm). PUVA has an antiproliferative effect and also helps to normalize\\nkeratinocyte differentiation. Doses of light are started low and increased as tolerated. Severe burns can\\nresult if the dose of drug or UVA is too high. Although the treatment is less messy than topical treatment\\nand may produce remissions lasting several months, repeated treatments may increase the incidence of\\nUV-induced skin cancer and melanoma. Less UV light is required when used with oral retinoids (the so-\\ncalled re-PUVA regimen). Narrow-band UVB light (311 to 312 nm) used without psoralens is similar in\\neffectiveness to PUVA. Excimer laser therapy is a type of phototherapy using extremely pure\\nwavelengths.\\nChoice of therapy:\\n Choice of specific agents and combinations requires close cooperation with the\\npatient, always keeping in mind the untoward effects of the treatments. There is no single ideal\\ncombination or sequence of \\nagents, but treatment should be kept as simple as possible. Monotherapy is\\npreferred, but combination therapy is the norm. Rotational therapy refers to the substitution of one\\ntherapy for another after 1 to 2 yr to reduce the adverse effects caused by chronic use and to circumvent\\ndisease resistance. Sequential therapy refers to initial use of potent agents (eg, cyclosporine) to quickly\\ngain control followed by use of agents with a better safety profile.\\nMild plaque psoriasis\\n can be treated with emollients, keratolytics, tar, topical corticosteroids, vitamin D\\n3\\nanalogs, or anthralin alone or in combination. Exposure to sunlight is beneficial, but sunburn can induce\\nexacerbations.\\nModerate to severe plaque psoriasis\\n should be treated with topical agents and either phototherapy or\\nsystemic agents. Immunosuppressants are used for quick, short-term control (eg, in allowing a break from\\nother modalities) and for the most severe disease. Immunomodulatory agents (biologics) are used for\\nmoderate to severe disease unresponsive to other agents.\\nScalp plaques\\n are notoriously difficult to treat because they resist systemic therapy, and because hair\\nblocks application of topical agents and scale removal and shields skin from UV light. A suspension of\\n10% salicylic acid in mineral oil may be rubbed into the scalp at bedtime manually or with a toothbrush,\\ncovered with a shower cap (to enhance penetration and avoid messiness), and washed out the next\\nmorning with a tar (or other) shampoo. More cosmetically acceptable corticosteroid solutions can be\\napplied to the scalp during the day. These treatments are continued until the desired clinical response is\\nachieved. Resistant skin or scalp patches may respond to local superficial intralesional injection of\\ntriamcinolone acetonide suspension diluted with saline to 2.5 or 5 mg/mL, depending on the size and\\nseverity of the lesion. Injections may cause local atrophy, which is usually reversible.\\nSpecial treatment needs for subtypes are described in \\nTable 78-1\\n.\\nFor psoriatic arthritis, treatment with systemic therapy is important to prevent joint destruction;\\nmethotrexate or a TNF-\\n\\n inhibitor may be effective.\\nParapsoriasis\\nParapsoriasis describes a poorly understood and poorly distinguished group of diseases that share\\nclinical features. There are 2 general forms: a small-plaque type, which is usually benign, and a large-\\nplaque type, which is a precursor of cutaneous T-cell lymphoma (CTCL). It is extremely rare for small-\\nplaque parapsoriasis to transform into CTCL.\\nThe plaques are usually asymptomatic; their typical appearance is thin, scaling, dull pink patches and\\nplaques with a slightly atrophic or wrinkled appearance. Small-plaque parapsoriasis is defined by lesions\\n< 5 cm in diameter, whereas large-plaque parapsoriasis has lesions > 6 cm in diameter. Sometimes\\ndigitate plaques develop along the dermatomes, especially on the flanks and abdomen, in small-plaque\\nparapsoriasis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 78. Psoriasis & Scaling Diseases\\n794'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 804, 'page_label': '795'}, page_content='Treatment of small-plaque parapsoriasis is unnecessary but can include emollients, topical tar\\npreparations or corticosteroids, phototherapy, or a combination. Treatment of large-plaque parapsoriasis\\nis phototherapy or topical corticosteroids.\\nCourse for both types is unpredictable; periodic clinical follow-up and biopsies give the best indication of\\nrisk of developing CTCL.\\nPityriasis Rosea\\nPityriasis rosea (PR) is an inflammatory disease characterized by diffuse, scaling papules or\\nplaques. Treatment is usually unnecessary.\\nPR most commonly occurs between ages 10 and 35. It affects women more often and peaks in incidence\\nin cooler months in temperate climates. The cause may be viral infection (some research has implicated\\nhuman herpesviruses 6 and 7). Drugs may cause a PR-like reaction.\\nSymptoms and Signs\\nThe condition classically begins with a single, primary, 2- to 10-cm herald patch that appears on the trunk\\nor proximal limbs (see\\nPlate 42\\n). A general centripetal eruption of 0.5- to 2-cm rose- or fawn-colored oval papules and plaques\\nfollows within 7 to 14 days. The lesions have a scaly, slightly raised border (collarette) and resemble\\nringworm (tinea corporis). Most patients itch, occasionally severely. Papules may dominate with little or no\\nscaling in blacks, children, and pregnant women. The rose or fawn color is not as evident in blacks;\\nblacks also more commonly have inverse PR (lesions in the axillae or groin that spread centrifugally).\\nClassically, lesions orient along skin lines, giving PR a Christmas tree-like distribution when multiple\\nlesions appear on the back. A prodrome of malaise and headache precedes the lesions in a minority of\\npatients.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is based on clinical appearance and distribution. Differential diagnosis includes tinea corporis,\\ntinea versicolor, drug eruptions, psoriasis, parapsoriasis, pityriasis lichenoides chronica, lichen planus,\\nand secondary syphilis. Serologic testing for syphilis is indicated when the palms or soles are affected,\\nwhen a herald patch is not seen, or when lesions occur in an unusual sequence or distribution.\\nTreatment\\n Antipruritic therapy\\nNo specific treatment is necessary because the eruption usually remits within 5 wk and recurrence is rare.\\nArtificial or natural sunlight may hasten resolution. Antipruritic therapy such as topical corticosteroids, oral\\nantihistamines, or topical measures may be used as needed.\\nPityriasis Rubra Pilaris\\nPityriasis rubra pilaris is a rare chronic disorder that causes hyperkeratotic yellowing of the\\npalms and soles and red follicular papules that merge to form red-orange scaling plaques and\\nconfluent areas of erythema with islands of normal skin between lesions.\\nThe cause of pityriasis rubra pilaris is unknown.\\nThe 2 most common forms of the disorder are\\n Juvenile classic (characterized by autosomal dominant inheritance and childhood onset)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 78. Psoriasis & Scaling Diseases\\n795'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 805, 'page_label': '796'}, page_content=\" Adult classic (characterized by no apparent inheritance and adult onset)\\nAtypical forms exist in both age groups. Sunlight can trigger a flare.\\nDiagnosis is by clinical appearance and may be supported by biopsy. Differential diagnosis includes\\nseborrheic dermatitis (in children) and psoriasis when disease occurs on the scalp, elbows, and knees.\\nTreatment is exceedingly difficult and empiric. The disorder may be ameliorated but almost never cured;\\nclassic forms of the disorder resolve slowly over 3 yr, whereas non-classic forms persist. Scaling may be\\nreduced with emollients or 12% lactic acid under occlusive dressing, followed by topical corticosteroids.\\nOral vitamin A may be effective. Oral retinoids or methotrexate is an option when a patient is resistant to\\ntopical treatment.\\nPityriasis Lichenoides\\nPityriasis lichenoides is a clonal T-cell disorder that may develop in response to foreign\\nantigens (eg, infections or drugs) and may be associated with cutaneous T-cell lymphoma.\\nPityriasis lichenoides has acute and chronic forms existing in a clinical continuum. The acute form\\ntypically appears in children and young adults, with crops of asymptomatic chickenpox-like lesions that\\ntypically resolve within weeks to months. Antibiotics (eg, tetracycline, erythromycin) or phototherapy may\\nhelp.\\nThe chronic form initially manifests as flatter, reddish brown, scaling papules that may take months or\\nlonger to resolve. No treatment has proved effective.\\nLichen Planus\\nLichen planus (LP) is a recurrent, pruritic, inflammatory eruption characterized by small,\\ndiscrete, polygonal, flat-topped, violaceous papules that may coalesce into rough scaly patches,\\noften accompanied by oral lesions. Diagnosis is usually clinical and supported by skin biopsy.\\nTreatment generally requires topical or intralesional corticosteroids. Severe cases may require\\nphototherapy or systemic immunosuppressants.\\nEtiology\\nLP is thought to be caused by a T cell-mediated autoimmune reaction against basal epithelial\\nkeratinocytes in people with genetic predisposition. Drugs (especially \\n\\n-blockers, NSAIDs, ACE inhibitors,\\nsulfonylureas, gold, antimalarial drugs, penicillamine, and thiazides) can cause LP; drug-induced LP\\n(sometimes called lichenoid drug eruption) may be indistinguishable from nondrug-induced LP or may\\nhave a pattern that is more eczematous. Associations with hepatitis C-induced liver insufficiency, primary\\nbiliary cirrhosis, and other forms of hepatitis have been reported.\\nSymptoms and Signs\\nTypical lesions are pruritic, purple, polygonal, flat-topped papules and plaques (see\\nPlate 39\\n). Lesions initially are 2 to 4 mm in diameter, with angular borders, a violaceous color, and a\\ndistinct sheen in cross-lighting. They are usually symmetrically distributed, most commonly on the flexor\\nsurfaces of the wrists, legs, trunk, glans penis, and oral and \\nvaginal mucosae but can be widespread.\\nThe face is rarely involved. Onset may be abrupt or gradual. Children are affected infrequently. During the\\nacute phase, new papules may appear at sites of minor skin injury (Koebner phenomenon), such as a\\nsuperficial scratch. Lesions may coalesce or change over time, becoming hyperpigmented, atrophic,\\nhyperkeratotic (hypertrophic LP), or vesiculobullous. Although pruritic, lesions are rarely excoriated or\\ncrusted. If the scalp is affected, patchy scarring alopecia (lichen planopilaris) may occur.\\nThe oral mucosa is involved in about 50% of cases; oral lesions may occur without cutaneous lesions\\nand usually persist for life. Reticulated, lacy, bluish-white, linear lesions (Wickham's striae) are a hallmark\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 78. Psoriasis & Scaling Diseases\\n796\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 806, 'page_label': '797'}, page_content='of oral LP, especially on the buccal mucosae. Tongue margins and gingival mucosae in edentulous areas\\nmay also be affected. An erosive form of LP may occur in which the patient develops shallow, often\\npainful, recurrent oral ulcers, which, if long-standing, rarely become cancerous. Chronic exacerbations\\nand remissions are common. Vulvar and vaginal mucosae are often involved. Up to 50% of women with\\noral mucosal findings have undiagnosed vulvar LP. In men, genital involvement is common, especially of\\nthe glans penis.\\nNails are involved in up to 10% of cases. Findings vary in intensity with nail bed discoloration, longitudinal\\nridging and lateral thinning, and complete loss of the nail matrix and nail, with scarring of the proximal nail\\nfold onto the nail bed (pterygium formation).\\nDiagnosis\\n Clinical evaluation\\n Biopsy\\nAlthough diagnosis is suggested by appearance of the lesions, similar lesions may result from any of the\\npapulosquamous disorders, lupus erythematosus, and secondary syphilis, among others. Oral or vaginal\\nLP may resemble leukoplakia, and the oral lesions must also be distinguished from candidiasis,\\ncarcinoma, aphthous ulcers, pemphigus, cicatricial pemphigoid, and chronic erythema multiforme.\\nTypically, biopsy is done.\\nIf LP is diagnosed, some clinicians do laboratory testing for liver dysfunction, including hepatitis B and C\\ninfections.\\nPrognosis\\nMany cases resolve without intervention, presumably because the inciting agent is no longer present.\\nRecurrence after years may be due to reexposure to the trigger or some change in the triggering\\nmechanism. Sometimes treatment of a previously occult infection, such as a dental abscess, results in\\nresolution.\\nVulvovaginal LP may be chronic and refractory to therapy, causing decreased quality of life.\\nTreatment\\n Topical treatments\\n Systemic treatments\\n Sometimes light therapy\\nAsymptomatic LP does not require treatment. Drugs suspected of triggering LP should be stopped.\\nFew controlled studies have evaluated treatments. Options differ by location and extent of disease. Most\\ncases of LP on the trunk or extremities can be treated with local drugs. Topical corticosteroids are first-\\nline treatment for most cases of localized disease. High-potency ointments or creams (eg, clobetasol,\\nfluocinonide) may be used on the thicker lesions on the extremities; lower-potency drugs (eg,\\ntriamcinolone, desonide) may be used on the face, groin, and axillae. As always, courses should be\\nlimited to reduce risk of corticosteroid atrophy. Potency may be enhanced with use of polyethylene\\nwrapping or flurandrenolide tape. Intralesional corticosteroids (triamcinolone acetonide solution diluted\\nwith saline to 5 to 10 mg/mL) can be used every 4 wk for hyperkeratotic plaques and those resistant to\\nother therapies.\\nTopical therapy is impractical for generalized LP; oral drugs or phototherapy is used. Oral corticosteroids\\n(eg, prednisone 20 mg once/day for 2 to 6 wk followed by a taper) may be used for severe cases. The\\ndisease may rebound when therapy ceases; however, long-term systemic corticosteroids should not be\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 78. Psoriasis & Scaling Diseases\\n797'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 807, 'page_label': '798'}, page_content='used.\\nOral retinoids (eg, acitretin 30 mg once/day for 8 wk) are indicated for otherwise recalcitrant cases.\\nGriseofulvin 250 mg po bid given for 3 to 6 mo may be effective. Cyclosporine (1.25 to 2.5 mg/kg bid) can\\nbe used when corticosteroids or retinoids fail. Light therapy using psoralen plus ultraviolet A (PUVA) or\\nnarrow-band UVB is an alternative to oral therapies, especially if they have failed or are contraindicated\\nfor medical reasons.\\nTreatment of oral LP differs slightly. Viscous lidocaine may help relieve symptoms of erosive ulcers.\\nTacrolimus 0.1% ointment applied twice daily may induce lasting remission, although it has not been fully\\nevaluated. Other treatment options include topical (in an adhesive base), intralesional, and systemic\\ncorticosteroids. \\nErosive oral LP may respond to oral dapsone or cyclosporine. Cyclosporine rinses also\\nmay be helpful.\\nDapsone, hydroxychloroquine, azathioprine, systemic cyclosporine, and topical tretinoin may also be\\nuseful. As with any disease with so many therapies, individual drugs have not been uniformly successful.\\nLichen Sclerosus\\nLichen sclerosus is an inflammatory dermatosis of unknown cause, possibly autoimmune, that\\nusually affects the anogenital area.\\nThe earliest signs are skin fragility, bruising, and sometimes blistering. Lesions typically cause mild to\\nsevere itching. When lichen sclerosus manifests in children, the appearance may be confused with sexual\\nabuse. With time, the involved tissue becomes atrophic, thinned, hypopigmented (there may be flecks of\\npostinflammatory hyperpigmentation), fissured, and scaly. Hyperkeratotic and fibrotic forms exist. Severe\\nand longstanding cases cause scarring and distortion of normal anogenital architecture. In women, this\\ndistortion can even lead to total absorption of the labia minora and fusion over the clitoris. In men,\\nphimosis or fusion of the foreskin to the coronal sulcus can occur.\\nDiagnosis can usually be based on appearance, especially in advanced cases; however, biopsy should\\nbe done on any anogenital dermatosis that does not resolve with mild conventional therapy (eg, topical\\nhydrocortisone, antifungal drug). It is especially important to biopsy any area that becomes thickened or\\nulcerated, because lichen sclerosus is a precursor of squamous cell carcinoma.\\nTreatment\\n Topical corticosteroids\\nTreatment consists of potent topical corticosteroids (drugs that otherwise should be used with extreme\\ncaution in this area). The disease is generally intractable, so long-term follow-up, especially to monitor for\\nsquamous cell carcinoma and sexual function and for psychologic support, is indicated.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 78. Psoriasis & Scaling Diseases\\n798'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 808, 'page_label': '799'}, page_content=\"Chapter 79. Hypersensitivity and Inflammatory Disorders\\nIntroduction\\nThe immune system plays a significant role in a large number of skin disorders, including dermatitis,\\nsunlight reactions, and bullous diseases. Although all of these disorders involve some level of\\ninflammation, certain skin disorders are primarily characterized by their inflammatory component or as a\\nhypersensitivity reaction, be it to a drug, infection, or cancer.\\nAcute Febrile Neutrophilic Dermatosis\\n(Sweet's Syndrome)\\nAcute febrile neutrophilic dermatosis is characterized by tender, indurated, dark-red papules\\nand plaques with prominent edema in the upper dermis and dense infiltrate of neutrophils.\\nCause is not known. It frequently occurs with underlying cancer, especially hematologic\\ncancers.\\nEtiology\\nAcute febrile neutrophilic dermatosis may occur with various disorders, including\\n Acute respiratory illness\\n GI infection\\n Cancer\\n Drug exposure\\n Inflammatory or autoimmune disorders\\n Pregnancy\\nAbout 25% of patients have an underlying cancer, 75% of which are hematologic cancers, especially\\nmyelodysplastic syndromes and acute myeloid leukemia. When not due to cancer, acute febrile\\nneutrophilic dermatosis affects mostly women ages 30 to 50, with a female: male ratio of 3:1. In contrast,\\nmen who develop the condition tend to be older (60 to 90).\\nThe cause is unknown; however, type 1 helper T-cell cytokines, including IL-2 and interferon-\\n\\n, are\\npredominant and may play a role in lesion formation.\\nSymptoms and Signs\\nPatients are febrile, with an elevated neutrophil count, and have tender, dark-red plaques or \\npapules,\\nmost often on the face, neck, and upper extremities, especially the dorsum of hands. Oral lesions can\\nalso occur. Rarely, bullous and pustular lesions are present. The lesions often develop in crops. Each\\ncrop is preceded by fever and persists for days to weeks.\\nExtracutaneous manifestations can involve the eyes (eg, conjunctivitis, episcleritis, iridocyclitis), joints\\n(eg, arthralgia, myalgia, arthritis), and internal organs (eg, neutrophilic alveolitis; sterile osteomyelitis;\\npsychiatric or neurologic changes; transient kidney, liver, and pancreatic insufficiency).\\nDiagnosis\\n Clinical evaluation\\n Skin biopsy\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n799\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 809, 'page_label': '800'}, page_content='Diagnosis is suggested by the appearance of the lesions and is supported by the presence of associated\\nconditions. Differential diagnosis includes erythema multiforme, erythema elevation diutinum, acute\\ncutaneous lupus erythematosus, pyoderma gangrenosum, and erythema nodosum. If diagnosis is\\nunclear, skin biopsy should be done. The histopathologic pattern is that of edema in the upper dermis\\nwith a dense infiltrate of neutrophils in the dermis. Vasculitis may be present but is secondary.\\nTreatment\\n Corticosteroids\\nTreatment involves systemic corticosteroids, chiefly prednisone 0.5 to 1.5 mg/kg po once/day tapered\\nover 3 wk. Antipyretics are also recommended. In difficult cases, dapsone 100 to 200 mg po once/day,\\nindomethacin 150 mg po once/day for 1 wk and 100 mg po once/day for 2 additional wk, or K iodide 900\\nmg po once/day or 300 mg po tid can be given.\\nDrug Eruptions and Reactions\\nDrugs can cause multiple skin eruptions and reactions. The most serious of these are discussed\\nelsewhere in THE MANUAL and include Stevens-Johnson syndrome and toxic epidermal necrolysis,\\nhypersensitivity syndrome, serum sickness, exfoliative dermatitis, angioedema and anaphylaxis, and drug-\\ninduced vasculitis. Drugs can also be implicated in hair loss, lichen planus, erythema nodosum,\\npigmentation changes, SLE, photosensitivity reactions, pemphigus, and pemphigoid. Other drug reactions\\nare classified by lesion type (see\\nTable 79-1\\n).\\n[\\nTable 79-1.\\n Types of Drug Reactions and Typical Causative Agents]\\nSymptoms and Signs\\nSymptoms and signs vary based on the cause and the specific reaction (see \\nTable 79-1\\n).\\nDiagnosis\\n Clinical evaluation and drug exposure history\\n Sometimes skin biopsy\\nA detailed history is often required for diagnosis, including recent use of OTC drugs. Because the\\nreaction may not occur until several days or even weeks after first exposure to the drug, it is important to\\nconsider all new drugs and not only the one that has been most recently started. No laboratory tests\\nreliably aid diagnosis, although biopsy of affected skin is often suggestive. Sensitivity can be definitively\\nestablished only by rechallenge with the drug, which may be hazardous and unethical in patients who\\nhave had severe reactions.\\nTreatment\\n Discontinuation of offending drug\\n Sometimes antihistamines and corticosteroids\\nMost drug reactions resolve when drugs are stopped and require no further therapy. Whenever possible,\\nchemically unrelated compounds should be substituted for suspect drugs. If no substitute drug is\\navailable and if the reaction is a mild one, it might be necessary to continue the treatment under careful\\nwatch despite the reaction. Pruritus can be controlled with antihistamines and topical corticosteroids. For\\nIgE-mediated reactions (eg, urticaria), desensitization (see p. \\n1124\\n) can be considered when there is\\ncritical need for a drug.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n800'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 810, 'page_label': '801'}, page_content=\"When progression from urticaria to anaphylaxis is a concern, treatment is with aqueous epinephrine\\n(1:1000) 0.2 mL sc or IM and with the slower-acting but more persistent soluble hydrocortisone 100 mg IV,\\nwhich may be followed by an oral corticosteroid for a short period (see also p. \\n1121\\n).\\nErythema Multiforme\\nErythema multiforme (EM) is an inflammatory reaction, characterized by target or iris skin\\nlesions. Oral mucosa may be involved. Diagnosis is clinical. Lesions spontaneously resolve but\\nfrequently recur. Erythema multiforme can occur as reaction to a drug or an infectious agent\\nsuch as herpes simplex virus or mycoplasma. Suppressive antiviral therapy may be indicated\\nfor patients with frequent or symptomatic recurrence due to herpes simplex virus.\\nFor years, EM was thought to represent the milder end of a spectrum of drug hypersensitivity disorders\\nthat included Stevens-Johnson syndrome and toxic epidermal \\nnecrolysis. Recent evidence suggests that\\nEM is different from these other disorders.\\nEtiology\\nThe majority of cases are caused by herpes simplex virus (HSV) infection (HSV-1 more so than HSV-2),\\nalthough it is unclear whether EM lesions represent a specific or nonspecific reaction to the virus. Current\\nthinking holds that EM is caused by a T-cell-mediated cytolytic reaction to HSV DNA fragments present in\\nkeratinocytes. A genetic disposition is presumed given that EM is such a rare clinical manifestation of\\nHSV infection, and several HLA subtypes have been linked with the predisposition to develop lesions.\\nLess commonly, cases are caused by drugs, vaccines, other viral diseases (especially hepatitis C), or\\npossibly SLE. EM that occurs in patients with SLE is sometimes referred to as Rowell's syndrome.\\nSymptoms and Signs\\nEM manifests as the sudden onset of asymptomatic, erythematous macules, papules, wheals, vesicles,\\nbullae, or a combination on the distal extremities (including palms and soles) and face. The classic lesion\\nis annular, with a violaceous center and pink halo separated by a pale ring (target or iris lesion).\\nDistribution is symmetric and centripetal; spread to the trunk is common. Some patients have itching. Oral\\nlesions include target lesions on the lips and vesicles and erosions on the palate and gingivae.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is by clinical appearance; biopsy is rarely necessary. Differential diagnosis includes essential\\nurticaria, vasculitis, bullous pemphigoid, pemphigus, linear IgA dermatosis, acute febrile neutrophilic\\ndermatosis, and dermatitis herpetiformis; oral lesions must be distinguished from aphthous stomatitis,\\npemphigus, herpetic stomatitis, and hand-foot-and-mouth disease. Patients with widely disseminated\\npurpuric macules and blisters and prominent involvement of the trunk and face are likely to have Stevens-\\nJohnson syndrome rather than EM.\\nTreatment\\n Supportive care\\n Sometimes prophylactic antivirals\\nEM spontaneously resolves, so treatment is usually unnecessary. Topical corticosteroids and anesthetics\\nmay ameliorate symptoms and reassure patients. Recurrences are common, and empiric oral\\nmaintenance therapy with acyclovir 400 mg po q 12 h, famciclovir 250 mg po q 12 h, or valacyclovir 1000\\nmg po q 24 h can be attempted if symptoms recur more than 5 times/yr and HSV association is suspected\\nor if recurrent EM is consistently preceded by herpes flares.\\nPanniculitis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n801\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 811, 'page_label': '802'}, page_content='Panniculitis describes inflammation of the subcutaneous fat that can result from multiple\\ncauses. Diagnosis is by clinical evaluation and biopsy. Treatment depends on the cause.\\nEtiology\\nThere are multiple causes of panniculitis, including\\n Infections (the most common)\\n Physical factors (eg, cold, trauma)\\n Proliferative disorders\\n Connective tissue disorders (eg, SLE, systemic sclerosis)\\nIdiopathic panniculitis is sometimes referred to as Weber-Christian disease.\\nSymptoms and Signs\\nPanniculitis is characterized by tender and erythematous subcutaneous nodules located over the\\nextremities and sometimes over the posterior thorax, abdominal area, breasts, face, or buttocks. Rarely,\\nnodules can involve the mesentery, lungs, scrotum, and cranium. Signs of systemic inflammation can\\naccompany panniculitis. In Weber-Christian disease, systemic involvement can result in fever as well as\\nsigns of organ dysfunction, including hepatic, pancreatic, and bone marrow insufficiency, which is\\npotentially fatal.\\nDiagnosis\\n Clinical evaluation\\n Excisional biopsy\\nDiagnosis is by usually by clinical appearance and can be confirmed by excisional biopsy.\\nTreatment\\n Supportive care\\n Anti-inflammatory drugs\\n Immunosuppressants\\nThere is no specific definitive treatment for panniculitis. A variety of strategies have been used with\\nmodest results, including NSAIDs, antimalarials, dapsone, and thalidomide. Corticosteroids (1 to 2 mg/kg\\npo or IV once/day) and other immunosuppressive or chemotherapeutic drugs have been used to treat\\npatients with progressive symptoms or signs of systemic involvement. Surgical abdominal panniculectomy\\nhas been used with varying levels of success in morbidly obese patients but should be reserved for\\npatients with serious disease that does not respond to other measures.\\nErythema Nodosum\\nErythema nodosum (EN) is a specific form of panniculitis (see p. \\n687\\n) characterized by tender,\\nred or violet, palpable, subcutaneous nodules on the shins and occasionally other locations. It\\noften occurs with an underlying systemic disease, notably streptococcal infections, sarcoidosis,\\ninflammatory bowel disease, and TB. Diagnosis is by clinical evaluation and biopsy. Treatment\\ndepends on the cause.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n802'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 812, 'page_label': '803'}, page_content='Etiology\\nEN primarily affects people in their 20s and 30s but can occur at any age; women are more often\\naffected. Etiology is unknown, but an immunologic reaction is suspected because EN is frequently\\naccompanied by other disorders; the most common are\\n Streptococcal infection (especially in children)\\n Sarcoidosis\\n Inflammatory bowel disease\\n TB\\nOther possible triggers include\\n Other bacterial infections (eg, \\nYersinia\\n, \\nSalmonella\\n, mycoplasma, chlamydia, leprosy, lymphogranuloma\\nvenereum)\\n Fungal infections (eg, coccidioidomycosis, blastomycosis, histoplasmosis)\\n Rickettsial infections\\n Viral infections (eg, Epstein-Barr, hepatitis B)\\n Use of drugs (eg, sulfonamides, iodides, bromides, oral contraceptives)\\n Hematologic and solid cancers\\n Pregnancy\\nUp to one third of cases of EN are idiopathic.\\nSymptoms and Signs\\nEN is a subset of panniculitis that manifests as erythematous, tender plaques or nodules, primarily in the\\npretibial region (see\\nPlate 34\\n), accompanied by fever, malaise, and arthralgia.\\nDiagnosis\\n Clinical evaluation\\n Excisional biopsy\\nDiagnosis is usually by clinical appearance and can be confirmed by excisional biopsy of a nodule when\\nnecessary. A diagnosis of EN should prompt evaluation for causes. Evaluation might include biopsy, skin\\ntesting (PPD or anergy panel), antinuclear antibodies, CBC, chest x-ray, and antistreptolysin O titer or\\npharyngeal culture. ESR is often high.\\nTreatment\\n Supportive care\\n Anti-inflammatory drugs\\n Corticosteroids\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n803'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 813, 'page_label': '804'}, page_content='EN almost always resolves spontaneously. Treatment includes bed rest, elevation, cool compresses, and\\nNSAIDs. K iodide 300 to 500 mg po tid can be given to decrease inflammation. Systemic corticosteroids\\nare effective but are an intervention of last resort as they can worsen an occult infection. If an underlying\\ndisorder is identified, it should be treated.\\nGranuloma Annulare\\nGranuloma annulare is a benign, chronic, idiopathic condition characterized by papules or\\nnodules that spread peripherally to form a ring around normal or slightly depressed skin.\\nEtiology\\nEtiology is unclear but proposed mechanisms include cell-mediated immunity (type IV), immune complex\\nvasculitis, and an abnormality of tissue monocytes. Granuloma annulare is not associated with systemic\\ndisorders, except that the incidence of abnormal glucose metabolism is increased among adults with\\nmany lesions. In some cases, exposure to sunlight, insect bites, TB skin testing, BCG vaccination,\\ntrauma, \\nBorrelia\\n infection, and viral infections have induced disease flares. The condition is twice as\\nprevalent among women.\\nSymptoms and Signs\\nLesions are erythematous, yellowish tan, bluish, or the color of the surrounding skin; one or more lesions\\nmay occur, most often on dorsal feet, legs, hands, or fingers. They are usually asymptomatic but may\\noccasionally be tender. The lesions often expand or join to form rings. The center of each ring may be a\\nslightly depressed, pale or light brown. In some cases, lesions may become generalized and widespread.\\nDiagnosis\\nDiagnosis is usually clinical but can be confirmed by skin biopsy.\\nTreatment\\n Sometimes corticosteroids, anti-inflammatory drugs, or psoralen plus ultraviolet A (PUVA) therapy\\nUsually no treatment is necessary; spontaneous resolution is common. For patients with more widespread\\nor bothersome lesions, quicker resolution may be promoted by the use of high-strength topical\\ncorticosteroids under occlusive dressings every night, flurandrenolide-impregnated tape, and intralesional\\ncorticosteroids. PUVA therapy is also effective and practical for patients with widespread disease. Recent\\nreports have suggested that tumor necrosis factor-\\n\\n inhibitors (eg, infliximab, adalimumab), 595-nm\\npulsed dye laser, and fractional photothermolysis are useful in managing disseminated and recalcitrant\\nlesions.\\nPyoderma Gangrenosum\\nPyoderma gangrenosum is a chronic progressive skin necrosis of unknown etiology often\\nassociated with systemic illness.\\nEtiology\\nEtiology is unknown, but pyoderma gangrenosum can be associated with vasculitis, gammopathies, RA,\\nleukemia, lymphoma, hepatitis C virus infection, SLE, sarcoidosis, polyarthritis, and especially\\ninflammatory bowel disease and is thought to be caused by an abnormal immune response.\\nPathophysiology\\nPathophysiology is poorly understood but may involve problems with neutrophil chemotaxis. Ulcerations\\nof pyoderma gangrenosum may occur after trauma or injury to the skin in 30% of patients; this process is\\ntermed pathergy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n804'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 814, 'page_label': '805'}, page_content='Symptoms and Signs\\nPyoderma gangrenosum begins as an inflamed erythematous papule, pustule, or nodule. The lesion,\\nwhich may resemble a furuncle or an arthropod bite at this stage, then ulcerates and expands rapidly,\\ndeveloping a swollen necrotic base and a raised dusky to violaceous border. An undermined border is\\ncommon, if not pathognomonic. Systemic symptoms such as fever, malaise, and arthralgias are common.\\nThe ulcers coalesce to form larger ulcers, often with cribriform or sieve-like scarring.\\nDiagnosis\\nDiagnosis is clinical. Biopsies of lesions are not often diagnostic but may be supportive; 40% of biopsies\\nfrom a leading edge show vasculitis with neutrophils and fibrin in superficial vessels.\\nTreatment\\n Corticosteroids\\n Sometimes other anti-inflammatory drugs or immunosuppressants\\n Avoidance of surgical debridement\\nPrednisone 60 to 80 mg po once/day is still the mainstay of treatment, although cyclosporine 3 mg/kg po\\nonce/day is also quite effective. Dapsone, clofazimine, thalidomide, tumor necrosis factor-\\n\\n inhibitors (eg,\\ninfliximab), and mycophenolate mofetil have also been used successfully. Surgical treatments are avoided\\nbecause of the risk of wound extension.\\nStevens-Johnson Syndrome and Toxic Epidermal Necrolysis\\nStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous\\nhypersensitivity reactions. Drugs, especially sulfa drugs, antiepileptics, and antibiotics, are the\\nmost common causes. Macules rapidly spread and coalesce, leading to epidermal blistering,\\nnecrosis, and sloughing. Diagnosis is usually obvious by appearance of initial lesions and\\nclinical syndrome. Treatment is supportive care; corticosteroids, cyclophosphamide, and other\\ndrugs may be tried. Prognosis depends on how early the disorders are diagnosed and treated.\\nMortality can be as high as 7.5% in children and 20 to 25% in adults.\\nSJS and TEN are clinically similar except for their distribution. By one commonly accepted definition,\\nchanges affect < 10% of \\nbody surface area in SJS and > 30% of body surface area in TEN; involvement\\nof 15 to 30% of body surface area is considered SJS-TEN overlap.\\nThe disorders affect between 1 and 5 people/million. Incidence, severity, or both of these disorders may\\nbe higher in bone-marrow transplant recipients, in \\nPneumocystis jirovecii\\n-infected HIV patients, in\\npatients with SLE, and in patients with other chronic rheumatologic diseases.\\nEtiology\\nDrugs precipitate over 50% of SJS cases and up to 95% of TEN cases. The most common drug causes\\ninclude\\n Sulfa drugs (eg, cotrimoxazole, sulfasalazine)\\n Other antibiotics (eg, aminopenicillins, fluoroquinolones, cephalosporins)\\n Antiepileptics (eg, phenytoin, carbamazepine, phenobarbital, valproate, lamotrigine)\\n Miscellaneous individual drugs (eg, piroxicam, allopurinol, chlormezanone)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n805'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 815, 'page_label': '806'}, page_content=\"Cases that are not caused by drugs are attributed to\\n Infection (mostly with \\nMycoplasma pneumoniae\\n)\\n Vaccination\\n Graft-vs-host disease\\nRarely, a cause cannot be identified.\\nPathophysiology\\nExact mechanism is unknown; however, one theory holds that altered drug metabolism in some patients\\ncauses formation of reactive metabolites that bind to and alter cell proteins, triggering a T-cell-mediated\\ncytotoxic reaction to drug antigens in keratinocytes.\\nAnother possible mechanism involves interactions between Fas (a cell-surface receptor that induces\\napoptosis) and its ligand, particularly a soluble form of Fas ligand released from mononuclear cells.\\nRecent findings suggest that granulysin released from cytotoxic T cells and natural killer cells might play a\\nrole in keratinocyte death.\\nSymptoms and Signs\\nWithin 1 to 3 wk after the start of the offending drug, patients develop a prodrome of malaise, fever,\\nheadache, cough, and conjunctivitis. Macules, often in a target configuration, then appear suddenly,\\nusually on the face, neck, and upper trunk. These macules simultaneously appear elsewhere on the body,\\ncoalesce into large flaccid bullae, and slough over a period of 1 to 3 days. Nails and eyebrows may be\\nlost along with epithelium.\\nIn severe cases of TEN, large sheets of epithelium slide off the entire body at pressure points (Nikolsky's\\nsign), exposing weepy, painful, and erythematous skin. Painful oral crusts and erosions,\\nkeratoconjunctivitis, and genital problems (eg, phimosis, vaginal synechiae) accompany skin sloughing in\\nup to 90% of cases. Bronchial epithelium may also slough, causing cough, dyspnea, pneumonia,\\npulmonary edema, and hypoxemia. Glomerulonephritis and hepatitis may develop.\\nDiagnosis\\n Clinical evaluation\\n Often skin biopsy\\nDiagnosis is often obvious from appearance of lesions and rapid progression of symptoms. Histologic\\nexamination of sloughed skin shows necrotic epithelium, a distinguishing feature.\\nDifferential diagnosis in SJS and early TEN includes erythema multiforme, viral exanthems, and drug\\nrash; and, in later stages of TEN, paraneoplastic pemphigus, toxic shock syndrome, exfoliative\\nerythroderma, and thermal burn. In children, TEN is less common and must be distinguished from\\nstaphylococcal scalded skin syndrome.\\nPrognosis\\nSevere TEN is similar to extensive burns; patients are acutely ill, may be unable to eat or open their eyes,\\nand suffer massive fluid and electrolyte losses. They are at high risk of infection, multiorgan failure, and\\ndeath. With early therapy, survival rates approach 90%. The severity-of-illness score for TEN (see\\nTable 79-2\\n) systematically scores 7 independent risk factors within the first 24 h of presentation to the\\nhospital to determine the mortality rate for a particular patient.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n806\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 816, 'page_label': '807'}, page_content=' Supportive care\\n Possibly immune modulator treatment\\n Possibly plasmapheresis\\nTreatment is most successful when SJS or TEN is recognized early and treated in an inpatient\\ndermatologic or ICU setting; treatment in a burn unit may be needed for severe disease. Ophthalmology\\nconsultation is mandatory for patients with ocular involvement. Drugs should be stopped immediately.\\nPatients\\n[\\nTable 79-2.\\n Severity-of-Illness Score for Toxic Epidermal Necrolysis (Scorten)]\\nare isolated to minimize exposure to infection and are given fluids, electrolytes, blood products, and\\nnutritional supplements as needed. Skin care includes prompt treatment of secondary bacterial infections.\\nProphylactic antibiotics are controversial.\\nDrug treatment of STS and TEN is controversial. High-dose systemic corticosteroids (eg,\\nmethylprednisolone 80 to 200 mg IV or prednisone 80 mg po once/day for 7 to 10 days or until\\nprogression stops) or cyclophosphamide (300 mg IV q 24 h for 7 days or until significant improvement)\\ncan be given to inhibit T-cell-mediated cytolysis. Cyclosporine (3 to 5 mg/kg po once/day) inhibits CD8\\ncells and has been shown to decrease the duration of active disease by 2 to 3 days in some instances.\\nHowever, corticosteroids are controversial and are thought by some to increase mortality. Plasmapheresis\\ncan remove reactive drug metabolites or antibodies. Early high-dose IV immune globulin (IVIG) 2.7 g/kg\\nover 3 days blocks antibodies and Fas ligand. Despite some remarkable results using high-dose IVIG for\\nTEN, clinical trials involving small cohorts have reported conflicting results.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 79. Hypersensitivity & Inflammatory Disorders\\n807'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 817, 'page_label': '808'}, page_content=\"Chapter 80. Sweating Disorders\\nIntroduction\\nThere are two types of sweat glands: apocrine and eccrine.\\nApocrine glands are clustered in the axillae, areolae, genitals, and anus; modified apocrine glands are\\nfound in the external auditory meatus. Apocrine glands become active at puberty; their excretions are oily\\nand viscid and are presumed to play a role in sexual olfactory messages. The most common disorders of\\napocrine glands are bromhidrosis and hidradenitis suppurativa (see p. \\n698\\n).\\nEccrine glands are sympathetically innervated, distributed over the entire body, and active from birth.\\nTheir secretions are watery and serve to cool the body in hot environments or during activity. Disorders of\\neccrine glands include hyperhidrosis, hypohidrosis, and miliaria.\\nBromhidrosis\\nBromhidrosis is excessive or abnormal body odor caused by decomposition by bacteria and\\nyeasts of apocrine secretions and cellular debris.\\nApocrine secretions are lipid-rich, sterile, and odorless but become odoriferous when decomposed.\\nEccrine bromhidrosis is not as fragrant because eccrine sweat is nearly 100% water. The cause of\\napocrine bromhidrosis is poor hygiene of skin and clothing.\\nIn some people, a few days of washing with an antiseptic soap, which may be combined with use of\\nantibacterial creams containing clindamycin or erythromycin, may be necessary. Shaving the hair in the\\narmpits may also help control odor.\\nHyperhidrosis\\nHyperhidrosis is excessive sweating, which can be focal or diffuse and has multiple causes.\\nSweating of the axillae, palms, and soles is most often due to stress; diffuse sweating is usually\\nidiopathic but should raise suspicions for cancer, infection, and endocrine disease. Diagnosis is\\nobvious, but tests for underlying causes may be indicated. Treatment is topical aluminum\\nchloride, tap water iontophoresis, botulinum toxin, and, in extreme cases, surgery.\\nEtiology\\nHyperhidrosis can be focal or generalized.\\nFocal sweating:\\n Emotional causes are common, causing sweating on the palms, soles, axillae, and\\nforehead at times of anxiety, excitement, anger, or fear. It may be due to a generalized stress-increased\\nsympathetic outflow. Although such sweating is a normal response, patients with hyperhidrosis sweat\\nexcessively and under conditions that do not cause sweating in most people.\\nGustatory sweating occurs around the lips and mouth when ingesting foods and beverages that are spicy\\nor hot in temperature. There is no known cause in most cases, but gustatory sweating can be increased\\nin diabetic neuropathy, facial herpes zoster, cervical sympathetic ganglion invasion, CNS injury or\\ndisease, or parotid gland injury. In the case of parotid gland injury, surgery, infection, or trauma may\\ndisrupt parotid gland innervation and lead to regrowth of parotid parasympathetic fibers into sympathetic\\nfibers innervating local sweat glands in skin where the injury took place, usually over the parotid gland.\\nThis condition is called Frey's syndrome.\\nOther causes of focal sweating include pretibial myxedema (shins), hypertrophic osteoarthropathy\\n(palms), and blue rubber bleb nevus syndrome and glomus tumor (over lesions). Compensatory sweating\\nis intense sweating after sympathectomy.\\nGeneralized sweating:\\n Generalized sweating involves most of the body. Although most cases are\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 80. Sweating Disorders\\n808\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 818, 'page_label': '809'}, page_content=\"idiopathic, numerous conditions can be involved (see\\nTable 80-1\\n).\\nSymptoms and Signs\\nSweating is often present during examination and sometimes is extreme. Clothing can be soaked, and\\npalms or soles may become macerated and fissured. Hyperhidrosis can cause emotional distress to\\npatients and may lead to social withdrawal. Palmar or plantar skin may appear pale.\\nDiagnosis\\n History and examination\\n Iodine and starch test\\n Tests to identify a cause\\nHyperhidrosis is diagnosed by history and examination but can be confirmed with the iodine and starch\\ntest (apply iodine solution to the affected area, let dry, dust on corn starch: areas of sweating appear\\ndark). Testing is necessary only to confirm foci of sweating (as in Frey's syndrome or to locate the\\n[\\nTable 80-1.\\n Some Causes of Generalized Sweating]\\narea needing surgical or botulinum toxin treatment) or in a semiquantitative way when following the\\ncourse of treatment.\\nTests to identify a cause of hyperhidrosis are guided by a review of symptoms and might include CBC to\\ndetect leukemia, serum glucose to detect diabetes, and thyroid-stimulating hormone to screen for thyroid\\ndysfunction.\\nTreatment\\n Aluminum chloride hexahydrate solution\\n Tap water iontophoresis\\n Botulinum toxin type A\\n Surgery\\nInitial treatment of focal and generalized sweating is similar.\\nAluminum chloride hexahydrate 6 to 20% solution in absolute ethyl alcohol is indicated for topical\\ntreatment of axillary, palmar, and plantar sweating; these preparations require a prescription. The solution\\nblocks sweat ducts and is most effective when applied nightly and covered tightly with a thin\\npolyvinylidene or polyethylene film; it should be washed off in the morning. Sometimes an anticholinergic\\ndrug is taken before applying to prevent sweat from washing the aluminum chloride away. Initially, several\\napplications weekly are needed to achieve control, then a maintenance schedule of once or twice weekly\\nis followed. If treatment under occlusion is irritating, it should be tried without occlusion. This solution\\nshould not be applied to inflamed, broken, wet, or recently shaved skin. High-concentration, water-based\\naluminum chloride solutions may provide adequate relief in milder cases. Topical alternatives to aluminum\\nchloride, including glutaraldehyde, formaldehyde, and tannic acid, are effective but can cause contact\\ndermatitis and skin discoloration. A solution of methenamine also may help.\\nTap water iontophoresis, in which salt ions are introduced into the skin using electric current, is an option\\nfor patients unresponsive to topical treatments. The affected areas (typically palms or soles) are placed in\\n2 tap water basins each containing an electrode across which a 15- to 25-mA current is applied for 10 to\\n20 min. This routine is done daily for 1 wk and then repeated weekly or bimonthly. Treatments may be\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 80. Sweating Disorders\\n809\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 819, 'page_label': '810'}, page_content=\"made more effective with topical or oral anticholinergic drugs. Although the treatments are usually\\neffective, the technique is time-consuming and somewhat cumbersome, and some patients tire of the\\nroutine.\\nBotulinum toxin type A is a neurotoxin that decreases the release of acetylcholine from sympathetic\\nnerves serving eccrine glands. Injected directly into the axillae, palms, or forehead, botulinum toxin\\ninhibits sweating for about 5 mo depending on dose. Complications include local muscle weakness and\\nheadache. Injections are effective but painful and expensive.\\nSurgery is indicated if more conservative treatments fail. Patients with axillary sweating can be treated\\nwith surgical excision of axillary sweat glands either through open dissection or by liposuction (the latter\\nseems to have lower morbidity). Patients with palmar sweating can be treated with endoscopic\\ntransthoracic sympathectomy. The potential morbidity of surgery must be considered, especially in\\nsympathectomy. Potential complications include phantom sweating, compensatory sweating, gustatory\\nsweating, neuralgia, and Horner's syndrome.\\nHypohidrosis\\nHypohidrosis is inadequate sweating.\\nHypohidrosis due to skin abnormalities is rarely clinically significant. It is most commonly focal and caused\\nby local skin injury (eg, from trauma, radiation, infection [eg, leprosy], or inflammation) or by atrophy of\\nglands from connective tissue disease (eg, systemic sclerosis, SLE, Sjogren's syndrome). Hypohidrosis\\nmay be caused by drugs, especially those with anticholinergic properties. It is also caused by diabetic\\nneuropathy and a variety of congenital syndromes. Heatstroke causes inadequate sweating but is a CNS\\nrather than a skin disorder (see p. \\n3265\\n). A rare presentation is fever of unknown origin.\\nDiagnosis is by clinical observation of decreased sweating or by heat intolerance. Treatment is by cooling\\nmeasures (eg, air-conditioning, wet garments).\\nMiliaria\\nIn miliaria, sweat flow is obstructed and trapped within the skin, causing papular lesions.\\nMiliaria most often occurs in warm humid weather but may occur in cool weather in an overdressed\\npatient. Lesions vary depending on the depth of tissue at which the sweat duct is obstructed.\\n \\nMiliaria crystallina\\n is ductal obstruction in the uppermost epidermis, with retention of sweat\\nsubcorneally. It causes clear droplike vesicles that rupture with light pressure.\\n \\nMiliaria rubra\\n (prickly heat) is ductal obstruction in the mid-epidermis with retention of sweat in the\\nepidermis and dermis. It causes irritated, pruritic papules (prickling).\\n \\nMiliaria pustulosa\\n is similar to miliaria rubra but manifests as pustules rather than papules.\\n \\nMiliaria profunda\\n is ductal obstruction at the entrance of the duct into the dermal papillae at the dermo-\\nepidermal junction, with retention of sweat in the dermis. It causes papules that are larger and more\\ndeeply seated than those of miliaria pustulosa. Papules are frequently painful.\\nDiagnosis is by clinical appearance in the context of hot environment.\\nTreatment is cooling and drying of the involved areas and avoidance of conditions that may induce\\nsweating; an air-conditioned environment is ideal. Once the rash develops, corticosteroid creams or\\nlotions are used, sometimes with a bit of menthol added.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 80. Sweating Disorders\\n810\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 820, 'page_label': '811'}, page_content='Chapter 81. Bacterial Skin Infections\\nIntroduction\\nBacterial skin infections may be uncomplicated or complicated. Uncomplicated infections usually respond\\npromptly to systemic antibiotics and local wound care. A skin infection is considered complicated when it\\nmeets 2 of the following 5 criteria:\\n Involves a preexisting wound or ulceration of the skin\\n Involves the deeper soft tissues\\n Requires surgical intervention\\n Is caused or exacerbated by underlying comorbid disease states (eg diabetes, systemic\\nimmunosuppression)\\n Is unresponsive to conventional antibiotic therapy or is recurrent\\nAll uncomplicated skin infections have the potential to become complicated. Complicated skin and soft-\\ntissue infections may require multidrug therapy and the assistance of other consultants (eg, surgeons,\\ninfectious disease specialists), particularly in light of resistance in many strains of bacteria and the rapid\\nloss of efficacy among more potent antibiotics. Recurrent skin infections should raise suspicion of\\ncolonization (eg, staphylococcal nasal carriage), resistant strains of bacteria (eg, methicillin-resistant\\nStaphylococcus aureus\\n [MRSA]), cancer, poorly controlled diabetes, or other reasons for\\nimmunocompromise (eg, HIV, hepatitis, advanced age, congenital susceptibility). Bacteria are involved in\\nthe pathophysiology of acne, but acne is not primarily considered a bacterial skin infection.\\nCellulitis\\nCellulitis is acute bacterial infection of the skin and subcutaneous tissue most often caused by\\nstreptococci or staphylococci. Symptoms and signs are pain, rapidly spreading erythema, and\\nedema; fever may occur, and regional lymph nodes may enlarge. Diagnosis is by appearance;\\ncultures are sometimes helpful but awaiting culture results should not delay empiric therapy.\\nTreatment is with antibiotics. Prognosis is excellent with timely treatment.\\nEtiology\\n \\nStreptococcus pyogenes\\n \\nStaphylococcus aureus\\nCellulitis is most often caused by group A \\n\\n-hemolytic streptococci (eg, \\nStreptococcus pyogenes\\n) or\\nStaphylococcus aureus\\n. Streptococci cause diffuse, rapidly spreading infection because enzymes\\nproduced by the organism (streptokinase, DNase, hyaluronidase) break down cellular components that\\nwould otherwise contain and localize the inflammation. Staphylococcal cellulitis is typically more localized\\nand usually occurs in open wounds or cutaneous abscesses.\\nRecently, methicillin-resistant \\nS. aureus\\n (MRSA) has become more common in the community\\n(community-associated MRSA [CA-MRSA]). Historically, MRSA was typically confined to patients who\\nwere exposed to the organism in a hospital or nursing facility. MRSA infection should now be considered\\nin patients with community-acquired cellulitis, particularly in those with cellulitis that is recurrent or\\nunresponsive to monotherapy.\\nLess common causes are group B streptococci (eg, \\nStreptococcus agalactiae\\n) in older patients with\\ndiabetes; gram-negative bacilli (eg, \\nHaemophilus influenzae\\n) in children; and \\nPseudomonas aeruginosa\\nin patients with diabetes or neutropenia, hot tub or spa users, and hospitalized patients. Animal bites may\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n811'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 821, 'page_label': '812'}, page_content=\"result in cellulitis; \\nPasteurella multocida\\n is the cause in cat bites, and \\nCapnocytophaga\\n sp is \\nresponsible\\nin dog bites. Immersion injuries in fresh water may result in cellulitis caused by \\nAeromonas hydrophila\\n; in\\nwarm salt water, by \\nVibrio vulnificus\\n.\\nRisk factors include skin abnormalities (eg, trauma, ulceration, fungal infection, other skin barrier\\ncompromise due to preexisting skin disease), which are common in patients with chronic venous\\ninsufficiency or lymphedema. Scars from saphenous vein removal for cardiac or vascular surgery are\\ncommon sites for recurrent cellulitis, especially if tinea pedis is present. Frequently, no predisposing\\ncondition or site of entry is evident.\\nSymptoms and Signs\\nInfection is most common in the lower extremities. Cellulitis is typically unilateral; stasis dermatitis closely\\nmimics cellulitis but is usually bilateral. The major findings are local erythema and tenderness, frequently\\nwith lymphangitis and regional lymphadenopathy. The skin is hot, red, and edematous (see\\nPlate 31\\n), often with surface appearance resembling the skin of an orange (peau d'orange). The borders\\nare usually indistinct, except in erysipelas (a type of cellulitis with sharply demarcated marginssee p.\\n696\\n). Petechiae are common; large areas of ecchymosis are rare. Vesicles and bullae may develop and\\nrupture, occasionally with necrosis of the involved skin. Cellulitis may mimic deep venous thrombosis but\\ncan often be differentiated by one or more features (see\\nTable 81-1\\n). Fever, chills, tachycardia, headache, hypotension, and delirium may precede cutaneous\\nfindings by several hours, but many patients do not appear ill. Leukocytosis is common.\\n[\\nTable 81-1.\\n Differentiating Cellulitis and Deep Venous Thrombosis]\\nDiagnosis\\n Examination\\n Blood and sometimes tissue cultures for immunocompromised patients\\nDiagnosis is by examination. Skin and (when present) wound cultures are generally not indicated\\nbecause they rarely identify the infecting organism. Blood cultures are useful in immunocompromised\\npatients to detect or rule out bacteremia. Culture of involved tissue may be required in\\nimmunocompromised patients if they are not responding to empiric therapy or if blood cultures do not\\nisolate an organism.\\nPrognosis\\nMost cellulitis resolves quickly with antibiotic therapy. Local abscesses occasionally form, requiring\\nincision and drainage. Serious but rare complications include severe necrotizing subcutaneous infection\\n(see p. \\n700\\n) and bacteremia with metastatic foci of infection.\\nRecurrences in the same area are common, sometimes causing serious damage to the lymphatics,\\nchronic lymphatic obstruction, and lymphedema.\\nTreatment\\n Antibiotics\\nTreatment is with antibiotics. For most patients, empiric treatment effective against both group A\\nstreptococci and \\nS. aureus\\n is used. Oral therapy is usually adequate with dicloxacillin 250 mg or\\ncephalexin 500 mg qid for mild infections. Levofloxacin 500 mg po once/day or moxifloxacin 400 mg\\nonce/day works well for patients who are unlikely to adhere to multiple daily dosing schedules. For more\\nserious infections, oxacillin or nafcillin 1 g IV q 6 h is given. Use of initial empiric therapy against MRSA is\\nnot typically advised unless there is compelling clinical evidence (eg, contact with a documented case or\\noutbreak; culture-documented prevalence of > 10% or 15% in a practice area). For penicillin-allergic\\npatients or those with suspected or confirmed MRSA infection, vancomycin 1 g IV q 12 h is the drug of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n812\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 822, 'page_label': '813'}, page_content='choice (see also p. \\n1230\\n). Linezolid is another option for the treatment of MRSA at a dose of 600 mg IV or\\npo q 12 h for 10 to 14 days. Teicoplanin has a mechanism of action similar to vancomycin. It is commonly\\nused outside the US to treat MRSA; the usual dose is 6 mg/kg IV q 12 h for 2 doses, followed by 6 mg/kg\\n(or 3 mg/kg) IV or IM once/day. Immobilization and elevation of the affected area help reduce edema; cool,\\nwet dressings relieve local discomfort.\\nCellulitis in a patient with neutropenia requires empiric antipseudomonal antibiotics (eg, tobramycin 1.5\\nmg/kg IV q 8 h and piperacillin 3 g IV q 4 h) until blood culture results are available. Penicillin is the drug\\nof choice for cellulitis caused by \\nP. multocida\\n; an aminoglycoside (eg, gentamicin) is effective against \\nA.\\nhydrophila\\n, and tetracycline is preferred for \\nV. vulnificus\\n infections.\\nRecurrent leg cellulitis is prevented by treating concomitant tinea pedis, which often eliminates the source\\nof bacteria residing in the inflamed, macerated tissue. If such therapy is unsuccessful or not indicated,\\nrecurrent cellulitis can sometimes be prevented by benzathine penicillin 1.2 million units IM monthly or\\npenicillin V or erythromycin 250 mg po qid for 1 wk/mo. If these regimens prove unsuccessful, tissue\\nculture may be required.\\nErysipelas\\nErysipelas is a type of superficial cellulitis (see p. \\n694\\n) with dermal lymphatic involvement.\\nErysipelas should not be confused with erysipeloid, a skin infection caused by \\nErysipelothrix\\n (see p.\\n1241\\n). Erysipelas is characterized clinically by shiny, raised, indurated, and tender plaque-like lesions\\nwith distinct margins (see\\nPlate 33\\n). There is also a bullous form of erysipelas. Erysipelas is most often caused by group A (or rarely\\ngroup C or G) \\n\\n-hemolytic streptococci and occurs most frequently on the legs and face. However, other\\ncauses have been reported, including \\nStaphylococcus aureus\\n (including methicillin-resistant \\nS. aureus\\n[MRSA]), \\nKlebsiella pneumoniae\\n, \\nHaemophilus influenzae\\n, \\nEscherichia coli\\n, \\nS. warneri\\n, \\nStreptococcus\\npneumoniae\\n, \\nS. pyogenes\\n, and \\nMoraxella\\n sp. Erysipelas of the face must be differentiated from herpes\\nzoster, angioedema, and contact dermatitis. It is commonly accompanied by high fever, chills, and\\nmalaise; MRSA is more common in facial erysipelas than in lower-extremity erysipelas. Erysipelas may be\\nrecurrent and may result in chronic lymphedema.\\nDiagnosis\\nDiagnosis is by characteristic appearance; blood culture is done in toxic-appearing patients. Diffuse\\ninflammatory carcinoma of the breast may also be mistaken for erysipelas.\\nTreatment\\n Usually penicillin for lower-extremity erysipelas\\n Initially vancomycin for facial erysipelas\\nTreatment of choice for lower-extremity erysipelas is penicillin V 500 mg po qid for  2 wk. In severe\\ncases, penicillin G 1.2 million units IV q 6 h is indicated, which can be replaced by oral therapy after 36 to\\n48 h. Dicloxacillin 500 mg po qid for 10 days can be used for infections with staphylococci. Erythromycin\\n500 mg po qid for 10 days may be used in penicillin-allergic patients; however, there is growing macrolide\\nresistance in streptococci. In infections resistant to these antibiotics, cloxacillin or nafcillin can be used. In\\nEurope, pristinamycin and roxithromycin have been shown to be good choices for erysipelas. If facial\\nerysipelas is present or if MRSA is otherwise suspected, empiric therapy should be initiated with\\nvancomycin 1 g IV q 12 h (which is active against MRSA). Cold packs and analgesics may relieve local\\ndiscomfort. Fungal foot infections may be an entry site for infection and may require antifungal treatment\\nto prevent recurrence.\\nCutaneous Abscess\\nA cutaneous abscess is a localized collection of pus in the skin and may occur on any skin\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n813'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 823, 'page_label': '814'}, page_content='surface. Symptoms and signs are pain and a tender, firm or fluctuant swelling. Diagnosis is\\nusually obvious by examination. Treatment is incision and drainage.\\nBacteria causing cutaneous abscesses are typically indigenous to the skin of the involved area. For\\nabscesses on the trunk, extremities, axillae, or head and neck, the most common organisms are\\nStaphylococcus aureus\\n and streptococci. In recent years, methicillin-resistant \\nS. aureus\\n (MRSA) has\\nbecome a more common cause.\\nAbscesses in the perineal (ie, inguinal, vaginal, buttock, perirectal) region contain organisms found in the\\nstool, commonly anaerobes or a combination of aerobes and anaerobes. Carbuncles and furuncles are\\nfollicle-based cutaneous abscesses with characteristic features (see p. \\n697\\n).\\nCutaneous abscesses tend to form in patients with bacterial overgrowth, antecedent trauma (particularly\\nwhen a foreign body is present), or immunologic or circulatory compromise.\\nSymptoms and Signs\\nCutaneous abscesses are painful, tender, indurated, and sometimes erythematous. They vary in size,\\ntypically 1 to 3 cm in length, but sometimes much larger. Initially the swelling is firm; later, as the abscess\\n\"points,\" the overlying skin becomes thin and feels fluctuant. \\nThe abscess may then spontaneously drain.\\nLocal cellulitis, lymphangitis, regional lymphadenopathy, fever, and leukocytosis are variable\\naccompanying features.\\nDiagnosis\\n Examination\\n Gram stain and culture to identify MRSA\\nDiagnosis is usually obvious by examination. Gram stain and culture are recommended, primarily to\\nidentify MRSA.\\nConditions resembling simple cutaneous abscesses include hidradenitis suppurativa (see p. \\n698\\n) and\\nruptured epidermal cysts. Epidermal cysts (often incorrectly referred to as sebaceous cysts) rarely\\nbecome infected; however, rupture releases keratin into the dermis, causing an exuberant inflammatory\\nreaction sometimes clinically resembling infection. Culture of these ruptured cysts seldom reveals any\\nbacteria. Perineal abscesses may represent cutaneous emergence of a deeper perirectal abscess or\\ndrainage from Crohn\\'s disease via a fistulous tract. These other conditions are usually recognizable by\\nhistory and rectal examination.\\nTreatment\\n Incision and drainage\\n Sometimes antibiotics\\nSome small abscesses resolve without treatment, coming to a point and draining. Warm compresses help\\naccelerate the process. Incision and drainage are indicated when significant pain, tenderness, and\\nswelling are present; it is unnecessary to await fluctuance. Under sterile conditions, local anesthesia is\\nadministered as either a lidocaine injection or a freezing spray.\\nPatients with large, extremely painful abscesses may benefit from IV sedation and analgesia during\\ndrainage. A single puncture with the tip of a scalpel is often sufficient to open the abscess. After the pus\\ndrains, the cavity should be bluntly probed with a gloved finger or curette to clear loculations, and then\\nirrigated with 0.9% saline solution. Some clinicians pack the cavity loosely with a gauze wick that is\\nremoved 24 to 48 h later. Local heat and elevation may hasten resolution of inflammation.\\nAntibiotics are unnecessary unless the patient has signs of systemic infection, cellulitis, multiple\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n814'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 824, 'page_label': '815'}, page_content='abscesses, immunocompromise, or a facial abscess in the area drained by the cavernous sinus. In these\\ncases, empiric therapy should be started with a drug active against MRSA (eg,\\ntrimethoprim/sulfamethoxazole, clindamycin; for severe infection, vancomycin) pending results of bacterial\\nculture.\\nFolliculitis\\nFolliculitis is a bacterial infection of hair follicles.\\nFolliculitis is usually caused by \\nStaphylococcus aureus\\n but occasionally \\nPseudomonas aeruginosa\\n (hot\\ntub folliculitis) or other organisms. Hot tub folliculitis occurs because of inadequate treatment of water\\nwith chlorine or bromine.\\nSymptoms of folliculitis are mild pain, pruritus, or irritation. Signs of folliculitis are a superficial pustule or\\ninflammatory nodule surrounding a hair follicle. Infected hairs easily fall out or are removed, but new\\npapules tend to develop. Growth of stiff hairs into the skin may cause chronic low-grade irritation or\\ninflammation that may mimic infectious folliculitis (pseudofolliculitis barbaesee p. \\n731\\n).\\nTreatment\\nBecause most folliculitis is caused by \\nS. aureus\\n, clindamycin 1% lotion or gel may be applied topically bid\\nfor 7 to 10 days. Alternatively, benzoyl peroxide 5% wash may be used when showering for 5 to 7 days.\\nExtensive cutaneous involvement may warrant systemic therapy (eg, cephalexin 250 to 500 mg po tid to\\nqid for 10 days). If these measures do not result in a cure, or folliculitis recurs, pustules are Gram stained\\nand cultured to rule out gram-negative or methicillin-resistant \\nS. aureus\\n (MRSA) etiology, and nares are\\ncultured to rule out nasal staphylococcal carriage. Potassium hydroxide wet mount should be done on a\\nplucked hair to rule out fungal folliculitis.\\nTreatment for MRSA usually requires 2 oral antibiotics, and the choice of therapeutic drugs should be\\nbased on culture and sensitivity reports.\\nHot tub folliculitis usually resolves without treatment. However, adequate chlorination of the hot tub is\\nnecessary to prevent recurrences and to protect others from infection.\\nFuruncles and Carbuncles\\nFuruncles are skin abscesses caused by staphylococcal infection, which involve a hair follicle\\nand surrounding tissue. Carbuncles are clusters of furuncles connected subcutaneously,\\ncausing deeper suppuration and scarring. They are smaller and more superficial than\\nsubcutaneous abscesses (see p. \\n696\\n). Diagnosis is by appearance. Treatment is warm\\ncompresses and often oral antistaphylococcal antibiotics.\\nBoth furuncles and carbuncles may affect healthy young people but are more common in the obese, the\\nimmunocompromised (including those with neutrophil defects), the elderly, and possibly those with\\ndiabetes. Clustered cases may occur among those living in crowded quarters with relatively poor hygiene\\nor among contacts of patients infected with virulent strains. Predisposing factors include bacterial\\ncolonization of skin or nares, hot and humid climates, and occlusion or abnormal follicular anatomy (eg,\\ncomedones in acne). Methicillin-resistant \\nStaphylococcus aureus\\n (MRSA) is a common cause.\\nFuruncles are common on the neck, breasts, face, and buttocks. They are uncomfortable and may be\\npainful when closely attached to underlying structures (eg, on the nose, ear, or fingers). Appearance is a\\nnodule or pustule that discharges necrotic tissue and sanguineous pus. Carbuncles may be accompanied\\nby fever and prostration.\\nDiagnosis\\nDiagnosis is by examination. Material for culture should be obtained.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n815'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 825, 'page_label': '816'}, page_content=\"Treatment\\n Drainage\\n Often antibiotics effective against MRSA\\nAbscesses are incised and drained. Intermittent hot compresses are used to facilitate drainage.\\nAntibiotics, when used, should be effective against MRSA, pending culture and sensitivity test results. In\\nafebrile patients, treatment of a single lesion < 5 mm requires no antibiotics. If a single lesion is  5 mm,\\nan oral antibiotic is given for 5 to 10 days; choices include trimethoprim/sulfamethoxazole (TMP/SMX)\\n160/800 mg to 320/1600 mg bid, clindamycin 300 to 600 mg q 6 to 8 h, and doxycycline or minocycline\\n100 mg q 12 h. Patients with fever, multiple abscesses, or carbuncles are given 10 days of TMP/SMX\\n160/800 mg to 320/1600 mg bid plus rifampin 300 mg bid. Systemic antibiotics are also needed for\\n Lesions < 5 mm that do not resolve with drainage\\n Evidence of expanding cellulitis\\n Immunocompromised patients\\n Patients at risk of endocarditis\\nFuruncles frequently recur and can be prevented by applying liquid soap containing either chlorhexidine\\ngluconate with isopropyl alcohol or 2 to 3% chloroxylenol and by giving maintenance antibiotics over 1 to\\n2 mo. Patients with recurrent furunculosis should be treated for predisposing factors such as obesity,\\ndiabetes, occupational or industrial exposure to inciting factors, and nasal carriage of \\nS. aureus\\n or MRSA\\ncolonization.\\nErythrasma\\nErythrasma is an intertriginous infection with \\nCorynebacterium minutissimum\\n that is most\\ncommon among patients with diabetes and among people living in the tropics.\\nErythrasma resembles tinea or intertrigo. It is most common in the foot, where it manifests as superficial\\nscaling, fissuring, and maceration most commonly confined to the 3rd and 4th web spaces. Erythrasma is\\nalso common in the groin, where it manifests as irregular but sharply marginated pink or brown patches\\nwith fine scaling. Erythrasma may also involve the axillae, submammary or abdominal folds, and\\nperineum, particularly in obese middle-aged women and in patients with diabetes.\\nErythrasma fluoresces a characteristic coral-red color under Wood's light. Absence of hyphae in skin\\nscrapings also distinguishes erythrasma from tinea.\\nTreatment is erythromycin or tetracycline 250 mg po qid for 14 days. Topical erythromycin or clindamycin\\nis also effective. Recurrence is common.\\nHidradenitis Suppurativa\\nHidradenitis suppurativa is a chronic, scarring inflammation of apocrine glands of the axillae,\\ngroin, and around the nipples and anus.\\nBlockage of apocrine ducts has been suggested as the cause, leading to subsequent inflammation,\\nbacterial overgrowth, and scarring. \\nStaphylococcus aureus\\n is almost always implicated in acute cases,\\nbut gram-negative organisms such as \\nProteus\\n may predominate in chronic cases.\\nSwollen, tender masses resembling cutaneous abscesses develop. Pain, fluctuance, discharge, and\\nsinus tract formation are characteristic in chronic cases. In chronic axillary cases, coalescence of inflamed\\nnodules causes palpable cordlike fibrotic bands. The condition may become disabling because of pain\\nand foul odor.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n816\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 826, 'page_label': '817'}, page_content='Diagnosis\\nDiagnosis is by examination. Bacterial cultures may be helpful if there appears to be a concomitant\\ncellulitis or loculated abscess.\\nTreatment\\nTreatment of acute cases consists of high-dose oral tetracycline (500 mg bid), doxycycline (100 to 200\\nmg once/day), minocycline (100 mg once/day), or erythromycin (250 to 500 mg qid) until the lesions\\nresolve. Topical clindamycin applied bid may be equally effective. Incision and drainage are necessary for\\nan abscess or fluctuance of the affected area but alone do not resolve the problem (unlike in cutaneous\\nabscesses). Isotretinoin 1 mg/kg po bid has also been effective in some patients, but recurrences are\\ncommon. Intralesional corticosteroid injections (eg, triamcinolone 1 to 10% suspension intradermally) may\\nhelp with inflammation and pain. Surgical excision and repair or grafting of the affected areas is often\\nnecessary if the disease persists. Ablative laser therapy (CO\\n2\\n or erbium:YAG) is an alternate surgical\\ntreatment. Several studies report success in treating hidradenitis suppurativa with etanercept or\\ninfliximab, injectable tumor necrosis factor-\\n\\n inhibitors. Although not the gold standard, this option may be\\nuseful when all other treatment modalities have failed.\\nImpetigo and Ecthyma\\nImpetigo is a superficial skin infection with crusting or bullae caused by streptococci,\\nstaphylococci, or both. Ecthyma is an ulcerative form of impetigo.\\nNo predisposing lesion is identified in most patients, but impetigo may follow any type of break in the skin.\\nGeneral risk factors seem to be moist environment, poor hygiene, and chronic nasal carriage of\\nstaphylococci. Impetigo may be bullous or nonbullous. \\nStaphylococcus aureus\\n is the predominant cause\\nof nonbullous impetigo and the cause of all bullous impetigo. Bullae are caused by exfoliative toxin\\nproduced by staphylococci. Methicillin-resistant \\nS. aureus\\n (MRSA) has been isolated in about 20% of\\nrecent cases of impetigo.\\nSymptoms and Signs\\nNonbullous impetigo typically manifests as clusters of vesicles or pustules that rupture and develop a\\nhoney-colored crust (exudate from the lesion base) over the lesions (see\\nPlate 35\\n). Bullous impetigo is similar except that vesicles typically enlarge rapidly to form bullae. The\\nbullae burst and expose larger bases, which become covered with honey-colored varnish or crust.\\nEcthyma is characterized by small, purulent, shallow, punched-out ulcers with thick, brown-black crusts\\nand surrounding erythema.\\nImpetigo and ecthyma cause mild pain or discomfort. Pruritus is common; scratching may spread\\ninfection, inoculating adjacent and nonadjacent skin.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is by characteristic appearance. Cultures of lesions are indicated only when the patient does\\nnot respond to empiric therapy. Patients with recurrent impetigo should have nasal culture. Persistent\\ninfections should be cultured to identify MRSA.\\nTreatment\\n Topical mupirocin or retapamulin\\n Sometimes oral antibiotics\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n817'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 827, 'page_label': '818'}, page_content='The affected area should be washed gently with soap and water several times a day to remove any\\ncrusts. Treatment for localized disease is topical mupirocin antibiotic ointment tid for 7 days or retapamulin\\nointment bid for 5 days. Oral antibiotics (eg, dicloxacillin or cephalexin 250 to 500 mg qid, 12.5 mg/kg qid\\nfor children, for 10 days) may be needed in patients with extensive or resistant lesions. Use of initial\\nempiric therapy against MRSA is not typically advised unless there is compelling clinical evidence (eg,\\ncontact with a documented case or outbreak; high culture-documented prevalence in a practice area).\\nTreatment of MRSA should be directed by culture and sensitivity test results; typically, clindamycin,\\nrifampin, and trimethoprim/sulfamethoxazole are effective against most strains of community-associated\\nMRSA.\\nOther therapy includes restoring a normal cutaneous barrier in patients with underlying atopic dermatitis\\nor extensive xerosis using topical emollients and corticosteroids if warranted. Chronic staphylococcal\\nnasal carriers are given topical antibiotics (mupirocin) for 1 wk each of 3 consecutive months.\\nPrompt recovery usually follows timely treatment. Delay can cause cellulitis, lymphangitis, furunculosis,\\nand hyperpigmentation or hypopigmentation with or without scarring. Children aged 2 to 4 yr are at risk of\\nacute glomerulonephritis if nephritogenic strains of group A streptococci are involved; nephritis seems to\\nbe more common in the southern US than in other regions.\\nLymphadenitis\\n(See also \\nLymphangitis\\n, below.)\\nLymphadenitis is an acute infection of one or more lymph nodes.\\nLymphadenitis is a feature of many bacterial, viral, fungal, and protozoal infections. Focal lymphadenitis is\\nprominent in streptococcal infection, TB or nontuberculous mycobacterial infection, tularemia, plague, cat-\\nscratch disease, primary syphilis, lymphogranuloma venereum, chancroid, and genital herpes simplex.\\nMultifocal lymphadenitis is common in infectious mononucleosis, cytomegalovirus infection,\\ntoxoplasmosis, brucellosis, secondary syphilis, and disseminated histoplasmosis.\\nSymptoms and Signs\\nLymphadenitis typically causes pain, tenderness, and lymph node enlargement. Pain and tenderness\\ntypically distinguish lymphadenitis from lymphadenopathy. With some infections, the overlying skin is\\ninflamed, occasionally with cellulitis. Abscesses may form, and penetration to the skin produces draining\\nsinuses. Fever is common.\\nDiagnosis\\nThe underlying disorder is usually suggested by history and examination. If not, aspiration and culture or\\nexcisional biopsy is indicated.\\nTreatment\\n Treatment of cause\\nTreatment is directed at the cause and is usually empiric. Options include IV antibiotics, antifungals, and\\nantiparasitics depending upon etiology or clinical suspicion. Many patients with lymphadenitis may\\nrespond to outpatient therapy with oral antibiotics. However, many also go on to form abscesses, which\\nrequire surgical drainage; an extensive procedure is done with accompanying IV antibiotics. In children, IV\\nantibiotics are commonly needed. Hot, wet compresses may relieve some pain. Lymphadenitis usually\\nresolves with timely treatment, although residual, persistent, nontender lymphadenopathy is common.\\nLymphangitis\\n(See also \\nLymphadenitis\\n, above.)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n818'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 828, 'page_label': '819'}, page_content=\"Lymphangitis is acute bacterial infection (usually streptococcal) of peripheral lymphatic\\nchannels.\\nBacteria enter the lymphatic channels from an abrasion, wound, or coexisting infection (usually cellulitis).\\nPatients with underlying lymphedema are at particular risk. Red, irregular, warm, tender streaks develop\\non an extremity and extend proximally from a peripheral lesion toward regional lymph nodes, which are\\ntypically enlarged and tender. Systemic manifestations (eg, fever, shaking chills, tachycardia, headache)\\nmay occur and may be more severe than cutaneous findings suggest. Leukocytosis is common.\\nBacteremia may occur. Rarely, cellulitis with suppuration, necrosis, and ulceration develops along the\\ninvolved lymph channels as a consequence of primary lymphangitis.\\nDiagnosis is clinical. Isolation of the responsible organism is usually unnecessary. Most cases respond\\nrapidly to antistreptococcal antibiotics (see \\nCellulitis\\n on p. \\n694\\n).\\nNecrotizing Subcutaneous Infection\\n(Necrotizing Fasciitis)\\nNecrotizing subcutaneous infection (NSI) is typically caused by a mixture of aerobic and\\nanaerobic organisms that cause necrosis of subcutaneous tissue, usually including the fascia.\\nThis infection most commonly affects the extremities and perineum. Affected tissues become\\nred, hot, and swollen, resembling severe cellulitis (see p. \\n694\\n). Without timely treatment, the\\narea becomes gangrenous. Patients are acutely ill. Diagnosis is by history and examination and\\nis supported by evidence of overwhelming infection. Treatment involves antibiotics and\\nsurgical debridement. Prognosis is poor without early, aggressive treatment.\\nEtiology\\nNSI typically results from infection with group A streptococci (eg, \\nStreptococcus pyogenes\\n) or a mixture of\\naerobic and anaerobic bacteria (eg, \\nBacteroides\\n sp). These organisms typically extend to subcutaneous\\ntissue from a contiguous ulcer, an infection, or after trauma. Streptococci can arrive from a remote site of\\ninfection via the bloodstream. Perineal involvement (also called Fournier's gangrene) is usually a\\ncomplication of recent surgery, perirectal abscess, periurethral gland infection, or retroperitoneal infection\\nfrom perforated abdominal viscera. Patients with diabetes are at particular risk of NSI.\\nPathophysiology\\nNSI causes tissue ischemia by widespread occlusion of small subcutaneous vessels. Vessel occlusion\\nresults in skin infarction and necrosis, which facilitates the growth of obligate anaerobes (eg,\\nBacteroides\\n) while promoting anaerobic metabolism by facultative organisms (eg, \\nEscherichia coli\\n),\\nresulting in gangrene. Anaerobic metabolism produces hydrogen and nitrogen, relatively insoluble gases\\nthat may accumulate in subcutaneous tissues.\\nSymptoms and Signs\\nThe primary symptom is intense pain. However, in areas denervated by peripheral neuropathy, pain may\\nbe minimal or absent. Affected tissue is red, hot, and swollen and rapidly becomes discolored. Bullae,\\ncrepitus (from soft-tissue gas), and gangrene may develop. Subcutaneous tissues (including adjacent\\nfascia) necrose, with widespread undermining of surrounding tissue. Muscles are spared initially. Patients\\nare acutely ill, with high fever, tachycardia, altered mental status ranging from confusion to obtundation,\\nand hypotension. Patients may be bacteremic or septic and may require aggressive hemodynamic\\nsupport.\\nDiagnosis\\n Clinical examination\\n Blood and wound cultures\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n819\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 829, 'page_label': '820'}, page_content='Diagnosis, made by history and examination, is supported by leukocytosis, soft-tissue gas on x-ray,\\npositive blood cultures, and deteriorating metabolic and hemodynamic status.\\nNSI must be differentiated from clostridial soft-tissue infections, in which cellulitis, myositis, and\\nmyonecrosis often occur (see p. \\n1295\\n). Such infections are anaerobic. Anaerobic cellulitis produces lots\\nof gas but little pain, edema, or change in skin; it very seldom travels into the muscle. Anaerobic\\nmyonecrosis has pronounced skin changes, pain, and edema and usually penetrates into muscle.\\nPrognosis\\nMortality rate is about 30%. Old age, underlying medical problems, delayed diagnosis and therapy, and\\ninsufficient surgical debridement worsen prognosis.\\nTreatment\\n Surgical debridement\\n Antibiotics\\n Amputation if necessary\\nTreatment of early NSI is primarily surgical. IV antibiotics are adjuncts, usually including 2 or more drugs,\\nbut regimens vary depending on results of Gram stain and culture (eg, penicillin G 4 million units q 4 h\\ncombined with clindamycin 600 to 900 mg q 8 h or ceftriaxone 2 g q 12 h). Evidence of bullae,\\necchymosis, fluctuance, crepitus, and systemic spread of infection requires immediate surgical\\nexploration and debridement. The initial incision should be extended until an instrument or finger can no\\nlonger separate the skin and subcutaneous tissue from the deep fascia. The most common error is\\ninsufficient surgical intervention; repeat operation every 1 to 2 days, with further incision and debridement\\nas needed, should be carried out routinely. Amputation of an extremity may be necessary.\\nIV fluids may be needed in large volumes before and after surgery. Antibiotic choices should be reviewed\\nbased on Gram stain and culture of tissues obtained during surgery. Hyperbaric O\\n2\\n therapy as adjuvant\\ntherapy may also be of benefit; however, the evidence is inconclusive.\\nStaphylococcal Scalded Skin Syndrome\\nStaphylococcal scalded skin syndrome (SSSS) is an acute epidermolysis caused by a\\nstaphylococcal toxin. Infants and children are most susceptible. Symptoms are widespread\\nbullae with epidermal sloughing. Diagnosis is by examination and sometimes biopsy. Treatment\\nis antistaphylococcal antibiotics and local care. Prognosis is excellent with timely treatment.\\nSSSS almost always affects children < 6 yr (especially infants); it rarely occurs in older patients unless\\nthey have renal failure or are immunocompromised. Epidemics may occur in nurseries, presumably\\ntransmitted by the hands of personnel who are in contact with an infected infant or who are nasal carriers\\nof \\nStaphylococcus aureus\\n. Sporadic cases also occur.\\nSSSS is caused by group II coagulase-positive staphylococci, usually phage type 71, which elaborate\\nexfoliatin (also called epidermolysin), a toxin that splits the upper part of the epidermis just beneath the\\ngranular cell layer (see also p. \\n1228\\n). The primary infection often begins during the first few days of life in\\nthe umbilical stump or diaper area; in older children, the face is the typical site. Toxin produced in these\\nareas enters the circulation and affects the entire skin.\\n[\\nTable 81-2.\\n Differentiating Staphylococcal Scalded Skin Syndrome (SSSS) and Toxic Epidermal\\nNecrolysis (TEN)]\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n820'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 830, 'page_label': '821'}, page_content=\"The initial lesion is usually superficial and crusted. Within 24 h, the surrounding skin becomes painful and\\nscarlet, changes that quickly spread to other areas. The skin may be exquisitely tender and have a\\nwrinkled tissue paper-like consistency. Large, flaccid blisters arise on the erythematous skin and quickly\\nbreak to produce erosions. Intact blisters extend laterally with gentle pressure (Nikolsky's sign). The\\nepidermis may peel easily, often in large sheets (see\\nPlate 45\\n). Widespread desquamation occurs within 36 to 72 h, and patients become very ill with systemic\\nmanifestations (eg, malaise, chills, fever). Desquamated areas appear scalded. Loss of the protective\\nskin barrier can lead to sepsis and to fluid and electrolyte imbalance.\\nDiagnosis\\n Biopsy\\n Cultures may be useful in adults\\nDiagnosis is suspected clinically, but confirmation usually requires biopsy (frozen section may give earlier\\nresults). Specimens show noninflammatory superficial splitting of the epidermis. In children, skin cultures\\nare seldom positive; in adults, they are frequently positive. Cultures should be taken from the nose,\\nconjunctiva, throat, and nasopharynx.\\nDifferential diagnosis:\\n Differential diagnosis includes drug hypersensitivity, viral exanthemas, scarlet\\nfever, thermal burns, genetic bullous diseases (eg, some types of epidermolysis bullosa), acquired\\nbullous diseases (eg, pemphigus vulgaris, bullous pemphigoid), and toxic epidermal necrolysis (see p.\\n689\\n and \\nTable 81-2\\n). Stevens-Johnson syndrome is characterized by mucosal involvement, which is\\nabsent in SSSS.\\nTreatment\\n Antibiotics\\n Corticosteroids not recommended\\n Gel dressings for weeping lesions\\nWith prompt diagnosis and therapy, death rarely occurs; the stratum corneum is quickly replaced, and\\nhealing usually occurs within 5 to 7 days after start of treatment.\\nPenicillinase-resistant antistaphylococcal antibiotics given IV must be started immediately. Nafcillin 12.5 to\\n25 mg/kg IV q 6 h for neonates > 2 kg and 25 to 50 mg/kg for older children is given until improvement is\\nnoted, followed by oral cloxacillin 12.5 mg/kg q 6 h (for infants and children weighing  20 kg) and 250 to\\n500 mg q 6 h (for older children). Corticosteroids are contraindicated. Topical therapy and patient\\nhandling must be minimized.\\nIf disease is widespread and lesions are weeping, the skin should be treated as for burns (see p.\\n3245\\n). Hydrolyzed polymer gel dressings may be very useful, and the number of dressing changes should\\nbe minimized.\\nSteps to detect carriers and prevent or treat nursery epidemics are discussed elsewhere (see p. \\n2828\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 81. Bacterial Skin Infections\\n821\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 831, 'page_label': '822'}, page_content=\"Chapter 82. Fungal Skin Infections\\nIntroduction\\nFungal skin infections are caused by yeasts (\\nCandida\\n sp) or dermatophytes (\\nEpidermophyton\\n,\\nMicrosporum\\n, and \\nTrichophyton\\n spp).\\nCandidiasis\\nCandidiasis (moniliasis) is skin infection with \\nCandida\\n sp, most commonly \\nCandida albicans\\n.\\nInfections can occur anywhere and are most common in skinfolds and web spaces and on the\\ngenitals, cuticles, and oral mucosa. Symptoms and signs vary by site. Diagnosis is by clinical\\nappearance and potassium hydroxide wet mount of skin scrapings. Treatment is with drying\\nagents and antifungals.\\nMost candidal infections are of the skin and mucous membranes, but invasive candidiasis is common in\\nimmunosuppressed patients and can be life threatening. Systemic candidiasis is discussed in \\nCh. 142\\n.\\nEtiology\\nCandida\\n is a group of about 150 yeast species. \\nC. albicans\\n is responsible for about 70 to 80% of all\\ncandidal infections. Other significant species include \\nC. glabrata\\n, \\nC. tropicalis\\n, \\nC. krusei\\n, and \\nC.\\ndubliniensis\\n.\\nCandida\\n is a ubiquitous yeast that resides harmlessly on skin and mucous membranes until dampness,\\nheat, and impaired local and systemic defenses provide a fertile environment for it to grow. Risk factors\\nfor candidiasis include\\n Hot weather\\n Restrictive clothing\\n Poor hygiene\\n Infrequent diaper or undergarment changes in children and elderly patients\\n Altered flora from antibiotic therapy\\n Inflammatory diseases (eg, psoriasis) that occur in skinfolds\\n Immunosuppression resulting from corticosteroids and immunosuppressive drugs, pregnancy, diabetes,\\nother endocrinopathies (eg, Cushing's disease, hypoadrenalism, hypothyroidism), blood dyscrasias, or\\nT-cell defects\\nCandidiasis occurs most commonly in intertriginous areas such as the axillae, groin, and gluteal folds (eg,\\ndiaper rashsee\\nPlate 30\\n), in digital web spaces, in the glans penis, and beneath the breasts. Vulvovaginal candidiasis is\\ncommon in women (see p. \\n2544\\n). Candidal nail infections and paronychia may develop after improperly\\ndone manicures and in kitchen workers and others whose hands are continually exposed to water (see p.\\n734\\n). In obese people, candidal infections may occur beneath the pannus (abdominal fold).\\nOropharyngeal candidiasis (see\\nPlate 32\\n) is a common sign of local or systemic immunosuppression.\\nChronic mucocutaneous candidiasis typically affects the nails, skin, and oropharynx. Patients have\\ncutaneous anergy to \\nCandida\\n, absent proliferative responses to \\nCandida\\n antigen (but normal proliferative\\nresponses to mitogens), and an intact antibody response to \\nCandida\\n and other antigens. Chronic\\nmucocutaneous candidiasis may occur as an autosomal recessive illness associated with\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n822\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 832, 'page_label': '823'}, page_content=\"hypoparathyroidism and Addison's disease (\\nCandida\\n-endocrinopathy syndrome).\\nSymptoms and Signs\\nIntertriginous infections manifest as pruritic, well-demarcated, erythematous patches of varying size and\\nshape; erythema may be difficult to detect in darker-skinned patients. Primary patches may have adjacent\\nsatellite papules and pustules. Perianal candidiasis produces white maceration and pruritus ani.\\nVulvovaginal candidiasis causes pruritus and discharge (see p. \\n2544\\n).\\nCandidal infection is a frequent cause of chronic paronychia, which manifests as painful red periungual\\nswelling. Subungual infections are characterized by distal separation of one or several fingernails\\n(onycholysis), with white or yellow discoloration of the subungual area (see p. \\n735\\n).\\nOropharyngeal candidiasis causes white plaques on oral mucous membranes that may bleed when\\nscraped.\\nPerleche is candidiasis at the corners of the mouth, which causes cracks and tiny fissures. It may stem\\nfrom chronic lip licking, thumb sucking, ill-fitting dentures, or other conditions that make the corners of the\\nmouth moist enough that yeast can grow.\\nChronic mucocutaneous candidiasis is characterized by red, pustular, crusted, and thickened plaques\\nresembling psoriasis, especially on the nose and forehead, and is invariably associated with chronic oral\\ncandidiasis.\\nDiagnosis\\n Clinical appearance\\n Potassium hydroxide wet mounts\\nDiagnosis is based on clinical appearance and identification of yeast and pseudohyphae in potassium\\nhydroxide wet mounts of scrapings from a lesion. Positive culture is usually meaningless because\\nCandida\\n is omnipresent.\\nTreatment\\n Sometimes drying agents\\n Topical or oral antifungals\\nIntertriginous infection\\n is treated with drying agents as needed (eg, Burow's solution for oozing lesions,\\ngentian violet for toe web spaces) and topical antifungals (see\\nTable 82-1\\n). Powdered formulations are ideal for dry lesions (eg, miconazole powder bid for 2 to 3 wk).\\nFluconazole 150 mg po once/wk for 2 to 4 wk is indicated for extensive intertriginous candidiasis; topical\\nantifungal agents may be used at the same time.\\nCandidal diaper rash\\n is treated with more frequent change of diapers, avoidance of disposable diapers\\nwith plastic coverings, and an imidazole cream bid. Oral nystatin is an option for infants with coexisting\\noropharyngeal candidiasis; 1 mL of suspension (100,000 units/mL) is placed in each buccal pouch qid.\\nCandidal paronychia\\n is treated by protecting the area from wetness and giving topical or oral\\nantifungals. These infections are often resistant to treatment.\\nOral candidiasis\\n is treated with fluconazole 200 mg po on the first day, then 100 mg po once/day for 2 to\\n3 wk thereafter.\\nChronic mucocutaneous candidiasis\\n requires long-term oral antifungal treatment with ketoconazole\\n400 mg once/day or itraconazole 200 mg once/day.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n823\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 833, 'page_label': '824'}, page_content='[\\nTable 82-1.\\n Options for Treatment of Superficial Fungal Infections*]\\nDermatophytoses\\nDermatophytoses are fungal infections of keratin in the skin and nails (nail infection is called\\ntinea unguiumsee p. \\n734\\n). Symptoms and signs vary by site of infection. Diagnosis is by\\nclinical appearance and by examination of skin scrapings on potassium hydroxide wet mount.\\nTreatment varies by site but always involves topical or oral antifungal drugs.\\nDermatophytes are molds that require keratin for nutrition and must live on stratum corneum, hair, or nails\\nto survive. Human infections are caused by \\nEpidermophyton\\n, \\nMicrosporum\\n, and \\nTrichophyton\\n spp. These\\ninfections differ from candidiasis in that they are rarely if ever invasive. Transmission is person-to-person,\\nanimal-to-person, and rarely, soil-to-person. The organism may persist indefinitely. Most people do not\\ndevelop clinical infection; those who do may have impaired T-cell responses from an alteration in local\\ndefenses (eg, from trauma with vascular compromise) or from primary (hereditary) or secondary (eg,\\ndiabetes, HIV) immunosuppression.\\nSymptoms and Signs\\nSymptoms and signs vary by site (skin, hair, nails). Organism virulence and host susceptibility \\nand\\nhypersensitivity determine severity. Most often, there is little or no inflammation; asymptomatic or mildly\\nitching lesions with a scaling, slightly raised border remit and recur intermittently. Occasionally,\\ninflammation is more severe and manifests as sudden vesicular or bullous disease (usually of the foot) or\\nas an inflamed boggy lesion of the scalp (kerion).\\nDiagnosis\\n Clinical appearance\\n Potassium hydroxide wet mount\\nDiagnosis is based on clinical appearance and site of infection and confirmed by skin scrapings and\\ndemonstration of hyphae on potassium hydroxide (KOH) wet mount. Identification of specific organisms\\nby culture is unnecessary except for scalp infection (where an animal source may be identified and\\ntreated) and nail infection (which may be caused by a nondermatophyte). Culture may also be useful\\nwhen overlying inflammation and bacterial infection are severe and/or accompanied by alopecia.\\nDifferential diagnosis includes\\n Folliculitis decalvans\\n Bacterial pyodermas\\n Entities that cause scarring alopecia, such as discoid lupus, lichen planopilaris, and pseudopelade\\nTreatment\\n Topical or oral antifungals\\n Sometimes corticosteroids\\nTopical antifungals are generally adequate (see \\nTable 82-1\\n). In general, OTC terbinafine is best;\\neconazole or ciclopirox may be better if candidal infection cannot be excluded. Oral antifungals are used\\nfor most nail and scalp infections, resistant skin infections, and patients unwilling or unable to adhere to\\nprolonged topical regimens; doses and duration differ by site of infection.\\nCorticosteroid creams can be used to help relieve itching and pain for the first few days. Low-dose\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n824'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 834, 'page_label': '825'}, page_content='hydrocortisone can be applied separately, or more potent corticosteroids may be added to the antifungal\\ncream. Oral corticosteroids are occasionally used for treatment of severe inflammatory lesions.\\nTinea Barbae\\n(Barber\\'s Itch)\\nTinea barbae is a dermatophyte infection of the beard area most often caused by \\nTrichophyton\\nmentagrophytes\\n or \\nT. verrucosum\\n.\\nTinea barbae manifests as superficial annular lesions, but deeper infection similar to folliculitis may occur.\\nIt may also occur as an inflammatory kerion that can result in scarring hair loss. Diagnosis is by KOH wet\\nmount, culture, or biopsy.\\nTreatment is micronized griseofulvin 500 mg to 1 g po once/day until 2 to 3 wk after clinical clearance.\\nTerbinafine 250 mg po once/day and itraconazole 200 mg po once/day have also been used. If the\\nlesions are severely inflamed, a short course of prednisone should be added (to lessen symptoms and\\nperhaps reduce the chance of scarring), starting with 40 mg po once/day (for adults) and tapering the\\ndose over 2 wk.\\nTinea Capitis\\n(Scalp Ringworm)\\nTinea capitis is a dermatophyte infection of the scalp.\\nTinea capitis mainly affects children, is contagious, and can be epidemic. \\nT. tonsurans\\n is the most\\ncommon cause in the US, followed by \\nMicrosporum canis\\n and \\nM. audouinii\\n; other \\nTrichophyton\\n sp (eg, \\nT.\\nschoenleinii\\n, \\nT. violaceum\\n) are common elsewhere.\\nTinea capitis causes the gradual appearance of round patches of dry scale, alopecia, or both. \\nT.\\ntonsurans\\n infection causes \"black dot ringworm,\" in which hair shafts break at the scalp surface; \\nM.\\naudouinii\\n infection causes \"gray patch ringworm,\" in which hair shafts break above the surface, leaving\\nshort stubs. Tinea capitis less commonly manifests as diffuse scaling, like dandruff, or in a diffuse\\npustular pattern.\\nKerion:\\n Dermatophyte infection occasionally leads to formation of a kerion, which is a large, boggy,\\ninflammatory scalp mass (see\\nPlate 48\\n) caused by a severe inflammatory reaction to the dermatophyte. A kerion may have pustules and\\ncrusting and can be mistaken for an abscess. A kerion may result in scarring hair loss.\\nDiagnosis\\n Clinical appearance\\n KOH wet mount\\n Sometimes Wood\\'s light examination\\nTinea capitis is diagnosed by clinical appearance and by KOH wet mount of plucked hairs or of hairs and\\nscale obtained by scraping or brushing. Spore size and appearance inside (endothrix) or outside\\n(ectothrix) the hair shaft distinguish organisms and can help \\nguide treatment. Blue-green fluorescence\\nduring Wood\\'s light examination is diagnostic for infection with \\nM. canis\\n and \\nM. audouinii\\n and can\\ndistinguish tinea from erythrasma.\\nDifferential diagnosis of tinea capitis includes\\n Seborrheic dermatitis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n825'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 835, 'page_label': '826'}, page_content=' Psoriasis\\nTreatment\\n Oral antifungals\\n Selenium sulfide shampoo\\n Sometimes prednisone\\nChildren are treated with micronized griseofulvin suspension 10 to 20 mg/kg po once/day (doses vary by\\nseveral parameters, but maximum dose is generally 1 g/day) or, if > 2 yr, with ultramicronized griseofulvin\\n5 to 10 mg/kg (maximum 750 mg/day) po once/day or in 2 divided doses with meals or milk for 4 to 6 wk\\nor until all signs of infection are gone. Terbinafine also may be used; children < 20 kg are given 62.5 mg\\nonce/day; those 20 to 40 kg, 125 mg once/day, and those > 40 kg, 250 mg once/day. An imidazole or\\nciclopirox cream should be applied to the scalp to prevent spread, especially to other children, until tinea\\ncapitis is cured; selenium sulfide 2.5% shampoo should also be used at least twice/wk. Children may\\nattend school during treatment.\\nAdults are treated with terbinafine 250 mg po once/day for 2 to 4 wk, which is more effective for endothrix\\ninfections, or itraconazole 200 mg once/day for 2 to 4 wk or 200 mg bid given for 1 wk, followed by 3 wk\\nwithout the drug (pulsed) for 2 to 3 mo.\\nFor severely inflamed lesions and for kerion, a short course of prednisone should be added (to lessen\\nsymptoms and perhaps reduce the chance of scarring), starting with 40 mg po once/day (1 mg/kg for\\nchildren) and tapering the dose over 2 wk.\\nTinea Corporis\\n(Body Ringworm)\\nTinea corporis is a dermatophyte infection of the face, trunk, and extremities.\\nCommon causes are \\nT. mentagrophytes\\n, \\nT. rubrum\\n, and \\nM. canis\\n.\\nTinea corporis causes pink-to-red annular patches and plaques with raised scaly borders that expand\\nperipherally and tend to clear centrally (see\\nPlate 49\\n). A variant form appears as nummular scaling patches studded with small papules or pustules.\\nDiagnosis\\n Clinical evaluation\\nDifferential diagnosis includes\\n Pityriasis rosea\\n Drug eruptions\\n Nummular dermatitis\\n Erythema multiforme\\n Tinea versicolor\\n Erythrasma\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n826'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 836, 'page_label': '827'}, page_content=' Psoriasis\\n Secondary syphilis\\nTreatment\\n Topical or oral antifungals\\nTreatment of mild-to-moderate lesions is an imidazole, ciclopirox, naftifine, or terbinafine in cream, lotion,\\nor gel. The drug should be rubbed in bid continuing at least 7 to 10 days after lesions disappear, typically\\nat about 2 to 3 wk.\\nExtensive and resistant lesions occur in patients infected with \\nT. rubrum\\n and in people with debilitating\\nsystemic diseases. For such cases, the most effective therapy is oral itraconazole 200 mg once/day or\\nterbinafine 250 mg once/day for 2 to 3 wk.\\nTinea Cruris\\n(Jock Itch)\\nTinea cruris is a dermatophyte infection of the groin.\\nCommon organisms include \\nT. rubrum\\n or \\nT. mentagrophytes\\n. The primary risk factors are associated with\\na moist environment (ie, warm weather, wet and restrictive clothing, obesity causing constant apposition\\nof skin folds). Men are affected more than women because of apposition of the scrotum and thigh.\\nTypically, a pruritic, ringed lesion extends from the crural fold over the adjacent upper inner thigh (see\\nPlate 50\\n). Infection may be bilateral. Lesions may be complicated by maceration, miliaria, secondary\\nbacterial or candidal infection, and reactions to treatment. In addition, scratch dermatitis and\\nlichenification can occur. Recurrence is common because fungi may repeatedly infect susceptible people.\\nFlare-ups occur more often during summer.\\nDiagnosis\\n Clinical evaluation\\nDifferential diagnosis includes\\n Contact dermatitis\\n Psoriasis\\n Erythrasma\\n Candidiasis\\nScrotal involvement is usually absent or slight; by contrast, the scrotum is often inflamed in candidal\\nintertrigo or lichen simplex chronicus.\\nTreatment\\n Topical antifungal cream or lotion\\nAntifungal choices include terbinafine, miconazole, clotrimazole, ketoconazole, econazole, naftifine, and\\nciclopirox applied bid for 10 to 14 days. Itraconazole 200 mg po once/day or terbinafine 250 mg po\\nonce/day for 3 to 6 wk may be needed in patients who have refractory, inflammatory, or widespread\\ninfections.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n827'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 837, 'page_label': '828'}, page_content=\"Tinea Pedis\\n(Athlete's Foot)\\nTinea pedis is a dermatophyte infection of the feet.\\nTinea pedis is the most common dermatophytosis because moisture from foot sweating facilitates fungal\\ngrowth. Tinea pedis may occur as any of 4 clinical forms or in combination:\\n Chronic hyperkeratotic\\n Chronic intertriginous\\n Acute ulcerative\\n Vesiculobullous\\nChronic hyperkeratotic\\n tinea pedis due to \\nT. rubrum\\n causes a distinctive pattern of lesion, manifesting\\nas scaling and thickening of the soles, which often extends beyond the plantar surface in a moccasin\\ndistribution. Differential diagnosis is sterile maceration (due to hyperhidrosis and occlusive footgear),\\ncontact dermatitis (due to type IV delayed hypersensitivity to various materials in shoes, particularly\\nadhesive cement, thiuram compounds in footwear that contains rubber, and chromate tanning agents\\nused in leather footwear), irritant dermatitis, and psoriasis.\\nChronic intertriginous\\n tinea pedis is characterized by scaling, erythema, and erosion of the interdigital\\nand subdigital skin of the feet, most commonly affecting the lateral 3 toes.\\nAcute ulcerative\\n tinea pedis (most often caused by \\nT. mentagrophytes\\n var. \\ninterdigitale\\n) typically begins\\nin the 3rd and 4th interdigital spaces and extends to the lateral dorsum and/or the plantar surface of the\\narch. These toe web lesions are usually macerated and have scaling borders (see\\nPlate 51\\n). Secondary bacterial infection, cellulitis, and lymphangitis are common complications.\\nVesiculobullous\\n tinea pedis, in which vesicles develop on the soles and coalesce into bullae, is the less\\ncommon result of a flare of interdigital tinea pedis; risk factors are occlusive shoes and environmental\\nheat and humidity.\\nDiagnosis\\nDiagnosis is usually obvious based on clinical examination and review of risk factors.\\nTreatment\\n Moisture reduction and drying agents\\n Topical and oral antifungals\\nThe safest treatment is topical antifungals, but recurrence is common and treatment must often be\\nprolonged. Alternatives that provide a more durable response include itraconazole 200 mg po once/day\\nfor 1 mo (or pulse therapy with 200 mg bid 1 wk/mo for 1 to 2 mo) and terbinafine 250 mg po once/day for\\n2 to 6 wk. Concomitant topical antifungal use may reduce recurrences.\\nMoisture reduction on the feet and in footwear is necessary for preventing recurrence. Permeable or\\nopen-toe footwear and sock changes are important especially during warm weather. Interdigital spaces\\nshould be manually dried after bathing. Drying agents are also recommended; options include antifungal\\npowders (eg, miconazole), gentian violet, Burow's solution (5% aluminum sub-acetate) soaks bid, and 20\\nto 25% aluminum chloride hexahydrate powder once/day.\\nDermatophytid Reaction\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n828\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 838, 'page_label': '829'}, page_content=\"Dermatophytid is an inflammatory reaction to dermatophytosis at a cutaneous site distant from\\nthe primary infection.\\nDermatophytid (identity or id) reactions are protean; they are not related to localized growth of the fungus\\nbut rather are an inflammatory reaction elsewhere on the body. Lesions are typically pruritic but may\\nmanifest as\\n Vesicular eruptions on the hands and feet\\n Follicular papules\\n Erysipelas-like plaques\\n Erythema nodosum\\n Erythema annulare centrifugum\\n Urticaria\\nDistribution may be extensive.\\nDiagnosis is by KOH wet mounts that are negative at the site of the id reaction and positive at the distant\\nsite of dermatophyte infection.\\nTreatment of the primary infection cures dermatophytid; pending cure, topical corticosteroids and/or\\nantipruritics (eg, hydroxyzine 25 mg qid) can be used to relieve symptoms.\\nIntertrigo\\nIntertrigo is skinfold changes caused by moisture and infection.\\nIntertrigo develops when friction and trapped moisture in intertriginous areas cause skin maceration with\\nformation of patches or plaques; bacterial, yeast, and dermatophyte infection is common. Typical\\nlocations are the inframammary, infrapannicular, interdigital, axillary, infragluteal, and genitocrural folds.\\nDiagnosis is based on clinical appearance; potassium hydroxide wet mounts and cultures can guide\\ntreatment.\\nIf no bacteria or yeast are detected, drying agents (powders such as talc rather than cornstarch, which\\ncan support fungal growth, Burow's solution) to decrease moisture should be therapeutic. If bacteria or\\nyeasts are present, topical antibacterial lotions or antifungal creams are given in addition to drying\\nagents.\\nTinea Versicolor\\n(Pityriasis Versicolor)\\nTinea versicolor is skin infection with \\nMalassezia furfur\\n that manifests as multiple asymptomatic\\nscaly patches varying in color from white to brown. Diagnosis is based on clinical appearance\\nand skin scrapings. Treatment is topical antifungals.\\nMalassezia furfur\\n is a dimorphic fungus that is normally a harmless component of normal skin flora but\\nthat in some people causes tinea versicolor. The high prevalence of tinea versi-color in young adults\\nsuggests a link to increased sebaceous secretions; other risk factors include heat and humidity and\\nimmunosuppression due to corticosteroids, pregnancy, undernutrition, diabetes, and other disorders.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n829\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 839, 'page_label': '830'}, page_content='Tinea versicolor usually is asymptomatic. Classically, it causes the appearance of multiple tan, brown,\\nsalmon, or white scaling lesions (see\\nPlate 52\\n) on the trunk, neck, abdomen, and occasionally face. The lesions coalesce. In whites, the\\ncondition is often diagnosed in summer months because the lesions, which do not tan, become more\\nobvious against tanned skin.\\nDiagnosis\\n Clinical appearance\\n Potassium hydroxide wet mount\\n Sometimes Wood\\'s light examination\\nDiagnosis is based on clinical appearance and by identification of hyphae and budding cells (\"spaghetti\\nand meatballs\") on potassium hydroxide wet mount. Wood\\'s light examination reveals golden-white\\nfluorescence.\\nTreatment\\n Topical antifungals\\n Sometimes oral antifungals\\nTreatment is any topical antifungal drug. Examples include selenium sulfide shampoo 2.5% (in 10-min\\napplications daily for 1 wk or 24-h applications weekly for 1 mo); topical azoles (eg, ketoconazole 2%\\ndaily for 2 wk); and bathing with zinc pyrithione soap 2% or sulfur-salicylic shampoo 2% for 1 to 2 wk.\\nOral treatment is indicated for patients with extensive disease and those with frequent recurrences. Two\\nconvenient regimens are a single 400-mg dose of fluconazole and ketoconazole 200 mg once/day for 1 to\\n5 days.\\nHypopigmentation from tinea versicolor is reversible in months to years after the yeast has cleared.\\nRecurrence is almost universal after treatment because the causative organism is a normal skin\\ninhabitant. Fastidious hygiene, regular use of zinc pyrithione soap, or once-monthly use of topical\\nantifungal therapy lowers the likelihood of recurrence.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 82. Fungal Skin Infections\\n830'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 840, 'page_label': '831'}, page_content=\"Chapter 83. Parasitic Skin Infections\\nIntroduction\\nParasitic skin infections can cause severe itching and be distressing. Most skin parasites are insects or\\nworms that burrow into the skin for part or all of their life cycle. Also, some systemic parasitic infections\\nhave cutaneous manifestations; these include certain nematodes (ancylostomiasis, dracunculosis,\\nstrongyloidiasis, toxocariasissee p. \\n1342\\n) and flukes (schistosomiasissee p. \\n1358\\n). Very rarely,\\npatients have delusional parasitosis.\\nCutaneous Larva Migrans\\n(Creeping Eruption)\\nCutaneous larva migrans (CLM) is the skin manifestation of hookworm infestation.\\nCLM is caused by \\nAncylostoma\\n sp, most commonly dog or cat hookworm \\nAncylostoma braziliense\\n.\\nHookworm ova in dog or cat feces develop into infective larvae when left in warm moist ground or sand;\\ntransmission occurs when skin directly contacts contaminated soil or sand and larvae penetrate\\nunprotected skin, usually of the feet, legs, buttocks, or back. CLM occurs worldwide but most commonly\\nin tropical environments.\\nCLM causes intense pruritus; signs are erythema and papules at the site of entry, with a winding,\\nthreadlike subcutaneous trail of reddish-brown inflammation. Diagnosis is by history and clinical\\nappearance.\\nTopical thiabendazole 15% liquid or cream (compounded) bid to tid for 5 days is extremely effective. Oral\\nthiabendazole is not well tolerated and not usually used. Albendazole (400 mg po once/day for 7 days)\\nand ivermectin can cure the infestation and are well tolerated.\\nCLM may be complicated by a self-limiting pulmonary reaction called Loffler's syndrome (patchy\\npulmonary infiltrates and peripheral blood eosinophilia).\\nCutaneous Myiasis\\nCutaneous myiasis is skin infestation by the larvae of certain fly species.\\nMyiasis involves the larvae of two-winged (dipterous) flies. Three types of cutaneous infestation exist,\\ndepending on the species involved:\\n Furuncular\\n Wound\\n Migratory\\nOther organs sometimes are involved (eg, nasopharynx, GI tract, GU tract). Infestation usually occurs in\\ntropical countries, so most cases in the US occur in people who have recently arrived from endemic\\nareas.\\nFuruncular myiasis:\\n Many of the common sources are known as bot flies. \\nDermatobia hominis\\n, native\\nto South and Central America, is the most common cause in travelers returning to the US. Other species\\ninclude \\nCordylobia anthropophaga\\n (in sub-Saharan Africa), and various \\nCuterebra\\n sp (in tropical Africa).\\nMany of the flies do not lay their eggs on humans but on other insects (eg, mosquitoes) or objects (eg,\\ndrying laundry) that may contact skin. Eggs on the skin hatch into larvae, which burrow into the skin and\\ndevelop through successive stages (instars) into mature larvae; mature larvae may be 1 to 2 cm long,\\ndepending on the species. If the infestation is untreated, larvae eventually emerge from the skin and drop\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 83. Parasitic Skin Infections\\n831\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 841, 'page_label': '832'}, page_content=\"to the ground to continue their life cycle.\\nTypical symptoms include itching, a sensation of movement, and sometimes lancinating pain. The initial\\nlesion may resemble an arthropod bite or bacterial furuncle but may be distinguished by the presence of a\\ncentral punctum with serosanguineous drainage; sometimes a small portion of the end of the larva is\\nvisible.\\nBecause larvae require atmospheric O\\n2\\n, occlusion of the skin opening may cause them to depart or at\\nleast come closer to the surface, facilitating manual removal. The numerous occlusal methods include use\\nof petrolatum, nail polish, bacon, or a paste of tobacco. However, larvae that die during occlusion are\\ndifficult to remove and often trigger an intense inflammatory reaction. Other options for removal include\\nmanual expression (ie, squeezing) and extraction through a small incision. Ivermectin, oral (200 \\n\\ng/kg,\\none dose) or topical, may kill the larvae or induce migration.\\nWound myiasis:\\n Open wounds, typically in the homeless, alcoholics, and other people in poor social\\ncircumstances, may be infested by fly larvae, most often from green or black blowflies. Unlike larvae of\\ncommon houseflies, most agents of wound myiasis invade healthy as well as necrotic tissue. Treatment is\\nusually with irrigation and manual debridement.\\nMigratory myiasis:\\n The most common agents are \\nGasterophilus intestinalis\\n and \\nHypoderma\\n sp. These\\nflies typically infest horses and cattle; people acquire them via contact with infested animals or, less often,\\nvia direct egg-laying on their skin. Larvae of these agents burrow under the skin, causing pruritic,\\nadvancing lesions, which may be mistaken for cutaneous larva migrans; however, fly larvae are much\\nlarger than nematodes, and the lesions created by fly larvae last longer. Treatment is similar to that of\\nfuruncular myiasis.\\nDelusional Parasitosis\\nIn delusional parasitosis, patients mistakenly believe that they are infested with parasites.\\nPatients have an unshakable belief that they are infested with insects, worms, mites, lice, or other\\norganisms. They often provide vivid descriptions of how the organisms enter their skin and move around\\ntheir bodies, and bring samples of hair, skin, and debris such as dried scabs, dust, and lint on slides or in\\ncontainers (the matchbox sign) to prove that the infestation is real. The condition is considered a\\nhypochondriacal psychosis, but the cause is unknown.\\nDiagnosis is suspected by history. Work-up requires ruling out true infestations and other physiologic\\ndisease by physical examination and judicious testing, such as skin scrapings and CBC.\\nTreatment is with antipsychotic drugs (see p. \\n1562\\n). Typically, the patient seeks confirmation that the drug\\ntreats the infestation itself, and any suggestion that the treatment is for something else is met with\\nresistance and/or rejection. Thus, effective treatment often requires diplomacy and a delicate balance\\nbetween offering proper treatment and respecting the patient's right to know.\\nLice\\n(Pediculosis)\\nLice can infect the scalp, body, pubis, and eyelashes. Head lice are transmitted by close\\ncontact; body lice, in cramped, crowded conditions; and pubic lice, by sexual contact.\\nSymptoms, signs, diagnosis, and treatment differ by location of infestation.\\nLice are wingless, blood-sucking insects that infest the head (\\nPediculus humanus\\n var. \\ncapitis\\n), body (\\nP.\\nhumanus\\n var. \\ncorporis\\n), or pubis (\\nPhthirus pubis\\n). The 3 kinds of lice differ substantially in morphology\\nand clinical features. Head lice and pubic lice live directly on the host; body lice live in garments. All types\\noccur worldwide.\\nHead lice:\\n Head lice are most common in girls aged 5 to 11 but can affect almost anyone; infestations\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 83. Parasitic Skin Infections\\n832\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 842, 'page_label': '833'}, page_content='are rare in blacks. Head lice are easily transmitted from person to person with close contact (as occurs\\nwithin households and classrooms) and may be ejected from hair by static electricity or wind; transmission\\nby these routes (or by sharing of combs, brushes, and hats) is likely but unproven. There is no\\nassociation between head lice and poor hygiene or low socioeconomic status.\\nInfestation typically involves the hair and scalp, but the eyebrows, eyelashes, and beard may be involved\\nas well. Active infection usually involves  20 lice and causes severe pruritus. Examination is most often\\nnormal but may reveal scalp excoriations and posterior cervical adenopathy.\\nDiagnosis depends on demonstration of living lice. Lice are detected by a thorough combing-through of\\nwet hair from the scalp with a fine-tooth detection comb; lice are usually found at the back of the head or\\nbehind the ears. Nits are ovoid, grayish white eggs fixed to the base of hair shafts (see\\nPlate 38\\n). Each adult female louse lays 3 to 5 eggs/day, so nits typically vastly outnumber lice and are not\\na measure of severity of infestation.\\nTreatment is outlined in\\nTable 83-1\\n. Drug resistance is common and should be managed with use of oral ivermectin and by\\nattempting to rotate pediculicides. Termination of live (viable) nits is important in preventing reinfestation;\\nlive nits fluoresce on illumination with a Wood\\'s lamp. Most pediculicides also kill nits. Dead nits remain\\nafter successful treatment and do not signify active infection; they do not have to be removed. Nits grow\\naway from the scalp with time; the absence of nits less than one fourth of an inch from the scalp rules out\\ncurrent active infection. Hot air has been shown to kill > 88% of eggs but has been variably effective in\\nkilling hatched lice. Thirty minutes of hot air, slightly cooler than a blow drier, may be an effective\\nadjunctive measure to treat head lice.\\nControversy surrounds the need to clean the personal items of people with lice or nits and the need to\\nexclude children with head lice or nits from school; there are no conclusive data supporting either\\napproach.\\nBody lice:\\n Body lice primarily live on bedding and clothing, not people, and are most frequently found in\\ncramped, crowded conditions (eg, military barracks) and in people of low socioeconomic status.\\nTransmission is by sharing of contaminated clothing and bedding. Body lice are important vectors of\\nepidemic typhus, trench fever, and relapsing fever.\\nBody lice cause pruritus; signs are small red puncta caused by bites, usually associated with linear\\nscratch marks, urticaria, or superficial bacterial infection. These findings are especially common on the\\nshoulders, buttocks, and abdomen. Nits may be present on body hairs.\\nDiagnosis is by demonstration of lice and nits in clothing, especially at the seams.\\nPrimary treatment is thorough cleaning or replacement of clothing and bedding, which is often difficult\\nbecause affected people often have few resources and little control over their environment.\\n[\\nTable 83-1.\\n Treatment Options for Scabies and Lice]\\nPubic lice:\\n Pubic lice (\"crabs\") are sexually transmitted in adolescents and adults and may be transmitted\\nto children by close parental contact. They may also be transmitted by fomites (towels, bedding, clothing).\\nThey most commonly infest pubic and perianal hairs but may spread to thighs, trunk, and facial hair\\n(beard, mustache, and, in children, eyelashes).\\nPubic lice cause pruritus. Physical signs are few, but some patients have excoriations and regional\\nlymphadenopathy and/or lymphadenitis. Pale, bluish gray skin macules (maculae caeruleae) on the trunk,\\nbuttocks, and thighs are caused by anticoagulant activity of louse saliva while feeding; they are unusual\\nbut characteristic of infestation. Eyelash infestation manifests as eye itching, burning, and irritation.\\nDiagnosis is by demonstration of nits and/or living lice by close inspection (Wood\\'s light) or microscopic\\nanalysis. A supporting sign of infestation is scattering of dark brown specks (louse excreta) on skin or\\nundergarments.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 83. Parasitic Skin Infections\\n833'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 843, 'page_label': '834'}, page_content=\"Treatment is outlined in \\nTable 83-1\\n. Treatment of eyelid and eyelash infestation is often difficult and\\ninvolves use of petrolatum, physostigmine ointment, oral ivermectin, or physical removal of lice with\\nforceps. Sex partners should also be treated.\\nScabies\\nScabies is an infestation of the skin with the mite \\nSarcoptes scabiei\\n. Scabies causes intensely\\npruritic lesions with erythematous papules and burrows in web spaces, wrists, waistline, and\\ngenitals. Diagnosis is based on examination and scrapings. Treatment is with topical scabicides\\nor, rarely, oral ivermectin.\\nEtiology\\nScabies is caused by the mite \\nSarcoptes scabiei\\n var. \\nhominis\\n, an obligate human parasite that lives in\\nburrowed tunnels in the stratum corneum. Scabies is easily transmitted from person to person through\\nphysical contact; animal and fomite transmission probably also occurs. The primary risk factor is crowded\\nconditions (as in schools, shelters, barracks, and some households); there is no clear association with\\npoor hygiene. For unknown reasons, crusted scabies is more common in immunosuppressed patients\\n(eg, those with HIV infection, hematologic cancer, chronic corticosteroid or other immunosuppressant\\nuse), patients with severe physical disabilities or intellectual disability, and Australian Aborigines.\\nInfestations occur worldwide. Patients in warm climates develop small \\nerythematous papules with few\\nburrows. Severity is related to the patient's immune status, not geography.\\nSymptoms and Signs\\nThe primary symptom is intense pruritus, classically worse at night, although that timing is not specific to\\nscabies.\\nClassic scabies:\\n Erythematous papules initially appear in finger web spaces, flexor surfaces of the wrist\\nand elbow, axillary folds, along the belt line, or on the lower buttocks. Papules can spread to any area of\\nthe body, including the breasts and penis. The face remains uninvolved in adults. Burrows are\\npathognomonic for disease, manifesting as fine, wavy, and slightly scaly lines several mm to 1 cm long. A\\ntiny dark papulethe miteis often visible at one end.\\nSigns of classic scabies may be atypical. In blacks and other people with dark skin, scabies can manifest\\nas granulomatous nodules. In infants, the palms, soles, face, and scalp may be involved, especially in the\\nposterior auricular folds. In elderly patients, scabies can cause intense pruritus with subtle skin findings,\\nmaking it a challenge to diagnose. In immunocompromised patients, there may be widespread nonpruritic\\nscaling (particularly on the palms and soles in adults and on the scalp in children).\\nOther forms:\\n Crusted (Norwegian) scabies is due to an impaired host immune response, allowing mites\\nto proliferate and number in the millions. Nodular scabies is more common in infants and young children\\nand may be due to hypersensitivity to retained organisms. Bullous scabies occurs more commonly in\\nchildren. When it occurs in the elderly, it can mimic bullous pemphigoid, resulting in a delay in diagnosis.\\nScalp scabies occurs in infants and immunocompromised people and can mimic dermatitis, particularly\\natopic or seborrheic dermatitis. Scabies incognito is a widespread atypical form resulting from application\\nof topical corticosteroids.\\nDiagnosis\\n Clinical evaluation\\n Burrow scrapings\\nDiagnosis is suspected by physical findings, especially burrows, and confirmed by mites, ova, or fecal\\npellets on microscopic examination of burrow scrapings. Scrapings should be obtained by placing\\nglycerol, mineral oil, or immersion oil over a burrow or papule (to prevent dispersion of mites and material\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 83. Parasitic Skin Infections\\n834\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 844, 'page_label': '835'}, page_content='during scraping), which is then unroofed with the edge of a scalpel. The material is then placed on a slide\\nand covered with a coverslip; potassium hydroxide should be avoided because it dissolves fecal pellets.\\nTreatment\\n Topical permethrin or lindane\\n Sometimes oral ivermectin\\nPrimary treatment is topical or oral scabicides (see \\nTable 83-1\\n). Permethrin is the 1st-line topical drug.\\nOlder children and adults should apply permethrin or lindane to the entire body from the neck down and\\nwash it off after 8 to 14 h. Treatments should be repeated in 7 days.\\nFor infants and young children, permethrin should be applied to the head and neck, avoiding periorbital\\nand perioral regions. Special attention should be given to intertriginous areas, fingernails, toenails, and\\nthe umbilicus. Mittens on infants can keep permethrin out of the mouth. Lindane is not recommended in\\nchildren < 2 yr and in patients with a seizure disorder because of potential neurotoxicity.\\nPrecipitated sulfur 6 to 10% in petrolatum, applied for 24 h for 3 consecutive days, is safe and effective.\\nIvermectin is indicated for patients who do not respond to topical treatment, are unable to adhere to\\ntopical regimens, or are immunocompromised with Norwegian scabies. Ivermectin has been used with\\nsuccess in epidemics involving close contacts, such as nursing homes.\\nClose contacts should also be treated, and personal items (eg, towels, clothing, bedding) should be\\nwashed or isolated for at least 3 days.\\nPruritus can be treated with corticosteroid ointments and/or oral antihistamines (eg, hydroxyzine 25 mg po\\nqid). Secondary infection should be considered in patients with weeping, yellow-crusted lesions and\\ntreated with the appropriate systemic or topical antistaphylococcal or antistreptococcal antibiotic.\\nSymptoms and lesions take up to 3 wk to resolve despite killing of the mites, making failed treatment due\\nto resistance, poor penetration, incompletely applied therapy, reinfection, or nodular scabies difficult to\\nrecognize. Skin scrapings can be done periodically to check for persistent scabies.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 83. Parasitic Skin Infections\\n835'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 845, 'page_label': '836'}, page_content='Chapter 84. Viral Skin Diseases\\nIntroduction\\nMany systemic viral infections cause skin lesions. Molluscum contagiosum and warts are the 2 most\\ncommon primary viral skin diseases without systemic manifestations. Herpes simplex virus infection is\\ndiscussed on p. \\n1417\\n.\\nMolluscum Contagiosum\\nMolluscum contagiosum is clusters of smooth, waxy, or pearly umbilicated papules 1 to 5 mm in\\ndiameter caused by molluscum contagiosum virus, a poxvirus.\\nMolluscum contagiosum virus commonly causes a localized chronic infection. Transmission is by direct\\ncontact; spread occurs by autoinoculation and via fomites (eg, towels, bath sponges).\\nSymptoms and Signs\\nMolluscum contagiosum can appear anywhere on the skin except the palms and soles. Lesions consist of\\nclusters of flesh-colored papules, which occur most commonly on the face, trunk, and extremities in\\nchildren and on the pubis, penis, or vulva in adults. Lesions may grow to 10 to 15 mm in diameter,\\nespecially among patients with HIV infection and other immunocompromised patients. Lesions are usually\\nnot pruritic or painful and may be discovered only coincidentally during a physical examination. However,\\nthe lesions can become inflamed and itchy as the body fights off the virus.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis is based on clinical appearance; hematoxylin and eosin staining of expressed fluid\\ndemonstrates inclusion bodies but is necessary only when diagnosis is uncertain. Differential diagnosis\\nincludes folliculitis, milia, and warts (for lesions < 2 mm) and juvenile xanthogranuloma and Spitz nevus\\n(for lesions > 2 mm).\\nTreatment\\n Curettage, cryosurgery, laser therapy, or electrocautery\\n Topical irritants (eg, trichloroacetic acid, cantharidin, tretinoin, tazarotene), imiquimod, or both\\n Sometimes combination therapies\\nMost lesions spontaneously regress in 1 to 2 yr, but they can remain for 2 to 3 yr. Treatment is indicated\\nfor cosmetic reasons or for prevention of sexual spread. Options include curettage, cryosurgery, laser\\ntherapy, electrocautery, trichloroacetic acid (25 to 40% solution), cantharidin, tretinoin, tazarotene and\\nimiquimod 5% cream. Especially in children, treatments that cause minimal pain (eg, tretinoin, imiquimod,\\ntazarotene, cantharidin) are used first. Curettage or liquid nitrogen can be used after application of a\\ntopical anesthetic such as EMLA (eutectic mixture of local anesthetics) or 4% lidocaine cream. EMLA\\ncream must be applied judiciously because it can cause systemic toxicity, especially in children. In adults,\\ncurettage is very effective but painful. Dermatologists often use combination therapy such as liquid\\nnitrogen or cantharidin in the office and imiquimod cream at home. This form of therapy is typically\\nsuccessful, but resolution often takes 1 to 2 mo in some patients.\\nNondermatologists should feel comfortable using imiquimod cream. The cream is applied at night, 1 drop\\nto each molluscum lesion and rubbed in well, until the cream turns clear. The area is washed with soap\\nand water. The cream can be applied 3 to 7 times/wk. Molluscum lesions within the orbital rim should not\\nbe treated, and those in the genital region can easily become irritated. Lesions should be treated until\\nthey develop a scant amount of redness; treatment is then withheld to avoid weeping and crusting.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 84. Viral Skin Diseases\\n836'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 846, 'page_label': '837'}, page_content='Cantharidin is safe and effective but can cause blistering. Cantharidin is applied in 1 small drop directly to\\nthe molluscum lesion. Areas that patients (especially children) may rub are covered with a bandage\\nbecause contact with the fingers should be avoided. Cantharidin should not be applied to the face or near\\nthe eyes because blistering is unpredictable. If cantharidin comes into contact with the cornea, it can scar\\nthe cornea. Cantharidin should be washed off with soap and water in 6 h. Parents should be warned\\nabout blistering if their children are prescribed this drug.\\nWarts\\n(Verrucae Vulgaris)\\nWarts are common, benign epidermal lesions caused by human papillomavirus infection. \\nThey\\ncan appear anywhere on the body in a variety of morphologies. Diagnosis is by examination.\\nWarts are usually self limited but may be treated by excision, cautery, cryotherapy, liquid\\nnitrogen, and topical or injected agents.\\nWarts are almost universal in the population; they affect all ages but are most common among children\\nand are uncommon among the elderly.\\nEtiology\\nWarts are caused by human papillomavirus (HPV) infection; there are over 100 HPV subtypes. Trauma\\nand maceration facilitate initial epidermal inoculation. Spread may then occur by autoinoculation. Local\\nand systemic immune factors appear to influence spread; immunosuppressed patients (especially those\\nwith HIV infection or a renal transplant) are at particular risk of developing generalized lesions that are\\ndifficult to treat. Humoral immunity provides resistance to HPV infection; cellular immunity helps\\nestablished infection to regress.\\nSymptoms and Signs\\nWarts are named by their clinical appearance and location; different forms are linked to different HPV\\ntypes (for unusual manifestations, see\\nTable 84-1\\n).\\nCommon warts:\\n Common warts (verrucae vulgaris) are caused by HPV 1, 2, 4, 27, and 29. They are\\nusually asymptomatic but sometimes cause mild pain, especially when they are located on a weight-\\nbearing surface (eg, bottom of the feet). They are sharply demarcated, rough, round or irregular, firm, and\\nlight gray, yellow, brown, or gray-black nodules 2 to 10 mm in diameter. They appear most often on sites\\nsubject to trauma (eg, fingers, elbows, knees, face) but may spread elsewhere. Variants of unusual shape\\n(eg, pedunculated or resembling a cauliflower) appear most frequently on the head and neck, especially\\nthe scalp and beard area.\\nFiliform warts:\\n These warts are long, narrow, frondlike growths, usually located on the eyelids, face,\\nneck, or lips. They are usually asymptomatic. This morphologically distinct variant of the common wart is\\nbenign and easy to treat.\\nFlat warts:\\n Flat warts, caused by HPV 3, 10, 28, and 49, are smooth, flat-topped, yellow-brown papules,\\nmost often located on the face and along scratch marks; they are more common among children and\\nyoung adults and develop by autoinoculation. They generally cause no symptoms but can be difficult to\\ntreat.\\nPalmar and plantar warts:\\n These warts, caused by HPV 1, occur on the palms and soles; they are\\nflattened by pressure and surrounded by cornified epithelium (see\\nPlate 55\\n). They are\\n[\\nTable 84-1.\\n Wart Variants]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 84. Viral Skin Diseases\\n837'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 847, 'page_label': '838'}, page_content=\"often tender and can make walking and standing uncomfortable. They can be distinguished from corns\\nand calluses by their tendency to pinpoint bleeding when the surface is pared away. Classically, warts\\nhurt with side-to-side pressure, and calluses hurt with direct pressure; in reality, this is not a reliable sign.\\nMosaic warts:\\n Mosaic warts are plaques formed by the coalescence of myriad smaller, closely set\\nplantar warts. As with other plantar warts, they are often tender.\\nPeriungual warts:\\n These warts appear as thickened, fissured cauliflower-like skin around the nail plate.\\nPatients frequently lose the cuticle and are susceptible to paronychia. Periungual warts are more common\\namong patients who bite their nails.\\nGenital warts:\\n Genital warts (see p. \\n1470\\n) manifest as discrete flat to broad-based smooth to velvety\\npapules on the perineal, perirectal, labial, and penile areas. Infection with high-risk HPV types (most\\nnotably types 16 and 18) is the main cause of cervical cancer. These warts are usually asymptomatic.\\nDiagnosis\\n Clinical evaluation\\n Rarely biopsy\\nDiagnosis is based on clinical appearance; biopsy is rarely needed. A cardinal sign of warts is the\\nabsence of skin lines crossing their surface and the presence of pinpoint black dots (thrombosed\\ncapillaries) or bleeding when warts are shaved. Differential diagnosis includes corns (clavi), lichen\\nplanus, seborrheic keratosis, skin tags, and squamous cell carcinomas. DNA typing is available in some\\nmedical centers but is generally not needed.\\nPrognosis\\nMany warts regress spontaneously; others persist for years and recur at the same or different sites, even\\nwith treatment. Factors influencing recurrence appear to be related to the patient's overall immune status\\nas well as local factors. Patients who subject themselves to local trauma (eg, athletes, mechanics,\\nbutchers) may have recalcitrant and recurrent HPV infection. Genital HPV infection has malignant\\npotential, but malignant transformation is rare in HPV-induced skin warts, except among\\nimmunosuppressed patients.\\nTreatment\\n Topical irritants (eg, salicylic acid, cantharidin, podophyllum resin)\\n Destructive methods (eg, cryosurgery, electrocautery, curettage, excision, laser)\\nTreatment is aimed at eliciting an immune response to HPV. In most instances, this response is achieved\\nby applying an irritant (eg, salicylic acid [SCA], trichloroacetic acid, 5-fluorouracil, podophyllum resin,\\ntretinoin, cantharidin).\\nThese compounds can be used in combination or with a destructive method (eg, cryosurgery,\\nelectrocautery, curettage, excision, laser). Direct antiviral effects can be achieved with bleomycin and\\ninterferon alfa-2b, but these treatments are reserved for the most recalcitrant warts. Topical imiquimod 5%\\ncream induces skin cells to locally produce antiviral cytokines. Topical cidofovir, HPV vaccines, and\\ncontact immunotherapy (eg, squaric acid dibutyl ester and \\nCandida\\n allergen) have been used to treat\\nwarts. Oral treatments include cimetidine, isotretinoin, and oral zinc. In most instances, modalities should\\nbe combined to increase the likelihood of success.\\nCommon warts:\\n In immunocompetent patients, common warts usually spontaneously regress within 2 to\\n4 yr, but some linger for many years. Numerous treatments are available. Destructive methods include\\n Electrocautery\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 84. Viral Skin Diseases\\n838\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 848, 'page_label': '839'}, page_content=\" Cryosurgery with liquid nitrogen\\n SCA preparations\\nWhich method is used depends on the location and severity of involvement. For example, 17% liquid SCA\\ncan be used on the fingers, and 40% plaster SCA can be used on the soles.\\nThe most common topical agent to be used is SCA. SCA is available in a liquid, plaster, or impregnated\\nwithin tape. Patients apply SCA to their warts at night and leave on for 8 to 48 h depending on the site.\\nCantharidin can be used alone or in combination (1%) with SCA (30%) and podophyllum (5%) in a\\ncollodion base. Cantharidin alone is removed with soap and water after 6 h; cantharidin with SCA or\\npodophyllum is removed in 2 h. The longer these agents are left in contact with the skin, the more brisk\\nthe blistering response.\\nCryosurgery is painful but extremely effective. Electrodesiccation with curettage, laser surgery, or both is\\neffective and indicated for isolated lesions but may cause scarring. Recurrent or new warts occur in about\\n35% of patients within 1 yr, so methods that scar should be avoided as much as possible.\\nFiliform warts:\\n Treatment is removal with scalpel, scissors, curettage, or liquid nitrogen. Liquid nitrogen\\nshould be applied so that up to 2 mm of skin surrounding the wart turns white. Damage to the skin occurs\\nwhen the \\nskin thaws, which usually takes 10 to 20 sec. Blisters can occur 24 to 48 h after treatment with\\nliquid nitrogen. Care must be taken when treating cosmetically sensitive sites, such as the face and neck,\\nbecause hypopigmentation frequently occurs after treatment with liquid nitrogen. Patients with darkly\\npigmented skin can develop permanent depigmentation.\\nFlat warts:\\n Treatment is daily tretinoin (retinoic acid 0.05% cream). If peeling is not sufficient for wart\\nremoval, another irritant (eg, 5% benzoyl peroxide) or 5% SCA cream can be applied sequentially with\\ntretinoin. Imiquimod 5% cream can be used alone or in combination with topical drugs or destructive\\nmeasures. Topical 5-fluorouracil (1% or 5% cream) can also be used. Spontaneous resolution may follow\\nunprovoked inflammation of the lesions; however, flat warts are frequently recalcitrant to treatment.\\nPlantar warts:\\n Treatment is vigorous maceration with 40% SCA plaster kept in place for several days.\\nThe wart is debrided while damp and soft, then destroyed by freezing or using caustics (eg, 30 to 70%\\ntrichloroacetic acid). Other destructive treatments (eg, CO\\n2\\n laser, pulsed-dye laser, various acids) are\\noften effective. Duct tape is effective when applied for 6-day intervals, followed by debridement of\\nmacerated tissue.\\nPeriungual warts:\\n Combination therapy with liquid nitrogen and imiquimod 5% cream, tretinoin, or SCA\\nis effective.\\nRecalcitrant warts:\\n Several methods whose long-term value and risks are not fully known are available\\nfor recalcitrant warts. Intralesional injection of small amounts of a 0.1% solution of bleomycin in saline\\noften cures stubborn plantar and periungual warts. However, Raynaud's syndrome or vascular damage\\nmay develop in injected digits, especially when the drug is injected at the base of the digit, so caution is\\nwarranted. Interferon, especially interferon alfa, administered intralesionally (3 times/wk for 3 to 5 wk) or\\nIM, has also cleared recalcitrant skin and genital warts. Extensive warts sometimes improve or clear with\\noral isotretinoin or acitretin. Cimetidine at doses up to 800 mg po tid has been used with success but is\\nmore effective when combined with another therapy.\\nZoonotic Diseases\\nTwo viral skin diseases are rarely transmitted from animals to humans.\\nContagious ecthyma:\\n Contagious ecthyma (contagious pustular dermatitis) is caused by orf virus, a\\npoxvirus that infects ruminants (most often sheep and goats). Farmers, veterinarians, zoo caretakers, and\\nothers with direct animal contact are at risk. The cutaneous findings pass through 6 stages that together\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 84. Viral Skin Diseases\\n839\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 849, 'page_label': '840'}, page_content=\"last about 1 wk:\\n Stage 1 (papular): A single red edematous papule on a finger (most commonly right index finder)\\n Stage 2 (target): A larger nodule with a red center surrounded by a white ring with a red periphery\\n Stage 3 (acute): A rapidly growing infected-looking tumor\\n Stage 4 (regenerative): A nodule with black dots covered with a thin transparent crust\\n Stage 5 (papillomatous): A nodule with a surface studded with small projections\\n Stage 6 (regressive): A flattened nodule with a thick crust\\nPatients can develop regional adenopathy, lymphangitis, and fever.\\nDiagnosis is by history of contact; differential diagnosis is extensive depending upon the stage of the\\nlesion. Acute lesions must be differentiated from milker's nodules, \\nMycobacterium marinum\\n infection, and\\nother bacterial infections; regressed lesions must be differentiated from cutaneous tumors, such as\\nBowen's disease or squamous cell carcinoma. Lesions spontaneously heal; no treatment is necessary.\\nMilker's nodules:\\n These nodules are caused by paravaccinia virus, a parapoxvirus that causes udder\\nlesions in cows. Infection requires direct contact and produces macules that progress to papules,\\nvesicles, and nodules. This infection has 6 stages, which are similar to those of contagious ecthyma.\\nFever and lymphadenopathy are uncommon. Diagnosis is by history of contact and cutaneous findings.\\nDifferential diagnosis varies depending upon morphology but includes primary inoculation TB,\\nsporotrichosis, anthrax, and tularemia. Lesions heal spontaneously; no treatment is necessary.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 84. Viral Skin Diseases\\n840\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 850, 'page_label': '841'}, page_content=\"Chapter 85. Pigmentation Disorders\\nIntroduction\\nPigmentation disorders involve hypopigmentation, depigmentation, or hyperpigmentation. Areas may be\\nfocal or diffuse.\\nFocal hypopigmentation\\n is most commonly a consequence of\\n Injury\\n Inflammatory dermatoses (eg, atopic dermatitis, psoriasis)\\n Burns\\n Chemical exposure\\nFocal hypopigmentation or depigmentation is also a feature of vitiligo (which may involve large areas of\\nskin), leprosy, nutritional deficiencies (kwashiorkor), and genetic conditions (tuberous sclerosis,\\npiebaldism, Waardenburg's syndrome).\\nDiffuse hypopigmentation\\n is most often caused by\\n \\nAlbinism\\n \\nVitiligo\\nFocal hyperpigmentation\\n typically occurs after inflammation of various causes, but it also may occur in\\npatients with a systemic disorder or cancer.\\nAlbinism\\nAlbinism (officially called oculocutaneous albinism) is an inherited defect in melanin formation\\nthat causes diffuse hypopigmentation of the skin, hair, and eyes; deficiency of melanin (and\\nhence pigmentary dilution) may be total or partial, but all areas of the skin are involved. Ocular\\ninvolvement causes strabismus, nystagmus, and decreased vision. Diagnosis is usually\\nobvious from the skin, but ocular evaluation is necessary. No treatment for the skin involvement\\nis available other than protection from sunlight.\\nPathophysiology\\nOculocutaneous albinism (OCA) is a group of rare inherited disorders in which a normal number of\\nmelanocytes are present but melanin production is absent or greatly decreased. Cutaneous and ocular\\npathologies (ocular albinism) are both present. Ocular albinism involves abnormal optic tract CNS\\ndevelopment manifested by foveal hypoplasia with decreased photoreceptors and misrouting of optic\\nchiasmal fibers. Ocular albinism may occur without cutaneous abnormalities.\\nMost cases are autosomal recessive; autosomal dominant inheritance is rare. There are 4 main genetic\\nforms:\\n Type I is caused by absent (OCA1A; 40% of all OCA) or reduced (OCA1B) tyrosinase activity;\\ntyrosinase catalyzes several steps in melanin synthesis.\\n Type II (50% of all OCA) is caused by mutations in the P (pink-eyed) gene. The function of the P protein\\nis not yet known. Tyrosinase activity is present.\\n Type III occurs only in people with dark skin (skin types III to V). It is caused by mutations in a tyrosinase-\\nrelated protein 1 gene whose product is important in eumelanin synthesis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 85. Pigmentation Disorders\\n841\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 851, 'page_label': '842'}, page_content=' Type IV is an extremely rare form in which the genetic defect is in a gene that codes a membrane\\ntransporter protein. Type IV is the most common form of OCA in Japan.\\nIn a group of inherited diseases, a clinical phenotype of OCA occurs in conjunction with bleeding\\ndisorders. In the Hermansky-Pudlak syndrome, OCA-like findings occur with platelet abnormalities and a\\nceroid-lipofuscin lysosomal storage disease. This syndrome is rare except in people with family origin in\\nPuerto Rico, where its incidence is 1 in 1800. In the Chediak-Higashi syndrome, OCA-like findings occur\\n(hair is silvery gray), and a decrease in platelet-dense granules results in a bleeding diathesis. Patients\\nhave severe immunodeficiency due to abnormal lymphocyte lytic granules. Progressive neurologic\\ndegeneration occurs.\\nSymptoms and Signs\\nThe different genetic forms have a variety of phenotypes.\\nType I (OCA1A) is classic tyrosinase-negative albinism; skin and hair are milky white, and eyes are blue-\\ngray. Pigmentary dilution in OCA1B ranges from obvious to subtle.\\nType II has phenotypes with pigmentary dilution that ranges from minimal to moderate. Pigmented nevi\\nand lentigines may develop if skin is exposed to the sun; some lentigines become large and dark. Eye\\ncolor varies greatly.\\nIn type III, skin is brown, hair is rufous (reddish), and eye color can be blue or brown.\\nIn type IV, the phenotype is similar to that for type II.\\nPatients with ocular involvement may have decreased retinal pigmentation (see\\nPlate 25\\n), leading to photophobia. In addition, nystagmus, strabismus, reduced visual acuity, and loss of\\nbinocular vision likely result from defective routing of the optic fibers.\\nDiagnosis\\n Clinical evaluation\\nDiagnosis of all types of OCA is based on examination of the skin. Early ocular examination may detect\\niris translucency, reduced retinal pigmentation, foveal hypoplasia, reduced visual acuity, and ocular\\nmovement disorders (strabismus and nystagmus).\\nTreatment\\n Sun protection\\n Sometimes surgical intervention for ocular movement disorders\\nThere is no treatment for albinism. Patients are at high risk of sunburn and skin cancers (especially\\nsquamous cell carcinoma) and should avoid direct sunlight, use sunglasses with UV filtration, wear\\nprotective clothing, and use sunscreen with an SPF of  30 that protects against UVA and UVB\\nwavelengths (see p. \\n673\\n). Some surgical interventions may lessen ocular movement disorders.\\nVitiligo\\nVitiligo is a loss of skin melanocytes that causes areas of skin depigmentation of varying sizes.\\nCause is unknown, but the condition may be autoimmune; up to one third of patients have\\nevidence of other autoimmune disease. Diagnosis is often obvious on examination. First-line\\ntreatment is topical corticosteroids. Calcineurin inhibitors (tacrolimus and pimecrolimus) and\\npsoralens plus ultraviolet A are commonly used. For severe widespread pigment loss,\\ndepigmentation (bleaching) of residual patches of normal skin may be done with hydroquinone.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 85. Pigmentation Disorders\\n842'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 852, 'page_label': '843'}, page_content=\"Vitiligo affects 0.5 to 2% of the population.\\nEtiology\\nEtiology is unclear, but melanocytes are lacking in affected areas. It is both familial (autosomal dominant,\\nwith incomplete penetrance and variable expression) and acquired. Proposed mechanisms include\\nautoimmune destruction of melanocytes, reduced survival of melanocytes, and primary melanocyte\\ndefects. Occasionally, vitiligo occurs after a direct physical injury to the skin (eg, as a response to\\nsunburn). This form of vitiligo is called the Koebner phenomenon. Patients may associate the onset of\\nvitiligo with emotional stress.\\nSome patients have antibodies to melanin. Up to 30% have other autoimmune antibodies (to\\nthyroglobulin, adrenal cells, and parietal cells) or clinical autoimmune endocrinopathies (Addison's\\ndisease, diabetes mellitus, pernicious anemia, and thyroid dysfunction), leading to speculation that vitiligo\\nis an autoimmune disease. However, the relationship is unclear and may be coincidental. The strongest\\nassociation is with hyperthyroidism (Graves' disease) and hypothyroidism (Hashimoto's thyroiditis).\\nSymptoms and Signs\\nVitiligo is characterized by depigmented areas (see\\nPlate 54\\n), usually sharply demarcated and often symmetric. Depigmentation may be localized, involving 1\\nor 2 spots or entire body segments (segmental vitiligo); rarely, it may be generalized, involving most of the\\nskin surface (universal vitiligo). However, vitiligo most commonly involves the face (especially around the\\norifices), digits, dorsal hands, flexor wrists, elbows, knees, shins, dorsal ankles, armpits, inguinal area,\\nanogenital area, umbilicus, and nipples. Cosmetic disfigurement can be especially devastating in dark-\\nskinned patients. Hair in vitiliginous areas is usually white.\\nDiagnosis\\n Clinical evaluation\\nDepigmented skin is typically obvious on examination. Skin lesions are accentuated under Wood's light.\\nDifferential diagnosis includes postinflammatory hypopigmentation, morphea, leprosy, chemical\\nleukoderma, and leukoderma due to melanoma. Additional testing for autoimmune endocrine disease is\\nprobably unnecessary unless symptoms or signs suggest a particular disorder.\\nTreatment\\n Protection of affected areas from sunlight\\n Topical corticosteroids\\n Topical calcineurin inhibitors when face or groin involved\\n Sometimes psoralen plus ultraviolet A (PUVA) therapy\\nTreatment is supportive and cosmetic. Physicians must be aware of individual and \\nethnic sensibilities\\nregarding uniform skin coloring; the disease can be psychologically devastating. All depigmented areas\\nare prone to severe sunburn and must be protected with clothing or sunscreen.\\nSmall, scattered lesions may be camouflaged with makeup. First-line therapy for more extensive\\ninvolvement is potent topical corticosteroids, which may cause hypopigmentation or atrophy in normal\\nsurrounding skin. Calcineurin inhibitors (tacrolimus and pimecrolimus) may be particularly useful for\\ntreating areas of the skin (such as the face and groin) where adverse effects of topical corticosteroid\\ntherapy most commonly occur. Oral and topical PUVA is often successful, although hundreds of treatment\\nsessions may be necessary. Narrowband UVB is as effective as topical PUVA and has few adverse\\neffects. Lasers may be useful, particularly for localized disease that does not respond to initial topical\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 85. Pigmentation Disorders\\n843\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 853, 'page_label': '844'}, page_content=\"therapy.\\nSurgery is reasonable only for patients with stable, limited disease when medical therapy has failed.\\nTherapies include autologous micrografting, suction blister grafting, and tattooing; tattooing is especially\\nuseful for difficult-to-repigment areas such as the nipples, lips, and fingertips.\\nDepigmentation of unaffected skin to achieve homogeneous skin tone is possible with 20% monobenzyl\\nether of hydroquinone applied twice daily and is indicated only when most of the skin is involved and the\\npatient is prepared for permanent pigment loss. This treatment can be extremely irritating, so a smaller\\ntest area should be treated before widespread use. Treatment for  1 yr may be required.\\nHyperpigmentation\\nHyperpigmentation has multiple causes and may be focal or diffuse. Most cases are due to an increase in\\nmelanin production and deposition.\\nFocal hyperpigmentation is most often postinflammatory in nature, occurring after injury (eg, cuts and\\nburns) or other causes of inflammation (eg, acne, lupus). Focal linear hyperpigmentation is commonly due\\nto phytophotodermatitis, which results from ultraviolet light combined with furocoumarins in limes, celery,\\nand other plants.\\nHyperpigmentation also has systemic and neoplastic causes.\\nMelasma (chloasma):\\n Melasma consists of dark brown, sharply marginated, roughly symmetric patches\\nof hyperpigmentation on the face (usually on the forehead, temples, and cheeks). It occurs primarily in\\npregnant women (melasma gravidarum, or the mask of pregnancy) and in women taking oral\\ncontraceptives. Ten percent of cases occur in nonpregnant women and dark-skinned men. Melasma is\\nmore prevalent and lasts longer in people with dark skin.\\nBecause all cases are associated with sun exposure, the mechanism probably involves overproduction of\\nmelanin by hyperfunctional melanocytes. Other than sun exposure, aggravating factors include\\n Autoimmune thyroid disorders\\n Photosensitizing drugs\\nIn women, melasma fades slowly and incompletely after childbirth or cessation of hormone use. In men,\\nmelasma rarely fades.\\nTreatment depends on whether the pigmentation is epidermal or dermal; epidermal pigmentation becomes\\naccentuated with Wood's light or can be diagnosed with biopsy. Only epidermal pigmentation responds to\\ntreatment. First-line therapy includes a combination of hydroquinone 2 to 4%, tretinoin 0.05 to 1%, and a\\nclass V to VII topical corticosteroid. Hydroquinone 3 to 4% applied twice daily is often effective, but long\\ncourses are usually required; 2% hydroquinone is useful as maintenance. Hydroquinone should be tested\\nbehind one ear or on a small patch on the forearm for 1 wk before use on the face because it may cause\\nirritation. Bleaching agents, such as 0.1% tretinoin and azelaic acid 15 to 20% cream, can be used in\\nplace of or with hydroquinone. Chemical peeling with glycolic acid or 30 to 50% trichloroacetic acid is an\\noption for patients with severe melasma unresponsive to topical bleaching agents.\\nLentigines:\\n Lentigines (singular: lentigo) are flat, tan to brown oval spots. They are commonly due to\\nchronic sun exposure (solar lentigines; sometimes called liver spots) and occur most frequently on the\\nface and back of the hands. They typically first appear during middle age and increase in number with\\nage. Although progression from lentigines to melanoma has not been established, lentigines are an\\nindependent risk factor for melanoma. They are treated with cryotherapy or laser; hydroquinone is not\\neffective.\\nNonsolar lentigines are sometimes associated with systemic disorders, such as Peutz-Jeghers syndrome\\n(in which profuse lentigines of the lips occur), multiple lentigines syndrome (Leopard syndrome), or\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 85. Pigmentation Disorders\\n844\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 854, 'page_label': '845'}, page_content=\"xeroderma pigmentosum.\\n[\\nTable 85-1.\\n Hyperpigmentation Effects of Some Drugs and Chemicals]\\nDiffuse hyperpigmentation due to systemic disorders:\\n Common systemic causes include Addison's\\ndisease (see p. \\n792\\n), hemochromatosis (see p. \\n1032\\n), and primary biliary cirrhosis (see p. \\n244\\n). Skin\\nfindings are nondiagnostic as to cause.\\nDrug-induced hyperpigmentation:\\n Changes are usually diffuse but sometimes have drug-specific\\ndistribution patterns or hues (see \\nTable 85-1\\n). Mechanisms include\\n Increased melanin in the epidermis (tends to be more brown)\\n Melanin in the epidermis and high dermis (mostly brown with hints of gray or blue)\\n Increased melanin in the dermis (tends to be more grayish or blue)\\n Dermal deposition of the drug or metabolite (usually slate or bluish gray)\\nFocal hyperpigmentation frequently follows drug-induced lichen planus (also known as lichenoid drug\\nreactions).\\nIn fixed drug eruptions, red plaques or blisters form at the same site each time a drug is taken; residual\\npostinflammatory hyperpigmentation usually persists. Typical lesions occur on the face (especially the\\nlips), hands, feet, and genitals. Typical inciting drugs include sulfonamides, tetracycline, NSAIDs\\n(especially phenazone derivatives), barbiturates, and carbamazepine.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 85. Pigmentation Disorders\\n845\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 855, 'page_label': '846'}, page_content='Chapter 86. Hair Disorders\\nIntroduction\\nHair growth in both men and women is regulated by androgens. Testosterone stimulates hair growth in\\nthe pubic area and underarms. Dihydrotestosterone stimulates beard hair growth and scalp hair loss.\\nHair disorders include alopecia, hypertrichosis, hirsutism, and pseudofolliculitis barbae. Although most\\nhair disorders are not serious, they are often perceived as major cosmetic issues that demand treatment.\\nDandruff is not a hair disorder but rather a skin disorder (seborrheic dermatitis) of the scalp (see p. \\n671\\n).\\nAlopecia\\n(Baldness)\\nAlopecia is defined as loss of hair. Hair loss is often a cause of great concern to the patient for cosmetic\\nand psychologic reasons, but it can also be an important sign of systemic disease.\\nPathophysiology\\nGrowth cycle:\\n Hair grows in cycles. Each cycle consists of a long growing phase (anagen), a brief\\ntransitional apoptotic phase (catagen), and a short resting phase (telogen). At the end of the resting\\nphase, the hair falls out (exogen) and a new hair starts growing in the follicle, beginning the cycle again.\\nNormally, about 100 scalp hairs reach the end of resting phase each day and fall out. When significantly\\nmore than 100 hairs/day go into resting phase, clinical hair loss (telogen effluvium) may occur. A\\ndisruption of the growing phase causing abnormal loss of anagen hairs is an anagen effluvium.\\nClassification:\\n Alopecia can be classified as focal or diffuse and by the presence or absence of scarring.\\nScarring alopecia is the result of active destruction of the hair follicle. The follicle is irreparably damaged\\nand replaced by fibrotic tissue. Several hair disorders show a biphasic pattern in which nonscarring\\nalopecia occurs early in the course of the disease, and then permanent hair loss occurs as the disease\\nprogresses. Scarring alopecias can be subdivided further into primary forms, where the target of\\ninflammation is the follicle itself, and secondary forms, where the follicle is destroyed as a result of\\nnonspecific inflammation (see\\nTable 86-1\\n).\\nNonscarring alopecia results from processes that reduce or slow hair growth without irreparably\\ndamaging the hair follicle. Disorders that primarily affect the hair shaft also are considered nonscarring\\nalopecia.\\nEtiology\\nThe alopecias comprise a large group of disorders with multiple and varying etiologies (see \\nTable 86-1\\n).\\nThe \\nmost common cause\\n of alopecia is\\n Androgenetic alopecia (male-pattern or female-pattern hair loss)\\nAndrogenetic alopecia is an androgen-dependent hereditary disorder in which dihydrotestosterone plays\\na major role.\\nOther common causes\\n of hair loss are\\n Drugs (including chemotherapeutic agents)\\n Infection\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n846'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 856, 'page_label': '847'}, page_content=' Systemic illnesses (particularly those that cause high fever, systemic lupus, endocrine disorders, and\\nnutritional deficiencies)\\nLess common causes\\n are primary hair shaft abnormalities, autoimmune disease, heavy metal\\npoisoning, and rare dermatologic conditions.\\nEvaluation\\nHistory: History of present illness\\n should cover the onset and duration of hair loss, whether hair\\nshedding is increased, and whether hair loss is generalized or localized. Associated symptoms such as\\npruritus and scaling should be noted. Patients should be asked about typical hair care practices, including\\nuse of braids, rollers, and hair dryers, and whether they routinely pull or twist their hair.\\nReview of systems\\n should include recent exposures to noxious stimuli (eg, drugs, toxins, radiation) and\\nstressors (eg, surgery, chronic illness, fever, psychologic stressors). Symptoms of possible causes should\\nbe sought, including fatigue and cold intolerance (hypothyroidism) and, in women, hirsutism, deepening of\\nthe voice, and increased libido (virilizing syndrome). Other features, including dramatic weight loss,\\ndietary practices (including vegetarianism), and obsessive-compulsive behavior, should be noted. In\\nwomen, a hormonal/gynecologic/obstetric history should be obtained.\\nPast medical history\\n should note known possible causes of hair loss, including endocrine and skin\\ndisorders. Current and recent\\n[\\nTable 86-1.\\n Classification and Causes of Alopecia]\\ndrug use should be reviewed for offending agents (see \\nTable 86-1\\n). A family history of hair loss should be\\nrecorded.\\nPhysical examination:\\n Examination of the scalp should note the distribution of hair loss, the presence\\nand characteristics of any skin lesions, and whether there is scarring. Part widths should be measured.\\nAbnormalities of the hair shafts should be noted.\\nA full skin examination should be done to evaluate hair loss elsewhere on the body (eg, eyebrows,\\neyelashes, arms, legs), rashes that may be associated with certain types of alopecia (eg, lichen planus,\\natopy, psoriasis, discoid lupus lesions, hidradenitis, signs of secondary syphilis or of other bacterial or\\nfungal infections), and signs of virilization in women (eg, hirsutism, acne, deepening voice, clitoromegaly).\\nSigns of potential underlying systemic disorders should be sought, and a thyroid examination should be\\ndone.\\nRed flags:\\n The following findings are of particular concern:\\n Virilization in women\\n Signs of systemic illness or constellations of nonspecific findings possibly indicating poisoning\\nInterpretation of findings:\\n Hair loss that begins at the temples or vertex and spreads to diffuse thinning\\nor nearly complete hair loss is typical of male-pattern hair loss. Hair thinning in the frontal, parietal, and\\ncrown regions is typical of female-pattern hair loss (see\\nFig. 86-1\\n).\\nHair loss that occurs 2 to 4 wk after chemotherapy or radiation therapy (anagen effluvium) can typically\\nbe ascribed to those causes. Hair loss that occurs 3 to 4 mo after a major stressor (pregnancy, febrile\\nillness, surgery, medication change, or severe psychologic stressor) suggests a diagnosis of telogen\\neffluvium.\\nOther findings help suggest alternative diagnoses (see\\nTable 86-2\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n847'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 857, 'page_label': '848'}, page_content='Other than hair loss, scalp symptoms (eg, itching, burning, tingling) are often absent and, when present,\\nare not specific to any cause.\\nSigns of hair loss in patterns other than those described above are nondiagnostic and may require\\nmicroscopic hair examination or scalp biopsy for definitive diagnosis.\\nTesting:\\n Evaluation for causative disorders (eg, endocrinologic, autoimmune, toxic) should be done\\nbased on clinical suspicion.\\nMale-pattern or female-pattern hair loss generally requires no testing. When it occurs in young men with\\nno family history, the physician should question the patient about use of anabolic steroids and other\\ndrugs. In addition to questions regarding drug and illicit drug use, women with significant hair loss and\\nevidence of virilization should have testosterone and dehydroepiandrosterone sulfate (DHEAS) levels\\nmeasured (see p.\\n730\\n).\\nThe \\npull test\\n helps evaluate diffuse scalp hair loss. Gentle traction is exerted on a bunch of hairs (40 to\\n60) on at least 3 different areas of the scalp, and the number of extracted hairs is counted and examined\\nmicroscopically. Normally, < 3 telogen-phase hairs should come out with each pull. If at least 3 hairs are\\nobtained with each pull or if > 10 hairs total are obtained, the pull test is positive and suggestive of\\ntelogen effluvium.\\nThe \\npluck test\\n pulls individual hairs out abruptly (\"by the roots\"). The roots of the plucked hairs are\\nexamined microscopically to determine the phase of growth and thus help diagnose a defect of telogen or\\nanagen or an occult systemic disease. Anagen hairs have sheaths attached to their roots; telogen hairs\\nhave tiny bulbs without sheaths at their roots. Normally, 85 to 90% of hairs are in the\\n[\\nFig. 86-1.\\n Male-pattern and female-pattern hair loss.]\\nanagen phase; about 10 to 15% are in telogen phase; and < 1% are in catagen phase. Telogen effluvium\\nshows an increased percentage of telogen-phase hairs on microscopic examination, whereas anagen\\neffluvium shows a decrease in telogen-phase hairs and an increased number of broken hairs. Primary\\nhair shaft abnormalities are usually obvious on microscopic examination of the hair shaft.\\nScalp biopsy\\n is indicated when alopecia persists and diagnosis is in doubt. Biopsy may differentiate\\nscarring from nonscarring forms. Specimens should be taken from areas of active inflammation, ideally at\\nthe border of a bald patch. Fungal and bacterial cultures may be useful; immunofluorescence studies may\\nhelp identify lupus erythematosus, lichen planopilaris, and systemic sclerosis.\\nDaily hair counts\\n can be done by the patient to quantify hair loss when the pull test is negative. Hairs\\nlost in the first morning combing or during washing are collected in clear plastic bags daily for 14 days.\\nThe number of hairs in each bag is then recorded. Scalp hair counts of > 100/day are abnormal except\\nafter shampooing, when hair counts of up to 250 may be normal. Hairs may be brought in by the patient\\nfor microscopic examination.\\nTreatment\\nAndrogenetic alopecia: Minoxidil\\n (2% for women, 2% or 5% for men) prolongs the anagen growth\\nphase and gradually enlarges miniaturized follicles (vellus hairs) into mature terminal hairs. Topical\\nminoxidil 1 mL bid applied to the scalp is most effective for vertex alopecia in male-pattern or female-\\npattern hair loss. However, usually only 30 to 40% of patients experience significant hair growth, and\\nminoxidil is generally not effective or indicated for other causes of hair loss except possibly alopecia\\nareata. Hair regrowth can take 8 to 12 mo. Treatment is continued indefinitely because, once treatment is\\nstopped, hair loss resumes. The most frequent adverse effects are mild scalp irritation, allergic contact\\ndermatitis, and increased facial hair.\\nFinasteride\\n inhibits the 5\\n\\n-reductase enzyme, blocking conversion of testosterone to\\ndihydrotestosterone, and is useful for male-pattern hair loss. Finasteride 1 mg po once/day can stop hair\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n848'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 858, 'page_label': '849'}, page_content='loss and can stimulate hair\\n[\\nTable 86-2.\\n Interpreting Findings in Alopecia]\\ngrowth. Efficacy is usually evident within 6 to 8 mo of treatment. Adverse effects include decreased libido,\\nerectile and ejaculatory dysfunction, hypersensitivity reactions, gynecomastia, and myopathy. There may\\nbe a decrease in prostate-specific antigen levels in older men, which should be taken into account when\\nthat test is used for cancer screening. Common practice is to continue treatment for as long as positive\\nresults persist. Once treatment is stopped, hair loss returns to previous levels. Finasteride is not indicated\\nfor women and is contraindicated in pregnant women because it has teratogenic effects in animals.\\nHormonal modulators\\n such as oral contraceptives or spironolactone may be useful for female-pattern\\nhair loss associated with hyperandrogenemia.\\nSurgical options\\n include follicle transplant, scalp flaps, and alopecia reduction. Few procedures have\\nbeen subjected to scientific scrutiny, but patients who are self-conscious about their hair loss may\\nconsider them.\\nHair loss due to other causes:\\n Underlying disorders are treated.\\nMultiple treatment options for alopecia areata exist and include topical, intralesional, or, in severe cases,\\nsystemic corticosteroids, topical minoxidil, topical anthralin, topical immunotherapy (diphencyprone or\\nsquaric acid dibutylester), or psoralen plus ultraviolet A (PUVA).\\nTreatment for traction alopecia is elimination of physical traction or stress to the scalp.\\nTreatment for tinea capitis is topical or oral antifungals (see p. \\n707\\n).\\nTrichotillomania is difficult to treat, but behavior modification, clomipramine, or an SSRI (eg, fluoxetine,\\nfluvoxamine, paroxetine, sertraline, citalopram) may be of benefit.\\nScarring alopecia as seen in central centrifugal scarring alopecia, dissecting cellulitis of the scalp, and\\nacne keloidalis nuchae is best treated by a long-acting oral tetracycline in combination with a potent\\ntopical corticosteroid.\\nLichen planopilaris and chronic cutaneous lupus lesions may be treated with oral antimalarials,\\ncorticosteroids, retinoids, or immunosuppressants.\\nHair loss due to chemotherapy is temporary and is best treated with a wig; when hair regrows, it may be\\ndifferent in color and texture from the original hair. Hair loss due to telogen effluvium or anagen effluvium\\nis usually temporary as well and abates after the precipitating agent is eliminated.\\nKey Points\\n Androgenetic alopecia (male-pattern and female-pattern hair loss) is the most common type of hair loss.\\n Concomitant virilization in women or scarring hair loss should prompt a thorough evaluation for the\\nunderlying disorder.\\n Microscopic hair examination or scalp biopsy may be required for definitive diagnosis.\\nAlopecia Areata\\nAlopecia areata is sudden patchy hair loss in people with no obvious skin or systemic disorder.\\nThe scalp and beard are most frequently affected, but any hairy area may be involved. Hair loss may\\naffect most or all of the body (alopecia universalis). Alopecia areata is thought to be an autoimmune\\ndisorder affecting genetically susceptible people exposed to unclear environmental triggers, such as\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n849'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 859, 'page_label': '850'}, page_content='infection or emotional stress. It occasionally coexists with autoimmune vitiligo or thyroiditis.\\nDiagnosis\\n Examination\\nDiagnosis is by inspection. Alopecia areata typically manifests as discrete circular patches of hair loss\\ncharacterized by short broken hairs at the margins, which resemble exclamation points. Nails are\\nsometimes pitted or display trachyonychia, a roughness of the nail also seen in lichen planus. Differential\\ndiagnosis includes tinea capitis, trichotillomania, discoid lupus, and secondary syphilis. Measures of\\nthyroid-stimulating hormone, vitamin B\\n12\\n, and autoantibodies are indicated only when coexisting disease\\nis suspected.\\nTreatment\\n Corticosteroids\\n Sometimes topical anthralin, minoxidil or both\\nTreatment is with corticosteroids. Triamcinolone acetonide suspension (in doses not to exceed 0.1 mL per\\ninjection site, eg, 10 mg/mL concentration to deliver 1 mg) can be injected intradermally if the lesions are\\nsmall. Potent topical corticosteroids (such as betamethasone 0.05% bid) can be used; however, they\\noften do not penetrate to the depth of the hair bulb where the inflammatory process is located. Oral\\ncorticosteroids are effective, but hair loss recurs after cessation of therapy and adverse effects limit use.\\nTopical anthralin (0.5 to 1% for 10 to 20 min daily, then washed off, frequency titrated as tolerated up to\\n30 min bid) and/or minoxidil may be used. Induction of allergic contact dermatitis using diphencyprone or\\nsquaric acid dibutylester leads to hair growth due to unknown mechanisms, but this treatment is best\\nreserved for patients with diffuse involvement who have not responded to other therapies.\\nAlopecia areata may spontaneously regress, become chronic, or spread diffusely. Risk factors for\\nchronicity include extensive involvement, onset before adolescence, atopy, and involvement of the\\nperipheral scalp (ophiasis).\\nHirsutism\\nHirsutism\\n is the excessive growth of thick or dark hair in women in locations that are more typical of\\nmale hair patterns (eg, mustache, beard, central chest, shoulders, lower abdomen, back, inner thigh). The\\namount of hair growth that is considered excessive may differ depending on ethnic background and\\ncultural interpretation. Men vary significantly in amount of body hair, some being quite hairy, but rarely\\npresent for medical evaluation.\\nHypertrichosis\\n is a separate condition. It is simply an increase in the amount of hair growth anywhere on\\nthe body. Hypertrichosis may be generalized or localized.\\nPathophysiology\\nHair growth depends on the balance between androgens (eg, testosterone, dehydroepiandrosterone\\nsulfate [DHEAS], dihydrotestosterone [DHT]) and estrogens. Androgens promote thick, dark hair growth,\\nwhereas estrogens slow hair growth or modulate it toward finer, lighter hairs.\\nWhen caused by increased androgen activity, hirsutism is often accompanied by virilization, which may\\nmanifest as loss of menses, increased muscle mass, voice deepening, and clitoral hypertrophy.\\nEtiology\\nThere are a number of causes of hirsutism (see\\nTable 86-3\\n). Overall, the most common causes are the following:\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n850'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 860, 'page_label': '851'}, page_content=' Polycystic ovary syndrome\\n Familial hirsutism\\nAndrogen excess:\\n Hirsutism typically results from abnormally high androgen activity as a result of\\nincreased central production of androgens (eg, from ovarian or adrenal disorders) or increased peripheral\\nconversion of testosterone to DHT by 5\\n\\n-reductase. Free androgen levels also can increase as a result\\nof decreased production of sex hormone-binding globulin, which can occur in a variety of conditions,\\nincluding hyperinsulinemia and liver disease. However, the severity of hirsutism does not correlate with\\nthe level of circulating\\n[\\nTable 86-3.\\n Some Causes of Hirsutism]\\nandrogens because of individual differences in androgen sensitivity of the hair follicle.\\nNo androgen excess:\\n Hirsutism not associated with androgen excess may be physiologic (eg,\\npostmenopausal, during pregnancy), the result of systemic nonandrogenic endocrine conditions, or a\\nfamilial phenomenon, especially in people of Mediterranean or Middle Eastern ancestry.\\nHypertrichosis\\n involves nonandrogenic hair growth and is usually caused by a drug, systemic illness\\n(see \\nTable 86-4\\n), or paraneoplastic syndrome. It also occurs as part of a rare familial disorder.\\nEvaluation\\nHistory: History of present illness\\n should cover the extent and acuity of hair growth as well as the age\\nof onset.\\nReview of systems\\n should seek signs of virilization (eg, deepening of the voice, increased libido) and\\nreview menstrual and fertility history. Symptoms of causative disorders should be sought, including cold\\nintolerance, fatigue, and weight gain (hypothyroidism); polyuria (diabetes); bingeing and purging (eating\\ndisorders); and weight loss and fevers (cancer).\\nPast medical history\\n should specifically seek known causative disorders such as endocrine disorders,\\nadrenal or ovarian pathology, and cancer.\\nFamily history\\n should inquire about excess hair growth in family members. Drug history should review\\nall prescribed drugs and specifically query for the surreptitious use of anabolic steroids.\\nPhysical examination:\\n The presence of excess coarse and dark hair growth should be assessed at\\nmultiple sites, including the face, chest, lower abdomen, back, buttocks, and inner thigh. Signs of\\nvirilization should be sought, including clitoromegaly, acne, male-pattern hair loss, breast atrophy, and\\nincreased muscle mass.\\nGeneral physical examination should note signs of potentially causative disorders.\\nThe eyes should be examined for extraocular movements, and the visual fields should be assessed.\\nThe breasts should be examined for galactorrhea.\\nThe abdomen (including pelvic examination) should be examined for masses.\\nThe skin should be examined for velvety, black pigmentation on the axillae and neck and under the\\nbreasts (acanthosis nigricans); acne; and striae.\\nThe general habitus should be examined for fat distribution (particularly a round face and accumulation of\\nfat at the base of the neck posteriorly).\\n[\\nTable 86-4.\\n Causes of Hypertrichosis]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n851'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 861, 'page_label': '852'}, page_content=\"Red flags:\\n The following findings are of particular concern:\\n Virilization\\n Abrupt appearance of hirsutism\\n Pelvic or abdominal mass\\nInterpretation of findings:\\n Excess hair growth beginning after use of an anabolic steroid or other\\ncausative drug (see \\nTables 86-3\\n and \\n86-4\\n) in an otherwise healthy female is likely due to that drug.\\nSymptoms and signs sometimes point to a diagnosis (see\\nTable 86-5\\n).\\nTesting:\\n Diagnostic testing in men with no other signs of illness is unnecessary.\\nWomen should have laboratory measurement of serum hormone levels, including the following:\\n Free and total testosterone\\n DHEAS\\n Follicle-stimulating hormone (FSH) and luteinizing hormone (LH)\\n Androstenedione\\n Thyroid-stimulating hormone\\n Prolactin\\nHigh levels of testosterone accompanied by a normal level of DHEAS indicate that the ovaries, and not\\nthe adrenal glands, are producing the excess androgen. High levels of testosterone accompanied by\\nmoderate elevations in DHEAS suggest an adrenal origin for the hirsutism.\\nOften, in women with polycystic ovary syndrome, LH levels are elevated and FSH levels are depressed,\\nwhich results in elevated LH/FSH ratios (> 3 is common).\\nImaging:\\n Pelvic ultrasonography, CT, or both should be done to rule out pelvic or adrenal cancer,\\nparticularly when a pelvic mass is appreciated, when the total testosterone level is > 200 ng/dL (> 100\\nng/dL in postmenopausal women), or when the DHEAS level is > 7000 ng/dL (> 4000 ng/dL in\\npostmenopausal women). However, the majority of patients with elevated DHEAS have adrenal\\nhyperplasia rather than adrenal carcinoma.\\nPatients with signs of Cushing's syndrome or an adrenal mass on imaging studies should have 24-h urine\\ncortisol levels measured.\\nTreatment\\nThe underlying disorder should be treated, including stopping or changing causative drugs. Treatment for\\nhirsutism itself is unnecessary if the patient does not find the excess hair cosmetically objectionable.\\nNonandrogen-dependent excess hair growth, such as hypertrichosis, is treated primarily with physical\\nhair removal methods. Patients with androgen-dependent hirsutism require a combination of hair removal\\nand medical antiandrogen therapy.\\nHair removal:\\n There are several techniques. Depilatory techniques remove hair from the surface of the\\nskin and include shaving and OTC depilatory creams, such as those containing barium sulfate and Ca\\nthioglycolate.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n852\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 862, 'page_label': '853'}, page_content='Epilation involves removing intact hairs and the roots and can be achieved via mechanical means (eg,\\ntweezing, plucking, waxing) or home epilating devices. Permanent epilation techniques, including\\nelectrolysis, thermolysis, and laser epilation, can result in more long-term hair removal but often require\\nmultiple treatments.\\nAs an alternative to hair removal, hair bleaching is inexpensive and works well when hirsutism is not\\nexcessive. Bleaches lighten the color of the hair, rendering it less noticeable. There are several types of\\ncommercial\\n[\\nTable 86-5.\\n Some Symptoms and Signs for Diagnosis of Hirsutism]\\nhair-bleaching products, most of which use hydrogen peroxide as the active ingredient.\\nTopical eflornithine, applied twice daily, decreases hair growth and, with long-term use, may decrease the\\nneed to manually remove hair.\\nHormonal treatment:\\n Hirsutism resulting from androgen excess usually requires long-term therapy\\nbecause the source of excess androgen rarely can be eliminated permanently. Hormonal treatments\\ninclude\\n Oral contraceptives\\n Antiandrogenic drugs\\n Sometimes other drugs\\nOral contraceptives in standard doses often are the initial treatment for hirsutism caused by ovarian\\nhyperandrogenism. Oral contraceptives reduce ovarian androgen secretion and increase sex hormone-\\nbinding globulin, thereby decreasing free testosterone levels.\\nAntiandrogenic therapy is also used and can include finasteride (5 mg po once/day), spironolactone (25\\nto 100 mg po bid), or flutamide (125 mg po once/day or bid). These drugs are contraindicated during\\npregnancy as they may cause feminization of a male fetus.\\nInsulin sensitizers such as metformin decrease insulin resistance, causing a decline in testosterone\\nlevels. However, they are less effective than other antiandrogenic drugs. Corticosteroids are used for\\nadrenal suppression. Gonadotropin-releasing hormone agonists (eg, leuprolide acetate, nafarelin,\\ntriptorelin) can be used for severe forms of ovarian hyperandrogenism under the direction of a\\ngynecologist or endocrinologist.\\nKey Points\\n Hirsutism may be familial, and the degree of hair growth may vary with ethnicity.\\n Polycystic ovary syndrome is the most frequent cause of hirsutism.\\n Virilization suggests an androgenic disorder that requires further evaluation.\\n Abrupt onset of hirsutism may indicate cancer.\\nPseudofolliculitis Barbae\\nPseudofolliculitis barbae (PFB) is irritation of the skin due to beard hairs that penetrate the skin\\nbefore leaving the hair follicle or that leave the follicle and curve back into the skin, causing a\\nforeign-body reaction.\\nPFB predominantly affects black men. It is most noticeable around the beard and neck. It causes small\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n853'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 863, 'page_label': '854'}, page_content='papules and pustules that can be confused with bacterial folliculitis.\\nDiagnosis is by physical examination.\\nTreatment\\nAcute PFB can be treated with warm compresses and manual removal of ingrown hairs with a needle or\\ntweezers. Topical hydrocortisone 1% or topical antibiotics can be used for mild inflammation. Oral\\ntetracycline (250 to 500 mg qid) or oral erythromycin (250 to 500 mg qid, 333 mg tid, 500 mg bid) can be\\nused for moderate to severe inflammation. \\nTretinoin (retinoic acid) liquid or cream or benzoyl peroxide\\ncream may also be effective in mild or moderate cases but may irritate the skin. Topical eflornithine\\nhydrochloride cream may help by slowing hair growth. Hairs should be allowed to grow out; grown hairs\\ncan then be cut to about 0.5 cm length. Depilatories are an alternative but may irritate the skin. Hair\\nfollicles can be permanently removed by electrolysis or laser treatment.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 86. Hair Disorders\\n854'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 864, 'page_label': '855'}, page_content=\"Chapter 87. Nail Disorders\\nIntroduction\\nA variety of disorders can affect nails, including deformities, infections of the nail, paronychia, and\\ningrown toenails. Nail changes may occur in many systemic conditions and genetic syndromes.\\nNails may also undergo changes due to local infection or trauma. For example, trauma to the finger may\\ncause changes in the nail. The nail may develop a white coloration that starts at the nail bed and grows\\nup with the nail. Sometimes, if a nail becomes separated from the nail bed, a new nail grows below the\\nexisting nail and replaces it when fully grown in.\\nMost nail infections are fungal (onychomycosissee p. \\n734\\n), but bacterial and viral infections can occur\\n(eg, green-nail syndrome [\\nPseudomonas\\n], herpetic whitlow [herpes simplex virus-1]). Paronychia is not\\nactually an infection of the nail but rather of periungual tissues.\\nCommon warts (verrucae vulgaris) result from papillomavirus infection and frequently infect the proximal\\nnail fold and sometimes the subungual area. Onychophagia (nail-biting) can help to spread this infection.\\nWarts involving these areas are especially difficult to treat. Freezing with liquid nitrogen may be effective.\\nToenails require special attention in the elderly and in people with diabetes or peripheral vascular\\ndisease; a podiatrist can help avoid local breakdown and secondary infections.\\nDeformities\\nAbout 50% of nail deformities result from fungal infection. The remainder result from various causes,\\nincluding trauma, psoriasis, lichen planus, and occasionally cancer. Diagnosis may be obvious on\\nexamination, but sometimes fungal scrapings and culture may be done. Deformities may resolve with\\ntreatment of the cause, but if not, manicurists may be able to hide nail deformities with appropriate\\ntrimming and polishes. Dystrophies are often considered together with deformities, but the two are slightly\\ndifferent; deformities are generally considered to be gross changes in nail shape, whereas dystrophies\\nare changes in nail texture or composition (eg, onychomycosis).\\nCongenital deformities:\\n In some congenital ectodermal dysplasias, patients have no nails (anonychia).\\nIn pachyonychia congenita, the nail beds are thickened, discolored, and hypercurved with a pincer nail\\ndeformity. Nail-patella syndrome (see p. \\n2910\\n) causes triangular lunulae and partially absent thumb nails.\\nPatients with Darier's disease can have nails with red and white streaks and a distal V-shaped nick.\\nDeformities associated with systemic problems:\\n In Plummer-Vinson syndrome, 50% of patients have\\nkoilonychia (concave, spoon-shaped nails). Yellow nail syndrome (characterized by hard, hypercurved,\\ntransversely thickened, yellow nails with loss of the cuticle) occurs in patients with lymphedema of limbs,\\npleural effusion, and ascites. Half-and-half nails occur with renal failure; the proximal half of the nail is\\nwhite, and the distal half is pink or pigmented. White nails occur with cirrhosis, although the distal third\\nmay remain pinker.\\nDeformities associated with dermatologic conditions:\\n In psoriasis, nails may have a number of\\nchanges, including irregular pits, oil spots (localized areas of tan-brown discoloration), onycholysis, and\\nthickening and crumbling of the nail plate. Lichen planus of the nail matrix causes scarring with early\\nlongitudinal ridging and splitting of the nail and later leads to pterygium formation. Pterygium of the nail is\\ncharacterized by scarring from the proximal nail outward in a V formation, which leads ultimately to loss of\\nthe nail. Alopecia areata can be accompanied by regular pits that form a pattern.\\nDiscoloration:\\n Cancer chemotherapy drugs (especially the taxanes) can cause melanonychia (nail plate\\npigmentation), which can be diffuse or may occur in transverse bands. Some drugs cause characteristic\\nchanges in nail coloration. For example, quinacrine can \\ncause nails to appear greenish yellow or white\\nunder ultraviolet light. Cyclophosphamide can cause the onychodermal bands (seal formed at the junction\\nof the nail plate and distal nail bed at the free edge of the nail plate) to become slate-gray or bluish. With\\narsenic intoxication, the nails may turn diffusely brown. Tetracyclines, ketoconazole, phenothiazines,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 87. Nail Disorders\\n855\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 865, 'page_label': '856'}, page_content=\"arsenic intoxication, the nails may turn diffusely brown. Tetracyclines, ketoconazole, phenothiazines,\\nsulfonamides, and phenindione can all cause brownish or blue discoloration. Gold therapy can turn nails\\nlight or dark brown. Tobacco use can result in yellow or brownish discoloration. In argyria, the nails may\\nbe diffusely blue-gray.\\nWhite transverse lines of the nails (Mees' lines) may occur with chemotherapy, acute arsenic intoxication,\\nmalignant tumors, MI, thallium and antimony intoxication, fluorosis, and even during etretinate therapy.\\nThey also develop with trauma to the finger, although traumatic white lines usually do not span the entire\\nnail. The fungus \\nTrichophyton mentagrophytes\\n causes a chalky white discoloration of the nail plate.\\nGreen-nail syndrome is caused by infection with \\nPseudomonas\\n. It is generally a harmless infection,\\nusually of 1 or 2 nails, and is noteworthy for its striking blue-green color. It often occurs in patients with\\nonycholysis or chronic paronychia whose nails have been immersed in fresh water for a long period.\\nTreatment is most effective with soaks of 1% acetic acid solution or alcohol diluted 1:4 with water.\\nPatients should soak their affected nails twice a day for 10 min and should avoid trauma and excess\\nmoisture. Frequent clipping of the nail increases the response to treatment.\\nMelanonychia striata:\\n Melanonychia striata are hyperpigmented bands that are longitudinal and extend\\nfrom the proximal nail fold and cuticle to the free distal end of the nail plate. In dark-skinned people, these\\nbands may be a normal physiologic variant requiring no treatment. Other causes include trauma;\\npregnancy; Addison's disease; post-inflammatory hyperpigmentation; and the use of certain drugs,\\nincluding doxorubicin, 5-fluorouracil, zidovudine (AZT), and psoralens. Melanonychia striata can also\\noccur in benign melanocytic nevi and malignant melanoma. Hutchinson's sign of the nail (melanin\\nextending through the lunula, cuticle, and proximal nail fold) may signal a melanoma in the nail matrix.\\nRapid biopsy and treatment are essential.\\nOnychogryphosis:\\n Onychogryphosis is a nail dystrophy in which the nail, most often on the big toe,\\nbecomes thickened and curved. It may be caused by ill-fitting shoes. It is common among the elderly.\\nTreatment consists of trimming the deformed nails.\\nOnycholysis:\\n Onycholysis is separation of the nail plate from the nail bed or complete nail plate loss. It\\ncan occur as a drug reaction in patients treated with tetracyclines (photo-onycholysis), doxorubicin, 5-\\nfluorouracil, cardiovascular drugs (particularly practolol and captopril), cloxacillin and cephaloridine\\n(rarely), trimethoprim/sulfamethoxazole, diflunisal, etretinate, indomethacin, isoniazid, and isotretinoin.\\nPartial onycholysis may also result from infection with \\nCandida albicans\\n as a component of\\nonychomycosis or from trauma. Partial onycholysis may occur in patients with psoriasis or thyrotoxicosis.\\nOnychotillomania:\\n In this disorder, patients pick at and self-mutilate their nails, which can lead to\\nparallel transverse grooves and ridges (washboard deformity or habit-tic nails). It most commonly\\nmanifests in patients who habitually push back the cuticle on one finger, causing dystrophy of the nail\\nplate as it grows. Subungual hemorrhages can also develop in onychotillomania.\\nPincer nail deformity:\\n Pincer nail deformity is a transverse over-curvature of the nail plate. It can occur\\nin patients with psoriasis, SLE, Kawasaki disease, cancer, end-stage renal disease, and some genetic\\nsyndromes. Patients often have pain at the borders of the nail where the nail plate curves into the tips of\\nthe fingers.\\nSubungual hematoma and nail bed trauma:\\n Subungual hematoma occurs when blood becomes\\ntrapped between the nail plate and nail bed, usually as a result of trauma. Subungual hematoma causes\\nsignificant pain and eventual separation of and temporary loss of the nail plate. When the cause is a\\ncrush injury, underlying fracture and nail bed damage are common. Nail bed damage may result in\\npermanent nail deformity.\\nIf the injury is acute, nail trephination (eg, creating a hole in the nail plate using a cautery device, 18-\\ngauge needle, or red-hot paperclip) can help relieve pain by draining accumulated blood. It is not clear\\nwhether removing the nail and repairing any nail bed damage reduces risk of permanent nail deformity.\\nTrachyonychia:\\n Trachyonychia (rough, opaque nails) may occur with alopecia areata, lichen planus,\\natopic dermatitis, and psoriasis. It is most common among children.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 87. Nail Disorders\\n856\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 866, 'page_label': '857'}, page_content=\"Tumors:\\n Benign and malignant tumors can affect the nail unit, causing deformity. These tumors include\\nbenign myxoid cysts, pyogenic granulomas, glomus tumors, Bowen's disease, squamous cell carcinoma,\\nand malignant melanoma. When cancer is suspected, expeditious biopsy followed by referral to a surgeon\\nis strongly advised.\\nOnychomycosis\\nOnychomycosis is fungal infection of the nail plate, nail bed, or both. The nails typically are\\ndeformed and discolored white or yellow. Diagnosis is by appearance, wet mount, culture, PCR,\\nor a combination. Treatment, when indicated, is with selective use of oral terbinafine or\\nitraconazole.\\nAbout 10% (range 2 to 14%) of the population has onychomycosis. Risk factors include\\n Tinea pedis\\n Preexisting nail dystrophy (eg, in patients with psoriasis)\\n Older age\\n Male sex\\n Exposure to someone with tinea pedis or onychomycosis (eg, a family member or through public\\nbathing)\\n Peripheral vascular disease or diabetes\\n Immunocompromise\\nToenails are 10 times more commonly infected than fingernails. About 60 to 80% of cases are caused by\\ndermatophytes (eg, \\nTrichophyton rubrum\\n); dermatophyte infection of the nails is called tinea unguium.\\nMany of the remaining cases are caused by nondermatophyte molds (eg, \\nAspergillus\\n, \\nScopulariopsis\\n,\\nFusarium\\n). Immunocompromised patients and those with chronic mucocutaneous candidiasis may have\\ncandidal onychomycosis (which is more common on the fingers). Subclinical onychomycosis can also\\noccur in patients with recurrent tinea pedis. Onychomycosis may predispose patients to lower extremity\\ncellulitis.\\nSymptoms and Signs\\nNails have asymptomatic patches of white or yellow discoloration and deformity. There are 3\\ncharacteristic manifestations:\\n Distal subungual, in which the nails thicken and yellow, keratin and debris accumulate distally and\\nunderneath, and the nail separates from the nail bed (onycholysis)\\n Proximal subungual, a form that starts proximally and is a marker of immunosuppression\\n White superficial, in which a chalky white scale slowly spreads beneath the nail surface\\nDiagnosis\\n Clinical evaluation\\n Potassium hydroxide wet mount examination\\n Culture\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 87. Nail Disorders\\n857\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 867, 'page_label': '858'}, page_content='Onychomycosis is suspected by appearance; predictive clinical features include involvement of the 3rd or\\n5th toenail, involvement of the 1st and 5th toenails on the same foot, and unilateral nail deformity.\\nSubclinical onychomycosis should be considered in patients with recurrent tinea pedis. Differentiation\\nfrom psoriasis or lichen planus is important, because the therapies differ, so diagnosis is typically\\nconfirmed by microscopic examination and culture of scrapings. Scrapings are taken from the most\\nproximal position that can be accessed on the affected nail and are examined for hyphae on potassium\\nhydroxide wet mount and cultured. Obtaining an adequate sample of nail can be difficult because the\\ndistal subungual debris, which is easy to sample, often does not contain living fungus. Therefore,\\nremoving the distal portion of the nail with clippers before sampling or using a small curette to reach more\\nproximally beneath the nail increases the yield. PCR can also be done on nail clippings if cultures are\\nnegative and the cost of finding a definitive diagnosis is warranted.\\nTreatment\\n Sometimes oral terbinafine or itraconazole\\nOnychomycosis is not always treated because many cases are asymptomatic or mild and unlikely to\\ncause complications, and the oral drugs that are the most effective treatments can potentially cause\\nhepatotoxicity and serious drug interactions. Some proposed indications for treatment include the\\nfollowing:\\n Previous ipsilateral cellulitis\\n Diabetes or other risk factors for cellulitis\\n Presence of bothersome symptoms\\n Psychosocial impact\\n Desire for cosmetic improvement (controversial)\\nTreatment is oral terbinafine or itraconazole. Terbinafine 250 mg once/day for 12 wk (6 wk for fingernail)\\nor itraconazole 200 mg bid 1 wk/mo for 3 mo is used and achieves a cure rate of 60 to 75%, but the\\nrecurrence rate is estimated to be as high as 10 to 50%. It is not necessary to treat until all abnormal nail\\nis gone because these drugs remain bound to the nail plate and continue to be effective after oral\\nadministration has ceased. The affected nail will not revert to normal; however, newly growing nail will\\nappear normal. Topical antifungal nail lacquer containing ciclopirox 8% or amorolfine 5% (not available in\\nthe US) is rarely effective as primary treatment but can improve cure rate when used as an \\nadjunct with\\noral drugs, particularly in resistant infections.\\nTo limit relapse, the patient should trim nails short, dry feet after bathing, wear absorbent socks, and use\\nantifungal foot powder. Old shoes may harbor a high density of spores and, if possible, should not be\\nworn.\\nParonychia\\nParonychia is infection of the periungual tissues. Acute paronychia causes redness, warmth,\\nand pain along the nail margin. Diagnosis is by inspection. Treatment is with antistaphylococcal\\nantibiotics and drainage of any pus.\\nParonychia is usually acute, but chronic cases occur. In acute paronychia, the causative organisms are\\nusually \\nStaphylococcus aureus\\n or streptococci and, less commonly, \\nPseudomonas\\n or \\nProteus\\n spp.\\nOrganisms enter through a break in the epidermis resulting from a hangnail, trauma to a nail fold, loss of\\nthe cuticle, or chronic irritation (eg, resulting from water and detergents). Biting or sucking the fingers can\\nalso predispose people to developing the infection. In toes, infection often begins at an ingrown toenail\\n(see p. \\n736\\n).\\nIn patients with diabetes and those with peripheral vascular disease, toe paronychia can threaten the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 87. Nail Disorders\\n858'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 868, 'page_label': '859'}, page_content='limb.\\nSymptoms and Signs\\nParonychia develops along the nail margin (lateral and proximal nail folds), manifesting over hours to\\ndays with pain, warmth, redness, and swelling. Pus usually develops along the nail margin and\\nsometimes beneath the nail. Infection can spread to the fingertip pulp, causing a felon. Rarely, infection\\npenetrates deep into the finger, sometimes causing infectious flexor tenosynovitis.\\nDiagnosis\\nDiagnosis is by inspection. Several skin conditions can cause changes that mimic paronychia and should\\nbe considered, particularly when treatment is not effective initially. These conditions include squamous\\ncell carcinoma, proximal onychomycosis, pyogenic granuloma, pyoderma gangrenosum, and herpetic\\nwhitlow.\\nTreatment\\n Antistaphylococcal antibiotics\\n Drainage of pus\\nEarly treatment is warm compresses or soaks and an antistaphylococcal antibiotic (eg, dicloxacillin or\\ncephalexin 250 mg po qid, clindamycin 300 mg po qid). In areas where methicillin-resistant \\nS. aureus\\n is\\ncommon, antibiotics that are effective against this organism (eg, trimethoprim/sulfamethoxazole) should be\\nchosen based on results of local sensitivity testing. In patients with diabetes and others with peripheral\\nvascular disease, toe paronychia should be monitored for signs of cellulitis or more severe infection (eg,\\nextension of edema or erythema, lymphadenopathy, fever).\\nFluctuant swelling or visible pus should be drained with a Freer elevator, small hemostat, or #11 scalpel\\nblade inserted between the nail and nail fold. Skin incision is unnecessary. A thin gauze wick should be\\ninserted for 24 to 48 h to allow drainage.\\nChronic Paronychia\\nChronic paronychia is recurrent or persistent nail fold inflammation, typically of the fingers.\\nChronic paronychia occurs almost always in people whose hands are chronically wet (eg, dishwashers,\\nbartenders, housekeepers), particularly if they are diabetic or immunocompromised. \\nCandida\\n is often\\npresent, but its role in etiology is unclear; fungal eradication does not always resolve the condition. The\\ncondition may be an irritant dermatitis with secondary fungal colonization.\\nThe nail fold is painful and red as in acute paronychia, but there is almost never pus accumulation.\\nEventually, there is loss of the cuticle and separation of the nail fold from the nail plate. This forms a\\nspace that allows entry of irritants and microorganisms. The nail becomes distorted.\\nDiagnosis is clinical.\\nTreatment\\n Keeping hands dry\\n Topical corticosteroid or tacrolimus\\nPrimary treatment is to keep the hands dry and to assist the cuticle in reforming to close the space\\nbetween the nail fold and nail plate. Gloves or barrier creams are used if water contact is necessary.\\nTopical drugs that may help include corticosteroids and, for their corticosteroid-sparing effects,\\nimmunosuppressants (eg, tacrolimus). Antifungal treatments are helpful only in reducing colonizing fungal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 87. Nail Disorders\\n859'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 869, 'page_label': '860'}, page_content='organisms. Thymol 3% in ethanol applied several times a day to the space left by loss of cuticle aids in\\nkeeping this space dry and free of microorganisms. If there is no response to therapy, squamous cell\\ncarcinoma should be considered and a biopsy should be done.\\nIngrown Toenail\\n(Onychocryptosis)\\nAn ingrown toenail is incurvation or impingement of a nail border into its adjacent nail fold,\\ncausing pain.\\nCauses include tight shoes, abnormal gait (eg, toe-walking), bulbous toe shape, excessive trimming of the\\nnail plate, or congenital variations in nail contour (congenital pincer nail deformity). Sometimes an\\nunderlying osteochondroma is responsible, especially in the young. In the elderly, peripheral edema is a\\nrisk factor. Eventually, infection can occur along the nail margin (paronychiasee p. \\n735\\n).\\nSymptoms and Signs\\nPain occurs at the corner of the nail fold or, less commonly, along its entire lateral margin. Initially only\\nmild discomfort may be present, especially when wearing certain shoes. In chronic cases, granulation\\ntissue becomes visible, more often in the young.\\nDiagnosis\\n Clinical evaluation\\nRedness, swelling, and pain suggest paronychia. In young patients (eg, < 20 yr) with ingrown toenails, x-\\nrays should be considered to exclude underlying osteochondroma. In the elderly, apparent granulation\\ntissue around the toe suggests the possibility of amelanotic melanoma, which is often overlooked; biopsy\\nis necessary.\\nTreatment\\n Usually nail excision and destruction of adjacent nail matrix\\nIn mild cases, inserting cotton between the ingrown nail plate and painful fold (using a thin toothpick) may\\nprovide immediate relief and, if continued, correct the problem. If the shoes are too tight, a larger toe box\\nis indicated. In most cases, however, particularly with paronychia, excision of the ingrown toenail after\\ninjecting a local anesthetic is the only effective treatment. If ingrown toenails recur, permanent destruction\\nof the nearby lateral nail matrix by applying phenol or trichloroacetic acetic acid or by surgical excision is\\nindicated. Phenol should not be used if there is arterial insufficiency.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 87. Nail Disorders\\n860'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 870, 'page_label': '861'}, page_content='Chapter 88. Pressure Ulcers\\nIntroduction\\n(Pressure Sores; Bedsores; Decubitus Ulcers; Decubiti)\\nPressure ulcers (PUs) are areas of necrosis and ulceration where tissues are compressed\\nbetween bony prominences and hard surfaces; they result from pressure alone or pressure in\\ncombination with friction, shearing forces, or both. Risk factors include old age, impaired\\ncirculation, immobilization, undernutrition, and incontinence. Severity ranges from\\nnonblanchable skin erythema to full-thickness skin loss with extensive soft-tissue necrosis.\\nDiagnosis is clinical. Prognosis is excellent for early-stage ulcers; neglected and late-stage\\nulcers pose risk of serious infection and nutritional stress and are difficult to heal. Treatment\\nincludes pressure reduction, avoidance of friction and shearing forces, local care, and\\nsometimes skin grafts or myocutaneous flaps.\\nEtiology\\nAn estimated 1.3 to 3 million patients in the US have PUs; incidence is highest in older patients,\\nespecially those who are hospitalized or in long-term care facilities. Aging increases risk, in part because\\nof reduced subcutaneous fat and decreased capillary blood flow. Immobility and comorbidities increase\\nrisk further.\\nPatients who are cognitively impaired, immobile, or both are at increased risk. Immobilitybecause of\\ndecreased spontaneous movement (eg, due to stroke, sedation, or severe illness) or inability to change\\nposition frequently because of weaknessis the most important factor. Other risk factors include urinary\\nand fecal incontinence; poor nutritional status, including dehydration; diabetes; and cardiovascular\\ndisease. Clinical assessment is sufficient to identify patients at risk; several scales (eg, Norton, Braden\\nsee\\nFig. 88-1\\n) are useful for predicting risk. The National Pressure Ulcer Advisory Panel has also issued\\nguidelines for the prediction and prevention of PUs.\\nPathophysiology\\nPUs develop when soft tissues are compressed between bony prominences and contact surfaces\\n[\\nFig. 88-1.\\n Braden scale for predicting risk for pressure ulcers.]\\n[\\nTable 88-1.\\n Pressure Ulcer Staging]\\nor when friction (eg, rubbing against clothing or bedding) or shearing forces (which develop when skin\\nclings to surfaces) cause erosion, tissue ischemia, and infarction. PUs most frequently develop over the\\nsacrum, ischial tuberosities, trochanters, malleoli, and heels, but they can develop elsewhere, including\\nbehind the ears when nasal cannulae are used for prolonged periods. Also, poorly fitting prosthetic\\ndevices can cause PUs to develop over bony prominences. Increased force and duration of pressure\\ndirectly influence risk and severity, but PUs can develop in as little as 3 to 4 h in some settings (eg,\\ntrauma patients who are immobilized on rigid spine-immobilization boards). Ulcers worsen when skin is\\noverly moist and macerated (eg, from perspiration or incontinence).\\nOther causes of skin ulcers:\\n Chronic arterial and venous insufficiency can result in skin ulcers,\\nparticularly on the lower extremities. Although the underlying mechanism is vascular, the same forces that\\ncause PUs can worsen these ulcers, and principles of treatment are similar.\\nSymptoms and Signs\\nSeveral staging systems exist; the most common classifies ulcers according to the depth of soft-tissue\\ndamage (see \\nTable 88-1\\n). PUs do not always present as Stage I and then progress to higher stages.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 88. Pressure Ulcers\\n861'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 871, 'page_label': '862'}, page_content=\"Sometimes the first sign of a PU is a deep, necrotic stage III or IV ulcer. In a rapidly developing PU,\\nsubcutaneous tissue can become necrotic before the epidermis erodes. A small ulcer might, like an\\niceberg, be quite large under the surface.\\nStage I\\n PUs manifest as nonblanchable erythema, usually over a bony prominence. Color changes may\\nnot be as visible in darkly pigmented skin. The lesion may also be warmer, cooler, firmer, softer, or more\\ntender than adjacent or contralateral tissue. This stage is a misnomer in the sense that an actual ulcer (a\\ndefect of skin into the dermis) is not yet present. However, ulceration will occur if the course is not\\narrested and reversed.\\nStage II\\n PUs involve loss of epidermis with or without erosion (defect of epidermis) or true ulceration\\n(partial-thickness loss of dermis); subcutaneous tissue is not exposed. The ulcers are shallow with a\\nreddish base. Intact or partially ruptured blisters due to pressure are also stage II PUs. (NOTE: Non-\\npressure-related causes of erosion, ulceration, or blisteringeg, skin tears, tape burns, perineal\\ndermatitis, maceration, excoriationare excluded from stage II description.)\\nStages III and IV\\n PUs have deeper involvement of underlying tissue with more extensive destruction.\\nUlcers covered with debris or eschar are by definition unstageable. However, stable, nonfluctuant heel\\nlesions with dry eschar should not be debrided for the sake of staging. Bruising of an apparent stage II\\nulcer should raise the suspicion of a deeper-stage PU. PUs at any stage may be painful or pruritic but\\nmay not be noticed by patients with blunted awareness or sensation. Tenderness, erythema of\\nsurrounding skin, exudate, or foul odor suggests \\ninfection. Fever should raise suspicion of bacteremia or\\nunderlying osteomyelitis.\\nComplications\\nNonhealing ulcers may be due to inadequate treatment but should raise suspicion of osteomyelitis or,\\nrarely, squamous cell carcinoma within the ulcer (Marjolin's ulcer). Other complications of nonhealing PUs\\ninclude sinus tracts, which can be superficial or connect the ulcer to deep adjacent structures (eg, to the\\nbowel in sacral ulcers), and tissue calcification. In addition, PUs are a reservoir for hospital-acquired\\nantibiotic-resistant organisms, which can slow healing and cause bacteremia and sepsis.\\nDiagnosis\\n Clinical evaluation with continuous assessment\\n Sometimes bone scan or MRI\\nDiagnosis is usually apparent clinically, but depth and extent can be difficult to determine. PUs are always\\ncolonized by bacteria, so wound surface cultures are uninterpretable. Underlying osteomyelitis is\\ndiagnosed with radionuclide bone scanning or gadolinium-enhanced MRI, but both techniques have poor\\nsensitivity and specificity. Diagnosis may require bone biopsy and culture.\\nContinuous assessment is mandatory for effective management. Serial photographs can also document\\nhealing.\\nPrognosis\\nPrognosis for early-stage PUs is excellent with timely, appropriate treatment, but healing typically requires\\nweeks. PUs often develop in patients with suboptimal care. If care cannot be improved, long-term\\noutcome is poor, even if short-term wound healing is accomplished.\\nTreatment\\n Pressure reduction\\n Direct ulcer care\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 88. Pressure Ulcers\\n862\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 872, 'page_label': '863'}, page_content=' Management of pain, infection, and undernutrition\\n Sometimes adjunctive therapy or surgery\\nTreatment requires multiple simultaneous elements.\\nReducing pressure:\\n Reducing tissue pressure is accomplished through careful positioning of the\\npatient, protective devices, and variation of support surfaces.\\nFrequent repositioning\\n (and selection of the proper position) is most important. A written schedule\\nshould be used to direct and document repositioning. Bedbound patients should be turned a minimum of\\nevery 2 h, should be placed at a 30 angle to the mattress when on their side (ie, lateral decubitus) to\\navoid direct trochanteric pressure, and should be elevated as minimally as possible to avoid the shear\\nforces on tissues that result from sliding down the bed. For repositioning patients, lifting devices (eg, a\\nStryker frame) or bed linen should be used instead of dragging the patient (which causes friction and\\nshear forces). Patients placed in chairs should be repositioned every hour, and they should be\\nencouraged to change position on their own every 15 min.\\nProtective padding\\n includes pillows or foam wedges placed between knees, ankles, and heels when\\npatients are on their side and pillows, foam, or heel protectors when patients are supine. Windows should\\nbe cut out of plaster casts at pressure sites in patients immobilized by fractures. Soft seat cushions\\nshould be provided for patients able to sit in a chair. Donut-shaped devices and sheepskins should be\\navoided as a treatment for PUs.\\nSupport surfaces\\n under bedbound patients can be changed to reduce pressure. A change from\\nstandard mattresses is indicated when patients are unable to reposition themselves and periodic\\nrepositioning care is unavailable.\\nSupport surfaces are static or dynamic.\\nStatic surfaces, which do not require electricity, include air, foam, gel, and water overlays and mattresses.\\nOld-fashioned \"egg crate\" mattresses offer no advantage. In general, static surfaces increase surface\\nsupport areas and decrease pressure and shear forces; they are indicated for high-risk patients without\\nPUs and for patients with stage I PUs.\\nDynamic surfaces require electricity. Alternating-air mattresses have air cells that are alternately inflated\\nand deflated by a pump, thus shifting supportive pressure from site to site. Low-air-loss mattresses are\\ngiant air-permeable pillows that are continuously inflated with air; the air flow has a drying effect on\\ntissues. These specialized mattresses are indicated for patients with stage I ulcers who develop\\nhyperemia on static surfaces and for patients with stage III or IV ulcers. Air-fluidized (high-air-loss)\\nmattresses contain silicone-coated beads that liquefy when air is pumped through the bed. Advantages\\ninclude reduction of moisture on surfaces and cooling. They are indicated for patients with nonhealing\\nstage III and IV ulcers or numerous truncal ulcers (see\\nTable 88-2\\n). Although specialized mattresses are designed to shift\\n[\\nTable 88-2.\\n Options for Support Surfaces]\\npressure and reduce forces that lead to PUs, they are best thought of as an adjunct to comprehensive\\ncare.\\nUlcer care:\\n Appropriate ulcer care involves cleaning, debridement, and dressings.\\nCleaning\\n should be done initially and with each dressing change; ordinary soap and water (not hot) is\\nusually best. Cleaning often involves irrigation with saline solution at pressures sufficient to remove\\nbacteria without traumatizing tissue; commercial syringes, squeeze bottles, or electrically pressurized\\nsystems can be used. Alternatively, a 35-mL syringe and an 18-gauge IV catheter can be used. Irrigation\\nshould continue until no further debris can be loosened. Antiseptics (eg, iodine, hydrogen peroxide) and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 88. Pressure Ulcers\\n863'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 873, 'page_label': '864'}, page_content=\"antiseptic washes interfere with tissue healing and should be avoided. Rubbing of skin should be\\nminimized, and moisturizer should be applied gently after each cleansing.\\nDebridement\\n is necessary to remove dead tissue. Methods include\\n Autolytic debridement: Synthetic occlusive dressings are used to facilitate digestion of dead tissues by\\nenzymes normally present in wound fluids. Autolytic debridement may be used for small wounds with\\nsimple accumulation of tissue proteins and wounds that need to be sealed off anyway (eg, for\\nprotection from feces or urine). DuoDERM or Contreet (which is impregnated with silver and thus offers\\nantimicrobial effects) are commonly applied. Infected wounds, however, should not be occluded.\\n Mechanical debridement: Hydrotherapy (whirlpool baths), ultrasound, medical maggots, wound\\nirrigation, or dextranomers (small carbohydrate-based beads that help absorb exudate and liquid debris)\\nshould be used to remove thick exudate or loose necrotic tissue. A scalpel or scissors can be used to\\nremove eschar (except in heel ulcers, in which dry eschar in the absence of edema, erythema,\\nfluctuance, or drainage can be safely left alone) or extensive areas of dead tissue. Modest amounts of\\neschar or tissue can be debrided at the patient's bedside, but extensive or deep areas should be\\ndebrided in the operating room. Urgent debridement is indicated in advancing cellulitis or sepsis.\\nDebridement with wet-to-dry dressings should be done only for wounds with very loose exudate and\\nonly with great care because it is often painful and it may remove healthy tissue or overdry the wound.\\n Enzymatic debridement (using collagenase, papain, fibrinolysin, or streptokinase/streptodornase): This\\nmethod can be used for patients whose caretakers are not trained to do mechanical debridement or for\\npatients unable to tolerate surgery. It is most effective after careful and judicious cross-hatching of the\\nwound with a scalpel to improve penetration. Collagenase is especially effective as collagen comprises\\n75% of the dry weight of skin.\\nDressings\\n should be used for stage I ulcers that are subject to friction or incontinence and for all other\\nulcers (see\\nTable 88-3\\n). Objectives are to keep the ulcer bed moist to retain tissue growth factors while allowing\\nsome evaporation and inflow of O\\n2\\n, to keep surrounding skin\\n[\\nTable 88-3.\\n Options for Pressure Ulcer Dressings]\\ndry, to facilitate autolytic debridement, and to establish a barrier to infection. Transparent films (eg,\\nOpSite, Tegaderm, Bioclusive) are sufficient for ulcers with limited exudate; they should not be used over\\ncavities and must be changed every 3 to 7 days. Some experts recommend a small amount of triple\\nantibiotic ointment under the dressing. Hydrogels (Clear-Site, Vigilon, FlexiGel), which are cross-linked\\npolymer dressings that come in sheets or gels, are indicated for very shallow wounds, such as re-\\nepithelializing wounds with minimal exudate.\\nHydrocolloids (eg, RepliCare, DuoDERM, Restore, Tegasorb), which combine gelatin, pectin, and\\ncarboxymethylcellulose in the form of wafers, powders, and pastes, are indicated for light-to-moderate\\nexudate; some have adhesive backings and others are typically covered with transparent films to ensure\\nadherence to the ulcer and must be changed every 3 days. Alginates (polysaccharide seaweed\\nderivatives containing alginic acid), which come as pads, ropes, and ribbons (AlgiSite, Sorbsan,\\nCurasorb), are indicated for absorbing extensive exudate and for controlling bleeding after surgical\\ndebridement. Foam dressings (Allevyn, LYOfoam, Hydrasorb, Mepilex, Curafoam, Contreet) are useful as\\nthey can handle various levels of exudate and provide a moist environment for wound healing.\\nWaterproof versions protect the skin from incontinence. Dressings with adhesive backings stay in place\\nlonger and need less frequent changing.\\nPain management:\\n Primary treatment of pain is treatment of the PU itself, but NSAIDs or\\nacetaminophen is used for mild-to-moderate pain. Opioids should be avoided if possible because\\nsedation promotes immobility. Opioids may be necessary during dressing changes and debridement. In\\ncognitively impaired patients, changes in vital signs can be used as an indication of pain.\\nInfection management:\\n PUs should be continually reassessed for bacterial infection using clinical signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 88. Pressure Ulcers\\n864\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 874, 'page_label': '865'}, page_content='of erythema, warmth, increased drainage, fever, and elevated WBC count. Options for topical treatment\\ninclude silver sulfadiazine, triple antibiotic, and metronidazole (the latter for anaerobic bacteria, which are\\noften foul smelling). Systemic antibiotics should be administered for cellulitis, bacteremia, or osteomyelitis;\\nusage should be guided by tissue culture or clinical suspicion and not by surface culture.\\nNutrition:\\n Undernutrition is common among patients with PUs and is a risk factor for nonhealing. Markers\\nof undernutrition include albumin < 3.5 mg/dL or weight < 80% of ideal. Protein intake of 1.25 to 1.5\\ng/kg/day, sometimes requiring oral or parenteral supplementation (see p. \\n20\\n), is desirable for optimal\\nhealing. Zinc supplementation supports wound healing, and replacement at a dose of 50 mg tid may be\\nuseful. Supplemental vitamin C 1 g/day may be provided. Providing a drink of water to patients at each\\nrepositioning may be useful to aid hydration.\\nAdjuncts:\\n Multiple adjunctive treatments have been tried or are under investigation. Negative pressure\\ntherapy (for clean wounds) and the use of various topical recombinant growth factors (eg, nerve growth\\nfactor, platelet-derived growth factor-BB) and skin equivalents are showing promise in wound\\nmanagement; however, they do not ameliorate mechanical forces and tissue ischemia. Electrical\\nstimulation, heat therapy, massage therapy, and hyperbaric O\\n2\\n therapy have not proven effective.\\nSurgery:\\n Surgical debridement is necessary for any ulcer with devitalized tissue, except for stable, dry,\\nnonfluctuant heel ulcers. Large defects, especially with exposure of musculoskeletal structures, require\\nsurgical closure. Skin grafts are useful for large, shallow defects. However, because grafts do not add to\\nblood supply, measures must be taken to prevent pressure from developing to the point of ischemia and\\nfurther breakdown. Myocutaneous flaps, because of their pressure-sharing bulk and rich vasculature, are\\nthe closures of choice over large bony prominences (eg, sacrum, ischia, trochanters).\\nIschemic and venous ulcers:\\n Wound care treatments also are useful for ischemic ulcers, but the\\nunderlying pathophysiology must be addressed (eg, better control of the inflammatory process in a\\nrheumatoid ulcer or surgical stenting or bypass surgery to improve circulation in atherosclerosis).\\nPentoxifylline has been tried with minimal success. Some evidence supports the use of dalteparin for\\ndiabetic foot ulcers (5000 units sc once/day until healed); however, this finding has not been\\ncorroborated. Ischemic ulcers can become infected, often with anaerobic organisms, and the infection\\nmay spread, causing septicemia or osteomyelitis.\\nVenous ulcers are typically sterile at first but tend to lead to cellulitis. The same local care as for PUs can\\nbe used. In addition, treatment includes measures to reduce venous hypertension, such as using\\ncompression stockings or Unna boot bandages (applied at a pressure of 35 to 40 mm Hg) and elevating\\nthe leg above the heart. Pentoxifylline 800 mg po tid for up to 24 wk may be useful.\\nPrevention\\nPrevention requires\\n Identification of high-risk patients\\n Repositioning\\n Conscientious skin care and hygiene\\n Avoidance of oversedation\\nThe mainstay of prevention is frequent repositioning. Pressure should not continue over any bony surface\\nfor > 2 h. Patients who cannot move themselves must be repositioned using pillows. Even when on low-\\npressure mattresses, patients must be turned. Pressure points should be checked for erythema or trauma\\nat least once/day under adequate lighting. Patients and family members must be taught a routine of daily\\nvisual inspection and palpation of sites for potential ulcer formation.\\nDaily attention to hygiene and dryness is necessary to prevent maceration and secondary infection.\\nAlthough sheepskin should not be used to redistribute pressure after ulceration has occurred, lying on a\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 88. Pressure Ulcers\\n865'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 875, 'page_label': '866'}, page_content='sheepskin as a preventive measure helps keep the skin in good condition. Protective padding, pillows, or\\na sheepskin can be used to separate body surfaces. Bedding and clothing should be changed frequently;\\nsheets should be soft, clean, and free from wrinkles and particulate matter. In hot weather, the skin should\\nbe sponge-bathed and thoroughly dried afterward. In incontinent patients, ulcers should be protected from\\ncontamination; synthetic dressings can help. Skin breakdown can be prevented with careful cleansing\\nand drying (patting and not rubbing the skin) and using anticandidal creams and moisture barrier creams\\nor skin protective wipes (eg, Skin-Prep). Use of adhesive tape should be minimized because it can irritate\\nand even tear fragile skin.\\nAreas subject to friction may be powdered with plain talc. Use of cornstarch is discouraged because it\\nmay allow microbial growth.\\nOversedation should be avoided, and activity should be encouraged. Adequate nutrition is important.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 88. Pressure Ulcers\\n866'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 876, 'page_label': '867'}, page_content='Chapter 89. Benign Tumors\\nIntroduction\\n(See also \\nWarts\\n on p. \\n715\\n and \\nGenital Warts\\n on p. \\n1470\\n)\\nMost skin tumors are benign. However, because skin cancers must be treated early, proper diagnosis of\\nunusual skin growths should always be made definitively and without undue delay.\\nDermatofibroma\\n(Fibrous Histiocytoma)\\nDermatofibroma is a firm, red-to-brown, small papule or nodule composed of fibroblastic tissue.\\nIt usually occurs on the thighs or legs.\\nDermatofibromas are common, more so in women, and typically appear when people are in their 20s.\\nTheir cause is unknown. Lesions are usually 0.5 to 1 cm in diameter and feel like a lentil embedded in the\\nskin. Most are asymptomatic, but some itch or ulcerate following minor trauma. Diagnosis is clinical;\\nlesions typically dimple when grasped between the fingers. They may regress spontaneously, but they\\ncan be excised if troublesome.\\nEpidermal Cysts\\n(Keratinous Cyst; Epidermal Inclusion Cyst; Sebaceous Cyst; Milia; Pilar Cyst [Wen]; Steatocystoma)\\nEpidermal cysts are slow-growing benign cysts containing material that is keratinous\\n(keratinous or epidermal inclusion cyst, sebaceous cyst, milia), follicular (pilar cyst, or wen), or\\nsebaceous (steatocystoma). They frequently occur on the scalp, ears, face, back, or scrotum.\\nOn palpation, the cystic mass is firm, globular, movable, and nontender; cysts range from about 1 to 5 cm\\nin diameter. This kind of cyst seldom causes discomfort unless it has ruptured internally, causing a rapidly\\nenlarging, painful foreign body reaction and abscess. Keratinous cysts, the most common, often are\\nsurmounted with a punctum or pore; their contents are cheesy and often fetid (due to secondary bacterial\\ncolonization). Milia are minute superficial keratinous cysts noted on the face.\\nTreatment\\nCysts may be left or removed. A small incision may be made to evacuate the contents, then the cyst wall\\nitself should be removed with a curet or hemostat; otherwise, the lesion will recur. Surgical excision with\\ncomplete removal of the cyst wall is also effective. Internally ruptured cysts should be incised and\\ndrained; a gauze drain is inserted and removed after 2 to 3 days. Antibiotics are not needed unless\\ncellulitis is present. Milia may be evacuated with a #11 blade.\\nKeloids\\nKeloids are smooth overgrowths of fibroblastic tissue that arise in an area of injury (eg,\\nlacerations, surgical scars, truncal acne) or, occasionally, spontaneously.\\nKeloids are more frequent in blacks. They tend to appear on the upper trunk, especially the upper back\\nand mid chest, and on deltoid areas. Unlike hyperplastic scars, keloidal scar tissue always extends\\nbeyond the area of original injury.\\nKeloids are shiny, firm, smooth, usually ovoid but sometimes contracted or webbed, and slightly pink or\\nhyperpigmented (see\\nPlate 37\\n). Diagnosis is clinical.\\nTreatment\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 89. Benign Tumors\\n867'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 877, 'page_label': '868'}, page_content='Treatment is often ineffective. Monthly corticosteroid injections (eg, triamcinolone acetonide 5 to 40\\nmg/mL) into the lesion sometimes flatten the keloid. Surgical or laser excision may debulk lesions, but\\nthey usually recur larger than before. Excision is more successful if preceded and followed by a series of\\nintralesional corticosteroid injections. Gel sheeting (applying a soft, semiocclusive dressing made of\\ncross-linked polymethylsiloxane polymer, or silicone) or pressure garments are other adjuncts to prevent\\nrecurrence.\\nKeratoacanthoma\\nKeratoacanthoma is a round, firm, usually flesh-colored nodule with sharply sloping borders and\\na characteristic central crater containing keratinous material; it usually resolves spontaneously.\\nEtiology is unknown. Most consider these lesions to be well-differentiated squamous cell carcinomas with\\na tendency to involute.\\nDevelopment is rapid. Usually the lesion reaches its full size, typically 1 to 3 cm but \\nmay be > 5 cm, within\\n1 or 2 mo. Common sites are sun-exposed areas, the face, the forearm, and the dorsum of the hand.\\nSpontaneous involution may start within a few months. However, because this lesion cannot be relied\\nupon to involute, biopsy or excision is recommended. Spontaneous involution may leave substantial\\nscarring; surgery or intralesional injections with methotrexate or 5-fluorouracil usually yield better\\ncosmetic results, and excision allows histologic confirmation of the diagnosis.\\nLipomas\\nLipomas are soft, movable, subcutaneous nodules of adipocytes (fat cells); overlying skin is\\nnormal.\\nA patient may have one or many lipomas. They occur more often in women than men, rarely grow to be >\\n7 to 8 cm in diameter, and appear most commonly on the trunk, nape, and forearms. They are rarely\\nsymptomatic, but they may be painful, especially in patients with familial variants presenting with multiple\\nlesions.\\nDiagnosis\\n Usually clinical\\nA lipoma is usually easily movable within the subcutis. Lipomas are generally soft, but some become\\nfirmer. Some superficial dimpling may occur, but frank inflammation is not normal.\\nA rapidly growing lesion should be biopsied, although lipomas rarely become malignant.\\nTreatment\\nTreatment is not usually required, but bothersome lipomas may be removed by excision or liposuction.\\nMoles\\n(Pigmented, Melanocytic, or Nevus Cell Nevi)\\nMoles are pigmented macules, papules, or nodules composed of clusters of melanocytes or\\nnevus cells. Their main significance (other than cosmetic) is their potential for being or\\nbecoming malignant. Lesions with characteristics of concern (changing or highly irregular\\nborders, color changes, pain, bleeding, ulceration, or itching) are biopsied.\\nAlmost everyone has a few moles, which usually appear in childhood or adolescence. There are different\\ntypes of moles (see\\nTable 89-1\\n). During adolescence and pregnancy, more moles often appear, and existing ones may\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 89. Benign Tumors\\n868'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 878, 'page_label': '869'}, page_content='enlarge or darken. Moles typically become more raised and less pigmented over the decades.\\nAn individual mole is unlikely to become malignant (lifetime risk is about 1 in 3,000 to 10,000), but the\\nsingle best predictor for risk of development of melanoma is the total number of moles. The presence of >\\n20 moles indicates a higher than average risk for melanoma; patients should be taught to self-monitor for\\nwarning signs and have skin surveillance as part of their primary care.\\nDiagnosis\\n Biopsy\\nBecause moles are extremely common and melanomas are uncommon, prophylactic removal is not\\njustifiable. However, a mole should be biopsied and examined histologically if it has certain characteristics\\nof concern:\\n Changing or highly irregular borders\\n Color changes\\n Pain\\n Bleeding\\n Ulceration\\n Itching\\nThe biopsy specimen must be deep enough for accurate microscopic diagnosis and should contain the\\nentire lesion if possible, especially if the concern for cancer is strong. However, wide primary excision\\nshould not be the initial procedure, even for highly abnormal-appearing lesions, because many such\\nlesions are not melanomas. Incisional biopsy does not increase the likelihood of metastasis if the lesion is\\nmalignant, and it avoids extensive surgery for a benign lesion.\\nTreatment\\n Sometimes excision\\nMoles can be removed by shaving or excision for cosmetic purposes, and all moles removed should be\\nexamined histologically. If hair growth is a concern for the patient, a hairy mole should be adequately\\nexcised rather than removed by shaving. Otherwise, hair regrowth will occur.\\nAtypical Moles\\n(Dysplastic Nevi)\\nAtypical moles (AM) are melanocytic nevi with irregular and ill-defined borders, variegated\\n[\\nTable 89-1.\\n Classification of Moles]\\ncolors usually of brown and tan tones, and macular or papular components. Management is by\\nmonitoring and biopsy of highly atypical or changed lesions. Patients should reduce sun\\nexposure and conduct regular self-examinations for new moles or changes in existing ones.\\nAM are nevi with a slightly different clinical and histologic appearance (disordered architecture and atypia\\nof melanocytes). Patients with AM are at increased risk of melanoma; risk increases as the number of AM\\nand as sun exposure increase. Some patients have only one or a few AM; others have many.\\nThe propensity to develop AM may be inherited (autosomal dominant) or sporadic without apparent\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 89. Benign Tumors\\n869'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 879, 'page_label': '870'}, page_content=\"familial association. Familial atypical mole-melanoma syndrome refers to the presence of multiple AM and\\nmelanoma in  2 1st-degree relatives. These patients are at markedly increased risk (25 times) for\\nmelanoma.\\nSymptoms and Signs\\nAM are often larger than other nevi (> 6 mm diameter) and primarily round (unlike many melanomas) but\\nwith indistinct borders and mild asymmetry. In contrast, melanomas have greater irregularity of color, not\\njust tan and brown, but dark brown, black, red, and blue or whitish areas of depigmentation.\\nDiagnosis\\n Regular physical examinations\\n Biopsy\\nAlthough clinical findings suggest the diagnosis of AM (see\\nTable 89-2\\n), biopsy of the worst-appearing lesions should be done to establish the diagnosis and to\\ndetermine the degree of atypia.\\nOne or more atypical-appearing lesions should be biopsied. Patients with multiple AM and a personal or\\nfamily history of melanoma should be examined regularly (eg, yearly for family history, more often for\\npersonal history, of melanoma).\\nTreatment\\nAtypical moles can be removed by excision or shaving.\\nPrevention\\nPatients with AM should avoid excessive sun exposure and use sunscreens. Also, they\\n[\\nTable 89-2.\\n Characteristics of Atypical vs Typical Moles]\\nshould be taught self-examination to detect changes in existing moles and to recognize features of\\nmelanomas. Some experts recommend yearly photographs of the skin surface. Regular follow-up\\nexaminations may be combined with baseline and follow-up color photographs of most of the patient's\\nbody; this method is most useful in patients with many AM.\\nIf patients have a family history of melanoma (whether developing from AM or de novo) or other skin\\ncancers, 1st-degree relatives should be examined. Patients who are from melanoma-prone families (ie, \\n2 1st-degree relatives with cutaneous melanomas) have a high lifetime risk of developing melanomas.\\nThe entire skin (including the scalp) of members of an at-risk family should be examined.\\nSeborrheic Keratoses\\nSeborrheic keratoses are pigmented superficial epithelial lesions that are usually warty but may\\noccur as smooth papules.\\nThe cause is unknown. The lesions commonly occur in middle or old age and most often appear on the\\ntrunk or temples; in blacks and Asians, especially women, lesions that are 1 to 3 mm often occur on the\\ncheekbones; this condition is termed dermatosis papulosa nigra.\\nSeborrheic keratoses vary in size and grow slowly. They may be round or oval and flesh-colored, brown,\\nor black. They usually appear stuck on and may have a verrucous, velvety, waxy, scaling, or crusted\\nsurface (see\\nPlate 44\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 89. Benign Tumors\\n870\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 880, 'page_label': '871'}, page_content=\"Diagnosis is clinical.\\nThey are not premalignant and need no treatment unless they are irritated, itchy, or cosmetically\\nbothersome. Lesions may be removed with little or no scarring by cryotherapy (which can cause\\nhypopigmentation) or by electro-desiccation and curettage after local injection of lidocaine.\\nSkin Tags\\nSkin tags (acrochordons, soft fibromas) are common soft, small, flesh-colored or\\nhyperpigmented, pedunculated lesions; there are usually multiple lesions, typically on the\\nneck, axilla, and groin.\\nSkin tags are usually asymptomatic but may be irritating. Irritating or unsightly skin tags can be removed\\nby freezing with liquid nitrogen, light electrodesiccation, or excision with a scalpel or scissors. The\\nstandard of care is to submit all skin tags individually for histologic examination, especially if there is any\\nquestion of the diagnosis. However, for a patient with dozens of identical lesions, an individual lesion is\\nunlikely to be anything other than a skin tag.\\nVascular Lesions\\nVascular lesions include acquired lesions (eg, pyogenic granuloma) and those that are present at birth or\\narise shortly after birth (vascular birthmarks). Vascular birthmarks include vascular tumors (eg, infantile\\nhemangioma) and vascular malformations. Vascular malformations are congenital, life-long, localized\\ndefects in vascular morphogenesis and include capillary (eg, nevus flammeus), venous, arteriovenous\\n(eg, cirsoid aneurysm), and lymphatic malformations. Vascular birthmarks usually involve only the skin\\nand subcutaneous tissues and rarely affect the CNS.\\nInfantile Hemangioma\\nInfantile hemangiomas (IH) are raised, red or purplish, hyperplastic vascular lesions appearing\\nin the first year of life. Most spontaneously involute; those obstructing vision, the airway, or\\nother structures require treatment, usually with oral corticosteroids. Surgery is rarely\\nrecommended.\\nIH is the most common tumor of infancy, affecting 10 to 12% of infants by age 1 yr. IH is present at birth in\\n10 to 20% of those affected and almost always within the first several weeks of life; occasionally, deeper\\nlesions may not be apparent until a few months after birth. Size and vascularity increase rapidly, usually\\npeaking at about age 1 yr.\\nIH can be classified by general appearance (superficial, deep, or cavernous) or by other descriptive terms\\n(eg, strawberry hemangioma). However, because all of these lesions share a common pathophysiology\\nand natural history, the inclusive term infantile hemangioma is preferred.\\nSymptoms and Signs\\nSuperficial lesions have a bright red appearance; deeper lesions have a bluish color. Lesions can bleed\\nor ulcerate from minor trauma; ulcers may be painful. IH in certain locations can interfere with function.\\nLesions on the face or oropharynx may interfere with vision or obstruct the airway; those near the urethral\\nmeatus or anus may interfere with elimination. A periocular hemangioma in an infant is an emergency\\nbecause even a few days of disrupted vision can result in permanent visual defects. Lumbosacral\\nhemangiomas may be a sign of neurologic or GU anomalies.\\nLesions slowly involute starting at 12 to 18 mo, decreasing in size and vascularity. Generally, IH involute\\nby 10%/year of age (eg, 50% by age 5, 60% by age 6), with maximal involution by age 10. Involuted\\nlesions commonly have a yellowish or telangiectatic color and a wrinkled or lax fibrofatty texture. Residual\\nchanges are almost always proportional to the lesion's maximal size and vascularity.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 89. Benign Tumors\\n871\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 881, 'page_label': '872'}, page_content=\"Diagnosis is clinical; the extent can be evaluated by MRI if lesions appear to encroach on vital structures.\\nTreatment\\n Sometimes laser therapy\\n Sometimes intralesional or systemic corticosteroid therapy\\n General wound care for ulcerated lesions\\nTreatment is controversial. Many physicians treat lesions early to prevent subsequent enlargement or to\\nmake them less noticeable; others do not treat unless a lesion causes (or risks) functional problems by its\\nlocation. When treatment is elected, laser therapy or intralesional or systemic corticosteroids are chosen\\nbased on the location, extent, and rate of growth of the lesion. For systemic corticosteroid therapy,\\nprednisone 1 to 3 mg/kg po bid or tid is given for  2 wk. If resolution starts, the prednisone should be\\ndecreased slowly; if not, the drug should be stopped.\\nTopical treatments and wound care are useful for ulcerated lesions and help prevent scarring, bleeding,\\nand pain. Compresses, topical mupirocin or metronidazole, barrier dressings (polyurethane film dressing\\nor petrolatum-impregnated gauze), or barrier creams may be used.\\nUnless complications are life threatening or vital organs are compromised, surgical excision or other\\ndestructive procedures should be avoided because they frequently cause more scarring than occurs with\\nspontaneous involution. To help parents accept nonintervention, the physician can review the natural\\nhistory (photographic examples are helpful), provide serial photography of the lesion to document\\ninvolution, and listen sympathetically to parents' concerns.\\nNevus Flammeus and Port-Wine Stain\\nNevus flammeus and port-wine stains are capillary vascular malformations that are present at\\nbirth and appear as flat, pink, red, or purplish lesions.\\nNevi flammei\\n are flat pink marks that are very common on the nape, glabella, and eyelids. Lesions\\naround the eyes disappear in a few months. Nape lesions may disappear in early childhood, only to recur\\nin middle age.\\nPort-wine stains\\n are flat, reddish to purple lesions appearing anywhere on the body. Lesions become\\ndarker and more palpable with time (often becoming quite hyperplastic by late middle age), but the lateral\\nextent increases only in proportion to the growth of the patient. Port-wine stains of the trigeminal area\\nmay be a component of the Sturge-Weber syndrome (in which a similar vascular lesion appears on the\\nunderlying meninges and cerebral cortex and is associated with epilepsy).\\nDiagnosis is clinical.\\nTreatment with vascular lasers produces excellent results in many cases, especially if the lesion is treated\\nas early in life as possible. \\nThe lesion can also be hidden with an opaque cosmetic cream prepared to\\nmatch the patient's skin color.\\nNevus Araneus\\n(Spider Nevus; Spider Angioma; Vascular Spider)\\nNevus araneus is a bright red, faintly pulsatile vascular lesion consisting of a central arteriole\\nwith slender projections resembling spider legs (see\\nPlate 26\\n).\\nThese lesions are acquired. One lesion or small numbers of lesions unrelated to internal disease may\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 89. Benign Tumors\\n872\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 882, 'page_label': '873'}, page_content='occur in children or adults. Patients with cirrhosis develop many spider angiomas that may become quite\\nprominent. Many women develop lesions during pregnancy or while taking oral contraceptives.\\nThe lesions are asymptomatic and usually resolve spontaneously about 6 to 9 mo postpartum or after oral\\ncontraceptives are stopped. Lesions are not uncommon on the faces of children. Compression of the\\ncentral vessel temporarily obliterates the lesion.\\nDiagnosis is clinical.\\nTreatment is not usually required. If resolution is not spontaneous or treatment is desired for cosmetic\\npurposes, the central arteriole can be destroyed with fine-needle electrodesiccation; vascular laser\\ntreatment may also be done.\\nPyogenic Granuloma\\nPyogenic granuloma is a fleshy, moist or crusty, usually scarlet vascular nodule composed of\\nproliferating capillaries in an edematous stroma.\\nThe lesion, composed of vascular tissue, is neither of bacterial origin nor a true granuloma. It develops\\nrapidly, often at the site of recent injury (although injury may not be recalled), typically grows no larger\\nthan 2 cm in diameter, and probably represents a vascular and fibrous response to injury. There is no sex\\nor age predilection. The overlying epidermis is thin, and the lesion tends to be friable, bleeds easily, and\\ndoes not blanch on pressure. The base may be pedunculated and surrounded by a collarette of\\nepidermis.\\nDuring pregnancy, pyogenic granulomas may become large and exuberant (eg, gingival pregnancy\\ntumors, or telangiectatic epulis).\\nDiagnosis involves biopsy and histologic examination. Histologic analysis is required for all removed\\ntissue because these lesions occasionally resemble and must be differentiated from melanomas or other\\nmalignant tumors.\\nTreatment consists of removal by excision or curettage and electrodesiccation, but the lesions may recur.\\nLymphatic Malformations\\n(Lymphangioma; Lymphangioma Circumscriptum; Cystic Hygroma; Cavernous Lymphangioma)\\nLymphatic vascular malformations are elevated lesions composed of dilated lymphatic vessels.\\nMost lymphatic malformations are present at birth or develop within the first 2 yr. Lesions are usually\\nyellowish tan but occasionally reddish or purple if small blood vessels are intermingled. Puncture of the\\nlesion yields a colorless or blood-tinged fluid.\\nDiagnosis is made clinically and by MRI.\\nTreatment is usually not needed. If the lesion is excised, recurrence is common, even when removal of\\ndermal and subcutaneous tissues is extensive.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 89. Benign Tumors\\n873'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 883, 'page_label': '874'}, page_content=\"Chapter 90. Cancers of the Skin\\nIntroduction\\nSkin cancer is the most common type of cancer and usually develops in sun-exposed areas of skin. The\\nincidence is highest among outdoor workers, sportsmen, and sunbathers and is inversely related to the\\namount of melanin skin pigmentation; fair-skinned people are most susceptible. Skin cancers may also\\ndevelop years after therapeutic x-rays or exposure to carcinogens (eg, arsenic ingestion).\\nOver one million new cases of skin cancer are diagnosed in the US yearly. About 80% are basal cell\\ncarcinoma, 16% are squamous cell carcinoma, and 4% are melanoma. Paget's disease of the nipple or\\nextramammary Paget's (usually near the anus), Kaposi's sarcoma, tumors of adnexa, and cutaneous T-\\ncell lymphoma (mycosis fungoidessee p. \\n1024\\n) make up the remaining, less common, forms of skin\\ncancer.\\nInitially, skin cancers are often asymptomatic. The most frequent presentation is a papule or blind pimple\\nthat does not go away. Any lesion that appears to be enlarging should be biopsiedwhether tenderness,\\nmild inflammation, crusting, or occasional bleeding is present or not. If treated early, most skin cancers\\nare curable.\\nScreening:\\n Routine screening for skin cancer is by patient self-examination, physician examination, or\\nboth.\\nPrevention:\\n Because many skin cancers seem to be related to ultraviolet (UV) exposure, a number of\\nmeasures are recommended to limit exposure.\\n Sun avoidance: Seeking shade, minimizing outdoor activities between 10 AM and 4 PM (when sun's\\nrays are strongest), and avoiding sunbathing and the use of tanning beds\\n Use of protective clothing: Long-sleeved shirt, pants, and broad-brimmed hat\\n Use of sunscreen: At least sun protection factor (SPF) 30 with UVA protection, used as directed; should\\nnot be used to prolong sun exposure\\nCurrent evidence is inadequate to determine whether these measures reduce incidence or mortality of\\nmelanoma; in nonmelanoma skin cancers (basal cell and squamous cell carcinoma), sun protection does\\ndecrease the incidence of new cancers.\\nBasal Cell Carcinoma\\n(Rodent Ulcer)\\nBasal cell carcinoma is a superficial, slowly growing papule or nodule (see\\nPlate 29\\n) that derives from certain epidermal cells. Basal cell carcinomas arise from\\nkeratinocytes near the basal layer and can be referred to as basaloid keratinocytes. Metastasis\\nis rare, but local growth can be highly destructive. Diagnosis is by biopsy. Treatment depends\\non the tumor's characteristics and may involve curettage and electrodesiccation, surgical\\nexcision, cryosurgery, topical chemotherapy, or, occasionally, radiation therapy.\\nBasal cell carcinoma is the most common type of skin cancer, with > 800,000 new cases yearly in the US.\\nIt is more common in fair-skinned people with a history of sun exposure and is very rare in blacks.\\nSymptoms and Signs\\nThe clinical manifestations and biologic behavior of basal cell carcinomas are highly variable. They may\\nappear as\\n Small, shiny, firm, almost translucent nodules\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 90. Cancers of the Skin\\n874\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 884, 'page_label': '875'}, page_content=\" Ulcerated, crusted papules or nodules\\n Flat, scarlike, indurated plaques\\n Red, marginated, thin papules or plaques that are difficult to differentiate from psoriasis or localized\\ndermatitis\\nMost commonly, the carcinoma begins as a shiny papule, enlarges slowly, and, after a few months or\\nyears, shows a shiny, pearly border with prominent engorged vessels (telangiectases) on the surface and\\na central dell or ulcer. Recurrent crusting or bleeding is not unusual. Commonly, the carcinomas may\\nalternately crust and heal, which may unjustifiably decrease patients' and physicians' concern about the\\nimportance of the lesion.\\nBasal cell carcinomas rarely metastasize but may invade healthy tissues. Rarely, patients die because the\\ncarcinoma invades or impinges on underlying vital structures or orifices (eyes, ears, mouth, bone, dura\\nmater).\\nDiagnosis\\n Biopsy and histologic examination\\nTreatment\\nTreatment should be done by a specialist. The clinical appearance, size, site, and histologic subtype\\ndetermine choice of treatmentcurettage and electrodesiccation, surgical excision, cryosurgery, topical\\nchemotherapy (imiquimod, 5-fluorouracil, and photodynamic therapy), or, occasionally, radiation therapy.\\nRecurrent or incompletely treated cancers, large cancers, cancers at recurrence-prone sites, and\\nmorphea-like cancers with vague borders are often treated with Mohs microscopically controlled surgery,\\nin which tissue borders are progressively excised until specimens are tumor-free (as determined by\\nmicroscopic examination during surgery). Almost 25% of patients with a history of basal cell carcinoma\\ndevelop a new basal cell cancer within 5 yr of the original carcinoma. Consequently, patients with a\\nhistory of basal cell carcinoma should be seen annually for a skin examination.\\nBowen's Disease\\n(Intraepidermal Squamous Cell Carcinoma)\\nBowen's disease is a superficial squamous cell carcinoma in situ.\\nBowen's disease is most common in sun-exposed areas but may arise at any location. \\nLesions can be\\nsolitary or multiple. They are red-brown and scaly or crusted, with little induration; they frequently\\nresemble a localized thin plaque of psoriasis, dermatitis, or a dermatophyte infection. Diagnosis is by\\nbiopsy.\\nTreatment depends on the tumor's characteristics and may involve topical chemotherapy, curettage and\\nelectrodesiccation, surgical excision, or cryosurgery.\\nSquamous Cell Carcinoma\\nSquamous cell carcinoma is a malignant tumor of epidermal keratinocytes that invades the\\ndermis; this cancer usually occurs in sun-exposed areas. Local destruction may be extensive,\\nand metastases occur in advanced stages. Diagnosis is by biopsy. Treatment depends on the\\ntumor's characteristics and may involve curettage and electrodesiccation, surgical excision,\\ncryosurgery, or, occasionally, radiation therapy.\\nSquamous cell carcinoma, the 2nd most common type of skin cancer, may develop in normal tissue, in a\\npreexisting actinic keratosis (see p. \\n674\\n), in a patch of leukoplakia, or in a burn scar. The incidence in the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 90. Cancers of the Skin\\n875\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 885, 'page_label': '876'}, page_content='US is 200,000 to 300,000 cases annually, with 2000 deaths.\\nThe clinical appearance is highly variable, but any nonhealing lesion on sun-exposed surfaces should be\\nsuspect. The tumor may begin as a red papule or plaque with a scaly or crusted surface and may become\\nnodular, sometimes with a warty surface. In some cases, the bulk of the lesion may lie below the level of\\nthe surrounding skin. Eventually the tumor ulcerates and invades the underlying tissue.\\nDiagnosis\\nBiopsy is essential. Differential diagnosis includes many types of benign and malignant lesions, such as\\nbasal cell carcinoma, keratoacanthoma, actinic keratosis, verruca vulgaris, and seborrheic keratosis.\\nPrognosis\\nIn general, the prognosis for small lesions removed early and adequately is excellent. Regional and\\ndistant metastases of squamous cell carcinomas on sun-exposed skin are uncommon but do occur,\\nparticularly with poorly differentiated tumors. However, about one third of lingual or mucosal cancers have\\nmetastasized before diagnosis (see p. \\n491\\n).\\nLate-stage disease, which may require extensive surgery, is far more likely to metastasize. It spreads\\ninitially regionally to surrounding skin and lymph nodes and eventually to nearby organs. Cancers that\\noccur near the ears, the vermilion, and in scars are more likely to metastasize. The overall 5-yr survival\\nrate for metastatic disease is 34% despite therapy.\\nTreatment\\nTreatment is similar to that for basal cell carcinoma and includes curettage and electrodesiccation,\\nsurgical excision, cryosurgery, topical chemotherapy (imiquimod, 5-fluorouracil), and photodynamic\\ntherapy, or, occasionally, radiation therapy (see p. \\n749\\n). Treatment and follow-up must be monitored\\nclosely because of the greater risk of metastasis. Squamous cell carcinoma on the lip or other\\nmucocutaneous junction should be excised; at times, cure is difficult. Recurrences and large tumors\\nshould be treated aggressively with Mohs microscopically controlled surgery, or by a team approach with\\nsurgery and radiation therapy.\\nMetastatic disease is responsive to radiation therapy if metastases can be identified and are isolated.\\nWidespread metastases do not respond well to chemotherapeutic regimens.\\nMelanoma\\n(Malignant Melanoma)\\nMalignant melanoma arises from melanocytes in a pigmented area (eg, skin, mucous\\nmembranes, eyes, or CNS). Metastasis is correlated with depth of dermal invasion. With spread,\\nprognosis is poor. Diagnosis is by biopsy. Wide surgical excision is the rule for operable tumors.\\nMetastatic disease requires chemotherapy but is difficult to cure.\\nAbout 60,000 new cases of melanoma occur yearly in the US, causing about 8400 deaths. Incidence has\\nremained steady over the last 8 yr (it had previously been increasing at a faster rate than any other\\nmalignant tumor).\\nMelanomas occur mainly on the skin but also on the mucosa of the oral and genital regions and\\nconjunctiva. Melanomas vary in size, shape, and color (usually pigmented) and in their propensity to\\ninvade and metastasize. Metastasis occurs via lymphatics and blood vessels. Local metastasis results in\\nthe formation of nearby satellite papules or nodules that may or may not be pigmented. Direct metastasis\\nto skin or internal organs may occur, and occasionally, metastatic nodules or enlarged lymph nodes are\\ndiscovered before the primary lesion is identified.\\nEtiology\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 90. Cancers of the Skin\\n876'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 886, 'page_label': '877'}, page_content=\"Risk factors include\\n Sun exposure\\n Family and personal history\\n Fair skin\\n Increased numbers of melanocytic nevi\\n Immunosuppression\\n Occurrence of lentigo maligna\\n Large congenital melanocytic nevus\\n Dysplastic nevus syndrome\\nPatients with a personal history of melanoma have an increased risk of additional melanomas. People\\nwho have one or more 1st-degree relatives with a history of melanoma have an increased risk (up to 6 or\\n8 times) over those without a family history. Melanoma is rare in blacks.\\nAbout 40 to 50% of melanomas develop from pigmented moles (see also p. \\n744\\n); almost all the rest arise\\nfrom melanocytes in normal skin. Atypical moles (dysplastic nevi) may be precursors to melanoma (see p.\\n744\\n). The very rare melanomas of childhood almost always arise from large pigmented moles (giant\\ncongenital nevi) present at birth. Although melanomas occur during pregnancy, pregnancy does not\\nincrease the likelihood that a mole will become a melanoma; moles frequently change in size and darken\\nuniformly during pregnancy. However, the following signs of malignant transformation should be carefully\\nsought:\\n Change in size\\n Irregular change in color, especially spread of red, white, and blue pigmentation to surrounding normal\\nskin\\n Change in surface characteristics, consistency, or shape\\n Signs of inflammation in surrounding skin, with possible bleeding, ulceration, itching, or tenderness\\nClassification\\nThere are 4 main types of melanoma.\\nLentigo maligna melanoma:\\n This type accounts for 5 to 15% of melanomas. It tends to arise in older\\npatients. It arises from lentigo maligna (Hutchinson's freckle or malignant melanoma in situ). It appears on\\nthe face or other sun-exposed areas as an asymptomatic, flat, tan or brown, irregularly shaped macule or\\npatch with darker brown or black spots scattered irregularly on its surface. In lentigo maligna, both normal\\nand malignant melanocytes are confined to the epidermis. When malignant melanocytes invade the\\ndermis, the lesion is called lentigo maligna melanoma, and the cancer may metastasize.\\nSuperficial spreading melanoma:\\n This type accounts for two thirds of melanomas. Typically\\nasymptomatic, it occurs most commonly on women's legs and men's torsos. The lesion is usually a plaque\\nwith irregular, raised, indurated, tan or brown areas, which often have red, white, black, and blue spots or\\nsmall, sometimes protuberant blue-black nodules (see\\nPlate 40\\n). Small notchlike indentations of the margins may be noted, along with enlargement or color\\nchange. Histologically, atypical melanocytes characteristically invade the dermis and epidermis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 90. Cancers of the Skin\\n877\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 887, 'page_label': '878'}, page_content='Nodular melanoma:\\n This type accounts for 10 to 15% of melanomas. It may occur anywhere on the\\nbody as a dark, protuberant papule or a plaque that varies from pearl to gray to black. Occasionally, a\\nlesion contains little if any pigment or may look like a vascular tumor. Unless it ulcerates, nodular\\nmelanoma is asymptomatic, but patients usually seek advice because the lesion enlarges rapidly.\\nAcral-lentiginous melanoma:\\n This type accounts for only 5 to 10% of melanomas, but it is the most\\ncommon form of melanoma in blacks. It arises on palmar, plantar, and subungual skin and has a\\ncharacteristic histologic picture similar to that of lentigo maligna melanoma.\\nDiagnosis\\n Biopsy\\nThe differential diagnosis includes basal cell and squamous cell carcinomas, seborrheic keratoses,\\natypical moles, blue nevi, dermatofibromas, moles, hematomas (especially on the hands or feet), venous\\nlakes, pyogenic granulomas, and warts with focal thromboses. If doubt exists, biopsy should include the\\nfull depth of the dermis and extend slightly beyond the edges of the lesion. Biopsy should be excisional\\nfor small lesions and incisional for larger lesions. By doing step sections, the pathologist can determine\\nthe maximal thickness of the melanoma. Definitive radical surgery should not precede histologic\\ndiagnosis.\\nPigmented lesions with the following features should be excised or biopsied:\\n Recent enlargement\\n Darkening\\n Bleeding\\n Ulceration\\nHowever, these features usually indicate that the melanoma has already invaded the skin deeply. Earlier\\ndiagnosis is possible if biopsy specimens can be obtained from lesions having variegated colors (eg,\\nbrown or black \\nwith shades of red, white, or blue), irregular elevations that are visible or palpable, and\\nborders with angular indentations or notches. Polarized light and immersion contact dermoscopy, which is\\nused to examine pigmented lesions, may be useful for distinguishing melanomas from benign lesions.\\nStaging:\\n The staging of melanoma is based on clinical and pathologic criteria and closely corresponds to\\nthe traditional tumor-node-metastasis (TNM) classification system. The staging system classifies\\nmelanomas based on local, regional, or distant disease.\\n Stage I and II: Localized primary melanoma\\n Stage III: Metastasis to regional lymph nodes\\n Stage IV: Distant metastatic disease\\nStage strongly correlates with survival. A minimally invasive microstaging technique, the so-called sentinel\\nlymph node biopsy (SLNB), is a major advance in the ability to stage cancers more accurately.\\nRecommended staging studies depend on the Breslow depth (how deeply tumor cells have invaded) and\\nhistologic characteristics of the melanoma. Staging studies may include SLNB, laboratory tests (CBC,\\nLDH, liver function tests), chest x-ray, CT, and PET and are done by a coordinated team that includes\\ndermatologists, oncologists, general surgeons, plastic surgeons, and dermatopathologists.\\nPrognosis\\nMelanoma may spread rapidly, causing death within months of its recognition, yet the 5-yr cure rate of\\nearly, very superficial lesions is nearly 100%. Thus, cure depends on early diagnosis and early treatment.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 90. Cancers of the Skin\\n878'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 888, 'page_label': '879'}, page_content=\"For tumors of cutaneous origin (not CNS and subungual melanomas) that have not metastasized, the\\nsurvival rate varies depending on the thickness of the tumor at the time of diagnosis (see\\nTable 90-1\\n). Mucosal melanomas (especially anorectal melanomas), which are more common in\\nnonwhites, have a poor prognosis, although they often seem quite limited when discovered. Once\\nmelanoma has metastasized to the lymph nodes, 5-yr survival ranges from 25 to 70% depending on the\\ndegree of ulceration and number of nodes involved. Once melanoma has metastasized to distant sites, 5-\\nyr survival is about 10%.\\nDegree of lymphocytic infiltration, which represents reaction by the patient's immunologic defense system,\\nmay correlate with the level of invasion and prognosis. Chances of cure are maximal when lymphocytic\\ninfiltration is limited to the most superficial lesions and decrease with deeper levels of tumor cell invasion,\\nulceration, and vascular or lymphatic invasion.\\n[\\nTable 90-1.\\n 5-yr Survival* for Malignant Melanoma Relative to Thickness and Ulceration]\\nTreatment\\n Surgical excision\\n Possibly adjuvant radiation therapy\\n Possibly adjuvant interferon alfa\\n Sometimes excision, imiquimod, and cryotherapy\\nTreatment is primarily by surgical excision. Although the width of margins is debated, most experts agree\\nthat a 1-cm lateral tumor-free margin is adequate for lesions < 1 mm thick. Thicker lesions may deserve\\nlarger margins, more radical surgery, and SLNB.\\nLentigo maligna melanoma and lentigo maligna are usually treated with wide local excision and, if\\nnecessary, skin grafting. Intensive radiation therapy is much less effective. Treatment of lentigo maligna\\nincludes early excision (before the lesion is very large), imiquimod, and controlled cryotherapy. Most other\\ntreatment methods usually do not penetrate deeply enough into involved follicles, which must be\\nremoved.\\nSpreading or nodular melanomas are usually treated with wide local excision extending down to the\\nfascia. Lymph node dissection may be recommended when nodes are involved. (See also the American\\nAcademy of Dermatology Association's Guidelines of Care for Primary Cutaneous Melanoma.)\\nMetastatic disease:\\n Metastatic disease is generally inoperable, but in certain cases, localized and\\nregional metastases can be excised. Chemotherapy with dacarbazine or temozolamide (oral dacarbazine\\nanalog) and aldesleukin can be used for the treatment of metastatic melanoma. Adjuvant therapy with\\nrecombinant biologic response modifiers (particularly interferon alfa) to suppress clinically inapparent\\nmicrometastases may also be used for inoperable metastatic melanoma. Brain metastases may be treated\\nwith palliative radiation, but the response is poor.\\nThe following are under study:\\n Infusion of lymphokine-activated killer cells or antibodies (for advanced-stage disease)\\n Vaccine therapy\\nKaposi's Sarcoma\\n(Multiple Idiopathic Hemorrhagic Sarcoma)\\nKaposi's sarcoma (KS) is a multicentric vascular tumor caused by herpesvirus type 8. It can\\noccur in classic, AIDS-associated, endemic, and iatrogenic forms. Diagnosis is by biopsy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 90. Cancers of the Skin\\n879\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 889, 'page_label': '880'}, page_content='Treatment for indolent superficial lesions involves cryotherapy, electrocoagulation, excision, or\\nelectron beam radiation therapy. Radiation therapy is used for more extensive disease. In the\\nAIDS-associated form, antiretrovirals provide the most improvement.\\nKS originates from endothelial cells in response to infection by human herpesvirus 8 (HHV-8).\\nImmunosuppression (particularly by AIDS and drugs for organ transplant recipients) markedly increases\\nthe likelihood of KS in HHV-8-infected patients. The tumor cells have a spindle shape, resembling smooth\\nmuscle cells, fibroblasts, and myofibroblasts.\\nClassification\\nClassic KS:\\n This form occurs most often in older (> 60 yr) men of Italian, Jewish, or Eastern European\\nancestry. The course is indolent, and the disease is usually confined to a small number of lesions on the\\nskin of the lower extremities (see\\nPlate 36\\n); visceral involvement occurs in < 10%. This form is usually not fatal.\\nAIDS-associated (epidemic) KS:\\n This form is the most common AIDS-associated cancer and is more\\naggressive than classic KS. Multiple cutaneous lesions are typically present, often involving the face and\\ntrunk. Mucosal, lymph node, and GI involvement is common. Sometimes KS is the first manifestation of\\nAIDS.\\nEndemic KS:\\n This form occurs in Africa independent of HIV infection. There are 2 main types:\\n Prepubertal lymphadenopathic form: It predominantly affects children; primary tumors involve lymph\\nnodes, with or without skin lesions. The course is usually fulminant and fatal.\\n Adult form: This form resembles classic KS.\\nIatrogenic (immunosuppressive) KS:\\n This form typically develops several years after organ\\ntransplantation. The course is more or less fulminant, depending on the degree of immunosuppression.\\nSymptoms and Signs\\nCutaneous lesions are asymptomatic purple, pink, or red macules that may coalesce into blue-violet to\\nblack plaques and nodules. Some edema may be present. Occasionally, nodules fungate or penetrate\\nsoft tissue and invade bone. Mucosal lesions appear as bluish to violaceous macules, plaques, and\\ntumors. GI lesions can bleed, sometimes extensively, but usually are asymptomatic.\\nDiagnosis\\n Biopsy\\nDiagnosis is confirmed by punch biopsy. Patients with AIDS or immunosuppression require evaluation for\\nvisceral spread by CT of the chest and abdomen. If CT is negative but pulmonary or GI symptoms are\\npresent, bronchoscopy or GI endoscopy should be considered.\\nTreatment\\n Surgical excision, cryotherapy, or electrocoagulation for superficial lesions\\n Local radiation therapy for multiple lesions or lymph node disease\\n Antiretroviral therapy or sometimes IV interferon alfa for AIDS-associated KS\\n Reduction of immunosuppressants for iatrogenic KS\\nIndolent lesions often require no treatment. One or a few superficial lesions can be removed by excision,\\ncryotherapy, or electrocoagulation. Intralesional vinblastine or interferon alfa is also useful. Multiple\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 90. Cancers of the Skin\\n880'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 890, 'page_label': '881'}, page_content=\"lesions and lymph \\nnode disease are treated locally with 10 to 20 Gy of radiation therapy.\\nAIDS-associated KS responds markedly to highly active antiretroviral therapy (HAART), probably because\\nCD4+ count improves and HIV viral load decreases; however, there is some evidence that protease\\ninhibitors in this regimen may block angiogenesis. AIDS patients with indolent disease and CD4+ counts >\\n150/\\n\\nL and HIV RNA < 500 copies/mL can be treated with IV interferon alfa. Patients with more extensive\\nor visceral disease can be given liposomal doxorubicin 20 mg/m\\n2\\n IV q 2 to 3 wk. If this regimen fails,\\npatients may receive paclitaxel. Other agents being investigated as adjuncts include IL-12,\\ndesferrioxamine, and oral retinoids. Treatment of KS does not prolong life in most AIDS patients because\\ninfections dominate the clinical course.\\nIatrogenic KS responds best to stopping immunosuppressants. In organ transplant patients, reduction of\\nimmunosuppressant dosage often results in reduction of KS lesions. If dosage reduction is not possible,\\nconventional local and systemic therapies used in other forms of KS should be instituted. Sirolimus may\\nalso improve iatrogenic KS.\\nTreatment of endemic KS is challenging and typically palliative.\\nPaget's Disease of the Nipple\\nPaget's disease is a rare type of carcinoma that appears as a unilateral eczematous to\\npsoriasiform plaque surrounding the nipple. It involves extension to the epidermis of an\\nunderlying ductal adenocarcinoma of the breast.\\nPaget's disease of the nipple should not be confused with the metabolic bone disease that is also called\\nPaget's disease. In Paget's disease of the nipple, metastatic disease is often present at the time of the\\ndiagnosis.\\nPaget's disease of the nipple also occurs at other sites, most often in the groin or perianal area\\n(extramammary Paget's disease). The bladder, anus, and rectum are the most common sites.\\nExtramammary Paget's disease is a rare intraepithelial adenocarcinoma of apocrine gland-bearing sites.\\nDiagnosis\\n Biopsy\\nThe redness, oozing, and crusting closely resemble dermatitis; but physicians should suspect carcinoma\\nbecause the lesion is sharply marginated, unilateral, and unresponsive to topical therapy. Biopsy shows\\ntypical histologic changes. Because this tumor is associated with underlying cancer, systemic evaluation\\nis required.\\nTreatment\\nTreatment involves surgical removal of discovered tumors, including possible mastectomy for disease\\ninvolving the nipple. Treatment may also involve ablation of overlying cutaneous involvement, either\\nsurgically or by CO\\n2\\n laser ablation.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 90. Cancers of the Skin\\n881\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 891, 'page_label': '882'}, page_content='8 - Endocrine and Metabolic Disorders\\nChapter 91. Principles of Endocrinology\\nIntroduction\\nThe endocrine system coordinates functioning between different organs through hormones, which are\\nreleased into the bloodstream from specific types of cells within endocrine (ductless) glands. Once in\\ncirculation, hormones affect function of the target tissue. Some hormones exert an effect on cells of the\\norgan from which they were released (paracrine effect), some even on the same cell type (autocrine\\neffect). Hormones can be peptides of various sizes, steroids (derived from cholesterol), or amino acid\\nderivatives.\\nHormones bind selectively to receptors located inside or on the surface of target cells. Receptors inside\\ncells interact with hormones that regulate gene function (eg, corticosteroids, vitamin D, thyroid hormone).\\nReceptors on the cell surface bind with hormones that regulate enzyme activity or affect ion channels (eg,\\ngrowth hormone, thyrotropin-releasing hormone).\\nHypothalamic-Pituitary Relationships\\nPeripheral endocrine organ functions are controlled to varying degrees by pituitary hormones (see also\\nCh. 92\\n). Some functions (eg, secretion of insulin by the pancreas, primarily controlled by the blood\\nglucose level) are controlled to a minimal extent, whereas many (eg, secretion of thyroid or gonadal\\nhormones) are controlled to a great extent. Secretion of pituitary hormones is controlled by the\\nhypothalamus.\\nThe interaction between the hypothalamus and pituitary (hypothalamic-pituitary axis) is a feedback control\\nsystem. The hypothalamus receives input from virtually all other areas of the CNS and uses it to provide\\ninput to the pituitary. In response, the pituitary releases various hormones that stimulate certain endocrine\\nglands throughout the body. Changes in circulating levels of hormones produced by these endocrine\\nglands are detected by the hypothalamus, which then increases or decreases its stimulation of the\\npituitary to maintain homeostasis.\\nThe hypothalamus modulates the activities of the anterior and posterior lobes of the pituitary in different\\nways. Neurohormones synthesized in the hypothalamus reach the anterior pituitary (adenohypophysis)\\nthrough a specialized portal vascular system and regulate synthesis and release of the 6 major peptide\\nhormones of the anterior pituitary. These anterior pituitary hormones regulate peripheral endocrine glands\\n(the thyroid, adrenals, and gonads) as well as growth and lactation. No direct neural connection exists\\nbetween the hypothalamus and the anterior pituitary. In contrast, the posterior pituitary (neurohypophysis)\\ncomprises axons originating from neuronal cell bodies located in the hypothalamus. These axons serve\\nas storage sites for 2 peptide hormones synthesized in the hypothalamus; these hormones act in the\\nperiphery to regulate water balance, milk ejection, and uterine contraction.\\nVirtually all hormones produced by the hypothalamus and the pituitary are released in a \\npulsatile fashion;\\nperiods of such release are interspersed with periods of inactivity. Some hormones (eg,\\nadrenocorticotropic hormone [ACTH], growth hormone, prolactin) have definite circadian rhythms; others\\n(eg, luteinizing hormone and follicle-stimulating hormone during the menstrual cycle) have month-long\\nrhythms with superimposed circadian rhythms.\\nHypothalamic Controls\\nThus far, 7 physiologically important hypothalamic neurohormones have been identified (see\\nTable 91-1\\n). Except for the biogenic amine dopamine, all are small peptides. Several are produced in the\\nperiphery as well as in the hypothalamus and function in local paracrine systems, especially in the GI\\ntract. Vasoactive intestinal peptide, which also stimulates the release of prolactin, is one. Neurohormones\\nmay control the release of multiple pituitary hormones. Regulation of most anterior pituitary hormones\\ndepends on stimulatory signals from the hypothalamus; the exception is prolactin, which is regulated by\\ninhibitory stimuli. If the pituitary stalk (which connects the pituitary to the hypothalamus) is severed,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 91. Principles of Endocrinology\\n882'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 892, 'page_label': '883'}, page_content='prolactin release increases, whereas release of all other anterior pituitary hormones decreases.\\nMany hypothalamic abnormalities (including tumors and encephalitis and other inflammatory lesions) can\\nalter the release of hypothalamic neurohormones. Because neurohormones are synthesized in different\\ncenters within the hypothalamus, some disorders affect only one neuropeptide, whereas others affect\\nseveral. The result can be undersecretion or oversecretion of neurohormones. Clinical syndromes that\\nresult from the ensuing pituitary hormone dysfunction (eg, diabetes insipidus, acromegaly,\\nhypopituitarism) are discussed in \\nCh. 92\\n.\\nAnterior Pituitary Function\\nThe cells of the anterior lobe (which constitutes 80% of the pituitary by weight) synthesize and release\\nseveral hormones necessary for normal growth and development and also stimulate the activity of several\\ntarget glands.\\nAdrenocorticotropic hormone (ACTH):\\n ACTH is also known as corticotropin. Corticotropin-releasing\\nhormone (CRH) is the primary stimulator of ACTH release, but antidiuretic hormone plays a role during\\nstress. ACTH induces the adrenal cortex to release cortisol and several weak androgens, such as\\ndehydroepiandrosterone (DHEA). Circulating cortisol and other corticosteroids (including exogenous\\ncorticosteroids) inhibit the release of CRH and ACTH. The CRH-ACTH-cortisol axis is a central\\ncomponent of the response to stress. Without ACTH, the adrenal cortex atrophies and cortisol release\\nvirtually ceases.\\n[\\nTable 91-1.\\n Hypothalamic Neurohormones]\\nThyroid-stimulating hormone (TSH):\\n TSH regulates the structure and function of the thyroid gland and\\nstimulates synthesis and release of thyroid hormones. TSH synthesis and release are stimulated by the\\nhypothalamic hormone thyrotropin-releasing hormone (TRH) and suppressed (by negative feedback) by\\ncirculating thyroid hormones.\\nLuteinizing hormone (LH) and follicle-stimulating hormone (FSH):\\n LH and FSH control the\\nproduction of the sex hormones. Synthesis and release of LH and FSH are stimulated by gonadotropin-\\nreleasing hormone (GnRH) and suppressed by estrogen and testosterone. \\nIn women, LH and FSH\\nstimulate ovarian follicular development and ovulation (see p. \\n2497\\n). In men, FSH acts on Sertoli cells\\nand is essential for spermatogenesis; LH acts on Leydig cells of the testes to stimulate testosterone\\nbiosynthesis (see p. \\n2339\\n).\\nGrowth hormone (GH):\\n GH stimulates somatic growth and regulates metabolism. Growth hormone-\\nreleasing hormone (GHRH) is the major stimulator and somatostatin is the major inhibitor of the synthesis\\nand release of GH. GH controls synthesis of insulin-like growth factor 1 (IGF-1, also called somatomedin-\\nC), which largely controls growth. Although IGF-1 is produced by many tissues, the liver is the major\\nsource. A variant of IGF-1 occurs in muscle, where it plays a role in enhancing muscle strength. It is less\\nunder control of GH than is the liver variant.\\nThe metabolic effects of GH are biphasic. GH initially exerts insulin-like effects, increasing glucose\\nuptake in muscle and fat, stimulating amino acid uptake and protein synthesis in liver and muscle, and\\ninhibiting lipolysis in adipose tissue. Several hours later, more profound anti-insulin-like metabolic effects\\noccur. They include inhibition of glucose uptake and use, causing blood glucose and lipolysis to increase,\\nwhich increases plasma free fatty acids. GH levels increase during fasting, maintaining blood glucose\\nlevels and mobilizing fat as an alternative metabolic fuel. Production of GH decreases with aging. Ghrelin,\\na hormone produced in the fundus of the stomach, promotes GH release from the pituitary, increases food\\nintake, and improves memory.\\nProlactin:\\n Prolactin is produced in cells called lactotrophs that constitute about 30% of the cells of the\\nanterior pituitary. The pituitary doubles in size during pregnancy, largely because of hyperplasia and\\nhypertrophy of lactotrophs. In humans, the major function of prolactin is stimulating milk production. Also,\\nprolactin release occurs during sexual activity and stress. Prolactin may be a sensitive indicator of\\npituitary dysfunction; prolactin is the hormone most frequently produced in excess by pituitary tumors, and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 91. Principles of Endocrinology\\n883'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 893, 'page_label': '884'}, page_content=\"it may be one of the hormones to become deficient from infiltrative disease or tumor compression of the\\npituitary.\\nOther hormones:\\n Several other hormones are produced by the anterior pituitary. These include pro-\\nopiomelanocortin (POMC, which gives rise to ACTH), \\n\\n- and \\n\\n-melanocyte-stimulating hormone (MSH), \\n\\n-\\nlipotropin (\\n\\n-LPH), the enkephalins, and the endorphins. POMC and MSH can cause hyperpigmentation\\nof the skin and are only significant clinically in disorders in which ACTH levels are markedly elevated (eg,\\nAddison's disease, Nelson syndrome). The function of \\n\\n-LPH is unknown. Enkephalins and endorphins\\nare endogenous opioids that bind to and activate opioid receptors throughout the CNS.\\nPosterior Pituitary Function\\nThe posterior pituitary releases antidiuretic hormone (also called vasopressin or arginine vasopressin)\\nand oxytocin. Both hormones are released in response to neural impulses and have half-lives of about 10\\nmin.\\nAntidiuretic hormone (ADH):\\n ADH acts primarily to promote water conservation by the kidney by\\nincreasing the permeability of the distal tubular epithelium to water. At high concentrations, ADH also\\ncauses vasoconstriction. Like aldosterone, ADH plays an important role in maintaining fluid homeostasis\\nand vascular and cellular hydration. The main stimulus for ADH release is increased osmotic pressure of\\nwater in the body, which is sensed by osmoreceptors in the hypothalamus. The other major stimulus is\\nvolume depletion, which is sensed by baroreceptors in the left atrium, pulmonary veins, carotid sinus, and\\naortic arch, and then transmitted to the CNS through the vagus and glossopharyngeal nerves. Other\\nstimulants for ADH release include pain, stress, emesis, hypoxia, exercise, hypoglycemia, cholinergic\\nagonists, \\n\\n-blockers, angiotensin, and prostaglandins. Inhibitors of ADH release include alcohol, \\n\\n-\\nblockers, and glucocorticoids.\\nA lack of ADH causes central diabetes insipidus (see p. \\n772\\n); an inability of the kidneys to respond\\nnormally to ADH causes nephrogenic diabetes insipidus (see p. \\n2424\\n). Removal of the pituitary gland\\nusually does not result in permanent diabetes insipidus because some of the remaining hypothalamic\\nneurons produce small amounts of ADH. Copeptin is coproduced with ADH in the posterior pituitary.\\nMeasuring it may be useful in distinguishing the cause of hyponatremia.\\nOxytocin:\\n Oxytocin has 2 major targets: the myoepithelial cells of the breast, which surround the alveoli\\nof the mammary gland, and the smooth muscle cells of the uterus. Suckling stimulates the production of\\noxytocin, which causes the myoepithelial cells to contract. This contraction causes milk to move from the\\nalveoli to large sinuses for ejection (ie, the milk letdown reflex of nursing mothers). Oxytocin stimulates\\ncontraction of uterine smooth muscle cells, and uterine sensitivity to oxytocin increases throughout\\npregnancy. \\nHowever, plasma levels do not increase sharply during parturition, and the role of oxytocin in\\nthe initiation of labor is unclear. There is no recognized stimulus for oxytocin release in men, although\\nmen have extremely low levels.\\nEndocrine Disorders\\nEndocrine disorders can result from dysfunction originating in the peripheral endocrine gland itself\\n(primary disorders) or from understimulation or overstimulation by the pituitary (secondary disorders). The\\ndisorders can result in hormone overproduction (hyperfunction) or underproduction (hypofunction).\\nRarely, endocrine disorders (usually hypofunction) occur because of abnormal tissue responses to\\nhormones. Clinical manifestations of hypofunction disorders are often insidious and nonspecific.\\nHyperfunction:\\n Hyperfunction of endocrine glands may result from overstimulation by the pituitary but is\\nmost commonly due to hyperplasia or neoplasia of the gland itself. In some cases, cancers from other\\ntissues can produce hormones (ectopic hormone production). Hormone excess also can result from\\nexogenous hormone administration. In some cases, patients take hormones without telling the physician\\n(factitious disease). Tissue hypersensitivity to hormones can occur. Antibodies can stimulate peripheral\\nendocrine glands, as occurs in hyperthyroidism of Graves' disease. Destruction of a peripheral endocrine\\ngland can rapidly release stored hormone (eg, thyroid hormones in thyroiditis). Enzyme defects in the\\nsynthesis of a peripheral endocrine hormone can result in overproduction of hormones proximal to the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 91. Principles of Endocrinology\\n884\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 894, 'page_label': '885'}, page_content=\"block. Finally, overproduction of a hormone can occur as an appropriate response to a disease state.\\nHypofunction:\\n Hypofunction of an endocrine gland can result from understimulation by the pituitary.\\nHypofunction originating within the peripheral gland itself can result from congenital or acquired disorders\\n(including autoimmune disorders, tumors, infections, vascular disorders, and toxins). Genetic disorders\\ncausing hypofunction can result from deletion of a gene or by production of an abnormal hormone. A\\ndecrease in hormone production by the peripheral endocrine gland with a resulting increase in production\\nof pituitary regulating hormone can lead to peripheral endocrine gland hyperplasia. For example, if\\nsynthesis of thyroid hormone is defective, thyroid-stimulating hormone (TSH) is produced in excessive\\namounts, causing goiter.\\nSeveral hormones require conversion to an active form after secretion from the peripheral endocrine\\ngland. Certain disorders can block this step (eg, renal disease can inhibit production of the active form of\\nvitamin D). Antibodies to the circulating hormone or its receptor can block the ability of the hormone to\\nbind to its receptor. Disease or drugs can cause increased rate of clearance of hormones. Circulating\\nsubstances may also block the function of hormones. Abnormalities of the receptor or elsewhere in the\\nperipheral endocrine tissue can also cause hypofunction.\\nLaboratory Testing\\nBecause symptoms of endocrine disorders can begin insidiously and may be nonspecific, clinical\\nrecognition is often delayed for months or years. For this reason, biochemical diagnosis is usually\\nessential; it typically requires measuring levels of the peripheral endocrine hormone, the pituitary\\nhormone, or both in the blood.\\nFree or bioavailable hormone (ie, hormone not bound to a specific binding hormone) is generally believed\\nto be the active form. Free or bioavailable hormones are measured using equilibrium dialysis,\\nultrafiltration, or a solvent-extraction method to separate the free and albumin-bound hormone from the\\nbinding globulin. These methods can be expensive and time-consuming. Analog and competitive free\\nhormone assays, although often used commercially, are not always accurate and should not be used.\\nFree hormone levels can also be estimated indirectly by assessing levels of the binding protein and using\\nthem to adjust levels of the total serum hormone. However, indirect methods are inaccurate if the binding\\ncapacity of the hormone-binding protein has been altered (eg, by a disorder).\\nBecause most hormones have circadian rhythms, measurements need to be made at a prescribed time of\\nday. Hormones that vary over short periods (eg, luteinizing hormone) necessitate obtaining 3 or 4 values\\nover 1 or 2 h or using a pooled blood sample. Hormones with week-to-week variation (eg, testosterone)\\nnecessitate obtaining separate values a week apart.\\nIn some cases, indirect estimates are used. For example, because growth hormone (GH) has a short\\nserum half-life and is difficult to detect in serum, serum insulin-like growth factor 1 (IGF-1), which is\\nproduced in response to GH, is often measured as an index of GH activity. Sometimes, urine (eg, free\\ncortisol when testing for Cushing's disease) or salivary hormone \\nlevels may be used. Whether\\nmeasurement of circulating hormone metabolites indicates the amount of bioavailable hormone is under\\ninvestigation.\\nIn many cases, a dynamic test is necessary. Thus, in the case of hypofunctioning organs, a stimulating\\ntest can be used. In hyperfunction, a suppressive test can be used.\\nTreatment\\nHypofunction disorders are usually treated by replacement of the peripheral endocrine hormone\\nregardless of whether the defect is primary or secondary (an exception is GH replacement for pituitary\\ndwarfism). If resistance to the hormone exists, drugs that reduce resistance can be used (eg, metformin or\\nthiazolidinediones for type 2 diabetes mellitus). Occasionally, a hormone-stimulating drug is used.\\nRadiation therapy, surgery, and drugs that suppress hormone production are used to treat hyperfunction\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 91. Principles of Endocrinology\\n885\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 895, 'page_label': '886'}, page_content='disorders. In some cases, a receptor antagonist is used.\\nAging and Endocrinology\\nHormones undergo many changes as a person ages. Most hormone levels decrease. Some remain\\nnormal, including TSH, ACTH (basal), thyroxine, cortisol (basal), 1,25-dihydroxycholecalciferol, insulin\\n(sometimes increases), and estradiol (in men). Hormones that increase, including ACTH (increased\\nresponse to corticotropin-releasing hormone), follicle-stimulating hormone, sex-hormone binding globulin,\\nand activin (in men), gonadotropins (in women), epinephrine (in the oldest old), parathyroid hormone,\\nnorepinephrine, cholecystokinin, vasoactive intestinal peptide and ADH (also loss of circadian rhythm),\\nand atrial natriuretic factor, are associated with either receptor defects or postreceptor defects, resulting\\nin hypofunction. Many age-related changes are similar to those in patients with hormone deficiency,\\nleading to the hypothesis of a hormonal fountain of youth (ie, speculation that some changes associated\\nwith aging can be reversed by the replacement of one or more deficient hormones). Some evidence\\nsuggests that replacing certain hormones in the elderly can improve functional outcomes (eg, muscle\\nstrength, bone mineral density), but little evidence exists regarding effects on mortality. In some cases,\\nreplacing hormones may be harmful, as in estrogen replacement in most older women.\\nA competing theory is that the age-related decline in hormone levels represents a protective slowing\\ndown of cellular metabolism. This concept is based on the rate of living theory of aging (ie, the faster the\\nmetabolic rate of an organism, the quicker it dies). This concept is seemingly supported by studies on the\\neffects of dietary restriction. Restriction decreases levels of hormones that stimulate metabolism, thereby\\nslowing metabolic rate; this prolongs life in rodents.\\nDehydroepiandrosterone (DHEA) and its sulfate levels decline dramatically with age. Despite optimism for\\nthe role of DHEA supplementation in older people, most controlled trials failed to show any major\\nbenefits.\\nPregnenolone is the precursor of all known steroid hormones. As with DHEA, its levels decline with age.\\nStudies in the 1940s showed its safety and benefits in people with arthritis, but additional studies failed to\\nshow any beneficial effects on memory and muscle strength.\\nLevels of GH and its peripheral endocrine hormone (IGF-1) decline with age. GH replacement in older\\npeople sometimes increases muscle mass but does not increase muscle strength (although it may in\\nmalnourished people). Adverse effects (eg, carpal tunnel syndrome, arthralgias, water retention) are very\\ncommon. GH may have a role in the short-term treatment of some undernourished older patients, but in\\ncritically ill undernourished patients GH increases mortality. Secretagogues that stimulate GH production\\nin a more physiologic pattern may improve benefit and decrease risk.\\nLevels of melatonin, a hormone produced by the pineal gland, also decline with aging. This decline may\\nplay an important role in the loss of circadian rhythms with aging. Estrogen replacement in older women is\\ndiscussed in \\nCh. 247\\n. Testosterone replacement in older men is discussed in \\nCh. 229\\n.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 91. Principles of Endocrinology\\n886'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 896, 'page_label': '887'}, page_content=\"Chapter 92. Pituitary Disorders\\nIntroduction\\nThe pituitary gland controls the functions of peripheral endocrine glands. Pituitary structure and function\\nand relationships between the hypothalamus and the pituitary gland are discussed in \\nCh. 91\\n.\\nPituitary Lesions\\nPatients with hypothalamic-pituitary lesions generally present with some combination of symptoms and\\nsigns of a mass lesion (eg, headaches, visual field defectsparticularly bitemporal hemianopia or the\\nhemifield slide phenomenon [images drifting apart]altered appetite, thirst); imaging evidence of a mass\\nlesion as an incidental finding; or hypersecretion or hyposecretion of one or more pituitary hormones.\\nThe most common cause of hypopituitary or hyperpituitary secretion is a pituitary or hypothalamic tumor.\\nA pituitary tumor tends to produce an enlarged sella (sella turcica). Alternatively, an enlarged sella may\\nrepresent empty sella syndrome.\\nEmpty sella syndrome:\\n In this disorder, the sella appears empty because it is filled with CSF, which\\nflattens the pituitary gland against the wall of the sella. The syndrome may be congenital, primary, or\\nsecondary to injury (eg, ischemia after childbirth, surgery, head trauma, or radiation therapy). The typical\\npatient is female (> 80%), obese (about 75%), and hypertensive (30%) and may have idiopathic\\nintracranial hypertension (10%) or spinal fluid rhinorrhea (10%). Pituitary function in patients with empty\\nsella syndrome is frequently normal. However, hypopituitarism may occur, as may headaches and visual\\nfield defects. Occasionally, patients have small coexisting pituitary tumors that secrete growth hormone\\n(GH), prolactin, or ACTH. Diagnosis can be confirmed by CT or MRI. No specific therapy is needed for an\\nempty sella alone.\\nAnterior lobe lesions:\\n Hypersecretion of anterior lobe hormones (hyperpituitarism) is almost always\\nselective. The anterior pituitary hormones most commonly secreted in excess are GH (as in acromegaly,\\ngigantism), prolactin (as in galactorrhea), and ACTH (as in the pituitary type of Cushing's syndrome).\\nHyposecretion of anterior lobe hormones (hypopituitarism) may be generalized, usually due to a pituitary\\ntumor, or is idiopathic, or may involve the selective loss of one or a few pituitary hormones.\\nPosterior lobe lesions:\\n The 2 posterior lobe hormones are oxytocin and ADH. In women, oxytocin\\ncauses myoepithelial cells of the breast and myometrial cells of the uterus to contract. Oxytocin is present\\nin men but has no proven function. Deficiency of ADH results in central diabetes insipidus (see p. \\n772\\n).\\nExcess ADH secretion results in the syndrome of inappropriate ADH secretion (see \\nSidebar 97-1\\n on p.\\n826\\n).\\nGeneralized Hypopituitarism\\nGeneralized hypopituitarism refers to endocrine deficiency syndromes due to partial or\\ncomplete loss of anterior lobe pituitary function. Various clinical features occur depending on\\nthe specific hormones that are deficient. Diagnosis involves imaging tests and measurement of\\npituitary hormone levels basally and after various provocative stimuli. Treatment depends on\\ncause but generally includes removal of any tumor and administration of replacement\\nhormones\\n.\\nThe many causes of hypopituitarism are listed in\\nTable 92-1\\n.\\nSymptoms and Signs\\nSymptoms and signs relate to the underlying disorder and to the specific pituitary hormones that are\\ndeficient or absent. Onset is usually insidious and may not be recognized by the patient; occasionally,\\nonset is sudden or dramatic.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n887\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 897, 'page_label': '888'}, page_content=\"Most commonly, growth hormone (GH) is lost first, then gonadotropins, and finally thyroid-stimulating\\nhormone (TSH) and ACTH. ADH deficiency is rare in primary pituitary disease but is common with stalk\\nand hypothalamic lesions. Function of all target glands decreases when all hormones are deficient\\n(panhypopituitarism).\\nLack of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in children leads to delayed\\npuberty (see \\nHypopituitarism in Children Resulting in Short Stature\\n on p. \\n767\\n). Premenopausal women\\ndevelop amenorrhea, reduced libido, regression of secondary sexual characteristics, and infertility. Men\\ndevelop erectile dysfunction, testicular\\n[\\nTable 92-1.\\n Causes of Hypopituitarism]\\natrophy, reduced libido, regression of secondary sexual characteristics, and decreased spermatogenesis\\nwith consequent infertility.\\nGH deficiency may contribute to decreased energy but is usually asymptomatic and clinically\\nundetectable in adults (see p. \\n767\\n for effects in children). Suggestions that GH deficiency accelerates\\natherosclerosis are unproved. TSH deficiency leads to hypothyroidism, with such symptoms as facial\\npuffiness, hoarse voice, bradycardia, and cold intolerance. ACTH deficiency results in hypoadrenalism\\nwith attendant fatigue, hypotension, and intolerance to stress and infection. ACTH deficiency does not\\nresult in the hyperpigmentation characteristic of primary adrenal failure.\\nHypothalamic lesions, which can result in hypopituitarism, can also disturb the centers that control\\nappetite, causing a syndrome resembling anorexia nervosa, or sometimes hyperphagia with massive\\nobesity.\\nSheehan's syndrome,\\n which affects postpartum women, is pituitary necrosis due to hypovolemia and\\nshock occurring in the immediate peripartum period. Lactation does not start after childbirth, and the\\npatient may complain of fatigue and loss of pubic and axillary hair.\\nPituitary apoplexy\\n is a symptom complex caused by hemorrhagic infarction of either a normal pituitary\\ngland or, more commonly, a pituitary tumor. Acute symptoms include severe headache, stiff neck, fever,\\nvisual field defects, and oculomotor palsies. The resulting edema may compress the hypothalamus,\\nresulting in somnolence or coma. Varying degrees of hypopituitarism may develop suddenly, and the\\npatient may present with vascular collapse because of deficient ACTH and cortisol. The CSF often\\ncontains blood, and MRI documents hemorrhage.\\nDiagnosis\\n MRI or CT\\n Free thyroxine (T\\n4\\n), TSH, and prolactin levels\\n Cortisol levels plus provocative testing of pituitary-adrenal axis\\n Sometimes other provocative testing\\nClinical features are often nonspecific, and the diagnosis must be established with certainty before\\ncommitting the patient to a lifetime of hormone replacement therapy. Pituitary dysfunction must be\\ndistinguished from anorexia nervosa, chronic liver disease, myotonia dystrophica, polyglandular\\nautoimmune disease (see\\nTable 92-2\\n), and disorders of the other endocrine glands. The clinical picture may be\\n[\\nTable 92-2.\\n Differentiation of Generalized Hypopituitarism from Other Selected Disorders]\\nparticularly confusing when the function of more than one gland decreases at the same time. Evidence of\\nstructural pituitary abnormalities and of hormonal deficiencies should be sought with imaging and\\nlaboratory tests.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n888\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 898, 'page_label': '889'}, page_content=\"Imaging tests:\\n Patients should undergo high-resolution CT or MRI, with contrast media as required (to\\nrule out structural abnormalities, such as pituitary adenomas). PET is a research tool used in a few\\nspecialized centers and therefore is rarely done. When no modern neuroradiologic facilities are available,\\na simple cone-down lateral x-ray of the sella turcica can identify pituitary macroadenomas with a diameter\\n> 10 mm. Cerebral angiography is indicated only when other imaging tests suggest perisellar vascular\\nanomalies or aneurysms.\\nLaboratory testing:\\n Initial evaluation should include testing for TSH and ACTH deficiencies, because\\nboth conditions are potentially life threatening. Testing for deficiencies of other hormones is also\\ndiscussed elsewhere (see p. \\n766\\n).\\nFree T\\n4\\n and TSH levels should be determined. Levels of both are usually low in generalized\\nhypopituitarism; a pattern of normal TSH level with low free T\\n4\\n may also occur. In contrast, elevated TSH\\nlevels with low free T\\n4\\n indicate a primary abnormality of the thyroid gland.\\nSynthetic thyrotropin-releasing hormone (TRH), 200 to 500 \\n\\ng IV given over 15 to 30 sec, may help\\nidentify patients with hypothalamic as opposed to pituitary dysfunction, although this test is not often\\ndone. Serum TSH levels are generally measured at 0, 20, and 60 min after injection. If pituitary function is\\nintact, TSH should rise by > 5 mU/L, peaking by 30 min after injection. A delayed rise in serum TSH levels\\nmay occur in patients with hypothalamic disease. However, some patients with primary pituitary disease\\nalso show a delayed rise.\\nSerum cortisol levels alone are not reliable indicators of ACTH-adrenal axis function. One of several\\nprovocative tests should be done. The \\nshort ACTH stimulation test\\n is a safer and less labor-intensive\\ntest for cortisol deficiency than the insulin tolerance test. In the short ACTH stimulation test, synthetic\\nACTH 250 \\n\\ng IV or IM (standard test) or 1 \\n\\ng IV (low-dose test) is given, and the blood cortisol response\\nis measured 30 and 60 min later. Cortisol should rise significantly; a peak of < 20 \\n\\ng/dL is abnormal.\\nHowever, the short ACTH stimulation test is abnormal in secondary cortisol deficiency only when done at\\nleast 2 to 4 wk after onset of the deficiency; before this time, the adrenal glands have not atrophied and\\nremain responsive to exogenous ACTH.\\nThe \\ninsulin tolerance test\\n is considered the most accurate way of evaluating ACTH (as well as GH and\\nprolactin) reserve, but because of its demands, it is probably best reserved for patients who fail the short\\nsynacthen test (if confirmation is needed) or when a test must be done within 2 to 4 wk of a possible\\npituitary injury. Regular insulin at a dosage of 0.1 units/kg body weight IV is given over 15 to 30 sec, and\\nvenous blood samples are obtained to determine GH, cortisol, and glucose levels at baseline (before\\ninsulin administration) and 20, 30, 45, 60, and 90 min later. If glucose drops to < 40 mg/dL (< 2.22\\nmmol/L) or symptoms of hypoglycemia develop, cortisol should increase by > 7 \\n\\ng/dL or to > 20 \\n\\ng/dL.\\n(CAUTION: \\nThis test is hazardous in patients with severe documented panhypopituitarism or diabetes\\nmellitus and in the elderly and is contraindicated in patients with coronary artery disease or epilepsy. A\\nhealth care practitioner should be present during the test.\\n) Usually, only transient perspiration,\\ntachycardia, and nervousness occur. If the patient complains of palpitations, loses consciousness, or has\\na seizure, the test should be stopped promptly by giving 50 mL of 50% glucose solution IV.\\nNeither the short ACTH stimulation test nor the insulin tolerance test alone will differentiate between\\nprimary (Addison's disease) and secondary (hypopituitary) adrenal insufficiency. Tests to make this\\ndistinction and to evaluate the hypothalamic-pituitary-adrenal axis are described under Addison's disease\\n(see p. \\n792\\n). An alternative provocative test that is done much less often is the corticotropin-releasing\\nhormone (CRH) test. CRH 1 \\n\\ng/kg IV is given by rapid injection. Serum ACTH and cortisol levels are\\nmeasured 15 min before, then at baseline, and 15, 30, 60, 90, and 120 min after the injection. Adverse\\neffects include temporary flushing, a metallic taste in the mouth, and slight and transient hypotension.\\nProlactin levels are routinely measured. These levels are often elevated up to 5 times normal values\\nwhen a large pituitary tumor is present, even if it does not produce prolactin. The tumor compresses the\\npituitary stalk, preventing dopamine, which inhibits pituitary prolactin production and release, from\\nreaching the pituitary. Patients with such hyperprolactinemia often have hypogonadotropism and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n889\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 899, 'page_label': '890'}, page_content='secondary hypogonadism.\\nMeasurement of basal levels of LH and FSH is most helpful in evaluating hypopituitarism in\\npostmenopausal women not taking exogenous estrogens in whom circulating gonadotropin\\nconcentrations are normally high (> 30 mIU/mL). Although gonadotropin levels tend to be low in other\\npatients with panhypopituitarism, overlap exists with the normal range. Levels of both hormones should\\nincrease in response to synthetic gonadotropin-releasing hormone (GnRH) at a dose of 100 \\n\\ng IV, with\\nLH peaking about 30 min and FSH peaking 40 min after GnRH administration. However, normal,\\ndiminished, or absent responses to GnRH may occur in hypothalamic-pituitary dysfunction. Normal\\nincreases in LH and FSH in response to GnRH vary. Administration of exogenous GnRH is not helpful in\\ndistinguishing primary hypothalamic disorders from primary pituitary disorders.\\nScreening for GH deficiency in adults is not recommended unless GH treatment is contemplated (eg, for\\nunexplained reduced energy and quality of life in patients with hypopituitarism in which other hormones\\nhave been fully replaced). GH deficiency is suspected if  2 other pituitary hormones are deficient.\\nBecause GH levels vary by time of day and other factors and are difficult to interpret, levels of insulin-like\\ngrowth factor 1 (IGF-1), which reflect GH, are used; low levels suggest GH deficiency, but normal levels\\ndo not rule it out. A provocative test of GH release (see p. \\n767\\n) may be necessary.\\nAlthough the usefulness of provocative testing of pituitary function using releasing hormones remains to\\nbe established, if such testing is elected, it is most efficient to evaluate multiple hormones simultaneously.\\nGrowth hormone-releasing hormone (1 \\n\\ng/kg), CRH (1 \\n\\ng/kg), TRH (200 \\n\\ng), and GnRH (100 \\n\\ng) are\\ngiven together IV over 15 to 30 sec. Glucose, cortisol, GH, TSH, prolactin, LH, FSH, and ACTH are\\nmeasured at frequent intervals for the ensuing 180 min. The normal responses are the same as those\\ndelineated earlier for individual testing.\\nTreatment\\n Hormone replacement\\n Treatment of cause (eg, tumor)\\nTreatment is replacement of the hormones of the hypofunctioning target glands, as discussed in the\\npertinent chapters in this section and elsewhere in THE MANUAL. Adults  50 yr deficient in GH are now\\nsometimes treated with GH doses of 0.002 to 0.012 mg/kg sc once/day. Benefits of treatment include\\nimproved energy and quality of life, increased body muscle mass, and decreased body fat mass.\\nSuggestions that GH replacement can prevent an acceleration of atherosclerosis induced by GH\\ndeficiency are unproved.\\nWhen hypopituitarism is due to a pituitary tumor, specific treatment must be directed at the tumor as well\\nas replacing hormones. The appropriate management of such tumors is controversial. If the tumor is small\\nand does not secrete prolactin, most endocrinologists favor transsphenoidal removal. Most\\nendocrinologists consider dopamine agonists, such as bromocriptine or the longer-acting cabergoline, the\\ninitial treatment of prolactinomas, regardless of size, if there is amenorrhea in a woman or erectile\\ndysfunction in a man (see \\nGalactorrhea\\n on p. \\n770\\n). Patients with macroadenomas > 2 cm with extremely\\nhigh circulating levels of prolactin may require surgery or irradiation in addition to \\ndopamine agonist\\ntreatment. Supervoltage irradiation of the pituitary may be added or used alone. With larger tumors and\\nsuprasellar extension, resection of the entire tumor, either transsphenoidally or transfrontally, may not be\\npossible, and adjunctive supervoltage irradiation may be warranted.\\nIn pituitary apoplexy, immediate surgery is warranted if visual field disturbances or oculomotor palsies\\ndevelop suddenly or if somnolence progresses to coma because of hypothalamic compression. Although\\nmanagement with high-dose corticosteroids and general support may suffice in a few cases,\\ntranssphenoidal decompression of the tumor should generally be undertaken promptly.\\nSurgery and irradiation may be followed by the loss of other pituitary hormone functions. Irradiated\\npatients may lose endocrine function slowly over years. Therefore, posttreatment hormonal status should\\nbe evaluated frequently, preferably at 3 and 6 mo and yearly thereafter. Such evaluation should include at\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n890'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 900, 'page_label': '891'}, page_content=\"least assessment of thyroid and adrenal function. Patients may also develop visual difficulties related to\\nfibrosis of the optic chiasm. Sellar imaging and visual field assessment should be done at least every 2 yr\\ninitially for about 10 yr, particularly if residual tumor tissue is present.\\nSelective Pituitary Hormone Deficiencies\\nSelective deficiencies of pituitary hormones may represent an early stage in the development of more\\ngeneralized hypopituitarism. Patients must be observed for signs of other pituitary hormone deficiencies,\\nand sellar imaging should be done at intervals to check for signs of a pituitary tumor.\\nIsolated growth hormone (GH)\\n deficiency is responsible for many cases of pituitary dwarfism (see p.\\n767\\n). Although one autosomal dominant form of complete GH deficiency is associated with a deletion of\\nthe GH structural gene, such gene defects probably account for a minority of cases. Treatment of GH\\ndeficiency in adults < 50 yr is discussed on p. \\n765\\n.\\nIsolated gonadotropin deficiency\\n occurs in both sexes and must be distinguished from primary\\nhypogonadism; men have low serum testosterone levels and infertility, and women have amenorrhea, low\\nserum estrogen levels, and infertility. A eunuchoid habitus is generally present. However, patients with\\nprimary hypogonadism (see p. \\n2341\\n) have elevated levels of luteinizing hormone (LH) and follicle-\\nstimulating hormone (FSH), whereas those with gonadotropin deficiency, either secondary (pituitary) or\\ntertiary (hypothalamic), have low-normal, low, or unmeasurable levels of LH and FSH. Although most\\ncases of hypogonadotropic hypogonadism involve deficiencies of both LH and FSH, in rare cases the\\nsecretion of only one is impaired. Isolated gonadotropin deficiency must also be distinguished from\\nhypogonadotropic amenorrhea secondary to exercise, diet, or mental stress (see p. \\n2501\\n). Although the\\nhistory may be helpful, differential diagnosis may be impossible.\\nIn \\nKallmann syndrome,\\n the specific lack of gonadotropin-releasing hormone (GnRH) is associated with\\nmidline facial defects, including anosmia and cleft lip or palate, and with color blindness. Embryologic\\nstudies have shown that GnRH neurons originally develop in the epithelium of the olfactory placode and\\nmigrate into the septal-preoptic region of the hypothalamus early in development. In at least some cases,\\ngene defects, localized to the X chromosome in the X-linked form of the disorder and termed the \\nKALIG-1\\n(Kallmann syndrome interval gene 1) gene, have been found in the adhesion proteins facilitating this\\nneuronal migration. Administration of GnRH may be indicated (see p. \\n2894\\n).\\nIsolated ACTH deficiency\\n is rare. Weakness, hypoglycemia, weight loss, and decreased axillary and\\npubic hair suggest the diagnosis. Blood and urinary steroid levels are low and rise to normal after ACTH\\nreplacement. Clinical and laboratory evidence of other hormonal deficiencies is absent. Treatment is with\\ncortisol replacement, as for Addison's disease (see p. \\n794\\n).\\nIsolated thyroid-stimulating hormone (TSH) deficiency\\n is likely when clinical features of\\nhypothyroidism exist, serum TSH levels are not elevated, and no other pituitary hormone deficiencies\\nexist. Serum TSH levels, as measured by immunoassay, are not always lower than normal, suggesting\\nthat the TSH secreted is biologically inactive. Administration of recombinant human TSH increases\\nthyroid hormone levels (see also \\nHypothyroidism\\n on p. \\n785\\n).\\nIsolated prolactin deficiency\\n has been noted rarely in women who fail to lactate after delivery. Basal\\nprolactin levels are low and do not increase in response to provocative stimuli, such as thyroid-releasing\\nhormone. Administration of prolactin is not indicated.\\nHypopituitarism in Children Resulting in Short Stature\\n(Pituitary Dwarfism)\\nHypopituitarism in children typically results in abnormally slow growth and short stature with\\nnormal proportions. It is usually due to a pituitary tumor but may be idiopathic. Diagnosis\\ninvolves measurement of growth hormone (GH) levels at baseline and in response to\\npharmacologic stimuli. Treatment usually involves removal of the causative tumor and GH\\nreplacement\\n.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n891\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 901, 'page_label': '892'}, page_content='Hypopituitarism in children may be generalized, involving deficiency of several pituitary hormones, but it is\\nusually first expressed clinically as short stature resulting from deficiency of GH. Isolated deficiency of GH\\nmay also occur.\\nHypopituitarism in children is usually due to a pituitary tumor (most commonly a craniopharyngioma) or is\\nidiopathic. The combination of lytic lesions of the bone or skull and diabetes insipidus suggests\\nLangerhans\\' cell histiocytosis (see p. \\n993\\n). Hypothalamic or pituitary hormone deficiency as well as\\nisolated GH deficiency may occur in patients with midline defects, such as cleft palate or septo-optic\\ndysplasia, which involves absence of the septum pellucidum, optic nerve atrophy, and hypopituitarism.\\nGH deficiency, either alone or in patients with other abnormalities, is hereditary in about 5% of cases.\\nTherapeutic radiation of the CNS for various cancers causes slowing of linear growth, which can often be\\nlinked to resulting GH deficiency. Radiation of the spine, either prophylactic or therapeutic, may further\\nimpair the growth potential of the vertebrae and further jeopardize height gain.\\nSymptoms and Signs\\nIn a child with hypopituitarism, height is below the 3rd percentile, and growth velocity is < 6 cm/yr before\\nage 4 yr, < 5 cm/yr from age 4 to 8 yr, and < 4 cm/yr before puberty. Skeletal maturation, assessed by\\nbone age determination, is > 2 yr behind chronologic age.\\nAlthough of small stature, a child with hypopituitarism retains normal proportionality between upper and\\nlower body segments. The child fails to begin pubertal development. However, a child with isolated GH\\ndeficiency secondary to hypopituitarism may undergo delayed pubertal development.\\nGrowth data for height and weight should be plotted on a growth chart (auxologic assessment) for all\\nchildren. When growth is abnormal, bone age should be determined from an x-ray of the left hand (by\\nconvention). In GH deficiency, skeletal maturation is usually delayed to the same extent as height.\\nEvaluating the pituitary gland and sella turcica with CT or MRI is indicated to rule out calcifications and\\ntumors; the sella turcica is abnormally small in 10 to 20% of patients.\\nDiagnosis\\n Insulin-like growth factor 1 (IGF-1) levels and sometimes IGF binding protein type 3 (IGFBP-3) levels\\n Usually confirmation by provocative testing\\nIn mid to late childhood, IGF-1 levels, which reflect GH activity, are measured because GH levels are\\nhighly variable and difficult to interpret. Normal IGF-1 levels help exclude GH deficiency. However, IGF-1\\nlevels are low in conditions other than GH deficiency, such as psychosocial deprivation, undernutrition,\\nand hypothyroidism. Because IGF-1 levels are normally low in infancy and early childhood, they do not\\nallow reliable discrimination between normal and subnormal in these age groups. In these children, levels\\nof IGFBP-3 (the major carrier of IGF peptides) are measured. IGFBP-3 is less affected by undernutrition\\nthan is IGF-1.\\nIn children with low levels of IGF-1 and IGFBP-3, GH deficiency is usually confirmed by measuring GH\\nlevels. Because basal GH levels are typically low or undetectable (except after the onset of sleep),\\nassessment of GH levels requires provocative testing. However, provocative testing is nonphysiologic,\\nsubject to laboratory error, and poorly reproducible, and interpretation of data relies on arbitrary\\ndefinitions of \"normal\" that vary by age and sex.\\nThe insulin tolerance test may be the most effective provocative test for stimulating GH release. Less\\ndangerous, but also less reliable, are tests using arginine infusion (500 mg/kg IV given over 30 min),\\nlevodopa (10 mg/kg to children; 500 mg po to adults), sleep, or 20 min of vigorous exercise. Generally,\\nany GH level > 10 ng/mL or any response of > 5 ng/mL after a stimulus is sufficient to rule out GH\\ndeficiency. Increases in GH of < 5 ng/mL or to levels < 10 ng/mL are difficult to interpret. What constitutes\\na normal response, however, is arbitrary, and all provocative tests of GH \\nsecretion occasionally produce\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n892'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 902, 'page_label': '893'}, page_content='misleading results. Because no single test is 100% effective in eliciting GH release, a 2nd provocative\\ntest should be done if the first is abnormal. GH levels generally peak 30 to 90 min after administration of\\ninsulin or the onset of arginine infusion, 30 to 120 min after levodopa, 60 to 120 min after the onset of\\nsleep, and after 20 min of vigorous exercise. Because GH responses are generally abnormal in patients\\nwith diminished thyroid or adrenal function, testing should be conducted in these patients only after\\nadequate hormone replacement therapy.\\nThe value of exogenous growth hormone-releasing hormone (GHRH) alone in evaluating GH secretion is\\nnot established. In normal people, a dose of 1 \\n\\ng/kg GHRH IV administered over 15 to 30 sec results in\\nmaximal but variable release of GH, typically reaching a peak about 60 min after GHRH injection. The\\nvariability in pituitary responsiveness to GHRH is consistent with the hypothesis that intermittent secretion\\nof somatostatin, which opposes GHRH, is responsible for modulating pituitary GH output. Presumably,\\nabsent or diminished increases in GH in response to GHRH identify patients with GH deficiency, but\\nwhether the pattern of response distinguishes primary hypothalamic disease from pituitary disease is\\nunclear. In children with GH deficiency presumably secondary to GHRH deficiency, highly variable GH\\nresponses to GHRH occur. The combination of arginine and GHRH improves the sensitivity for\\ndiagnosing GH deficiency.\\nProvocative testing may not detect subtle defects in the regulation of GH release. For example, in\\nchildren with short stature secondary to GH secretory dysfunction, results of provocative testing for GH\\nrelease are usually normal. However, serial measurements of GH levels over 12 to 24 h indicate\\nabnormally low 12- or 24-h integrated GH secretion.\\nIf diminished GH release is confirmed, secretion of other pituitary hormones and (if abnormal) hormones\\nof their target peripheral endocrine glands also must be evaluated.\\nTreatment\\n Recombinant GH supplements\\nRecombinant GH is indicated for all children with short stature who have documented GH deficiency.\\nDosing is usually from 0.03 to 0.05 mg/kg sc once/day. With therapy, height velocity often increases to 10\\nto 12 cm/yr in the first year and, although it increases more slowly thereafter, remains above pretreatment\\nrates. Therapy is continued until an acceptable height is reached or growth rate falls below 2.5 cm/yr.\\nAdverse effects of GH therapy are few but include idiopathic intracranial hypertension (pseudotumor\\ncerebri), slipped capital femoral epiphysis, and transient mild peripheral edema. Before the advent of\\nrecombinant GH, GH extracted from pituitary glands was used. This preparation rarely led to Creutzfeldt-\\nJakob disease 20 to 40 yr after treatment (see p. \\n1729\\n). Pituitary-extracted GH was last used in the\\n1980s.\\nIt is controversial whether short children with clinical features of GH deficiency but with normal GH\\nsecretion and normal IGF-1 levels should be treated with GH. Many experts recommend a trial of GH\\ntherapy for 6 to 12 mo, continuing GH only if there is a doubling of or an increase of 3 cm/yr over the\\npretreatment height velocity. Others object to this approach because it is expensive, is experimental, may\\nlead to adverse effects, labels otherwise healthy children as abnormal, and raises ethical and\\npsychosocial concerns that feed into the bias of \"heightism.\"\\nCortisol and thyroid hormone should be replaced throughout childhood, adolescence, and adulthood in\\npatients with short stature due to pituitary dwarfism when circulating levels of these hormones are low\\n(see pp. \\n786\\n and \\n794\\n). When puberty fails to occur normally, treatment with gonadal sex steroids is\\nindicated (see p. \\n2894\\n).\\nGH therapy in children with short stature due to therapeutic radiation of the pituitary gland for cancer\\ncarries a theoretic risk of causing cancer recurrence. However, studies have not shown a greater-than-\\nexpected incidence of new cancers or a greater recurrence rate. GH replacement can probably be safely\\ninstituted at least 1 yr after the successful completion of anticancer therapy.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n893'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 903, 'page_label': '894'}, page_content='Gigantism and Acromegaly\\nGigantism and acromegaly are syndromes of excessive secretion of growth hormone\\n(hypersomatotropism) that are nearly always due to a pituitary adenoma. Before closure of the\\nepiphyses, the result is gigantism. Later, the result is acromegaly, which causes distinctive\\nfacial and other features. Diagnosis is clinical and by skull and hand x-rays and measurement of\\ngrowth hormone levels. Treatment involves removal or destruction of the responsible\\nadenoma.\\nMany growth hormone (GH)-secreting adenomas contain a mutant form of the G\\ns\\n protein, which is a\\nstimulatory regulator of adenylate cyclase. Cells with the mutant form of G\\ns\\n protein secrete GH even in\\nthe absence of growth hormone-releasing hormone (GHRH). A few cases of ectopic GHRH-producing\\ntumors, especially of the pancreas and lung, also have been described.\\nSymptoms and Signs\\nPituitary gigantism:\\n This rare condition occurs if GH hypersecretion begins in childhood, before closure\\nof the epiphyses. Skeletal growth velocity and ultimate stature are increased, but little bony deformity\\noccurs. However, soft-tissue swelling occurs, and the peripheral nerves are enlarged. Delayed puberty or\\nhypogonadotropic hypogonadism is also frequently present, resulting in a eunuchoid habitus.\\nAcromegaly:\\n In acromegaly, GH hypersecretion usually starts between the 20s and 40s. When GH\\nhypersecretion begins after epiphyseal closure, the earliest clinical manifestations are coarsening of the\\nfacial features (see\\nPlate 21\\n) and soft-tissue swelling of the hands and feet. Appearance changes, and larger rings, gloves,\\nand shoes are needed. Photographs of the patient are important in delineating the course of the disease.\\nIn adults with acromegaly, coarse body hair increases and the skin thickens and frequently darkens. The\\nsize and function of sebaceous and sweat glands increase, such that patients frequently complain of\\nexcessive perspiration and offensive body odor. Overgrowth of the mandible leads to protrusion of the\\njaw (prognathism) and malocclusion of teeth. Cartilaginous proliferation of the larynx leads to a deep,\\nhusky voice. The tongue is frequently enlarged and furrowed. In longstanding acromegaly, costal cartilage\\ngrowth leads to a barrel chest. Articular cartilaginous proliferation occurs early in response to GH excess,\\nwith the articular cartilage possibly undergoing necrosis and erosion. Joint symptoms are common, and\\ncrippling degenerative arthritis may occur.\\nPeripheral neuropathies occur commonly because of compression of nerves by adjacent fibrous tissue\\nand endoneural fibrous proliferation. Headaches are common because of the pituitary tumor. Bitemporal\\nhemianopia may develop if suprasellar extension compresses the optic chiasm. The heart, liver, kidneys,\\nspleen, thyroid, parathyroid glands, and pancreas are larger than normal. Cardiac disease occurs in\\nperhaps one third of patients, with a doubling in the risk of death from cardiac disease. Hypertension\\noccurs in up to one third of patients. The risk of cancer, particularly of the GI tract, increases 2-fold to 3-\\nfold. GH increases tubular reabsorption of phosphate and leads to mild hyperphosphatemia. Impaired\\nglucose tolerance occurs in nearly one half the patients with acromegaly and in gigantism, but clinically\\nsignificant diabetes mellitus occurs in only about 10% of patients.\\nGalactorrhea occurs in some women with acromegaly, usually in association with hyperprolactinemia (see\\np. \\n770\\n). However, galactorrhea may occur with GH excess alone, because GH itself stimulates lactation.\\nDecreased gonadotropin secretion often occurs with GH-secreting tumors. About one third of men with\\nacromegaly develop erectile dysfunction, and nearly all women develop menstrual irregularities or\\namenorrhea.\\nDiagnosis\\n CT or MRI\\n Insulin-like growth factor 1 (IGF-1) levels\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n894'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 904, 'page_label': '895'}, page_content=' Usually GH levels\\nDiagnosis can be made from the characteristic clinical findings. CT, MRI, or skull x-rays disclose cortical\\nthickening, enlargement of the frontal sinuses, and enlargement and erosion of the sella turcica. X-rays of\\nthe hands show tufting of the terminal phalanges and soft-tissue thickening. Generally, glucose tolerance\\nis abnormal and serum phosphate levels are mildly elevated.\\nSerum IGF-1 should be measured in patients with suspected acromegaly; IGF-1 levels are typically\\nsubstantially elevated (3-fold to 10-fold), and because IGF-1 levels do not fluctuate like GH levels do,\\nthey are the simplest way to assess GH hypersecretion. IGF-1 levels also can be used to monitor\\nresponse to therapy.\\nPlasma GH levels measured by radioimmunoassay are typically elevated. Blood should be taken before\\nthe patient eats breakfast (basal state); in normal people, basal GH levels are < 5 ng/mL. Transient\\nelevations of GH are normal and must be distinguished from pathologic hypersecretion. The degree of\\nGH suppression after a glucose load remains the standard and thus should be measured in patients with\\nelevated plasma GH; however, the results are assay-dependent, and the cutoff for normal suppression is\\ncontroversial. Secretion in normal people is suppressed to < 2 ng/mL (a cutoff of < 1 ng/mL is often used)\\nwithin 90 min of administration of glucose 75 g po. Most patients with acromegaly have substantially\\nhigher values. Basal plasma GH levels \\nare also important in monitoring response to therapy.\\nCT or MRI of the head should be done to look for a tumor. If a tumor is not visible, excessive secretion of\\npituitary GH may be due to a non-CNS tumor producing excessive amounts of ectopic GHRH.\\nDemonstration of elevated levels of plasma GHRH can confirm the diagnosis. Lungs and pancreas may\\nbe first evaluated in searching for the sites of ectopic production.\\nTreatment\\n Surgery or radiation therapy\\nAblative therapy with surgery or radiation is generally indicated. Transsphenoidal resection is preferred,\\nbut choices vary at different institutions. Stereotactic supervoltage radiation, delivering about 5000 cGy to\\nthe pituitary, is used, but GH levels may not fall to normal for several years. Treatment with accelerated\\nprotons (heavy particle radiation) permits delivery of larger doses of radiation (equivalent to 10,000 cGy)\\nto the pituitary; such therapy poses higher risk of cranial nerve and hypothalamic damage and is available\\nonly in a few centers. Development of hypopituitarism several years after irradiation is common. Because\\nradiation damage is cumulative, proton beam therapy should not be used after conventional \\n\\n-irradiation.\\nA combined approach with both surgery and radiation therapy is indicated for patients with progressive\\nextrasellar involvement by a pituitary tumor and for patients whose entire tumor cannot be resected, which\\nis often the case.\\nSurgical removal of the tumor is likely to have been curative if GH levels after the glucose tolerance test\\nand IGF-1 levels reach normal values. If one or both values are abnormal, further therapy is usually\\nneeded. If GH excess is poorly controlled, hypertension, heart failure, and a doubling in the death rate\\noccur. If GH levels are < 5 ng/mL, however, mortality does not increase.\\nIn general, drug therapy is indicated if surgery and radiation therapy are contraindicated, if they have not\\nbeen curative, or if radiation therapy is being given time to work. In such instances, a somatostatin\\nanalog, octreotide, is given at 0.05 to 0.15 mg sc q 8 to 12 h; it suppresses GH secretion effectively in\\npatients refractory to bromocriptine, surgery, or irradiation. Longer-acting somatostatin analogs, such as\\nmannitol-modified release octreotide (octreotide LAR) given 10 to 30 mg IM q 4 to 6 wk and lanreotide\\ngiven 30 mg IM q 10 to 14 days, are more convenient. Bromocriptine mesylate (1.25 to 5 mg po bid) may\\neffectively lower GH levels in a small percentage of patients but is less effective than somatostatin\\nanalogs.\\nPegvisomant, a GH receptor blocker, has been shown to reduce the effects of GH and lower IGF-1 levels\\nin people with acromegaly, without apparent increase in pituitary tumor size. This drug may find a place in\\ntreating patients who are partially or totally unresponsive to somatostatin analogs.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n895'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 905, 'page_label': '896'}, page_content='Galactorrhea\\nGalactorrhea is lactation in men or in women who are not breastfeeding. It is generally due to a\\nprolactin-secreting pituitary adenoma. Diagnosis is by measurement of prolactin levels and\\nimaging tests. Treatment involves tumor inhibition with dopamine agonist drugs and sometimes\\nremoval or destruction of the adenoma\\n.\\nEtiology\\nGalactorrhea is generally due to a prolactin-secreting pituitary adenoma (prolactinoma). Most tumors in\\nwomen are microadenomas (< 10 mm in diameter), but a small percentage are macroadenomas (> 10\\nmm) when diagnosed. The frequency of microadenomas is much lower in men, perhaps because of later\\nrecognition.\\nHyperprolactinemia and galactorrhea also may be caused by ingestion of certain drugs, including\\nphenothiazines, other antipsychotics, certain antihypertensives (especially \\n\\n-methyldopa), and opioids.\\nPrimary hypothyroidism can cause hyperprolactinemia and galactorrhea, because increased levels of\\nthyroid-releasing hormone increase secretion of prolactin as well as thyroid-stimulating hormone (TSH). It\\nis unclear why hyperprolactinemia is associated with hypogonadotropism and hypogonadism. Causes of\\nhyperprolactinemia are listed in\\nTable 92-3\\n.\\nSymptoms and Signs\\nAbnormal lactation is not defined quantitatively; it is milk release that is inappropriate, persistent, or\\nworrisome to the patient. Spontaneous lactation is more unusual than milk released in response to\\nmanual expression. The milk is white. Women with galactorrhea commonly also have amenorrhea or\\noligomenorrhea. Women with galactorrhea and amenorrhea may also have symptoms and signs of\\nestrogen deficiency, including dyspareunia, due to inhibition of pulsatile luteinizing hormone and follicle-\\nstimulating hormone release\\n[\\nTable 92-3.\\n Causes of Hyperprolactinemia]\\nby high prolactin levels. However, estrogen production may be normal, and signs of androgen excess\\nhave been observed in some women with hyperprolactinemia. Hyperprolactinemia may occur with other\\nmenstrual cycle disturbances besides amenorrhea, including infrequent ovulation and corpus luteum\\ndysfunction.\\nMen with prolactin-secreting pituitary tumors typically have headaches or visual difficulties. About two\\nthirds of affected men have loss of libido and erectile dysfunction.\\nDiagnosis\\n Prolactin levels\\n Thyroxine (T\\n4\\n) and TSH levels\\n CT or MRI\\nDiagnosis of galactorrhea due to a prolactin-secreting pituitary adenoma is based on elevated prolactin\\nlevels. In general, prolactin levels correlate with the size of a pituitary tumor and can be used to follow\\npatients over time. Serum gonadotropin and estradiol levels are either low or in the normal range in\\nwomen with hyperprolactinemia. Primary hypothyroidism is easily ruled out by absence of elevated TSH.\\nHigh-resolution CT or MRI is the method of choice in identifying microadenomas. Visual field examination\\nis indicated in all patients with macroadenomas and in any patient who elects drug therapy or surveillance\\nonly.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n896'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 906, 'page_label': '897'}, page_content=\"Treatment\\n Depends on cause, symptoms, and other factors\\nThe treatment of microprolactinomas is controversial. Asymptomatic patients who have prolactin levels <\\n100 ng/mL and normal CT or MRI results or who have only microadenomas can probably be observed;\\nserum prolactin often normalizes within years. Patients with hyperprolactinemia should be monitored with\\nquarterly measurement of prolactin levels and undergo sellar CT or MRI annually for at least an additional\\n2 yr. The frequency of sellar imaging can then be reduced if prolactin levels do not increase. Indications\\nfor treatment in women include the desire for pregnancy, amenorrhea or significant oligomenorrhea\\n(because of the risk of osteoporosis), hirsutism, low libido, and troublesome galactorrhea. Indications in\\nmen include hypogonadism (because of the risk of osteoporosis), erectile dysfunction, low libido, and\\ntroublesome infertility.\\nThe initial treatment is usually a dopamine agonist such as bromocriptine (1.25 to 5 mg po bid) or the\\nlonger-acting cabergoline (0.25 to 1.0 mg po once/wk or twice/wk). Cabergoline is the treatment of choice\\nbecause it seems to be more easily tolerated and more potent than bromocriptine. Women trying to\\nbecome pregnant should switch to bromocriptine at least 1 mo before planned conception and stop\\nbromocriptine use at the time of a positive pregnancy test; long-term safety data are better established for\\nbromocriptine than for cabergoline. Exogenous estrogen can be given to women with a microadenoma\\nwho are clinically hypoestrogenic or have low estradiol levels. Exogenous estrogen is unlikely to cause\\ntumor expansion.\\nPatients with macroadenomas generally should be treated with dopamine agonists or surgically but only\\nafter thorough testing of pituitary function and evaluation for radiation therapy. Dopamine agonists are\\nusually the initial treatment of choice and usually shrink the tumor. If prolactin levels fall and symptoms\\nand signs of compression by the tumor abate, no other therapy may be necessary. Surgery or radiation\\ntherapy may be easier to do or yield better results after tumor shrinkage induced by a dopamine agonist.\\nAlthough dopamine agonist treatment usually needs to be continued long-term, prolactin-secreting tumors\\nsometimes remit, either spontaneously or perhaps aided by the drug therapy. Sometimes, therefore,\\ndopamine agonists can be stopped without a recurrence of the tumor or a rise in prolactin levels;\\nremission is more likely with microadenomas than macroadenomas. Remission is also more likely after\\npregnancy.\\nHigh doses of dopamine agonists, particularly cabergoline and pergolide, are thought to have caused\\nvalvular heart disease in some patients with Parkinson's disease. It is not clear whether the lower doses\\nof dopamine agonists used for hyperprolactinemia similarly increase the risk of valvular heart disease, but\\nthe possibility should be discussed with patients, and echocardiographic surveillance should be\\nconsidered. The risk may be less with bromocriptine or a nonergot-derived dopamine agonist (eg,\\nquinagolide).\\nRadiation therapy should be used only in patients with progressive disease who do not respond to other\\nforms of therapy. With irradiation, hypopituitarism often develops several years after therapy. Monitoring\\nendocrine function and sellar imaging are indicated yearly for life.\\nCentral Diabetes Insipidus\\n(Vasopressin-Sensitive Diabetes Insipidus)\\n(See also \\nSidebar 97-1\\n on p. \\n826\\n and \\nNephrogenic Diabetes Insipidus\\n on p. \\n2424\\n.)\\nDiabetes insipidus (DI) results from a deficiency of ADH due to a hypothalamic-pituitary disorder\\n(central DI [CDI]) or from resistance of the kidney to ADH (nephrogenic DI [NDI]). Polyuria and\\npolydipsia develop. Diagnosis is by water deprivation test showing failure to maximally\\nconcentrate urine; ADH levels and response to exogenous ADH help distinguish CDI from NDI.\\nTreatment is with intranasal desmopressin or lypressin. Nonhormonal treatment includes use of\\ndiuretics (mainly thiazides) and ADH-releasing drugs, such as chlorpropamide\\n.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n897\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 907, 'page_label': '898'}, page_content=\"Pathophysiology\\nPolyuria may result from CDI, a deficiency of ADH, NDI, or compulsive or habitual water drinking\\n(psychogenic polydipsia). The posterior lobe of the pituitary is the major site of ADH storage and release,\\nbut ADH is synthesized within the hypothalamus. Newly synthesized hormone can still be released into\\nthe circulation as long as the hypothalamic nuclei and part of the neurohypophyseal tract are intact. Only\\nabout 10% of neurosecretory neurons must remain intact to avoid CDI. The pathology of CDI thus always\\ninvolves the supraoptic and paraventricular nuclei of the hypothalamus or a major portion of the pituitary\\nstalk.\\nCDI may be complete (absence of ADH) or partial (insufficient amounts of ADH). CDI may be primary, in\\nwhich there is a marked decrease in the hypothalamic nuclei of the neurohypophyseal system.\\nEtiology\\nPrimary CDI:\\n Genetic abnormalities of the ADH gene on chromosome 20 are responsible for autosomal\\ndominant forms of primary CDI, but many cases are idiopathic.\\nSecondary CDI:\\n CDI may also be secondary (acquired), caused by various lesions, including\\nhypophysectomy, cranial injuries (particularly basal skull fractures), suprasellar and intrasellar tumors\\n(primary or metastatic), Langerhans' cell histiocytosis (Hand-Schuller-Christian disease), granulomas\\n(sarcoidosis or TB), vascular lesions (aneurysm and thrombosis), and infections (encephalitis or\\nmeningitis).\\nSymptoms and Signs\\nOnset may be insidious or abrupt, occurring at any age. The only symptoms in primary CDI are polydipsia\\nand polyuria. In secondary CDI, symptoms and signs of the associated lesions are also present.\\nEnormous quantities of fluid may be ingested, and large volumes (3 to 30 L/day) of very dilute urine (sp gr\\nusually < 1.005 and osmolality < 200 mOsm/L) are excreted. Nocturia almost always occurs. Dehydration\\nand hypovolemia may develop rapidly if urinary losses are not continuously replaced.\\nDiagnosis\\n Water deprivation test\\n Sometimes ADH levels\\nCDI must be differentiated from other causes of polyuria (see\\nTable 92-4\\n), particularly psychogenic polydipsia and NDI. All tests for CDI (and for NDI) are based on the\\nprinciple that increasing the plasma osmolality in normal people will lead to decreased excretion of urine\\nwith increased osmolality.\\nThe water deprivation test is the simplest and most reliable method for diagnosing CDI but \\nshould be\\ndone only while the patient is under constant supervision. Serious dehydration may result.\\n Additionally,\\nif psychogenic\\n[\\nTable 92-4.\\n Common Causes of Polyuria]\\npolydipsia is suspected, the patient must be observed to prevent surreptitious drinking. The test is started\\nin the morning by weighing the patient, obtaining venous blood to determine electrolyte concentrations\\nand osmolality, and measuring urinary osmolality. Voided urine is collected hourly, and its sp gr or,\\npreferably, osmolality is measured. Dehydration is continued until orthostatic hypotension and postural\\ntachycardia appear,  5% of the initial body weight has been lost, or the urinary concentration does not\\nincrease > 0.001 sp gr or > 30 mOsm/L in sequentially voided specimens. Serum electrolytes and\\nosmolality are again determined, and 5 units of aqueous vasopressin are injected sc. Urine for sp gr or\\nosmolality measurement is collected one final time 60 min postinjection, and the test is terminated.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n898\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 908, 'page_label': '899'}, page_content='A normal response produces maximum urine osmolality after dehydration (often > 1.020 sp gr or > 700\\nmOsm/L), exceeding the plasma osmolality; osmolality does not increase more than an additional 5% after\\ninjection of vasopressin. Patients with CDI are generally unable to concentrate urine to greater than the\\nplasma osmolality but are able to increase their urine osmolality by > 50% after vasopressin\\nadministration. Patients with partial CDI are often able to concentrate urine to above the plasma\\nosmolality but show a rise in urine osmolality of > 9% after vasopressin administration. Patients with NDI\\nare unable to concentrate urine to greater than the plasma osmolality and show no additional response to\\nvasopressin administration.\\nMeasurement of circulating ADH is the most direct method of diagnosing CDI; levels at the end of the\\nwater deprivation test (before the vasopressin injection) are low in CDI and appropriately elevated in NDI.\\nHowever, ADH levels are difficult to measure, and the test is not routinely available. In addition, water\\ndeprivation is so accurate that direct measurement of ADH is unnecessary. Plasma ADH levels are\\ndiagnostic after either dehydration or infusion of hypertonic saline.\\nPsychogenic polydipsia:\\n Psychogenic polydipsia may present a difficult problem in differential\\ndiagnosis. Patients may ingest and excrete up to 6 L of fluid/day and are often emotionally disturbed.\\nUnlike patients with CDI and NDI, they usually do not have nocturia, nor does their thirst wake them at\\nnight. Continued ingestion of large volumes of water in this situation can lead to life-threatening\\nhyponatremia (see p. \\n823\\n).\\nPatients with acute psychogenic water drinking are able to concentrate their urine during water\\ndeprivation. However, because chronic water intake diminishes medullary tonicity in the kidney, patients\\nwith longstanding polydipsia are not able to concentrate their urine to maximal levels during water\\ndeprivation, a response similar to that of patients with partial CDI. However, unlike CDI, patients with\\npsychogenic polydipsia show no response to exogenous ADH after water deprivation. This response\\nresembles NDI, except that basal ADH levels are low compared with the elevated levels present in NDI.\\nAfter prolonged restriction of fluid intake to  2 L/day, normal concentrating ability returns within several\\nweeks.\\nTreatment\\n Desmopressin\\nCDI can be treated with hormone replacement and treatment of any correctable cause. In the absence of\\nappropriate management, permanent renal damage can result.\\nDesmopressin, a synthetic analog of ADH with minimal vasoconstrictive properties, has prolonged\\nantidiuretic activity lasting for 12 to 24 h in most patients and may be administered intranasally, sc, IV, or\\norally. Desmopressin is the preparation of choice for both adults and children and is available as an\\nintranasal solution in 2 forms. A dropper bottle with a calibrated nasal catheter has the advantage of\\ndelivering incremental doses from 5 to 20 \\n\\ng but is awkward to use. A spray bottle that delivers 10 \\n\\ng of\\ndesmopressin in 0.1 mL of fluid is easier to use but delivers a fixed quantity. For each patient, the duration\\nof action of a given dose must be established, because variation among individuals is great. The duration\\nof action can be established by following timed urine volumes and osmolality. The nightly dose is the\\nlowest dose required to prevent nocturia. The morning and evening doses should be adjusted separately.\\nThe usual dosage range in adults is 10 to 40 \\n\\ng, with most adults requiring 10 \\n\\ng bid. For children age 3\\nmo to 12 yr, the usual dosage range is 2.5 to 10 \\n\\ng bid. Overdosage can lead to fluid retention and\\ndecreased plasma osmolality, possibly resulting in seizures in small children. In such instances,\\nfurosemide can be given to induce diuresis. Headache may be a troublesome adverse effect but generally\\ndisappears if the dosage is reduced. Infrequently, desmopressin causes a slight increase in BP.\\nAbsorption from the nasal mucosa may be erratic, especially when URI or allergic rhinitis occurs. When\\nintranasal delivery of desmopressin is inappropriate, it may be administered sc using about one tenth the\\nintranasal dose. Desmopressin may \\nbe used IV if a rapid effect is necessary (eg, for hypovolemia). With\\noral desmopressin, dose equivalence with the intranasal formulation is unpredictable, so individual dose\\ntitration is needed. The initial dose is 0.1 mg po tid, and the maintenance dose is usually 0.1 to 0.2 mg tid.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n899'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 909, 'page_label': '900'}, page_content='Lypressin (lysine-8-vasopressin), a synthetic agent, is given by nasal spray at doses of 2 to 4 units (7.5 to\\n15 \\n\\ng) q 3 to 8 h but, because of its short duration of action, has been largely replaced by desmopressin.\\nAqueous vasopressin 5 to 10 units sc or IM can be given to provide an antidiuretic response that usually\\nlasts  6 h. Thus, this drug has little use in long-term treatment but can be used in the initial therapy of\\nunconscious patients and in patients with CDI who are undergoing surgery. Synthetic vasopressin can\\nalso be administered bid to qid as a nasal spray, with the dosage and interval tailored to each patient.\\nVasopressin tannate in oil 0.3 to 1 mL (1.5 to 5 units) IM may control symptoms for up to 96 h.\\nAt least 3 groups of nonhormonal drugs are useful in reducing polyuria: various diuretics, primarily\\nthiazides; ADH-releasing drugs, such as chlorpropamide, carbamazepine, and clofibrate; and\\nprostaglandin inhibitors, which are modestly effective. These drugs have been particularly useful in partial\\nCDI and do not cause the adverse effects of exogenous ADH.\\nThe thiazides paradoxically reduce urine volume in partial and complete CDI (and NDI), primarily as a\\nconsequence of reducing ECF volume and increasing proximal tubular resorption. Urine volumes may fall\\nby 25 to 50% with 15 to 25 mg/kg of chlorothiazide. Restricting salt intake may also help because it\\nreduces urine output by reducing solute load.\\nChlorpropamide, carbamazepine, and clofibrate can reduce or eliminate the need for vasopressin in some\\npatients with partial CDI. None are effective in NDI. Chlorpropamide (3 to 5 mg/kg po once/day or bid)\\ncauses some release of ADH and also potentiates the action of ADH on the kidney. Clofibrate (500 to\\n1000 mg po bid) or carbamazepine (100 to 400 mg po bid) is recommended for adults only. These drugs\\nmay be used synergistically with a diuretic. However, significant hypoglycemia may result from\\nchlorpropamide.\\nProstaglandin inhibitors (such as indomethacin 0.5 to 1.0 mg/kg po tid, although most NSAIDs are\\neffective) may reduce urine volume, but generally by no more than 10 to 25%, perhaps by decreasing\\nrenal blood flow and GFR. Together with indomethacin, restriction of Na intake and a thiazide diuretic\\nhelp further reduce urine volume in NDI.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 92. Pituitary Disorders\\n900'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 910, 'page_label': '901'}, page_content='Chapter 93. Thyroid Disorders\\nIntroduction\\nThe thyroid gland, located in the anterior neck just below the cricoid cartilage, consists of 2 lobes\\nconnected by an isthmus. Follicular cells in the gland produce the 2 main thyroid hormones,\\ntetraiodothyronine (thyroxine, T\\n4\\n) and triiodothyronine (T\\n3\\n). These hormones act on cells in virtually\\nevery body tissue by combining with nuclear receptors and altering expression of a wide range of gene\\nproducts. Thyroid hormone is required for normal brain and somatic tissue development in the fetus and\\nneonate, and, in people of all ages, regulates protein, carbohydrate, and fat metabolism.\\nT\\n3\\n is the most active form; T\\n4\\n has only minimal hormonal activity. However, T\\n4\\n is much longer lasting and\\ncan be converted to T\\n3\\n (in most tissues) and thus serves as a reservoir for T\\n3\\n. A 3rd form of thyroid\\nhormone, reverse T\\n3\\n (rT\\n3\\n), has no metabolic activity; levels of rT\\n3\\n increase in certain diseases.\\nAdditionally, parafollicular cells (C cells) secrete the hormone calcitonin, which is released in response to\\nhypercalcemia and lowers serum Ca levels (see p. \\n838\\n).\\nSynthesis and Release of Thyroid Hormones\\nSynthesis of thyroid hormones requires iodine (see\\nFig. 93-1\\n). Iodine, ingested in food and water as iodide, is actively concentrated by the thyroid and\\nconverted to organic iodine (organification) within follicular cells by thyroid peroxidase. The follicular cells\\nsurround a space filled with colloid, which consists of thyroglobulin, a glycoprotein containing tyrosine\\nwithin its matrix. Tyrosine in contact with the membrane of the follicular cells is iodinated at 1\\n(monoiodotyrosine) or 2 (diiodotyrosine) sites and then coupled to produce the 2 forms of thyroid\\nhormone (diiodotyrosine + diiodotyrosine \\n T\\n4\\n; diiodotyrosine + monoiodotyrosine \\n T\\n3\\n).\\n[\\nFig. 93-1.\\n Synthesis of thyroid hormones.]\\nT\\n3\\n and T\\n4\\n remain incorporated in thyroglobulin within the follicle until the follicular cells take up\\nthyroglobulin as colloid droplets. Once inside the thyroid follicular cells, T\\n3\\n and T\\n4\\n are cleaved from\\nthyroglobulin. Free T\\n3\\n and T\\n4\\n are then released into the bloodstream, where they are bound to serum\\nproteins for transport, the major one being thyroxine-binding globulin (TBG), which has high affinity but\\nlow capacity for T\\n3\\n and T\\n4\\n. TBG normally carries about 75% of bound thyroid hormones. The other\\nbinding proteins are thyroxine-binding prealbumin (transthyretin), which has high affinity but low capacity\\nfor T\\n4\\n, and albumin, which has low affinity but high capacity for T\\n3\\n and T\\n4\\n. About 0.3% of total serum T\\n3\\nand 0.03% of total serum T\\n4\\n are free and in equilibrium with bound hormones. Only free T\\n3\\n and free T\\n4\\nare available to act on the peripheral tissues.\\nAll reactions necessary for the formation and release of T\\n3\\n and T\\n4\\n are controlled by thyroid-stimulating\\nhormone (TSH), which is secreted by pituitary thyrotropic cells. TSH secretion is controlled by a negative\\nfeedback mechanism in the pituitary: Increased levels of free T\\n4\\n and T\\n3\\n inhibit TSH synthesis and\\nsecretion, whereas decreased levels increase TSH secretion. TSH secretion is also influenced by\\nthyrotropin-releasing hormone (TRH), which is synthesized in the hypothalamus. The precise\\nmechanisms regulating TRH synthesis and release are unclear, although negative feedback from thyroid\\nhormones inhibits TRH synthesis.\\nMost circulating T\\n3\\n is produced outside the thyroid by monodeiodination of T\\n4\\n. Only one fifth of\\ncirculating T\\n3\\n is secreted directly by the thyroid.\\nLaboratory Testing of Thyroid Function\\nTSH measurement is the best means of determining thyroid dysfunction (see\\nTable 93-1\\n). Normal results essentially rule out hyperthyroidism or hypothyroidism, except in rare patients\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n901'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 911, 'page_label': '902'}, page_content=\"with pituitary resistance to thyroid hormone or with central hypothyroidism due to disease in the\\nhypothalamus, pituitary gland, or both. Serum TSH can be falsely low in very sick people. The serum\\nTSH level also defines the syndromes of subclinical hyperthyroidism (low serum TSH) and subclinical\\nhypothyroidism (elevated serum TSH), both\\n[\\nTable 93-1.\\n Results of Thyroid Function Tests in Various Clinical Situations]\\nof which are characterized by normal serum T\\n4\\n, free T\\n4\\n, serum T\\n3\\n, and free T\\n3\\n levels.\\nTotal serum T\\n4\\n is a measure of bound and free hormone. Changes in levels of thyroid hormone-binding\\nserum proteins produce corresponding changes in total T\\n4\\n, even though levels of physiologically active\\nfree T\\n4\\n are unchanged. Thus, a patient may be physiologically normal but have an abnormal total serum\\nT\\n4\\n level. Free T\\n4\\n in the serum can be measured directly, avoiding the pitfalls of interpreting total T\\n4\\nlevels.\\nFree T\\n4\\n index is a calculated value that corrects total T\\n4\\n for the effects of varying amounts of thyroid\\nhormone-binding serum proteins and thus gives an estimate of free T\\n4\\n when total T\\n4\\n is measured. The\\nthyroid hormone-binding ratio or T\\n3\\n resin uptake is used to estimate protein binding. Free T\\n4\\n index is\\nreadily available and compares well with direct measurement of free T\\n4\\n.\\nTotal serum T\\n3\\n and free T\\n3\\n can also be measured. Because T\\n3\\n is tightly bound to TBG (although 10\\ntimes less so than T\\n4\\n), total serum T\\n3\\n levels are influenced by alterations in serum TBG level and by\\ndrugs that affect binding to TBG. Free T\\n3\\n levels in the serum are measured by the same direct and\\nindirect methods (free T\\n3\\n index) described for T\\n4\\n and are used mainly for evaluating thyrotoxicosis.\\nTBG can be measured; it is increased in pregnancy, by estrogen therapy or oral contraceptive use, and in\\nthe acute phase of infectious hepatitis. TBG may also be increased by an X-linked abnormality. It is most\\ncommonly decreased by illnesses that reduce hepatic protein synthesis, use of anabolic steroids, and\\nexcessive corticosteroid use. Large doses of certain drugs, such as phenytoin and aspirin and their\\nderivatives, displace T\\n4\\n from its binding sites on TBG, which spuriously lowers total serum T\\n4\\n levels.\\nAutoantibodies to thyroid peroxidase are present in almost all patients with Hashimoto's thyroiditis (some\\nof whom also have autoantibodies to thyroglobulin) and in most patients with Graves' disease. These\\nautoantibodies are markers of autoimmune disease but probably do not cause disease. However, an\\nautoantibody directed against the TSH receptor on the thyroid follicular cell is responsible for the\\nhyperthyroidism in Graves' disease. \\nAntibodies against T\\n4\\n and T\\n3\\n may be found in patients with\\nautoimmune thyroid disease and may affect T\\n4\\n and T\\n3\\n measurements but are rarely clinically significant.\\nThe thyroid is the only source of thyroglobulin, which is readily detectable in the serum of healthy people\\nand is usually elevated in patients with nontoxic or toxic goiter. The principal use of serum thyroglobulin\\nmeasurement is in evaluating patients after near-total or total thyroidectomy (with or without \\n131\\nI ablation)\\nfor differentiated thyroid cancer. Normal or elevated serum thyroglobulin values indicate the presence of\\nresidual normal or cancerous thyroid tissue in patients receiving TSH-suppressive doses of L-thyroxine or\\nafter withdrawal of L-thyroxine. However, thyroglobulin antibodies can interfere with thyroglobulin\\nmeasurement.\\nRadioactive iodine uptake can be measured. A trace amount of radioiodine is given orally or IV; a scanner\\nthen detects the amount of radioiodine taken up by the thyroid. The preferred radioiodine isotope is \\n123\\nI,\\nwhich exposes the patient to minimal radiation (much less than \\n131\\nI). Thyroid \\n123\\nI uptake varies widely\\nwith iodine ingestion and is low in patients exposed to excess iodine.\\nThe test is valuable in the differential diagnosis of hyperthyroidism (high uptake in Graves' disease, low\\nuptake in thyroiditissee p. \\n782\\n). It may also help in the calculation of the dose of \\n131\\nI needed for\\ntreatment of hyperthyroidism.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n902\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 912, 'page_label': '903'}, page_content=\"Imaging by a scintillation camera can be done after radioisotope administration (radioiodine or technetium\\n99m pertechnetate) to produce a graphic representation of isotope uptake. Focal areas of increased (hot)\\nor decreased (cold) uptake help distinguish areas of possible cancer (thyroid cancers exist in < 1% of hot\\nnodules compared with 10 to 20% of cold nodules).\\nScreening:\\n Screening every 5 yr by measuring serum TSH is recommended for all men  65 and for all\\nwomen  35. For those with risk factors for thyroid disease, the serum TSH should be checked more\\noften. Screening for hypothyroidism is as cost effective as screening for hypertension,\\nhypercholesterolemia, and breast cancer. This single test is highly sensitive and specific in diagnosing or\\nexcluding two prevalent and serious disorders (hypothyroidism and hyperthyroidism), both of which can\\nbe treated effectively. Because of the high incidence of hypothyroidism in older people, screening on an\\nannual basis is reasonable for those > age 70.\\nApproach to the Patient With a Thyroid Nodule\\nThyroid nodules are common, increasingly so with increasing age. The reported incidence varies with the\\nmethod of assessment. In middle-aged and elderly patients, palpation reveals nodules in about 5%.\\nResults of ultrasonography and autopsy studies suggest that nodules are present in about 50% of adults.\\nMany nodules are found incidentally on thyroid imaging studies done for other disorders.\\nEtiology\\nMost nodules are benign. Benign causes include hyperplastic colloid goiter, thyroid cysts, thyroiditis, and\\nthyroid adenomas. Malignant causes include thyroid cancers (see p. \\n789\\n).\\nEvaluation\\nHistory:\\n Pain suggests thyroiditis or hemorrhage into a cyst. An asymptomatic nodule may be malignant\\nbut is usually benign. Symptoms of hyperthyroidism suggest a hyperfunctioning adenoma or thyroiditis,\\nwhereas symptoms of hypothyroidism suggest Hashimoto's thyroiditis. Risk factors for thyroid cancer\\ninclude\\n History of thyroid irradiation, especially in infancy or childhood\\n Age < 20 yr\\n Male sex\\n Family history of thyroid cancer or multiple endocrine neoplasia\\n A solitary nodule\\n Dysphagia\\n Dysphonia\\n Increasing size (particularly rapid growth or growth while receiving thyroid suppression treatment)\\nPhysical examination:\\n Signs that suggest thyroid cancer include stony hard consistency or fixation to\\nsurrounding structures, cervical lymphadenopathy, and hoarseness due to recurrent laryngeal nerve\\nparalysis.\\nTesting:\\n Initial evaluation of a thyroid nodule consists of measurement of levels of\\n Thyroid-stimulating hormone (TSH)\\n Free thyroxine (T\\n4\\n)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n903\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 913, 'page_label': '904'}, page_content=\" Antithyroid peroxidase antibodies\\nIf TSH is suppressed, radioiodine scanning is done. Nodules with increased radionuclide uptake (hot) are\\nseldom malignant. If thyroid function tests do not indicate hyperthyroidism \\nor Hashimoto's thyroiditis, or if\\nnodules are indeterminate or cold, fine-needle aspiration biopsy is done to distinguish benign from\\nmalignant nodules. Early use of fine-needle aspiration biopsy is a more economic approach than routine\\nuse of radioiodine scans. Ultrasonography is useful in determining the size of the nodule but is rarely\\ndiagnostic of cancer, although cancer is suggested by ultrasonographic or x-ray evidence of fine,\\nstippled, psammomatous calcification (papillary carcinoma) or dense, homogeneous calcification\\n(medullary carcinoma). Fine-needle aspiration biopsy is not routinely indicated for nodules < 1 cm on\\nultrasonography.\\nTreatment\\nTreatment is directed at the underlying disorder. Thyroxine suppression of TSH to shrink smaller benign\\nnodules is effective in no more than half the cases.\\nEuthyroid Sick Syndrome\\nEuthyroid sick syndrome is low serum levels of thyroid hormones in clinically euthyroid\\npatients with nonthyroidal systemic illness. Diagnosis is based on excluding hypothyroidism.\\nTreatment is of the underlying illness; thyroid hormone replacement is not indicated\\n.\\nPatients with various acute or chronic nonthyroid disorders may have abnormal thyroid function tests.\\nSuch disorders include acute and chronic illness, particularly fasting, starvation, protein-energy\\nundernutrition, major trauma, MI, chronic renal failure, diabetic ketoacidosis, anorexia nervosa, cirrhosis,\\nthermal injury, and sepsis.\\nDecreased triiodothyronine (T\\n3\\n) levels are most common. Patients with more severe or prolonged illness\\nalso have decreased thyroxine (T\\n4\\n) levels. Serum reverse T\\n3\\n (rT\\n3\\n) is increased. Patients are clinically\\neuthyroid and do not have elevated thyroid-stimulating hormone (TSH) levels.\\nPathogenesis is unknown but may include decreased peripheral conversion of T\\n4\\n to T\\n3\\n, decreased\\nclearance of rT\\n3\\n generated from T\\n4\\n, and decreased binding of thyroid hormones to thyroxine-binding\\nglobulin (TBG). Proinflammatory cytokines (eg, tumor necrosis factor-\\n\\n, IL-1) may be responsible for\\nsome changes.\\nInterpretation of abnormal thyroid function test results in ill patients is complicated by the effects of\\nvarious drugs, including the iodine-rich contrast agents and amiodarone, which impairs the peripheral\\nconversion of T\\n4\\n to T\\n3\\n, and by drugs such as dopamine and corticosteroids, which decrease pituitary\\nsecretion of TSH, resulting in low serum TSH levels and subsequent decreased T\\n4\\n secretion.\\nDiagnosis\\n TSH\\n Serum cortisol\\n Clinical judgment\\nThe diagnostic dilemma is whether the patient has hypothyroidism or euthyroid sick syndrome. The best\\ntest is measurement of TSH, which in euthyroid sick syndrome is low, normal, or slightly elevated but not\\nas high as it would be in hypothyroidism. Serum rT\\n3\\n is elevated, although this measurement is rarely\\ndone. Serum cortisol is often elevated in euthyroid sick syndrome and low or low-normal in\\nhypothyroidism due to pituitary-hypothalamic disease. Because tests are nonspecific, clinical judgment is\\nrequired to interpret abnormal thyroid function tests in the acutely or chronically ill patient. Unless thyroid\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n904\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 914, 'page_label': '905'}, page_content=\"dysfunction is highly suspected, thyroid function tests should not be ordered for patients in the ICU.\\nTreatment\\nTreatment with thyroid hormone replacement is not appropriate. When the underlying disorder is treated,\\nresults of thyroid tests normalize.\\nHashimoto's Thyroiditis\\n(Autoimmune Thyroiditis; Chronic Lymphocytic Thyroiditis; Hashimoto's Struma)\\nHashimoto's thyroiditis is chronic autoimmune inflammation of the thyroid with lymphocytic\\ninfiltration. Findings include painless thyroid enlargement and symptoms of hypothyroidism.\\nDiagnosis involves demonstration of high titers of thyroid peroxidase antibodies. Lifelong L-\\nthyroxine replacement is typically required\\n.\\nHashimoto's thyroiditis is believed to be the most common cause of primary hypothyroidism in North\\nAmerica. It is twice as prevalent among women. Incidence increases with age and in patients with\\nchromosomal disorders, including Down, Turner's, and Klinefelter's syndromes. A family history of thyroid\\ndisorders is common.\\nHashimoto's thyroiditis, like Graves' disease, is sometimes associated with other autoimmune disorders,\\nincluding Addison's disease (adrenal insufficiency), type 1 diabetes mellitus, hypoparathyroidism, vitiligo,\\npremature graying of hair, pernicious anemia, connective tissue diseases (eg, RA, SLE, Sjogren's\\nsyndrome), and Schmidt's syndrome (Addison's disease, diabetes, and hypothyroidism secondary to\\nHashimoto's thyroiditis). There may be an increased incidence of thyroid tumors, rarely thyroid lymphoma.\\nPathologically, there is extensive infiltration of lymphocytes with lymphoid follicles and scarring.\\nSymptoms and Signs\\nPatients complain of painless enlargement of the thyroid or fullness in the throat. Examination reveals a\\nnontender goiter that is smooth or nodular, firm, and more rubbery than the normal thyroid. Many patients\\npresent with symptoms of hypothyroidism, but some present with hyperthyroidism.\\nDiagnosis\\n Thyroxine (T\\n4\\n)\\n Thyroid-stimulating hormone (TSH)\\n Thyroid autoantibodies\\nTesting consists of measuring T\\n4\\n, TSH, and thyroid autoantibodies; early in the disease T\\n4\\n and TSH\\nlevels are normal and there are high levels of thyroid peroxidase antibodies and less commonly of\\nantithyroglobulin antibodies. Thyroid radioactive iodine uptake may be increased, perhaps because of\\ndefective iodide organification together with a gland that continues to trap iodine. Patients later develop\\nhypothyroidism with decreased T\\n4\\n, decreased thyroid radioactive iodine uptake, and increased TSH.\\nTesting for other autoimmune disorders is warranted only when clinical manifestations are present.\\nTreatment\\nOccasionally, the hypothyroidism is transient, but most patients require lifelong thyroid hormone\\nreplacement, typically L-thyroxine 75 to 150 \\n\\ng po once/day.\\nHyperthyroidism\\n(Thyrotoxicosis)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n905\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 915, 'page_label': '906'}, page_content=\"Hyperthyroidism is characterized by hypermetabolism and elevated serum levels of free\\nthyroid hormones. Symptoms are many but include tachycardia, fatigue, weight loss,\\nnervousness, and tremor. Diagnosis is clinical and with thyroid function tests. Treatment\\ndepends on cause\\n.\\nHyperthyroidism can be classified on the basis of thyroid radioactive iodine uptake and the presence or\\nabsence of circulating thyroid stimulators (see \\nTable 93-1\\n).\\nEtiology\\nHyperthyroidism may result from increased synthesis and secretion of thyroid hormones (thyroxine [T\\n4\\n]\\nand triiodothyronine [T\\n3\\n]) from the thyroid, caused by thyroid stimulators in the blood or by autonomous\\nthyroid hyperfunction. It can also result from excessive release of thyroid hormone from the thyroid\\nwithout increased synthesis. Such release is commonly caused by the destructive changes of various\\ntypes of thyroiditis. Various clinical syndromes also cause hyperthyroidism.\\nGraves' disease (toxic diffuse goiter),\\n the most common cause of hyperthyroidism, is characterized by\\nhyperthyroidism and one or more of the following:\\n Goiter\\n Exophthalmos\\n Infiltrative dermopathy\\nGraves' disease is caused by an autoantibody against the thyroid receptor for thyroid-stimulating\\nhormone (TSH); unlike most autoantibodies, which are inhibitory, this autoantibody is stimulatory, thus\\ncausing continuous synthesis and secretion of excess T\\n4\\n and T\\n3\\n. Graves' disease (like Hashimoto's\\nthyroiditis) sometimes occurs with other autoimmune disorders, including type 1 diabetes mellitus, vitiligo,\\npremature graying of hair, pernicious anemia, connective tissue diseases, and polyglandular deficiency\\nsyndrome. The pathogenesis of infiltrative ophthalmopathy (responsible for the exophthalmos in Graves'\\ndisease) is poorly understood but may result from immunoglobulins directed to specific receptors in the\\norbital fibroblasts and fat that result in release of proinflammatory cytokines, inflammation, and\\naccumulation of glycosaminoglycans. Ophthalmopathy may also occur before the onset of\\nhyperthyroidism or as late as 20 yr afterward and frequently worsens or abates independently of the\\nclinical course of hyperthyroidism. Typical ophthalmopathy in the presence of normal thyroid function is\\ncalled euthyroid Graves' disease.\\nInappropriate TSH secretion\\n is a rare cause. Patients with hyperthyroidism have essentially\\nundetectable TSH except for those with a TSH-secreting anterior pituitary \\nadenoma or pituitary resistance\\nto thyroid hormone. TSH levels are high, and the TSH produced in both disorders is biologically more\\nactive than normal TSH. An increase in the \\n\\n-subunit of TSH in the blood (helpful in differential diagnosis)\\noccurs in patients with a TSH-secreting pituitary adenoma.\\nMolar pregnancy, choriocarcinoma, and hyperemesis gravidarum\\n produce high levels of serum\\nhuman chorionic gonadotropin (hCG), a weak thyroid stimulator. Levels of hCG are highest during the 1st\\ntrimester of pregnancy and result in the decrease in serum TSH and mild increase in serum free T\\n4\\nsometimes observed at that time. The increased thyroid stimulation may be caused by increased levels of\\npartially desialated hCG, an hCG variant that seems to be a more potent thyroid stimulator than more\\nsialated hCG. Hyperthyroidism in molar pregnancy, choriocarcinoma, and hyperemesis gravidarum is\\ntransient; normal thyroid function resumes when the molar pregnancy is evacuated, the choriocarcinoma\\nis appropriately treated, or the hyperemesis gravidarum abates.\\nNonautoimmune autosomal dominant hyperthyroidism\\n manifests during infancy. It results from\\nmutations in the TSH receptor gene that produce continuous thyroid stimulation.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n906\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 916, 'page_label': '907'}, page_content=\"Toxic solitary or multinodular goiter (Plummer's disease)\\n sometimes results from TSH receptor\\ngene mutations producing continuous thyroid stimulation. Patients with toxic nodular goiter have none of\\nthe autoimmune manifestations or circulating antibodies observed in patients with Graves' disease. Also,\\nin contrast to Graves' disease, toxic solitary and multinodular goiters usually do not remit.\\nInflammatory thyroid disease (thyroiditis)\\n includes subacute granulomatous thyroiditis, Hashimoto's\\nthyroiditis, and silent lymphocytic thyroiditis, a variant of Hashimoto's thyroiditis (see p. \\n787\\n).\\nHyperthyroidism results from destructive changes in the gland and release of stored hormone, not from\\nincreased synthesis. Hypothyroidism may follow.\\nDrug-induced hyperthyroidism\\n can result from amiodarone and interferon alfa, which may induce\\nthyroiditis with hyperthyroidism and other thyroid disorders. Although more commonly causing\\nhypothyroidism, lithium can rarely cause hyperthyroidism. Patients receiving these drugs should be\\nclosely monitored.\\nThyrotoxicosis factitia\\n is hyperthyroidism resulting from conscious or accidental overingestion of thyroid\\nhormone.\\nExcess iodine ingestion\\n causes hyperthyroidism with a low thyroid radioactive iodine uptake. It most\\noften occurs in patients with underlying nontoxic nodular goiter (especially elderly patients) who are given\\ndrugs that contain iodine (eg, amiodarone, iodine-containing expectorants) or who undergo radiologic\\nstudies using iodine-rich contrast agents. The etiology may be that the excess iodine provides substrate\\nfor functionally autonomous (ie, not under TSH regulation) areas of the thyroid to produce hormone.\\nHyperthyroidism usually persists as long as excess iodine remains in the circulation.\\nMetastatic thyroid cancer\\n is a possible cause. Overproduction of thyroid hormone occurs rarely from\\nfunctioning metastatic follicular carcinoma, especially in pulmonary metastases.\\nStruma ovarii\\n develops when ovarian teratomas contain enough thyroid tissue to cause true\\nhyperthyroidism. Radioactive iodine uptake occurs in the pelvis, and uptake by the thyroid is usually\\nsuppressed.\\nPathophysiology\\nIn hyperthyroidism, serum T\\n3\\n usually increases more than does T\\n4\\n, probably because of increased\\nsecretion of T\\n3\\n as well as conversion of T\\n4\\n to T\\n3\\n in peripheral tissues. In some patients, only T\\n3\\n is\\nelevated (T\\n3\\n toxicosis). T\\n3\\n toxicosis may occur in any of the usual disorders that cause hyperthyroidism,\\nincluding Graves' disease, multinodular goiter, and the autonomously functioning solitary thyroid nodule. If\\nT\\n3\\n toxicosis is untreated, the patient usually also develops laboratory abnormalities typical of\\nhyperthyroidism (ie, elevated T\\n4\\n and \\n123\\nI uptake). The various forms of thyroiditis commonly have a\\nhyperthyroid phase followed by a hypothyroid phase.\\nSymptoms and Signs\\nMost symptoms and signs are the same regardless of the cause. Exceptions include infiltrative\\nophthalmopathy and dermopathy, which occur only in Graves' disease.\\nThe clinical presentation may be dramatic or subtle. A goiter or nodule may be present. Many common\\nsymptoms and signs of hyperthyroidism are similar to those of adrenergic excess, such as nervousness,\\npalpitations, hyperactivity, increased sweating, heat hypersensitivity, fatigue, increased appetite, weight\\nloss, insomnia, weakness, and frequent bowel movements (occasionally diarrhea). Hypomenorrhea may\\nbe present. Signs may include warm, moist skin; tremor; tachycardia; widened pulse pressure; atrial\\nfibrillation; and palpitations.\\nElderly patients, particularly those with toxic nodular goiter, may present atypically (apathetic or masked\\nhyperthyroidism) with symptoms more akin to depression or dementia. Most do not have exophthalmos or\\ntremor. Atrial fibrillation, syncope, altered sensorium, heart failure, and weakness are more likely.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n907\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 917, 'page_label': '908'}, page_content=\"Symptoms and signs may involve only a single organ system.\\nEye signs include stare, eyelid lag, eyelid retraction, and mild conjunctival injection and are largely due to\\nexcessive adrenergic stimulation. They usually remit with successful treatment. Infiltrative\\nophthalmopathy, a more serious development, is specific to Graves' disease and can occur years before\\nor after hyperthyroidism. It is characterized by orbital pain, lacrimation, irritation, photophobia, increased\\nretro-orbital tissue, exophthalmos, and lymphocytic infiltration of the extraocular muscles, causing ocular\\nmuscle weakness that frequently leads to double vision.\\nInfiltrative dermopathy, also called pretibial myxedema (a confusing term, because myxedema suggests\\nhypothyroidism), is characterized by nonpitting infiltration by proteinaceous ground substance, usually in\\nthe pretibial area. It rarely occurs in the absence of Graves' ophthalmopathy. The lesion is often pruritic\\nand erythematous in its early stages and subsequently becomes brawny. Infiltrative dermopathy may\\nappear years before or after hyperthyroidism.\\nThyroid storm:\\n Thyroid storm is an acute form of hyperthyroidism that results from untreated or\\ninadequately treated severe hyperthyroidism. It is rare, occurring in patients with Graves' disease or toxic\\nmultinodular goiter (a solitary toxic nodule is less common and generally less severe). It may be\\nprecipitated by infection, trauma, surgery, embolism, diabetic ketoacidosis, or preeclampsia. Thyroid\\nstorm causes abrupt florid symptoms of hyperthyroidism with one or more of the following: fever, marked\\nweakness and muscle wasting, extreme restlessness with wide emotional swings, confusion, psychosis,\\ncoma, nausea, vomiting, diarrhea, and hepatomegaly with mild jaundice. The patient may present with\\ncardiovascular collapse and shock. \\nThyroid storm is a life-threatening emergency requiring prompt\\ntreatment.\\nDiagnosis\\n TSH\\n Free T\\n4\\n Sometimes radioactive iodine uptake\\nDiagnosis is based on history, physical examination, and thyroid function tests. Serum TSH measurement\\nis the best test, because TSH is suppressed in hyperthyroid patients except in the rare instance when the\\netiology is a TSH-secreting pituitary adenoma or pituitary resistance to thyroid hormone. Screening\\nselected populations for TSH level is warranted (see p. \\n776\\n). Free T\\n4\\n is increased in hyperthyroidism.\\nHowever, T\\n4\\n can be falsely normal in true hyperthyroidism in patients with a severe systemic illness\\n(similar to the falsely low levels that occur in euthyroid sick syndrome) and in T\\n3\\n toxicosis. If free T\\n4\\n level\\nis normal and TSH is low in a patient with subtle symptoms and signs of hyperthyroidism, then serum T\\n3\\nshould be measured to detect T\\n3\\n toxicosis; an elevated level confirms that diagnosis.\\nThe cause can often be diagnosed clinically (eg, exposure to a drug, the presence of signs specific to\\nGraves' disease). If not, thyroid radioactive iodine uptake may be obtained by using \\n123\\nI. When\\nhyperthyroidism is due to hormone overproduction, thyroid radioactive iodine uptake is usually elevated.\\nTSH receptor antibodies can be measured to detect Graves' disease, but measurement is rarely\\nnecessary except during the 3rd trimester of pregnancy to assess the risk of neonatal Graves' disease;\\nTSH receptor antibodies readily cross the placenta to stimulate the fetal thyroid. Most patients with\\nGraves' disease have circulating antithyroid peroxidase antibodies, and fewer have antithyroglobulin\\nantibodies.\\nInappropriate TSH secretion is uncommon. The diagnosis is confirmed when hyperthyroidism occurs with\\nelevated circulating free T\\n4\\n and T\\n3\\n concentrations and normal or elevated serum TSH.\\nIf thyrotoxicosis factitia is suspected, serum thyroglobulin can be measured; it is usually low or low-normal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n908\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 918, 'page_label': '909'}, page_content=\"unlike in all other causes of hyperthyroidism.\\nIn hyperthyroidism caused by excess iodine ingestion, low radioactive iodine uptake is typical because\\nthyroid radioactive iodine uptake is inversely proportional to iodine intake.\\nTreatment\\nTreatment depends on cause but may include\\n Propylthiouracil or methimazole\\n \\n\\n-Blockers\\n Iodine\\n Radioactive iodine\\n Surgery\\nIodine:\\n Iodine in pharmacologic doses inhibits the release of T\\n3\\n and T\\n4\\n within hours and inhibits the\\norganification of iodine, a transitory effect lasting from a few days to a week, after \\nwhich inhibition usually\\nceases. Iodine is used for emergency management of thyroid storm, for hyperthyroid patients undergoing\\nemergency nonthyroid surgery, and (because it also decreases the vascularity of the thyroid) for\\npreoperative preparation of hyperthyroid patients undergoing subtotal thyroidectomy. Iodine generally is\\nnot used for routine treatment of hyperthyroidism. The usual dosage is 2 to 3 drops (100 to 150 mg) of a\\nsaturated K iodide solution po tid or qid or 0.5 to 1 g Na iodide in 1 L 0.9% saline solution given IV slowly\\nq 12 h.\\nComplications of iodine therapy include inflammation of the salivary glands, conjunctivitis, and rash.\\nPropylthiouracil and methimazole:\\n These antithyroid drugs block thyroid peroxidase, decreasing the\\norganification of iodide, and impair the coupling reaction. Propylthiouracil in high doses also inhibits the\\nperipheral conversion of T\\n4\\n to T\\n3\\n. About 20 to 50% of patients with Graves' disease remain in remission\\nafter a 1- to 2-yr course of either drug. The return to normal or a marked decrease in gland size, the\\nrestoration of a normal serum TSH level, and less severe hyperthyroidism before therapy are good\\nprognostic signs of long-term remission. The concomitant use of antithyroid drug therapy and L-thyroxine\\ndoes not improve the remission rate in patients with Graves' disease. Because toxic nodular goiter rarely\\ngoes into remission, antithyroid drug therapy is given only in preparation for surgical treatment or \\n131\\nI\\ntherapy.\\nThe usual starting dosage of propylthiouracil is 100 to 150 mg po q 8 h and of methimazole 5 to 20 mg po\\ntid. When T\\n4\\n and T\\n3\\n levels normalize, the dosage is decreased to the lowest effective amount, usually\\npropylthiouracil 50 mg tid or methimazole 5 to 15 mg once/day. Usually, control is achieved in 2 to 3 mo.\\nMore rapid control can be achieved by increasing the dosage of propylthiouracil to 150 to 200 mg q 8 h.\\nSuch dosages or higher ones (up to 400 mg q 8 h) are generally reserved for severely ill patients,\\nincluding those with thyroid storm. Maintenance doses can be continued for one or many years\\ndepending on the clinical circumstances. Carbimazole, which is used widely in Europe, is rapidly\\nconverted to methimazole. The usual starting dose is similar to that of methimazole; maintenance dosage\\nis 5 to 20 mg po once/day, 2.5 to 10 mg bid, or 1.7 to 6.7 mg tid.\\nAdverse effects include rash, allergic reactions, abnormal liver function, and, in about 0.1% of patients,\\nreversible agranulocytosis. Patients allergic to one drug can be switched to the other, but cross-sensitivity\\nmay occur. If agranulocytosis occurs, the patient cannot be switched to the other drug; other therapy (eg,\\nradioiodine, surgery) should be used.\\nEach drug has advantages and disadvantages. Methimazole need only be given once/day, which\\nimproves adherence. Furthermore, when methimazole is used in dosages of < 40 mg/day, agranulocytosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n909\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 919, 'page_label': '910'}, page_content=\"is less common; with propylthiouracil, agranulocytosis may occur at any dosage. Propylthiouracil may be\\npreferred if antithyroid drugs must be used during pregnancy or breastfeeding because it is less likely to\\ncross the placenta or enter breast milk. Methimazole has been used successfully in pregnant and nursing\\nwomen without fetal or infant complications, but rarely methimazole has been associated with scalp and\\nGI defects in the neonate. Propylthiouracil is also preferred for the treatment of thyroid storm, because\\nthe dosages used (800 to 1200 mg/day) partially block the peripheral conversion of T\\n4\\n to T\\n3\\n.\\nThe combination of high-dose propylthiouracil and dexamethasone, also a potent inhibitor of T\\n4\\n to T\\n3\\nconversion, can relieve symptoms of hyperthyroidism and restore the serum T\\n3\\n level to normal within a\\nweek.\\n\\n-Blockers:\\n Symptoms and signs of hyperthyroidism due to adrenergic stimulation may respond to \\n\\n-\\nblockers; propranolol has had the greatest use, but atenolol or metoprolol may be preferable.\\nOther manifestations typically do not respond.\\n Manifestations typically responding to \\n\\n-blockers: Tachycardia, tremor, mental symptoms, eyelid lag;\\noccasionally heat intolerance and sweating, diarrhea, proximal myopathy\\n Manifestations typically not responding to \\n\\n-blockers: O\\n2\\n consumption, exophthalmos, goiter, bruit,\\ncirculating thyroxine levels, weight loss\\nPropranolol is indicated in thyroid storm (see\\nTable 93-2\\n). It rapidly decreases heart rate, usually within 2 to 3 h when given orally and within minutes\\nwhen given IV. Esmolol may be used in the ICU because it requires careful titration and monitoring.\\nPropranolol is also indicated for tachycardia with hyperthyroidism, especially in elderly patients, because\\nantithyroid drugs usually take several weeks to become fully effective. Ca channel blockers may control\\ntachyarrhythmias in patients in whom \\n\\n-blockers are contraindicated.\\nRadioactive sodium iodine (\\n131\\nI, radioiodine):\\n In the US, \\n131\\nI is the most common treatment for\\nhyperthyroidism. Radioiodine is often recommended as the treatment of choice for\\n[\\nTable 93-2.\\n Treatment of Thyroid Storm]\\nGraves' disease and toxic nodular goiter in all patients, including children. Dosage of \\n131\\nI is difficult to\\nadjust because the response of the gland cannot be predicted; some physicians give a standard dose of\\n8 to 10 mCi. Others adjust the dose based on estimated thyroid size and the 24-h uptake to provide a\\ndose of 80 to 120 \\n\\nCi/g thyroid tissue.\\nWhen sufficient \\n131\\nI is given to cause euthyroidism, about 25% of patients become hypothyroid 1 yr later,\\nand the incidence continues to increase yearly. Thus, most patients eventually become hypothyroid.\\nHowever, if smaller doses are used, incidence of recurrence is higher. Larger doses, such as 10 to 15\\nmCi, often cause hypothyroidism within 6 mo.\\nRadioactive iodine is not used during pregnancy. There is no proof that radioiodine increases the\\nincidence of tumors, leukemia, thyroid cancer, or birth defects in children born to women who become\\npregnant later in life.\\nSurgery:\\n Surgery is indicated for patients with Graves' disease whose hyperthyroidism has recurred after\\ncourses of antithyroid drugs and who refuse \\n131\\nI therapy, patients who cannot tolerate antithyroid drugs,\\npatients with very large goiters, and in some younger patients with toxic adenoma and multinodular goiter.\\nSurgery may be done in elderly patients with giant nodular goiters.\\nSurgery usually restores normal function. Postoperative recurrences vary between 2 and 16%; risk of\\nhypothyroidism is directly related to the extent of surgery and occurs in about one half of patients. Vocal\\ncord paralysis and hypoparathyroidism are uncommon complications. Saturated solution of K iodide 3\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n910\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 920, 'page_label': '911'}, page_content=\"drops (about 100 to 150 mg) po tid should be given for 10 days before surgery to reduce the vascularity\\nof the gland. Propylthiouracil or methimazole must also be given, because the patient should be euthyroid\\nbefore iodide is given. Dexamethasone can be added to rapidly restore euthyroidism. Surgical procedures\\nare more difficult in patients who previously underwent thyroidectomy or radioiodine therapy.\\nTreatment of thyroid storm:\\n A treatment regimen for thyroid storm is shown in \\nTable 93-2\\n.\\nTreatment of infiltrative dermopathy and ophthalmopathy:\\n In infiltrative dermopathy (in Graves'\\ndisease), topical corticosteroids sometimes relieve the pruritus. Dermopathy usually remits spontaneously\\nafter months or years. Ophthalmopathy should be treated jointly by the endocrinologist and\\nophthalmologist and may require corticosteroids, orbital radiation, and surgery.\\nSubclinical Hyperthyroidism\\nSubclinical hyperthyroidism is low serum TSH in patients with normal serum free T\\n4\\n and T\\n3\\n and\\nabsent or minimal symptoms of hyperthyroidism\\n.\\nSubclinical hyperthyroidism is far less common than subclinical hypothyroidism (see p. \\n787\\n). Patients with\\nserum TSH < 0.1 mU/L have an increased incidence of atrial fibrillation (particularly elderly patients),\\nreduced bone mineral density, increased fractures, and increased mortality. Patients with serum TSH that\\nis only slightly below normal are less likely to have these features. Many patients with subclinical\\nhyperthyroidism are taking L-thyroxine; in these patients, reduction of the dose is the most appropriate\\nmanagement unless therapy is aimed at maintaining a suppressed \\nTSH in patients with thyroid cancer or\\nnodules. The other causes of subclinical hyperthyroidism are the same as those for clinically apparent\\nhyperthyroidism.\\nTherapy is indicated for patients with endogenous subclinical hyperthyroidism (serum TSH < 0.1 mU/L),\\nespecially those with atrial fibrillation or reduced bone mineral density. The usual treatment is \\n131\\nI. In\\npatients with milder symptoms (eg, nervousness), a trial of antithyroid drug therapy is worthwhile.\\nHypothyroidism\\n(Myxedema)\\nHypothyroidism is thyroid hormone deficiency. It is diagnosed by clinical features such as a\\ntypical facies, hoarse slow speech, and dry skin and by low levels of thyroid hormones.\\nManagement includes treatment of the cause and administration of thyroxine\\n.\\nHypothyroidism occurs at any age but is particularly common among the elderly. It occurs in close to 10%\\nof women and 6% of men > 65. Although typically easy to diagnose in younger adults, it may be subtle\\nand manifest atypically in the elderly.\\nPrimary hypothyroidism:\\n Primary hypothyroidism is due to disease in the thyroid; thyroid-stimulating\\nhormone (TSH) is increased. The most common cause is probably autoimmune. It usually results from\\nHashimoto's thyroiditis and is often associated with a firm goiter or, later in the disease process, with a\\nshrunken fibrotic thyroid with little or no function. The 2nd most common cause is post-therapeutic\\nhypothyroidism, especially after radioactive iodine therapy or surgery for hyperthyroidism or goiter.\\nHypothyroidism during overtreatment with propylthiouracil, methimazole, and iodide abates after therapy\\nis stopped.\\nMost patients with non-Hashimoto's goiters are euthyroid or have hyperthyroidism, but goitrous\\nhypothyroidism may occur in endemic goiter. Iodine deficiency decreases thyroid hormonogenesis. In\\nresponse, TSH is released, which causes the thyroid to enlarge and trap iodine avidly; thus, goiter\\nresults. If iodine deficiency is severe, the patient becomes hypothyroid, a rare occurrence in the US since\\nthe advent of iodized salt.\\nIodine deficiency can cause endemic cretinism in children; endemic cretinism is the most common cause\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n911\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 921, 'page_label': '912'}, page_content=\"of congenital hypothyroidism in severely iodine-deficient regions and a major cause of mental deficiency\\nworldwide.\\nRare inherited enzymatic defects can alter the synthesis of thyroid hormone and cause goitrous\\nhypothyroidism (see p. \\n2887\\n).\\nHypothyroidism may occur in patients taking lithium, perhaps because lithium inhibits hormone release by\\nthe thyroid. Hypothyroidism may also occur in patients taking amiodarone or other iodine-containing\\ndrugs, and in patients taking interferon alfa. Hypothyroidism can result from radiation therapy for cancer\\nof the larynx or Hodgkin lymphoma (Hodgkin's disease). The incidence of permanent hypothyroidism after\\nradiation therapy is high, and thyroid function (through measurement of serum TSH) should be evaluated\\nat 6- to 12-mo intervals.\\nSecondary hypothyroidism:\\n Secondary hypothyroidism occurs when the hypothalamus produces\\ninsufficient thyrotropin-releasing hormone (TRH) or the pituitary produces insufficient TSH. Sometimes,\\ndeficient TSH secretion due to deficient TRH secretion is termed tertiary hypothyroidism.\\nSymptoms and Signs\\nSymptoms and signs of primary hypothyroidism are often subtle and insidious. Symptoms may include\\ncold intolerance, constipation, forgetfulness, and personality changes. Modest weight gain is largely the\\nresult of fluid retention and decreased metabolism. Paresthesias of the hands and feet are common, often\\ndue to carpal-tarsal tunnel syndrome caused by deposition of proteinaceous ground substance in the\\nligaments around the wrist and ankle. Women with hypothyroidism may develop menorrhagia or\\nsecondary amenorrhea.\\nThe facial expression is dull; the voice is hoarse and speech is slow; facial puffiness and periorbital\\nswelling occur due to infiltration with the mucopolysaccharides hyaluronic acid and chondroitin sulfate;\\neyelids droop because of decreased adrenergic drive; hair is sparse, coarse, and dry; and the skin is\\ncoarse, dry, scaly, and thick. The relaxation phase of deep tendon reflexes is slowed. Hypothermia is\\ncommon. Dementia or frank psychosis (myxedema madness) may occur.\\nCarotenemia is common, particularly notable on the palms and soles, caused by deposition of carotene in\\nthe lipid-rich epidermal layers. Deposition of proteinaceous ground substance in the tongue may cause\\nmacroglossia. A decrease in both thyroid hormone and adrenergic stimulation causes bradycardia. The\\nheart may be enlarged, partly because of dilation but chiefly because of pericardial effusion. Pleural or\\nabdominal effusions also may be noted. The pericardial and pleural effusions \\ndevelop slowly and only\\nrarely cause respiratory or hemodynamic distress.\\nElderly patients have significantly fewer symptoms than do younger adults, and complaints are often\\nsubtle and vague. Many elderly patients with hypothyroidism present with nonspecific geriatric syndromes\\nconfusion, anorexia, weight loss, falling, incontinence, and decreased mobility. Musculoskeletal\\nsymptoms (especially arthralgias) occur often, but arthritis is rare. Muscular aches and weakness, often\\nmimicking polymyalgia rheumatica or polymyositis, and an elevated CK level may occur. In the elderly,\\nhypothyroidism may mimic dementia or parkinsonism.\\nAlthough secondary hypothyroidism is uncommon, its causes often affect other endocrine organs\\ncontrolled by the hypothalamic-pituitary axis. In a woman with hypothyroidism, indications of secondary\\nhypothyroidism are a history of amenorrhea rather than menorrhagia and some suggestive differences on\\nphysical examination. Secondary hypothyroidism is characterized by skin and hair that are dry but not\\nvery coarse, skin depigmentation, only minimal macroglossia, atrophic breasts, and low BP. Also, the\\nheart is small, and serous pericardial effusions do not occur. Hypoglycemia is common because of\\nconcomitant adrenal insufficiency or growth hormone deficiency.\\nMyxedema coma:\\n Myxedema coma is a life-threatening complication of hypothyroidism, usually\\noccurring in patients with a long history of hypothyroidism. Its characteristics include coma with extreme\\nhypothermia (temperature 24 to 32.2 C), areflexia, seizures, and respiratory depression with CO\\n2\\nretention. Severe hypothermia may be missed unless low-reading thermometers are used. Rapid\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n912\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 922, 'page_label': '913'}, page_content='diagnosis based on clinical judgment, history, and physical examination is imperative, because death is\\nlikely without rapid treatment. Precipitating factors include illness, infection, trauma, drugs that suppress\\nthe CNS, and exposure to cold.\\nDiagnosis\\n TSH\\n Free thyroxine (T\\n4\\n)\\nSerum TSH is the most sensitive test, and screening of selected populations is warranted (see p. \\n776\\n). In\\nprimary hypothyroidism, there is no feedback inhibition of the intact pituitary, and serum TSH is always\\nelevated, whereas serum free T\\n4\\n is low. In secondary hypothyroidism, free T\\n4\\n and serum TSH are low\\n(sometimes TSH is normal but with decreased bioactivity).\\nMany patients with primary hypothyroidism have normal circulating levels of triiodothyronine (T\\n3\\n),\\nprobably caused by sustained TSH stimulation of the failing thyroid, resulting in preferential synthesis and\\nsecretion of biologically active T\\n3\\n. Therefore, serum T\\n3\\n is not sensitive for hypothyroidism.\\nAnemia is often present, usually normocytic-normochromic and of unknown etiology, but it may be\\nhypochromic because of menorrhagia and sometimes macrocytic because of associated pernicious\\nanemia or decreased absorption of folate. Anemia is rarely severe (Hb > 9 g/dL). As the hypometabolic\\nstate is corrected, anemia subsides, sometimes requiring 6 to 9 mo.\\nSerum cholesterol is usually high in primary hypothyroidism but less so in secondary hypothyroidism.\\nIn addition to primary and secondary hypothyroidism, other conditions may cause decreased levels of\\ntotal T\\n4\\n, such as serum thyroxine-binding globulin (TBG) deficiency, some drugs (see p. \\n785\\n), and\\neuthyroid sick syndrome (see p. \\n779\\n).\\nTreatment\\n L-Thyroxine, adjusted until TSH levels are in midnormal range\\nVarious thyroid hormone preparations are available for replacement therapy, including synthetic\\npreparations of T\\n4\\n (L-thyroxine), T\\n3\\n (liothyronine), combinations of the 2 synthetic hormones, and\\ndesiccated animal thyroid extract. L-Thyroxine is preferred; the usual maintenance dose is 75 to 150 \\n\\ng\\npo once/day, depending on age, body mass index, and absorption (for pediatric doses, see p. \\n2888\\n).\\nTherapy is begun with low doses, especially in the elderly, usually 25 \\n\\ng once/day. The dose is adjusted\\nevery 6 wk until maintenance dose is achieved. The maintenance dose may need to be decreased in\\nelderly patients and increased in pregnant women. Dose may also need to be increased if drugs that\\ndecrease T\\n4\\n absorption or increase its biliary excretion are administered concomitantly. The dose used\\nshould be the lowest that restores serum TSH levels to the midnormal range (though this criterion cannot\\nbe used in patients with secondary hypothyroidism).\\nLiothyronine should not be used alone for long-term replacement because of its short half-life and the\\nlarge peaks in serum T\\n3\\n levels it produces. The administration of standard replacement amounts (25 to\\n37.5 \\n\\ng bid) results in rapidly increasing serum T\\n3\\n to between 300 and 1000 ng/dL (4.62 to 15.4 nmol/L)\\nwithin \\n4 h due to its almost complete absorption; these levels return to normal by 24 h. Additionally,\\npatients receiving liothyronine are chemically hyperthyroid for at least several hours a day, potentially\\nincreasing cardiac risks.\\nSimilar patterns of serum T\\n3\\n occur when mixtures of T\\n3\\n and T\\n4\\n are taken po, although peak T\\n3\\n is lower\\nbecause less T\\n3\\n is given. Replacement regimens with synthetic T\\n4\\n preparations reflect a different pattern\\nin serum T\\n3\\n response. Increases in serum T\\n3\\n occur gradually, and normal levels are maintained when\\nadequate doses of T\\n4\\n are given. Desiccated animal thyroid preparations contain variable amounts of T\\n3\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n913'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 923, 'page_label': '914'}, page_content='and T\\n4\\n and should not be prescribed unless the patient is already taking the preparation and has normal\\nserum TSH.\\nIn patients with secondary hypothyroidism, L-thyroxine should not be given until there is evidence of\\nadequate cortisol secretion (or cortisol therapy is given), because L-thyroxine could precipitate adrenal\\ncrisis.\\nMyxedema coma:\\n Myxedema coma is treated as follows:\\n T\\n4\\n given IV\\n Corticosteroids\\n Supportive care as needed\\n Conversion to oral T\\n4\\n when patient is stable\\nPatients require a large initial dose of T\\n4\\n (300 to 500 \\n\\ng IV) or T\\n3\\n (25 to 50 \\n\\ng IV). The IV maintenance\\ndose of T\\n4\\n is 75 to 100 \\n\\ng once/day and of T\\n3\\n, 10 to 20 \\n\\ng bid until T\\n4\\n can be given orally.\\nCorticosteroids are also given, because the possibility of central hypothyroidism usually cannot be initially\\nruled out. The patient should not be rewarmed rapidly, which may precipitate hypotension or arrhythmias.\\nHypoxemia is common, so PaO\\n2\\n should be monitored. If ventilation is compromised, immediate\\nmechanical ventilatory assistance is required. The precipitating factor should be rapidly and appropriately\\ntreated and fluid replacement given carefully, because hypothyroid patients do not excrete water\\nappropriately. Finally, all drugs should be given cautiously because they are metabolized more slowly than\\nin healthy people.\\nSubclinical Hypothyroidism\\nSubclinical hypothyroidism is elevated serum TSH in patients with absent or minimal symptoms\\nof hypothyroidism and normal serum levels of free T\\n4\\n.\\nSubclinical thyroid dysfunction is relatively common; it occurs in more than 15% of elderly women and\\n10% of elderly men, particularly in those with underlying Hashimoto\\'s thyroiditis.\\nIn patients with serum TSH > 10 mU/L, there is a high likelihood of progression to overt hypothyroidism\\nwith low serum levels of free T\\n4\\n in the next 10 yr. These patients are also more likely to have\\nhypercholesterolemia and atherosclerosis. They should be treated with L-thyroxine, even if they are\\nasymptomatic. For patients with TSH levels between 4.5 and 10 mU/L, a trial of L-thyroxine is reasonable\\nif symptoms of early hypothyroidism (eg, fatigue, depression) are present. L-Thyroxine therapy is also\\nindicated in pregnant women and in women who plan to become pregnant to avoid deleterious effects of\\nhypothyroidism on the pregnancy and fetal development. Patients should have annual measurement of\\nserum TSH and free T\\n4\\n to assess progress of the condition if untreated or to adjust the L-thyroxine\\ndosage.\\nSilent Lymphocytic Thyroiditis\\nSilent lymphocytic thyroiditis is a self-limited, subacute disorder occurring most commonly in\\nwomen during the postpartum period. Symptoms are initially of hyperthyroidism, then\\nhypothyroidism, and then generally recovery to the euthyroid state. Treatment of the\\nhyperthyroid phase is with a \\n\\n-blocker. If hypothyroidism is permanent, lifelong thyroxine\\nsupplementation is needed\\n.\\nThe term \"silent\" refers to the absence of thyroid tenderness in contrast with subacute thyroiditis, which\\nusually causes thyroid tenderness. Silent lymphocytic thyroiditis causes most cases of postpartum thyroid\\ndysfunction. It occurs in about 5 to 10% of postpartum women.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n914'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 924, 'page_label': '915'}, page_content=\"Thyroid biopsy reveals lymphocytic infiltration as in Hashimoto's thyroiditis but without lymphoid follicles\\nand scarring. Thyroid peroxidase autoantibodies and, less commonly, antithyroglobulin antibodies are\\nalmost always positive during pregnancy and the postpartum period. Thus, this disorder would seem to\\nbe a variant of Hashimoto's thyroiditis (see p. \\n779\\n).\\nSymptoms and Signs\\nThe condition begins in the postpartum period, usually within 12 to 16 wk. Silent lymphocytic thyroiditis is\\ncharacterized by a variable degree of painless thyroid enlargement with a hyperthyroid phase of several\\nweeks, often followed by transient hypothyroidism due to depleted thyroid hormone stores but usually\\neventual recovery to the euthyroid state (as noted for painful subacute thyroiditis). The hyperthyroid\\nphase is self-limited and may be brief or overlooked. Many women with this disorder are diagnosed when\\nthey become hypothyroid, which occasionally is permanent.\\nDiagnosis\\n Clinical evaluation\\n Serum thyroxine (T\\n4\\n), triiodothyronine (T\\n3\\n), and thyroid-stimulating hormone (TSH) levels\\nSilent lymphocytic thyroiditis is frequently undiagnosed. Suspicion of the diagnosis generally depends on\\nclinical findings, typically once hypothyroidism has occurred. Eye signs and pretibial myxedema do not\\noccur.\\nThyroid function test results vary depending on the phase of illness. Initially, serum T\\n4\\n and T\\n3\\n are\\nelevated and TSH is suppressed. In the hypothyroid phase, these findings are reversed. WBC count and\\nESR are normal. Needle biopsy provides definitive diagnosis but is usually unnecessary.\\nTreatment\\n Usually a \\n\\n-blocker\\n Sometimes thyroid hormone replacement\\nBecause silent lymphocytic thyroiditis lasts only a few months, treatment is conservative, usually requiring\\nonly a \\n\\n-blocker (eg, propranolol) during the hyperthyroid phase (see p. \\n783\\n). Antithyroid drugs, surgery,\\nand radioiodine therapy are contraindicated. Thyroid hormone replacement may be required during the\\nhypothyroid phase. Most patients recover normal thyroid function, although some remain permanently\\nhypothyroid. Therefore, thyroid function should be reevaluated after 9 to 12 mo of thyroxine therapy;\\nreplacement is stopped for 5 wk, and TSH is remeasured. This disorder usually recurs after subsequent\\npregnancies.\\nSubacute Thyroiditis\\n(de Quervain's Thyroiditis; Giant Cell Thyroiditis; Granulomatous Thyroiditis)\\nSubacute thyroiditis is an acute inflammatory disease of the thyroid probably caused by a virus.\\nSymptoms include fever and thyroid tenderness. Initial hyperthyroidism is common,\\nsometimes followed by a transient period of hypothyroidism. Diagnosis is clinical and with\\nthyroid function tests. Treatment is with high doses of NSAIDs or with corticosteroids. The\\ndisease usually resolves spontaneously within months\\n.\\nHistory of an antecedent viral URI is common. Histologic studies show less lymphocytic infiltration of the\\nthyroid than in Hashimoto's thyroiditis or silent thyroiditis, but there is characteristic giant cell infiltration,\\nPMNs, and follicular disruption.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n915\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 925, 'page_label': '916'}, page_content=\"There is pain in the anterior neck and fever of 37.8 to 38.3 C. Neck pain characteristically shifts from\\nside to side and may settle in one area, frequently radiating to the jaw and ears. It is often confused with\\ndental pain, pharyngitis, or otitis and is aggravated by swallowing or turning of the head. Symptoms of\\nhyperthyroidism are common early in the disease because of hormone release from the disrupted\\nfollicles. There is more lassitude and prostration than in other thyroid disorders. On physical examination,\\nthe thyroid is asymmetrically enlarged, firm, and tender.\\nDiagnosis\\n Clinical findings\\n Free thyroxine (T\\n4\\n) and thyroid-stimulating hormone (TSH) levels\\n ESR\\n Radioactive iodine uptake\\nDiagnosis is primarily clinical, based on finding an enlarged, tender thyroid in patients with the\\nappropriate clinical history. Thyroid testing with TSH and at least a free T\\n4\\n measurement is usually also\\ndone. Radioactive iodine uptake should be measured to confirm the diagnosis. When the diagnosis is\\nuncertain, finer needle aspiration biopsy is useful. Thyroid ultrasonography with color Doppler shows\\nreduced blood flow in contrast with the increased flow of Graves' disease. Laboratory findings early in the\\ndisease include an increase in free T\\n4\\n and triiodothyronine (T\\n3\\n), a marked decrease in TSH and thyroid\\nradioactive iodine uptake (often 0), and a high ESR. After several weeks, the thyroid is depleted of T\\n4\\nand T\\n3\\n stores, and transient hypothyroidism develops accompanied by a decrease in free T\\n4\\n and T\\n3\\n, a\\nrise in TSH, and recovery of thyroid radioactive iodine uptake. Weakly positive thyroid antibodies may be\\npresent. Measurement of free T\\n4\\n, T\\n3\\n, and TSH at 2- to 4-wk intervals identifies the stages of the\\ndisease.\\nPrognosis\\nSubacute thyroiditis is self-limited, generally subsiding in a few months; occasionally, it \\nrecurs and may\\nresult in permanent hypothyroidism when follicular destruction is extensive.\\nTreatment\\n NSAIDs\\n Sometimes corticosteroids, a \\n\\n-blocker, or both\\nDiscomfort is treated with high doses of aspirin or NSAIDs. In severe and protracted cases,\\ncorticosteroids (eg, prednisone 30 to 40 mg po once/day, gradually decreasing the dose over 3 to 4 wk)\\neradicate all symptoms within 48 h.\\nBothersome hyperthyroid symptoms may be treated with a short course of a \\n\\n-blocker. If hypothyroidism\\nis pronounced or persists, thyroid hormone replacement therapy may be required, rarely permanently.\\nSimple Nontoxic Goiter\\n(Euthyroid Goiter)\\nSimple nontoxic goiter, which may be diffuse or nodular, is noncancerous hypertrophy of the\\nthyroid without hyperthyroidism, hypothyroidism, or inflammation. Except in severe iodine\\ndeficiency, thyroid function is normal and patients are asymptomatic except for an obviously\\nenlarged, nontender thyroid. Diagnosis is clinical and with determination of normal thyroid\\nfunction. Treatment is directed at the underlying cause, but partial surgical removal may be\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n916\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 926, 'page_label': '917'}, page_content=\"required for very large goiters\\n.\\nSimple nontoxic goiter, the most common type of thyroid enlargement, is frequently noted at puberty,\\nduring pregnancy, and at menopause. The cause at these times is usually unclear. Known causes include\\nintrinsic thyroid hormone production defects and, in iodine-deficient countries, ingestion of foods that\\ncontain substances that inhibit thyroid hormone synthesis (goitrogens, eg, cassava, broccoli, cauliflower,\\ncabbage). Other causes include the use of drugs that can decrease the synthesis of thyroid hormone (eg,\\namiodarone or other iodine-containing compounds, lithium).\\nIodine deficiency is rare in North America but remains the most common cause of goiter worldwide\\n(termed endemic goiter). Compensatory small elevations in thyroid-stimulating hormone (TSH) occur,\\npreventing hypothyroidism, but the TSH stimulation results in goiter formation. Recurrent cycles of\\nstimulation and involution may result in nontoxic nodular goiters. However, the true etiology of most\\nnontoxic goiters in iodine-sufficient areas is unknown.\\nSymptoms and Signs\\nThe patient may have a history of low iodine intake or overingestion of food goitrogens, but these\\nphenomena are rare in North America. In the early stages, the goiter is typically soft, symmetric, and\\nsmooth. Later, multiple nodules and cysts may develop.\\nDiagnosis\\n Thyroidal radioactive iodine uptake\\n Thyroid scan\\n Thyroxine (T\\n4\\n), triiodothyronine (T\\n3\\n), and TSH levels\\nIn the early stages, thyroidal radioactive iodine uptake may be normal or high with normal thyroid scans.\\nThyroid function tests are usually normal. Thyroid antibodies are measured to rule out Hashimoto's\\nthyroiditis.\\nIn endemic goiter, serum TSH may be slightly elevated, and serum T\\n4\\n may be low-normal or slightly low,\\nbut serum T\\n3\\n is usually normal or slightly elevated.\\nTreatment\\n Depends on cause\\nIn iodine-deficient areas, iodine supplementation of salt; oral or IM administration of iodized oil yearly; and\\niodination of water, crops, or animal fodder eliminates iodine-deficiency goiter. Goitrogens being ingested\\nshould be stopped.\\nIn other instances, suppression of the hypothalamic-pituitary axis with thyroid hormone blocks TSH\\nproduction (and hence stimulation of the thyroid). Full TSH-suppressive doses of L-thyroxine (100 to 150\\n\\ng/day po depending on the serum TSH) are useful in younger patients. L-Thyroxine is contraindicated in\\nolder patients with nontoxic nodular goiter, because these goiters rarely shrink and may harbor areas of\\nautonomy so that L-thyroxine therapy can result in hyperthyroidism. Large goiters occasionally require\\nsurgery or \\n131\\nI to shrink the gland enough to prevent interference with respiration or swallowing or to\\ncorrect cosmetic problems.\\nThyroid Cancers\\nThe 4 general types of thyroid cancer are papillary, follicular, medullary, and anaplastic. Papillary\\nand follicular carcinoma together are called differentiated thyroid cancer because of their\\nhistologic resemblance to normal thyroid tissue and because differentiated function (eg,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n917\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 927, 'page_label': '918'}, page_content='thyroglobulin secretion) is preserved. Most thyroid \\ncancers manifest as asymptomatic nodules.\\nRarely, lymph node, lung, or bone metastases cause the presenting symptoms of small thyroid\\ncancers. Diagnosis is often by fine-needle aspiration biopsy but may involve other tests. Except\\nfor anaplastic and metastatic medullary carcinoma, most thyroid cancers are not highly\\nmalignant and are seldom fatal. Treatment is surgical removal, usually followed by ablation of\\nresidual tissue with radioactive iodine\\n.\\nPapillary Carcinoma\\nPapillary carcinoma accounts for 70 to 80% of all thyroid cancers. The female:male ratio is 3:1. It may be\\nfamilial in up to 5% of patients. Most patients present between ages 30 and 60. The tumor is often more\\naggressive in elderly patients. Many papillary carcinomas contain follicular elements.\\nThe tumor spreads via lymphatics to regional lymph nodes in one third of patients and may metastasize to\\nthe lungs. Patients < 45 yr with small tumors confined to the thyroid have an excellent prognosis.\\nTreatment\\n Surgical resection\\n Sometimes radioactive iodine\\nTreatment for encapsulated tumors < 1.5 cm localized to one lobe is usually near-total thyroidectomy,\\nalthough some experts recommend only lobectomy and isthmectomy; surgery is almost always curative.\\nThyroid hormone in thyroid-stimulating hormone (TSH)-suppressive doses is given to minimize chances\\nof regrowth and cause regression of any microscopic remnants of papillary carcinoma.\\nTumors > 4 cm or that are diffusely spreading require total or near-total thyroidectomy with postoperative\\nradioiodine ablation of residual thyroid tissue with appropriately large doses of \\n131\\nI administered when\\nthe patient is hypothyroid or after recombinant TSH injections. Treatment may be repeated every 6 to 12\\nmo to ablate any remaining thyroid tissue. TSH-suppressive doses of L-thyroxine are given after\\ntreatment, and serum thyroglobulin levels help detect recurrent or persistent disease. About 20 to 30% of\\npatients, mainly older patients, have recurrent or persistent disease.\\nFollicular Carcinoma\\nFollicular carcinoma, including the Hurthle cell variant, accounts for about 15% of thyroid cancers. It is\\nmore common among older patients and in regions of iodine deficiency. It is more malignant than papillary\\ncarcinoma, spreading hematogenously with distant metastases.\\nTreatment requires near-total thyroidectomy with postoperative radioiodine ablation of residual thyroid\\ntissue as in treatment for papillary carcinoma. Metastases are more responsive to radioiodine therapy\\nthan are those of papillary carcinoma. TSH-suppressive doses of L-thyroxine are given after treatment.\\nSerum thyroglobulin should be monitored to detect recurrent or persistent disease.\\nMedullary Carcinoma\\nMedullary (solid) carcinoma constitutes about 3% of thyroid cancers and is composed of parafollicular\\ncells (C cells) that produce calcitonin. It may be sporadic (usually unilateral); however, it is often familial,\\ncaused by a mutation of the \\nret\\n proto-oncogene. The familial form may occur in isolation or as a\\ncomponent of multiple endocrine neoplasia (MEN) syndromes types 2A and 2B (see pp. \\n912\\n and \\n913\\n).\\nAlthough calcitonin can lower serum Ca and phosphate, serum Ca is normal because the high level of\\ncalcitonin ultimately down-regulates its receptors. Characteristic amyloid deposits that stain with Congo\\nred are also present.\\nMetastases spread via the lymphatic system to cervical and mediastinal nodes and sometimes to liver,\\nlungs, and bone.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n918'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 928, 'page_label': '919'}, page_content=\"Symptoms and Signs\\nPatients typically present with an asymptomatic thyroid nodule, although many cases are now diagnosed\\nduring routine screening of affected kindreds with MEN-2A or MEN-2B before a palpable tumor develops.\\nMedullary carcinoma may have a dramatic biochemical presentation when associated with ectopic\\nproduction of other hormones or peptides (eg, ACTH, vasoactive intestinal polypeptide, prostaglandins,\\nkallikreins, serotonin).\\nDiagnosis\\n Serum calcitonin levels\\nThe best test is measurement of serum calcitonin, which is greatly elevated. A challenge with Ca (15\\nmg/kg IV over 4 h) provokes excessive secretion of calcitonin. X-rays may show a dense, homogenous,\\nconglomerate calcification.\\nAll patients with medullary carcinoma should have genetic testing; relatives of those with mutations\\nshould have genetic testing and measurement of basal and stimulated calcitonin levels.\\nTreatment\\n Surgical resection\\nTotal thyroidectomy is indicated even if bilateral involvement is not obvious. Lymph nodes are also\\ndissected. If hyperparathyroidism is present, removal of hyperplastic or adenomatous parathyroids is\\nrequired. Pheochromocytoma, if present, is usually bilateral. Pheochromocytomas should be identified\\nand removed before thyroidectomy because of the danger of provoking hypertensive crisis during the\\noperation. Long-term survival is common in patients with medullary carcinoma and MEN-IIA; more than\\ntwo thirds of affected patients are alive at 10 yr. Medullary carcinoma of the sporadic type has a worse\\nprognosis.\\nRelatives with an elevated calcitonin level without a palpable thyroid abnormality should undergo\\nthyroidectomy, because there is a greater chance of cure at this stage. Some experts recommend surgery\\nin relatives who have normal basal and stimulated serum calcitonin levels but who have the \\nret\\n proto-\\noncogene mutation.\\nAnaplastic Carcinoma\\nAnaplastic carcinoma is an undifferentiated cancer that accounts for about 2% of thyroid cancers. It\\noccurs mostly in elderly patients and slightly more often in women. The tumor is characterized by rapid,\\npainful enlargement. Rapid enlargement of the thyroid may also suggest thyroid lymphoma, particularly if\\nfound in association with Hashimoto's thyroiditis.\\nNo effective therapy exists, and the disease is generally fatal. About 80% of patients die within 1 yr of\\ndiagnosis. In a few patients with smaller tumors, thyroidectomy followed by external radiation has been\\ncurative. Chemotherapy is mainly experimental.\\nRadiation-Induced Thyroid Cancer\\nThyroid tumors develop in people exposed to large amounts of environmental thyroid radiation, as occurs\\nfrom atomic bomb blasts, nuclear reactor accidents, or incidental thyroid irradiation due to radiation\\ntherapy. Tumors may be detected 10 yr after exposure, but risk remains increased for 30 to 40 yr. Such\\ntumors are usually benign; however, about 10% are papillary thyroid carcinoma. The tumors are\\nfrequently multicentric or diffuse.\\nPatients who had thyroid irradiation should undergo yearly thyroid palpation, ultrasonography, and\\nmeasurement of thyroid autoantibodies (to exclude Hashimoto's thyroiditis). A thyroid scan does not\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n919\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 929, 'page_label': '920'}, page_content='always reflect areas of involvement.\\nIf ultrasonography reveals a nodule, fine-needle aspiration biopsy should be done. In the absence of\\nsuspicious or malignant lesions, many physicians recommend lifelong TSH-lowering doses of thyroid\\nhormone to suppress thyroid function and thyrotropin secretion and possibly decrease the chance of\\ndeveloping a thyroid tumor.\\nSurgery is required if fine-needle aspiration biopsy suggests cancer. Near-total or total thyroidectomy is\\nthe treatment of choice, to be followed by radioiodine ablation of any residual thyroid tissue if a cancer is\\nfound (depending on the size, histology, and invasiveness).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 93. Thyroid Disorders\\n920'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 930, 'page_label': '921'}, page_content='Chapter 94. Adrenal Disorders\\nIntroduction\\nThe adrenal glands, located on the cephalad portion of each kidney, consist of a cortex and medulla,\\neach with separate endocrine functions.\\nCortex:\\n The adrenal cortex produces glucocorticoids (primarily cortisol), mineralocorticoids (primarily\\naldosterone), and androgens (primarily dehydroepiandrosterone and androstenedione). Physiology of the\\nhypothalamic-pituitary-adrenocortical system is further discussed in \\nCh. 91\\n.\\nGlucocorticoids promote and inhibit gene transcription in many cells and organ systems. Prominent\\neffects include anti-inflammatory actions and increased hepatic gluconeogenesis.\\nMineralocorticoids regulate electrolyte transport across epithelial surfaces, particularly renal conservation\\nof Na in exchange for K.\\nAdrenal androgens\\' chief physiologic activity occurs after conversion to testosterone and\\ndihydrotestosterone.\\nMedulla:\\n The adrenal medulla is composed of chromaffin cells, which synthesize and secrete\\ncatecholamines (mainly epinephrine and lesser amounts of norepinephrine). Chromaffin cells also\\nproduce bioactive amines and peptides (eg, histamine, serotonin, chromogranins, neuropeptide\\nhormones). Epinephrine and norepinephrine, the major effector amines of the \\nsympathetic nervous\\nsystem, are responsible for the \"flight or fight\" response (ie, chronotropic and inotropic effects on the\\nheart; bronchodilation; peripheral and splanchnic vasoconstriction with skeletal muscular vasodilation;\\nmetabolic effects including glycogenolysis, lipolysis, and renin release).\\nClinical syndromes:\\n Most deficiency syndromes affect output of all adrenocortical hormones.\\nHypofunction may be primary (malfunction of the adrenal gland itself, as in Addison\\'s disease) or\\nsecondary (due to lack of adrenal stimulation by the pituitary or hypothalamus, although some experts\\nrefer to hypothalamic malfunction as tertiary).\\nHyperfunction causes distinct clinical syndromes. Hypersecretion of androgens results in adrenal virilism;\\nof glucocorticoids, Cushing\\'s syndrome; and of aldosterone, hyperaldosteronism (aldosteronism). These\\nsyndromes frequently have overlapping features. Hyperfunction may be compensatory, as in congenital\\nadrenal hyperplasia (see p. \\n2889\\n), or due to acquired hyperplasia, adenomas, or adenocarcinomas.\\nExcess quantities of epinephrine and norepinephrine are produced in pheochromocytoma.\\nAddison\\'s Disease\\n(Primary or Chronic Adrenocortical Insufficiency)\\nAddison\\'s disease is an insidious, usually progressive hypofunctioning of the adrenal cortex. It\\ncauses various symptoms, including hypotension and hyperpigmentation, and can lead to\\nadrenal crisis with cardiovascular collapse. Diagnosis is clinical and by finding elevated plasma\\nACTH with low plasma cortisol. Treatment depends on the cause but generally includes\\nhydrocortisone and sometimes other hormones\\n.\\nAddison\\'s disease develops in about 4/100,000 annually. It occurs in all age groups, about equally in each\\nsex, and tends to become clinically apparent during metabolic stress or trauma. Onset of severe\\nsymptoms (adrenal crisis) may be precipitated by acute infection (a common cause, especially with\\nsepticemia). Other causes include trauma, surgery, and Na loss from excessive sweating. With treatment,\\nAddison\\'s disease should not typically reduce life expectancy.\\nEtiology\\nAbout 70% of cases in the US are due to idiopathic atrophy of the adrenal cortex, probably caused by\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n921'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 931, 'page_label': '922'}, page_content=\"autoimmune processes. The remainder result from destruction of the adrenal gland by granuloma (eg,\\nTB), tumor, amyloidosis, hemorrhage, or inflammatory necrosis. Hypoadrenocorticism can also result from\\nadministration of drugs that block corticosteroid synthesis (eg, ketoconazole, the anesthetic etomidate).\\nAddison's disease may coexist with diabetes mellitus or hypothyroidism in polyglandular deficiency\\nsyndrome (see p. \\n804\\n). In children, the most common cause of primary adrenal insufficiency is congenital\\nadrenal hyperplasia (CAHsee also \\nCongenital Adrenal Hyperplasia\\n on p. \\n2889\\n).\\nPathophysiology\\nBoth mineralocorticoids and glucocorticoids are deficient.\\nMineralocorticoid deficiency:\\n Because mineralocorticoids stimulate Na reabsorption and K excretion,\\ndeficiency results in increased excretion of Na and decreased excretion of K, chiefly in urine but also in\\nsweat, saliva, and the GI tract. A low serum concentration of Na and a high concentration of K result.\\nInability to concentrate the urine, combined with changes in electrolyte balance, cause severe\\ndehydration, plasma hypertonicity, acidosis, decreased circulatory volume, hypotension, and, eventually,\\ncirculatory collapse. However, when adrenal insufficiency is caused by inadequate ACTH production\\n(secondary adrenal insufficiencysee p. \\n795\\n), electrolyte levels are often normal or only mildly deranged.\\nGlucocorticoid deficiency:\\n Glucocorticoid deficiency contributes to hypotension and causes severe\\ninsulin sensitivity and disturbances in carbohydrate, fat, and protein metabolism. In the absence of\\ncortisol, insufficient carbohydrate is formed from protein; hypoglycemia and diminished liver glycogen\\nresult. Weakness follows, due in part to deficient neuromuscular function. Resistance to infection, trauma,\\nand other stress is diminished. Myocardial weakness and dehydration reduce cardiac output, and\\ncirculatory failure can occur. Decreased blood cortisol results in increased pituitary ACTH production and\\nincreased blood \\n\\n-lipotropin, which has melanocyte-stimulating activity and, together with ACTH, causes\\nthe hyperpigmentation of skin and mucous membranes characteristic of Addison's disease. Thus, adrenal\\ninsufficiency secondary to pituitary failure (see p. \\n795\\n) does not cause hyperpigmentation.\\nSymptoms and Signs\\nWeakness, fatigue, and orthostatic hypotension are early symptoms and signs. \\nHyperpigmentation is\\ncharacterized by diffuse tanning of exposed and, to a lesser extent, unexposed portions of the body,\\nespecially on pressure points (bony prominences), skin folds, scars, and extensor surfaces. Black\\nfreckles are common on the forehead, face, neck, and shoulders. Areas of vitiligo develop, as do bluish\\nblack discolorations of the areolae and mucous membranes of the lips, mouth, rectum, and vagina.\\nAnorexia, nausea, vomiting, and diarrhea often occur. Decreased tolerance to cold, with hypometabolism,\\nmay be noted. Dizziness and syncope may occur. The gradual onset and nonspecific nature of early\\nsymptoms often lead to an incorrect initial diagnosis of neurosis. Weight loss, dehydration, and\\nhypotension are characteristic of the later stages of Addison's disease.\\nAdrenal crisis:\\n Adrenal crisis is characterized by profound asthenia; severe pain in the abdomen, lower\\nback, or legs; peripheral vascular collapse; and, finally, renal shutdown with azotemia. Body temperature\\nmay be low, although severe fever often occurs, particularly when crisis is precipitated by acute infection.\\nA significant number of patients with partial loss of adrenal function (limited adrenocortical reserve)\\nappear well but experience adrenal crisis when under physiologic stress (eg, surgery, infection, burns,\\ncritical illness). Shock and fever may be the only signs.\\nDiagnosis\\n Electrolytes\\n Serum cortisol\\n Serum ACTH\\n Sometimes ACTH stimulation testing\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n922\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 932, 'page_label': '923'}, page_content=\"Clinical symptoms and signs suggest adrenal insufficiency. Sometimes the diagnosis is considered only\\non discovery of characteristic abnormalities of serum electrolytes, including low Na (< 135 mEq/L), high K\\n(> 5 mEq/L), low HCO\\n3\\n (15 to 20 mEq/L), and high BUN (see\\nTable 94-1\\n).\\nDifferential diagnosis:\\n Hyperpigmentation can result from bronchogenic carcinoma, ingestion of heavy\\nmetals (eg, iron, silver), chronic skin conditions, or hemochromatosis. Peutz-Jeghers syndrome is\\ncharacterized by pigmentation of the buccal and rectal mucosa. Frequently, hyperpigmentation occurs\\nwith vitiligo, which may indicate Addison's disease, although other diseases can cause this association.\\nWeakness resulting from Addison's disease subsides with rest, unlike neuropsychiatric weakness, which\\nis often worse in the morning than after activity. Most myopathies that cause weakness can be\\ndifferentiated by their distribution, lack of abnormal pigmentation, and characteristic laboratory findings.\\n[\\nTable 94-1.\\n Test Results that Suggest Addison's Disease]\\nPatients with adrenal insufficiency develop hypoglycemia after fasting because of decreased\\ngluconeogenesis. In contrast, patients with hypoglycemia due to oversecretion of insulin can have attacks\\nat any time, usually have increased appetite with weight gain, and have normal adrenal function. Low\\nserum Na due to Addison's disease must be differentiated from that of edematous patients with cardiac or\\nliver disease (particularly those taking diuretics), the dilutional hyponatremia of the syndrome of\\ninappropriate ADH secretion, and salt-losing nephritis. These patients are not likely to have\\nhyperpigmentation, hyperkalemia, and increased BUN.\\nTesting:\\n Laboratory tests, beginning with serum cortisol and ACTH levels, confirm adrenal insufficiency.\\nElevated ACTH ( 50 pg/mL) with low cortisol (< 5 \\n\\ng/dL [< 138 nmol/L]) is diagnostic, particularly in\\npatients who are severely stressed or in shock. Low ACTH (< 5 pg/mL) and cortisol suggest secondary\\nadrenal insufficiency (see p. \\n795\\n); it is important \\nto note that ACTH levels within the normal range are\\ninappropriate for very low cortisol levels.\\nIf ACTH and cortisol levels are borderline and adrenal insufficiency is clinically suspectedparticularly in\\na patient who is about to undergo major surgeryprovocative testing must be done. If time is too short\\n(eg, emergency surgery), the patient is given hydrocortisone empirically (eg, 100 mg IV or IM), and\\nprovocative testing is done subsequently.\\nAddison's disease is diagnosed by showing failure of exogenous ACTH to increase serum cortisol.\\nSecondary adrenal insufficiency is diagnosed by a prolonged ACTH stimulation test, insulin tolerance\\ntest, or glucagon test.\\nACTH stimulation testing is done by injecting cosyntropin (synthetic ACTH) 250 \\n\\ng IV or IM. Some\\nauthorities believe that in patients with suspected secondary adrenal insufficiency, a low-dose ACTH\\nstimulation test using 1 \\n\\ng IV instead of the standard 250 \\n\\ng should be done, because such patients may\\nreact normally to the higher dose. Patients taking glucocorticoid supplements or spironolactone should\\nnot take them on the day of the test. Normal preinjection serum cortisol ranges from 5 to 25 \\n\\ng/dL (138 to\\n690 nmol/L) and doubles in 30 to 90 min, reaching at least 20 \\n\\ng/dL (552 nmol/L). Patients with Addison's\\ndisease have low or low-normal values that do not rise above 20 \\n\\ng/dL at 30 min. A normal response to\\ncosyntropin may occur in secondary adrenal insufficiency. However, because pituitary failure may cause\\nadrenal atrophy (and hence failure to respond to ACTH), the patient may need to be primed with long-\\nacting ACTH 1 mg IM once/day for 3 days before the cosyntropin test if pituitary disease is suspected.\\nA prolonged ACTH stimulation test (sampling for 24 h) may be used to diagnose secondary (or tertiary\\nhypothalamic) adrenal insufficiency. Cosyntropin 1 mg IM is given and cortisol measured at intervals for\\n24 h. Results for the first hour are similar for both the short (sampling stopped after 1 h) and prolonged\\ntests, but in Addison's disease there is no further rise beyond 60 min. In secondary and tertiary adrenal\\ninsufficiency, cortisol levels continue to rise for  24 h. Only in cases of prolonged adrenal atrophy is\\nadrenal priming (with long-acting ACTH) necessary. The simple short test is usually done initially, because\\na normal response obviates the need for further investigation.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n923\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 933, 'page_label': '924'}, page_content=\"If adrenal crisis is suspected, confirmation of Addison's disease by ACTH stimulation testing is deferred\\nuntil the patient has recovered. If ACTH stimulation testing is done, elevated ACTH levels together with\\nlow cortisol levels confirm the diagnosis.\\nIn Western societies, the cause is usually assumed to be autoimmune, unless there is evidence\\notherwise. Adrenal autoantibodies can be assessed. A chest x-ray should be done for TB; if doubt exists,\\nCT of the adrenals is helpful. In patients with autoimmune disease, the adrenals are atrophied, whereas\\nin patients with TB or other granulomas, the adrenals are enlarged (initially) with frequent calcification.\\nBilateral adrenal hyperplasia suggests an enzyme defect.\\nTreatment\\n Hydrocortisone or prednisone\\n Fludrocortisone\\n Dose increase during intercurrent illness\\nNormally, cortisol is secreted maximally in the early morning and minimally at night. Thus, hydrocortisone\\n(identical to cortisol) is given in 2 or 3 divided doses with a typical total daily dose of 15 to 30 mg. One\\nregimen gives half the total in the morning, and the remaining half split between lunchtime and early\\nevening (eg, 10 mg, 5 mg, 5 mg). Others give two thirds in the morning and one third in the evening.\\nDoses immediately before retiring should generally be avoided because they may cause insomnia.\\nAlternatively, prednisone 5 mg po in the morning and 2.5 mg po in the evening may be used. Additionally,\\nfludrocortisone 0.1 to 0.2 mg po once/day is recommended to replace aldosterone. The easiest way to\\nadjust the dosage is to ensure that the renin level is within the normal range. Normal hydration and\\nabsence of orthostatic hypotension are evidence of adequate replacement therapy. In some patients,\\nfludrocortisone causes hypertension, which is treated by reducing the dosage or starting a nondiuretic\\nantihypertensive. Some clinicians tend to give too little fludrocortisone in an effort to avoid use of\\nantihypertensives.\\nIntercurrent illnesses (eg, infections) are potentially serious and should be vigorously treated; the patient's\\nhydrocortisone dose should be doubled during the illness. If nausea and vomiting preclude oral therapy,\\nparenteral therapy is necessary. Patients should be instructed when to take supplemental prednisone and\\ntaught to self-administer parenteral hydrocortisone for urgent situations. A preloaded syringe with 100 mg\\nhydrocortisone should be available to the patient. A bracelet or wallet card giving the diagnosis and\\ncorticosteroid \\ndose may help in case of adrenal crisis that renders the patient unable to communicate.\\nWhen salt loss is severe, as in very hot climates, the dose of fludrocortisone may need to be increased.\\nIn coexisting diabetes mellitus and Addison's disease, the hydrocortisone dose usually should not be > 30\\nmg/day; otherwise, insulin requirements are increased.\\nAdrenal crisis:\\n Therapy should be instituted immediately upon suspicion. (CAUTION: \\nIn adrenal crisis, a\\ndelay in instituting corticosteroid therapy, particularly if there is hypoglycemia and hypotension, may be\\nfatal.\\n) If the patient is acutely ill, confirmation by an ACTH stimulation test should be postponed until the\\npatient has recovered.\\nHydrocortisone 100 mg is injected IV over 30 sec and repeated q 6 to 8 h for the first 24 h. Immediate\\nintravascular volume expansion is done by giving 1 L of a 5% dextrose in 0.9% saline solution over 1 to 2\\nh. Additional 0.9% saline is given IV until hypotension, dehydration, and hyponatremia have been\\ncorrected. Serum K may fall during rehydration, requiring replacement. Mineralocorticoids are not\\nrequired when high-dose hydrocortisone is given. When illness is less acute, hydrocortisone 50 or 100\\nmg can be given IM q 6 h. Restoration of BP and general improvement should occur within 1 h after the\\ninitial dose of hydrocortisone. Inotropic agents may be needed until the effects of hydrocortisone are\\nachieved.\\nA total dose of 150 mg hydrocortisone is usually given over the 2nd 24-h period if the patient has\\nimproved markedly, and 75 mg is given on the 3rd day. Maintenance oral doses of hydrocortisone (15 to\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n924\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 934, 'page_label': '925'}, page_content=\"30 mg) and fludrocortisone (0.1 mg) are given daily thereafter, as described above. Recovery depends on\\ntreatment of the underlying cause (eg, infection, trauma, metabolic stress) and adequate hydrocortisone\\ntherapy.\\nFor patients with some residual adrenal function who develop adrenal crisis when under stress,\\nhydrocortisone treatment is the same, but fluid requirements may be much lower.\\nTreatment of complications:\\n Fever > 40.6 C occasionally accompanies the rehydration process.\\nExcept in the presence of falling BP, antipyretics (eg, aspirin 650 mg) may be given po with caution.\\nComplications of corticosteroid therapy may include psychotic reactions. If psychotic reactions occur after\\nthe first 12 h of therapy, the hydrocortisone dose should be reduced to the lowest level consistent with\\nmaintaining BP and good cardiovascular function. Antipsychotics may be temporarily required, but use\\nshould not be prolonged.\\nSecondary Adrenal Insufficiency\\nSecondary adrenal insufficiency is adrenal hypofunction due to a lack of ACTH. Symptoms are\\nthe same as for Addison's disease, but there is usually less hypovolemia (see p. \\n792\\n). Diagnosis\\nis clinical and by laboratory findings, including low plasma ACTH with low plasma cortisol.\\nTreatment depends on the cause but generally includes hydrocortisone\\n.\\nSecondary adrenal insufficiency may occur in panhypopituitarism, in isolated failure of ACTH production,\\nin patients receiving corticosteroids, or after corticosteroids are stopped. Inadequate ACTH can also\\nresult from failure of the hypothalamus to stimulate pituitary ACTH production, which is sometimes called\\ntertiary adrenal insufficiency.\\nPanhypopituitarism (see p. \\n762\\n) may occur secondary to pituitary tumors; craniopharyngioma in younger\\npeople; and various tumors, granulomas, and, rarely, infection or trauma that destroys pituitary tissue.\\nPatients receiving corticosteroids for > 4 wk may have insufficient ACTH secretion during metabolic stress\\nto stimulate the adrenals to produce adequate quantities of corticosteroids, or they may have atrophic\\nadrenals that are unresponsive to ACTH. These problems may persist for up to 1 yr after corticosteroid\\ntreatment is stopped.\\nSymptoms and Signs\\nSymptoms and signs are similar to those of Addison's disease (see p. \\n792\\n). Differentiating clinical or\\ngeneral laboratory features include the absence of hyperpigmentation and relatively normal electrolyte\\nand BUN levels; hyponatremia, if it occurs, is usually dilutional.\\nPatients with panhypopituitarism have depressed thyroid and gonadal function and hypoglycemia, and\\ncoma may supervene when symptomatic secondary adrenal insufficiency occurs. Adrenal crisis is\\nespecially likely if a patient is treated for a single endocrine gland problem, particularly with thyroxine,\\nwithout hydrocortisone replacement.\\nDiagnosis\\n Serum cortisol\\n Serum ACTH\\n ACTH stimulation testing\\n CNS imaging\\nTests to differentiate primary and secondary adrenal insufficiency are discussed under Addison's disease\\n(see p. \\n793\\n). Patients with \\nconfirmed secondary adrenal insufficiency should have CT or MRI of the brain\\nto rule out pituitary tumor or atrophy. Adequacy of the hypothalamic-pituitary-adrenal axis during tapering\\nor after stopping long-term corticosteroid treatment can be determined by injecting cosyntropin 250 \\n\\ng IV\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n925\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 935, 'page_label': '926'}, page_content=\"or IM. After 30 min, serum cortisol should be > 20 \\n\\ng/dL (> 552 nmol/L). An insulin stress test to induce\\nhypoglycemia and a rise in cortisol is the gold standard for testing integrity of the hypothalamic-pituitary-\\nadrenal axis.\\nThe corticotropin-releasing hormone (CRH) test can be used to distinguish between hypothalamic and\\npituitary causes but is rarely used in clinical practice. After administration of CRH 100 \\n\\ng (or 1 \\n\\ng/kg) IV,\\nthe normal response is a rise of serum ACTH of 30 to 40 pg/mL; patients with pituitary failure do not\\nrespond, whereas those with hypothalamic disease usually do.\\nTreatment\\n Hydrocortisone or prednisone\\n Fludrocortisone not indicated\\n Dose increase during intercurrent illness\\nGlucocorticoid replacement is similar to that described for Addison's disease. Each case varies regarding\\nthe type and degree of specific hormone deficiencies. Fludrocortisone is not required because the intact\\nadrenals produce aldosterone. During acute febrile illness or after trauma, patients receiving\\ncorticosteroids for nonendocrine disorders may require supplemental doses to augment their endogenous\\nhydrocortisone production. In panhypopituitarism, other pituitary deficiencies should be treated\\nappropriately (see p. \\n766\\n).\\nAdrenal Virilism\\n(Adrenogenital Syndrome)\\nAdrenal virilism is a syndrome in which excessive adrenal androgens cause virilization.\\nDiagnosis is clinical and confirmed by elevated androgen levels with and without\\ndexamethasone suppression; determining the cause may involve adrenal imaging. Treatment\\ndepends on the cause\\n.\\nAdrenal virilism is caused by an androgen-secreting adrenal tumor or by adrenal hyperplasia. Malignant\\nadrenal tumors may secrete excess androgens, cortisol, or mineralocorticoids (or all three), resulting in\\nCushing's syndrome (see p. \\n797\\n) with suppression of ACTH secretion and atrophy of the contralateral\\nadrenal as well as hypertension. Adrenal hyperplasia is usually congenital; delayed virilizing adrenal\\nhyperplasia is a variant of congenital adrenal hyperplasia (see p. \\n2889\\n). Both are caused by a defect in\\nhydroxylation of cortisol precursors; cortisol precursors accumulate and are shunted into the production\\nof androgens. The defect is only partial in delayed virilizing adrenal hyperplasia, so clinical disease may\\nnot develop until adulthood.\\nSymptoms and Signs\\nEffects depend on the patient's sex and age at onset and are more noticeable in women than in men.\\nSymptoms and signs include hirsutism (sometimes the only sign in mild cases), baldness, acne, and\\ndeepening of the voice. Libido may increase. In prepubertal children, growth may accelerate. If untreated,\\npremature epiphyseal closure and short stature occur. Affected prepubertal males may experience\\npremature sexual maturation. Females may have amenorrhea, atrophy of the uterus, clitoral hypertrophy,\\ndecreased breast size, and increased muscularity. In adult men, the excess adrenal androgens may\\nsuppress gonadal function and cause infertility. Ectopic adrenal tissue in the testes may enlarge and\\nsimulate tumors.\\nDiagnosis\\n Testosterone\\n Other adrenal androgens (dehydroepiandrosterone sulfate [DHEAS], androstenedione)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n926\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 936, 'page_label': '927'}, page_content=\" Dexamethasone suppression test\\n Adrenal imaging\\n 17-hydroxyprogesterone\\nAdrenal virilism is suspected clinically, although mild hirsutism and virilization with hypomenorrhea and\\nelevated plasma testosterone may also occur in polycystic ovary (Stein-Leventhal) syndrome (see p.\\n2514\\n). Adrenal virilism is confirmed by showing elevated levels of adrenal androgens. In adrenal\\nhyperplasia, urinary dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) are elevated, pregnanetriol\\nexcretion is often increased, and urinary free cortisol is normal or diminished. Plasma DHEA, DHEAS, 17-\\nhydroxyprogesterone, testosterone, and androstenedione may be elevated. A level of > 30 nmol/L of 17-\\nhydroxyprogesterone 30 min after administration of cosyntropin 0.25 mg IM strongly suggests the most\\ncommon form of adrenal hyperplasia.\\nVirilizing tumors are excluded if dexamethasone 0.5 mg po q 6 h for 48 h suppresses production of excess\\nandrogens. If excessive \\nandrogen excretion is not suppressed, CT or MRI of the adrenals and\\nultrasonography of the ovaries are done to search for a tumor.\\nTreatment\\n Oral corticosteroids for hyperplasia\\n Removal of tumors\\nRecommended treatment for adrenal hyperplasia is dexamethasone 0.5 to 1 mg po at bedtime, but even\\nthese small doses may cause signs of Cushing's syndrome. Cortisol 25 mg po once/day or prednisone 5\\nto 10 mg po once/day can be used instead. Although most symptoms and signs of virilism disappear,\\nhirsutism and baldness disappear slowly, the voice may remain deep, and fertility may be impaired.\\nTumors require adrenalectomy. For patients with cortisol-secreting tumors, hydrocortisone should be\\ngiven preoperatively and postoperatively because their nontumerous adrenal cortex will be atrophic and\\nsuppressed.\\nCushing's Syndrome\\nCushing's syndrome is a constellation of clinical abnormalities caused by chronic high blood\\nlevels of cortisol or related corticosteroids. Cushing's disease is Cushing's syndrome that\\nresults from excess pituitary production of ACTH, usually secondary to a pituitary adenoma.\\nTypical symptoms include moon facies and truncal obesity with thin arms and legs. Diagnosis is\\nby history of receiving corticosteroids or by finding elevated serum cortisol. Treatment\\ndepends on the cause\\n.\\nEtiology\\nHyperfunction of the adrenal cortex can be ACTH dependent or ACTH independent. ACTH-dependent\\nhyperfunction may result from\\n Hypersecretion of ACTH by the pituitary gland\\n Secretion of ACTH by a nonpituitary tumor, such as small cell carcinoma of the lung or a carcinoid tumor\\n(ectopic ACTH syndrome)\\n Administration of exogenous ACTH\\nACTH-independent hyperfunction usually results from therapeutic administration of corticosteroids or from\\nadrenal adenomas or carcinomas. Rare causes include primary pigmented nodular adrenal dysplasia\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n927\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 937, 'page_label': '928'}, page_content=\"(usually in adolescents) and macronodular dysplasia (in older patients).\\nWhereas the term Cushing's syndrome denotes the clinical picture resulting from cortisol excess from any\\ncause, Cushing's disease refers to hyperfunction of the adrenal cortex from pituitary ACTH excess.\\nPatients with Cushing's disease usually have a small adenoma of the pituitary gland.\\nSymptoms and Signs\\nClinical manifestations include moon facies with a plethoric appearance (see\\nPlate 22\\n), truncal obesity with prominent supraclavicular and dorsal cervical fat pads (buffalo hump), and,\\nusually, very slender distal extremities and fingers. Muscle wasting and weakness are present. The skin is\\nthin and atrophic, with poor wound healing and easy bruising. Purple striae may appear on the abdomen.\\nHypertension, renal calculi, osteoporosis, glucose intolerance, reduced resistance to infection, and\\nmental disturbances are common. Cessation of linear growth is characteristic in children. Females usually\\nhave menstrual irregularities. In females with adrenal tumors, increased production of androgens may\\nlead to hypertrichosis, temporal balding, and other signs of virilism.\\nDiagnosis\\n Dexamethasone suppression test\\n Urinary free cortisol (UFC) level\\n ACTH levels; if detectable, provocative testing\\nDiagnosis is usually suspected based on the characteristic symptoms and signs. Confirmation (and\\nidentification of the cause) generally requires hormonal and imaging tests.\\nIn some centers, testing begins with measurement of UFC, the best assay for urinary excretion (normal,\\n20 to 100 \\n\\ng/24 h [55.2 to 276 nmol/24 h]). UFC is elevated > 120 \\n\\ng/24 h (> 331 nmol/24 h) in almost all\\npatients with Cushing's syndrome. However, many patients with UFC elevations between 100 and 150\\n\\ng/24 h (276 and 414 nmol/24 h) have obesity, depression, or polycystic ovaries but not Cushing's\\nsyndrome. A patient with suspected Cushing's syndrome with grossly elevated UFC (> 4 times the upper\\nlimit of normal) almost certainly has Cushing's syndrome. Two to 3 normal collections virtually exclude the\\ndiagnosis. Slightly elevated levels generally necessitate further investigation.\\nAn alternative approach to investigation uses the dexamethasone suppression test, in which 1, 1.5, or 2\\nmg of dexamethasone is given po at 11 to 12 PM and serum cortisol is measured at 8 to 9 AM the next\\nmorning. In most \\nnormal patients, this drug suppresses morning serum cortisol to  1.8 \\n\\ng/mL ( 50\\nnmol/L), whereas patients with Cushing's syndrome virtually always have a higher level. A more specific\\nbut equally sensitive test is to give dexamethasone 0.5 mg po q 6 h for 2 days (low dose). In general, a\\nclear failure to suppress levels in response to low-dose dexamethasone establishes the diagnosis.\\nIf results of these tests are indeterminate, the patient is hospitalized for measurement of serum cortisol at\\nmidnight, which is more likely to be conclusive. Cortisol normally ranges from 5 to 25 \\n\\ng/dL (138 to 690\\nnmol/L) in the early morning (6 to 8 AM) and declines gradually to < 1.8 \\n\\ng/dL (< 50 nmol/L) at midnight.\\nPatients with Cushing's syndrome occasionally have a normal morning cortisol level but lack normal\\ndiurnal decline in cortisol production, such that the midnight serum cortisol levels are above normal and\\nthe total 24-h cortisol production is elevated. Alternatively, salivary cortisol samples may be collected and\\nstored in the refrigerator at home. Serum cortisol may be spuriously elevated in patients with congenital\\nincreases of corticosteroid-binding globulin or in those receiving estrogen therapy, but diurnal variation is\\nnormal in these patients.\\nACTH levels are measured to determine the cause of Cushing's syndrome. Undetectable levels, both\\nbasally and particularly in response to corticotropin-releasing hormone (CRH), suggest a primary adrenal\\ncause. High levels suggest a pituitary cause. If ACTH is detectable (ACTH-dependent Cushing's\\nsyndrome), provocative tests help differentiate Cushing's disease from ectopic ACTH syndrome, which is\\nrarer. In response to high-dose dexamethasone (2 mg po q 6 h for 48 h), the 9 AM serum cortisol falls by\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n928\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 938, 'page_label': '929'}, page_content=\"> 50% in most patients with Cushing's disease but infrequently in those with ectopic ACTH syndrome.\\nConversely, ACTH rises by > 50% and cortisol rises by > 20% in response to human or ovine-sequence\\nCRH (100 \\n\\ng IV or 1 \\n\\ng/kg IV) in most patients with Cushing's disease but very rarely in those with ectopic\\nACTH syndrome (see\\nTable 94-2\\n). An alternative approach to localization, which is more accurate but more invasive, is to\\ncatheterize both petrosal veins (which drain the pituitary) and measure ACTH from these veins 5 min after\\na bolus of CRH 100 \\n\\ng or 1 \\n\\ng/kg. A central-to-peripheral ACTH ratio > 3 virtually excludes ectopic ACTH\\nsyndrome, whereas a ratio < 3 suggests a need to seek such a source.\\nPituitary imaging is done if ACTH levels and provocative tests suggest a pituitary cause; gadolinium-\\nenhanced MRI is most accurate, but some microadenomas are visible on CT. If testing suggests a\\nnonpituitary cause, imaging includes high-resolution CT of the chest, pancreas, and adrenals;\\nscintiscanning with radiolabeled octreotide; and PET scanning.\\nIn children with Cushing's disease, pituitary tumors are very small and usually cannot be detected with\\nMRI. Petrosal sinus sampling is particularly useful in this situation. MRI is preferred to CT in pregnant\\nwomen to avoid fetal exposure to radiation.\\nTreatment\\n Metyrapone or ketoconazole\\n Surgery or radiation to remove tumors\\n[\\nTable 94-2.\\n Diagnostic Tests in Cushing's Syndrome]\\nInitially, the patient's general condition should be supported by high protein intake and appropriate\\nadministration of K. If clinical manifestations are severe, it may be reasonable to block corticosteroid\\nsecretion with metyrapone 250 mg to 1 g po tid or ketoconazole 400 mg po once/day, increasing to a\\nmaximum of 400 mg tid. Ketoconazole is more readily available but slower in onset and sometimes\\nhepatotoxic.\\nPituitary tumors that produce excessive ACTH are removed surgically or extirpated with radiation. If no\\ntumor is shown on imaging but a pituitary source is likely, total hypophysectomy may be attempted,\\nparticularly in older patients. Younger patients usually receive supervoltage irradiation of the pituitary,\\ndelivering 45 Gy. Improvement usually occurs in < 1 yr. However, in children, irradiation may reduce\\nsecretion of growth hormone and occasionally cause precocious puberty. In special centers, heavy\\nparticle beam irradiation, providing about 100 Gy, is often successful, as is a single focused beam of\\nradiation therapy given as a single doseradiosurgery. Response to irradiation occasionally requires\\nseveral years, but response is more rapid in children.\\nBilateral adrenalectomy is reserved for patients with pituitary hyperadrenocorticism who do not respond to\\nboth pituitary exploration (with possible adenomectomy) and irradiation. Adrenalectomy requires life-long\\ncorticosteroid replacement.\\nNelson syndrome occurs when the pituitary gland continues to expand after adrenalectomy, causing a\\nmarked increase in the secretion of ACTH and its precursors, resulting in severe hyperpigmentation. It\\noccurs in  50% of patients who undergo adrenalectomy. The risk is probably reduced if the patient\\nundergoes pituitary radiation. Although irradiation may arrest continued pituitary growth, many patients\\nalso require hypophysectomy. The indications for hypophysectomy are the same as for any pituitary\\ntumor: an increase in size such that the tumor encroaches on surrounding structures, causing visual field\\ndefects, pressure on the hypothalamus, or other complications. Routine irradiation is often done after\\nhypophysectomy if it was not done previously, especially when a tumor is clearly present. Radiosurgery,\\nor focused radiation therapy, can be given in a single fraction when standard external beam radiation\\ntherapy has already been done, as long as the lesion is at a reasonable distance from the optic nerve and\\nchiasm.\\nAdrenocortical tumors are removed surgically. Patients must receive cortisol during the surgical and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n929\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 939, 'page_label': '930'}, page_content=\"postoperative periods because their nontumorous adrenal cortex will be atrophic and suppressed. Benign\\nadenomas can be removed laparoscopically. With multinodular adrenal hyperplasia, bilateral\\nadrenalectomy may be necessary. Even after a presumed total adrenalectomy, functional regrowth occurs\\nin a few patients.\\nEctopic ACTH syndrome is treated by removing the nonpituitary tumor that is producing the ACTH.\\nHowever, in some cases, the tumor is disseminated and cannot be excised. Adrenal inhibitors, such as\\nmetyrapone 500 mg po tid (and up to a total of 6 g/day) or mitotane 0.5 g po once/day, increasing to a\\nmaximum of 3 to 4 g/day, usually control severe metabolic disturbances (eg, hypokalemia). When\\nmitotane is used, large doses of hydrocortisone or dexamethasone may be needed. Measures of cortisol\\nproduction may be unreliable, and severe hypercholesterolemia may develop. Ketoconazole 400 to 1200\\nmg po once/day also blocks corticosteroid synthesis, although it may cause liver toxicity and can cause\\naddisonian symptoms. Alternatively, the corticosteroid receptors can be blocked with mifepristone (RU\\n486). Mifepristone increases serum cortisol but blocks effects of the corticosteroid. Sometimes ACTH-\\nsecreting tumors respond to long-acting somatostatin analogs, although administration for > 2 yr requires\\nclose follow-up, because mild gastritis, gallstones, cholangitis, and malabsorption may develop.\\nPrimary Aldosteronism\\n(Conn's Syndrome)\\nPrimary aldosteronism is aldosteronism caused by autonomous production of aldosterone by\\nthe adrenal cortex (due to hyperplasia, adenoma, or carcinoma). Symptoms and signs include\\nepisodic weakness, elevated BP, and hypokalemia. Diagnosis includes measurement of plasma\\naldosterone levels and plasma renin activity. Treatment depends on cause. A tumor is removed\\nif possible; in hyperplasia, spironolactone or related drugs may normalize BP and eliminate\\nother clinical features\\n.\\nAldosterone is the most potent mineralocorticoid produced by the adrenals. It causes Na retention and K\\nloss. In the kidney, aldosterone causes transfer of Na from the lumen of the distal tubule into the tubular\\ncells in exchange for K and hydrogen. The same effect occurs in salivary glands, sweat glands, cells of\\nthe intestinal mucosa, and in exchanges between ICFs and ECFs.\\nAldosterone secretion is regulated by the renin-angiotensin system and, to a lesser extent, by ACTH.\\nRenin, a proteolytic enzyme, is stored in the juxtaglomerular cells of the kidneys. Reduction in blood\\nvolume and flow in the afferent renal arterioles induces secretion of renin. Renin transforms\\nangiotensinogen from the liver to angiotensin I, which is transformed by ACE to angiotensin II. Angiotensin\\nII causes secretion of aldosterone and, to a much lesser extent, secretion of cortisol and\\ndeoxycorticosterone; it also has pressor activity. Na and water retention resulting from increased\\naldosterone secretion increases the blood volume and reduces renin secretion.\\nPrimary aldosteronism is caused by an adenoma, usually unilateral, of the glomerulosa cells of the\\nadrenal cortex or, more rarely, by adrenal carcinoma or hyperplasia. Adenomas are extremely rare in\\nchildren, but the syndrome sometimes occurs in childhood adrenal carcinoma or hyperplasia. In adrenal\\nhyperplasia, which is more common among older men, both adrenals are overactive, and no adenoma is\\npresent. The clinical picture can also occur with congenital adrenal hyperplasia from deficiency of 11 \\n\\n-\\nhydroxylase and the dominantly inherited dexamethasone-suppressible hyperaldosteronism. Hyperplasia\\nas a cause of hyperaldosteronism may be more common than previously recognized but remains an\\ninfrequent cause in the presence of hypokalemia.\\nSymptoms and Signs\\nHypernatremia, hypervolemia, and a hypokalemic alkalosis may occur, causing episodic weakness,\\nparesthesias, transient paralysis, and tetany. Diastolic hypertension and hypokalemic nephropathy with\\npolyuria and polydipsia are common. In many cases, the only manifestation is mild to moderate\\nhypertension. Edema is uncommon.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n930\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 940, 'page_label': '931'}, page_content=\" Electrolytes\\n Plasma aldosterone\\n Plasma renin activity (PRA)\\n Adrenal imaging\\n Bilateral adrenal vein catheterization (for cortisol and aldosterone levels)\\nDiagnosis is suspected in patients with hypertension and hypokalemia. Initial laboratory testing consists\\nof plasma aldosterone levels and PRA. Ideally, tests are done after the patient has not taken any drugs\\nthat affect the renin-angiotensin system (eg, thiazide diuretics, ACE inhibitors, angiotensin antagonists, \\n\\n-\\nblockers) for 4 to 6 wk. PRA is usually measured in the morning with the patient recumbent. Patients with\\nprimary aldosteronism typically have plasma aldosterone > 15 ng/dL (> 0.42 nmol/L) and low levels of\\nPRA, with a ratio of plasma aldosterone (in ng/dL) to PRA (in ng/mL/h) > 20.\\nLow levels of both PRA and aldosterone suggest nonaldosterone mineralocorticoid excess (eg, due to\\nlicorice ingestion, Cushing's syndrome, or Liddle syndrome). High levels of both PRA and aldosterone\\nsuggest secondary hyperaldosteronism (see p. \\n801\\n). The principal differences between primary and\\nsecondary aldosteronism are shown in\\nTable 94-3\\n. In children, Bartter syndrome\\n[\\nTable 94-3.\\n Differential Diagnosis of Aldosteronism]\\n(see p. \\n2988\\n) is distinguished from primary hyperaldosteronism by the absence of hypertension and\\nmarked elevation of renin.\\nPatients with findings suggesting primary hyperaldosteronism should undergo CT or MRI to determine\\nwhether the cause is a tumor or hyperplasia. Aldosterone levels measured on awakening and 2 to 4 h\\nlater while standing also may help make this distinction; in adenoma, levels decline and in hyperplasia,\\nlevels increase. In most cases, bilateral catheterization of the adrenal veins to measure cortisol and\\naldosterone should be used to confirm whether the aldosterone excess is unilateral (tumor) or bilateral\\n(hyperplasia).\\nTreatment\\n Surgical removal of tumors\\n Spironolactone or eplerenone for hyperplasia\\nTumors should be removed laparoscopically. After removal of an adenoma, BP decreases in all patients;\\ncomplete remission occurs in 50 to 70%.\\nWith adrenal hyperplasia, 70% remain hypertensive after bilateral adrenalectomy; thus, surgery is not\\nrecommended. Hyperaldosteronism in these patients can usually be controlled by spironolactone, starting\\nwith 300 mg po once/day and decreasing over 1 mo to a maintenance dose, usually around 100 mg\\nonce/day; or by amiloride 5 to 10 mg po once/day or another K-sparing diuretic. The newer more specific\\ndrug eplerenone may be used because, unlike spironolactone, it does not block the androgen receptor.\\nAbout half of patients with hyperplasia need additional antihypertensive treatment (see p. \\n2069\\n).\\nSecondary Aldosteronism\\nSecondary aldosteronism is increased adrenal production of aldosterone in response to\\nnonpituitary, extra-adrenal stimuli, including renal artery stenosis and hypovolemia. Symptoms\\nare those of primary aldosteronism. Treatment involves correcting the cause\\n.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n931\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 941, 'page_label': '932'}, page_content=\"Secondary aldosteronism is caused by reduced renal blood flow, which stimulates the renin-angiotensin\\nmechanism with resultant hypersecretion of aldosterone. Causes of reduced renal blood flow include\\nobstructive renal artery disease (eg, atheroma, stenosis), renal vasoconstriction (as occurs in accelerated\\nhypertension), and edematous disorders (eg, heart failure, cirrhosis with ascites, nephrotic syndrome).\\nSecretion may be normal in heart failure, but hepatic blood flow and aldosterone metabolism are reduced,\\nso circulating levels of the hormone are high.\\nPheochromocytoma\\nA pheochromocytoma is a catecholamine-secreting tumor of chromaffin cells typically located\\nin the adrenals. It causes persistent or paroxysmal hypertension. Diagnosis is by measuring\\ncatecholamine products in blood or urine. Imaging tests, especially CT or MRI, help localize\\ntumors. Treatment involves removal of the tumor when possible. Drug therapy for control of BP\\nincludes \\n\\n-blockade, usually combined with \\n\\n-blockade\\n.\\nThe catecholamines secreted include norepinephrine, epinephrine, dopamine, and dopa in varying\\nproportions. About 90% of pheochromocytomas are in the adrenal medulla, but they may also be located\\nin other tissues derived from neural crest cells. Possible sites include the following:\\n Paraganglia of the sympathetic chain\\n Retroperitoneally along the course of the aorta\\n Carotid body\\n Organ of Zuckerkandl (at the aortic bifurcation)\\n GU system\\n Brain\\n Pericardial sac\\n Dermoid cysts\\nPheochromocytomas in the adrenal medulla occur equally in both sexes, are bilateral in 10% of cases\\n(20% in children), and are malignant in < 10%. Of extra-adrenal tumors, 30% are malignant. Although\\npheochromocytomas occur at any age, peak incidence is between the 20s and 40s. About 25% are now\\nthought to be due to germline mutations.\\nPheochromocytomas vary in size but average 5 to 6 cm in diameter. They weigh 50 to 200 g, but tumors\\nweighing several kilograms have been reported. Rarely, they are large enough to be palpated or cause\\nsymptoms due to pressure or obstruction. Regardless of the histologic appearance, the tumor is\\nconsidered benign if it has not invaded the capsule and no metastases are found, although exceptions\\noccur.\\nPheochromocytomas may be part of the syndrome of familial multiple endocrine neoplasia (MEN), types\\n2A and 2B, in which other endocrine tumors (parathyroid or medullary carcinoma of the thyroid) coexist or\\ndevelop subsequently (see p. \\n909\\n). Pheochromocytoma develops in 1% of patients with\\nneurofibromatosis (von Recklinghausen's disease) and may occur with hemangiomas and renal cell\\ncarcinoma, as in von Hippel-Lindau disease. Familial pheochromocytomas and carotid body tumors may\\nbe due to mutations of the enzyme succinate dehydrogenase.\\nSymptoms and Signs\\nHypertension, which is paroxysmal in 45% of patients, is prominent. About 1/1000 hypertensive patients\\nhas a pheochromocytoma. Common symptoms and signs are tachycardia, diaphoresis, postural\\nhypotension, tachypnea, cold and clammy skin, severe headache, angina, palpitations, nausea, vomiting,\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n932\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 942, 'page_label': '933'}, page_content='epigastric pain, visual disturbances, dyspnea, paresthesias, constipation, and a sense of impending\\ndoom. Paroxysmal attacks may be provoked by palpation of the tumor, postural changes, abdominal\\ncompression or massage, induction of anesthesia, emotional trauma, unopposed \\n\\n-blockade (which\\nparadoxically increases BP by blocking \\n\\n-mediated vasodilation), or micturition (if the tumor is in the\\nbladder). In elderly patients, severe weight loss with persistent hypertension is suggestive of\\npheochromocytoma.\\nPhysical examination, except for the presence of hypertension, is usually normal unless done during a\\nparoxysmal attack. Retinopathy and cardiomegaly are often less severe than might be expected for the\\ndegree of hypertension, but a specific catecholamine cardiomyopathy can occur.\\nDiagnosis\\n Plasma free metanephrines or urinary metanephrines\\n Chest and abdomen imaging (CT or MRI) if catecholamine screen positive\\n Possibly nuclear imaging with \\n123\\nI-meta-iodobenzylguanidine (MIBG)\\nPheochromocytoma is suspected in patients with typical symptoms or particularly sudden, severe, or\\nintermittent unexplained hypertension. Diagnosis involves demonstrating high levels of catecholamine\\nproducts in the serum or urine.\\nBlood tests:\\n Plasma free metanephrine is up to 99% sensitive. This test has superior sensitivity to\\nmeasurement of circulating epinephrine and norepinephrine because plasma metanephrines are elevated\\ncontinuously, unlike epinephrine and norepinephrine, which are secreted intermittently; however, grossly\\nelevated plasma norepinephrine renders the diagnosis highly probable.\\nUrine tests:\\n Urinary metanephrine is less specific than plasma free metanephrine, but sensitivity is about\\n95%. Two or 3 normal results while the patient is hypertensive render the diagnosis extremely unlikely.\\nMeasurement of urinary norepinephrine and epinephrine is nearly as accurate. The principal urinary\\nmetabolic products of epinephrine and norepinephrine are the metanephrines vanillylmandelic acid (VMA)\\nand homovanillic acid (HVA). Healthy people excrete only very small amounts of these substances.\\nNormal values for 24 h are as follows: free epinephrine and norepinephrine < 100 \\n\\ng (< 582 nmol), total\\nmetanephrine < 1.3 mg (< 7.1 \\n\\nmol), VMA < 10 mg (< 50 \\n\\nmol), HVA < 15 mg (< 82.4 \\n\\nmol). In\\npheochromocytoma, increased urinary excretion of epinephrine and norepinephrine and their metabolic\\nproducts is intermittent. Elevated excretion of these compounds may also occur in other disorders (eg,\\nneuroblastoma, coma, dehydration, sleep apnea) or extreme stress; in patients being treated with\\nrauwolfia alkaloids, methyldopa, or catecholamines; or after ingestion of foods containing large quantities\\nof vanilla (especially if renal insufficiency is present).\\nOther tests:\\n Blood volume is constricted and may falsely elevate Hb and Hct levels. Hyperglycemia,\\nglycosuria, or overt diabetes mellitus may be present, with elevated fasting levels of plasma free fatty acid\\nand glycerol. Plasma insulin level is inappropriately low for the plasma glucose. After removal of the\\npheochromocytoma, hypoglycemia may occur, especially in patients treated with oral antihyperglycemics.\\nProvocative tests\\n with histamine or tyramine \\nare hazardous and should not be used.\\n Glucagon 0.5 to 1\\nmg injected rapidly IV provokes a rise in BP of > 35/25 mm Hg within 2 min in normotensive patients with\\npheochromocytoma but is now generally unnecessary. \\nPhentolamine mesylate must be available to\\nterminate any hypertensive crisis.\\nScreening tests\\n are preferred to provocative tests. The general approach is to measure plasma\\nmetanephrines, 24-h urinary catecholamines, or their metabolites as a screening test and to avoid\\nprovocative tests. In patients with elevated plasma catecholamines, a suppression test using oral\\nclonidine or IV pentolinium can be used but is rarely necessary.\\nImaging tests to localize tumors\\n are usually done in patients with abnormal screening results. Tests\\nshould include CT and MRI of the chest and abdomen with and without contrast. \\nWith isotonic contrast\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n933'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 943, 'page_label': '934'}, page_content='should include CT and MRI of the chest and abdomen with and without contrast. \\nWith isotonic contrast\\nmedia, no adrenoceptor blockade is necessary. PET has also been used successfully. Repeated\\nsampling of plasma catecholamine concentrations during catheterization of the vena cava with sampling\\nat different locations, including the adrenal veins, can help localize the tumor: there will be a step up in\\nnorepinephrine level in a vein draining the tumor. Adrenal vein norepinephrine:epinephrine ratios may\\nhelp in the hunt for a small adrenal source. Radiopharmaceuticals with nuclear imaging techniques can\\nalso help localize pheochromocytomas. \\n123\\nI-MIBG is the most used compound outside the US; 0.5 mCi is\\ninjected IV, and the patient is scanned on days 1, 2, and 3. Normal adrenal tissue rarely picks up this\\nisotope, but 85% of pheochromocytomas do. The imaging is usually positive only when the lesion is large\\nenough to be obvious on CT or MRI, but it can help confirm that a mass is likely to be the source of the\\ncatecholamines. \\n131\\nI-MIBG is a less sensitive alternative.\\nSigns of an associated genetic disorder\\n (eg, cafe-au-lait patches in neurofibromatosis) should be\\nsought. Patients should be screened for MEN with a serum Ca (and possibly calcitonin) and any other\\ntests as directed by clinical findings.\\nTreatment\\n Hypertension control with combination of \\n\\n-blockers and \\n\\n-blockers\\n Surgical removal of tumor\\nSurgical removal is the treatment of choice. The operation is usually delayed until hypertension is\\ncontrolled by a combination of \\n\\n-blockers and \\n\\n-blockers (usually phenoxybenzamine 20 to 40 mg po tid\\nand propranolol 20 to 40 mg po tid). \\n\\n-Blockers should not be used until adequate \\n\\n-blockade has been\\nachieved. Some \\n\\n-blockers, such as doxazosin, may be equally effective but better tolerated.\\nThe most effective and safest preoperative \\n\\n-blockade is phenoxybenzamine 0.5 mg/kg IV in 0.9% saline\\nover 2 h on each of the 3 days before the operation. Na nitroprusside can be infused for hypertensive\\ncrises preoperatively or intraoperatively. When bilateral tumors are documented or suspected (as in a\\npatient with MEN), sufficient hydrocortisone (100 mg IV bid) given before and during surgery avoids acute\\nglucocorticoid insufficiency due to bilateral adrenalectomy.\\nMost pheochromocytomas can be removed laparoscopically. BP must be continuously monitored via an\\nintra-arterial catheter, and volume status is closely monitored. Anesthesia should be induced with a\\nnonarrhythmogenic drug (eg, a thiobarbiturate) and continued with enflurane. During surgery, paroxysms\\nof hypertension should be controlled with injections of phentolamine 1 to 5 mg IV or nitroprusside infusion\\n(2 to 4 \\n\\ng/kg/min), and tachyarrhythmias should be controlled with propranolol 0.5 to 2 mg IV. If a muscle\\nrelaxant is needed, drugs that do not release histamine are preferred. \\nAtropine should not be used\\npreoperatively.\\n Preoperative blood transfusion (1 to 2 units) may be given before the tumor is removed in\\nanticipation of blood loss. If BP has been well controlled before surgery, a diet high in salt is\\nrecommended to increase blood volume. An infusion of norepinephrine 4 to 12 mg/L in a dextrose-\\ncontaining solution should be started if hypotension develops. Some patients whose hypotension\\nresponds poorly to levarterenol may benefit from hydrocortisone 100 mg IV, but adequate fluid\\nreplacement is usually all that is required.\\nMalignant metastatic pheochromocytoma\\n should be treated with \\n\\n- and \\n\\n-blockers. The tumor may\\nbe indolent and survival long-lasting. However, even with rapid tumor growth, BP can be controlled. \\n131\\nI-\\nMIBG prolongs life when used to treat residual disease. Radiation therapy may reduce bone pain;\\nchemotherapy is rarely effective but can be attempted if all else fails.\\nNonfunctional Adrenal Masses\\nNonfunctional adrenal masses are spaceoccupying lesions of the adrenal glands that have no\\nhormonal activity. Symptoms, signs, and treatment depend on the nature and size of the mass\\n.\\nThe most common nonfunctioning adrenal mass in adults is an adenoma (50%), followed by carcinomas\\nand metastatic tumors. Cysts and lipomas make up most of the remainder. However, the precise\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n934'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 944, 'page_label': '935'}, page_content=\"proportions depend on the clinical presentation. Masses discovered on incidental screening are usually\\nadenomas. Less commonly, in neonates, spontaneous adrenal hemorrhage may cause large adrenal\\nmasses, simulating neuroblastoma or Wilms' tumor. In adults, bilateral massive adrenal hemorrhage may\\nresult from thromboembolic disease or coagulopathy. Benign cysts are observed in elderly patients and\\nmay be due to cystic degeneration, vascular accidents, lymphomas, bacterial infections, fungal infections\\n(eg, histoplasmosis), or parasitic infestations (eg, due to \\nEchinococcus\\n). Hematogenous spread of TB\\norganisms may cause adrenal masses. A nonfunctional adrenal carcinoma produces a diffuse and\\ninfiltrating retroperitoneal process. Hemorrhage can occur, causing adrenal hematomas.\\nSymptoms and Signs\\nMost patients are asymptomatic. With any adrenal mass, adrenal insufficiency is rare unless both glands\\nare involved.\\nThe major signs of bilateral massive adrenal hemorrhage are abdominal pain, falling Hct, signs of acute\\nadrenal failure, and suprarenal masses on CT or MRI. TB of the adrenals may cause calcification and\\nAddison's disease. Nonfunctional adrenal carcinoma usually manifests as metastatic disease and may\\ntherefore not be amenable to surgery, though mitotane may afford chemotherapeutic control when used\\nwith supportive exogenous corticosteroids.\\nDiagnosis\\n Adrenal hormone measurements\\n Fine-needle biopsy\\nNonfunctional adrenal masses are usually found incidentally during tests such as CT or MRI conducted\\nfor other reasons. Nonfunctionality is established clinically and confirmed by adrenal hormonal\\nmeasurements (see p. \\n797\\n). If metastatic disease is possible, fine-needle biopsy can be diagnostic but is\\ncontraindicated if adrenal carcinoma is strongly suspected.\\nTreatment\\n Excision\\n Periodic monitoring\\nIf the tumor is solid, of adrenal origin, and > 4 cm, it should be excised, because biopsy cannot always\\ndistinguish benign from malignant tumors.\\nTumors 2 to 4 cm in diameter are a particularly difficult clinical problem. If scanning does not suggest\\ncancer and hormonal function does not seem altered (eg, normal electrolytes and catecholamines, no\\nevidence of Cushing's syndrome), it is reasonable to reevaluate periodically, usually for up to 4 yr. If no\\nprogression is seen by then, further follow-up is unnecessary. However, many of these tumors secrete\\ncortisol in quantities too small to cause symptoms, and whether they would eventually cause symptoms\\nand morbidity if untreated is unclear. Most clinicians merely observe patients with these tumors.\\nAdrenal adenomas < 2 cm require no special treatment but should be observed for growth or\\ndevelopment of secretory function (such as by looking for clinical signs and periodically measuring\\nelectrolytes).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 94. Adrenal Disorders\\n935\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 945, 'page_label': '936'}, page_content=\"Chapter 95. Polyglandular Deficiency Syndromes\\nIntroduction\\n(Autoimmune Polyglandular Syndromes; Polyendocrine Deficiency Syndromes)\\nPolyglandular deficiency syndromes (PDS) are characterized by sequential or simultaneous\\ndeficiencies in the function of several endocrine glands that have a common cause. Etiology is\\nmost often autoimmune. Symptoms depend on the combination of deficiencies, which fall\\nwithin 1 of 3 types. Diagnosis requires measurement of hormone levels and autoantibodies\\nagainst affected endocrine glands. Treatment includes replacement of missing or deficient\\nhormones and sometimes immunosuppressants\\n.\\nEtiology\\nAlthough individual endocrine glands can be damaged by numerous causes, including infection,\\ninfarction, and tumors, these syndromes usually result from an autoimmune reaction, probably triggered\\nby a virus or other environmental antigen.\\nGenetic factors increase susceptibility to these syndromes, as shown by the increased presence of\\ncertain HLA subtypes in affected people and the recognition of several inheritance patterns (see\\nTable 95-1\\n).\\nPathophysiology\\nThe underlying autoimmune reaction involves autoantibodies against endocrine tissues, cell-mediated\\nautoimmunity, or both and leads to inflammation, lymphocytic infiltration, and partial or complete gland\\ndestruction. More\\n[\\nTable 95-1.\\n Characteristics of Types I, II, and III Polyglandular Deficiency Syndromes]\\nthan one endocrine gland is involved, although clinical manifestations are not always simultaneous. The\\nautoimmune reaction and associated immune system dysfunction can also damage nonendocrine tissues.\\nClassification\\nThree patterns of autoimmune failure have been described (see \\nTable 95-1\\n), which likely reflect different\\nautoimmune abnormalities.\\nType I:\\n Type I usually begins in childhood. The 3 primary components are\\n Chronic mucocutaneous candidiasis\\n Hypoparathyroidism\\n Adrenal insufficiency (Addison's disease)\\nCandidiasis is usually the initial clinical manifestation, most often occurring in patients < 5 yr.\\nHypoparathyroidism occurs next, usually in patients < 10 yr. Lastly, adrenal insufficiency occurs in\\npatients < 15 yr. Accompanying endocrine and nonendocrine disorders (see \\nTable 95-1\\n) continue to\\nappear at least until patients are about age 40.\\nType II (Schmidt's syndrome):\\n Type II usually occurs in adults; peak incidence is age 30. It occurs 3\\ntimes more often in women. It typically manifests with\\n Adrenal insufficiency\\n Hypothyroidism or hyperthyroidism\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 95. Polyglandular Deficiency Syndromes\\n936\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 946, 'page_label': '937'}, page_content=' Type 1 diabetes (autoimmune etiology)\\nMore rare features may also be present (see \\nTable 95-1\\n).\\nType III:\\n Type III is characterized by\\n Glandular failure occurring in adults, particularly middle-aged women\\n Hypothyroidism\\n At least one of a variety of other disorders (see \\nTable 95-1\\n)\\nType III does not involve the adrenal cortex.\\nSymptoms and Signs\\nThe clinical appearance of patients with PDS is the sum of the individual endocrine deficiencies and\\nassociated nonendocrine disorders; their symptoms and signs are discussed elsewhere in THE MANUAL.\\nThe deficiencies do not always appear at the same time and may require a period of years to manifest; in\\nsuch cases they do not follow a particular sequence.\\nDiagnosis\\n Measurement of hormone levels\\n Sometimes autoantibody titers\\nDiagnosis is suggested clinically and confirmed by detecting deficient hormone levels. Other causes of\\nmultiple endocrine deficiencies include hypothalamic-pituitary dysfunction and coincidental endocrine\\ndysfunction due to separate causes (eg, tuberculous hypoadrenalism and nonautoimmune\\nhypothyroidism in the same patient). Detecting autoantibodies to each affected glandular tissue can help\\ndifferentiate PDS from the other causes, and elevated levels of pituitary tropic hormones (eg, thyroid-\\nstimulating hormone) suggest the hypothalamic-pituitary axis is intact (although some patients with type II\\nPDS have hypothalamic-pituitary insufficiency).\\nBecause decades may pass before the appearance of all manifestations, lifelong follow-up is prudent;\\nunrecognized hypoparathyroidism or adrenal insufficiency can be life threatening.\\nRelatives should be made aware of the diagnosis and screened when appropriate; measurement of\\nglutamic acid decarboxylase antibodies may be useful in determining risk.\\nTreatment\\n Hormone replacement\\nTreatment of the various individual glandular deficiencies is discussed elsewhere in THE MANUAL; the\\ntreatment of multiple deficiencies can be more complex than treatment of an isolated endocrine\\ndeficiency.\\nChronic mucocutaneous candidiasis usually requires lifelong antifungal therapy (eg, oral fluconazole or\\nketoconazolesee p. \\n1103\\n). If given early (within the first few weeks to months) in the course of\\nendocrine failure, immunosuppressive doses of cyclosporine may benefit some patients.\\nIPEX Syndrome\\nIPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) is a recessive\\nsyndrome involving aggressive autoimmunity\\n.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 95. Polyglandular Deficiency Syndromes\\n937'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 947, 'page_label': '938'}, page_content='This rare disorder results from mutation of the transcriptional activator, \\nFoxP3\\n, which causes regulatory\\nT-cell dysfunction and a subsequent autoimmune disorder.\\nIPEX syndrome manifests as severe enlargement of the secondary lymphoid organs, type 1 diabetes\\nmellitus, eczema, food allergies, and infections. Secondary enteropathy leads to persistent diarrhea.\\nDiagnosis is suggested by clinical features and confirmed by genetic analysis.\\nUntreated, IPEX syndrome is usually fatal in the first year of life. Immunosuppressants and bone marrow\\ntransplantation can prolong life but are rarely curative.\\nPOEMS Syndrome\\n(Crow-Fukase Syndrome)\\nPOEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin\\nchanges) is a nonautoimmune polyglandular deficiency syndrome\\n.\\nPOEMS syndrome is probably caused by circulating immunoglobulins caused by a plasma cell dyscrasia\\n(see also p. \\n1025\\n). Circulating cytokines (IL-1-\\n\\n, IL-6), vascular endothelial growth factor, and tumor\\nnecrosis factor-\\n\\n are also increased.\\nPatients may have the following:\\n Hepatomegaly\\n Lymphadenopathy\\n Hypogonadism\\n Diabetes mellitus type 2\\n Primary hypothyroidism\\n Hyperparathyroidism\\n Adrenal insufficiency\\n Excess production of monoclonal IgA and IgG due to plasmacytomas and skin abnormalities (eg,\\nhyperpigmentation, dermal thickening, hirsutism, angiomas, hypertrichosis)\\nOther symptoms and signs may include edema, ascites, pleural effusion, papilledema, and fever.\\nLike other syndromes of undefined pathophysiology, POEMS syndrome is diagnosed based on the\\nconstellation of symptoms and signs. Criteria include the presence of polyneuropathy and monoclonal\\nparaproteinemia plus any 2 of the other manifestations of the disorder.\\nTreatment consists of chemotherapy and radiation therapy followed by autologous hematopoietic or stem\\ncell transplantation. Five-year survival is about 60%.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 95. Polyglandular Deficiency Syndromes\\n938'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 948, 'page_label': '939'}, page_content='Chapter 96. Porphyrias\\nIntroduction\\nPorphyrias result from genetic deficiencies of enzymes of the heme biosynthetic pathway.\\nThese deficiencies allow heme precursors to accumulate, causing toxicity. Porphyrias are\\ndefined by the specific enzyme deficiency. Two major clinical manifestations occur:\\nneurovisceral abnormalities (the acute porphyrias) and cutaneous photosensitivity (the\\ncutaneous porphyrias)\\n.\\nHeme, an iron-containing pigment, is synthesized mostly in the bone marrow (by erythroblasts and\\nreticulocytes) and is incorporated into hemoglobin. Heme is also synthesized in the liver and incorporated\\ninto certain enzymes (eg, cytochromes). Heme synthesis requires 8 enzymes (see\\nTable 96-1\\n). These enzymes produce and transform molecular species called porphyrins (and their\\nprecursors), which are toxic if they accumulate.\\nEtiology\\nMost porphyrias are autosomal dominant. Homozygous or double heterozygous states may be\\nincompatible with life, generally causing fetal death; the exceptions are \\n\\n-aminolevulinic acid (ALA)\\ndehydratase (ALAD)-deficiency porphyria and uroporphyrinogen III cosynthase deficiency, in which only\\nhomozygous or double heterozygous conditions (ie, 2 separate heterozygous mutations in the same gene\\nin the same patient) cause disease. Disease penetrance in heterozygotes varies. In terms of genetic\\nprevalence, the 2 most common porphyrias are acute intermittent porphyria (AIP) and porphyria cutanea\\ntarda (PCT). The prevalence of each is about 1/10,000.\\nPathophysiology\\nPorphyrias result from a deficiency of any of the last 7 enzymes of the heme biosynthetic pathway\\n(deficiency of the first enzyme in the pathway, ALA synthase, causes sideroblastic anemia). Single genes\\nencode each enzyme; any of numerous possible mutations can incapacitate the enzyme encoded by that\\ngene. When an enzyme of heme synthesis is deficient or defective, its substrate and any other heme\\nprecursors normally modified by that enzyme may accumulate in bone marrow, liver, skin, or other tissues\\nand have toxic effects. These precursors may appear in excess in the blood and be excreted in urine,\\nbile, or stool.\\n[\\nTable 96-1.\\n Substrates and Enzymes of the Heme Biosynthetic Pathway and the Diseases Associated\\nwith their Deficiency]\\nAlthough porphyrias are most precisely defined according to the deficient enzyme, classification by major\\nclinical features (phenotype) is often useful. Thus, porphyrias are usually divided into 2 classes:\\n Acute\\n Cutaneous\\nAcute porphyrias manifest as intermittent attacks of abdominal, mental, and neurologic symptoms. They\\nare typically triggered by drugs and other exogenous factors. Cutaneous porphyrias tend to cause\\ncontinuous or undulating symptoms involving cutaneous photosensitivity. Some acute porphyrias also\\nhave cutaneous manifestations. Because of variable penetrance in heterozygous porphyrias, clinically\\nexpressed disease is less common than genetic prevalence (see\\nTable 96-2\\n).\\nUrine discoloration (red or reddish brown) may occur in the symptomatic phase of all porphyrias except\\nerythropoietic protoporphyria (EPP) and ALAD-deficiency porphyria. Discoloration results from oxidized\\nporphyrins, the porphyrin\\n[\\nTable 96-2.\\n Major Features of the Two Most Common Porphyrias]\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n939'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 949, 'page_label': '940'}, page_content='precursor porphobilinogen (PBG), or both. Sometimes the color develops after the urine has stood in light\\nfor about 30 min, allowing time for oxidation. In the acute porphyrias, except in ALAD-deficiency porphyria,\\nabout 1 in 3 heterozygotes (more frequently in females than males) also have increased urinary excretion\\nof PBG (and urine discoloration) in the latent phase.\\nDiagnosis\\nPatients with symptoms suggesting porphyria are screened by blood or urine tests for porphyrins or the\\nporphyrin precursors PBG and ALA (see\\nTable 96-3\\n). Abnormal results on screening are confirmed by further testing.\\nAsymptomatic patients, including suspected carriers and people who are between attacks, are evaluated\\nsimilarly. However, the tests are less sensitive in these circumstances; measurement of RBC or WBC\\nenzyme activity is considerably more sensitive. Genetic analysis is highly accurate and preferentially used\\nwithin families when the mutation is known. Prenatal testing (involving amniocentesis or chorionic villus\\nsampling) is possible but rarely indicated.\\nAcute Porphyrias\\nAcute porphyrias cause intermittent attacks of abdominal pain and neurologic symptoms.\\nAttacks are precipitated by certain drugs and other factors. Patients with variegate porphyria\\nand hereditary coproporphyria may develop\\n[\\nTable 96-3.\\n Screening for Porphyrias]\\nbullous eruptions due to sunlight exposure. Diagnosis is based on elevated levels of \\n\\n-\\naminolevulinic acid and porphyrin precursor porphobilinogen in the urine during attacks.\\nAttacks are treated with glucose or, if more severe, IV heme. Symptomatic treatment, including\\nanalgesia, is given as necessary\\n.\\nAcute porphyrias include, in order of prevalence, acute intermittent porphyria (AIP), variegate porphyria\\n(VP), hereditary coproporphyria (HCP), and the exceedingly rare \\n\\n-aminolevulinic acid dehydratase\\n(ALAD)-deficiency porphyria.\\nAmong heterozygotes, acute porphyrias are rarely expressed clinically before puberty and, after puberty,\\nin only about 20 to 30%. Among homozygotes and double heterozygotes, onset generally is in childhood,\\nand symptoms are often severe.\\nPrecipitating Factors\\nMany precipitating factors exist, typically accelerating heme biosynthesis above the catalytic capacity of\\nthe defective enzyme. Accumulation of porphyrin precursor porphobilinogen (PBG) and \\n\\n-aminolevulinic\\nacid (ALA), or in the case of ALAD-deficiency porphyria, ALA alone, results.\\nHormonal factors are important. Women are more prone to attacks than men, particularly during periods\\nof hormonal change (eg, just before menstruation, during use of oral contraceptives, during the early\\nweeks of gestation, just after delivery). Nevertheless, pregnancy is not contraindicated.\\nOther factors include drugs (including barbiturates, other antiepileptic drugs, and sulfonamide antibiotics\\nsee\\nTable 96-4\\n) and reproductive hormones (progesterone and related steroids), particularly those that induce\\nhepatic ALA synthase and cytochrome P-450 enzymes. Attacks usually occur within 24 h after exposure to\\na precipitating drug. Low-calorie and low-carbohydrate diets, alcohol ingestion, and exposure to organic\\nsolvents can also precipitate symptoms. Infection or other illness, surgery, and mental problems are\\nsometimes implicated. Attacks usually result from several, sometimes unidentifiable, factors.\\nSunlight precipitates cutaneous symptoms in VP and HCP.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n940'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 950, 'page_label': '941'}, page_content='Symptoms and Signs\\nSymptoms and signs involve the nervous system, abdomen, or both (neurovisceral). Attacks develop over\\nhours or days and can last\\n[\\nTable 96-4.\\n Drugs and Porphyria*]\\nup to several weeks. Most gene carriers experience no, or only a few, attacks in their lifetime. Others\\nexperience recurrent symptoms. In women, attacks often coincide with phases of the menstrual cycle.\\nThe acute porphyric attack:\\n Constipation, fatigue, irritability, and insomnia typically precede an acute\\nattack. The most common symptoms with an attack are abdominal pain and vomiting. The pain may be\\nexcruciating and is disproportionate to abdominal tenderness. Abdominal manifestations may result from\\neffects on visceral nerves or from local vasoconstrictive ischemia. Because there is no inflammation, the\\nabdomen is not tender and there are no peritoneal signs. Temperature and WBC count are normal or\\nslightly increased. Bowel distention may develop as a result of paralytic ileus. The urine is red or reddish\\nbrown and positive for PBG during an attack.\\nAll components of the peripheral and central nervous systems may be involved. Motor neuropathy is\\ncommon with severe and prolonged attacks. Muscle weakness usually begins in the extremities but can\\ninvolve any motor neuron or cranial nerve and proceed to tetraplegia. Bulbar involvement can cause\\nventilatory failure.\\nCNS involvement may cause seizures or mental disturbances (eg, apathy, depression, agitation, frank\\npsychosis, hallucinations). Seizures, psychotic behavior, and hallucinations may be due to hyponatremia\\nor hypomagnesemia, which can also contribute to cardiac arrhythmias.\\nExcess catecholamines generally cause restlessness and tachycardia. Rarely, catecholamine-induced\\narrhythmias cause sudden death. Labile hypertension with transiently high BP may cause vascular\\nchanges progressing to irreversible hypertension if untreated. Renal failure in acute porphyria is\\nmultifactorial; acute hypertension (possibly leading to chronic hypertension) is likely a main precipitating\\nfactor.\\nSubacute or subchronic symptoms:\\n Some patients have prolonged symptoms of lesser intensity (eg,\\nobstipation, fatigue, headache, back or thigh pain, paresthesia, tachycardia, dyspnea, insomnia, mental\\ndisturbance, seizures).\\nSkin symptoms in VP and HCP:\\n Fragile skin and bullous eruptions may develop on sun-exposed\\nareas, even in the absence of neurovisceral symptoms. Often patients are not aware of the connection to\\nsun exposure. Cutaneous manifestations are identical to those of porphyria cutanea tarda.\\nLate manifestations:\\n Motor involvement during acute attacks may cause persistent weakness between\\nattacks. Hepatocellular cancer, hypertension, and renal impairment become more common after middle\\nage in AIP and possibly also in VP and HCP, especially in patients with previous porphyric attacks.\\nDiagnosis\\n Urine screen for PBG\\n If urine results are positive, quantitative ALA and PBG determination\\n Genetic analysis if type must be identified\\nAcute attack:\\n Misdiagnosis is common because the acute attack is confused with other causes of acute\\nabdomen (sometimes leading to unnecessary surgery) or with a primary neurologic or mental disorder.\\nHowever, in patients previously diagnosed as gene carriers or who have a positive family history,\\nporphyria should be suspected. Still, even in known gene carriers, other causes must be considered.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n941'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 951, 'page_label': '942'}, page_content='Red or reddish brown urine, not present before onset of symptoms, is a cardinal sign and is present\\nduring full-blown attacks. A urine specimen should be examined in patients with abdominal pain of\\nunknown cause, especially if severe constipation, vomiting, tachycardia, muscle weakness, bulbar\\ninvolvement, or mental symptoms occur.\\nIf porphyria is suspected, the urine is analyzed for PBG using a rapid qualitative or semiquantitative\\ndetermination. A positive result or high clinical suspicion necessitates quantitative ALA and PBG\\nmeasurements preferentially obtained from the same specimen. PBG and ALA levels > 5 times normal\\nindicate an acute porphyric attack unless patients are gene carriers in whom porphyrin precursor\\nexcretion occurs at similar levels even during the latent phase of the disorder.\\nIf urinary PBG and ALA levels are normal, an alternative diagnosis must be considered. Elevated ALA with\\nnormal or slightly increased PBG suggests lead poisoning or ALAD-deficiency porphyria. Analysis of a 24-\\nh urine specimen is not useful. Instead, a random urine specimen is used, and PBG and ALA levels are\\ncorrected for dilution by relating to the creatinine level of the sample. Electrolytes and Mg should be\\nmeasured. Hyponatremia may be present because of excessive vomiting or diarrhea after hypotonic fluid\\nreplacement or because of the syndrome of inappropriate ADH secretion (SIADH).\\nDetermination of type:\\n Because treatment does not depend on the type of acute porphyria,\\nidentification of the specific type is valuable mainly for finding gene carriers among relatives. When the\\ntype and mutation are already known from previous testing of relatives, the diagnosis is clear but may be\\nconfirmed by gene analysis. Enzymatic diagnosis is not necessary. If there is no family history to guide the\\ndiagnosis, the different forms of acute porphyria are distinguished by characteristic patterns of porphyrin\\n(and precursor) accumulation and excretion in plasma, urine, and stool. When urine analysis reveals\\nincreased levels of ALA and PBG, fecal porphyrins may be measured. Fecal porphyrins are usually\\nnormal or minimally increased in AIP but elevated in HCP and VP. Often, these markers are not present in\\nthe quiescent phase of the disorder. In HCP and VP, plasma porphyrins with characteristic fluorescence\\nare sought. RBC PBG deaminase levels that are about 50% of normal suggest AIP. Diminished WBC\\nprotoporphyrinogen oxidase levels suggest VP, and diminished coproporphyrinogen oxidase levels\\nsuggest HCP.\\nFamily studies:\\n Children of a gene carrier have a 50% risk of inheriting the disorder. Because diagnosis\\nfollowed by counseling reduces the risk of morbidity, children in affected families should be tested before\\nthe onset of puberty. Genetic testing is used if the mutation has been identified in the index case. If not,\\npertinent RBC or WBC enzyme levels are measured. Gene analysis can be used for in utero diagnosis\\n(using amniocentesis or chorionic villus sampling) but is seldom indicated because of the favorable\\noutlook for most gene carriers.\\nPrognosis\\nAdvances in medical care and self-care have improved the prognosis for symptomatic patients. Still, some\\npatients develop recurrent crises or progressive disease with permanent paralysis or renal failure. Also,\\nfrequent need for potent analgesics may give rise to drug addiction.\\nTreatment\\n Triggers eliminated if possible\\n Dextrose (oral or IV)\\n IV heme\\nTreatment of the acute attack is identical for all the acute porphyrias. Possible triggers (eg, drugs) are\\nidentified and eliminated. Unless the attack is mild, patients are hospitalized in a darkened, quiet, private\\nroom. Heart rate, BP, and fluid and electrolyte balance are \\nmonitored. Neurologic status, bladder function,\\nmuscle and tendon function, respiratory function, and pulse oximetry are continuously monitored.\\nSymptoms (eg, pain, vomiting) are treated with nonporphyrinogenic drugs as needed (see \\nTable 96-4\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n942'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 952, 'page_label': '943'}, page_content='Dextrose 300 to 500 g daily inhibits ALA synthase and relieves symptoms. It can be given by mouth if\\npatients are not vomiting; otherwise, it is given IV. To avoid overhydration with consequent hyponatremia,\\n1 L of a 50% dextrose solution can be given by central venous catheter over 24 h.\\nIV heme is more effective than dextrose and should be given immediately in severe attacks, electrolyte\\nimbalance, or muscle weakness. Heme usually resolves symptoms in 3 to 4 days. If heme therapy is\\ndelayed, nerve damage is more severe and recovery is slower and possibly incomplete. Heme is\\navailable in the US as lyophilized hematin to be reconstituted in a glass vial with sterile water. The dose is\\n3 mg/kg IV once/day for 4 days. In this form, heme degradation products form rapidly and may cause\\nphlebitis at the infusion site; they also have a transient anticoagulant effect. Adverse effects can be\\nreduced by reconstitution with, eg, 20% human albumin. Heme arginate is a more stable, generally\\ntoxicity-free alternative.\\nIn patients with severe recurrent attacks, who are at risk of renal damage or permanent neurologic\\ndamage, liver transplantation is an option. Renal transplantation, with or without simultaneous liver\\nexchange, should be considered in patients with active disease and terminal renal failure, because there\\nis considerable risk that nerve damage will progress at the start of dialysis.\\nPrevention\\nCarriers of acute porphyria should avoid the following:\\n Potentially harmful drugs (see \\nTable 96-4\\n)\\n Alcohol\\n Emotional stress\\n Exposure to organic solvents (eg, in painting or dry cleaning)\\n Crash diets\\n Periods of starvation\\nDiets for obesity should provide gradual weight loss and be adopted only during periods of remission.\\nCarriers of VP or HCP should minimize sun exposure; sunscreens that block only ultraviolet B light are\\nineffective, but opaque titanium dioxide preparations are beneficial. Support associations for porphyria\\npatients can provide written information and direct counseling.\\nPatients should be identified prominently in the medical record as carriers and should carry a card\\nverifying the carrier state and precautions to be observed.\\nA high-carbohydrate diet may decrease the risk of acute attacks. A high-carbohydrate diet or a lump of\\nsugar every hour may help relieve symptoms of an acute attack. Prolonged use should be avoided in\\norder to decrease risk of obesity and dental caries.\\nPatients who experience recurrent and predictable attacks (typically women with attacks related to the\\nmenstrual cycle) may benefit from prophylactic heme therapy given shortly before the expected onset.\\nThere is no standardized regimen; a specialist should be consulted. Frequent premenstrual attacks in\\nsome women are aborted by administration of a gonadotropin-releasing hormone analog plus low-dose\\nestrogen. Oral contraceptives are sometimes used successfully, but the progestin component is likely to\\nexacerbate the porphyria.\\nTo prevent renal damage, chronic hypertension is treated (using safe drugs). Patients with evidence of\\nimpaired renal function are referred to a nephrologist.\\nThe incidence of hepatocellular cancer is high among carriers of acute porphyria, especially in patients\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n943'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 953, 'page_label': '944'}, page_content='with active disease. Patients who are > 50 should undergo yearly or twice yearly surveillance, including\\nliver screening with contrast-enhanced ultrasonography. Early intervention can be curative and increases\\nlife expectancy.\\nCutaneous Porphyrias\\nCutaneous porphyrias tend to manifest as undulating or unremitting disease with a relatively\\nsteady production of phototoxic porphyrins in the liver or bone marrow. These porphyrins\\naccumulate in the skin and, on sunlight exposure (visible light, including near-ultraviolet [UV]),\\ngenerate cytotoxic radicals that cause cutaneous manifestations\\n.\\nCutaneous porphyrias include porphyria cutanea tarda, erythropoietic protoporphyria (EPP), and the\\nextremely rare hepatoerythropoietic porphyria and congenital erythropoietic porphyria (see\\nTable 96-5\\n). The acute porphyrias variegate porphyria and hereditary coproporphyria also have\\ncutaneous manifestations.\\nIn all cutaneous porphyrias except EPP, cutaneous photosensitivity manifests as fragile skin and bullous\\neruptions. Skin changes generally occur on sun-exposed areas (eg, face, neck, dorsal sides of fingers\\nand hands) or traumatized skin. The cutaneous reaction is\\n[\\nTable 96-5.\\n Some Less Common Porphyrias]\\ninsidious, and often patients are unaware of the connection to sun exposure. In contrast, the\\nphotosensitivity in EPP occurs within minutes or hours after sun exposure, manifesting as a burning pain\\nthat persists for hours, often without any objective signs on the skin.\\nPorphyria Cutanea Tarda\\nPorphyria cutanea tarda (PCT) is a comparatively common porphyria affecting mainly the skin.\\nLiver disease is common. Symptoms include fragile skin and blisters affecting sun-exposed\\nareas. \\nIron plays a key role in pathogenesis. Several environmental factors lower the threshold\\nfor the phototoxic skin reaction, including alcohol ingestion, estrogens, hepatitis C infection,\\nand possibly HIV infection. Drugs, with the exceptions of iron and estrogens, are not triggers.\\nDiagnosis is by porphyrin analysis of urine and stool. Differentiation from the acute cutaneous\\nporphyrias hereditary coproporphyria and variegate porphyria is important. Treatment includes\\niron depletion by phlebotomy and forced porphyrin excretion by treatment with chloroquine.\\nPrevention is by avoidance of sunlight, alcohol, estrogens, and iron-containing drugs\\n.\\nPathophysiology\\nPCT results from hepatic deficiency of uroporphyrinogen decarboxylase (UPGDsee \\nTable 96-1\\n). In\\nabout 80% of patients, the responsible mutation is sporadic; the remaining 20% are hereditary.\\nPorphyrins accumulate in the liver and are transported to the skin, where they cause photosensitivity. The\\n50% decrease in UPGD activity in heterozygous patients is insufficient to cause clinical PCT. Other\\nfactors must further impair enzyme activity. Iron plays a central role, probably by generating oxygen\\nradicals that inhibit UPGD by oxidizing its substrate; thus, hemochromatosis is a significant risk factor.\\nAlcohol, estrogens, and chronic viral infection probably contribute in different ways by increasing iron\\nactivity in hepatic tissue. The drugs that commonly trigger acute porphyria (see \\nTable 96-4\\n) do not trigger\\nPCT.\\nLiver disease is common in PCT and may be due partly to porphyrin accumulation, chronic hepatitis C\\ninfection, concomitant hemosiderosis, or excess alcohol ingestion. Cirrhosis occurs in  35% of patients,\\nand hepatocellular carcinoma occurs in 7 to 24% (more common among middle-aged men).\\nThe 2 major forms of the disease, types 1 and 2, have the same precipitants, symptoms, and treatment.\\nOverall prevalence may be on the order of 1/10,000.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n944'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 954, 'page_label': '945'}, page_content='In type 1 PCT (sporadic), decarboxylase deficiency is restricted to the liver and no genetic background is\\nrecognized. It usually manifests in middle age or later.\\nIn type 2 PCT (familial), decarboxylase deficiency is inherited in an autosomal dominant fashion with\\nlimited penetrance. Prevalence is lower than in sporadic PCT. Deficiency occurs in all cells, including\\nRBCs. It may develop earlier than type 1, occasionally in childhood.\\nSecondary PCT-like conditions (pseudoporphyria) may occur with certain photosensitizing drugs (eg,\\nfurosemide, tetracyclines, sulfonamides, some NSAIDs). Because porphyrins are poorly dialyzed, some\\npatients receiving long-term hemodialysis develop a skin condition that resembles PCT; this condition is\\ntermed pseudoporphyria of end-stage renal disease.\\nSymptoms and Signs\\nPatients present with fragile skin, mainly on sun-exposed areas. Phototoxicity is delayed: patients do not\\nalways connect sun exposure with symptoms.\\nSpontaneously or after minor trauma, tense bullae develop. Accompanying erosions and ulcers may\\ndevelop secondary infection; they heal slowly, leaving atrophic scars. Sun exposure occasionally leads to\\nerythema, edema, or itching. Hyperemic conjunctivitis may develop, but other mucosal sites are not\\naffected. Areas of hypopigmentation or hyperpigmentation may develop, as may facial hypertrichosis and\\npseudosclerodermoid changes.\\nDiagnosis\\n Levels of plasma porphyrins, urinary uroporphyrin and heptacarboxyl porphyrin, and fecal\\nisocoproporphyrin\\nIn otherwise healthy patients, fragile skin and blister formation suggest PCT. Differentiation from acute\\nporphyrias with cutaneous symptoms (variegate porphyria [VP] and hereditary coproporphyria [HCP]) is\\nimportant because in patients with VP and HCP, the erroneous prescription of porphyrogenic drugs may\\ntrigger the severe neurovisceral symptoms of the acute porphyrias. Previous unexplained neurologic\\nsymptoms or abdominal pain may suggest an acute porphyria. A history of exposure to chemicals that can\\ncause pseudoporphyria should be sought.\\nAlthough all porphyrias that cause skin lesions are accompanied by elevated plasma porphyrins, elevated\\nurinary uroporphyrin and heptacarboxyl porphyrin and fecal isocoproporphyrin indicate PCT. Urine levels\\nof porphyrin precursor porphobilinogen (PBG) and, usually, \\n\\n-aminolevulinic acid (ALA) are normal in\\nPCT. RBC activity of UPGD is normal in type 1 PCT but decreased in type 2.\\nBecause concurrent hepatitis C infection is common and may be asymptomatic, serum markers for\\nhepatitis C (see p.\\n253\\n) should be investigated.\\nTreatment\\nTwo different therapeutic strategies are available:\\n Reduction of body iron stores\\n Increase in porphyrin excretion\\nThese strategies can be combined for more rapid remission. The treatment is monitored by\\ndeterminations of urinary porphyrin excretion every other or every 3rd month until full remission.\\nIron removal by phlebotomy is usually effective. A pint of blood is removed every 2nd or every 3rd week;\\nshorter intervals unnecessarily risk causing anemia. When serum ferritin falls slightly below normal,\\nphlebotomy is stopped. Usually, only 5 to 6 sessions are needed. Urine and plasma porphyrins fall\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n945'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 955, 'page_label': '946'}, page_content='gradually with treatment, lagging behind but paralleling the fall in ferritin. The skin eventually becomes\\nnormal. After remission, further phlebotomy is needed only if there is a recurrence.\\nLow-dose chloroquine or hydroxychloroquine (100 to 125 mg po twice/wk) removes excess porphyrins\\nfrom the liver by increasing the excretion rate. Higher doses can cause transient liver damage and\\nworsening of porphyria. When remission is achieved, the regimen is stopped.\\nChloroquine and hydroxychloroquine are not effective in advanced renal disease, and phlebotomy is\\nusually contraindicated because of underlying anemia. However, recombinant erythropoietin mobilizes\\nexcess iron and resolves the anemia enough to permit phlebotomy. In end-stage renal disease,\\ndeferoxamine is an adjunct to phlebotomy for reduction of hepatic iron, the complexed iron being removed\\nduring dialysis. Dialyzers with ultrapermeable membranes and extra high blood flow rates are needed.\\nPatients with overt PCT and hepatitis C infection are preferentially treated with pegylated interferon alfa-\\n2a and ribavirin. Previous iron depletion augments the response to antiviral therapy.\\nChildren with symptomatic PCT are treated with small-volume phlebotomies or oral chloroquine; dosage\\nis determined by body weight.\\nSkin symptoms occurring during pregnancy are treated with phlebotomy. In refractory cases, low-dose\\nchloroquine can be added; no teratogenic effects have been recognized. Depending on degree of\\nhemodilution and iron depletion, the skin symptoms usually abate as pregnancy advances.\\nPostmenopausal estrogen supplementation is interrupted during treatment for PCT. Stopping estrogens\\noften induces remission. After remission, estrogens can be reintroduced, preferentially in transdermal\\nadministration to reduce hepatic porphyrogenic exposure.\\nPrevention\\nPatients should avoid sun exposure; hats and clothing protect best, as do zinc or titanium oxide\\nsunscreens. Typical sunscreens that block UV light are ineffective, but UVA-absorbing sunscreens, such\\nas those containing dibenzylmethanes, may help somewhat. Alcohol ingestion should be avoided\\npermanently, but estrogen supplementation can usually be resumed safely after a disease remission.\\nErythropoietic Protoporphyria\\nErythropoietic protoporphyria (EPP) typically manifests in infancy with burning skin pain after\\neven short exposure to sunlight. Gallstones are common later in life, and acute liver failure\\noccurs in about 10%. Diagnosis is based on symptoms and increased levels of protoporphyrin\\nin RBCs and plasma. Treatment is with \\n\\n-carotene or dihydroxyacetone and avoidance of\\nsunlight. In patients with liver failure, combined liver and bone marrow transplantation may be\\nlife saving as well as curative\\n.\\nEtiology\\nEPP results from deficiency of the enzyme ferrochelatase in erythroid tissue. Clinical prevalence is\\nabout1/75,000. Phototoxic protoporphyrins accumulate in bone marrow and RBCs, enter the plasma, and\\nare deposited in the skin or excreted by the liver into bile and stool. Heavy biliary protoporphyrin excretion\\ncan cause gallstones. These cytotoxic molecules sometimes damage the hepatobiliary tract, resulting in\\nhepatic protoporphyrin accumulation that leads to acute liver failure; liver failure may become clinically\\nacute within days.\\nInheritance pattern is basically autosomal dominant but complex. Clinical manifestations occur only in\\npeople who have both the defective EPP gene and an unusual low-output (but otherwise normal) allele\\nfrom the healthy parent.\\nSymptoms and Signs\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n946'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 956, 'page_label': '947'}, page_content='Severity varies greatly, even among patients within a single family. Usually, an infant or young child with\\nEPP cries for hours after even short exposure to sun. However, because cutaneous signs are usually\\nabsent and young children cannot describe their symptoms, EPP often goes undiagnosed.\\nIf unrecognized, EPP causes psychosocial problems because children inexplicably refuse to go outdoors.\\nThe pain may be so distressing that it causes nervousness, tenseness, aggressiveness, or even feelings\\nof detachment from the surroundings or suicidal thoughts.\\nDuring childhood, crusting may develop around the lips and on the back of the hands after prolonged sun\\nexposure. Blistering and scarring do not occur. If skin protection is chronically neglected, rough,\\nthickened, and leathery skin may \\ndevelop, especially over the knuckles. Linear perioral furrows (carp\\nmouth) may develop.\\nBiliary excretion of large amounts of protoporphyrin can cause cholestasis that progresses to nodular\\ncirrhosis and acute liver failure in  10% of patients; symptoms include jaundice, malaise, upper\\nabdominal pain, and tender hepatic enlargement.\\nDiagnosis\\n RBC and plasma protoporphyrin measurement\\nEPP should be suspected in children and adults with painful cutaneous photosensitivity who experience\\nno blisters or scarring. Family history is usually negative. The diagnosis is confirmed by finding increased\\nRBC and plasma protoporphyrin levels. A genetic marker for susceptibility to cholestatic complications\\nhas been identified.\\nScreening of potential carriers among relatives is by showing increased RBC protoporphyrin contents and\\ndecreased ferrochelatase activity (assayed in lymphocytes) or by genetic testing if the mutation has been\\nidentified in the index case. Susceptibility for cutaneous disease in carriers is indicated by finding the low-\\noutput ferrochelatase allele.\\nTreatment\\n Avoidance of triggers (eg, sun exposure, alcohol, fasting)\\n Symptomatic treatment\\n Sometimes oral \\n\\n-carotene\\nAcute skin symptoms are alleviated by cold baths or wet towels, analgesics, and antihistamines. Regular\\nphysician-patient consultations that provide information, discussion, and opportunities for genetic\\ncounseling together with physical checkups are important.\\nPatients should avoid sun exposure; opaque titanium dioxide or zinc oxide sunscreens are beneficial, and\\nUVA-absorbing sunscreens, such as those containing dibenzylmethanes, may help somewhat. Protection\\nagainst the operating light is strictly required in liver transplantation to avoid serious phototoxic injury to\\ninner organs. Covering of light sources with filters that block wavelengths < 470 nm is required.\\nEndoscopy, laparoscopy, and nontransplant abdominal surgery are not connected with risk of phototoxic\\ndamage.\\n[\\nTable 96-6.\\n Doses of \\n\\n-Carotene in Erythropoietic Protoporphyria]\\nPatients should avoid alcohol and fasting, both of which increase the rate of RBC production and thus the\\nprotoporphyrin load. Drugs that trigger acute porphyrias (see \\nTable 96-4\\n) need not be avoided.\\nSystemic \\n\\n-carotene causes slight yellow protective skin coloration and neutralizes the toxic radicals in\\nthe skin that cause symptoms. Dose depends on patient age (see \\nTable 96-6\\n).\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n947'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 957, 'page_label': '948'}, page_content='Another antioxidant, cysteine, may also lessen photosensitivity. The brown protective skin color obtained\\nwith topically applied dihydroxyacetone is generally cosmetically preferable to the yellowish tint caused by\\n\\n-carotene.\\nIf the above-mentioned measures are ineffective (eg, patients have increasing photosensitivity, rising\\nporphyrin levels, or progressive jaundice), RBC hypertransfusion (ie, to abovenormal Hb levels) can\\nreduce the production rate of porphyrin-loaded RBCs. Administration of bile acids facilitates biliary\\nexcretion of protoporphyrin. Oral cholestyramine or charcoal interrupts the enterohepatic circulation. Liver\\nfailure may require immediate liver transplantation. Bone marrow exchange corrects the basic metabolic\\ndefect.\\nPatients with EPP should undergo annual surveillance for risks of cholestasis. Tests include RBC\\nporphyrin levels, porphyrin excretion patterns, and liver function. Abnormal findings should be evaluated\\nby a porphyria specialist and a hepatologist. If the liver appears involved, biopsy is done to identify\\nprogressive disease. Patients should be vaccinated against hepatitis A and B and advised to avoid\\nalcohol.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 96. Porphyrias\\n948'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 958, 'page_label': '949'}, page_content='Chapter 97. Fluid and Electrolyte Metabolism\\nIntroduction\\nBody fluid volume and electrolyte concentration are normally maintained within very narrow limits despite\\nwide variations in dietary intake, metabolic activity, and environmental stresses. Homeostasis of body\\nfluids is preserved primarily by the kidneys.\\nWater and Sodium Balance\\nWater and Na balance are closely interdependent. Total body water (TBW) is about 60% of body weight\\n(ranging from about 50% in obese people to 70% in lean people). Almost two thirds of TBW is in the\\nintracellular compartment (intracellular fluid, or ICF); the other one third is extracellular (extracellular fluid,\\nor ECF). Normally, about 25% of the ECF is in the intravascular compartment; the other 75% is interstitial\\nfluid (see\\nFig. 97-1\\n).\\nThe major intracellular cation is K, with an average concentration of 140 mEq/L. The extracellular K\\nconcentration is 3.5 to 5 mEq/L. The major extracellular cation is Na, with an average concentration of\\n140 mEq/L and an intracellular Na concentration of 12 mEq/L.\\nOsmotic forces:\\n The concentration of combined solutes in water is osmolarity (amount of solute per L of\\nsolution), which, in body fluids, is similar to osmolality (amount of solute per kg of solution). Plasma\\nosmolality can be measured in the laboratory or estimated according to the formula\\nPlasma osmolality (mOsm/kg) =\\nwhere serum Na is expressed in mEq/L and glucose and BUN are expressed in mg/dL. Osmolality of\\nbody fluids is normally between 275 and 290 mOsm/kg. Na is the major determinant of serum osmolality.\\nApparent changes in osmolality may result from errors in the measurement of Na with electrodes that are\\nnot ion selective (see under Diagnosis on p. \\n826\\n). An osmolar gap is present when measured osmolality\\nexceeds estimated osmolality by  10 mOsm/kg. It is caused by unmeasured osmotically active\\nsubstances present in the plasma. The most common are alcohols (ethanol, methanol, isopropanol,\\nethylene glycol), mannitol, and glycine.\\nWater crosses cell membranes freely from areas of low solute concentration to areas of high solute\\nconcentration. Thus, osmolality tends to equalize across the various body fluid compartments, resulting\\nprimarily from movement of water, not solutes. Solutes such as urea that freely diffuse across cell\\nmembranes have little or no effect on water shifts (little or no osmotic activity), whereas solutes that are\\nrestricted primarily to one fluid compartment, such as Na and K, have the greatest osmotic activity.\\nTonicity, or effective osmolality, reflects osmotic activity and determines the force drawing water across\\nfluid compartments (the osmotic force). Osmotic force can be opposed by other forces. For example,\\nplasma proteins have a small osmotic effect that tends to draw water into the plasma; this osmotic effect\\nis normally counteracted by vascular hydrostatic forces that drive water out of the plasma.\\nWater intake and excretion:\\n The average daily fluid intake is about 2.5 L. The amount needed to\\nreplace losses from the urine and other sources is about 1 to 1.5 L/day in healthy adults. However, on a\\nshort-term basis, an average\\n[\\nFig. 97-1.\\n Fluid compartments in an average 70-kg man.]\\nyoung adult with normal kidney function may ingest as little as 200 mL of water each day to excrete the\\nnitrogenous and other wastes generated by cellular metabolism. More is needed in people with any loss\\nof renal concentrating capacity. Renal concentrating capacity is lost in\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n949'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 959, 'page_label': '950'}, page_content=' The elderly\\n People with diabetes insipidus, certain renal disorders, hypercalcemia, severe salt restriction, chronic\\noverhydration, or hyperkalemia\\n People who ingest ethanol, phenytoin, lithium, demeclocycline, or amphotericin B\\n People with osmotic diuresis (eg, due to high-protein diets or hyperglycemia)\\nOther obligatory water losses are mostly insensible losses from the lungs and skin, averaging about 0.4\\nto 0.5 mL/kg/h or about 650 to 850 mL/day in a 70-kg adult. With fever, another 50 to 75 mL/day may be\\nlost for each degree C of temperature elevation above normal. GI losses are usually negligible, except\\nwhen marked vomiting, diarrhea, or both occur. Sweat losses can be significant during environmental\\nheat exposure or excessive exercise.\\nWater intake is regulated by thirst. Thirst is triggered by receptors in the anterolateral hypothalamus that\\nrespond to increased serum osmolality (as little as 2%) or decreased body fluid volume. Rarely\\nhypothalamic dysfunction decreases the capacity for thirst.\\nWater excretion by the kidneys is regulated primarily by ADH (vasopressin). ADH is released by the\\nposterior pituitary and results in increased water reabsorption in the distal nephron. ADH release is\\nstimulated by any of the following:\\n Increased serum osmolality\\n Decreased blood volume\\n Decreased BP\\n Stress\\nADH release may be impaired by certain substances (eg, ethanol, phenytoin) and central diabetes\\ninsipidus (see p. \\n772\\n).\\nWater intake decreases serum osmolality. Low serum osmolality inhibits ADH secretion, allowing the\\nkidneys to produce dilute urine. The diluting capacity of healthy kidneys in young adults is such that\\nmaximum daily fluid intake can be as much as 25 L; greater amounts quickly lower serum osmolality.\\nDisorders of Fluid Volume\\nBecause Na is the major osmotically active ion in the ECF, total body Na content determines ECF volume.\\nDeficiency or excess of total body Na content causes ECF volume depletion or overload. Plasma Na\\nconcentration does not necessarily reflect total body Na.\\nDietary intake and renal excretion regulate total body Na content. When total Na content and ECF volume\\nare low, the kidneys increase Na conservation. When total Na content and ECF volume are high, Na\\nexcretion (natriuresis) increases so that volume decreases.\\nRenal Na excretion can be adjusted widely to match Na intake. Renal Na excretion requires delivery of\\nNa to the kidneys and so depends on renal blood flow and GFR. Thus, inadequate Na excretion may be\\nsecondary to decreased renal blood flow, as in chronic kidney disease or heart failure.\\nRenin-angiotensin-aldosterone axis:\\n The renin-angiotensin-aldosterone axis is the main regulatory\\nmechanism of renal Na excretion. In volume-depleted states, GFR and Na delivery to the distal nephrons\\ndecreases, causing release of renin. Renin cleaves angiotensinogen (renin substrate) to form angiotensin\\nI. ACE then cleaves angiotensin I to angiotensin II. Angiotensin II does the following:\\n Increases Na retention by decreasing the filtered load of Na and enhancing proximal tubular Na\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n950'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 960, 'page_label': '951'}, page_content='reabsorption.\\n Increases BP (has pressor activity)\\n Increases thirst\\n Directly impairs water excretion\\n Stimulates the adrenal cortex to secrete aldosterone, which increases Na reabsorption via multiple renal\\nmechanisms\\nAngiotensin I can also be transformed to angiotensin III, which stimulates aldosterone release as much as\\nangiotensin II but has much less pressor activity. Aldosterone release is also stimulated by hyperkalemia.\\nOther natriuretic factors:\\n Several other natriuretic factors have been identified, including atrial\\nnatriuretic peptide (ANP), brain natriuretic peptide (BNP), and a C-type natriuretic peptide (CNP).\\nANP\\n is secreted by cardiac atrial tissue. Concentration increases in response to ECF volume overload\\n(eg, heart failure, chronic kidney disease, cirrhosis with ascites) and primary aldosteronism and in some\\npatients with primary hypertension. Decreases have occurred in the subset of patients with nephrotic\\nsyndrome who have presumed ECF volume contraction. High concentrations increase Na excretion and\\nincrease GFR even when BP is low.\\nBNP\\n is synthesized mainly in the atria and left ventricle and has similar triggers and effects to ANP. BNP\\nassays are readily available. High BNP concentration is used to diagnose volume overload.\\nCNP\\n, in contrast to ANP and BNP, is primarily vasodilatory.\\nNa depletion and excess:\\n Na depletion requires inadequate Na intake plus abnormal losses from the\\nskin, GI tract, or kidneys (defective renal Na conservation). Defective renal Na conservation may be\\ncaused by primary renal disease, adrenal insufficiency, or diuretic therapy.\\nNa overload requires higher Na intake than excretion; however, because normal kidneys can excrete\\nlarge amounts of Na, Na overload generally reflects defective regulation of renal blood flow and Na\\nexcretion (eg, as occurs in heart failure, cirrhosis, or chronic kidney disease).\\nVolume Depletion\\nVolume depletion, or ECF volume contraction, occurs as a result of loss of total body Na.\\nCauses include vomiting, excessive sweating, diarrhea, burns, diuretic use, and kidney failure.\\nClinical features include diminished skin turgor, dry mucous membranes, tachycardia, and\\northostatic hypotension. Diagnosis is clinical. Treatment involves administration of Na and\\nwater\\n.\\nBecause water crosses plasma membranes in the body through passive osmosis, loss of the major\\nextracellular cation (Na) quickly results in water loss from the ECF space as well. In this way, Na loss\\nalways causes water loss. However, depending on many factors, serum Na concentration can be high,\\nlow, or normal in volume-depleted patients (despite the decreased total body Na content). ECF volume is\\nrelated to effective circulating volume. A decrease in ECF (hypovolemia) generally causes a decrease in\\neffective circulating volume, which in turn causes decreased organ perfusion and leads to clinical\\nsequelae. Common causes of volume depletion are listed in\\nTable 97-1\\n.\\nSymptoms and Signs\\nIn mild volume depletion (< 5% of ECF), the only sign may be diminished skin turgor (best assessed at\\nthe upper torso). Skin turgor may be low in elderly patients regardless of volume status. Patients may\\ncomplain of thirst. Dry mucous membranes do not always correlate with volume depletion, especially in\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n951'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 961, 'page_label': '952'}, page_content='the elderly and in mouth-breathers. Oliguria is typical.\\nWhen ECF volume has diminished by 5 to 10%, orthostatic tachycardia, hypotension, or both are usually,\\nbut not always, present. Also, orthostatic changes can occur in patients without ECF volume depletion,\\nparticularly patients deconditioned or bedridden. Skin turgor may decrease further.\\n[\\nTable 97-1.\\n Common Causes of Volume Depletion]\\nWhen fluid loss exceeds 10% of ECF volume, signs of shock can occur (eg, tachypnea, tachycardia,\\nhypotension, confusion, poor capillary refill).\\nDiagnosis\\n Clinical findings\\n Sometimes serum electrolytes, BUN, and creatinine\\n Rarely serum osmolality and urine chemistries\\nVolume depletion is suspected in patients at risk, most often in patients with a history of inadequate fluid\\nintake (especially in comatose or disoriented patients), increased fluid losses, diuretic therapy, and renal\\nor adrenal disorders.\\nDiagnosis is usually clinical. When the cause is obvious and easily correctable (eg, acute gastroenteritis\\nin otherwise healthy patients), laboratory testing is unnecessary; otherwise, serum electrolytes, BUN, and\\ncreatinine are measured. Serum osmolality and urine Na, creatinine, and osmolality are measured when\\nthere is suspicion of clinically meaningful electrolyte abnormality that is not clear from serum tests and for\\npatients with cardiac or renal disease. When metabolic alkalosis is present, urine Cl is also measured.\\nCentral venous pressure and pulmonary artery occlusion pressure are decreased in volume depletion, but\\nmeasurement is rarely required. Measurement, which requires an invasive procedure, is occasionally\\nnecessary for patients for whom even small amounts of added volume may be detrimental, such as those\\nwith unstable heart failure or advanced chronic kidney disease.\\nThe following concepts are helpful when interpreting urine electrolyte and osmolality values:\\n During volume depletion, normally functioning kidneys conserve Na. Thus, the urine Na concentration is\\nusually < 15 mEq/L; the fractional excretion of Na (urine Na/serum Na divided by urine creatinine/serum\\ncreatinine) is usually < 1%; also, urine osmolality is often > 450 mOsm/kg.\\n When metabolic alkalosis is combined with volume depletion, urine Na concentration may be high\\nbecause large amounts of HCO\\n3\\n are spilled in the urine, obligating the excretion of Na to maintain\\nelectrical neutrality. In this instance, a urine Cl concentration of < 10 mEq/L more reliably indicates\\nvolume depletion.\\n Misleadingly high urinary Na (generally > 20 mEq/L) or low urine osmolality can also occur due to renal\\nNa losses resulting from renal disease, diuretics, or adrenal insufficiency.\\nVolume depletion frequently increases the BUN and serum creatinine concentrations with the ratio of\\nBUN to creatinine often > 20:1. Values such as Hct often increase in volume depletion but are difficult to\\ninterpret unless baseline values are known.\\nTreatment\\n Replacement of Na and water\\nThe cause of volume depletion is corrected and fluids are given to replace existing volume deficits as well\\nas any ongoing fluid losses and to provide daily fluid requirements. Mild-to-moderate volume deficits may\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n952'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 962, 'page_label': '953'}, page_content='be replaced by increased oral intake of Na and water when patients are conscious and not vomiting.\\nWhen volume deficits are severe or when oral fluid replacement is impractical, IV 0.9% saline is given.\\nTypical IV regimens are discussed on p. \\n2297\\n; oral regimens are discussed on p.\\n2809\\n.\\nVolume Overload\\nVolume overload generally refers to expansion of the ECF volume. ECF volume expansion\\ntypically occurs in heart failure, nephrotic syndrome, and cirrhosis. Renal Na retention leads to\\nincreased total body Na content. This increase results in varying degrees of volume overload.\\nIn heart failure, the increased ECF volume results in decreased effective circulating volume,\\nwhich in turn causes decreased organ perfusion leading to clinical sequelae. Serum Na\\nconcentration can be high, low, or normal in volume-overloaded patients (despite the increased\\ntotal body Na content)\\n.\\nAn increase in total body Na is the key pathophysiologic event. It increases osmolality, which triggers\\ncompensatory mechanisms that cause water retention. When sufficient fluid accumulates in the ECF\\n(usually > 2.5 L), edema (see p. \\n2031\\n) develops.\\nAmong the most common causes of ECF volume overload are the following:\\n Heart failure\\n Cirrhosis\\n Renal failure\\n Nephrotic syndrome\\n Premenstrual edema\\n Pregnancy\\nClinical features include weight gain and edema. Diagnosis is clinical. Treatment aims to correct the\\ncause.\\nHyponatremia\\nHyponatremia is decrease in serum Na concentration < 136 mEq/L caused by an excess of\\nwater relative to solute. Common causes include diuretic use, diarrhea, heart failure, and renal\\ndisease. Clinical manifestations are primarily neurologic (due to an osmotic shift of water into\\nbrain cells causing edema), especially in acute hyponatremia, and include headache, confusion,\\nand stupor; seizures and coma may occur. \\nDiagnosis is by measuring serum Na. Serum and\\nurine electrolytes and osmolality help determine the cause. Treatment involves restricting\\nwater intake and promoting its loss, replacing any Na deficit, and treating the cause.\\nEtiology\\nHyponatremia reflects an excess of total body water (TBW) relative to total body Na content. Because\\ntotal body Na content is reflected by ECF volume status, hyponatremia must be considered along with\\nstatus of the ECF volume: hypovolemia, euvolemia, and hypervolemia (see\\nTable 97-2\\n). Note that the ECF volume is not the same as effective plasma volume. For example,\\ndecreased effective plasma volume may occur with decreased ECF volume, but it may also occur with an\\nincreased ECF volume (eg, in heart failure, hypoalbuminemia, or capillary leak syndrome).\\nHypovolemic hyponatremia:\\n Deficiencies in both TBW and total body Na exist, although proportionally\\nmore Na than water has been lost; the Na deficit causes hypovolemia. In hypovolemic hyponatremia, both\\nserum osmolality and blood volume decrease. ADH secretion increases despite a decrease in osmolality\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n953'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 963, 'page_label': '954'}, page_content=\"to maintain blood volume. The resulting water retention increases plasma dilution and hyponatremia.\\n[\\nTable 97-2.\\n Principal Causes of Hyponatremia]\\nExtrarenal fluid losses\\n, such as those that occur with the losses of Na-containing fluids as in protracted\\nvomiting, severe diarrhea, or sequestration of fluids in a 3rd space (see\\nTable 97-3\\n), can cause hyponatremia typically when losses are replaced by ingesting plain water or\\nliquids low in Na (see\\nTable 97-4\\n) or by hypotonic IV fluid. Significant ECF fluid losses also cause release of ADH, causing\\nwater retention by the kidneys, which can maintain or worsen hyponatremia. In extrarenal causes of\\nhypovolemia, because the normal renal response to volume loss is Na conservation, urine Na\\nconcentration is typically < 10 mEq/L.\\nRenal fluid losses\\n resulting in hypovolemic hyponatremia may occur with mineralocorticoid deficiency,\\ndiuretic therapy, osmotic diuresis, or salt-losing nephropathy. Salt-losing nephropathy encompasses a\\nloosely defined group of intrinsic renal disorders with primarily renal tubular dysfunction. This group\\nincludes interstitial nephritis, medullary cystic disease, partial urinary tract obstruction, and, occasionally,\\npolycystic kidney disease. Renal causes of hypovolemic hyponatremia can usually be differentiated from\\nextrarenal causes by the history. Patients with ongoing renal fluid losses can also be distinguished from\\npatients with extrarenal fluid losses because the urine Na concentration is inappropriately high (> 20\\nmEq/L). Urine Na concentration may not help in differentiation when metabolic alkalosis (as occurs with\\nprotracted vomiting) is present and large amounts of HCO\\n3\\n are spilled in the urine, obligating the\\nexcretion of Na to maintain electrical neutrality. In metabolic alkalosis, urine Cl concentration frequently\\ndifferentiates renal from extrarenal sources of volume depletion (see p. \\n862\\n).\\n[\\nTable 97-3.\\n Composition of Body Fluids]\\n[\\nTable 97-4.\\n Approximate Na Content of Common Beverages]\\nDiuretics\\n may also cause hypovolemic hyponatremia. Thiazide diuretics, in particular, decrease the\\nkidneys' diluting capacity and increase Na excretion. Once volume depletion occurs, the nonosmotic\\nrelease of ADH causes water retention and worsens hyponatremia. Concomitant hypokalemia shifts Na\\nintracellularly and enhances ADH release, thereby worsening hyponatremia. This effect of thiazides may\\nlast for up to 2 wk after cessation of therapy; however, hyponatremia usually responds to replacement of\\nK and volume deficits along with judicious monitoring of water intake until the drug effect dissipates.\\nElderly patients may have increased Na diuresis and are especially susceptible to thiazide-induced\\nhyponatremia, particularly when they have a preexisting defect in renal capacity to excrete free water.\\nRarely, such patients develop severe, life-threatening hyponatremia within a few weeks after the initiation\\nof a thiazide diuretic. Loop diuretics much less commonly cause hyponatremia.\\nEuvolemic hyponatremia:\\n In euvolemic (dilutional) hyponatremia, total body Na and thus ECF volume\\nare normal or near-normal; however, TBW is increased.\\nPrimary polydipsia can cause hyponatremia only when water intake overwhelms the kidneys' ability to\\nexcrete water. Because normal kidneys can excrete up to 25 L urine/day, hyponatremia due solely to\\npolydipsia results only from the ingestion of large amounts of water or from defects in renal capacity to\\nexcrete free water. Patients affected include those with psychosis or more modest degrees of polydipsia\\nplus renal insufficiency.\\nEuvolemic hyponatremia may also result from excessive water intake in the presence \\nof Addison's\\ndisease, hypothyroidism, or nonosmotic ADH release (eg, due to stress; postoperative states; use of\\ndrugs such as chlorpropamide, tolbutamide, opioids, barbiturates, vincristine, clofibrate, or\\ncarbamazepine). Postoperative hyponatremia most commonly occurs because of a combination of\\nnonosmotic ADH release and excessive administration of hypotonic fluids after surgery. Certain drugs (eg,\\ncyclophosphamide, NSAIDs, chlorpropamide) potentiate the renal effect of endogenous ADH, whereas\\nothers (eg, oxytocin) have a direct ADH-like effect on the kidneys. A deficiency in water excretion is\\ncommon in all these conditions. Diuretics can cause or contribute to euvolemic hyponatremia if another\\nfactor causes water retention or excessive water intake. The syndrome of inappropriate ADH secretion\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n954\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 964, 'page_label': '955'}, page_content='(SIADHsee \\nSidebar 97-1\\n) is another cause of euvolemic hyponatremia.\\nHypervolemic hyponatremia:\\n Hypervolemic hyponatremia is characterized by an increase in both total\\nbody Na (and thus ECF volume) and TBW with a relatively greater increase in TBW. Various edematous\\ndisorders, including heart failure and cirrhosis, cause hypervolemic hyponatremia. Rarely, hyponatremia\\noccurs in nephrotic syndrome, although pseudohyponatremia may be due to interference with Na\\nmeasurement by elevated lipids. In each of these disorders, a decrease in effective circulating volume\\nresults in the release of ADH and angiotensin II. The following factors contribute to hyponatremia:\\n The antidiuretic effect of ADH on the kidneys\\n Direct impairment of renal water excretion by angiotensin II\\n Decreased GFR\\n Stimulation of thirst by angiotensin II\\nUrine Na excretion is usually < 10 mEq/L, and urine osmolality is high relative to serum osmolality.\\nHyponatremia in AIDS:\\n Hyponatremia has been reported in > 50% of hospitalized patients with AIDS.\\nAmong the many potential contributing factors are\\n Administration of hypotonic fluids\\n Impaired renal function\\n Nonosmotic ADH release due to intravascular volume depletion\\n Administration of drugs that impair renal water excretion\\nIn addition, adrenal insufficiency has become increasingly common among AIDS patients as the result of\\ncytomegalovirus adrenalitis, mycobacterial infection, or interference with adrenal glucocorticoid and\\nmineralocorticoid synthesis by ketoconazole. SIADH may be present because of coexistent pulmonary or\\nCNS infections.\\nSidebar 97-1 Syndrome of Inappropriate ADH Secretion\\nThe syndrome of inappropriate ADH secretion (SIADH) is attributed to excessive ADH release. It is\\ndefined as less-than-maximally-dilute urine in the presence of plasma hypo-osmolality (hyponatremia)\\nwithout volume depletion or overload, emotional stress, pain, diuretics, or other drugs that stimulate ADH\\nsecretion in patients with normal cardiac, hepatic, renal, adrenal, and thyroid function. SIADH is\\nassociated with myriad disorders (see\\nTable 97-5\\n).\\nSymptoms and Signs\\nSymptoms mainly involve CNS dysfunction. However, when hyponatremia is accompanied by\\ndisturbances in total body Na content, signs of ECF volume depletion or overload also occur (see p. \\n823\\n).\\nIn general, older chronically ill patients with hyponatremia develop more symptoms than younger\\notherwise healthy patients. Symptoms are also more severe with faster-onset hyponatremia. Symptoms\\ngenerally occur when the effective plasma osmolality falls to < 240 mOsm/kg. Symptoms can be subtle\\nand consist mainly of changes in mental status, including altered personality, lethargy, and confusion. As\\nthe serum Na falls to < 115 mEq/L, stupor, neuromuscular hyperexcitability, hyperreflexia, seizures, coma,\\nand death can result.\\nSevere cerebral edema may occur in premenopausal women with acute hyponatremia, perhaps because\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n955'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 965, 'page_label': '956'}, page_content='estrogen and progesterone inhibit brain Na\\n+\\n, K\\n+\\n-ATPase and decrease solute extrusion from brain cells.\\nSequelae include hypothalamic and posterior pituitary infarction and occasionally brain stem herniation.\\nDiagnosis\\n Serum and urine electrolytes and osmolality\\n Clinical assessment of volume status\\nHyponatremia is occasionally suspected in patients who have neurologic abnormalities and are at risk.\\nHowever, because findings are nonspecific, hyponatremia is often recognized only after serum electrolyte\\nmeasurement.\\n[\\nTable 97-5.\\n Disorders Associated with Syndrome of Inappropriate ADH Secretion]\\nSerum Na may be low when severe hyperglycemia increases osmolality and water moves out of cells into\\nthe ECF. Serum Na concentration falls about 1.6 mEq/L for every 100-mg/dL (5.55-mmol/L) rise in the\\nserum glucose concentration above normal. This condition is often called translocational hyponatremia\\nbecause it is caused by translocation of Na across cell membranes. Pseudohyponatremia with normal\\nserum osmolality may occur in hyperlipidemia or extreme hyperproteinemia, because the lipid or protein\\noccupies space in the volume of serum taken for analysis; the concentration of Na in serum itself is not\\naffected. Newer methods of measuring serum electrolytes with ion-selective electrodes circumvent this\\nproblem.\\nIdentification of the cause:\\n Identifying the cause can be complex. The history sometimes suggests a\\ncause (eg, significant fluid loss due to vomiting or diarrhea, renal disease, compulsive fluid ingestion,\\nintake of drugs that stimulate ADH release or enhance ADH action).\\nThe volume status, particularly the presence of obvious volume depletion or overload, suggests certain\\ncauses (see \\nTable 97-1\\n). Overtly hypovolemic patients usually have an obvious source of fluid loss\\n(typically treated with hypotonic fluid replacement). Overtly hypervolemic patients usually have a readily\\nrecognizable condition, such as heart failure or hepatic or renal disease. Euvolemic patients and patients\\nwith equivocal volume status require more laboratory testing to identify a cause.\\nLaboratory tests should include serum and urine osmolality and electrolytes. Euvolemic patients should\\nalso have thyroid and adrenal function tested. Hypo-osmolality in euvolemic patients should cause\\nexcretion of a large volume of dilute urine (eg, osmolality < 100 mOsm/kg and sp gr < 1.003). Serum Na\\nconcentration and serum osmolality that are low and urine osmolality that is inappropriately high (120 to\\n150 mmol/L) with respect to the low serum osmolality suggest volume overload, volume contraction, or\\nSIADH. Volume overload and volume contraction are differentiated clinically (see pp. \\n822\\n and \\n823\\n). When\\nneither volume overload nor volume contraction appears likely, SIADH is considered. Patients with SIADH\\nare usually euvolemic or slightly hypervolemic. BUN and creatinine values are normal, and serum uric\\nacid is generally low. Urine Na concentration is usually > 30 mmol/L, and fractional excretion of Na is >\\n1% (for calculation, see p.\\n2310\\n).\\nIn patients with hypovolemia and normal renal function, Na reabsorption results in a urine Na of < 20\\nmmol/L. Urine Na > 20 mmol/L in hypovolemic patients suggests mineralocorticoid deficiency or salt-\\nlosing nephropathy. Hyperkalemia suggests adrenal insufficiency.\\nTreatment\\n When hypovolemic, 0.9% saline\\n When hypervolemic, fluid restriction and sometimes a diuretic\\n When euvolemic, treatment of cause\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n956'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 966, 'page_label': '957'}, page_content=' Rarely cautious correction with hypertonic (3%) saline\\nRapid correction of hyponatremia, even mild hyponatremia, risks neurologic complications (see p. \\n828\\n).\\nExcept possibly in the first few hours of treatment of severe hyponatremia, Na should be corrected no\\nfaster than 0.5 mEq/L/h. Even with severe hyponatremia, increase in serum Na concentration should not\\nexceed 10 mEq/L over the first 24 h. Any identified cause of hyponatremia is treated concurrently.\\nMild hyponatremia:\\n Mild, asymptomatic hyponatremia (ie, serum Na > 120 mEq/L) requires restraint\\nbecause small adjustments are \\ngenerally sufficient. In diuretic-induced hyponatremia, elimination of the\\ndiuretic may be enough; some patients need some Na or K replacement. Similarly, when mild\\nhyponatremia results from inappropriate hypotonic parenteral fluid administration in patients with impaired\\nwater excretion, merely altering fluid therapy may suffice.\\nWith \\nhypovolemia\\n and normal adrenal function, administration of 0.9% saline usually corrects both\\nhyponatremia and hypovolemia. When the serum Na is < 120 mEq/L, hyponatremia may not completely\\ncorrect upon restoration of intravascular volume; restriction of free water ingestion to  500 to 1000\\nmL/24 h may be needed.\\nIn \\nhypervolemic patients\\n, in whom hyponatremia is due to renal Na retention (eg, heart failure,\\ncirrhosis, nephrotic syndrome) and dilution, water restriction combined with treatment of the underlying\\ndisorder is required. In patients with heart failure, an ACE inhibitor, in conjunction with a loop diuretic, can\\ncorrect refractory hyponatremia. In other patients in whom simple fluid restriction is ineffective, a loop\\ndiuretic in escalating doses can be used, sometimes in conjunction with IV 0.9% normal saline. K and\\nother electrolytes lost in the urine must be replaced. When hyponatremia is more severe and\\nunresponsive to diuretics, intermittent or continuous hemofiltration may be needed to control ECF volume\\nwhile hyponatremia is corrected with IV 0.9% normal saline.\\nIn \\neuvolemia,\\n treatment is directed at the cause (eg, hypothyroidism, adrenal insufficiency, diuretic use).\\nWhen SIADH is present, severe water restriction (eg, 250 to 500 mL/24 h) is generally required.\\nAdditionally, a loop diuretic may be combined with IV 0.9% saline as in hypervolemic hyponatremia.\\nLasting correction depends on successful treatment of the underlying disorder. When the underlying\\ndisorder is not correctable, as in metastatic cancer, and patients find severe water restriction\\nunacceptable, demeclocycline (300 to 600 mg q 12 h) may be helpful by inducing a concentrating defect\\nin the kidneys. However, demeclocycline may cause acute renal failure. Renal failure is usually reversible\\nwhen the drug is stopped. IV conivaptan, an ADH receptor antagonist, causes effective water diuresis\\nwithout significant loss of electrolytes in the urine and can be used in hospitalized patients for treatment\\nof resistant hyponatremia.\\nSevere hyponatremia:\\n Severe hyponatremia (serum Na < 109 mEq/L; effective osmolality < 238\\nmOsm/kg) in asymptomatic patients can be treated safely with stringent restriction of water intake.\\nTreatment is more controversial when neurologic symptoms (eg, confusion, lethargy, seizures, coma) are\\npresent. The debate primarily concerns the pace and degree of hyponatremia correction. Many experts\\nrecommend that serum Na be raised no faster than 1 mEq/L/h, but replacement rates of up to 2 mEq/L/h\\nfor the first 2 to 3 h have been suggested for patients with seizures. Regardless, the rise should be  10\\nmEq/L over the first 24 h. More vigorous correction risks precipitation of osmotic demyelination syndrome.\\nHypertonic (3%) saline (containing 513 mEq Na/L) may be used, but only with frequent (q 2 to 4 h)\\nelectrolyte determinations. For patients with seizures or coma,  100 mL/h may be administered over 4 to\\n6 h in amounts sufficient to raise the serum Na 4 to 6 mEq/L. This amount (in mEq) may be calculated\\nusing the Na deficit formula as\\n(Desired change in Na)  TBW\\nwhere TBW is 0.6  body weight in kg in men and 0.5  body weight in kg in women.\\nFor example, the amount of Na needed to raise the Na from 106 to 112 in a 70-kg man can be calculated\\nas follows:\\n(112 mEq/L - 106 mEq/L)  (0.6 L/kg  70 kg) = 252 mEq\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n957'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 967, 'page_label': '958'}, page_content='Because there is 513 mEq Na/L in hypertonic saline, roughly 0.5 L of hypertonic saline is needed to raise\\nthe Na from 106 to 112 mEq/L.\\nAdjustments may be needed based on serum Na concentrations, which are monitored closely for the first\\nfew hours of treatment. Patients with seizures, coma, or altered mental status need supportive treatment,\\nwhich may involve endotracheal intubation, mechanical ventilation, and benzodiazepines (eg, lorazepam 1\\nto 2 mg IV q 5 to 10 min prn) for seizures.\\nOsmotic demyelination syndrome:\\n Osmotic demyelination syndrome (previously called central pontine\\nmyelinolysis) may follow too-rapid correction of hyponatremia. Demyelination may affect the pons and\\nother areas of the brain. Lesions are more common among patients with alcoholism, undernutrition, or\\nother chronic debilitating illness. Flaccid paralysis, dysarthria, and dysphagia can evolve over a few days\\nor weeks. The lesion may extend dorsally to involve sensory tracts and leave patients with a locked-in\\nsyndrome (an awake and sentient state in which patients, because of generalized motor paralysis, cannot\\ncommunicate, except possibly by coded eye movements). Damage often is permanent. When Na is\\nreplaced too rapidly (eg, > 14 mEq/L/8 h) and neurologic symptoms \\nstart to develop, it is critical to\\nprevent further serum Na increases by stopping hypertonic fluids. In such cases, inducing hyponatremia\\nwith hypotonic fluid may mitigate the development of permanent neurologic damage.\\nHypernatremia\\n(For hypernatremia in neonates, see p. \\n2797\\n.)\\nHypernatremia is serum Na concentration > 145 mEq/L. It implies a deficit of total body water\\nrelative to total body Na, caused by water intake being less than water losses. A major symptom\\nis thirst; other clinical manifestations are primarily neurologic (due to an osmotic shift of water\\nout of brain cells), including confusion, neuromuscular excitability, seizures, and coma.\\nDiagnosis requires measurement of serum Na and sometimes other tests. Treatment is usually\\ncontrolled water replacement. When the response is poor, testing (eg, monitored water\\ndeprivation or administration of vasopressin) is directed at detecting causes other than\\ndecreased water intake.\\nEtiology\\nHypernatremia reflects a deficit of total body water (TBW) relative to total body Na content. Because total\\nbody Na content is reflected by ECF volume status, hypernatremia must be considered along with status\\nof the ECF volume: hypovolemia, euvolemia, and hypervolemia. Note that the ECF volume is not the\\nsame as effective plasma volume. For example, decreased effective plasma volume may occur with\\ndecreased ECF volume, but it may also occur with an increased ECF volume (eg, in heart failure,\\nhypoalbuminemia, or capillary leak syndrome).\\nHypernatremia usually implies either an impaired thirst mechanism or limited access to water. The\\nseverity of the underlying disorder that results in an inability to drink in response to thirst and the effects\\nof brain hyperosmolality are thought to be responsible for a high mortality rate in hospitalized adults with\\nhypernatremia. There are several common causes of hypernatremia (see\\nTable 97-6\\n).\\nHypovolemic hypernatremia:\\n Hypernatremia associated with hypovolemia occurs with Na loss\\naccompanied by a relatively greater loss of water from the body. Common extrarenal causes include most\\nof those that cause hyponatremia and volume depletion (see p. \\n823\\n). Either hypernatremia or\\nhyponatremia can occur with severe volume loss, depending on the relative amounts of Na and water lost\\nand the amount of water ingested before presentation.\\nRenal causes of hypernatremia and volume depletion include therapy with diuretics. Loop diuretics inhibit\\nNa reabsorption in the concentrating portion of the nephrons and can increase water clearance. Osmotic\\ndiuresis can also impair renal concentrating capacity because of a hypertonic substance present in the\\ntubular lumen of the distal nephron. Glycerol, mannitol, and occasionally urea can cause osmotic diuresis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n958'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 968, 'page_label': '959'}, page_content=\"resulting in hypernatremia. The most common cause of hypernatremia due to osmotic diuresis is\\nhyperglycemia in patients with diabetes. Because glucose does not penetrate cells in the absence of\\ninsulin, hyperglycemia further dehydrates the ICF compartment. The degree of hyperosmolality in\\nhyperglycemia may be obscured by the lowering of serum Na resulting from movement of water out of\\ncells into the ECF (translational hyponatremiasee \\nHyponatremia\\n on p. \\n823\\n). Patients with renal disease\\ncan also be predisposed to hypernatremia when their kidneys are unable to maximally concentrate urine.\\nEuvolemic hypernatremia:\\n Hypernatremia with euvolemia is a decrease in TBW with nearnormal total\\nbody Na (pure water deficit). Extrarenal causes of water loss, such as excessive sweating, result in some\\nNa loss, but because sweat is hypotonic, hypernatremia can result before significant hypovolemia. A\\ndeficit of almost purely water also occurs in central and nephrogenic diabetes insipidus.\\nEssential hypernatremia (primary hypodipsia) occasionally occurs in children with brain damage and in\\nchronically ill elderly adults. It is characterized by an impaired thirst mechanism (eg, caused by lesions of\\nthe brain's thirst center). Altered osmotic trigger for ADH release is another possible cause of euvolemic\\nhypernatremia; some lesions cause both an impaired thirst mechanism and an altered osmotic trigger.\\nThe nonosmotic release of ADH seems intact, and these patients are generally euvolemic.\\nHypervolemic hypernatremia:\\n Hypernatremia in rare cases is associated with volume overload. In this\\ncase, hypernatremia results from a grossly elevated Na intake associated with limited access to water.\\nOne example is the excessive administration of hypertonic NaHCO\\n3\\n during treatment of lactic acidosis.\\nHypernatremia can also be caused by the administration of hypertonic saline or incorrectly formulated\\nhyperalimentation.\\nHypernatremia in the elderly:\\n Hypernatremia is common among the elderly, particularly postoperative\\npatients and those receiving tube feedings or parenteral nutrition. Other contributing factors may include\\nthe following:\\n[\\nTable 97-6.\\n Principal Causes of Hypernatremia]\\n Dependence on others to obtain water\\n Impaired thirst mechanism\\n Impaired renal concentrating capacity (due to diuretics, impaired ADH release, or nephron loss\\naccompanying aging or other renal disease)\\n Impaired angiotensin II production (which may contribute directly to the impaired thirst mechanism)\\nSymptoms and Signs\\nThe major symptom of hypernatremia is thirst. The absence of thirst in conscious patients with\\nhypernatremia suggests an impaired thirst mechanism. Patients with difficulty communicating may be\\nunable to express thirst or obtain access to water.\\nThe major signs of hypernatremia result from CNS dysfunction due to brain cell shrinkage. Confusion,\\nneuromuscular excitability, hyperreflexia, seizures, or coma may result; cerebrovascular damage with\\nsubcortical or subarachnoid hemorrhage and venous thromboses are common among patients who died\\nfrom severe hypernatremia.\\nIn chronic hypernatremia, osmotically active substances occur in CNS cells (idiogenic osmoles) and\\nincrease intracellular osmolality. Therefore, the degree of brain cell dehydration and resultant CNS\\nsymptoms are less severe in chronic than in acute hypernatremia.\\nWhen hypernatremia occurs with abnormal total body Na, the typical symptoms of volume depletion or\\noverload are present (see \\nVolume Depletion\\n on p. \\n822\\n and \\nVolume Overload\\n on p. \\n823\\n). A large volume of\\nhypotonic urine is characteristically excreted in patients with renal concentrating defects. When losses\\nare extrarenal, the route of water loss is often evident (eg, vomiting, diarrhea, excessive sweating), and\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n959\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 969, 'page_label': '960'}, page_content='the urinary Na concentration is low.\\nDiagnosis\\n Serum Na\\nThe diagnosis is clinical and by measuring serum Na. In patients who do not respond to simple\\nrehydration or in whom hypernatremia recurs despite adequate access to water, further diagnostic testing\\nis warranted. Determination of the underlying disorder requires assessment of urine volume and\\nosmolality, particularly after water deprivation.\\nIn patients with increased urine output, a water deprivation test (see p. \\n773\\n) is occasionally used to\\ndifferentiate among several polyuric states, such as central and nephrogenic diabetes insipidus.\\nTreatment\\n Replacement of intravascular volume and of free water\\nReplacement of intravascular volume and of free water is the main goal of treatment. Oral hydration is\\neffective in conscious patients without significant GI dysfunction. In severe hypernatremia or in patients\\nunable to drink because of continued vomiting or mental status changes, IV hydration is preferred.\\nHypernatremia that lasts < 24 h should be corrected within 24 h. However, hypernatremia that is chronic\\nor of unknown duration should be corrected over 48 h, and the serum osmolality should be lowered at a\\nrate of no faster than 2 mOsm/L/h to avoid cerebral edema caused by excess brain solute. The amount of\\nwater (in liters) necessary to replace existing deficits may be estimated by the following formula:\\nFree water deficit = TBW  [serum Na/140) - 1]\\nwhere TBW is in liters and is estimated by multiplying weight in kilograms by 0.6; serum Na is in mEq/L.\\nThis formula assumes constant total body Na content. In patients with hypernatremia and depletion of\\ntotal body Na content (ie, who have volume depletion), the free water deficit is greater than that estimated\\nby the formula.\\nIn patients with hypernatremia and ECF volume overload (excess total body Na content), the free water\\ndeficit can be replaced with 5% D/W, which can be supplemented with a loop diuretic. However, too-rapid\\ninfusion of 5% D/W may cause glycosuria, thereby increasing salt-free water excretion and hypertonicity,\\nespecially in patients with diabetes mellitus. Other electrolytes, including serum K, should be monitored\\nand should be replaced as needed.\\nIn patients with hypernatremia and euvolemia, free water can be replaced using either 5% D/W or 0.45%\\nsaline.\\nTreatment of patients with central diabetes insipidus is discussed on p. \\n774\\n. Acquired nephrogenic\\ndiabetes insipidus is discussed on p. \\n2424\\n.\\nIn patients with hypernatremia and hypovolemia, particularly in patients with diabetes with nonketotic\\nhyperglycemic coma, 0.45% saline can be given as an alternative to a combination of 0.9% normal saline\\nand 5% D/W to replenish Na and free water. Alternatively, ECF volume and free water can be replaced\\nseparately, using the formula given previously to estimate the free water deficit. When severe acidosis\\n(pH < 7.10) is present, NaHCO\\n3\\n solution can be added to 5% D/W or 0.45% saline, as long as the final\\nsolution remains hypotonic.\\nDisorders of Potassium Concentration\\nK is the most abundant intracellular cation, but only about 2% of total body K is extracellular. Because\\nmost intracellular K is contained within muscle cells, total body K is roughly proportional to lean body\\nmass. An average 70-kg adult has about 3500 mEq of K.\\nK is a major determinant of intracellular osmolality. The ratio between ICF and ECF K concentrations\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n960'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 970, 'page_label': '961'}, page_content=\"K is a major determinant of intracellular osmolality. The ratio between ICF and ECF K concentrations\\nstrongly influences cell membrane polarization, which in turn influences important cell processes, such as\\nthe conduction of nerve impulses and muscle (including myocardial) cell contraction. Thus, relatively\\nsmall alterations in serum K concentration can have significant clinical manifestations.\\nIn the absence of factors that shift K in or out of cells (see p. \\n832\\n), the serum K concentration correlates\\nclosely with total body K content. Once intracellular and extracellular concentrations are stable, a\\ndecrease in serum K concentration of about 1 mEq/L indicates a total K deficit of about 200 to 400 mEq.\\nPatients with K < 3 mEq/L typically have a significant K deficit.\\nK shifts:\\n Factors that shift K in or out of cells include the following:\\n Insulin concentrations\\n \\n\\n-Adrenergic activity\\n Acid-base status\\nInsulin moves K into cells; high concentrations of insulin thus lower serum K concentration. Low insulin\\nconcentrations, as in diabetic ketoacidosis, cause K to move out of cells, thus raising serum K, sometimes\\neven in the presence of total body K deficiency.\\n\\n-Adrenergic agonists, especially selective \\n\\n2\\n-agonists, move K into cells, whereas \\n\\n-blockade and \\n\\n-\\nagonists promote movement of K out of cells.\\nAcute metabolic acidosis causes K to move out of cells, whereas acute metabolic alkalosis causes K to\\nmove into cells. However, changes in serum HCO\\n3\\n concentration may be more important than changes in\\npH; acidosis caused by accumulation of mineral acids (nonanion gap, hyperchloremic acidosis) is more\\nlikely to elevate serum K. In contrast, metabolic acidosis due to accumulation of organic acids (increased\\nanion gap acidosis) is not associated with hyperkalemia. Thus, the hyperkalemia common in diabetic\\nketoacidosis results more from insulin deficiency than from acidosis. Acute respiratory acidosis and\\nalkalosis affect serum K concentration less than metabolic acidosis and alkalosis. Nonetheless, serum K\\nconcentration should always be interpreted in the context of the serum pH (and HCO\\n3\\n concentration).\\nK metabolism:\\n Dietary K intake normally varies between 40 and 150 mEq/day. In the steady state, fecal\\nlosses are usually close to 10% of intake. Urinary excretion contributes to K balance.\\nWhen K intake is > 150 mEq/day, about 50% of the excess K appears in the urine over the next several\\nhours. Most of the remainder is transferred into the intracellular compartment, thus minimizing the rise in\\nserum K. When elevated K intake continues, aldosterone secretion is stimulated and thus renal K\\nexcretion rises. In addition, K absorption from stool appears to be under some regulation and may fall by\\n50% in chronic K excess.\\nWhen K intake falls, intracellular K again serves to buffer wide swings in serum K concentration. Renal K\\nconservation develops relatively slowly in response to decreases in dietary K and is far less efficient than\\nthe kidneys' ability to conserve Na. Thus, K depletion is a frequent clinical problem. Urinary K excretion of\\n10 mEq/day represents near-maximal renal K conservation and implies significant K depletion.\\nAcute acidosis impairs K excretion, whereas chronic acidosis and acute alkalosis can promote K\\nexcretion. Increased delivery of Na to the distal nephrons, as occurs with high Na intake or loop diuretic\\ntherapy, promotes K excretion.\\nFalse K concentrations:\\n Pseudohypokalemia, or falsely low serum K, occasionally occurs in patients\\nwith chronic myelocytic leukemia with a WBC count > 10\\n5\\n/\\n\\nL when the specimen remains at room\\ntemperature before being processed because of uptake of serum K by abnormal leukocytes in the\\nsample. It is prevented by prompt separation of plasma or serum in blood samples.\\nPseudohyperkalemia, or falsely elevated serum K, is more common, typically occurring due to hemolysis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n961\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 971, 'page_label': '962'}, page_content=\"and release of intracellular K. To prevent false results, phlebotomy personnel should not rapidly aspirate\\nblood through a narrow-gauge needle or excessively agitate blood samples. Pseudohyperkalemia can\\nalso result from platelet count > 400,000/\\n\\nL due to release of K from platelets during clotting. In cases of\\npseudohyperkalemia, the plasma K (unclotted blood), as opposed to serum K, is normal.\\nHypokalemia\\nHypokalemia is serum K concentration < 3.5 mEq/L caused by a deficit in total body K stores or\\nabnormal movement of K into cells. The most common causes are excess losses from the\\nkidneys or GI tract. Clinical features include muscle weakness and polyuria; cardiac\\nhyperexcitability may occur with severe hypokalemia. Diagnosis is by serum measurement.\\nTreatment is giving K and managing the cause\\n.\\nEtiology\\nHypokalemia can be caused by decreased intake of K but is usually caused by excessive losses of K in\\nthe urine or from the GI tract.\\nGI tract losses:\\n Abnormal GI K losses occur in all of the following:\\n Chronic diarrhea, including chronic laxative abuse and bowel diversion\\n Clay (bentonite) ingestion, which binds K and greatly decreases absorption\\n Vomiting\\n Protracted gastric suction (which removes volume and HCl, causing the kidneys to excrete HCO\\n3\\n and,\\nto electrically balance lost HCO\\n3\\n, K)\\n Rarely, villous adenoma of the colon, which causes massive K secretion\\nGI K losses may be compounded by concomitant renal K losses due to metabolic alkalosis and\\nstimulation of aldosterone due to volume depletion.\\nIntracellular shift:\\n The transcellular shift of K into cells may also cause hypokalemia. This shift can\\noccur in any of the following:\\n Glycogenesis during TPN or enteral hyperalimentation (stimulating insulin release)\\n After administration of insulin\\n Stimulation of the sympathetic nervous system, particularly with \\n\\n2\\n-agonists (eg, albuterol, terbutaline),\\nwhich may increase cellular K uptake\\n \\nThyrotoxicosis (occasionally) due to excessive \\n\\n-sympathetic stimulation (hypokalemic thyrotoxic\\nperiodic paralysis)\\n Familial periodic paralysis (see p. \\n3008\\n), a rare autosomal dominant disorder characterized by transient\\nepisodes of profound hypokalemia thought to be due to sudden abnormal shifts of K into cells.\\nEpisodes frequently involve varying degrees of paralysis. They are typically precipitated by a large\\ncarbohydrate meal or strenuous exercise.\\nRenal losses:\\n Various disorders can increase renal K excretion. Excess mineralocorticoid effect can\\ndirectly increase K secretion by the distal nephrons and occurs in any of the following:\\n Adrenal steroid excess that is due to Cushing's syndrome, primary hyperaldosteronism, rare renin-\\nsecreting tumors, glucocorticoid-remediable aldosteronism (a rare inherited disorder involving abnormal\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n962\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 972, 'page_label': '963'}, page_content=\"aldosterone metabolism), and congenital adrenal hyperplasia.\\n Ingestion of substances such as glycyrrhizin (present in natural licorice and used in the manufacture of\\nchewing tobacco), which inhibits the enzyme 11\\n\\n-hydroxysteroid dehydrogenase (11\\n\\n-HSDH),\\npreventing the conversion of cortisol, which has some mineralocorticoid activity, to cortisone, which\\ndoes not, resulting in high circulating concentrations of cortisol and renal K wasting.\\n Bartter and Gitelman's syndromes, uncommon genetic disorders characterized by renal K and Na\\nwasting, excessive production of renin and aldosterone, and normotension. Bartter syndrome (see also\\np. \\n2988\\n) is caused by mutations in a loop diuretic-sensitive ion transport mechanism in the loop of\\nHenle. Gitelman's syndrome is caused by loss of function mutations in a thiazide-sensitive ion transport\\nmechanism in the distal nephron.\\nLiddle syndrome (see also p. \\n2423\\n) is a rare autosomal dominant disorder characterized by severe\\nhypertension and hypokalemia. Liddle syndrome is caused by unrestrained Na reabsorption in the distal\\nnephron due to one of several mutations found in genes encoding for epithelial Na channel subunits.\\nInappropriately high reabsorption of Na results in both hypertension and renal K wasting.\\nRenal K wasting can also be caused by numerous congenital and acquired renal tubular diseases, such\\nas the renal tubular acidoses and Fanconi syndrome, an unusual syndrome resulting in renal wasting of\\nK, glucose, phosphate, uric acid, and amino acids.\\nHypomagnesemia is a common correlate of hypokalemia. Much of this is attributable to common\\nunderlying causes (ie, diuretics, diarrhea), but hypomagnesemia itself may also result in increased renal\\nK losses.\\nDrugs:\\n Diuretics are by far the most commonly used drugs that cause hypokalemia. K-wasting diuretics\\nthat block Na reabsorption proximal to the distal nephron include\\n Thiazides\\n Loop diuretics\\n Osmotic diuretics\\nBy inducing diarrhea, laxatives, especially when abused, can cause hypokalemia. Surreptitious diuretic or\\nlaxative abuse or both is a frequent cause of persistent hypokalemia, particularly among patients\\npreoccupied with weight loss and among health care practitioners with access to prescription drugs.\\nOther drugs that can cause hypokalemia include\\n Amphotericin B\\n Antipseudomonal penicillins (eg, carbenicillin)\\n Penicillin in high doses\\n Theophylline intoxication (both acute and chronic)\\nSymptoms and Signs\\nMild hypokalemia (serum K 3 to 3.5 mEq/L) rarely causes symptoms. Serum K < 3 mEq/L generally\\ncauses muscle weakness and may lead to paralysis and respiratory failure. Other muscular dysfunction\\nincludes cramping, fasciculations, paralytic ileus, hypoventilation, hypotension, tetany, and\\nrhabdomyolysis. Persistent hypokalemia can impair renal concentrating ability, causing polyuria with\\nsecondary polydipsia.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n963\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 973, 'page_label': '964'}, page_content=\" Serum K measurement\\n ECG\\n When the mechanism not evident clinically, 24-h urinary K excretion and serum Mg concentration\\nHypokalemia (serum K < 3.5 mEq/L) may be found on routine serum electrolyte measurement. It should\\nbe suspected in patients with typical changes on an ECG or who have muscular symptoms and risk\\nfactors and confirmed by blood testing.\\nECG:\\n ECG should be done on patients with hypokalemia. Cardiac effects of hypokalemia are usually\\nminimal until serum K concentrations are < 3 mEq/L. Hypokalemia causes sagging of the ST segment,\\ndepression of the T wave, and elevation of the U wave. With \\nmarked hypokalemia, the T wave becomes\\nprogressively smaller and the U wave becomes increasingly larger. Sometimes, a flat or positive T wave\\nmerges with a positive U wave, which may be confused with QT prolongation (see\\nFig. 97-2\\n). Hypokalemia may cause premature ventricular and atrial contractions, ventricular and atrial\\ntachyarrhythmias, and 2nd- or 3rd-degree atrioventricular block. Such arrhythmias become more severe\\nwith increasingly severe hypokalemia; eventually, ventricular fibrillation may occur. Patients with\\nsignificant preexisting heart disease and patients receiving digoxin are at risk of cardiac conduction\\nabnormalities even from mild hypokalemia.\\nDiagnosis of cause:\\n The cause is usually apparent by history (particularly the drug history); when it is\\nnot, further investigation is warranted. After acidosis and other causes of intracellular K shift (increased \\n\\n-\\nadrenergic effect, hyperinsulinemia) have been eliminated, 24-h urinary K and serum Mg concentrations\\nare measured. In hypokalemia, K secretion is normally < 15 mEq/L. Extrarenal (GI) K loss or decreased K\\ningestion is suspected in chronic unexplained hypokalemia when renal K secretion is < 15 mEq/L.\\nSecretion of > 15 mEq/L suggests a renal cause for K loss. Unexplained hypokalemia with increased\\nrenal K secretion and hypertension suggests an aldosterone-secreting tumor or Liddle syndrome.\\nUnexplained hypokalemia with increased renal K loss and normal BP suggests Bartter or Gitelman's\\nsyndrome, but hypomagnesemia, surreptitious vomiting, and diuretic abuse are more common and should\\nalso be considered.\\nTreatment\\n Oral K supplements\\n IV K supplements for severe hyperkalemia or ongoing K losses\\nMany oral K supplements are available. Because high single doses can cause GI irritation and occasional\\nbleeding, deficits are usually replaced in divided doses. Liquid KCl given orally elevates concentrations\\nwithin 1 to 2 h but has a bitter taste and is tolerated particularly poorly in doses > 25 to 50 mEq. Wax-\\nimpregnated KCl preparations are safe and better tolerated. GI bleeding may be even less common with\\nmicroencapsulated KCl preparations. Several of these preparations contain 8 or 10 mEq/capsule.\\nBecause a decrease in serum K of 1 mEq/L correlates with about a 200- to 400-mEq deficit in total body\\nK stores, total deficit can be estimated and replaced over a number of days at 20 to 80 mEq/day.\\nWhen hypokalemia is severe (eg, with ECG changes or severe symptoms), is unresponsive\\n[\\nFig. 97-2.\\n ECG patterns in hypokalemia and hyperkalemia.]\\nto oral therapy, or occurs in hospitalized patients who are taking digitalis or who have significant heart\\ndisease or ongoing losses, K must be replaced IV. Because K solutions can irritate peripheral veins, the\\nconcentration should not exceed 40 mEq/L. The rate of correction of hypokalemia is limited because of\\nthe lag in K movement into cells. \\nRoutine infusion rates should not exceed 10 mEq/h.\\n In hypokalemic-\\ninduced arrhythmia, IV KCl must be given more rapidly, usually through a central vein or using multiple\\nperipheral veins simultaneously. Infusion of 40 mEq KCl/h can be undertaken but only with continuous\\ncardiac monitoring and hourly serum K determinations. Glucose solutions are avoided because elevation\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n964\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 974, 'page_label': '965'}, page_content='in the serum insulin concentrations could result in transient worsening of hypokalemia.\\nEven when K deficits are severe, it is rarely necessary to give > 100 to 120 mEq of K in a 24-h period\\nunless K loss continues. In K deficit with high serum K concentration, as in diabetic ketoacidosis, IV K is\\ndeferred until the serum K starts to fall. When hypokalemia occurs with hypomagnesemia, both the K and\\nMg deficiencies must be corrected to stop ongoing renal K wasting (see \\nHypomagnesemia\\n on p. \\n852\\n).\\nPrevention\\nRoutine K replacement is not necessary in most patients receiving diuretics. However, serum K should be\\nmonitored during diuretic use when risk of hyperkalemia or of its complications is high. Risk is high in\\n Patients with decreased left ventricular function\\n Patients taking digoxin\\n Patients with diabetes (in whom insulin concentrations can fluctuate)\\n Patients with asthma who are taking \\n\\n2\\n-agonists\\nTriamterene 100 mg po once/day or spironolactone 25 mg po qid does not increase K excretion and may\\nbe useful in patients who become hypokalemic but must use diuretics. When hypokalemia develops, K\\nsupplementation, usually with oral KCl, is indicated.\\nHyperkalemia\\nHyperkalemia is serum K concentration > 5.5 mEq/L resulting from excess total body K stores\\nor abnormal movement of K out of cells. There are usually several simultaneous contributing\\nfactors, including increased K intake, drugs that impair renal K excretion, and acute or chronic\\nkidney disease. It can also occur in metabolic acidosis as in diabetic ketoacidosis. Clinical\\nmanifestations are generally neuromuscular, resulting in muscle weakness and cardiac toxicity\\nthat, when severe, can degenerate to ventricular fibrillation or asystole. Diagnosis is by\\nmeasuring serum K. Treatment may involve decreasing K intake, adjusting drugs, giving a\\ncation exchange resin and, in emergencies, Ca gluconate, insulin, and dialysis\\n.\\nEtiology\\nThe most common cause of increased serum K concentration is probably pseudohyperkalemia caused by\\nhemolysis of RBCs in the blood sample. Normal kidneys eventually excrete K loads, so sustained,\\nnonartifactual hyperkalemia usually implies diminished renal K excretion. However, other factors usually\\ncontribute. They can include increased K intake, increased K release from cells, or both (see\\nTable 97-7\\n). When sufficient KCl is ingested or given parenterally, severe hyperkalemia may result even\\nwith normal renal function but is usually temporary.\\nHyperkalemia due to total body K excess is particularly common in oliguric states (especially acute renal\\nfailure) and with rhabdomyolysis, burns, bleeding into soft tissue or the GI tract, and adrenal insufficiency.\\nIn chronic renal failure, hyperkalemia is uncommon until the GFR falls to < 10 to 15 mL/min unless dietary\\nor IV K intake is excessive.\\nSymptoms and Signs\\nAlthough flaccid paralysis occasionally occurs, hyperkalemia is usually asymptomatic until cardiac toxicity\\ndevelops.\\nIn the rare disorder hyperkalemic familial periodic paralysis, weakness frequently develops during attacks\\nand can progress to frank paralysis.\\nDiagnosis\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n965'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 975, 'page_label': '966'}, page_content=' Serum K measurement\\n ECG\\n Review of drug use\\n Assessment of renal function\\nHyperkalemia (serum K > 5.5 mEq/L) may be found on routine serum electrolyte measurement. It should\\nbe suspected in patients with typical changes on an ECG or patients at high risk, such as those with renal\\nfailure, advanced heart failure treated with ACE inhibitors and K-sparing diuretics, or urinary obstruction.\\nECG:\\n ECG should be done on patients with hyperkalemia. ECG changes (see \\nFig. 97-2\\n) are frequently\\nvisible when serum K is > 5.5 mEq/L. Slowing of conduction characterized by an increased PR interval\\nand shortening of the QT interval as well as tall, symmetric, peaked T\\n[\\nTable 97-7.\\n Factors Contributing to Hyperkalemia]\\nwaves are visible initially. K > 6.5 mEq/L causes further slowing of conduction with widening of the QRS\\ninterval, disappearance of the P wave, and nodal and escape ventricular arrhythmias. Finally, the QRS\\ncomplex degenerates into a sine wave pattern, and ventricular fibrillation or asystole ensues.\\nDiagnosis of the cause:\\n Pseudohyperkalemia should be considered in patients without risk factors or\\nECG abnormalities. Hemolysis may be reported by the laboratory. When pseudohyperkalemia is\\nsuspected, K concentration should be repeated, taking measures to avoid hemolysis of the sample.\\nDiagnosis of the cause of hyperkalemia requires a detailed history, including a review of drugs, a physical\\nexamination with emphasis on volume status, and measurement of electrolytes, BUN, and creatinine. In\\ncases in which renal failure is present, additional tests, including renal ultrasonography to exclude\\nobstruction, are needed (see p. \\n2438\\n).\\nTreatment\\n Treatment of the cause\\n For mild hyperkalemia, Na polystyrene sulfonate\\nFor moderate or severe hyperkalemia, IV insulin and glucose, an IV Ca solution, possibly an inhaled \\n\\n2\\n-\\nagonist, and usually hemodialysis\\nMild hyperkalemia:\\n Patients with serum K < 6 mEq/L and no ECG abnormalities may respond to\\ndiminished K intake or stopping K-elevating drugs. The addition of a loop diuretic enhances renal K\\nexcretion as long as volume depletion is not present.\\nNa polystyrene sulfonate in sorbitol can be given (15 to 30 g in 30 to 70 mL of 70% sorbitol po q 4 to 6 h).\\nIt acts as a cation exchange resin and removes K through the GI mucosa. Sorbitol is administered with the\\nresin to ensure passage through the GI tract. Patients unable to take drugs orally because of nausea or\\nother reasons may be given similar doses by enema. Enemas are not as effective at lowering K in\\npatients with ileus. Enemas should not be used if acute abdomen is suspected. About 1 mEq of K is\\nremoved per gram of resin given. Resin therapy is slow and often fails to lower serum K significantly in\\nhypercatabolic states. Because Na is exchanged for K when Na polystyrene sulfonate is used, Na\\noverload may occur, particularly in oliguric patients with preexisting volume overload.\\nModerate to severe hyperkalemia:\\n Serum K between 6 and 6.5 mEq/L needs prompt attention, but the\\nactual treatment depends on \\nthe clinical situation. If no ECG changes are present and renal function is\\nintact, maneuvers described previously are usually effective. Follow-up serum K levels are needed to\\nensure that the hyperkalemia has been successfully treated. If serum K is > 6.5 mEq/L, more aggressive\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n966'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 976, 'page_label': '967'}, page_content='therapy is required. Administration of regular insulin 5 to 10 units IV is followed immediately by or\\nadministered simultaneously with rapid infusion of 50 mL 50% glucose. Infusion of 10% D/W should\\nfollow at 50 mL/h to prevent hypoglycemia. The effect on serum K peaks in 1 h and lasts for several\\nhours.\\nIf ECG changes include the loss of P-wave or widening of the QRS complex, treatment with IV Ca as well\\nas insulin and glucose is indicated; 10 to 20 mL 10% Ca gluconate (or 5 to 10 mL 22% Ca gluceptate) is\\ngiven IV over 5 to 10 min. Ca antagonizes the effect of hyperkalemia on cardiac muscle. Ca should be\\ngiven with caution to patients taking digoxin because of the risk of precipitating hypokalemia-related\\narrhythmias. If the ECG shows a sine wave pattern or asystole, Ca gluconate may be given more rapidly\\n(5 to 10 mL IV over 2 min). CaCl can also be used but can be irritating to peripheral veins and cause\\ntissue necrosis if extravasated. CaCl should be given only through a correctly positioned central venous\\ncatheter. The benefits of Ca occur within minutes but last only 20 to 30 min. Ca infusion is a temporizing\\nmeasure while awaiting the effects of other treatments or initiation of hemodialysis and may need to be\\nrepeated.\\nA high-dose \\n\\n2\\n-agonist, such as albuterol 10 to 20 mg inhaled over 10 min (5 mg/mL concentration), can\\nlower serum K by 0.5 to 1.5 mEq/L and may be a helpful adjunct. The peak effect occurs in 90 min.\\nHowever, \\n\\n2\\n-agonists are contraindicated in patients with unstable angina and acute MI.\\nAdministration of IV NaHCO\\n3\\n is controversial. It may lower serum K over several hours. Reduction may\\nresult from alkalinization or the hypertonicity due to the concentrated Na in the preparation. The\\nhypertonic Na that it contains may be harmful for dialysis patients who also may have volume overload.\\nWhen given, the usual dose is 45 mEq (1 ampule of 7.5% NaHCO\\n3\\n) infused over 5 min and repeated in\\n30 min. HCO\\n3\\n therapy has little effect when used by itself in patients with severe renal insufficiency\\nunless acidemia is also present.\\nIn addition to strategies for lowering K by shifting it into cells, maneuvers to remove K from the body\\nshould also be done early in the treatment of severe or symptomatic hyperkalemia. K can be removed via\\nthe GI tract by administration of Na polystyrene sulfonate (see p. \\n836\\n) or by hemodialysis. Hemodialysis\\nshould be instituted promptly after emergency measures in patients with renal failure or when emergency\\ntreatment is ineffective. Dialysis should be considered early in patients with end-stage renal disease and\\nhyperkalemia because they are at increased risk of progression to more severe hyperkalemia and serious\\ncardiac arrhythmias. Peritoneal dialysis is relatively inefficient at removing K.\\nDisorders of Calcium Concentration\\nCa is required for the proper functioning of muscle contraction, nerve conduction, hormone release, and\\nblood coagulation. In addition, proper Ca concentration is required for various other metabolic processes.\\nMaintenance of body Ca stores depends on\\n Dietary Ca intake\\n Absorption of Ca from the GI tract\\n Renal Ca excretion\\nIn a balanced diet, roughly 1000 mg of Ca is ingested each day and about another 200 mg/day is\\nsecreted into the GI tract in the bile and other GI secretions. Depending on the concentration of\\ncirculating vitamin D, particularly 1,25(OH)\\n2\\nD (1,25-dihydroxycholecalciferol, calcitriol, or active vitamin D,\\nwhich is converted in the kidney from 25(OH)D, the inactive form), roughly 200 to 400 mg of Ca is\\nabsorbed from the intestine each day. The remaining 800 to 1000 mg appears in the stool. Ca balance is\\nmaintained through renal Ca excretion averaging 200 mg/day.\\nBoth extracellular and intracellular Ca concentrations are tightly regulated by bidirectional Ca transport\\nacross the plasma membrane of cells and intracellular organelles, such as the endoplasmic reticulum, the\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n967'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 977, 'page_label': '968'}, page_content='sarcoplasmic reticulum of muscle cells, and the mitochondria. Cytosolic ionized Ca is maintained within\\nthe micromolar range (< 1/1000 of the serum concentration). Ionized Ca acts as an intracellular 2nd\\nmessenger; it is involved in skeletal muscle contraction, excitation-contraction coupling in cardiac and\\nsmooth muscle, and activation of protein kinases and enzyme phosphorylation. Ca is also involved in the\\naction of other intracellular messengers, such as cAMP and inositol 1,4,5-triphosphate, and thus\\nmediates the cellular response to \\nnumerous hormones, including epinephrine, glucagon, ADH\\n(vasopressin), secretin, and cholecystokinin. Parathyroid hormone (PTH) increases urinary cAMP.\\nDespite its important intracellular roles, about 99% of body Ca is in bone, mainly as hydroxyapatite\\ncrystals. About 1% of bone Ca is freely exchangeable with the ECF and, therefore, is available for\\nbuffering changes in Ca balance.\\nNormal total serum Ca concentration ranges from 8.8 to 10.4 mg/dL (2.20 to 2.60 mmol/L). About 40% of\\nthe total blood Ca is bound to plasma proteins, primarily albumin. The remaining 60% includes ionized Ca\\nplus Ca complexed with phosphate (PO\\n4\\n) and citrate. Total Ca (ie, protein-bound, complexed, and ionized\\nCa) is usually what is determined by clinical laboratory measurement. Ideally, ionized or free Ca should be\\ndetermined because it is the physiologically active form of Ca in plasma; this determination, because of\\nits technical difficulty, is usually restricted to patients in whom significant alteration of protein binding of\\nserum Ca is suspected. Ionized Ca is generally assumed to be about 50% of the total serum Ca.\\nRegulation of Calcium Metabolism\\nThe metabolism of Ca and of PO\\n4\\n (see p. \\n850\\n) is intimately related. The regulation of both Ca and PO\\n4\\nbalance is greatly influenced by concentrations of circulating PTH, vitamin D, and, to a lesser extent,\\ncalcitonin. Ca and inorganic PO\\n4\\n concentrations are also linked by their ability to chemically react to form\\nCaPO\\n4\\n. The product of concentrations of Ca and PO\\n4\\n (in mEq/L) is estimated to be 60 normally; when\\nthe product exceeds 70, precipitation of CaPO\\n4\\n crystals in soft tissue is much more likely. Calcification of\\nvascular tissue accelerates arteriosclerotic vascular disease and may occur when the Ca  PO\\n4\\n product\\nis even lower (> 55), especially in patients with chronic kidney disease.\\nPTH is secreted by the parathyroid glands. It has several actions, but perhaps the most important is to\\ndefend against hypocalcemia. Parathyroid cells sense decreases in serum Ca and, in response, release\\npreformed PTH into the circulation. PTH increases serum Ca within minutes by increasing renal and\\nintestinal absorption of Ca and by rapidly mobilizing Ca and PO\\n4\\n from bone (bone resorption). Renal Ca\\nexcretion generally parallels Na excretion and is influenced by many of the same factors that govern Na\\ntransport in the proximal tubule. However, PTH enhances distal tubular Ca reabsorption independently of\\nNa. PTH also decreases renal PO\\n4\\n reabsorption and thus increases renal PO\\n4\\n losses. Renal PO\\n4\\n loss\\nprevents the solubility product of Ca and PO\\n4\\n from being exceeded in plasma as Ca concentrations rise\\nin response to PTH. PTH also increases serum Ca by stimulating conversion of vitamin D (see p. \\n41\\n) to\\nits most active form, calcitriol. This form of vitamin D increases the percentage of dietary Ca absorbed by\\nthe intestine. Despite increased Ca absorption, long-term increases in PTH secretion generally result in\\nfurther bone resorption by inhibiting osteoblastic function and promoting osteoclastic activity. PTH and\\nvitamin D both function as important regulators of bone growth and bone remodeling (see p. \\n41\\n).\\nRadioimmunoassays for the intact PTH molecule are still the recommended way to test for PTH. Second-\\ngeneration assays for intact PTH are available. These tests measure bioavailable PTH or complete PTH.\\nThey give values equal to 50 to 60% of those obtained with the older assay. Usefulness of the newer\\nassays is under investigation. Sometimes total or nephrogenous cAMP excretion is measured in diagnosis\\nof pseudohypoparathyroidism.\\nCalcitonin is secreted by the thyroid parafollicular cells (C cells). Calcitonin tends to lower serum Ca\\nconcentration by enhancing cellular uptake, renal excretion, and bone formation. The effects of calcitonin\\non bone metabolism are much weaker than those of either PTH or vitamin D.\\nHypocalcemia\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n968'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 978, 'page_label': '969'}, page_content=\"(Hypocalcemia in neonates is discussed on p. \\n2794\\n.)\\nHypocalcemia is total serum Ca concentration < 8.8 mg/dL (< 2.20 mmol/L) in the presence of\\nnormal plasma protein concentrations or a serum ionized Ca concentration < 4.7 mg/dL (< 1.17\\nmmol/L). Causes include hypoparathyroidism, vitamin D deficiency, and renal disease.\\nManifestations include paresthesias, tetany, and, when severe, seizures, encephalopathy, and\\nheart failure. Diagnosis involves measurement of serum Ca with adjustment for serum albumin\\nconcentration. Treatment is administration of Ca, sometimes with vitamin D\\n.\\nEtiology\\nHypocalcemia has a number of causes, including\\n \\nHypoparathyroidism\\n Pseudohypoparathyroidism\\n Vitamin D deficiency and dependency\\n Renal disease\\nHypoparathyroidism:\\n Hypoparathyroidism is characterized by hypocalcemia and hyperphosphatemia\\nand often causes chronic tetany. Hypoparathyroidism results from deficient parathyroid hormone (PTH),\\nwhich can occur in autoimmune disorders or after the accidental removal of or damage to several\\nparathyroid glands during thyroidectomy. Transient hypoparathyroidism is common after subtotal\\nthyroidectomy, but permanent hypoparathyroidism occurs after < 3% of such thyroidectomies done by\\nexperienced surgeons. Manifestations of hypocalcemia usually begin about 24 to 48 h postoperatively but\\nmay occur after months or years. PTH deficiency is more common after radical thyroidectomy for cancer\\nor as the result of surgery on the parathyroid glands (subtotal or total parathyroidectomy). Risk factors for\\nsevere hypocalcemia after subtotal parathyroidectomy include\\n Severe preoperative hypercalcemia\\n Removal of a large adenoma\\n Elevated alkaline phosphatase\\n Chronic kidney disease\\nIdiopathic hypoparathyroidism is an uncommon sporadic or inherited condition in which the parathyroid\\nglands are absent or atrophied. It manifests in childhood. The parathyroid glands are occasionally absent\\nand thymic aplasia and abnormalities of the arteries arising from the brachial arches (DiGeorge\\nsyndrome) are present. Other inherited forms include Addison's disease, autoimmune hypoparathyroidism\\nassociated with mucocutaneous candidiasis, and X-linked recessive idiopathic hypoparathyroidism.\\nPseudohypoparathyroidism:\\n Pseudohypoparathyroidism is an uncommon group of disorders\\ncharacterized not by hormone deficiency but by target organ resistance to PTH. Complex genetic\\ntransmission of these disorders occurs.\\nPatients with type Ia pseudohypoparathyroidism (Albright's hereditary osteodystrophy) have a mutation in\\nthe stimulatory Gs-\\n\\n1 protein of the adenylyl cyclase complex (\\nGNAS1\\n). The result is failure of normal\\nrenal phosphaturic response or increase in urinary cAMP to PTH. Patients are usually hypocalcemic as a\\nresult of hyperphosphatemia. Secondary hyperparathyroidism and hyperparathyroid bone disease can\\noccur. Associated abnormalities include short stature, round facies, intellectual disability with calcification\\nof the basal ganglia, shortened metacarpal and metatarsal bones, mild hypothyroidism, and other subtle\\nendocrine abnormalities. Because only the maternal allele for \\nGNAS1\\n is expressed in the kidneys,\\npatients whose abnormal gene is paternal, although they have many of the somatic features of the\\ndisease, do not have hypocalcemia, hyperphosphatemia, or secondary hyperparathyroidism; this\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n969\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 979, 'page_label': '970'}, page_content='condition is sometimes described as pseudopseudohypoparathyroidism.\\nLess is known about type Ib pseudohypoparathyroidism. Affected patients have hypocalcemia,\\nhyperphosphatemia, and secondary hyperparathyroidism but do not have the other associated\\nabnormalities.\\nType II pseudohypoparathyroidism is even less common than type I. In affected patients, exogenous PTH\\nraises the urinary cAMP normally but does not raise serum Ca or urinary phosphate (PO\\n4\\n). An\\nintracellular resistance to cAMP has been proposed.\\nVitamin D deficiency and dependency:\\n Vitamin D deficiency and dependency are discussed in full\\nelsewhere (see p. \\n41\\n). Vitamin D is ingested in foods naturally high in vitamin D or fortified with it. It is also\\nformed in the skin in response to sunlight. Vitamin D deficiency may result from inadequate dietary intake\\nor decreased absorption due to hepatobiliary disease or intestinal malabsorption. It can also result from\\nalterations in vitamin D metabolism as occur with certain drugs (eg, phenytoin, phenobarbital, rifampin) or\\ndecreased formation in the skin due to lack of exposure to sunlight. Aging also decreases skin synthetic\\ncapacity. Decreased skin synthesis is an important cause of acquired vitamin D deficiency among people\\nwho spend a great deal of time indoors, who live in high northern or southern latitudes, and who wear\\nclothing that covers them completely. Accordingly, subclinical vitamin D deficiency is fairly common,\\nespecially during winter months in temperate climates among the elderly. The institutionalized elderly are\\nat particular risk because of decreased skin synthetic capacity, undernutrition, and lack of sun exposure.\\nIn fact, most people with deficiency have both decreased skin synthesis and dietary deficiency (see also\\np. \\n41\\n).\\nType I vitamin D-dependent rickets (pseudovitamin D-deficiency rickets) is an autosomal recessive\\ndisorder involving a mutation in the gene encoding the 1-\\n\\n-hydroxylase enzyme. Normally expressed in\\nthe kidney, 1-\\n\\n-hydroxylase is needed to convert inactive vitamin D to the active form calcitriol.\\nIn type II vitamin D-dependent rickets, target organs cannot respond to calcitriol. Vitamin \\nD deficiency,\\nhypocalcemia, and severe hypophosphatemia occur. Muscle weakness, pain, and typical bone\\ndeformities can occur.\\nRenal disease:\\n Renal tubular disease, including acquired proximal renal tubular acidosis due to\\nnephrotoxins (eg, heavy metals) and distal renal tubular acidosis, can cause severe hypocalcemia due to\\nabnormal renal loss of Ca and decreased renal conversion to 1,25(OH)\\n2\\nD. Cadmium, in particular,\\ncauses hypocalcemia by injuring proximal tubular cells and interfering with vitamin D conversion.\\nRenal failure can result in hypocalcemia due to diminished formation of 1,25(OH)\\n2\\nD from direct renal cell\\ndamage as well as suppression of 1-\\n\\n-hydroxylase by hyperphosphatemia.\\nOther causes:\\n Other causes of hypocalcemia include\\n Mg depletion (can cause relative PTH deficiency and end-organ resistance to PTH action, usually when\\nserum Mg concentrations are < 1.0 mg/dL [< 0.5 mmol/L]; Mg repletion increases PTH concentrations\\nand improves renal Ca conservation)\\n Acute pancreatitis (when lipolytic products released from the inflamed pancreas chelate Ca)\\n Hypoproteinemia (reduces the protein-bound fraction of serum Ca; hypocalcemia due to diminished\\nprotein binding is asymptomaticbecause ionized Ca is unchanged, this entity has been termed\\nfactitious hypocalcemia)\\n Hungry bone syndrome (persistent hypocalcemia and hypophosphatemia occurring after surgical or\\nmedical correction of moderate to severe hyperparathyroidism in patients in whom serum Ca levels had\\nbeen supported by high bone turnover induced by greatly elevated PTHhungry bone syndrome has\\nbeen described after parathyroidectomy, after renal transplantation, and rarely in patients with end-\\nstage renal disease treated with calcimimetics)\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n970'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 980, 'page_label': '971'}, page_content=\" Septic shock (due to suppression of PTH release and decreased conversion of 25(OH)D to\\n1,25(OH)\\n2\\nD)\\n Hyperphosphatemia (causes hypocalcemia by poorly understood mechanisms; patients with renal failure\\nand subsequent PO\\n4\\n retention are particularly prone)\\n Drugs including anticonvulsants (eg, phenytoin, phenobarbital) and rifampin, which alter vitamin D\\nmetabolism, and drugs generally used to treat hypercalcemia (see p. \\n847\\n)\\n Transfusion of > 10 units of citrate-anticoagulated blood and use of radiocontrast agents containing the\\ndivalent ion-chelating agent ethylenediaminetetraacetate (can decrease the concentration of\\nbioavailable ionized Ca while total serum Ca concentrations remain unchanged)\\n Infusion of gadolinium (may spuriously lower Ca concentration)\\nAlthough excessive secretion of calcitonin might be expected to cause hypocalcemia, low serum Ca\\nconcentrations rarely occur in patients with large amounts of circulating calcitonin due to medullary\\ncarcinoma of the thyroid.\\nSymptoms and Signs\\nHypocalcemia is frequently asymptomatic. The presence of hypoparathyroidism is often suggested by the\\nclinical manifestations of the underlying disorder (eg, short stature, round facies, intellectual disability,\\nbasal ganglia calcification in type Ia pseudohypoparathyroidism).\\nMajor clinical manifestations of hypocalcemia are due to disturbances in cellular membrane potential,\\nresulting in neuromuscular irritability.\\nNeurologic manifestations:\\n Muscle cramps involving the back and legs are common. Insidious\\nhypocalcemia may cause mild, diffuse encephalopathy and should be suspected in patients with\\nunexplained dementia, depression, or psychosis. Papilledema occasionally occurs. Severe hypocalcemia\\nwith serum Ca < 7 mg/dL (< 1.75 mmol/L) may cause hyperreflexia, tetany, laryngospasm, or generalized\\nseizures.\\nTetany characteristically results from severe hypocalcemia but can result from reduction in the ionized\\nfraction of serum Ca without marked hypocalcemia, as occurs in severe alkalosis. Tetany is characterized\\nby the following:\\n Sensory symptoms consisting of paresthesias of the lips, tongue, fingers, and feet\\n Carpopedal spasm, which may be prolonged and painful\\n Generalized muscle aching\\n Spasm of facial musculature\\nTetany may be overt with spontaneous symptoms or latent and requiring provocative tests to elicit. Latent\\ntetany generally occurs at less severely decreased serum Ca concentrations: 7 to 8 mg/dL (1.75 to 2.20\\nmmol/L).\\nChvostek's and Trousseau's signs are easily elicited at the bedside to identify latent tetany. Chvostek's\\nsign is an involuntary twitching of the facial muscles elicited by a light tapping of the facial nerve just\\nanterior to the exterior auditory meatus. It is present in  10% of healthy people and in most people with\\nacute hypocalcemia but is often absent in chronic hypocalcemia. Trousseau's sign is the precipitation of\\ncarpopedal spasm by reduction of the blood supply to the hand with \\na tourniquet or BP cuff inflated to 20\\nmm Hg above systolic BP applied to the forearm for 3 min. Trousseau's sign also occurs in alkalosis,\\nhypomagnesemia, hypokalemia, and hyperkalemia and in about 6% of people with no identifiable\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n971\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 981, 'page_label': '972'}, page_content='electrolyte disturbance.\\nOther manifestations:\\n Many other abnormalities may occur with chronic hypocalcemia, such as dry and\\nscaly skin, brittle nails, and coarse hair. \\nCandida\\n infections occasionally occur in hypocalcemia but most\\ncommonly occur in patients with idiopathic hypoparathyroidism. Cataracts occasionally occur with long-\\nstanding hypocalcemia and are not reversible by correction of serum Ca.\\nDiagnosis\\n Estimation or measurement of ionized Ca\\n Sometimes further testing with Mg, PTH, PO\\n4\\n, alkaline phosphatase, and vitamin D concentrations in\\nblood and cAMP and PO\\n4\\n concentrations in urine\\nHypocalcemia may be suspected in patients with characteristic neurologic manifestations or cardiac\\narrhythmias but is often found incidentally. Hypocalcemia is diagnosed by a total serum Ca concentration\\n< 8.8 mg/dL (< 2.20 mmol/L). However, because low plasma protein can lower total, but not ionized,\\nserum Ca, ionized Ca should be estimated based on albumin concentration (see \\nSidebar 97-2\\n). Suspicion\\nof low ionized Ca mandates its direct measurement, despite normal total serum Ca. Hypocalcemic\\npatients should undergo measurement of renal function (eg, BUN, creatinine), serum PO\\n4\\n, Mg, and\\nalkaline phosphatase.\\nWhen no etiology (eg, alkalosis, renal failure, drugs, or massive blood transfusion) is obvious, further\\ntesting is needed (see\\nTable 97-8\\n). Additional testing begins with serum concentrations of Mg, PO\\n4\\n, PTH, alkaline phosphatase,\\nand occasionally vitamin D levels (25(OH)D, and 1,25(OH)\\n2\\nD). Urinary PO\\n4\\n and cAMP concentrations\\nare measured when pseudohypoparathyroidism is suspected.\\nPTH concentration should be measured as an assay of the intact molecule. Because hypocalcemia is the\\nmajor stimulus for PTH secretion, PTH should be elevated in hypocalcemia. Thus,\\n Low or even low-normal PTH concentrations are inappropriate and suggest hypoparathyroidism.\\n An undetectable PTH concentration suggests idiopathic hypoparathyroidism.\\n A high PTH concentration suggests pseudohypoparathyroidism or an abnormality of vitamin D\\nmetabolism.\\nSidebar 97-2 Estimation of Ionized Calcium Concentration\\nIonized Ca concentration can be estimated from routine laboratory tests, usually with reasonable\\naccuracy. In hypoalbuminemia, measured serum Ca is often low, mainly reflecting a low concentration of\\nprotein-bound Ca, while ionized Ca can be normal. Measured total serum Ca decreases or increases by\\nabout 0.8 mg/dL (0.20 mmol/L) for every 1-g/dL decrease or increase in albumin. Thus, an albumin\\nconcentration of 2.0 g/dL (normal, 4.0 g/dL) should itself reduce measured serum Ca by 1.6 mg/dL.\\nSimilarly, increases in serum proteins, as occur in multiple myeloma, can raise total serum Ca. Acidosis\\nincreases ionized Ca by decreasing protein binding, whereas alkalosis decreases ionized Ca.\\nHypoparathyroidism is further characterized by high serum PO\\n4\\n and normal alkaline phosphatase.\\nIn type I pseudohypoparathyroidism, despite the presence of a high concentration of circulating PTH,\\nurinary cAMP and urinary PO\\n4\\n are absent. Provocative testing by injection of parathyroid extract or\\nrecombinant human PTH fails to raise serum or urinary cAMP. Patients with type Ia\\npseudohypoparathyroidism frequently also have skeletal abnormalities, including short stature and\\nshortened 1st, 4th, and 5th metacarpals. Patients with type Ib disease have renal manifestations without\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n972'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 982, 'page_label': '973'}, page_content='skeletal abnormalities.\\nIn vitamin D deficiency, osteomalacia or rickets may be present, usually with typical skeletal abnormalities\\non x-ray. Diagnosis of vitamin D deficiency and dependency and measurement of vitamin D\\nconcentrations are discussed on p. \\n42\\n.\\nSevere hypocalcemia can affect the ECG. It typically shows prolongation of the QTc and ST intervals.\\nChanges in repolarization, such as T-wave peaking or inversion, also occur. ECG may show arrhythmia\\nor heart block occasionally in patients with severe hypocalcemia. However, evaluation of hypocalcemia\\ndoes not mandate ECG testing.\\nTreatment\\n IV Ca gluconate for tetany\\n Oral Ca for postoperative hypoparathyroidism\\n Oral Ca and vitamin D for chronic hypocalcemia\\n[\\nTable 97-8.\\n Typical Laboratory Test Results in Some Disorders Causing Hypocalcemia]\\nFor tetany, Ca gluconate 10 mL of 10% solution IV over 10 min is given. Response can be dramatic but\\nmay last for only a few hours. Repeated boluses or a continuous infusion with 20 to 30 mL of 10% Ca\\ngluconate in 1 L of 5% D/W over the next 12 to 24 h may be needed. Infusions of Ca are hazardous in\\npatients receiving digoxin and should be given slowly and with continuous ECG monitoring. When tetany\\nis associated with hypomagnesemia, it may respond transiently to Ca or K administration but is\\npermanently relieved only by repletion of Mg, typically given as a 10% Mg sulfate (MgSO\\n4\\n) solution (1\\ng/10 mL) IV, followed by oral Mg salts (eg, Mg gluconate 500 to 1000 mg po tid).\\nIn transient hypoparathyroidism after thyroidectomy or partial parathyroidectomy, supplemental oral Ca\\nmay be sufficient; 1 to 2 g of elemental Ca/day may be given as Ca gluconate (90 mg elemental Ca/1 g)\\nor Ca carbonate (400 mg elemental Ca/1 g). However, hypocalcemia may be particularly severe and\\nprolonged after subtotal parathyroidectomy, particularly in patients with chronic kidney disease or in\\npatients from whom a large tumor was removed. Prolonged parenteral administration of Ca may be\\nnecessary postoperatively; supplementation with as much as 1 g/day of elemental Ca (eg, 111 mL of Ca\\ngluconate, which contains 90 mg elemental Ca/10 mL) may be required for 5 to 10 days before oral Ca\\nand vitamin D are sufficient. Elevated serum alkaline phosphatase in such patients may be a sign of rapid\\nuptake of Ca into bone. The need for large amounts of parenteral Ca usually does not fall until the\\nalkaline phosphatase concentration begins to decrease.\\nIn chronic hypocalcemia, oral Ca and occasionally vitamin D supplements are usually sufficient: 1 to 2 g\\nof elemental Ca/day may be given as Ca gluconate or Ca carbonate. In patients without renal failure,\\nvitamin D is given as a standard oral supplement (eg, cholecalciferol 800 IU once/day). Vitamin D therapy\\nis not effective unless adequate dietary or supplemental Ca and PO\\n4\\n (see p. \\n851\\n) are supplied.\\nFor patients with renal failure, calcitriol or another 1,25(OH)\\n2\\nD analog is used because these drugs\\nrequire no renal metabolic alteration. Patients with hypoparathyroidism have difficulty converting\\ncholecalciferol to its active form and also usually require calcitriol, usually 0.5 to 2 \\n\\ng po once/day.\\nPseudohypoparathyroidism can occasionally be managed with oral Ca supplementation alone. When\\nused, calcitriol requires 1 to 3 \\n\\ng/day.\\nVitamin D analogs include dihydrotachysterol (usually given orally at 0.8 to 2.4 once/day for a few days,\\nfollowed by 0.2 to 1.0 mg once/day) and calcidiol (eg, 4000 to 6000 IU po once/wk). Use of vitamin D\\nanalogs, particularly the longer-acting calcidiol, can be complicated by vitamin D toxicity, with severe\\nsymptomatic hypercalcemia. Serum Ca concentration should be monitored weekly at first and then at 1- to\\n3-mo intervals after Ca concentrations have stabilized. The maintenance dose of calcitriol or its analog,\\ndihydrotachysterol, usually decreases with time.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n973'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 983, 'page_label': '974'}, page_content=\"Hypercalcemia\\nHypercalcemia is total serum Ca concentration > 10.4 mg/dL (> 2.60 mmol/L) or ionized serum\\nCa > 5.2 mg/dL (> 1.30 mmol/L). Principal causes include hyperparathyroidism, vitamin D\\ntoxicity, and cancer. Clinical features include polyuria, constipation, muscle weakness,\\nconfusion, and coma. Diagnosis is by serum ionized Ca and parathyroid hormone\\nconcentrations. Treatment to increase Ca excretion and reduce bone resorption of Ca involves\\nsaline, Na diuresis, and drugs such as pamidronate\\n.\\nEtiology\\nHypercalcemia usually results from excessive bone resorption. There are many causes of hypercalcemia\\n(see\\nTable 97-9\\n), but the most common are hyperparathyroidism and cancer.\\nPathophysiology\\nPrimary hyperparathyroidism\\n is a generalized disorder resulting from excessive secretion of\\nparathyroid hormone (PTH) by one or more parathyroid glands. It probably is the most common cause of\\nhypercalcemia, particularly among patients who are not hospitalized. Incidence increases with age and is\\nhigher in postmenopausal women. It also occurs in high frequency  3 decades after neck irradiation.\\nFamilial and sporadic forms exist. Familial forms due to parathyroid adenoma occur in patients with other\\nendocrine tumors (see p. \\n909\\n). Primary hyperparathyroidism causes hypophosphatemia and excessive\\nbone resorption. Although asymptomatic hypercalcemia is the most frequent presentation, nephrolithiasis\\nis also common, particularly when hypercalciuria occurs due to long-standing hypercalcemia. Histologic\\nexamination shows a parathyroid adenoma in about 85% of patients with primary hyperparathyroidism,\\nalthough it is sometimes difficult to distinguish an adenoma from a normal gland. About 15% of cases are\\ndue to hyperplasia of  2 glands. Parathyroid cancer occurs in < 1% of cases.\\nThe syndrome of \\nfamilial hypocalciuric hypercalcemia (FHH)\\n is transmitted as an autosomal dominant\\ntrait. Most cases involve an inactivating mutation of the Ca-sensing receptor gene, resulting in higher\\nconcentrations of serum Ca being needed to inhibit PTH secretion. Subsequent PTH secretion induces\\nrenal phosphate (PO\\n4\\n) excretion. Persistent hypercalcemia (usually asymptomatic), often from an early\\nage; normal to slightly elevated concentrations of PTH; hypocalciuria; and hypermagnesemia occur.\\nRenal function is normal, and nephrolithiasis is unusual. However, severe pancreatitis occasionally\\noccurs. This syndrome, which is associated with parathyroid hyperplasia, is not relieved by subtotal\\nparathyroidectomy.\\nSecondary hyperparathyroidism\\n occurs most commonly in advanced chronic kidney\\n[\\nTable 97-9.\\n Principal Causes of Hypercalcemia]\\ndisease when decreased formation of active vitamin D in the kidneys and other factors lead to\\nhypocalcemia and chronic stimulation of PTH secretion. Hyperphosphatemia that develops in response to\\nchronic kidney disease also contributes. Once established, hypercalcemia or normocalcemia may occur.\\nThe sensitivity of the parathyroid to Ca may be diminished because of pronounced glandular hyperplasia\\nand elevation of the Ca set point (ie, the amount of Ca necessary to reduce secretion of PTH).\\nTertiary hyperparathyroidism\\n results in autonomous hypersecretion of PTH regardless of serum Ca\\nconcentration. Tertiary hyperparathyroidism generally occurs in patients with long-standing secondary\\nhyperparathyroidism, as in patients with end-stage renal disease of several years' duration.\\nCancer\\n is a common cause of hypercalcemia, usually in hospitalized patients. Although there are several\\nmechanisms, elevated serum Ca ultimately occurs as a result of bone resorption. Humoral hypercalcemia\\nof cancer (ie, hypercalcemia with no or minimal bone metastases) occurs most commonly with squamous\\ncell carcinoma, renal cell carcinoma, breast cancer, prostate cancer, and ovarian cancer. Many cases of\\nhumoral hypercalcemia of cancer were formerly attributed to ectopic production of PTH. However, some\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n974\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 984, 'page_label': '975'}, page_content=\"of these tumors secrete a PTH-related peptide that binds to PTH receptors in both bone and kidney and\\nmimics many of the effects of the hormone, including osteoclastic bone resorption. Hematologic cancers,\\nmost often multiple myeloma, but also certain lymphomas and lymphosarcomas, cause hypercalcemia by\\nelaborating a group of cytokines that stimulate osteoclasts to resorb bone, resulting in osteolytic lesions,\\ndiffuse osteopenia, or both. Hypercalcemia may result from local elaboration of osteoclast-activating\\ncytokines or prostaglandins, direct bone resorption by the metastatic tumor cells, or both.\\nVitamin D toxicity\\n can be caused by high concentrations of endogenous 1,25(OH)\\n2\\nD. Although serum\\nconcentrations are low in most patients with solid tumors, patients with lymphoma and T-cell leukemia\\nsometimes have elevated concentrations due to dysregulation of the 1-\\n\\n-hydroxylase enzyme present in\\ntumor cells. Exogenous vitamin D in pharmacologic doses causes excessive bone resorption as well as\\nincreased intestinal Ca absorption, resulting in hypercalcemia and hypercalciuria (see p. \\n44\\n).\\nGranulomatous disorders\\n, such as sarcoidosis, TB, leprosy, berylliosis, histoplasmosis, and\\ncoccidioidomycosis, lead to hypercalcemia \\nand hypercalciuria. In sarcoidosis, hypercalcemia and\\nhypercalciuria seem to be due to unregulated conversion of 25(OH)D to 1,25(OH)\\n2\\nD, presumably due to\\nexpression of the 1-\\n\\n-hydroxylase enzyme in mononuclear cells within sarcoid granulomas. Similarly,\\nelevated serum concentrations of 1,25(OH)\\n2\\nD have been reported in hypercalcemic patients with TB and\\nsilicosis. Other mechanisms must account for hypercalcemia in some instances, because depressed\\n1,25(OH)\\n2\\nD concentrations occur in some patients with hypercalcemia and leprosy.\\nImmobilization\\n, particularly complete prolonged bed rest in patients at risk (see \\nTable 97-9\\n), can result\\nin hypercalcemia due to accelerated bone resorption. Hypercalcemia develops within days to weeks of\\nonset of bed rest. Reversal of hypercalcemia occurs promptly on resumption of weight bearing. Young\\nadults with several bone fractures and people with Paget's disease of bone are particularly prone to\\nhypercalcemia when at bed rest.\\nIdiopathic infantile hypercalcemia\\n (Williams syndromesee\\nTable 299-2\\n on p. \\n3003\\n) is an extremely rare sporadic disorder with dysmorphic facial features,\\ncardiovascular abnormalities, renovascular hypertension, and hypercalcemia. PTH and vitamin D\\nmetabolism are normal, but the response of calcitonin to Ca infusion may be abnormal.\\nIn \\nmilk-alkali syndrome\\n, excessive amounts of Ca and absorbable alkali are ingested, usually during\\nself-treatment with Ca carbonate antacids for dyspepsia or to prevent osteoporosis, resulting in\\nhypercalcemia, metabolic alkalosis, and renal insufficiency. The availability of effective drugs for peptic\\nulcer disease and osteoporosis has greatly reduced the incidence of this syndrome.\\nSymptoms and Signs\\nIn mild hypercalcemia, many patients are asymptomatic. Clinical manifestations of hypercalcemia include\\nconstipation, anorexia, nausea and vomiting, abdominal pain, and ileus. Impairment of the renal\\nconcentrating mechanism leads to polyuria, nocturia, and polydipsia. Elevation of serum Ca > 12 mg/dL\\n(> 3.00 mmol/L) can cause emotional lability, confusion, delirium, psychosis, stupor, and coma.\\nHypercalcemia may cause neuromuscular symptoms, including skeletal muscle weakness. Hypercalciuria\\nwith nephrolithiasis is common. Less often, prolonged or severe hypercalcemia causes reversible acute\\nrenal failure or irreversible renal damage due to nephrocalcinosis (precipitation of Ca salts within the\\nkidney parenchyma). Peptic ulcers and pancreatitis may occur in patients with hyperparathyroidism for\\nreasons that are not related to hypercalcemia.\\nSevere hypercalcemia causes a shortened QT\\nc\\n interval on ECG, and arrhythmias may occur, particularly\\nin patients taking digoxin. Hypercalcemia > 18 mg/dL (> 4.50 mmol/L) may cause shock, renal failure, and\\ndeath.\\nDiagnosis\\n Total serum Ca concentration\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n975\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 985, 'page_label': '976'}, page_content=\" Chest x-ray; measurement of electrolytes, BUN, creatinine, ionized Ca, PO\\n4\\n, and alkaline phosphatase;\\nand serum protein immunoelectrophoresis to determine the cause\\n Sometimes PTH and urinary excretion of Ca with or without PO\\n4\\nHypercalcemia is diagnosed by a serum Ca concentration > 10.4 mg/dL (> 2.60 mmol/L) or ionized serum\\nCa > 5.2 mg/dL (> 1.30 mmol/L). The condition is frequently discovered during routine laboratory\\nscreening. Serum Ca can be artifactually elevated (see\\nTable 97-10\\n). Hypercalcemia can also be masked by low serum protein. When protein and albumin are\\nabnormal and when ionized hypercalcemia is suspected because of clinical findings (eg, because of\\nsymptoms of hypercalcemia), ionized serum Ca should be measured.\\nInitial evaluation:\\n Initial evaluation should include a review of the history, particularly of past serum Ca\\nconcentration; physical examination; a chest x-ray; and laboratory studies, including electrolytes, BUN,\\ncreatinine, ionized Ca, PO\\n4\\n, alkaline phosphatase, and serum protein immunoelectrophoresis. The cause\\nis apparent from clinical data and results of these tests in  95% of patients. Patients without an obvious\\ncause of hypercalcemia after this evaluation should undergo measurement of intact PTH and 24-h urinary\\nCa. When hyperparathyroidism is suspected, PO\\n4\\n renal excretion is often measured.\\nAsymptomatic hypercalcemia that has been present for years or is present in several family members\\nraises the possibility of FHH. Primary hyperparathyroidism generally manifests late in life but can be\\npresent for several years before symptoms occur. When no cause is obvious, concentrations of serum Ca\\n< 11 mg/dL (< 2.75 mmol/L) suggest hyperparathyroidism or other nonmalignant causes, whereas\\nconcentration > 13 mg/dL (> 3.25 mmol/L) suggest cancer.\\nMeasurement of intact PTH levels help differentiate PTH-mediated hypercalcemia (eg, caused by\\nhyperparathyroidism or FHH), in which PTH levels are high or high-normal,\\n[\\nTable 97-10.\\n Laboratory and Clinical Findings in Some Disorders Causing Hypercalcemia]\\nfrom most other (PTH-independent) causes. In PTH-independent causes, levels are usually < 20 pg/mL.\\nThe chest x-ray is particularly helpful, revealing most granulomatous disorders, such as TB, sarcoidosis,\\nand silicosis, as well as primary lung cancer and lytic and Paget's lesions in bones of the shoulder, ribs,\\nand thoracic spine.\\nChest and bone (eg, skull, extremity) x-rays can also show the bony effects of secondary\\nhyperparathyroidism, most commonly in long-term dialysis patients. In osteitis fibrosa cystica (often due to\\nprimary hyperparathyroidism), increased osteoclastic activity from over-stimulation by PTH causes\\nrarefaction of bone with fibrous degeneration and cyst and fibrous nodule formation. Because\\ncharacteristic bone lesions occur only with relatively advanced disease, bone x-rays are recommended\\nonly for symptomatic patients. X-rays typically show bone cysts, a heterogeneous appearance of the\\nskull, and subperiosteal resorption of bone in the phalanges and distal clavicles.\\nHyperparathyroidism:\\n In hyperparathyroidism, the serum Ca is rarely > 12 mg/dL (> 3.00 mmol/L), but\\nthe ionized serum Ca is almost always elevated. Low serum PO\\n4\\n concentration suggests\\nhyperparathyroidism, especially when coupled with elevated PO\\n4\\n renal excretion. When\\nhyperparathyroidism results in increased bone turnover, serum alkaline phosphatase is frequently\\nincreased. Increased intact PTH, particularly inappropriate elevation (ie, a high concentration in the\\nabsence of hypocalcemia) or an inappropriate high-normal concentration (ie, despite hypercalcemia), is\\ndiagnostic. Urinary Ca excretion is usually normal or high in hyperparathyroidism. Primary\\nhyperparathyroidism is suggested by an absence of a family history of endocrine neoplasia, childhood\\nneck irradiation, or other obvious cause. Chronic kidney disease suggests the presence of secondary\\nhyperparathyroidism, but primary hyperparathyroidism can also be present. In patients with chronic kidney\\ndisease, high serum Ca and normal serum PO\\n4\\n suggest primary hyperparathyroidism, whereas elevated\\nPO\\n4\\n suggests secondary hyperparathyroidism.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n976\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 986, 'page_label': '977'}, page_content=\"The need for localization of parathyroid tissue before surgery on the parathyroid(s) is controversial. High-\\nresolution CT with or without CT-guided biopsy and immunoassay of thyroid venous drainage, MRI, high-\\nresolution ultrasonography, digital subtraction angiography, and thallium-201-technetium-99 scanning all\\nhave been used and are highly accurate, but they have not improved the usually high cure rate of\\nparathyroidectomy done by experienced surgeons. Technetium-99 sestamibi, a newer radionuclide agent\\nfor parathyroid imaging, is more sensitive and specific than older agents and may be useful for identifying\\nsolitary adenomas.\\nFor residual or recurrent hyperparathyroidism after initial parathyroid surgery, imaging is necessary and\\nmay reveal abnormally functioning parathyroid glands in unusual locations throughout the neck and\\nmediastinum. Technetium-99 sestamibi is probably the most sensitive imaging test. Use of several\\nimaging studies (MRI, CT, or high-resolution ultrasonography in addition to technetium-99 sestamibi)\\nbefore repeat parathyroidectomy is sometimes necessary.\\nCancer:\\n A serum Ca > 13 mg/dL (> 3.00 mmol/L) suggests some cause of hypercalcemia other than\\nhyperparathyroidism. Urinary Ca excretion is usually normal or high in cancer. In humoral hypercalcemia\\nof cancer, PTH is often decreased or undetectable; PO\\n4\\n is often decreased; and metabolic alkalosis,\\nhypochloremia, and hypoalbuminemia are often present. Suppressed PTH differentiates humoral\\nhypercalcemia of cancer from primary hyperparathyroidism. Humoral hypercalcemia of cancer can also\\nbe diagnosed by detection of PTH-related peptide in serum.\\nMultiple myeloma is suggested by simultaneous anemia, azotemia, and hypercalcemia or by the presence\\nof a monoclonal gammopathy. Myeloma is confirmed by bone marrow examination.\\nFHH:\\n FHH should be considered in patients with hypercalcemia and elevated or high-normal intact PTH\\nlevels. FHH is distinguished from primary hyperparathyroidism by the early age of onset, frequent\\noccurrence of hypermagnesemia, and presence of hypercalcemia without hypercalciuria in other family\\nmembers. The fractional excretion of Ca (ratio of Ca clearance to creatinine clearance) is low (< 1%) in\\nFHH; it is almost always elevated (1 to 4%) in primary hyperparathyroidism. Intact PTH can be elevated\\nor normal, perhaps reflecting altered feedback regulation of the parathyroid glands.\\nMilk-alkali syndrome:\\n In addition to a history of increased intake of Ca antacids, milk-alkali syndrome is\\nrecognized by the combination of hypercalcemia, metabolic alkalosis, and, occasionally, azotemia with\\nhypocalciuria. The diagnosis can be confirmed when the serum Ca concentration rapidly returns to\\nnormal when Ca and alkali ingestion stops, although renal insufficiency can persist when\\nnephrocalcinosis is present. Circulating PTH usually is suppressed.\\nOther causes:\\n In hypercalcemia due to sarcoidosis, other granulomatous disorders, and some\\nlymphomas, serum concentration of 1,25(OH)\\n2\\nD may be elevated. Vitamin D toxicity is also characterized\\nby elevated 1,25(OH)\\n2\\nD concentration. In other endocrine causes of hypercalcemia, such as\\nthyrotoxicosis and Addison's disease, typical laboratory findings of the underlying disorder help establish\\nthe diagnosis. When Paget's disease is suspected, plain x-rays (see p. \\n361\\n) are done first and may show\\ncharacteristic abnormalities.\\nTreatment\\n Oral PO\\n4\\n for serum Ca < 11.5 mg/dL with mild symptoms and no kidney disease\\n IV saline and furosemide for more rapid correction for serum Ca < 18 mg/dL\\n Bisphosphonates or other Ca-lowering drugs for serum Ca < 18 mg/dL and > 11.5 mg/dL or moderate\\nsymptoms\\n Hemodialysis for serum Ca > 18 mg/dL\\n Surgical removal for moderate, progressive primary hyperparathyroidism and sometimes for mild disease\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n977\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 987, 'page_label': '978'}, page_content=\" PO\\n4\\n restriction and binders and sometimes calcitriol for secondary hyperparathyroidism\\nThere are 4 main strategies for lowering serum Ca:  Decrease intestinal Ca absorption\\n Increase urinary Ca excretion\\n Decrease bone resorption\\n Remove excess Ca through dialysis\\nThe treatment used depends on both the degree and the cause of hypercalcemia.\\nMild hypercalcemia:\\n In mild hypercalcemia (serum Ca < 11.5 mg/dL [< 2.88 mmol/L]), in which\\nsymptoms are mild, treatment is deferred pending definitive diagnosis. After diagnosis, the underlying\\ndisorder is treated. When symptoms are significant, treatment aimed at lowering serum Ca is necessary.\\nOral PO\\n4\\n can be used. When taken with meals, it binds some Ca, preventing its absorption. A starting\\ndose is 250 mg of elemental PO\\n4\\n (as Na or K salt) qid. The dose can be increased to 500 mg qid prn\\nunless diarrhea develops. Another treatment is increasing urinary Ca excretion by giving isotonic saline\\nplus a loop diuretic. Initially, 1 to 2 L of saline is given over 2 to 4 h unless significant heart failure is\\npresent, because nearly all patients with significant hypercalcemia are hypovolemic. Furosemide 20 to 40\\nmg IV q 2 to 4 h is given as needed to maintain a urine output of roughly 250 mL/h (monitored hourly).\\nCare must be taken to avoid volume depletion. K and Mg are monitored as often as every 4 h during\\ntreatment and replaced IV as needed to avoid hypokalemia and hypomagnesemia. Serum Ca begins to\\ndecrease in 2 to 4 h and falls to nearnormal within 24 h.\\nModerate hypercalcemia:\\n Moderate hypercalcemia (serum Ca > 11.5 mg/dL [< 2.88 mmol/L] and < 18\\nmg/dL [< 4.51 mmol/L]) can be treated with isotonic saline and a loop diuretic as is done for mild\\nhypercalcemia or, depending on its cause, agents that decrease bone resorption (usually\\nbisphosphonates, calcitonin, or infrequently plicamycin or gallium nitrate), corticosteroids, or chloroquine.\\nBisphosphonates\\n inhibit osteoclasts. They are usually the drugs of choice for cancer-associated\\nhypercalcemia. Pamidronate can be given for cancer-associated hypercalcemia as a one-time dose of 30\\nto 90 mg IV, repeated only after 7 days. It lowers serum Ca for  2 wk. Zoledronate can also be given in\\ndoses of 4 to 8 mg IV and lowers serum Ca very effectively for an average of > 40 days. Ibandronate 4 to\\n6 mg IV can be given for cancer-associated hypercalcemia; it is effective for about 14 days. Etidronate 7.5\\nmg/kg IV once/day for 3 to 5 days is used to treat Paget's disease and cancer-associated hypercalcemia.\\nMaintenance dosage is 20 mg/kg po once/day, but the dose must be reduced when GFR is low.\\nRepetitive use of IV bisphosphonates to treat hypercalcemia associated with metastatic bone disease or\\nmyeloma has been associated with osteonecrosis of the jaw. Some reports suggest this finding may be\\nmore common with zoledronate. Renal toxicity has been reported in patients receiving zoledronate. Oral\\nbisphosphonates (eg, alendronate or risedronate) can be given to maintain Ca in the normal range but\\nare not generally used for treating hypercalcemia acutely.\\nCalcitonin\\n (thyrocalcitonin) is a rapidly acting peptide hormone normally secreted in response to\\nhypercalcemia by the C cells of the thyroid. Calcitonin seems to lower serum Ca by inhibiting osteoclastic\\nactivity. A dosage of 4 to 8 IU/kg sc q 12 h of salmon calcitonin is safe. Its usefulness in the treatment of\\ncancer-associated hypercalcemia is limited by its short duration of action with the development of\\ntachyphylaxis (often after about 48 h) and by the lack of response in  40% of patients. However, the\\ncombination of salmon calcitonin and prednisone may control serum Ca for several months in some\\npatients with cancer. If calcitonin stops working, it can be stopped for 2 days (while prednisone is\\ncontinued) and then resumed.\\nCorticosteroids\\n (eg, prednisone 20 to 40 mg po once/day) can help control hypercalcemia as adjunctive\\ntherapy by decreasing calcitriol production and thus intestinal Ca absorption in most patients with vitamin\\nD toxicity, idiopathic hypercalcemia of infancy, and sarcoidosis. Some patients with myeloma, lymphoma,\\nleukemia, or metastatic cancer require 40 to 60 mg of prednisone once/day. However, > 50% of such\\npatients fail to respond to corticosteroids, and response, when it occurs, takes several days; thus, other\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n978\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 988, 'page_label': '979'}, page_content='treatment usually is necessary.\\nChloroquine PO\\n4\\n 500 mg po once/day inhibits 1,25(OH)\\n2\\nD synthesis and reduces serum Ca\\nconcentration in patients with sarcoidosis. Routine ophthalmologic surveillance (eg, retinal examinations\\nevery 6 to 12 mo) is mandatory to detect dose-related retinal damage.\\nPlicamycin\\n 25 \\n\\ng/kg IV once/day in 50 mL of 5% D/W over 4 to 6 h is effective in patients with\\nhypercalcemia due to cancer but is rarely used because other treatments are safer.\\nGallium nitrate\\n is also effective in hypercalcemia due to cancer but is used infrequently because of renal\\ntoxicity and limited clinical experience.\\nSevere hypercalcemia:\\n In severe hypercalcemia (serum Ca > 18 mg/dL [> 4.50 mmol/L] or with severe\\nsymptoms), hemodialysis with low-Ca dialysate may be needed in addition to other treatments. Although\\nthere is no completely satisfactory way to correct severe hypercalcemia in patients with renal failure,\\nhemodialysis is probably the safest and most reliable short-term treatment.\\nIV PO\\n4\\n (disodium PO\\n4\\n or monopotassium PO\\n4\\n) should be used only when hypercalcemia is life\\nthreatening and unresponsive to other methods and when short-term hemodialysis is not possible. No\\nmore than 1 g should be given IV in 24 h; usually 1 or 2 doses over 2 days lower serum Ca for 10 to 15\\ndays. Soft-tissue calcification and acute renal failure may result. (NOTE: IV infusion of Na sulfate is even\\nmore hazardous and less effective than PO\\n4\\n infusion and should not be used.)\\nHyperparathyroidism:\\n Treatment for hyperparathyroidism depends on severity.\\nPatients with \\nasymptomatic primary hyperparathyroidism\\n with no indications for surgery may be\\ntreated conservatively with methods to ensure that serum Ca concentrations remain low. Patients should\\nremain active (ie, avoid immobilization that could exacerbate hypercalcemia), follow a low-Ca diet, drink\\nplenty of fluids to minimize the chance of nephrolithiasis, and avoid drugs that can raise serum Ca, such\\nas thiazide diuretics. Serum Ca and renal function are monitored every 6 mo. Bone density is monitored\\nevery 12 mo. However, subclinical bone disease, hypertension, and longevity are concerns. Osteoporosis\\nis treated with bisphosphonates.\\nSurgery\\n is indicated for patients with symptomatic or progressive hypoparathyroidism. The indications for\\nsurgery in patients with asymptomatic, primary hyperparathyroidism are controversial. Surgical\\nparathyroidectomy increases bone density and may have modest effects on some quality of life\\nsymptoms, but most patients do not have progressive deterioration in biochemical abnormalities or bone\\ndensity. Still, concerns about hypertension and longevity remain. Many experts recommend surgery in the\\nfollowing circumstances:\\n Serum Ca 1 mg/dL (0.25 mmol/L) greater than the upper limits of normal Calciuria > 400 mg/day (> 10\\nmmol/day)\\n Creatinine clearance 30% less than that of age-matched controls\\nPeak bone density at the hip, lumbar spine, or radius 2.5 standard deviations below controls (T score = -\\n2.5)\\nAge < 50 yr\\n The possibility of poor adherence with follow-up\\nSurgery consists of removal of adenomatous glands. PTH concentration can be measured before and\\nafter removal of the presumed abnormal gland using rapid assays. A fall of 50% or more 10 min after\\nremoval of the adenoma indicates successful treatment. In patients with disease of > 1 gland, several\\nglands are removed, and often a small portion of a normalappearing parathyroid gland is reimplanted in\\nthe belly of the sternocleidomastoid muscle or subcutaneously in the forearm to prevent\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n979'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 989, 'page_label': '980'}, page_content='hypoparathyroidism. Parathyroid tissue is also occasionally preserved using cryopreservation to allow for\\nlater autologous transplantation in case persistent hypoparathyroidism develops.\\nWhen hyperparathyroidism is mild, the serum Ca concentration drops to just below normal within 24 to 48\\nh after surgery; serum Ca must be monitored. In patients with severe osteitis fibrosa cystica, prolonged,\\nsymptomatic hypocalcemia may occur postoperatively unless 10 to 20 g elemental Ca is given in the days\\nbefore surgery. Even with preoperative Ca administration, large doses of Ca and vitamin D may be\\nrequired (see p. \\n841\\n) while bone Ca is repleted.\\nHyperparathyroidism in renal failure\\n is usually secondary. Measures used for treatment can also be\\nused for prevention. One aim is to prevent hyperphosphatemia. Treatment combines dietary PO\\n4\\nrestriction and PO\\n4\\n-binding agents, such as Ca carbonate or sevelamer. Despite the use of PO\\n4\\n binders,\\ndietary restriction of PO\\n4\\n is needed. Aluminum-containing compounds have been used to limit PO\\n4\\nconcentration, but they should be avoided, especially in patients receiving long-term dialysis, to prevent\\naluminum accumulation in bone resulting in severe osteomalacia. Vitamin D administration is potentially\\nhazardous in renal failure because it can increase PO\\n4\\n absorption and contribute to hypercalcemia;\\nadministration requires frequent monitoring of Ca and PO\\n4\\n. Treatment should be limited to patients with\\nany of the following:\\n Symptomatic osteomalacia (unrelated to aluminum)\\n Secondary hyperparathyroidism\\n Postparathyroidectomy hypocalcemia\\nAlthough oral calcitriol is often given along with oral Ca to suppress secondary hyperparathyroidism, the\\nresults are variable in patients with end-stage renal disease. The parenteral form of calcitriol, or vitamin D\\nanalogs such as paricalcitol, may better prevent secondary hyperparathyroidism in such patients,\\nbecause the higher attained serum concentration of 1,25(OH)\\n2\\nD directly suppresses PTH release.\\nSimple osteomalacia may respond to 0.25 to 0.5 \\n\\ng once/day of oral calcitriol, whereas correction of\\npostparathyroidectomy hypocalcemia may require prolonged administration \\nof as much as 2 \\n\\ng of\\ncalcitriol once/day and  2 g of elemental Ca/day. The calcimimetic, cinacalcet, modulates the set point of\\nthe Ca-sensing receptor on parathyroid cells and decreases PTH concentration in dialysis patients\\nwithout increasing serum Ca. In patients with osteomalacia caused by having taken large amounts of\\naluminum-containing PO\\n4\\n binders, removal of aluminum with deferoxamine is necessary before calcitrol\\nadministration reduces bone lesions.\\nFHH:\\n Although FHH results from histologically abnormal parathyroid tissue, the response to subtotal\\nparathyroidectomy is unsatisfactory. Because overt clinical manifestations are rare, drug therapy is not\\nroutinely indicated.\\nDisorders of Phosphate Concentration\\nPhosphorus is one of the most abundant elements in the human body. Most phosphorus in the body is\\ncomplexed with O\\n2\\n as phosphate (PO\\n4\\n). About 85% of the about 500 to 700 g of PO\\n4\\n in the body is\\ncontained in bone, where it is an important constituent of crystalline hydroxyapatite. In soft tissues, PO\\n4\\n is\\nmainly found in the intracellular compartment as an integral component of several organic compounds,\\nincluding nucleic acids and cell membrane phospholipids. PO\\n4\\n is also involved in aerobic and anaerobic\\nenergy metabolism. RBC 2,3-diphosphoglycerate (2,3-DPG) plays a crucial role in O\\n2\\n delivery to tissue.\\nAdenosine diphosphate (ADP) and ATP contain PO\\n4\\n and use chemical bonds between PO\\n4\\n groups to\\nstore energy. Inorganic PO\\n4\\n is a major intracellular anion but is also present in plasma. The normal serum\\ninorganic PO\\n4\\n concentration in adults ranges from 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L). PO\\n4\\nconcentration is 50% higher in infants and 30% higher in children, possibly because of the important roles\\nthese PO\\n4\\n-dependent processes play in growth.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n980'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 990, 'page_label': '981'}, page_content=\"The typical American diet contains about 800 to 1500 mg of PO\\n4\\n. The amount in the stool varies\\ndepending on the amount of PO\\n4\\n binding compounds (mainly Ca) in the diet. Also, like Ca, GI PO\\n4\\nabsorption is enhanced by vitamin D. Renal PO\\n4\\n excretion roughly equals GI absorption to maintain PO\\n4\\nbalance. PO\\n4\\n depletion can occur in various disorders and normally results in conservation of PO\\n4\\n by the\\nkidneys. Bone PO\\n4\\n serves as a reservoir, which can buffer changes in plasma and intracellular PO\\n4\\n.\\nHypophosphatemia\\nHypophosphatemia is serum phosphate (PO\\n4\\n) concentration < 2.5 mg/dL (0.81 mmol/L). Causes\\ninclude alcoholism, burns, starvation, and diuretic use. Clinical features include muscle\\nweakness, respiratory failure, and heart failure; seizures and coma can occur. Diagnosis is by\\nserum PO\\n4\\n concentration. Treatment consists of PO\\n4\\n supplementation\\n.\\nEtiology\\nHypophosphatemia occurs in 2% of hospitalized patients but is more prevalent in certain populations (eg,\\nit occurs in up to 10% of hospitalized patients with alcoholism).\\nHypophosphatemia has numerous causes, but clinically significant acute hypophosphatemia occurs in\\nrelatively few clinical settings, including the following:\\n The recovery phase of diabetic ketoacidosis\\n Acute alcoholism\\n Severe burns\\n When receiving TPN\\n Refeeding after prolonged undernutrition\\n Severe respiratory alkalosis\\nAcute severe hypophosphatemia with serum PO\\n4\\n < 1 mg/dL (< 0.32 mmol/L) is most often caused by\\ntranscellular shifts of PO\\n4\\n, often superimposed on chronic PO\\n4\\n depletion.\\nChronic hypophosphatemia usually is the result of decreased renal PO\\n4\\n reabsorption. Causes include\\nthe following:\\n Hyperparathyroidism\\n Other hormonal disturbances, such as Cushing's syndrome and hypothyroidism\\n Electrolyte disorders, such as hypomagnesemia and hypokalemia\\n Theophylline intoxication\\n Long-term diuretic use\\nSevere chronic hypophosphatemia usually results from a prolonged negative PO\\n4\\n balance. Causes\\ninclude\\n Chronic starvation or malabsorption, especially when combined with vomiting or copious diarrhea\\n Long-term ingestion of large amounts of PO\\n4\\n-binding aluminum, usually in the form of antacids\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n981\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 991, 'page_label': '982'}, page_content='Ingestion of aluminum is particularly prone to cause PO\\n4\\n depletion when combined with decreased\\ndietary intake and dialysis losses of PO\\n4\\n in patients with end-stage renal disease.\\nSymptoms and Signs\\nAlthough hypophosphatemia usually is asymptomatic, anorexia, muscle weakness, and \\nosteomalacia can\\noccur in severe chronic depletion. Serious neuromuscular disturbances may occur, including progressive\\nencephalopathy, seizures, coma, and death. The muscle weakness of profound hypophosphatemia may\\nbe accompanied by rhabdomyolysis, especially in acute alcoholism. Hematologic disturbances of\\nprofound hypophosphatemia include hemolytic anemia, decreased release of O\\n2\\n from Hb, and impaired\\nleukocyte and platelet function.\\nDiagnosis\\n Serum PO\\n4\\n levels\\nHypophosphatemia is diagnosed by a serum PO\\n4\\n concentration < 2.5 mg/dL (< 0.81 mmol/L). Most\\ncauses of hypophosphatemia (eg, diabetic ketoacidosis, burns, refeeding) are readily apparent. Testing\\nto diagnose the cause is done when clinically indicated (eg, suggestive liver function test results or signs\\nof cirrhosis in patients with suspected alcoholism).\\nTreatment\\n Oral PO\\n4\\n replacement\\n IV PO\\n4\\n when serum PO\\n4\\n is < 0.5 mEq/L or symptoms are severe\\nOral treatment:\\n Treatment of the underlying disorder and oral PO\\n4\\n replacement are usually adequate in\\nasymptomatic patients, even when the serum concentration is very low. PO\\n4\\n can be given in doses up to\\nabout 1 g po tid in tablets containing Na or K PO\\n4\\n. Oral Na or K PO\\n4\\n may be poorly tolerated because of\\ndiarrhea. Ingestion of 1 L of low-fat or skim milk provides 1 g of PO\\n4\\n and may be more acceptable.\\nRemoval of the cause of hypophosphatemia may include stopping PO\\n4\\n-binding antacids or diuretics or\\ncorrecting hypomagnesemia.\\nParenteral treatment:\\n Parenteral PO\\n4\\n is usually given IV. It should be administered in any of the\\nfollowing circumstances:\\n When serum PO\\n4\\n is < 0.5 mEq/L (< 0.16 mmol/L)\\n Rhabdomyolysis, hemolysis, or CNS symptoms are present\\n Oral replacement is not feasible due to underlying disorder\\nIV administration of KPO\\n4\\n (as buffered mix of K\\n2\\nHPO\\n4\\n and KH\\n2\\nPO\\n4\\n) is relatively safe when renal\\nfunction is well preserved. NaPO\\n4\\n (rather than KPO\\n4\\n) preparations generally should be used in patients\\nwith impaired renal function. The usual parenteral dose of KPO\\n4\\n is 2.5 mg (0.08 mmol)/kg IV over 6 h.\\nPatients with alcoholism may require  1 g/day during TPN; supplemental PO\\n4\\n is stopped when oral\\nintake is resumed. Serum Ca and PO\\n4\\n concentrations should be monitored during therapy, particularly\\nwhen PO\\n4\\n is given IV or to patients with impaired renal function. In most cases, no more than 7 mg/kg\\n(about 500 mg for a 70-kg adult) of PO\\n4\\n should be given over 6 h. Close monitoring is done and more\\nrapid rates of PO\\n4\\n administration should be avoided to prevent hypocalcemia, hyperphosphatemia, and\\nmetastatic calcification due to excessive Ca  PO\\n4\\n product.\\nHyperphosphatemia\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n982'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 992, 'page_label': '983'}, page_content=\"Hyperphosphatemia is serum phosphate (PO\\n4\\n) concentration > 4.5 mg/dL (> 1.46 mmol/L).\\nCauses include chronic renal failure, hypoparathyroidism, and metabolic or respiratory acidosis.\\nClinical features may be due to accompanying hypocalcemia and include tetany. Diagnosis is by\\nserum PO\\n4\\n. Treatment includes restriction of PO\\n4\\n intake and administration of PO\\n4\\n-binding\\nantacids, such as Ca carbonate\\n.\\nThe usual cause of hyperphosphatemia is a decrease in renal excretion of PO\\n4\\n. Advanced renal\\ninsufficiency (GFR < 30 mL/min) reduces excretion sufficiently to increase serum PO\\n4\\n. Defects in renal\\nexcretion of PO\\n4\\n in the absence of renal failure also occur in pseudohypoparathyroidism and\\nhypoparathyroidism. Hyperphosphatemia can also occur with excessive oral PO\\n4\\n administration and\\noccasionally with overzealous use of enemas containing PO\\n4\\n.\\nHyperphosphatemia occasionally results from a transcellular shift of PO\\n4\\n into the extracellular space that\\nis so large that the renal excretory capacity is overwhelmed. This transcellular shift occurs most\\nfrequently in diabetic ketoacidosis (despite total body PO\\n4\\n depletion), crush injuries, and nontraumatic\\nrhabdomyolysis as well as in overwhelming systemic infections and tumor lysis syndrome.\\nMajor causes of hyperphosphatemia include\\n GFR < 30 mL/min\\n Hypoparathyroidism\\n Pseudohypoparathyroidism\\n Excessive oral PO\\n4\\n administration\\n Overzealous use of enemas containing PO\\n4\\n Shifts of PO\\n4\\n into the extracellular space (eg, in diabetic ketoacidosis, rhabdomyolysis, overwhelming\\nsystemic infections, and tumor lysis syndrome)\\nHyperphosphatemia plays a critical role in the development of secondary hyperparathyroidism and renal\\nosteodystrophy in patients \\nwith advanced chronic kidney disease as well as in patients on dialysis. Lastly,\\nhyperphosphatemia can be spurious in cases of hyperproteinemia (multiple myeloma or Waldenstrom's\\nmacroglobulinemia), hyperlipidemia, hemolysis, or hyperbilirubinemia.\\nHyperphosphatemia can lead to hypocalcemia by causing Ca and PO\\n4\\n precipitation into soft tissues,\\nespecially when the serum Ca  PO\\n4\\n product is chronically > 55 in patients with chronic kidney disease.\\nSymptoms and Signs\\nMost patients with hyperphosphatemia are asymptomatic, although symptoms of hypocalcemia, including\\ntetany, can occur when concomitant hypocalcemia is present. Soft-tissue calcifications are common\\namong patients with chronic kidney disease.\\nDiagnosis\\n PO\\n4\\n concentration > 4.5 mg/dL (> 1.46 mmol/L)\\nHyperphosphatemia is diagnosed by PO\\n4\\n concentration. When the etiology is not obvious (eg,\\nrhabdomyolysis, tumor lysis syndrome, renal failure, overingestion of PO\\n4\\n,-containing laxatives),\\nadditional evaluation is warranted to exclude hypoparathyroidism or pseudohypoparathyroidism, which is\\nend-organ resistance to parathyroid hormone (PTHsee p. \\n839\\n). False elevation of serum PO\\n4\\n also\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n983\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 993, 'page_label': '984'}, page_content=\"should be excluded by measuring serum protein, lipid, and bilirubin concentrations.\\nTreatment\\n PO\\n4\\n restriction\\n PO\\n4\\n binders\\nThe mainstay of treatment in patients with renal failure is reduction of PO\\n4\\n intake, which is usually\\naccomplished with avoidance of foods containing high amounts of PO\\n4\\n and with use of PO\\n4\\n-binding\\ndrugs taken with meals. Because of the possibility of aluminum-related osteomalacia, Ca carbonate and\\nCa acetate replace aluminum-containing antacids in patients with end-stage renal disease. Because of\\nthe possibility of excessive Ca  PO\\n4\\n product causing vascular calcification in dialysis patients taking Ca-\\ncontaining binders, a PO\\n4\\n-binding resin without Ca, sevelamer, is widely used in dialysis patients in\\ndoses of 800 to 2400 mg tid with meals. Lanthanum carbonate, another PO\\n4\\n binder that lacks Ca, can\\nalso be used in dialysis patients. It is given in doses of 500 to 1000 mg tid with meals.\\nDisorders of Magnesium Concentration\\nMg is the 4th most plentiful cation in the body. A 70-kg adult has about 2000 mEq of Mg. About 50% is\\nsequestered in bone and is not readily exchangeable with Mg in other compartments. The ECF contains\\nonly about 1% of total body Mg. The remainder resides in the intracellular compartment. Normal serum\\nMg concentration ranges from 1.4 to 2.1 mEq/L (0.70 to 1.05 mmol/L).\\nThe maintenance of serum Mg concentration is largely a function of dietary intake and effective renal and\\nintestinal conservation. Within 7 days of initiation of a Mg-deficient diet, renal and stool Mg excretion\\neach fall to about 1 mEq/day (0.5 mmol/day).\\nAbout 70% of serum Mg is ultrafiltered (filtered through minute pores) by the kidney; the remainder is\\nbound to protein. Protein binding of Mg is pH dependent. Serum Mg concentration is not closely related\\nto either total body Mg or intracellular Mg content. However, severe serum hypomagnesemia may reflect\\ndiminished total body Mg.\\nMany enzymes are activated by or are dependent on Mg. Mg is required by all enzymatic processes\\ninvolving ATP and by many of the enzymes involved in nucleic acid metabolism. Mg is required for\\nthiamine pyrophosphate cofactor activity and seems to stabilize the structure of macromolecules such as\\nDNA and RNA. Mg is also related to Ca and K metabolism in an intimate but poorly understood way.\\nHypomagnesemia\\nHypomagnesemia is serum Mg concentration < 1.4 mEq/L (< 0.70 mmol/L). Causes include\\ninadequate Mg intake and absorption or increased excretion due to hypercalcemia or drugs\\nsuch as furosemide. Clinical features are often due to accompanying hypokalemia and\\nhypocalcemia and include lethargy, tremor, tetany, seizures, and arrhythmias. Treatment is with\\nMg replacement\\n.\\nSerum Mg concentration, even when free Mg ion is measured, may be normal even with decreased\\nintracellular or bone Mg stores. Mg depletion usually results from inadequate intake plus impairment of\\nrenal \\nconservation or GI absorption. There are numerous causes of clinically significant Mg deficiency\\n(see\\nTable 97-11\\n).\\nSymptoms and Signs\\nClinical manifestations are anorexia, nausea, vomiting, lethargy, weakness, personality change, tetany\\n(eg, positive Trousseau's or Chvostek's sign or spontaneous carpopedal spasm, hyperreflexia), and\\ntremor and muscle fasciculations. The neurologic signs, particularly tetany, correlate with development of\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n984\"),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 994, 'page_label': '985'}, page_content='concomitant hypocalcemia, hypokalemia, or both. Myopathic potentials are found on electromyography\\nbut are also compatible with hypocalcemia or hypokalemia. Severe hypomagnesemia may cause\\ngeneralized tonicclonic seizures, especially in children.\\nDiagnosis\\n Considered in patients with risk factors and with unexplained hypocalcemia or hypokalemia\\n Serum Mg concentration < 1.4 mEq/L (< 0.70 mmol/L)\\nHypomagnesemia is diagnosed by a serum Mg concentration. Severe hypomagnesemia usually results in\\nconcentrations of < 1.0 mEq/L (< 0.50 mmol/L). Associated hypocalcemia and hypocalciuria are common.\\nHypokalemia with increased urinary K excretion and metabolic alkalosis may be present. Mg deficiency\\nshould be suspected even when serum Mg concentration is normal in patients with unexplained\\nhypocalcemia or refractory hypokalemia. Mg deficiency should also be suspected in patients with\\nunexplained neurologic symptoms and alcoholism, with chronic diarrhea, or after cyclosporine,\\ncisplatinum-based chemotherapy or prolonged therapy with amphotericin B or aminoglycosides.\\n[\\nTable 97-11.\\n Causes of Hypomagnesemia]\\nTreatment\\n Oral Mg salts\\n IV or IM Mg sulfate for severe hypomagnesemia or inability to tolerate or adhere to oral therapy\\nTreatment with Mg salts is indicated when Mg deficiency is symptomatic or persistently < 1 mEq/L (< 0.50\\nmmol/L). Patients with alcoholism are treated empirically. In such cases, deficits approaching 12 to 24\\nmg/kg are possible. About twice the amount of the estimated deficit should be given in patients with intact\\nrenal function, because about 50% of the administered Mg is excreted in urine. Oral Mg salts (eg, Mg\\ngluconate 500 to 1000 mg po tid) are given for 3 to 4 days. Oral treatment is limited by the onset of\\ndiarrhea. Parenteral administration is reserved for patients with severe, symptomatic hypomagnesemia\\nwho cannot tolerate oral drugs. Sometimes a single injection is given in patients with alcoholism who are\\nunlikely to adhere to ongoing oral therapy. When Mg must be replaced parenterally, a 10% Mg sulfate\\n(MgSO\\n4\\n) solution (1 g/10 mL) is available for IV use and a 50% solution (1 g/2 mL) is available for IM use.\\nThe serum Mg concentration should be monitored frequently during Mg therapy, particularly when Mg is\\ngiven to patients with renal insufficiency or in repeated parenteral doses. In these patients, treatment is\\ncontinued until a normal serum Mg concentration is achieved.\\nIn severe, symptomatic hypomagnesemia (eg, Mg < 1 mEq/L [< 0.5 mmol/L] with seizures or other severe\\nsymptoms), 2 to 4 g of MgSO\\n4\\n IV is given over 5 to 10 min. When seizures persist, the dose may be\\nrepeated up to a total of 10 g over the next 6 h. In patients in whom seizures stop, 10 g in 1 L of 5% D/W\\ncan be infused over 24 h, followed by up to 2.5 g q 12 h to replace the deficit in total Mg stores and\\nprevent further drops in serum Mg. \\nWhen serum Mg is  1 mEq/L (< 0.5 mmol/L) but symptoms are less\\nsevere, MgSO\\n4\\n may be given IV in 5% D/W at a rate of 1 g/h as slow infusion for up to 10 h. In less\\nsevere cases of hypomagnesemia, gradual repletion may be achieved by administration of smaller\\nparenteral doses over 3 to 5 days until the serum Mg concentration is normal.\\nHypermagnesemia\\nHypermagnesemia is a serum Mg concentration > 2.1 mEq/L (> 1.05 mmol/L). The major cause is\\nrenal failure. Symptoms include hypotension, respiratory depression, and cardiac arrest.\\nDiagnosis is by serum Mg concentration. Treatment includes IV administration of Ca gluconate\\nand possibly furosemide; hemodialysis can be helpful in severe cases\\n.\\nSymptomatic hypermagnesemia is fairly uncommon. It occurs most commonly in patients with renal failure\\nafter ingestion of Mg-containing drugs, such as antacids or purgatives.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n985'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 995, 'page_label': '986'}, page_content='Symptoms and signs include hyporeflexia, hypotension, respiratory depression, and cardiac arrest.\\nDiagnosis\\nSerum Mg concentrations > 2.1 mEq/L (> 1.05 mmol/L)\\nAt serum Mg concentrations of 5 to 10 mEq/L (2.5 to 5 mmol/L), the ECG shows prolongation of the PR\\ninterval, widening of the QRS complex, and increased T-wave amplitude. Deep tendon reflexes disappear\\nas the serum Mg concentration approaches 10 mEq/L (5.0 mmol/L); hypotension, respiratory depression,\\nand narcosis develop with increasing hypermagnesemia. Cardiac arrest may occur when blood Mg\\nconcentration is > 12 to 15 mEq/L (6.0 to 7.5 mmol/L).\\nTreatment\\n Ca gluconate\\n Diuresis or dialysis\\nTreatment of severe Mg toxicity consists of circulatory and respiratory support with administration of 10%\\nCa gluconate 10 to 20 mL IV. Ca gluconate may reverse many of the Mg-induced changes, including\\nrespiratory depression. Administration of IV furosemide can increase Mg excretion when renal function is\\nadequate; volume status should be maintained. Hemodialysis may be valuable in severe\\nhypermagnesemia, because a relatively large fraction (about 70%) of blood Mg is not protein bound and\\nthus removable with hemodialysis. When hemodynamic compromise occurs and hemodialysis is\\nimpractical, peritoneal dialysis is an option.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 97. Fluid & Electrolyte Metabolism\\n986'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 996, 'page_label': '987'}, page_content='Chapter 98. Acid-Base Regulation and Disorders\\nIntroduction\\nMetabolic processes continually produce acid and, to a lesser degree, base. Hydrogen ion (H\\n+\\n) is\\nespecially reactive; it can attach to negatively charged proteins and, in high concentrations, alter their\\noverall charge, configuration, and function. To maintain cellular function, the body has elaborate\\nmechanisms that maintain blood H\\n+\\n concentration within a narrow rangetypically 37 to 43 nmol/L (pH\\n7.43 to 7.37, where pH = -log [H\\n+\\n]) and ideally 40 nmol/L (pH = 7.40). Disturbances of these mechanisms\\ncan have serious clinical consequences.\\nAcid-base equilibrium is closely tied to fluid and electrolyte balance, and disturbances in one of these\\nsystems often affect another. Fluid and electrolytes are discussed in \\nCh. 97\\n.\\nAcid-Base Physiology\\nMost acid comes from carbohydrate and fat metabolism, which generates 15,000 to 20,000 mmol of CO\\n2\\ndaily. CO\\n2\\n is not an acid itself but combines with water (H\\n2\\nO) in the blood to create carbonic acid\\n(H\\n2\\nCO\\n3\\n), which in the presence of the enzyme carbonic anhydrase dissociates into H\\n+\\n and HCO\\n3\\n-\\n. The\\nH\\n+\\n binds with Hb in RBCs and is released with oxygenation in the alveoli, at which time the reaction is\\nreversed, creating H\\n2\\nO and CO\\n2\\n, which is exhaled in each breath.\\nLesser amounts of organic acid derive from the following:\\n Incomplete metabolism of glucose and fatty acids into lactic acid and ketoacids\\n Metabolism of sulfur-containing amino acids (cysteine, methionine) into sulfuric acid\\n \\nMetabolism of cationic amino acids (arginine, lysine)\\n Hydrolysis of dietary phosphate\\nThis \"fixed\" or \"metabolic\" acid load cannot be exhaled and therefore must be neutralized or excreted.\\nMost base comes from metabolism of anionic amino acids (glutamate and aspartate) and from oxidation\\nand consumption of organic anions such as lactate and citrate, which produce HCO\\n3\\n-\\n.\\nAcid-Base Balance\\nAcid-base balance is maintained by chemical buffering and by pulmonary and renal elimination.\\nChemical buffering:\\n Chemical buffers are solutions that resist changes in pH. Intracellular and\\nextracellular buffers provide an immediate response to acid-base disturbances. Bone also plays an\\nimportant buffering role. A buffer is made up of a weak acid and its conjugate base. The conjugate base\\ncan accept H\\n+\\n and the weak acid can relinquish it thereby minimizing changes in free H\\n+\\n concentration.\\nThe most important extracellular buffer is the HCO\\n3\\n-\\n/CO\\n2\\n system, described by the equation:\\nH\\n+\\n + HCO\\n3\\n-\\n \\n\\n H\\n2\\nCO\\n3\\n \\n\\n CO\\n2\\n + H\\n2\\nO\\nAn increase in H\\n+\\n drives the equation to the right and generates CO\\n2\\n. This important buffer system is\\nhighly regulated; CO\\n2\\n concentrations can be finely controlled by alveolar ventilation, and H\\n+\\n and HCO\\n3\\n-\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 98. Acid-Base Regulation & Disorders\\n987'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 997, 'page_label': '988'}, page_content='concentrations can be finely regulated by renal excretion.\\nThe relationship between HCO\\n3\\n-\\n and CO\\n2\\n in the system can be described by the Kassirer-Bleich\\nequation, derived from the Henderson-Hasselbalch equation:\\nH\\n+\\n = 24  PCO\\n2\\n/HCO\\n3\\n-\\nThis equation illustrates that acid-base balance depends on the ratio of PCO\\n2\\n and HCO\\n3\\n-\\n, not on the\\nabsolute value of either one alone. With this formula, any 2 values (usually H\\n+\\n and PCO\\n2\\n) can be used to\\ncalculate the other (usually HCO\\n3\\n-\\n).\\nOther important physiologic buffers include intracellular organic and inorganic phosphates and proteins,\\nincluding Hb in RBCs. Less important are extracellular phosphate and plasma proteins. Bone becomes an\\nimportant buffer after consumption of extracellular HCO\\n3\\n-\\n. Bone initially releases sodium carbonate\\n(NaHCO\\n3\\n) and potassium carbonate (KHCO\\n3\\n) in exchange for H\\n+\\n. With prolonged acid loads, bone\\nreleases calcium carbonate (CaCO\\n3\\n) and calcium phosphate (CaPO\\n4\\n). Long-standing acidemia therefore\\ncontributes to bone demineralization and osteoporosis.\\nPulmonary regulation:\\n CO\\n2\\n concentration is finely regulated by changes in tidal volume and respiratory\\nrate (minute ventilation). A decrease in pH is sensed by arterial chemoreceptors and leads to increases in\\ntidal volume or respiratory rate; CO\\n2\\n is exhaled and blood pH increases. In contrast to chemical buffering,\\nwhich is immediate, pulmonary regulation occurs over minutes to hours. It is about 50 to 75% effective; it\\ndoes not completely normalize pH.\\nRenal regulation:\\n The kidneys control pH by adjusting the amount of HCO\\n3\\n-\\n that is reabsorbed and the\\namount of H\\n+\\n that is excreted; increase in HCO\\n3\\n-\\n is equivalent to removing free H\\n+\\n. Changes in renal\\nacid-base handling occur hours to days after changes in acid-base status.\\nHCO\\n3\\n-\\n reabsorption occurs mostly in the proximal tubule and, to a lesser degree, in the collecting tubule.\\nH\\n2\\nO within the tubular cell dissociates into H\\n+\\n and hydroxide (OH\\n-\\n); in the presence of carbonic\\nanhydrase, the OH\\n-\\n combines with CO\\n2\\n to form HCO\\n3\\n-\\n, which is transported back into the peritubular\\ncapillary, while the H\\n+\\n is secreted into the tubular lumen and joins with freely filtered HCO\\n3\\n-\\n to form CO\\n2\\nand H\\n2\\nO, which are also reabsorbed. Thus, reabsorbed HCO\\n3\\n-\\n ions are newly generated and not the\\nsame as those that were filtered. Decreases in effective circulating volume (such as occur with diuretic\\ntherapy) increase HCO\\n3\\n-\\n reabsorption, while increases in parathyroid hormone in response to an acid\\nload decrease HCO\\n3\\n-\\n reabsorption. Also, increased PCO\\n2\\n leads to increased HCO\\n3\\n-\\n reabsorption, while\\nCl\\n-\\n depletion (typically from volume depletion) leads to increased Na\\n+\\n reabsorption and HCO\\n3\\n-\\ngeneration by the proximal tubule.\\nAcid is actively excreted into the proximal and distal tubules where it combines with urinary buffers\\nprimarily freely filtered HPO\\n4\\n-2\\n, creatinine, uric acid, and ammoniato be transported outside the body.\\nThe ammonia buffering system is especially important because other buffers are filtered in fixed\\nconcentrations and can be depleted by high acid loads; by contrast, tubular cells actively regulate\\nammonia production in response to changes in acid load. Arterial pH is the main determinant of acid\\nsecretion, but excretion is also influenced by K\\n+\\n, Cl\\n-\\n, and aldosterone levels. Intracellular K\\n+\\nconcentration and H\\n+\\n secretion are reciprocally related; K\\n+\\n depletion causes increased H\\n+\\n secretion and\\nhence metabolic alkalosis.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 98. Acid-Base Regulation & Disorders\\n988'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 998, 'page_label': '989'}, page_content='Acid-Base Disorders\\nAcid-base disorders are changes in arterial PCO\\n2\\n, serum HCO\\n3\\n-\\n, and serum pH.\\n Acidemia is serum pH < 7.35.\\n Alkalemia is serum pH > 7.45.\\n Acidosis refers to physiologic processes that cause acid accumulation or alkali loss.\\n Alkalosis refers to physiologic processes that cause alkali accumulation or acid loss.\\nActual changes in pH depend on the degree of physiologic compensation and whether multiple processes\\nare present.\\nClassification\\nPrimary acid-base disturbances are defined as metabolic or respiratory based on clinical context and\\nwhether the primary change in pH is due to an alteration in serum HCO\\n3\\n-\\n or in PCO\\n2\\n.\\nMetabolic acidosis\\n is serum HCO\\n3\\n-\\n < 24 mEq/L. Causes are\\n Increased acid production\\n Acid ingestion\\n Decreased renal acid excretion\\n GI or renal HCO\\n3\\n-\\n loss\\nMetabolic alkalosis\\n is serum HCO\\n3\\n-\\n > 24 mEq/L. Causes are\\n Acid loss\\n HCO\\n3\\n-\\n retention\\nRespiratory acidosis\\n is PCO\\n2\\n > 40 mm Hg (hypercapnia). Cause is\\n Decrease in minute ventilation (hypoventilation)\\nRespiratory alkalosis\\n is PCO\\n2\\n < 40 mm Hg (hypocapnia). Cause is\\n Increase in minute ventilation (hyperventilation)\\nWhenever an acid-base disorder is present, compensatory mechanisms begin to correct the pH (see\\nTable 98-1\\n). Compensation cannot return pH completely to normal and never overshoots.\\n[\\nTable 98-1.\\n Primary Changes and Compensations in Simple Acid-Base Disorders]\\n[\\nTable 98-2.\\n Clinical Consequences of Acid-Base Disorders]\\nA simple acid-base disorder is a single acid-base disturbance with its accompanying compensatory\\nresponse.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 98. Acid-Base Regulation & Disorders\\n989'),\n",
       " Document(metadata={'producer': 'Atop CHM to PDF Converter', 'creator': 'Atop CHM to PDF Converter', 'creationdate': '2012-06-15T05:44:40+00:00', 'moddate': '2014-04-21T07:53:19+10:00', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'total_pages': 4114, 'page': 999, 'page_label': '990'}, page_content='Mixed acid-base disorders comprise 2 or more primary disturbances.\\nSymptoms and Signs\\nCompensated or mild acid-base disorders cause few symptoms or signs. Severe, uncompensated\\ndisorders have multiple cardiovascular, respiratory, neurologic, and metabolic consequences (see \\nTable\\n98-2\\n and\\nFig. 189-4\\n on p. \\n1857\\n).\\nDiagnosis\\n ABG\\n Serum electrolytes\\n Anion gap calculated\\n If metabolic acidosis is present, delta gap calculated and Winter\\'s formula applied\\n Search for compensatory changes\\nEvaluation is with ABG and serum electrolytes. The ABG directly measures arterial pH and PCO\\n2\\n. HCO\\n3\\n-\\nlevels on ABG are calculated using the Henderson-Hasselbalch equation; levels on serum chemistry\\npanels are directly measured and are more accurate. Acid-base balance is generally most accurately\\nassessed with measurement of pH and pCO\\n2\\n on arterial blood. In cases of circulatory failure or during\\ncardiopulmonary resuscitation, measurements on venous blood may more accurately reflect conditions at\\nthe tissue level and may be a more useful guide to bicarbonate administration and adequacy of\\nventilation.\\nThe pH establishes the primary process (acidosis or alkalosis), although it moves toward the normal\\nrange with compensation. Changes in PCO\\n2\\n reflect the respiratory component, and changes in HCO\\n3\\n-\\nreflect the metabolic component. However, several calculations may be required to determine whether\\nchanges in PCO\\n2\\n and HCO\\n3\\n-\\n are primary or compensatory and whether a mixed disorder is present; in\\nmixed \\ndisorders, values may be deceptively normal. Interpretation must also consider clinical conditions\\n(eg, chronic lung disease, renal failure, drug overdose).\\nSidebar 98-1 The Anion Gap\\nThe anion gap is defined as plasma Na concentration minus the sum of Cl\\n-\\n and HCO\\n3\\n-\\n concentrations;\\nNa\\n+\\n - (Cl\\n-\\n + HCO\\n3\\n-\\n). The term \"gap\" is misleading, because the law of electroneutrality requires the\\nsame number of positive and negative charges in an open system; the gap appears on laboratory testing\\nbecause certain cations (+) and anions (-) are not measured on routine laboratory chemistry panels. Thus\\nNa\\n+\\n + unmeasured cations (UC) = Cl\\n-\\n + HCO\\n3\\n-\\n + unmeasured anions (UA)\\nand\\nthe anion gap, Na\\n+\\n - (Cl\\n-\\n + HCO\\n3\\n-\\n) = UA - UC\\nThe predominant unmeasured anions are PO\\n4\\n3-\\n, sulfate (SO\\n4\\n-\\n), various negatively charged proteins,\\nand some organic acids, accounting for 20 to 24 mEq/L. The predominant unmeasured extracellular\\ncations are K\\n+\\n, Ca\\n++\\n, and Mg\\n++\\n and account for about 11 mEq/L. Thus the typical anion gap is 23 - 11 =\\n12 mEq/L. The anion gap can be affected by increases or decreases in the UC or UA.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 98. Acid-Base Regulation & Disorders\\n990'),\n",
       " ...]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extracted_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "def text_split(extracted_data):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(chunk_size=500, chunk_overlap=20)\n",
    "    text_chunks = text_splitter.split_documents(extracted_data)\n",
    "\n",
    "    return text_chunks\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Length of text_chunks:  30465\n"
     ]
    }
   ],
   "source": [
    "text_chunks = text_split(extracted_data)\n",
    "print(\"Length of text_chunks: \", len(text_chunks))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.embeddings import HuggingFaceEmbeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Download the Embeddings from Hugging Face\n",
    "def download_hugging_face_embeddings():\n",
    "    embeddings = HuggingFaceEmbeddings(model_name='sentence-transformers/all-MiniLM-L6-v2')\n",
    "    return embeddings\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\acer\\AppData\\Local\\Temp\\ipykernel_13904\\697957399.py:3: LangChainDeprecationWarning: The class `HuggingFaceEmbeddings` was deprecated in LangChain 0.2.2 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-huggingface package and should be used instead. To use it run `pip install -U :class:`~langchain-huggingface` and import as `from :class:`~langchain_huggingface import HuggingFaceEmbeddings``.\n",
      "  embeddings = HuggingFaceEmbeddings(model_name='sentence-transformers/all-MiniLM-L6-v2')\n",
      "c:\\Users\\acer\\.conda\\envs\\mbt\\lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "embeddings=download_hugging_face_embeddings()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query Result:  [-0.05281347408890724, -0.001374902087263763, 0.017714640125632286, -0.041204363107681274, -0.07703106105327606, -0.012953074648976326, 0.08606577664613724, -0.035605158656835556, -0.007505625952035189, 0.011056408286094666, -0.00831371545791626, -0.03916935622692108, -0.010008127428591251, -0.013129576109349728, 0.05076593533158302, -0.010774414986371994, -0.012444491498172283, -0.008539211936295033, 0.026145555078983307, -0.006662552244961262, -0.0873192623257637, 0.05264405533671379, 0.013883042149245739, -0.05309411138296127, -0.10256103426218033, -0.002758856862783432, -0.012859216891229153, 0.01733781024813652, 0.030651090666651726, 0.012479221448302269, -0.05459626391530037, 0.02546037547290325, 0.06263039261102676, 0.005438545253127813, -0.029814807698130608, -0.024091437458992004, -0.036041129380464554, -0.060643650591373444, 0.04598749056458473, 0.05024239420890808, 0.010332739911973476, -0.03231607377529144, 0.013480001129209995, -0.008511165156960487, 0.006421380210667849, 0.044966623187065125, 0.04280611500144005, -0.01543918251991272, 0.06352835148572922, -0.0956159457564354, -0.08550463616847992, 0.07047990709543228, -0.061374250799417496, 0.01407630741596222, 0.07433324307203293, -0.004671082831919193, -0.017320072278380394, 0.03714129328727722, -0.028978386893868446, -0.09301881492137909, 0.09271274507045746, -0.0037378831766545773, -0.04432167857885361, -0.002250205259770155, 0.17122986912727356, 0.019829271361231804, -0.07573509216308594, 0.045091982930898666, -0.031128140166401863, 0.07151129841804504, -0.004985809791833162, -0.014084565453231335, -0.05378372594714165, 0.009241572581231594, -0.013765660114586353, 0.013129178434610367, 0.046072717756032944, -0.09696565568447113, 0.06269058585166931, 0.06002376601099968, 0.05394618958234787, -0.03572529926896095, -0.02691105753183365, 0.04892069846391678, -0.03634196147322655, -0.008483449928462505, 0.039258621633052826, -0.026285016909241676, 0.01724700815975666, 0.04165733605623245, -0.030760934576392174, 0.06555431336164474, 0.04274901747703552, 0.0290809478610754, -0.005615853704512119, -0.03336791321635246, -0.006213608663529158, 0.03295633941888809, -0.13095155358314514, 0.1520567685365677, 0.06319589167833328, 0.03547561541199684, 0.014629337936639786, -0.08245842158794403, 0.03811957314610481, 0.025847751647233963, 0.0004185653233435005, 0.13173343241214752, -0.013010173104703426, -0.06846319884061813, 0.0036913626827299595, 0.04097246006131172, -0.04366492107510567, 0.11816643923521042, 0.02697034366428852, 0.0376632958650589, 0.0008763858932070434, 0.031172877177596092, 0.03183361515402794, -0.04252525418996811, 0.015261546708643436, 0.026774469763040543, 0.015732185915112495, 0.05909352749586105, -0.019711101427674294, -0.05285799130797386, 0.01967504806816578, -7.103184692968792e-33, 0.03951501473784447, -0.02056245133280754, 0.09123779833316803, 0.04196574166417122, -0.044790491461753845, 0.06594578176736832, -0.013105697929859161, -0.04834596812725067, 0.031957924365997314, -0.012312140315771103, -0.0021481269504874945, 0.07840927690267563, -0.061157479882240295, 0.030131075531244278, -0.020199570804834366, -0.00948080513626337, 0.005064873490482569, -0.019117159768939018, 0.023452291265130043, 0.06211353465914726, -0.021360276266932487, -0.0756639838218689, -0.02976292371749878, -0.0463813953101635, -0.03854631632566452, 0.04356587305665016, -0.005797251593321562, -0.0583360455930233, 0.029197094962000847, 0.017345333471894264, -0.05238901451230049, 0.04906075447797775, 0.04248254373669624, 0.01972990483045578, 0.009722686372697353, -0.025560004636645317, -0.09870590269565582, 0.023733239620923996, -0.040104497224092484, -0.005535525735467672, -0.035800203680992126, 0.022028081119060516, -0.008988727815449238, -0.03827961906790733, 0.023017775267362595, -0.031753815710544586, -0.03147201985120773, -0.02839459478855133, -0.02766869217157364, -0.038759950548410416, -0.02776453271508217, -0.06531338393688202, 0.02860938012599945, -0.04881167411804199, 0.014520418830215931, -0.005313430447131395, 0.06152951717376709, 0.14677943289279938, -0.06440317630767822, 0.012337746098637581, 0.02836431935429573, 0.03897562995553017, -0.04327395558357239, -0.00907246582210064, -0.11885178089141846, 0.005244365893304348, 0.059227026998996735, -0.011723484843969345, 0.0627426952123642, -0.033257924020290375, 0.01774071715772152, -0.006739660631865263, 0.001107756863348186, 0.05745948851108551, 0.09056825935840607, 0.031226640567183495, -0.0966607928276062, 0.05848442390561104, -0.041383519768714905, 0.01554038841277361, 0.03215000405907631, 0.02907879464328289, -0.026519982144236565, 0.015842275694012642, 0.1314380168914795, -0.026149729266762733, -0.07153761386871338, 0.002893314464017749, 0.08108840882778168, 0.06165091320872307, -0.0028517702594399452, 0.029215022921562195, 0.03666830435395241, 0.04233323037624359, -0.01940968632698059, 5.7471186141548617e-33, 0.07746203988790512, 0.07029344886541367, 0.061433397233486176, 0.06222497671842575, -0.022087235003709793, -0.010092590935528278, -0.014038324356079102, 0.11511849611997604, -0.0829552412033081, 0.13044291734695435, 0.02709190733730793, -0.03208991140127182, 0.08310136944055557, -0.014191332273185253, 0.07585611194372177, -0.07853139191865921, 0.028565024957060814, -0.022334076464176178, 0.005046091508120298, -0.020641805604100227, -0.051993172615766525, 0.04942058399319649, -0.06205837428569794, 0.010367045179009438, -0.010476673021912575, 0.039174485951662064, 0.006466977763921022, -0.06749867647886276, -0.024841923266649246, 0.013609251007437706, 0.03766845539212227, -0.07597416639328003, -0.1519884467124939, 0.027128111571073532, 0.0029418310150504112, 0.015089339576661587, 0.0321333110332489, -0.024673890322446823, 0.027675138786435127, -0.025610938668251038, -0.045169901102781296, 0.08487451076507568, 0.021368877962231636, 0.024165891110897064, -0.0024088474456220865, 0.010118280537426472, 0.015117957256734371, 0.0021026884205639362, -0.004582044202834368, -0.033040232956409454, -0.021282052621245384, -0.05383257940411568, -0.05634181573987007, -0.024879662320017815, 0.021793976426124573, 0.058374661952257156, 0.07114101946353912, -0.02811535634100437, 0.044129543006420135, -0.021168256178498268, -0.15190719068050385, 0.03236394748091698, -0.073721744120121, 0.059332430362701416, 0.06522282212972641, -0.005387279205024242, -0.038680098950862885, 0.0015684382524341345, -0.07521982491016388, -0.016478996723890305, -0.04271143674850464, 0.008110594935715199, 0.054079316556453705, 0.016239656135439873, -0.01434647012501955, -0.0869985893368721, 0.013911550864577293, -0.016729701310396194, -0.02158506214618683, -0.18525099754333496, -0.07599766552448273, -0.01378671731799841, 0.019312668591737747, 0.03638327121734619, 0.004691299516707659, 0.019794782623648643, 0.0524413101375103, 0.020303767174482346, 0.048194341361522675, 0.022997260093688965, 0.003939556889235973, 0.029633529484272003, -0.02206195518374443, -0.029371431097388268, 0.018365729600191116, -1.849376651819057e-08, 0.02139534242451191, -0.006416561082005501, 0.031918227672576904, -0.07206345349550247, -0.07039632648229599, -0.010839909315109253, -0.040557559579610825, -0.02328282780945301, 0.03300580382347107, -0.08686285465955734, 0.017559709027409554, -0.02668163925409317, -0.05422241985797882, -0.03172451630234718, 0.09298231452703476, 0.016945060342550278, 0.01770823448896408, -0.03526204079389572, -0.027514858171343803, -0.016652939841151237, 0.08213986456394196, 0.034163303673267365, 0.02342553809285164, 0.03543298318982124, 0.0073740785010159016, 0.08447658270597458, -0.03661027550697327, -0.02954951860010624, -0.09695558995008469, 0.0482521653175354, 0.09525108337402344, 0.14365032315254211, -0.07057488709688187, -0.03409036248922348, 0.052256107330322266, 0.03954209014773369, -0.05802852287888527, -0.06438698619604111, 0.0709807351231575, 0.01789291575551033, 0.001064792973920703, 0.017216386273503304, 0.0034568512346595526, 0.05021287128329277, -0.05321432277560234, 0.01380409486591816, 0.029840296134352684, 0.10369528084993362, -0.06176791712641716, -0.0327228307723999, 0.027626175433397293, 0.0037438597064465284, 0.04847452789545059, 0.040562957525253296, -0.004739951342344284, -0.022481465712189674, 0.04540533199906349, -0.013186100870370865, 0.010900105349719524, -0.09919298440217972, 0.05503292754292488, -0.08983227610588074, -0.06900033354759216, -0.06071518361568451]\n"
     ]
    }
   ],
   "source": [
    "query_result=embeddings.embed_query(\"I am a good man\")\n",
    "print(\"Query Result: \", query_result)\n",
    "# print(\"Length of Query Result: \", len(query_result))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PINECONE_API_KEY:  pcsk_TfmYV_7TQz5LhQ7oYx33ZSpAjYY1Kgnzvnaz9bSZFiJqK9eYGva1wuiFC8xRBEMa9hYNm\n"
     ]
    }
   ],
   "source": [
    "PINECONE_API_KEY=os.environ.get('PINECONE_API_KEY')\n",
    "print(\"PINECONE_API_KEY: \", PINECONE_API_KEY)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from pinecone import Pinecone, ServerlessSpec\n",
    "\n",
    "# Retrieve the API key from your environment or set it directly\n",
    "PINECONE_API_KEY = os.environ.get(\"PINECONE_API_KEY\")\n",
    "\n",
    "# Create an instance of the Pinecone client\n",
    "pc = Pinecone(api_key=PINECONE_API_KEY)\n",
    "\n",
    "index_name = \"medbot\"\n",
    "\n",
    "# Optionally, check if the index already exists before creating it\n",
    "existing_indexes = [index.name for index in pc.list_indexes()]\n",
    "if index_name not in existing_indexes:\n",
    "    pc.create_index(\n",
    "        name=index_name,\n",
    "        dimension=384,\n",
    "        metric=\"cosine\",\n",
    "        spec=ServerlessSpec(\n",
    "            cloud=\"aws\",\n",
    "            region=\"us-east-1\"\n",
    "        )\n",
    "    )\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "os.environ['PINECONE_API_KEY']=PINECONE_API_KEY"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Embed each chunk and upsert the embeddings into your Pinecone index.\n",
    "from langchain_pinecone import PineconeVectorStore\n",
    "\n",
    "docsearch = PineconeVectorStore.from_documents(\n",
    "    documents=text_chunks,\n",
    "    index_name=index_name,\n",
    "    embedding=embeddings,\n",
    "    batch_size=50\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<langchain_pinecone.vectorstores.PineconeVectorStore at 0x19b4a661f30>"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docsearch"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load Existing index\n",
    "from langchain_pinecone import PineconeVectorStore\n",
    "\n",
    "index_name = \"medbot\"\n",
    "\n",
    "# Embed each chunk and upsert the embeddings into your Pinecone index.\n",
    "docsearch = PineconeVectorStore.from_existing_index(\n",
    "    index_name=index_name,\n",
    "    embedding=embeddings\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "retriever = docsearch.as_retriever(search_type=\"similarity\", search_kwargs={\"k\": 3})\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "retrieved_docs = retriever.invoke(\"What is acne?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id='5617d694-03ce-4865-b886-f147020f4084', metadata={'creationdate': '2012-06-15T05:44:40+00:00', 'creator': 'Atop CHM to PDF Converter', 'moddate': '2014-04-21T07:53:19+10:00', 'page': 769.0, 'page_label': '760', 'producer': 'Atop CHM to PDF Converter', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'total_pages': 4114.0}, page_content='The Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 73. Acne & Related Disorders\\n760'),\n",
       " Document(id='ce67ffa7-04cb-4b4f-a4ef-5f14dceb7f1f', metadata={'creationdate': '2012-06-15T05:44:40+00:00', 'creator': 'Atop CHM to PDF Converter', 'moddate': '2014-04-21T07:53:19+10:00', 'page': 769.0, 'page_label': '760', 'producer': 'Atop CHM to PDF Converter', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'total_pages': 4114.0}, page_content='Chapter 73. Acne and Related Disorders\\nIntroduction\\nAcne vulgaris is a common skin problem, affecting most adolescents and many adults. Perioral dermatitis\\nand rosacea can produce similar lesions.\\nAcne Vulgaris\\nAcne vulgaris (acne) is the formation of comedones, papules, pustules, nodules, and/or cysts as\\na result of obstruction and inflammation of pilosebaceous units (hair follicles and their\\naccompanying sebaceous gland). It most often affects adolescents. Diagnosis is by'),\n",
       " Document(id='d73acb2f-d873-4842-9ce9-29e5e66cdf74', metadata={'creationdate': '2012-06-15T05:44:40+00:00', 'creator': 'Atop CHM to PDF Converter', 'moddate': '2014-04-21T07:53:19+10:00', 'page': 774.0, 'page_label': '765', 'producer': 'Atop CHM to PDF Converter', 'source': 'Data\\\\Merck Sharp & Dohme Corp. - The Merck Manual of Diagnosis & Therapy, 19th Edition (2012) - libgen.li.pdf', 'title': 'The Merck Manual of Diagnosis & Therapy, 19th Edition', 'total_pages': 4114.0}, page_content='good.\\nThe Merck Manual of Diagnosis & Therapy, 19th Edition Chapter 73. Acne & Related Disorders\\n765')]"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "retrieved_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_openai import OpenAI\n",
    "llm=OpenAI(temperature=0.4,max_tokens=500)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "\n",
    "gemini_api_key = os.environ['GEMINI_API_KEY']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_google_genai import GoogleGenerativeAI\n",
    "\n",
    "llm = GoogleGenerativeAI(model=\"gemini-pro\", api_key=gemini_api_key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_google_genai import GoogleGenerativeAI\n",
    "\n",
    "llm = GoogleGenerativeAI(model=\"gemini-2.0-flash\", temperature=0.4, max_output_tokens=500,api_key=gemini_api_key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import create_retrieval_chain\n",
    "from langchain.chains.combine_documents import create_stuff_documents_chain\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "\n",
    "system_prompt = (\n",
    "    \"You are an assistant for question-answering tasks. \"\n",
    "    \"Use the following pieces of retrieved context to answer \"\n",
    "    \"the question. If you don't know the answer, say that you \"\n",
    "    \"don't know. Use three sentences maximum and keep the \"\n",
    "    \"answer concise.\"\n",
    "    \"\\n\\n\"\n",
    "    \"{context}\"\n",
    ")\n",
    "\n",
    "prompt=ChatPromptTemplate.from_messages(\n",
    "    [\n",
    "        (\"system\", system_prompt),\n",
    "        (\"human\",\"{input}\"),\n",
    "  ]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "question_answering_chain = create_stuff_documents_chain(llm,prompt)\n",
    "rag_chain = create_retrieval_chain(retriever, question_answering_chain)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Acne vulgaris is the formation of comedones, papules, pustules, nodules, and/or cysts. It results from obstruction and inflammation of pilosebaceous units. It most often affects adolescents.\n"
     ]
    }
   ],
   "source": [
    "response = rag_chain.invoke({\"input\":\"What is acne?\"})\n",
    "print(response[\"answer\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "models/gemini-1.0-pro-vision-latest\n",
      "models/gemini-pro-vision\n",
      "models/gemini-1.5-pro-latest\n",
      "models/gemini-1.5-pro-001\n",
      "models/gemini-1.5-pro-002\n",
      "models/gemini-1.5-pro\n",
      "models/gemini-1.5-flash-latest\n",
      "models/gemini-1.5-flash-001\n",
      "models/gemini-1.5-flash-001-tuning\n",
      "models/gemini-1.5-flash\n",
      "models/gemini-1.5-flash-002\n",
      "models/gemini-1.5-flash-8b\n",
      "models/gemini-1.5-flash-8b-001\n",
      "models/gemini-1.5-flash-8b-latest\n",
      "models/gemini-1.5-flash-8b-exp-0827\n",
      "models/gemini-1.5-flash-8b-exp-0924\n",
      "models/gemini-2.0-flash-exp\n",
      "models/gemini-2.0-flash\n",
      "models/gemini-2.0-flash-001\n",
      "models/gemini-2.0-flash-exp-image-generation\n",
      "models/gemini-2.0-flash-lite-001\n",
      "models/gemini-2.0-flash-lite\n",
      "models/gemini-2.0-flash-lite-preview-02-05\n",
      "models/gemini-2.0-flash-lite-preview\n",
      "models/gemini-2.0-pro-exp\n",
      "models/gemini-2.0-pro-exp-02-05\n",
      "models/gemini-exp-1206\n",
      "models/gemini-2.0-flash-thinking-exp-01-21\n",
      "models/gemini-2.0-flash-thinking-exp\n",
      "models/gemini-2.0-flash-thinking-exp-1219\n",
      "models/learnlm-1.5-pro-experimental\n",
      "models/gemma-3-27b-it\n"
     ]
    }
   ],
   "source": [
    "import google.generativeai as genai\n",
    "import os\n",
    "\n",
    "# Make sure you have your API key configured\n",
    "genai.configure(api_key=os.environ.get(\"GEMINI_API_KEY\"))\n",
    "\n",
    "for m in genai.list_models():\n",
    "    if \"generateContent\" in m.supported_generation_methods:\n",
    "        print(m.name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "I am sorry, but the provided text does not contain information about the field of statistics. The text discusses IQ levels, leukocyte esterase tests, and statin use, but it does not define or explain \"stats.\"\n"
     ]
    }
   ],
   "source": [
    "response = rag_chain.invoke({\"input\":\"What is stats?\"})\n",
    "print(response[\"answer\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Acromegaly is a syndrome caused by excessive growth hormone secretion, typically due to a pituitary adenoma. Diagnosis involves clinical evaluation, skull and hand x-rays, and measurement of growth hormone levels that are not suppressed by glucose administration. Treatment focuses on removing or destroying the adenoma.\n"
     ]
    }
   ],
   "source": [
    "response = rag_chain.invoke({\"input\":\"Acromegaly\"})\n",
    "print(response[\"answer\"])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "mbt",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
